<SEC-DOCUMENT>0001628280-21-001852.txt : 20210211
<SEC-HEADER>0001628280-21-001852.hdr.sgml : 20210211
<ACCEPTANCE-DATETIME>20210210204803
ACCESSION NUMBER:		0001628280-21-001852
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20210101
FILED AS OF DATE:		20210211
DATE AS OF CHANGE:		20210210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		21616188

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exel-20210101.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:3705d550-318f-4f51-9de6-06eba39f6ea7,g:2df53114-27bb-4237-9a9c-80b7c8353f30,d:68bf8bfb5b59421792b5711a409e9ffd--><html xmlns:exel="http://www.exelixis.com/20210101" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20210101</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF80L2ZyYWc6MjdkYzE1NjQxOGE3NDE2Mzk4Njk5YjEyYTNlMGNmMjMvdGFibGU6OTgyZDAxNDMxMGY3NDMzN2IzMzQ5Njg1YTdkNTFlZjIvdGFibGVyYW5nZTo5ODJkMDE0MzEwZjc0MzM3YjMzNDk2ODVhN2Q1MWVmMl8yLTEtMS0xLTM5Mzg_8804e1ab-67a3-49b3-9e18-0c0be76811b6">false</ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF80L2ZyYWc6MjdkYzE1NjQxOGE3NDE2Mzk4Njk5YjEyYTNlMGNmMjMvdGFibGU6OTgyZDAxNDMxMGY3NDMzN2IzMzQ5Njg1YTdkNTFlZjIvdGFibGVyYW5nZTo5ODJkMDE0MzEwZjc0MzM3YjMzNDk2ODVhN2Q1MWVmMl80LTEtMS0xLTA_d894cb1a-7bce-4a47-b4ae-f8b8dd671e25">2020</ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF80L2ZyYWc6MjdkYzE1NjQxOGE3NDE2Mzk4Njk5YjEyYTNlMGNmMjMvdGFibGU6OTgyZDAxNDMxMGY3NDMzN2IzMzQ5Njg1YTdkNTFlZjIvdGFibGVyYW5nZTo5ODJkMDE0MzEwZjc0MzM3YjMzNDk2ODVhN2Q1MWVmMl81LTEtMS0xLTA_823f0c2b-1aed-4947-afc8-48511c2f3006">FY</ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF80L2ZyYWc6MjdkYzE1NjQxOGE3NDE2Mzk4Njk5YjEyYTNlMGNmMjMvdGFibGU6OTgyZDAxNDMxMGY3NDMzN2IzMzQ5Njg1YTdkNTFlZjIvdGFibGVyYW5nZTo5ODJkMDE0MzEwZjc0MzM3YjMzNDk2ODVhN2Q1MWVmMl82LTEtMS0xLTM5Mzk_23bc055b-40ab-4422-a7c8-629bd23f66e6">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_4bd66db9-0068-4d77-8491-049fcf2c6704">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_a8b46ed7-baae-4463-b21f-4d4716438745">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDkyL2ZyYWc6N2U5ZDViZTU3YzkyNDQwYWI5NjJiNDY2N2EzMTU1Y2EvdGFibGU6ZDliMzdiYjQ1OGRiNDFlNjlkNzY5OGVmNmI1MTgxZDkvdGFibGVyYW5nZTpkOWIzN2JiNDU4ZGI0MWU2OWQ3Njk4ZWY2YjUxODFkOV8xLTEtMS0xLTE3ODI4_33e972be-7643-4af4-9b17-0e9a5a58c256">us-gaap:otherassetsnoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDkyL2ZyYWc6N2U5ZDViZTU3YzkyNDQwYWI5NjJiNDY2N2EzMTU1Y2EvdGFibGU6ZDliMzdiYjQ1OGRiNDFlNjlkNzY5OGVmNmI1MTgxZDkvdGFibGVyYW5nZTpkOWIzN2JiNDU4ZGI0MWU2OWQ3Njk4ZWY2YjUxODFkOV8xLTEtMS0xLTE3ODI4_e1be24de-1d1f-4569-a6d0-20d08ca7d5db">us-gaap:otherassetsnoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20210101.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib4fd9aaa36234bf69289fc29d0946344_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic1de7713dd784687b13406c4c8917075_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibc3c42d191c44c598831337fe0fcd696_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017544c12e89414a8fbb94db33dba5ca_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ae4188c769426b89292d8f4cb182cd_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f75b6132534e759b7a2f8f4f543224_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd63dabbf6d046f6a7c8d265a33ee88c_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aafd53bd39d4ffc9927ea4ffcd6a8ed_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08966774bb054fc088e3056e8afeee22_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b8b4097af0141c0b296cf3b6ba2950f_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0062b098130b4f129d9e3ab3551e84ba_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-28</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf18789764c45368c669217aaffdb67_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd92776c3fd4e93a43d434422c20d5d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf8a6adb4b164967870e4ec8b407494a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5eee05a10d6452b9488c1814f28b285_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc77df98a1c43b7b450a7d15340ba09_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8951b2a4fc794481a8bec7526b2fe718_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51f4593048134c2aae052c2684c52ab7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e8fcb09c95f4a81a55d006ee3b40c7c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05f1fb499cf24490b6739fd15fde0a70_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee659f1b4184a299e8ef1cd870aaacb_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52da6ed6384349dab85a714e3d9f3121_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e75e71919b493ba1d1e2d3f874d754_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ccaed2e3f744d798f678ef8e8f549bf_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30eaa7c0999b426ebb923dec46907033_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd2971170a1e4aa7b66cf3c6bff48467_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452886d25bad4d378ac6e98c1cbf46b2_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdfd210ed07043f6a95731b55f3bff0f_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f9755c807a24f8cb306629ef867b038_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i884c78d408784785ad24fc34a5d0c20e_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf0a67523fe04dd69a9519798a6eee12_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c9376ae494c4c59acb1a1ea66a6591b_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie30c343186df43e1b9b015ce00d68641_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a1936b47924d069d3624adfa0f5429_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de1f6ea286142e1a15d7747bbae50f2_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4fbc439858a4ae4bbb8754989dd1aad_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64bf936cf9074f0d908fdc47b6f7a66d_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42dc949dd41c462aa7f7f0448c9e0258_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8532508de83a49b88e77f0e2c020cf28_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i558c4cfa6cb240c793e2ddc4e22b9288_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c6817fdc914e70b2207f8d04c39cfb_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aaae69174fa4f95900ea3fcd832f187_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8bcdd3025c0460d83a19962b5f3e147_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa081489d4f49229307745612d68ff4_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:context id="i70d57544c852419d89d807ca969cf9dc_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ae6057ccd8434a925a70647c5631e9_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8f792de05b44b5c9f144e5e61238bfe_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="i8a33372a3f1347209075c0020d6bc068_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">exel:FinalCalculationOfBrandedPrescriptionDrugFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i68ed0b3579a44a409ff3f00c4b884aa2_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec86aacc21384a4996d1876a8cb648cf_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie579a8fa324847dabc4b5225b2c0c290_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1461cd4bfd3c47c3967b22b8dfbe9be7_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib990f420d40b4a3789297972cf1c7e68_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73502ab4116542529d603ec4cd2116b8_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if458bc56436a40b686b3ffa6d5c137e1_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ca0bb3135aa44d8bd3287f9952cab2f_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1493217f6b6d4b069dce0c3795c0b005_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f9d798ccb34676b3e9f4fa0c493d84_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c6f0b98ffb341dcbd502a864903e546_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10483cca017b4a299e08efb033233f44_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa643e65f4a54355aecef91480e17f63_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670b9bb21b274bf1a4d1c34421fc3303_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88900c20d16b466197d1afc11b84f873_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa2590ddc5b443eae95962cb972cbdb_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib16eb294fd16430ab148fb14f058af49_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8836d60836b24ea9a6548c71ad67321d_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be59e66b12446da9b1ef0b4f3d06cac_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc1d30b7d3a4f06af43da57ce01f0d0_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31bb491021104aef928b3404ad05a9ff_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b5a944195d8434c8b42f2f1eb355ef6_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df29850b2244253875bb007d882a698_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb1450fd8a55400fa9281132060b8fcc_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if81951ec5a864326b312312ad51008a9_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d9b118c50947b99a376ebee947e030_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5a25303cb764f61869e826e0f35954d_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4ca2a47a8b64d7ca69c61e19f993397_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1016e220053480cb358c5dc63979dcb_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf42c7314ce4ba9a503ca92535ee0e1_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d5dbf6fabd4ed8b76f6fac38c3a1ac_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7007d99a1d42f18d5f5f017813107a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib39c621c29354744ba506f00b8b68407_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14840edd307b453b8993c676800c743f_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd263e91c514880aab3ad046d770b1a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfce732a0e594583ae51712fb488f5f1_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc8d4270737e40e39a71be8687219600_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if76434a400d24ae7b1196c9db3361389_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ed95db610746868908b7b47b43533a_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70f8ef5fe5f34df2867857968fdd5135_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idddf53d05cdc4b41a5f8f99bc44c6c7b_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ba8f2854a74c39969dbab674b0387f_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i927f62b2ab254dd19dcd6f11991f1c06_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia435deed54c84325b684daa442718f36_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1b0da10f24b48bb8d2940b955a6c0e4_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib930a4d0eb864dda920bd8ef624bdca7_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice8e7eb846bd436b99ddee2ea5d4de93_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if799ebcc579c4d499fe23a1a040367cf_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28dd4195ecbd4524a57b68e9b5121e06_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703818facc0749cea8bf6a915c610cf2_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972f61963894489d8bd8d96975249ff6_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if514cdad25cc48d282b48650879ae9b7_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18681346850c4142b0cd3f7611f296f7_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569e8490f11c4c2397bf2fb735ab9284_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i068e290e4adf43a6ae27c34e6c1a6b8d_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0014908918c44efd817e3fd6b0997259_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7037c5690ef4f0eb73f27b75981598e_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i588f2ef914e74116ac5406f6a9c01b36_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5ede1c91f84818b0783db0bb304518_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40b5a386ffe8410abe781ee1be62b794_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41ebfdbd93854a33891fe6df6de3c3b6_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7cfa1b7a7f4ba38dc76cc810d3400d_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c97e81888f485bb64fd4ed361390ac_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i485f8f534a3b4af3bbd86f765dd82388_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4e2d4955acf43d8b9d5c3180cca3657_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d678bb169b48699b45ef9f3a5ee83a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac85cedb1c81483cabfe7f110f14f7bf_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3448dcea3614442a9a77d8d52fcb6e28_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id261962031d24c9c96d500feae66c4cb_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3edf5cd51c4c429ca9fd36162d5bfb83_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i175c1256c42e4ceb969e04284a7f0b85_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e51030563a74e4ab6a25f0c1af5638f_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbfee036b7344af7acf82053445607ff_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbb74c8b1eec4b309ba8b185f47e746e_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i798095a51aa64ee99fae753389f50df8_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3a269af46e46d4ba478888e3772c6b_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7aa81d937ec42618a7404c5d7df25a4_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic048c678e69e4a2696e357c75149ef17_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647bc5092dce48c290e3e40bd7a16822_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98980155e99342fdb4084a583ee15d45_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a84efaf8d1449868eee0a1f360e49d0_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife1791e1be864b11836b55144b0c084d_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73471fb9991d403ba0e68dd720fe1b50_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c7b509b13bc4e9d939f403b1f05c90e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie037b8583ad749bc9122949aec189228_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5718b7dcecd84defac7a854084c0bf25_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice580bea9a0e497face411c0858d3839_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26c711accea64d95bdd1a6048b3bc497_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide639614f81d4101bd26fa5346aa6494_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e2147b6a2c4b3e97bebda7cfdbb8a8_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69c49af6cac24b6aaf78ac9bf15ebf13_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59310ff945004ea6a249b2f169b44e59_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2ffb053e94f427c97510610790a7fa1_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f066209f19547159b014cc341b71222_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6abb9ba6ee941bf966fb2b8bdb7c6eb_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33fe3c37c9e4d0e83192b2e14809965_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia166fd55b459460880c354bf9715e1c8_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55343bda1c447eaaec24e61aced15a2_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4da49014e834ce4a25784b67ff9a020_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie33ee4113b464bb8805d9fd13ec03adc_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ccf4e0d483843eb99b3aae67e446fb1_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic692135e06904b4e9f53251b1bda6e6a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12696a9f70bb4520879173dd02953d2e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6443bf806be740278539f1341106b36e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d73fb71dcc4abba01472ab63322c3d_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b172a5ff906435aadf5f99c85c38a22_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5706545d66894d3d921d401e933a36d5_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ebd3eeeea5e4c2f8ffd32d9ad345d16_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:MINNEBROMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2544c6fb6a9b4a6fa37e6ca31e607dbb_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:MINNEBROMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914e005fdf1940ce8583162f9bd6ea5c_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithCatalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc77b7509ab54848ab388e7bd8d55ff7_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithCatalentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ccf58a565b40458488b69646144466_D20200104-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithNBETherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib21b7306bafe44138821e7d078f9b318_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithNBETherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>exel:program</xbrli:measure></xbrli:unit><xbrli:context id="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6901a20ec19b4d62afcecb76296051f6_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1dacedabe3d4737800441a7d9194116_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i955e5bb70aeb486b8c2d62388f3e44a0_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i983d2a459669479ea167c4f7883b0a2a_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d59bfad27b4babaf33ea9828f5e7db_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b3fd10a6b8e4b88964207e8afc24c36_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f84a4833d5496fafe3fb2b06ee4da2_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:AdditionalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18fefd085e3c45968805d31566f5a911_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:ProductCommercializationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bf737b2abae44928037ed75a133e223_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DiscoveryProjectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81c0e0276859476d8764f5e4a7c6a702_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5be837eaece4b1e827b2ac075babd6c_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:FirstProductToReachMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d081623400481896632ff697c68f09_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af67120954b4cc4a261206766a42684_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719d03a237a8464abb14ec240d32bb64_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dc5c758e799403d8bf389459a614860_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30b2890deda415d995921e5add2f92e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3abfb693aa34441595492bf56588fe6f_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a4320d1955404c9d175bf4c6946164_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d0a04be132f455c9b521c192c5d4816_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a6aa1d2955343a4891ce98d02c37c65_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia13a4caccaf947b896a2346494374f6d_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:context id="iaf372caf57ca4f559b15221706d0804e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0157be3fc964514bc2958bfb787c58a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fc6a38873324d77a83f8d597f112838_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0eaa96e028b4053b1efe87fba0c9717_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fc2641cbeaa48948ef1c5857c38598b_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i069a49e8f5be408d82aaa57b1a6719ac_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida017550b79b42f19804feb9178fe6eb_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d1bc6310d94e49a10dfa40633813f8_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d9fe388a10f409382aa696ce09464b2_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20ed515384c7421c990b3a08dbbd6099_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c49a80af73c4beba087da528040761f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c0f3562ea854a648ae333d957392a30_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7639ff188d85446bb4eb34d103edacad_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d5ef12d4ebf4f4cb3fc541d5b53ab44_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad45f83363a4cb8a086062be42c031e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1df0270288443da1ddfde204282b4e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e63c05de294a7cbe329b32c4008c0f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife44d28f1dee43d38997d75f2a09fa60_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i986255f527ad4a68a1be4173bed991ad_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c8c3490b0545f487d8a0d33ebd6813_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35781ca0758f401a8c144a5efb7fe50c_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if18b5f0c5ebb43f6b8c762bf61f6bda2_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb849f127a4644bf8dcdc6b5433726b0_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d84ea6c5fb486b9667f60233ed45e3_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7119ffed0114f1ba08264ccb9cca54b_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if934e0098e2b485187fb3417498f8c7f_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc5bb0744d9e4ad8afb77bb50648a4eb_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39b2e5c3b01d455c8647c0de87550b58_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8094749dc1cf43faa8d4a49cc37284a4_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id214d22093b342b5bb46f742fa9a8d1d_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa35986fd3ca43b8a2ae20dce6d9597d_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402214e5b6cd492ea640e28a56b8c84e_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf947a15c2442f7b9c355990703eea0_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id59418bb9d714b4aa3e6fca17c908d91_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia39618bc0e2441e6a4d20c14598583b9_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if21e1073886448ea9bd7d5e0a33dfbf3_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6557679589e544abacc2ec388a331430_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5519e86b5a4926b1ec10602426647e_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62e1b62fcdc14ca6a9f31d5d9be0052f_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac617d311944d31900ede53774bb2e2_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a8ac00f5aec4ccabaefa0b0d9356610_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838461c261004859a7bee283a1308e10_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84bd021da59c4253a45563017be7db6d_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i860abaa1da4847479d900fa60c22e404_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6cf0349c204074bedad9d2664384d1_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b8747a320f44fe4a77fe534734d347a_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d449cb77a0446d693fd6c3747eba20d_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f0498a995a2400bbec4140ae912e037_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0bd3de5abe4d67bbbb22990c63c5a0_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5915973202f4822a05789837fd15e95_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9908b52633254703886d1ac7263e2148_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29200dad69e047a8b7cbecb940c93115_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1bacc0a00bf43eba9ebd3d73dc83589_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f71d3e4f66641b59129ea1f7de0d2cf_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42ce43d4b56040f2843d79745b7c30b1_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i311c3d1a54394d4a813f2d882cd22021_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee23e46acdf243f48669d23de632fc77_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib25087bb5db74d7892082c9d2e8abbb9_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820a33ad0ad94d8bafca231d31e69e59_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1cc29eb8f243d28b13b3d0dca0006a_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986427a5d3f3498d96c6bb4bbd51dfe2_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44d1190b6c354c31b284d1b82fbdecea_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bceefc7e604400898f9025b1854d66c_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1948960d554e495d831941884b909a9f_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if16546baee294f93bd2321559abcd2b2_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i848fd90527f24228a2613e80e7e75990_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea1e1804983544d4b95b89863885736c_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e926b7757e84307b3dcf2ffb4e5018e_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i387d9657f5c347799d82def766e2b85c_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30cc87f6da8e43de85cc36cc45397719_D20200520-20200520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-20</xbrli:startDate><xbrli:endDate>2020-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff59e3f4289c4d0ab16af9324d631d8e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ce9985487045a6bbff1b6565bb56c1_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b8d59c75c8249ba84de243ad87e2493_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49dea6f971c2436c9436d84debc9c88a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaccd048b7b154d2f9b562e5fe5bbec80_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474cd4190d014fb9afd7d07dbde355fc_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f2592c3afb4c108a552d2de2e9f677_I20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e626170338d40c684a71ad8956f3dc8_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed65fc14d1f42458a26dcd149381df1_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i630c039e42614958998ad44ba50df6a3_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd5c77b48af4ab390becbba00955ec9_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48fddf5f44ab4d8295e428acbb15cc42_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae79675a497d45819d1a3047a416388b_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6987ce3f2e0b4c65ba714f40a364ffbd_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesClinicalTrialResultsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cbb645856904aa9809681fb8a88fa50_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d6b47f808c84efd8f867da26a8406f6_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74084a38afc04950ad513c20f60c8d62_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aeea19c58964ece8f259c21248b26ca_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8b3be356ff4b8c971e27c9baa061e5_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22de33cb9fa4466693147fb2b3a08fde_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f1e640f034c4c9a8c524f75ba45a4ab_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd294e2e4ab4132b8b50c9a18c91bd6_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i728bdf824bce4e3a8e6c9be0a205fc81_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib61e2f06dd994f53bfa706d07d66963c_D20181229-20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2020-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36021c41bb5446e8080959a3441b6a9_D20180101-20181228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i2793983ce6e243b5ad8af2ec5ec6c289_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6703fce613684225b4063ab7dc405264_I20210601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewal_option"><xbrli:measure>exel:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="i655272f3bcac4b5e8db4788f93444fb2_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3a848bbc8a48e9aa6faab6645fee01_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5942d56a0a5c4771a6eaf148a1122cca_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerSqft"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie2db56eb211748d2a452eafb230ca08e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60096daf93c14de585b95a04778a59d9_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19a576c9dd734120a4d6a896a2880fb4_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-04</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9976757837ac4b5ab75920208383f366_D20201003-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-03</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-30</xbrli:startDate><xbrli:endDate>2019-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-29</xbrli:startDate><xbrli:endDate>2019-09-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_1"></div><div style="min-height:36pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">FORM </span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MjViOTBiYzRkMDM0NDU2MDg5OTcyNjBlZGU1YmYzMmIvdGFibGVyYW5nZToyNWI5MGJjNGQwMzQ0NTYwODk5NzI2MGVkZTViZjMyYl8wLTEtMS0xLTA_407d3e23-7029-4182-9deb-37f14964955e">10-K</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTcx_5aa169d3-0638-486b-9896-f33afd6fd8c1">&#9746;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8xOTY_8100a2d3-9ba1-4fd9-9098-70fe8c8351e8"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8xOTY_9c6dac3f-b525-4e0f-9efe-d3bea642f12e">January&#160;1</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTcy_335f9ddb-9cde-428e-88e2-eec39f909924">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the transition period from               to                     </span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMTc_1a2d546d-3753-48fe-961c-158fc7912210">000-30235</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:204.00pt"><tr><td style="width:1.0pt"></td><td style="width:202.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20210101_g1.jpg" alt="exel-20210101_g1.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:148px"/></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6YzhhM2YxYmRjNzIwNDI5M2JlZGUzYjZmNzZjZGU0YWUvdGFibGVyYW5nZTpjOGEzZjFiZGM3MjA0MjkzYmVkZTNiNmY3NmNkZTRhZV8xLTAtMS0xLTA_77d5e7c6-3066-4d92-acf1-94b4ced29d83">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTE3OTMzZjM5OGMxNDhjMjgxNjdkZWM3NjcxYjRkMjMvdGFibGVyYW5nZToxMTc5MzNmMzk4YzE0OGMyODE2N2RlYzc2NzFiNGQyM18wLTAtMS0xLTA_c5ce9fca-b881-4ab4-8bb4-e8a809329c4e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTE3OTMzZjM5OGMxNDhjMjgxNjdkZWM3NjcxYjRkMjMvdGFibGVyYW5nZToxMTc5MzNmMzk4YzE0OGMyODE2N2RlYzc2NzFiNGQyM18wLTEtMS0xLTA_9efb2cb6-39dc-4527-8b08-4befb52d5a16">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMzA_17a5e658-9e17-437f-b89a-87dd55737cfd">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMzQ_cdebb02a-9d05-42db-9016-aed081d8ee69">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMzc_88360484-4923-49aa-a7de-e105fdbd9f56">CA</ix:nonNumeric> <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNDA_c5c79ba9-0c1e-460d-88ad-2382bbe54af0">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNDU_99885d73-6346-400e-ba99-a3cadf86b219">650</ix:nonNumeric>) <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNDk_d6e82757-08ee-4603-bf82-4a14bb9e6bab">837-7000</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6ZTI4NGFiYWIwZjQxNDkxYWJiODc5YzBlNjZlYjk3NjMvdGFibGVyYW5nZTplMjg0YWJhYjBmNDE0OTFhYmI4NzljMGU2NmViOTc2M18xLTAtMS0xLTA_d90ffebc-39fc-4c63-8aec-a784758019fd">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6ZTI4NGFiYWIwZjQxNDkxYWJiODc5YzBlNjZlYjk3NjMvdGFibGVyYW5nZTplMjg0YWJhYjBmNDE0OTFhYmI4NzljMGU2NmViOTc2M18xLTEtMS0xLTA_8ef824db-5e98-4e9c-9bb2-34b806d1d9f0">EXEL</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6ZTI4NGFiYWIwZjQxNDkxYWJiODc5YzBlNjZlYjk3NjMvdGFibGVyYW5nZTplMjg0YWJhYjBmNDE0OTFhYmI4NzljMGU2NmViOTc2M18xLTItMS0xLTA_b9bc0129-342d-4be7-9372-68cdc15670a6">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTcz_71364c1b-fe65-413d-a735-353a01310cb4">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTc0_93e54b47-11a5-450e-b552-c87a3d872442">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTY5_a71c78a7-a219-4b45-a6c7-6af1ecb0faeb">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTY2_3325aacf-b662-4734-9618-f38ed6b04008">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTNhNjg2YmNiMjRhNGI3Y2FlZmU4Y2NhZWE1OTQ5NDMvdGFibGVyYW5nZToxM2E2ODZiY2IyNGE0YjdjYWVmZThjY2FlYTU5NDk0M18wLTAtMS0xLTA_8e3225ad-6b4d-4b5d-832b-4ddba4ced85e">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTNhNjg2YmNiMjRhNGI3Y2FlZmU4Y2NhZWE1OTQ5NDMvdGFibGVyYW5nZToxM2E2ODZiY2IyNGE0YjdjYWVmZThjY2FlYTU5NDk0M18xLTQtMS0xLTA_ac268a1c-cf2a-49f6-9a28-be2a8bcf8001">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTNhNjg2YmNiMjRhNGI3Y2FlZmU4Y2NhZWE1OTQ5NDMvdGFibGVyYW5nZToxM2E2ODZiY2IyNGE0YjdjYWVmZThjY2FlYTU5NDk0M18yLTQtMS0xLTA_a922d05d-9c8b-4c0b-bb83-5863410e1f7e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8xODE0MTk0MTg2Mjc5OA_b89cf926-5220-4705-97f3-97b24bcc3fa1">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTY3_9941c610-3c47-4de3-b210-bddadcb7ef2c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter: $<ix:nonFraction unitRef="usd" contextRef="ib4fd9aaa36234bf69289fc29d0946344_I20200703" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8yNTk5_f942afee-00a1-44d2-93fb-42dc0b46d0f3">6,399,562,142</ix:nonFraction>. Excludes shares of the registrant&#8217;s common stock held by persons who were </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">directors and/or executive officers of the registrant at&#160;July&#160;3, 2020&#160;on the basis that such persons may be deemed to have been affiliates of the registrant at such date. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Number shares of the registrant&#8217;s common stock outstanding as of February&#160;1, 2021: <ix:nonFraction unitRef="shares" contextRef="ic1de7713dd784687b13406c4c8917075_I20210201" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMTkz_0512a829-8d69-47d5-90e5-fc968c0f6bf6">311,989,661</ix:nonFraction> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTY4_e31e128a-46ff-48e8-8622-c292f59e64f3" escape="true">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than May 3, 2021, in connection with the registrant&#8217;s 2021 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_10">PART&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_16">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_19">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_22">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_25">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_28">59</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_31">PART&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_34">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_37">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_37">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_40">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_55">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_55">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_58">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_58">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_139">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_139">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_142">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_142">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_145">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_145">123</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_148">PART&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_151">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_151">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_154">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_154">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_157">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_157">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_160">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_160">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_163">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_163">124</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_166">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_169">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_169">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_172">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_172">129</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_175">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_175">130</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of the statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business&#8221; and elsewhere in this Annual Report on Form&#160;10-K are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed under the heading &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading &#8220;Item 1A. Risk Factors&#8221; below.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Legislation and regulatory action designed to facilitate the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the revenue we derive from our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">We are subject to healthcare laws, regulations and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy for those products sufficiently impressive to compete in our highly competitive market environment.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">The regulatory approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for cabozantinib or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance, which subjects us to a number of risks. For example, we rely  on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S. In addition, our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Data breaches, cyber attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BASIS OF PRESENTATION</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2021, January 3, 2020 and December 28, 2018 are indicated as being as of and for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_13"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program, and is being investigated both alone and in combination with other therapies in a wide variety of cancers. The growth that we have experienced in recent years is largely attributable to cabozantinib&#8217;s clinical and commercial success; consistent with our values and legal obligations, we are committed to ensuring that all patients who are prescribed cabozantinib are able to access this critical medicine.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo). For additional information about these products, see &#8220;&#8212;Collaborations&#8212;Other Collaborations.&#8221;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the course of 2020, revenues from CABOMETYX and COMETRIQ sales and from the royalties and milestone payments we have received pursuant to collaboration agreements with our partners, coupled with disciplined expense management, fueled the growth of our organization. We believe in our long-term growth prospects, which are supported by a healthy cash position and annual profitability over the past four fiscal years. We have and plan to continue to utilize our cash and investments to maximize the likelihood of future success by expanding the development program for the cabozantinib franchise, and by advancing and expanding our pipeline of new drug candidates through drug discovery efforts, which include several research collaborations and in-licensing arrangements and has resulted in two compounds entering the clinic. The following report details the progress we have made executing our growth strategy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis Marketed Products: CABOMETYX and COMETRIQ</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products have been approved to treat patients with various forms of cancer by the U.S. Food and Drug Administration (FDA), the European Commission (EC), the Japanese Ministry of Health, Labour and Welfare (MHLW) and other regulatory authorities across major markets worldwide.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approval Date</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Regimen</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Major Markets</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="11" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX&#174;<br/>(cabozantinib)</span></td><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RCC</span></td></tr><tr style="height:51pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patients with advanced RCC who have received prior anti-angiogenic therapy</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 25, 2016</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:42pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advanced RCC in adults following prior VEGF-targeted therapy</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 9, 2016</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:33pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 19, 2017</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:56pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-line treatment of adults with intermediate- or poor-risk advanced RCC</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 17, 2018</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with curatively unresectable or metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2020</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line treatment of patients with advanced RCC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 22, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination with OPDIVO&#174; (nivolumab)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:15pt"><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HCC</span></td></tr><tr style="height:38pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCC in adults who have previously been treated with sorafenib</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2018</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with HCC who have been previously treated with sorafenib</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 14, 2019</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:53pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with unresectable HCC that has progressed after cancer chemotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 27, 2020</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ&#174;<br/>(cabozantinib)</span></td><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MTC</span></td></tr><tr style="height:35pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients with progressive, metastatic MTC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2012</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:65pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adult patients with progressive, unresectable locally advanced or metastatic MTC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 25, 2014</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monotherapy</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, 2019 and 2018, we generated $741.6 million, $760.0 million and $619.3 million, respectively, in net product revenues from sales of CABOMETYX and COMETRIQ in the U.S. Outside the U.S. and Japan, CABOMETYX and COMETRIQ are marketed by our collaboration partner Ipsen Pharma SAS (Ipsen), and in Japan, CABOMETYX is marketed by our collaboration partner Takeda Pharmaceutical Company Limited (Takeda). In 2020, 2019 and 2018, we earned $78.4 million, $62.4 million and $32.3 million, respectively, of royalties on net sales of cabozantinib products outside of the U.S. For additional information on the terms of our collaboration agreements with Ipsen and Takeda, see &#8220;&#8212;Collaborations&#8212;Cabozantinib Commercial Collaborations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Renal Cell Carcinoma - CABOMETYX is a Leading Tyrosine Kinase Inhibitor (TKI) Treatment Option for Patients with Advanced RCC</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kidney cancer is among the top ten most commonly diagnosed forms of cancer among both men and women in the U.S. Estimates suggest that approximately 32,000 patients in the U.S. and over 71,000 worldwide will require systemic treatment for kidney cancer in 2021, with nearly 15,000 patients in need of a first-line treatment in the U.S. A growing number of these patients with RCC have been or will be treated with CABOMETYX, which has become a standard of care for the treatment of patients suffering from this difficult-to-treat disease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since CABOMETYX was first approved, we have deployed our promotional and medical affairs teams to educate physicians about CABOMETYX&#8217;s unique clinical profile. We believe that the success of CABOMETYX is attributable to this clinical profile, which incorporates the results of the METEOR, CABOSUN and CheckMate -9ER clinical trials. In July 2015, we announced positive results of METEOR, a phase 3 pivotal trial comparing CABOMETYX to everolimus in patients with advanced RCC who have experienced disease progression following treatment with at least one prior VEGF receptor inhibitor. These results formed the basis for the FDA&#8217;s approval in April 2016, following which CABOMETYX became the first and only single-agent therapy approved for previously treated advanced RCC to demonstrate statistically significant and clinically meaningful improvements in three key efficacy parameters in a global pivotal trial: overall survival (OS); progression-free survival (PFS); and objective response rate (ORR). Subsequently, in October 2016, we announced positive results from CABOSUN, a randomized, open-label, active-controlled phase 2 trial conducted by the Alliance for Clinical Trials in Oncology, comparing cabozantinib with sunitinib in patients with previously untreated advanced RCC with intermediate- or poor-risk disease. These results formed the basis for the FDA&#8217;s approval in December 2017 of CABOMETYX for previously untreated patients with advanced RCC, and for this patient population, CABOMETYX is the only approved single-agent therapy to improve PFS compared with sunitinib, a first-generation TKI that was the previous standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CABOMETYX has also demonstrated strong clinical results in combination with immune checkpoint inhibitors (ICIs), most notably the positive results from CheckMate -9ER, an open-label, randomized, multi-national phase 3 pivotal trial evaluating OPDIVO, an ICI developed by BMS, in combination with CABOMETYX versus sunitinib in patients with previously untreated, advanced or metastatic RCC. Results from CheckMate -9ER formed the basis for the FDA&#8217;s approval of the combination in January 2021 as a first-line treatment of patients with advanced RCC. For additional information about CABOMETYX&#8217;s efficacy in combination with ICIs, including as demonstrated in the CheckMate -9ER clinical trial data, see &#8220;&#8212;Exelixis Development Programs&#8212;Cabozantinib Development Program&#8212;Trials Conducted under our Clinical Collaboration Agreements.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In markets outside the U.S. in 2020, we continued to work closely with our collaboration partner Ipsen in support of its regulatory strategy and commercialization efforts for CABOMETYX as a treatment for advanced RCC, both as a single agent and in preparation for potential approvals of CABOMETYX in combination with other therapies, and similarly with our collaboration partner Takeda with respect to the Japanese market. As a result of the approvals of CABOMETYX for RCC indications in 57 countries outside of the U.S., including the Member States of the EU, Japan, Canada, Brazil, Taiwan, South Korea and Australia, CABOMETYX has continued to grow outside the U.S. both in sales revenue and the number of RCC patients benefiting from its clinical effect. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hepatocellular Carcinoma - the CABOMETYX Label Expanded to Include Previously Treated HCC</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to published studies, liver cancer is a leading cause of cancer death worldwide, accounting for more than 800,000 deaths and 900,000 new cases each year. In the U.S., the incidence of liver cancer has more than tripled since 1980. Although HCC is the most common form of liver cancer, making up about three-fourths of the more than 42,000 cases of liver cancer estimated to be diagnosed in the U.S. during 2021, this patient population has long been underserved. Prior to 2017, there was only one approved systemic therapy for the treatment of HCC. Since that time, multiple new therapies were approved in the U.S. for HCC, both for previously untreated patients and for patients previously treated with sorafenib. Given the introduction of new and demonstrably more effective therapies, including ICI combination therapies, we believe the second- and later-line market for HCC therapies has the potential to grow significantly in coming years, as these new treatment options are expected to improve longer-term outcomes, thereby resulting in a greater number of patients receiving multiple lines of therapy. With the approval of CABOMETYX in January 2019 for HCC patients previously treated with sorafenib, we expect to continue to play a key role in the treatment landscape for these patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s approval of CABOMETYX&#8217;s HCC indication was based on our phase 3 pivotal study, CELESTIAL. The CELESTIAL study met its primary endpoint, demonstrating that cabozantinib significantly improved OS, as compared to placebo. The National Comprehensive Cancer Network has included CABOMETYX in its Clinical Practice Guidelines for </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hepatobiliary Cancers as a Category 1 option for the treatment of patients with HCC (Child-Pugh Class A only) who have been previously treated with sorafenib, providing further support for CABOMETYX as an important treatment option for eligible HCC patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the EC&#8217;s approval of CABOMETYX provided physicians in the EU with a second approved therapy for the second-line treatment of this aggressive and difficult-to-treat cancer, and approvals from Health Canada and the Japanese MHLW brought a much-needed therapy to HCC patients in those countries. In addition to the Member States of the EU, Japan and Canada, CABOMETYX is also approved for previously treated HCC indications in Taiwan, South Korea, Australia and Hong Kong, among other countries.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medullary Thyroid Cancer - COMETRIQ, the First Commercial Approval of Cabozantinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates suggest that there will be approximately 900 MTC cases diagnosed in the U.S. in 2021, and COMETRIQ has served as an important treatment option for these patients since November 2012. The FDA&#8217;s approval of COMETRIQ for progressive, metastatic MTC was based on our phase 3 trial, EXAM. The EXAM trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful prolongation in PFS for cabozantinib, as compared to placebo. In connection with the approval of COMETRIQ for the treatment of progressive, metastatic MTC, we were subject to post-marketing requirements, including a requirement to conduct the EXAMINER clinical study, comparing a lower dose of cabozantinib with the labeled dose of 140 mg. For additional information on the EXAMINER post-marketing study, see &#8220;&#8212;Exelixis Development Programs&#8212;Cabozantinib Development Program&#8212;Late-Stage Exelixis Sponsored Trials Evaluating Cabozantinib as a Monotherapy&#8212;MTC - EXAMINER.&#8221; </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis Development Programs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our mission to help cancer patients recover stronger and live longer, we deploy our resources and invest in clinical development programs designed to identify and advance potential new cancer therapies that prove to be both safe and effective. Most of our resources remain dedicated to exploring the use of cabozantinib in new indications as a single-agent or in combination with other therapies, and in the near-term our growth strategy will continue to focus on the achievement of positive clinical trial results and new regulatory approvals for cabozantinib. However, we are steadily advancing additional small molecules and biologics through our pipeline of potential development candidates. In 2020, in addition to the standard complexities typically associated with the execution of global clinical trials, we were also presented with new challenges arising from the COVID-19 pandemic, which required us to make operational adjustments to our clinical study programs both to preserve their scientific integrity and to protect the safety of patients.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more detailed discussion of the impact of the COVID-19 pandemic and our risk mitigation efforts, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;COVID-19 Update&#8221; in Part II, Item 7 and of this Annual Report on Form 10-K.      </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cabozantinib and other development programs is provided below.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cabozantinib inhibits the activity of tyrosine kinases, including MET, AXL, VEGF receptors, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance and maintenance of the tumor microenvironment. Objective tumor responses have been observed in patients treated with cabozantinib in more than 20 individual tumor types investigated in phase 1 and 2 clinical trials to date, reflecting the medicine&#8217;s broad clinical potential. We are currently evaluating cabozantinib, both as a single agent and in combination with ICIs, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple indications. We, along with our collaboration partners, sponsor some of those trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial (IST) program. In addition to co-funding select trials with us, our collaboration partners Ipsen and Takeda also conduct trials in their territories through similar independently-sponsored programs.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following two tables summarize select cabozantinib clinical development activities, one describing studies that evaluate the potential of cabozantinib as a single-agent, and the other describing studies that evaluate the potential of cabozantinib in combination with other therapies, including ICIs:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, SINGLE-AGENT</span></td></tr><tr><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#40aeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status Update</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thyroid Cancer</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Progressive, metastatic medullary thyroid cancer</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in U.S. and EU (EXAM)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Progressive, metastatic medullary thyroid cancer</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Post-marketing study (EXAMINER)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Differentiated thyroid cancer (DTC)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (COSMIC-311)</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Renal Cell Carcinoma (RCC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in U.S., EU and Japan (METEOR and CABOSUN)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First- or second-line papillary RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randomized phase 2&#8224; (PAPMET/SWOG S1500)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic Variant Histology RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (CABOSUN II)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Locally Advanced Non-Metastatic Clear Cell RCC</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hepatocellular Carcinoma (HCC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second- and later-line HCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in U.S., EU and Japan (CELESTIAL)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced HCC with Child-Pugh class B cirrhosis after first-line therapy</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Small Cell Lung Cancer (NSCLC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular alterations in RET, ROS1, MET, AXL, or NTRK1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Trials </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-risk prostate cancer</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (SPARC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic castration-resistant prostate cancer (mCRPC) with genomic alterations</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic urothelial carcinoma (UC)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (ATLANTIS)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorectal cancer (CRC)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-grade uterine sarcomas</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#167;</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic gastrointestinal stromal tumor</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#167; (CABOGIST)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pancreatic neuroendocrine tumors and carcinoid tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* and Phase 3&#8224; (CABINET)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plexiform neurofibromas (pediatric and adult cohorts)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neuroendocrine neoplasms</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Relapsed osteosarcoma or Ewing sarcoma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224; (CABONE)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soft-tissue sarcomas</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Trial conducted through our IST program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224; &#160;&#160;&#160;&#160;Trial conducted through collaboration with NCI-CTEP.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#167; &#160;&#160;&#160;&#160;Trial sponsored by the European Organization for Research and Treatment of Cancer.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, IN COMBINATION WITH OTHER THERAPIES</span></td></tr><tr><td colspan="3" style="background-color:#40aeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="background-color:#40aeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Combination Regimen</span></td><td colspan="3" style="background-color:#40aeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status Update</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Genitourinary Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line advanced RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Approved in U.S. (CheckMate -9ER)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line advanced or metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (COSMIC-313)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">mCRPC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (CONTACT-02)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced RCC who progressed during or following treatment with an immune checkpoint inhibitor</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (CONTACT-03)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab vs. nivolumab after 4 cycles of nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3&#8224; randomized (PDIGREE)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced or metastatic non-clear cell RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced RCC with bone metastasis</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ radium-223 dichloride</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224; (RadiCal)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cisplatin-Ineligible advanced UC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (PemCab)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neoadjuvant muscle-invasive UC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (ABATE)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genitourinary tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab &#177; ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1b&#8224;</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Genitourinary tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224; (ICONIC)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced non-clear cell RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic RCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab after cytoreductive surgery</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* (Cyto-KIK)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic RCC</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ avelumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1b*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gastrointestinal Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-line advanced HCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (COSMIC-312), including a single-agent cabozantinib arm</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second- and later-line advanced HCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab &#177; ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1/2 (CheckMate 040)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neoadjuvant locally advanced HCC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#177; nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1b*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCC who are not candidates for curative intent treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab + transarterial chemoembolization</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced HCC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thyroid Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced DTC</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lung Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic NSCLC</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 3 pivotal trial (CONTACT-01)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously treated non-squamous NSCLC</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#177; nivolumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gynecologic Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced or metastatic endometrial cancer</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic, triple negative breast cancer</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroendocrine Tumors (NET) and Carcinoid</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced carcinoid tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poorly differentiated neuroendocrine carcinomas</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Head and Neck Cancers</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurrent, metastatic squamous cell carcinoma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ cetuximab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recurrent, metastatic squamous cell carcinoma</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Melanoma</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresectable, advanced melanoma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab + ipilimumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced, metastatic melanoma</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sarcoma</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ temozolomide</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2* </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sarcomas of the extremities</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ radiation therapy</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic soft tissue sarcomas</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ PD-1 + CTLA-4 inhibition</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angiosarcoma pre-treated with taxane</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ nivolumab</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2&#8224;</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Trials in Multiple Tumor Types</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced solid tumors</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ atezolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1b with 20 cabozantinib and atezolizumab expansion cohorts, including mCRPC (pivotal cohort), RCC, UC, HCC, colorectal adenocarcinoma, DTC, NSCLC, endometrial cancer, ovarian cancer, breast cancer, gastric or gastroesophageal junction adenocarcinoma and head and neck cancer, and three single-agent cabozantinib exploratory cohorts (UC, NSCLC and mCRPC), and one single-agent atezolizumab exploratory cohort (mCRPC) (COSMIC-021)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced CRC, HCC, gastric, gastroesophageal or esophageal adenocarcinoma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ durvalumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1* (CAMILLA)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metastatic or recurrent gastric or gastro-esophageal adenocarcinoma</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pembrolizumab</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 2*</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced non-squamous NSCLC, UC and advanced malignant mesothelioma</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ pemetrexed</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1*</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Trial conducted through our IST program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224; &#160;&#160;&#160;&#160;Trial conducted through collaboration with NCI-CTEP.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#167; &#160;&#160;&#160;&#160;Trial sponsored by the European Organization for Research and Treatment of Cancer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late-Stage Exelixis Sponsored Trials Evaluating Cabozantinib as a Monotherapy</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Differentiated Thyroid Cancer (DTC) - COSMIC-311. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Published studies indicate that approximately 44,000 new cases of thyroid cancer will be diagnosed in the U.S. in 2021. Differentiated thyroid tumors, which make up about 90% of all thyroid cancers, are typically treated with surgery followed by ablation of the remaining thyroid with radioiodine (RAI). Approximately 5% to 15% of differentiated thyroid tumors are resistant to RAI treatment. With limited treatment options, these patients have a life expectancy of only three to six years from the time metastatic lesions are detected. New treatment options are therefore urgently needed.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 we announced that COSMIC-311, our ongoing phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two prior VEGF receptor-targeted therapies, met its co-primary endpoint of demonstrating significant improvement in PFS. Cabozantinib reduced the risk of disease progression or death by 78% with a hazard ratio (HR) of 0.22 (96% confidence interval [CI] 0.13 &#8211; 0.36; p&lt;0.0001). The safety profile of cabozantinib observed in the study was consistent with the established profile of cabozantinib, and no new safety signals emerged. Given these results, the independent data monitoring committee for the study recommended to stop enrollment and unblind sites and patients. We intend to discuss the study results, proposed changes to the study conduct, as well as plans for filing a supplemental New Drug Application (sNDA) with the FDA in 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MTC - EXAMINER. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the approval of COMETRIQ for the treatment of progressive, metastatic MTC, we were subject to post-marketing requirements, including a requirement to conduct the EXAMINER clinical study, comparing a lower 60 mg dose of cabozantinib (tablet formulation) with the labeled dose of 140 mg (capsule formulation). EXAMINER evaluated </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 as assessed by independent </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review as a primary endpoint, as well as ORR and safety as secondary endpoints, in </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progressive, metastatic MTC patients. EXAMINER was designed as a non-inferiority trial for PFS comparing 60 mg cabozantinib (tablet formulation) with 140 mg cabozantinib (capsule formulation). EXAMINER did not reach its primary endpoint. We intend to submit the results of EXAMINER to regulatory authorities as part of our post-marketing requirements, and we will continue to market COMETRIQ capsules for MTC patients consistent with the existing approval. Detailed results of the study will be presented at an upcoming medical conference.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trials Conducted Under our Clinical Collaboration Agreements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cabozantinib has shown clinical anti-tumor activity with objective responses observed in more than 20 forms of cancer in phase 1 and 2 evaluation; we are, therefore, focused on advancing a broad cabozantinib clinical development program to fully investigate its therapeutic potential, both alone and in combination with other therapies. In particular, given that clinical observations from clinical trials evaluating cabozantinib in combination with ICIs have shown preliminary promising activity across a diverse range of tumors, and that patients have been able to tolerate these drug combinations, we are focused on exploring the potential of cabozantinib in combination with ICIs in late-stage or other potentially label-enabling trials. </span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Combination Studies with BMS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our development strategy for the cabozantinib franchise, in February 2017, we entered into a clinical collaboration agreement with BMS for the purpose of conducting clinical studies combining cabozantinib with BMS&#8217; PD-1 ICI, nivolumab, both with or without BMS&#8217; CTLA-4 ICI, ipilimumab. As part of this collaboration, we are evaluating these combinations in two phase 3 pivotal trials in previously untreated advanced RCC and in a phase 1/2 trial in both previously treated and previously untreated advanced HCC. We may also evaluate these combinations in other clinical trials in various other tumor types. Pursuant to our agreements with BMS, each party will be responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each trial will be determined on a trial-by-trial basis. For additional information on the terms of the clinical trial collaboration agreement, see &#8220;&#8212;Collaborations&#8212;Cabozantinib Development Collaborations&#8212;BMS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RCC - CheckMate -9ER</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced positive results from CheckMate -9ER, an open-label, randomized, multi-national phase 3 pivotal trial evaluating nivolumab in combination with cabozantinib versus sunitinib in patients with previously untreated, advanced or metastatic RCC. Patients were randomized 1:1 to receive either 40 mg of cabozantinib daily and 240 mg of nivolumab every 2 weeks, or 50 mg of sunitinib daily on a 4-weeks-on/2-weeks-off schedule. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial met its primary endpoint of PFS at final analysis, as well as its secondary endpoints of OS at a pre-specified interim analysis and ORR. The combination of cabozantinib with nivolumab: significantly reduced the risk of disease progression or death compared with sunitinib (HR=0.51; 95% CI 0.41 to 0.64; p&lt;0.0001); significantly improved OS, reducing the risk of death by 40% compared with sunitinib (HR=0.60; 98.89% CI 0.40 to 0.89; p&lt;0.0010); and demonstrated a superior ORR of 56% versus 27% for sunitinib. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety profile of the combination observed in the study was consistent with the established profile of each agent. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from CheckMate -9ER were presented at Presidential Symposium I at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 in September 2020 and </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be presented at the virtual American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in February 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the data from the CheckMate -9ER trial, the FDA approved the combination of CABOMETYX and OPDIVO on January 22, 2021 as a first-line treatment of patients with advanced RCC, and we and BMS commenced the commercial launch of the combination upon such approval. Additionally, in September 2020, the EMA validated the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">type II variation applications submitted by Ipsen and BMS to approve the combination of CABOMETYX and OPDIVO as a treatment for advanced RCC and commenced the EMA&#8217;s centralized review process. Both Ipsen and BMS have also submitted applications to approve the combination in territories beyond the EU, including Australia, Canada and Brazil, and plan to submit additional applications in other territories. In October 2020, Takeda and Ono Pharmaceutical Co., Ltd. (Ono), BMS&#8217; development and commercialization partner in Japan, submitted a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RCC - COSMIC-313. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we initiated COSMIC-313, a multicenter, randomized, double-blinded, controlled phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. The study aims to enroll approximately 840 patients at up to 180 sites globally. Patients are being randomized 1:1 to the experimental arm of the triplet combination of cabozantinib, nivolumab and ipilimumab or to the control arm of nivolumab and ipilimumab in combination with matched placebo. The primary endpoint for the trial is PFS, and secondary endpoints </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include OS and ORR. Based on recent publication of long-term follow-up results for CheckMate 214, in which the combination of nivolumab and ipilimumab showed a longer median OS compared to original assumptions, we expanded the enrollment target for COSMIC-313 to 840 patients to provide additional power to assess the secondary endpoint of OS for COSMIC-313, and we expect to complete the expanded enrollment in early 2021 and report top-line results of the event-driven analyses from the trial in 2022. We are sponsoring COSMIC-313, and BMS is providing nivolumab and ipilimumab for the study free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HCC- CheckMate 040</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. CheckMate 040 is a large, multi-cohort phase 1/2 trial in patients with previously treated and previously untreated advanced HCC, including a cohort evaluating treatment regimens that include cabozantinib in combination with nivolumab or in combination with both nivolumab and ipilimumab. This cohort was designed to enroll approximately 30 patients into each of two groups, with one group receiving 40 mg of cabozantinib daily and 3 mg/kg of nivolumab every two weeks, and the other group receiving 40 mg of cabozantinib daily, 3 mg/kg of nivolumab every two weeks and 1 mg/kg ipilimumab every six weeks. The primary endpoints for the cohorts are safety and tolerability and ORR; secondary endpoints include duration of response (DOR), PFS and OS. Results for CheckMate 040 were presented at the ASCO Gastrointestinal Cancers Symposium in January 2020. For the 36 patients treated with the combination of cabozantinib and nivolumab, ORR was 19%, and DCR was 75%. Median PFS was 5.4 months, and median OS was 21.5 months. For the 35 patients treated with the combination of cabozantinib, nivolumab and ipilimumab, ORR was 29%, and DCR was 83%. Median PFS was 6.8 months, and median OS had not yet been reached as of the data cut-off date. The safety profile of the combinations observed in the study were consistent with the established profile of each agent, and no new safety signals emerged.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Combination Studies with Roche</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diversifying our exploration of cabozantinib combinations with ICIs, in February 2017, we entered into a master clinical supply agreement with F. Hoffmann-La Roche Ltd. (Roche) for the purpose of evaluating cabozantinib and Roche&#8217;s anti-PD-L1 ICI, atezolizumab, in locally advanced or metastatic solid tumors. As part of the clinical supply agreement, we are evaluating this combination in a phase 1b trial in locally advanced or metastatic tumors and a phase 3 pivotal trial in previously untreated advanced HCC. Informed by the data generated from the phase 1b trial, COSMIC-021, we also entered into a joint clinical research agreement with Roche in December 2019, pursuant to which we are evaluating this combination in three late-stage clinical trials: the first, CONTACT-01, focuses on patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy; the second, CONTACT-02, focuses on patients with mCRPC who have been previously treated with one novel hormonal therapy; and the third, CONTACT-03, focuses on patients with inoperable, locally advanced or metastatic RCC who have progressed during or following treatment with an ICI as the immediate preceding therapy. For additional information on the terms of the joint clinical research agreement, see &#8220;&#8212;Collaborations&#8212;Cabozantinib Development Collaborations&#8212;Roche</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Locally Advanced or Metastatic Solid Tumors - COSMIC-021</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. We are the trial sponsor of COSMIC-021, and Roche is providing atezolizumab free of charge. The study is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion cohort phase, which is ongoing. The dose-escalation phase of the study determined the optimal dose of cabozantinib as 40 mg daily when given in combination with the standard atezolizumab dosing regimen of 1200 mg infusion once every 3 weeks. No dose-limiting toxicities or serious adverse events (AEs) were noted. Dose reductions and higher-grade AEs were less frequent with the 40 mg cabozantinib dosing cohort. Encouraging clinical activity was also observed. The safety profile of the combination in the dose-escalation phase of the trial was consistent with the established profile of each combination agent, and no new safety signals emerged.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Enrollment in the expansion stage of this study, which is currently ongoing, includes the following 20 combination tumor expansion cohorts:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with advanced non-squamous NSCLC without a defined tumor genetic alteration (EGFR, ALK, ROS1, or BRAF) who have not received prior therapy with an ICI;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with NSCLC without a defined tumor genetic alteration who have progressed following treatment with an ICI;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with NSCLC with an EGFR mutation who have progressed following treatment with an EGFR-targeting TKI for metastatic disease;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with UC who have progressed following treatment with an ICI;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with mCRPC who have previously received enzalutamide and/or abiraterone acetate without prior docetaxel for mCRPC and experienced radiographic disease progression in soft tissue;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with mCRPC who have previously received enzalutamide and/or abiraterone acetate with prior docetaxel therapy for mCRPC;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with mCRPC who have previously received enzalutamide and/or abiraterone acetate without prior docetaxel therapy for mCRPC;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with RCC with clear cell histology who have not received prior systemic anti-cancer therapy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with RCC with non-clear cell histology who have received no more than one prior VEGF receptor-targeted therapy and no other systemic anti-cancer therapy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with urothelial carcinoma (UC) who have progressed on or after platinum-containing chemotherapy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with UC who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with UC who are eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with triple-negative breast cancer who have progressed following treatment with at least one prior systemic therapy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with epithelial ovarian cancer who have platinum-resistant or refractory disease;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with endometrial cancer who have progressed following treatment with at least one prior systemic therapy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with advanced HCC who have a Child-Pugh score of A and have not received prior systemic anti-cancer therapy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with gastric or gastroesophageal junction adenocarcinoma who have progressed following treatment with platinum-containing or fluoropyrimidine-containing chemotherapy;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with colorectal adenocarcinoma who have progressed following treatment with systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan for metastatic disease;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with head and neck cancer of squamous cell histology who have progressed following treatment with platinum-containing chemotherapy; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">patients with DTC who are radio-refractory or deemed ineligible for treatment with iodine-131.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each expansion cohort was designed to initially enroll approximately 30 patients. However, based on continuing encouraging efficacy and safety data, certain cohorts have been and may be further expanded, including the cohorts of patients with NSCLC who have been previously treated with an ICI and mCRPC who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue. In addition, in order to address the contribution of components, there are three exploratory cohorts that will evaluate cabozantinib as a single-agent therapy in (1) patients with NSCLC without a defined tumor genetic alteration who have progressed following treatment with an ICI, (2) patients with UC who have progressed following treatment with an ICI and (3) patients with mCRPC, as well as a fourth exploratory cohort that will evaluate atezolizumab as a single-agent therapy in patients with mCRPC. We anticipate completing enrollment of up to 1,732 patients in the trial in the first half of 2021, although both the timing and final number of patients are subject to the initiation of additional cohorts or expansion of selected existing cohorts, as well as any further delays resulting from the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the initiation of the trial, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, CONTACT-01, CONTACT-02 and CONTACT-03. Encouraging results from interim analyses from the mCRPC, NSCLC, clear cell RCC and non-clear cell RCC cohorts of COSMIC-021, which were presented at various medical conferences throughout 2020, are described below: </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">mCRPC: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim analysis of 44 mCRPC patients treated with the combination of cabozantinib and atezolizumab demonstrated an ORR per RECIST v. 1.1 of 32% and a DCR of 80%. Among the 36 of those mCRPC patients with high-risk clinical features, the ORR was 33%. Based on regulatory feedback from the FDA, and if supported by the clinical data, we intend to file with the FDA for accelerated approval in an mCRPC indication in 2021.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">NSCLC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Initial results from 30 NSCLC patients demonstrated an ORR per RECIST v. 1.1 of 27% and a DCR of 83%. Median PFS was 4.2 months (95% CI 2.7-7.0), and median DOR was 5.7 months.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Clear cell RCC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Initial results from 34 RCC patients with clear cell histology who received 40 mg of cabozantinib daily in combination with atezolizumab demonstrated an ORR per RECIST v. 1.1 of 53% and a DCR of 94%. Median PFS was 19.5 months (95% CI 11.0&#8212;NE), and median DOR had not been reached as of the date of the analysis. Initial results from an additional 36 RCC patients with clear cell histology who received 60 mg of cabozantinib daily in combination with atezolizumab demonstrated an ORR per RECIST v. 1.1 of 58% and a DCR of 92%. Median PFS was 15.1 months (95% CI 8.2&#8212;22.3), and median DOR was 15.4 months.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:4.02pt">Non-clear cell RCC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial results from 30 RCC patients with non-clear cell histology who received 40 mg of cabozantinib in combination with atezolizumab demonstrated an ORR per RECIST v. 1.1 of 33% and a DCR of 93%. Median PFS was 9.5 months (95% CI 5.5&#8212;NE), and median DOR was 8.3 months.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety profile of the combination was consistent with the established profile of each agent, and no new safety signals emerged.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HCC - COSMIC-312. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. The trial also includes a third arm evaluating cabozantinib monotherapy in this first-line setting in order to address the contribution of components. In August 2020, we announced the completion of patient enrollment in COSMIC-312, providing the requisite patient population to conduct the event-driven analyses of the trial&#8217;s co-primary endpoints of PFS and OS. Separately, patient enrollment remains open in China in order to enroll a sufficient number of patients to enable local registration, if supported by the clinical data. Patients are being randomized to one of three arms: cabozantinib (40 mg) and atezolizumab; sorafenib; or cabozantinib (60 mg). </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on current event rates, we anticipate announcing top-line results in the first half of 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are sponsoring COSMIC-312, and Ipsen is co-funding the trial. Ipsen will have access to the results to support potential future regulatory submissions outside of the U.S. and Japan. Roche is providing atezolizumab free of charge. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the data are supportive, we anticipate filing an sNDA with the FDA in 2021, and Ipsen would also seek to file marketing applications with regulatory agencies in its respective territories based on the results</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NSCLC - CONTACT-01. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lung cancer is the second most common type of cancer in the U.S., with more than 235,000 new cases expected to be diagnosed in 2021. The disease is the leading cause of cancer-related mortality in both men and women, causing 25% of all cancer-related deaths. The majority (84%) of lung cancer cases are NSCLC, which mainly comprise adenocarcinoma, squamous cell carcinoma and large cell carcinoma. The five-year survival rate for patients with NSCLC is 24%, but that rate falls to just 6% for those with advanced or metastatic disease. More than half of lung cancer cases are diagnosed at an advanced stage, and more options are needed for these patients.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the ongoing urgent need for treatment options for patients with NSCLC and based on the positive early-stage results from COSMIC-021, in June 2020, we and Roche initiated CONTACT-01, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he trial aims to enroll approximately 350 patients at up to 121 sites globally. Patients are being randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or to the control arm of docetaxel. The primary endpoint for the trial is OS, and secondary endpoints include PFS, ORR and DOR.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CONTACT-01 is sponsored by Roche and co-funded by us. In addition, both Ipsen and Takeda have opted into and are co-funding the trial, and both companies will have access to the results to support potential future regulatory submissions in their respective territories outside of the U.S. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mCRPC - CONTACT-02. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Cancer Society</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in 2021, approximately 250,000 new cases of prostate cancer will be diagnosed, and 34,000 people will die from the disease. Prostate cancer that has spread beyond the prostate and does not respond to androgen-suppression therapies&#8212;a common treatment for prostate cancer&#8212;is known as mCRPC. Researchers estimate that in 2020, 43,000 men were diagnosed with mCRPC, which has a median survival of less than two years. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to this significant unmet need and based on the positive early-stage results from COSMIC-021, in June 2020, we and Roche initiated CONTACT-02, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with mCRPC who have been previously treated with one novel hormonal therapy. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he trial aims to enroll approximately 580 patients at up to 250 sites globally. Patients are being randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or to the control arm of a second novel hormonal therapy (either abiraterone and prednisone or enzalutamide). The co-primary endpoints for the trial are OS and PFS, and secondary endpoints include ORR, prostate-specific antigen response rate and DOR. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONTACT-02 is sponsored by us and co-funded by Roche. In addition, both Ipsen and Takeda have opted into and are co-funding the trial, and both companies will have access to the results to support potential future regulatory submissions in their respective territories outside of the U.S.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RCC - CONTACT-03. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taking into account the rapidly evolving treatment landscape for RCC and based on the positive early-stage results from COSMIC-021, in July 2020, we and Roche initiated CONTACT-03, a global, multicenter, randomized, open-label phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with inoperable, locally advanced or metastatic RCC who progressed </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during or following treatment with an ICI as the immediate preceding therapy</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he trial aims to enroll approximately 500 patients at up to 167 sites globally. Patients are being randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or to the control arm of cabozantinib alone. The co-primary endpoints for the trial are PFS per RECIST v. 1.1 as assessed by independent review and OS, and secondary endpoints include PFS, ORR and DOR as assessed by the investigators. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONTACT-03 is sponsored by Roche and co-funded by us. In addition, both Ipsen and Takeda have the right to opt in and co-fund the trial and if doing so, they will have access to the results to support potential future regulatory submissions in their respective territories outside of the U.S.  We intend to use the data from CONTACT-03 to further study the therapeutic potential of cabozantinib in this patient population, both as a single agent and in combination with ICIs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Trials Evaluating Cabozantinib in Combination with other Therapies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RCC - CANTATA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In January 2021 Calithera Biosciences, Inc. (Calithera) announced that the CANTATA trial did not meet its primary endpoint of improving PFS per independent review for Calithera&#8217;s teleaglenastat (also known as CB-839) plus cabozantinib as compared with cabozantinib alone in previously treated advanced or metastatic RCC. The HR was 0.94 (p=0.65), and median PFS was 9.2 months among patients treated with telaglenastat and cabozantinib as compared to 9.3 months for patients treated with cabozantinib and placebo. Exelixis provided cabozantinib for the trial through a material supply agreement with Calithera.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trials Conducted through our CRADA with NCI-CTEP and our IST Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2011, we entered into a CRADA with NCI-CTEP for the clinical development of cabozantinib. Through our CRADA with NCI-CTEP and our IST program we have been able to expand the development program for the cabozantinib franchise while avoiding over-burdening our development resources. Our CRADA reflects a major commitment by NCI-CTEP to support the broad exploration of cabozantinib&#8217;s potential in a wide variety of cancers, each representing a substantial unmet medical need. Through this mechanism, NCI-CTEP provides funding for as many as 20 active clinical trials of cabozantinib each year for a five-year period. The term of the CRADA was extended in October 2016 for an additional five-year period through October 2021, provided that both parties maintain the right to terminate the CRADA for any reason upon sixty days&#8217; notice, for an uncured material breach upon thirty days&#8217; notice and immediately for safety concerns. Investigational New Drug (IND) applications for trials under the CRADA are held by NCI-CTEP. NCI-CTEP also retains rights to any inventions made in whole or in part by NCI-CTEP investigators.&#160;However, for inventions that claim the use and/or the composition of cabozantinib, we have an automatic option to elect a worldwide, non-exclusive license to cabozantinib inventions for commercial purposes, with the right to sublicense to affiliates or collaborators working on our behalf, as well as an additional, separate option to negotiate an exclusive license to cabozantinib inventions.&#160;Further, before any trial proposed under the CRADA may commence, the protocol is subject to our review and approval, and the satisfaction of certain other conditions. As reflected by the results from completed trials and given the numerous ongoing and planned clinical trials, we believe our CRADA with NCI-CTEP has and will enable us to continue to expand the cabozantinib development program broadly in a cost-efficient manner.  A summary of key ongoing trials under this collaboration is provided below.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advanced Genitourinary Tumors</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDIGREE is a phase 3 trial led by The Alliance that is enrolling 1,046 intermediate- or poor-risk advanced RCC patients who have a clear cell component in their tumors. All patients are initially treated with up to 4 cycles of induction ipilimumab combined with nivolumab. Subsequently, patients are treated based on their response to the induction therapy. Patients achieving a complete response (CR) continue on maintenance nivolumab, while patients with progressive disease (PD) are switched to cabozantinib monotherapy. Patients who neither achieve a CR nor develop PD during induction are randomized 1:1 to either maintenance nivolumab or nivolumab in combination with cabozantinib 40 mg daily. The primary endpoint is OS, while PFS, CR rate, ORR and safety are among the secondary endpoints.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, positive initial results were announced from PAPMET (also known as SWOG S1500), a randomized phase 2 trial conducted by the Southwest Oncology Group evaluating cabozantinib versus sunitinib in patients with metastatic papillary RCC. PAPMET met its primary endpoint, demonstrating a statistically significant and clinically meaningful prolongation of PFS, and more detailed results from PAPMET will be presented at the virtual ASCO Genitourinary Cancers Symposium in February 2021.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RADICAL is a randomized phase 2 trial being conducted by The Alliance that plans to enroll up to 210 patients with advanced RCC. All patients must have at least 2 sites of bone metastases and may have received up to 2 prior lines of systemic therapy. Patients are randomized 1:1 to be treated with cabozantinib in combination with radium-223 dichloride or cabozantinib as a single agent. The primary endpoint is symptomatic skeletal event-free survival, while secondary endpoints include PFS, OS, ORR and safety.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neuroendocrine Tumors</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Alliance is leading the CABINET study that treats patients with well- or moderately-differentiated neuroendocrine tumors (NETs). CABINET includes 2 separate randomized studies, one for patients with pancreatic NETs and the other for patients with carcinoid tumors. The planned enrollment for the pancreatic NET study is 185 patients and for the carcinoid study is 210 patients. Both studies randomize previously treated patients 2:1 to cabozantinib 60 mg daily or placebo. The primary endpoint for both studies is PFS per Response Evaluation Criteria in Solid Tumors 1.1 as determined by a blinded IRRC. </span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Cancer Indications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are 60 ongoing and 32 planned externally sponsored trials evaluating the clinical and therapeutic potential of cabozantinib, including those administered through our CRADA with NCI-CTEP and our IST program.&#160;Like our CRADA with NCI-CTEP, our IST program helps us to continue to evaluate cabozantinib across a broad range of tumor types.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These externally sponsored trials include signal seeking studies of single-agent cabozantinib, novel combinations, and randomized trials.&#160;The monotherapy trials are focused on solid tumors including genitourinary neoplasms, gastrointestinal malignancies, lung cancer and a variety of less common tumor types.&#160;The combination studies include trials combining cabozantinib with several different ICIs, as well as studies adding cabozantinib to various other anti-cancer therapies, including monoclonal antibodies (mAbs), chemotherapeutic agents, small molecules which target specific cellular pathways, or radiation.&#160;In addition to the various trials described above, our CRADA includes a randomized phase 2 study in recurrent endometrial cancer, in which the combination of cabozantinib and nivolumab demonstrated improved PFS compared with nivolumab, and an ongoing randomized phase 2 study in NSCLC, also in combination with an ICI.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A complete listing of all ongoing cabozantinib trials can be found at </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.ClinicalTrials.gov</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XL092 Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first compound discovered at Exelixis to enter the clinic following our re-initiation of drug discovery activities was XL092, a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing XL092, we sought to build upon our experience with cabozantinib, retaining the target profile of cabozantinib while improving key characteristics, including the pharmacokinetic half-life. We are evaluating XL092 in a growing clinical development program across various tumor types.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the FDA&#8217;s acceptance of our IND for XL092, we initiated a multicenter phase 1 clinical trial in February 2019 designed to evaluate the pharmacokinetics, safety, tolerability and preliminary anti-tumor activity of XL092. The trial is divided into dose-escalation and expansion phases. The dose-escalation phase of the trial is enrolling patients with advanced solid tumors, with the primary objective of determining a dose for daily oral administration of XL092 suitable for further evaluation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we presented data </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at the 32nd EORTC-NCI-AACR (ENA) Symposium that suggest XL092 has a desirable therapeutic profile, pairing the potential for significant anti-tumor activity with a much shorter clinical pharmacokinetic half-life than cabozantinib, while also presenting the potential for synergistic effects in combination with ICIs. In consideration of these data, we amended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the phase 1 study protocol in October 2020 to include dose-escalation and expansion cohorts for XL092 in combination with atezolizumab and are actively enrolling patients into the dose-escalation cohorts of the combination part of the trial. We expect that</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> once recommended doses of both single-agent XL092 and XL092 in combination with atezolizumab are established, the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell RCC, hormone-receptor positive breast cancer and mCRPC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our experience with cabozantinib, the clinical profile of XL092 and initial data of the phase 1 dose-escalation trial evaluating XL092, we are also pursuing additional combination trials evaluating XL092 with multiple therapeutic agents across various tumor types.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XL102 Development Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XL102 (formerly AUR102) is the lead compound under our research collaboration with Aurigene Discovery Technologies Limited (Aurigene). It is a potent, selective and orally bioavailable covalent inhibitor of c</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">yclin-dependent kinase 7 (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDK7), which is an important regulator of the cellular transcriptional and cell cycle machinery. Based on encouraging</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical data for XL102, which we and Aurigene presented at the 32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ENA Symposium in October 2020, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we exercised our exclusive option to license XL102 in December 2020, resulting in our assuming responsibility for all subsequent clinical development of XL102. For additional information on our collaboration with Aurigene, see &#8220;&#8212;Collaborations&#8212;Research Collaborations and In-licensing Arrangements&#8212;Aurigene.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XL102 is the subject of an active IND that we submitted to the FDA in November 2020, and that the FDA accepted in December 2020. We are studying the compound in a multicenter phase 1, open-label clinical trial</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiated in January 2021 and designed to evaluate its</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety, tolerability, pharmacokinetics and preliminary anti-tumor activity, both as a single agent and in combination with other anti-cancer therapies, in up to 298 patients with inoperable, locally advanced or metastatic solid tumors. The trial is divided into dose-escalation and cohort-expansion phases. The dose-escalation phase of the trial is enrolling patients with advanced solid tumors, with the primary objective of determining the maximum tolerated dose or recommended dose levels for daily oral administration of XL102 as a single agent. Additional tumor-specific dose-escalation cohorts will determine the recommended XL102 dose level for use in combination with fulvestrant for patients with hormone-receptor positive breast cancer and with abiraterone and prednisone for patients with mCRPC, and potentially with other anti-cancer regimens. Assuming positive data from the initial phase of the trial, the cohort-expansion phase is designed to further explore the selected dose of XL102 in individual tumor cohorts, including ovarian cancer, triple-negative breast cancer, hormone-receptor positive breast cancer and mCRPC, and evaluate the anti-tumor activity of XL102, as assessed per RECIST v. 1.1, as well as its safety, tolerability and pharmacokinetic profile.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expansion of the Exelixis Pipeline</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are actively focused on expanding our oncology product pipeline through our drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. This approach provides a high degree of flexibility with respect to target selection and allows us to prioritize those targets that we believe have the greatest chance of yielding impactful therapeutics. As part of our strategy, our drug discovery activities include research collaborations and in-licensing arrangements that serve to increase our discovery bandwidth and allow us to access a wide range of technology platforms. We will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Small Molecule Programs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6 million compounds. We have extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 1994, our drug discovery group has advanced 23 compounds to the IND stage, either independently or with collaboration partners, and today we deploy our drug discovery expertise in medicinal chemistry, tumor biology and pharmacology to advance small molecule drug candidates toward and through preclinical development. Notably, these efforts are led by some of the same experienced scientists that led the efforts to discover cabozantinib, cobimetinib and esaxerenone, each of which are now commercially distributed drug products. In pursuit of new drug discoveries, we concentrate our in-house work on the most demanding and time-sensitive aspects of lead optimization and use contract research organizations to support more routine activities, thereby minimizing our footprint while still maintaining an agile, competitive approach. We also augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies engaged in small molecule discovery, including:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Aurigene, which is focused on the discovery and development of novel small molecules as therapies for cancer; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">StemSynergy</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutics, Inc. (StemSynergy), which is focused on the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1 alpha (CK1&#945;).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on these research collaborations and in-licensing arrangements related to our small molecule programs, see &#8220;&#8212;Collaborations&#8212;Research Collaborations and In-licensing Arrangements.&#8221;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amongst our small molecule programs, furthest along is XL092, which was discovered at Exelixis and entered the clinic in 2019. For additional information on XL092, see &#8220;&#8212;Exelixis Development Programs&#8212;XL092 Development Program</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;  We also submitted an IND to the FDA in November 2020 for XL102, the lead Aurigene program targeting CDK7, and initiated the first in-human phase 1 clinical trial in January 2021. For additional information on XL102, see &#8220;&#8212;Exelixis Development Programs&#8212;XL102 Development Program.&#8221; In addition, we continue to make progress on multiple, additional lead optimization programs for inhibitors of a variety of targets that we believe play significant roles in tumor growth, and we anticipate that some of these other programs could reach development candidate status in 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics Programs</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also focusing our drug discovery activities on discovering and advancing various biologics, such as bispecific antibodies, antibody-drug conjugates (ADCs) and other innovative biologics that have the potential to become anti-cancer therapies. We believe that biotherapeutics of these classes have the potential to be significant cancer therapies, as evidenced, for example, by the multiple regulatory approvals for the commercial sale of ADCs in the past year. To facilitate the growth of our biologics programs, we have established multiple research collaborations and in-licensing arrangements that provide us with access to antibodies and other binders, which are the starting point for use with additional technology platforms that we employ to generate next-generation ADCs or bispecific antibodies. Our current research collaborations and in-licensing arrangements for biologics programs include: </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Adagene Inc. (Adagene), which is focused on using Adagene&#8217;s SAFEbody</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to develop novel masked ADCs or other innovative biologics with potential for improved therapeutic index;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc. (individually and collectively referred to as Catalent), which is focused on the discovery and development of multiple ADCs using Catalent&#8217;s proprietary SMARTag&#174; site-specific bioconjugation technology;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">N</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BE-Therapeutics AG (NBE), which is focused on the discovery and development of multiple ADCs by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, including NBE&#8217;s SMAC-Technology&#8482; (a site-specific conjugation technology) and novel payloads;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Iconic Therapeutics, Inc. (Iconic), which is focused on the advancement of a next-generation ADC program targeting Tissue Factor in solid tumors; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Invenra, Inc. (Invenra), which is focused on the discovery and development of novel binders and multispecific antibodies for the treatment of cancer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have already made significant progress under these research collaborations and in-licensing arrangements and believe we will continue to do so in 2021, including for example, XB002, the lead Tissue Factor ADC program with Iconic (formerly ICON-2). Tissue Factor is highly expressed on tumor cells and in the tumor microenvironment, and Tissue Factor overexpression, while not oncogenic itself, facilitates angiogenesis, metastasis and other processes important to tumor development and progression. XB002 has continued to progress through preclinical development, and we plan to submit an IND once the drug product release assays are finalized. For additional information on these research collaborations and in-licensing arrangements related to our biologics programs, see &#8220;&#8212;Collaborations&#8212;Research Collaborations and In-licensing Arrangements.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of the cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. We expect to enter into additional, external collaborative relationships around assets and technologies that complement our drug discovery and clinical development efforts. Consistent with our business strategy prior to the commercialization of our first product, COMETRIQ, we also entered into other collaborations with leading pharmaceutical companies including Genentech and Daiichi Sankyo for other compounds and programs in our portfolio. Under each of our collaborations, we are entitled to receive milestones and royalties or, in the case of cobimetinib, royalties from sales outside the U.S. and a share of profits (or losses) from commercialization in the U.S.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ipsen Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of $210.0 million in 2016. As of December 31, 2020, we achieved aggregate milestone payments of $350.0 million related to regulatory and commercial progress by Ipsen since the inception of the collaboration agreement, including milestone payments during 2020 of $20.0 million upon our achievement of a cabozantinib development milestone.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also eligible to receive future development and regulatory milestone payments from Ipsen, totaling an aggregate of $59.0 million upon additional approvals of cabozantinib in future indications and/or jurisdictions, as well as contingent payments of up to $450.0 million and CAD$26.5 million associated with future sales volume milestones. We will further receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. We were initially entitled to receive a tiered royalty of 2% to 12% on the initial $150.0 million of net sales; this amount was reached in the second quarter of 2018. During the year ended December&#160;31, 2020 and going forward, we are entitled to receive a tiered royalty of 22% to 26% on annual net sales, with separate tiers for Canada; these 22% to 26% royalty tiers reset each calendar year. As of December 31, 2020, we have earned royalties of $174.9 million on net sales of cabozantinib by Ipsen since the inception of the collaboration agreement. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our historical agreement with GlaxoSmithKline (GSK), we are required to pay a 3% royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding certain ongoing clinical trials, including COSMIC-021, COSMIC-312, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen to supply finished and labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a pharmacovigilance agreement, which defines each partner&#8217;s responsibilities for safety reporting. The pharmacovigilance agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from territories outside of the U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive, as well as modify certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $50.0 million from Takeda in 2017. As of December&#160;31, 2020, we have also achieved regulatory and development milestones in the aggregate of $92.0 million related to regulatory and commercial progress by Takeda since the inception of the collaboration agreement, including milestone payments during 2020 of (1)  $31.0 million upon Takeda&#8217;s first commercial sale of CABOMETYX as a treatment for patients in Japan with curatively unresectable or metastatic RCC, (2) $10.0 million upon Takeda&#8217;s and Ono&#8217;s submission of a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with OPDIVO for the treatment for patients in Japan with unresectable, advanced or metastatic RCC, (3) $10.0 million upon Takeda&#8217;s submission of a regulatory application to the Japanese MHLW for Manufacturing and Marketing Approval of cabozantinib as a treatment for patients in Japan with unresectable HCC who progressed after prior systemic therapy, and (4) $15.0 million upon Takeda&#8217;s first commercial sale of CABOMETYX as a treatment for patients in Japan with unresectable HCC who progressed after prior systemic therapy. We are eligible to receive additional regulatory and development milestone payments, without limit, for additional potential future indications. We also earned $15.0 million in milestones during the first quarter of 2021 in connection with the initiations of CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of up to&#160;$139.0 million. We also receive royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;15%&#160;to&#160;24%&#160;on the initial $300.0 million of net sales, and following this initial $300.0 million of net sales, we are then entitled to receive a tiered royalty of 20%&#160;to&#160;30%&#160;on annual net sales thereafter; these 20% to 30% royalty tiers reset each calendar year. As of December 31, 2020, we have earned royalties of $2.3&#160;million on net sales of cabozantinib by Takeda since the inception of the collaboration agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our historical agreement with GSK, we are required to pay a 3% royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for CONTACT-01 and CONTACT-02, Takeda is responsible for 20% of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. In accordance with the collaboration agreement, Takeda has opted into and is co-funding certain cohorts of COSMIC-021, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) two years after first generic entry with respect to such product in Japan or (2) the later of (A) the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Development Collaborations </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BMS</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s ICIs, nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC in the CheckMate -9ER and COSMIC-313 trials and for HCC in the CheckMate 040 trial. We may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. For descriptions of the CheckMate -9ER, COSMIC-313 and CheckMate 040 trials, see &#8220;&#8212;Exelixis Development Programs&#8212;Cabozantinib Development Program&#8212;Trials Conducted Under our Clinical Collaboration Agreements&#8212;Combination Studies with BMS.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination IND application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Following the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, we and BMS commenced the commercial launch of the combination and have agreed to pursue commercialization and marketing efforts independently.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated COSMIC-021 and in December 2018, we initiated COSMIC-312. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge. For descriptions of the COSMIC-021 and COSMIC-312 trials, see &#8220;&#8212;Exelixis Development Programs&#8212;Cabozantinib Development Program&#8212;Trials Conducted Under our Clinical Collaboration Agreements&#8212;Combination Studies with Roche.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building upon encouraging clinical activity observed in COSMIC-021, in December 2019 we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in the CONTACT-01, CONTACT-02 and CONTACT-03 studies. If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these three ongoing phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XL092 Clinical Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to diversify our exploration of the therapeutic potential of XL092, we have also entered into multiple supply agreements to evaluate XL092 in various combination trials, including with Roche&#8217;s atezolizumab.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These supply agreements will facilitate exploration of the safety and efficacy of XL092 in combinations with multiple established cancer therapies with fixed expenses as we continue to build a broad development program for XL092. For descriptions of our ongoing clinical trials evaluating XL092 in combination with other therapies, see &#8220;&#8212;Exelixis Development Programs&#8212;XL092 Development Program.&#8221; </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaborations and In-licensing Arrangements </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adagene</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we entered into a collaboration and license agreement with Adagene to utilize Adagene&#8217;s SAFEbody technology platform to generate masked versions of mAbs from our growing preclinical </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pipeline for the development of ADCs or other innovative biologics against Exelixis-nominated targets. Under the terms of the agreement, Exelixis will make an upfront payment of $11.0 million in exchange for an exclusive, worldwide license to develop and commercialize any potential ADC products generated by Adagene with respect to an initial target, as well as a second target we may nominate during the collaboration term. For each target that we nominate, we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization for that program.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the aggregate, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adagene will be eligible for up to $55.0 million, $200.0 million and $525.0 million in potential development, regulatory and commercial milestone payments, respectively, as well as royalties on potential sales of products developed around both targets.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Catalent</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with Catalent to develop multiple ADCs using Catalent&#8217;s proprietary SMARTag site-specific bioconjugation technology. Under the terms of the agreement, we made an upfront payment of $10.0 million in exchange for an exclusive option to license up to four targets using Catalent&#8217;s ADC platform over a three-year period. In addition, we have the right to extend the target selection term to five years and nominate up to two additional targets for an additional payment of $4.0 million. For each option we decide to exercise, we will be required to pay an exercise fee of $2.0 million, and we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization for that program. Catalent would then become eligible for up to $44.0 million per program in potential development and regulatory milestone payments and $60.0 million per program in potential commercial milestone payments, as well as royalties on potential sales. We have also committed to contribute research funding to Catalent for discovery and preclinical development work.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NBE</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with NBE to discover and develop multiple ADCs for oncology applications by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, including NBE&#8217;s SMAC-Technology and novel payloads. Under the terms of the Agreement, we made an upfront payment of $25.0 million in exchange for exclusive options to nominate four targets using NBE&#8217;s ADC platform over a two-year period. In addition, within the first 18 months of the agreement term, we also have the right to extend the target selection term to three years for an additional payment of $2.0 million. For each option we decide to exercise, we will be required to pay an exercise fee of $10.0 million, and we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization connected with any resulting program. NBE would then become eligible for up to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$90.0 million per program in potential development and regulatory milestone payments and $135.0 million per program in potential commercial milestone payments, as well as royalties on potential sales. We have also committed to contribute research funding to NBE for discovery and preclinical development work.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aurigene</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as six&#160;programs to discover and develop small molecules as therapies for cancer. Under the terms of the agreement, we made aggregate upfront payments of $17.5 million for exclusive options to license up to six programs, including three pre-existing programs. Based on encouraging preclinical data for XL102, the lead Aurigene program targeting CDK7, we exercised our exclusive option to license XL102 in December 2020, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL102 and payment of a $12.0 million option exercise fee to Aurigene. We also submitted an IND for XL102 in November 2020, and following the FDA&#8217;s acceptance of the IND in December 2020, we initiated a phase 1 clinical trial of XL102 in January 2021 designed to evaluate its pharmacokinetics, safety, tolerability and preliminary efficacy, both as a single agent and in combination with other anticancer therapies. For additional information on this new phase 1 trial, see &#8220;&#8212;Exelixis Development Programs&#8212;XL102 Development Program.&#8221; With respect to XL102, Aurigene will be eligible for up to $148.8 million in potential development and regulatory milestone payments, and $280.0 million in potential commercial milestone payments, as well as royalties on potential sales. In addition, we are working with Aurigene to advance other small molecule programs through preclinical development.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each additional option we decide to exercise, we will be required to pay an exercise fee of $10.0 million, and we would then assume responsibility for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for up to $148.8 million per program in potential development and regulatory milestone payments, $280.0 million per program in potential commercial milestone payments, as well as royalties on potential sales. We are also responsible for research funding for the discovery and preclinical development work on these programs. Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Iconic</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer, leveraging Iconic&#8217;s expertise in targeting Tissue Factor in solid tumors. Under the terms of the agreement, we gained an exclusive option to license XB002, Iconic&#8217;s lead Tissue Factor ADC program, in exchange for an upfront payment to Iconic of $7.5 million and a commitment for preclinical development funding. Based on encouraging preclinical data, we exercised our exclusive option to license XB002 in December 2020, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization for XB002 and payment of a $20.0 million option exercise fee to Iconic, and we anticipate submitting an IND for XB002 once the drug product release assays are finalized. With respect to XB002, Iconic will be eligible for up to $190.6 million in potential development, regulatory and first-sale milestone payments, and $262.5 million in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invenra</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a collaboration and license agreement with&#160;Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities.&#160;The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform, or with other platforms and formats at our option. In March 2020, we amended the agreement to enable the use of target binders in non-Invenra platform-based modalities, such as ADC platforms. As of December 31, 2020, we have initiated three additional discovery projects and all six binder projects. Invenra is eligible to receive up to&#160;$131.5 million&#160;in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a B-Body product in the first indication, or in lieu of such payments, up to $43.4 million in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a non- B-Body product. Upon successful </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization of a product, Invenra is eligible to receive sales-based milestone payments up to&#160;$325.0 million as well as single-digit tiered royalties on net sales of the approved product. We have the right to initiate three additional discovery projects for development subject to an upfront payment of&#160;$2.0 million&#160;for each B-Body project, as well as additional milestone payments and royalties for any products that arise from these efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">StemSynergy</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting CK1&#945;, a component of the Wnt signaling pathway implicated in key oncogenic processes. Activation of &#946;-catenin, a key downstream component of the pathway, is increased in multiple tumors, including a majority of colorectal cancers, where mutations in the APC gene that result in &#946;-catenin stabilization are prevalent. Compounds targeting CK1&#945; have also been shown to induce degradation of &#946;-catenin and pygopus, another member of the pathway, in preclinical CRC models, and to inhibit the growth of tumors. Importantly, their GI-sparing qualities may help overcome limitations of other approaches targeting the Wnt pathway. Under the terms of the agreement,&#160;we&#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&#945;. We paid&#160;StemSynergy an upfront payment of&#160;$3.0 million&#160;in 2018. StemSynergy is eligible for up to $0.5 million in additional research and development funding on an as needed basis. StemSynergy will also be eligible for up to&#160;$56.5 million&#160;in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, commercial milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commercialization of our first product, COMETRIQ, our primary business strategy was focused on the development and out-license of compounds to pharmaceutical and biotechnology companies under collaboration agreements that allowed us to retain economic participation in compounds and support additional development of our proprietary products.&#160;Our collaboration agreements with Genentech and Daiichi Sankyo described below are representative of this historical strategy. We have since evolved and are now a fully-integrated biopharmaceutical company focused on driving the expansion and depth of our product offerings through the continued development of the cabozantinib franchise and drug discovery efforts, including research collaborations and in-licensing arrangements that align with our oncology drug development, regulatory and commercialization expertise, all to improve care and outcomes for people with cancer around the world. While the historical collaboration agreements described below have the potential to provide future revenue, and while we have already received some collaboration revenues from these arrangements, we do not expect to receive significant revenues from these historical collaboration agreements unless and until our partnered compounds generate substantial sales in the territories and indications where they are approved. If these events occur, then the milestone payments, royalties or other rights and benefits under our historical collaboration agreements could become substantial.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genentech - Cobimetinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the further development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Cobimetinib is a reversible inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and in March 2009, granted Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and subsequent clinical development. On&#160;November&#160;10, 2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S.; however, following a review of the commercial landscape, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. in January 2018. This decision is not indicative of any change in our intention to promote COTELLIC for other therapeutic indications for which it may be approved in the future. On July 30, 2020, the FDA approved COTELLIC, in combination with Genentech&#8217;s ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of BRAF V600 mutation-positive advanced melanoma in previously untreated patients. Notwithstanding this latest approval, we do not intend to co-promote COTELLIC in this indication.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cobimetinib Profit Sharing and Royalty Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive 50% of profits and losses from the first $200.0 million of U.S. actual sales, decreasing to 30% of profits and losses from U.S. actual sales in excess of $400.0 million. These tiers reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. During 2020, we earned royalties of $5.1 million on net sales of COTELLIC outside the U.S. and a $6.3 million profit on the profit and loss sharing of U.S. actual sales which are recorded in Collaboration services revenues. Since the inception of the collaboration agreement, we have also received aggregate upfront and milestone payments of&#160;$50.0&#160;million and are not eligible for any additional milestone payments.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cobimetinib Clinical Development Program </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its established commercialization of COTELLIC, Genentech continues to progress the clinical development, regulatory status and commercial potential of cobimetinib. Cobimetinib is being evaluated in a broad development program consisting of more than 50 clinical trials by Genentech or through Genentech&#8217;s IST program, including an ongoing phase 1b trial exploring the combination of cobimetinib with atezolizumab and bevacizumab in previously treated metastatic colorectal cancer, as well as additional clinical trials investigating the combination of cobimetinib and other therapies in multiple tumor settings. Should these trials prove positive and Genentech obtain regulatory approvals based on such positive results, we believe that cobimetinib could provide us with an additional source of revenue in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Melanoma - coBRIM. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we announced positive top-line results from coBRIM, the phase 3 pivotal trial conducted by Genentech evaluating cobimetinib in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600E or V600K mutation. CoBRIM served as the basis for the regulatory approval of COTELLIC in combination with ZELBORAF as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma in the U.S., Switzerland, the EU, Canada, Australia, Brazil and other countries.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Melanoma - IMspire150. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we announced positive results from IMspire150, a phase 3 pivotal trial evaluating the combination of cobimetinib, vemurafenib and atezolizumab vs. cobimetinib plus vemurafenib in previously untreated BRAF V600 mutation-positive patients with metastatic or unresectable locally advanced melanoma. IMspire150 served as the basis for the July 2020 regulatory approval of the combination of TECENTRIQ, COTELLIC and ZELBORAF for the treatment of BRAF V600 mutation-positive advanced melanoma in previously untreated patients in the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daiichi Sankyo - Esaxerenone</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the MR, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds and we do not have rights to reacquire such compounds, except as described below. During the research term, which concluded in November 2007, we jointly identified drug candidates with Daiichi Sankyo for further development. Esaxerenone is the only remaining drug candidate identified under the collaboration that continues to be developed by Daiichi Sankyo, and we are entitled to receive payments upon attainment of pre-specified development, regulatory and commercialization milestones for esaxerenone.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Daiichi Sankyo reported positive top-line results from ESAX-HTN, a phase 3 pivotal trial of esaxere</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">none, and submitted a Japanese regulatory application for esaxerenone for an essential hypertension indication in February 2018. Daiichi Sankyo&#8217;s application was then approved by the MHLW in January 2019, and the first commercial sale of the branded esaxerenone product MINNEBRO in Japan in May 2019. As of December 31, 2020, we have received an </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggreg</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ate of $65.5 million in deve</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lopment, regulatory and commercialization milestone payments related to MINNEBRO over the life of the collaboration agreement and are eligible to receive commercialization milestone payments of up to $90.0 million. In addition, we are entitled to re</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ceive low double-digit royalties on sales of MINNEBRO. Daiichi Sankyo may terminate the agreement upon 90 days&#8217; written notice, in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of 0.5% to Ligand on net sales of MINNEBRO. As of December 31, 2020, we have earned royalties of $1.5 million on net sales of MINNEBRO by Daiichi Sankyo since the approval of MINNEBRO in January 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daiichi Sankyo also continues to advance the development program for esaxerenone, and in November 2019, Daiichi Sankyo announced positive results from a phase 3 pivotal trial evaluating esaxerenone as a treatment option for patients in Japan with diabetic nephropathy. Should Daiichi Sankyo obtain regulatory approval based on these positive results, and taking into account the approval of MINNEBRO by the MHLW for the treatment of hypertension and Daiichi Sankyo&#8217;s subsequent commercial sales of MINNEBRO, we believe that esaxerenone will provide an additional source of revenue in the future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Product Supply</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities, distribution facilities or resources for chemistry, manufacturing and control (CMC) development activities, preclinical, clinical or commercial production and distribution for our current products. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through secondary third-party contract manufacturers, distributors and suppliers. Specifically, we entered into agreements with secondary contract manufacturing organizations to produce additional commercial supplies of CABOMETYX tablets and cabozantinib drug substance, which bolsters our commercial supply chain and serves to mitigate the risk of supply chain interruptions or other failures. For our portfolio of small molecules and biologics, we have selected well-established and reputable global third-party contract manufacturers for our CMC development, drug substance and drug product manufacturing that have good regulatory standing, large manufacturing capacities and multiple manufacturing sites within their business footprint. These third parties must comply with applicable regulatory requirements, including the FDA&#8217;s Current Good Manufacturing Practice (GMP), the EC&#8217;s Guidelines on Good Distribution Practice (GDP), as well as other stringent regulatory requirements enforced by the FDA or foreign regulatory agencies, as applicable, and are subject to routine inspections by such regulatory agencies. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor and evaluate the performance of our third-party contract manufacturers on an ongoing basis for compliance with these requirements and to affirm their continuing capabilities to meet both our commercial and clinical needs. We also have contracted with a third-party logistics provider, with multiple distribution locations, to provide shipping and warehousing services for our commercial supply of both CABOMETYX and COMETRIQ in the U.S. We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our third-party contract manufacturers and other supply chain partners, and our quality department audits them on a periodic basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source raw materials that are used to manufacture our drug substance from multiple third-party suppliers in Asia and Europe. We stock sufficient quantities of these materials and provide them to our third-party drug substance contract manufacturers so they can manufacture adequate drug substance quantities per our requirements, for both clinical and commercial purposes. We then store drug substance at third-party facilities and provide appropriate amounts to our third-party drug product contract manufacturers, who then manufacture, package and label our specified quantities of finished goods for COMETRIQ and CABOMETYX, respectively. In addition, we rely on our third-party contract manufacturers to source materials such as excipients, components and reagents, which are required to manufacture our drug substance and finished drug product.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to having expanded our supply chain to include secondary contract manufacturing organizations, we have established and continue to maintain substantial safety stock inventories for our drug substance and drug products, and we store these quantities in multiple locations. The quantities that we store are based on our business needs and take into account scenarios for market demand, production lead times, potential supply interruptions and shelf life for our drug substance and drug products. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our response to the COVID-19 pandemic has included more frequent engagement with our vendors to maintain the consistency and effectiveness of our third-party contract manufacturers and other supply chain </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partners, we have not experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more detailed discussion of the impact of the COVID-19 pandemic and our risk mitigation efforts, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;COVID-19 Update&#8221; in Part II, Item 7 and of this Annual Report on Form 10-K. We believe that our current manufacturing network has the appropriate capacity to produce sufficient commercial quantities of CABOMETYX to support the currently approved advanced RCC and HCC indications, as well as potential additional indications if trials evaluating CABOMETYX in those indications prove to be successful and gain regulatory approval in the future. Our manufacturing footprint also enables us to fulfill our supply obligations for CABOMETYX and COMETRIQ to our collaboration partners for global development and commercial purposes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing and Sales</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions. Our sales team promotes CABOMETYX and COMETRIQ in the U.S. We market our products in the U.S. and concentrate our efforts on oncologists, oncology nurses, pharmacists and other healthcare professionals. In addition to using customary pharmaceutical company practices, we have also adopted digital marketing technologies to engage with customers. Our reliance on digital marketing increased as a result of the COVID-19 pandemic, which required us to shift from in-person to primarily telephonic and virtual interactions with healthcare professionals. For a more detailed discussion of the impact of the COVID-19 pandemic and our risk mitigation efforts, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;COVID-19 Update&#8221; in Part II, Item 7 and of this Annual Report on Form 10-K.&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial products, CABOMETYX and COMETRIQ, are sold initially through wholesale distribution and specialty pharmacy channels and then, if applicable, resold to hospitals and other organizations that provide CABOMETYX and COMETRIQ to end-user patients. To facilitate our commercial activities in the U.S., we also employ various third parties, such as advertising agencies, market research firms and vendors providing other sales-support related services as needed, including digital marketing and other non-personal promotion. We believe that our commercial team and distribution practices are sufficient to facilitate our marketing efforts in reaching our target audience and our delivery of our products to patients in a timely and compliant fashion.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on Ipsen and Takeda for ongoing and further commercialization and distribution of CABOMETYX in territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs or similar programs with the effect of introducing earlier patient access to CABOMETYX, and we also rely on Ipsen for these same activities with respect to the commercialization and distribution of COMETRIQ outside of the U.S. For COTELLIC, we rely on Genentech, as our collaboration partner, for all current and future commercialization and marketing activities, with the exception of the limited co-promotion activities highlighted above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help ensure that all eligible patients in the U.S. have appropriate access to CABOMETYX and COMETRIQ, we have established a comprehensive reimbursement and patient support program called Exelixis Access Services (EASE). Through EASE, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free drug to uninsured or under-insured patients who meet certain clinical and financial criteria. In addition, EASE provides comprehensive reimbursement support services, such as prior authorization support, benefits investigation and, if needed, appeals support.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Health and Safety</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of certain hazardous materials and chemicals. We are subject to federal, state and local environmental, health and workplace safety laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials. While we have incurred, and may continue to incur, expenditures to maintain compliance with these laws and regulations, we do not expect the cost of complying with these laws and regulations to be material.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laboratory Safety Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the focus of our business in discovering and developing drug products, many of our employees work in our on-site laboratory facilities. All new laboratory staff are trained on chemical hygiene, the use of personal protective equipment, and certain other relevant laboratory safety topics, such as working with blood-borne pathogens, and current staff are retrained regularly. We also extend these trainings to facilities staff and others who support our work in the labs. To maintain a safe environment for all staff, we regularly perform thorough safety inspections of our laboratories, and continuously update our procedures based on the observations made during these inspections. Additionally, we conduct periodic industrial hygiene monitoring to ensure lab staff working with certain known hazardous chemicals do not exceed regulated exposure limits, and we regularly test and certify fume hoods, biosafety cabinets and other individual pieces of equipment on which employees rely to maintain a safe work environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Workplace Safety Measures in Response to COVID-19</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health and safety of our staff members has remained a top priority during the COVID-19 pandemic. In March 2020, ahead of the shelter in place orders issued by the State of California and Alameda County, we implemented a work-from-home policy for all of our employees other than minimal on-site staffing to maintain critical infrastructure operations. During the months that followed, we implemented numerous additional precautions and enhanced safety and social distancing protocols to help diminish the risk of transmission of the virus as certain employees began to return to working at our Alameda, California headquarters in June 2020. In particular, we reduced the number of employees working on-site to primarily those laboratory and site operations personnel required to continue our important drug discovery work, provided such employees were comfortable working on-site. These staff members &#8211; already familiar with personal protective equipment and enhanced safety measures &#8211; have undergone additional detailed training on our COVID-19 safety and social distancing protocols that are necessary to safely perform their job duties in our on-site facilities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer on-site, rapid PCR COVID-19 testing, and utilize a mobile device app and web interface for our team members who regularly work at our headquarters, which enables registered users to schedule their on-site tests at Exelixis and provides them with daily symptom tracking, as well as contact tracing and educational resources for any team member who may have tested positive.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the latest guidance issued by health authorities and have instituted several policies and procedures to protect against the spread of COVID-19 among our workforce. These policies and procedures currently include frequent disinfection of common areas by our operations staff and investments in re-engineering workspace safety, such as installing plexiglass partitions, providing ample supplies of hand sanitizer, sanitizing wipes and facemasks for use by our staff, and adjusting our ventilation systems in an effort to minimize risks of airborne transmission. Although having most of our employees continue to work remotely has required us to devise new ways of working and collaborating, to date, the COVID-19 pandemic has only had a modest impact on our productivity and has not caused significant interruptions in our general business operations. For a more detailed discussion of the impact of the COVID-19 pandemic and our risk mitigation efforts, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;COVID-19 Update&#8221; in Part II, Item 7 and of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing, marketing approval, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, post-marketing safety reporting, export, import, record keeping, advertising and promotion of our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before product candidates may be marketed in the U.S. generally involves the following:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">nonclinical laboratory and animal tests, some of which must be conducted in accordance with Good Laboratory Practices (GLP);</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">submission of an IND, which contains results of nonclinical studies (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, laboratory evaluations of the chemistry, formulation, stability and toxicity of the product candidate), together with manufacturing information, analytical </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data, any available clinical data or literature and a proposed clinical protocol, and must become effective before human clinical trials may begin;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">approval by an independent institutional review board or ethics committee at each clinical trial site before each trial may be initiated;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">adequate and well-controlled human clinical trials conducted in accordance with the protocol, IND and Good Clinical Practice (GCP) to establish the safety and efficacy of the investigational drug candidate for its proposed intended use;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">for drug products, submission of a New Drug Application (NDA) to the FDA for commercial marketing, or generally of an sNDA, for approval of a new indication if the product is already approved for another indication;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">for biological products, submission of a Biologics License Application (BLA) to the FDA for commercial marketing, or generally a supplemental Biologics License Application (sBLA) for approval of a new indication if the product is already approved for another indication;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">pre-approval inspection of manufacturing facilities and selected clinical investigators, clinical trial sites and/or Exelixis as the clinical trial sponsor for their compliance with GMP and GCP, respectively;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">payment of user fees for FDA review of an NDA or BLA unless a fee waiver applies;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">agreement with the FDA on the final labeling for the product;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">if the FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">FDA approval of the NDA or sNDA, or BLA or sBLA.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Phase 1 - Studies, which involve the initial introduction of a new drug product candidate into humans, are initially conducted in a limited number of subjects to test the product candidate for safety, tolerability, absorption, metabolism, distribution and excretion in healthy humans or patients. In rare cases, a Phase 1 study that is designed to assess effectiveness may serve as the basis for FDA marketing approval of a drug or for a label expansion. For instance, at FDA&#8217;s discretion, a product may receive approval based on a Phase 1b study if effectiveness results from the study are extremely compelling, approval of the drug would address a significant unmet patient need, and the drug is being approved through the Accelerated Approval pathway.&#160;As discussed below, Accelerated Approval generally requires a post-approval study to confirm clinical benefit.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Phase 2 - Studies are conducted with groups of patients afflicted with a specified disease in order to provide enough data to evaluate the preliminary efficacy, optimal dosage, and common short-term side effect and risks associated with the drug. Multiple phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive phase 3 clinical trials. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Phase 3 - When earlier phase evaluations provide preliminary evidence suggesting that a dosage range of the product is effective and has an acceptable safety profile, phase 3 trials are performed to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called phase 4 studies may be deemed a condition to be satisfied after a drug receives approval. Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up to and including withdrawal of NDA approval. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Review and Approval</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For approval of a new drug or changes to an approved drug, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of an NDA, or as part of an sNDA. The submission of an NDA requires payment of a substantial user fee to the FDA. The FDA may convene an advisory committee to provide clinical insight on NDA review questions, although the FDA is not required to follow the recommendations of an advisory committee. The FDA may deny approval of an NDA or sNDA by way of a Complete Response letter if the applicable regulatory criteria are not satisfied, or it may require additional clinical and/or nonclinical data and/or an additional phase 3 pivotal clinical trial. Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market. Satisfaction of FDA development and approval requirements or similar requirements </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of state, local and foreign regulatory agencies typically takes several years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including obtaining prior FDA approval of certain changes to the approved NDA, record-keeping requirements, and reporting of adverse experiences with, and interruptions in the manufacture of, the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies. Thus, we and our third-party contract manufacturing organizations are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP, which impose certain manufacturing requirements (including procedural and documentation requirements) upon us and our third-party contract manufacturing organizations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Orphan Drug Act of 1983, as amended, provides incentives for the development of drugs and biological products for rare diseases or conditions that affect fewer than 200,000 people in the U.S. (or for which there is no reasonable expectation that the cost of developing and making available the drug in the U.S. for such disease or condition will be recovered from sales of the drug in the U.S.). Certain of the incentives turn on the drug first being designated as an orphan drug. To be eligible for designation as an orphan drug (Orphan Drug Designation), the drug must have the potential to treat such rare disease or condition as described above. In addition, the FDA must not have previously approved a drug considered the &#8220;same drug,&#8221; as defined in the FDA&#8217;s orphan drug regulations, for the same orphan-designated indication or the sponsor of the subsequent drug must provide a plausible hypothesis of clinical superiority over the previously approved same drug. Upon receipt of Orphan Drug Designation, the sponsor is eligible for tax credits of up to 25% for qualified clinical trial expenses and waiver of the Prescription Drug User Fee Act application fee. In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years of market exclusivity if no drug considered the same drug was previously approved for the same orphan condition (or if the subsequent drug is demonstrated to be clinically superior to any such previously approved same drug). Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication. Moreover, a subsequent same drug could break an approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has various programs that are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. Examples of such programs included Fast Track designation, breakthrough therapy designation, priority review and accelerated approval, and the eligibility criteria of and benefits for each program vary: </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Fast Track is a process designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening diseases or conditions that demonstrate the potential to fill unmet medical needs, by providing, among other things, eligibility for accelerated approval if relevant criteria are met, and rolling review, which allows submission of individually completed sections of an NDA or for FDA review before the entire submission is completed. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Breakthrough therapy designation is a process designed to expedite the development and review of drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review, and rolling review.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Priority review is designed to shorten the review period for drugs that treat serious conditions and that, if approved, would offer significant advances in safety or effectiveness or would provide a treatment where no adequate therapy exists. Under priority review, the FDA aims to take action on the application within six months as compared to a standard review time of 10 months.  Sponsors may also obtain a priority review voucher upon approval of an NDA for certain qualifying diseases and conditions that can be applied to a subsequent NDA submission</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint, or a certain intermediate clinical endpoint, reasonably likely to predict clinical benefit. As a condition of approval, the FDA may require that a sponsor of a product candidate receiving accelerated approval perform post-marketing </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials to confirm the clinically meaningful outcome as predicted by the surrogate marker trial. The failure to conduct such trials, or confirm the clinically meaningful outcome in such trials, may result in withdrawal of the NDA.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to oncology products, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA may review applications under the Real-Time Oncology Review (RTOR) pilot program established by the FDA&#8217;s Oncology Center of Excellence. The RTOR pilot program, which allows an applicant to pre-submit components of the application to allow the FDA to review clinical data before the complete filings is submitted, aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as early as possible, while maintaining and improving review quality. Drugs considered for review under the RTOR pilot program must be likely to demonstrate substantial improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same or other indications, and must have straight-forward study designs and endpoints that can be easily interpreted.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Drug Price Competition and Patent Term Restoration Act of 1984 (The Hatch-Waxman Act) established two abbreviated approval pathways for drug products in which potential competitors may rely upon the FDA&#8217;s prior approval of the same or similar drug product.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abbreviated New Drug Application (ANDA).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> An ANDA may be approved by the FDA if the applicant demonstrates that the proposed generic product is the same as the approved drug, which is referred to as the Reference Listed Drug (RLD).&#160;Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (1)&#160;have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (2)&#160;are intended for the same uses, and (3)&#160;are bioequivalent.&#160;This is instead of independently demonstrating the proposed product&#8217;s safety and effectiveness through clinical development. Conducting bioequivalence testing is generally less time consuming and costly than conducting a full set of clinical trials in humans. In this regard, the FDA has published draft guidance containing product-specific bioequivalence recommendations for drug products containing cabozantinib, the active pharmaceutical ingredient in CABOMETYX and COMETRIQ, as it does for many FDA-approved drug products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">505(b)(2)&#160;NDAs.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;A 505(b)(2) application is one for which one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. Under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA), an applicant may rely, in part, on the FDA&#8217;s previous approval of a similar product, or published literature, in support of its application. If the 505(b)(2) applicant establishes that reliance on FDA&#8217;s prior findings of safety and efficacy for an approved product is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies. The FDA may require additional studies or measurements, including comparability studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike a full NDA for which the sponsor has conducted or obtained a right of reference to all the data essential to approval, the filing of an ANDA application or a 505(b)(2) application may be delayed due to patent or exclusivity protections covering an approved product. The Hatch-Waxman Act provides (a) up to five years of exclusivity for the first approval of a new chemical entity (NCE) exclusivity and (b) three years of exclusivity for approval of an NDA or sNDA for a product that is not an NCE but rather where the application contains new clinical studies conducted or sponsored by the sponsor and considered essential to the approval of the NDA or sNDA (three-year &#8220;changes&#8221; exclusivity). NCE exclusivity runs from the time of approval of the NDA and bars FDA from accepting for review of any ANDA or 505(b)(2) application for a drug containing the same active moiety for five years (or for four years if the application contains a Paragraph IV certification that a reference product patent is invalid or not infringed by the ANDA/505(b)(2) product). The three-year &#8220;changes&#8221; exclusivity generally bars the FDA from approving any ANDA or 505(b)(2) application that relies on the information supporting the approval of the drug or the change to the drug for which the information was submitted and the exclusivity granted.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book Listing.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;An NDA sponsor must identify to the FDA patents that claim the drug substance or drug product or approved method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is referred to as the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any applicant who files an ANDA or a 505(b)(2) NDA must certify, for each patent listed in the Orange Book for the RLD that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the listed patent will expire on a particular date and approval is sought after patent expiration, or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. An ANDA or 505(b)(2) applicant may also submit a statement that it intends to carve-out from the labeling of its product an RLD&#8217;s use that is protected by exclusivity or a method of use patent. The fourth certification described above is known as a Paragraph IV certification. A notice of the Paragraph IV certification </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">must be provided to each owner of the patent that is the subject of the certification and to the reference NDA holder. The reference NDA holder and patent owners may initiate a patent infringement lawsuit in response to the Paragraph IV notice. Filing such a lawsuit within 45 days of the receipt of the Paragraph IV certification notice prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) applicant. The ANDA or 505(b)(2) application also will not receive final approval until any applicable non-patent exclusivity listed in the Orange Book for the RLD has expired. We intend to defend vigorously any patents for our approved products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a Paragraph IV certification notice letter from MSN Pharmaceuticals, Inc. (MSN), that it had filed an ANDA with the FDA for a generic version of CABOMETYX tablets, which MSN then amended with additional Paragraph IV certifications in May 2020. In response, we filed patent infringement lawsuits against MSN on October 29, 2019 and May 11, 2020, which were later consolidated. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Approval Outside of the United States </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we are subject to regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the U.S. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The way clinical trials are conducted in the EU will undergo a major change when Regulation (EU) 536/2014 governing clinical trials in the EU, repealing the existing Directive 2001/20/EC, comes into application. Once fully implemented, this regulation will harmonize the assessment and supervision processes for clinical trials throughout the EU, via an EU portal and database. The EMA will set up and maintain the portal and database, in collaboration with the Member States and the EC. Although Regulation (EU) 536/2014 was adopted and entered into force in 2014, the timing of its application depends on confirmation of full functionality of the Clinical Trials Information System (CTIS) through an independent audit. Regulation (EU) 536/2014 will then become applicable six months after the EC publishes notice of this confirmation. The system's go-live date has been postponed several times due to technical difficulties with the development of the information technology systems. At its meeting held in June 2020, the EMA Management Board endorsed the methodology and next steps to further develop the CTIS &#8220;Go-Live&#8221; plan. As a working assumption, it is proposed to fix the &#8220;Go-Live&#8221; date of CTIS to December 2021, which means the Clinical Trial Regulation would also enter in application at that time (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the end of the six-month period after the EC publishes its notice in the Official Journal of the European Union).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under EU regulatory systems, a company may submit a marketing authorization application (MAA) either under centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the EMA for scientific review by the Committee for Medicinal Products for Human Use (CHMP) so that an opinion is issued on product approvability. The opinion is considered by the EC which is responsible for granting the centralized marketing authorization in the form of a binding EC decision. If the application is approved, the EC grants a single marketing authorization that is valid for all EU member states as well as Iceland, Liechtenstein and Norway, collectively the European Economic Area. The decentralized and mutual recognition procedures, as well as national authorization procedure are available for products for which the centralized procedure is not compulsory. The mutual recognition procedure provides for the EU member states selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another member state, referred to as the Reference Member State (RMS). The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any member state. Under this procedure the applicant can select the member state that will act as the RMS. In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the member states where marketing authorizations are being sought, referred to as Concerned Member States. Within 90 days of receiving the application and assessment report, each Concerned Member State must decide whether to recognize the RMS assessment. If a member state does not agree with the assessment and the disputed points cannot be resolved, the matter is eventually referred to the Coordination Group on Mutual Recognition and Decentralised Procedures in the first instance to reach an agreement and failing to reach such an agreement, a referral to the EMA and the CHMP for arbitration that will result in an opinion to form the basis of a decision to be issued by the EC binding on all member states. If the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application is successful during the decentralized or mutual recognition procedure, national marketing authorizations will be granted by the competent authorities in each of the member states chosen by the applicant.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditional marketing authorizations may be granted in the centralized procedure for a limited number of medicinal products for human use referenced in EU law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if (1) the risk-benefit balance of the product is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) unmet medical needs will be fulfilled and (4) the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the U.S., we may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the application for marketing authorization is made. In the EU, orphan designation is available for products in development which are either: (a) intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the EU; or (b) intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the Community and when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the medicinal product. Additionally, the sponsor of an application for orphan drug designation must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drugs in the EU enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant for a similar medicinal product can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product. The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare and Privacy Regulation </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also govern our business. If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. The laws that may affect our ability to operate include, but are not limited to: the federal Anti-Kickback Statute (AKS), which prohibits, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce or reward for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare and Medicaid; the FDCA and its implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded; and federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent. Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a governmental healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. For example, the California Consumer Privacy Act of 2018, as amended (CCPA), went into operation on January 1, 2020 and broadly defines personal information, affords California residents expanded privacy rights and protections and provides for civil penalties for violations and a private right of action related to certain data security breaches. These protections will be expanded by the California Privacy Rights Act (CPRA), which was approved by California voters in November 2020 and will be operational in most key respects on January 1, 2023. There are similar legislative proposals being advanced in other states, as well as in Congress. In addition, most healthcare providers who are expected to prescribe our products and from whom we may obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act (HIPAA). Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including laws in all 50 states requiring security breach notification in some circumstances. The CCPA, CPRA, HIPAA and these other laws could create liability for us or increase our cost of doing business. International laws, such as the EU General Data </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Protection Regulation 2016/679 (GDPR), could also apply to our operations. Failure to provide adequate privacy protections and maintain compliance with applicable privacy laws could jeopardize business transactions across borders and result in significant penalties.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Patient Protection and Affordable Care Act of 2010, as amended (PPACA) created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare &amp; Medicaid Services annually certain payments and other transfers of value provided to physicians and teaching hospitals, as well as ownership interests held by such physicians and their immediate family during the previous calendar year. Beginning in 2022, manufacturers also will be required to report such information regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year. There are also an increasing number of state laws that control pharmaceutical product pricing or require manufacturers to make reports to states on pricing and marketing information. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our products are covered in the U.S. by the Medicaid programs, we have various obligations, including government price reporting and rebate requirements, which generally require us to pay substantial rebates or offer our drugs at substantial discounts to certain purchasers (including &#8220;covered entities&#8221; purchasing under the 340B Drug Discount Program). We are also required to discount our products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply. These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas and regulatory guidance, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing such calculations is not always clear. Compliance with such requirements can require significant investment in personnel, systems and resources. Failure to properly calculate prices, or to offer required discounts or rebates could subject us to substantial penalties.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our approved products and any future products of ours will depend, in part, on the extent to which their costs will be covered by third-party payers, such as government health programs, commercial insurance and managed healthcare organizations. Each third-party payer may have its own policy regarding what products it will cover, the conditions under which it will cover such products, and how much it will pay for such products. Third-party payers may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a third-party payer&#8217;s decision to provide coverage for a drug product does not guarantee what reimbursement rate, if any, will be approved. Patients may be less likely to use our products if coverage is not provided and reimbursement may not cover a significant portion of the cost of our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and other potentially significant markets for our products, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products and therapies, which may result in lower average selling prices. In some cases, for example, third-party payers try to encourage the use of less expensive generic products through their prescription benefits coverage and reimbursement and co-pay policies. Further, the increased emphasis on managed healthcare in the U.S. and on country-specific and national pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing coverage and/or reimbursement controls and measures, could have a material adverse impact on our net product revenues and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and some foreign jurisdictions are considering proposals or have enacted legislative and regulatory changes to the healthcare system that could affect our ability to sell our products profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing practices. In particular, there have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as Executive Orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs; bring more transparency to drug pricing rationale and methodologies; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid, which affect the amount of rebates that we pay on prescription drugs under Medicaid and to covered entities under the 340B Drug Discount Program; eliminate the AKS discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and facilitate the importation of certain lower-cost drugs from other countries. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. pharmaceutical industry has already been significantly impacted by major legislative initiatives and related political contests. For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA, some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. It is also possible that additional governmental actions will be taken in response to the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these developments and trends, third-party payers are increasingly attempting to contain healthcare costs by limiting coverage and the level of reimbursement of new drugs. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting, including, for example, the movement by insurers towards &#8220;value-based&#8221; contracting, any of which could adversely affect product sales. Due to general uncertainty in the current regulatory and healthcare policy environment, and specifically regarding positions that the new Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before its cost may be funded within the respective national healthcare system. The requirements governing drug pricing vary widely from country to country. For example, EU Member States may restrict the range of medicinal products for which their national healthcare systems provide reimbursement and may control the prices of medicinal products for human use. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profits the medicinal product generates for the company placing it on the market. Pricing and reimbursement negotiations with governmental authorities or payers in EU member states can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. To obtain reimbursement and/or pricing approval in some countries, drug manufacturers and collaboration partners may also be required to conduct a study that seeks to establish the cost effectiveness of a new drug compared with other available established therapies. There can be no assurance that any country that has price controls, reimbursement limitations or other requirements for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products on cost-effectiveness grounds. Historically, products launched in countries in the EU do not follow the price structures of the U.S. and they generally tend to be priced significantly lower.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many companies focused on the development of small molecules, antibodies and other treatments for cancer. Our competitors and potential competitors include major pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Many of the organizations competing with us have greater capital resources, larger research and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for Cabozantinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ability to successfully compete will depend on, among other things:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">efficacy, safety and reliability of cabozantinib, both alone and in combination with other therapies;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">timing and scope of regulatory approval;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the speed at which we develop cabozantinib for the treatment of additional tumor types beyond its approved indications;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to complete clinical development and obtain regulatory approvals for cabozantinib, both alone and in combination with other therapies;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to manufacture and sell commercial quantities of cabozantinib product to the market;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to successfully commercialize cabozantinib, both as a single agent and as part of any combination therapy regimen, and secure coverage and adequate reimbursement in approved indications;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">product acceptance by physicians and other health care providers;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the level of our collaboration partners&#8217; investments in the resources necessary to successfully commercialize cabozantinib, or any combination therapy regimen that includes cabozantinib, in&#160;territories where they are approved;&#160;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">skills of our employees and our ability to recruit and retain skilled employees;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">protection of our intellectual property, including our ability to enforce our intellectual property rights against potential generic competition; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the availability of substantial capital resources to fund development and commercialization activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the quality and breadth of activity observed with cabozantinib, the skill of our employees and our ability to recruit and retain skilled employees, our patent portfolio and our capabilities for research and drug development are competitive strengths. However, many large pharmaceutical and biotechnology companies have significantly larger intellectual property estates than we do, more substantial capital resources than we have, and greater capabilities and experience than we do in preclinical and clinical development, sales, marketing, manufacturing and regulatory affairs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for which we intend to pursue regulatory approval of cabozantinib are becoming increasingly competitive. In addition to cancer treatments that are already approved in these markets, we are aware of products in research or development by our competitors that are intended to treat all of the tumor types we are targeting, and should they demonstrate suitable clinical evidence, any of these products may compete with cabozantinib or any combination therapy regimen that includes cabozantinib. Given the shifting landscape of therapeutic strategy following the advent of immunotherapy, we believe our future success will depend upon our ability to achieve positive clinical trial results for therapies combining cabozantinib with ICIs across multiple indications, and if approved, successfully commercialize such combination therapies. While we have had success in adapting our development strategy for the cabozantinib franchise to address the expanding role of therapies that combine ICIs with other targeted agents, including the recent FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, we cannot ensure that our current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in HCC, NSCLC and mCRPC, will lead to regulatory approvals, or whether physicians will prescribe regimens containing cabozantinib instead of competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the principal competition for cabozantinib in the indications for which it is approved or for which it has been or is currently being evaluated in potentially label-enabling trials, both as a single agent and in combination with other therapies. The information below does not include all competitor products, but rather those approved products that have or we anticipate will capture significant market share within their respective indications, or with respect to therapies still in development, those that are likely to overlap with patient populations that are or may be treated with cabozantinib or a combination therapy regimen that includes cabozantinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition in Approved Cabozantinib Indications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CABOMETYX - RCC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe the principal competition for CABOMETYX in advanced RCC includes: the combination of Merck &amp; Co.&#8217;s pembrolizumab and Pfizer&#8217;s axitinib; the combination of BMS&#8217;s ipilimumab and nivolumab; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s sunitinib; and Novartis&#8217; pazopanib. Additionally, there are a variety of therapies being developed for advanced RCC, including: the combination of Merck &amp; Co.&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib; Peloton Therapeutics&#8217; (a wholly owned subsidiary of Merck &amp; Co.) belzutifan (also known as MK-6482); the combination of Peloton Therapeutics&#8217; belzutifan and Eisai&#8217;s lenvatinib; and generic versions of sunitinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The competitive landscape for RCC is evolving rapidly, especially given the entrance of ICI and ICI-TKI combination therapies into the RCC treatment landscape, particularly in the first-line setting. This will lead to new trends in prescribing and sequencing of certain drugs and combinations across different lines of therapy. It is therefore difficult to predict how these changes will affect sales of CABOMETYX during 2021 and going forward.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CABOMETYX - HCC: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the principal competition for CABOMETYX in previously treated HCC includes: Bayer&#8217;s regorafenib; and Eisai&#8217;s levantinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competitive landscape for HCC is also changing with the increased adoption of ICI combination therapies in the first-line setting, which may lead to an increase in prescribing and sequencing of TKIs in subsequent treatment indications. It is therefore difficult to predict how these changes will affect sales of CABOMETYX during 2021 and going forward.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COMETRIQ - MTC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that the principal competing anti-cancer therapy&#160;to COMETRIQ in progressive, metastatic MTC is Genzyme&#8217;s vandetanib, which has been approved by the FDA and the EC for the treatment of symptomatic or progressive MTC in patients with unresectable, locally advanced, or metastatic disease, as well as other therapies that have been recently approved to treat patients with advanced or metastatic RET-mutant MTC who require systemic therapy, including: Blueprint Medicine&#8217;s and Roche&#8217;s pralsetinib; and Loxo Oncology&#8217;s (a wholly owned subsidiary of Eli Lilly) selpercatinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the recent approvals of RET inhibitors to treat certain MTC patients, there has been little change in the treatment landscape for progressive, metastatic MTC during recent years, and due to the limited number of ongoing late-stage clinical trials in this indication, we do not expect many additional competitors to emerge in 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition in Potential Cabozantinib Indications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cabozantinib - DTC: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have announced positive results from the first 100 patients randomized in COSMIC-311, a phase 3 pivotal trial evaluating cabozantinib in patients with DTC who have progressed after up to two prior VEGF receptor-targeted therapies. Should cabozantinib be approved for this indication of DTC, we believe its principal competition may include two treatments that are also approved for previously untreated DTC: Bayer&#8217;s and Onyx&#8217;s sorafenib; and Eisai&#8217;s lenvatinib. There may also be competition from therapies approved to treat patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are RAI-refractory (if RAI is appropriate), including: Blueprint Medicine&#8217;s and Roche&#8217;s pralsetinib; and Loxo Oncology&#8217;s selpercatinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cabozantinib in combination with ICI - HCC: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated COSMIC-312, a phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab in patients with previously untreated HCC. Should the combination of cabozantinib and atezolizumab be approved for the treatment of patients with previously untreated advanced HCC, we believe its principal competition may include: the combination of Merck &amp; Co.&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib; and the combination of Roche&#8217;s bevacizumab and atezolizumab.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cabozantinib in combination with ICI &#8211; NSCLC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are evaluating the combination of cabozantinib and atezolizumab in COSMIC-021, a phase 1b trial in locally advanced or metastatic solid tumors, including NSCLC, and we have also initiated CONTACT-01, a phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab in patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy. Should the combination of cabozantinib and atezolizumab be approved for the treatment of patients with NSCLC, we believe its principal competition may include: Sanofi&#8217;s docetaxel; the combination of Sanofi&#8217;s docetaxel and Eli Lilly&#8217;s ramucirumab; the combination of BMS&#8217; nivolumab and Mirati&#8217;s sitravatinib; the combination of Merck &amp; Co.&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib; and generic versions of docetaxel.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cabozantinib in combination with ICI &#8211; mCRPC:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are evaluating the combination of cabozantinib and atezolizumab in COSMIC-021, a phase 1b trial in locally advanced or metastatic solid tumors, including mCRPC, and we have also initiated CONTACT-02, a phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab in patients with mCRPC who have been previously treated with one novel hormonal therapy. Based on regulatory feedback from the FDA, and if supported by the clinical data, we intend to file with the FDA for accelerated approval in an mCRPC indication in 2021. Should the combination of cabozantinib and atezolizumab be approved for the treatment of patients with mCRPC, we </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believe its principal competition may include: Janssen Biotech&#8217;s (a wholly owned subsidiary of Johnson &amp; Johnson) abiraterone; Astellas Pharma&#8217;s and Pfizer&#8217;s enzalutamide; Sanofi&#8217;s docetaxel; the combination of Merck &amp; Co.&#8217;s pembrolizumab and Sanofi&#8217;s docetaxel; the combination of Merck &amp; Co.&#8217;s pembrolizumab and Astellas Pharma&#8217;s and Pfizer&#8217;s enzalutamide; the combination of BMS&#8217; nivolumab and Sanofi&#8217;s docetaxel; and generic versions of abiraterone and docetaxel.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for Cobimetinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that cobimetinib&#8217;s principal competition amongst targeted agents includes: the combination of Array&#8217;s encorafenib and binimetinib; and the combination of Novartis&#8217; trametinib and dabrafenib. Within the class of ICIs, we believe that cobimetinib&#8217;s principal competition includes: the combination of BMS&#8217;s ipilimumab and nivolumab; and Merck &amp; Co.&#8217;s pembrolizumab. The second category, ICIs, are of particular competitive importance vis-a-vis cobimetinib in advanced melanoma as they are already FDA approved in melanoma patient populations that overlap with those that may be eligible for cobimetinib, they have been rapidly incorporated into the NCCN treatment guidelines, and they are viewed with a high degree of enthusiasm by physicians and key opinion leaders. Ongoing and future trials incorporating ICIs, including combination trials, may further impact usage of cobimetinib in melanoma and potentially in additional tumor types in which cobimetinib may ultimately gain approval.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for Esaxerenone</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that esaxerenone&#8217;s principal competition for the treatment of hypertension in Japan will be Bayer&#8217;s MR antagonist, finerenone, if and when it is approved by the MHLW. Finerenone is still in development for this indication, and results from ongoing clinical studies are still forthcoming. Other potential competitors for the treatment of hypertension in Japan, if and when they are approved by the MHLW, include: Janssen Pharmaceuticals&#8217; canagliflozin; Reata Pharmaceuticals&#8217; bardoxolone methyl; and Gilead Sciences&#8217; selonsertib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that esaxerenone&#8217;s principal competition for the treatment of diabetic nephropathy in Japan will be finerenone, if and when it is approved by the MHLW. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Customers</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as a single business segment and have operations solely in the U.S. During the year ended December&#160;31, 2020, we derived  15% of our revenues from Ipsen, 14% of our revenues from affiliates of CVS Health Corporation, 12% of our revenues from affiliates of McKesson Corporation, 11% of our revenues from affiliates of Optum Specialty Pharmacy and 11% of our revenues from affiliates of AmerisourceBergen Corporation. See &#8220;Note 2. Revenues&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K for information about significant customers in prior years. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek patent protection in the U.S., Europe and selected other foreign countries to cover our drug candidates and related technologies. Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country. We have numerous patents and pending patent applications that relate to methods of screening drug targets, compounds that modulate drug targets, as well as methods of making and using such compounds.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many patent applications have been filed relating to the drug candidates that we have developed, the majority of these are not yet issued or allowed. To our knowledge, we own all global patents associated with cabozantinib and cobimetinib, and we either own or have in-licensed all global patents for our other drug candidates, as further described below.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cabozantinib is covered by more than 10 issued patents in the U.S., building from U.S. Pat. No.&#160;7,579,473, for the composition-of-matter of cabozantinib (the &#8216;473 Patent) and pharmaceutical compositions thereof. This composition of matter patent would expire in September 2024, but we have been granted a patent term extension to extend the term to August 2026. The following table describes the US patents that cover our marketed cabozantinib products, and which are listed in the Orange Book. Except as otherwise noted, the stated expiration dates include any patent term extensions </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">already granted. In addition to the composition of matter patent referenced above, the table includes patents directed to, among other things, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. We continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our cabozantinib products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent No.</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">General Subject Matter</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Expiration</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579,473</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,497,284</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877,776</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib </span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,724,342</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulations of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,039,757</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,034,873</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,579,473</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877,776</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,717,720</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulations of cabozantinib</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the importance of our intellectual property portfolio to our business operations, we intend to vigorously enforce our rights and defend against challenges that have arisen or may arise with respect to patents and patent applications required for the commercialization of medicines containing cabozantinib. For example, in September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets.&#160;MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against the &#8216;473 Patent, which expires on August 16, 2026, or U.S. Patent No. 8,497,284, which expires on September 24, 2024. On October 29, 2019, we filed a complaint for patent infringement against MSN asserting U.S. Patent No. 8,877,776 in the United States District Court for the District of Delaware (the Delaware District Federal Court) arising from MSN&#8217;s ANDA filing with the FDA. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously-unasserted CABOMETYX patents: the &#8216;473 Patent and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting the &#8216;473 Patent and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. We cannot predict the outcome of this lawsuit or assure you that the lawsuit will prevent the introduction of a generic version of CABOMETYX for any particular length of time, or at all.&#160;For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, cabozantinib is protected by issued patents covering the composition-of-matter and methods of use. The issued patent would expire in September 2024, but we have applied for and either have obtained, or expect to obtain Supplementary Protection Certificates in Europe to extend the term to 2029. In addition to the composition of matter patent, the table below includes later-expiring patents directed to the commercial product, including, particular salts, polymorphs, formulations, or use of the compound in the treatment of specified diseases or conditions. </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent No.</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">General Subject Matter</span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Expiration</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2213661</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter and methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2387563</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib and methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ </span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2213661</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter and methods of treatment</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2387563</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salt and polymorphic forms of cabozantinib and methods of treatment</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, in Japan, cabozantinib is protected by an issued patent covering the composition-of-matter, and salts thereof, as well as pharmaceutical compositions and related methods of use. We intend to apply for patent term extension in Japan to extend the term to 2029. Foreign counterparts of the issued U.S. and European composition of matter patents have been issued in Australia and Canada and are anticipated to expire in 2024. We have other filed patent applications and </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued patents in the U.S. and other selected countries covering certain synthetic methods, salts, polymorphs, formulations, prodrugs, metabolites and combinations of cabozantinib that, if issued, are anticipated to expire as late as 2035. Outside the U.S. and Japan, cabozantinib is licensed to Ipsen; in Japan cabozantinib is licensed to Takeda, each in accordance with the respective collaboration agreements. A discussion of risks and uncertainties that may affect our patent position and other proprietary rights is set forth in &#8220;Risk Factors,&#8221; contained in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Drug Candidates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have issued patents and pending patent applications, and will continue to file new patent applications, in the U.S., Europe and other selected countries covering our other drug candidates in clinical and/or preclinical development, including XL092, XL102 and XB002.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained licenses from various parties that give us rights to technologies that we deem to be necessary or desirable for our research and development. These licenses (both exclusive and non-exclusive) may require us to pay royalties as well as upfront and milestone payments.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require our scientific personnel to maintain laboratory notebooks and other research records in accordance with our policies, which are designed to strengthen and support our intellectual property protection. In addition to our patented intellectual property, we also rely on trade secrets and other proprietary information, especially when we do not believe that&#160;patent</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection is appropriate or can be obtained. We also require all of our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive proprietary information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all proprietary information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Furthermore, our agreements with employees and, in most circumstances, our agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors expressly provide that all inventions, concepts, developments, copyrights, trademarks or other intellectual property developed by an employee during the employment period, or developed by a service provider during the service period or utilizing our proprietary drugs or information, shall be our exclusive property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Employees and Commitment to Diversity, Equity and Inclusion</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had 773 full-time equivalent employees, representing a 25% increase in our employee workforce as compared to December 31, 2019. Of these employees, 409 are members of our various research and development teams and 364 are members of our various commercial and general and administrative teams. Of these employees, 126 hold Ph.D. degrees, 12 hold M.D. (or foreign equivalent) degrees, 20 hold PharmD degrees and 65 hold other professional degrees such as a J.D. or M.B.A. None of our employees are represented by a labor union, and we consider our employee relations to be good.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the past five years, our employee turnover has remained consistently below average for the U.S. life sciences industry generally, as well as for life sciences companies located in northern California.  Given our expanding operations and need to further grow our headcount to support our business, we continually assess employee turnover, recruitment initiatives, compensation and benefits programs, safety in performing critical laboratory work, diversity and other matters relevant to human capital management, and we review results with our Board of Directors on a periodic basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an equal opportunity employer and maintain policies that prohibit unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital and veteran status. We are proud to employ a diverse workforce that, as December 31, 2020, was 52% non-white and 53% women. In addition, as of December 31, 2020, 48% of our positions that manage other employees directly were held by non-whites and 46% were held by women, and women made up 33% of our senior leadership team. We strive to build and nurture a culture where all employees feel empowered to be their authentic selves. We respect and appreciate each employee&#8217;s unique perspective and experiences, and value their contribution to our mission.  It is important that we celebrate, encourage and support similarities and differences to drive innovation for the benefit of our employees, patients and community.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Culture, Compensation and Benefits</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Exelixis, we value being exceptional in what we do and how we lead, excelling for patients by going the extra mile to care for them and exceeding together as a business and contributor to the scientific community. We strive to live these values every day across the company, integrating them into everything from our interview, hiring and onboarding processes, to our performance evaluation, rewards and promotion programs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide generous compensation packages designed to attract and retain high-quality employees, and all of our employees are eligible for cash bonuses and grants of equity awards. We regularly evaluate our compensation programs with an independent compensation consultant and utilize industry benchmarking in an effort to ensure they are competitive compared to similar biotechnology and biopharmaceutical companies with which we compete for talent, as well as fair and equitable across our workforce with respect to gender, race and other personal characteristics. In addition, we are proud to provide a variety of programs and services to help employees meet and balance their needs at work, at home and in life, including an attractive mix of healthcare, insurance and other benefit plans. We deliver a benefits program that is designed to keep our employees and their families healthy, which includes not only medical, dental and vision benefits, but also dependent care, mental health and other wellness benefits. For a discussion of workplace safety measures we have taken, including as a result of the COVID-19 pandemic, see &#8220;&#8212;Environmental, Health and Safety.&#8221;       </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond compensation, we also value career development for all employees, and we offer a tuition reimbursement program, as well as professional development courses ranging from technical training, competency-based workshops and leadership development programs facilitated by external partners who are experts in their respective fields. Direct managers also take an active role in identifying individualized development plans to assist their employees in realizing their full potential and creating opportunities for promotions and added responsibilities that enhance the engagement and retention of our workforce.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in November 1994 as Exelixis Pharmaceuticals, Inc. and changed our name to Exelixis, Inc. in February 2000. Our principal executive offices are located at 1851 Harbor Bay Parkway, Alameda, California 94502. Our telephone number is (650) 837-7000. We maintain a site on the worldwide web at www.exelixis.com; however, information found on our website is not incorporated by reference into this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on or through our website our Securities and Exchange Commission (SEC) filings, including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a site on the worldwide web that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_16"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that make an investment in our securities speculative or risky, and that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business and the value of your investment in our company could be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indications for the cabozantinib franchise to increase the number of cancer patients who could benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the labeled indications in major commercial markets where CABOMETYX is approved, or if we or our partners fail to achieve anticipated product royalties and collaboration milestones, whether as a result of the COVID-19 pandemic or otherwise, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could depend on numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts and changes in pricing and reimbursement for CABOMETYX. For example, with respect to the recent FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, we cannot predict whether our commercialization efforts will lead to increased adoption of this combination by healthcare professionals, who may continue to treat first-line RCC patients with competing product combinations and reserve CABOMETYX for later in their treatment plan. If CABOMETYX does not continue to be prescribed broadly for the treatment of its approved RCC and HCC indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products, combination therapies and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology, biopharmaceutical and pharmaceutical industries are competitive and are characterized by constant technological change and diverse offerings of products, particularly in the area of novel oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. Given the shifting landscape of therapeutic strategy following the advent of ICIs, we believe our future success will depend upon our ability to achieve positive clinical trial results for therapies combining cabozantinib with ICIs across multiple indications, and if approved, successfully commercialize such combination therapies. While we have had success in adapting our development strategy for the cabozantinib franchise to address the expanding role of therapies that combine ICIs with other targeted agents, including the recent FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, it is uncertain whether current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in HCC, NSCLC and mCRPC, will lead to regulatory approvals, or whether physicians will prescribe regimens containing cabozantinib instead of competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biotechnology companies seeking to build out and maintain their commercial organizations, as well as other large pharmaceutical and biotechnology organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, or should we have to maintain primarily telephonic and virtual interactions in lieu of in-person meetings with healthcare professionals for an extended period of time as a result of the COVID-19 pandemic, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs, improving quality and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA, some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. Although such efforts have not significantly impacted our business to date, there is no assurance that the repeal, modification or invalidation of some or all of the provisions of the PPACA in the future, will not have a material adverse impact on our business, financial condition and results of operations, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. It is also possible that additional governmental actions will be taken in response to the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products. Furthermore, the expansion of the 340B Drug Discount Program has increased the number of purchasers who claim eligibility for significant discounts on branded drugs, including our marketed products. Due to general uncertainty in the current regulatory and healthcare policy environment, and specifically regarding positions that the new Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, we and any third parties we may engage may be unable to adapt to any changes implemented as a result of such measures, and we may have difficulties in sustaining profitability or otherwise experience a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as Executive Orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs; bring more transparency to drug pricing rationale and methodologies; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid, which affect the amount of rebates that we pay on prescription drugs under Medicaid and to covered entities under the 340B Drug Discount Program; eliminate the AKS discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and facilitate the importation of certain lower-cost drugs from other countries. While we cannot know the final form or timing of any such legislative, regulatory and/or administrative measures, some of the pending and enacted legislative proposals or executive rulemaking, such as those incorporating International Pricing Index or Most-Favored-Nation models, if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase general and administrative costs and/or diminish our revenues as a result of the imposition of caps on pricing and price increases. Therefore, the implementation of these cost-containment measures or other healthcare reforms may result in fluctuations in our results of operations and limit our ability to generate product revenue or commercialize our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., particularly in the EU, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In EU countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partner Ipsen may also be required to conduct a study that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives, increasingly based on affordability, could decrease the price we and Ipsen might establish for CABOMETYX, which would result in lower license revenues to us.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislation and regulatory action designed to facilitate the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the revenue we derive from our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve an NDA under section 505(b)(2) of the FDCA that relies in whole or in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug. Both the ANDA and 505(b)(2) processes are discussed in more detail above in &#8220;Item 1. Business&#8221; under the heading &#8220;Government Regulation&#8212;FDA Review and Approval&#8221; in this Annual Report on Form 10-K. In either case, if an ANDA or 505(b)(2) applicant submits an application referencing one of our marketed products prior to the expiry of one or more our </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs and divert the attention of management, and could have an adverse impact on our stock price. For example, MSN has submitted an ANDA to the FDA requesting approval to market a generic version of CABOMETYX tablets. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K. It is possible that MSN or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. The FDA Reauthorization Act of 2017 includes, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter alia,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. In addition, the FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2019, signed into law as part of the 2019 year-end federal spending package, purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing generic manufacturers access to branded drug samples. While the full impact of the CREATES Act is unclear at this time, its provisions do have the potential to facilitate the development and future approval of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the federal AKS;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the FDCA and its implementing regulations;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">HIPAA and its implementing regulations; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">state law equivalents of each of the above federal laws;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the Open Payments program of the PPACA;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">state and federal pharmaceutical price and price reporting laws and regulations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Furthermore, responding to any such allegation and/or defending against any such enforcement actions can be time-consuming and would require significant financial and personnel resources. Therefore, if any state or the federal government initiates an enforcement action against us, our business may be impaired, and even if we are ultimately successful in our defense, litigating these actions could result in substantial costs and divert the attention of management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The U.S. Department of Health and Human Services Office of Inspector General established guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities.  Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support. Should we or our hub providers receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve globally and in the U.S. For example, the CCPA went into operation in 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. These protections will be expanded by CPRA, which will be operational in most key respects on January 1, 2023. Similar legislative proposals are being advanced in other states and Congress is also considering federal privacy legislation. In addition, most healthcare providers are subject to privacy and security requirements under HIPAA. Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are developing, laws governing the collection, use and transmission of personal information. For example, the EU General Data Protection Regulation 2016/679 (GDPR) regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also restricts transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA, CPRA and GDPR, we could be subject to sanctions or other penalties, litigation or an increase in our cost of doing business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy for those products sufficiently impressive to compete in our highly competitive market environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of that product for a particular indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib (or of other product candidates) in new indications, and in some cases, as described in the risk factor titled, &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; the COVID-19 pandemic has already increased and may further increase the potential for such developments to occur. These may include:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our inability to identify and maintain a sufficient number of trial sites; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">additional complexities posed by clinical trials evaluating cabozantinib or our other product candidates in combination with other therapies, including the failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib or our other product candidates due to any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of the cabozantinib franchise or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of the cabozantinib franchise or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others: characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trials; and the length of time required to enroll eligible patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for cabozantinib or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable authorities in other territories. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or an MAA to the EMA or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-approval studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib in one or more new indications. For example, based on the regulatory feedback from the FDA, and if supported by the clinical data from COSMIC-021, we intend to submit an sNDA to the FDA seeking accelerated approval of cabozantinib in an mCRPC indication in 2021. We expect that as a condition of any potential approval accelerated approval, the FDA will require us to perform confirmatory post-marketing clinical trials to confirm the clinical benefit, if any, of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, such as mCRPC. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib in that indication. Further, regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. In response to the COVID-19 pandemic, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act and the Coronavirus Response and Relief Supplemental Appropriations Act of 2021, Presidents Trump and Biden have issued various executive orders, and additional legislative, executive, and regulatory proposals are pending to, among other things, prevent drug shortages and reduce the dependency of the United States on foreign supply chains and manufacturing. While we are still assessing these enacted and proposed changes, they could have a material adverse impact on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a highly competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160;We may also be unable to in-license or acquire additional product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our drug discovery efforts, including research collaborations and in-licensing arrangements, do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Financial Matters and Capital Requirements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $111.8 million and $321.0 million for the years ended December 31, 2020 and 2019, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; our achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including those associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates. For example, we reported a net loss for the quarter ended September 30, 2020, primarily due to substantial increases in clinical trial costs, license and other collaboration costs, and personnel expenses relative to the prior fiscal quarters, and it is possible that we may experience net losses in future fiscal quarters or fiscal years, whether due to increases in costs and expenses or otherwise. We expect to continue to spend substantial amounts to fund the continued development of the cabozantinib franchise for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including research collaborations and in-licensing arrangements that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of the cabozantinib franchise and increasing drug discovery activities, as well as through the execution of business development transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing&#160;economic conditions&#160;and financial, business and other factors beyond our control. Disruptions in the U.S. and&#160;global&#160;financial markets, including </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disruptions that have resulted and may continue to result from the COVID-19 pandemic and the related downturn in the U.S. and global economy, as well as future potential U.S. federal government shutdowns, rising interest rate environments, increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise additional funds in the capital markets. Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business.&#160;In particular, our inability to access additional funds, whether due to the COVID-19 pandemic or otherwise, could in the future inhibit our ability to engage in larger-scale strategic transactions or investments. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, the operations of our collaboration partners, and ultimately their foreign sales of CABOMETYX, could be adversely affected by the degree and effectiveness of their respective corporate responses to the COVID-19 pandemic, as well as by the imposition of governmental price or other controls, political and economic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or otherwise. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biotechnology, biopharmaceutical and pharmaceutical companies, including, Ipsen, Takeda, Roche and Genentech, BMS and Daiichi Sankyo, for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to a number of risks, including:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial (including as a result of the COVID-19 pandemic), or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our collaboration partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic which prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our drug discovery activities with multiple research collaborations and in-licensing arrangements with other companies, including StemSynergy, Invenra, Iconic, Aurigene, Catalent, NBE and Adagene. Our dependence on our relationships with these research and in-licensing partners subjects us to numerous risks, including:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our research and in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">disputes that may arise between us and our research and in-licensing partners that result in the delay or termination of research activities with respect to any in-licensed assets or supporting technology platforms;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the possibility that our research and in-licensing partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic, which prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our research and in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets or utilize technology platforms; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our research and in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to GMP and GLP.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new potential product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, whether as a result of the COVID-19 pandemic or otherwise, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical trial or data security protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to further our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities, distribution facilities or resources for CMC development activities, preclinical, clinical or commercial production and distribution for our current products and new product </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through secondary third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements, including as a result of the COVID-19 pandemic. Although we have not yet experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the DSCSA. If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by external factors, as we experienced in the early stages of the COVID-19 pandemic. If we experience additional delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber attack. Such vulnerabilities may be further exacerbated by the fact that our workforce is operating remotely as we comply with shelter in place orders and the recent rise in COVID-19 phishing attacks targeting remote workers. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber attacks on our operations and financial condition has not been material to date, we and our third-party service providers have frequently been the target of threats of this nature and expect them to continue. Any data breach and/or unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information or sensitive business information of our collaboration partners, which may lead to significant liability for us. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others and result in harm to our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents including the GDPR, subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our third-party service providers may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN concerning the ANDA that it had filed with the FDA seeking approval to market a generic version of CABOMETYX tablets. Should MSN or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. In addition, we may be subject to claims that our employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent inventions belonging to their former employers. Furthermore, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event of any third party&#8217;s successful claim of patent infringement or misappropriation of trade secrets, we may lose valuable intellectual property rights or personnel, which could impede or prevent the achievement of our product development goals, or we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations, Managing Our Growth and Employee Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular on our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials being conducted in regions impacted by COVID-19, we experienced declines in screening and enrollment activity, delays in new site activations, and restrictions on access to treatment sites that is necessary to monitor clinical study progress and initiation. However, as the COVID-19 pandemic continues to surge in various parts of the world, the impact on our clinical development operations could grow more severe. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing clinical trials. Disruptions to medical and administrative operations at clinical trial sites and the implementation of crisis management initiatives have and may </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to reduce personnel and other resources necessary to conduct our clinical trials, which could delay our clinical trial plans or require certain trials to be temporarily suspended. Moreover, quarantines and travel restrictions have impeded and may continue to impede patient movement or interrupt healthcare services, which we anticipate over time, could also interfere with and potentially negatively impact clinical trial execution, and ultimately results. In addition, increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in conducting those clinical trials to increase considerably. Specifically, with respect to our clinical trials evaluating cabozantinib in combination with therapies that must be administered via professional intravenous infusion, such as COSMIC-312, COSMIC-313, COSMIC-021, CONTACT-01, CONTACT-02, CONTACT-03, or our early-stage trials evaluating XL092 and other product candidates to the extent they may incorporate additional therapies that must be administered via professional intravenous infusion, limited patient movement or interrupted healthcare services at medical institutions have delayed in some instances, and may continue to delay or prevent, on-site infusion of the therapies being evaluated in combination with cabozantinib. If a sizable portion of patients in our combination studies are unable or unwilling to receive all components of the combination therapy being tested in accordance with the applicable clinical trial protocol, it could cause those studies to be delayed, suspended or prevented from producing statistically significant results.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the duration and severity of the COVID-19 pandemic, we could also experience delays in the commencement of new clinical trials of cabozantinib, or our earlier-stage investigative product candidates. The COVID-19 pandemic could also impede clinical operations and delay our planning and preparation timelines for new clinical trials, as well as adversely affect our ability to obtain regulatory approval for clinical protocols and increase the operating expenses connected with these new clinical trials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic caused us to suspend drug discovery work in our laboratories temporarily while we observed the shelter in place orders issued by the State of California and Alameda County. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. While both drug discovery work in our laboratories and outsourced drug discovery activities have since partially resumed, we may be unable to maximize the potential of these programs due to reduced staffing and the imposition of increased safety protocols, and should the COVID-19 pandemic continue to grow in severity, we may have to further scale back or suspend activities in the future. For example, as a result of spikes or surges in infection, positivity or hospitalization rates, we may choose or be required to suspend work in our laboratories, which will once again impede our drug discovery efforts. With respect to the preclinical development work and drug discovery activities outsourced to third-party contractors, the COVID-19 pandemic could again impede these third parties from providing timely deliverables to us in the future. In addition, should we experience delays in the construction of new laboratory facilities due to the COVID-19 pandemic, our ability to expand our drug discovery activities may be impaired. As a result, should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our commercial business has, to date, only experienced a modest impact related to the COVID-19 pandemic, it remains possible that over a longer period, changes to our standard sales and marketing practices, including the shift from in-person to primarily telephonic and virtual interactions with healthcare professionals, could negatively impact the flow of important information regarding our medicines, which along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although as of the date of this Annual Report, we continue to maintain substantial safety stock inventories for our drug substance and drug products and have not experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. These delays or disruptions could be further exacerbated if the COVID-19 pandemic begins to impact essential distribution systems, which could substantially increase delivery times and costs, or otherwise adversely affect our ability to provide our products to customers and clinical trial sites and generate product revenues. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have taken numerous temporary precautions to help mitigate the risk of transmission of the virus, including: reducing the number of our employees working on-site at our Alameda headquarters under enhanced safety and social distancing protocols; suspending all non-essential business travel for our employees; and limiting the circumstances under which our field employees may engage in in-person promotional activities with healthcare professionals. Over a longer period, these measures could delay our research and development programs, reduce engagements with potential prescribers for our products, and impede our ability to execute on our long-term business </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plans. Further, extended periods of remote work could impede the focused attention of management or reduce the productivity of teams that would otherwise be working closely together.&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of broad economic shifts during and as a consequence of efforts to address unemployment and other negative economic effects the COVID-19 pandemic, we may experience further reductions in the net price of our products. For example, there may be a substantial shift from private health insurance coverage to government insurance coverage, or additional downward pressure on the prices government purchasers will pay for our products due to significant increases in government debt incurred in connection with relief efforts, as well as significant increases in demand for our patient assistance and/or free drug program or other impacts that may not be foreseeable, all or any of which would adversely affect our product revenues.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect the COVID-19 pandemic to continue to have varying degrees of adverse impact on our business operations and, potentially in the future, our financial results, the extent of such adverse impact will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease, including the rate at which vaccinations are made available and the percentage of the population that becomes vaccinated.  These effects could materially and adversely affect our business, financial condition, results of operations and growth prospects, and exacerbate the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations, in particular as we continue to expand the cabozantinib franchise into new indications and grow our pipeline of product candidates. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, including as a result of the COVID-19 pandemic or otherwise, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development program for the cabozantinib franchise and our other product candidates, successfully executing upon our commercialization plan for the cabozantinib franchise and our proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Similarly, the COVID-19 pandemic could negatively impact the health of key personnel or make it difficult to recruit qualified personnel for critical positions. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third parties of these materials, and such liability may exceed our insurance coverage and our total assets. In addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. We maintain limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib. However, our insurance may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and it may remain highly volatile or fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of FDA approval or non-approval, or delays in the FDA review process with respect to cabozantinib, our collaboration partners&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for the cabozantinib franchise or any of our other programs or product candidates;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to make future investments in the expansion of our pipeline through drug discovery, including future research collaborations, in-licensing arrangements and other business development activities;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib; </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of regulatory applications, such as MSN&#8217;s ANDA, seeking approval of generic versions of our marketed products;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the disposition of any of our technologies or compounds; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors, such as the impact of the COVID-19 pandemic on financial markets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and economic conditions, including the effects of the COVID-19 pandemic, policies governing foreign trade and healthcare spending and delivery, or future potential U.S. federal government shutdowns, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected, and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_19"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located in Alameda, California, where&#160;we lease a total of 228,941 square feet of space. We expect to take possession of an additional 25,749 square feet of space on or prior to June 1, 2021. The lease expires in October 2031. We have two five-year options to extend the lease. In October 2019, we entered into a build-to-suit lease agreement (the Build-to-Suit Lease) for approximately 220,000 square feet of additional office facilities adjacent to our current corporate headquarters. The term of the Build-to-Suit Lease is for a period of 242 months, which will begin on the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the term will begin in April 2022. We believe these leased facilities are sufficient to accommodate our current and near-term needs.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_25"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orange Book. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_28"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_34"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has traded on the Nasdaq Global Select Market under the symbol &#8220;EXEL&#8221; since April 11, 2000.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;1, 2021, there were 361 holders of record of our common stock. The number of record holders is based upon the actual number of holders registered on our books at such date and does not include holders of shares in &#8220;street names&#8221; or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have not paid dividends on our common stock. We currently intend to retain all future earnings, if any, for use in our business and currently do not plan to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board of Directors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unregistered sales of equity securities by us during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repurchases of Equity Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no repurchases&#160;of our common stock during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of ours under the Securities Act of 1933, as amended.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares, for the five-year period ended December&#160;31, 2020, the cumulative total return for our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The graph assumes that $100 was invested on December&#160;31, 2015 in each of our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes reinvestment of any dividends. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-top:9pt;text-indent:36pt"><img src="exel-20210101_g2.jpg" alt="exel-20210101_g2.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2015</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2016</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Composite Total Return</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Biotechnology Total Return</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_37"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Selected Financial Data</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Selected Financial Data has been derived from our audited Consolidated Financial Statements and should be read in conjunction with Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and Part II, Item 8. &#8220;Financial Statements and Supplementary Data&#8221; contained in this Annual Report on Form 10-K. The consolidated financial information as of December 31, 2020 and 2019, and for the years ended, December 31, 2020, 2019 and 2018 are derived from audited Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K. The consolidated financial information as of December 31, 2018, 2017 and 2016, and for each of the years ended December 31, 2017 and 2016, are derived from audited Consolidated Financial Statements not included in this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020; fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018; fiscal year 2017, which was a 52-week fiscal year, ended on December 29, 2017 and fiscal year 2016, which was a 52-week fiscal year, ended on December 30, 2016.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:38.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Income Data:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:38.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2017</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and investments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,137,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,885,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Revenues for the years ended December 31, 2020, 2019 and 2018 are presented under Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), while revenues for the years ended December 31, 2017 and 2016  continue to be reported in accordance with our historic accounting under previous revenue recognition guidance, Accounting Standards Codification Topic 605: Revenue Recognition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    See &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of this Annual Report on Form 10-K for additional discussion of our operating results.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)    Net income for the year ended December 31, 2018 included a $244.1 million income tax benefit related to the release of substantially all of the valuation allowance against our deferred tax assets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)    The decreases in long-term obligations were primarily due to the repayment of the Secured Convertible Notes due 2018 held by entities associated with Deerfield Management Company, L.P. in 2017, the repayment of the $80.0 million term loan with Silicon Valley Bank in 2017, and the conversions and redemption in 2016 of the 4.25% convertible senior subordinated notes due 2019.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of the statements under in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January&#160;3, 2020, and fiscal year 2018, which was a 52-week fiscal year, ended on December&#160;28, 2018. For convenience, references in this report as of and for the fiscal years ended January&#160;1, 2021, January&#160;3, 2020 and December&#160;28, 2018 are indicated as being as of and for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis generally addresses 2020 and 2019 items and year-over-year comparisons between 2020 and 2019. Discussions of 2018 items and year-over-year comparisons between 2019 and 2018 that are not included in this Annual Report on Form 10-K can be found in &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019, filed with the SEC on February&#160;25, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, four products resulting from our discovery efforts have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX tablets approved for advanced RCC, both alone and in combination with OPDIVO, and for previously treated HCC; and COMETRIQ capsules approved for progressive, metastatic MTC. For these types of cancer, cabozantinib has become or is becoming a standard of care. The other two products resulting from our discovery efforts are: COTELLIC, an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech; and MINNEBRO, an oral, non-steroidal, selective blocker of the MR, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA first approved CABOMETYX for previously treated patients with advanced RCC in April 2016, and in December 2017 the FDA expanded CABOMETYX&#8217;s approval to include previously untreated patients with advanced RCC. Additionally, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib. Most recently on January 22, 2021, the FDA approved CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen and Takeda. We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the EU and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in September 2020, Ipsen and BMS submitted type II variation applications to the EMA to approve the combination of CABOMETYX and OPDIVO as a treatment for advanced RCC, with the EMA validating the type II variations and beginning its centralized review process, and both Ipsen and BMS plan to submit applications to approve the combination in other territories beyond the EU. With respect to the Japanese market, Takeda achieved important milestones in 2020, including receipt of Manufacturing and Marketing Approvals from the Japanese MHLW of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. In October 2020, Takeda and Ono submitted a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could benefit from this medicine. We are evaluating cabozantinib, both as a single agent and in combination with other therapies, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple indications. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our CRADA with NCI-CTEP or our IST program. Informed by the available data from these clinical trials, we continue to advance the development program for the cabozantinib franchise with potentially label-enabling trials. One pivotal trial that has resulted from this effort is COSMIC-311, our ongoing phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with RAI-refractory DTC who have progressed after up to two VEGF receptor-targeted therapies. In December 2020, we announced that COSMIC-311 had met its co-primary endpoint of demonstrating significant improvement in PFS. We intend to discuss the study results, proposed changes to the study conduct, as well as plans for filing an sNDA with the FDA in 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are particularly interested in continuing to evaluate cabozantinib&#8217;s potential in combination with ICIs to determine if these combinations further improve outcomes for patients. Building on preclinical and clinical observations that cabozantinib may promote a more immune-permissive tumor environment potentially resulting in cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of ICIs. CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of cabozantinib and nivolumab compared to sunitinib in previously untreated advanced or metastatic RCC, for which we and our collaboration partner BMS announced positive top-line results in April 2020, is reflective of this strategy. The trial met its primary endpoint of PFS at final analysis, as well as the secondary endpoints of OS at a pre-specified interim analysis and ORR, and showed that the combination of cabozantinib with nivolumab significantly reduced the risk of disease progression or death compared with sunitinib. Data from CheckMate -9ER were presented at Presidential Symposium I at the ESMO Virtual Congress 2020 in September 2020 and served as the basis for the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021. We have also collaborated with BMS on CheckMate 040, a multi-cohort phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with previously treated or previously untreated advanced HCC, for which initial clinically meaningful results were presented at the ASCO Gastrointestinal Cancers Symposium in January 2020, and COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. We expect to complete enrollment for COSMIC-313 in early 2021 and report top-line results of the event-driven analyses from the trial in 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to diversify our exploration of combinations with ICIs, we have also initiated multiple trials evaluating cabozantinib in combination with Roche&#8217;s ICI, atezolizumab. COSMIC-312 is a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, for which we announced in August 2020 that enrollment was completed. Based on current event rates, we anticipate announcing top-line results in the first half of 2021, and if the data are supportive, we anticipate filing an sNDA with the FDA in 2021. COSMIC-021 is a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Based on continuing encouraging efficacy and safety data certain cohorts have been or may be further expanded, including the cohorts of patients with NSCLC who have been previously treated with an ICI and mCRPC who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue. We anticipate completing enrollment of up to 1,732 patients in the trial in the first half of 2021, although both the timing and final number of patients are subject to the initiation of additional cohorts or expansion of selected existing cohorts, as well as any further delays resulting from the COVID-19 pandemic. Since the initiation of the trial, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, and three phase 3 pivotal trials in collaboration with Roche, CONTACT-01, CONTACT-02 and CONTACT-03, evaluating the combination of cabozantinib with atezolizumab in patients with metastatic NSCLC, mCRPC and  advanced RCC, respectively. Encouraging results from interim analyses from the mCRPC, NSCLC, clear cell RCC and non-clear cell RCC cohorts of COSMIC-021 were presented at various medical conferences throughout 2020. Based on regulatory feedback from the FDA, and if supported by the clinical data, we intend to file with the FDA for accelerated approval in an mCRPC indication in 2021. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6 million compounds. We have extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases. We also augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies engaged in small molecule discovery, including StemSynergy and Aurigene. For additional information on these research collaborations and in-licensing arrangements related to our small molecule programs, see &#8220;Business&#8212;Collaborations&#8212;Research Collaborations and In-licensing Arrangements&#8221; in Part I, Item 1 of this Annual Report on Form 10-K. The first compound to advance from our recent internal drug discovery efforts is XL092, a next-generation oral TKI that is currently in a phase 1 clinical trial in patients with advanced solid malignancies for which dose-escalation cohorts evaluating the compound, both as a single agent and in combination with atezolizumab, are currently enrolling. We presented data that support the ongoing clinical development of XL092 at the 32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> EORTC-NCI-AACR (ENA) Symposium in October 2020, and we expect that once recommended doses of both single-agent XL092 and XL092 in combination with atezolizumab are established, the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell RCC, hormone-receptor positive breast cancer and mCRPC. We also submitted an IND in November 2020 for XL102, the lead Aurigene program targeting CDK7, and initiated a phase 1 clinical trial in January 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also focusing our drug discovery activities on discovering and advancing various biologics, such as bispecific antibodies, ADCs and other innovative biologics that have the potential to become anti-cancer therapies. We believe that biotherapeutics of these classes have the potential to be significant cancer therapies, as evidenced, for example, by the multiple regulatory approvals for the commercial sale of ADCs in the past year. To facilitate the growth of our biologics programs, we have established multiple research collaborations and in-licensing arrangements that provide us with access to antibodies or other binders, which are the starting point for use with additional technology platforms that we employ to generate next-generation ADCs or bispecific antibodies. Our current research collaborations and in-licensing arrangements for biologics programs include Invenra, Iconic, NBE, Catalent and Adagene. We have already made significant progress under these research collaborations and in-licensing arrangements and believe we will continue to do so in 2021. For example, XB002, the lead Tissue Factor ADC program with Iconic, has continued to progress through preclinical development, and we plan to submit an IND once the drug product release assays are finalized. For additional information on these research collaborations and in-licensing arrangements related to our biologics programs, see &#8220;Business&#8212;Collaborations&#8212;Research Collaborations and In-licensing Arrangements&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. In total, we are advancing drug candidates across approximately 20 ongoing discovery programs toward and through preclinical development, and subject to preclinical data, we have the potential to submit multiple INDs in 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, the COVID-19 pandemic continues to have a modest impact on our business operations, in particular on our clinical trial, drug discovery and commercial activities. We have and continue to undertake considerable efforts to mitigate the various problems presented by this crisis, including as described below:</span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To varying degrees and at different rates across our clinical trials being conducted in regions impacted by COVID-19, we have experienced declines in screening and enrollment activity, delays in new site activations, and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. However, beginning with the second quarter of 2020 and throughout the rest of 2020, we experienced an increase in screening and enrollment activity, and overall, we and our collaboration partners, including principal investigators and personnel at clinical trial sites, have been successful in preventing material delays to our ongoing and planned clinical trials. We have done this through ongoing assessment of the COVID-19 pandemic&#8217;s impact and, wherever possible, taking proactive steps in compliance with guidance issued by the FDA, EMA and other regulatory agencies to support the safety of our patients and their access to treatment, as well as to maintain the high quality of our clinical trials. We recognize, however, that we may have to make further operational adjustments to our ongoing and planned clinical trials and that patient enrollment, and new clinical trial site initiations may be further slowed due to the COVID-19 pandemic, especially if it is further prolonged or grows in severity. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Discovery and Preclinical Development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have partially resumed internal drug discovery in our laboratories following a temporary suspension of these activities while we observed the shelter in place orders issued by the State of California and Alameda County. While this temporary suspension did not result in any significant changes to the timelines for our late-stage discovery work, we did experience modest delays in the advancement of certain of our early-stage programs. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. However, those service providers have resumed discovery work and are meeting their contractual obligations in accordance with planned timelines. With respect to the preclinical development work outsourced to third-party contractors, to date that work has continued without substantial delay or interference resulting from the COVID-19 pandemic. While we continue to utilize our resources effectively to move new product candidates toward the clinic, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines due to the COVID-19 pandemic, especially if it is further prolonged or grows in severity.</span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Although our field employees have limited their in-person promotional activities and transitioned to primarily telephonic and virtual interactions, they remain engaged with healthcare professionals and are available to them as an informational resource. Nevertheless, with healthcare professionals acutely focused on the COVID-19 pandemic and patient access to healthcare professionals limited due to shelter in place orders, we experienced a decrease in prescriptions for CABOMETYX in 2020, which we believe was, at least in part, attributable to the COVID-19 pandemic. We also observed fluctuations in CABOMETYX ordering, and we believe that this effect could continue depending on developments related to the COVID-19 pandemic. Overall, despite the challenges posed by the pandemic, our commercial business has only experienced a modest impact. We believe this is the case largely because of the gravity of the cancer conditions that our products are indicated to treat and the fact that CABOMETYX has been available as an orally administrable cancer treatment in the U.S. since 2016, thereby establishing a safety and efficacy profile that is well known to healthcare professionals. It remains possible, however, that over a longer period, changes to our standard sales and marketing practices resulting from the COVID-19 pandemic, including the shift from in-person to primarily telephonic and virtual interactions with healthcare professionals, along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products. </span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have not experienced production delays or seen any significant impairment to our supply chain as a result of the COVID-19 pandemic. In addition, we continue to maintain substantial safety stock inventories for our commercial drug substance and drug products, which should be sufficient to maintain robust long-term supply. We continue to work closely with our third-party contract manufacturers, distributors, suppliers, comparator drug sourcing vendors and collaboration partners to safeguard both the timely production and delivery of our products. If the COVID-19 pandemic is further prolonged or becomes more severe, however, we are prepared to modify our manufacturing and supply chain operations as appropriate in response. </span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Business Operations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have taken numerous temporary precautions to help mitigate the risk of transmission of the virus, including reducing the number of our employees working on-site at our Alameda headquarters under enhanced safety and social distancing protocols and initiating an on-site testing program. Although having most of our employees continue to work remotely has required that we devise new ways of working and collaborating, to date, the COVID-19 pandemic has only had a modest impact on our productivity and has not caused significant interruptions in our general business operations. If the COVID-19 pandemic is further prolonged or becomes more severe, however, we may find it more challenging to maintain that level of productivity, to grow the company as we have anticipated, and to execute on our long-term business plans. For a discussion of workplace safety measures we have taken as a result of the COVID-19 pandemic, see &#8220;Business&#8212;Environmental, Health and Safety&#8212;Workplace Safety Measures in Response to COVID-19&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The circumstances surrounding the COVID-19 pandemic are volatile and subject to rapid change. Despite our mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business, which are described in more detail in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. We recognize that this pandemic will continue to present unique challenges for us throughout 2021, and potentially into 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our business, see &#8220;Business&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Business Updates and Financial Highlights</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we continued to execute on our business objectives, generating significant revenue from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for 2020 and subsequent to year-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In January 2020, clinically meaningful data from CheckMate 040, the phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with previously treated or previously untreated advanced HCC, were presented at the ASCO Gastrointestinal Cancers Symposium.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In February 2020, we presented clinically meaningful results from the mCRPC cohort of COSMIC-021 at the ASCO Genitourinary Cancers Symposium.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In March 2020, Takeda received regulatory approval from the Japanese MHLW to manufacture and market CABOMETYX as a treatment for patients in Japan with curatively unresectable or metastatic RCC.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In May 2020, we filed a second complaint in our patent infringement lawsuit against MSN, following receipt of notice from MSN that it had amended its ANDA, originally filed with the FDA in September 2019, to assert additional Paragraph IV certifications. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part I, Item 3 of this Annual Report on Form 10-K. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In June 2020, we announced the initiation of CONTACT-01, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy. The primary endpoint of the trial is OS, and the secondary endpoints include PFS, ORR and DOR.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In June 2020, we announced the initiation of CONTACT-02, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with mCRPC who have been previously treated with one novel hormonal therapy. The co-primary endpoints of the trial are PFS and OS, and the secondary endpoints include ORR, prostate-specific antigen response rate and DOR.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In July 2020, we announced the initiation of CONTACT-03, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with inoperable, locally advanced or metastatic RCC who progressed during or following treatment with an ICI as the immediate preceding therapy. The co-primary endpoints for the trial are PFS per RECIST v. 1.1 as assessed by independent review and OS, and secondary endpoints include PFS, ORR and DOR as assessed by the investigators.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In July 2020, the FDA approved the sBLA submitted by Genentech for atezolizumab plus cobimetinib and vemurafenib for the treatment of BRAF V600-mutation positive advanced melanoma in previously untreated patients. </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In August 2020, we announced the completion of patient enrollment in COSMIC-312, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, providing the patient population for the event-driven analyses of the study&#8217;s endpoints of PFS and OS. Separately, patient enrollment remains open in China in order to enroll a sufficient number of patients to potentially enable local registration. We anticipate announcing top-line results in the first half of 2021, and if the data are supportive, we anticipate filing an sNDA with the FDA in 2021.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In September 2020, we announced a collaboration and license agreement with Catalent&#8217;s subsidiary Redwood Bioscience to develop multiple ADCs using Catalent&#8217;s proprietary SMARTag&#174; site-specific bioconjugation technology.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In September 2020, we announced a collaboration and license agreement with NBE to discover and develop multiple ADCs for oncology applications by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, including NBE&#8217;s SMAC-Technology and novel payloads.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In September 2020, we announced that our collaboration partners Ipsen and BMS each submitted type II variation applications for the combination of CABOMETYX and OPDIVO as a treatment for advanced RCC to the EMA.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In October 2020, we presented data that support the ongoing clinical development of XL092 at the 32nd ENA Symposium and announced enrollment of the first patient into the dose-escalation cohort of the combination arm of the phase 1 trial evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL092 alone and in combination with atezolizumab in patients with advanced solid tumors. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In October 2020, our collaboration partner Takeda, along with Ono, submitted a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of the combination of CABOMETYX and OPDIVO as a treatment for patients with advanced RCC.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In November 2020, Takeda received regulatory approval from the Japanese MHLW to manufacture and market CABOMETYX as a treatment for patients in Japan with unresectable HCC that progressed after cancer chemotherapy.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In December 2020, we and Iconic announced that we exercised our exclusive option for XB002, Iconic&#8217;s lead oncology ADC program under the collaboration, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization for XB002. We anticipate submitting an IND for XB002 in 2021 once the drug product release assays are finalized and, pending the FDA&#8217;s acceptance of the IND, initiating a phase 1 clinical trial.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In December 2020, we and Aurigene announced that we exercised our exclusive option for XL102, Aurigene&#8217;s lead program targeting CDK7, resulting in our assuming responsibility for all subsequent clinical development, manufacturing and commercialization of XL102. Following the FDA&#8217;s acceptance of the IND for XL102, in January 2021, we initiated a phase 1 clinical trial evaluating XL102, both as a single agent and in combination with other anti-cancer therapies for the treatment of inoperable, locally advanced or metastatic solid tumors.  </span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In December 2020, we announced that COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib in patients with RAI-refractory DTC who have progressed after up to two prior VEGF receptor-targeted therapies, met its co-primary endpoint of significantly improving PFS. We intend to discuss the study results, proposed changes to the study conduct, as well as plans for filing an sNDA with the FDA in 2021.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In January 2021, the FDA approved the combination of CABOMETYX and OPDIVO as a first-line treatment of patients with advanced RCC, and we and BMS commenced the commercial launch of the combination upon such approval. The approval was based on positive results from the phase 3 pivotal trial, CheckMate -9ER, in which the combination met its primary endpoint of significantly improving PFS at final analysis, as well as the secondary endpoints of OS at a pre-specified interim analysis and ORR, versus sunitinib. Data from the study were presented as part of the Presidential Symposium I at the ESMO Virtual Congress 2020 in September 2020 and will be presented at the virtual ASCO Genitourinary Cancers Symposium in February 2021</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">In February 2021, we announced a collaboration and license agreement with Adagene to utilize Adagene&#8217;s SAFEbody technology platform to generate masked versions of mAbs from our growing preclinical pipeline for the development of ADCs or other innovative biologics.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Financial Highlights</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Net product revenues for 2020 were $741.6 million, compared to $760.0 million for 2019.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Total revenues for 2020 were $987.5 million, compared to $967.8 million for 2019.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Research and development expenses for 2020 were $547.9 million, compared to $337.0 million for 2019.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Selling, general and administrative expenses for 2020 were $293.4 million, compared to $228.2 million for 2019.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Provision for income taxes for 2020 was $19.1 million, compared to $77.1 million for 2019.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Net income for 2020 was $111.8 million, or $0.36 per share, basic and $0.35 per share, diluted, compared to $321.0 million, or $1.06 per share, basic and $1.02 per share diluted, for 2019.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Cash and investments increased to $1.5 billion at December&#160;31, 2020, compared to $1.4 billion at December&#160;31, 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Challenges and Risks</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the challenges and risks imposed by the COVID-19 pandemic and described under &#8220;&#8212;COVID-19 Update&#8221; above, we will also continue to face challenges and risks that may impact our ability to execute on our 2021 business objectives, and some of these risks to our business have been or may be exacerbated by the COVID-19 pandemic. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone or in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at limiting access to, and restricting the prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our 2021 business objectives will also depend on our ability to maintain a competitive position with respect to the shifting landscape of therapeutic strategy for the treatment of cancer, which we may not be able to do. While we have had success in adapting our development strategy for the cabozantinib franchise and other product candidates to address the expanding role of therapies that combine targeted agents with ICIs and/or with other mechanisms of action, it is uncertain whether current and future clinical trials will lead to regulatory approvals, or whether physicians will prescribe regimens containing our products instead of competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic version of CABOMETYX tablets that is the subject of an ANDA submitted to the FDA by MSN, which if approved, could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with drug discovery operations, all of which may be increased as a result of the COVID-19 pandemic. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, and others are common to companies in the biotechnology, biopharmaceutical and pharmaceutical industries with development and commercial operations. Moreover, as described under &#8220;&#8212;COVID-19 Update&#8221; above, these risks have been or may be exacerbated by the COVID-19 pandemic. For a more detailed discussion of challenges and risks we face, including those relating to the COVID-19 pandemic, see &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_43"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020, and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2021, January 3, 2020 and December 28, 2018 are indicated as being as of and for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis generally addresses 2020 and 2019 items and year-over-year comparisons between 2020 and 2019. Discussions of 2018 items and year-over-year comparisons between 2019 and 2018 that are not included in this Annual Report on Form 10-K can be found in &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019, filed with the SEC on February&#160;25, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.292%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.046%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in net product revenues for CABOMETYX for the year ended December&#160;31, 2020, as compared to 2019, was primarily due to a decrease in sales volume and an increase in discounts and allowances, partially offset by an increase in the average selling price. The decrease in sales volume was driven by a decrease in prescriptions, consistent with a decline in the market for TKIs, and which we believe was, at least in part, attributable to the COVID -19 pandemic. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in net product revenues for COMETRIQ for the year ended December&#160;31, 2020, as compared to 2019, was primarily due to a decrease in the number of units of COMETRIQ sold, including a decrease in units sold for use as a comparator in clinical trials, partially offset by an increase in the average selling price. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our 2021 net product revenues to increase over 2020, primarily as a result of the growth in the number of units sold following the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first line treatment of patients with advanced RCC, as well as an increase in selling price, reflecting the continued evolution of the metastatic RCC and HCC treatment landscapes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances as described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K. The increase in discounts and allowances for the year ended December&#160;31, 2020, as compared to 2019, was primarily the result of an increase in Public Health Service hospital utilization and the dollar amount of the related chargebacks, and to a lesser extent, an increase in utilization and the dollar amount of the related Medicaid utilization. We expect an increase in our discounts and allowances as a percentage of gross product revenues during 2021 as the number of patients participating in government programs continues to increase, and as the discounts given and rebates paid to government payers also increase.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues include the recognition of the portion of milestone revenues allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and the profit on the U.S. commercialization of COTELLIC from Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Milestone Revenues. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues, which are allocated between license revenues and collaboration services revenues, were $86.5 million for the year ended December&#160;31, 2020, as compared to $96.2 million for 2019. Due to the nature and timing of milestone events, their achievement can vary significantly from year to year. Milestone revenues by period primarily included the following:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Milestone revenues for the year ended December 31, 2020 primarily included: (1) recognition of $25.7 million in revenues in connection with a $31.0 million milestone achieved upon Takeda&#8217;s first commercial sale of CABOMETYX for the treatment of patients with curatively unresectable or metastatic RCC in Japan; (2) recognition of $19.0 million in revenues in connection with a $20.0 million development milestone from Ipsen for the initiation of a phase 3 pivotal trial; (3) recognition of $9.3 million in revenues in connection with a $10.0 million milestone for Takeda&#8217;s and Ono&#8217;s submission of a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC; (4) recognition of $14.0 million in revenues in connection with a $15.0 million in milestone we achieved upon Takeda&#8217;s first commercial sale of CABOMETYX for the treatment of patients with advanced HCC; and (5) recognition of $14.0 million in revenues in connection with $15.0 million milestones from Takeda for the initiation of two phase 3 pivotal clinical trials that were deemed probable of being achieved in 2021.</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Milestone revenues for the year ended December 31, 2019 primarily included: (1) recognition of a $50.0 million milestone from Ipsen upon their achievement of $250.0 million in net sales of cabozantinib in their territories over four consecutive quarters; (2) recognition of a $20.0 million milestone from Daiichi Sankyo for the first commercial sale of MINNEBRO tablets as a treatment for patients with hypertension in Japan; (3) recognition of $9.9 million in revenues related to a $16.0 million milestone from Takeda for the submission of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese MHLW; (4) recognition of $9.1 million in revenues related to a $10.0 million milestone from Takeda for the submission of a regulatory application in January 2020 for cabozantinib as a treatment for patients with advanced HCC to the Japanese MHLW; and (5) recognition of two milestones totaling $5.0 million from Ipsen on the approvals by Health Canada of cabozantinib for the treatment of adults with first-line RCC and for the treatment of adults with advanced HCC who have been previously treated with sorafenib. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestones revenues and milestones can vary significantly from period to period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Royaltie</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties increased primarily as a result of an increase in royalties on Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan driven by increased demand for CABOMETYX, which, as of December&#160;31, 2020, is approved and commercially available in 57 countries outside of the U.S. Royalties also increased due to the commercial launch of CABOMETYX for the treatment of patients with curatively unresectable or metastatic RCC in Japan by Takeda during the second quarter of 2020 and of HCC in the fourth quarter of 2020.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COTELLIC Profit Share.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $6.3 million for the year ended December 31, 2020, as compared to $4.6 million for 2019. We also earned royalties on ex-U.S. net sales of COTELLIC by Genentech of $5.1 million for the year ended December 31, 2020, compared to $5.7 million for 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our license revenues to decrease in 2021, as compared to fiscal 2020, as a result of the anticipated achievement of fewer milestones in 2021, partially offset by an increase in royalty revenues related to an increase in product sales by Ipsen and Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations,  development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs and the royalties we pay to GlaxoSmithKline (GSK) on sales by Ipsen and Takeda of products containing cabozantinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements increased to $76.3 million in 2020, as compared to $44.8 million in 2019, primarily as a result of reimbursements from Ipsen and Takeda associated with their decisions in 2020 to opt in and co-fund CONTACT-01, CONTACT-02 and additional cohorts of COSMIC-021, and their respective share of the increase in spending on the COSMIC-312, COSMIC-021 and CONTACT-02 studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $10.6 million for the 3% royalty we are required to pay GSK on the net sales by Ipsen and Takeda of any product incorporating cabozantinib for the year ended December 31, 2020, as compared to $8.4 million in 2019. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments to GSK have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues to decrease in 2021, as compared to fiscal 2020, primarily as a result of lower development cost reimbursements projected to be earned under our collaboration agreements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margins were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty payable to GSK on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring and excess inventory, and other third-party logistics costs. The increase in cost of goods sold for the year ended December&#160;31, 2020, as compared to 2019, was primarily the result of increases in write-downs of excess and expiring inventory and certain other period costs. We project our 2021 gross margin to remain consistent with 2020.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,902&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Includes stock-based compensation and the allocation of general corporate costs to research and development services, and development cost reimbursements in connection with the December 2019 collaboration arrangement with Roche.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in research and development expenses for the year ended December 31, 2020, as compared to  2019, was primarily related to increases in clinical trial costs, license and other collaboration costs, personnel expenses and stock-based compensation, partially offset by the impact of increased development cost reimbursements. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, increased primarily due to costs associated with the expanding clinical trial program for cabozantinib. License and other collaboration costs increased primarily due to increases in upfront license fees, option exercise fees and research funding commitments related to business development activities. Personnel expenses increased primarily due to increases in headcount to support our expanding discovery and development organization. Stock-based compensation increased primarily due to the performance-based restricted stock units (PSUs) granted in 2019 that became probable of achievement during 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the year ended December 31, 2020 and 2019 were offset by $15.1 million and $1.1 million, respectively, as a result of development cost reimbursements in connection with our collaboration arrangement with Roche.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focusing our development efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a significant portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over 100 ongoing or planned clinical trials across multiple indications. Notable company-sponsored studies resulting from this program include: COSMIC-021 and COSMIC-312, for which Roche is providing atezolizumab free of charge; COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; CONTACT-02 for which Roche is sharing in the development costs including the provision of atezolizumab free of charge; and COSMIC-311.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to expanding our oncology product pipeline through our drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. In this regard, we conduct drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. In addition, we will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses will continue to increase in 2021 as compared to 2020, driven by our ongoing clinical evaluation of cabozantinib, the initiation of clinical trials evaluating other product candidates in our pipeline, (including XL092 and XL102) and anticipated business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of, or total costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs and certain other administrative costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in selling, general and administrative expenses for the year ended December 31, 2020, as compared to 2019, was primarily related to the increases in stock-based compensation, corporate giving and personnel expenses. The </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in stock-based compensation was primarily due to PSUs granted in 2019 that became probable of achievement during 2020. Personnel expenses increased primarily due to increases in administrative headcount to support our commercial and research and development organizations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses will continue to increase in 2021, as compared to 2020 in support of our continued commercial investment in CABOMETYX and the growth in the broader organization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,639&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in non-operating income for the year ended December&#160;31, 2020, as compared to 2019, was primarily the result of lower interest income due to lower interest rates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.347%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.035%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in provision for income taxes for the year ended December 31, 2020, as compared to 2019, was primarily due to the decrease in pre-tax income. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e effective tax rate for the year ended December 31, 2020 differed from the U.S. federal statutory rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits, offset by non-deductible executive compensation during the periods. The effective tax rate for the year ended December 31, 2019 differed from the U.S. federal statutory ra</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">te of 21% primarily due to excess tax benefits related to the exercise of certain stock options and federal tax credits during the periods. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project that our effective tax rate will be between 20% and 22% in 2021.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had $1.5 billion in cash and investments, compared to $1.4 billion as of December 31, 2019. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project that we will continue to spend significant amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations and in-licensing arrangements that align with our oncology drug development, regulatory and commercial expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $1.6 million as of December&#160;31, 2020 and 2019, respectively. None of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into standby letter of credit of $45.9 million in the aggregate as guarantee of our obligation to fund our portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which will be recorded as restricted cash and will be reduced as we fund our portion of the tenant improvements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(587,247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as stock-based compensation, deferred taxes, depreciation, non-cash lease expense, and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant factors that contributed to the decrease in cash provided by operating activities for the year ended December&#160;31, 2020, as compared to 2019, were the decrease in net income, and changes in operating assets and liabilities, primarily trade receivables, prepaid expenses and other assets and inventory. </span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the year ended December&#160;31, 2020 consisted of investment purchases of $1.1 billion, and purchases of property, equipment and other of $30.3 million, partially offset by cash provided by the maturity and sale of investments of $969.4 million.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the year ended December&#160;31, 2019 consisted of investment purchases of $1.2 billion and purchases of property and equipment of $12.8 million, partially offset by cash provided by the maturity and sale of investments of $608.3 million.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities for the year ended December&#160;31, 2020 consisted of $50.0 million of withholding taxes paid related to net share settlements of equity awards, partially offset by $24.9 million in proceeds from the issuance of common stock under our equity incentive plans.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the year ended December&#160;31, 2019 consisted of $22.5 million in proceeds from the issuance of common stock under our equity incentive plans, partially offset by $9.9 million of withholding taxes paid related to net share settlements of equity awards.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations as of December 31, 2020 were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual Obligations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 1 Year</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1 - 3 Years</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3 - 5 Years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">More than 5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual cash obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,830&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)    In addition to the amounts presented, we have committed to make payments for potential future milestones, research funding commitments and royalties to certain collaboration partners as part of our agreements with those parties. Because the amount and timing of those payments are uncertain, they have not been included in the table above. For more information about these obligations, see &#8220;Note 3. Collaboration Agreements&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    We entered into the build-to-suit lease agreement in October 2019, the term of the lease is for a period of 242 months, which is expected to begin in April 2022. The amounts presented include the estimated lease commitment payments at the estimated commencement of the lease, subject to adjustment dependent upon the actual total development costs of the premises. For more information about our lease obligations, see &#8220;Note 11. Commitments&#8221; in our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)    Purchase obligations include firm purchase commitments related to manufacturing and maintenance of inventory, software services and other facilities and equipment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the more significant estimates and assumptions used in the preparation of our Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete description of our significant accounting policies, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenues and Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when our customers obtain control of promised goods or services, in an amount that reflects the consideration to which we are entitled to in exchange for those goods or services. We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&#160;trade allowances, such as discounts for prompt payment; (b)&#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies, distributors and commercial payors; and (d) returns. Discounts and allowances are complex and require significant judgment by management. Management assesses estimates each period and updates them to reflect current information.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initially record estimates for these deductions at the time we recognize the related gross product revenue. We base our estimates for the expected utilization on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. For a further description of our discounts and allowances, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenues &amp; Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; product supply services; development cost reimbursements; profit sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. We use key assumptions to determine the standalone selling price, which may include forecast revenues and costs, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. At the end of each subsequent reporting period, we re-evaluate the probability of earning of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. In addition, in recording revenues for our research and development services performance obligations, we use projected development cost estimates to determine the amount of revenue to record as we satisfy this performance obligation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial Accruals</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We execute all of our clinical trials with support from contract research organizations and other vendors and we accrue costs for clinical trial activities performed by these third parties based upon the estimated amount of work </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the activities to be performed for each patient, the number of active clinical sites and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us, which may allow us to make a more accurate estimate in future periods. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense requires us to estimate the fair value of stock options, including performance-based stock options, and the estimated the number of shares subject to PSUs that will ultimately vest. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value models require a number of complex and subjective assumptions including our stock price volatility, employee exercise patterns and risk-free interest rates. The most significant assumptions are our estimates of the expected volatility and the expected term of the stock option. The value of a stock option is derived from its potential for appreciation. The more volatile the stock, the more valuable the option becomes because of the greater possibility of significant changes in stock price. Because there is a market for options on our common stock, we consider implied volatilities as well as our historical volatilities when developing an estimate of expected volatility. The expected option term also has a significant effect on the value of the option. The longer the term, the more time the option holder has to allow the stock price to increase without a cash investment and thus, the more valuable the option. Further, lengthier option terms provide more opportunity to take advantage of market highs. However, empirical data show that employees typically do not wait until the end of the contractual term of a nontransferable option to exercise. Accordingly, we are required to estimate the expected term of the option for input to an option-pricing model. As required under generally accepted accounting principles, we review our valuation assumptions at each grant date and, as a result, from time to time we change the valuation assumptions we use to value stock options granted. The assumptions used in calculating the fair value of stock options represent management&#8217;s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation could be materially different in the future. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize stock-based compensation for PSUs over the requisite service period only for awards which we estimate will ultimately vest, which requires judgment as to the probability and timing of the achievement of the underlying performance goals. Significant factors we consider in making those judgments include forecasts of our product revenues and those of our collaboration partners, estimates regarding the operational progress of late-stage clinical development programs and discovery pipeline expansion performance targets. To the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional description of our stock-based compensation, see &#8220;Note&#160;8. Employee Benefit Plans&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute our income tax provision or benefit under the asset and liability method. Significant estimates are required in determining our income tax provision or benefit. We base some of these estimates on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that we deem a reversal of any portion of our valuation allowance against our deferred tax assets to be appropriate, we recognize a tax benefit against our income tax provision in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December 31, 2018 and forecasts of future operating </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 9. Provision for (Benefit from) Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_55"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to cash flow and earnings fluctuations as a result of certain market risks. These market risks primarily relate to credit risk, changes in interest rates and foreign exchange rates. Our investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes. We do not have derivative financial instruments in our investment portfolio.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment-grade corporate bonds and commercial paper, and money market funds. These investments are denominated in U.S. Dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative and short-term nature of these instruments, we do not believe that we have a material exposure to interest rate risk. If market interest rates were to increase or decrease by one percentage point, the fair value of our investment portfolio would increase or decrease by an immaterial amount.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange Rate Risk </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in the exchange rates of the U.S. dollar and foreign currencies may have the effect of increasing or decreasing our revenues and expenses. Royalty revenues and sales-based milestones we receive from our collaboration agreements with Ipsen and Genentech are a percentage of the net sales made by those collaboration partners from sales made in countries outside the U.S. and are denominated in currencies in which the product is sold, which is predominantly the Euro. Research and development expenses include clinical trial services performed by third-party contract research organizations and other vendors located outside the U.S. that may bill us in currencies where their services are provided, which is also predominantly the Euro. If the U.S. dollar strengthens against a foreign currency, then our royalty revenues will decrease for the same number of units sold in that foreign currency and the date we achieve certain sales-based milestones may also be delayed. Similarly, if the U.S. dollar weakens against a foreign currency, then our research and development expenses would increase. However, we believe that we are not subject to material risks arising from changes in foreign exchange rates and that a hypothetical 10% increase or decrease in foreign exchange rates would not have a material adverse impact on our financial condition, results of operations or cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_61">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_61">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_64">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_70">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_70">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_73">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_73">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_76">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_76">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_79">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_79">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_82">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_82">88</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Exelixis, Inc.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Exelixis, Inc. (the Company) as of January 1, 2021 and January 3, 2020, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three fiscal years in the period ended January 1, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8220;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at January 1, 2021 and January 3, 2020, and the results of its operations and its cash flows for each of the three fiscal years in the period ended January 1, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of January 1, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 10, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Revenue recognition - product sales and accounts receivable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended January&#160;1, 2021, the Company&#8217;s gross product revenues were $962.6 million. As discussed in Note 1 of the financial statements, the Company sells its products principally to specialty distributors and specialty pharmacy providers, or collectively, Customers. These Customers subsequently resell the products to health care providers and patients. Revenues from product sales are recognized when control is transferred to the Customer.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s product sales was challenging, specifically related to the effort required to audit Customer sales activity to assess whether incentives resulted in orders in excess of demand and whether any such transactions meet the criteria for revenue recognition. This involved judgmentally assessing factors including market demand, Customer ordering patterns, Customer inventory levels, contractual terms and incentives offered.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#24282d;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls designed to monitor and review inventory levels in the channel and sales under Customer incentive programs. This includes testing relevant controls over the information systems that are important to the initiation, recording and billing of revenue transactions as well as controls over the completeness and accuracy of the data used.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#212529;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures over the Company&#8217;s product sales included, among others, examination of inventory channel reports for unusual trends or transactions as well as performing analytical procedures to detect and investigate anomalies within the data. Procedures included those to detect sales of short dated product near year end as well as testing the completeness and accuracy of the underlying data. We also examined the terms and conditions of any new or amended contracts with Customers and its impact on the Company&#8217;s returns reserve. We also confirmed the terms and conditions of contracts directly with a selection of Customers, including whether there are side agreements and terms not formally included in the contract that may impact the Company&#8217;s returns reserve. In addition, we obtained written representations from members of the commercial function and the market access group regarding changes to Customer incentives and the completeness of the terms and conditions reported to the legal and accounting departments.</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst&#160;&amp; Young LLP</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2002.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;10, 2021</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNi0xLTEtMS0w_f55d3bca-eb7c-40db-9c5c-ed7a2f302c81">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNi0zLTEtMS0w_6cbaa6f1-b4f6-45ea-ab22-e2cdaeba975e">266,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNy0xLTEtMS0w_a132d08c-c6c6-4b83-80e1-8c36083c87e5">887,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNy0zLTEtMS0w_b37729ca-5bc5-4876-ae08-bf8d43390f3b">585,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfOC0xLTEtMS0w_1d7f1604-3f10-417d-a485-cf27b75355d7">160,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfOC0zLTEtMS0w_8207284d-3a5f-4310-a2c5-13531a3d0b46">119,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfOS0xLTEtMS0w_6037a375-c925-4ca7-842f-e0ba0b8f159b">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfOS0zLTEtMS0w_26526bd8-2f34-4aea-b4ab-d96b92e2bb83">12,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTEtMS0xLTEtMA_da427be6-6e4e-4ca1-b516-a548fb05de6e">57,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTEtMy0xLTEtMA_fc1a9b3e-3420-47f5-98bb-0cdb65e8d254">26,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTItMS0xLTEtMA_d2624911-cb30-4fa9-a5ce-24bba730a5b4">1,445,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTItMy0xLTEtMA_69ba8570-78e0-4093-a57c-010cc99dc3ce">1,011,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTMtMS0xLTEtMA_b691be1a-b0f3-430f-92f0-4aeccf1b0684">332,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTMtMy0xLTEtMA_cdc3aa4f-489c-4c15-ac36-b9c67994375c">536,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTQtMS0xLTEtMA_8a8cc335-6a3e-473e-a997-94e84d6a9e66">67,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTQtMy0xLTEtMA_87405877-8155-49bc-8ba7-bf417a86ae33">48,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTUtMS0xLTEtMA_7ed10690-82f0-4303-b020-7787fb67bef6">156,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTUtMy0xLTEtMA_92b2e77f-4e4a-47f9-afc5-d6e9841f70ed">172,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTYtMS0xLTEtMA_d5bfe52f-23ee-48af-bdf2-fecb10a70f08">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTYtMy0xLTEtMA_9cac92e5-1d3e-48f2-9c8f-e52e4273c7df">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTctMS0xLTEtMA_07f2f529-ce10-4068-b9f8-c5a4c30ff7eb">71,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTctMy0xLTEtMA_1bf86256-82a4-4e69-ad77-c9d8a345272b">53,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTgtMS0xLTEtMA_374d9112-76cf-445f-a42d-f0cd6dd36614">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTgtMy0xLTEtMA_91bfc0c8-d9ac-4d23-9531-eb245eb6bc08">1,885,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjEtMS0xLTEtMA_003d53f8-2724-4d17-92a4-7c2d34772e22">23,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjEtMy0xLTEtMA_461ce639-60df-4f4e-b3df-6f9b1ca80f07">11,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjItMS0xLTEtMA_de873365-67e2-4884-99b9-fe804ae346a3">51,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjItMy0xLTEtMA_1f6d1082-0fb4-4e00-84bb-4fc4ab560a68">37,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjMtMS0xLTEtMA_1e2a2ae4-e1a1-48b6-8cb5-130424e4adaf">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjMtMy0xLTEtMA_692a55e3-f7ec-44fc-b5f7-478b0c03b6e8">38,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjQtMS0xLTEtMA_4cdc4e75-b69d-4132-91c2-946ca2dceeea">20,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjQtMy0xLTEtMA_fcfec1d9-03c6-48c3-923a-1b42f998384f">18,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjUtMS0xLTEtMA_1c4792ef-c31f-4992-8b74-4b34ed06c020">12,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjUtMy0xLTEtMA_56b25c1b-c6d6-4909-8e03-254bb3fb9528">11,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjctMS0xLTEtMA_e180e064-3606-4826-a9ea-cda2d8c51f60">44,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjctMy0xLTEtMA_cb7229b7-b1fd-4907-b46e-f674b38b1b99">24,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjgtMS0xLTEtMA_d017bd15-719e-4e3d-85b2-c14b79f057b0">204,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjgtMy0xLTEtMA_3d25c362-748b-4af3-8876-ba79f0911a0a">142,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjktMS0xLTEtMA_7986779c-7cdc-439f-8ed4-061806212126">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjktMy0xLTEtMA_2ac63b9d-5136-4769-b837-8d0802ed6db6">6,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzAtMS0xLTEtMA_26aaf161-b159-461e-a9b1-c7392ff11c13">49,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzAtMy0xLTEtMA_11bba8c1-edc1-4b29-9b21-74215aa31f0f">48,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzEtMS0xLTEtMA_d57307ca-d078-4bd8-99b7-6374c9b14618">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzEtMy0xLTEtMA_32cf5c6c-4d31-4fcb-b4e3-5f2efe1eff9a">2,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzItMS0xLTEtMA_2829dd98-f18d-4f1c-ac25-5e8fb65316b1">258,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzItMy0xLTEtMA_ee49e719-c4c7-484a-b6f8-a99f83d097b7">199,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzMtMS0xLTEtMA_848deaff-4493-4961-bb21-cb759c310124"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzMtMy0xLTEtMA_e72b3eb1-45a6-4896-bb0d-a5e9fa18f752"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2MzQ_479c21e0-fef2-4a9e-95f6-3b16ebe95d2a"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2MzQ_5d196ed2-1c60-4666-906f-d8c6a23f1087">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2NDQ_2496802b-c1a8-4866-828a-4598b55c3279"><ix:nonFraction unitRef="shares" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2NDQ_68153813-367e-4f20-958b-7ec703ea3c01">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2NTA_659b42fe-d03e-4557-8e34-027a4cf927f8"><ix:nonFraction unitRef="shares" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2NTA_8bbeb7fc-286b-457a-8d53-f883c35dff6d">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMS0xLTEtMA_5c76a376-393c-4821-8c19-d58ee303ecf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMy0xLTEtMA_9ec9d919-f192-45d4-876c-f890f2c1abe3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzcxNDY4MjU1ODA2NzU_13136dec-6937-4bc7-82f1-47ad157a3466"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzcxNDY4MjU1ODA2NzU_efd6e78a-37d3-452a-b1c5-2a5f1e144a13">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzcxNDY4MjU1ODA2ODY_9a72b846-53b7-421c-b0fd-77736adba440"><ix:nonFraction unitRef="shares" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzcxNDY4MjU1ODA2ODY_f92644ec-d595-4c9b-9529-1078e223d598">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzg4_31d80fc4-c74c-4929-89f0-d23f3f8e1e4f"><ix:nonFraction unitRef="shares" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzg4_82a70e77-e3ef-4d70-b3f6-6846117e8b45">311,627</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzk2_2f386eaa-c1e9-4a3f-91d3-8c0ec5d18981"><ix:nonFraction unitRef="shares" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzk2_926f9f70-5762-4e92-95b3-d088ed3eb384">304,831</ix:nonFraction></ix:nonFraction> at December&#160;31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMS0xLTEtMA_d57ad19c-e90c-47d4-ac63-a9309ec6a301">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMy0xLTEtMA_0da66c61-ccc0-4ab9-8097-a1d06071d613">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzctMS0xLTEtMA_b6923014-60ae-4f93-8b79-6f7448dd8330">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzctMy0xLTEtMA_06999d8d-7547-4a2a-8bd1-4555288343df">2,241,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzgtMS0xLTEtMA_cf88d808-e8bc-4d43-85b4-725804542f42">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzgtMy0xLTEtMA_af31c21b-9f3c-4efa-a431-ad910b1281f5">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzktMS0xLTEtMA_67aa5280-a6d2-4aab-892b-2cbf4fb3693b">447,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzktMy0xLTEtMA_44803d55-dc21-47f9-bccb-09868c5f25c8">559,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNDAtMS0xLTEtMA_8c4b24b5-c12c-4e0c-9d7f-1a445f15c1c5">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNDAtMy0xLTEtMA_1fbfacaa-119e-4336-8f8d-0eacd13850fb">1,685,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNDEtMS0xLTEtMA_26806cdd-bae0-42c3-998d-f5607283c140">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNDEtMy0xLTEtMA_c95a007b-cfc3-499c-bc36-473446a9831a">1,885,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3c42d191c44c598831337fe0fcd696_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMy01LTEtMS0w_0b9dea40-7200-4b35-9fc6-d650d6464035">741,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017544c12e89414a8fbb94db33dba5ca_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMy03LTEtMS0w_581a2c31-2fe7-4480-948c-ccd1a271fe48">759,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ae4188c769426b89292d8f4cb182cd_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMy05LTEtMS0w_fee54294-4ac0-4f82-87a8-88e544e39e0c">619,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f75b6132534e759b7a2f8f4f543224_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC01LTEtMS0yMzcx_dab3a4ce-f44c-46ff-91ad-a35e486add4c">167,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd63dabbf6d046f6a7c8d265a33ee88c_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC03LTEtMS0yMzUy_351635b6-70a3-44e6-a9a3-5781fabcfbea">165,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aafd53bd39d4ffc9927ea4ffcd6a8ed_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC05LTEtMS0yMzY0_c57fd49f-ce7a-442c-9004-d70a2015d100">200,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08966774bb054fc088e3056e8afeee22_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC01LTEtMS0w_7778ef7a-460b-4fc3-94d4-e95458f9b478">78,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8b4097af0141c0b296cf3b6ba2950f_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC03LTEtMS0w_6711a4ac-cf56-4da3-82a5-090f7f338b1c">41,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0062b098130b4f129d9e3ab3551e84ba_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC05LTEtMS0w_a0f5a8e4-e451-470f-8256-7e11d2f45f76">34,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNS01LTEtMS0w_6b482854-1188-4765-97e5-c57cbba1d6f2">987,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNS03LTEtMS0w_8a1b5165-2f14-40d0-b234-e1e3adec99ed">967,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNS05LTEtMS0w_179e68cd-617b-4a44-b7a1-8e6d46261d18">853,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNy01LTEtMS0w_19bce8a6-00ce-4cf2-953c-0c0506d9085a">36,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNy03LTEtMS0w_3a3bac7f-e8a1-474c-89ef-5e6450430313">33,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNy05LTEtMS0w_a8aa5847-27fe-4bd3-a434-bc82b7ae336e">26,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOC01LTEtMS0w_e47bcb97-8311-4ca8-8a56-7b89e1077f93">547,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOC03LTEtMS0w_089d8030-ab17-4b08-882e-934ac8702b10">336,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOC05LTEtMS0w_52b6c1ed-596f-4ff8-bf3b-839ed1475e96">182,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOS01LTEtMS0w_2955ad71-1b6e-4b7d-b233-7d8affad4463">293,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOS03LTEtMS0w_a0e1857e-1bb9-4ff4-bd5e-1303028573bd">228,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOS05LTEtMS0w_f1ff149d-de8c-428c-a327-a2c2f5129139">206,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTAtNS0xLTEtMA_e19223c5-d79b-4a99-85e0-51f26d5012cf">877,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTAtNy0xLTEtMA_04e0869c-7d56-48b8-af73-0521f21b8e94">598,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTAtOS0xLTEtMA_46c7c0cf-0519-4a35-b9f3-f57887bf32e0">414,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTEtNS0xLTEtMA_48ad007c-48f4-49d2-a6c6-ddc70c14d593">110,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTEtNy0xLTEtMA_20b15321-54bf-4ba7-9103-dfa54828d7f5">369,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTEtOS0xLTEtMA_821411b4-9891-4a33-b7cc-9920f9805dd1">438,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTItNS0xLTEtMA_6f9a1ed4-5a51-43f9-8585-032f3f1ca721">19,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTItNy0xLTEtMA_afd6b480-8387-4f48-ad4d-376ff31daeda">27,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTItOS0xLTEtMA_b64d99d8-5b68-4b3a-8385-2231156d0139">12,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTQtNS0xLTEtMA_23c85a26-1873-4d53-85f4-4ee8b31f0f51">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTQtNy0xLTEtMA_7bc82468-89dc-4869-b4e5-33707bd83b95">680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTQtOS0xLTEtMA_e75ad382-659c-498d-9b2c-173ac739c401">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTUtNS0xLTEtMA_f3c76a7e-ec7a-4d7d-8a63-e56dda90884d">130,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTUtNy0xLTEtMA_7ae91f80-a6a1-42f1-ab44-2517d407f093">398,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTUtOS0xLTEtMA_5372a779-e6e7-4a42-829f-a505a9f572f9">452,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTYtNS0xLTEtMA_188fc480-08de-4098-a6ec-3b9855779ed8">19,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTYtNy0xLTEtMA_60be30a0-7973-42ab-b6a2-16da10e250fa">77,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTYtOS0xLTEtMA_61a427a0-3115-4eaa-9db4-eeb6458f6fa9">237,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTctNS0xLTEtMA_0233ee16-3849-4354-a1c6-7deed24f3116">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTctNy0xLTEtMA_54698d9d-355a-4983-8a78-1e4325685b13">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTctOS0xLTEtMA_71954d78-296a-47aa-b453-1c0d6fb08477">690,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTktNS0xLTEtMA_d28a696a-982e-404b-9143-60d754541daa">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTktNy0xLTEtMA_eaedea13-12fd-476b-a541-71b73da97e35">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTktOS0xLTEtMA_8d90e575-b48d-41dd-9977-4c71beed5244">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjAtNS0xLTEtMA_83ab8308-0dcd-440e-b337-df33ef846d21">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjAtNy0xLTEtMA_94f11cd9-6ec9-47f7-97b6-752ace117dda">1.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjAtOS0xLTEtMA_c2f746a9-b2ab-46d8-b64a-24ca0e571fa3">2.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjItNS0xLTEtMA_e8097716-0ce6-4f71-a3e0-6d4aaac91bb6">308,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjItNy0xLTEtMA_e67c9716-2eb0-4f34-a651-338315e0e5d7">302,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjItOS0xLTEtMA_b988c492-8c2f-4050-a523-6faf7bafba14">297,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjMtNS0xLTEtMA_6a952b94-c5f7-4c51-8bd9-5a4e71b64f0a">318,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjMtNy0xLTEtMA_12226a9b-f29c-4b0f-9b91-949c8a83b5eb">315,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjMtOS0xLTEtMA_5a0ced7c-48b5-475a-bf6e-dcfde6f25b4f">312,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_73"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfMi01LTEtMS0w_0233ee16-3849-4354-a1c6-7deed24f3116">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfMi03LTEtMS0w_54698d9d-355a-4983-8a78-1e4325685b13">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfMi05LTEtMS0w_71954d78-296a-47aa-b453-1c0d6fb08477">690,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC0wLTEtMS0wL3RleHRyZWdpb246OWE1YjZjMGI4YTQ2NDY1YjhjYTZjNGQ2MDY2MzJlMzBfMjE5OTAyMzI1NTY4Nw_87f6cc37-ab4a-4831-a9ac-46dd039d0b75">394</ix:nonFraction>), $(<ix:nonFraction unitRef="usd" contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC0wLTEtMS0wL3RleHRyZWdpb246OWE1YjZjMGI4YTQ2NDY1YjhjYTZjNGQ2MDY2MzJlMzBfOTg_5f5e6802-141e-4da3-bf7e-615b13c58aa5">1,049</ix:nonFraction>), and $<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC0wLTEtMS0wL3RleHRyZWdpb246OWE1YjZjMGI4YTQ2NDY1YjhjYTZjNGQ2MDY2MzJlMzBfMTA2_85396faf-230a-4d14-a4dc-4cc3f1e974f3">156</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC01LTEtMS0w_54c8e7fd-ebbd-4058-a78e-06d21372bbb3">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC03LTEtMS0w_27fbe2d8-e631-4180-aae8-c2ff43dc0893">3,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC05LTEtMS0w_9fb53a53-3169-474a-9362-d023e3a33b3d">354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNi01LTEtMS0w_a211010a-c902-40a3-8ebe-d965e725d03e">113,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNi03LTEtMS0w_9453ee2d-edbd-4694-bc16-c60a6af2996d">324,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNi05LTEtMS0w_12f7c916-2ea0-4f9b-96b2-e0a2c943644a">689,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_76"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.678%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cf18789764c45368c669217aaffdb67_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItMS0xLTEtMA_87a73b8c-3630-4f1d-a8f4-6d52a7d19d76">296,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf18789764c45368c669217aaffdb67_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItMy0xLTEtMA_21e690ba-0b30-4e66-bb82-568dbd9bfe7d">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd92776c3fd4e93a43d434422c20d5d_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItNS0xLTEtMA_f2cbc797-b5ad-4b38-8518-cf251713156d">2,114,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf8a6adb4b164967870e4ec8b407494a_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItNy0xLTEtMA_f25448d0-8d39-4528-88b1-80e3bd07254c">347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5eee05a10d6452b9488c1814f28b285_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItOS0xLTEtMA_828ae86e-83b3-4622-b145-117a815ec5c0">1,829,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc77df98a1c43b7b450a7d15340ba09_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItMTEtMS0xLTA_7c7e05f6-1fa3-4565-83c3-98ddc174a258">284,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASU No. 2014-09, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenue from Contracts with Customers (Topic 606)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8951b2a4fc794481a8bec7526b2fe718_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjMtOS0xLTEtMA_5ad0b712-b2f7-4069-8edd-b4662fdfacfe">258,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f4593048134c2aae052c2684c52ab7_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjMtMTEtMS0xLTA_f499c60b-503a-4fbb-baa4-f4706c2b52f5">258,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption of ASU No.&#160;2016-02, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Leases (Topic 842)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e8fcb09c95f4a81a55d006ee3b40c7c_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjQtOS0xLTEtMA_2dbc1daa-28b4-4b14-acb5-5e120c300d3c">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f1fb499cf24490b6739fd15fde0a70_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjQtMTEtMS0xLTA_c095b1aa-4f8f-45b5-9463-dfe4d4a658f1">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee659f1b4184a299e8ef1cd870aaacb_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjUtOS0xLTEtMA_bc97336a-67ca-4680-9b1a-7bbb9c017206">690,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjUtMTEtMS0xLTA_b166d20f-c2fc-4d6a-aca4-c43af3be6a7b">690,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52da6ed6384349dab85a714e3d9f3121_D20180101-20181228" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjYtNy0xLTEtMA_2eca4990-7251-4618-9473-3d2ee81b849b">354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjYtMTEtMS0xLTA_2adc6a7b-d951-4853-a42a-8590d6fc5fcc">354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08e75e71919b493ba1d1e2d3f874d754_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjctMS0xLTEtMA_1cb2e95c-9276-42e2-bc43-8f2642a50682">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e75e71919b493ba1d1e2d3f874d754_D20180101-20181228" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjctMy0xLTEtMA_8f619186-98da-44ed-b0b2-c7dc9eb3fabe">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ccaed2e3f744d798f678ef8e8f549bf_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjctNS0xLTEtMA_e01b8c99-a902-4aba-95ad-69e41ae888dc">20,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjctMTEtMS0xLTA_1831e169-3e3c-43da-94ed-1d489b9af4a2">20,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ccaed2e3f744d798f678ef8e8f549bf_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjgtNS0xLTEtMTk4NA_d09d7bd9-edba-4010-ac97-ed66c61ea9be">7,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjgtMTEtMS0xLTE5ODQ_06b05473-b85d-4314-91a8-a294f07553f0">7,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ccaed2e3f744d798f678ef8e8f549bf_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjgtNS0xLTEtMA_140daa6e-539e-471c-aa90-61f430b73211">40,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjgtMTEtMS0xLTA_eceb3b19-b6c5-41d9-bec2-99a0900d0226">40,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30eaa7c0999b426ebb923dec46907033_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktMS0xLTEtMA_0a0ae176-e5b5-4030-8cf9-adb6d5b85a9c">299,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30eaa7c0999b426ebb923dec46907033_I20181228" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktMy0xLTEtMA_e960bd59-1684-42e4-a4ae-fb9cf921c412">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2971170a1e4aa7b66cf3c6bff48467_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktNS0xLTEtMA_21594bb1-77fa-404d-b7f5-668b544a6cc8">2,168,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i452886d25bad4d378ac6e98c1cbf46b2_I20181228" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktNy0xLTEtMA_1acf5612-0a07-4b21-a1bb-d191d448830f">701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdfd210ed07043f6a95731b55f3bff0f_I20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktOS0xLTEtMA_c258d44f-bb3b-4467-a780-7ddec1c6bfef">880,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktMTEtMS0xLTA_612ecad0-c501-4baa-a0af-22fedc1396e0">1,287,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884c78d408784785ad24fc34a5d0c20e_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzAtOS0xLTEtMA_a63d5173-34ca-4c69-8f89-c9796168b8ad">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzAtMTEtMS0xLTA_9775e9e8-579f-4dd4-9dbe-129890778940">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf0a67523fe04dd69a9519798a6eee12_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzEtNy0xLTEtMA_643ccec4-fe95-41ea-8d35-7965e4cffedd">3,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzEtMTEtMS0xLTA_40e2700f-f13d-4a86-a669-aced2433a954">3,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c9376ae494c4c59acb1a1ea66a6591b_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzItMS0xLTEtMA_57eecb52-d081-409b-8571-52d64e3f1f21">4,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9376ae494c4c59acb1a1ea66a6591b_D20181229-20200103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzItMy0xLTEtMA_404e63c9-b50f-49d5-8d29-4051f4ca7a3f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30c343186df43e1b9b015ce00d68641_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzItNS0xLTEtMA_8d2e274f-0ca3-4933-838b-598db3fe9c41">27,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzItMTEtMS0xLTA_dbc18fbd-460d-4802-bea1-5dea3e43cd0a">27,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie30c343186df43e1b9b015ce00d68641_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtNS0xLTEtMTc0Mw_128bf1d6-a15e-4291-8455-433fee2ebd84">9,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtMTEtMS0xLTE3NDM_71504c76-80b0-46b9-9a3a-b4cf0f391be5">9,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30c343186df43e1b9b015ce00d68641_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzMtNS0xLTEtMA_10015229-ffd9-4416-985f-cc58402c2dca">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzMtMTEtMS0xLTA_ad7e8a9f-0311-4a8b-b1da-561de0201f5b">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46a1936b47924d069d3624adfa0f5429_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtMS0xLTEtMA_a141849f-08ec-491f-a7af-41ee2730309b">304,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a1936b47924d069d3624adfa0f5429_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtMy0xLTEtMA_96ee162d-17f4-4593-84dc-45eab30cb299">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de1f6ea286142e1a15d7747bbae50f2_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtNS0xLTEtMA_79f8022c-b510-443b-9501-bc128e297181">2,241,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4fbc439858a4ae4bbb8754989dd1aad_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtNy0xLTEtMA_64359f1f-b14e-4c0c-a93f-e2b8eab532ae">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64bf936cf9074f0d908fdc47b6f7a66d_I20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtOS0xLTEtMA_e4568924-04b1-4230-af54-e572e60fd2ca">559,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtMTEtMS0xLTA_ce4b2c10-840d-4933-8cbe-04e8e2326cf5">1,685,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzctOS0xLTEtMTc1Mw_0233ee16-3849-4354-a1c6-7deed24f3116">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzctMTEtMS0xLTE3NTM_3ffb3892-2695-4208-a9ac-ca410681108d">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42dc949dd41c462aa7f7f0448c9e0258_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzgtNy0xLTEtMTc1Mw_c7b5d63f-f11b-43e2-b01e-9720cfd961bc">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzgtMTEtMS0xLTE3NTM_01592b3b-59fb-4049-af46-dd0380119a3a">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8532508de83a49b88e77f0e2c020cf28_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzktMS0xLTEtMTc1Mw_2c1a7341-82d1-4309-acde-64ab9873efc7">6,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8532508de83a49b88e77f0e2c020cf28_D20200104-20210101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzktMy0xLTEtMTc1Mw_1dd21ab4-e49f-4649-a7ca-dc7ebf7e555a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558c4cfa6cb240c793e2ddc4e22b9288_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzktNS0xLTEtMTc1Mw_92710647-9e1f-410b-968c-8ff6108e7d1a">24,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzktMTEtMS0xLTE3NTM_958ea81f-5b34-4cb5-b684-64f8a41f3f0c">24,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i558c4cfa6cb240c793e2ddc4e22b9288_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDAtNS0xLTEtMTc0OA_fc762a9f-cb41-4e02-a2a2-58ea81647b9e">50,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDAtMTEtMS0xLTE3NDg_6e942c00-7109-47a7-bf62-c85c8b1fa524">50,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558c4cfa6cb240c793e2ddc4e22b9288_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDEtNS0xLTEtMTc1Mw_3e46a568-edcf-4ed7-adfd-49492d5fc720">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDEtMTEtMS0xLTE3NTM_a48b49d8-f831-4820-94db-c5a6dd48abd5">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84c6817fdc914e70b2207f8d04c39cfb_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItMS0xLTEtNDA1MA_5a26bc70-28c4-46b6-9105-85a68c7b7bcf">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c6817fdc914e70b2207f8d04c39cfb_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItMy0xLTEtNDA1MA_b37d8ebd-65ed-490e-a62f-b37f1cf75994">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aaae69174fa4f95900ea3fcd832f187_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItNS0xLTEtNDA1MA_4e6b094b-10d7-4496-99e4-23ac0e3cbf54">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8bcdd3025c0460d83a19962b5f3e147_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItNy0xLTEtNDA1MA_466077fd-b03f-413e-a7f7-9681f8b946ab">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6aa081489d4f49229307745612d68ff4_I20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItOS0xLTEtNDA1MA_d5164e90-7314-4ee2-98ac-700e33e175a6">447,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItMTEtMS0xLTQwNTA_87394a3e-ed16-4508-b224-85b1a63f5236">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_79"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMi0xLTEtMS0w_0233ee16-3849-4354-a1c6-7deed24f3116">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMi0zLTEtMS0w_54698d9d-355a-4983-8a78-1e4325685b13">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMi01LTEtMS0w_71954d78-296a-47aa-b453-1c0d6fb08477">690,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNC0xLTEtMS0w_eea54fbb-a63b-4a3f-8ae6-9bcb31ef156b">9,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNC0zLTEtMS0w_c55ad9cd-f62e-4b4e-a99f-33ff5c49b4f9">8,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNC01LTEtMS0w_294ee03a-23d6-46c7-a69f-9f2e6b9a08ef">4,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNS0xLTEtMS0w_d355489e-84bb-4ae2-9a07-65e925f46c2d">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNS0zLTEtMS0w_bd0f5792-9c6b-4ff4-8ba8-759006125fb5">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNS01LTEtMS0w_11525910-a837-4682-9f5e-e41c7627839e">40,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNi0xLTEtMS0w_30363865-4598-4a93-bb80-2b50b09ad32a">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNi0zLTEtMS0w_0f59ccf3-43af-4740-a1ba-2c9f4f2d2820">2,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNi01LTEtMS0w_8e947324-6192-4186-95d4-07be9cc4693e">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNy0xLTEtMS0w_018b1471-fd3b-48d7-bca8-19cb0aeb3e39">15,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNy0zLTEtMS0w_c2633e57-0884-4a21-981d-cf70222d0dde">71,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNy01LTEtMS0w_89cd9200-2265-403b-960c-672739dfab79">244,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfOC0xLTEtMS0w_1bf4db2f-7e75-4bf1-985b-a516d2e0b955">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfOC0zLTEtMS0w_f506a24c-f043-4f44-9fa4-839c82fc49d5">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfOC01LTEtMS0w_e88d3657-6182-4695-9763-b1448ff12271">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTAtMS0xLTEtMA_32fae0fe-6872-4d0f-b45a-86564689d875">42,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTAtMy0xLTEtMA_0206dbf8-d1eb-4e2f-95d9-067a61c109fd">43,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTAtNS0xLTEtMA_27e283b4-1432-4819-b405-d2099be7b049">85,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTEtMS0xLTEtMA_494502f4-672e-407a-93ae-c790e7c4625f">21,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTEtMy0xLTEtMA_09017018-8b51-43da-9be9-971d2b9925b5">5,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTEtNS0xLTEtMA_4ad5c34d-3a37-4299-b556-2233df7648b8">3,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTMtMS0xLTEtMA_a3c15b19-2c53-4386-adfb-1d4966885275">25,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTMtMy0xLTEtMA_dc210b30-0bcf-48d5-8dfe-fb494ac79e1f">5,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTMtNS0xLTEtMA_4a466726-c94d-480f-a91c-26ffe10cc41d">8,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTUtMS0xLTEtMA_9b516c27-b2c9-402e-abd8-081a68890ed2">1,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTUtMy0xLTEtMA_92364a36-db33-47b6-9da8-78fa262cf7c7">9,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTUtNS0xLTEtMA_0f993d46-be2e-4b95-b9a6-09c442f9db85">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTYtMS0xLTEtMA_24ec122f-9aeb-4466-9b0f-d8224c03dc16">51,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTYtMy0xLTEtMA_6657313d-650d-48c8-ba93-5fd471d5278d">44,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTYtNS0xLTEtMA_98ca99fb-f593-48ba-8c58-2a98ab498ea4">17,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTctMS0xLTEtMA_49ec7271-f792-4432-ba11-2ef48a7e5a89">208,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTctMy0xLTEtMA_082a276e-4e21-4317-9b77-06982ec413aa">526,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTctNS0xLTEtMA_e287e520-1952-4b65-8df5-18ac53b38d92">415,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTktMS0xLTEtMA_ed59d706-4159-440f-865c-828de329d6b4">30,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTktMy0xLTEtMA_2700b250-6f2a-482d-8b0a-2dd3b9649ab3">12,834</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTktNS0xLTEtMA_9b3d60b4-ddcd-4ba8-b098-8fb130585f19">33,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjAtMS0xLTEtMA_3a5da3ce-ca45-48e7-ae31-5b5839b8b9bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjAtMy0xLTEtMA_5b8c12a1-d568-442b-ac0c-f598fe8a6733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjAtNS0xLTEtMA_7048dbb5-8679-4902-af66-cfd91aff9ae1">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjEtMS0xLTEtMA_ddb7a9ac-41e3-4554-bd5b-dee27afd770f">1,070,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjEtMy0xLTEtMA_1d410743-e1e9-4037-b55f-d15e86151576">1,182,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjEtNS0xLTEtMA_4e77572f-3955-42d1-aa4e-2cac153aa231">557,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjItMS0xLTEtMA_c7b24234-b97e-424b-a5dc-d99748dfa682">969,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjItMy0xLTEtMA_d2d6dcaa-97cc-49fb-86a6-b146b6ed84fe">608,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjItNS0xLTEtMA_b642b874-20c1-434a-b827-7887aa950d1e">292,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjMtMS0xLTEtMA_565883bc-89ec-41b1-b1ec-df7db8378df6">131,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjMtMy0xLTEtMA_948dee7a-5644-45e7-85c4-02d01eba25b5">587,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjMtNS0xLTEtMA_0591bfe5-fe19-4d8b-9e0f-11a48983b567">297,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjUtMS0xLTEtMA_c411a89a-93d8-4e73-a253-8e25a4d926e2">24,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjUtMy0xLTEtMA_eea32dd5-c689-488b-9126-b6956f6d77e8">22,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjUtNS0xLTEtMA_9c109c92-db5d-4130-bcf2-f9857433e39f">17,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjYtMS0xLTEtMA_58b956e4-4027-4695-b47d-0bf619ba03e2">50,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjYtMy0xLTEtMA_452845e1-6546-465e-a5ae-3679cc078ea1">9,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjYtNS0xLTEtMA_6ddecab1-2e4b-4c95-972d-df1dbebfa980">7,574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjgtMS0xLTEtMA_c0cc482a-6f3d-40e5-88de-4db95a602c35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjgtMy0xLTEtMA_57b9de4b-27e3-40ff-ba94-d83e4f613fd5">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjgtNS0xLTEtMA_16c9d480-e0da-4d43-902a-5914abb760a9">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjktMS0xLTEtMA_e5c6098d-92e6-499d-b535-b52a5073e036">25,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjktMy0xLTEtMA_890898fd-eef5-43aa-8155-1cc77d5910a8">12,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjktNS0xLTEtMA_e91acee8-1128-4b75-8b3b-2fd509f14772">9,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzAtMS0xLTEtMA_b8fbff06-8624-40d0-8fee-2e9e7463d110">52,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzAtMy0xLTEtMA_b64d9ec0-d797-4280-861d-01c7c53d9256">47,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzAtNS0xLTEtMA_01235148-78e0-4ad4-ad7e-89d80e3190e4">127,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzEtMS0xLTEtMA_332818f3-936d-4bc0-a2f8-429847f7bd28">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzEtMy0xLTEtMA_1e7e0c13-a285-46f2-b986-61baba51b26b">315,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc77df98a1c43b7b450a7d15340ba09_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzEtNS0xLTEtMA_c34475ab-80bd-4b78-bd3f-acf9d9776ec3">188,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzItMS0xLTEtMA_3209da6d-730e-48e5-82c9-98062ea39815">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzItMy0xLTEtMA_6d54716d-d560-4f79-9b01-c031bc985f21">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzItNS0xLTEtMA_53eaf67b-6a2f-4c20-8aec-822e1fc600b6">315,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzUtMS0xLTEtMA_a2b90264-5a2a-4767-b183-54d846a1a1ec">4,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzUtMy0xLTEtMA_b51bd83b-e69c-4151-911c-6e6ca6079bb9">7,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzUtNS0xLTEtMA_c0e96dd8-8c3e-45f9-b4c2-cc7af3d7e0f8">10,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzctMS0xLTEtMA_afa69fc5-c045-41c8-a4e2-6536b1e2251a">4,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzctMy0xLTEtMA_b51dce65-d337-4fce-924f-b601e0dde1fc">29,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzctNS0xLTEtMA_cc5a7a49-db42-46ef-b3f4-35101fa6307e">17,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzgtMS0xLTEtMTM4NzU_ddd73502-9361-445d-bd02-d545111d2c8b">842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzgtMy0xLTEtMTM4NzU_10915bb4-0db9-4262-a782-76477dd594b1">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzgtNS0xLTEtMTM4NzU_4d0bc1ae-a1ce-4667-86bd-bc662269c475">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for unsettled investment purchases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:InvestmentsPurchasesIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNDAtMS0xLTEtMA_0b47154c-7711-4caf-bdec-34f5f18ecdbd">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:zerodash" name="exel:InvestmentsPurchasesIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNDAtMy0xLTEtMA_916f734a-0c33-4c7f-aae8-1502901a37f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:zerodash" name="exel:InvestmentsPurchasesIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNDAtNS0xLTEtMA_45b24d1e-8ffd-4b3a-9a2e-3d8c6cb7a644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable for unsettled investment sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:AccountsReceivableForUnsettledInvestmentSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzktMS0xLTEtMTA4NDQ_640f865b-8bf4-438a-9fb9-f35a5bddece2">6,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:zerodash" name="exel:AccountsReceivableForUnsettledInvestmentSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNDAtMy0xLTEtMTM5Mzc_d11ffeb7-673a-4877-982e-d13ab8cd2dd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:zerodash" name="exel:AccountsReceivableForUnsettledInvestmentSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzktNS0xLTEtMTA4NTY_8da05522-2d50-4cbc-b4ce-67adca202842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwNTg_2bc249c6-872a-400e-aafb-ba6b069b19f6" continuedAt="id486d27391ed4f1bb7c461a696777a4e" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="id486d27391ed4f1bb7c461a696777a4e" continuedAt="ie7a770f62e08459cb2a889689d9783ff"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, <ix:nonFraction unitRef="product" contextRef="i70d57544c852419d89d807ca969cf9dc_D20200104-20210101" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNTcx_75196d4a-4e06-40d6-8c96-0840f63b8261">four</ix:nonFraction> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. <ix:nonFraction unitRef="product" contextRef="i05ae6057ccd8434a925a70647c5631e9_D20200104-20210101" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNzc0_7c0c1930-e0fb-4b70-be55-e2055272217a">Two</ix:nonFraction> are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program, and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="ib8f792de05b44b5c9f144e5e61238bfe_D20200104-20210101" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTUwMg_aa18b255-fc41-4e3e-9102-f3d48b17b7e1">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple regimens to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to expanding our oncology product pipeline through our drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwNDY_2c94e652-cb8e-47d6-a2f1-f0859558a97a" continuedAt="i24dd752f382d4d4e8d346c2fd8aeb8f5" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i24dd752f382d4d4e8d346c2fd8aeb8f5">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made&#160;reclassifications&#160;to our prior years&#8217; Consolidated Financial Statements to conform to the current year&#8217;s presentation. These&#160;reclassifications&#160;did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#8217; equity.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMDU_d99ea7b7-273d-48f8-8709-2b1c93ad3648" escape="true">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2021, January 3, 2020 and December 28, 2018 are indicated as being as of and for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMjU_c11fdd7e-17a7-4b13-a3a3-0d5dbaf056ab" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzIxNA_386a34a3-36bc-479f-bff2-fe87bf539aaf">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="ie7a770f62e08459cb2a889689d9783ff" continuedAt="i780d8af0b5da4741a29ed638d1920333"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMTI_9723afb5-544f-47df-90f7-f64d924f4900" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In  March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. Accordingly, we recorded an adjustment to increase selling, general and administrative expenses for these fees by $<ix:nonFraction unitRef="usd" contextRef="i8a33372a3f1347209075c0020d6bc068_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTM3NDM4OTU0NjczODI_750aae0f-002c-437c-ae70-f7254f8f4d47">5.1</ix:nonFraction>&#160;million during the fiscal year ended December 31, 2020. This adjustment resulted in a $<ix:nonFraction unitRef="usdPerShare" contextRef="i8a33372a3f1347209075c0020d6bc068_D20200104-20210101" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjE5OTAyMzM3MzMwOQ_a1b26790-f994-4592-b6ba-1e8570c593f1">0.02</ix:nonFraction> decrease in basic and diluted </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings per share for the fiscal year ended December 31, 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMjA_271c4c16-47f7-4eb8-8ce8-b39f05cd04c1" continuedAt="ieb0e1d7fd97d4a4aa418a17888372156" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we adopted Accounting Standards Update (ASU) No.&#160;201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-18,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606) when the counterparty is a customer for a distinct good or service (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter 2020, we adopted ASU No.&#160;2017-04,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2017-04)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we adopted ASU No.&#160;2016-13,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-13)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, contract assets, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Consolidated Financial Statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzk5ODQ_1133cdac-94f7-491f-93db-bb798c268810" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwNDI_95c48a03-2bd8-4288-976d-20bcf0f03808" continuedAt="i62feb70fabdb4911b26bb5078ea7f736" escape="true">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i780d8af0b5da4741a29ed638d1920333" continuedAt="ie684875e28ff4b6bb3e05e487e1b3cf6"><ix:continuation id="i62feb70fabdb4911b26bb5078ea7f736"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.</span></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTI2NDQzODM4Mjc2NzU_05e07204-8f46-4fb8-9eb1-cc465d779dd4" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMzc_5832e7a6-4088-4a53-a2a3-fc0065f3f778" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTg2OTE2OTc3OTEyNzY_b7ad002a-9c30-407b-8b4d-1f55689f92ca" continuedAt="i05e248b99eae4f699b1b1822956ed5d3" escape="true">As of December&#160;31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </ix:nonNumeric></span></div><div style="margin-top:9pt"><ix:continuation id="i05e248b99eae4f699b1b1822956ed5d3" continuedAt="ic2c8b254a5254d63bfb976a42008ef67"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:73.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration partners</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68ed0b3579a44a409ff3f00c4b884aa2_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfMy0xLTEtMS04Mzg4_fe91b791-e0a7-42c0-a19e-25c18b0a50df">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec86aacc21384a4996d1876a8cb648cf_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfMy0zLTEtMS04Mzg4_a6bd69ea-cf12-4618-b460-c226aaf5f98f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie579a8fa324847dabc4b5225b2c0c290_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNC0xLTEtMS04Mzky_af09e418-658b-4fb5-8809-0ef098f510b1">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1461cd4bfd3c47c3967b22b8dfbe9be7_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNC0zLTEtMS04Mzky_eea6b6bb-0414-458a-a8db-ee0ef06ed2a4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib990f420d40b4a3789297972cf1c7e68_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNi0xLTEtMS04Mzk2_f9e440bc-951c-43d7-a369-585485eda434">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i73502ab4116542529d603ec4cd2116b8_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNi0zLTEtMS04Mzk2_867c3724-2e81-4204-b72d-fa4b5e63efbf">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if458bc56436a40b686b3ffa6d5c137e1_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNy0xLTEtMS04NDAw_1c9e59e3-ac33-43f4-aae3-0b318d717c0d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ca0bb3135aa44d8bd3287f9952cab2f_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNy0zLTEtMS04NDAw_a1ced206-c728-48ca-b6e6-f80f940e0f16">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1493217f6b6d4b069dce0c3795c0b005_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfOC0xLTEtMS04NDA0_ced913ce-e648-4d9f-af46-bc7d6e94c1cd">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67f9d798ccb34676b3e9f4fa0c493d84_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfOC0zLTEtMS04NDA0_04683c04-19a6-4d64-a51e-df3aae0b77e4">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c6f0b98ffb341dcbd502a864903e546_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfOS0xLTEtMS05ODEy_bb6e1fb2-b3b7-451d-a629-3608c8876c0f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10483cca017b4a299e08efb033233f44_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfOS0zLTEtMS05ODEy_72210d0d-fba4-400e-84b6-5defc904cf37">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="ie684875e28ff4b6bb3e05e487e1b3cf6" continuedAt="id4562f5c259149b9b62bd169456f0a81"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwODk_7b924c7d-0917-4fa1-822f-37c9241158a7" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzk5ODU_7d13d567-028c-465f-a54a-122a0d6117b5" continuedAt="i7661a523480d457896ef429cdc0c7cc8" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7661a523480d457896ef429cdc0c7cc8">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to <ix:nonNumeric contextRef="iaa643e65f4a54355aecef91480e17f63_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTIxOTE_6f6200a6-226f-4d56-95ea-150fae6aaa98">15</ix:nonNumeric> years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwNjM_c5d4cafe-0af9-4344-ac11-fb1c269b1b7d" continuedAt="ie34c71df73ce42d0b411179546afb0f9" escape="true">Goodwill</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie34c71df73ce42d0b411179546afb0f9">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in <ix:nonFraction unitRef="segment" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTM1MDc_386a34a3-36bc-479f-bff2-fe87bf539aaf">one</ix:nonFraction> business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level.</ix:continuation> We did <ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTM2NjQ_e0c334ca-788e-4492-9696-5215108339cd">no</ix:nonFraction>t recognize any impairment charges in any of the periods presented.</span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMTY_9a2aba97-03bb-48fe-99d0-75fc57d7b3b2" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzk5ODY_aef35a3f-5627-4431-ae04-e1b20cde2add" continuedAt="i6b4206e720e944b4973eec8ab8c6cd72" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="id4562f5c259149b9b62bd169456f0a81" continuedAt="i21d7dbbebd934db29b49a3413d292882"><ix:continuation id="i6b4206e720e944b4973eec8ab8c6cd72" continuedAt="ie11bbd8ed4ef498791d6452e1f08a110"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts for Prompt Payment:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Customers in the U.S. receive a discount of <ix:nonFraction unitRef="number" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="2" name="exel:SalesRevenuePercentDiscountForPromptPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTkyMjY_39774fee-fe76-40f6-af07-31da1d43cf84">2</ix:nonFraction>% for prompt payment. We expect our Customers will earn <ix:nonFraction unitRef="number" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="INF" name="exel:SalesRevenueDiscountExpectedtobeEarnedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTkyODM_52a6e27f-94d2-4b38-9945-30e40a557d5d">100</ix:nonFraction>% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund <ix:nonFraction unitRef="number" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="2" name="exel:MedicarePartDFundingMandate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTgxNDE5NDE5NzYwMTc_f915b58d-3aa9-45f1-9d68-82d0e1835afb">70</ix:nonFraction>% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i21d7dbbebd934db29b49a3413d292882" continuedAt="i31fdc5564c55417baed772f914cbf344"><ix:continuation id="ie11bbd8ed4ef498791d6452e1f08a110" continuedAt="ie5d8e512a0fa41b0af2e7286974145b7"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Customer Credits: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i31fdc5564c55417baed772f914cbf344" continuedAt="i6c4ecdcc26e140d8a7322e5b32452d0b"><ix:continuation id="ie5d8e512a0fa41b0af2e7286974145b7" continuedAt="i7006f27f3f1f4954883ffb9d629fd84d"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a <ix:nonFraction unitRef="number" contextRef="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjc0OTM_bff152e5-346f-4079-ae09-ac754b332089">3</ix:nonFraction>% royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. </span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7006f27f3f1f4954883ffb9d629fd84d">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs.</ix:continuation> </span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzk5ODg_1cadfc3d-bdbb-43ba-9915-1b0e930e8431" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial projects have been executed with support from third-party contract research organizations (CROs), who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMjM_ced960bf-4278-413d-8273-9e22148dae6a" continuedAt="i8cee49cbedac49ecb3a129923e543553" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i6c4ecdcc26e140d8a7322e5b32452d0b" continuedAt="i3522bb682cba4da5811702dcb3c624fc"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8cee49cbedac49ecb3a129923e543553">options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of Topic 842 for short-term leases.</ix:continuation></span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAxMTk_3eca80de-7821-4bc2-8916-366bd467860e" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses were $<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjE5OTAyMzM3NjE3NQ_1672c1d9-cf15-4178-b9fd-819bba0214b1">25.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzE2MTM_03c9e7f2-9dcf-4c51-a73e-f432e7ae1e84">17.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjE5OTAyMzM2Mjc4NQ_be6ba6a7-ba38-4709-9af5-6a612053b926">14.8</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMDc_2c64f41f-dc9f-4411-849c-45abeaab38e9" continuedAt="ibe700b2a18564ad997cbfa191c20ffb6" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:continuation id="ibe700b2a18564ad997cbfa191c20ffb6" continuedAt="i2f328a3a259a484b95af9be00807daa6"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock&#160;Compensation</span></ix:continuation><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f328a3a259a484b95af9be00807daa6">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis.</ix:continuation> </span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTI2NDQzODM4Mjc2Nzc_39f5d3e2-84e1-4ba9-a314-66f0a8be4a90" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for (Benefit from) Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for (benefit from) income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for (benefit from) income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for (benefit from) income taxes in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December&#160;31, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 9. Provision For (Benefit From) Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMzA_bb236e9b-5e3d-41a6-bc76-4677dc174a4d" continuedAt="i3453acfe478744cbb6cf241b7a877111" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i3522bb682cba4da5811702dcb3c624fc"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3453acfe478744cbb6cf241b7a877111">accompanying Consolidated Statements of Income.</ix:continuation> Net foreign currency gains were $<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjc0ODc3OTE4NzIyMw_4586dc22-3aaf-4c4e-89a3-56e584416727">0.9</ix:nonFraction> million for the year ended December&#160;31, 2020, and not material for the years December&#160;31, 2019 and 2018.</span></div><ix:continuation id="ieb0e1d7fd97d4a4aa418a17888372156"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will b</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e effective for us in the first quarter of 2021 with early adoption permitted. The adoption of ASU 2019-12 on January 1, 2021 will not have a significant impact on our Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div id="i68bf8bfb5b59421792b5711a409e9ffd_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNTMxOA_bbe14a28-6656-4925-beaa-b86aaa6cc31b" continuedAt="id6e52ba8766246258ae54363c32d99c9" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="id6e52ba8766246258ae54363c32d99c9" continuedAt="ic95240c9ec574647bd160583004b19ad"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNTMyMA_47c5912a-ed3d-4f40-bc36-39f00de3eded" continuedAt="i5799778f4d1f465fa99dc4acdaa77d04" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i670b9bb21b274bf1a4d1c34421fc3303_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMy01LTEtMS0w_b56f5d03-9c22-43c6-84a9-69a4d1dcd4de">962,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88900c20d16b466197d1afc11b84f873_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMy03LTEtMS0w_7843ec5e-9f49-4cb2-8fda-922002532721">957,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa2590ddc5b443eae95962cb972cbdb_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMy05LTEtMS0w_2d0c48f6-361e-4918-8424-84ca4a371884">738,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib16eb294fd16430ab148fb14f058af49_D20200104-20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNC01LTEtMS0w_5fd4d6ba-268f-49c6-8087-c2046c3da5be">221,041</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8836d60836b24ea9a6548c71ad67321d_D20181229-20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNC03LTEtMS0w_5f2bc4f2-ef82-4d12-ba8b-cd78ac5edb55">197,671</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0be59e66b12446da9b1ef0b4f3d06cac_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNC05LTEtMS0w_4d4d8e93-81c1-4790-a73b-b26df050956e">119,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3c42d191c44c598831337fe0fcd696_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNS01LTEtMS0w_0b9dea40-7200-4b35-9fc6-d650d6464035">741,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017544c12e89414a8fbb94db33dba5ca_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNS03LTEtMS0w_581a2c31-2fe7-4480-948c-ccd1a271fe48">759,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ae4188c769426b89292d8f4cb182cd_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNS05LTEtMS0w_fee54294-4ac0-4f82-87a8-88e544e39e0c">619,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f75b6132534e759b7a2f8f4f543224_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNy01LTEtMS0w_dab3a4ce-f44c-46ff-91ad-a35e486add4c">167,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd63dabbf6d046f6a7c8d265a33ee88c_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNy03LTEtMS0w_351635b6-70a3-44e6-a9a3-5781fabcfbea">165,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aafd53bd39d4ffc9927ea4ffcd6a8ed_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNy05LTEtMS0w_c57fd49f-ce7a-442c-9004-d70a2015d100">200,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08966774bb054fc088e3056e8afeee22_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfOC01LTEtMS0w_7778ef7a-460b-4fc3-94d4-e95458f9b478">78,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8b4097af0141c0b296cf3b6ba2950f_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfOC03LTEtMS0w_6711a4ac-cf56-4da3-82a5-090f7f338b1c">41,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0062b098130b4f129d9e3ab3551e84ba_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfOC05LTEtMS0w_a0f5a8e4-e451-470f-8256-7e11d2f45f76">34,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc1d30b7d3a4f06af43da57ce01f0d0_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTAtNS0xLTEtMA_c5dd6636-a47e-4cd5-9a4b-af2c96769330">245,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bb491021104aef928b3404ad05a9ff_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTAtNy0xLTEtMA_43fb19d2-64e2-47ab-a4cc-d3ca3f20034e">207,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5a944195d8434c8b42f2f1eb355ef6_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTAtOS0xLTEtMA_f85ee708-481d-439c-94fd-298bb143bb97">234,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTEtNS0xLTEtMA_6b482854-1188-4765-97e5-c57cbba1d6f2">987,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTEtNy0xLTEtMA_8a1b5165-2f14-40d0-b234-e1e3adec99ed">967,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTEtOS0xLTEtMA_3d7a54e7-59c5-460e-af79-6c9bc7c4f135">853,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GSK on sales of products containing cabozantinib by our collaboration partners. </span></div><ix:continuation id="i5799778f4d1f465fa99dc4acdaa77d04"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df29850b2244253875bb007d882a698_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMi01LTEtMS0w_fafe1f0c-519a-4e75-b218-0491baa5dbe8">718,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb1450fd8a55400fa9281132060b8fcc_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMi03LTEtMS0w_b178dd96-00b1-4b49-be47-af202b98f99d">733,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81951ec5a864326b312312ad51008a9_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMi05LTEtMS0w_dba34b6c-5d94-4124-b68a-62897cad12e5">599,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d9b118c50947b99a376ebee947e030_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMy01LTEtMS0w_b832cf61-e376-423c-90f8-bdc89f6d563c">22,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5a25303cb764f61869e826e0f35954d_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMy03LTEtMS0w_64ade714-025d-4e77-878d-536c1ced73a5">26,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4ca2a47a8b64d7ca69c61e19f993397_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMy05LTEtMS0w_a2e5fb5a-dae9-40c1-9dd4-1be038b3b696">19,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3c42d191c44c598831337fe0fcd696_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfNC01LTEtMS0w_b428e935-7ab4-4975-b791-2eef700a04e3">741,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i017544c12e89414a8fbb94db33dba5ca_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfNC03LTEtMS0w_b1682041-3ee9-45bf-8c4c-161e4e89de2e">759,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ae4188c769426b89292d8f4cb182cd_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfNC05LTEtMS0w_3ada0684-ee35-4344-9c58-f77bcc5c8218">619,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="ic95240c9ec574647bd160583004b19ad" continuedAt="i5d35a4d8a00c41388dd73f1ce652bca2"><ix:continuation id="ic2c8b254a5254d63bfb976a42008ef67"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1016e220053480cb358c5dc63979dcb_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMi0xLTEtMS0w_7fe36842-d3d2-4894-b588-0859f78e04e6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcf42c7314ce4ba9a503ca92535ee0e1_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMi0zLTEtMS0w_eca7f4b4-4498-4ce0-b21b-d23343567316">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7d5dbf6fabd4ed8b76f6fac38c3a1ac_D20180101-20181228" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMi01LTEtMS0w_d022cac6-3557-4e0e-93a0-ff1860558452">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a7007d99a1d42f18d5f5f017813107a_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMy0xLTEtMS0w_f527bde1-0d51-49a9-bdb9-e3770caf9771">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib39c621c29354744ba506f00b8b68407_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMy0zLTEtMS0w_89abbb8a-7afa-49a6-9274-d893e4953cc0">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14840edd307b453b8993c676800c743f_D20180101-20181228" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMy01LTEtMS0w_298aaa1e-6867-4a4c-9e95-aca0ed440d72">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcd263e91c514880aab3ad046d770b1a_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC0xLTEtMS04Mjkz_6eafbd1e-98aa-47fb-bd17-9a3d1191efa4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfce732a0e594583ae51712fb488f5f1_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC0zLTEtMS04Mjkz_4eafa4a3-8f6b-4b4d-a296-1ceceb825f6b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc8d4270737e40e39a71be8687219600_D20180101-20181228" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC01LTEtMS04Mjkz_de304009-db1b-42b3-a646-6084238da1c4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if76434a400d24ae7b1196c9db3361389_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC0xLTEtMS02NDQ4_d115cb1c-1e2d-4d93-9bf1-ca4cec30c3b1">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18ed95db610746868908b7b47b43533a_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC0zLTEtMS02NDQw_888d7f16-955a-460f-9bbf-7a6872a7455a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70f8ef5fe5f34df2867857968fdd5135_D20180101-20181228" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC01LTEtMS02NDQ0_fdbad962-1c4b-4b71-ae2e-6a815954c168">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idddf53d05cdc4b41a5f8f99bc44c6c7b_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNS0xLTEtMS0w_37c706df-80f1-4a1b-b056-602bb909417e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1ba8f2854a74c39969dbab674b0387f_D20181229-20200103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNS0zLTEtMS0w_3591ebe4-5e62-4b7c-ba71-c06c4a101df6">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i927f62b2ab254dd19dcd6f11991f1c06_D20180101-20181228" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNS01LTEtMS0w_fdf0fc8c-8dbc-4867-a980-05cf5eb02f6b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNTMyNA_39415e08-7b2d-4d94-8eaa-1df1ab073b54" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia435deed54c84325b684daa442718f36_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMi01LTEtMS0w_6d1ebb22-4e76-4daa-b3c2-a09b546a309c">752,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b0da10f24b48bb8d2940b955a6c0e4_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMi03LTEtMS0w_46fef87b-75a4-4c6a-97fa-79e750bd3504">770,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib930a4d0eb864dda920bd8ef624bdca7_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMi05LTEtMS0w_4fe0313b-f78e-48ae-9366-78aa528b5ae4">632,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8e7eb846bd436b99ddee2ea5d4de93_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMy01LTEtMS0w_6137e91d-e7c1-4855-9bd4-344b0ef482d8">151,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if799ebcc579c4d499fe23a1a040367cf_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMy03LTEtMS0w_f4f57ed4-786d-4482-8cba-a4618d013014">152,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dd4195ecbd4524a57b68e9b5121e06_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMy05LTEtMS0w_90537502-e01b-4d28-af43-d17f8af686a3">182,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703818facc0749cea8bf6a915c610cf2_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNC01LTEtMS0w_9f6f72c1-8c20-4e1c-9ef2-474113242fdc">83,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972f61963894489d8bd8d96975249ff6_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNC03LTEtMS0w_2facc6d2-e1a8-4bb9-a656-87d3237bbff5">44,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if514cdad25cc48d282b48650879ae9b7_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNC05LTEtMS0w_f2a09c8d-27fa-49bd-8483-b95065a8df1a">38,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNS01LTEtMS0w_4fac9952-0cb9-4992-a5bb-bbde9f2ebd04">987,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNS03LTEtMS0w_601daefe-be16-41aa-bf0f-726f8029a8e8">967,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNS05LTEtMS0w_40103182-c140-48b6-a26e-54347a572ccc">853,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues are comprised of net product revenues which are attributed to geographic regions based on the ship-to location and license and collaboration services revenues which are attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNTMyNQ_be1087b5-8b6d-4624-9c47-1d75fe6260da" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending allowance balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2018</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18681346850c4142b0cd3f7611f296f7_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMS0xLTEtMS0w_588e621f-6e90-4017-95b3-c666592914db">2,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569e8490f11c4c2397bf2fb735ab9284_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMS0zLTEtMS0w_3a9649e3-3d3b-457c-9c82-be0d5cb16b19">3,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i068e290e4adf43a6ae27c34e6c1a6b8d_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMS01LTEtMS0w_e2455940-dde5-4348-b302-44f44a99ce42">11,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMS03LTEtMS0w_db738b69-dec4-4bd6-b7ef-0b001efd91ce">17,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0014908918c44efd817e3fd6b0997259_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMy0xLTEtMS0w_723536e4-8701-47e4-b444-b95cb29b6ab2">129,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7037c5690ef4f0eb73f27b75981598e_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMy0zLTEtMS0w_2a097672-6d68-4ab4-b364-28befe3977e8">15,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588f2ef914e74116ac5406f6a9c01b36_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMy01LTEtMS0w_d32e8c76-e451-48c4-8c1a-e4481216ad95">48,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMy03LTEtMS0w_d4bcbbc7-c782-40bc-a7c0-8ee1e6f1cda5">193,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0014908918c44efd817e3fd6b0997259_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNC0xLTEtMS0w_f0323f03-2150-4f49-a986-1da3266db94b">3,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7037c5690ef4f0eb73f27b75981598e_D20181229-20200103" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNC0zLTEtMS0w_3dff4b7f-d236-4f1c-a198-e4f27d7d7dca">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588f2ef914e74116ac5406f6a9c01b36_D20181229-20200103" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNC01LTEtMS0w_d94e6767-4346-4588-bc5d-8161c351a839">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNC03LTEtMS0w_084f61ce-8bb2-4149-8a68-5719a2681ea4">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0014908918c44efd817e3fd6b0997259_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNS0xLTEtMS0w_ecfa8d64-64c1-440a-9f33-2113541683ef">128,733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7037c5690ef4f0eb73f27b75981598e_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNS0zLTEtMS0w_b81d15ae-4af2-4973-915b-6aa15397b313">15,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i588f2ef914e74116ac5406f6a9c01b36_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNS01LTEtMS0w_bc415b62-0206-4b20-b2a9-a3a0a8844964">44,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNS03LTEtMS0w_957f9aed-0993-4146-8d18-3a8afce14db3">188,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5ede1c91f84818b0783db0bb304518_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNi0xLTEtMS0w_6528857b-a8ee-445e-b4f1-dd931bdb8848">7,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b5a386ffe8410abe781ee1be62b794_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNi0zLTEtMS0w_8f428b52-5b8b-490f-8af8-0cd9755bf202">3,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41ebfdbd93854a33891fe6df6de3c3b6_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNi01LTEtMS0w_010492b3-0f06-4327-be85-a6b4920ff619">15,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNi03LTEtMS0w_5922aa2a-4837-4044-8ed1-946e7137b9ae">26,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7cfa1b7a7f4ba38dc76cc810d3400d_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOC0xLTEtMS0w_75f2307e-eccc-4d6f-bd86-a9435e523a28">146,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c97e81888f485bb64fd4ed361390ac_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOC0zLTEtMS0w_583e442f-f6b6-4209-83c9-c7529a78008f">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485f8f534a3b4af3bbd86f765dd82388_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOC01LTEtMS0w_51d499bc-930b-4611-84b4-948090ea9f5f">58,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOC03LTEtMS0w_055c573c-fa64-4872-a6b2-a2b581507d4b">220,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7cfa1b7a7f4ba38dc76cc810d3400d_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOS0xLTEtMS0w_e36b3132-a55f-4f32-bcc1-2e1ab775c5d7">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c97e81888f485bb64fd4ed361390ac_D20200104-20210101" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOS0zLTEtMS0w_fbf6c561-3586-493f-aa08-c2689cbf41c2">352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485f8f534a3b4af3bbd86f765dd82388_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOS01LTEtMS0w_7ddffcfd-f277-49ea-bc8f-06b20387aa0b">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOS03LTEtMS0w_04f780ad-4ee5-4146-8914-8cbdf3b30122">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a7cfa1b7a7f4ba38dc76cc810d3400d_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTAtMS0xLTEtMA_cfc08754-a4b4-4abb-befe-0d9f8f636632">144,231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9c97e81888f485bb64fd4ed361390ac_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTAtMy0xLTEtMA_71d1fc7f-ead3-4879-b164-52b31d7f3751">16,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485f8f534a3b4af3bbd86f765dd82388_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTAtNS0xLTEtMA_b1bc3f1b-d18e-4bfc-a0f9-8f18f948751e">56,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTAtNy0xLTEtMA_45d8b29f-9b3f-4019-bd75-b984b173480a">216,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4e2d4955acf43d8b9d5c3180cca3657_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTEtMS0xLTEtMA_c878dceb-7fbc-4064-8dbe-da220a9d0ace">9,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d678bb169b48699b45ef9f3a5ee83a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTEtMy0xLTEtMA_51bfcc33-5761-4214-92c8-2adb549c2209">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac85cedb1c81483cabfe7f110f14f7bf_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTEtNS0xLTEtMA_685bd337-90a7-41ff-bb3e-58201434b63c">17,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTEtNy0xLTEtMA_5eb2d03e-0432-471f-8d9a-e0750f7fab1b">30,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i5d35a4d8a00c41388dd73f1ce652bca2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfMTI2NDQzODM3MzUxODA_f39f79c9-4775-4d49-8f43-1b22732cff51" continuedAt="i8e9e8eb18a96418cb9795c8c14c0a3e8" escape="true">Contract assets and liabilities were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i8e9e8eb18a96418cb9795c8c14c0a3e8" continuedAt="ica9b1d825c194b398fcb4fd23c6e5b3a"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfMi0xLTEtMS0xODA5_f7d10668-0b4a-4128-92dd-99d80b60fb46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfMi0zLTEtMS0xODA5_6e3905fe-20cd-4dea-ab43-5ee8041bd86b">1,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNS0xLTEtMS0xODE0_1f975427-ef9f-42fb-a185-07fa24f708e4">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNS0zLTEtMS0xODE0_8619c76b-ebd8-45e0-aa3e-edd6e70d7898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNi0xLTEtMS0xODE5_f902bb12-7ee6-4842-b5f0-19c4d6fc240c">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNi0zLTEtMS0xODE5_1632d884-75a4-4655-ae6f-552fa9ac8450">6,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNy0xLTEtMS0xODE0_253d2be1-8cbf-4f5d-9b31-e27c27144e7d">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNy0zLTEtMS0xODE0_477ec9a6-1d51-4b15-bfcb-63f27f5bc9af">6,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Presented in prepaid expenses and other current assets in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ica9b1d825c194b398fcb4fd23c6e5b3a">(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018, we recognized $<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDUwNw_3ba6dde1-4846-407f-9bc4-cef86cc1783f">9.2</ix:nonFraction> million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDUxNA_69cb6c4c-84f9-4457-9425-16e9533abbf5">6.5</ix:nonFraction> million and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfMjc0ODc3OTA4NTI3Mw_4a447cfa-a381-44d8-97c5-24339bc932b3">8.7</ix:nonFraction> million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, in revenues that were included in the beginning deferred revenue balance for those years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2020, 2019 and 2018, we recognized $<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDY2Mg_97f8e980-6fac-416b-b1e1-fe6ca94f463f">169.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDY2OQ_23f064fc-bea6-4fd1-be19-0774c9c58269">161.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfMjc0ODc3OTA4NTI4NA_2701fa98-ef4d-4857-87fb-0540b2c71f5a">198.1</ix:nonFraction> million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to milestone and royalty payments allocated to our license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDk0NA_ad24ce00-39f4-4e97-89dc-d64aa8cdeaf5">86.1</ix:nonFraction> million of the combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; for additional information about the expected timing to satisfy these performance obligations.</span></div></ix:continuation><div id="i68bf8bfb5b59421792b5711a409e9ffd_94"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMzc0MDc_de2d2fb0-b9eb-4215-ac5b-6f9c30676df8" continuedAt="ia8a82c5604bd46528d5533f356cb4115" escape="true">COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="ia8a82c5604bd46528d5533f356cb4115" continuedAt="i15a3c64b051d4b4989eb5c1d8a65b15c"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib franchise. Additionally, we have entered into several research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Consistent with our business strategy prior to the commercialization of cabozantinib, we also entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, to receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i15a3c64b051d4b4989eb5c1d8a65b15c" continuedAt="if5ea4b7c4b6e4dc7814a6e0c90f0e6e5"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) <ix:nonNumeric contextRef="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101" format="ixt-sec:durwordsen" name="exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ0Ng_36e34e99-423f-49d1-b3f9-aa2f0ea03a28">ten years</ix:nonNumeric> after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the U.S. Food and Drug Administration (FDA) or European Medicines Agency orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of $<ix:nonFraction unitRef="usd" contextRef="i3448dcea3614442a9a77d8d52fcb6e28_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="exel:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNDI0MA_a0dd7407-d61c-4417-bb17-ab10baf4c523">210.0</ix:nonFraction> million from Ipsen in 2016. As of December&#160;31, 2020, we have achieved aggregate milestones of $<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarnedToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMxMTI2OQ_16fee832-3eb7-4da1-8402-d7f17a8f5941">350.0</ix:nonFraction> million related to regulatory, development and sales-based threshold by Ipsen since the inception of the collaboration agreement, including $<ix:nonFraction unitRef="usd" contextRef="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwNTA1Mw_f0333f27-e3ad-453b-9500-a6f06062749a">20.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id261962031d24c9c96d500feae66c4cb_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwNTA0OQ_ea6ebe45-3e5a-4c57-9b0d-3c3d6538ae55">55.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3edf5cd51c4c429ca9fd36162d5bfb83_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NTQ4NDQ_8f7672c5-2aa0-4fb8-b78e-849b21bd4d36">140.0</ix:nonFraction>&#160;million in milestones achieved during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMxNTU0Mw_2edba791-6e86-476a-98c3-0c58acf65887">59.0</ix:nonFraction> million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $<ix:nonFraction unitRef="usd" contextRef="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NjMyNDM_fbbb72d7-c635-4ba5-9546-3bc1222948b1">450.0</ix:nonFraction>&#160;million and CAD$<ix:nonFraction unitRef="cad" contextRef="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NjMyNTk_9eb44cc7-7166-4316-a23a-a8b9e8a0ce5d">26.5</ix:nonFraction>&#160;million. We excluded these milestones from the transaction price as of December&#160;31, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMxNjE1Mg_65147a6e-cbf2-4c90-9899-4b9858402ebd">41.3</ix:nonFraction> million of the transaction price allocated to our research and development services performance obligation had not been satisfied. See &#8220;&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, below, for additional information related to the revenue recognition for this collaboration.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive royalties on the net sales of cabozantinib by Ipsen outside of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he U.S. and Japan. During the year ended December&#160;31, 2020 and going forward, we are entitled to receive a tiered royalty of <ix:nonFraction unitRef="number" contextRef="i175c1256c42e4ceb969e04284a7f0b85_D20200104-20210101" decimals="INF" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1ODYwNA_2565ccbd-bb63-4d82-b0a7-06a47d3f8dcd">22</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6e51030563a74e4ab6a25f0c1af5638f_D20200104-20210101" decimals="INF" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1ODcxNg_53ad76ec-d17a-4f24-bb28-420ffdc9322d">26</ix:nonFraction>% on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a <ix:nonFraction unitRef="number" contextRef="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNTMzNQ_bff152e5-346f-4079-ae09-ac754b332089">3</ix:nonFraction>% royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for <ix:nonFraction unitRef="number" contextRef="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101" decimals="2" name="exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNTcyMA_a876380c-dbef-4e99-b2c7-e14ad6696826">35</ix:nonFraction>% of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding the following clinical trials which are described in greater detail below: COSMIC-021, COSMIC-312, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="if5ea4b7c4b6e4dc7814a6e0c90f0e6e5" continuedAt="i404c9abdfbed401b9e9abe94da04120a"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product is supplied at our cost, as defined in the agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration </span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY2NjY_a3e6389c-8e17-47f5-b1d6-43392e1fe3a2" continuedAt="iff726be8271d4dd18361087b95803e06" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbfee036b7344af7acf82053445607ff_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMi01LTEtMS0xMTEx_7008c5d1-6e76-4589-b6ff-86eee39a6190">93,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb74c8b1eec4b309ba8b185f47e746e_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMi03LTEtMS0xMTEx_20a2345b-f28c-4f2b-ada2-6e76c63e35ae">117,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i798095a51aa64ee99fae753389f50df8_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMi05LTEtMS0xMTEx_dc300f4e-113a-471f-b639-6420ec47d440">157,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3a269af46e46d4ba478888e3772c6b_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMy01LTEtMS0xMTEx_e0b936da-5e96-42e7-9e3f-5cbf603a77c0">58,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7aa81d937ec42618a7404c5d7df25a4_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMy03LTEtMS0xMTEx_b7dd05ab-08a1-40f1-a5f8-91985096bada">35,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic048c678e69e4a2696e357c75149ef17_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMy05LTEtMS0xMTEx_a9fc541c-314a-408f-ad0a-c0cd30ed3f5e">25,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfNC01LTEtMS0xMTEx_b51e6711-bc1f-4670-a003-95dafd993d08">151,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id261962031d24c9c96d500feae66c4cb_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfNC03LTEtMS0xMTEx_a731ec9f-9590-43de-949e-4dbd3f0a43cc">152,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3edf5cd51c4c429ca9fd36162d5bfb83_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfNC05LTEtMS0xMTEx_cc286448-b9fc-49cc-94e1-ea32c1e237bd">182,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive and modified certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02 clinical trials. We determined the amendment in September 2020 represented a contract modification that was treated as a termination of an existing contract and the creation of a new contract under Topic 606. As a result, we allocated the remaining transaction price to the performance obligations identified in the contract. The two remaining performance obligations are the research and development services associated with committed studies and the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. In allocating the transaction price for the modified contract we estimated the standalone selling price for the performance obligations. We utilized development costs incurred for these obligations in process and the projections of costs through the term of the arrangement. Revenue is recognized when, or as, we satisfy our performance obligations by transferring the promised services to Takeda. Revenue is being recognized using the cost proportional performance method, based on costs incurred to perform the research and development services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is responsible for a portion of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and <ix:nonFraction unitRef="number" contextRef="i647bc5092dce48c290e3e40bd7a16822_D20200104-20210101" decimals="INF" name="exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyMTI1Mw_bd8efa03-d987-4d7f-8554-5927d34e7520">100</ix:nonFraction>% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding the following clinical trials which are described in greater detail below: CheckMate -9ER, CONTACT-01 and CONTACT-02, and certain cohorts of COSMIC-021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) <ix:nonNumeric contextRef="i647bc5092dce48c290e3e40bd7a16822_D20200104-20210101" format="ixt-sec:durwordsen" name="exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNzk2NA_12f76ad4-8e47-46cb-8c33-310f1e4d1cdb">two years</ix:nonNumeric> after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first <ix:nonNumeric contextRef="ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101" format="ixt-sec:durwordsen" name="exel:PeriodOfSpecificSalesVolumeThreshold" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfODUyMg_ea20202a-fe80-4852-833c-e24d4951eea7">six years</ix:nonNumeric> of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i404c9abdfbed401b9e9abe94da04120a" continuedAt="i88074d506102494f844413803b6d9f45"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i98980155e99342fdb4084a583ee15d45_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="exel:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfOTYyMw_9a99a0c8-517b-40a7-88d2-9966940ddc36">50.0</ix:nonFraction> million from Takeda in 2017. As of December&#160;31, 2020, we have also achieved regulatory and development milestones in the aggregate of $<ix:nonFraction unitRef="usd" contextRef="i6a84efaf8d1449868eee0a1f360e49d0_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarnedToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwNTYxNw_22b9cd21-bd34-4032-b49c-035b5fe64eb2">92.0</ix:nonFraction> million since the inception of the collaboration agreement, including $<ix:nonFraction unitRef="usd" contextRef="ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwNTU5Ng_a02af88f-babf-4050-97a6-af29f320562e">66.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ife1791e1be864b11836b55144b0c084d_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfOTgwMg_4e0145a3-9772-4082-a1ca-8d652a6c1380">16.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i73471fb9991d403ba0e68dd720fe1b50_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NTQ4NjA_e45f20cd-7b99-41f8-bbf7-a7ebbc1f18c3">10.0</ix:nonFraction>&#160;million in milestones achieved during the years ended December&#160;31, 2020, 2019 and 2018, respectively. As of December 31, 2020, we have also determined that it was probable that we will earn milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="i6a84efaf8d1449868eee0a1f360e49d0_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsYetToBeEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMzI5ODUzNDk4OTU1NQ_6061768b-cb42-461b-b1da-9bc1a042f1a1">15.0</ix:nonFraction>&#160;million for the initiation of two phase 3 pivotal clinical trials for additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, as amended, as of December 31, 2020, we are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of up to $<ix:nonFraction unitRef="usd" contextRef="i6a84efaf8d1449868eee0a1f360e49d0_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1NzczMw_09d1b8fe-8479-4738-894c-014f644ad47d">139.0</ix:nonFraction> million. We excluded these milestones from the transaction price as of December 31, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also receive royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of <ix:nonFraction unitRef="number" contextRef="i4c7b509b13bc4e9d939f403b1f05c90e_D20200104-20210101" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNTY_73e816f5-b7d8-4f24-8f46-c73e226f1656">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie037b8583ad749bc9122949aec189228_D20200104-20210101" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNTE_e40b848e-c8e4-4997-83e6-5655edbf84e4">24</ix:nonFraction>% on the initial $<ix:nonFraction unitRef="usd" contextRef="i5718b7dcecd84defac7a854084c0bf25_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:RoyaltyTier" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwMzU_3f51c5c5-765e-4a22-ae10-1835a09d6940">300.0</ix:nonFraction>&#160;million of net sales, and following this initial $<ix:nonFraction unitRef="usd" contextRef="i5718b7dcecd84defac7a854084c0bf25_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:RoyaltyTier" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwMTk_21f09cea-45c0-449b-b539-cef5e4356a7a">300.0</ix:nonFraction>&#160;million of net sales, we are then entitled to receive a tiered royalty of <ix:nonFraction unitRef="number" contextRef="ice580bea9a0e497face411c0858d3839_D20200104-20210101" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNjE_26f2270e-9066-41ba-b357-59e4ea0ed48c">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i26c711accea64d95bdd1a6048b3bc497_D20200104-20210101" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNjY_f9e7a575-ac8d-4d28-b0dd-d427fe374398">30</ix:nonFraction>% on annual net sales thereafter; these <ix:nonFraction unitRef="number" contextRef="ice580bea9a0e497face411c0858d3839_D20200104-20210101" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNzE_8e6fec68-36e4-43b6-9c10-87110121f895">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i26c711accea64d95bdd1a6048b3bc497_D20200104-20210101" decimals="2" name="exel:PercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNzY_ae3eca1f-37ef-4c1f-8c2b-a9eab660adba">30</ix:nonFraction>% royalty tiers reset each calendar year. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a <ix:nonFraction unitRef="number" contextRef="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTEyNjg_bff152e5-346f-4079-ae09-ac754b332089">3</ix:nonFraction>% royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration</span></div><ix:continuation id="iff726be8271d4dd18361087b95803e06" continuedAt="ic89e028b6aac418aa344b49d9f0cb40a"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):  </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide639614f81d4101bd26fa5346aa6494_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMi01LTEtMS0xMTI2_1f9f268b-7688-416a-9110-f4d34a95c192">61,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e2147b6a2c4b3e97bebda7cfdbb8a8_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMi03LTEtMS0xMTI2_5be04714-cf4d-4386-8589-43260e5e032a">18,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c49af6cac24b6aaf78ac9bf15ebf13_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMi05LTEtMS0xMTI2_2cd10e4c-22d5-4fb0-9f20-25d7119be7ac">9,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59310ff945004ea6a249b2f169b44e59_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMy01LTEtMS0xMTI2_0dab27df-3704-4dbd-bee0-5d05cfe9d196">20,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ffb053e94f427c97510610790a7fa1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMy03LTEtMS0xMTI2_dbe07789-8880-460d-ad39-eb9d5145a10e">6,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f066209f19547159b014cc341b71222_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMy05LTEtMS0xMTI2_13a34e43-bc91-47aa-9276-0ee040e36b8d">8,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfNC01LTEtMS0xMTI2_d7bd1f24-ce9a-4524-b9ce-83303560cc99">81,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1791e1be864b11836b55144b0c084d_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfNC03LTEtMS0xMTI2_88440c0f-4d89-471f-8aa5-f15d076849c0">24,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73471fb9991d403ba0e68dd720fe1b50_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfNC05LTEtMS0xMTI2_ffe36027-4e00-4b5d-ab4c-735e77532dbd">18,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i6a84efaf8d1449868eee0a1f360e49d0_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwMDgxNw_04e384a7-251e-4647-b89c-a2515562b055">44.8</ix:nonFraction>&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified two performance obligations for the Ipsen collaboration agreement: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i88074d506102494f844413803b6d9f45" continuedAt="i37d22eba2ac14ec78d8f84106ae4da96"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified two remaining performance obligations for the Takeda collaboration agreement due to the amendment in September 2020: (1) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements) and (2) the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. As part of the original contract, we had a performance obligation associated with the exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2017.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have allocated the transaction price for each of these collaborations to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We re-evaluate the transaction price for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended December&#160;31, 2020, 2019 and 2018, the transaction price of the Ipsen and Takeda collaboration agreements increased as a result of the achievement of various milestones, and the reimbursements of research and development services related to committed and opt-in studies. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December&#160;31, 2020, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Development Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC in the CheckMate -9ER and COSMIC-313 trials and for HCC in the CheckMate 040 trial. Under the terms of the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i37d22eba2ac14ec78d8f84106ae4da96" continuedAt="ib59fbc1b3c1740ebac8d433143ab209f"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">F. Hoffmann-La Roche Ltd. (Roche) Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in three planned phase 3 pivotal clinical trials in advanced non-small cell lung cancer (CONTACT-01), metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03). If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, a supplement to the joint clinical research agreement was signed amongst us, Roche and Takeda due to Takeda opting into fund the combined therapy trial of CONTACT-01 sponsored by Roche. Chugai was added as an affiliate of Roche. All parties including Chugai conduct combined therapy trials in Japan upon the terms of the joint clinical research agreement.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply of their drug for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated during 2014, we continue to be required to pay a <ix:nonFraction unitRef="number" contextRef="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQyOTg_bff152e5-346f-4079-ae09-ac754b332089">3</ix:nonFraction>% royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of other </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="ib59fbc1b3c1740ebac8d433143ab209f" continuedAt="i6b0d9a4da4df4e7eb7d47821bfe4b1c3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration revenues for sales by our collaboration partners. Such royalties were $<ix:nonFraction unitRef="usd" contextRef="ib6abb9ba6ee941bf966fb2b8bdb7c6eb_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ2NDU_7107b926-39a6-48f4-9eef-88d90d8beda8">32.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id33fe3c37c9e4d0e83192b2e14809965_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ2NDk_8805b529-d26a-4def-a377-0323426ae5ad">31.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia166fd55b459460880c354bf9715e1c8_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ2NTY_69dc9705-2793-4b7a-8ec6-aea621ba5e9d">24.0</ix:nonFraction> million during the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech </span></div><ix:continuation id="ic89e028b6aac418aa344b49d9f0cb40a"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits and losses on the U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55343bda1c447eaaec24e61aced15a2_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMi01LTEtMS00Mjg0_23276a9a-1eb4-49a4-a91d-9e2d9cdf9bdb">6,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4da49014e834ce4a25784b67ff9a020_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMi03LTEtMS00Mjg0_36e2e7b1-ff04-452d-8bc4-0dedffd0c749">4,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33ee4113b464bb8805d9fd13ec03adc_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMi05LTEtMS00Mjg0_f73231d7-d495-4303-93d7-e4132fb8551b">8,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55343bda1c447eaaec24e61aced15a2_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMy01LTEtMS00Mjg0_01420b9f-9b07-4913-a370-0240f70694ae">5,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4da49014e834ce4a25784b67ff9a020_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMy03LTEtMS00Mjg0_6778eeae-e5c0-4320-866c-99a2d16b7a6a">5,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33ee4113b464bb8805d9fd13ec03adc_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMy05LTEtMS00Mjg0_79e8af8d-3794-42e0-9d6d-6104d9ac8a85">5,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cobimetinib Profit Sharing and Royalty Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. On July 30, 2020, the FDA approved COTELLIC, in combination with Genentech&#8217;s ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of BRAF V600 mutation-positive advanced melanoma in previously untreated patients. Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive <ix:nonFraction unitRef="number" contextRef="i6ccf4e0d483843eb99b3aae67e446fb1_D20200104-20210101" decimals="2" name="exel:ProfitSharingAgreementPercentOfProfits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyNjc1Mg_42b0df1f-ee75-4035-a159-f0275b98ae83">50</ix:nonFraction>% of profits and losses from the first $<ix:nonFraction unitRef="usd" contextRef="ic692135e06904b4e9f53251b1bda6e6a_D20200104-20210101" decimals="INF" format="ixt:numdotdecimal" name="exel:ProfitSharingAgreementProfitThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyNjc5Mw_d2c93f22-f22d-40dd-a467-3a91a19a7c4f">200.0</ix:nonFraction> million of U.S. actual sales, decreasing to <ix:nonFraction unitRef="number" contextRef="i12696a9f70bb4520879173dd02953d2e_D20200104-20210101" decimals="2" name="exel:ProfitSharingAgreementPercentOfProfits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyNjgzMw_9cc9d800-ffcf-4a30-9676-02f032047dc7">30</ix:nonFraction>% of profits and losses from U.S. actual sales in excess of $<ix:nonFraction unitRef="usd" contextRef="i6443bf806be740278539f1341106b36e_D20200104-20210101" decimals="INF" format="ixt:numdotdecimal" name="exel:ProfitSharingAgreementProfitThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyNjg5NQ_0cd77450-c45e-488e-9125-d44f9219f727">400.0</ix:nonFraction> million. These tiers reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. We are not eligible for any additional milestone payments under the collaboration agreement with Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo was responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i6b0d9a4da4df4e7eb7d47821bfe4b1c3" continuedAt="i8406422fdcda44e5bce23c53145206fa"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In&#160;January 2019, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May 2019, Daiichi Sankyo had its first commercial sale of MINNEBRO. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have achieved milestones of $<ix:nonFraction unitRef="usd" contextRef="i04d73fb71dcc4abba01472ab63322c3d_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementAchievedMilestoneAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwOTU_29f155b1-8395-4f70-a615-7ac2dbe60f9c"><ix:nonFraction unitRef="usd" contextRef="i0b172a5ff906435aadf5f99c85c38a22_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementAchievedMilestoneAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwOTU_f2f77cc2-fad0-4dc2-80f0-ca921175b177">20.0</ix:nonFraction></ix:nonFraction>&#160;million each during the years ended December&#160;31, 2019 and 2018 for the approval and first commercial sale of MINNEBRO. We are eligible to receive additional sales-based milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i5706545d66894d3d921d401e933a36d5_I20210101" decimals="INF" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyOTU0NQ_d2896e32-4a12-4120-8c2f-30d2a0867791">90.0</ix:nonFraction> million under this collaboration agreement. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Such revenues were $<ix:nonFraction unitRef="usd" contextRef="i9ebd3eeeea5e4c2f8ffd32d9ad345d16_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1MzM1MA_14e37047-170c-49a5-a261-9534c7307a14">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2544c6fb6a9b4a6fa37e6ca31e607dbb_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcxMjM_7cdf18c0-872c-442f-9ef0-80f7e0716e3d">0.1</ix:nonFraction>&#160;million during the year ended December 31, 2020 and 2019, respectively. Those revenues are presented in license revenue in our Consolidated Statements of Income. Daiichi Sankyo may terminate the agreement upon <ix:nonNumeric contextRef="i914e005fdf1940ce8583162f9bd6ea5c_D20200104-20210101" format="ixt-sec:durday" name="exel:CollaborationAgreementTerminationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcxODg_2bcbbf94-19fa-453e-b0a0-52eb1aa37e7c">90</ix:nonNumeric> days&#8217; written notice, in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue under the collaboration agreement with Daiichi Sankyo w</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $<ix:nonFraction unitRef="usd" contextRef="i914e005fdf1940ce8583162f9bd6ea5c_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTM3NDM4OTU0NDU0NzE_5c4ce70d-7898-4813-ab44-71431bceb928">1.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i0b172a5ff906435aadf5f99c85c38a22_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1MzQwOA_188759c0-c3c2-44aa-bb9a-a393a541870d">20.1</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i04d73fb71dcc4abba01472ab63322c3d_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NTQ5MDU_198b56d0-0493-4015-83b3-3b8207c4a2dc">20.0</ix:nonFraction>&#160;million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Research Collaborations and In-Licensing Arrangements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions LLC</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., (individually and collectively referred to as Catalent). Under the terms of the agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeAgreementsUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY4MTc_679c2de2-b650-4476-9cd5-e2906f05813a">10.0</ix:nonFraction>&#160;million in exchange to nominate and have the exclusive option to license four targets using Catalent&#8217;s ADC platform over a <ix:nonNumeric contextRef="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementTargetSelectionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNzE0NjgyNTY4NTYxNQ_9330db65-d654-481a-88cf-0836afd3e0cc">three-year</ix:nonNumeric> period. In addition, we have a right to extend the target selection term to <ix:nonNumeric contextRef="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcyMjI_2e200088-a4b8-4ed4-bf84-8273384e8c32">five years</ix:nonNumeric> and nominate up to two additional targets for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementsAdditionalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY4MDM_0c7d2096-48f0-42c2-89d0-f5c54279f915">4.0</ix:nonFraction>&#160;million. For each option we decide to exercise, we will pay an exercise fee of $<ix:nonFraction unitRef="usd" contextRef="idc77b7509ab54848ab388e7bd8d55ff7_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3ODk_88197786-a877-476a-91cc-08c0907e1597">2.0</ix:nonFraction>&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. Catalent would then become eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="idc77b7509ab54848ab388e7bd8d55ff7_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY4MzI_ec104510-f985-4a2f-8eb0-e6e4c241ec71">44.0</ix:nonFraction>&#160;million per compound in potential development milestone payments, $<ix:nonFraction unitRef="usd" contextRef="idc77b7509ab54848ab388e7bd8d55ff7_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3NzQ_06627157-c3fe-4cbc-a6a2-b935b2fbb23a">60.0</ix:nonFraction>&#160;million per product in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBE Therapeutics AG (NBE)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with NBE. Under the terms of the agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeAgreementsUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3NTk_8bfd96e1-64f3-4aa8-913a-135d0b1b4a1e">25.0</ix:nonFraction>&#160;million in exchange for exclusive options to nominate four targets using NBE&#8217;s ADC platform over a <ix:nonNumeric contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementTargetSelectionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNzE0NjgyNTY4NTYxNg_1edb350e-9156-4ab7-ad13-fc28782aeddd">two-year</ix:nonNumeric> period. In addition, within the first <ix:nonNumeric contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTE1NDQ4NzIxODM4MTI_5badd50b-e27b-4679-8e8f-d86637d4f334">eighteen months</ix:nonNumeric> of the agreement, we also have a right to extend the target selection term to <ix:nonNumeric contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002" format="ixt-sec:durwordsen" name="exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTE1NDQ4NzIxODM4MzM_0fba7ddb-b9f5-4e84-b0ab-6b34201a5905">three years</ix:nonNumeric> for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementsAdditionalUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY2OTk_e786152a-bb94-4d11-aaff-3e0f3cc896a3">2.0</ix:nonFraction>&#160;million. For each option we decide to exercise, we will be required to pay an exercise fee of $<ix:nonFraction unitRef="usd" contextRef="ib21b7306bafe44138821e7d078f9b318_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY2ODQ_2a407ee1-848b-4dc5-9d40-c83c36809f8f">10.0</ix:nonFraction>&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. NBE would then become eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ib21b7306bafe44138821e7d078f9b318_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3MTM_eec16115-fcb4-42f2-a57e-2b4696b568be">90.0</ix:nonFraction>&#160;million per program in potential development milestone payments, $<ix:nonFraction unitRef="usd" contextRef="ib21b7306bafe44138821e7d078f9b318_I20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3NDM_95a72f4e-3f9c-4499-b607-84eab14bd6df">135.0</ix:nonFraction>&#160;million per program in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aurigene Discovery Technologies Limited (Aurigene)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as <ix:nonFraction unitRef="program" contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731" decimals="INF" format="ixt-sec:numwordsen" name="exel:CollaborationAgreementNumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ5MzE_8c4e5947-6219-4b9f-8c81-981452a08fb3">six</ix:nonFraction> programs to discover and develop small molecules as therapies for cancer. Under the terms of the agreement, we made aggregate upfront payments of $<ix:nonFraction unitRef="usd" contextRef="i6901a20ec19b4d62afcecb76296051f6_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="exel:UpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjUwODA_704d81b7-7230-49b2-b551-921b4f18ba5f">17.5</ix:nonFraction> million for exclusive options to license up to <ix:nonFraction unitRef="program" contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731" decimals="INF" format="ixt-sec:numwordsen" name="exel:CollaborationAgreementNumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjUxMjI_8c4e5947-6219-4b9f-8c81-981452a08fb3">six</ix:nonFraction> programs, including <ix:nonFraction unitRef="program" contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731" decimals="INF" format="ixt-sec:numwordsen" name="exel:CollaborationAgreementNumberOfPreexistingPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjUxNDU_e814a89a-8e54-4f1e-a8c9-730ae33ac4cb">three</ix:nonFraction> pre-existing programs. We are also responsible for research funding for the discovery and preclinical development work on these programs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, we exercised the exclusive option to in-license Aurigene&#8217;s novel XL102 inhibitor and incurred an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="ie1dacedabe3d4737800441a7d9194116_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NTQ5NDk_954917f5-15a0-4939-84be-0aca72e0c6b7">12.0</ix:nonFraction>&#160;million. For each remaining option we decide to exercise, we will be required to pay an exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i955e5bb70aeb486b8c2d62388f3e44a0_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjU1MDk_c40a1fc2-f375-4a9e-bcf4-724ae2f4842e">10.0</ix:nonFraction> million and would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for up to $<ix:nonFraction unitRef="usd" contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjU3MjU_d14c7b0f-6e52-4584-8d2a-cc0ec92f0845">148.8</ix:nonFraction> million per program in potential development and regulatory milestone payments, $<ix:nonFraction unitRef="usd" contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjU4MDA_178aca65-5a90-4ef1-9147-8d22915d61ed">280.0</ix:nonFraction> million per program in potential commercial milestone payments, as well as royalties on potential sales. Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i8406422fdcda44e5bce23c53145206fa"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Iconic Therapeutics, Inc. (Iconic)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer, leveraging Iconic&#8217;s expertise in targeting Tissue Ffactor in solid tumors. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#8217;s lead oncology ADC program, in exchange for an upfront payment to Iconic of $<ix:nonFraction unitRef="usd" contextRef="i983d2a459669479ea167c4f7883b0a2a_D20190501-20190531" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementsUpfrontPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjY0Nzk_5d80a3af-9124-4ac9-944f-6f962f940838">7.5</ix:nonFraction> million and a commitment for preclinical development funding.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, we exercised our exclusive option to in-license XB002, Iconic&#8217;s lead oncology ADC program and made an option exercise fee payment of $<ix:nonFraction unitRef="usd" contextRef="ic9d59bfad27b4babaf33ea9828f5e7db_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjY5Mjc_40da5c16-38b8-4130-bf11-593fbfb4dc8d">20.0</ix:nonFraction> million to Iconic; we concurrently assumed responsibilities for all subsequent clinical development, manufacturing and commercialization activities, and Iconic  became eligible for up to $<ix:nonFraction unitRef="usd" contextRef="ic9d59bfad27b4babaf33ea9828f5e7db_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjcxMTE_c45f7f2b-0b79-44ae-b11b-aff784084fce">190.6</ix:nonFraction> million in potential development, regulatory and first-sale milestone payments, $<ix:nonFraction unitRef="usd" contextRef="ic9d59bfad27b4babaf33ea9828f5e7db_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjcxODY_82c3930f-3367-4ccf-a63f-06e0fd2bf55c">262.5</ix:nonFraction> million in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Invenra, Inc. (Invenra)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a collaboration and license agreement with&#160;Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities.&#160;The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform, or with other platforms and formats at our option. In March 2020, we amended the agreement to enable the use of target binders in non-Invenra platform-based modalities, such as ADC platforms. As of December 31, 2020, we have initiated three additional discovery projects and six binder projects. Invenra is eligible to receive up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i2b3fd10a6b8e4b88964207e8afc24c36_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjg2MzQ_65c26bac-ab16-4dd1-b43a-74adbbd5a629">131.5</ix:nonFraction> million&#160;in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a B-Body product in the first indication, or in lieu of such payments, up to $<ix:nonFraction unitRef="usd" contextRef="i31f84a4833d5496fafe3fb2b06ee4da2_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:ProjectInitiationFeePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjg4NDM_d42f1bcf-d67d-46a6-89f4-720518ccba2b">43.4</ix:nonFraction> million in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a non- B-Body product. Upon successful commercialization of a product, Invenra is eligible to receive sales-based milestone payments up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i18fefd085e3c45968805d31566f5a911_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjkxMTQ_1700341b-3e72-4fa8-950a-64ab5b6807cd">325.0</ix:nonFraction> million&#160;as well as single-digit tiered royalties on net sales of the approved product. We have the right to initiate three additional discovery projects for development subject to an upfront payment of&#160;$<ix:nonFraction unitRef="usd" contextRef="i4bf737b2abae44928037ed75a133e223_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:UpfrontAndMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjkzMTE_b2ee02b6-ba2e-4014-b218-4af234d0ac6d">2.0</ix:nonFraction> million&#160;for each B-Body project, as well as additional milestone payments and royalties for any products that arise from these efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">StemSynergy Therapeutics, Inc. (StemSynergy)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1&#945;), a component of the Wnt signaling pathway implicated in key oncogenic processes. Under the terms of the agreement,&#160;we&#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&#945;. We paid StemSynergy an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i81c0e0276859476d8764f5e4a7c6a702_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="exel:UpfrontAndMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NjMzNjI_bd8d6f4d-0e17-4e4b-9f1c-6d76b8441c3b">3.0</ix:nonFraction>&#160;million in 2018. StemSynergy will also be eligible for up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia5be837eaece4b1e827b2ac075babd6c_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMzA0MDM_15ed8724-5746-40cd-be87-ef169f392c35">56.5</ix:nonFraction> million </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, sales-based milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_100"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxNjc_029d65e4-784e-4cba-8e4e-a62509eaeb9c" continuedAt="i0946d9567e014aacb02433e102347584" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i0946d9567e014aacb02433e102347584" continuedAt="i5ddb78d71e6c40c49b4eca7d43ddeb56"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxNzI_c7dc9da7-23ab-4701-adc3-e13ee4cbe7ac" escape="true"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxODI_2c577f19-92ce-412c-b2b8-5e1f28c963e2" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.470%"><tr><td style="width:1.0%"></td><td style="width:73.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzItMS0xLTEtMA_f55d3bca-eb7c-40db-9c5c-ed7a2f302c81">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzItMy0xLTEtMA_6cbaa6f1-b4f6-45ea-ab22-e2cdaeba975e">266,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzQtMS0xLTEtMA_9611a1ae-94b0-4e19-926b-14dfbbdfeb13">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzQtMy0xLTEtMA_0d5dfe0c-43d5-47d9-8b40-54106fb70580">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzUtMS0xLTEtMA_8856bb40-8f73-49a0-8b81-a1a18a52dcc3">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzUtMy0xLTEtMA_cf8d5cb9-ba28-4f51-b2ed-3a4ff2b0ec1a">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit and, during prior periods, a purchasing card program. The long-term classification of restricted cash equivalents is based upon the remaining term of the underlying restriction. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Investments</span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxNzU_623cd6fd-1708-4fca-9cb4-1089fe3f19b4" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d081623400481896632ff697c68f09_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzMtMS0xLTEtMA_2c73cd3a-d7ac-4b63-9d49-4800174c080a">569,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d081623400481896632ff697c68f09_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzMtMy0xLTEtMA_7eeeb037-6a15-49c6-ba80-d59e0c3acd0b">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d081623400481896632ff697c68f09_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzMtNS0xLTEtMA_8ba5cd6e-fae2-41ab-8cae-91596f4d66d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d081623400481896632ff697c68f09_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzMtNy0xLTEtMA_0580f808-c954-4e88-b2c9-d630244ba7fc">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af67120954b4cc4a261206766a42684_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzQtMS0xLTEtMA_d838e16a-4547-48e9-928d-c2325c79126f">543,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af67120954b4cc4a261206766a42684_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzQtMy0xLTEtMA_59370034-e393-4888-942c-28c575957b2b">5,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7af67120954b4cc4a261206766a42684_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzQtNS0xLTEtMA_6118e8a4-6bbf-4068-9594-70e1e44a1de9">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af67120954b4cc4a261206766a42684_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzQtNy0xLTEtMA_7971d703-4d4b-4848-b153-630be8901472">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzUtMS0xLTEtMA_8588427e-d984-4d2a-8124-ab08a0ca4498">208,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzUtMy0xLTEtMA_fb128b03-9d24-4e1e-be6c-2fb5861f793e">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzUtNS0xLTEtMA_275fa0f1-f47c-4f89-81c8-805f862eff75">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzUtNy0xLTEtMA_c2ea075a-d1ff-4993-ba7a-14ef2bd8f637">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtMS0xLTEtMTA3Nzc_7ff82bda-5d8a-4fab-90bc-0d1ed100fd97">28,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtMy0xLTEtMTA3Nzc_396e85e3-ae3d-47fb-91d5-6d298a754c87">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtNS0xLTEtMTA3Nzc_bff29e0a-188a-458b-a599-0accb02a21e9">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtNy0xLTEtMTA3Nzc_b6aa855c-40a5-4d1c-aba4-52ffc45085ad">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtMS0xLTEtMA_485c3ed0-54b0-43f0-9aa1-e76efd6d46f8">1,349,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtMy0xLTEtMA_16d75d3b-3636-4f1b-b40c-274d4dbee880">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtNS0xLTEtMA_8efadbf0-9b70-4a7f-9d9a-d4a9a685328a">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtNy0xLTEtMA_abef4e5a-a0f7-422f-b090-4b4866ac0926">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc5c758e799403d8bf389459a614860_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzctMS0xLTEtMA_702c88ac-3a04-4e4e-91bf-f3ce8a083e5e">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc5c758e799403d8bf389459a614860_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzctMy0xLTEtMA_ae70809b-7cd8-48f2-98e0-90106db9621d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc5c758e799403d8bf389459a614860_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzctNS0xLTEtMA_b1d54423-f985-49b0-a060-ff083264b9a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc5c758e799403d8bf389459a614860_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzctNy0xLTEtMA_2d65a7f8-5563-4005-8a45-16b898278201">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzgtMS0xLTEtMA_9981361f-ac6a-441c-8b2f-3de018921d3b">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzgtMy0xLTEtMA_d6d812f0-6b5f-4a7e-941c-327c5eb8801a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzgtNS0xLTEtMA_20dcf11d-667c-4af2-b3cc-f438519fd03a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzgtNy0xLTEtMA_054e50c6-8af7-4078-97a2-c39d1a90333b">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30b2890deda415d995921e5add2f92e_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzktMS0xLTEtMA_bdee9a67-2328-47eb-8f74-7f0b1db5754b">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30b2890deda415d995921e5add2f92e_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzktMy0xLTEtMA_5ca65e06-995a-40a4-8e31-1e2b36e10893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30b2890deda415d995921e5add2f92e_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzktNS0xLTEtMA_11853d6f-c550-424d-bb4a-304c121a7bce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30b2890deda415d995921e5add2f92e_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzktNy0xLTEtMA_ce43e3dc-32d0-4e1c-b36e-1924af93c8d6">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzEwLTEtMS0xLTA_49e8a09b-79ce-4376-853d-c3edf3bedfe9">1,532,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzEwLTMtMS0xLTA_f48e1c80-ff10-4a55-8372-bd68d80c700f">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzEwLTUtMS0xLTA_f6709cc6-da40-4506-8c58-8be4d5b9eb9f">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzEwLTctMS0xLTA_1afb58b4-e0bb-4ace-b4d5-ec8596779930">1,538,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3abfb693aa34441595492bf56588fe6f_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzMtMS0xLTEtMA_687f29c5-880b-4939-858b-8e6f3ef2d4b4">389,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3abfb693aa34441595492bf56588fe6f_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzMtMy0xLTEtMA_6826a0ad-e1b4-4f00-ad5f-59f728ae2897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3abfb693aa34441595492bf56588fe6f_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzMtNS0xLTEtMA_093db4f1-cba3-4b0c-bf09-ff481e5dbe19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3abfb693aa34441595492bf56588fe6f_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzMtNy0xLTEtMA_e90b507c-cdc2-4350-b602-16294e8dfab7">389,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzQtMS0xLTEtMA_668fee18-be0b-47e9-a9ad-b913b6544120">752,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzQtMy0xLTEtMA_81e3cf9a-8001-4e79-85b9-e5c1199612ba">3,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzQtNS0xLTEtMA_8de13ac6-ffbb-437e-9a2f-7e5e9f9b3934">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzQtNy0xLTEtMA_63471485-a587-4cde-a2d5-4380180f1755">756,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzUtMS0xLTEtMA_a11342e1-d846-4ab4-8536-84d76bb98c26">166,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzUtMy0xLTEtMA_4c46f064-965f-4093-b85d-cc670f06a378">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzUtNS0xLTEtMA_f0784180-8978-48a0-bc33-829bb1243f2c">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzUtNy0xLTEtMA_55b86582-1a8e-4402-99f2-5d1f4f9484d2">166,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzYtMS0xLTEtMA_9a68d92f-dd0e-4a41-8d8a-5b4ad3af523d">1,308,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzYtMy0xLTEtMA_436da75e-dd6d-4aa6-8416-c8bca5480e15">4,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzYtNS0xLTEtMA_ae544b6a-d64c-4e73-aaa6-bd0c0061dd59">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzYtNy0xLTEtMA_ae9174d8-4b03-4656-9889-f67ebab86108">1,312,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzctMS0xLTEtMA_4780961c-7954-4295-ae3a-ef205da9e35b">40,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzctMy0xLTEtMA_1337f740-51c3-4b9e-a1bd-b502395a3ca4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzctNS0xLTEtMA_fe3fecf2-0521-43b0-bfff-9577dcee60bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzctNy0xLTEtMA_35de8e9e-1fa6-4a20-8a9b-81cbf43446c7">40,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6aa1d2955343a4891ce98d02c37c65_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzgtMS0xLTEtMA_c2d28581-5f57-4c9f-8b72-e5600229e1bb">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6aa1d2955343a4891ce98d02c37c65_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzgtMy0xLTEtMA_a724893f-738f-4a2a-b8ec-8ce93de2072f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6aa1d2955343a4891ce98d02c37c65_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzgtNS0xLTEtMA_71a83717-2a85-4b87-a2b5-e8ba4502877e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6aa1d2955343a4891ce98d02c37c65_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzgtNy0xLTEtMA_b8f57a07-44d4-4bd6-a46e-7431e9af0057">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13a4caccaf947b896a2346494374f6d_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzktMS0xLTEtMA_da42bbe0-aa91-44a3-9bf9-841e07f3eaaf">32,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13a4caccaf947b896a2346494374f6d_I20200103" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzktMy0xLTEtMA_92fb7684-4d97-4f1e-a54b-46bb21d90e62">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13a4caccaf947b896a2346494374f6d_I20200103" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzktNS0xLTEtMA_5f20b998-2ec9-4f3c-bd0a-81b6e29c11a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13a4caccaf947b896a2346494374f6d_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzktNy0xLTEtMA_46bc328c-f66b-4afc-b72f-67d5137ed73f">32,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzEwLTEtMS0xLTA_df90dd7b-5930-4e57-8d54-8c8c220a70f9">1,384,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzEwLTMtMS0xLTA_c63ec277-263b-4ada-b20b-0b635c46cd50">4,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzEwLTUtMS0xLTA_720492cd-9119-4cf9-ad57-821f54f1879d">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzEwLTctMS0xLTA_e83be208-24c6-42cc-a9ac-b8108ee9d4ee">1,388,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i5ddb78d71e6c40c49b4eca7d43ddeb56"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxOTkwMjMyNTkxMTg_c474a7bb-1f26-4254-89c2-3d677f44c03f">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxOTkwMjMyNTkxMjQ_0043f151-40f2-45bf-97bd-7d031f41ed05">6.2</ix:nonFraction> million as of December 31, 2020 and 2019, respectively, and is included in prepaid and other current assets in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxNjA_203daaf7-a795-403d-9faa-1ba9a94064d9" continuedAt="ib389ef83c63e4189b1247a7d80e224c8" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="ib389ef83c63e4189b1247a7d80e224c8"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.809%"><tr><td style="width:1.0%"></td><td style="width:73.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.950%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af67120954b4cc4a261206766a42684_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzMtMS0xLTEtMA_d035a4fe-bb4f-4482-a499-6e919948ceae">28,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7af67120954b4cc4a261206766a42684_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzMtMy0xLTEtMA_5fb52b6e-126b-431d-92c6-9cfaad314364">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzQtMS0xLTEtMA_cffa1728-404d-4f53-84c2-4692d661065f">21,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzQtMy0xLTEtMA_4755e176-e23a-4475-ae6b-1a686c722073">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzUtMS0xLTEtMTM2ODc_a1eeacc4-03e5-4d8d-a99b-df06ff9a9672">5,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzUtMy0xLTEtMTM2ODc_5f4f9451-4bab-4acc-802e-4789d34556ef">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzUtMS0xLTEtMA_1da44907-5203-4e98-9741-6a1a612c14bb">56,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzUtMy0xLTEtMA_32d6425e-7650-407c-9196-5d2f7b117613">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:73.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.877%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzMtMS0xLTEtMA_eff5ece7-5895-40fe-b307-91e4101844b4">14,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzMtMy0xLTEtMA_651b23ab-36df-4af8-bb8a-3a0e5f7c6421">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzQtMS0xLTEtMA_f5a77891-cd52-4e26-9fc3-db569467f067">2,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzQtMy0xLTEtMA_0c31287b-3edf-401a-9e84-98bd66d1a1f2">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzYtMS0xLTEtMA_b1dc3c8d-f2f3-4df9-9b30-8afae8ec541b">17,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzYtMy0xLTEtMA_5b59dc75-65d2-4895-92bc-b6943d897003">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were <ix:nonFraction unitRef="investment" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzEzNTQ_10f8d054-72f4-4833-a43c-6dc80f6ce384">14</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzEzNjE_8aff97de-f7ad-41be-a8cc-fe8aa73eab04">9</ix:nonFraction> debt securities in an unrealized loss position as of December&#160;31, 2020 and 2019, respectively. During the years ended December&#160;31, 2020 and 2019, we did <ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzE0ODM_1e110bf2-6057-41e8-a4f5-986a078bc4ed"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzE0ODM_a16aa40d-c9ff-4c19-9f64-748123dcd490">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges on our debt securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. </span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxODQ_1c91a5d5-b91f-4be1-a599-705ce434e233" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzItMS0xLTEtMA_c16a9bf5-cc19-436b-a2c4-39dcf4ebc8c7">1,034,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzItMy0xLTEtMA_76bd69b4-dae7-4321-ac41-d526d2433760">789,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzMtMS0xLTEtMA_e67cb74b-d9e8-497c-ab68-b19585ca6e7f">321,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzMtMy0xLTEtMA_fa2101c4-141e-4ebd-abf2-f1acfa037132">522,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzQtMS0xLTEtMA_54ecbe43-6056-42b4-8912-cb37d004ffff">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzQtMy0xLTEtMA_17fc3a3f-ec4f-49d2-85c5-8931ddcf2838">1,312,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i68bf8bfb5b59421792b5711a409e9ffd_106"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90ZXh0cmVnaW9uOjgzZmIxNGM1YmJkNzRlMGZhMWZmNGY2NGMxNzI1ODI5XzE1Mzc_38386169-4037-483c-af1a-1a7482e02aec" continuedAt="i3d44d019f815446c9942206538b54827" escape="true">FAIR VALUE MEASUREMENTS </ix:nonNumeric></span></div><ix:continuation id="i3d44d019f815446c9942206538b54827" continuedAt="ie43f41a799eb4c66bb9fb39b6350f3ce"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="ie43f41a799eb4c66bb9fb39b6350f3ce" continuedAt="ia1df664a13604ff99efc4dd5b501cafb"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90ZXh0cmVnaW9uOjgzZmIxNGM1YmJkNzRlMGZhMWZmNGY2NGMxNzI1ODI5XzE1MzY_5241c8f5-ac22-485a-8ad0-97e9cddff248" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf372caf57ca4f559b15221706d0804e_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzItMS0xLTEtMA_d5271092-c2f2-4a90-9f2f-24c746c803e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0157be3fc964514bc2958bfb787c58a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzItMy0xLTEtMA_f827eabc-98a1-48f7-9d43-0fab437e0880">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc6a38873324d77a83f8d597f112838_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzItNS0xLTEtMA_08fbec96-e252-463a-b671-71299ea6dcde">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0eaa96e028b4053b1efe87fba0c9717_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzMtMS0xLTEtMA_6c6b6441-ef7b-4ca1-ac8b-13ce06c93977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc2641cbeaa48948ef1c5857c38598b_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzMtMy0xLTEtMA_82f2bf59-25b9-4e69-9503-17fb3b5c50e0">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069a49e8f5be408d82aaa57b1a6719ac_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzMtNS0xLTEtMA_2f168818-20b5-4915-82e5-98997cdecbb9">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida017550b79b42f19804feb9178fe6eb_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzQtMS0xLTEtMA_23e67f23-e474-48ca-a2d6-31d76d5b885f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d1bc6310d94e49a10dfa40633813f8_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzQtMy0xLTEtMA_4aaa6fdc-a6b3-40ae-a264-026c29450966">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d9fe388a10f409382aa696ce09464b2_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzQtNS0xLTEtMA_ba98feed-0f66-49b7-8066-9f5c4a71c0aa">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ed515384c7421c990b3a08dbbd6099_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtMS0xLTEtMzY4Nw_786d7a1d-e5a6-4e48-9473-10d83d1d8855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c49a80af73c4beba087da528040761f_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtMy0xLTEtMzY4Nw_73e10dcb-b55d-45dc-9694-d093886274a1">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0f3562ea854a648ae333d957392a30_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtNS0xLTEtNjExMQ_68ed19ae-98c7-4953-97bc-48c2801c0588">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7639ff188d85446bb4eb34d103edacad_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtMS0xLTEtMA_72d568f7-de66-475e-80e4-703d06e09e22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5ef12d4ebf4f4cb3fc541d5b53ab44_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtMy0xLTEtMA_18ed2603-febc-4b0b-9e75-388eaf4cbe21">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad45f83363a4cb8a086062be42c031e_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtNS0xLTEtMA_e705e025-ab55-4553-b128-a84ca7073a6c">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1df0270288443da1ddfde204282b4e_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzYtMS0xLTEtMA_c2b2ec5e-1b29-4be6-8f67-ad7f2dccc25c">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e63c05de294a7cbe329b32c4008c0f_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzYtMy0xLTEtMA_9af610cc-75ec-4e67-b74e-5c95d7c42734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife44d28f1dee43d38997d75f2a09fa60_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzYtNS0xLTEtMA_2824fd9a-6531-4e0b-a8ec-9e8c74740032">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986255f527ad4a68a1be4173bed991ad_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzctMS0xLTEtMA_732aa79c-b210-406d-8586-dd2e3b32c774">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c8c3490b0545f487d8a0d33ebd6813_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzctMy0xLTEtMA_a26bc113-5af7-416b-95e1-a8b4c95de1ce">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35781ca0758f401a8c144a5efb7fe50c_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzctNS0xLTEtMA_6b8abec7-9ce9-4f2c-a75a-c1f95afda02f">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7639ff188d85446bb4eb34d103edacad_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzgtMS0xLTEtMA_b8e0e101-b097-4ff5-ab05-1021c2e3906d">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5ef12d4ebf4f4cb3fc541d5b53ab44_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzgtMy0xLTEtMA_2e8aef7e-347a-4326-b7ae-834ad4f97399">1,415,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad45f83363a4cb8a086062be42c031e_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzgtNS0xLTEtMA_54d5ed74-0c9b-41ef-810a-84bf36228876">1,456,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18b5f0c5ebb43f6b8c762bf61f6bda2_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzItMS0xLTEtMA_0094125d-5002-49f7-b46e-c536eaef2bbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb849f127a4644bf8dcdc6b5433726b0_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzItMy0xLTEtMA_b6d37bf0-c327-463d-a00b-0fcb8037f61b">389,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d84ea6c5fb486b9667f60233ed45e3_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzItNS0xLTEtMA_8ff183fb-c46d-4662-b4da-e9022b7c13c1">389,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7119ffed0114f1ba08264ccb9cca54b_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzMtMS0xLTEtMA_b4bbe3f6-d415-46c5-9e39-3cdeab82dd16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if934e0098e2b485187fb3417498f8c7f_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzMtMy0xLTEtMA_2d6ed05e-8ef3-4a6b-bc91-12d506b87e98">756,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc5bb0744d9e4ad8afb77bb50648a4eb_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzMtNS0xLTEtMA_1d5f1b61-abd4-458d-a48f-a6e0e275c9bd">756,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39b2e5c3b01d455c8647c0de87550b58_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzQtMS0xLTEtMA_86f69c00-357e-465c-974b-6db958704c10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8094749dc1cf43faa8d4a49cc37284a4_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzQtMy0xLTEtMA_23efbcea-e9c6-4618-a548-584796db30b5">166,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id214d22093b342b5bb46f742fa9a8d1d_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzQtNS0xLTEtMA_3555224c-9eb2-46c7-86e0-dce4fd5ebb8e">166,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa35986fd3ca43b8a2ae20dce6d9597d_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzUtMS0xLTEtMA_05f82300-2ac0-478c-b8b8-410dbd918768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402214e5b6cd492ea640e28a56b8c84e_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzUtMy0xLTEtMA_45c26c56-98a8-47ad-99d3-e504e203c3ed">1,312,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf947a15c2442f7b9c355990703eea0_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzUtNS0xLTEtMA_3bf18142-88fb-4939-a738-7939e70c525c">1,312,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59418bb9d714b4aa3e6fca17c908d91_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzYtMS0xLTEtMA_5cccc7de-2af4-4eb5-bb71-943e6ae122b6">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39618bc0e2441e6a4d20c14598583b9_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzYtMy0xLTEtMA_e0e95be7-5822-4e93-ba73-e9091f02c32f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if21e1073886448ea9bd7d5e0a33dfbf3_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzYtNS0xLTEtMA_f6c5899c-9542-4ef6-b56d-9cf83e2b0dcb">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6557679589e544abacc2ec388a331430_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzctMS0xLTEtMA_fe265eb6-e419-41dd-924b-fea8df0c378e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5519e86b5a4926b1ec10602426647e_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzctMy0xLTEtMA_31818b85-0df3-43c1-a1ec-126c09c541f1">32,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e1b62fcdc14ca6a9f31d5d9be0052f_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzctNS0xLTEtMA_135d679b-f1bd-4531-99b8-e9d6b0191874">32,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa35986fd3ca43b8a2ae20dce6d9597d_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzgtMS0xLTEtMA_10952b1a-16b3-44a2-a364-c936ca30ef21">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402214e5b6cd492ea640e28a56b8c84e_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzgtMy0xLTEtMA_18168b46-1cbe-4ff8-97b2-6dafe5398936">1,345,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf947a15c2442f7b9c355990703eea0_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzgtNS0xLTEtMA_4cf45dc4-cfb8-4921-98d9-600f98c359ca">1,347,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia1df664a13604ff99efc4dd5b501cafb">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</ix:continuation> </span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzIxMg_dc3b1ef7-e3e5-4dc1-b274-206dd715e72d" continuedAt="i7e9a5dc5731941a6a952b88b89108732" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i7e9a5dc5731941a6a952b88b89108732"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzIxNA_2fb0708f-abe3-4a46-acaa-dcb90a2d08f9" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzItMS0xLTEtMA_b1dc9d6b-57b0-4c79-9ff5-7ff1031c55da">7,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzItMy0xLTEtMA_52780be4-a473-48f5-ae50-acf2ccdd9808">2,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzMtMS0xLTEtMA_fb3a052a-8d47-42f1-bbce-56cb69f900d3">20,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzMtMy0xLTEtMA_b278e9f6-2c30-4f6e-91ef-c8e8730901b6">9,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzQtMS0xLTEtMA_9674c78d-92ef-45c2-95ef-d64e3a0c64b2">7,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzQtMy0xLTEtMA_2e755234-7bb1-4306-b055-2a34ccbf1187">4,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzUtMS0xLTEtMA_8d148202-d523-47e9-abad-06216f387f3a">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzUtMy0xLTEtMA_f58a0fb2-d3dc-47e9-b0d6-78e667da8deb">16,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac617d311944d31900ede53774bb2e2_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzctMS0xLTEtMA_778c08c5-4ef2-4f6d-b225-ae4c98942a89">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a8ac00f5aec4ccabaefa0b0d9356610_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzctMy0xLTEtMA_47d73503-5587-4883-b2da-7d02a78ee1d9">12,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838461c261004859a7bee283a1308e10_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzgtMS0xLTEtMA_59102005-788b-4df1-8328-2dd1badd909c">14,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84bd021da59c4253a45563017be7db6d_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzgtMy0xLTEtMA_af520108-3587-4d3b-9236-1a10db4b14e4">3,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzktMS0xLTEtMA_8f6be0ca-ee3a-4165-acb8-5e84624bf02c">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzktMy0xLTEtMA_2bd6ce18-53ba-412e-9bdc-f36aa8bda32d">16,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-downs related to excess and expiring inventory were $<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzEzOA_11394b0b-934e-4a44-b902-fb19fa85510a">2.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzE0Mg_503e6e84-c228-4db5-85ba-6ee6b66ed8c4">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzE0OQ_4611bf94-4d9f-461e-af3c-6e10a9667baa">1.1</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_112"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzE5OA_fef16978-c35d-400c-91a5-ff53b8f3c615" continuedAt="i5c5cb18be9fb44faad84a2a8ce92475f" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i5c5cb18be9fb44faad84a2a8ce92475f"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzE5Ng_a7672512-44a8-450c-bb37-0c32dd2f362e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to <ix:nonNumeric contextRef="i860abaa1da4847479d900fa60c22e404_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzItMS0xLTEtMC90ZXh0cmVnaW9uOjc5MzFkYzNiNzVhMDQ3NGRiYzAzMzQ1OWJjZDg5NjhjXzcxNDY4MjU1ODA1NzA_a415934e-8e58-4325-b4d3-285338539515">15</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6cf0349c204074bedad9d2664384d1_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzItMy0xLTEtMA_e587dd60-2283-4ed4-b7d0-9561c5b8ed21">40,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b8747a320f44fe4a77fe534734d347a_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzItNS0xLTEtMA_e00d3799-dd04-4ccd-ad79-3a1200edffc2">33,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d449cb77a0446d693fd6c3747eba20d_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzMtMS0xLTEtNjk2Mg_6adc13ab-6ae6-4d99-91d5-6111d2fdf195">3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0498a995a2400bbec4140ae912e037_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzMtMy0xLTEtMA_4e25a3aa-15fc-49ec-a06a-b230a18d5273">18,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0bd3de5abe4d67bbbb22990c63c5a0_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzMtNS0xLTEtMA_bf11c1dc-3851-4704-9cfc-4c0da3efaf21">17,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5915973202f4822a05789837fd15e95_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzUtMS0xLTEtNjk2Mg_88b4d216-d8ae-4040-bb29-f055e2ec4974">7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9908b52633254703886d1ac7263e2148_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzUtMy0xLTEtMA_399d71a9-2baf-4bd4-8704-fb15443e7b29">14,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29200dad69e047a8b7cbecb940c93115_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzUtNS0xLTEtMA_8c507094-4a51-4886-ad00-5a57bfbcd4d2">13,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1bacc0a00bf43eba9ebd3d73dc83589_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzYtMS0xLTEtNjk2Mg_58b83ad9-1ce4-460e-bf55-73429a59a789">5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f71d3e4f66641b59129ea1f7de0d2cf_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzYtMy0xLTEtMA_eccc2d3f-5b1d-491e-87c1-29cd675c668b">11,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ce43d4b56040f2843d79745b7c30b1_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzYtNS0xLTEtMA_93f620ca-d03b-4fec-aaaf-0c6dd6784c0f">8,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311c3d1a54394d4a813f2d882cd22021_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzctMy0xLTEtMA_bbae70c0-fdc2-4f8d-bbd9-2f502db55fc0">16,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee23e46acdf243f48669d23de632fc77_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzctNS0xLTEtMA_63afd910-3261-47bc-95be-ba4b2e3b5e10">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzgtMy0xLTEtMA_534e546c-d9d3-415c-a868-86bb2c32d001">102,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzgtNS0xLTEtMA_cd5aee0d-cfbe-4082-a6a4-0934e569d8fa">74,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzktMy0xLTEtMA_7f5f6e52-f026-41e2-bc94-29b0da3cc364">34,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzktNS0xLTEtMA_279166f8-b2f2-48d7-86ed-5cee9ad0f4e9">25,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzEwLTMtMS0xLTA_bb15b3e4-3755-4844-b015-2745a3912d71">67,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzEwLTUtMS0xLTA_73979b35-4b15-46ab-8289-4240668755c4">48,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzEzMQ_60d37fe8-5942-482a-888f-781430158e5b">9.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzEzNQ_0945ef71-3056-4df8-9763-63e50ab8b6b7">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzE0Mg_3ea96c8b-bbbc-420f-a125-f20740c6e8dc">4.9</ix:nonFraction> million during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div id="i68bf8bfb5b59421792b5711a409e9ffd_118"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxMDI_1ccae2b4-39c5-48f8-94a2-bfbb1f9233f8" continuedAt="i79bb60b7cd274d22a31593d7417c4087" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i79bb60b7cd274d22a31593d7417c4087" continuedAt="i489236568bc74305aa9609195d79ed5d"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans and ESPP</span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxMDA_3ccc8a6d-628e-4566-9c1d-76a62097ab81" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25087bb5db74d7892082c9d2e8abbb9_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzItMS0xLTEtMA_41cf378d-e524-47cc-b859-503965b81037">37,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820a33ad0ad94d8bafca231d31e69e59_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzItMy0xLTEtMA_77cbf62f-e1b3-4c07-907f-b966f711e89e">19,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd1cc29eb8f243d28b13b3d0dca0006a_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzItNS0xLTEtMA_19f03531-70d7-49e2-86fa-64fbba53c731">13,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986427a5d3f3498d96c6bb4bbd51dfe2_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzMtMS0xLTEtMA_394da7ed-f3e0-43d7-b033-f2a5d869e42e">67,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d1190b6c354c31b284d1b82fbdecea_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzMtMy0xLTEtMA_fc56fb54-a784-448c-a438-bd41e58fd5e3">37,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bceefc7e604400898f9025b1854d66c_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzMtNS0xLTEtMA_c2ea0e21-5ba4-4e56-8674-7a9e17b16273">27,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzQtMS0xLTEtMA_36adbba5-73c2-4422-8f49-799305f706fe">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzQtMy0xLTEtMA_ecc12be5-b11f-443c-b7a6-4cb6f71ea81d">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzQtNS0xLTEtMA_8204baaa-b06f-479c-881b-bb35ea47c349">40,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzItMS0xLTEtODc2_41bab354-e837-468d-963b-b4f86949b534">19,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzItMy0xLTEtODc2_bee0ccfd-ac1e-4314-a9a8-9165a4fe7457">23,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzItNS0xLTEtODc2_8147c25f-f685-445f-8e4f-85b4b34ef8ac">18,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzMtMS0xLTEtODc2_12f8086d-5f2c-4be9-8bae-6115d0142ff7">35,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if16546baee294f93bd2321559abcd2b2_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzMtMy0xLTEtODc2_c8710cce-ac47-4b95-a8e9-a29dd5d5da93">26,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848fd90527f24228a2613e80e7e75990_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzMtNS0xLTEtODc2_70b9d704-db1e-4742-b8c6-c94e6b729c0e">19,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzQtMS0xLTEtODc2_983ddbd6-5d7c-4d67-a6c7-1dbae5c35444">47,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzQtMy0xLTEtODc2_9b6a7f34-f524-4f7a-b4e7-e887c8eae7f9">4,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e926b7757e84307b3dcf2ffb4e5018e_D20180101-20181228" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzQtNS0xLTEtODc2_48dd27d6-f045-4458-88a1-cba34de51473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzUtMS0xLTEtODc2_7c998b32-4495-4e96-adec-f133a797b14c">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzUtMy0xLTEtODc2_1bbb0500-d722-446b-8e64-6881366922f0">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzUtNS0xLTEtODc2_6cec6873-5119-42c3-83c1-b3d862f2969c">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzYtMS0xLTEtODc2_32aa273e-5084-4da7-a5be-793cba7a2f99">105,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzYtMy0xLTEtODc2_99b19d3d-42bc-4c6d-a44b-d08b692d29ca">56,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzYtNS0xLTEtODc2_1e8f74bf-bc92-4a90-8e58-a34b70d0bd54">40,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several equity incentive plans under which we granted stock options and RSUs, including PSOs and PSUs, to employees and directors. At December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzMzOQ_0041d6d9-23a4-4416-b2cf-66ac20651b91">17,100,727</ix:nonFraction> shares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzExNTQ0ODcyMTA2OTYx_12c4ffcb-2162-4ba8-8632-e715c03d12b7">1</ix:nonFraction> share for each share issued pursuant to a stock option award and <ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzExNTQ0ODcyMTA2ODk5_d039248e-fad3-4ffc-bca8-7edec85bce08">1.5</ix:nonFraction> shares for full value awards granted in the form of RSUs or PSUs. On May 20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by <ix:nonFraction unitRef="shares" contextRef="i30cc87f6da8e43de85cc36cc45397719_D20200520-20200520" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzExNTQ0ODcyMTA2OTA0_ecd7045e-c24c-463d-b8fe-bbe05ec1cf7a">21,000,000</ix:nonFraction> shares, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors (the Board) delegated responsibility for administration of our equity incentive plans to the Compensation Committee of the Board, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a <ix:nonNumeric contextRef="iff59e3f4289c4d0ab16af9324d631d8e_D20200104-20210101" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTYyMDk_2007db4f-c11c-43a0-8e34-19710915307a">four-year</ix:nonNumeric> vesting term and a <ix:nonNumeric contextRef="i46ce9985487045a6bbff1b6565bb56c1_D20200104-20210101" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTY1MTQ_ed8f8938-a819-4bc4-8f9a-a3275387603f">one-year</ix:nonNumeric> vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a <ix:nonNumeric contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTYyMDg_81849f00-a069-4952-97d5-4fb6d3017e55">seven-year</ix:nonNumeric> life from the date of grant. RSUs granted to our employees and directors generally have a <ix:nonNumeric contextRef="i8b8d59c75c8249ba84de243ad87e2493_D20200104-20210101" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTYyMDc_58d00fbb-5974-4f63-a723-636cd0f0aedb">four-year</ix:nonNumeric> vesting term and a </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i489236568bc74305aa9609195d79ed5d" continuedAt="i33f59251f5ea4ce6aea9f13e3107d0c2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i49dea6f971c2436c9436d84debc9c88a_D20200104-20210101" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzEzNzQzODk1MzYzMzU4_bbf12abe-dc1c-439d-8689-787cd9771e4e">one-year</ix:nonNumeric> vesting term, respectively. PSUs and PSOs granted pursuant to our equity incentive plans vest upon specified service conditions and the achievement of a performance target or market condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of <ix:nonFraction unitRef="number" contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIwNjQ_ca1a5a04-48b4-4891-9115-698eb227cb92">85</ix:nonFraction>% of the closing price at the beginning of the offering period or <ix:nonFraction unitRef="number" contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxMzE_f0128213-ed51-4580-8b56-e267663714a5">85</ix:nonFraction>% of the closing price at the end of each <ix:nonNumeric contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" format="ixt-sec:durwordsen" name="exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTg5Nzc_9df895ad-96ca-4bcb-b956-083e7616deb0">six month</ix:nonNumeric> purchase period. As of December&#160;31, 2020, we had </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaccd048b7b154d2f9b562e5fe5bbec80_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIzMjY_8eb8a9ec-f27b-4e76-8fbc-b5bae856d61f">3,704,580</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under our ESPP. Pursuant to the ESPP, we issued <ix:nonFraction unitRef="shares" contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI0MDc_3375fb16-5ffc-4358-82d0-20bd60f8f5fc">534,419</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjM4MjY_9fe7d879-f935-47f5-876c-36c5771c6381">483,009</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjQwMjE_83eda3ab-7b2d-42b3-9238-3ae4e27809da">330,492</ix:nonFraction> shares of common stock at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaccd048b7b154d2f9b562e5fe5bbec80_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI0Nzc_12200719-eeac-4a46-b456-016524fc58bb">14.55</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i474cd4190d014fb9afd7d07dbde355fc_I20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI0ODE_bf9d2e6e-f1dd-4da7-8f45-0cd42bb78725">12.60</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i44f2592c3afb4c108a552d2de2e9f677_I20181228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjQwNTE_4e85f10f-46c2-4b17-b2b6-fafb392a567c">15.74</ix:nonFraction> during the years ended December&#160;31, 2020, 2019 and 2018, respectively. Cash received </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from purchases under the ESPP for the years ended December 31, 2020, 2019 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $<ix:nonFraction unitRef="usd" contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI2Mzg_e0f4479e-38dc-4984-b295-83a7803451af">7.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI2NDI_71fc7838-e7fd-4ff1-9e23-7ecd51104ebb">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjM4NTg_0055e40c-bcfd-4e9c-b506-2061ecddcc85">5.2</ix:nonFraction> million, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used a Monte Carlo simulation pricing model to value PSOs that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxMTk_8a98a731-110a-47cc-be56-29db22a00b8a" continuedAt="ibe975ec83e3b42928e99698fd8d0b91e" escape="true">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="ibe975ec83e3b42928e99698fd8d0b91e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, including PSOs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzItMS0xLTEtMA_67ff2638-d579-4188-bf0b-86fdd271a189">9.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzItMy0xLTEtMA_e88d1ca9-1e45-4865-ac01-cc6a45c23243">8.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzItNS0xLTEtMA_1427c393-cb0b-4956-9819-1dad3e318eaf">9.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzMtMS0xLTEtMA_5228693c-c259-404c-b2ed-bd0ce14bdc95">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzMtMy0xLTEtMA_87623b17-d65d-4820-b0a4-cd81921e8d1b">4.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzMtNS0xLTEtMA_628fee52-210a-4800-b3fb-cb9b4d3fea1f">6.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgwOTQ_66ad8a2a-4d0b-4f3c-b36c-905c27cf856b" escape="true"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxNDI_ad77efaf-6c8e-4738-b713-aa394311bc69" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, including PSOs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzMtMS0xLTEtMA_fa778310-bb4d-492d-ba4f-2bbd015f5dc8">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzMtMy0xLTEtMA_f6c3e6df-6f4e-4d24-935c-b4408fb51dc7">1.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzMtNS0xLTEtMA_c5194ddb-d7a9-40ff-ad08-c7619a8e1c0a">2.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzQtMS0xLTEtMA_82653c7b-2e01-4929-9673-fbda2b7639ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzQtMy0xLTEtMA_b2a87a54-7597-4b7b-b317-02431c7d7261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzQtNS0xLTEtMA_8128ffc3-c5c2-40a9-80d7-4d3d71c74ae5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzUtMS0xLTEtMA_6497a8d5-f865-4fd2-bff7-272d8b508008">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzUtMy0xLTEtMA_607a2b4e-03e1-45ba-ba24-d937a32bb19f">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzUtNS0xLTEtMA_9d252a9d-e2a0-4f84-a558-daba60a89468">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzYtMS0xLTEtMA_04310358-7094-4c59-bc44-007ecacdd2d1">4.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzYtMy0xLTEtMA_a8591083-b0af-4ce9-9eba-2847c80ec9a3">4.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzYtNS0xLTEtMA_e0cd8f74-422f-49da-bfc4-8e135b165fa7">4.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzgtMS0xLTEtMA_2e6e48d1-2800-45e9-b023-724c2c3613ab">0.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzgtMy0xLTEtMA_34b7f87c-08ac-4e4f-af5e-b6174cebbb39">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzgtNS0xLTEtMA_9c1482fe-5c55-4069-9759-f7e3218c551c">1.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzktMS0xLTEtMA_f2662874-7a09-425b-b310-c5609e11fe42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzktMy0xLTEtMA_b28d8390-2a8d-4356-9c63-775b16f2715e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzktNS0xLTEtMA_1f9b6202-e158-4f36-a939-9ad26f5e06a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzEwLTEtMS0xLTA_9e454835-7129-4c64-8671-aefe4105da24">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzEwLTMtMS0xLTA_463f4207-6d5b-4de9-aca7-9051046591ad">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzEwLTUtMS0xLTA_7f104b98-e144-4dc4-b732-07457d043054">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzExLTEtMS0xLTA_cd9e7aed-b1a0-403c-9a95-2c695822fc28">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzExLTMtMS0xLTA_cdcc6fbb-c2e1-447e-9350-62e44db75c87">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzExLTUtMS0xLTA_fb0db89c-cf1e-4934-acf1-e49ecbd8d231">6</ix:nonNumeric> months</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered both implied and historical volatilities in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs, including the PSUs, was based on the closing price of the underlying common stock on the date of grant. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i33f59251f5ea4ce6aea9f13e3107d0c2" continuedAt="i113f99fa82a1418eba821754e5dc4ff2"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxNDA_fc6ae57e-c843-44d5-97cb-42fae0993ee5" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options, including PSOs, during the year ended December&#160;31, 2020 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzEtMS0xLTEtMA_3394916a-8718-4539-96db-d698a35849fe">20,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzEtMy0xLTEtMA_053504b4-69d0-478c-a72d-e4ef28765b21">9.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzItMS0xLTEtMA_ccda8792-8afe-4511-9505-5cdb9381709a">1,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzItMy0xLTEtMA_fdc12190-7fe2-464f-b487-46dd13d9e5ee">21.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzMtMS0xLTEtMA_db0f47f4-38d2-45f8-adac-ee0ff8736767">5,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzMtMy0xLTEtMA_d227c9a9-4184-45c9-958a-4e16b75050db">4.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzUtMS0xLTEtMA_8ab1fb2f-0694-4937-adee-0cc070434bc3">318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzUtMy0xLTEtMA_54921791-d373-41d9-91e6-1f07c930e15f">20.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzYtMS0xLTEtMA_6b812290-aabe-42ab-a68e-035a7d0e10e7">16,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzYtMy0xLTEtMA_8fd9b56b-b4a3-4ef8-bd61-274a1de4afb2">12.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzYtNS0xLTEtMA_2f863d74-7fb8-431a-91a2-45a3dafdffd0">3.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzYtNy0xLTEtMA_29d97107-a0fa-4df0-84c3-ddaec389cc42">131,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzctMS0xLTEtMA_c7af5460-7398-4979-8809-46d3b01bcea7">12,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzctMy0xLTEtMA_a62a67f2-a566-42ce-91e8-511673e93abe">10.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzctNS0xLTEtMA_6a36796a-9c84-420d-abe1-d4006cdf8ffe">2.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzctNy0xLTEtMA_0a32605b-829d-4a55-8064-43eb980301b1">128,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i9e626170338d40c684a71ad8956f3dc8_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzM4MzA_1dee2c74-b7a5-4bfd-b1cc-9a97bcc0e76f">27.1</ix:nonFraction> million of unrecognized compensation expense related to our unvested stock options, including PSOs. The compensation expense for the unvested stock options will be recognized over a weighted-average period of <ix:nonNumeric contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzQwMzQ_a3f873f5-332f-49ae-916b-aba1c0535bdd">2.3</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted <ix:nonFraction unitRef="shares" contextRef="i0ed65fc14d1f42458a26dcd149381df1_D20180101-20181228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzQxNTY_a406387e-461b-4f6d-a54d-87679993405d">308,365</ix:nonFraction> PSOs to our President and Chief Executive Officer. In addition to the standard service-based vesting conditions included in our other stock options, these PSOs contain a market vesting condition such that they may not be exercised until, at any time after the grant date, the closing market price of a share of our Common Stock is equal to or greater than <ix:nonFraction unitRef="number" contextRef="i0ed65fc14d1f42458a26dcd149381df1_D20180101-20181228" decimals="INF" name="exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzQ0NTE_ef53100e-56e7-4a95-8e9f-4c4376b64239">125</ix:nonFraction>% of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. This market vesting condition was achieved during the second quarter of the fiscal 2020. The stock-based compensation expense for the PSOs is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant. The achievement of the market vesting condition did not impact the compensation expense recognized during the period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal 2020 and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on December&#160;31, 2020. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUxOTI_f2e1b326-3616-47da-9e51-479a522c1424">106.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUxOTY_f2b4eab2-b8d8-4091-a816-3040b6c4f5d7">54.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUyMDM_5cc2f717-51c9-4f06-bcc2-c1fa6cb19397">39.1</ix:nonFraction> million, respectively. Cash received from stock option exercises during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUzMDQ_17bf22e1-7558-41a0-95fe-3c903de1d242">26.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUzMDg_f06e47aa-b0ac-4c48-9a39-6f6876f18d96">16.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUzMTU_271ff0fd-325d-4b75-a80b-275bca3190dd">12.1</ix:nonFraction> million, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxMTI_5f886c10-a9ba-4606-ad47-374b0140fdc3" continuedAt="i43cf7e90f7094f23838bb6eeca6bf0fe" escape="true">Activity for RSUs during the year ended December&#160;31, 2020 was as follows (in thousands</ix:nonNumeric></span><ix:continuation id="i43cf7e90f7094f23838bb6eeca6bf0fe" continuedAt="iaba9fc8cead048fc9e92a161bec3676a"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></ix:continuation></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="iaba9fc8cead048fc9e92a161bec3676a" continuedAt="ie0534c4ae08647ccbe1a1541e7329b4d"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i630c039e42614958998ad44ba50df6a3_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzEtMS0xLTEtMA_743514d9-8667-4483-a9d9-5cede79d2204">4,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i630c039e42614958998ad44ba50df6a3_I20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzEtMy0xLTEtMA_4416c3ef-5fa0-45fe-8dd1-1ec90150cff8">19.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzItMS0xLTEtMA_c2b8e15c-060f-4219-b9f1-b6647b62c596">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzItMy0xLTEtMA_3a250e87-21c0-4bd8-b087-420b0a7cf09b">23.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzMtMS0xLTEtMA_fd10aea1-698f-45b6-b3e0-b7486aed5da1">1,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101" decimals="2" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzMtMy0xLTEtMA_ab5d947e-3311-41a2-bb1a-3c47787d11a8">18.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzQtMS0xLTEtMA_85c50bcd-11d2-45bc-9917-33f95db01f98">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzQtMy0xLTEtMA_78f70936-e60d-4ed6-9d33-68e4e7352c58">20.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecd5c77b48af4ab390becbba00955ec9_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzUtMS0xLTEtMA_488fdb10-0ff2-4a19-8f94-ea1dcb7f66a4">5,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecd5c77b48af4ab390becbba00955ec9_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzUtMy0xLTEtMA_b72a5b58-a2c2-450b-bdba-3247f556a58e">21.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzUtNS0xLTEtMA_110b5c43-163c-4acc-9f77-36244cbde948">1.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd5c77b48af4ab390becbba00955ec9_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzUtNy0xLTEtMA_8a65cde3-da92-4840-8f90-a2b4d7c5c304">107,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="iecd5c77b48af4ab390becbba00955ec9_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzU2MTU_d554bf12-5335-42ad-9537-625fbad7e651">103.6</ix:nonFraction> million of unrecognized compensation expense related to our unvested RSUs which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzU4MDE_bc1b183c-8123-47b0-8e07-0084da7a91ee">3.0</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i113f99fa82a1418eba821754e5dc4ff2" continuedAt="iefb693f08a504914bbadc6759e885681"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:continuation id="ie0534c4ae08647ccbe1a1541e7329b4d" continuedAt="i3dcd7771a8594abeae7833a5b24b8019">Activity for PSUs, during the year ended December&#160;31, 2020 was as follows (in thousands</ix:continuation></span><ix:continuation id="i3dcd7771a8594abeae7833a5b24b8019" continuedAt="id6e87c1750a142c3ae3a746ec2bc5720"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></ix:continuation></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="id6e87c1750a142c3ae3a746ec2bc5720"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48fddf5f44ab4d8295e428acbb15cc42_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzEtMS0xLTEtOTY5_a7a22a96-e33e-4def-b50e-77346acb1b46">4,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48fddf5f44ab4d8295e428acbb15cc42_I20200103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzEtMy0xLTEtOTY5_5cc16734-4057-4646-bd66-e3d3fe31a863">19.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzItMS0xLTEtOTY5_cf71819c-ed5a-44d2-97ba-48763039a3ab">4,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzItMy0xLTEtOTY5_31ee5fd5-75f2-48aa-8ac9-fb2333b5d925">23.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzMtMS0xLTEtOTY5_03b78a35-052b-4bc0-8103-e35609e960ea">1,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" decimals="2" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzMtMy0xLTEtOTY5_883fae4c-41b5-4105-8496-937d1732626d">19.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzQtMS0xLTEtOTY5_0276a1f9-b613-4de4-958c-8ad301cc8d9d">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzQtMy0xLTEtOTY5_165daa5c-c4e0-4919-b491-7bd9778d7d6f">21.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae79675a497d45819d1a3047a416388b_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzUtMS0xLTEtOTY5_27272400-c14c-4608-9427-d7c0d9a99b24">7,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae79675a497d45819d1a3047a416388b_I20210101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzUtMy0xLTEtOTY5_78e3e9f7-4377-4dfa-aad0-4e87fa50672b">21.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzUtNS0xLTEtOTY5_61c328d0-ad02-44ff-b512-4fd4dbf2476d">3.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae79675a497d45819d1a3047a416388b_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzUtNy0xLTEtOTY5_2b0094ec-ef16-40fa-b303-56c1e161dcde">148,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, in connection with our long-term incentive compensation program, we awarded <ix:nonFraction unitRef="shares" contextRef="i6987ce3f2e0b4c65ba714f40a364ffbd_D20200104-20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjcxNzM_4b329931-96d3-4378-bd8b-c0bcdc7c5ad8">2,327,840</ix:nonFraction> PSUs (the target amount) that will vest upon the achievement of certain performance targets related to clinical trial positive top-line results and product approvals by the FDA (the 2020 PSUs). Pursuant to the terms of the 2020 PSUs, employees may earn up to <ix:nonFraction unitRef="number" contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzExNTQ0ODcyMTA2OTE3_73fbd61e-47ce-42a3-8992-3dc374523fdf">200</ix:nonFraction>% of the target amount, or <ix:nonFraction unitRef="shares" contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" decimals="INF" format="ixt:numdotdecimal" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjcxODc_edfae773-acd2-4aee-bff5-262ca801e988">4,655,680</ix:nonFraction> shares, depending on the volume and timing of achievement of the performance targets. The 2020 PSUs were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2024.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2019, we awarded <ix:nonFraction unitRef="shares" contextRef="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzU4OTQ_33516b2d-594b-4d32-886a-6071d8f1bdca">1,926,605</ix:nonFraction> PSUs (the target amount) that vest upon the achievement of performance targets related to product approvals by the FDA (the 2019 PSUs). Pursuant to the terms of the 2019 PSUs, employees may earn up to <ix:nonFraction unitRef="number" contextRef="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103" decimals="INF" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzYyMTg_6465f56c-2e23-476b-931a-95e4b23a84df">200</ix:nonFraction>% of the target amount, or up to an additional <ix:nonFraction unitRef="shares" contextRef="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103" decimals="INF" format="ixt:numdotdecimal" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzYyNjY_64a6ddef-34cf-4d6a-9e0c-5926267d8390">1,926,605</ix:nonFraction> shares relative to the target amount, depending on the volume and timing of achievement of the performance targets. The performance condition for early achievement of the 2019 PSUs occurred during 2020 representing <ix:nonFraction unitRef="number" contextRef="i4cbb645856904aa9809681fb8a88fa50_D20181229-20200103" decimals="INF" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzE4MTQxOTQxODc2NzI3_9b014f3e-d4c7-411f-97bf-ba9e93638433">150</ix:nonFraction>% of the target amount. Employees have the ability to earn the remaining <ix:nonFraction unitRef="number" contextRef="i4d6b47f808c84efd8f867da26a8406f6_D20181229-20200103" decimals="INF" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzE4MTQxOTQxODc2NzMz_2330a7f7-bff7-4014-ac66-2adfe93f9a52">50</ix:nonFraction>% of the target amount if the additional performance condition is met before December 31, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2018, we awarded <ix:nonFraction unitRef="shares" contextRef="i4e926b7757e84307b3dcf2ffb4e5018e_D20180101-20181228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzYzOTI_cf95a0f8-fc4d-4d9b-a177-c68c372e11e9">693,131</ix:nonFraction> PSUs that vest upon the achievement of certain product revenue, late-stage clinical development programs and discovery pipeline expansion performance targets (the 2018 PSUs). The 2018 PSUs and 2019 PSUs will be forfeited if the performance targets are not met by December 31, 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. Of the aggregate outstanding PSUs, <ix:nonFraction unitRef="shares" contextRef="i74084a38afc04950ad513c20f60c8d62_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzE4MTQxOTQxODc0NTAx_477534b7-2537-487c-9d74-0f0ee502b6db">3,206,897</ix:nonFraction> relate to awards for which we achieved the performance target or had determined that it was probable that we would achieve the performance target. As of December 31, 2020, the remaining unrecognized compensation expense for the PSUs achieved or deemed probable of achievement related to the PSUs was $<ix:nonFraction unitRef="usd" contextRef="i6aeea19c58964ece8f259c21248b26ca_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNzEyOTU_2dbbe08f-4e4c-45ec-9f62-78d853cb8930">11.8</ix:nonFraction> million, which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNzI5NTc_6980f019-86e3-4104-8a10-52bdd077f8cd">3.5</ix:nonNumeric> years. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance target is probable was $<ix:nonFraction unitRef="usd" contextRef="ice8b3be356ff4b8c971e27c9baa061e5_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNzEzMDY_51b4b4fc-4d42-4c75-8667-6660086fa05d">128.5</ix:nonFraction> million as of December&#160;31, 2020.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis, Inc. 401(k) Plan (the 401(k) Plan)</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iefb693f08a504914bbadc6759e885681">We sponsor the 401(k) Plan under which we have historically made matching contributions to our employees&#8217; 401(k) accounts in the form of our common stock. Beginning in 2020, our matching contributions are in the form of cash. We recorded compensation expense of $<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzc5MjQ_1fb23e1f-b831-44f3-9ff5-f052ceabd67d">6.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzc5Mjg_5a29dd30-83f6-44d5-9388-9d84e44f65f8">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzc5MzY_fe5e6301-5c56-4fd4-bad4-d5d764ca1942">3.6</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, for matching contributions to our employees 401(k) accounts.</ix:continuation> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_124"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzcxNDY4MjU1ODg1ODY_20823593-baac-4cd6-9e14-a55b4bbc37a2" continuedAt="ib242b87cf4564e038330c95e4e550b96" escape="true">PROVISION FOR (BENEFIT FROM) INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="ib242b87cf4564e038330c95e4e550b96" continuedAt="id0c61eebb36e4644bf5523b85bd73093"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzUxNjg_837f2246-8a17-4985-a2a8-ebf444bf0c48" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income before income taxes is derived solely from within the U.S. Our provision for (benefit from) income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzMtMS0xLTEtMA_7741d7b4-7328-4aa8-aa50-707022c894af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzMtMy0xLTEtMA_207f3ea2-bb61-49c6-a317-442d82f105e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzMtNS0xLTEtMA_6c594cb4-2668-4b32-85d7-c9f55f6c22ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzQtMS0xLTEtMA_33892abf-f936-4694-9d28-734c4e2cd00c">3,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzQtMy0xLTEtMA_30547ebe-bf8f-4700-9a14-fd6c9b4485cc">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzQtNS0xLTEtMA_0ccad3f9-355f-48c2-a69e-3b52313ee105">6,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzUtMS0xLTEtMA_168ba646-287b-479e-a145-bec9adacde08">3,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzUtMy0xLTEtMA_67e3742e-83cb-4da4-985f-02da92f754d2">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzUtNS0xLTEtMA_16881f08-dc85-44c5-b590-a73b45d62dd8">6,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzctMS0xLTEtMA_618a3e0f-799e-40ae-9c2c-24dfa6ca4465">14,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzctMy0xLTEtMA_a321db14-e724-4e8a-bb56-c3551aba5cff">71,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzctNS0xLTEtMA_5393d7bf-e8b7-47bb-b3ae-42989d5a1942">238,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzgtMS0xLTEtMA_c29c3e1e-7458-45bc-8608-8edd2dd4dbe8">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzgtMy0xLTEtMA_0e489cd0-8780-483a-a102-00516cc8433b">578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzgtNS0xLTEtMA_5c27b2ac-81b7-43ca-a314-e164d8974c75">5,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzktMS0xLTEtMA_5b6e0426-04c5-4a51-8eb7-2d9feb8eb934">15,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzktMy0xLTEtMA_ddc99fd8-b393-4d46-b074-0dceae322105">71,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzktNS0xLTEtMA_7f8ce76b-0cd7-45df-9694-78131a491f6b">244,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzEwLTEtMS0xLTA_031e53f5-45cc-4268-825d-ed3d1f4e56f6">19,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzEwLTMtMS0xLTA_60fde132-8201-4554-9e53-8307c774fcf8">77,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzEwLTUtMS0xLTA_45a89169-1678-49c4-82ce-0ee2872bc566">237,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2020 and 2019 primarily relates to the utilization of federal net operating loss and state taxes in jurisdictions outside of California, for which w</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e do not have net operating loss carryforwards due to a limited operating history. The benefit from income taxes for the year ended December&#160;31, 2018 primarily relates to the release of our valuation allowance against significantly all of our deferred tax assets offset by state taxes in jurisdictions outside of California. Our historical net operating losses were sufficient to fully offset any federal taxable income for the years ended December 31, 2020, 2019 and 2018. </span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzUxNTc_531527ff-f6f7-4c49-9fd1-0070182b9567" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2020, 2019 and 2018, respectively, to our provision for (benefit from) income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax provision at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzItMS0xLTEtMA_ea141903-f5d7-4588-a029-5c5830eb1faf">27,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzItMy0xLTEtMA_6b21d3cb-052a-4c01-b1c2-bf622ff2bf35">83,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzItNS0xLTEtMA_1717298f-8541-401f-8644-698ca11dfbba">94,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (benefit) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzMtMS0xLTEtMA_fdab122d-73e5-4aca-9a72-3d5ab44782b5">2,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzMtMy0xLTEtMA_b8887604-ebe4-46fa-b377-0522d376ae91">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzMtNS0xLTEtMA_b4746693-e4a0-4030-bd9a-96610b703bd0">4,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzQtMS0xLTEtMA_fed735fe-617d-4afc-ab87-562aa67897fc">5,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzQtMy0xLTEtMA_3574c832-2265-4578-829c-b4cd43655e46">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzQtNS0xLTEtMA_4f3a8981-f88f-48d7-b9de-0a8e18ad16ae">315,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzUtMS0xLTEtMA_4a466174-d0f0-4ecd-9389-86e579c1fb85">11,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzUtMy0xLTEtMA_3ace14a6-2a38-499b-b1d4-55abb42822b8">8,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzUtNS0xLTEtMA_2b8836f2-b45a-4aac-a83c-c88c2fa2d3ff">18,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzYtMS0xLTEtMA_658f3e4d-4c64-469c-b951-66aa8355314f">20,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzYtMy0xLTEtMA_d2c31d46-7146-49b9-8dda-56f6a41561b7">9,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzYtNS0xLTEtMA_5fb18d11-cbd5-4a38-8303-bf48278408af">5,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzctMS0xLTEtMA_c81ae627-2503-412a-9236-66a48b57453f">18,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzctMy0xLTEtMA_4a259748-24ae-4147-b5e5-d544b8e3a1f5">4,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzctNS0xLTEtMA_fd888ca3-9951-49f6-91e2-c3618a42c8b5">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzgtMS0xLTEtMTM3NDQ_c688a94b-9daa-41e1-8bda-d5c85b5d7ef4">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzgtMy0xLTEtMTM3NDQ_d1182cd3-f0a3-447d-bcf1-cdca7ae3f262">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" name="exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzgtNS0xLTEtMTM3NDQ_ea876ba8-d5be-4e99-8523-d6da584c3b93">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzktMS0xLTEtMA_243db141-f2aa-4ba4-8c2a-084b3538b99e">562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzktMy0xLTEtMA_7e5f67ba-d1ed-4038-a5e1-55b5d786f7b7">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzktNS0xLTEtMA_818ddeb0-f266-46a5-8856-539b5ccb87a1">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzEwLTEtMS0xLTA_8c9f8afa-f7fe-45a1-b94b-62b41e1d4a80">19,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzEwLTMtMS0xLTA_dfee0845-c0b6-42d3-920a-27a7807fe287">77,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzEwLTUtMS0xLTA_fe9ae364-80f2-4267-b363-84ba79aef3b4">237,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="id0c61eebb36e4644bf5523b85bd73093" continuedAt="i32b6f3e4d0e04766a40c97265dcb3c0a"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzUxNTk_74c049cc-f8f6-408d-9a62-78ac7b3a09a4" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzMtMS0xLTEtMA_4696229f-5d12-4d0a-a5a3-2b1cd3c916f6">37,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzMtMy0xLTEtMA_61181a52-0cf7-491a-b9ea-ce8b766d8907">65,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzQtMS0xLTEtMA_1a66215e-3763-4fb8-8f4e-363076697820">126,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzQtMy0xLTEtMA_2f54fff3-34dc-41eb-91b9-0045190ac0a0">110,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzUtMS0xLTEtMA_502dba9c-b0c8-4ac0-a2a9-5f56f44f9250">18,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzUtMy0xLTEtMA_f4d99b02-573c-40bb-8154-e34fe45f8325">26,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzYtMS0xLTEtMA_2a3688f3-01ed-4791-895c-7d4e99c0bce3">19,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzYtMy0xLTEtMA_69404a38-31b7-4f9e-95e7-3b5fe695f10d">14,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzctMS0xLTEtMA_bbb474cc-3122-4c60-9b2b-e97c1bff7d63">11,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzctMy0xLTEtMA_f2354af6-fcf5-45a8-919f-63662d6d66a1">11,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves not currently deductible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzgtMS0xLTEtMA_3991fc30-8095-4f25-b8d3-b66d0e300959">12,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzgtMy0xLTEtMA_7c22ee7d-3995-4b8b-8ccb-fe537a29c5fd">8,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzktMS0xLTEtMA_500404ee-1e2f-4a63-b772-69c8d6e24780">7,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzktMy0xLTEtMA_90d0c4f5-7594-4677-b864-0036746c1519">6,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEwLTEtMS0xLTA_7c9aaf78-283c-42a8-9df0-73cba4472e8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEwLTMtMS0xLTA_2aaf8a56-98ed-46b7-b2c0-cfee027b254f">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzExLTEtMS0xLTA_5dbb399a-9bb9-47bc-bd22-dda297b3b491">234,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzExLTMtMS0xLTA_7cc14728-0109-45c7-92e2-aa4c0920110a">243,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEyLTEtMS0xLTA_455b7bd2-a887-4d31-b12b-4d63efc81ae4">67,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEyLTMtMS0xLTA_9b9248bb-0569-442c-a908-f04a96b74168">61,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEzLTEtMS0xLTA_eb248992-9d31-42e8-9059-b9c920bdfac6">166,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEzLTMtMS0xLTA_21726f76-cb41-405c-9d27-bbb6a94a0584">181,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE1LTEtMS0xLTA_29292b31-53d4-45dd-b9f7-73ac2625c691">9,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE1LTMtMS0xLTA_9f291214-eff8-4628-814d-e23bf50264b1">9,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE2LTEtMS0xLTg4NTY_fb885cae-4a19-4edb-895d-89c04e98753d">657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE2LTMtMS0xLTg4NTY_3ea61146-effa-4a65-a970-5ccbab883849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE2LTEtMS0xLTA_032f4174-bec5-4bb1-8bf3-7353a2ac49c6">10,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE2LTMtMS0xLTA_4a285182-5a0f-4454-a277-8163c0fd7f32">9,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE3LTEtMS0xLTA_6c733d3d-871a-4644-8ca8-c1694a5ccbc2">156,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE3LTMtMS0xLTA_9cceda92-5984-419d-b428-ddc2d09b642b">172,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December&#160;31, 2020, based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December&#160;31, 2020 and forecasts of future operating results, as well as considering the utilization of net operating losses and tax credits prior to their expiration, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December&#160;31, 2020 and 2019, we continue to carry a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM2NDk_94840e89-1d72-49f0-9e19-451c53423e6c">67.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzI3MTM_029d3228-6027-4192-92fa-df12920c9a2d">61.7</ix:nonFraction> million, respectively, against our California state deferred tax assets. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM2NjM_8823a3ae-6817-406e-ba2d-98c55f058708">5.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM2OTM_11fa450a-3e81-4893-a7e8-cf6381b2dfb9">3.5</ix:nonFraction> million during the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i22de33cb9fa4466693147fb2b3a08fde_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjE3MzU_b8662e54-5d29-48f0-830c-99a7f27d0c7d">92.6</ix:nonFraction> million, which will begin to expire in 2036, and federal business tax credits of approximately $<ix:nonFraction unitRef="usd" contextRef="i22de33cb9fa4466693147fb2b3a08fde_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjE3Mzk_ec08edfc-979a-4aed-8d5c-881daac54d6b">127.4</ix:nonFraction> million which expire in the years 2021 through 2040. We also had state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i0f1e640f034c4c9a8c524f75ba45a4ab_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjE3NDM_af8d410d-ece3-4e11-b30e-56a969e4518d">427.9</ix:nonFraction> million, which expire in the years 2021 through 2036, and California research and development tax credits of approximately $<ix:nonFraction unitRef="usd" contextRef="ibdd294e2e4ab4132b8b50c9a18c91bd6_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjE3NDc_1e649b3e-2dd6-42c8-bcb6-21a0719da038">42.9</ix:nonFraction> million, which do not expire, and California Competes Tax Credits of approximately $<ix:nonFraction unitRef="usd" contextRef="ibdd294e2e4ab4132b8b50c9a18c91bd6_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:TaxCreditCarryforwardAmountWithExpirationPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM4MjY_a1979184-9fd1-48cc-a51c-ebe91baa0022">1.6</ix:nonFraction> million, which expire in 2026.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through December&#160;31, 2020, and concluded that an ownership change, as defined under Section 382, had not occurred. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="i32b6f3e4d0e04766a40c97265dcb3c0a" continuedAt="ie615710a7c6646e0b929ee5933d90388"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzUxODk_293649ed-352e-4a69-839f-783525812e6a" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzItMS0xLTEtMA_7095b94e-eab2-41b6-9b1f-8314f72e3598">79,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzItMy0xLTEtMA_b2303f88-3af1-4382-a544-9857d09f03ef">76,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc77df98a1c43b7b450a7d15340ba09_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzItNS0xLTEtMA_06832bbf-6584-45b7-9ee3-24a1564eb230">79,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to prior year provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" name="exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzMtMS0xLTEtMA_f815579d-ac59-4dec-b0ca-6e9dafc6ebb7">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" name="exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzMtMy0xLTEtMA_a918366e-7543-4867-b913-6706654d9a16">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" sign="-" format="ixt:numdotdecimal" name="exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzMtNS0xLTEtMA_cd172e82-caa0-4ce1-8e00-34069557ea1f">4,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to current year provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzQtMS0xLTEtMA_52855a76-bebe-4860-a7ee-e77358cdbc57">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzQtMy0xLTEtMA_7a5f4629-b6aa-4aa0-81f3-9905a9dd0da0">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzQtNS0xLTEtMA_a0913307-a7d7-4898-8fe5-03107c7b1b53">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on the lapse of the applicable statutes of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzUtMS0xLTEtMA_ee8f0ffb-1dd0-49ac-b8f1-d56880533fdd">2,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzUtMy0xLTEtMA_9790eaaa-fb09-44e6-82f9-fb2555acf39f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzUtNS0xLTEtMA_725b27f3-0096-4c4a-9c10-093c9214bde1">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzYtMS0xLTEtMA_71ffa4f2-975e-4956-923d-5e192b72272e">80,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzYtMy0xLTEtMA_36da8a26-9100-4712-a0b7-b16331221b18">79,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzYtNS0xLTEtMA_89584081-76e4-4113-abed-d567b0e6c0f7">76,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2020 will significantly change over the next 12 months. As of December&#160;31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzQ0MDM_bce773a3-85c6-4b75-8cd5-8c9b54cde0a9">80.9</ix:nonFraction> million in unrecognized tax benefits, of which <ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM4NjY_e918bed3-69d8-441c-b007-1ee83a75582e">50.1</ix:nonFraction> million would reduce our provision for income taxes and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes. </span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie615710a7c6646e0b929ee5933d90388">We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 2001 through 2020 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</ix:continuation> </span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_130"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90ZXh0cmVnaW9uOmUwNGIxMjU0OGQ4YTQ4MWJiM2I0OGRlNzZiYzUzMWMxXzkxNQ_1cb90c37-7914-4954-8815-76481a38581e" continuedAt="i2cafd5bbe58745148babf0220239c67c" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i2cafd5bbe58745148babf0220239c67c"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90ZXh0cmVnaW9uOmUwNGIxMjU0OGQ4YTQ4MWJiM2I0OGRlNzZiYzUzMWMxXzg5Ng_9b567503-6744-47c2-a108-5a69970b65e3" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzMtNS0xLTEtMA_0233ee16-3849-4354-a1c6-7deed24f3116">111,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzMtNy0xLTEtMA_54698d9d-355a-4983-8a78-1e4325685b13">321,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzMtOS0xLTEtMA_71954d78-296a-47aa-b453-1c0d6fb08477">690,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzktNS0xLTEtMA_e8097716-0ce6-4f71-a3e0-6d4aaac91bb6">308,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzktNy0xLTEtMA_e67c9716-2eb0-4f34-a651-338315e0e5d7">302,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzktOS0xLTEtMA_b988c492-8c2f-4050-a523-6faf7bafba14">297,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEwLTUtMS0xLTA_80e3fbe9-cd64-4592-9f5f-bd349208b237">9,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEwLTctMS0xLTA_78cd963c-c24c-4054-a95b-e8755c0feee2">12,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEwLTktMS0xLTA_f3c4afbe-d3c9-47e2-b39b-1b5bd93c3b23">14,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzExLTUtMS0xLTA_a50ad356-55f1-4835-afbf-70bde3f16d1f">318,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzExLTctMS0xLTA_58a517fa-db9c-4d16-8fb7-f8e442e6bddf">315,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzExLTktMS0xLTA_9ba39d1e-b2ba-4025-8e08-a1d10e40d6b9">312,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEyLTUtMS0xLTA_d28a696a-982e-404b-9143-60d754541daa">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEyLTctMS0xLTA_eaedea13-12fd-476b-a541-71b73da97e35">1.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEyLTktMS0xLTA_8d90e575-b48d-41dd-9977-4c71beed5244">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEzLTUtMS0xLTA_83ab8308-0dcd-440e-b337-df33ef846d21">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEzLTctMS0xLTA_94f11cd9-6ec9-47f7-97b6-752ace117dda">1.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEzLTktMS0xLTA_c2f746a9-b2ab-46d8-b64a-24ca0e571fa3">2.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options and PSOs, unvested RSUs and PSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they are related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. See to &#8220;Note 8. Employee Benefit Plans&#8221; for a further description of our equity awards. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90ZXh0cmVnaW9uOmUwNGIxMjU0OGQ4YTQ4MWJiM2I0OGRlNzZiYzUzMWMxXzkyMQ_b687d729-4e00-4e9c-8f79-0d4710441332" continuedAt="i6fe6632540394ce091930e3b1351e7eb" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i6fe6632540394ce091930e3b1351e7eb"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i728bdf824bce4e3a8e6c9be0a205fc81_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTpmNjhmYjJmMzM1ZmU0YWM3YTE3ZTllYTJhNzgzZmFkNy90YWJsZXJhbmdlOmY2OGZiMmYzMzVmZTRhYzdhMTdlOWVhMmE3ODNmYWQ3XzItNS0xLTEtMA_cc2ac7dd-1749-48f0-9446-4f076fc3ceb9">10,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61e2f06dd994f53bfa706d07d66963c_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTpmNjhmYjJmMzM1ZmU0YWM3YTE3ZTllYTJhNzgzZmFkNy90YWJsZXJhbmdlOmY2OGZiMmYzMzVmZTRhYzdhMTdlOWVhMmE3ODNmYWQ3XzItNy0xLTEtMA_20271ba4-1c60-49d0-a244-8122be671975">9,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic36021c41bb5446e8080959a3441b6a9_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTpmNjhmYjJmMzM1ZmU0YWM3YTE3ZTllYTJhNzgzZmFkNy90YWJsZXJhbmdlOmY2OGZiMmYzMzVmZTRhYzdhMTdlOWVhMmE3ODNmYWQ3XzItOS0xLTEtMA_aa21c183-f9d1-4317-b3ba-8050b7dee59a">3,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzExNTQ0ODcyMTA3NTQ2_443aa7b8-f1b1-4329-9fca-6a2ac4191e97" continuedAt="i2dfc1d63c7f54943967f5174dcd41462" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i2dfc1d63c7f54943967f5174dcd41462" continuedAt="if594bdfb3c4840438a2c7799e6e0a04b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Headquarters Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located in Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018, April 2019, August 2019, January 2020 and December 2020, resulting in, among other things, an increase to the amount of space leased and changes to the lease term. Our right-of-use asset, lease liability and the related lease costs reflect the <ix:nonFraction unitRef="sqft" contextRef="i2793983ce6e243b5ad8af2ec5ec6c289_I20210101" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzIxOTkwMjMyNjE3MDE_81eb296a-40bf-45d9-aae5-3bd0040f2011">228,941</ix:nonFraction> square feet of space we have taken possession of as of December 31, 2020 (the Current Premises) under the amended Lease. We expect to take possession of the additional space provided for under the December 2020 amendment on or prior to June 1, 2021, which will increase the space leased to <ix:nonFraction unitRef="sqft" contextRef="i6703fce613684225b4063ab7dc405264_I20210601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzc3NA_3a5c6e57-8d62-4354-a9b9-cc29378bd1ae">254,690</ix:nonFraction> square feet. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Lease continues through October 31, 2031 (the Lease Term). We have <ix:nonFraction unitRef="renewal_option" contextRef="i655272f3bcac4b5e8db4788f93444fb2_D20200104-20210101" decimals="INF" format="ixt-sec:numwordsen" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzg3NA_fcec5a08-4128-4158-aa71-13e71d732a5b">two</ix:nonFraction> <ix:nonNumeric contextRef="i2793983ce6e243b5ad8af2ec5ec6c289_I20210101" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzcxNDY4MjU1OTY5NDI_c644d400-ab4b-45f2-97b1-8bc2c345c6ed">five-year</ix:nonNumeric> options to extend the Lease; these optional periods have not been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made certain tenant improvements on the Initial Premises, for which we received $<ix:nonFraction unitRef="usd" contextRef="i4a3a848bbc8a48e9aa6faab6645fee01_I20190131" decimals="-5" format="ixt:numdotdecimal" name="exel:TenantLeaseImprovementsAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzEyMjE_485806b0-f2d9-4f18-86bd-a4c4974ac0a5">8.2</ix:nonFraction> million in reimbursements in January 2019. At December 31, 2020, a reimbursement of $<ix:nonFraction unitRef="usd" contextRef="i2793983ce6e243b5ad8af2ec5ec6c289_I20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:TenantLeaseImprovementsAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzEzMDM_a0dfd327-31a9-4f8e-b0c6-6eb805d23d58">1.7</ix:nonFraction> million was due to us for tenant improvements to the space we obtained under the April 2019 amendment. We were also provided an allowance of up to $<ix:nonFraction unitRef="usd" contextRef="i6703fce613684225b4063ab7dc405264_I20210601" decimals="-5" format="ixt:numdotdecimal" name="exel:TenantLeaseImprovementsAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzExNTQ0ODcyMTA3NTQ4_e361790c-d2ee-4012-a807-cc5a0b6abef9">1.4</ix:nonFraction>&#160;million for tenant improvements to the space expected to be obtained under the December 2020 amendment. </span></div><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="exel:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUzNDk_ed8f61cf-6fc3-4156-aa8e-165e3cf80a00" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in other long-term assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzMtMS0xLTEtMA_c9941575-545c-450f-a1f7-1ab5ea2f2e1f">43,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzMtMy0xLTEtMA_c2327f2e-2d35-419a-90eb-a0436a2c1e08">41,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_4bd66db9-0068-4d77-8491-049fcf2c6704"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_a8b46ed7-baae-4463-b21f-4d4716438745">Current portion included in other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMS0xLTEtMA_82ab717c-5b8a-479e-8620-16c9a8f3acae">3,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMy0xLTEtMA_d79c3006-ca9d-465e-aa72-262d881648d8">2,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzYtMS0xLTEtMA_4d21baa8-e74e-4996-bdf5-5327951ca0c7">49,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzYtMy0xLTEtMA_5d90d67f-c684-4e60-ac3c-bacb98ae2ec3">48,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzctMS0xLTEtMA_957755a4-67d2-45b7-af90-1b918e17ebc2">52,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzctMy0xLTEtMA_eaa289a6-9c22-451b-a310-36691e2278ec">50,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUzNTg_7cea1c9c-9ef6-42d3-b064-c57c13ab2529" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzItNS0xLTEtMA_3b7abded-1ef5-4fa4-893b-5ea213ac7bff">4,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzItNy0xLTEtMA_a5e8df5e-680f-47ff-b593-c0abe4dbeba4">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzItOS0xLTEtMA_6c6c8542-d583-4ace-9c31-d97537ca4519">4,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzMtNS0xLTEtMA_b24961db-b373-4a41-aded-2b322fd47083">2,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzMtNy0xLTEtMA_b84be88b-b8fd-4f12-b01f-3c9cb73192e3">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzMtOS0xLTEtMA_e4e1b126-90e7-499b-a9cb-3b65bf9cd1da">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzUtNS0xLTEtMA_03205c15-1b45-4cae-9042-2bc0900ed9c6">7,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzUtNy0xLTEtMA_bff78d2b-2cf3-4a97-a2df-b980d5c11f5e">3,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzUtOS0xLTEtMA_94274440-ea17-4fb9-9e58-cb1ef85d4e42">5,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the year ended December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzIwMTM_cabb709c-0dce-46fe-8f82-691ff570915f">4.6</ix:nonFraction> million and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="if594bdfb3c4840438a2c7799e6e0a04b" continuedAt="iac03580c952a488392db7d02749326e5"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUzNTU_fd5742c4-960e-412d-bb64-ad12f46b1010" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.186%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzEtMi0xLTEtMA_b3d244c8-f532-4c33-853d-7189a0ec60ae">4,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzItMi0xLTEtMA_556dfaad-4cf3-4073-abf5-b22a09f49d56">4,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzMtMi0xLTEtMA_d8381117-20a0-4670-94d1-3c811f77ed29">5,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzQtMi0xLTEtMA_5ea9d0b2-f2ba-49cc-b010-047fccea0949">5,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzUtMi0xLTEtMA_41923e1c-96ca-4d07-9602-371da5975265">5,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzYtMi0xLTEtMA_43946714-6da9-47bd-aec5-f717f69ac475">37,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzctMi0xLTEtMA_144e13f9-7fc6-4b9a-aaf7-c739f288761f">63,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzktMi0xLTEtMA_e4825b8e-e541-42de-8864-53e2a1e26701">9,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future tenant improvement reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzEwLTItMS0xLTA_d90aeeb9-ed0f-4ce9-afab-489c3a1ab766">1,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzExLTItMS0xLTA_c9b2128f-c55c-4046-9079-937f1314e78d">52,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the weighted average discount rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzIzMTc_125f24ee-1c50-4967-bb9a-a48a1aa7b0f6">3.1</ix:nonFraction>% and the weighted average remaining lease term is <ix:nonNumeric contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzIzNjk_698077a2-8f6c-4c21-bd52-9867de57867b">10.8</ix:nonNumeric> years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Build-to-Suit Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) for approximately <ix:nonFraction unitRef="sqft" contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzI1MDM_0fdaf1a4-18b0-4d7c-a9ee-80ae722c1254">220,000</ix:nonFraction> square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Build-to-Suit Lease is for a period of <ix:nonNumeric contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzI2NzQ_f5a8c7dd-01d4-400c-accd-f296de705053">242</ix:nonNumeric> months (the Term), which will begin upon the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the Term will begin in April 2022 (the Lease Commencement Date). The monthly base rent under the Build-to-Suit Lease will equal a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by the lessor and any development costs we pay) and is currently estimated to be about $<ix:nonFraction unitRef="usd" contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031" decimals="-5" format="ixt:numdotdecimal" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzMyMzc_52a5aae0-829c-4548-8c4c-4934d6dbebeb">0.7</ix:nonFraction> million, subject to an annual increase of <ix:nonFraction unitRef="number" contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031" decimals="INF" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzMyNzQ_9eda8931-48fd-4165-bbf1-bde47475f1ff">3</ix:nonFraction>% during the Term. We will also be responsible for paying operating expenses related to the New Premises. The rent payments will begin <ix:nonNumeric contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031" format="ixt-sec:durwordsen" name="exel:LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM0MTA_a57bf032-f0fe-46bf-afde-e5d0976161bc">sixty days</ix:nonNumeric> following commencement of the Term. We have been provided a tenant improvement allowance for the New Premises of approximately $<ix:nonFraction unitRef="usd" contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031" decimals="-5" format="ixt:numdotdecimal" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM1NDA_fb21a725-4a75-4693-9fa7-946237ff6a7f">16.5</ix:nonFraction> million. To the extent that the total development costs of the New Premises exceeds $<ix:nonFraction unitRef="usdPerSqft" contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031" decimals="INF" name="exel:AreaOfRealEstatePropertyAvailableToLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM2MTk_39c18453-f4a7-4374-ad18-d8a9d5a78f1f">525</ix:nonFraction> per square foot, we will also pay <ix:nonFraction unitRef="number" contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031" decimals="2" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM2NTY_d0c1da77-bed7-4b42-98d8-d38709b2d3d5">50</ix:nonFraction>% of such excess costs prior to the commencement of the Term, and we are required to secure such amount by providing a letter of credit or depositing such amounts in an account with the lessor&#8217;s lender.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Build-to-Suit Lease includes <ix:nonFraction unitRef="renewal_option" contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031" decimals="INF" format="ixt-sec:numwordsen" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM5OTU_02f7867e-194d-49f6-9b6e-ba581d9a1c34">two</ix:nonFraction> <ix:nonNumeric contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzcxNDY4MjU1OTY5NDM_7a83689c-d6ec-4066-be1c-888dd2b63abc">five-year</ix:nonNumeric> options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the <ix:nonNumeric contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031" format="ixt-sec:durmonth" name="exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzQyNjE_a65428b0-23c3-4746-b8d9-4bbde27c8222">180</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that, under the guidance provided in Topic 842, we do not have control of the New Premises during the construction period. Therefore, we will not record a right-of-use asset or lease liability for the Build-to-Suit Lease until the Lease Commencement Date. We will evaluate the classification of the Build-to-Suit Lease as an operating lease or financing lease at the Lease Commencement Date. We determined the cost of tenant improvements during the construction period are lessor assets and considered a prepayment of lease under Topic 842. The costs incurred as of December 31, 2020 of $<ix:nonFraction unitRef="usd" contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzE4MTQxOTQxODc0Njg5_9367fc04-982d-44ea-b8b5-742127fb06f4">2.8</ix:nonFraction>&#160;million are recorded as other long-term assets in the Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of and $<ix:nonFraction unitRef="usd" contextRef="ie2db56eb211748d2a452eafb230ca08e_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUxODI_7d5e416f-df32-484e-8dcb-8f3284a515d0"><ix:nonFraction unitRef="usd" contextRef="i60096daf93c14de585b95a04778a59d9_I20200103" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUxODI_e08f78e1-89e7-45d7-924f-1528a8bb634a">1.6</ix:nonFraction></ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. <ix:nonFraction unitRef="usd" contextRef="ie2db56eb211748d2a452eafb230ca08e_I20210101" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LettersOfCreditOutstandingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUyMTY_e67c3355-b485-46b0-9f08-c68ba68d5671">None</ix:nonFraction> of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><ix:continuation id="iac03580c952a488392db7d02749326e5"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into standby letter of credit of $<ix:nonFraction unitRef="usd" contextRef="i19a576c9dd734120a4d6a896a2880fb4_I20210131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GuarantyLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzE4MTQxOTQxODgxODM1_65d3dd95-fd72-4057-bbfa-cbe3be718699">45.9</ix:nonFraction>&#160;million in the aggregate as guarantee of our obligation to fund our portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which will be recorded as restricted cash. The letter of credit will be reduced as we fund our portion of the tenant improvements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. The sale of a generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_1486"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzIxOA_37b57195-c959-4802-9c8c-596ecc5a58c1" continuedAt="ic706bfd846ba4aa19188e1b41c986819" escape="true">QUARTERLY FINANCIAL DATA (UNAUDITED)</ix:nonNumeric></span></div><ix:continuation id="ic706bfd846ba4aa19188e1b41c986819"><ix:nonNumeric contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzIxOQ_eea2750d-ec54-4101-83de-fe7de8876610" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected unaudited quarterly financial data was as follows (in thousands, except per share data):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal 2020 Quarter Ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8yLTEtMS0xLTE3NTA3_e678c4b4-edea-4230-a186-5fc1d0e0ab2e">226,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8yLTMtMS0xLTE3NTA3_745aff82-9ee0-4631-a9e6-76d7e27076d0">259,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8yLTUtMS0xLTE3NTA3_a1702b30-7d6d-41cf-b583-99a105f9f785">231,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8yLTctMS0xLTE3NTA3_cc03c269-6129-499c-acb7-13baf15809ed">270,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8zLTEtMS0xLTE3NTA3_fb3f0a0b-77ff-4381-8a51-b41b8385e07e">184,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8zLTMtMS0xLTE3NTA3_eda0410c-b74a-42c5-af06-2d29050f8c9d">169,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8zLTUtMS0xLTE3NTA3_7e0fb72a-9733-41f8-b5f5-b7002012a274">159,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8zLTctMS0xLTE3NTA3_300da5bf-12d8-4385-b0f2-523f54b9c106">191,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV80LTEtMS0xLTE3NTA3_7154063a-5274-419d-959a-a5a527a0fff4">52,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV80LTMtMS0xLTE3NTA3_21322e43-6fec-4175-80e7-b92590768936">75,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV80LTUtMS0xLTE3NTA3_125cb53d-2d70-43ec-b0b5-c78dbcd85f55">42,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV80LTctMS0xLTE3NTA3_fa319eb1-b60d-419d-b83e-d4b43b523e9c">24,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV81LTEtMS0xLTE3NTA3_c89585a8-560a-42f9-a475-ea5f5c82a813">48,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV81LTMtMS0xLTE3NTA3_b01dd264-50c6-4163-b12e-8bb9f84f17e6">66,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV81LTUtMS0xLTE3NTA3_1090c1e4-ea86-4125-b47e-4ec096a2a61a">32,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV81LTctMS0xLTE3NTA3_9eac3bfa-4a98-4524-99bd-89ce642ffb07">28,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTEtMS0xLTE3NTA3_de0b1174-ae48-4bbc-af16-003c357e8c71">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTMtMS0xLTE3NTA3_6fae2ce8-4b4c-4639-9620-56d4d222f877">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTUtMS0xLTE3NTA3_c2a99e7d-df29-4356-a07e-09c2631457dc">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTctMS0xLTE3NTA3_1c8b9e56-0f0b-4cb1-870a-5cc583a56432"><ix:nonFraction unitRef="usdPerShare" contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTctMS0xLTE3NTA3_bec29640-38d2-49cd-9270-ee7d1348c952">0.09</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTEtMS0xLTE3NTA3_8bf30de0-1da7-4a63-b684-da014917df32">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTMtMS0xLTE3NTA3_1a788ef1-4cf2-4b8d-9c63-8c6f67bc89c2">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTUtMS0xLTE3NTA3_c4ddd035-ba9f-4fb8-9a72-03bfab08e46a">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTctMS0xLTE3NTA3_0f0b210e-dd55-4092-8872-278b9771acf1"><ix:nonFraction unitRef="usdPerShare" contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTctMS0xLTE3NTA3_3fcbe78d-bbb3-45ea-ab66-da5acf6f6a1a">0.09</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:41.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.312%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.312%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal 2019 Quarter Ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8yLTEtMS0xLTE3NTEx_c771b4ef-bb4f-4f60-8524-7cd293ebf844">215,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8yLTMtMS0xLTE3NTEx_e22c9b35-45c1-49e8-a356-7f99d52010aa">240,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8yLTUtMS0xLTE3NTEx_48589aca-5224-4e19-ab6c-0361a712e6c4">271,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8yLTctMS0xLTE3NTEx_feec5cf6-1d2d-45b1-b91f-45472e67189c">240,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8zLTEtMS0xLTE3NTEx_49a4e900-8b82-44a9-bbe7-3700c0a849c1">172,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8zLTMtMS0xLTE3NTEx_37f89102-edfc-44a0-adec-68c1a10b85f9">186,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8zLTUtMS0xLTE3NTEx_0b0b570b-096f-47c4-951e-0b9ec233af40">184,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8zLTctMS0xLTE3NTEx_89fa72fe-7702-4d15-9fc4-32e9dd18fba4">184,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF80LTEtMS0xLTE3NTEx_d189c86d-54cb-46fb-8a8d-34aa36202fd9">84,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF80LTMtMS0xLTE3NTEx_d0cb6ec5-e02f-416e-b65b-f7206c871b2e">91,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF80LTUtMS0xLTE3NTEx_974613ff-8cc0-4578-bad6-00f5f82a7302">115,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF80LTctMS0xLTE3NTEx_f81db746-3e47-49dd-92b8-1061980a9614">77,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF81LTEtMS0xLTE3NTEx_549798c7-9d28-4b71-a246-2f639954c7fd">75,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF81LTMtMS0xLTE3NTEx_7b995dda-6ab9-492b-bf61-4bcae4aebc85">79,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF81LTUtMS0xLTE3NTEx_4a3ab4b0-4bf6-42e7-b84a-56cfff6b8ee5">97,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF81LTctMS0xLTE3NTEx_f0bb9467-2c9d-4911-8399-f7602993da4d">68,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF83LTEtMS0xLTE3NTEx_84be3e03-c29e-4f19-8518-16db6d0dcbae">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF83LTMtMS0xLTE3NTEx_21242ae2-b56a-4461-94ac-b3e89c06113a">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF83LTUtMS0xLTE3NTEx_d66b21e7-e121-4fda-9caa-466673ad9a23">0.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF83LTctMS0xLTE3NTEx_d85bac77-3fab-4f20-901a-7b64efa725c9">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF84LTEtMS0xLTE3NTEx_bf83e51d-ed03-4529-9ab3-595f0556e67b">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF84LTMtMS0xLTE3NTEx_4c1ec441-c682-40b4-9711-ffd1834a895e">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF84LTUtMS0xLTE3NTEx_925dbccf-715c-433c-ab08-03a7d4533aa6">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF84LTctMS0xLTE3NTEx_f49cea00-f446-4edf-9a37-36697ffa4644">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Total revenues for the quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, included      milestone revenue of $<ix:nonFraction unitRef="usd" contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzIyMQ_53d8c290-8059-48ff-b0d6-d1ba910e7784">0.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzIzNQ_eb89b919-6b44-416e-bfa6-7b956060ec7b">43.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzI1MA_6c004084-7796-400a-b3bc-9c7ca4721d33">13.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzI2NQ_d6b829ee-6137-42e3-9044-139b5125bdde">29.4</ix:nonFraction>&#160;million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzI4MA_0e79bf0e-2ac0-45b2-9936-8c74b275d0d1">10.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzI5NQ_3f1c9dd4-d8cf-4393-8647-9172a13a276e">20.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzMxMA_7dc5489a-fbd1-41ef-b3d8-c4ef1df61639">50.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103" decimals="-5" format="ixt:numdotdecimal" name="exel:MilestonePaymentsEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzMyNQ_0de8fd4a-64be-48bb-82ac-45bf61d01910">15.1</ix:nonFraction>&#160;million during the comparable periods in 2019. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    Gross profit is computed as net product revenues less cost of goods sold.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)    The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_139"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_142"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined under Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) required by Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended, our Chief Executive Officer and our Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the Effectiveness of Controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S.&#160;generally accepted accounting principles.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of our 2020 fiscal year, management conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework established in the original </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;&#8211; Integrated Framework</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO). Based on this assessment, management has determined that our internal control over financial reporting as of January&#160;1, 2021 was effective. There were no material weaknesses in internal control over financial reporting identified by management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The independent registered public accounting firm Ernst&#160;&amp; Young LLP has issued an audit report on our internal control over financial reporting, which is included on the following page.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Exelixis, Inc.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Exelixis, Inc.&#8217;s internal control over financial reporting as of January&#160;1, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Exelixis, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of January&#160;1, 2021, based on the COSO criteria.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of January 1, 2021 and January 3, 2020 and, the related consolidated statements of income, comprehensive income, stockholders&#8216; equity and cash flows for each of the three fiscal years in the period ended January&#160;1, 2021, and the related notes and our report dated February&#160;10, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;10, 2021</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_145"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_148"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_151"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.73pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item relating to our directors and nominees, including information with respect to our audit committee, audit committee financial experts and procedures by which stockholders may recommend nominees to our board of directors, is incorporated by reference to the section entitled &#8220;Proposal&#160;1&#160;&#8211; Election of Directors&#8221; appearing in our Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after January&#160;1, 2021, which we refer to as our 2021 Proxy Statement. The information required by this item regarding our executive officers is incorporated by reference to the section entitled &#8220;Information about our Executive Officers&#8221; appearing in our 2021 Proxy Statement. The information, if any, required by this item regarding compliance with Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, is incorporated by reference to the section entitled &#8220;Delinquent Section 16(a) Reports&#8221; appearing in our 2021 Proxy Statement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Ethics</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Corporate Code of Conduct that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. The Corporate Code of Conduct is posted on our website at www.exelixis.com under the caption &#8220;Investors &amp; Media&#8212;Corporate Governance&#8212;Corporate Governance Documents.&#8221;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Corporate Code of Conduct by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of the Nasdaq Stock Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_154"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the sections entitled &#8220;Compensation of Executive Officers,&#8221; &#8220;Compensation of Directors,&#8221; &#8220;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation Committee Report&#8221; appearing in our 2021 Proxy Statement.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_157"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item relating to security ownership of certain beneficial owners and management is incorporated by reference to the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; appearing in our 2021 Proxy Statement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information about our common stock that may be issued upon the exercise of stock options and other rights under all of our existing equity compensation plans as of December&#160;31, 2020, which consists of our 2000 Employee Stock Purchase Plan (the ESPP), our 2011 Equity Incentive Plan (the 2011 Plan), our 2014 Equity Incentive Plan (the 2014 Plan), our 2016 Inducement Award Plan (the 2016 Plan) and our 2017 Equity Incentive Plan (the 2017 Plan):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">securities to&#160;be issued upon exercise of outstanding&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options, warrants and rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise&#160;price of outstanding&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options, warrants&#160;and&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">rights</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by stockholders</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,708,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,805,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by stockholders</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,885,179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,805,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Equity plans approved by our shareholders include the Director Plan, the 2011 Plan, the 2014 Plan, the 2017 Plan and the ESPP. As of December&#160;31, 2020, a total of 3,704,580 shares of our common stock remained available for issuance under the ESPP, and up to a maximum of 601,566 shares of our common stock may be purchased in the current purchase period. The shares issuable pursuant to our ESPP are not included in the number of shares to be issued pursuant to rights outstanding or and the weighted-average exercise&#160;price of such rights as of December&#160;31, 2020, as those numbers are not known.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The weighted-average exercise price takes into account the shares subject to outstanding restricted stock units, including such awards with performance conditions (RSUs) which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $12.65.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Represents shares of our common stock issuable pursuant to the 2016 Plan. As of December&#160;31, 2020, no shares of our common stock remained available for additional grants under the 2016 Plan. In November 2016, the Board adopted the 2016 Plan pursuant to which we reserved 1,500,000 shares of our common stock for issuance under the 2016 Plan. The only persons eligible to receive grants of Awards under the 2016 Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 - that is, generally, a person not previously an employee or director of Exelixis, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Exelixis. An &#8220;Award&#8221; is any right to receive Exelixis common stock pursuant to the 2016 Plan, consisting of non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, or any other stock award.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The weighted-average exercise price takes into account the shares subject to outstanding RSUs, which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $19.53.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_160"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the sections entitled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Proposal 1 &#8211; Election of Directors&#8221; appearing in our2021 Proxy Statement.</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_163"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the section entitled &#8220;Proposal 2&#160;&#8211; Ratification of Selection of Independent Registered Public Accounting Firm&#8221; appearing in our 2021 Proxy Statement. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_166"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_169"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.15pt">The following documents are being filed as part of this report:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;The following financial statements and the Report of Independent Registered Public Accounting Firm are included in Part II, Item&#160;8:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.285%"><tr><td style="width:1.0%"></td><td style="width:83.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_61">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_61">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_64">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_64">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_70">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_70">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_73">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_73">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_76">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_76">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_79">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_79">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_82">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_82">88</a></span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;All financial statement schedules are omitted because the information is inapplicable or presented in the Notes to Consolidated Financial Statements.</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The following Exhibits are filed as part of this report.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/10/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/10/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/25/2012</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/15/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit31certificateofamen.htm">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/23/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000024/exhibit31amendedandres.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/20/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt">Specimen Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as amended</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-96335</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/7/2000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit42.htm">Description of the Common Stock of Exelixis, Inc. Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001409/0001012870-00-001409.txt">Form of Indemnity Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1,<br/>as amended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-96335</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/17/2000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000170/def14a-20160413xproxy.htm">Exelixis, Inc. 2000 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 14A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/13/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit101.htm">Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit102.htm">Form of Stock Option Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit104.htm">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit105.htm">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit102.htm">Exelixis, Inc. 2016 Inducement Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm">Form of Stock Option Agreement under the 2016 Inducement Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/22/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm">Form of Restricted Stock Unit Agreement under the 2016 Inducement Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/22/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit103.htm">Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20201231exhibit1011.htm">Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1022.htm">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit105.htm">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000117/exel20200630exhibit106.htm">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000068/exel20200331exhibit104.htm">Non-Employee Director Equity Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/5/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904022709/a04-8650_1ex10d43.htm">Offer Letter Agreement, dated February 3, 2000, between Exelixis, Inc. and Michael Morrissey, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/5/2004</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976715000102/exel20150930exhibit105.htm">Offer Letter Agreement, dated June 30, 2015, between Exelixis, Inc. and Christopher Senner</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/10/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000119312506135893/dex101.htm">Offer Letter Agreement, dated June&#160;20, 2006, between Exelixis, Inc. and Gisela M. Schwab,&#160;M.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/26/2006</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000018/exel20140331exhibit104.htm">Offer Letter Agreement, dated February 10, 2014, between Exelixis, Inc. and Jeffrey J. Hessekiel.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000149/exel20151231exhibit1024.htm">Offer Letter Agreement, dated August 11, 2000, between Exelixis, Inc. and Peter Lamb.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/29/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1026.htm">Offer Letter Agreement, dated August 19, 2010, between Exelixis, Inc. and Patrick J. Haley</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000013/exel20180212exhibit101.htm">Annual Cash Bonus Compensation Plan for Executives</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/16/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1029.htm">Cash Compensation Information for Non-Employee Directors.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000069/exel20180331exhibit105.htm">Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/2/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000109/exel20190331exhibit104.htm">Policy for Recoupment of Variable Compensation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000137/exel20170630exhibit101.htm">Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1039.htm">First Amendment dated October 16, 2017, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit102.htm">Second Amendment dated June 13, 2018, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000090/exel20190401exhibit101.htm">Third Amendment dated April 1, 2019, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/5/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000190/exel20190930exhibit102.htm">Fourth Amendment dated August 30, 2019, to Lease Agreement dated May 2, 2017, between Hillwood Enterprises, L.P. (as successor in interest to Ascentris 105, LLC) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/30/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1037.htm">Fifth Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Waterfront EDP, LLC (as successor in interest to Hillwood Enterprises, L.P.) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20201231exhibit1032.htm">Sixth Amendment dated December 11, 2020, to Lease Agreement dated May 2, 2017, between SCG Harbor Bay Parkway Phase I, LLC (as successor in interest to Waterfront EDP, LLC) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000190/exel20190930exhibit103.htm">Lease Agreement dated October 25, 2019, between Ernst Development Partners, Inc. and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/30/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1039.htm">First Amendment dated January 16, 2020, to Lease Agreement dated May 2, 2017, between Alameda BTS EDP, LLC (as successor in interest to Ernst Development Partners, Inc.) and Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000260/exel20160331exhibit103-ame.htm">Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1049.htm">First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000183/exel20170930exhibit102.htm">Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/1/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1046.htm">Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000260/exel20160331exhibit104-ame.htm">Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000023/exel20171231exhibit1048.htm">First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000157/exel20190630exhibit102.htm">Second Amendment dated May 17, 2019, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000126/exel2017033110-qaexhibit101.htm">Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/14/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000136/exel20180630exhibit101.htm">First Amendment dated March 22, 2018, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000157/exel20190630exhibit103.htm">Second Amendment dated May </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000157/exel20190630exhibit103.htm">7, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/939767/000093976720000150/exel20200930exhibit101.htm">Third Amendment dated September 3, 2020, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/5/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976720000035/exel20191231exhibit1062.htm">Joint Clinical Research Agreement dated December 18, 2019, by and between Exelixis, Inc. and F. Hoffmann-La Roche Ltd</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20201231exhibit211.htm">Subsidiaries of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20201231exhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_175">Power of Attorney (contained on signature page)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.840%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20201231exhibit311.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20201231exhibit312.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20201231exhibit321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formatted as Inline XBRL and contained in Exhibit 101.</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8224;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment granted for certain portions of this exhibit.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Annual Report on Form 10-K, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_172"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;None provided.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i68bf8bfb5b59421792b5711a409e9ffd_175"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that each person whose signature appears below constitutes and appoints </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MICHAEL M. MORRISSEY</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHRISTOPHER J. SENNER </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> JEFFREY J. HESSEKIEL </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signatures</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, President and</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Chief&#160;Executive&#160;Officer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Executive&#160;Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HRISTOPHER</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ENNER</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Chief&#160;Financial&#160;Officer </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 10, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Financial and</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounting&#160;Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TELIOS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> P</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">APADOPOULOS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stelios Papadopoulos, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HARLES</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OHEN&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charles Cohen, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;C</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. F</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ELDBAUM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carl B. Feldbaum, Esq.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARIA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. F</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">REIRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maria C. Freire, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i68bf8bfb5b59421792b5711a409e9ffd_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;A</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LAN</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. G</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARBER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alan M. Garber, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;V</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">INCENT</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> T. M</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARCHESI&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vincent T. Marchesi, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;G</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EORGE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> P</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSTE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">George Poste, DVM, Ph.D., FRS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ULIE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. S</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MITH&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Julie A. Smith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;L</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ANCE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILLSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 9, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lance Willsey, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACK</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. W</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">YSZOMIERSKI&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 8, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jack L. Wyszomierski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>exel20201231exhibit1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iba9d4ba3399247468e15c487b9b452c6_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.11</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2017 Equity Incentive Plan</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Option Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Incentive Stock Option or Nonstatutory Stock Option)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to your Notice of Grant of Stock Option (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and this Option Agreement and in consideration of your services, Exelixis, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has granted you an option under its 2017 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to purchase the number of shares of the Company&#8217;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Your option is granted to you effective as of the Date of Grant set forth in the Grant Notice. This Option Agreement shall be deemed to be agreed to by the Company and you upon the signing or electronically accepting by you of the Grant Notice to which it is attached. Capitalized terms not explicitly defined in this Option Agreement shall have the same meanings given to them in the Plan. In the event of any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan shall control. The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the limitations contained herein, your option will vest as provided in your Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Number Of Shares And Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to time for Capitalization Adjustments. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Exercise Restriction For Non-Exempt Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (i.e., a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Non-Exempt Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant specified in your Grant Notice, notwithstanding any other provision of your option. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Method Of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Payment of the exercise price is due in full upon exercise of all or any part of your option. You may elect to make payment of the exercise price in cash or by check or by any of the following methods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> unless prohibited by your Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">interests, with a Fair Market Value on the date of exercise that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by such delivery in cash or other permitted form of payment. Notwithstanding the foregoing, you may not exercise your option by tender to the Company of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#8217;s stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Subject to the consent of the Company and&#47;or the Committee, as applicable, at or prior to the time of exercise, if your option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Company shall accept a cash or other payment from you to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided further, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter to the extent that (1) shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (2) shares are delivered to you as a result of such exercise, and (3) shares are withheld to satisfy tax withholding obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Whole Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You may exercise your option only for whole shares of Common Stock. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Securities Law Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You may not exercise your option before the commencement or after the expiration of its term. The term of your option commences on the Date of Grant and expires upon the earliest of the following&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">immediately upon the termination of your Continuous Service for Cause&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">three (3) months after the termination of your Continuous Service for any reason other than Cause, Disability or death, provided that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section above relating to &#8220;Securities Law Compliance,&#8221; your option shall not expire until the earlier of the expiration date indicated in your Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or until it shall have been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service&#59; and provided further that if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant specified in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">your Grant Notice, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option shall not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant specified in your Grant Notice or (B) the date that is three (3) months after the termination of your Continuous Service, or (y) the Expiration Date&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">twelve (12) months after the termination of your Continuous Service due to your Disability&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">eighteen (18) months after your death if you die during your Continuous Service&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the Expiration Date indicated in your Grant Notice. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing, if you die during the period provided in Section 7(b) or 7(c) above, the term of your option shall not expire until the earlier of eighteen (18) months after your death or the Expiration Date indicated in your Grant Notice. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your option and ending on the day three (3) months before the date of your option&#8217;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment with the Company or an Affiliate terminates. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">You may exercise the vested portion of your option during its term by delivering a notice (in a form designated by the Company) or taking such other action as the Company may require together with delivering the exercise price to the Secretary of the Company, or to such other person as the Company may designate (such as any broker designated by the Company to effect option exercises) during regular business hours, together with such additional documents as the Company may then require. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company or any Affiliate of any tax withholding obligation of the Company or any Affiliate arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Certain Trusts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust, provided that you and the trustee enter into transfer and other agreements required by the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Domestic Relations Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order, official marital settlement agreement or other divorce or separation instrument to help ensure the required information is contained within the domestic relations order, official marital settlement agreement or other divorce or separation instrument. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Beneficiary Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. By delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company and any broker designated by the Company to effect option exercises, you may designate a third party who, in the event of your death, shall thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate shall be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Option Not A Service Contract. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Your Continuous Service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the Company or an Affiliate at any time, for any reason, with or without cause and with or without notice. Nothing in this Option Agreement (including, but not limited to, the vesting of your option pursuant to the schedule set forth in Section 1 herein or the issuance of the shares upon exercise of your option), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Option Agreement or the Plan shall&#58; (i) confer upon you any right to continue in the employ of, or affiliation with, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company or an Affiliate&#59; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation&#59; (iii) confer any right or benefit under this Option Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Option Agreement or Plan&#59; or (iv) deprive the Company or an Affiliate of the right to terminate you at will and without regard to any future vesting opportunity that you may have. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">By accepting this option, you acknowledge and agree that the right to continue vesting in the option pursuant to the schedule set forth in Section 1 is earned only by continuing as an employee, director or consultant at the will of the Company or an Affiliate (not through the act of being hired, being granted this option or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a &#8220;reorganization&#8221;). You further acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Option Agreement, including but not limited to, the termination of the right to continue vesting in the option. You further acknowledge and agree that this Option Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement as an employee or consultant for the term of this Option Agreement, for any period, or at all, and shall not interfere in any way with your right or the Company&#8217;s or an Affiliate&#8217;s right to terminate your Continuous Service at any time, with or without cause and with or without notice. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Withholding Obligations. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and&#47;or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate which arise in connection with the exercise of your option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Additionally, the Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your option by any of the following means or by a combination of such means&#58; (i) withholding from any compensation otherwise payable to you by the Company or an Affiliate&#59; (ii) causing you to tender a cash payment&#59; or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the exercise of your option with a Fair Market Value equal to the amount of such Withholding Taxes&#59; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of your option as a liability for financial accounting purposes).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to this Section 11 shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">You may not exercise your option unless the tax withholding obligations of the Company and&#47;or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock unless such obligations are satisfied. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Tax Consequences</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#8220;fair market value&#8221; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notices provided for in your option or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Governing Plan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your option and those of the Plan, the provisions of the Plan shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Other Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;6.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company&#8217;s insider trading policy, including the policy permitting officers and directors to sell shares only during certain &#8220;window&#8221; periods, in effect from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Miscellaneous. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The rights and obligations of the Company under your option shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns. Your rights and obligations under your option may only be assigned with the prior written consent of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">This Option Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">All obligations of the Company under the Plan and this Option Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and&#47;or assets of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Effect On Other Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The value of the option subject to this Option Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating the Employee&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Choice Of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The interpretation, performance and enforcement of this Option Agreement will be governed by the law of the state of California without regard to such state&#8217;s conflicts of laws rules. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;7.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 21(g), this Option Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company. Notwithstanding the foregoing, this Option Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Option Agreement, so long as a copy of such amendment is delivered to you, and provided that no such amendment materially impairing your rights hereunder may be made without your written consent, except as otherwise provided in Section 21(g). Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Option Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of your option which is then subject to restrictions as provided herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Clawback&#47;Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You acknowledge and agree that, notwithstanding anything to the contrary in this Option Agreement or the Grant Notice but subject to applicable law, to the extent that any Clawback Policy (as defined below) is applicable to your option&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Your option, any shares issued (or issuable) or other compensation paid (or payable) pursuant to your option, and any gains you realize with respect to the sale of any shares issued pursuant to your option (in an amount determined by the Board in its discretion) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Option Gains</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) are subject to recoupment in accordance with the following (each of which will be considered a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; for purposes of this Option Agreement)&#58; (i) the Exelixis, Inc. Policy for Recoupment of Variable Compensation, adopted by the Board on February 28, 2019 and as may be amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Variable Compensation Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and (ii) any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">For purposes of any Clawback Policy, your option, any shares issued (or issuable) or other compensation paid (or payable) pursuant to your option, and any Option Gains are not earned until no longer subject to recoupment in accordance with such Clawback Policy&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">As a condition to the grant of your option&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You expressly agree and consent to the Company&#8217;s application, implementation and enforcement of any Clawback Policy and any provision of applicable law relating to cancellation, recoupment, rescission or payback of compensation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You expressly agree that the Company may take such actions as are necessary or appropriate to effectuate any Clawback Policy or applicable law without any further consent or action being required by you&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of the foregoing, you expressly and explicitly authorize the Company to issue instructions, on your behalf, to any brokerage firm and&#47;or third party administrator engaged by the Company to hold any shares issued pursuant to your option and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;8.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any other amounts acquired pursuant to your option and&#47;or to re-convey, transfer or otherwise return such shares and&#47;or other amounts to the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">The Company has provided you with a copy of the Variable Compensation Clawback Policy&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In the event of any conflict between the terms of your option (including this Section 21) and any Clawback Policy, the terms of such Clawback Policy will control&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">In the event that your option is subject to more than one Clawback Policy, the Clawback Policy with the most restrictive recoupment provisions (as applied to your option) will control&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Option Agreement may be unilaterally amended by the Board (without your consent) at any time to comply with any Clawback Policy, as it may be amended from time to time. </font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;9.</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>3
<FILENAME>exel20201231exhibit1032.htm
<DESCRIPTION>EX-10.32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3e8fac68025e488fa7235d7aaf687244_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.32</font></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIXTH AMENDMENT TO LEASE AGREEMENT</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS SIXTH AMENDMENT TO LEASE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of December 11, 2020, by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC. a Delaware corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;Landlord (as successor in interest to Ascentris 105, LLC, a Colorado limited liability company) and Tenant are parties to that certain Lease Agreement, dated May 2, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Original Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which Original Lease has been previously amended by that certain First Amendment to Lease Agreement dated October 16, 2017, that certain Second Amendment to Lease Agreement dated June 13, 2018, that certain Third Amendment to Lease Agreement dated April 1, 2019, that certain Fourth Amendment to Lease Agreement dated August 30, 2019 and that certain Fifth Amendment to Lease Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fifth Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) dated January 16, 2020 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Pursuant to the Lease, Landlord has leased to Tenant space currently containing approximately </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">228,941 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rentable square feet (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Original Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) described as (i) 37,544 rentable square feet comprising the entire building located at 1601 Harbor Bay Parkway, (ii) 59,335 rentable square feet comprising the entire building located at 1701 Harbor Bay Parkway, (iii) 58,417 rentable square feet comprising the entire building located at 1801 Harbor Bay Parkway, (iv) 57,476 rentable square feet comprised of the entire building located at 1851 Harbor Bay Parkway, and (v) 16,169 comprised of Suites 150 and 225 of the building located at 1751 Harbor Bay Parkway (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1751 Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;Tenant has requested that additional space containing approximately </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">25,749 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rentable square feet described as Suite 100 on the first floor of the 1751 Building shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit&#160;A-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expansion Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) be added to the Original Premises and that the Lease be appropriately amended and Landlord is willing to do the same on the following terms and conditions.</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows&#58;</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Expansion and Effective Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Effective as of the date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expansion Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that is the later of (i) June 1, 2021 and (ii) sixty (60) days following the Expansion Delivery Date (defined below), the Original Premises is increased from approximately </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">228,941 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> rentable square feet of the Project to approximately </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">254,690 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">rentable square feet of the Project by the addition of the Expansion Space, and from and after the Expansion Effective Date, the Original Premises and the Expansion Space, collectively, shall be deemed the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, as defined in the Lease, and as used herein.  The Term for the Expansion Space shall commence on the Expansion Effective Date and end on the Expiration Date unless sooner terminated in accordance with the terms of the Lease, as amended hereby. The Expansion Space is subject to all the terms and conditions of the Lease except as expressly modified herein. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expansion Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the date on which Landlord tenders possession of the Expansion Space to Tenant in its current condition and configuration (normal wear and tear excepted) free from occupancy by any party and in good, vacant, broom clean condition.  The Expansion Delivery Date is anticipated to occur on April&#160;1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Estimated Expansion Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  During the period beginning on the Expansion Delivery Date and ending on the date immediately preceding the Expansion Effective Date, all provisions of the Lease relating to the Expansion Space shall apply as if the Expansion Effective Date had occurred&#59; provided, however, that during such period Tenant shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">not be required to pay Rent for the Expansion Space other than the payment of Operating Expenses and other charges for services requested by Tenant with respect to the Expansion Space pursuant to the applicable provisions of the Lease. Any delay in the Expansion Delivery Date shall not subject Landlord to any liability for any loss or damage resulting therefrom.  If the Expansion Delivery Date is delayed, the Expiration Date under the Lease shall not be similarly extended.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord acknowledges that the Expansion Space is currently occupied by a tenant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Existing Expansion Space Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) pursuant to a lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Existing Expansion Space Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with a term expiring on March 31, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Existing Expansion Space Lease Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Landlord shall use commercially reasonable efforts to cause the Existing Expansion Space Tenant to surrender and vacate the Expansion Space on or prior to the Existing Expansion Space Lease Expiration Date with the Expansion Space in its current configuration and otherwise in the condition required by the Existing Expansion Space Lease.  If the Existing Expansion Space Tenant does not so surrender the Expansion Space by the Existing Expansion Space Lease Expiration Date, then Landlord shall use commercially reasonable efforts to cause the Existing Expansion Space Tenant to so surrender and vacate the Expansion Premises, including, without limitation, promptly commencing and pursuing unlawful detainer and eviction proceedings if the Existing Expansion Space Tenant fails to surrender and vacate the Expansion Premises by April 30, 2021.  Notwithstanding anything to the contrary in this Amendment, if Landlord fails to cause the Expansion Delivery Date to occur for any reason by the date that is one hundred twenty (120) days after the Estimated Expansion Delivery Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Outside Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then Tenant shall be entitled to an abatement of Base Rent for the Expansion Space following the Expansion Effective Date in an amount equal to $1,735.41 for every day in the period beginning on the Outside Delivery Date and ending on the Expansion Delivery Date.  Landlord and Tenant acknowledge and agree that the Outside Delivery Date shall not be postponed by the number of days the Expansion Delivery Date is delayed due to strikes, acts of God, shortages of labor or materials, war, terrorist acts, civil disturbances, governmental orders, and other causes beyond the reasonable control of Landlord.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Base Rent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  In addition to Tenant&#8217;s obligation to pay Base Rent for the Original Premises, Tenant shall pay Landlord Base Rent for the Expansion Space as follows&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:31.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Period</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rentable Square Footage</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Monthly Rate per Square Foot</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Annual Rate Per Square Foot</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Annual Rent</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Monthly Base Rent</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expansion Effective Date  -  Month 12</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.05</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$24.60</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$633,425.40</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$52,785.45</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 13 &#8211; Month 24</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.11</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$25.32</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$651,964.68</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$54,330.39</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 25 &#8211; Month 36</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.17</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$26.04</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$670,503.96</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$55,875.33</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 37 &#8211; Month 48</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.24</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$26.88</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$692,133.12</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$57,677.76</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 49 &#8211; Month 60</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.31</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$27.72</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$713,762.28</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$59,480.19</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 61 &#8211; Month 72</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.38</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$28.56</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$735,391.44</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$61,282.62</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 73 &#8211; Month 84</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.45</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$29.40</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$757,020.60</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$63,085.05</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 85 &#8211; Month 96</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.52</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$30.24</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$778,649.76</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$64,887.48</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 97 &#8211; Month 108</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.60</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$31.20</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$803,368.80</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$66,947.40</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 109 &#8211; Month 120</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.68</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$32.16</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$828,087.84</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$69,007.32</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Month 121 &#8211; October&#160;31, 2031</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$2.76</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$33.12</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$852,806.88</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$71,067.24</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All such Base Rent shall be payable by Tenant in accordance with the terms of the Lease, as amended hereby.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything in this Lease to the contrary, Tenant shall be entitled to an abatement of Base Rent solely with respect to the Expansion Space in the amount of $52,785.45 per month for the first four full month(s) of the Term with respect to the Expansion Space (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Abated Expansion Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).&#160; Only Base Rent with respect to the Expansion Space shall be abated pursuant to this Section, as more particularly described herein, and Base Rent for the Original Premises, Operating Expenses for the entire Premises (including the Expansion Space), all other Rent and other costs and charges specified in the Lease, as amended hereby, shall remain as due and payable pursuant to the provisions of the Lease, as amended hereby.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Security Deposit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  No additional Security Deposit shall be required in connection with this Amendment.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant&#8217;s Share.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  For the period commencing with the Expansion Effective Date and ending on the Expiration Date, Tenant's Building Share for the Expansion Space is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">34.86%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and Tenant&#8217;s Project Share for the Expansion Space is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.67%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Accordingly, Tenant's Building Share is increased to 56.76% of the 1751 Building and Tenant&#8217;s Project Share is 65.99%. </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Rentable Area of the Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective as of the Expansion Effective Date, the last paragraph of Section 1.1(d) of the Lease is hereby amended by replacing the Rentable Area table set forth in Exhibit A of the Lease, as previously replaced, with the Rentable Area table attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Improvements to Expansion Space.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condition of Expansion Space.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Except as otherwise provided in this Amendment and the Lease, Tenant agrees to accept the same in its current condition and configuration (normal wear and tear excepted), but otherwise &#8220;as is&#8221; without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements.  Notwithstanding the foregoing, Landlord agrees that the base Building electrical, heating, ventilation and air conditioning, plumbing, fire&#47;life safety and other systems located in and&#47;or serving the Expansion Space shall be in good working order as of the Expansion Delivery Date.  Except to the extent caused by the acts or omissions of Tenant or any of Tenant&#8217;s employees, agents, contractors, representatives or invitees, or by any alterations or improvements performed by or on behalf of Tenant, if such systems are not in good working order as of the date possession of the Expansion Space is delivered to Tenant and Tenant provides Landlord with notice of the same within ninety (90) days following the date Landlord delivers possession of the Expansion Space to Tenant, Landlord shall be responsible for repairing or restoring the same at Landlord&#8217;s sole cost and not as an Operating Expense.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Responsibility for Improvements to Expansion Space.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Any construction, alterations or improvements to the Expansion Space shall be performed by Tenant in accordance with the Lease and this Amendment, including the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Other Pertinent Provisions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Landlord and Tenant agree that, effective as of the date of this Amendment (unless different effective date(s) is&#47;are specifically referenced in this Section), the Lease shall be amended in the following additional respects&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord&#8217;s Manager&#8217;s Address.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Landlord&#8217;s Manager&#8217;s Address set forth in Section 1.1(m) of the Original Lease is hereby deleted and replaced with the following&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCG Harbor Bay Parkway Phase I, LLC</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c&#47;o JLL</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1701 Harbor Bay Parkway, Suite 150</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alameda, CA 94502</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord&#8217;s General Address.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord&#8217;s General Address set forth in Section 1.1(n) of the Original Lease is hereby deleted and replaced with the following&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCG Harbor Bay Parkway Phase I, LLC</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c&#47;o Stockbridge Capital Group</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Four Embarcadero Center, Suite 3300</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Francisco, CA 94111</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Asset Manager</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord&#8217;s Payment Address.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Landlord&#8217;s Payment Address set forth in Section 1.1(o) of the Original Lease is hereby deleted and replaced with the following&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">By ACH Transfer&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">XXXXXX</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">By Domestic Wire&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">XXXXXX</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">By Lockbox&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">XXXXXX</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Parking.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Effective as of the Expansion Effective Date, Tenant&#8217;s unreserved parking spaces shall be increased by seventy-seven (77) unreserved parking spaces at no charge to Tenant for a total of 764 unreserved parking spaces for the Premises.  Except as modified herein, the use of such unreserved parking spaces shall be subject to the terms of the Lease.  Landlord agrees that if all or any portion of the parking lots serving the Project are restriped in a manner that creates additional parking and such additional parking is not needed to satisfy the parking requirements for the BTS Site (as defined in the Fifth Amendment), then such excess parking spaces shall be automatically added to Tenant&#8217;s parking rights under the Lease until Tenant&#8217;s allocated parking at the Project is in accordance with the Targeted Parking Allocation (as defined in the Fifth Amendment).</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Landlord, at its sole cost and expense, shall provide Tenant with initial Building standard signage in the 1751 Building&#8217;s lobby, tenant directory and exterior tenant directory. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Generator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.1&#160;&#160;&#160;&#160;Tenant, shall have the right to use the existing generator serving the Expansion Space (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Generator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;) and the existing above ground fuel tank (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to provide emergency additional electrical capacity to the Expansion Space during the Term.&#160; The Generator and the Tank is in the location outlined on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">attached hereto and made a part hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Generator Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).&#160; Tenant accepts the Generator in its as-is condition as of the Expansion Effective Date, and Landlord makes no warranties or representations to Tenant as to the condition of the Generator or the Tank.&#160; Tenant shall comply with all applicable Laws, including Environmental Laws, pertaining to Tenant&#8217;s use of the Generator Area.&#160; Tenant shall also be responsible for the cost of all utilities consumed in the operation of the Generator and the Tank.&#160; </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.2&#160;&#160;&#160;&#160;Tenant shall be responsible for assuring that the maintenance, operation and removal of the Generator and the Tank shall in no way damage any portion of the Building or Project.&#160; To the maximum extent permitted by Laws, Landlord shall have no liability to Tenant if the Generator, the Tank or any appurtenances installations are damaged for any reason. Subject to the provisions of Section 9.3 of the Lease, Tenant agrees to be responsible for any damage caused to the Building in connection with the maintenance, operation or removal of the Generator by Tenant and, to indemnify, defend and hold Landlord and the Landlord Parties harmless from all liabilities, obligations, damages, penalties, claims, costs, charges and expenses, including, without limitation, reasonable architects' and attorneys' fees (if and to the extent permitted by Laws), which may be imposed upon, incurred by, or asserted against Landlord or any of the Landlord Parties in connection with the maintenance, operation or removal of the Generator and the Tank by Tenant, including, without limitation, any environmental and hazardous materials claims&#59; provided, that Landlord shall not be released or indemnified from any such liabilities, obligations, damages, penalties, claims, costs, charges and expenses arising from the maintenance, operation or location of the Generator and the Tank prior to the Expansion Delivery Date, including, without limitation, any environmental and hazardous materials claims arising from the maintenance, operation or location of the Generator and the Tank prior to the Expansion Delivery Date.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3&#160;&#160;&#160;&#160;Tenant shall be responsible for the operation, cleanliness, maintenance and removal of the Generator and the Tank and the appurtenances, all of which shall remain the personal property of Tenant, and shall be removed by Tenant at its own expense at the expiration or earlier termination of the Lease.&#160; Tenant shall repair any damage caused by such removal, including the patching of any holes to match, as closely as possible, the color surrounding the area where the Generator, Tank and appurtenances were attached. Such maintenance and operation shall be performed in a manner to avoid any unreasonable interference with any other tenants or Landlord.&#160;&#160; Tenant shall have no right to make any changes, alterations, additions, decorations or other improvements to the Generator Area without Landlord&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. Tenant agrees to maintain the Generator and the Tank, including without limitation, any enclosure installed around the Generator and the Tank in good condition and repair.&#160; Tenant shall be responsible for performing any maintenance and improvements to any enclosure surrounding the Generator and the Tank so as to keep such enclosure in good condition.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.4&#160;&#160;&#160;&#160;Tenant, subject to the rules and regulations enacted by Landlord, shall have access to the Generator and the Tank and its surrounding area for the purpose of installing, repairing, maintaining and removing said Generator and the Tank.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.5&#160;&#160;&#160;&#160;Tenant shall be permitted to use the Generator Area solely for the maintenance and operation of the Generator and the Tank, and the Generator, Tank and Generator Area are solely for the benefit of Tenant.&#160; All electricity generated by the Generator may only be consumed by Tenant in the Expansion Space.  Landlord shall have no obligation to provide any services, including, without limitation, electric current, to the Generator Area.  Tenant shall have no right to sublet the Generator Area or to assign its interest therein except in connection with an assignment or sublease of the Expansion Space.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Miscellaneous.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.1&#160;&#160;&#160;&#160;This Amendment, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Outline and Location of Expansion Space) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto, sets forth the entire agreement between the parties with respect to the matters set forth herein.  There have been no additional oral or written representations or agreements.  </font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.2&#160;&#160;&#160;&#160;Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.  In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control.  The capitalized terms used in this Amendment shall have the same definitions as set forth in the Lease to the extent that such capitalized terms are defined therein and not redefined in this Amendment.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.3&#160;&#160;&#160;&#160;Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant.  Landlord shall not be bound by this Amendment until Landlord has executed and delivered the same to Tenant.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.4&#160;&#160;&#160;&#160;Landlord and Tenant each hereby represents that each has dealt with no broker other than Kidder Mathews, representing Tenant, and Cushman &#38; Wakefield of California, Inc., representing Landlord, in connection with this Amendment.  Tenant agrees to indemnify and hold Landlord, its members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) harmless from all claims of any other brokers claiming to have represented Tenant in connection with this Amendment.  Landlord shall pay Kidder Mathews and Cushman &#38; Wakefield of California, Inc. a market brokerage commission pursuant to a separate written agreement.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.5&#160;&#160;&#160;&#160;Each of Landlord and Tenant represents hereby that the individuals executing this Amendment on its behalf have the authority to execute and deliver the same on behalf of the party hereto for which such signatory is acting.  Tenant hereby represents and warrants that Tenant is not (i) the target of any sanctions program that is established by Executive Order of the President or published by the Office of Foreign Assets Control, U.S. Department of the Treasury (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; (ii) designated by the President or OFAC pursuant to the Trading with the Enemy Act, 50 U.S.C. App.  &#167; 5, the International Emergency Economic Powers Act, 50 U.S.C. &#167;&#167; 1701-06, the Patriot Act, Public Law 107-56, Executive Order 13224 (September 23, 2001) or any Executive Order of the President issued pursuant to such statutes&#59; or (iii) named on the following list that is published by OFAC&#58; &#8220;List of Specially Designated Nationals and Blocked Persons.&#8221; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.6&#160;&#160;&#160;&#160;Signatures to this Amendment transmitted by telecopy or electronic signatures shall be valid and effective to bind the party so signing.&#160; This Amendment may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and same agreement.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.7&#160;&#160;&#160;&#160;If Tenant (or any party claiming by, through or under Tenant) pays directly to the provider for any energy consumed at the Building, Tenant, promptly upon request, shall deliver to Landlord (or, at Landlord&#8217;s option, execute and deliver to Landlord an instrument enabling Landlord to obtain from such provider) any data about such consumption that Landlord, in its reasonable judgment, is required to disclose to a prospective buyer, tenant or mortgage lender under California Public Resources Code &#167;&#160;25402.10 or any similar law.</font></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.8&#160;&#160;&#160;&#160;Pursuant to California Civil Code Section 1938, Landlord hereby notifies Tenant that as of the date of this Amendment, the Premises have not undergone inspection by a &#8220;Certified Access Specialist&#8221; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CASp</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to determine whether the Premises meet all applicable construction-related accessibility standards under California Civil Code Section 55.53.&#160; Landlord hereby discloses pursuant to California Civil Code Section 1938 as follows&#58; &#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant.  The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#8221;&#160; Landlord and Tenant hereby acknowledge and agree that in the event that Tenant elects to perform a CASp inspection of the Premises hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inspection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), such Inspection shall be (a) performed at Tenant&#8217;s sole cost and expense, (b) limited to the Premises and (c) performed by a CASp who has been approved or designated by Landlord prior to the Inspection.  Any Inspection must be performed in a manner which minimizes the disruption of business activities in the Building, and at a time reasonably approved by Landlord.  Landlord reserves the right to be present during the Inspection.  Tenant agrees to&#58; (i) promptly provide to Landlord a copy of the report or certification prepared by the CASp inspector upon request (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (ii) keep the information contained in the Report confidential, except to the extent required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or to the extent disclosure is needed in order to complete any necessary modifications or improvements required to comply with all applicable accessibility standards under state or federal Law, as well as any other repairs, upgrades, improvements, modifications or alterations required by the Report or that may be otherwise required to comply with applicable Laws or accessibility requirements  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Access Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  If Tenant performs an Inspection, Tenant shall be solely responsible for the cost of Access Improvements to the Premises or the Building necessary to correct any such violations of construction-related accessibility standards identified by such Inspection as required by Law, which Access Improvements may, at Landlord&#8217;s option, be performed in whole or in part by Landlord at Tenant&#8217;s expense, payable as Additional Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">within ten (10) days following Landlord&#8217;s demand.&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Landlord and Tenant have duly executed this Amendment as of the day and year first above written.</font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:52.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LANDLORD&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TENANT&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SCG HARBOR BAY PARKWAY PHASE I, LLC,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">a Delaware limited liability company</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXELIXIS, INC. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">a Delaware corporation </font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Meghan Concannon</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Michael M. Morrissey</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;  Meghan Concannon</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Michael M. Morrissey</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;  Vice President</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;  President and  Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58; 12&#47;14&#47;2020</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58; 12&#47;11&#47;2020</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;9</font></div></div></div><div id="i3e8fac68025e488fa7235d7aaf687244_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A - OUTLINE AND LOCATION OF EXPANSION SPACE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">attached to and made a part of the Amendment dated as of December 11, 2020, between SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company, as Landlord and EXELIXIS, INC. a Delaware corporation, as Tenant</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is intended only to show the general layout of the Expansion Space as of the beginning of the Expansion Effective Date.  It does not in any way supersede any of Landlord&#8217;s rights set forth in the Lease with respect to arrangements and&#47;or locations of public parts of the Building and changes in such arrangements and&#47;or locations.  It is not to be scaled&#59; any measurements or distances shown should be taken as approximate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><img alt="image_01.jpg" src="image_01.jpg" style="height:624px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;A-1</font></div></div></div><div id="i3e8fac68025e488fa7235d7aaf687244_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT A-2 &#8211; PLANS SHOWING THE PREMISES AND TABLE OF RENTABLE AREAS OF THE PREMISES</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">attached to and made a part of the Amendment dated as of December 11, 2020, between SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company, as Landlord and EXELIXIS, INC. a Delaware corporation, as Tenant</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><img alt="image_11.jpg" src="image_11.jpg" style="height:581px;margin-bottom:5pt;vertical-align:text-bottom;width:686px"></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_21.jpg" src="image_21.jpg" style="height:564px;margin-bottom:5pt;vertical-align:text-bottom;width:699px"></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_31.jpg" src="image_31.jpg" style="height:576px;margin-bottom:5pt;vertical-align:text-bottom;width:656px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><img alt="image_41.jpg" src="image_41.jpg" style="height:586px;margin-bottom:5pt;vertical-align:text-bottom;width:654px"></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><img alt="image_51.jpg" src="image_51.jpg" style="height:585px;margin-bottom:5pt;vertical-align:text-bottom;width:645px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_61.jpg" src="image_61.jpg" style="height:934px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_71.jpg" src="image_71.jpg" style="height:885px;margin-bottom:5pt;vertical-align:text-bottom;width:668px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Table of Rentable Areas of The Premises</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Building</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Suite</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Building RSF</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Premises RSF</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1601</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">37,544</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">37,544</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1701</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,335</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,140</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1701</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">125</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,335</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,355</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1701</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">115-200</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,335</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,858</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1701</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">150</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,335</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">982</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1751</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">150-225</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">73,854</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,169</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1751</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">73,854</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,749</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1801</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">58,417</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">58,417</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1851</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">57,476</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">57,476</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total RSF of Premises&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">254,690</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;A-2</font></div></div></div><div id="i3e8fac68025e488fa7235d7aaf687244_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT B &#8211; TENANT ALTERATIONS</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">attached to and made a part of the Amendment dated as of December 11, 2020, between SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company, as Landlord and EXELIXIS, INC. a Delaware corporation, as Tenant</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As used in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the &#8220;Premises&#8221; shall be deemed to mean the Expansion Space, as defined in the Amendment to which this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is attached.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant shall have the right to perform alterations and improvements in the Premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant Alterations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the Lease, provided, however, that the provisions of Exhibit B to the Original Lease, as modified, shall not apply to the Tenant Alterations.  Notwithstanding the foregoing, Tenant and its contractors shall not have the right to perform the Tenant Alterations in the Premises unless and until Tenant has complied with all of the terms and conditions of Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the Original Lease, including, without limitation, approval by Landlord of the final plans for the Tenant Alterations and the contractors to be retained by Tenant to perform such Tenant Alterations. Tenant shall be responsible for all elements of the design of Tenant&#8217;s plans (including, without limitation, compliance with law, functionality of design, the structural integrity of the design, the configuration of the Premises and the placement of Tenant&#8217;s furniture, appliances and equipment), and Landlord&#8217;s approval of Tenant&#8217;s plans shall in no event relieve Tenant of the responsibility for such design.  In addition to the foregoing and except as otherwise provided in the Amendment and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Tenant shall be solely liable for all costs and expenses associated with or otherwise caused by Tenant&#8217;s performance and installment of the Tenant Alterations (including, except as otherwise provided in the Amendment and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, without limitation, any legal compliance requirements arising outside of the Premises).  Landlord&#8217;s approval of the contractors to perform the Tenant Alterations shall not be unreasonably withheld.  If Landlord fails to respond to Tenant&#8217;s written request for approval of plans and specifications within five (5) days, Tenant shall provide a second written notice to Landlord.  Failure of Landlord to approve or disapprove any submission of plans and specification by Tenant within five (5) days following the second written notice shall be deemed to constitute approval of such submission.  The parties agree that Landlord&#8217;s approval of the general contractor to perform the Tenant Alterations shall not be considered to be unreasonably withheld if any such general contractor (a)&#160;does not have trade references reasonably acceptable to Landlord, (b)&#160;does not maintain insurance as required pursuant to the terms of the Lease, (c)&#160;does not have the ability to be bonded for the work in an amount of no less than one hundred fifty percent (150%) of the total estimated cost of the Tenant Alterations, (d)&#160;does not provide current financial statements reasonably acceptable to Landlord, (e) does not execute the Responsible Contractor Policy Statement provided by Landlord, or (f)&#160;is not licensed as a contractor in the state&#47;municipality in which the Premises is located.  Tenant acknowledges the foregoing is not intended to be an exclusive list of the reasons why Landlord may reasonably withhold its consent to a general contractor.  Notwithstanding the foregoing, Landlord shall not withhold approval of any architect, contractor or subcontractor that is currently or has previously performed alterations in the Premises and was approved by the Landlord executing this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord agrees to contribute the sum of $1,416.195.00 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) toward the cost of performing the Tenant Alterations in preparation of Tenant&#8217;s occupancy of the Premises.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Allowance may only be used for the cost of preparing design and construction documents and mechanical and electrical plans for the Tenant Alterations and for hard and soft costs in connection with the Tenant Alterations, including, without limitation, permit fees and project management fees.  The Allowance shall be paid to Tenant or, at Tenant&#8217;s request, to the order of the general contractor that performs the Tenant Alterations, in periodic disbursements within thirty (30) days after receipt of the following </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;B-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">documentation&#58; (a)&#160;an application for payment and sworn statement of contractor substantially in the form of AIA Document G-702 covering all work for which disbursement is to be made to a date specified therein&#59; (b)&#160;a certification from an AIA architect substantially in the form of the Architect&#8217;s Certificate for Payment which is located on AIA Document G702, Application and Certificate of Payment&#59; (c)&#160;contractor&#8217;s, subcontractor&#8217;s and material supplier&#8217;s waivers of liens which shall cover all Tenant Alterations for which disbursement is being requested and all other statements and forms required for compliance with the mechanics&#8217; lien laws of the state in which the Premises is located together with all such invoices, contracts, or other supporting data as Landlord or Landlord&#8217;s Mortgagee may reasonably require&#59; and (d)&#160;a request to disburse from Tenant containing an approval by Tenant of the work done.  Upon completion of the Tenant Alterations, Tenant shall furnish Landlord with&#58;  (i)&#160;general contractor and architect&#8217;s completion affidavits&#59; (ii)&#160;full and final waivers of lien&#59; and (iii)&#160; as-built plans of the Tenant Alterations.  In no event shall Landlord be required to disburse the Allowance more than one time per month.  Notwithstanding anything herein to the contrary, Landlord shall not be obligated to disburse any portion of the Allowance during the continuance of an uncured default beyond notice and cure periods under the Lease, and Landlord&#8217;s obligation to disburse shall only resume when and if such default is cured.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;In no event shall the Allowance be used for the purchase of equipment, furniture or other items of personal property of Tenant.  Landlord shall be entitled to deduct from the Allowance a construction management fee for Landlord&#8217;s oversight of the Tenant Alterations in an amount equal to one and one-half percent (1.5%) of the Allowance. Notwithstanding anything to the contrary set forth herein, Tenant shall be entitled to apply up to $128,745.00 of the Allowance as a credit against the next installment(s) of Base Rent payable by Tenant under the Lease, as amended hereby by delivery of written notice to Landlord no later than December 31, 2023.  Tenant shall be responsible for all applicable state sales or use taxes, if any, payable in connection with the Tenant Alterations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;In no event shall Tenant be required to remove the Tenant Alterations at the expiration or earlier termination of the Lease except for specialized trade fixtures and equipment installed by Tenant and designated as such on the plans and specifications submitted by Tenant for Landlord&#8217;s approval (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Specialized Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and designated by Landlord in writing for removal concurrently with Landlord&#8217;s approval of such plans and specifications. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;If, during Tenant&#8217;s construction of the Tenant Alterations, Tenant discovers within the Expansion Space any Hazardous Materials for which Tenant is not liable under the terms of the Lease, then Landlord, at Landlord&#8217;s expense, will remediate such Hazardous Materials to the extent required by applicable laws and to the extent necessary for Tenant&#8217;s use of the Expansion Space or construction of the Tenant Alterations.  If such remediation delays substantial completion of the Tenant Alterations beyond the later of the projected date of substantial completion reflected in Tenant&#8217;s construction schedule (which Tenant shall have delivered to Landlord) and the Expansion Effective Date, then Tenant shall be entitled to a per diem abatement of Base Rent for the Expansion Space for each day that substantial completion of the Tenant Alterations is actually delayed as a result of Landlord&#8217;s remediation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not be deemed applicable to any additional space added to the Premises at any time or from time to time, whether by any options under the Lease or otherwise, or to any portion of the original Premises or any additions to the Premises in the event of a renewal or extension of the original Term of the Lease, whether by any options under the Lease or otherwise, unless expressly so provided in the Lease or any amendment or supplement to the Lease.</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;B-2</font></div></div></div><div id="i3e8fac68025e488fa7235d7aaf687244_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT C &#8211; GENERATOR AREA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">attached to and made a part of the Amendment dated as of December 11, 2020, between SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company, as Landlord and EXELIXIS, INC. a Delaware corporation, as Tenant</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="image_81.jpg" src="image_81.jpg" style="height:520px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;C-1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exel20201231exhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iff0465b92f8f437997dee5bd13e45f56_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF EXELIXIS, INC.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:298.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:201.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State or Other Jurisdiction of Incorporation or Organization</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis International (Bermuda) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis Patent Company, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis Plant Sciences, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exelixis U.S., LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exel20201231exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7458c62104b94a2196a5ce3f62a41eb0_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-241667, 333-226493, 333-223225, 333-218236, 333-214766, 333-212866, 333-209824, 333-203758, 333-196761, 333-176674, 333-165389, 333-159280, 333-157825, 333-149834, 333-147063, 333-133237, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026 and 333-35862) of Exelixis, Inc. and the Registration Statement  (Form S-3 No. 333-205397) and related Prospectus of Exelixis, Inc. of our reports dated  February&#160;10, 2021, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended  January&#160;1, 2021.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young&#160;LLP</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;10, 2021</font></div><div style="margin-top:9pt"><font><br></font></div><div style="margin-top:9pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exel20201231exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i59595a36b2a947e8a01f3f347bb767f0_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-K of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;10, 2021 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exel20201231exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib986d4e4358a451284272bd8d1adfbcd_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-K of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;10, 2021 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exel20201231exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i67c2461ab0964e648ba6f0012ec4d38e_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   1. &#160;&#160;&#160;&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended January&#160;1, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In Witness Whereof, the undersigned have set their hands hereto as of the 10th day of February 2021.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. M</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. S</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNER&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>exel-20210101.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3705d550-318f-4f51-9de6-06eba39f6ea7,g:2df53114-27bb-4237-9a9c-80b7c8353f30-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20210101" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20210101">
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210101_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210101_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210101_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210101_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome">
        <link:definition>1003004 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails">
        <link:definition>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies (Greater Than 10% of Our Trade Receivables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2106102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2307302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>2408403 - Disclosure - Revenues (Revenues by Disaggregated Category) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>2409404 - Disclosure - Revenues (Net Product Revenues Disaggregated by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
        <link:definition>2410405 - Disclosure - Revenues (Revenues Disaggregated by Significant Customer) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>2411406 - Disclosure - Revenues (Revenues Disaggregated by Geographic Region) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>2412407 - Disclosure - Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>2413408 - Disclosure - Revenues (Contract Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2114103 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2315303 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails">
        <link:definition>2416409 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>2417410 - Disclosure - Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Ipsen) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails">
        <link:definition>2418411 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>2419412 - Disclosure - Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Takeda) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails">
        <link:definition>2420413 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
        <link:definition>2421414 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with Genentech) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsOtherCollaborationsNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails">
        <link:definition>2422415 - Disclosure - Collaboration Agreements (Other Collaborations, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails">
        <link:definition>2423416 - Disclosure - Collaboration Agreements (Research Collaborations and In-Licensing Arrangements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInvenraCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails">
        <link:definition>2424417 - Disclosure - Collaboration Agreements (Invenra Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsStemSynergyCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails">
        <link:definition>2425418 - Disclosure - Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>2126104 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>2327304 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2428419 - Disclosure - Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsSummarybySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails">
        <link:definition>2429420 - Disclosure - Cash and Investments (Summary by Security Type) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>2430421 - Disclosure - Cash and Investments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsGrossUnrealizedLossesDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails">
        <link:definition>2431422 - Disclosure - Cash and Investments (Gross Unrealized Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsSummarybyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails">
        <link:definition>2432423 - Disclosure - Cash and Investments (Summary by Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2133105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2334305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2435424 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2136106 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2337306 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2438425 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.exelixis.com/role/PropertyandEquipment">
        <link:definition>2139107 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyandEquipmentTables">
        <link:definition>2340307 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>2441426 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2442427 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans">
        <link:definition>2143108 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansTables" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables">
        <link:definition>2344308 - Disclosure - Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2445428 - Disclosure - Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
        <link:definition>2446429 - Disclosure - Employee Benefit Plans (Schedule of Employee Service Share - Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansNarrativeDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails">
        <link:definition>2447430 - Disclosure - Employee Benefit Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails">
        <link:definition>2448431 - Disclosure - Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails">
        <link:definition>2449432 - Disclosure - Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails">
        <link:definition>2450433 - Disclosure - Employee Benefit Plans (Summary of All Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails">
        <link:definition>2451434 - Disclosure - Employee Benefit Plans (Summary of All RSU &amp; PSU Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes">
        <link:definition>2152109 - Disclosure - Provision For (Benefit From) Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxesTables" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables">
        <link:definition>2353309 - Disclosure - Provision For (Benefit From) Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>2454435 - Disclosure - Provision For (Benefit From) Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails">
        <link:definition>2455436 - Disclosure - Provision For (Benefit From) Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails">
        <link:definition>2456437 - Disclosure - Provision For (Benefit From) Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxesNarrativeDetails" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails">
        <link:definition>2457438 - Disclosure - Provision For (Benefit From) Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>2458439 - Disclosure - Provision For (Benefit From) Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2159110 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2360310 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2461440 - Disclosure - Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails">
        <link:definition>2462441 - Disclosure - Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>2163111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesTables">
        <link:definition>2364311 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2465442 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails">
        <link:definition>2466443 - Disclosure - Commitments and Contingencies (Balance Sheet Classification of Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails">
        <link:definition>2467444 - Disclosure - Commitments And Contingencies (Components of Lease Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>2468445 - Disclosure - Commitments and Contingencies (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>2468445 - Disclosure - Commitments and Contingencies (Maturities of Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2169112 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2370312 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetails" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails">
        <link:definition>2471446 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_AffiliatesofOptumSpecialtyPharmacyMember" abstract="true" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementNumberOfPreexistingPrograms" abstract="false" name="CollaborationAgreementNumberOfPreexistingPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" abstract="false" name="CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProfitSharingTierThreeMember" abstract="true" name="ProfitSharingTierThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_PercentOfRoyaltyOnNetSale" abstract="false" name="PercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_PerformanceSharesAchievedBeforeDecember312020Member" abstract="true" name="PerformanceSharesAchievedBeforeDecember312020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementTerminationPeriod" abstract="false" name="CollaborationAgreementTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_ProductsDerivedFromCabozantinibMember" abstract="true" name="ProductsDerivedFromCabozantinibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_PerformanceShareOptionsPSOMember" abstract="true" name="PerformanceShareOptionsPSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProjectInitiationFeePayment" abstract="false" name="ProjectInitiationFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" abstract="false" name="EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SalesRevenuePercentDiscountForPromptPayment" abstract="false" name="SalesRevenuePercentDiscountForPromptPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProfitSharingTierTwoMember" abstract="true" name="ProfitSharingTierTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_RoyaltyTier" abstract="false" name="RoyaltyTier" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" abstract="false" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_GlaxoSmithKlineMember" abstract="true" name="GlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_NotProbableMember" abstract="true" name="NotProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" abstract="true" name="EarningsPerShareBasicDilutedOtherDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exel_CollaborationAgreementNumberOfPrograms" abstract="false" name="CollaborationAgreementNumberOfPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_OperatingLeaseAssetsAbstract" abstract="true" name="OperatingLeaseAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_RoyaltyTierAxis" abstract="true" name="RoyaltyTierAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_MilestonePaymentsEarned" abstract="false" name="MilestonePaymentsEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_RoyaltytierDomain" abstract="true" name="RoyaltytierDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" abstract="false" name="CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_StatusDomain" abstract="true" name="StatusDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementsUpfrontPayments" abstract="false" name="CollaborationAgreementsUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" abstract="false" name="CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementWithNBETherapeuticsMember" abstract="true" name="CollaborativeArrangementWithNBETherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" abstract="false" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementAchievedMilestoneAmount" abstract="false" name="CollaborativeArrangementAchievedMilestoneAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" abstract="false" name="DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_InvestmentsPurchasesIncurredButNotYetPaid" abstract="false" name="InvestmentsPurchasesIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_FirstProductToReachMarketMember" abstract="true" name="FirstProductToReachMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_MilestonePaymentsEarnedToDate" abstract="false" name="MilestonePaymentsEarnedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" abstract="false" name="ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" abstract="true" name="LesseeOperatingLeaseReductionOfPaymentsDueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" abstract="false" name="LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProfitSharingTierOneMember" abstract="true" name="ProfitSharingTierOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AreaOfRealEstatePropertyAvailableToLease" abstract="false" name="AreaOfRealEstatePropertyAvailableToLease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType"/>
  <xs:element id="exel_MedicarePartDFundingMandate" abstract="false" name="MedicarePartDFundingMandate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_CollaborativeAgreementsUpfrontPayments" abstract="false" name="CollaborativeAgreementsUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_InitialMember" abstract="true" name="InitialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementWithCatalentMember" abstract="true" name="CollaborativeArrangementWithCatalentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="exel_CollaborativeArrangementWithStemSynergyMember" abstract="true" name="CollaborativeArrangementWithStemSynergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborationAndLicenseAgreementTargetSelectionTerm" abstract="false" name="CollaborationAndLicenseAgreementTargetSelectionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_BuiltToSuitLeaseMember" abstract="true" name="BuiltToSuitLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" abstract="true" name="CollaborationAgreementWithIconicTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_AchievedMember" abstract="true" name="AchievedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember" abstract="true" name="FinalCalculationOfBrandedPrescriptionDrugFeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementwithDaiichiSankyoMember" abstract="true" name="CollaborationAgreementwithDaiichiSankyoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_PeriodOfSpecificSalesVolumeThreshold" abstract="false" name="PeriodOfSpecificSalesVolumeThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" abstract="true" name="CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_TenantLeaseImprovementsAllowance" abstract="false" name="TenantLeaseImprovementsAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccredoHealthIncorporatedMember" abstract="true" name="AccredoHealthIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" abstract="false" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_UpfrontPayments" abstract="false" name="UpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" abstract="true" name="AdditionalDevelopmentAndRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProbableMember" abstract="true" name="ProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_PerformanceSharesAchievedBeforeDecember312021Member" abstract="true" name="PerformanceSharesAchievedBeforeDecember312021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_PerformanceSharesClinicalTrialResultsMember" abstract="true" name="PerformanceSharesClinicalTrialResultsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProfitSharingAgreementPercentOfProfits" abstract="false" name="ProfitSharingAgreementPercentOfProfits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_MINNEBROMember" abstract="true" name="MINNEBROMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_MilestonePaymentsYetToBeEarned" abstract="false" name="MilestonePaymentsYetToBeEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProfitSharingTiersAxis" abstract="true" name="ProfitSharingTiersAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" abstract="false" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_UpfrontAndMilestonePayments" abstract="false" name="UpfrontAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_FinalTierMember" abstract="true" name="FinalTierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProfitSharingTiersDomain" abstract="true" name="ProfitSharingTiersDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_MilestoneObjectiveDomain" abstract="true" name="MilestoneObjectiveDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" abstract="false" name="LesseeOperatingLeaseOptionToTerminateAfterPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_ProfitSharingAgreementProfitThreshold" abstract="false" name="ProfitSharingAgreementProfitThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" abstract="false" name="EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" abstract="false" name="CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" abstract="false" name="CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exel_StatusAxis" abstract="true" name="StatusAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_SalesRevenueDiscountExpectedtobeEarnedPercent" abstract="false" name="SalesRevenueDiscountExpectedtobeEarnedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="exel_AccountsReceivableForUnsettledInvestmentSales" abstract="false" name="AccountsReceivableForUnsettledInvestmentSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationAgreementsAdditionalUpfrontPayments" abstract="false" name="CollaborationAgreementsAdditionalUpfrontPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" abstract="false" name="CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_TakedaMember" abstract="true" name="TakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_DiscoveryProjectMember" abstract="true" name="DiscoveryProjectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_DevelopmentAndRegulatoryMilestoneMember" abstract="true" name="DevelopmentAndRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_OperatingLeaseLiabilitiesAbstract" abstract="true" name="OperatingLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_CollaborativeArrangementWithInvenraMember" abstract="true" name="CollaborativeArrangementWithInvenraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_ProductCommercializationMember" abstract="true" name="ProductCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_HeadquartersLeaseMember" abstract="true" name="HeadquartersLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_TaxCreditCarryforwardAmountWithExpirationPeriod" abstract="false" name="TaxCreditCarryforwardAmountWithExpirationPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" abstract="false" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_MilestoneObjectiveAxis" abstract="true" name="MilestoneObjectiveAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>exel-20210101_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3705d550-318f-4f51-9de6-06eba39f6ea7,g:2df53114-27bb-4237-9a9c-80b7c8353f30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20210101.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c53a786-1db7-4ac2-85e1-a23288c245af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_14170585-6d6e-49f9-9ab1-77eeea03144f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c53a786-1db7-4ac2-85e1-a23288c245af" xlink:to="loc_us-gaap_Liabilities_14170585-6d6e-49f9-9ab1-77eeea03144f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_242281a1-50c6-4307-a301-19f847ea0c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c53a786-1db7-4ac2-85e1-a23288c245af" xlink:to="loc_us-gaap_CommitmentsAndContingencies_242281a1-50c6-4307-a301-19f847ea0c90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_37be414a-3d78-42a5-94b5-6ea5e916f496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1c53a786-1db7-4ac2-85e1-a23288c245af" xlink:to="loc_us-gaap_StockholdersEquity_37be414a-3d78-42a5-94b5-6ea5e916f496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4f1e6b2a-0da4-48a6-aeb7-879c349892c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dc01e888-a7f7-47e7-9c25-69844571d699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4f1e6b2a-0da4-48a6-aeb7-879c349892c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dc01e888-a7f7-47e7-9c25-69844571d699" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_878c1456-ecc9-4b9d-a99a-c5e003aa3d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4f1e6b2a-0da4-48a6-aeb7-879c349892c2" xlink:to="loc_us-gaap_ShortTermInvestments_878c1456-ecc9-4b9d-a99a-c5e003aa3d3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_95e1ccb7-3990-4fe8-a825-60e0e20b0e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4f1e6b2a-0da4-48a6-aeb7-879c349892c2" xlink:to="loc_us-gaap_ReceivablesNetCurrent_95e1ccb7-3990-4fe8-a825-60e0e20b0e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_40b3f6e6-7d51-429c-9d98-05d70ad689f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4f1e6b2a-0da4-48a6-aeb7-879c349892c2" xlink:to="loc_us-gaap_InventoryNet_40b3f6e6-7d51-429c-9d98-05d70ad689f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffc6ef2e-4723-45ed-868d-1b5b8cf2418b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4f1e6b2a-0da4-48a6-aeb7-879c349892c2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffc6ef2e-4723-45ed-868d-1b5b8cf2418b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_120b1d32-4bba-409a-a06d-bf48a5f62690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f62474cb-c839-4f4f-8cfd-03a17715df06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_120b1d32-4bba-409a-a06d-bf48a5f62690" xlink:to="loc_us-gaap_PreferredStockValue_f62474cb-c839-4f4f-8cfd-03a17715df06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f4e2f564-5df0-49b2-b515-1f29cf804bdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_120b1d32-4bba-409a-a06d-bf48a5f62690" xlink:to="loc_us-gaap_CommonStockValue_f4e2f564-5df0-49b2-b515-1f29cf804bdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2ca5507d-ece3-4a95-a95b-152a62387955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_120b1d32-4bba-409a-a06d-bf48a5f62690" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2ca5507d-ece3-4a95-a95b-152a62387955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d968ed99-1a2d-4d1d-ab56-dbc8cd4f68b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_120b1d32-4bba-409a-a06d-bf48a5f62690" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d968ed99-1a2d-4d1d-ab56-dbc8cd4f68b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89f5ea4e-61b1-4c84-b04f-ef7864136f62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_120b1d32-4bba-409a-a06d-bf48a5f62690" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89f5ea4e-61b1-4c84-b04f-ef7864136f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8871c52f-c2a1-49d3-918a-5f99050de2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d5383ecb-c54b-4228-9c99-45ce972084d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8871c52f-c2a1-49d3-918a-5f99050de2d6" xlink:to="loc_us-gaap_LiabilitiesCurrent_d5383ecb-c54b-4228-9c99-45ce972084d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c141e346-0617-4d3c-a35e-486080a4632a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8871c52f-c2a1-49d3-918a-5f99050de2d6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c141e346-0617-4d3c-a35e-486080a4632a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83be0263-80f4-409c-83bb-1b3898988924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8871c52f-c2a1-49d3-918a-5f99050de2d6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83be0263-80f4-409c-83bb-1b3898988924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_270e91ea-b16d-436b-a216-68401150a804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8871c52f-c2a1-49d3-918a-5f99050de2d6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_270e91ea-b16d-436b-a216-68401150a804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dd811e0c-b2b4-4e83-92e0-ad6e487422c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_39c18dcd-9912-41cd-a8f4-8c5200df1ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd811e0c-b2b4-4e83-92e0-ad6e487422c1" xlink:to="loc_us-gaap_AssetsCurrent_39c18dcd-9912-41cd-a8f4-8c5200df1ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_637818ff-0a51-4817-affe-7109962fd300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd811e0c-b2b4-4e83-92e0-ad6e487422c1" xlink:to="loc_us-gaap_LongTermInvestments_637818ff-0a51-4817-affe-7109962fd300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bcaa275c-4d06-4e68-bc5c-204554b51469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd811e0c-b2b4-4e83-92e0-ad6e487422c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bcaa275c-4d06-4e68-bc5c-204554b51469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b0ee7c8b-f000-4cb9-b72e-7c153d15e712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd811e0c-b2b4-4e83-92e0-ad6e487422c1" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b0ee7c8b-f000-4cb9-b72e-7c153d15e712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b53a3a69-3035-4ae8-9c19-e2cee092f059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd811e0c-b2b4-4e83-92e0-ad6e487422c1" xlink:to="loc_us-gaap_Goodwill_b53a3a69-3035-4ae8-9c19-e2cee092f059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_86940ff7-14d6-49bc-b12a-d586e1b71f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dd811e0c-b2b4-4e83-92e0-ad6e487422c1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_86940ff7-14d6-49bc-b12a-d586e1b71f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_341de4d9-3aa4-48cb-8b2e-ec6802796860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d4d04fd1-103a-42fc-8c17-1b63ed324502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_341de4d9-3aa4-48cb-8b2e-ec6802796860" xlink:to="loc_us-gaap_AccountsPayableCurrent_d4d04fd1-103a-42fc-8c17-1b63ed324502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1ed55d1c-5efe-4bf2-847d-9a8972698d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_341de4d9-3aa4-48cb-8b2e-ec6802796860" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1ed55d1c-5efe-4bf2-847d-9a8972698d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_3f6bcad7-d871-4007-9f90-a73ea4c66f8a" xlink:href="exel-20210101.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_341de4d9-3aa4-48cb-8b2e-ec6802796860" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_3f6bcad7-d871-4007-9f90-a73ea4c66f8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_8e46c99d-d701-47c0-b5cb-807e2396fc95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_341de4d9-3aa4-48cb-8b2e-ec6802796860" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_8e46c99d-d701-47c0-b5cb-807e2396fc95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_1712d85e-bac9-4f2a-aa07-6eaf6014fe10" xlink:href="exel-20210101.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_341de4d9-3aa4-48cb-8b2e-ec6802796860" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_1712d85e-bac9-4f2a-aa07-6eaf6014fe10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0195d74f-cee9-4ff0-bd5c-58707f176890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_341de4d9-3aa4-48cb-8b2e-ec6802796860" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0195d74f-cee9-4ff0-bd5c-58707f176890" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e01ddd8a-7617-4c90-895e-27944766cce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_be7112ec-0bbe-40a3-a16e-f714422e284d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e01ddd8a-7617-4c90-895e-27944766cce5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_be7112ec-0bbe-40a3-a16e-f714422e284d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c7c984a6-58f4-4eb6-aab5-0b2dbc353372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e01ddd8a-7617-4c90-895e-27944766cce5" xlink:to="loc_us-gaap_CostsAndExpenses_c7c984a6-58f4-4eb6-aab5-0b2dbc353372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a0b6ebd-4f2e-4f2d-b16a-f940c1c7a1e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6c31aba6-0b5a-4ffd-9248-e0b2ac01f340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1a0b6ebd-4f2e-4f2d-b16a-f940c1c7a1e9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6c31aba6-0b5a-4ffd-9248-e0b2ac01f340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0a4c8e45-e76b-4d97-bc31-1b303cdcca7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1a0b6ebd-4f2e-4f2d-b16a-f940c1c7a1e9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0a4c8e45-e76b-4d97-bc31-1b303cdcca7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2d85a3ed-bc53-46a8-8efa-7cf560012b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0dd4d191-8936-48da-9001-5513aee7f5f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d85a3ed-bc53-46a8-8efa-7cf560012b2e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0dd4d191-8936-48da-9001-5513aee7f5f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a3d02f36-29c9-4a1d-a2a0-8b911c247ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d85a3ed-bc53-46a8-8efa-7cf560012b2e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a3d02f36-29c9-4a1d-a2a0-8b911c247ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4ed7f395-b7c9-46be-82f6-dcf0d0769136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2d85a3ed-bc53-46a8-8efa-7cf560012b2e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4ed7f395-b7c9-46be-82f6-dcf0d0769136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55d9f5a4-8c9a-48a1-b74b-6988a806c601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c6f51ee-564b-4395-a0b3-b5b98a972413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55d9f5a4-8c9a-48a1-b74b-6988a806c601" xlink:to="loc_us-gaap_OperatingIncomeLoss_6c6f51ee-564b-4395-a0b3-b5b98a972413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_f5aab66d-de01-4d0b-b061-50fd5dfd3e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55d9f5a4-8c9a-48a1-b74b-6988a806c601" xlink:to="loc_us-gaap_InterestIncomeOther_f5aab66d-de01-4d0b-b061-50fd5dfd3e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_17bbbb1d-5feb-444b-814e-8f450cd130ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_55d9f5a4-8c9a-48a1-b74b-6988a806c601" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_17bbbb1d-5feb-444b-814e-8f450cd130ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fcb67d82-6db5-4506-9fcf-c07e7a3756cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fcad2c0b-5011-4cad-ae98-740183067d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fcb67d82-6db5-4506-9fcf-c07e7a3756cc" xlink:to="loc_us-gaap_NetIncomeLoss_fcad2c0b-5011-4cad-ae98-740183067d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f8a257f7-332e-4506-a76e-c5d91c079a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fcb67d82-6db5-4506-9fcf-c07e7a3756cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f8a257f7-332e-4506-a76e-c5d91c079a85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35002b44-7317-4bdb-9ed4-bcccb4ef8bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51084d55-8589-4aa0-b2e0-f20094a3f83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35002b44-7317-4bdb-9ed4-bcccb4ef8bd6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_51084d55-8589-4aa0-b2e0-f20094a3f83f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc3e8d3a-7901-4e97-a81f-4862cf5cc7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35002b44-7317-4bdb-9ed4-bcccb4ef8bd6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc3e8d3a-7901-4e97-a81f-4862cf5cc7dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4db1621e-a553-4366-9604-fdbfc9c792d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_35002b44-7317-4bdb-9ed4-bcccb4ef8bd6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4db1621e-a553-4366-9604-fdbfc9c792d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_24e0254d-77db-4dcf-9b7c-7a5c75ae1da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_81555290-860d-4a6f-b209-fc80690b14e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_24e0254d-77db-4dcf-9b7c-7a5c75ae1da4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_81555290-860d-4a6f-b209-fc80690b14e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_41580a88-0cf6-466e-9122-de1c562bdc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_24e0254d-77db-4dcf-9b7c-7a5c75ae1da4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_41580a88-0cf6-466e-9122-de1c562bdc77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0ca1951b-fd6f-4972-a73a-9cb8160a0eab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_24e0254d-77db-4dcf-9b7c-7a5c75ae1da4" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0ca1951b-fd6f-4972-a73a-9cb8160a0eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ccee8bf7-fe71-436d-9c20-93b38503cfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_NetIncomeLoss_ccee8bf7-fe71-436d-9c20-93b38503cfa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fd8919bf-7154-4350-b859-05f141f0031e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fd8919bf-7154-4350-b859-05f141f0031e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_88c18732-c41d-4b45-908d-81105efdfe05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_ShareBasedCompensation_88c18732-c41d-4b45-908d-81105efdfe05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_9bebec18-f6a0-4719-a2a2-48dd41ba058c" xlink:href="exel-20210101.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_exel_NoncashLeaseExpense_9bebec18-f6a0-4719-a2a2-48dd41ba058c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_5c1f5c10-23a2-48a2-bd32-e5bc2b5cf090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_5c1f5c10-23a2-48a2-bd32-e5bc2b5cf090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_f9ca4700-3a11-4e5d-b087-a2e7b670d196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_f9ca4700-3a11-4e5d-b087-a2e7b670d196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e734006b-307a-4da3-9c7b-ca87d5322174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e734006b-307a-4da3-9c7b-ca87d5322174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ddffd032-07fc-46be-97f0-cdb92a422184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ddffd032-07fc-46be-97f0-cdb92a422184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ed3e3479-2e33-4aca-b80d-acd7a0103dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ed3e3479-2e33-4aca-b80d-acd7a0103dbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_42e4a7b4-e05e-4187-b1bc-2be85d3b8ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_42e4a7b4-e05e-4187-b1bc-2be85d3b8ada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10695f3f-e3ee-45dc-a78c-f0a76a55842e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4bd2b89-a84e-4e73-aa07-1cb27004c87f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10695f3f-e3ee-45dc-a78c-f0a76a55842e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00399cd3-e269-4a28-b6b8-415562df097f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6a008e75-4b68-438b-91f3-b4b86a5a63bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00399cd3-e269-4a28-b6b8-415562df097f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6a008e75-4b68-438b-91f3-b4b86a5a63bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e32fc2e8-f38a-4156-ae49-f07befa3a26e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00399cd3-e269-4a28-b6b8-415562df097f" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e32fc2e8-f38a-4156-ae49-f07befa3a26e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b00c3ae2-ffe4-4eb4-a11c-cc0f24532268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00399cd3-e269-4a28-b6b8-415562df097f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b00c3ae2-ffe4-4eb4-a11c-cc0f24532268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0a143e59-4b82-42ea-8acf-6a7ecb58c1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00399cd3-e269-4a28-b6b8-415562df097f" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0a143e59-4b82-42ea-8acf-6a7ecb58c1e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20210101.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_871a0b81-d05c-4b87-818e-2957bc2f6c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_14a63cb8-21bb-49a4-9931-1aed9c4ac247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_871a0b81-d05c-4b87-818e-2957bc2f6c30" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_14a63cb8-21bb-49a4-9931-1aed9c4ac247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a6ff4bd3-a6b3-4446-83f0-f0a23e7ea6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_871a0b81-d05c-4b87-818e-2957bc2f6c30" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a6ff4bd3-a6b3-4446-83f0-f0a23e7ea6bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsOtherCollaborationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsInvenraCollaborationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsStemSynergyCollaborationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestments"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7da5d85f-b4f2-40f9-aba5-6947ca6836f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24d4f029-fba4-42c9-bfb7-a3c94113c1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7da5d85f-b4f2-40f9-aba5-6947ca6836f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24d4f029-fba4-42c9-bfb7-a3c94113c1dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_2c3921af-ccaf-4554-ad6c-c64359d8a180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7da5d85f-b4f2-40f9-aba5-6947ca6836f2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_2c3921af-ccaf-4554-ad6c-c64359d8a180" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsSummarybySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_b6efa38a-7cff-46bb-a067-6c8216095b67" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_b82f48ab-f134-404e-9485-42200f7edb7a" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_b6efa38a-7cff-46bb-a067-6c8216095b67" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_b82f48ab-f134-404e-9485-42200f7edb7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e372a5dc-19f5-40a2-a289-920a9904a3b3" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_b6efa38a-7cff-46bb-a067-6c8216095b67" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e372a5dc-19f5-40a2-a289-920a9904a3b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_9d351d55-3f4b-436a-8e26-32f7d4416a78" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_b6efa38a-7cff-46bb-a067-6c8216095b67" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_9d351d55-3f4b-436a-8e26-32f7d4416a78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c7ff2924-aeeb-403e-97cc-920da7b20264" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4b0dbaf8-4528-4e4d-b53c-b59754f64367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c7ff2924-aeeb-403e-97cc-920da7b20264" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4b0dbaf8-4528-4e4d-b53c-b59754f64367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_cde70c78-6b6a-4ff2-b084-46a2f3754ff8" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c7ff2924-aeeb-403e-97cc-920da7b20264" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_cde70c78-6b6a-4ff2-b084-46a2f3754ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b52a53e5-9f6c-48da-83bf-3eea0fad961a" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_988d44a7-c064-45a1-b9e7-8e795377eaa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b52a53e5-9f6c-48da-83bf-3eea0fad961a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_988d44a7-c064-45a1-b9e7-8e795377eaa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_f9e880f2-f544-4fe8-833d-c1b5be100313" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b52a53e5-9f6c-48da-83bf-3eea0fad961a" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_f9e880f2-f544-4fe8-833d-c1b5be100313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_945d4684-3444-44aa-aaa4-2be63d095658" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2529ead6-7cce-4caa-afbb-f92c21db917c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_945d4684-3444-44aa-aaa4-2be63d095658" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2529ead6-7cce-4caa-afbb-f92c21db917c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_62d612e5-2265-4839-935c-1c278750963c" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_945d4684-3444-44aa-aaa4-2be63d095658" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_62d612e5-2265-4839-935c-1c278750963c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_390f58b8-2d63-4279-85f9-65414a8b64b1" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b5a1ac1a-0309-4f85-aa3a-300c0ec74ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_390f58b8-2d63-4279-85f9-65414a8b64b1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b5a1ac1a-0309-4f85-aa3a-300c0ec74ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_a671baf5-2c15-445d-8bbe-9d71ad529933" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_390f58b8-2d63-4279-85f9-65414a8b64b1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_a671baf5-2c15-445d-8bbe-9d71ad529933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bfd3ca58-5499-4c10-ad1f-499bffd83708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ed247d18-c0b3-49df-8d1d-7393aed94afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bfd3ca58-5499-4c10-ad1f-499bffd83708" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ed247d18-c0b3-49df-8d1d-7393aed94afe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5713812c-3366-4c47-be36-3e632bf35e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bfd3ca58-5499-4c10-ad1f-499bffd83708" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5713812c-3366-4c47-be36-3e632bf35e8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a49a2173-45ce-4ca7-9158-d5c36da3110a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bfd3ca58-5499-4c10-ad1f-499bffd83708" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a49a2173-45ce-4ca7-9158-d5c36da3110a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsGrossUnrealizedLossesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsSummarybyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c977084-721c-4a09-ba1b-871878ea9dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0a55c49f-70f0-4789-a4ff-00917b512a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c977084-721c-4a09-ba1b-871878ea9dd7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0a55c49f-70f0-4789-a4ff-00917b512a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_43c51ecd-0339-4ead-a344-9d03e7ae17d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c977084-721c-4a09-ba1b-871878ea9dd7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_43c51ecd-0339-4ead-a344-9d03e7ae17d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20210101.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20210101.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0b31aa7c-b766-4314-b0b8-b9b9f62ae9e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3c72b2bb-5a27-4fd2-b20c-ce619c209b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0b31aa7c-b766-4314-b0b8-b9b9f62ae9e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3c72b2bb-5a27-4fd2-b20c-ce619c209b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e579871d-2258-479e-80a9-b25e62d9ac5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0b31aa7c-b766-4314-b0b8-b9b9f62ae9e5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e579871d-2258-479e-80a9-b25e62d9ac5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20210101.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20210101.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_9dd97b75-490b-4908-8bcd-f7d4f4abaf4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_eed09e1f-73be-4adb-a835-e9e802b003f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_9dd97b75-490b-4908-8bcd-f7d4f4abaf4c" xlink:to="loc_us-gaap_InventoryRawMaterials_eed09e1f-73be-4adb-a835-e9e802b003f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_e1262cfe-9152-43b9-9dfc-61145599dcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_9dd97b75-490b-4908-8bcd-f7d4f4abaf4c" xlink:to="loc_us-gaap_InventoryWorkInProcess_e1262cfe-9152-43b9-9dfc-61145599dcfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_a70fede2-c7a8-43e5-9bdc-355982395ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_9dd97b75-490b-4908-8bcd-f7d4f4abaf4c" xlink:to="loc_us-gaap_InventoryFinishedGoods_a70fede2-c7a8-43e5-9bdc-355982395ea2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_20d2d160-e170-4af0-8692-0e87264ecb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_39af13dc-5e15-4caa-9a1a-519fe6661137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_20d2d160-e170-4af0-8692-0e87264ecb99" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_39af13dc-5e15-4caa-9a1a-519fe6661137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02ae504b-351f-4949-a5b1-924f49cb5288" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_20d2d160-e170-4af0-8692-0e87264ecb99" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02ae504b-351f-4949-a5b1-924f49cb5288" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20e09dc9-96f8-481f-94a6-e43e890f8bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1a1eafc5-110f-4e71-83a4-697a3afa052f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20e09dc9-96f8-481f-94a6-e43e890f8bf1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1a1eafc5-110f-4e71-83a4-697a3afa052f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1ef69ce9-0f03-4132-9fbe-69c7fc279259" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20e09dc9-96f8-481f-94a6-e43e890f8bf1" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1ef69ce9-0f03-4132-9fbe-69c7fc279259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78f5b0a8-bd29-4a5e-a3d2-517a82e354e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_de7666a2-3c55-451d-91f1-37752ecf35bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78f5b0a8-bd29-4a5e-a3d2-517a82e354e8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_de7666a2-3c55-451d-91f1-37752ecf35bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_921e1adb-64e0-4fa5-b306-faf299202ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78f5b0a8-bd29-4a5e-a3d2-517a82e354e8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_921e1adb-64e0-4fa5-b306-faf299202ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8ab11252-f0d8-46ac-ac42-f21187eab5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ac9f4b29-6d85-4090-927c-e05ac496b01a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8ab11252-f0d8-46ac-ac42-f21187eab5c5" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ac9f4b29-6d85-4090-927c-e05ac496b01a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c13ac3b4-d346-49b9-a1ed-6716f796e3c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8ab11252-f0d8-46ac-ac42-f21187eab5c5" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c13ac3b4-d346-49b9-a1ed-6716f796e3c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_54344808-cf3c-44b6-936f-3871f15b574c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_9b881488-2725-44d2-9170-4ba3cc0e4efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_54344808-cf3c-44b6-936f-3871f15b574c" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_9b881488-2725-44d2-9170-4ba3cc0e4efb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ec1d2927-8f57-4981-91eb-d38eee14559f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_54344808-cf3c-44b6-936f-3871f15b574c" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ec1d2927-8f57-4981-91eb-d38eee14559f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_70866fcc-f09b-4c20-a554-0e1a0d2cdc42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_54344808-cf3c-44b6-936f-3871f15b574c" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_70866fcc-f09b-4c20-a554-0e1a0d2cdc42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_284bf732-8cdf-45fb-a310-53f7bb6cd0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_54344808-cf3c-44b6-936f-3871f15b574c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_284bf732-8cdf-45fb-a310-53f7bb6cd0c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_45330f5f-4148-4375-9e76-536612150936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_54344808-cf3c-44b6-936f-3871f15b574c" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_45330f5f-4148-4375-9e76-536612150936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_a30b489f-2e83-4142-9009-4838328c7f6f" xlink:href="exel-20210101.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_54344808-cf3c-44b6-936f-3871f15b574c" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_a30b489f-2e83-4142-9009-4838328c7f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2454dd43-cf68-4b44-ad7e-81865e310ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_54344808-cf3c-44b6-936f-3871f15b574c" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_2454dd43-cf68-4b44-ad7e-81865e310ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_e0832ad3-8d49-49a0-be50-e0551d3119c2" xlink:href="exel-20210101.xsd#exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_54344808-cf3c-44b6-936f-3871f15b574c" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_e0832ad3-8d49-49a0-be50-e0551d3119c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d22e9659-e507-463d-91fe-7890d13f7490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_20acf041-9d6e-4f64-a8fd-a468ff03c956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d22e9659-e507-463d-91fe-7890d13f7490" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_20acf041-9d6e-4f64-a8fd-a468ff03c956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_efd4be98-ec32-433f-bb95-24e4ee127967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d22e9659-e507-463d-91fe-7890d13f7490" xlink:to="loc_us-gaap_DeferredTaxLiabilities_efd4be98-ec32-433f-bb95-24e4ee127967" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9fc74d81-27a2-4879-b943-1fbf71f6f143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_57dfe471-1b69-440e-a045-ae5e8a6a2f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9fc74d81-27a2-4879-b943-1fbf71f6f143" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_57dfe471-1b69-440e-a045-ae5e8a6a2f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_98e439a1-610a-45e9-b5cc-759526d090c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9fc74d81-27a2-4879-b943-1fbf71f6f143" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_98e439a1-610a-45e9-b5cc-759526d090c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_919d8495-d595-41f6-b047-8806305f868e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9fc74d81-27a2-4879-b943-1fbf71f6f143" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_919d8495-d595-41f6-b047-8806305f868e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_db4a8711-afef-404a-a134-8170f3b81a0d" xlink:href="exel-20210101.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9fc74d81-27a2-4879-b943-1fbf71f6f143" xlink:to="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_db4a8711-afef-404a-a134-8170f3b81a0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsLeaseLiabilities_3a3f5dca-5382-410b-a0b2-894f31e42012" xlink:href="exel-20210101.xsd#exel_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9fc74d81-27a2-4879-b943-1fbf71f6f143" xlink:to="loc_exel_DeferredTaxAssetsLeaseLiabilities_3a3f5dca-5382-410b-a0b2-894f31e42012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_b1e2428e-539c-40a3-b185-e260692b4559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9fc74d81-27a2-4879-b943-1fbf71f6f143" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_b1e2428e-539c-40a3-b185-e260692b4559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_55596b00-4ed4-4a6e-9bc9-f45a01ab961d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9fc74d81-27a2-4879-b943-1fbf71f6f143" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_55596b00-4ed4-4a6e-9bc9-f45a01ab961d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c8666db1-fc4f-43fb-98a0-6fa89e7c545b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9fc74d81-27a2-4879-b943-1fbf71f6f143" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c8666db1-fc4f-43fb-98a0-6fa89e7c545b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_800f66d8-aa27-448c-a5a6-6b23d2ed020b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_6e550227-6ea0-4fd5-8bf4-3dc7c1c149cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_800f66d8-aa27-448c-a5a6-6b23d2ed020b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_6e550227-6ea0-4fd5-8bf4-3dc7c1c149cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_19196d79-95ee-42cc-a956-01bdad1591ce" xlink:href="exel-20210101.xsd#exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_800f66d8-aa27-448c-a5a6-6b23d2ed020b" xlink:to="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_19196d79-95ee-42cc-a956-01bdad1591ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_26606c8f-c105-43c6-a567-1bf576e2f10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c7b8cc47-f4d3-41a4-9fdd-79d4d4232b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_26606c8f-c105-43c6-a567-1bf576e2f10c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c7b8cc47-f4d3-41a4-9fdd-79d4d4232b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_47b73f0e-afc0-4722-8ca6-8a756dd36a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_26606c8f-c105-43c6-a567-1bf576e2f10c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_47b73f0e-afc0-4722-8ca6-8a756dd36a23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerShare"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerShareTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59353fc9-c02f-415d-9374-3e0d14f8c6ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_542f7b06-5fc4-4592-8abb-aac2729b05bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59353fc9-c02f-415d-9374-3e0d14f8c6ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_542f7b06-5fc4-4592-8abb-aac2729b05bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ac1c1298-1e5f-4e86-902b-80f329079b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_59353fc9-c02f-415d-9374-3e0d14f8c6ba" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ac1c1298-1e5f-4e86-902b-80f329079b32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2165b6c1-60f3-4ee6-9d12-34b5c9a7d1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8378f23b-4f50-48e8-8622-4c32f58b60fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2165b6c1-60f3-4ee6-9d12-34b5c9a7d1a2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8378f23b-4f50-48e8-8622-4c32f58b60fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4422c15d-10a4-4cd2-99bc-131bde764ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2165b6c1-60f3-4ee6-9d12-34b5c9a7d1a2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4422c15d-10a4-4cd2-99bc-131bde764ca1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_626f7c3a-3597-47bd-b9a9-4b3fb7022ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8f206a78-c2b1-48af-bea1-62fdd8346b4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_626f7c3a-3597-47bd-b9a9-4b3fb7022ca3" xlink:to="loc_us-gaap_OperatingLeaseCost_8f206a78-c2b1-48af-bea1-62fdd8346b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e6e3e59c-49e5-4894-966b-2f36b2cca668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_626f7c3a-3597-47bd-b9a9-4b3fb7022ca3" xlink:to="loc_us-gaap_VariableLeaseCost_e6e3e59c-49e5-4894-966b-2f36b2cca668" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2cccceda-70df-4c49-a2d2-9cd94fe88a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a95df55d-8f8e-421a-835a-424f1f394a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2cccceda-70df-4c49-a2d2-9cd94fe88a7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a95df55d-8f8e-421a-835a-424f1f394a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6ecca92b-6130-4ea2-b9e9-8858eaead524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2cccceda-70df-4c49-a2d2-9cd94fe88a7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6ecca92b-6130-4ea2-b9e9-8858eaead524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5547f1a8-6ade-4ac3-a81e-5284dcde81c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2cccceda-70df-4c49-a2d2-9cd94fe88a7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5547f1a8-6ade-4ac3-a81e-5284dcde81c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0c07fde8-1100-406d-a0bb-e343e3fce955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2cccceda-70df-4c49-a2d2-9cd94fe88a7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0c07fde8-1100-406d-a0bb-e343e3fce955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_951257a6-7642-4f75-82ba-a503944e1700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2cccceda-70df-4c49-a2d2-9cd94fe88a7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_951257a6-7642-4f75-82ba-a503944e1700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6efd03f2-c58e-4931-850d-8d429e25c39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2cccceda-70df-4c49-a2d2-9cd94fe88a7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6efd03f2-c58e-4931-850d-8d429e25c39e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6be7e098-4c3e-432d-8cdf-60ee1efd977a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_814fab29-cae1-4e31-9f57-6d6a81f1e389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6be7e098-4c3e-432d-8cdf-60ee1efd977a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_814fab29-cae1-4e31-9f57-6d6a81f1e389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8f4e6514-b633-4248-b287-0e9a296a93d9" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6be7e098-4c3e-432d-8cdf-60ee1efd977a" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_8f4e6514-b633-4248-b287-0e9a296a93d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_753df407-2379-4041-9268-dfedf58bbd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6be7e098-4c3e-432d-8cdf-60ee1efd977a" xlink:to="loc_us-gaap_OperatingLeaseLiability_753df407-2379-4041-9268-dfedf58bbd4f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="exel-20210101.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="exel-20210101.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#QuarterlyFinancialDataUnauditedDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>exel-20210101_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3705d550-318f-4f51-9de6-06eba39f6ea7,g:2df53114-27bb-4237-9a9c-80b7c8353f30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20210101.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" id="i4eff6b021ce94caca514189c329d9425_CoverPage"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i57d7866e6e5d4d7f90182feb20f63d7b_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i84cbd46e11204968bb5b8de4b207702e_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="i5b20fc5d4a9e442a9a6e9843d83c17f5_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_585381e4-3904-4092-a6a1-2afc3e109f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_RevenuesAbstract_585381e4-3904-4092-a6a1-2afc3e109f2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2bcf1f6-3fce-4b66-8ea6-d09a0e32844a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_585381e4-3904-4092-a6a1-2afc3e109f2d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2bcf1f6-3fce-4b66-8ea6-d09a0e32844a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2ec87a23-ec48-4cdc-a9d9-ef236af71f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2ec87a23-ec48-4cdc-a9d9-ef236af71f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7a896900-c27a-414f-9f43-80d27e431d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7a896900-c27a-414f-9f43-80d27e431d43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21419c14-1e63-4a36-8e51-5c11ad70485d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21419c14-1e63-4a36-8e51-5c11ad70485d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a128a8e3-62e7-4c19-8d22-9765972957b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:to="loc_us-gaap_CostsAndExpenses_a128a8e3-62e7-4c19-8d22-9765972957b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6643f12c-05a0-495e-8d01-c9495ee10ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_OperatingIncomeLoss_6643f12c-05a0-495e-8d01-c9495ee10ba3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_2ccf4e22-1f2b-46ca-8f69-28bee494f91d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_InterestIncomeOther_2ccf4e22-1f2b-46ca-8f69-28bee494f91d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_081ba0bf-01ec-4fe3-ad3f-d4fef37285c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_081ba0bf-01ec-4fe3-ad3f-d4fef37285c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c687fdda-bcc6-46fb-8eef-d3638f436bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c687fdda-bcc6-46fb-8eef-d3638f436bc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_322f6907-eade-41b9-81d3-1d97a80b6a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_322f6907-eade-41b9-81d3-1d97a80b6a27" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8e431e33-665c-432a-bbac-9203ec3fedce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_NetIncomeLoss_8e431e33-665c-432a-bbac-9203ec3fedce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6d5382de-2d83-4005-aa2b-3d762664c71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_EarningsPerShareAbstract_6d5382de-2d83-4005-aa2b-3d762664c71e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_62ad7dd6-a1ac-4df3-925b-e5d0a95cfcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d5382de-2d83-4005-aa2b-3d762664c71e" xlink:to="loc_us-gaap_EarningsPerShareBasic_62ad7dd6-a1ac-4df3-925b-e5d0a95cfcd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_67bcb222-20e9-43cf-b7ca-a7073faa2289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d5382de-2d83-4005-aa2b-3d762664c71e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_67bcb222-20e9-43cf-b7ca-a7073faa2289" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_5447f751-2b9d-4e50-aca0-21a9e08b9adc" xlink:href="exel-20210101.xsd#exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_5447f751-2b9d-4e50-aca0-21a9e08b9adc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14a86a4b-667f-4971-a148-759cdb499df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_5447f751-2b9d-4e50-aca0-21a9e08b9adc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14a86a4b-667f-4971-a148-759cdb499df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_570c69e7-eba2-431f-9fe7-36afebe137f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_5447f751-2b9d-4e50-aca0-21a9e08b9adc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_570c69e7-eba2-431f-9fe7-36afebe137f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_92a378b2-2ab7-4383-9d58-d8d0f5971180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_StatementTable_92a378b2-2ab7-4383-9d58-d8d0f5971180" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_807af3f8-ccd6-43a1-a3f9-a5fb445f8d2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_92a378b2-2ab7-4383-9d58-d8d0f5971180" xlink:to="loc_srt_ProductOrServiceAxis_807af3f8-ccd6-43a1-a3f9-a5fb445f8d2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_807af3f8-ccd6-43a1-a3f9-a5fb445f8d2e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_807af3f8-ccd6-43a1-a3f9-a5fb445f8d2e" xlink:to="loc_srt_ProductsAndServicesDomain_807af3f8-ccd6-43a1-a3f9-a5fb445f8d2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_807af3f8-ccd6-43a1-a3f9-a5fb445f8d2e" xlink:to="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3c61f0e1-7117-4cd5-879b-50661a3ccd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:to="loc_us-gaap_ProductMember_3c61f0e1-7117-4cd5-879b-50661a3ccd6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3644d6b0-1544-4d14-b6a0-61d184630019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:to="loc_us-gaap_LicenseMember_3644d6b0-1544-4d14-b6a0-61d184630019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_b3770bc0-b16e-4de3-a7e8-a03944f995bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:to="loc_us-gaap_ServiceMember_b3770bc0-b16e-4de3-a7e8-a03944f995bb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended" id="iab1e3eb94f8b437f88ace63e35b93b0e_ConsolidatedStatementsofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended" id="if579b6c07fa944068fc9cb827b4e25ec_ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i7d69827c7e8c44a5a0f8fd391fc3431e_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2a814833-0be7-4f74-9b80-74d046f5b9c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a814833-0be7-4f74-9b80-74d046f5b9c8" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0b55913f-ad2d-4df2-983c-f3d96929af31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0b55913f-ad2d-4df2-983c-f3d96929af31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_94aa7d7f-93d2-4a92-9bb9-b2a365476a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_StockholdersEquity_94aa7d7f-93d2-4a92-9bb9-b2a365476a3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f28a9c2-0be0-4114-a126-92e9dd442ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_NetIncomeLoss_8f28a9c2-0be0-4114-a126-92e9dd442ac9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f2ed7f7d-c700-4056-9f92-ae76f81474b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f2ed7f7d-c700-4056-9f92-ae76f81474b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_76ca8544-9026-4f0f-9e63-6c5e218dbd22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_76ca8544-9026-4f0f-9e63-6c5e218dbd22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_165730aa-577b-42ff-b812-e2bc24255695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_165730aa-577b-42ff-b812-e2bc24255695" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a5c12fbc-3ab6-4cf3-b9e0-ec0df982ce0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a5c12fbc-3ab6-4cf3-b9e0-ec0df982ce0e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c003ff1e-a64d-4b2b-907a-d2c56a202983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c003ff1e-a64d-4b2b-907a-d2c56a202983" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_02cf39a9-0f30-4c37-b614-429257524487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8cf5d21e-bf66-4b37-9b21-bc36931f1b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2a814833-0be7-4f74-9b80-74d046f5b9c8" xlink:to="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_97b16a36-1286-4d5c-9788-109d968fd8c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_97b16a36-1286-4d5c-9788-109d968fd8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_97b16a36-1286-4d5c-9788-109d968fd8c2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_97b16a36-1286-4d5c-9788-109d968fd8c2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_97b16a36-1286-4d5c-9788-109d968fd8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5cea0ee0-df5a-4a4b-86f6-24739aa51ae6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_97b16a36-1286-4d5c-9788-109d968fd8c2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5cea0ee0-df5a-4a4b-86f6-24739aa51ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3fbe8b80-2080-42be-a708-65ca3970b9b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5cea0ee0-df5a-4a4b-86f6-24739aa51ae6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3fbe8b80-2080-42be-a708-65ca3970b9b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2bf389d0-22af-4c4c-b4f9-dde0a33fa223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2bf389d0-22af-4c4c-b4f9-dde0a33fa223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_2bf389d0-22af-4c4c-b4f9-dde0a33fa223_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2bf389d0-22af-4c4c-b4f9-dde0a33fa223" xlink:to="loc_us-gaap_TypeOfAdoptionMember_2bf389d0-22af-4c4c-b4f9-dde0a33fa223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_37287502-5cc5-4ab9-a700-ae596261fc22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2bf389d0-22af-4c4c-b4f9-dde0a33fa223" xlink:to="loc_us-gaap_TypeOfAdoptionMember_37287502-5cc5-4ab9-a700-ae596261fc22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_70b964a4-8bfc-404a-ad46-ba442ccd1f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_37287502-5cc5-4ab9-a700-ae596261fc22" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_70b964a4-8bfc-404a-ad46-ba442ccd1f5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_2a6a3abb-3d25-4c15-af98-e8a8c2cdee28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_37287502-5cc5-4ab9-a700-ae596261fc22" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_2a6a3abb-3d25-4c15-af98-e8a8c2cdee28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c19af89a-888c-4349-9cfe-cc89090cc746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c19af89a-888c-4349-9cfe-cc89090cc746" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c19af89a-888c-4349-9cfe-cc89090cc746_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c19af89a-888c-4349-9cfe-cc89090cc746" xlink:to="loc_us-gaap_EquityComponentDomain_c19af89a-888c-4349-9cfe-cc89090cc746_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c19af89a-888c-4349-9cfe-cc89090cc746" xlink:to="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_807a9aae-80f2-47dd-82b0-cd9aa47f0aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:to="loc_us-gaap_CommonStockMember_807a9aae-80f2-47dd-82b0-cd9aa47f0aa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d2c24f33-75ae-4012-8ed9-4e43b089c218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d2c24f33-75ae-4012-8ed9-4e43b089c218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db1c624f-26b8-434a-bc1c-850a3f57c275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db1c624f-26b8-434a-bc1c-850a3f57c275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_22eaec16-6a85-4d0c-bd4e-1dd85c46e91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:to="loc_us-gaap_RetainedEarningsMember_22eaec16-6a85-4d0c-bd4e-1dd85c46e91e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i40f1450b8c024512964b5112d9bd7920_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i85dd24ca7fc3420cae265b215a66d788_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i5100237e9fb94e0f8280370162e73fe9_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="id8ec918b6d224f12acbf1b4f6c1eb0a8_OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i8218eb09802b492896803d42bb00609b_OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:href="exel-20210101.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_e516165a-39b9-4be2-b966-5edb4c9de2b4" xlink:href="exel-20210101.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_NumberofProductsinCommercialMarket_e516165a-39b9-4be2-b966-5edb4c9de2b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_48966e64-2d68-40a5-adef-e7cfca13f7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_NumberOfOperatingSegments_48966e64-2d68-40a5-adef-e7cfca13f7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8c912fd-06e3-4ef6-b98b-bc17ed52ec9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8c912fd-06e3-4ef6-b98b-bc17ed52ec9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_39c58241-c8dc-4a99-9120-9281f67c2f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_39c58241-c8dc-4a99-9120-9281f67c2f41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_df6eeeb6-37df-4886-8500-b574234e5248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_df6eeeb6-37df-4886-8500-b574234e5248" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_65df135a-cda8-46e8-9075-01da998ff904" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_65df135a-cda8-46e8-9075-01da998ff904" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_cdee56a9-960b-4be9-b375-f547b739f116" xlink:href="exel-20210101.xsd#exel_SalesRevenuePercentDiscountForPromptPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_cdee56a9-960b-4be9-b375-f547b739f116" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_bef37c5d-9529-4233-a9cf-edef3985311b" xlink:href="exel-20210101.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_bef37c5d-9529-4233-a9cf-edef3985311b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MedicarePartDFundingMandate_bc58f90d-3e7e-4901-9188-3325f0a5fd5d" xlink:href="exel-20210101.xsd#exel_MedicarePartDFundingMandate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_MedicarePartDFundingMandate_bc58f90d-3e7e-4901-9188-3325f0a5fd5d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_a7348739-17e7-4c58-be14-eaec9e3c26f0" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_a7348739-17e7-4c58-be14-eaec9e3c26f0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_9e7d0070-8178-4cfc-9ca0-2392e9066cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_AdvertisingExpense_9e7d0070-8178-4cfc-9ca0-2392e9066cce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1de844e3-8ad0-4ffc-a0a6-a01d2a4ae3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1de844e3-8ad0-4ffc-a0a6-a01d2a4ae3fb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:href="exel-20210101.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1ccc5f50-dbf6-4180-a3c5-64e75938da99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:to="loc_srt_ProductOrServiceAxis_1ccc5f50-dbf6-4180-a3c5-64e75938da99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1ccc5f50-dbf6-4180-a3c5-64e75938da99_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1ccc5f50-dbf6-4180-a3c5-64e75938da99" xlink:to="loc_srt_ProductsAndServicesDomain_1ccc5f50-dbf6-4180-a3c5-64e75938da99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1ccc5f50-dbf6-4180-a3c5-64e75938da99" xlink:to="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_e87e90fe-2f8f-40f7-a313-a3224ca60461" xlink:href="exel-20210101.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_e87e90fe-2f8f-40f7-a313-a3224ca60461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_6e2db43b-3f76-4ead-ba53-d179f3d8dcfc" xlink:href="exel-20210101.xsd#exel_ProductsDerivedFromCabozantinibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_6e2db43b-3f76-4ead-ba53-d179f3d8dcfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_0f5f7fb1-1faa-444a-ad17-f3a85e534df3" xlink:href="exel-20210101.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_0f5f7fb1-1faa-444a-ad17-f3a85e534df3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_3c8e4974-ab20-4288-b330-d083e99d00e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_3c8e4974-ab20-4288-b330-d083e99d00e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_3c8e4974-ab20-4288-b330-d083e99d00e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_3c8e4974-ab20-4288-b330-d083e99d00e7" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_3c8e4974-ab20-4288-b330-d083e99d00e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dc9eee99-4e6c-4dac-88c3-bf1ec11a04f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_3c8e4974-ab20-4288-b330-d083e99d00e7" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dc9eee99-4e6c-4dac-88c3-bf1ec11a04f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember_34eafc31-a0c9-4f69-b687-a6c57f0f1935" xlink:href="exel-20210101.xsd#exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dc9eee99-4e6c-4dac-88c3-bf1ec11a04f4" xlink:to="loc_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember_34eafc31-a0c9-4f69-b687-a6c57f0f1935" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_baf81291-8393-4f28-90bf-740d5356568d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:to="loc_srt_RangeAxis_baf81291-8393-4f28-90bf-740d5356568d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_baf81291-8393-4f28-90bf-740d5356568d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_baf81291-8393-4f28-90bf-740d5356568d" xlink:to="loc_srt_RangeMember_baf81291-8393-4f28-90bf-740d5356568d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a912cd9f-acde-4993-8e17-ec7b3c998d9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_baf81291-8393-4f28-90bf-740d5356568d" xlink:to="loc_srt_RangeMember_a912cd9f-acde-4993-8e17-ec7b3c998d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb364e95-7167-49e7-8f68-fea70195bac9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a912cd9f-acde-4993-8e17-ec7b3c998d9b" xlink:to="loc_srt_MaximumMember_fb364e95-7167-49e7-8f68-fea70195bac9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_78c5db6d-d198-44b6-b2e6-db2c336329d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:to="loc_srt_MajorCustomersAxis_78c5db6d-d198-44b6-b2e6-db2c336329d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_78c5db6d-d198-44b6-b2e6-db2c336329d3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_78c5db6d-d198-44b6-b2e6-db2c336329d3" xlink:to="loc_srt_NameOfMajorCustomerDomain_78c5db6d-d198-44b6-b2e6-db2c336329d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d383c943-3476-4acf-852a-bb77b31b16a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_78c5db6d-d198-44b6-b2e6-db2c336329d3" xlink:to="loc_srt_NameOfMajorCustomerDomain_d383c943-3476-4acf-852a-bb77b31b16a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_778d1731-198d-4e44-ad28-6d54ff0a1fb3" xlink:href="exel-20210101.xsd#exel_GlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d383c943-3476-4acf-852a-bb77b31b16a4" xlink:to="loc_exel_GlaxoSmithKlineMember_778d1731-198d-4e44-ad28-6d54ff0a1fb3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails" xlink:type="extended" id="if00a0eaf0edc44dbbe7b6d878b105d27_OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4ed23459-d2d5-47c1-8dfc-380a6bea3b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_03af52c1-e56a-4198-b4dd-0f41e5669fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4ed23459-d2d5-47c1-8dfc-380a6bea3b38" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_03af52c1-e56a-4198-b4dd-0f41e5669fce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4ed23459-d2d5-47c1-8dfc-380a6bea3b38" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_55247efb-90d1-47ae-a2d0-c1499501cb36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_55247efb-90d1-47ae-a2d0-c1499501cb36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_55247efb-90d1-47ae-a2d0-c1499501cb36_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_55247efb-90d1-47ae-a2d0-c1499501cb36" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_55247efb-90d1-47ae-a2d0-c1499501cb36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_463353e0-8cb0-4c59-8768-088b0fcafd72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_55247efb-90d1-47ae-a2d0-c1499501cb36" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_463353e0-8cb0-4c59-8768-088b0fcafd72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e4f9b428-e102-49a2-93d9-152aa8a8237a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_463353e0-8cb0-4c59-8768-088b0fcafd72" xlink:to="loc_us-gaap_AccountsReceivableMember_e4f9b428-e102-49a2-93d9-152aa8a8237a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_12528bcb-cf44-4041-ace2-1e5ebeafca3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_12528bcb-cf44-4041-ace2-1e5ebeafca3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_12528bcb-cf44-4041-ace2-1e5ebeafca3c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_12528bcb-cf44-4041-ace2-1e5ebeafca3c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_12528bcb-cf44-4041-ace2-1e5ebeafca3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fefd1e4f-018e-4684-ae71-7cda5753bf52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_12528bcb-cf44-4041-ace2-1e5ebeafca3c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fefd1e4f-018e-4684-ae71-7cda5753bf52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_99d191c0-46e0-4077-812d-53edda94b927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fefd1e4f-018e-4684-ae71-7cda5753bf52" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_99d191c0-46e0-4077-812d-53edda94b927" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a4b19b04-30c2-4b78-b84c-741cc07a25b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:to="loc_srt_MajorCustomersAxis_a4b19b04-30c2-4b78-b84c-741cc07a25b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a4b19b04-30c2-4b78-b84c-741cc07a25b7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a4b19b04-30c2-4b78-b84c-741cc07a25b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_a4b19b04-30c2-4b78-b84c-741cc07a25b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a4b19b04-30c2-4b78-b84c-741cc07a25b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_09d15eac-0680-4603-aa16-36ba4a64398a" xlink:href="exel-20210101.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_IpsenMember_09d15eac-0680-4603-aa16-36ba4a64398a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_8c5af89c-0257-470f-80ae-7fa723441d7c" xlink:href="exel-20210101.xsd#exel_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_TakedaMember_8c5af89c-0257-470f-80ae-7fa723441d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_c252d87d-bde5-4fb3-ab68-556f024296b8" xlink:href="exel-20210101.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_c252d87d-bde5-4fb3-ab68-556f024296b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_7e161e84-7d60-4b04-9f73-a1846bc5bdbd" xlink:href="exel-20210101.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_7e161e84-7d60-4b04-9f73-a1846bc5bdbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_b41c5ac1-5d9c-4375-a6ef-7103b5afca05" xlink:href="exel-20210101.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_b41c5ac1-5d9c-4375-a6ef-7103b5afca05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_5439c40b-3062-4f11-9348-f38cea9bdb77" xlink:href="exel-20210101.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_5439c40b-3062-4f11-9348-f38cea9bdb77" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20210101.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" id="ia7ae3d540a05408d9f4369acde353bd7_Revenues"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" id="ic0303b4aa4714bd5b12060f5e96be5ba_RevenuesTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="ife257c123f7e41929dea6235bc923323_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_02db2bb9-dc8b-46bc-9cc3-83b8aaba8623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a44453b-50d9-41ce-b159-52ba5302d2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_02db2bb9-dc8b-46bc-9cc3-83b8aaba8623" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a44453b-50d9-41ce-b159-52ba5302d2f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2f4a22a6-7446-4669-b08c-f3a81b06c0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_02db2bb9-dc8b-46bc-9cc3-83b8aaba8623" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2f4a22a6-7446-4669-b08c-f3a81b06c0db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3081380d-f155-4073-a78c-cf60142ef55f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2f4a22a6-7446-4669-b08c-f3a81b06c0db" xlink:to="loc_srt_ProductOrServiceAxis_3081380d-f155-4073-a78c-cf60142ef55f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3081380d-f155-4073-a78c-cf60142ef55f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3081380d-f155-4073-a78c-cf60142ef55f" xlink:to="loc_srt_ProductsAndServicesDomain_3081380d-f155-4073-a78c-cf60142ef55f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3081380d-f155-4073-a78c-cf60142ef55f" xlink:to="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_e4ff729b-711b-4e96-aab3-e80033851b1b" xlink:href="exel-20210101.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_exel_ProductGrossMember_e4ff729b-711b-4e96-aab3-e80033851b1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_c0c858d5-d88c-41bb-90bc-17149ecb209b" xlink:href="exel-20210101.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_c0c858d5-d88c-41bb-90bc-17149ecb209b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4552dcd4-e21e-4cf8-8958-d5e6d4ba283e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_us-gaap_ProductMember_4552dcd4-e21e-4cf8-8958-d5e6d4ba283e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c9af748c-fad7-409f-9ea5-22667742f74a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_us-gaap_LicenseMember_c9af748c-fad7-409f-9ea5-22667742f74a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_dca7d590-4aa5-43be-91fd-a20401dc3004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_us-gaap_ServiceMember_dca7d590-4aa5-43be-91fd-a20401dc3004" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_382ab891-3cd7-4b4c-aad6-bfdf6ec4e573" xlink:href="exel-20210101.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_exel_CollaborationMember_382ab891-3cd7-4b4c-aad6-bfdf6ec4e573" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="i7aefe1beef1b493aadffde17e2503dd7_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_40894dc2-4546-4582-bc60-724b4977afba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ef465507-f0e4-45d2-81c4-6135ef4c2f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_40894dc2-4546-4582-bc60-724b4977afba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ef465507-f0e4-45d2-81c4-6135ef4c2f12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2d6c7688-e705-40d4-9253-644dd6eac96d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_40894dc2-4546-4582-bc60-724b4977afba" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2d6c7688-e705-40d4-9253-644dd6eac96d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4340849a-28d9-44b5-9413-582c0fab2a4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2d6c7688-e705-40d4-9253-644dd6eac96d" xlink:to="loc_srt_ProductOrServiceAxis_4340849a-28d9-44b5-9413-582c0fab2a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4340849a-28d9-44b5-9413-582c0fab2a4e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4340849a-28d9-44b5-9413-582c0fab2a4e" xlink:to="loc_srt_ProductsAndServicesDomain_4340849a-28d9-44b5-9413-582c0fab2a4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4340849a-28d9-44b5-9413-582c0fab2a4e" xlink:to="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_f6dc921f-5a08-4150-9eb1-54a55b99ca75" xlink:href="exel-20210101.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:to="loc_exel_CabometyxMember_f6dc921f-5a08-4150-9eb1-54a55b99ca75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_78040025-9917-4b66-bbbc-088cff5979b2" xlink:href="exel-20210101.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:to="loc_exel_CometriqMember_78040025-9917-4b66-bbbc-088cff5979b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2eda8667-3a0f-4fc6-b643-0c3061f3d9ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:to="loc_us-gaap_ProductMember_2eda8667-3a0f-4fc6-b643-0c3061f3d9ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended" id="i6238e6951ffe414e9ebfc37ca0deacb9_RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_904a7139-195f-4981-9758-4a9960a9d9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bf2a628e-6251-4a65-86c5-522ccad1daab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_904a7139-195f-4981-9758-4a9960a9d9bd" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bf2a628e-6251-4a65-86c5-522ccad1daab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_904a7139-195f-4981-9758-4a9960a9d9bd" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c6630d5b-02ee-4a17-b135-69b1964dbebe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:to="loc_srt_MajorCustomersAxis_c6630d5b-02ee-4a17-b135-69b1964dbebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c6630d5b-02ee-4a17-b135-69b1964dbebe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c6630d5b-02ee-4a17-b135-69b1964dbebe" xlink:to="loc_srt_NameOfMajorCustomerDomain_c6630d5b-02ee-4a17-b135-69b1964dbebe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c6630d5b-02ee-4a17-b135-69b1964dbebe" xlink:to="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_b90eeabf-39c3-4bb2-b77c-ca17c27d7766" xlink:href="exel-20210101.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_IpsenMember_b90eeabf-39c3-4bb2-b77c-ca17c27d7766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_c820c21e-89de-40d4-80f3-fa9f5ccbf4de" xlink:href="exel-20210101.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_c820c21e-89de-40d4-80f3-fa9f5ccbf4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_740a73ed-8149-4532-9b0a-f0ac3dee7951" xlink:href="exel-20210101.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_740a73ed-8149-4532-9b0a-f0ac3dee7951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_56636906-d9af-4953-ae24-4bac849cb8f5" xlink:href="exel-20210101.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_AccredoHealthIncorporatedMember_56636906-d9af-4953-ae24-4bac849cb8f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0e7433ae-82d4-4a77-977f-fa5fe4ebe483" xlink:href="exel-20210101.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0e7433ae-82d4-4a77-977f-fa5fe4ebe483" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e7afce5-edf6-43fa-b93f-3a4b0b1ae689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e7afce5-edf6-43fa-b93f-3a4b0b1ae689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6e7afce5-edf6-43fa-b93f-3a4b0b1ae689_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e7afce5-edf6-43fa-b93f-3a4b0b1ae689" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6e7afce5-edf6-43fa-b93f-3a4b0b1ae689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_198d97c7-c760-4c63-845c-773fef12a516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e7afce5-edf6-43fa-b93f-3a4b0b1ae689" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_198d97c7-c760-4c63-845c-773fef12a516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_647a474b-a230-4913-b5c1-e97b9b79e8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_198d97c7-c760-4c63-845c-773fef12a516" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_647a474b-a230-4913-b5c1-e97b9b79e8bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3477288f-a19c-49da-82b6-37c5458440a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3477288f-a19c-49da-82b6-37c5458440a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3477288f-a19c-49da-82b6-37c5458440a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3477288f-a19c-49da-82b6-37c5458440a9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3477288f-a19c-49da-82b6-37c5458440a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a76a3266-d794-496c-a192-909de9fd2b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3477288f-a19c-49da-82b6-37c5458440a9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a76a3266-d794-496c-a192-909de9fd2b2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_302aaba3-7b8b-4004-b8e0-686da555b1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a76a3266-d794-496c-a192-909de9fd2b2a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_302aaba3-7b8b-4004-b8e0-686da555b1f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="iaa5b16fc2dea4d528eaf3f660ef30f87_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4deebbc8-996f-425b-86f5-757bb2acb649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f888351-c205-44b6-a8ab-5217f1c80f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4deebbc8-996f-425b-86f5-757bb2acb649" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f888351-c205-44b6-a8ab-5217f1c80f26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f11cb111-de71-4211-8586-a12c682a088f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4deebbc8-996f-425b-86f5-757bb2acb649" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f11cb111-de71-4211-8586-a12c682a088f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1f8d4b1c-91b7-49ba-a9ea-749b9f37a363" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f11cb111-de71-4211-8586-a12c682a088f" xlink:to="loc_srt_StatementGeographicalAxis_1f8d4b1c-91b7-49ba-a9ea-749b9f37a363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f8d4b1c-91b7-49ba-a9ea-749b9f37a363_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1f8d4b1c-91b7-49ba-a9ea-749b9f37a363" xlink:to="loc_srt_SegmentGeographicalDomain_1f8d4b1c-91b7-49ba-a9ea-749b9f37a363_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1f8d4b1c-91b7-49ba-a9ea-749b9f37a363" xlink:to="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_8cd6c1dd-7d56-403a-a72f-2332bce08d93" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:to="loc_country_US_8cd6c1dd-7d56-403a-a72f-2332bce08d93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_830fae3c-fda4-44ce-bda6-e2dbc6998920" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:to="loc_srt_EuropeMember_830fae3c-fda4-44ce-bda6-e2dbc6998920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_9e3f31a5-2e06-4653-a1a7-b6527a0001a8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:to="loc_country_JP_9e3f31a5-2e06-4653-a1a7-b6527a0001a8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="i53a19d804d164c4398480fcebb7aa29b_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_74ad41a3-e932-402c-a3d0-dd4d4aac2b5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_74ad41a3-e932-402c-a3d0-dd4d4aac2b5e" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6c947b82-9296-4885-92d6-854f7d8b7ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6c947b82-9296-4885-92d6-854f7d8b7ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24305bbe-7496-4bd4-8c82-63c3bce5e3ea" xlink:href="exel-20210101.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24305bbe-7496-4bd4-8c82-63c3bce5e3ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_836f0d69-0b56-49ea-8e6f-1a8d7578854a" xlink:href="exel-20210101.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24305bbe-7496-4bd4-8c82-63c3bce5e3ea" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_836f0d69-0b56-49ea-8e6f-1a8d7578854a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_ed1f6ed1-8257-41a1-8b51-c7854d022152" xlink:href="exel-20210101.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24305bbe-7496-4bd4-8c82-63c3bce5e3ea" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_ed1f6ed1-8257-41a1-8b51-c7854d022152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_e5c74280-8265-4638-9890-3d371f9ceb15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_e5c74280-8265-4638-9890-3d371f9ceb15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_eb20e8b3-68b1-4a5e-af13-9aa37f3cd605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c2ccbda8-fc76-4670-9c5f-48fb83c70b1c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_74ad41a3-e932-402c-a3d0-dd4d4aac2b5e" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c2ccbda8-fc76-4670-9c5f-48fb83c70b1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e46ee1d7-6d26-4072-a926-ccbe61bb85a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c2ccbda8-fc76-4670-9c5f-48fb83c70b1c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e46ee1d7-6d26-4072-a926-ccbe61bb85a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e46ee1d7-6d26-4072-a926-ccbe61bb85a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e46ee1d7-6d26-4072-a926-ccbe61bb85a1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e46ee1d7-6d26-4072-a926-ccbe61bb85a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e46ee1d7-6d26-4072-a926-ccbe61bb85a1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_76647f7e-1f50-4f7e-86b8-debd387206f6" xlink:href="exel-20210101.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_76647f7e-1f50-4f7e-86b8-debd387206f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_920faf7f-1234-4dd4-af55-239906719c8c" xlink:href="exel-20210101.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_920faf7f-1234-4dd4-af55-239906719c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_6c665b48-cdee-42b9-95e1-37e429512db3" xlink:href="exel-20210101.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:to="loc_exel_AllowanceForProductRebatesMember_6c665b48-cdee-42b9-95e1-37e429512db3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i05c714ade98c4fafb911aae1c014b491_RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" id="i5b626f3aab2147feb3466fbf037c534d_CollaborationAgreements"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" id="ia28bd2888d4d4c3eb16a452b29b88eb0_CollaborationAgreementsTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended" id="i18385df12000457f9211b1e1d13853cf_CollaborationAgreementsIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_2af2fc8e-20b6-4f37-9505-05978408b302" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_2af2fc8e-20b6-4f37-9505-05978408b302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_cf1f5487-7241-4c6c-9b83-62cb4be21a9c" xlink:href="exel-20210101.xsd#exel_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_UpfrontPayments_cf1f5487-7241-4c6c-9b83-62cb4be21a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_9631b0b5-8d7d-405f-a2d6-ba242f35d1a6" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_9631b0b5-8d7d-405f-a2d6-ba242f35d1a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_19e71a18-d645-494e-a9db-760a2cc7b4a7" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_MilestonePaymentsEarned_19e71a18-d645-494e-a9db-760a2cc7b4a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_ff75598b-5817-4197-8029-d6a868214b24" xlink:href="exel-20210101.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_ff75598b-5817-4197-8029-d6a868214b24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_23659ec3-18de-4c8b-9f45-39739e89c4f6" xlink:href="exel-20210101.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_23659ec3-18de-4c8b-9f45-39739e89c4f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_72811460-6383-4d86-b3c4-f046d50eed42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_72811460-6383-4d86-b3c4-f046d50eed42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_57baa482-0666-4a04-a808-cafbbb431897" xlink:href="exel-20210101.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_57baa482-0666-4a04-a808-cafbbb431897" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_6053c30d-f0d0-4a94-8dd1-8a483de5310b" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_6053c30d-f0d0-4a94-8dd1-8a483de5310b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_2951404a-20e8-4bff-9038-0f2a3f78b122" xlink:href="exel-20210101.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_2951404a-20e8-4bff-9038-0f2a3f78b122" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1f941bb5-a228-4d20-8233-42b809b23566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1f941bb5-a228-4d20-8233-42b809b23566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f941bb5-a228-4d20-8233-42b809b23566_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1f941bb5-a228-4d20-8233-42b809b23566" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f941bb5-a228-4d20-8233-42b809b23566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b72c124-5d1f-4bbc-b0a4-e16e40a67a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1f941bb5-a228-4d20-8233-42b809b23566" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b72c124-5d1f-4bbc-b0a4-e16e40a67a7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_4459d1c9-c72d-4fb2-b1a1-2f03d9c50169" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b72c124-5d1f-4bbc-b0a4-e16e40a67a7b" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_4459d1c9-c72d-4fb2-b1a1-2f03d9c50169" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da0531bb-81ee-44f4-9bc9-2cc01bc8b700" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:to="loc_srt_RangeAxis_da0531bb-81ee-44f4-9bc9-2cc01bc8b700" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da0531bb-81ee-44f4-9bc9-2cc01bc8b700_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_da0531bb-81ee-44f4-9bc9-2cc01bc8b700" xlink:to="loc_srt_RangeMember_da0531bb-81ee-44f4-9bc9-2cc01bc8b700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83b79fd6-6cc7-4656-ad64-056cfea09e98" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_da0531bb-81ee-44f4-9bc9-2cc01bc8b700" xlink:to="loc_srt_RangeMember_83b79fd6-6cc7-4656-ad64-056cfea09e98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_53fb6095-45a8-479f-8eba-102bbf3fb979" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_83b79fd6-6cc7-4656-ad64-056cfea09e98" xlink:to="loc_srt_MinimumMember_53fb6095-45a8-479f-8eba-102bbf3fb979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e2f0232d-2929-41c7-87fa-e058d616cd81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_83b79fd6-6cc7-4656-ad64-056cfea09e98" xlink:to="loc_srt_MaximumMember_e2f0232d-2929-41c7-87fa-e058d616cd81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_67d42b33-5480-4758-85e9-17bac630ad1f" xlink:href="exel-20210101.xsd#exel_RoyaltyTierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:to="loc_exel_RoyaltyTierAxis_67d42b33-5480-4758-85e9-17bac630ad1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_67d42b33-5480-4758-85e9-17bac630ad1f_default" xlink:href="exel-20210101.xsd#exel_RoyaltytierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_67d42b33-5480-4758-85e9-17bac630ad1f" xlink:to="loc_exel_RoyaltytierDomain_67d42b33-5480-4758-85e9-17bac630ad1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_8ccec285-cff9-40d2-9ea2-271d2b4986e9" xlink:href="exel-20210101.xsd#exel_RoyaltytierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_67d42b33-5480-4758-85e9-17bac630ad1f" xlink:to="loc_exel_RoyaltytierDomain_8ccec285-cff9-40d2-9ea2-271d2b4986e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_0f1339c7-9cfc-4914-8448-a092f082dd96" xlink:href="exel-20210101.xsd#exel_FinalTierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_8ccec285-cff9-40d2-9ea2-271d2b4986e9" xlink:to="loc_exel_FinalTierMember_0f1339c7-9cfc-4914-8448-a092f082dd96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7c134e98-7c83-43f7-852f-11d0a1214876" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:to="loc_srt_MajorCustomersAxis_7c134e98-7c83-43f7-852f-11d0a1214876" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7c134e98-7c83-43f7-852f-11d0a1214876_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7c134e98-7c83-43f7-852f-11d0a1214876" xlink:to="loc_srt_NameOfMajorCustomerDomain_7c134e98-7c83-43f7-852f-11d0a1214876_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_75d6e782-777f-4132-8af3-aca850b156c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7c134e98-7c83-43f7-852f-11d0a1214876" xlink:to="loc_srt_NameOfMajorCustomerDomain_75d6e782-777f-4132-8af3-aca850b156c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_cbb46db9-f00f-423c-8f12-6ec3776eabc1" xlink:href="exel-20210101.xsd#exel_GlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_75d6e782-777f-4132-8af3-aca850b156c0" xlink:to="loc_exel_GlaxoSmithKlineMember_cbb46db9-f00f-423c-8f12-6ec3776eabc1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="i5533fb75838e40f2b6f31aaa992405b8_CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1b42da68-c1df-4191-b8ae-607212b8b3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b156852-179d-476b-bf6e-477d75feb1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1b42da68-c1df-4191-b8ae-607212b8b3c0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b156852-179d-476b-bf6e-477d75feb1b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73df77f5-0b6e-4709-a348-218908de1d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1b42da68-c1df-4191-b8ae-607212b8b3c0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73df77f5-0b6e-4709-a348-218908de1d16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5367b2fe-783b-41ca-92b4-fa7579d1c95b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73df77f5-0b6e-4709-a348-218908de1d16" xlink:to="loc_srt_ProductOrServiceAxis_5367b2fe-783b-41ca-92b4-fa7579d1c95b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5367b2fe-783b-41ca-92b4-fa7579d1c95b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5367b2fe-783b-41ca-92b4-fa7579d1c95b" xlink:to="loc_srt_ProductsAndServicesDomain_5367b2fe-783b-41ca-92b4-fa7579d1c95b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_142f04ea-8231-4b55-af0d-ab9c9ebd0724" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5367b2fe-783b-41ca-92b4-fa7579d1c95b" xlink:to="loc_srt_ProductsAndServicesDomain_142f04ea-8231-4b55-af0d-ab9c9ebd0724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_67a34ba4-af33-4cfd-833c-e95db6a914ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_142f04ea-8231-4b55-af0d-ab9c9ebd0724" xlink:to="loc_us-gaap_LicenseMember_67a34ba4-af33-4cfd-833c-e95db6a914ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_fa96a249-7da3-4d48-bde6-76c4560b24b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_142f04ea-8231-4b55-af0d-ab9c9ebd0724" xlink:to="loc_us-gaap_ServiceMember_fa96a249-7da3-4d48-bde6-76c4560b24b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2d876d24-7ee2-48ca-ad39-8d9cc49c62e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73df77f5-0b6e-4709-a348-218908de1d16" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2d876d24-7ee2-48ca-ad39-8d9cc49c62e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d876d24-7ee2-48ca-ad39-8d9cc49c62e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2d876d24-7ee2-48ca-ad39-8d9cc49c62e2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d876d24-7ee2-48ca-ad39-8d9cc49c62e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58eca248-b2c1-484a-9c04-0539a3c8d2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2d876d24-7ee2-48ca-ad39-8d9cc49c62e2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58eca248-b2c1-484a-9c04-0539a3c8d2dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_85d655b5-762e-4c59-84a5-942e3b63e8d7" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58eca248-b2c1-484a-9c04-0539a3c8d2dc" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_85d655b5-762e-4c59-84a5-942e3b63e8d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended" id="i5dc682a1547944d2a332672328279298_CollaborationAgreementsTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_ab40ec31-1c02-4e12-8cbe-3ae4ed9035a9" xlink:href="exel-20210101.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_ab40ec31-1c02-4e12-8cbe-3ae4ed9035a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_269f0f41-fcc5-42b3-b45e-f43620928a83" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_269f0f41-fcc5-42b3-b45e-f43620928a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_01c160a5-ac52-401b-9fa8-1799e0d5a556" xlink:href="exel-20210101.xsd#exel_PeriodOfSpecificSalesVolumeThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_01c160a5-ac52-401b-9fa8-1799e0d5a556" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_dbb23274-2404-4501-ae08-a9828c076b12" xlink:href="exel-20210101.xsd#exel_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_UpfrontPayments_dbb23274-2404-4501-ae08-a9828c076b12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_04b4e9ad-c81a-4921-93c9-e61fba54820e" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_04b4e9ad-c81a-4921-93c9-e61fba54820e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_265a2a05-29f2-4542-9245-bab8a9ee16c7" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_MilestonePaymentsEarned_265a2a05-29f2-4542-9245-bab8a9ee16c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsYetToBeEarned_fdc8c389-0c13-4726-aaff-029a48749a4d" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsYetToBeEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_MilestonePaymentsYetToBeEarned_fdc8c389-0c13-4726-aaff-029a48749a4d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_76c90716-3e4f-43a9-a7aa-4d634567af04" xlink:href="exel-20210101.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_76c90716-3e4f-43a9-a7aa-4d634567af04" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_a7403ade-41a8-47ed-a003-34170234d181" xlink:href="exel-20210101.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_a7403ade-41a8-47ed-a003-34170234d181" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTier_8534974d-a0d1-48da-a1b5-e4edb1deba0f" xlink:href="exel-20210101.xsd#exel_RoyaltyTier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_RoyaltyTier_8534974d-a0d1-48da-a1b5-e4edb1deba0f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_dd34e113-7786-43cd-a9bb-efc5b582d8f2" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_dd34e113-7786-43cd-a9bb-efc5b582d8f2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6f1c2e34-1392-4550-8a06-6b703db074a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6f1c2e34-1392-4550-8a06-6b703db074a6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92e97891-7ea8-42d4-a4e9-6e59295380cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92e97891-7ea8-42d4-a4e9-6e59295380cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92e97891-7ea8-42d4-a4e9-6e59295380cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92e97891-7ea8-42d4-a4e9-6e59295380cb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92e97891-7ea8-42d4-a4e9-6e59295380cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1327f879-8561-4e7b-8ac6-7f44eb8339b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92e97891-7ea8-42d4-a4e9-6e59295380cb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1327f879-8561-4e7b-8ac6-7f44eb8339b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_ea3118b4-acee-4a5e-9592-08d79cb67f36" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1327f879-8561-4e7b-8ac6-7f44eb8339b7" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_ea3118b4-acee-4a5e-9592-08d79cb67f36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b5bf8eb6-68c8-4487-829b-366c22132c41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_srt_StatementGeographicalAxis_b5bf8eb6-68c8-4487-829b-366c22132c41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b5bf8eb6-68c8-4487-829b-366c22132c41_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b5bf8eb6-68c8-4487-829b-366c22132c41" xlink:to="loc_srt_SegmentGeographicalDomain_b5bf8eb6-68c8-4487-829b-366c22132c41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46d8b7d0-ca04-4bf4-b396-9a1bbbcae37f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b5bf8eb6-68c8-4487-829b-366c22132c41" xlink:to="loc_srt_SegmentGeographicalDomain_46d8b7d0-ca04-4bf4-b396-9a1bbbcae37f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_43326e8e-2478-40b0-ae84-468c31c6c5d3" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_46d8b7d0-ca04-4bf4-b396-9a1bbbcae37f" xlink:to="loc_country_JP_43326e8e-2478-40b0-ae84-468c31c6c5d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_7c0851e1-19c1-4cc9-8ff4-f25948c601c0" xlink:href="exel-20210101.xsd#exel_RoyaltyTierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_exel_RoyaltyTierAxis_7c0851e1-19c1-4cc9-8ff4-f25948c601c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_7c0851e1-19c1-4cc9-8ff4-f25948c601c0_default" xlink:href="exel-20210101.xsd#exel_RoyaltytierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltyTierAxis_7c0851e1-19c1-4cc9-8ff4-f25948c601c0" xlink:to="loc_exel_RoyaltytierDomain_7c0851e1-19c1-4cc9-8ff4-f25948c601c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_209914ca-47d1-4e5d-aa4a-25ecc7e10392" xlink:href="exel-20210101.xsd#exel_RoyaltytierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltyTierAxis_7c0851e1-19c1-4cc9-8ff4-f25948c601c0" xlink:to="loc_exel_RoyaltytierDomain_209914ca-47d1-4e5d-aa4a-25ecc7e10392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InitialMember_4c387c3d-f962-4bf4-bf2b-391424d74a12" xlink:href="exel-20210101.xsd#exel_InitialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_209914ca-47d1-4e5d-aa4a-25ecc7e10392" xlink:to="loc_exel_InitialMember_4c387c3d-f962-4bf4-bf2b-391424d74a12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_4e5abf40-b40f-4f7c-8f78-d347ecd268ff" xlink:href="exel-20210101.xsd#exel_FinalTierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_209914ca-47d1-4e5d-aa4a-25ecc7e10392" xlink:to="loc_exel_FinalTierMember_4e5abf40-b40f-4f7c-8f78-d347ecd268ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a4dad40-e44f-4e3f-a71d-a46074ce9843" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_srt_RangeAxis_7a4dad40-e44f-4e3f-a71d-a46074ce9843" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a4dad40-e44f-4e3f-a71d-a46074ce9843_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7a4dad40-e44f-4e3f-a71d-a46074ce9843" xlink:to="loc_srt_RangeMember_7a4dad40-e44f-4e3f-a71d-a46074ce9843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_972da010-fa20-4523-bdfd-8d0673f3e3bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7a4dad40-e44f-4e3f-a71d-a46074ce9843" xlink:to="loc_srt_RangeMember_972da010-fa20-4523-bdfd-8d0673f3e3bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff830f3a-c8fc-4fbc-b4db-3d2c7f712b79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_972da010-fa20-4523-bdfd-8d0673f3e3bd" xlink:to="loc_srt_MinimumMember_ff830f3a-c8fc-4fbc-b4db-3d2c7f712b79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c21eeb57-a850-4df4-9f11-cb17c7e9e9fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_972da010-fa20-4523-bdfd-8d0673f3e3bd" xlink:to="loc_srt_MaximumMember_c21eeb57-a850-4df4-9f11-cb17c7e9e9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_73d15499-04de-4a92-b9d5-c9f30bbb7ceb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_srt_MajorCustomersAxis_73d15499-04de-4a92-b9d5-c9f30bbb7ceb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_73d15499-04de-4a92-b9d5-c9f30bbb7ceb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_73d15499-04de-4a92-b9d5-c9f30bbb7ceb" xlink:to="loc_srt_NameOfMajorCustomerDomain_73d15499-04de-4a92-b9d5-c9f30bbb7ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d45f461e-3fd4-432a-b206-d5788e1bd67f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_73d15499-04de-4a92-b9d5-c9f30bbb7ceb" xlink:to="loc_srt_NameOfMajorCustomerDomain_d45f461e-3fd4-432a-b206-d5788e1bd67f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_16bbbaba-93ed-4702-bdff-cc9c5f8df4be" xlink:href="exel-20210101.xsd#exel_GlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d45f461e-3fd4-432a-b206-d5788e1bd67f" xlink:to="loc_exel_GlaxoSmithKlineMember_16bbbaba-93ed-4702-bdff-cc9c5f8df4be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="ide8e0dcdad5a47e5b0749cf81bd4ec35_CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c9f6efd5-cf14-49ba-a468-cfe0913c333c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8d70624-6f07-454b-9224-68a02c4f44e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c9f6efd5-cf14-49ba-a468-cfe0913c333c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8d70624-6f07-454b-9224-68a02c4f44e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e410fae0-82c2-48c8-8e26-cfb7bd00c2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c9f6efd5-cf14-49ba-a468-cfe0913c333c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e410fae0-82c2-48c8-8e26-cfb7bd00c2ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fa46cba3-de36-4e18-bd92-870e7ea35b6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e410fae0-82c2-48c8-8e26-cfb7bd00c2ec" xlink:to="loc_srt_ProductOrServiceAxis_fa46cba3-de36-4e18-bd92-870e7ea35b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fa46cba3-de36-4e18-bd92-870e7ea35b6a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fa46cba3-de36-4e18-bd92-870e7ea35b6a" xlink:to="loc_srt_ProductsAndServicesDomain_fa46cba3-de36-4e18-bd92-870e7ea35b6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e04ed72e-ca6e-414b-ab97-d859ee7b369c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fa46cba3-de36-4e18-bd92-870e7ea35b6a" xlink:to="loc_srt_ProductsAndServicesDomain_e04ed72e-ca6e-414b-ab97-d859ee7b369c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1fd7a107-4daf-4acb-ad9b-22f08ee7f92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e04ed72e-ca6e-414b-ab97-d859ee7b369c" xlink:to="loc_us-gaap_LicenseMember_1fd7a107-4daf-4acb-ad9b-22f08ee7f92e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ba7b6e60-f423-40d2-9bef-610aacb708b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e04ed72e-ca6e-414b-ab97-d859ee7b369c" xlink:to="loc_us-gaap_ServiceMember_ba7b6e60-f423-40d2-9bef-610aacb708b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_324b6138-96c9-457a-ae28-acba324921a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e410fae0-82c2-48c8-8e26-cfb7bd00c2ec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_324b6138-96c9-457a-ae28-acba324921a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_324b6138-96c9-457a-ae28-acba324921a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_324b6138-96c9-457a-ae28-acba324921a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_324b6138-96c9-457a-ae28-acba324921a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbc80d1c-641a-4751-9471-8d6a6bf5a0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_324b6138-96c9-457a-ae28-acba324921a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbc80d1c-641a-4751-9471-8d6a6bf5a0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_795c67fb-d693-4897-8a6e-e26ae36f8de9" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbc80d1c-641a-4751-9471-8d6a6bf5a0b2" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_795c67fb-d693-4897-8a6e-e26ae36f8de9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails" xlink:type="extended" id="i227cda7695264076bd70d66bba8ba75b_CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c1f8603-bfd7-4912-b2e0-981cbb7c7497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_09636d44-68a3-427e-981b-711d0c357be7" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c1f8603-bfd7-4912-b2e0-981cbb7c7497" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_09636d44-68a3-427e-981b-711d0c357be7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_1b9fe133-b857-4769-9ed3-752203e82029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c1f8603-bfd7-4912-b2e0-981cbb7c7497" xlink:to="loc_us-gaap_RoyaltyExpense_1b9fe133-b857-4769-9ed3-752203e82029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eaa5c8c3-7ee7-405a-8abc-b44ce3cee4ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c1f8603-bfd7-4912-b2e0-981cbb7c7497" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eaa5c8c3-7ee7-405a-8abc-b44ce3cee4ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ddd99225-0b2a-41e3-93d5-591f82c6c35f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eaa5c8c3-7ee7-405a-8abc-b44ce3cee4ed" xlink:to="loc_srt_MajorCustomersAxis_ddd99225-0b2a-41e3-93d5-591f82c6c35f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ddd99225-0b2a-41e3-93d5-591f82c6c35f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ddd99225-0b2a-41e3-93d5-591f82c6c35f" xlink:to="loc_srt_NameOfMajorCustomerDomain_ddd99225-0b2a-41e3-93d5-591f82c6c35f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_966254b6-ded3-4a34-a261-31c04b664709" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ddd99225-0b2a-41e3-93d5-591f82c6c35f" xlink:to="loc_srt_NameOfMajorCustomerDomain_966254b6-ded3-4a34-a261-31c04b664709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_a91a01b6-9288-49c5-b7e0-97ab16a4c99d" xlink:href="exel-20210101.xsd#exel_GlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_966254b6-ded3-4a34-a261-31c04b664709" xlink:to="loc_exel_GlaxoSmithKlineMember_a91a01b6-9288-49c5-b7e0-97ab16a4c99d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0a735292-33cd-4ebf-b89f-308f7976fc62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eaa5c8c3-7ee7-405a-8abc-b44ce3cee4ed" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0a735292-33cd-4ebf-b89f-308f7976fc62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a735292-33cd-4ebf-b89f-308f7976fc62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0a735292-33cd-4ebf-b89f-308f7976fc62" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0a735292-33cd-4ebf-b89f-308f7976fc62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c8aeb6d-8481-459c-9d32-bfc335baca29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0a735292-33cd-4ebf-b89f-308f7976fc62" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c8aeb6d-8481-459c-9d32-bfc335baca29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_d5d8b027-11e7-4e6d-b924-ba7e2836c840" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c8aeb6d-8481-459c-9d32-bfc335baca29" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_d5d8b027-11e7-4e6d-b924-ba7e2836c840" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended" id="i039933c66ac44fb19dfbf8d4be7a8289_CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f51537e4-6179-4eee-9f3a-f8a7f828cdde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_92bc6166-7f24-472e-984d-f78ca1e1dfcd" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f51537e4-6179-4eee-9f3a-f8a7f828cdde" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_92bc6166-7f24-472e-984d-f78ca1e1dfcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f79987f-b638-4cbf-8ff8-68cd6e448431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f51537e4-6179-4eee-9f3a-f8a7f828cdde" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f79987f-b638-4cbf-8ff8-68cd6e448431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87d46090-27a2-4a47-9376-1e51b8bf193a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f51537e4-6179-4eee-9f3a-f8a7f828cdde" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87d46090-27a2-4a47-9376-1e51b8bf193a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5dc82d35-ef66-43d7-a378-ae6258aa73f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87d46090-27a2-4a47-9376-1e51b8bf193a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5dc82d35-ef66-43d7-a378-ae6258aa73f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5dc82d35-ef66-43d7-a378-ae6258aa73f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5dc82d35-ef66-43d7-a378-ae6258aa73f5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5dc82d35-ef66-43d7-a378-ae6258aa73f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d6adf33-766f-44ad-9d3a-fe4faa40edf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5dc82d35-ef66-43d7-a378-ae6258aa73f5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d6adf33-766f-44ad-9d3a-fe4faa40edf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_9fbda4b3-1e52-4495-b2ab-4f3d61432c6b" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d6adf33-766f-44ad-9d3a-fe4faa40edf2" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_9fbda4b3-1e52-4495-b2ab-4f3d61432c6b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsOtherCollaborationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="extended" id="i3d90c147a9df45a89a4764ea98173ba5_CollaborationAgreementsOtherCollaborationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_4bb2d3fc-e6d0-42d8-8f45-54de7fae5721" xlink:href="exel-20210101.xsd#exel_ProfitSharingAgreementPercentOfProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_4bb2d3fc-e6d0-42d8-8f45-54de7fae5721" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_a5634807-72a6-4512-a1de-fee3e16a710a" xlink:href="exel-20210101.xsd#exel_ProfitSharingAgreementProfitThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_a5634807-72a6-4512-a1de-fee3e16a710a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_4f0754e5-cd0c-47d6-8118-d1d2c53b3ba2" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementAchievedMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_4f0754e5-cd0c-47d6-8118-d1d2c53b3ba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_e19c6582-1903-4284-9458-e499679fae09" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_e19c6582-1903-4284-9458-e499679fae09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90a21e36-1fde-4163-b89a-21d5aa46edee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90a21e36-1fde-4163-b89a-21d5aa46edee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementTerminationPeriod_bcf1ec84-910e-40eb-8751-0e897b7cc822" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_CollaborationAgreementTerminationPeriod_bcf1ec84-910e-40eb-8751-0e897b7cc822" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTiersAxis_3761dbcc-666b-4d51-ac84-49f37576beb4" xlink:href="exel-20210101.xsd#exel_ProfitSharingTiersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:to="loc_exel_ProfitSharingTiersAxis_3761dbcc-666b-4d51-ac84-49f37576beb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTiersDomain_3761dbcc-666b-4d51-ac84-49f37576beb4_default" xlink:href="exel-20210101.xsd#exel_ProfitSharingTiersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_ProfitSharingTiersAxis_3761dbcc-666b-4d51-ac84-49f37576beb4" xlink:to="loc_exel_ProfitSharingTiersDomain_3761dbcc-666b-4d51-ac84-49f37576beb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:href="exel-20210101.xsd#exel_ProfitSharingTiersDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_ProfitSharingTiersAxis_3761dbcc-666b-4d51-ac84-49f37576beb4" xlink:to="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTierOneMember_2804c8ab-4554-43ea-be59-93e4cf538e5e" xlink:href="exel-20210101.xsd#exel_ProfitSharingTierOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:to="loc_exel_ProfitSharingTierOneMember_2804c8ab-4554-43ea-be59-93e4cf538e5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTierTwoMember_29e0d0a2-1c39-444d-ba51-f92aa6bd1a20" xlink:href="exel-20210101.xsd#exel_ProfitSharingTierTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:to="loc_exel_ProfitSharingTierTwoMember_29e0d0a2-1c39-444d-ba51-f92aa6bd1a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTierThreeMember_64e5d4c1-66cf-4399-8c5d-b29c505a21e7" xlink:href="exel-20210101.xsd#exel_ProfitSharingTierThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:to="loc_exel_ProfitSharingTierThreeMember_64e5d4c1-66cf-4399-8c5d-b29c505a21e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_78bd5ebf-391a-42e9-aad4-60147d4ae5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:to="loc_us-gaap_TypeOfArrangementAxis_78bd5ebf-391a-42e9-aad4-60147d4ae5d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78bd5ebf-391a-42e9-aad4-60147d4ae5d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_78bd5ebf-391a-42e9-aad4-60147d4ae5d9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78bd5ebf-391a-42e9-aad4-60147d4ae5d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b510354d-305f-44b1-93a6-0fa0d56630de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_78bd5ebf-391a-42e9-aad4-60147d4ae5d9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b510354d-305f-44b1-93a6-0fa0d56630de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_d0a9de27-bb69-4908-aa76-d20799260281" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b510354d-305f-44b1-93a6-0fa0d56630de" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_d0a9de27-bb69-4908-aa76-d20799260281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_6d1886ee-be6a-46af-acad-f4b4e9cce42c" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b510354d-305f-44b1-93a6-0fa0d56630de" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_6d1886ee-be6a-46af-acad-f4b4e9cce42c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8148429-d7dd-47cf-a6c6-a3dc5dca3746" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:to="loc_srt_RangeAxis_b8148429-d7dd-47cf-a6c6-a3dc5dca3746" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b8148429-d7dd-47cf-a6c6-a3dc5dca3746_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b8148429-d7dd-47cf-a6c6-a3dc5dca3746" xlink:to="loc_srt_RangeMember_b8148429-d7dd-47cf-a6c6-a3dc5dca3746_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b9a726d-7441-4147-8fae-4d6ed34038dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b8148429-d7dd-47cf-a6c6-a3dc5dca3746" xlink:to="loc_srt_RangeMember_3b9a726d-7441-4147-8fae-4d6ed34038dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5af34737-386d-4edd-b307-81d4a85dc451" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b9a726d-7441-4147-8fae-4d6ed34038dc" xlink:to="loc_srt_MinimumMember_5af34737-386d-4edd-b307-81d4a85dc451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6872511f-80cd-417e-a4e6-9d2dc10fb3f9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b9a726d-7441-4147-8fae-4d6ed34038dc" xlink:to="loc_srt_MaximumMember_6872511f-80cd-417e-a4e6-9d2dc10fb3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d62f822-b572-4225-ace9-61bca77b9296" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:to="loc_srt_ProductOrServiceAxis_4d62f822-b572-4225-ace9-61bca77b9296" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d62f822-b572-4225-ace9-61bca77b9296_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4d62f822-b572-4225-ace9-61bca77b9296" xlink:to="loc_srt_ProductsAndServicesDomain_4d62f822-b572-4225-ace9-61bca77b9296_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b178f64-c56d-4d08-b47b-b5973502ddb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4d62f822-b572-4225-ace9-61bca77b9296" xlink:to="loc_srt_ProductsAndServicesDomain_9b178f64-c56d-4d08-b47b-b5973502ddb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MINNEBROMember_013578f3-9b69-458e-9d72-526a3f2e1c33" xlink:href="exel-20210101.xsd#exel_MINNEBROMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b178f64-c56d-4d08-b47b-b5973502ddb2" xlink:to="loc_exel_MINNEBROMember_013578f3-9b69-458e-9d72-526a3f2e1c33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="extended" id="ic1ee5aa7efbe4fb3b6cbb3f2251df1ad_CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments_53e7cf5e-80c1-49e4-8c92-7cc5f2e5594c" xlink:href="exel-20210101.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborativeAgreementsUpfrontPayments_53e7cf5e-80c1-49e4-8c92-7cc5f2e5594c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_1c338788-127b-4d61-ab5b-134fc0b071b0" xlink:href="exel-20210101.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_1c338788-127b-4d61-ab5b-134fc0b071b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_96680e19-a9d8-44d5-84d3-6c4523699368" xlink:href="exel-20210101.xsd#exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_96680e19-a9d8-44d5-84d3-6c4523699368" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_cf8d720b-9934-4e6d-9390-1e8203f071fa" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementsAdditionalUpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_cf8d720b-9934-4e6d-9390-1e8203f071fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_d515d89b-5d0c-4d8c-8584-9ead3ea3b36b" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_d515d89b-5d0c-4d8c-8584-9ead3ea3b36b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_a17817f9-68c0-454b-9ea7-fb4b2cd7e2ac" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_a17817f9-68c0-454b-9ea7-fb4b2cd7e2ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_c8650726-9cd5-49f0-bf9e-c6097d863912" xlink:href="exel-20210101.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_c8650726-9cd5-49f0-bf9e-c6097d863912" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_75f74760-f30b-4315-959a-cb0529e70216" xlink:href="exel-20210101.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_75f74760-f30b-4315-959a-cb0529e70216" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_3ef1949c-bb47-4806-b058-767d321addae" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementNumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementNumberOfPrograms_3ef1949c-bb47-4806-b058-767d321addae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_365c336b-0964-4b6d-b272-996e31d6a0d4" xlink:href="exel-20210101.xsd#exel_UpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_UpfrontPayments_365c336b-0964-4b6d-b272-996e31d6a0d4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_abc437d8-434c-421d-8845-7d9615d432c4" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementNumberOfPreexistingPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_abc437d8-434c-421d-8845-7d9615d432c4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_60c47517-1f6b-4ceb-9018-c0786c8032b0" xlink:href="exel-20210101.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_60c47517-1f6b-4ceb-9018-c0786c8032b0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_434ffd33-5371-40f5-a063-919dd1ba9bcd" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementsUpfrontPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_434ffd33-5371-40f5-a063-919dd1ba9bcd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1925536-9692-428e-9b71-9b0766f9efbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1925536-9692-428e-9b71-9b0766f9efbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_120b5932-3a3b-479d-9b1b-5ca6960e6130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1925536-9692-428e-9b71-9b0766f9efbf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_120b5932-3a3b-479d-9b1b-5ca6960e6130" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_120b5932-3a3b-479d-9b1b-5ca6960e6130_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_120b5932-3a3b-479d-9b1b-5ca6960e6130" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_120b5932-3a3b-479d-9b1b-5ca6960e6130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_120b5932-3a3b-479d-9b1b-5ca6960e6130" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithCatalentMember_2e0b44f9-a7c1-46e4-9f3a-88f4ee2be3ab" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithCatalentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:to="loc_exel_CollaborativeArrangementWithCatalentMember_2e0b44f9-a7c1-46e4-9f3a-88f4ee2be3ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember_7f35cf49-5e91-42cd-b001-badfdae994b3" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithNBETherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:to="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember_7f35cf49-5e91-42cd-b001-badfdae994b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_30d3b222-7347-4fc0-93e8-40b28a54f167" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:to="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_30d3b222-7347-4fc0-93e8-40b28a54f167" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_f04b1d21-9339-4674-a54b-eccd9a0d2802" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_f04b1d21-9339-4674-a54b-eccd9a0d2802" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3da02ac6-d061-4ada-b116-1cbcde28036d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1925536-9692-428e-9b71-9b0766f9efbf" xlink:to="loc_srt_RangeAxis_3da02ac6-d061-4ada-b116-1cbcde28036d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3da02ac6-d061-4ada-b116-1cbcde28036d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3da02ac6-d061-4ada-b116-1cbcde28036d" xlink:to="loc_srt_RangeMember_3da02ac6-d061-4ada-b116-1cbcde28036d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_442708be-d7e1-47f8-a460-b27f6220e539" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3da02ac6-d061-4ada-b116-1cbcde28036d" xlink:to="loc_srt_RangeMember_442708be-d7e1-47f8-a460-b27f6220e539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_469831a9-3b35-47bc-b275-a564e09b0d61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_442708be-d7e1-47f8-a460-b27f6220e539" xlink:to="loc_srt_MaximumMember_469831a9-3b35-47bc-b275-a564e09b0d61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e311fe36-eb57-4183-a06a-46cd4e6f1438" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_442708be-d7e1-47f8-a460-b27f6220e539" xlink:to="loc_srt_MinimumMember_e311fe36-eb57-4183-a06a-46cd4e6f1438" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsInvenraCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="extended" id="i8a135237f27d43e8a178673d9b6ea71e_CollaborationAgreementsInvenraCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1fb4a786-1fe5-4357-9c5c-a4b0757cc0ef" xlink:href="exel-20210101.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1fb4a786-1fe5-4357-9c5c-a4b0757cc0ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProjectInitiationFeePayment_f256fd28-2a67-499d-aa24-6fc0ede5b7bc" xlink:href="exel-20210101.xsd#exel_ProjectInitiationFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:to="loc_exel_ProjectInitiationFeePayment_f256fd28-2a67-499d-aa24-6fc0ede5b7bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontAndMilestonePayments_eda93755-76df-481e-a276-4473922185a1" xlink:href="exel-20210101.xsd#exel_UpfrontAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:to="loc_exel_UpfrontAndMilestonePayments_eda93755-76df-481e-a276-4473922185a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96cad599-f71b-4aba-9716-305b51e134b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96cad599-f71b-4aba-9716-305b51e134b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dc7bb111-9bc0-4b08-b494-80e72c01bb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96cad599-f71b-4aba-9716-305b51e134b7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dc7bb111-9bc0-4b08-b494-80e72c01bb18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc7bb111-9bc0-4b08-b494-80e72c01bb18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dc7bb111-9bc0-4b08-b494-80e72c01bb18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dc7bb111-9bc0-4b08-b494-80e72c01bb18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e0c7ef-e6f7-48d1-ab30-32215c6923f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dc7bb111-9bc0-4b08-b494-80e72c01bb18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e0c7ef-e6f7-48d1-ab30-32215c6923f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_bd866be8-2592-4162-8f34-70acc3ad642f" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithInvenraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e0c7ef-e6f7-48d1-ab30-32215c6923f7" xlink:to="loc_exel_CollaborativeArrangementWithInvenraMember_bd866be8-2592-4162-8f34-70acc3ad642f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveAxis_2b3945de-f321-406f-b66c-64c1b7942ab8" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96cad599-f71b-4aba-9716-305b51e134b7" xlink:to="loc_exel_MilestoneObjectiveAxis_2b3945de-f321-406f-b66c-64c1b7942ab8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveDomain_2b3945de-f321-406f-b66c-64c1b7942ab8_default" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_2b3945de-f321-406f-b66c-64c1b7942ab8" xlink:to="loc_exel_MilestoneObjectiveDomain_2b3945de-f321-406f-b66c-64c1b7942ab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_2b3945de-f321-406f-b66c-64c1b7942ab8" xlink:to="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_805d300a-a9ea-4a7a-a246-8d8ce0e6f383" xlink:href="exel-20210101.xsd#exel_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:to="loc_exel_DevelopmentAndRegulatoryMilestoneMember_805d300a-a9ea-4a7a-a246-8d8ce0e6f383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_2929cad5-cd62-4bb6-8e80-7fd75eafcf1f" xlink:href="exel-20210101.xsd#exel_AdditionalDevelopmentAndRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:to="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_2929cad5-cd62-4bb6-8e80-7fd75eafcf1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductCommercializationMember_909aa511-8699-426d-9854-c5f3ca410a3e" xlink:href="exel-20210101.xsd#exel_ProductCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:to="loc_exel_ProductCommercializationMember_909aa511-8699-426d-9854-c5f3ca410a3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DiscoveryProjectMember_d9097436-9ad1-4fb0-8155-656a26f15805" xlink:href="exel-20210101.xsd#exel_DiscoveryProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:to="loc_exel_DiscoveryProjectMember_d9097436-9ad1-4fb0-8155-656a26f15805" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsStemSynergyCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails" xlink:type="extended" id="i4f806a38a3954f7cbee7a930139e09e3_CollaborationAgreementsStemSynergyCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8b3f4258-b3e9-4fb3-a2d6-750193532839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontAndMilestonePayments_98623d13-4910-46b7-9e47-444789daae46" xlink:href="exel-20210101.xsd#exel_UpfrontAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8b3f4258-b3e9-4fb3-a2d6-750193532839" xlink:to="loc_exel_UpfrontAndMilestonePayments_98623d13-4910-46b7-9e47-444789daae46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_c79d3b56-b584-458d-8fbd-4c13473e4ed7" xlink:href="exel-20210101.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8b3f4258-b3e9-4fb3-a2d6-750193532839" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_c79d3b56-b584-458d-8fbd-4c13473e4ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f373e43-6da8-4cc0-98a0-40e71b22abf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8b3f4258-b3e9-4fb3-a2d6-750193532839" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f373e43-6da8-4cc0-98a0-40e71b22abf2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a7bd98e1-ea9c-447e-8c79-820d7c7166e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f373e43-6da8-4cc0-98a0-40e71b22abf2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a7bd98e1-ea9c-447e-8c79-820d7c7166e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7bd98e1-ea9c-447e-8c79-820d7c7166e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a7bd98e1-ea9c-447e-8c79-820d7c7166e6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7bd98e1-ea9c-447e-8c79-820d7c7166e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d34dad-f8cb-4cc6-a36c-1f3f994b66d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a7bd98e1-ea9c-447e-8c79-820d7c7166e6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d34dad-f8cb-4cc6-a36c-1f3f994b66d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_013c23d5-a177-4189-8f54-26068e8e948c" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithStemSynergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d34dad-f8cb-4cc6-a36c-1f3f994b66d2" xlink:to="loc_exel_CollaborativeArrangementWithStemSynergyMember_013c23d5-a177-4189-8f54-26068e8e948c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveAxis_a8155c5e-d99c-4972-ae8e-7951cb004a0f" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f373e43-6da8-4cc0-98a0-40e71b22abf2" xlink:to="loc_exel_MilestoneObjectiveAxis_a8155c5e-d99c-4972-ae8e-7951cb004a0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveDomain_a8155c5e-d99c-4972-ae8e-7951cb004a0f_default" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_a8155c5e-d99c-4972-ae8e-7951cb004a0f" xlink:to="loc_exel_MilestoneObjectiveDomain_a8155c5e-d99c-4972-ae8e-7951cb004a0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveDomain_caf57cbf-050c-47c2-9615-4d589294d54f" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_a8155c5e-d99c-4972-ae8e-7951cb004a0f" xlink:to="loc_exel_MilestoneObjectiveDomain_caf57cbf-050c-47c2-9615-4d589294d54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FirstProductToReachMarketMember_72702d53-b1d8-48ce-9484-4de860637d91" xlink:href="exel-20210101.xsd#exel_FirstProductToReachMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_caf57cbf-050c-47c2-9615-4d589294d54f" xlink:to="loc_exel_FirstProductToReachMarketMember_72702d53-b1d8-48ce-9484-4de860637d91" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestments"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended" id="ie3165eea7aa64d71b52521d91ec7bcc4_CashandInvestments"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended" id="i02b8a6b5c6b3424cbc44e559e491c5ac_CashandInvestmentsTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i8bfb6c8572c5485dafb684ab6a842948_CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsSummarybySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails" xlink:type="extended" id="i9515a64fd6b14e24b99a746761689830_CashandInvestmentsSummarybySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a1d967a2-1a7e-4e59-a374-9fa16750c2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a1d967a2-1a7e-4e59-a374-9fa16750c2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cb6d1dc7-ee49-4c00-acd1-3be77d695a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cb6d1dc7-ee49-4c00-acd1-3be77d695a43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aabc6b4e-9a38-4747-8f4c-7b8d37fa79c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aabc6b4e-9a38-4747-8f4c-7b8d37fa79c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0494e7a7-2097-442c-8fad-9c9bdf5e7bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0494e7a7-2097-442c-8fad-9c9bdf5e7bd9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_e6c2fcce-f41d-41a7-ba2b-c95b4f54ecd6" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_e6c2fcce-f41d-41a7-ba2b-c95b4f54ecd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_a9b711ed-2632-4195-8938-5c944ac46f7c" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_a9b711ed-2632-4195-8938-5c944ac46f7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e1be027f-64ab-4ac5-bd98-e0acd241aea6" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e1be027f-64ab-4ac5-bd98-e0acd241aea6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_10aa16d9-fa55-4154-ad65-772d4c43f1d2" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_10aa16d9-fa55-4154-ad65-772d4c43f1d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_acfa6f78-5ea2-4c2b-8910-db89e9a01520" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_acfa6f78-5ea2-4c2b-8910-db89e9a01520" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07ec2dc4-37d0-41a9-8eaa-509e8b52623d" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07ec2dc4-37d0-41a9-8eaa-509e8b52623d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f0b36ee-2e3d-4d76-ac23-810270933dc2" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f0b36ee-2e3d-4d76-ac23-810270933dc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_095b8840-fcd7-46c1-8afe-f16e3d7ebd59" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_095b8840-fcd7-46c1-8afe-f16e3d7ebd59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a1557562-2a7c-4e50-87ae-ff8e8d98ec7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a1557562-2a7c-4e50-87ae-ff8e8d98ec7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c06eab52-7ea7-4410-9d0a-d7355c19b631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a1557562-2a7c-4e50-87ae-ff8e8d98ec7e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c06eab52-7ea7-4410-9d0a-d7355c19b631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c06eab52-7ea7-4410-9d0a-d7355c19b631_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c06eab52-7ea7-4410-9d0a-d7355c19b631" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c06eab52-7ea7-4410-9d0a-d7355c19b631_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c06eab52-7ea7-4410-9d0a-d7355c19b631" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cf8ab468-f43a-498c-a905-dc1e00c19148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_CommercialPaperMember_cf8ab468-f43a-498c-a905-dc1e00c19148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_f74a93ca-5854-46d1-b70d-622ece253498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_f74a93ca-5854-46d1-b70d-622ece253498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_61987d68-5f2c-4f40-b8bc-6badc11601d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_61987d68-5f2c-4f40-b8bc-6badc11601d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2db14830-bb0f-42f2-842d-e58a8b6b6e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_MunicipalBondsMember_2db14830-bb0f-42f2-842d-e58a8b6b6e86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_9f1b7574-6b50-4ded-8c4f-fa6c403ac576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_CashMember_9f1b7574-6b50-4ded-8c4f-fa6c403ac576" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b7d7b728-db1c-4f81-958e-fdfea61dcf7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b7d7b728-db1c-4f81-958e-fdfea61dcf7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f5926c33-c6bc-4666-83e7-0ec4a62e7338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f5926c33-c6bc-4666-83e7-0ec4a62e7338" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended" id="iea26575499074b44b48e9080bff88edc_CashandInvestmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsGrossUnrealizedLossesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails" xlink:type="extended" id="id9d57cfd530b4e80aa269f6f6f240c8a_CashandInvestmentsGrossUnrealizedLossesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a05aa682-721d-4289-a9a3-7e2931c1b61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_28dd97f9-2474-4543-a272-fb7321ae723d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a05aa682-721d-4289-a9a3-7e2931c1b61d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_28dd97f9-2474-4543-a272-fb7321ae723d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_899311fb-b6ce-4669-b0df-558b564357ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a05aa682-721d-4289-a9a3-7e2931c1b61d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_899311fb-b6ce-4669-b0df-558b564357ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2facf1b3-5d74-4ac5-be26-395192480119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a05aa682-721d-4289-a9a3-7e2931c1b61d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2facf1b3-5d74-4ac5-be26-395192480119" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_721fc3fb-6d85-4ef7-9a6c-b5f597700a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2facf1b3-5d74-4ac5-be26-395192480119" xlink:to="loc_us-gaap_FinancialInstrumentAxis_721fc3fb-6d85-4ef7-9a6c-b5f597700a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_721fc3fb-6d85-4ef7-9a6c-b5f597700a99_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_721fc3fb-6d85-4ef7-9a6c-b5f597700a99" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_721fc3fb-6d85-4ef7-9a6c-b5f597700a99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_721fc3fb-6d85-4ef7-9a6c-b5f597700a99" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ce5233bf-ae4c-41e0-8f1a-67b8290deccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ce5233bf-ae4c-41e0-8f1a-67b8290deccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_3b8f704e-2c4a-4610-aa6a-409ff8250f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_3b8f704e-2c4a-4610-aa6a-409ff8250f54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_d09d431e-3078-476b-876c-69d76b11ef6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:to="loc_us-gaap_MunicipalBondsMember_d09d431e-3078-476b-876c-69d76b11ef6b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsSummarybyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails" xlink:type="extended" id="i45dd3faf1c4c4a93bc71be2bc3442f39_CashandInvestmentsSummarybyContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20210101.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" id="i564f704720154b59869c70ece5022111_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20210101.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" id="iab05931f47bf4b46b4dce09c8f4f12bb_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="iaadf57a109194e609ca0580f24bad29e_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a3e897b-a2c7-4408-898a-9e9cdbaaed17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a3e897b-a2c7-4408-898a-9e9cdbaaed17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d850088f-5395-404f-9289-062ea5f5cb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d850088f-5395-404f-9289-062ea5f5cb21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d43f2930-fbb8-4173-bbba-962ced60f86c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d43f2930-fbb8-4173-bbba-962ced60f86c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_112b1e11-bc98-48aa-9d76-ee237ee9b477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:to="loc_us-gaap_FinancialInstrumentAxis_112b1e11-bc98-48aa-9d76-ee237ee9b477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_112b1e11-bc98-48aa-9d76-ee237ee9b477_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_112b1e11-bc98-48aa-9d76-ee237ee9b477" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_112b1e11-bc98-48aa-9d76-ee237ee9b477_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_112b1e11-bc98-48aa-9d76-ee237ee9b477" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f39b7284-7f3d-4c06-8bf5-5d6588f77005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_CommercialPaperMember_f39b7284-7f3d-4c06-8bf5-5d6588f77005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_5570e008-3e33-4adc-81c6-5251b030a11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_5570e008-3e33-4adc-81c6-5251b030a11e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2a15e18c-5f6b-4608-b0d2-afcc4fce73db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2a15e18c-5f6b-4608-b0d2-afcc4fce73db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_7ce007a5-ec80-4526-9bf8-ab7be424b1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_MunicipalBondsMember_7ce007a5-ec80-4526-9bf8-ab7be424b1d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bc49dc7f-61f6-4889-b03b-5efd856e2678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bc49dc7f-61f6-4889-b03b-5efd856e2678" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5bd44d23-faf3-43b7-979f-d4174136b058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5bd44d23-faf3-43b7-979f-d4174136b058" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cfbd751a-e01c-4e4a-b67f-10342b150d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cfbd751a-e01c-4e4a-b67f-10342b150d4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfbd751a-e01c-4e4a-b67f-10342b150d4f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cfbd751a-e01c-4e4a-b67f-10342b150d4f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cfbd751a-e01c-4e4a-b67f-10342b150d4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9794b54-13d5-45e6-99d0-c9e7e00c39e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cfbd751a-e01c-4e4a-b67f-10342b150d4f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9794b54-13d5-45e6-99d0-c9e7e00c39e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5f85c000-53bb-444d-9cca-b37849f7c403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9794b54-13d5-45e6-99d0-c9e7e00c39e5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5f85c000-53bb-444d-9cca-b37849f7c403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_655887ed-ac07-4739-a03d-9bb98df26a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9794b54-13d5-45e6-99d0-c9e7e00c39e5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_655887ed-ac07-4739-a03d-9bb98df26a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0816c2af-bd03-4a66-ab1b-99b1a8de581f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0816c2af-bd03-4a66-ab1b-99b1a8de581f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0816c2af-bd03-4a66-ab1b-99b1a8de581f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0816c2af-bd03-4a66-ab1b-99b1a8de581f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0816c2af-bd03-4a66-ab1b-99b1a8de581f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fd66d4f5-e8c5-4c1b-95d0-5180d6f9cb9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0816c2af-bd03-4a66-ab1b-99b1a8de581f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fd66d4f5-e8c5-4c1b-95d0-5180d6f9cb9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0af93358-b213-4dd1-87a8-bae702fb0cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_fd66d4f5-e8c5-4c1b-95d0-5180d6f9cb9e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0af93358-b213-4dd1-87a8-bae702fb0cd1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20210101.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" id="i1fa6cb02f87640b1839847d578ba1e8e_Inventory"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20210101.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" id="i22d2de49adb74f7a85720982184e1818_InventoryTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="i56c75842f1524570a235b173383de1a1_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_cde61fda-f25d-442e-b4ab-643ca5a15d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryRawMaterials_cde61fda-f25d-442e-b4ab-643ca5a15d11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_aa8517de-fed6-4b32-9204-3ed8a8fbb226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryWorkInProcess_aa8517de-fed6-4b32-9204-3ed8a8fbb226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_fe5e204b-5d63-4fb4-a5f6-4000d842e8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryFinishedGoods_fe5e204b-5d63-4fb4-a5f6-4000d842e8d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_63b18ae0-f8cd-4c58-862a-1089828a5098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryGross_63b18ae0-f8cd-4c58-862a-1089828a5098" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_67bb7d24-ace4-45f2-b401-e4554e0c18a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryWriteDown_67bb7d24-ace4-45f2-b401-e4554e0c18a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_cc1b4f7c-d2a0-4a58-89f5-51b9c5806782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryCurrentTable_cc1b4f7c-d2a0-4a58-89f5-51b9c5806782" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fc436f35-5662-4cf6-9afa-364c53eccaa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_cc1b4f7c-d2a0-4a58-89f5-51b9c5806782" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fc436f35-5662-4cf6-9afa-364c53eccaa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc436f35-5662-4cf6-9afa-364c53eccaa2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fc436f35-5662-4cf6-9afa-364c53eccaa2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc436f35-5662-4cf6-9afa-364c53eccaa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f57ef8a9-5bb9-4c99-a680-bbf5b6ec205e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fc436f35-5662-4cf6-9afa-364c53eccaa2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f57ef8a9-5bb9-4c99-a680-bbf5b6ec205e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_2911d3fb-459a-48d0-a42f-5d4de058f6d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f57ef8a9-5bb9-4c99-a680-bbf5b6ec205e" xlink:to="loc_us-gaap_InventoriesMember_2911d3fb-459a-48d0-a42f-5d4de058f6d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_a020b6a0-3766-4560-8a11-1da36bfe6729" xlink:href="exel-20210101.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f57ef8a9-5bb9-4c99-a680-bbf5b6ec205e" xlink:to="loc_exel_OtherLongtermAssetsMember_a020b6a0-3766-4560-8a11-1da36bfe6729" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="extended" id="idf6483048c9144b28f270a42eadf52e3_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="extended" id="i7f6fd9872c0b48fe8c0be61e5bbdc86e_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="ibe696ed83f7e4577bf40605ba3c8831a_PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0d03ad46-b58c-44fe-b8f9-e2447b3e70a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0d03ad46-b58c-44fe-b8f9-e2447b3e70a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_138346f8-81d7-4628-a677-6ceca682718a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_138346f8-81d7-4628-a677-6ceca682718a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0931d411-b137-4d05-a45a-dca14d616891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0931d411-b137-4d05-a45a-dca14d616891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_70032315-ee1b-4b87-ae14-b40c2b8b7285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_70032315-ee1b-4b87-ae14-b40c2b8b7285" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6be43199-32c9-4c55-b5a9-2c1c928bebe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6be43199-32c9-4c55-b5a9-2c1c928bebe7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_864631f3-2e17-4195-a7b7-0857cf35b942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6be43199-32c9-4c55-b5a9-2c1c928bebe7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_864631f3-2e17-4195-a7b7-0857cf35b942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864631f3-2e17-4195-a7b7-0857cf35b942_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_864631f3-2e17-4195-a7b7-0857cf35b942" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_864631f3-2e17-4195-a7b7-0857cf35b942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_864631f3-2e17-4195-a7b7-0857cf35b942" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0f3e4310-6d48-40f1-bd43-5d4459ba8913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0f3e4310-6d48-40f1-bd43-5d4459ba8913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_9a831f36-32cb-4304-b271-6f88f6417066" xlink:href="exel-20210101.xsd#exel_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_9a831f36-32cb-4304-b271-6f88f6417066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2622658d-0cff-464a-871c-a6f93f78795b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2622658d-0cff-464a-871c-a6f93f78795b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LaboratoryEquipmentMember_d393fef5-dd40-4df9-b69b-a95350dcee49" xlink:href="exel-20210101.xsd#exel_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_exel_LaboratoryEquipmentMember_d393fef5-dd40-4df9-b69b-a95350dcee49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_0e1f98a8-af2b-4a67-9ed5-784784be50f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_us-gaap_ConstructionInProgressMember_0e1f98a8-af2b-4a67-9ed5-784784be50f7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended" id="i6dce749a652f48a38b643b8a1c3ec5cf_PropertyandEquipmentNarrativeDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="extended" id="i36af5dd7460546a2b096ed2c6c4539e0_EmployeeBenefitPlans"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="extended" id="i5249a9cb6bba44e88b81f0c308762eae_EmployeeBenefitPlansTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="ic677c93bf1a746a5a73c7d3a93c8209e_EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2fd03e7a-7f56-4a92-8a46-9ee0844035c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1026907-431f-40a4-848c-55a3f4ffa4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2fd03e7a-7f56-4a92-8a46-9ee0844035c3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1026907-431f-40a4-848c-55a3f4ffa4b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_87e09168-1372-4d63-b575-9e6a6258741b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2fd03e7a-7f56-4a92-8a46-9ee0844035c3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_87e09168-1372-4d63-b575-9e6a6258741b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_966649e0-dcca-4fdd-a993-ff1c31dc4f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_87e09168-1372-4d63-b575-9e6a6258741b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_966649e0-dcca-4fdd-a993-ff1c31dc4f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_966649e0-dcca-4fdd-a993-ff1c31dc4f55_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_966649e0-dcca-4fdd-a993-ff1c31dc4f55" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_966649e0-dcca-4fdd-a993-ff1c31dc4f55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9c6c5ad8-b8e9-4ea7-8750-36b94594ae13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_966649e0-dcca-4fdd-a993-ff1c31dc4f55" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9c6c5ad8-b8e9-4ea7-8750-36b94594ae13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b72b14d6-4430-40ae-abc4-8e24ec9593e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c6c5ad8-b8e9-4ea7-8750-36b94594ae13" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b72b14d6-4430-40ae-abc4-8e24ec9593e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4f23f293-c0d5-4f13-9518-af53389e46c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c6c5ad8-b8e9-4ea7-8750-36b94594ae13" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4f23f293-c0d5-4f13-9518-af53389e46c4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended" id="i39107898fec347e0a132e8645e1afbf3_EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9af0334-0d38-40fe-940f-d633fd79e1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f0d74f41-014a-4ba8-a1b8-06e7659ce5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9af0334-0d38-40fe-940f-d633fd79e1d6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f0d74f41-014a-4ba8-a1b8-06e7659ce5fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4b79fe53-7156-47d5-b305-936e269ed5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9af0334-0d38-40fe-940f-d633fd79e1d6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4b79fe53-7156-47d5-b305-936e269ed5c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3fe8c44d-e618-4410-a785-ae2f8f40dddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4b79fe53-7156-47d5-b305-936e269ed5c5" xlink:to="loc_us-gaap_AwardTypeAxis_3fe8c44d-e618-4410-a785-ae2f8f40dddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fe8c44d-e618-4410-a785-ae2f8f40dddd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3fe8c44d-e618-4410-a785-ae2f8f40dddd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fe8c44d-e618-4410-a785-ae2f8f40dddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3fe8c44d-e618-4410-a785-ae2f8f40dddd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bd03919a-77c2-4614-97dc-6f86dac79064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bd03919a-77c2-4614-97dc-6f86dac79064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d1c702d8-d76e-4bc2-ace4-abd623f93fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d1c702d8-d76e-4bc2-ace4-abd623f93fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3242c14c-afa4-44ea-9e93-7ea672fda8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:to="loc_us-gaap_PerformanceSharesMember_3242c14c-afa4-44ea-9e93-7ea672fda8c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6b419911-b9d0-458e-b304-30d4e3e34760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:to="loc_us-gaap_EmployeeStockMember_6b419911-b9d0-458e-b304-30d4e3e34760" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended" id="i838637f6e6d945e48bd8f036397dff92_EmployeeBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b312f38b-b43e-485c-9717-2490c5a6abb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b312f38b-b43e-485c-9717-2490c5a6abb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_2b0907ea-134c-4b73-8da0-6d06912a548a" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_2b0907ea-134c-4b73-8da0-6d06912a548a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_aeba09dc-bd23-4ee2-be24-82b75ef8aa19" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_aeba09dc-bd23-4ee2-be24-82b75ef8aa19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f3a6e929-f0d4-4ba2-8a93-add2c0636c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f3a6e929-f0d4-4ba2-8a93-add2c0636c78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19804043-239f-444e-916a-28bc3e9227f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19804043-239f-444e-916a-28bc3e9227f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fea6b3fe-c099-4f21-aa68-9bdd7e941a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fea6b3fe-c099-4f21-aa68-9bdd7e941a89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_334ec582-cef4-4851-a0ab-5e41c0cccbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_334ec582-cef4-4851-a0ab-5e41c0cccbbb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_28db1e4d-f122-435f-99de-e508e54f9032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_28db1e4d-f122-435f-99de-e508e54f9032" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_a23ecf69-8324-420f-a9bc-e97f4b7d6f78" xlink:href="exel-20210101.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_a23ecf69-8324-420f-a9bc-e97f4b7d6f78" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_80e279b2-79ce-4e03-835d-c18297ce0f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_80e279b2-79ce-4e03-835d-c18297ce0f7a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d7c52526-34b6-48dc-974b-1cd322ee2636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d7c52526-34b6-48dc-974b-1cd322ee2636" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_5ebe5cb2-468e-4768-b8e2-a417f0f684b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_5ebe5cb2-468e-4768-b8e2-a417f0f684b0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_5712d44e-4e75-4788-9e6f-cc722c1f8975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ProceedsFromStockPlans_5712d44e-4e75-4788-9e6f-cc722c1f8975" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a7b61bea-28f4-4eaf-a463-d144bf113bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a7b61bea-28f4-4eaf-a463-d144bf113bbb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2e176af5-f3a8-4ab6-8fb5-466736d5f0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2e176af5-f3a8-4ab6-8fb5-466736d5f0b4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29316c9f-11d6-4833-969b-a2f4907c9544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29316c9f-11d6-4833-969b-a2f4907c9544" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_b9cdc9ea-3521-443c-8c44-bec2e6ff8477" xlink:href="exel-20210101.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_b9cdc9ea-3521-443c-8c44-bec2e6ff8477" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b878011c-6d02-4ea0-99be-e6228e18c743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b878011c-6d02-4ea0-99be-e6228e18c743" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ba9888cc-f422-4ae5-94da-8fe903f51a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ba9888cc-f422-4ae5-94da-8fe903f51a07" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a1801e99-c425-4617-b209-200b149f2e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a1801e99-c425-4617-b209-200b149f2e0e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_c9698412-053a-4a37-ae53-9240aba1cf0b" xlink:href="exel-20210101.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_c9698412-053a-4a37-ae53-9240aba1cf0b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_972eac25-e9c1-4bd7-925a-dbada8767662" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_972eac25-e9c1-4bd7-925a-dbada8767662" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_103222c0-d757-4813-8c91-e231475db7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_103222c0-d757-4813-8c91-e231475db7f3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_dd4cc856-d21b-4dbf-8339-02c25644db0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_dd4cc856-d21b-4dbf-8339-02c25644db0f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_028edc9f-c3fa-451e-98da-2cb7ce0c3a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:to="loc_us-gaap_AwardTypeAxis_028edc9f-c3fa-451e-98da-2cb7ce0c3a7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_028edc9f-c3fa-451e-98da-2cb7ce0c3a7c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_028edc9f-c3fa-451e-98da-2cb7ce0c3a7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_028edc9f-c3fa-451e-98da-2cb7ce0c3a7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_028edc9f-c3fa-451e-98da-2cb7ce0c3a7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f557fcb9-e3ee-4272-a003-8628042a73b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f557fcb9-e3ee-4272-a003-8628042a73b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8a54c314-771e-4d0d-b863-e53517e6abfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8a54c314-771e-4d0d-b863-e53517e6abfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f75bea30-7b58-4a6c-a636-94bf0789ebc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_us-gaap_EmployeeStockMember_f75bea30-7b58-4a6c-a636-94bf0789ebc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_23917d99-3360-41b2-b538-3a1a3774b794" xlink:href="exel-20210101.xsd#exel_PerformanceShareOptionsPSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_23917d99-3360-41b2-b538-3a1a3774b794" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_455fff7a-af54-438b-bccf-6f335292e3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_us-gaap_PerformanceSharesMember_455fff7a-af54-438b-bccf-6f335292e3f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesClinicalTrialResultsMember_5fc4b424-eeb6-4566-af58-d80d418a7ba4" xlink:href="exel-20210101.xsd#exel_PerformanceSharesClinicalTrialResultsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_exel_PerformanceSharesClinicalTrialResultsMember_5fc4b424-eeb6-4566-af58-d80d418a7ba4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_30bc1a8b-47c5-454f-9d12-f5b07e31940c" xlink:href="exel-20210101.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_30bc1a8b-47c5-454f-9d12-f5b07e31940c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member_155c3e7a-1ed3-4cdb-80df-a0a0f9ff222d" xlink:href="exel-20210101.xsd#exel_PerformanceSharesAchievedBeforeDecember312021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member_155c3e7a-1ed3-4cdb-80df-a0a0f9ff222d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_3a75c4bf-f702-4b1e-baeb-8360aab220ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:to="loc_us-gaap_GranteeStatusAxis_3a75c4bf-f702-4b1e-baeb-8360aab220ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_3a75c4bf-f702-4b1e-baeb-8360aab220ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_3a75c4bf-f702-4b1e-baeb-8360aab220ad" xlink:to="loc_us-gaap_GranteeStatusDomain_3a75c4bf-f702-4b1e-baeb-8360aab220ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_699972cb-a8c8-45cd-98fc-d138144e434d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_3a75c4bf-f702-4b1e-baeb-8360aab220ad" xlink:to="loc_us-gaap_GranteeStatusDomain_699972cb-a8c8-45cd-98fc-d138144e434d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_e64915d7-b35e-4d48-bddd-239f4d2db32e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_699972cb-a8c8-45cd-98fc-d138144e434d" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_e64915d7-b35e-4d48-bddd-239f4d2db32e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d21a3e9c-bb8b-455b-9a92-656e6fdf192c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_699972cb-a8c8-45cd-98fc-d138144e434d" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d21a3e9c-bb8b-455b-9a92-656e6fdf192c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_ef61b350-0d6d-429f-8fc7-db41816bc5da" xlink:href="exel-20210101.xsd#exel_StatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:to="loc_exel_StatusAxis_ef61b350-0d6d-429f-8fc7-db41816bc5da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_ef61b350-0d6d-429f-8fc7-db41816bc5da_default" xlink:href="exel-20210101.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_ef61b350-0d6d-429f-8fc7-db41816bc5da" xlink:to="loc_exel_StatusDomain_ef61b350-0d6d-429f-8fc7-db41816bc5da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:href="exel-20210101.xsd#exel_StatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_ef61b350-0d6d-429f-8fc7-db41816bc5da" xlink:to="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_2a76f5c4-45c5-4c97-84c5-1a0c1adcbc2c" xlink:href="exel-20210101.xsd#exel_AchievedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:to="loc_exel_AchievedMember_2a76f5c4-45c5-4c97-84c5-1a0c1adcbc2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_3216a210-4e25-4f40-bb8a-8507509f9233" xlink:href="exel-20210101.xsd#exel_ProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:to="loc_exel_ProbableMember_3216a210-4e25-4f40-bb8a-8507509f9233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NotProbableMember_6c872e6d-e0bd-4de6-9151-0e267d30acea" xlink:href="exel-20210101.xsd#exel_NotProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:to="loc_exel_NotProbableMember_6c872e6d-e0bd-4de6-9151-0e267d30acea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended" id="if9aeb9189cf14c34be48f3f9a4a2a52c_EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4c331f5-31d2-4a5d-a932-e5720d612ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_464c66c4-194c-4855-a61e-2898a2317605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4c331f5-31d2-4a5d-a932-e5720d612ab0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_464c66c4-194c-4855-a61e-2898a2317605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a29bd0d6-ea7e-459e-8eba-55cfa8ec7ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4c331f5-31d2-4a5d-a932-e5720d612ab0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a29bd0d6-ea7e-459e-8eba-55cfa8ec7ee0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca64da0e-2180-4ab3-8cd8-ecd576533532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a29bd0d6-ea7e-459e-8eba-55cfa8ec7ee0" xlink:to="loc_us-gaap_AwardTypeAxis_ca64da0e-2180-4ab3-8cd8-ecd576533532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca64da0e-2180-4ab3-8cd8-ecd576533532_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ca64da0e-2180-4ab3-8cd8-ecd576533532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca64da0e-2180-4ab3-8cd8-ecd576533532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4941bb07-e754-4507-ad17-a94a220c09d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ca64da0e-2180-4ab3-8cd8-ecd576533532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4941bb07-e754-4507-ad17-a94a220c09d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b00904c9-6feb-47fb-8cc5-b9eb13313a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4941bb07-e754-4507-ad17-a94a220c09d0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b00904c9-6feb-47fb-8cc5-b9eb13313a2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_204db885-bb56-4785-8126-3eed2ed15223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4941bb07-e754-4507-ad17-a94a220c09d0" xlink:to="loc_us-gaap_EmployeeStockMember_204db885-bb56-4785-8126-3eed2ed15223" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="extended" id="i79738c44f0474301a4113b6263f2e160_EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8defeae3-2c32-4663-bf73-3976ad006b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8defeae3-2c32-4663-bf73-3976ad006b76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2acf07ce-332e-44fd-9a5c-dd623ec657b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2acf07ce-332e-44fd-9a5c-dd623ec657b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_a0a623e3-f30d-4fb6-a7d0-6b447620dafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_a0a623e3-f30d-4fb6-a7d0-6b447620dafd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9fefd57-557b-4b53-95c8-1bf949392689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9fefd57-557b-4b53-95c8-1bf949392689" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54183360-1eb9-4116-92d1-12a06aad9a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54183360-1eb9-4116-92d1-12a06aad9a39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_758a69a3-6cda-4efc-bcfc-e5c6a4ad95a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54183360-1eb9-4116-92d1-12a06aad9a39" xlink:to="loc_us-gaap_AwardTypeAxis_758a69a3-6cda-4efc-bcfc-e5c6a4ad95a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_758a69a3-6cda-4efc-bcfc-e5c6a4ad95a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_758a69a3-6cda-4efc-bcfc-e5c6a4ad95a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_758a69a3-6cda-4efc-bcfc-e5c6a4ad95a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f52343d-c628-4e61-9718-8458f4b91093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_758a69a3-6cda-4efc-bcfc-e5c6a4ad95a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f52343d-c628-4e61-9718-8458f4b91093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1c850db4-d2cb-4277-980b-22bd3cfb4aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f52343d-c628-4e61-9718-8458f4b91093" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1c850db4-d2cb-4277-980b-22bd3cfb4aac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_67ff9f3e-352d-47a6-a78f-cb437c61e84c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f52343d-c628-4e61-9718-8458f4b91093" xlink:to="loc_us-gaap_EmployeeStockMember_67ff9f3e-352d-47a6-a78f-cb437c61e84c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="extended" id="i710307ed33014e29a7452d0af86863f2_EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="extended" id="i518a1f33842b417abbb3cbdcf2db28be_EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83df1afa-df4b-46f3-89ac-efc9a091487b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83df1afa-df4b-46f3-89ac-efc9a091487b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f31896c7-4bff-4fd3-ace8-d195312d7c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f31896c7-4bff-4fd3-ace8-d195312d7c76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_78030ae3-7f96-408d-b3b0-0e63f1015731" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_78030ae3-7f96-408d-b3b0-0e63f1015731" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0f8170f0-41c4-4892-812b-1b05c9ce2248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0f8170f0-41c4-4892-812b-1b05c9ce2248" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45734973-fce9-4428-b788-8ee3ae13c186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4fee2f18-98e5-4cba-91f6-60e8c4028735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4fee2f18-98e5-4cba-91f6-60e8c4028735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7addd1b6-fe1c-4a37-868a-53c74695e0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7addd1b6-fe1c-4a37-868a-53c74695e0e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_c0713dc9-7021-4a65-9cf6-d5f350e6eb46" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_c0713dc9-7021-4a65-9cf6-d5f350e6eb46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4519306f-ebfc-4acd-af00-60bfe07fbd6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4519306f-ebfc-4acd-af00-60bfe07fbd6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05312408-4abf-4220-b852-e448ddb88edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_92ab41dc-9bca-49da-892d-c64ef2987b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_92ab41dc-9bca-49da-892d-c64ef2987b67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_528b6fad-f678-449b-b8e2-750c097b8666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_528b6fad-f678-449b-b8e2-750c097b8666" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84879db2-040c-4e40-8c00-163b6bb66069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84879db2-040c-4e40-8c00-163b6bb66069" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c97767e7-7ad7-4774-be17-10185aa77f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84879db2-040c-4e40-8c00-163b6bb66069" xlink:to="loc_us-gaap_AwardTypeAxis_c97767e7-7ad7-4774-be17-10185aa77f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c97767e7-7ad7-4774-be17-10185aa77f34_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c97767e7-7ad7-4774-be17-10185aa77f34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c97767e7-7ad7-4774-be17-10185aa77f34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda67431-7879-4683-a973-8201fc3ad410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c97767e7-7ad7-4774-be17-10185aa77f34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda67431-7879-4683-a973-8201fc3ad410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_826d5f67-eefd-4321-9d04-4d4b84910639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda67431-7879-4683-a973-8201fc3ad410" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_826d5f67-eefd-4321-9d04-4d4b84910639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6f2203b9-97d5-40e0-83e7-e63123c6107b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda67431-7879-4683-a973-8201fc3ad410" xlink:to="loc_us-gaap_PerformanceSharesMember_6f2203b9-97d5-40e0-83e7-e63123c6107b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="extended" id="i39e6d087e5ab47b189876653bb882c1b_ProvisionForBenefitFromIncomeTaxes"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables" xlink:type="extended" id="i7f43d2a779b44172ac55c50a537968bc_ProvisionForBenefitFromIncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended" id="ib6b006b1008f4f5196c34cdfac4c718d_ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="extended" id="i7e6bdc43b4634b7fae83a627bd76405c_ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="extended" id="id33cb3f166044ed69858f7c01edae7c1_ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails" xlink:type="extended" id="i9391932bf2174f4d8cc5b276b7e676d6_ProvisionForBenefitFromIncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_10a72885-de4d-4fe1-8318-e4653db18d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_10a72885-de4d-4fe1-8318-e4653db18d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_efde9240-7851-4af9-afac-2ee5767867dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_efde9240-7851-4af9-afac-2ee5767867dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3a19460c-b458-4b13-8712-7d27139e2a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3a19460c-b458-4b13-8712-7d27139e2a4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_accc8974-63d6-4306-8c63-17d4d47761ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_accc8974-63d6-4306-8c63-17d4d47761ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_3487ddfe-846d-49fb-a2d9-d9a2230ade3f" xlink:href="exel-20210101.xsd#exel_TaxCreditCarryforwardAmountWithExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_3487ddfe-846d-49fb-a2d9-d9a2230ade3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8db96b5f-3250-4f6f-98d8-8359055522ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8db96b5f-3250-4f6f-98d8-8359055522ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a203e3b2-0a7c-460c-a1cb-4a561f46eb15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a203e3b2-0a7c-460c-a1cb-4a561f46eb15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_d1552e0c-6179-42ea-80f3-0e7398e6ed8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_d1552e0c-6179-42ea-80f3-0e7398e6ed8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ab17d43d-2284-4dd7-828f-4ca8326cff12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_d1552e0c-6179-42ea-80f3-0e7398e6ed8a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ab17d43d-2284-4dd7-828f-4ca8326cff12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ab17d43d-2284-4dd7-828f-4ca8326cff12_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ab17d43d-2284-4dd7-828f-4ca8326cff12" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ab17d43d-2284-4dd7-828f-4ca8326cff12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0269abc4-3a2e-4db9-874d-5d26a888403d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ab17d43d-2284-4dd7-828f-4ca8326cff12" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0269abc4-3a2e-4db9-874d-5d26a888403d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_27258fb3-b372-4705-a6e8-ac6b305d180b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0269abc4-3a2e-4db9-874d-5d26a888403d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_27258fb3-b372-4705-a6e8-ac6b305d180b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0601d6b0-3aa6-401e-8fc7-007132ef4f31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0269abc4-3a2e-4db9-874d-5d26a888403d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0601d6b0-3aa6-401e-8fc7-007132ef4f31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_257abaf9-af0e-43c6-b19e-6acfcc819e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_d1552e0c-6179-42ea-80f3-0e7398e6ed8a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_257abaf9-af0e-43c6-b19e-6acfcc819e2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_257abaf9-af0e-43c6-b19e-6acfcc819e2e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_257abaf9-af0e-43c6-b19e-6acfcc819e2e" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_257abaf9-af0e-43c6-b19e-6acfcc819e2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f1477c38-156d-4358-8a57-792786554ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_257abaf9-af0e-43c6-b19e-6acfcc819e2e" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f1477c38-156d-4358-8a57-792786554ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_43b83e84-dce0-4c11-b87a-794f3c2d4d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f1477c38-156d-4358-8a57-792786554ba6" xlink:to="loc_us-gaap_ResearchMember_43b83e84-dce0-4c11-b87a-794f3c2d4d28" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="iba03de574ac9439ca34266f1a8b05198_ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerShare"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" id="iabd7702b4fc84e8eadc71b7882ae6ff3_NetIncomePerShare"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerShareTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" id="ifd51aea6151046b08bd6b34e5f74f70e_NetIncomePerShareTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended" id="ida5d0ca976814506a9a2abecab2f41ac_NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="extended" id="ib769baeb9675404c9e275843ef6c98b3_NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_77449eb0-ac71-445f-85a3-2ea6930a6d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47a71e46-b4f8-457c-8bd2-977d704d5417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_77449eb0-ac71-445f-85a3-2ea6930a6d5d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47a71e46-b4f8-457c-8bd2-977d704d5417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fa4609f4-f3aa-4fa1-9b91-293b9ccb9cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_77449eb0-ac71-445f-85a3-2ea6930a6d5d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fa4609f4-f3aa-4fa1-9b91-293b9ccb9cf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c4f25222-10d1-459f-b9c1-4fcefffc65d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fa4609f4-f3aa-4fa1-9b91-293b9ccb9cf0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c4f25222-10d1-459f-b9c1-4fcefffc65d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c4f25222-10d1-459f-b9c1-4fcefffc65d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c4f25222-10d1-459f-b9c1-4fcefffc65d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c4f25222-10d1-459f-b9c1-4fcefffc65d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d22948c-2601-4d91-839b-ab8600be06a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c4f25222-10d1-459f-b9c1-4fcefffc65d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d22948c-2601-4d91-839b-ab8600be06a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_2db0a2b3-e015-49b8-a22d-130dfde30eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d22948c-2601-4d91-839b-ab8600be06a0" xlink:to="loc_us-gaap_StockCompensationPlanMember_2db0a2b3-e015-49b8-a22d-130dfde30eb2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended" id="id630b5c891014beeba06be6c1ed8064d_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="i76b3493d1b3e4738bdc2473ec763ba2e_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i96db95a6344f4c53a6af3e90fde4eb40_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_e3609c72-20d2-49f7-bb4a-a778c6d1fff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_e3609c72-20d2-49f7-bb4a-a778c6d1fff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_e01106fd-0cda-4f96-8eb9-ef787ef060be" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_e01106fd-0cda-4f96-8eb9-ef787ef060be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b64b3aed-f487-435f-81db-fbd4c6bb6892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b64b3aed-f487-435f-81db-fbd4c6bb6892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_85ef0330-6798-45b8-a8b7-d4549e685e8c" xlink:href="exel-20210101.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_85ef0330-6798-45b8-a8b7-d4549e685e8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8b1ad3f4-7372-4c99-b6e6-ed5fd8e6e9a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_OperatingLeasePayments_8b1ad3f4-7372-4c99-b6e6-ed5fd8e6e9a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ad6d6e7b-cb58-4376-8033-f4c0431a7972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ad6d6e7b-cb58-4376-8033-f4c0431a7972" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c63ae543-20e3-4edb-84ed-a9475f730530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c63ae543-20e3-4edb-84ed-a9475f730530" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7a8e195b-edb8-4f6c-bc2a-cf728c8bb722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7a8e195b-edb8-4f6c-bc2a-cf728c8bb722" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_a7353006-096d-44b0-bc17-679b9493b2cf" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_a7353006-096d-44b0-bc17-679b9493b2cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_ab3c2547-5d8d-4866-9281-374de7919aab" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_ab3c2547-5d8d-4866-9281-374de7919aab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_c189e7fb-d5bb-424a-8267-f581ee6043e6" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_c189e7fb-d5bb-424a-8267-f581ee6043e6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_94df50ea-292d-489b-a267-fa10fdef4948" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_94df50ea-292d-489b-a267-fa10fdef4948" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_01065d7e-ea28-4001-9a90-11a0bd2e4ebf" xlink:href="exel-20210101.xsd#exel_AreaOfRealEstatePropertyAvailableToLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_AreaOfRealEstatePropertyAvailableToLease_01065d7e-ea28-4001-9a90-11a0bd2e4ebf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_740c494a-4d2a-4d4b-8fca-79ed72ba29c9" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_740c494a-4d2a-4d4b-8fca-79ed72ba29c9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_e2229215-c9f2-4dba-b46e-fbdc536e54e6" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_e2229215-c9f2-4dba-b46e-fbdc536e54e6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_9fc9be80-bb7f-4aa0-a74f-8dc5ea8853ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_TenantImprovements_9fc9be80-bb7f-4aa0-a74f-8dc5ea8853ec" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dabaa54d-8082-4989-9cdd-b4d99ec795ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dabaa54d-8082-4989-9cdd-b4d99ec795ef" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b1233700-2d6c-4eb7-b2fc-0a71d438823e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b1233700-2d6c-4eb7-b2fc-0a71d438823e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities_e8baf028-2c38-4c9a-b2a5-3e8df8b602b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuarantyLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_GuarantyLiabilities_e8baf028-2c38-4c9a-b2a5-3e8df8b602b1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_281ce60e-1288-4088-9cde-68032cc7b3ea" xlink:href="exel-20210101.xsd#exel_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:to="loc_exel_LeaseArrangementsAxis_281ce60e-1288-4088-9cde-68032cc7b3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_281ce60e-1288-4088-9cde-68032cc7b3ea_default" xlink:href="exel-20210101.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_LeaseArrangementsAxis_281ce60e-1288-4088-9cde-68032cc7b3ea" xlink:to="loc_exel_LeaseArrangementsDomain_281ce60e-1288-4088-9cde-68032cc7b3ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_16ce2f5d-202c-4ed5-8421-83fbc3389ece" xlink:href="exel-20210101.xsd#exel_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_LeaseArrangementsAxis_281ce60e-1288-4088-9cde-68032cc7b3ea" xlink:to="loc_exel_LeaseArrangementsDomain_16ce2f5d-202c-4ed5-8421-83fbc3389ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseMember_cb322cac-5f41-441f-9fcc-639b15aa1526" xlink:href="exel-20210101.xsd#exel_HeadquartersLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_16ce2f5d-202c-4ed5-8421-83fbc3389ece" xlink:to="loc_exel_HeadquartersLeaseMember_cb322cac-5f41-441f-9fcc-639b15aa1526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseMember_4b8db859-ef1b-49b0-853b-a0444beb33ba" xlink:href="exel-20210101.xsd#exel_BuiltToSuitLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_16ce2f5d-202c-4ed5-8421-83fbc3389ece" xlink:to="loc_exel_BuiltToSuitLeaseMember_4b8db859-ef1b-49b0-853b-a0444beb33ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cab9b398-f771-44b5-ada2-7e3cfa424bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:to="loc_us-gaap_CreditFacilityAxis_cab9b398-f771-44b5-ada2-7e3cfa424bd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cab9b398-f771-44b5-ada2-7e3cfa424bd3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_cab9b398-f771-44b5-ada2-7e3cfa424bd3" xlink:to="loc_us-gaap_CreditFacilityDomain_cab9b398-f771-44b5-ada2-7e3cfa424bd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c055c297-4552-4360-b6e6-293b9a9318c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_cab9b398-f771-44b5-ada2-7e3cfa424bd3" xlink:to="loc_us-gaap_CreditFacilityDomain_c055c297-4552-4360-b6e6-293b9a9318c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_e9684e35-a067-4b78-b135-db30b8fa8e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c055c297-4552-4360-b6e6-293b9a9318c2" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_e9684e35-a067-4b78-b135-db30b8fa8e0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fbafc217-997b-4ac2-a2f5-cb7a8d38ce2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:to="loc_srt_StatementScenarioAxis_fbafc217-997b-4ac2-a2f5-cb7a8d38ce2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fbafc217-997b-4ac2-a2f5-cb7a8d38ce2f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_fbafc217-997b-4ac2-a2f5-cb7a8d38ce2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fbafc217-997b-4ac2-a2f5-cb7a8d38ce2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e2bc5d83-7371-411b-bb88-bf8b8da12b85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_fbafc217-997b-4ac2-a2f5-cb7a8d38ce2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e2bc5d83-7371-411b-bb88-bf8b8da12b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_69169f7f-4172-4205-b4a6-902963e6c408" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e2bc5d83-7371-411b-bb88-bf8b8da12b85" xlink:to="loc_srt_ScenarioForecastMember_69169f7f-4172-4205-b4a6-902963e6c408" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="extended" id="i72d41de7627f4cd0a38e5d07ef0d9c62_CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="extended" id="i6e8bb104fb454e9fb2908a66d97d93a5_CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended" id="i7bf833d5d3c44d808f24175a9c3f8f7f_CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="exel-20210101.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" id="idf0c70d2eb5f486c9c86e1c69817a386_QuarterlyFinancialDataUnaudited"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="exel-20210101.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" id="i51493535767e4052a397b6498e6cb2cf_QuarterlyFinancialDataUnauditedTables"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#QuarterlyFinancialDataUnauditedDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" id="ic9be7248ef8a4411aa7beffc863a6aab_QuarterlyFinancialDataUnauditedDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>exel-20210101_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3705d550-318f-4f51-9de6-06eba39f6ea7,g:2df53114-27bb-4237-9a9c-80b7c8353f30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_87a8b4dc-d000-46a5-a319-75d761f49719_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased property (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5c566f8c-b030-48fa-b9f6-350421697489_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a97a6578-868a-4281-b8ac-dfe4fa1528dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_79526098-e885-4dbd-b20e-0138d14e76c8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_8a7009e5-7638-48c3-b188-a04f1c375d12_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_523d98a6-ed07-4e6a-a91f-f1156c6f586c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding at end of the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_572fa13b-113c-402b-b02d-f41a94d311aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MINNEBROMember_0f9b1f66-6bfe-4fb4-bc50-469d0a8803ce_terseLabel_en-US" xlink:label="lab_exel_MINNEBROMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MINNEBRO</link:label>
    <link:label id="lab_exel_MINNEBROMember_label_en-US" xlink:label="lab_exel_MINNEBROMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MINNEBRO [Member]</link:label>
    <link:label id="lab_exel_MINNEBROMember_documentation_en-US" xlink:label="lab_exel_MINNEBROMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MINNEBRO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MINNEBROMember" xlink:href="exel-20210101.xsd#exel_MINNEBROMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MINNEBROMember" xlink:to="lab_exel_MINNEBROMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProbableMember_110accb4-bc4b-4498-9c4d-15bbc00e8bfc_terseLabel_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable</link:label>
    <link:label id="lab_exel_ProbableMember_label_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_documentation_en-US" xlink:label="lab_exel_ProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember" xlink:href="exel-20210101.xsd#exel_ProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember" xlink:to="lab_exel_ProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3d6e183d-c801-4e1e-b1ba-0357511e4b5e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_26604650-466d-4330-a7eb-67b3021a7e46_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f3ee4baa-72ea-40e0-a0a1-1576b42f0781_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_568469fb-1d37-4584-a21b-523bcefed1a3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_9c227dea-91b3-4855-86eb-0931e6505a27_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_af94b1ca-f7b8-4298-a5b6-915782289f51_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_1fd5f947-45cc-4c4b-a4da-4a359d11d60c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_54730aff-aba4-4fbd-9c8e-78cd47d53b84_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1edea187-7969-47df-a782-320429abbac0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in share reserve under 2017 plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_38b50c15-310c-4b55-be39-7e4554001263_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_45ce600b-d8bf-438d-be7d-b2825bb7ae93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_24c43d31-1d27-4371-a905-1e677fa7bc0d_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20210101.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_aaa51236-215f-4975-a2f6-448a867a43a8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_f0442417-c5aa-436f-8856-9bae598c3d73_verboseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen</link:label>
    <link:label id="lab_exel_IpsenMember_bf179523-afd4-4e4d-ad4a-bcfff3d56e4f_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20210101.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_65b9d395-b583-4314-b74a-fd7568a7dce7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_acae9a7e-38c3-4aa2-bbbc-643829e73e7f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_53673d80-98db-4af0-9955-b83ff884df06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a3dfe304-c556-4253-a355-2bc43d5f4abc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_e5adfe89-6071-4655-be88-d8c6987f1faf_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold" xlink:href="exel-20210101.xsd#exel_ProfitSharingAgreementProfitThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementProfitThreshold" xlink:to="lab_exel_ProfitSharingAgreementProfitThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_a043781f-b84d-4c53-8a3f-d9201e3f293a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate from market value on purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_984bca4c-16a2-4530-940b-e92d9b52f4d4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0f7aede8-a6ac-4b8d-848d-b9201ec9f296_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_03e7cf58-6eb3-47f4-897f-782aaf222ecd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_e7760ec9-ccbb-419a-a86c-7fa797bffab8_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_74197bda-c1d1-4464-9a84-1b4fdf136327_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0df1714f-ae73-4781-b7ca-76c2ad60a3bd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_daf6c810-a930-4108-af1c-f6d31650323b_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc4dbbb7-4d4b-4575-a5d8-73a43cf41708_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0c0cb756-fed9-4d08-b3c3-2494b46ab6f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f6b44d46-627a-4ad3-b5da-e7cb0cda77f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4982b525-6409-4acb-be03-8de673443b67_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8e4c7d31-939f-4fbe-9568-774f53301df4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_da144fa6-2687-4b49-9df1-123945eb18ab_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_677948ae-3e12-4b2c-9c5b-efe1b1a6a583_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2869450e-294e-477a-8ae2-933e78ab01d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_86863c2c-946b-4cb4-bc62-d5f9c1ddb3d3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_b440b4a7-f45a-4ac3-af41-ce3fc8eb7f98_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_967fa879-cfda-467c-8ab8-e41f356ffdac_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cae66cee-fc08-4048-895b-227bb859f18e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_fbc100dd-f81a-4acd-a24b-1493521f9935_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_eb01420b-54cb-4e9b-8580-69c382599582_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_80c6ca7b-6e27-4389-a344-b117dcd3c871_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal income tax provision at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_bfae8e37-64ae-4b65-8fce-7b62d3a4a90c_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20210101.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1ee9d050-176c-4f6d-a07e-34cfb66e6c38_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_b186e56f-2947-4abb-9838-eb37e1066ccf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_505caca1-db04-43ab-964f-6b2fd4acb0ac_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20210101.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MedicarePartDFundingMandate_51553bcc-3359-4154-b398-e489b695a0c0_terseLabel_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D funding mandate</link:label>
    <link:label id="lab_exel_MedicarePartDFundingMandate_label_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D Funding Mandate</link:label>
    <link:label id="lab_exel_MedicarePartDFundingMandate_documentation_en-US" xlink:label="lab_exel_MedicarePartDFundingMandate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D Funding Mandate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MedicarePartDFundingMandate" xlink:href="exel-20210101.xsd#exel_MedicarePartDFundingMandate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MedicarePartDFundingMandate" xlink:to="lab_exel_MedicarePartDFundingMandate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_aa6925a4-43b6-4626-828f-8c49909341d6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_031f7094-c547-47ce-8fc6-e982901f5fed_terseLabel_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of property available for lease (in squire feet)</link:label>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_label_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Real Estate Property, Available To Lease</link:label>
    <link:label id="lab_exel_AreaOfRealEstatePropertyAvailableToLease_documentation_en-US" xlink:label="lab_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Real Estate Property, Available To Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:href="exel-20210101.xsd#exel_AreaOfRealEstatePropertyAvailableToLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:to="lab_exel_AreaOfRealEstatePropertyAvailableToLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1dc36ce0-9264-45b0-bcb6-932fcfdc8c6c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_HeadquartersLeaseMember_c4851706-7893-44af-82c0-24b67e293f61_terseLabel_en-US" xlink:label="lab_exel_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease</link:label>
    <link:label id="lab_exel_HeadquartersLeaseMember_label_en-US" xlink:label="lab_exel_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:label id="lab_exel_HeadquartersLeaseMember_documentation_en-US" xlink:label="lab_exel_HeadquartersLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Headquarters Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseMember" xlink:href="exel-20210101.xsd#exel_HeadquartersLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_HeadquartersLeaseMember" xlink:to="lab_exel_HeadquartersLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_17fa170a-0c39-4012-985f-d334313dec4d_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20210101.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_60553b80-bce5-4133-a9bc-a26dfdac327f_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_56e28965-5388-4271-bf2b-c52e511112ce_terseLabel_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement extended target selection term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_label_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement Extended Target Selection Term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_documentation_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement Extended Target Selection Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:href="exel-20210101.xsd#exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:to="lab_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_1eddf170-d981-453a-b8a5-e1bda54f909d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_6ed7bce1-ee87-4355-9174-aeb82179988b_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1f787e51-d6fb-4b49-a438-7fcfdba96562_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_a6c3b2c9-19a0-4704-8b59-336f02a44107_terseLabel_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Classification of Lease Liabilities</link:label>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="exel-20210101.xsd#exel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_exel_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25cd6cb9-5f1f-4fc4-ab29-cbb15fbdac87_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a0f1e33-c5f1-4899-9d79-bd7c311df49e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at ending of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3b08b867-cf4e-42e1-a1b2-9466cf09b34b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c97b3586-6697-4be5-ad8e-5ced62237719_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_13cfc1bb-a6df-4aeb-9e41-0df2e70135dd_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_42589d8c-f982-4f02-b957-3f21624b73d8_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_6472f223-7f4f-42f8-85be-099f15db97f2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_df349500-3a03-47e6-b0ed-ffed8e042322_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_59f750fe-afe4-408f-a8dd-b5ee5eb8f5d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (Benefit from) Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_4141b183-4392-4d77-b527-f8152e22fe6e_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_20921f40-5456-4b9f-93b6-5d7ecfe02efc_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_8192fa7d-0d85-46d1-a1cf-8fec968f9ab2_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7d76cc58-ddbf-4316-b876-ce2d3fb9b6b1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d6d80148-27ae-405a-8416-cc9b1c3c3972_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_1b43d717-743e-4d4a-8f1e-20d7a262a728_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived from Cabozantinib</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember" xlink:href="exel-20210101.xsd#exel_ProductsDerivedFromCabozantinibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromCabozantinibMember" xlink:to="lab_exel_ProductsDerivedFromCabozantinibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0923a4dc-a09c-4fed-a3ce-998fdd769e5f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ee66a9e5-3f4f-4b9f-8c7d-c757ec86225c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_a3ba722f-39f8-453d-8f73-c0418ffe59dc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a34dc9e7-727e-4829-8d0a-cb9c7f10b165_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee4948bb-9fbb-42cf-a4ec-a5d0a850c3bc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1a67940b-cb74-443a-9212-70a94454315c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_d0c130a8-7a7f-417e-b4d7-0be7692afef9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81f6a5ec-c3da-4c0b-a30e-d6b7634dad70_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_20f57492-4e52-4986-9f85-85017e28d968_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6bb66ce8-596e-4217-bb2e-3eafafdace15_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3df01943-a8a9-47ad-9a97-5c6d87b86963_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_afa12321-5a7e-47d2-b82d-c458db952d96_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_0a9cce8d-47c3-41fb-8ab9-8e8d1810d40e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_ae51fad2-fcab-4191-8b52-6d2643f83f56_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20210101.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_3bc5dca7-0547-4ec1-a58f-9343b83c337d_terseLabel_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension option term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_label_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Target Selection, Extension Option Term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_documentation_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Target Selection, Extension Option Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:href="exel-20210101.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:to="lab_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_bd45b400-847f-4454-b3e2-cf42a94836b0_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables percent</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_54f1ddea-ef93-401a-9796-9871ddff768e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ed93bfa4-c8b3-4bbd-94d5-9714a0f86dde_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ecea8fb5-d520-4a6d-8664-cdd49405a77c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c6cb5af6-9a64-4c9b-aa2a-e290637627c5_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember_bf63f50b-2387-4df6-a27a-571bbfb3bc89_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With N B E Therapeutics</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With N B E Therapeutics [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With N B E Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithNBETherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:to="lab_exel_CollaborativeArrangementWithNBETherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_635ae809-5c55-4dc5-9417-b9836a366527_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_21eeeceb-5049-4019-b56c-701a768153a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_05f6b705-c660-48fe-bfd5-aedbee1bafc0_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e1194894-1f14-4f66-ba8e-dd17ae27a84b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_367f6eb9-f944-4547-92a5-6c75e4976eeb_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_dcef0550-4547-49b9-930b-cd572fbb2647_negatedTerseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c14e0bc0-38f6-4af6-b55f-10084739d31c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_43249168-2cd4-47d3-ba4d-239d198aa31e_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_5cd1c2a2-e914-409c-82af-219c56503847_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5b59c5ff-7222-486e-8ad6-b46af1ba8536_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_69b4c7d4-6a6f-4c25-83fa-133d1488db92_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_9af82e8f-046b-4f0d-82f6-1eab58c57fa5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c2af72a8-0e5f-4258-8d32-397211e172e7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_010e9a0a-92ee-4879-a349-4dd7f3461bb2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_52328e54-2e28-4ad2-a40d-31027e84039a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_725dbe55-e381-41a4-93ae-4e9acb9605a2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in earnings per share due to change in accounting estimate (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b609dedc-17fe-40c8-93ac-eaaf23372937_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_254660d7-3172-4ba0-8786-571ce50ece32_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b3e5c829-917f-4c30-892b-64120bca5134_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a5b8f43-b571-4200-8e9c-509c631544c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_382f575d-77bf-4c6f-b956-1042617cf5b6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, exercisable at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f5a30183-e736-49d6-b2b6-a2ff1c5d269e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f6d11bb7-d6f9-471e-9745-bde4024f4b11_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e873ec6d-eb21-4633-a2d0-000e56c5f731_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_c81c82e1-f036-478f-8165-ed94d76f20f8_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9886def9-f2a2-40db-88f6-c11f9526d886_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_d4324419-faf0-4fda-8bc8-7f53b7e7a8c4_terseLabel_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory Milestone</link:label>
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_label_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_exel_DevelopmentAndRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_exel_DevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember" xlink:href="exel-20210101.xsd#exel_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DevelopmentAndRegulatoryMilestoneMember" xlink:to="lab_exel_DevelopmentAndRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProfitSharingTiersAxis_3ea89d19-b021-4f99-a54a-a331d7c05212_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_label_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTiersAxis" xlink:href="exel-20210101.xsd#exel_ProfitSharingTiersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersAxis" xlink:to="lab_exel_ProfitSharingTiersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_7018e060-805f-48f4-a330-5bf71a91025b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_80478247-d30b-411c-ae2a-78f0088e5c11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a17d6ced-e294-4891-ac8c-e56a4ab32dd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c360f855-684c-4fac-b915-796ef7c14dd3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_3ec39175-ebd9-47ff-b4f8-b05a4c2e0313_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20210101.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_cdfea300-6c33-444a-9c71-1e0a00ccc820_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20210101.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_451e5217-151d-4597-8443-34c040bd97c8_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration period to achieve specified levels of commercial performance</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:to="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsDomain_fbcaa58a-dae3-4910-b038-fb44ab5f3013_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_label_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain" xlink:href="exel-20210101.xsd#exel_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsDomain" xlink:to="lab_exel_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProjectInitiationFeePayment_574fd15f-2523-47c4-97ac-32ed397c5ecc_terseLabel_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project initiation fee</link:label>
    <link:label id="lab_exel_ProjectInitiationFeePayment_label_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Initiation Fee Payment</link:label>
    <link:label id="lab_exel_ProjectInitiationFeePayment_documentation_en-US" xlink:label="lab_exel_ProjectInitiationFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Initiation Fee Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProjectInitiationFeePayment" xlink:href="exel-20210101.xsd#exel_ProjectInitiationFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProjectInitiationFeePayment" xlink:to="lab_exel_ProjectInitiationFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc922e9e-35a1-49a0-95ef-bd51e8cb5231_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_7f78f0ee-6b6c-4655-8e21-95199508aa79_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_88e18a0d-c9d4-4d79-9650-10c090c8c1de_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TakedaMember_18c91734-5b5d-493f-892c-90cfc4a8e15e_terseLabel_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_exel_TakedaMember_label_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_exel_TakedaMember_documentation_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember" xlink:href="exel-20210101.xsd#exel_TakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaMember" xlink:to="lab_exel_TakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f94bdb45-4ad6-4b1b-b286-fa0036d4ce60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_18570102-269d-4e69-9f09-7d64d4663147_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase percentage</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_3b28ac04-fb01-4010-b866-c5bd7f2528eb_terseLabel_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_label_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_documentation_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseMember" xlink:href="exel-20210101.xsd#exel_BuiltToSuitLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BuiltToSuitLeaseMember" xlink:to="lab_exel_BuiltToSuitLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e1ad681-a6f2-4d30-9e96-706d0b487494_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_51a1170a-8610-4f80-9b31-8aa0feb9c0ac_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:href="exel-20210101.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:to="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_ca5203e0-7c83-499c-97ef-709a9ac1ab75_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_ef6502e3-70ec-4296-baa7-4916caec4e7f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_7c93d56f-bf7a-4638-97cd-ec9263f83d31_terseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible executive compensation</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:href="exel-20210101.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_64bf7fe3-d838-4b27-9015-7df7e018b29c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_6a39e591-b1c3-4fd8-a842-b083f696dcda_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_ff376873-8386-411d-979d-30aa1dc9a834_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_6b56b733-974c-4958-a9c6-410bbf640cba_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c66dc9a7-81ef-4984-a977-aac63fd8b754_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_f7d21719-a503-4336-85af-1019d614417d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c242b523-81f9-4597-b789-4208932d8cb3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_417ffb24-14f4-440c-8ede-cb5e25a304ed_verboseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_0ebd55bb-75a0-485a-9a98-eef73d2716e2_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20210101.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_eea5e91f-4525-4d37-bfd8-228c502f23c6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_644afed6-4b87-48a1-897b-42c4cd5ae9e5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_331763d8-8c8d-49f1-9d1e-2048f8fa5b75_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_1112e7f4-32de-4080-956a-42be3d622947_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_85ba4510-f800-4082-bdae-6e929740a797_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestoneObjectiveDomain_f40abd14-bec5-4171-beea-bad4ef29caf3_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Objective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_label_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Objective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for MilestoneObjective [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveDomain" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveDomain" xlink:to="lab_exel_MilestoneObjectiveDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_763734f5-d23c-4b53-86f0-55d8aaae475a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4cb238c5-a65c-41c0-b746-9afc63e6c2a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_976d64ae-665b-42be-a794-0dce474f8ffc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bef9a0e6-b9ea-4650-ab7f-4f78c97fbc9b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_bc868f0a-6f27-4164-8ec0-2e4990af3447_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_b590ba94-0671-4271-956b-3886010233c0_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_efeab424-5fce-4f2f-8cbb-20eb4e0a0480_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a53187e5-ce5f-430e-a07a-df2e047817ed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_d3efa396-88e0-4ef1-a0a2-cbfa74b70849_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2949c82e-cadc-401b-a42e-a1e30e89843a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6661ebe8-7d37-4de4-9582-d9b68fb20285_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3615160d-818c-4221-9ac8-40f338e4406a_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_d0a2b029-b057-4f25-ae7e-7f17edc7fcb7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_657c421a-e7b9-4e78-b5ea-bea56f5f40ab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_14ad975f-c11a-40d9-b6ee-54032de3d0cb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_29eb063e-1cc6-49de-a980-aacc0a10318e_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Basic Diluted Other Disclosures [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_documentation_en-US" xlink:label="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Basic Diluted Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" xlink:href="exel-20210101.xsd#exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" xlink:to="lab_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_1ba03f6b-eec5-4354-bcbf-4918b2ce37a1_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliatesof Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliatesof Optum Specialty Pharmacy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:href="exel-20210101.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_55889507-c0f7-4476-a387-dad9601ccdf1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_87a131ac-dd51-4840-bd38-37dca0e94e9d_terseLabel_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change relating to prior year provision</link:label>
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</link:label>
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:href="exel-20210101.xsd#exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:to="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_bf544814-429b-4174-adbc-db0712f878cd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_1b03486c-76ef-47ef-94a5-1ca95792afbc_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, number of programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_label_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementNumberOfPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementNumberOfPrograms" xlink:to="lab_exel_CollaborationAgreementNumberOfPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_86c53a41-4d03-443f-b217-c5e955155db2_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7d7504e9-d32f-482a-bced-3c54d7b136d1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_1c0a67cb-dd85-4d29-88c2-bd7f6928da92_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e2e19fde-45c4-456f-9077-d9926056c8a6_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProfitSharingTierOneMember_a6001d21-a9c1-4792-9558-e926bb668bd5_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tier One</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_label_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTierOneMember" xlink:href="exel-20210101.xsd#exel_ProfitSharingTierOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierOneMember" xlink:to="lab_exel_ProfitSharingTierOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_3ade26ca-80f9-41bc-a215-b047196340d2_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_547139ee-991f-4833-8bba-a659c92f22b8_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_5b8378d2-fa49-446d-99bd-87ce8bbc514c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_8036989d-2c1c-4153-89da-eb071907695c_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20210101.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6630ebd8-636e-4bc6-9678-6e32f84ba9b5_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d8d59ddf-ad0f-4519-a250-1ecced4ce901_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ad98950f-41c1-49f6-a0a8-733f04375d31_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e43caf21-60e1-442d-986f-f65b2e904750_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c551ce77-1e65-47ef-8779-93238cb58091_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cf38a091-86fa-4ded-842b-c00d93c68fc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_aa6e73bb-40b9-470c-9e5e-9c3ddeda080f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $(394), $(1,049), and $156, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7eed2d48-5e9d-4396-86ae-e416367e6e4a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5148337e-2bef-468a-90c4-ad32b4667eaa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b0a3bc35-04a9-4cbd-a5f6-0ff9309bed7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains or losses on available-for-sale securities, tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_d52fe440-237a-47d5-8fac-c004a9c07d0f_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract" xlink:href="exel-20210101.xsd#exel_OperatingLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract" xlink:to="lab_exel_OperatingLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7d592d9d-3fad-46ec-9555-78de1989032d_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_d3838fa9-fb6a-45e4-9d5c-9c9e7fb20d04_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d5f9a13b-47f6-4327-8530-120540883cda_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_be50ba2d-41a0-415d-b7f1-c9277f20b9be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_1b91853b-3720-44bf-89e0-350442daefba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a59fa0b8-360b-4b7e-9cc8-d2abc8ef9f12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementTerminationPeriod_2a8866f9-8fef-4140-a694-97bff1b3a9f7_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_exel_CollaborationAgreementTerminationPeriod_label_en-US" xlink:label="lab_exel_CollaborationAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Period</link:label>
    <link:label id="lab_exel_CollaborationAgreementTerminationPeriod_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementTerminationPeriod" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementTerminationPeriod" xlink:to="lab_exel_CollaborationAgreementTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_78a0c2f4-a574-414b-aa54-80d363ddb4db_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_88cf63f6-a8eb-47df-825d-76feac2907ee_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e3a081b2-0284-4280-bf2f-e6ab76e04e98_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_20cb5813-6a5d-4dd5-b0f0-0f7561debbaa_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_UpfrontPayments_f065f498-c479-436d-8774-bc4d0b6060f5_terseLabel_en-US" xlink:label="lab_exel_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments</link:label>
    <link:label id="lab_exel_UpfrontPayments_label_en-US" xlink:label="lab_exel_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:label id="lab_exel_UpfrontPayments_documentation_en-US" xlink:label="lab_exel_UpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment(s)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments" xlink:href="exel-20210101.xsd#exel_UpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontPayments" xlink:to="lab_exel_UpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b5a1fbf5-bfc0-4eaf-b705-5c911468e79c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense weighted-average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_572900dc-3df4-4cff-a950-abd0cb520e56_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:to="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_10b89159-aeb1-4075-b0f3-b94fab8aa2e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f289db0a-8e2c-49b4-b581-c2951d9e6e2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e8ab0708-3cf5-4b66-8e3e-bf28de3d4781_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6458f1f0-4394-4ecb-b838-439d8718034c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuarantyLiabilities_8d6c0dd1-1111-49bf-ab84-c97ac16990f8_terseLabel_en-US" xlink:label="lab_us-gaap_GuarantyLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranty liabilities</link:label>
    <link:label id="lab_us-gaap_GuarantyLiabilities_label_en-US" xlink:label="lab_us-gaap_GuarantyLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranty Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuarantyLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuarantyLiabilities" xlink:to="lab_us-gaap_GuarantyLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_6cdcfb39-f67c-4f8c-b6a6-8af4460ed7e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_15fe7b43-a381-4637-b1ba-834768896821_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_label_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Assets [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseAssetsAbstract_documentation_en-US" xlink:label="lab_exel_OperatingLeaseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseAssetsAbstract" xlink:href="exel-20210101.xsd#exel_OperatingLeaseAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseAssetsAbstract" xlink:to="lab_exel_OperatingLeaseAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c510306b-c455-4629-adee-257417c8b09a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_4fcc4ee8-a638-4c03-98ac-26b3a4982ee4_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:href="exel-20210101.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4ad52945-8124-4d57-8f44-42742c6d489a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2512a927-5c66-47a3-b633-508ab947edd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_c385ff6c-b0bd-4457-8a6d-6bd575d4fffe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b9c3bd6c-927a-4e06-b7db-811927003854_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_7ae075ef-7b2f-4867-b0c5-34a6e89874d9_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement performed for others, reimbursement for costs incurred, percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:href="exel-20210101.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:to="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6623472d-40c6-40f6-b53b-f4446785d589_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_234c6036-f90a-4800-a7b8-241b2ad81277_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_61db836e-e5d0-4761-bd33-4d0c81a9b122_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b689e789-09b9-48b6-8ce2-1471c3faaccc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_FirstProductToReachMarketMember_10c89e5f-70cb-4411-9e3f-588e8cefb69d_terseLabel_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Product To Reach Market</link:label>
    <link:label id="lab_exel_FirstProductToReachMarketMember_label_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Product To Reach Market [Member]</link:label>
    <link:label id="lab_exel_FirstProductToReachMarketMember_documentation_en-US" xlink:label="lab_exel_FirstProductToReachMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Product To Reach Market [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FirstProductToReachMarketMember" xlink:href="exel-20210101.xsd#exel_FirstProductToReachMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FirstProductToReachMarketMember" xlink:to="lab_exel_FirstProductToReachMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ffdcebcf-7dca-4f36-92cc-42ca9f7e1f95_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyaltytierDomain_671c14c2-baf8-4b93-b672-9d51f806dc21_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_label_en-US" xlink:label="lab_exel_RoyaltytierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_documentation_en-US" xlink:label="lab_exel_RoyaltytierDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for royalty tier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain" xlink:href="exel-20210101.xsd#exel_RoyaltytierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierDomain" xlink:to="lab_exel_RoyaltytierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_53866c28-de3d-4365-8bff-87dad20d9cdc_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_247bd5e2-d583-4109-a502-6c1c46f3f192_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_6b3c51e8-5545-4fd0-95f6-524e4447f9fc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8da658d3-8984-43ac-968a-a92a18705513_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7094969b-038a-44c5-846c-9801a0de5f1e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0b19de83-6608-4ed7-9bb6-f533810e71a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_24ceff82-f6c7-4fc0-8876-7ede1a253329_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_ac8a52c6-a158-40e8-acb9-924121a2d8d6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_935207ba-c421-4232-9758-d9d57bceff7a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_e1b9d7e3-cf83-4931-ac29-04c3230a57e8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d188466a-05d3-4301-8a3f-354fe1761135_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4a746f89-922b-44bb-8c26-14d000411716_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_0fd4849c-6a42-476a-a4f1-385dddf05a16_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement option exercise fee payment, upon exercising option</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_label_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:to="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9b4074e7-4e83-4655-a67a-0538e0215886_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1c9e2c6d-62cf-4722-8a8d-8210416d0a5d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at ending of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_359a0d45-1fc4-4f13-ad3f-529606fe67e5_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_363cbf55-fbc6-4c5a-a559-e6b2fc38e28d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestoneObjectiveAxis_3c3d6c47-2241-4a46-889a-8298633e7f90_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Objective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_label_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Objective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Objective [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveAxis" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveAxis" xlink:to="lab_exel_MilestoneObjectiveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_9a210c28-e5d1-44bf-95d8-9595b61c8174_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d33cbeb7-005f-4f1c-b5f4-ce8d37a98aa1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from option exercises and purchases under the ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_7d254985-b3ea-49ed-a2cc-c198c39c4e09_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_4d14c85f-d515-406f-82e4-35225937a2df_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_a17f253c-04d5-49ee-93c4-f96d2efa746a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_babbd26c-008c-46b3-848f-f470dab5011c_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise threshold, percentage of per share exercise price of the PSO</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:href="exel-20210101.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeAgreementsUpfrontPayments_6399b91a-7769-4c3c-a41c-2882fdd63e32_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements upfront payments</link:label>
    <link:label id="lab_exel_CollaborativeAgreementsUpfrontPayments_label_en-US" xlink:label="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborativeAgreementsUpfrontPayments_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments" xlink:href="exel-20210101.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementsUpfrontPayments" xlink:to="lab_exel_CollaborativeAgreementsUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_073b99f2-53f0-4512-bd07-82abe8ecbd9f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_39fd3aa9-13b4-46c6-9a0f-1220ebdbf4af_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ff7ba126-f76b-4d07-b704-a1cdbb20c4b9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_9b971c48-e7ff-4813-9a9e-26f2ce597bde_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_dd9bd252-b531-41f0-a1f9-36f24db998ce_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20210101.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_acbeb41e-e159-4789-a64c-b97f6f9af16b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_6e007853-77ce-467f-a9e7-f85de0d9a861_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c4df779f-51eb-491d-8a33-79c52eabba03_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceSharesClinicalTrialResultsMember_249a9d41-675c-4f20-8a9f-e257256bd4ae_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Clinical Trial Results</link:label>
    <link:label id="lab_exel_PerformanceSharesClinicalTrialResultsMember_label_en-US" xlink:label="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Clinical Trial Results [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesClinicalTrialResultsMember_documentation_en-US" xlink:label="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Clinical Trial Results [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesClinicalTrialResultsMember" xlink:href="exel-20210101.xsd#exel_PerformanceSharesClinicalTrialResultsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesClinicalTrialResultsMember" xlink:to="lab_exel_PerformanceSharesClinicalTrialResultsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_82b8525d-ec6f-4386-b771-fa52dc964925_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_65a18ae4-1998-4450-b2cf-511210bc6a0e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5bb6f0a9-7b76-437d-949f-92c568a6ea18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_e568ea7e-998b-4bd0-917d-094bd36af15a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_56e1760b-527a-4701-ba27-0d7fd90f8dd8_negatedTerseLabel_en-US" xlink:label="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease right-of-use assets</link:label>
    <link:label id="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_label_en-US" xlink:label="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:href="exel-20210101.xsd#exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:to="lab_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_415e03c3-3a87-4537-82c1-9d81f14bd9ca_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend the lease</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments_afaa8703-adab-45b8-8056-7d343bd3dd0d_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements additional upfront payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments_label_en-US" xlink:label="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements Additional Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements Additional Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementsAdditionalUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:to="lab_exel_CollaborationAgreementsAdditionalUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_830f7dae-3bbb-4d5f-a275-cf7289e82dfd_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_657ada05-16f4-401c-b995-2039c99033e7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_3e772ee8-742c-4199-9b91-053afc452a32_terseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant lease improvements allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_label_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_documentation_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance" xlink:href="exel-20210101.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance" xlink:to="lab_exel_TenantLeaseImprovementsAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_67a03050-9b46-4d28-81f4-2b1ba90a2ac0_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_3ae24513-cb0d-4a70-9041-1fe64ed0bcdd_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_d885dbd0-fe7c-416d-afec-66433db26a54_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_71bf4207-30a1-4543-b574-7fcaea6d3853_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_8bfd6f23-f332-4e20-8b8c-1870e24778ff_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20210101.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_2c4719d6-ca55-4c8c-a8a0-453c559ed8c1_terseLabel_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount expected to be earned</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_label_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_documentation_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:href="exel-20210101.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:to="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_29ebabd4-161c-4708-92e4-b4b103f9901e_negatedLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_62da6af0-165f-4e41-af3a-24181c7bea48_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ac75b843-f8db-4b90-9f82-1490b1ef3df2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_191d0944-f6df-46dc-ad2b-bfdd36943f81_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_50414318-cafc-45f9-9e1d-310a205f264f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_30ee820b-1684-4302-8875-70c74192e101_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_e635e4e8-3f51-4a33-8972-5683fa526116_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_750b2fcd-5d2b-4e07-bc56-4b7dca62e1af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_187363d2-0414-4237-9417-823ed1203147_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20210101.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_b2a5cd04-b8b2-489d-be14-481bca77f47b_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b9368441-eb0a-4f11-b299-b31d707553df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fe5f7cf7-7e29-4fe8-8d46-464e3eba5623_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyaltyTier_ceef2d7d-9c7a-4038-870b-253e46a82b18_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_label_en-US" xlink:label="lab_exel_RoyaltyTier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_documentation_en-US" xlink:label="lab_exel_RoyaltyTier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTier" xlink:href="exel-20210101.xsd#exel_RoyaltyTier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier" xlink:to="lab_exel_RoyaltyTier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_7595c42b-5a38-4a52-8d54-c1780a37717d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_603053d9-f2bd-4054-9eb6-9fea6b5ee6b7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e17c74a2-321d-422c-9d99-6c7bbe1a5028_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_88a4ec2b-87be-4ada-9da8-20e38e006060_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a674eac1-8a1f-413c-b36e-05c13426135b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_DiscoveryProjectMember_aa91fb80-ddf6-45f5-a4ca-eeee6b0567ab_terseLabel_en-US" xlink:label="lab_exel_DiscoveryProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery Project</link:label>
    <link:label id="lab_exel_DiscoveryProjectMember_label_en-US" xlink:label="lab_exel_DiscoveryProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery Project [Member]</link:label>
    <link:label id="lab_exel_DiscoveryProjectMember_documentation_en-US" xlink:label="lab_exel_DiscoveryProjectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discovery Project [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DiscoveryProjectMember" xlink:href="exel-20210101.xsd#exel_DiscoveryProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiscoveryProjectMember" xlink:to="lab_exel_DiscoveryProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6ae603d1-249d-4fc8-b5f8-ee9d99922056_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProfitSharingTierTwoMember_bc6de858-5f14-486c-9074-5c40344fc401_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tier Two</link:label>
    <link:label id="lab_exel_ProfitSharingTierTwoMember_label_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tier Two [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierTwoMember_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tier Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTierTwoMember" xlink:href="exel-20210101.xsd#exel_ProfitSharingTierTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierTwoMember" xlink:to="lab_exel_ProfitSharingTierTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_7da326a0-78d0-40f6-a87a-78984d715ea9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_77598b74-d6fb-40ed-89cf-d5222f180172_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_89f7f052-6c47-4b88-9088-c7961039b925_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_bfe8b036-1e9d-4761-8d46-2d99c99c6ad8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-suit lease period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_7c2c8171-cadf-4aec-94c0-11fc93c171a9_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20210101.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_00fd5f40-e2e9-48c0-8901-dc30c67dc851_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_c77096e4-9b4c-4d6f-9aec-ba3709fc1b58_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_371e7eb8-2ea8-44de-8359-ad81e21f1412_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_dd9175ff-f885-428b-80c2-3d751f8a7990_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_1acc0f74-a6f1-4e60-aba7-d9e1ef300691_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_caf46e56-6ffd-43b0-a79d-2f7b653af759_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bbfd8f71-4873-4bc5-b74f-42ec702575a7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a3fb4629-d1cf-4744-a731-522febcc2c75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a1072e9f-e120-4dff-b6e4-544c91ac269c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_09817cd8-24a5-4de7-b381-81422d27bbd7_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_11f261d3-13f0-448c-8246-f30fc223c4df_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment commencement period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_05c821cf-6c36-4bbf-abcc-f6445cce2656_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_2c2e131d-10ce-43d2-ad8a-3ab81f7527bc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_4cfa24d5-f636-4f3c-bbf7-949ed1fd07de_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_74da8fcd-e69c-405b-8053-fec14bf2556b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7c3552f6-7236-489c-8d07-e34e552883f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4c74fd79-996c-45cc-99e9-68cc13b6d701_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_InitialMember_8c23be51-1a28-49d2-a12f-3af23feade25_terseLabel_en-US" xlink:label="lab_exel_InitialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial</link:label>
    <link:label id="lab_exel_InitialMember_label_en-US" xlink:label="lab_exel_InitialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_documentation_en-US" xlink:label="lab_exel_InitialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InitialMember" xlink:href="exel-20210101.xsd#exel_InitialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InitialMember" xlink:to="lab_exel_InitialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_c23c83d7-10c9-4fd9-98a5-185cc7179c7f_terseLabel_en-US" xlink:label="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward amount with expiration dates</link:label>
    <link:label id="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_label_en-US" xlink:label="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount With Expiration Period</link:label>
    <link:label id="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_documentation_en-US" xlink:label="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount With Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:href="exel-20210101.xsd#exel_TaxCreditCarryforwardAmountWithExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:to="lab_exel_TaxCreditCarryforwardAmountWithExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_89832bfe-31e4-4148-862e-2d8262245aed_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_296cc681-d627-4aa0-bb7b-34ef5143e58e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a95262e0-9bee-4b14-9453-eec1b5a51596_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8aeb635d-d741-4ef1-87c4-b7f374afc48a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c3f4f3db-fb69-4828-a1b3-7635af911c44_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ccca926b-d785-412f-a4a6-3b70e0701cce_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_08bb6b56-439a-451f-89a6-f381b059105e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_15a023ca-d872-46f2-9c89-87db8734cc80_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cb448a70-f28f-4ecf-a9dd-ba96c1a433f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_493d12bf-bb63-41bf-8c4d-fe3eb31ab545_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_b704b27e-7773-41f6-bab7-feacb999cced_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f32df2c8-da7d-4cf7-bb36-ba222753037c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_50f6d94f-e4de-4c01-8560-68ff8977397c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_ef09dd72-aa4d-435f-8321-1c6d0be40d30_terseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded prescription drug fee</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:href="exel-20210101.xsd#exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_3507be5d-f383-481e-9a33-4280044ab7d4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_dd62ecee-45e8-43b5-bdf6-68fee7e0d558_terseLabel_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Options (PSO)</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_label_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_documentation_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceShareOptionsPSOMember" xlink:href="exel-20210101.xsd#exel_PerformanceShareOptionsPSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceShareOptionsPSOMember" xlink:to="lab_exel_PerformanceShareOptionsPSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_0992c5ff-897f-4afa-a479-825f546a5f84_verboseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold is related to product</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_c3ae37ca-d84a-4777-8e8b-cab7568eaa05_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_1e98530f-7a6a-4058-8158-3d8b488a31cb_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_bbc33397-6f75-4b73-9bb7-879e3469046a_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20210101.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8c629f2d-c968-4e76-bc91-a7f7be80d397_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5116d203-6565-450f-8a82-3f4d7e3d0e9f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_b5ca9002-67f2-449c-b0bf-5be81fdbd037_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_7f01c5f6-b102-4e8d-b3be-9aff294ec1c0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_3907a6e9-ba76-4311-91fd-86996c946f82_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_b5403d6b-a209-409e-97b2-83507628e350_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_0e10dff2-b30d-4fef-ac99-8df3a26ed88a_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_38a07270-dc52-4e79-8abe-202068baec6f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_a86edb50-5fd6-49bf-b315-f3ee4078bdf5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_ca7c1ec0-4bda-402d-8191-9cc0f4ce17c4_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20210101.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_dc762488-3b4e-4335-9b23-2ca1c7316b97_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AchievedMember_42b56d75-dc65-40ea-ba8a-bdc56629bf3e_terseLabel_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved</link:label>
    <link:label id="lab_exel_AchievedMember_label_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_documentation_en-US" xlink:label="lab_exel_AchievedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember" xlink:href="exel-20210101.xsd#exel_AchievedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedMember" xlink:to="lab_exel_AchievedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_41b72064-a25d-4089-8573-24ad79ca2f07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_c04bba2c-ade4-47cc-b190-febdd34f2a51_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20210101.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7a5d590a-6761-49b0-b940-34d78b42f6b9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_FinalTierMember_b1faf2c6-ecd9-43bd-a5d2-449faefd13ad_terseLabel_en-US" xlink:label="lab_exel_FinalTierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final tier</link:label>
    <link:label id="lab_exel_FinalTierMember_label_en-US" xlink:label="lab_exel_FinalTierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_documentation_en-US" xlink:label="lab_exel_FinalTierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Tier[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember" xlink:href="exel-20210101.xsd#exel_FinalTierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember" xlink:to="lab_exel_FinalTierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ac3f2f31-2fed-4f03-b45c-96a73b2542ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of All Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_38dd8bd4-285a-4860-93fa-1c6e797958de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_4e048157-5556-4bb0-9a19-8ceb0797464f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0df57c3d-e85a-4734-b167-411c595dfd93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_20f3c9ae-4991-4674-af24-98592adfe218_negatedLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_7d2c57a1-2ca4-40c4-aa81-0eaba0c8dda4_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20210101.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_1b915ef4-34cd-48a4-8b48-10e39a488f1d_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8ac014ac-b50c-4db9-9777-596fa0816f7d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_746f4b37-cb88-46cc-86ff-ab70d36fbaf4_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_1a7f098b-7fd2-44d9-aad9-6c532ab8c35e_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_e3f80010-b0b6-4187-8cf3-b753f77a832d_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currently estimated amount</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_40590db3-af72-4f1f-ba12-7462eda4aeec_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8614c7da-d6d0-47ce-b4eb-92aadb5fff52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a0b80399-04d3-48c9-9402-2396cca4282b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average operating discount rate used to determine the operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_d161295d-e32a-46b5-b440-cbb5636eb354_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_b081a812-198a-45c9-b9a1-a25f75dc7a7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_b7e29289-1870-40dc-9c34-d09fff043981_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0a79a477-e712-4a48-b15a-8e97c0d4c135_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_44dc244e-0f64-4471-9303-011c8a9af5fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_a3af6590-4ac3-4d8f-bc8c-1e12c5ccfaaa_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_be457b94-c2c0-4794-ab42-0ed03c678c84_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_b5a2f124-72ce-4203-88d5-f955dd935675_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tier Three</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_label_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTierThreeMember" xlink:href="exel-20210101.xsd#exel_ProfitSharingTierThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierThreeMember" xlink:to="lab_exel_ProfitSharingTierThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c2bae145-6c37-4b9d-b413-52e03d82dafa_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_5896b6f5-db2d-4b0e-8e93-2623b8c202cc_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares to be earned (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_86cc2cf1-2459-4623-b8ed-828c7c890a2f_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With StemSynergy</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With StemSynergy [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithStemSynergyMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithStemSynergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With StemSynergy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithStemSynergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithStemSynergyMember" xlink:to="lab_exel_CollaborativeArrangementWithStemSynergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_5617aac5-6f45-4f2a-93c8-2c8be83abb57_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge on goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_a8d8f6bf-9b14-4677-8b74-cdd0ff267249_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cda572b3-b43e-4dbe-b076-bb19289c4657_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_31b47d43-74cc-4c5a-a449-13167e94a82c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_994cae37-cac6-48d9-97e1-47bc1760a5bb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_556607b2-b9b8-4267-b880-8eb65eaf850b_terseLabel_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales volume period</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_label_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_documentation_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:href="exel-20210101.xsd#exel_PeriodOfSpecificSalesVolumeThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:to="lab_exel_PeriodOfSpecificSalesVolumeThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ce45c62e-8d7b-428e-bae7-0f290b74c5fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5ee12188-74d6-4663-9989-94743a5c0a2f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_020d1738-4a2c-4999-b16b-6451252aadfc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in long-term investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bbf031f9-7d11-495e-b6a3-969767b6176a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_e5646041-acf3-4054-a704-ae2b81422eac_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:href="exel-20210101.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_09a79c2e-1ce1-45ff-8377-62d9553479f7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_90fbe078-f893-44a4-8040-72f705fe0e4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7bb8d7f0-efd8-446d-a36c-41ca78f2087d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ee464e69-b459-49b9-9b5f-9162ee6567a0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LaboratoryEquipmentMember_87fb02b2-ddd6-4860-a3f6-10d37e5ab865_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LaboratoryEquipmentMember" xlink:href="exel-20210101.xsd#exel_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember" xlink:to="lab_exel_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_a5c4e629-0290-4ff9-a697-fdb28e3394c3_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3097bdad-4e91-4e96-84cf-7ef71b8e9b5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_360bf567-0929-4b9a-aadf-442e28c8a7c1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_788b3400-8154-4b99-a03a-df3c190fb46a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7c96cc79-3a65-4129-a0ea-214451794b11_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_a9b69dcc-5474-439f-9425-3ffa1b6d8b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_6ae98e89-1bd7-4ee2-8193-1f146303ee25_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_95c16c79-e6cd-49de-b338-10b3e04d0541_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e64727d4-4c3b-428b-bcad-87af0cd320cb_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_GlaxoSmithKlineMember_51f5cc68-acba-4636-a395-8dd1aec84bb6_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember" xlink:href="exel-20210101.xsd#exel_GlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember" xlink:to="lab_exel_GlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a2610d12-d057-4f5f-a7d4-a36054464e5f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ebd2ce3e-c27d-48e2-96fe-c03ef2f5f95f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5b893bcb-b90c-45ee-ba74-0f4da1f2febb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6a48f677-93ce-4d2a-8cb9-896ef0efdc3d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_891e4148-e6a6-4bba-b8f0-1a35eb1e4d03_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_05c85051-6ef3-4d30-aad6-104c2c1c1e7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d256b4ab-6b52-4183-ac03-507cf34c6635_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_8238b3a8-d765-41b8-93ea-29f11334ca32_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20210101.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_268c4ab9-1e70-485d-a071-92a38d82e20f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_53230ef4-3ecd-4bfc-9e12-ce3ffa7686fb_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_322254d8-f1e8-4f0a-9c89-3e7b1eb2d4fc_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_83be6aa7-98a5-41c6-b782-382d0f87a235_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_888ccdf4-6f78-4171-aeed-c9a29d540f47_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d2e881fa-184b-4841-83d5-cbdceeea812b_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_7fc03eb8-159f-444e-8619-4a41a9b950af_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achieved milestone amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achieved Milestone Amount</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievedMilestoneAmount_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Achieved Milestone Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementAchievedMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:to="lab_exel_CollaborativeArrangementAchievedMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_79b14cc7-fa73-4f5e-8142-c50c69abb192_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a1bdd596-eb11-445d-bd1d-004025d2becb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_35b80f62-34c2-429b-980f-1097b3b766cb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b10dee09-0a89-4ac6-853d-b6b3fd8213f8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_108ea828-0185-4371-99c6-356e28fd9736_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9f727bd7-e909-4f4e-9454-91f65371a5d4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8aa9e5b0-9175-42ce-b57d-4e54bc710bf7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NotProbableMember_e624bfd7-11bb-4bf0-aa5e-6c108bb0ce05_terseLabel_en-US" xlink:label="lab_exel_NotProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Probable</link:label>
    <link:label id="lab_exel_NotProbableMember_label_en-US" xlink:label="lab_exel_NotProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:label id="lab_exel_NotProbableMember_documentation_en-US" xlink:label="lab_exel_NotProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NotProbableMember" xlink:href="exel-20210101.xsd#exel_NotProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NotProbableMember" xlink:to="lab_exel_NotProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_aedf1710-f273-43ab-a5f2-6c70af69ae97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_832b9ea8-b665-44c3-bde9-c47842bcbfed_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:href="exel-20210101.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e979ac43-2c96-4ce7-990f-403584af82f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_90e026e4-1a57-4b19-80fe-9b0dcf51ff3e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_0ec55a66-77e7-48e7-8d1c-8986fe8d5255_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_7a131ef3-864e-407a-a4e4-4067ec718e80_terseLabel_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent discount for prompt payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_label_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_documentation_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:href="exel-20210101.xsd#exel_SalesRevenuePercentDiscountForPromptPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:to="lab_exel_SalesRevenuePercentDiscountForPromptPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a27c6fca-9462-4109-9454-9a1b015cae20_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_e190d102-6c40-4827-837f-40b46248aa54_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20210101.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_8c6d6d6d-b288-4636-823b-2223d00a9556_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price allocated to our performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_b81bd20a-3a24-46b2-92b7-4af821f0f8df_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2dcba2d8-4a9c-4ce1-bd3a-3da013e65135_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6ac37c06-dda3-4b8b-ba8d-0557bb2208ec_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_04c9956e-32f6-4bfe-a770-111d0fa34bcb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_13422de7-f874-43ef-b64b-2246b514c2b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_35e3fb2c-3b96-47e8-9282-b96434bceee3_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_c999f1fe-b84f-48fd-86eb-8664585bbf52_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b2aca6fb-5938-4222-a602-501feab3ed97_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_2f747f85-fafb-4ffa-b628-1197a5d354dd_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_fa3be804-d9a0-4777-bf36-cf385761a27f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 311,627 and 304,831 at December&#160;31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_65bb2796-772a-438d-8d3c-31cabbc6527c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8f2610f1-4c4a-4eb7-bffc-76e361ab920e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_2c6f5c38-3905-491c-a624-16b8cfef4441_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_04bd1d67-91e0-407c-b48d-9d0068966d94_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:to="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestonePaymentsEarned_03d7bc20-cc04-42ff-a128-200bbf96dfc1_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarned" xlink:to="lab_exel_MilestonePaymentsEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_86b5382d-abe2-48b6-a8fd-2cd02f13ed3c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_609010d9-5d5d-47ca-85f8-d89b1d1d8299_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4c22bf77-e861-46b1-aa98-3671693af8d6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_fcb8797e-6683-46f6-8bb4-67a1095d6e35_terseLabel_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_label_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_documentation_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontAndMilestonePayments" xlink:href="exel-20210101.xsd#exel_UpfrontAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontAndMilestonePayments" xlink:to="lab_exel_UpfrontAndMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1830ecb7-da2a-4d74-87dc-e17645721088_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_7295f78d-7115-4e87-bd7d-3639038364d1_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments earned to date</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned To Date</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarnedToDate_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarnedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Earned To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarnedToDate" xlink:to="lab_exel_MilestonePaymentsEarnedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember_c8b05d56-ee4f-4a55-b242-3ee585729b6c_terseLabel_en-US" xlink:label="lab_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Calculation Of Branded Prescription Drug Fee</link:label>
    <link:label id="lab_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember_label_en-US" xlink:label="lab_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Calculation Of Branded Prescription Drug Fee [Member]</link:label>
    <link:label id="lab_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember_documentation_en-US" xlink:label="lab_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Calculation Of Branded Prescription Drug Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember" xlink:href="exel-20210101.xsd#exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember" xlink:to="lab_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusDomain_8fa71754-1bc8-46f7-83bd-51cccdb14a00_terseLabel_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_label_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_documentation_en-US" xlink:label="lab_exel_StatusDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain" xlink:href="exel-20210101.xsd#exel_StatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain" xlink:to="lab_exel_StatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_20822467-44fe-4dc2-b3a9-ae9ac35b8fe5_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember" xlink:href="exel-20210101.xsd#exel_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_207e2024-f006-419e-97ca-5559f5ecb542_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20210101.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_98283ecd-9261-4887-9d88-ba69078c0c53_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_82c7377a-94fa-448c-9bd5-f0d39a969b80_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20210101.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1371aac2-bb55-4b7d-b320-b3674e83d20e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_73afa58c-a64f-439b-8ee8-24731f553d7b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_458fc51b-2d63-4eb3-939c-d3a83d0e2d3f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9df9f48f-88e8-4bc2-b82d-e27a89cd1228_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_277d03f7-cc2e-4253-b980-c90c684f7946_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c018f8e-c0fc-43cd-a804-0ea8ab466489_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_811f22a6-fd88-4db5-b758-bbc10360ff36_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_48e1d162-825e-4d9f-ae75-b16d5317f69d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7a829408-5f4a-4de9-b788-b5c50325f3c2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_88239ca9-c348-447c-a1be-8fc8b24b6d9a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_507ff98f-ad92-4e15-91f0-251a644f0884_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_eed02e6e-39df-49b8-b8f3-d163cc01a9cc_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to terminate lease (after period)</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:to="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_155810ce-d960-44ad-adb0-e6d1191e7715_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20210101.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_358c7965-5ff7-466a-8f8f-5c36d8b05d63_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_25259808-29dc-4152-9fd1-61ee62702a22_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fcf9f6da-689b-4659-9b26-0b5d68a96f03_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_897b4896-b090-4ca7-8f79-8e0b3f7a0d15_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b6d3c623-aff6-46d6-898e-5a0e4f255449_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_9f648723-8d38-48f9-bc6e-d7aa9db767f2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_51768e01-beaf-48fc-be7e-92152255e51b_verboseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_27318142-2250-44fb-9c67-6bdf430e653f_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20210101.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5ab3e8a3-a630-4923-9078-71e8cf4e4409_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20210101.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2a8f5404-8d97-45cd-af3a-6d012ee5b625_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_79cf8e24-8892-4a8f-bcf3-3d9edb94310c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34269d4a-9dc7-4792-84f9-628658f41668_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_863e7104-94b3-4946-91c9-b8d8c34d2b1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For (Benefit From) Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_534c80a1-5401-4d5c-b613-0cce0b509f6c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1d28f59d-0817-4aea-adf6-83e464778e31_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_5573008d-7c29-41bc-8cd0-4b718ad5d99f_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7cd33c0d-43ad-4729-964e-504ee37d7d80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_874fdd8c-e0ae-4eec-bfd5-e9225e55d244_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e06d0328-51e1-4c94-a4eb-0c9cb3f25184_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4a2f47e5-584b-4e0f-a0e8-e5661fdd6a62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions based on the lapse of the applicable statutes of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_272c61cf-0e50-416f-9408-8293afcd4d0f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4e56dc1f-5d2f-46fc-9539-4f482caadb45_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_d7b2fe11-0d8f-410f-9dc4-6856439e5358_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6aaf1b1d-fded-4459-86f6-598e1336da57_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1c4f847b-830a-4dce-977b-9653fdd2199a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_c9c6f3c5-5f1b-424f-b6d1-c845907964bc_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_c19e1cea-5b25-4eec-806c-2f41cc614991_terseLabel_en-US" xlink:label="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Development and Regulatory Milestone</link:label>
    <link:label id="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_label_en-US" xlink:label="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Development And Regulatory Milestone [Member]</link:label>
    <link:label id="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Development And Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:href="exel-20210101.xsd#exel_AdditionalDevelopmentAndRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:to="lab_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_a48608d1-04ba-4619-8840-61dc6b979eeb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_9ad2c41f-7d8b-477a-b773-a4f9b59c3ccc_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_108f86f4-e60d-414b-bd3f-030b27ab2b4e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4d357701-85ab-4fdc-a0ea-8198390004ae_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change relating to current year provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_71f76ba1-5768-4625-8f7e-a2c5d1db1cff_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_312bb362-15fe-4e8a-8495-43c2e88b3628_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate from market value on offering date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_b2efc9ff-35c6-4e80-adf2-a6124e951a70_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_eef68aaf-d6c5-4019-abce-a6030009d4ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9a3d3be8-de26-49b4-a558-8168aab33958_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_745092d8-b1a9-4bf2-85e6-6a207fe8e248_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a356c028-dd85-4064-adfc-de1f3dec2efa_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1ae8ad72-e8cc-4671-84cc-9be945ff6de4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_f4844fee-51b6-45ad-9db2-38055f4a18db_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_6c27c312-0c5a-4e66-b3d3-77f2424384cc_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_41e6f1b7-70ab-4611-b99a-ed34d27669d7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6db5ac35-4013-400d-b7bb-b131b57fde8c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c3eb6c7f-7cc3-41ab-9876-e938e5eccb72_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_79f3fcd9-a37a-4b5a-89eb-293ce5d42cdf_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_482e841f-4463-492d-a161-2b42ddb98676_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4fc750f4-fc98-4d80-863b-32dbfbbcb9cd_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_24282457-ff6b-4989-8898-8bd01a2eb936_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c0c05c9b-1827-4fcc-870f-1315b8c7bcde_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9bbf998d-e8d8-46da-863d-bc3b875c9ab4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_a74c2265-f2a5-4419-adc8-6b79aaddf499_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_b1df4a57-307b-4354-9850-fcf69c577124_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_b4a97889-2e5f-44df-b23f-dfa1ed1a01bb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_07ece93d-a0aa-4a4e-a213-756e43190fea_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4da03780-feaf-4822-8533-d2d4aa962934_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_afb61e21-a2e0-4e49-a24f-66cef7ac696a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_8c4870f3-a25e-45f7-958d-a3422f38e692_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d31a16f1-2cd5-4db3-9d22-850af101964e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4ae2c7ca-1212-4aa8-8d0d-a676af76d90c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_21a21efa-5823-44bd-aa43-b0fb070a1a78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8572e760-0263-4bf6-b079-0843c6cd4e4c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_03df533a-ab70-4578-bfd0-ecd851bc5021_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_97e66ba4-a71c-41e3-a125-017ae5a09f0f_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement pre-existing programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_label_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Preexisting Programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Preexisting Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementNumberOfPreexistingPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:to="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductCommercializationMember_abf46436-90c2-4985-8342-c3c778e14eba_terseLabel_en-US" xlink:label="lab_exel_ProductCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Commercialization</link:label>
    <link:label id="lab_exel_ProductCommercializationMember_label_en-US" xlink:label="lab_exel_ProductCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Commercialization [Member]</link:label>
    <link:label id="lab_exel_ProductCommercializationMember_documentation_en-US" xlink:label="lab_exel_ProductCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Commercialization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductCommercializationMember" xlink:href="exel-20210101.xsd#exel_ProductCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductCommercializationMember" xlink:to="lab_exel_ProductCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_4bf7f314-3dcb-4352-983e-cd8b9eea7944_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_label_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020 [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_documentation_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:href="exel-20210101.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:to="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_341e4084-1498-4c89-ba80-273dd80b953c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_30fcb782-1274-4b8b-85f9-3dc2bdd9cd3b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_633de5e2-15a3-49f4-98eb-2edaec84d4c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e44830ae-5381-4eeb-9a45-b35dcd95cbb6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_dd1cdd0c-343d-432e-a91d-0a5701d2ba89_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_02b1bcad-369b-4c35-b8a3-c1426bb0baa3_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_9c5b0eb9-8658-421d-a54f-e0c6610346f2_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_13096cec-7d66-4b6b-9311-b43e1c4d11ba_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees percentage</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20210101.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_b2b7b783-7923-4839-9158-ea22397403d2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ff634bd0-c4cf-42e4-a1fd-ddbfa71ebca7_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ea42afcc-202c-4694-af29-c19d8c6e3660_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_StatusAxis_e6a8ecfa-c90d-4acb-974b-6b90689cfbe2_terseLabel_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_label_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_documentation_en-US" xlink:label="lab_exel_StatusAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis" xlink:href="exel-20210101.xsd#exel_StatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis" xlink:to="lab_exel_StatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProfitSharingTiersDomain_9564285e-8b30-4eac-8249-020573978a63_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_label_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTiersDomain" xlink:href="exel-20210101.xsd#exel_ProfitSharingTiersDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersDomain" xlink:to="lab_exel_ProfitSharingTiersDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_d286bc7d-d936-44a4-aa4b-dc8cdb7ca02b_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f682b233-f41d-4d8e-b8b7-c316898e3f6f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02e333d7-0ddc-4989-b6ae-7bce9d69cfa7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e2922a27-520a-4bc5-9214-ea7f31570ab1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_23862fa7-029b-4e50-a8e5-98ebac41886c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_095c9820-78a5-4a0d-92c0-b433b7a91194_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_72f02be8-5101-4ec1-8aca-316dd4091468_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6367542b-aa4c-49fb-a846-4441be3f62ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_254ce222-05ee-46a6-a505-ce98f8fe0b9d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ed81831-0393-4c5c-b65e-b79aef0eef50_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_7fd96e11-1973-4f05-8462-94129ba53998_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_16750346-1288-4f81-bccb-ed65cd90decc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses relating to stock match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member_c54eea7a-6b0b-4a69-9541-13383a8dffd3_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2021</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member_label_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2021 [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member_documentation_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:href="exel-20210101.xsd#exel_PerformanceSharesAchievedBeforeDecember312021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:to="lab_exel_PerformanceSharesAchievedBeforeDecember312021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f8d1e3df-966b-4d1f-898d-ad61626b16c6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_MilestonePaymentsYetToBeEarned_9182ce02-bbb4-4bfc-964c-9b1b11c7d9a8_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsYetToBeEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, yet to be earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsYetToBeEarned_label_en-US" xlink:label="lab_exel_MilestonePaymentsYetToBeEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Yet to be Earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsYetToBeEarned_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsYetToBeEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments, Yet to be Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsYetToBeEarned" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsYetToBeEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsYetToBeEarned" xlink:to="lab_exel_MilestonePaymentsYetToBeEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_a7187076-10e9-4c32-8399-f81f0b77d359_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0237927c-6a94-4d46-a246-525595e5970d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b9fc3dbe-f72d-4c9c-ac61-981c515a6e7b_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_00295826-3817-4b9f-8d6a-67ad6c6f92fe_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_8ca21a83-94e1-419f-bad0-4894b173263c_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_de266db8-acbb-4b81-afeb-e43d5213eb43_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_e988d938-844d-4ecd-9e7d-de26484db5cf_terseLabel_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_label_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Amortization Of Deferred Stock Compensation - Non-Qualified</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_documentation_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets amortization of deferred stock compensation - non-qualified.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:href="exel-20210101.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:to="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid_4beb5184-c369-484e-95a1-c9fdd53ec831_terseLabel_en-US" xlink:label="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for unsettled investment purchases</link:label>
    <link:label id="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid_label_en-US" xlink:label="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Purchases Incurred But Not Yet Paid</link:label>
    <link:label id="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Purchases Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:href="exel-20210101.xsd#exel_InvestmentsPurchasesIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:to="lab_exel_InvestmentsPurchasesIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1cd36c08-a638-49d9-aa7b-3a6b16b3e986_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_7cce2491-3cf8-4be1-bfd7-56aab876c96b_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of excess costs</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_a7585b8d-cb1b-4973-a208-3b6794ae7532_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b9679628-53e1-415a-ba49-19be9093c080_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a31b944c-2277-4f2f-ae87-40716bec787b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_ea999243-0e82-4e91-9917-cbaabe4d9fe5_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2d20e1cb-860d-490c-87c3-fcb7b3dfef71_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_d9c5b37f-40a4-4d5d-9f39-16b342dfdfe0_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc.</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:to="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_27a1339b-dc4e-4ece-992d-dc11eb929307_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_DeferredTaxAssetsLeaseLiabilities_3cc82799-f1c5-4575-9fd5-e5c48cde7078_terseLabel_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsLeaseLiabilities" xlink:href="exel-20210101.xsd#exel_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_exel_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8a3e3f22-9b7e-4344-aef0-60e994a141d0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d48e48f1-ecb2-449c-acf6-bfce6be781e6_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, including PSOs</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bbb49eb8-a33e-48ab-9ddc-f5caa2c8a492_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_935803b9-1ef2-4451-932e-f91958ce370a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e6aa136e-3c12-4eac-a9e7-36b502a6a0df_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_7e3839e6-2a7c-4bce-a407-2699234b5aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_72725152-6bf8-4d16-8233-38d554131789_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_df5d26df-187e-4db2-b7f8-23bdb3ac4093_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_65de67a4-c363-444d-9018-11ae2c09ff8b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_aa888a72-064b-4dc4-9b93-20e0bfde9692_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_4d25d6e1-f4ef-4189-9105-d94d7c4090da_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_a6892e3a-f72d-4a65-8334-b7b2ccaa828a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d02a6557-3ba6-4f48-931d-96096052837d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3dadfd80-298d-4520-80fe-4faf4fdf60ec_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_427885f0-2c91-4df1-af1a-e37686998e89_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LeaseArrangementsAxis_459d5f89-5008-42bb-a988-8cd3760743d2_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_label_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis" xlink:href="exel-20210101.xsd#exel_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsAxis" xlink:to="lab_exel_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bd39e8c2-7d53-4516-88be-72be2e3b400b_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_e00a199d-b214-4dea-9371-18b5fc7e7c74_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With Invenra</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With Invenra [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithInvenraMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithInvenraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With Invenra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithInvenraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithInvenraMember" xlink:to="lab_exel_CollaborativeArrangementWithInvenraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_18595960-3fec-4aa6-8fcb-57d1341a75b6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_962879e5-aeca-4915-a0de-3455daf4a7ff_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_30be683c-56be-4ed1-a4b7-24de1b31547c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency gains and losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_d7295080-7263-40fd-ad22-de26f7b3280b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_73b755cf-cb8a-47af-9a0e-5029626f93dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4d608fd9-0727-4877-9d74-bb6d9d1d1d4a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccountsReceivableForUnsettledInvestmentSales_3ffaa1ae-85cf-470f-8d81-e16a27726f4b_terseLabel_en-US" xlink:label="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable for unsettled investment sales</link:label>
    <link:label id="lab_exel_AccountsReceivableForUnsettledInvestmentSales_label_en-US" xlink:label="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable For Unsettled Investment Sales</link:label>
    <link:label id="lab_exel_AccountsReceivableForUnsettledInvestmentSales_documentation_en-US" xlink:label="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable For Unsettled Investment Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:href="exel-20210101.xsd#exel_AccountsReceivableForUnsettledInvestmentSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:to="lab_exel_AccountsReceivableForUnsettledInvestmentSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_d8fc363b-7977-4742-800e-27f3b3776bc2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ba5560ff-c519-487a-a9f2-b87cea4a5d13_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of All RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fec47373-0521-46fc-9a95-eed776d476f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a8ff9950-33ab-439d-bb7e-cac3d845d59e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e43df575-2097-4d9b-a056-92c5794c4828_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fc9ab6c9-0845-49fd-b97e-88032db863ae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_37419cf5-cc0c-4302-b1b7-9f36a1c7173e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_864dd3ce-1fe3-4406-9c9b-c9a65026574a_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_930e8789-aff1-4936-837e-6feaf2605787_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_64d07152-f348-4779-894f-958dfea847ec_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyaltyTierAxis_ae72f723-2e64-451e-ab7a-b9363490b86d_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_label_en-US" xlink:label="lab_exel_RoyaltyTierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltyTierAxis_documentation_en-US" xlink:label="lab_exel_RoyaltyTierAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis" xlink:href="exel-20210101.xsd#exel_RoyaltyTierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTierAxis" xlink:to="lab_exel_RoyaltyTierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9826e890-571f-4ba3-af19-9050357b2ea8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_dcc61fae-590d-4af6-8945-1651d5aaafc9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_32f67f6e-d413-4d39-b0a2-a0dfc4f64cb7_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_bcb0d4be-1752-4bea-9114-813f0fffbf1b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b80d508e-5dd7-4e84-847a-953e534463dc_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7d1ad8e7-0725-40fe-8724-86281e02e7f0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_6163ffff-da1f-4ce6-a7bc-cb886b21f5c4_terseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale" xlink:href="exel-20210101.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_620fdc0b-42f5-4248-8746-21d0a1ca86f0_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3ef57fbb-01a9-416c-a114-ddc34dd79f7b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_b5826519-69fd-4144-88f9-c0e23ea59764_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember" xlink:href="exel-20210101.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember" xlink:to="lab_exel_AccredoHealthIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7c7d257d-fb49-4940-a3af-2fa30cad063a_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c9de3e04-15c1-4bec-91af-acc542353de7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_9e219dd3-185e-4940-9850-2a07b5bc6925_verboseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_6dc711b2-d913-4e63-8742-af16fcd5c935_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20210101.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_19fe79f0-18eb-42e5-9ba8-4cecc96cf056_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_272fdf92-0b40-4d5a-8ecb-93744635fb92_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_e860d1bd-e1c0-4768-9ec6-430390dce13c_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fcb641aa-d9a8-4e88-b25d-a2ddb1db29fa_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bfe82693-6c6b-4fb8-a1fc-4de30ae9f1df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Grant&#160;Date Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_db0df028-c05b-4b18-83c7-b29e3663fe92_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_label_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:to="lab_exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fe751ae2-225a-4283-9874-a501a0aa7f5e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2fef4264-6186-4254-b371-bfecfb91e514_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f4ba7759-7151-4938-b0f0-88aa5fc46352_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_7dc3b3d8-fa92-4a1c-aeaa-15c0b1cdf3d4_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_label_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements, Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementsUpfrontPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementsUpfrontPayments" xlink:to="lab_exel_CollaborationAgreementsUpfrontPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a6cf6b0b-0639-45fa-a8ef-efa77e34c884_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e72ab1df-cc50-4742-910c-8ca55e7919b7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_675ee848-2fe0-4d78-acaf-083802f5a188_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fad8e379-4084-4164-94e0-97a4bd6ed1ce_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options outstanding at end of the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19ec9a9f-afc7-4f48-b231-5d64ecb1623d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c46f30fa-5673-47d1-97cc-78adc01468f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d2846418-4927-4a60-82d2-b37c78bbc659_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_47310551-7468-43d3-90d8-8a73671f7a06_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_02216d64-aea0-429f-8083-655176c49c22_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementWithCatalentMember_98365050-ba88-49f4-b130-23e8d3a523d4_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementWithCatalentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With Catalent</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithCatalentMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementWithCatalentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With Catalent [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementWithCatalentMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementWithCatalentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement With Catalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithCatalentMember" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithCatalentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementWithCatalentMember" xlink:to="lab_exel_CollaborativeArrangementWithCatalentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4c8dfa68-7852-4817-845b-18efcf4d36d6_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7a11d853-2576-451a-9e2c-88ae26ccaebe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160; Average Remaining Contractual&#160; Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_54d36327-ded7-4ada-8cb8-f0ac64f44857_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_ebc17052-e386-42c3-968e-c0e3067839cf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_6b3ba0cd-ba89-4616-a1f1-93600457c155_terseLabel_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement target selection term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_label_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement Target Selection Term</link:label>
    <link:label id="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_documentation_en-US" xlink:label="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement Target Selection Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:href="exel-20210101.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:to="lab_exel_CollaborationAndLicenseAgreementTargetSelectionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_bc645861-dab3-4293-a870-8d04a7cf73df_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_813c2f6d-8629-4d93-8ccd-6ad0250366bd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_3d029ed7-ab09-4823-9a2a-e37a6114bbb5_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits" xlink:href="exel-20210101.xsd#exel_ProfitSharingAgreementPercentOfProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementPercentOfProfits" xlink:to="lab_exel_ProfitSharingAgreementPercentOfProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_71cea963-85cb-402d-be39-f1250fee3954_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_eacfe323-1f12-4290-a899-00bc29757b1b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5e41204f-a72e-46ba-8a9e-0d0b709590e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6ce8d488-c383-4b67-a71c-436fff77b686_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_23fda498-3391-4777-b49a-69118d13bd9b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_1074332b-8f6f-46e4-8286-78d3bbeb25ac_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_19089cc7-d9b2-4e66-9e98-d97091f2bc01_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_1d1a8ce8-f644-4766-9d41-5ca9abbdc58d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>exel-20210101_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:3705d550-318f-4f51-9de6-06eba39f6ea7,g:2df53114-27bb-4237-9a9c-80b7c8353f30-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20210101.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0e64f318-a19e-4337-b88e-597f4004a1e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_DocumentType_0e64f318-a19e-4337-b88e-597f4004a1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ac576a53-557d-4d5d-bc5c-8efeb633020b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_DocumentAnnualReport_ac576a53-557d-4d5d-bc5c-8efeb633020b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ae916da6-221e-4480-b5e2-58c001cde8a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_DocumentPeriodEndDate_ae916da6-221e-4480-b5e2-58c001cde8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2d4138f7-0803-494e-9b3c-5f5e87cbcebb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_CurrentFiscalYearEndDate_2d4138f7-0803-494e-9b3c-5f5e87cbcebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5121a89e-e370-4f05-9961-be5550c49c2f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_DocumentTransitionReport_5121a89e-e370-4f05-9961-be5550c49c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3943953f-ace1-4939-a412-26ff3ec30547" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityFileNumber_3943953f-ace1-4939-a412-26ff3ec30547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0ffa5828-edcc-486e-abdb-b8e87fcf3a5b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityRegistrantName_0ffa5828-edcc-486e-abdb-b8e87fcf3a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5903b866-f38e-4925-86f1-b87fe97d1e6e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5903b866-f38e-4925-86f1-b87fe97d1e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_39c0fdc7-a596-4ef4-8bc8-1f65831383a3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityTaxIdentificationNumber_39c0fdc7-a596-4ef4-8bc8-1f65831383a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6c4ea03c-367f-4f0d-94e2-b7a31e8a1ee8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityAddressAddressLine1_6c4ea03c-367f-4f0d-94e2-b7a31e8a1ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7a0f3092-c359-460f-804e-6e02fefab0f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityAddressCityOrTown_7a0f3092-c359-460f-804e-6e02fefab0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_38e4a135-5559-4e35-8e35-1ff793ca96a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityAddressStateOrProvince_38e4a135-5559-4e35-8e35-1ff793ca96a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_55834c1b-cc1e-486e-bde7-8d63df4fa090" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityAddressPostalZipCode_55834c1b-cc1e-486e-bde7-8d63df4fa090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3ccfd232-ae0c-4122-a6e1-af9c4873b450" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_CityAreaCode_3ccfd232-ae0c-4122-a6e1-af9c4873b450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_968c9fc4-d8ec-4225-b17e-b1618b7c36db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_LocalPhoneNumber_968c9fc4-d8ec-4225-b17e-b1618b7c36db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_861b6518-7b33-4605-964a-2244b208e325" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_Security12bTitle_861b6518-7b33-4605-964a-2244b208e325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e1ad689c-e562-4ace-a9a1-7819e46d7756" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_TradingSymbol_e1ad689c-e562-4ace-a9a1-7819e46d7756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_801e4696-cd13-44af-9a92-fd0feef91532" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_SecurityExchangeName_801e4696-cd13-44af-9a92-fd0feef91532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5316a1ad-cc4f-488f-a4ff-3045702f1e46" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_5316a1ad-cc4f-488f-a4ff-3045702f1e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_40efbbed-7e30-4a8a-b909-eaf68875cb5c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityVoluntaryFilers_40efbbed-7e30-4a8a-b909-eaf68875cb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_372cba1e-d340-43c9-9c8f-7316c12ff121" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityCurrentReportingStatus_372cba1e-d340-43c9-9c8f-7316c12ff121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1330faa9-edf8-4d40-9d64-9e336f9bb084" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityInteractiveDataCurrent_1330faa9-edf8-4d40-9d64-9e336f9bb084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_eaf3dcc5-48bc-47bc-9b0e-2796686f2f18" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityFilerCategory_eaf3dcc5-48bc-47bc-9b0e-2796686f2f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_bf15019e-51a7-4ffa-90e8-29d42b8eeb7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntitySmallBusiness_bf15019e-51a7-4ffa-90e8-29d42b8eeb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_22e7a05c-53a0-47ea-86ed-e57b59b4e8b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityEmergingGrowthCompany_22e7a05c-53a0-47ea-86ed-e57b59b4e8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_f4672b6b-418d-4a3a-ad59-b07c4682bd88" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_f4672b6b-418d-4a3a-ad59-b07c4682bd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_76bf026b-c7c9-4761-aec3-d27bb7352524" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityShellCompany_76bf026b-c7c9-4761-aec3-d27bb7352524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_ff8a54d7-6110-48dd-9688-150fa7695f7d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityPublicFloat_ff8a54d7-6110-48dd-9688-150fa7695f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_98ef46c2-5287-4f83-9559-b125b941ef2c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_98ef46c2-5287-4f83-9559-b125b941ef2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7c68b359-680d-471d-8199-711bd76e8c38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7c68b359-680d-471d-8199-711bd76e8c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0d0c9d5a-abcb-4780-a5a1-4852b49bf2f2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_AmendmentFlag_0d0c9d5a-abcb-4780-a5a1-4852b49bf2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5c22f55e-0289-44bc-bf14-00d48f89ecff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_DocumentFiscalYearFocus_5c22f55e-0289-44bc-bf14-00d48f89ecff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bf7ca47d-be77-4ea6-8430-f4c9dde6d005" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bf7ca47d-be77-4ea6-8430-f4c9dde6d005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_06d7cee7-23b9-42f3-ad14-7475546d906f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a41aa90-b042-4090-a656-d696df28228a" xlink:to="loc_dei_EntityCentralIndexKey_06d7cee7-23b9-42f3-ad14-7475546d906f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_922ec8d9-4afb-4bd3-a06c-2df17592f1ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e36f04ff-a0b4-4359-bb1b-703fd80f0b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_922ec8d9-4afb-4bd3-a06c-2df17592f1ea" xlink:to="loc_us-gaap_AssetsAbstract_e36f04ff-a0b4-4359-bb1b-703fd80f0b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9c420239-5180-4e79-aeaf-e1da8407da97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e36f04ff-a0b4-4359-bb1b-703fd80f0b05" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9c420239-5180-4e79-aeaf-e1da8407da97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_779346c3-dba2-4b8b-8489-6b9ad5c37a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c420239-5180-4e79-aeaf-e1da8407da97" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_779346c3-dba2-4b8b-8489-6b9ad5c37a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_4af4eb77-db55-4e2a-a80c-ecb9f9e30576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c420239-5180-4e79-aeaf-e1da8407da97" xlink:to="loc_us-gaap_ShortTermInvestments_4af4eb77-db55-4e2a-a80c-ecb9f9e30576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_8b0bb39b-54b7-4651-90ca-dc9ce5fc645a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c420239-5180-4e79-aeaf-e1da8407da97" xlink:to="loc_us-gaap_ReceivablesNetCurrent_8b0bb39b-54b7-4651-90ca-dc9ce5fc645a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6540f2a7-1c5c-4e37-a096-7f469471c279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c420239-5180-4e79-aeaf-e1da8407da97" xlink:to="loc_us-gaap_InventoryNet_6540f2a7-1c5c-4e37-a096-7f469471c279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1049f04d-1bfe-46f9-804e-65ccbb266f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c420239-5180-4e79-aeaf-e1da8407da97" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1049f04d-1bfe-46f9-804e-65ccbb266f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_84f952b8-90d5-4efc-9c5c-b12be63d7199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9c420239-5180-4e79-aeaf-e1da8407da97" xlink:to="loc_us-gaap_AssetsCurrent_84f952b8-90d5-4efc-9c5c-b12be63d7199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_b99f158c-8494-40cc-b155-e4172f525e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e36f04ff-a0b4-4359-bb1b-703fd80f0b05" xlink:to="loc_us-gaap_LongTermInvestments_b99f158c-8494-40cc-b155-e4172f525e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f85a6e32-ad74-4508-a7a7-8ce3824ba72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e36f04ff-a0b4-4359-bb1b-703fd80f0b05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f85a6e32-ad74-4508-a7a7-8ce3824ba72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c2780d83-69ef-4bf5-bb23-8876972c5345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e36f04ff-a0b4-4359-bb1b-703fd80f0b05" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c2780d83-69ef-4bf5-bb23-8876972c5345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f61c4475-8977-46ca-9f39-fa11d3b2400c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e36f04ff-a0b4-4359-bb1b-703fd80f0b05" xlink:to="loc_us-gaap_Goodwill_f61c4475-8977-46ca-9f39-fa11d3b2400c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cc3356b2-24d0-4a91-8bc9-ab57079d9558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e36f04ff-a0b4-4359-bb1b-703fd80f0b05" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cc3356b2-24d0-4a91-8bc9-ab57079d9558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e3fdd5f4-ece5-481e-8495-dc389b9b9555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e36f04ff-a0b4-4359-bb1b-703fd80f0b05" xlink:to="loc_us-gaap_Assets_e3fdd5f4-ece5-481e-8495-dc389b9b9555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b889b1b7-392d-4cae-81f7-24487ded1451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_922ec8d9-4afb-4bd3-a06c-2df17592f1ea" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b889b1b7-392d-4cae-81f7-24487ded1451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d5f0f1d0-d86e-493b-90cc-9fd9841f3d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b889b1b7-392d-4cae-81f7-24487ded1451" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d5f0f1d0-d86e-493b-90cc-9fd9841f3d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_38731033-9ad1-4088-9e5e-a3cd2665ae0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5f0f1d0-d86e-493b-90cc-9fd9841f3d97" xlink:to="loc_us-gaap_AccountsPayableCurrent_38731033-9ad1-4088-9e5e-a3cd2665ae0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f4c1c0ed-f479-4525-a045-3d6f50f0624e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5f0f1d0-d86e-493b-90cc-9fd9841f3d97" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f4c1c0ed-f479-4525-a045-3d6f50f0624e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_540dc495-d818-46d6-900a-3f04418bcff0" xlink:href="exel-20210101.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5f0f1d0-d86e-493b-90cc-9fd9841f3d97" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_540dc495-d818-46d6-900a-3f04418bcff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_9e7e90e0-8ffd-43f2-91f2-fc7e9bb6946f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5f0f1d0-d86e-493b-90cc-9fd9841f3d97" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_9e7e90e0-8ffd-43f2-91f2-fc7e9bb6946f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_5c386e6f-74a4-48ae-91b1-4149053b082d" xlink:href="exel-20210101.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5f0f1d0-d86e-493b-90cc-9fd9841f3d97" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_5c386e6f-74a4-48ae-91b1-4149053b082d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3cb1829c-dfb6-4ce8-b26a-5fe4622376e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5f0f1d0-d86e-493b-90cc-9fd9841f3d97" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3cb1829c-dfb6-4ce8-b26a-5fe4622376e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c5498748-0477-499e-ab93-91174ee108da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5f0f1d0-d86e-493b-90cc-9fd9841f3d97" xlink:to="loc_us-gaap_LiabilitiesCurrent_c5498748-0477-499e-ab93-91174ee108da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cf0fbf03-1c12-474c-af12-17b87b6fc84c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b889b1b7-392d-4cae-81f7-24487ded1451" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_cf0fbf03-1c12-474c-af12-17b87b6fc84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2a054174-e111-4194-a6e8-365614f3d7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b889b1b7-392d-4cae-81f7-24487ded1451" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2a054174-e111-4194-a6e8-365614f3d7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e103bfd6-998f-4c8b-b81b-4dff528a0c88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b889b1b7-392d-4cae-81f7-24487ded1451" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e103bfd6-998f-4c8b-b81b-4dff528a0c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_330b86fc-aa81-4fc7-b110-40deb6f4a47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b889b1b7-392d-4cae-81f7-24487ded1451" xlink:to="loc_us-gaap_Liabilities_330b86fc-aa81-4fc7-b110-40deb6f4a47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0dd696bd-c4b3-4e6f-856b-0f6f9ab31e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b889b1b7-392d-4cae-81f7-24487ded1451" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0dd696bd-c4b3-4e6f-856b-0f6f9ab31e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9aae12fb-48b3-4b43-ae66-888bd40f1103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_922ec8d9-4afb-4bd3-a06c-2df17592f1ea" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9aae12fb-48b3-4b43-ae66-888bd40f1103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fbc9bb1f-3a91-40a4-b413-16ea50e72aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9aae12fb-48b3-4b43-ae66-888bd40f1103" xlink:to="loc_us-gaap_PreferredStockValue_fbc9bb1f-3a91-40a4-b413-16ea50e72aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_57e96676-048e-42cb-b9cb-e4c68efdda52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9aae12fb-48b3-4b43-ae66-888bd40f1103" xlink:to="loc_us-gaap_CommonStockValue_57e96676-048e-42cb-b9cb-e4c68efdda52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ef6e733e-fd33-4748-af32-d499c125ada6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9aae12fb-48b3-4b43-ae66-888bd40f1103" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ef6e733e-fd33-4748-af32-d499c125ada6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9b0c87ff-0f1b-437e-b3a1-2d6231bd6fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9aae12fb-48b3-4b43-ae66-888bd40f1103" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9b0c87ff-0f1b-437e-b3a1-2d6231bd6fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4db65529-c1b4-4ce5-a248-bae756f04471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9aae12fb-48b3-4b43-ae66-888bd40f1103" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4db65529-c1b4-4ce5-a248-bae756f04471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9758f809-4b3a-47d2-b3af-806a3631c7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9aae12fb-48b3-4b43-ae66-888bd40f1103" xlink:to="loc_us-gaap_StockholdersEquity_9758f809-4b3a-47d2-b3af-806a3631c7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b957eaba-979f-4eeb-8988-10fe001edc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_922ec8d9-4afb-4bd3-a06c-2df17592f1ea" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b957eaba-979f-4eeb-8988-10fe001edc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ecbd3d19-c253-4724-a748-29f001aa2595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4fabceb4-38ad-4e3f-9618-ddc685aae180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ecbd3d19-c253-4724-a748-29f001aa2595" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4fabceb4-38ad-4e3f-9618-ddc685aae180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c9b0571c-7c4f-48a3-aeca-191b78624c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4fabceb4-38ad-4e3f-9618-ddc685aae180" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c9b0571c-7c4f-48a3-aeca-191b78624c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_96217acf-aee7-4616-b021-ff6eba06bc61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4fabceb4-38ad-4e3f-9618-ddc685aae180" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_96217acf-aee7-4616-b021-ff6eba06bc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_31788870-567c-4d30-83d5-49e83ea7de90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4fabceb4-38ad-4e3f-9618-ddc685aae180" xlink:to="loc_us-gaap_PreferredStockSharesIssued_31788870-567c-4d30-83d5-49e83ea7de90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dc8c35be-bc6a-4fef-8658-e6ea6f51d442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ecbd3d19-c253-4724-a748-29f001aa2595" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dc8c35be-bc6a-4fef-8658-e6ea6f51d442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd92e90f-0de8-4d99-a8c1-0fb7ab79c815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dc8c35be-bc6a-4fef-8658-e6ea6f51d442" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd92e90f-0de8-4d99-a8c1-0fb7ab79c815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1adae183-2df0-4059-b043-bd96ae0e9b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dc8c35be-bc6a-4fef-8658-e6ea6f51d442" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1adae183-2df0-4059-b043-bd96ae0e9b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6fe2f432-9542-442f-86c5-0dbb4610f73f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dc8c35be-bc6a-4fef-8658-e6ea6f51d442" xlink:to="loc_us-gaap_CommonStockSharesIssued_6fe2f432-9542-442f-86c5-0dbb4610f73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_812e500a-9a68-4bf9-9b1c-ed551bd56175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_dc8c35be-bc6a-4fef-8658-e6ea6f51d442" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_812e500a-9a68-4bf9-9b1c-ed551bd56175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2f34d0c6-72b2-4db9-8f5b-0ad971839bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_92a378b2-2ab7-4383-9d58-d8d0f5971180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f34d0c6-72b2-4db9-8f5b-0ad971839bcc" xlink:to="loc_us-gaap_StatementTable_92a378b2-2ab7-4383-9d58-d8d0f5971180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_807af3f8-ccd6-43a1-a3f9-a5fb445f8d2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92a378b2-2ab7-4383-9d58-d8d0f5971180" xlink:to="loc_srt_ProductOrServiceAxis_807af3f8-ccd6-43a1-a3f9-a5fb445f8d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_807af3f8-ccd6-43a1-a3f9-a5fb445f8d2e" xlink:to="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3c61f0e1-7117-4cd5-879b-50661a3ccd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:to="loc_us-gaap_ProductMember_3c61f0e1-7117-4cd5-879b-50661a3ccd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3644d6b0-1544-4d14-b6a0-61d184630019" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:to="loc_us-gaap_LicenseMember_3644d6b0-1544-4d14-b6a0-61d184630019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_b3770bc0-b16e-4de3-a7e8-a03944f995bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2972bc3b-c169-468f-90ad-0662739339e2" xlink:to="loc_us-gaap_ServiceMember_b3770bc0-b16e-4de3-a7e8-a03944f995bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92a378b2-2ab7-4383-9d58-d8d0f5971180" xlink:to="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_585381e4-3904-4092-a6a1-2afc3e109f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_RevenuesAbstract_585381e4-3904-4092-a6a1-2afc3e109f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2bcf1f6-3fce-4b66-8ea6-d09a0e32844a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_585381e4-3904-4092-a6a1-2afc3e109f2d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d2bcf1f6-3fce-4b66-8ea6-d09a0e32844a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2ec87a23-ec48-4cdc-a9d9-ef236af71f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2ec87a23-ec48-4cdc-a9d9-ef236af71f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7a896900-c27a-414f-9f43-80d27e431d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7a896900-c27a-414f-9f43-80d27e431d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21419c14-1e63-4a36-8e51-5c11ad70485d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_21419c14-1e63-4a36-8e51-5c11ad70485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a128a8e3-62e7-4c19-8d22-9765972957b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ca7b9454-be39-436a-ae7e-f19a88ef0eb6" xlink:to="loc_us-gaap_CostsAndExpenses_a128a8e3-62e7-4c19-8d22-9765972957b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6643f12c-05a0-495e-8d01-c9495ee10ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_OperatingIncomeLoss_6643f12c-05a0-495e-8d01-c9495ee10ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_2ccf4e22-1f2b-46ca-8f69-28bee494f91d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_InterestIncomeOther_2ccf4e22-1f2b-46ca-8f69-28bee494f91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_081ba0bf-01ec-4fe3-ad3f-d4fef37285c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_081ba0bf-01ec-4fe3-ad3f-d4fef37285c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c687fdda-bcc6-46fb-8eef-d3638f436bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c687fdda-bcc6-46fb-8eef-d3638f436bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_322f6907-eade-41b9-81d3-1d97a80b6a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_322f6907-eade-41b9-81d3-1d97a80b6a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8e431e33-665c-432a-bbac-9203ec3fedce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_NetIncomeLoss_8e431e33-665c-432a-bbac-9203ec3fedce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6d5382de-2d83-4005-aa2b-3d762664c71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_us-gaap_EarningsPerShareAbstract_6d5382de-2d83-4005-aa2b-3d762664c71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_62ad7dd6-a1ac-4df3-925b-e5d0a95cfcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d5382de-2d83-4005-aa2b-3d762664c71e" xlink:to="loc_us-gaap_EarningsPerShareBasic_62ad7dd6-a1ac-4df3-925b-e5d0a95cfcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_67bcb222-20e9-43cf-b7ca-a7073faa2289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d5382de-2d83-4005-aa2b-3d762664c71e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_67bcb222-20e9-43cf-b7ca-a7073faa2289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_5447f751-2b9d-4e50-aca0-21a9e08b9adc" xlink:href="exel-20210101.xsd#exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b3e8396-eaca-4f4b-a2b3-f22c435fa683" xlink:to="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_5447f751-2b9d-4e50-aca0-21a9e08b9adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14a86a4b-667f-4971-a148-759cdb499df3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_5447f751-2b9d-4e50-aca0-21a9e08b9adc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14a86a4b-667f-4971-a148-759cdb499df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_570c69e7-eba2-431f-9fe7-36afebe137f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract_5447f751-2b9d-4e50-aca0-21a9e08b9adc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_570c69e7-eba2-431f-9fe7-36afebe137f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9148d903-0f33-4083-b1ce-74ca3fa07fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_084ae58a-374a-4212-a017-ee78cfb1f230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9148d903-0f33-4083-b1ce-74ca3fa07fb6" xlink:to="loc_us-gaap_NetIncomeLoss_084ae58a-374a-4212-a017-ee78cfb1f230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_923fc7e0-4fbe-4c66-b297-695d6aff8e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9148d903-0f33-4083-b1ce-74ca3fa07fb6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_923fc7e0-4fbe-4c66-b297-695d6aff8e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_32dd8cd8-5274-40a9-9db5-5bb36b4d81f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_923fc7e0-4fbe-4c66-b297-695d6aff8e00" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_32dd8cd8-5274-40a9-9db5-5bb36b4d81f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_59cdca91-482a-49e8-9a8c-db4aa0ee1221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_923fc7e0-4fbe-4c66-b297-695d6aff8e00" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_59cdca91-482a-49e8-9a8c-db4aa0ee1221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e86e3391-8f45-497a-92ae-aeb0606e4829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_f7525442-3673-49af-adb5-e1798980aca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e86e3391-8f45-497a-92ae-aeb0606e4829" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_f7525442-3673-49af-adb5-e1798980aca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f84dd4fc-1f4f-4378-a655-eb0f6914689c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f84dd4fc-1f4f-4378-a655-eb0f6914689c" xlink:to="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_97b16a36-1286-4d5c-9788-109d968fd8c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_97b16a36-1286-4d5c-9788-109d968fd8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5cea0ee0-df5a-4a4b-86f6-24739aa51ae6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_97b16a36-1286-4d5c-9788-109d968fd8c2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5cea0ee0-df5a-4a4b-86f6-24739aa51ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3fbe8b80-2080-42be-a708-65ca3970b9b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5cea0ee0-df5a-4a4b-86f6-24739aa51ae6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3fbe8b80-2080-42be-a708-65ca3970b9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2bf389d0-22af-4c4c-b4f9-dde0a33fa223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2bf389d0-22af-4c4c-b4f9-dde0a33fa223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_37287502-5cc5-4ab9-a700-ae596261fc22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2bf389d0-22af-4c4c-b4f9-dde0a33fa223" xlink:to="loc_us-gaap_TypeOfAdoptionMember_37287502-5cc5-4ab9-a700-ae596261fc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_70b964a4-8bfc-404a-ad46-ba442ccd1f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_37287502-5cc5-4ab9-a700-ae596261fc22" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_70b964a4-8bfc-404a-ad46-ba442ccd1f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_2a6a3abb-3d25-4c15-af98-e8a8c2cdee28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_37287502-5cc5-4ab9-a700-ae596261fc22" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_2a6a3abb-3d25-4c15-af98-e8a8c2cdee28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c19af89a-888c-4349-9cfe-cc89090cc746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c19af89a-888c-4349-9cfe-cc89090cc746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c19af89a-888c-4349-9cfe-cc89090cc746" xlink:to="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_807a9aae-80f2-47dd-82b0-cd9aa47f0aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:to="loc_us-gaap_CommonStockMember_807a9aae-80f2-47dd-82b0-cd9aa47f0aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d2c24f33-75ae-4012-8ed9-4e43b089c218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d2c24f33-75ae-4012-8ed9-4e43b089c218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db1c624f-26b8-434a-bc1c-850a3f57c275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db1c624f-26b8-434a-bc1c-850a3f57c275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_22eaec16-6a85-4d0c-bd4e-1dd85c46e91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_78ab8335-7ace-4487-9720-f57c4d831e3e" xlink:to="loc_us-gaap_RetainedEarningsMember_22eaec16-6a85-4d0c-bd4e-1dd85c46e91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2a814833-0be7-4f74-9b80-74d046f5b9c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a1cc2294-ba78-44bd-a0ac-e230a8ce1b05" xlink:to="loc_us-gaap_StatementLineItems_2a814833-0be7-4f74-9b80-74d046f5b9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a814833-0be7-4f74-9b80-74d046f5b9c8" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0b55913f-ad2d-4df2-983c-f3d96929af31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0b55913f-ad2d-4df2-983c-f3d96929af31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_94aa7d7f-93d2-4a92-9bb9-b2a365476a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_StockholdersEquity_94aa7d7f-93d2-4a92-9bb9-b2a365476a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f28a9c2-0be0-4114-a126-92e9dd442ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_NetIncomeLoss_8f28a9c2-0be0-4114-a126-92e9dd442ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f2ed7f7d-c700-4056-9f92-ae76f81474b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f2ed7f7d-c700-4056-9f92-ae76f81474b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_76ca8544-9026-4f0f-9e63-6c5e218dbd22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_76ca8544-9026-4f0f-9e63-6c5e218dbd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_165730aa-577b-42ff-b812-e2bc24255695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_165730aa-577b-42ff-b812-e2bc24255695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a5c12fbc-3ab6-4cf3-b9e0-ec0df982ce0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a5c12fbc-3ab6-4cf3-b9e0-ec0df982ce0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c003ff1e-a64d-4b2b-907a-d2c56a202983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c003ff1e-a64d-4b2b-907a-d2c56a202983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_02cf39a9-0f30-4c37-b614-429257524487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_02cf39a9-0f30-4c37-b614-429257524487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8cf5d21e-bf66-4b37-9b21-bc36931f1b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d39837a2-33fc-407f-a402-24911bc9b50a" xlink:to="loc_us-gaap_StockholdersEquity_8cf5d21e-bf66-4b37-9b21-bc36931f1b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20210101.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_50703a57-9b4f-4eb0-981b-5f02df631f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136c3a30-3dab-40ab-8b1e-e734d7b6fb02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_50703a57-9b4f-4eb0-981b-5f02df631f18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136c3a30-3dab-40ab-8b1e-e734d7b6fb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6b27de77-b676-47c9-a25a-e39ea0b9f7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136c3a30-3dab-40ab-8b1e-e734d7b6fb02" xlink:to="loc_us-gaap_NetIncomeLoss_6b27de77-b676-47c9-a25a-e39ea0b9f7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dbe71b41-c39c-429d-9211-d1c388549e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136c3a30-3dab-40ab-8b1e-e734d7b6fb02" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dbe71b41-c39c-429d-9211-d1c388549e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2b4c9d07-60bf-4300-8bfb-3020982f0c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dbe71b41-c39c-429d-9211-d1c388549e30" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2b4c9d07-60bf-4300-8bfb-3020982f0c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_10425de3-e9de-4e95-8210-fff923ea0871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dbe71b41-c39c-429d-9211-d1c388549e30" xlink:to="loc_us-gaap_ShareBasedCompensation_10425de3-e9de-4e95-8210-fff923ea0871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_d64adbab-955f-427c-823e-27670185da53" xlink:href="exel-20210101.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dbe71b41-c39c-429d-9211-d1c388549e30" xlink:to="loc_exel_NoncashLeaseExpense_d64adbab-955f-427c-823e-27670185da53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_386bf7af-bf36-458c-bafa-58ecc2f90cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dbe71b41-c39c-429d-9211-d1c388549e30" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_386bf7af-bf36-458c-bafa-58ecc2f90cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3fc05ce3-ff7d-4ce4-ac06-93d7905ef860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dbe71b41-c39c-429d-9211-d1c388549e30" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3fc05ce3-ff7d-4ce4-ac06-93d7905ef860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2dd7752-f552-43fb-86ce-56ebbefffac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dbe71b41-c39c-429d-9211-d1c388549e30" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2dd7752-f552-43fb-86ce-56ebbefffac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1303a80a-23c8-4aa6-99da-866367b71641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2dd7752-f552-43fb-86ce-56ebbefffac0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1303a80a-23c8-4aa6-99da-866367b71641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0abbe0ff-e744-4758-9b39-5aea78d73bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2dd7752-f552-43fb-86ce-56ebbefffac0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0abbe0ff-e744-4758-9b39-5aea78d73bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_54a8b8ac-861c-4a55-9fcb-0d8b79ceac09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2dd7752-f552-43fb-86ce-56ebbefffac0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_54a8b8ac-861c-4a55-9fcb-0d8b79ceac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_942563e7-1aa4-4157-9c32-32ec082732f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2dd7752-f552-43fb-86ce-56ebbefffac0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_942563e7-1aa4-4157-9c32-32ec082732f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c9176016-35ac-41f8-a942-a6a439b10214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c2dd7752-f552-43fb-86ce-56ebbefffac0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c9176016-35ac-41f8-a942-a6a439b10214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_edcc8443-5d3f-4696-b8ab-98247b5096fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136c3a30-3dab-40ab-8b1e-e734d7b6fb02" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_edcc8443-5d3f-4696-b8ab-98247b5096fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc49daf6-4289-4684-b78e-7c10db5794ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_50703a57-9b4f-4eb0-981b-5f02df631f18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc49daf6-4289-4684-b78e-7c10db5794ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_73ba1230-ad46-49f7-a453-0290d7559cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc49daf6-4289-4684-b78e-7c10db5794ad" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_73ba1230-ad46-49f7-a453-0290d7559cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_493fce21-562c-49e6-a41f-aed6b215cb70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc49daf6-4289-4684-b78e-7c10db5794ad" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_493fce21-562c-49e6-a41f-aed6b215cb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4d43248e-a370-4e93-8164-2ad8be4b1124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc49daf6-4289-4684-b78e-7c10db5794ad" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4d43248e-a370-4e93-8164-2ad8be4b1124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a106d32c-9914-4e16-9cdf-4c22e4392030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc49daf6-4289-4684-b78e-7c10db5794ad" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a106d32c-9914-4e16-9cdf-4c22e4392030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15cf47e5-515c-4279-a682-fcda0e43e275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc49daf6-4289-4684-b78e-7c10db5794ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15cf47e5-515c-4279-a682-fcda0e43e275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b434696-476e-495c-8275-a89f130f0cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_50703a57-9b4f-4eb0-981b-5f02df631f18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b434696-476e-495c-8275-a89f130f0cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a6de7f78-819e-4f14-aa9a-06e8e750850b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b434696-476e-495c-8275-a89f130f0cda" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a6de7f78-819e-4f14-aa9a-06e8e750850b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7ff98c07-a427-471f-9aa3-519ddcdfc825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b434696-476e-495c-8275-a89f130f0cda" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7ff98c07-a427-471f-9aa3-519ddcdfc825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f3237f84-325c-4261-8594-179c4fa7639d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b434696-476e-495c-8275-a89f130f0cda" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f3237f84-325c-4261-8594-179c4fa7639d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e96ff25-4c5a-4fa4-aba6-8f4565f3fee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0b434696-476e-495c-8275-a89f130f0cda" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e96ff25-4c5a-4fa4-aba6-8f4565f3fee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f22708f-34e0-44df-9d71-72efee136dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_50703a57-9b4f-4eb0-981b-5f02df631f18" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6f22708f-34e0-44df-9d71-72efee136dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bec5678a-1483-4221-844a-138082e7d41e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_50703a57-9b4f-4eb0-981b-5f02df631f18" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bec5678a-1483-4221-844a-138082e7d41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19cd3ed4-ea33-4660-b54f-aa22e11e2341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_50703a57-9b4f-4eb0-981b-5f02df631f18" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19cd3ed4-ea33-4660-b54f-aa22e11e2341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1f16d3b3-379a-46f0-999b-e28277cd5b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_50703a57-9b4f-4eb0-981b-5f02df631f18" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1f16d3b3-379a-46f0-999b-e28277cd5b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_fff7fa99-32b8-429d-9af8-0f37bde97209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1f16d3b3-379a-46f0-999b-e28277cd5b0f" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_fff7fa99-32b8-429d-9af8-0f37bde97209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_42090373-911a-40f3-afd4-eafceb186c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1f16d3b3-379a-46f0-999b-e28277cd5b0f" xlink:to="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_42090373-911a-40f3-afd4-eafceb186c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_89c24c71-e3d9-4d03-8523-8b05747fe3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_42090373-911a-40f3-afd4-eafceb186c00" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_89c24c71-e3d9-4d03-8523-8b05747fe3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_58a28237-d73a-4d86-9944-c43c9069b064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1f16d3b3-379a-46f0-999b-e28277cd5b0f" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_58a28237-d73a-4d86-9944-c43c9069b064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b9d5f79d-3e97-4a72-8fd1-00d804f239e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_58a28237-d73a-4d86-9944-c43c9069b064" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b9d5f79d-3e97-4a72-8fd1-00d804f239e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid_86c84f67-dfbd-432c-8626-80dca58931e1" xlink:href="exel-20210101.xsd#exel_InvestmentsPurchasesIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_58a28237-d73a-4d86-9944-c43c9069b064" xlink:to="loc_exel_InvestmentsPurchasesIncurredButNotYetPaid_86c84f67-dfbd-432c-8626-80dca58931e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccountsReceivableForUnsettledInvestmentSales_89f160d6-cb11-45a7-825d-cdc26da252e8" xlink:href="exel-20210101.xsd#exel_AccountsReceivableForUnsettledInvestmentSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_58a28237-d73a-4d86-9944-c43c9069b064" xlink:to="loc_exel_AccountsReceivableForUnsettledInvestmentSales_89f160d6-cb11-45a7-825d-cdc26da252e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_100f5c38-e3ce-43e5-8683-24eaf537db6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f642971d-b286-4b4d-aa52-93e5cae6c2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_100f5c38-e3ce-43e5-8683-24eaf537db6d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f642971d-b286-4b4d-aa52-93e5cae6c2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9ad68068-71a2-4dbe-a5ae-4364b69ee969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9ad68068-71a2-4dbe-a5ae-4364b69ee969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_c7465c09-d7b2-4ff9-a9b5-14ed1b593d07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_FiscalPeriod_c7465c09-d7b2-4ff9-a9b5-14ed1b593d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3ddddf7c-e4bd-43be-be26-13e54e8f529b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3ddddf7c-e4bd-43be-be26-13e54e8f529b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f9b47d68-0e78-46bb-b113-9962905e1a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_UseOfEstimates_f9b47d68-0e78-46bb-b113-9962905e1a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f2fdf184-11d6-411c-a0fe-98a4dbb24b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f2fdf184-11d6-411c-a0fe-98a4dbb24b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e72c3410-fccc-4020-8f29-4d5e63acccc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e72c3410-fccc-4020-8f29-4d5e63acccc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_4631e07c-33b3-40ff-ae2d-bf1a30b67d78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_4631e07c-33b3-40ff-ae2d-bf1a30b67d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_f32ccaea-6317-464e-9d2a-c86884cfcdc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_f32ccaea-6317-464e-9d2a-c86884cfcdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_5f114ac5-6a22-4e35-94fa-f48c766920ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_5f114ac5-6a22-4e35-94fa-f48c766920ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_af97263c-71fc-4bab-965d-18efdaa54116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_af97263c-71fc-4bab-965d-18efdaa54116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e627a0a2-6220-499f-9b49-50a652fe00c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e627a0a2-6220-499f-9b49-50a652fe00c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6f8a6993-b9a0-4093-88bb-dbfc4180f581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6f8a6993-b9a0-4093-88bb-dbfc4180f581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2cafd1a4-064f-4ef4-872e-aae677372ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2cafd1a4-064f-4ef4-872e-aae677372ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d0a50dd6-38fe-4610-992e-a9cdf3ab85d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d0a50dd6-38fe-4610-992e-a9cdf3ab85d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9838157e-ed59-458b-8427-99c1d8d92e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9838157e-ed59-458b-8427-99c1d8d92e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_98a89d3a-48ba-4aa6-a0b2-35e507b0a9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_98a89d3a-48ba-4aa6-a0b2-35e507b0a9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_98ff7419-b3f0-44e5-ba3f-e7e4c6d2c586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_98ff7419-b3f0-44e5-ba3f-e7e4c6d2c586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_36209093-4ea1-40b3-a1b3-23b1f5dfa4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_36209093-4ea1-40b3-a1b3-23b1f5dfa4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_855f1f43-0f53-43c0-814c-72059000e108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_855f1f43-0f53-43c0-814c-72059000e108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_914792c8-dd2b-4f04-846c-816b4cc608f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_36d67a5f-1b92-4127-9de8-9a87f31a5894" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_914792c8-dd2b-4f04-846c-816b4cc608f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c1792d0-6fa3-4c7e-a9b3-570704c99bde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7f7c3fb5-0615-42d5-a6ac-ac59b5eea639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c1792d0-6fa3-4c7e-a9b3-570704c99bde" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_7f7c3fb5-0615-42d5-a6ac-ac59b5eea639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_174c6350-8e53-4cce-979b-cceeecd0b1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:href="exel-20210101.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_174c6350-8e53-4cce-979b-cceeecd0b1c6" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1ccc5f50-dbf6-4180-a3c5-64e75938da99" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:to="loc_srt_ProductOrServiceAxis_1ccc5f50-dbf6-4180-a3c5-64e75938da99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1ccc5f50-dbf6-4180-a3c5-64e75938da99" xlink:to="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_e87e90fe-2f8f-40f7-a313-a3224ca60461" xlink:href="exel-20210101.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_e87e90fe-2f8f-40f7-a313-a3224ca60461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_6e2db43b-3f76-4ead-ba53-d179f3d8dcfc" xlink:href="exel-20210101.xsd#exel_ProductsDerivedFromCabozantinibMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_6e2db43b-3f76-4ead-ba53-d179f3d8dcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_0f5f7fb1-1faa-444a-ad17-f3a85e534df3" xlink:href="exel-20210101.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a90932c-9ce8-40b7-84e9-237b7bae264e" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_0f5f7fb1-1faa-444a-ad17-f3a85e534df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_3c8e4974-ab20-4288-b330-d083e99d00e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_3c8e4974-ab20-4288-b330-d083e99d00e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dc9eee99-4e6c-4dac-88c3-bf1ec11a04f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_3c8e4974-ab20-4288-b330-d083e99d00e7" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dc9eee99-4e6c-4dac-88c3-bf1ec11a04f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember_34eafc31-a0c9-4f69-b687-a6c57f0f1935" xlink:href="exel-20210101.xsd#exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_dc9eee99-4e6c-4dac-88c3-bf1ec11a04f4" xlink:to="loc_exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember_34eafc31-a0c9-4f69-b687-a6c57f0f1935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_baf81291-8393-4f28-90bf-740d5356568d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:to="loc_srt_RangeAxis_baf81291-8393-4f28-90bf-740d5356568d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a912cd9f-acde-4993-8e17-ec7b3c998d9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_baf81291-8393-4f28-90bf-740d5356568d" xlink:to="loc_srt_RangeMember_a912cd9f-acde-4993-8e17-ec7b3c998d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb364e95-7167-49e7-8f68-fea70195bac9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a912cd9f-acde-4993-8e17-ec7b3c998d9b" xlink:to="loc_srt_MaximumMember_fb364e95-7167-49e7-8f68-fea70195bac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_78c5db6d-d198-44b6-b2e6-db2c336329d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:to="loc_srt_MajorCustomersAxis_78c5db6d-d198-44b6-b2e6-db2c336329d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d383c943-3476-4acf-852a-bb77b31b16a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_78c5db6d-d198-44b6-b2e6-db2c336329d3" xlink:to="loc_srt_NameOfMajorCustomerDomain_d383c943-3476-4acf-852a-bb77b31b16a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_778d1731-198d-4e44-ad28-6d54ff0a1fb3" xlink:href="exel-20210101.xsd#exel_GlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d383c943-3476-4acf-852a-bb77b31b16a4" xlink:to="loc_exel_GlaxoSmithKlineMember_778d1731-198d-4e44-ad28-6d54ff0a1fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:href="exel-20210101.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_fbf25053-a0f6-4865-b558-b2797198a86b" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_e516165a-39b9-4be2-b966-5edb4c9de2b4" xlink:href="exel-20210101.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_NumberofProductsinCommercialMarket_e516165a-39b9-4be2-b966-5edb4c9de2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_48966e64-2d68-40a5-adef-e7cfca13f7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_NumberOfOperatingSegments_48966e64-2d68-40a5-adef-e7cfca13f7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8c912fd-06e3-4ef6-b98b-bc17ed52ec9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a8c912fd-06e3-4ef6-b98b-bc17ed52ec9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_39c58241-c8dc-4a99-9120-9281f67c2f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_39c58241-c8dc-4a99-9120-9281f67c2f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_df6eeeb6-37df-4886-8500-b574234e5248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_df6eeeb6-37df-4886-8500-b574234e5248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_65df135a-cda8-46e8-9075-01da998ff904" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_65df135a-cda8-46e8-9075-01da998ff904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_cdee56a9-960b-4be9-b375-f547b739f116" xlink:href="exel-20210101.xsd#exel_SalesRevenuePercentDiscountForPromptPayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_cdee56a9-960b-4be9-b375-f547b739f116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_bef37c5d-9529-4233-a9cf-edef3985311b" xlink:href="exel-20210101.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_bef37c5d-9529-4233-a9cf-edef3985311b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MedicarePartDFundingMandate_bc58f90d-3e7e-4901-9188-3325f0a5fd5d" xlink:href="exel-20210101.xsd#exel_MedicarePartDFundingMandate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_MedicarePartDFundingMandate_bc58f90d-3e7e-4901-9188-3325f0a5fd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_a7348739-17e7-4c58-be14-eaec9e3c26f0" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_a7348739-17e7-4c58-be14-eaec9e3c26f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_9e7d0070-8178-4cfc-9ca0-2392e9066cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_AdvertisingExpense_9e7d0070-8178-4cfc-9ca0-2392e9066cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1de844e3-8ad0-4ffc-a0a6-a01d2a4ae3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_b320363e-a3df-4e01-a10e-8e4cbf92ae20" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1de844e3-8ad0-4ffc-a0a6-a01d2a4ae3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02cbe575-f095-471e-b0e6-120b27e9011d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02cbe575-f095-471e-b0e6-120b27e9011d" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_55247efb-90d1-47ae-a2d0-c1499501cb36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_55247efb-90d1-47ae-a2d0-c1499501cb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_463353e0-8cb0-4c59-8768-088b0fcafd72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_55247efb-90d1-47ae-a2d0-c1499501cb36" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_463353e0-8cb0-4c59-8768-088b0fcafd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e4f9b428-e102-49a2-93d9-152aa8a8237a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_463353e0-8cb0-4c59-8768-088b0fcafd72" xlink:to="loc_us-gaap_AccountsReceivableMember_e4f9b428-e102-49a2-93d9-152aa8a8237a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_12528bcb-cf44-4041-ace2-1e5ebeafca3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_12528bcb-cf44-4041-ace2-1e5ebeafca3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fefd1e4f-018e-4684-ae71-7cda5753bf52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_12528bcb-cf44-4041-ace2-1e5ebeafca3c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fefd1e4f-018e-4684-ae71-7cda5753bf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_99d191c0-46e0-4077-812d-53edda94b927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fefd1e4f-018e-4684-ae71-7cda5753bf52" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_99d191c0-46e0-4077-812d-53edda94b927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a4b19b04-30c2-4b78-b84c-741cc07a25b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:to="loc_srt_MajorCustomersAxis_a4b19b04-30c2-4b78-b84c-741cc07a25b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a4b19b04-30c2-4b78-b84c-741cc07a25b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_09d15eac-0680-4603-aa16-36ba4a64398a" xlink:href="exel-20210101.xsd#exel_IpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_IpsenMember_09d15eac-0680-4603-aa16-36ba4a64398a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_8c5af89c-0257-470f-80ae-7fa723441d7c" xlink:href="exel-20210101.xsd#exel_TakedaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_TakedaMember_8c5af89c-0257-470f-80ae-7fa723441d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_c252d87d-bde5-4fb3-ab68-556f024296b8" xlink:href="exel-20210101.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_c252d87d-bde5-4fb3-ab68-556f024296b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_7e161e84-7d60-4b04-9f73-a1846bc5bdbd" xlink:href="exel-20210101.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_7e161e84-7d60-4b04-9f73-a1846bc5bdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_b41c5ac1-5d9c-4375-a6ef-7103b5afca05" xlink:href="exel-20210101.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_b41c5ac1-5d9c-4375-a6ef-7103b5afca05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_5439c40b-3062-4f11-9348-f38cea9bdb77" xlink:href="exel-20210101.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb246333-b8d4-4e7c-890e-7b668f42d837" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_5439c40b-3062-4f11-9348-f38cea9bdb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4ed23459-d2d5-47c1-8dfc-380a6bea3b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_7aad047a-6b06-4013-b848-4b309af93b92" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4ed23459-d2d5-47c1-8dfc-380a6bea3b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_03af52c1-e56a-4198-b4dd-0f41e5669fce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_4ed23459-d2d5-47c1-8dfc-380a6bea3b38" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_03af52c1-e56a-4198-b4dd-0f41e5669fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20210101.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1377957a-f199-48ab-97cd-2d63a24c5d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_07538872-cda8-49c1-9234-94d5fa464347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1377957a-f199-48ab-97cd-2d63a24c5d6c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_07538872-cda8-49c1-9234-94d5fa464347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d2b2e35b-4d60-4d9a-a3d2-9f906d68715f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3e247bdb-cddc-4bdd-9a1f-7545e92ec840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d2b2e35b-4d60-4d9a-a3d2-9f906d68715f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3e247bdb-cddc-4bdd-9a1f-7545e92ec840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e7e68638-1f61-4661-82b6-69905c866b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d2b2e35b-4d60-4d9a-a3d2-9f906d68715f" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e7e68638-1f61-4661-82b6-69905c866b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_6e27a8e1-dd55-432b-8858-2460d409d1bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d2b2e35b-4d60-4d9a-a3d2-9f906d68715f" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_6e27a8e1-dd55-432b-8858-2460d409d1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_cc966687-7d08-45d3-9a93-637930b8876f" xlink:href="exel-20210101.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d2b2e35b-4d60-4d9a-a3d2-9f906d68715f" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_cc966687-7d08-45d3-9a93-637930b8876f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b843d380-3b5f-439d-80f1-86533b069c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d2b2e35b-4d60-4d9a-a3d2-9f906d68715f" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b843d380-3b5f-439d-80f1-86533b069c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1786e470-4f26-4cc7-928d-25ae43cd2947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2f4a22a6-7446-4669-b08c-f3a81b06c0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1786e470-4f26-4cc7-928d-25ae43cd2947" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2f4a22a6-7446-4669-b08c-f3a81b06c0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3081380d-f155-4073-a78c-cf60142ef55f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2f4a22a6-7446-4669-b08c-f3a81b06c0db" xlink:to="loc_srt_ProductOrServiceAxis_3081380d-f155-4073-a78c-cf60142ef55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3081380d-f155-4073-a78c-cf60142ef55f" xlink:to="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_e4ff729b-711b-4e96-aab3-e80033851b1b" xlink:href="exel-20210101.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_exel_ProductGrossMember_e4ff729b-711b-4e96-aab3-e80033851b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_c0c858d5-d88c-41bb-90bc-17149ecb209b" xlink:href="exel-20210101.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_c0c858d5-d88c-41bb-90bc-17149ecb209b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4552dcd4-e21e-4cf8-8958-d5e6d4ba283e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_us-gaap_ProductMember_4552dcd4-e21e-4cf8-8958-d5e6d4ba283e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c9af748c-fad7-409f-9ea5-22667742f74a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_us-gaap_LicenseMember_c9af748c-fad7-409f-9ea5-22667742f74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_dca7d590-4aa5-43be-91fd-a20401dc3004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_us-gaap_ServiceMember_dca7d590-4aa5-43be-91fd-a20401dc3004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_382ab891-3cd7-4b4c-aad6-bfdf6ec4e573" xlink:href="exel-20210101.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a934210-be77-4ecb-8cdc-80c876ffda13" xlink:to="loc_exel_CollaborationMember_382ab891-3cd7-4b4c-aad6-bfdf6ec4e573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_02db2bb9-dc8b-46bc-9cc3-83b8aaba8623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2f4a22a6-7446-4669-b08c-f3a81b06c0db" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_02db2bb9-dc8b-46bc-9cc3-83b8aaba8623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a44453b-50d9-41ce-b159-52ba5302d2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_02db2bb9-dc8b-46bc-9cc3-83b8aaba8623" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a44453b-50d9-41ce-b159-52ba5302d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3d16d0b5-0eec-496e-b694-71e7996fe46e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2d6c7688-e705-40d4-9253-644dd6eac96d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3d16d0b5-0eec-496e-b694-71e7996fe46e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2d6c7688-e705-40d4-9253-644dd6eac96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4340849a-28d9-44b5-9413-582c0fab2a4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2d6c7688-e705-40d4-9253-644dd6eac96d" xlink:to="loc_srt_ProductOrServiceAxis_4340849a-28d9-44b5-9413-582c0fab2a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4340849a-28d9-44b5-9413-582c0fab2a4e" xlink:to="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_f6dc921f-5a08-4150-9eb1-54a55b99ca75" xlink:href="exel-20210101.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:to="loc_exel_CabometyxMember_f6dc921f-5a08-4150-9eb1-54a55b99ca75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_78040025-9917-4b66-bbbc-088cff5979b2" xlink:href="exel-20210101.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:to="loc_exel_CometriqMember_78040025-9917-4b66-bbbc-088cff5979b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2eda8667-3a0f-4fc6-b643-0c3061f3d9ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e5111feb-3408-40f0-8184-82299d759a24" xlink:to="loc_us-gaap_ProductMember_2eda8667-3a0f-4fc6-b643-0c3061f3d9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_40894dc2-4546-4582-bc60-724b4977afba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2d6c7688-e705-40d4-9253-644dd6eac96d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_40894dc2-4546-4582-bc60-724b4977afba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ef465507-f0e4-45d2-81c4-6135ef4c2f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_40894dc2-4546-4582-bc60-724b4977afba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ef465507-f0e4-45d2-81c4-6135ef4c2f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_171ef5c0-6471-4a83-9a2d-79681b1b7962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_171ef5c0-6471-4a83-9a2d-79681b1b7962" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c6630d5b-02ee-4a17-b135-69b1964dbebe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:to="loc_srt_MajorCustomersAxis_c6630d5b-02ee-4a17-b135-69b1964dbebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c6630d5b-02ee-4a17-b135-69b1964dbebe" xlink:to="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_b90eeabf-39c3-4bb2-b77c-ca17c27d7766" xlink:href="exel-20210101.xsd#exel_IpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_IpsenMember_b90eeabf-39c3-4bb2-b77c-ca17c27d7766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_c820c21e-89de-40d4-80f3-fa9f5ccbf4de" xlink:href="exel-20210101.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_c820c21e-89de-40d4-80f3-fa9f5ccbf4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_740a73ed-8149-4532-9b0a-f0ac3dee7951" xlink:href="exel-20210101.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_740a73ed-8149-4532-9b0a-f0ac3dee7951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_56636906-d9af-4953-ae24-4bac849cb8f5" xlink:href="exel-20210101.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_AccredoHealthIncorporatedMember_56636906-d9af-4953-ae24-4bac849cb8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0e7433ae-82d4-4a77-977f-fa5fe4ebe483" xlink:href="exel-20210101.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9b2e898a-ab05-478c-9253-f404e2b24ee9" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_0e7433ae-82d4-4a77-977f-fa5fe4ebe483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e7afce5-edf6-43fa-b93f-3a4b0b1ae689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e7afce5-edf6-43fa-b93f-3a4b0b1ae689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_198d97c7-c760-4c63-845c-773fef12a516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6e7afce5-edf6-43fa-b93f-3a4b0b1ae689" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_198d97c7-c760-4c63-845c-773fef12a516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_647a474b-a230-4913-b5c1-e97b9b79e8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_198d97c7-c760-4c63-845c-773fef12a516" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_647a474b-a230-4913-b5c1-e97b9b79e8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3477288f-a19c-49da-82b6-37c5458440a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3477288f-a19c-49da-82b6-37c5458440a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a76a3266-d794-496c-a192-909de9fd2b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3477288f-a19c-49da-82b6-37c5458440a9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a76a3266-d794-496c-a192-909de9fd2b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_302aaba3-7b8b-4004-b8e0-686da555b1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a76a3266-d794-496c-a192-909de9fd2b2a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_302aaba3-7b8b-4004-b8e0-686da555b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_904a7139-195f-4981-9758-4a9960a9d9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6c4ee14f-5b03-49dd-8204-821eec1aca3c" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_904a7139-195f-4981-9758-4a9960a9d9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bf2a628e-6251-4a65-86c5-522ccad1daab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_904a7139-195f-4981-9758-4a9960a9d9bd" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bf2a628e-6251-4a65-86c5-522ccad1daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1031daf4-4cce-4c1c-8a5f-e689653abcaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f11cb111-de71-4211-8586-a12c682a088f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1031daf4-4cce-4c1c-8a5f-e689653abcaf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f11cb111-de71-4211-8586-a12c682a088f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1f8d4b1c-91b7-49ba-a9ea-749b9f37a363" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f11cb111-de71-4211-8586-a12c682a088f" xlink:to="loc_srt_StatementGeographicalAxis_1f8d4b1c-91b7-49ba-a9ea-749b9f37a363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1f8d4b1c-91b7-49ba-a9ea-749b9f37a363" xlink:to="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_8cd6c1dd-7d56-403a-a72f-2332bce08d93" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:to="loc_country_US_8cd6c1dd-7d56-403a-a72f-2332bce08d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_830fae3c-fda4-44ce-bda6-e2dbc6998920" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:to="loc_srt_EuropeMember_830fae3c-fda4-44ce-bda6-e2dbc6998920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_9e3f31a5-2e06-4653-a1a7-b6527a0001a8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d5ce95d1-5f3c-4617-9eba-13b9bd46b0b7" xlink:to="loc_country_JP_9e3f31a5-2e06-4653-a1a7-b6527a0001a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4deebbc8-996f-425b-86f5-757bb2acb649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f11cb111-de71-4211-8586-a12c682a088f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4deebbc8-996f-425b-86f5-757bb2acb649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f888351-c205-44b6-a8ab-5217f1c80f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4deebbc8-996f-425b-86f5-757bb2acb649" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f888351-c205-44b6-a8ab-5217f1c80f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_818d8bf1-bd88-41b5-966b-16313fab8653" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c2ccbda8-fc76-4670-9c5f-48fb83c70b1c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_818d8bf1-bd88-41b5-966b-16313fab8653" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c2ccbda8-fc76-4670-9c5f-48fb83c70b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e46ee1d7-6d26-4072-a926-ccbe61bb85a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c2ccbda8-fc76-4670-9c5f-48fb83c70b1c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e46ee1d7-6d26-4072-a926-ccbe61bb85a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_e46ee1d7-6d26-4072-a926-ccbe61bb85a1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_76647f7e-1f50-4f7e-86b8-debd387206f6" xlink:href="exel-20210101.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_76647f7e-1f50-4f7e-86b8-debd387206f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_920faf7f-1234-4dd4-af55-239906719c8c" xlink:href="exel-20210101.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_920faf7f-1234-4dd4-af55-239906719c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_6c665b48-cdee-42b9-95e1-37e429512db3" xlink:href="exel-20210101.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_53b06dde-81dd-4dbc-a8bd-3546aa0b0bad" xlink:to="loc_exel_AllowanceForProductRebatesMember_6c665b48-cdee-42b9-95e1-37e429512db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_74ad41a3-e932-402c-a3d0-dd4d4aac2b5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c2ccbda8-fc76-4670-9c5f-48fb83c70b1c" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_74ad41a3-e932-402c-a3d0-dd4d4aac2b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_74ad41a3-e932-402c-a3d0-dd4d4aac2b5e" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6c947b82-9296-4885-92d6-854f7d8b7ab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6c947b82-9296-4885-92d6-854f7d8b7ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24305bbe-7496-4bd4-8c82-63c3bce5e3ea" xlink:href="exel-20210101.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24305bbe-7496-4bd4-8c82-63c3bce5e3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_836f0d69-0b56-49ea-8e6f-1a8d7578854a" xlink:href="exel-20210101.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24305bbe-7496-4bd4-8c82-63c3bce5e3ea" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_836f0d69-0b56-49ea-8e6f-1a8d7578854a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_ed1f6ed1-8257-41a1-8b51-c7854d022152" xlink:href="exel-20210101.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_24305bbe-7496-4bd4-8c82-63c3bce5e3ea" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_ed1f6ed1-8257-41a1-8b51-c7854d022152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_e5c74280-8265-4638-9890-3d371f9ceb15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_e5c74280-8265-4638-9890-3d371f9ceb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_eb20e8b3-68b1-4a5e-af13-9aa37f3cd605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_06e23256-43f8-46d0-a0c4-d3851a9a512c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_eb20e8b3-68b1-4a5e-af13-9aa37f3cd605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a854061-403b-41cf-82d5-c2c7b06d34b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_68b5ba06-0c78-41cd-a03c-fa2a6dc5df58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a854061-403b-41cf-82d5-c2c7b06d34b5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_68b5ba06-0c78-41cd-a03c-fa2a6dc5df58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_042687ed-381f-4513-841d-d537c3266ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a854061-403b-41cf-82d5-c2c7b06d34b5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_042687ed-381f-4513-841d-d537c3266ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_002e68c4-adc9-41c6-a17e-fb9e2da7d99d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a854061-403b-41cf-82d5-c2c7b06d34b5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_002e68c4-adc9-41c6-a17e-fb9e2da7d99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_279fc89b-c49e-4069-944f-bb986a38ae97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a854061-403b-41cf-82d5-c2c7b06d34b5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_279fc89b-c49e-4069-944f-bb986a38ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_b2945c2d-3255-445b-9a04-af9d23f47c5b" xlink:href="exel-20210101.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a854061-403b-41cf-82d5-c2c7b06d34b5" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_b2945c2d-3255-445b-9a04-af9d23f47c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_ea248ce0-8a83-4639-a99e-b0202e96c3c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a854061-403b-41cf-82d5-c2c7b06d34b5" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_ea248ce0-8a83-4639-a99e-b0202e96c3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_10957c7b-f541-45a8-9ec7-be1e554a2b75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6a854061-403b-41cf-82d5-c2c7b06d34b5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_10957c7b-f541-45a8-9ec7-be1e554a2b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1067f816-55be-4a7c-a509-74ab94e9ee6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ddfae5d1-d4e3-42dd-b8f9-f12b1c68cc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1067f816-55be-4a7c-a509-74ab94e9ee6d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ddfae5d1-d4e3-42dd-b8f9-f12b1c68cc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b73c05b7-d803-436c-8df9-8d6604860e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_a1ba58c0-78ee-4b32-9f21-655ffdfbc8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b73c05b7-d803-436c-8df9-8d6604860e79" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_a1ba58c0-78ee-4b32-9f21-655ffdfbc8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e52c1743-7cbe-4201-b669-7787247db7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e52c1743-7cbe-4201-b669-7787247db7d6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1f941bb5-a228-4d20-8233-42b809b23566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1f941bb5-a228-4d20-8233-42b809b23566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b72c124-5d1f-4bbc-b0a4-e16e40a67a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1f941bb5-a228-4d20-8233-42b809b23566" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b72c124-5d1f-4bbc-b0a4-e16e40a67a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_4459d1c9-c72d-4fb2-b1a1-2f03d9c50169" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b72c124-5d1f-4bbc-b0a4-e16e40a67a7b" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_4459d1c9-c72d-4fb2-b1a1-2f03d9c50169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da0531bb-81ee-44f4-9bc9-2cc01bc8b700" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:to="loc_srt_RangeAxis_da0531bb-81ee-44f4-9bc9-2cc01bc8b700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83b79fd6-6cc7-4656-ad64-056cfea09e98" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_da0531bb-81ee-44f4-9bc9-2cc01bc8b700" xlink:to="loc_srt_RangeMember_83b79fd6-6cc7-4656-ad64-056cfea09e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_53fb6095-45a8-479f-8eba-102bbf3fb979" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_83b79fd6-6cc7-4656-ad64-056cfea09e98" xlink:to="loc_srt_MinimumMember_53fb6095-45a8-479f-8eba-102bbf3fb979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e2f0232d-2929-41c7-87fa-e058d616cd81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_83b79fd6-6cc7-4656-ad64-056cfea09e98" xlink:to="loc_srt_MaximumMember_e2f0232d-2929-41c7-87fa-e058d616cd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_67d42b33-5480-4758-85e9-17bac630ad1f" xlink:href="exel-20210101.xsd#exel_RoyaltyTierAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:to="loc_exel_RoyaltyTierAxis_67d42b33-5480-4758-85e9-17bac630ad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_8ccec285-cff9-40d2-9ea2-271d2b4986e9" xlink:href="exel-20210101.xsd#exel_RoyaltytierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_67d42b33-5480-4758-85e9-17bac630ad1f" xlink:to="loc_exel_RoyaltytierDomain_8ccec285-cff9-40d2-9ea2-271d2b4986e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_0f1339c7-9cfc-4914-8448-a092f082dd96" xlink:href="exel-20210101.xsd#exel_FinalTierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_8ccec285-cff9-40d2-9ea2-271d2b4986e9" xlink:to="loc_exel_FinalTierMember_0f1339c7-9cfc-4914-8448-a092f082dd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7c134e98-7c83-43f7-852f-11d0a1214876" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:to="loc_srt_MajorCustomersAxis_7c134e98-7c83-43f7-852f-11d0a1214876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_75d6e782-777f-4132-8af3-aca850b156c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7c134e98-7c83-43f7-852f-11d0a1214876" xlink:to="loc_srt_NameOfMajorCustomerDomain_75d6e782-777f-4132-8af3-aca850b156c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_cbb46db9-f00f-423c-8f12-6ec3776eabc1" xlink:href="exel-20210101.xsd#exel_GlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_75d6e782-777f-4132-8af3-aca850b156c0" xlink:to="loc_exel_GlaxoSmithKlineMember_cbb46db9-f00f-423c-8f12-6ec3776eabc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_245a8932-452d-4ab3-bf1e-03068a138855" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_2af2fc8e-20b6-4f37-9505-05978408b302" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_2af2fc8e-20b6-4f37-9505-05978408b302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_cf1f5487-7241-4c6c-9b83-62cb4be21a9c" xlink:href="exel-20210101.xsd#exel_UpfrontPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_UpfrontPayments_cf1f5487-7241-4c6c-9b83-62cb4be21a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_9631b0b5-8d7d-405f-a2d6-ba242f35d1a6" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_9631b0b5-8d7d-405f-a2d6-ba242f35d1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_19e71a18-d645-494e-a9db-760a2cc7b4a7" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarned"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_MilestonePaymentsEarned_19e71a18-d645-494e-a9db-760a2cc7b4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_ff75598b-5817-4197-8029-d6a868214b24" xlink:href="exel-20210101.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_ff75598b-5817-4197-8029-d6a868214b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_23659ec3-18de-4c8b-9f45-39739e89c4f6" xlink:href="exel-20210101.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_23659ec3-18de-4c8b-9f45-39739e89c4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_72811460-6383-4d86-b3c4-f046d50eed42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_72811460-6383-4d86-b3c4-f046d50eed42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_57baa482-0666-4a04-a808-cafbbb431897" xlink:href="exel-20210101.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_57baa482-0666-4a04-a808-cafbbb431897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_6053c30d-f0d0-4a94-8dd1-8a483de5310b" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_6053c30d-f0d0-4a94-8dd1-8a483de5310b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_2951404a-20e8-4bff-9038-0f2a3f78b122" xlink:href="exel-20210101.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ab494fc7-56b9-4daf-bb29-3447de5e2dcf" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_2951404a-20e8-4bff-9038-0f2a3f78b122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb7d855a-fd20-4849-bcbd-654be5857a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73df77f5-0b6e-4709-a348-218908de1d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb7d855a-fd20-4849-bcbd-654be5857a85" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73df77f5-0b6e-4709-a348-218908de1d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5367b2fe-783b-41ca-92b4-fa7579d1c95b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73df77f5-0b6e-4709-a348-218908de1d16" xlink:to="loc_srt_ProductOrServiceAxis_5367b2fe-783b-41ca-92b4-fa7579d1c95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_142f04ea-8231-4b55-af0d-ab9c9ebd0724" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5367b2fe-783b-41ca-92b4-fa7579d1c95b" xlink:to="loc_srt_ProductsAndServicesDomain_142f04ea-8231-4b55-af0d-ab9c9ebd0724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_67a34ba4-af33-4cfd-833c-e95db6a914ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_142f04ea-8231-4b55-af0d-ab9c9ebd0724" xlink:to="loc_us-gaap_LicenseMember_67a34ba4-af33-4cfd-833c-e95db6a914ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_fa96a249-7da3-4d48-bde6-76c4560b24b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_142f04ea-8231-4b55-af0d-ab9c9ebd0724" xlink:to="loc_us-gaap_ServiceMember_fa96a249-7da3-4d48-bde6-76c4560b24b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2d876d24-7ee2-48ca-ad39-8d9cc49c62e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73df77f5-0b6e-4709-a348-218908de1d16" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2d876d24-7ee2-48ca-ad39-8d9cc49c62e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58eca248-b2c1-484a-9c04-0539a3c8d2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2d876d24-7ee2-48ca-ad39-8d9cc49c62e2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58eca248-b2c1-484a-9c04-0539a3c8d2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_85d655b5-762e-4c59-84a5-942e3b63e8d7" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_58eca248-b2c1-484a-9c04-0539a3c8d2dc" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_85d655b5-762e-4c59-84a5-942e3b63e8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1b42da68-c1df-4191-b8ae-607212b8b3c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73df77f5-0b6e-4709-a348-218908de1d16" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1b42da68-c1df-4191-b8ae-607212b8b3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b156852-179d-476b-bf6e-477d75feb1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1b42da68-c1df-4191-b8ae-607212b8b3c0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b156852-179d-476b-bf6e-477d75feb1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c9d9febc-7b8d-4454-83cf-e9aa9e20f39e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c9d9febc-7b8d-4454-83cf-e9aa9e20f39e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92e97891-7ea8-42d4-a4e9-6e59295380cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92e97891-7ea8-42d4-a4e9-6e59295380cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1327f879-8561-4e7b-8ac6-7f44eb8339b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92e97891-7ea8-42d4-a4e9-6e59295380cb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1327f879-8561-4e7b-8ac6-7f44eb8339b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_ea3118b4-acee-4a5e-9592-08d79cb67f36" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1327f879-8561-4e7b-8ac6-7f44eb8339b7" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_ea3118b4-acee-4a5e-9592-08d79cb67f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b5bf8eb6-68c8-4487-829b-366c22132c41" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_srt_StatementGeographicalAxis_b5bf8eb6-68c8-4487-829b-366c22132c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46d8b7d0-ca04-4bf4-b396-9a1bbbcae37f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b5bf8eb6-68c8-4487-829b-366c22132c41" xlink:to="loc_srt_SegmentGeographicalDomain_46d8b7d0-ca04-4bf4-b396-9a1bbbcae37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_43326e8e-2478-40b0-ae84-468c31c6c5d3" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_46d8b7d0-ca04-4bf4-b396-9a1bbbcae37f" xlink:to="loc_country_JP_43326e8e-2478-40b0-ae84-468c31c6c5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTierAxis_7c0851e1-19c1-4cc9-8ff4-f25948c601c0" xlink:href="exel-20210101.xsd#exel_RoyaltyTierAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_exel_RoyaltyTierAxis_7c0851e1-19c1-4cc9-8ff4-f25948c601c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltytierDomain_209914ca-47d1-4e5d-aa4a-25ecc7e10392" xlink:href="exel-20210101.xsd#exel_RoyaltytierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltyTierAxis_7c0851e1-19c1-4cc9-8ff4-f25948c601c0" xlink:to="loc_exel_RoyaltytierDomain_209914ca-47d1-4e5d-aa4a-25ecc7e10392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_InitialMember_4c387c3d-f962-4bf4-bf2b-391424d74a12" xlink:href="exel-20210101.xsd#exel_InitialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_209914ca-47d1-4e5d-aa4a-25ecc7e10392" xlink:to="loc_exel_InitialMember_4c387c3d-f962-4bf4-bf2b-391424d74a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FinalTierMember_4e5abf40-b40f-4f7c-8f78-d347ecd268ff" xlink:href="exel-20210101.xsd#exel_FinalTierMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_209914ca-47d1-4e5d-aa4a-25ecc7e10392" xlink:to="loc_exel_FinalTierMember_4e5abf40-b40f-4f7c-8f78-d347ecd268ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a4dad40-e44f-4e3f-a71d-a46074ce9843" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_srt_RangeAxis_7a4dad40-e44f-4e3f-a71d-a46074ce9843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_972da010-fa20-4523-bdfd-8d0673f3e3bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7a4dad40-e44f-4e3f-a71d-a46074ce9843" xlink:to="loc_srt_RangeMember_972da010-fa20-4523-bdfd-8d0673f3e3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff830f3a-c8fc-4fbc-b4db-3d2c7f712b79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_972da010-fa20-4523-bdfd-8d0673f3e3bd" xlink:to="loc_srt_MinimumMember_ff830f3a-c8fc-4fbc-b4db-3d2c7f712b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c21eeb57-a850-4df4-9f11-cb17c7e9e9fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_972da010-fa20-4523-bdfd-8d0673f3e3bd" xlink:to="loc_srt_MaximumMember_c21eeb57-a850-4df4-9f11-cb17c7e9e9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_73d15499-04de-4a92-b9d5-c9f30bbb7ceb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_srt_MajorCustomersAxis_73d15499-04de-4a92-b9d5-c9f30bbb7ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d45f461e-3fd4-432a-b206-d5788e1bd67f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_73d15499-04de-4a92-b9d5-c9f30bbb7ceb" xlink:to="loc_srt_NameOfMajorCustomerDomain_d45f461e-3fd4-432a-b206-d5788e1bd67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_16bbbaba-93ed-4702-bdff-cc9c5f8df4be" xlink:href="exel-20210101.xsd#exel_GlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d45f461e-3fd4-432a-b206-d5788e1bd67f" xlink:to="loc_exel_GlaxoSmithKlineMember_16bbbaba-93ed-4702-bdff-cc9c5f8df4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_de4e109e-eae4-4384-87b8-ed0ada7e3ae3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_ab40ec31-1c02-4e12-8cbe-3ae4ed9035a9" xlink:href="exel-20210101.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_ab40ec31-1c02-4e12-8cbe-3ae4ed9035a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_269f0f41-fcc5-42b3-b45e-f43620928a83" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_269f0f41-fcc5-42b3-b45e-f43620928a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_01c160a5-ac52-401b-9fa8-1799e0d5a556" xlink:href="exel-20210101.xsd#exel_PeriodOfSpecificSalesVolumeThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_01c160a5-ac52-401b-9fa8-1799e0d5a556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_dbb23274-2404-4501-ae08-a9828c076b12" xlink:href="exel-20210101.xsd#exel_UpfrontPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_UpfrontPayments_dbb23274-2404-4501-ae08-a9828c076b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarnedToDate_04b4e9ad-c81a-4921-93c9-e61fba54820e" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarnedToDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_MilestonePaymentsEarnedToDate_04b4e9ad-c81a-4921-93c9-e61fba54820e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_265a2a05-29f2-4542-9245-bab8a9ee16c7" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarned"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_MilestonePaymentsEarned_265a2a05-29f2-4542-9245-bab8a9ee16c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsYetToBeEarned_fdc8c389-0c13-4726-aaff-029a48749a4d" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsYetToBeEarned"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_MilestonePaymentsYetToBeEarned_fdc8c389-0c13-4726-aaff-029a48749a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_76c90716-3e4f-43a9-a7aa-4d634567af04" xlink:href="exel-20210101.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_76c90716-3e4f-43a9-a7aa-4d634567af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_a7403ade-41a8-47ed-a003-34170234d181" xlink:href="exel-20210101.xsd#exel_PercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_a7403ade-41a8-47ed-a003-34170234d181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyaltyTier_8534974d-a0d1-48da-a1b5-e4edb1deba0f" xlink:href="exel-20210101.xsd#exel_RoyaltyTier"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_RoyaltyTier_8534974d-a0d1-48da-a1b5-e4edb1deba0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_dd34e113-7786-43cd-a9bb-efc5b582d8f2" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_dd34e113-7786-43cd-a9bb-efc5b582d8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6f1c2e34-1392-4550-8a06-6b703db074a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e008b437-7f93-412f-b00e-6e3a4a869341" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6f1c2e34-1392-4550-8a06-6b703db074a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02340bb4-1bab-4cb6-9ead-3ee0c7463093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e410fae0-82c2-48c8-8e26-cfb7bd00c2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02340bb4-1bab-4cb6-9ead-3ee0c7463093" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e410fae0-82c2-48c8-8e26-cfb7bd00c2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fa46cba3-de36-4e18-bd92-870e7ea35b6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e410fae0-82c2-48c8-8e26-cfb7bd00c2ec" xlink:to="loc_srt_ProductOrServiceAxis_fa46cba3-de36-4e18-bd92-870e7ea35b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e04ed72e-ca6e-414b-ab97-d859ee7b369c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fa46cba3-de36-4e18-bd92-870e7ea35b6a" xlink:to="loc_srt_ProductsAndServicesDomain_e04ed72e-ca6e-414b-ab97-d859ee7b369c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_1fd7a107-4daf-4acb-ad9b-22f08ee7f92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e04ed72e-ca6e-414b-ab97-d859ee7b369c" xlink:to="loc_us-gaap_LicenseMember_1fd7a107-4daf-4acb-ad9b-22f08ee7f92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ba7b6e60-f423-40d2-9bef-610aacb708b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e04ed72e-ca6e-414b-ab97-d859ee7b369c" xlink:to="loc_us-gaap_ServiceMember_ba7b6e60-f423-40d2-9bef-610aacb708b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_324b6138-96c9-457a-ae28-acba324921a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e410fae0-82c2-48c8-8e26-cfb7bd00c2ec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_324b6138-96c9-457a-ae28-acba324921a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbc80d1c-641a-4751-9471-8d6a6bf5a0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_324b6138-96c9-457a-ae28-acba324921a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbc80d1c-641a-4751-9471-8d6a6bf5a0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_795c67fb-d693-4897-8a6e-e26ae36f8de9" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbc80d1c-641a-4751-9471-8d6a6bf5a0b2" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_795c67fb-d693-4897-8a6e-e26ae36f8de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c9f6efd5-cf14-49ba-a468-cfe0913c333c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e410fae0-82c2-48c8-8e26-cfb7bd00c2ec" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c9f6efd5-cf14-49ba-a468-cfe0913c333c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8d70624-6f07-454b-9224-68a02c4f44e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c9f6efd5-cf14-49ba-a468-cfe0913c333c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8d70624-6f07-454b-9224-68a02c4f44e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3eecb00-f26a-448c-89b3-e463a3d8d6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eaa5c8c3-7ee7-405a-8abc-b44ce3cee4ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3eecb00-f26a-448c-89b3-e463a3d8d6bd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eaa5c8c3-7ee7-405a-8abc-b44ce3cee4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ddd99225-0b2a-41e3-93d5-591f82c6c35f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eaa5c8c3-7ee7-405a-8abc-b44ce3cee4ed" xlink:to="loc_srt_MajorCustomersAxis_ddd99225-0b2a-41e3-93d5-591f82c6c35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_966254b6-ded3-4a34-a261-31c04b664709" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ddd99225-0b2a-41e3-93d5-591f82c6c35f" xlink:to="loc_srt_NameOfMajorCustomerDomain_966254b6-ded3-4a34-a261-31c04b664709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_a91a01b6-9288-49c5-b7e0-97ab16a4c99d" xlink:href="exel-20210101.xsd#exel_GlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_966254b6-ded3-4a34-a261-31c04b664709" xlink:to="loc_exel_GlaxoSmithKlineMember_a91a01b6-9288-49c5-b7e0-97ab16a4c99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0a735292-33cd-4ebf-b89f-308f7976fc62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eaa5c8c3-7ee7-405a-8abc-b44ce3cee4ed" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0a735292-33cd-4ebf-b89f-308f7976fc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c8aeb6d-8481-459c-9d32-bfc335baca29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0a735292-33cd-4ebf-b89f-308f7976fc62" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c8aeb6d-8481-459c-9d32-bfc335baca29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_d5d8b027-11e7-4e6d-b924-ba7e2836c840" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c8aeb6d-8481-459c-9d32-bfc335baca29" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_d5d8b027-11e7-4e6d-b924-ba7e2836c840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c1f8603-bfd7-4912-b2e0-981cbb7c7497" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_eaa5c8c3-7ee7-405a-8abc-b44ce3cee4ed" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c1f8603-bfd7-4912-b2e0-981cbb7c7497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_09636d44-68a3-427e-981b-711d0c357be7" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c1f8603-bfd7-4912-b2e0-981cbb7c7497" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_09636d44-68a3-427e-981b-711d0c357be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_1b9fe133-b857-4769-9ed3-752203e82029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5c1f8603-bfd7-4912-b2e0-981cbb7c7497" xlink:to="loc_us-gaap_RoyaltyExpense_1b9fe133-b857-4769-9ed3-752203e82029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_daf3c693-91bd-43d9-9013-9b5d7cfb5e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87d46090-27a2-4a47-9376-1e51b8bf193a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_daf3c693-91bd-43d9-9013-9b5d7cfb5e39" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87d46090-27a2-4a47-9376-1e51b8bf193a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5dc82d35-ef66-43d7-a378-ae6258aa73f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87d46090-27a2-4a47-9376-1e51b8bf193a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5dc82d35-ef66-43d7-a378-ae6258aa73f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d6adf33-766f-44ad-9d3a-fe4faa40edf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5dc82d35-ef66-43d7-a378-ae6258aa73f5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d6adf33-766f-44ad-9d3a-fe4faa40edf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_9fbda4b3-1e52-4495-b2ab-4f3d61432c6b" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d6adf33-766f-44ad-9d3a-fe4faa40edf2" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_9fbda4b3-1e52-4495-b2ab-4f3d61432c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f51537e4-6179-4eee-9f3a-f8a7f828cdde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_87d46090-27a2-4a47-9376-1e51b8bf193a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f51537e4-6179-4eee-9f3a-f8a7f828cdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_92bc6166-7f24-472e-984d-f78ca1e1dfcd" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f51537e4-6179-4eee-9f3a-f8a7f828cdde" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_92bc6166-7f24-472e-984d-f78ca1e1dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f79987f-b638-4cbf-8ff8-68cd6e448431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f51537e4-6179-4eee-9f3a-f8a7f828cdde" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f79987f-b638-4cbf-8ff8-68cd6e448431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsOtherCollaborationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae102440-db34-4d94-b8dd-36470064dd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ae102440-db34-4d94-b8dd-36470064dd6f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTiersAxis_3761dbcc-666b-4d51-ac84-49f37576beb4" xlink:href="exel-20210101.xsd#exel_ProfitSharingTiersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:to="loc_exel_ProfitSharingTiersAxis_3761dbcc-666b-4d51-ac84-49f37576beb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:href="exel-20210101.xsd#exel_ProfitSharingTiersDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersAxis_3761dbcc-666b-4d51-ac84-49f37576beb4" xlink:to="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTierOneMember_2804c8ab-4554-43ea-be59-93e4cf538e5e" xlink:href="exel-20210101.xsd#exel_ProfitSharingTierOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:to="loc_exel_ProfitSharingTierOneMember_2804c8ab-4554-43ea-be59-93e4cf538e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTierTwoMember_29e0d0a2-1c39-444d-ba51-f92aa6bd1a20" xlink:href="exel-20210101.xsd#exel_ProfitSharingTierTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:to="loc_exel_ProfitSharingTierTwoMember_29e0d0a2-1c39-444d-ba51-f92aa6bd1a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingTierThreeMember_64e5d4c1-66cf-4399-8c5d-b29c505a21e7" xlink:href="exel-20210101.xsd#exel_ProfitSharingTierThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_9baca1bf-d24a-4034-b4a6-8c6b2f456603" xlink:to="loc_exel_ProfitSharingTierThreeMember_64e5d4c1-66cf-4399-8c5d-b29c505a21e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_78bd5ebf-391a-42e9-aad4-60147d4ae5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:to="loc_us-gaap_TypeOfArrangementAxis_78bd5ebf-391a-42e9-aad4-60147d4ae5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b510354d-305f-44b1-93a6-0fa0d56630de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_78bd5ebf-391a-42e9-aad4-60147d4ae5d9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b510354d-305f-44b1-93a6-0fa0d56630de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_d0a9de27-bb69-4908-aa76-d20799260281" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b510354d-305f-44b1-93a6-0fa0d56630de" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_d0a9de27-bb69-4908-aa76-d20799260281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_6d1886ee-be6a-46af-acad-f4b4e9cce42c" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b510354d-305f-44b1-93a6-0fa0d56630de" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_6d1886ee-be6a-46af-acad-f4b4e9cce42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8148429-d7dd-47cf-a6c6-a3dc5dca3746" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:to="loc_srt_RangeAxis_b8148429-d7dd-47cf-a6c6-a3dc5dca3746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b9a726d-7441-4147-8fae-4d6ed34038dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b8148429-d7dd-47cf-a6c6-a3dc5dca3746" xlink:to="loc_srt_RangeMember_3b9a726d-7441-4147-8fae-4d6ed34038dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5af34737-386d-4edd-b307-81d4a85dc451" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b9a726d-7441-4147-8fae-4d6ed34038dc" xlink:to="loc_srt_MinimumMember_5af34737-386d-4edd-b307-81d4a85dc451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6872511f-80cd-417e-a4e6-9d2dc10fb3f9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b9a726d-7441-4147-8fae-4d6ed34038dc" xlink:to="loc_srt_MaximumMember_6872511f-80cd-417e-a4e6-9d2dc10fb3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d62f822-b572-4225-ace9-61bca77b9296" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:to="loc_srt_ProductOrServiceAxis_4d62f822-b572-4225-ace9-61bca77b9296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b178f64-c56d-4d08-b47b-b5973502ddb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4d62f822-b572-4225-ace9-61bca77b9296" xlink:to="loc_srt_ProductsAndServicesDomain_9b178f64-c56d-4d08-b47b-b5973502ddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MINNEBROMember_013578f3-9b69-458e-9d72-526a3f2e1c33" xlink:href="exel-20210101.xsd#exel_MINNEBROMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b178f64-c56d-4d08-b47b-b5973502ddb2" xlink:to="loc_exel_MINNEBROMember_013578f3-9b69-458e-9d72-526a3f2e1c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0f24dad-e0eb-46f7-aec3-a7848031f807" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_4bb2d3fc-e6d0-42d8-8f45-54de7fae5721" xlink:href="exel-20210101.xsd#exel_ProfitSharingAgreementPercentOfProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_4bb2d3fc-e6d0-42d8-8f45-54de7fae5721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_a5634807-72a6-4512-a1de-fee3e16a710a" xlink:href="exel-20210101.xsd#exel_ProfitSharingAgreementProfitThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_a5634807-72a6-4512-a1de-fee3e16a710a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_4f0754e5-cd0c-47d6-8118-d1d2c53b3ba2" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementAchievedMilestoneAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_CollaborativeArrangementAchievedMilestoneAmount_4f0754e5-cd0c-47d6-8118-d1d2c53b3ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_e19c6582-1903-4284-9458-e499679fae09" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_e19c6582-1903-4284-9458-e499679fae09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90a21e36-1fde-4163-b89a-21d5aa46edee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90a21e36-1fde-4163-b89a-21d5aa46edee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementTerminationPeriod_bcf1ec84-910e-40eb-8751-0e897b7cc822" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementTerminationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b80aa28-f735-439b-b78b-126464b34d56" xlink:to="loc_exel_CollaborationAgreementTerminationPeriod_bcf1ec84-910e-40eb-8751-0e897b7cc822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9cffc73-eade-4b03-83d2-9a5cae6f1d7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1925536-9692-428e-9b71-9b0766f9efbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9cffc73-eade-4b03-83d2-9a5cae6f1d7b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1925536-9692-428e-9b71-9b0766f9efbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_120b5932-3a3b-479d-9b1b-5ca6960e6130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1925536-9692-428e-9b71-9b0766f9efbf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_120b5932-3a3b-479d-9b1b-5ca6960e6130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_120b5932-3a3b-479d-9b1b-5ca6960e6130" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithCatalentMember_2e0b44f9-a7c1-46e4-9f3a-88f4ee2be3ab" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithCatalentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:to="loc_exel_CollaborativeArrangementWithCatalentMember_2e0b44f9-a7c1-46e4-9f3a-88f4ee2be3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember_7f35cf49-5e91-42cd-b001-badfdae994b3" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithNBETherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:to="loc_exel_CollaborativeArrangementWithNBETherapeuticsMember_7f35cf49-5e91-42cd-b001-badfdae994b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_30d3b222-7347-4fc0-93e8-40b28a54f167" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:to="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_30d3b222-7347-4fc0-93e8-40b28a54f167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_f04b1d21-9339-4674-a54b-eccd9a0d2802" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8768532c-f9e5-4d21-9c6d-add39283d7c1" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_f04b1d21-9339-4674-a54b-eccd9a0d2802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3da02ac6-d061-4ada-b116-1cbcde28036d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1925536-9692-428e-9b71-9b0766f9efbf" xlink:to="loc_srt_RangeAxis_3da02ac6-d061-4ada-b116-1cbcde28036d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_442708be-d7e1-47f8-a460-b27f6220e539" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3da02ac6-d061-4ada-b116-1cbcde28036d" xlink:to="loc_srt_RangeMember_442708be-d7e1-47f8-a460-b27f6220e539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_469831a9-3b35-47bc-b275-a564e09b0d61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_442708be-d7e1-47f8-a460-b27f6220e539" xlink:to="loc_srt_MaximumMember_469831a9-3b35-47bc-b275-a564e09b0d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e311fe36-eb57-4183-a06a-46cd4e6f1438" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_442708be-d7e1-47f8-a460-b27f6220e539" xlink:to="loc_srt_MinimumMember_e311fe36-eb57-4183-a06a-46cd4e6f1438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1925536-9692-428e-9b71-9b0766f9efbf" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementsUpfrontPayments_53e7cf5e-80c1-49e4-8c92-7cc5f2e5594c" xlink:href="exel-20210101.xsd#exel_CollaborativeAgreementsUpfrontPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborativeAgreementsUpfrontPayments_53e7cf5e-80c1-49e4-8c92-7cc5f2e5594c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_1c338788-127b-4d61-ab5b-134fc0b071b0" xlink:href="exel-20210101.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionTerm_1c338788-127b-4d61-ab5b-134fc0b071b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_96680e19-a9d8-44d5-84d3-6c4523699368" xlink:href="exel-20210101.xsd#exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm_96680e19-a9d8-44d5-84d3-6c4523699368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_cf8d720b-9934-4e6d-9390-1e8203f071fa" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementsAdditionalUpfrontPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementsAdditionalUpfrontPayments_cf8d720b-9934-4e6d-9390-1e8203f071fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_d515d89b-5d0c-4d8c-8584-9ead3ea3b36b" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_d515d89b-5d0c-4d8c-8584-9ead3ea3b36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_a17817f9-68c0-454b-9ea7-fb4b2cd7e2ac" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_a17817f9-68c0-454b-9ea7-fb4b2cd7e2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_c8650726-9cd5-49f0-bf9e-c6097d863912" xlink:href="exel-20210101.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_c8650726-9cd5-49f0-bf9e-c6097d863912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_75f74760-f30b-4315-959a-cb0529e70216" xlink:href="exel-20210101.xsd#exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm_75f74760-f30b-4315-959a-cb0529e70216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_3ef1949c-bb47-4806-b058-767d321addae" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementNumberOfPrograms"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementNumberOfPrograms_3ef1949c-bb47-4806-b058-767d321addae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontPayments_365c336b-0964-4b6d-b272-996e31d6a0d4" xlink:href="exel-20210101.xsd#exel_UpfrontPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_UpfrontPayments_365c336b-0964-4b6d-b272-996e31d6a0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_abc437d8-434c-421d-8845-7d9615d432c4" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementNumberOfPreexistingPrograms"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_abc437d8-434c-421d-8845-7d9615d432c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_60c47517-1f6b-4ceb-9018-c0786c8032b0" xlink:href="exel-20210101.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_60c47517-1f6b-4ceb-9018-c0786c8032b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_434ffd33-5371-40f5-a063-919dd1ba9bcd" xlink:href="exel-20210101.xsd#exel_CollaborationAgreementsUpfrontPayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7b244b45-c0b0-4660-95b3-b6a28f339797" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_434ffd33-5371-40f5-a063-919dd1ba9bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsInvenraCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_722d390b-faa1-468e-878c-bc7750bd01f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96cad599-f71b-4aba-9716-305b51e134b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_722d390b-faa1-468e-878c-bc7750bd01f5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96cad599-f71b-4aba-9716-305b51e134b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dc7bb111-9bc0-4b08-b494-80e72c01bb18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96cad599-f71b-4aba-9716-305b51e134b7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dc7bb111-9bc0-4b08-b494-80e72c01bb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e0c7ef-e6f7-48d1-ab30-32215c6923f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dc7bb111-9bc0-4b08-b494-80e72c01bb18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e0c7ef-e6f7-48d1-ab30-32215c6923f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithInvenraMember_bd866be8-2592-4162-8f34-70acc3ad642f" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithInvenraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e0c7ef-e6f7-48d1-ab30-32215c6923f7" xlink:to="loc_exel_CollaborativeArrangementWithInvenraMember_bd866be8-2592-4162-8f34-70acc3ad642f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveAxis_2b3945de-f321-406f-b66c-64c1b7942ab8" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96cad599-f71b-4aba-9716-305b51e134b7" xlink:to="loc_exel_MilestoneObjectiveAxis_2b3945de-f321-406f-b66c-64c1b7942ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_2b3945de-f321-406f-b66c-64c1b7942ab8" xlink:to="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DevelopmentAndRegulatoryMilestoneMember_805d300a-a9ea-4a7a-a246-8d8ce0e6f383" xlink:href="exel-20210101.xsd#exel_DevelopmentAndRegulatoryMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:to="loc_exel_DevelopmentAndRegulatoryMilestoneMember_805d300a-a9ea-4a7a-a246-8d8ce0e6f383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_2929cad5-cd62-4bb6-8e80-7fd75eafcf1f" xlink:href="exel-20210101.xsd#exel_AdditionalDevelopmentAndRegulatoryMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:to="loc_exel_AdditionalDevelopmentAndRegulatoryMilestoneMember_2929cad5-cd62-4bb6-8e80-7fd75eafcf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductCommercializationMember_909aa511-8699-426d-9854-c5f3ca410a3e" xlink:href="exel-20210101.xsd#exel_ProductCommercializationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:to="loc_exel_ProductCommercializationMember_909aa511-8699-426d-9854-c5f3ca410a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DiscoveryProjectMember_d9097436-9ad1-4fb0-8155-656a26f15805" xlink:href="exel-20210101.xsd#exel_DiscoveryProjectMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_829d0b2e-ef37-4841-8838-1859997d7eb3" xlink:to="loc_exel_DiscoveryProjectMember_d9097436-9ad1-4fb0-8155-656a26f15805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_96cad599-f71b-4aba-9716-305b51e134b7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1fb4a786-1fe5-4357-9c5c-a4b0757cc0ef" xlink:href="exel-20210101.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_1fb4a786-1fe5-4357-9c5c-a4b0757cc0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProjectInitiationFeePayment_f256fd28-2a67-499d-aa24-6fc0ede5b7bc" xlink:href="exel-20210101.xsd#exel_ProjectInitiationFeePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:to="loc_exel_ProjectInitiationFeePayment_f256fd28-2a67-499d-aa24-6fc0ede5b7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontAndMilestonePayments_eda93755-76df-481e-a276-4473922185a1" xlink:href="exel-20210101.xsd#exel_UpfrontAndMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_551e39ef-6e44-4719-9de8-31278b27461b" xlink:to="loc_exel_UpfrontAndMilestonePayments_eda93755-76df-481e-a276-4473922185a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CollaborationAgreementsStemSynergyCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ad832d3-ff6c-48bb-96ae-e0f974e1e42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f373e43-6da8-4cc0-98a0-40e71b22abf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ad832d3-ff6c-48bb-96ae-e0f974e1e42a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f373e43-6da8-4cc0-98a0-40e71b22abf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a7bd98e1-ea9c-447e-8c79-820d7c7166e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f373e43-6da8-4cc0-98a0-40e71b22abf2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a7bd98e1-ea9c-447e-8c79-820d7c7166e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d34dad-f8cb-4cc6-a36c-1f3f994b66d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a7bd98e1-ea9c-447e-8c79-820d7c7166e6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d34dad-f8cb-4cc6-a36c-1f3f994b66d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementWithStemSynergyMember_013c23d5-a177-4189-8f54-26068e8e948c" xlink:href="exel-20210101.xsd#exel_CollaborativeArrangementWithStemSynergyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22d34dad-f8cb-4cc6-a36c-1f3f994b66d2" xlink:to="loc_exel_CollaborativeArrangementWithStemSynergyMember_013c23d5-a177-4189-8f54-26068e8e948c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveAxis_a8155c5e-d99c-4972-ae8e-7951cb004a0f" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f373e43-6da8-4cc0-98a0-40e71b22abf2" xlink:to="loc_exel_MilestoneObjectiveAxis_a8155c5e-d99c-4972-ae8e-7951cb004a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestoneObjectiveDomain_caf57cbf-050c-47c2-9615-4d589294d54f" xlink:href="exel-20210101.xsd#exel_MilestoneObjectiveDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_a8155c5e-d99c-4972-ae8e-7951cb004a0f" xlink:to="loc_exel_MilestoneObjectiveDomain_caf57cbf-050c-47c2-9615-4d589294d54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_FirstProductToReachMarketMember_72702d53-b1d8-48ce-9484-4de860637d91" xlink:href="exel-20210101.xsd#exel_FirstProductToReachMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_caf57cbf-050c-47c2-9615-4d589294d54f" xlink:to="loc_exel_FirstProductToReachMarketMember_72702d53-b1d8-48ce-9484-4de860637d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8b3f4258-b3e9-4fb3-a2d6-750193532839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f373e43-6da8-4cc0-98a0-40e71b22abf2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8b3f4258-b3e9-4fb3-a2d6-750193532839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UpfrontAndMilestonePayments_98623d13-4910-46b7-9e47-444789daae46" xlink:href="exel-20210101.xsd#exel_UpfrontAndMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8b3f4258-b3e9-4fb3-a2d6-750193532839" xlink:to="loc_exel_UpfrontAndMilestonePayments_98623d13-4910-46b7-9e47-444789daae46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_c79d3b56-b584-458d-8fbd-4c13473e4ed7" xlink:href="exel-20210101.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8b3f4258-b3e9-4fb3-a2d6-750193532839" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_c79d3b56-b584-458d-8fbd-4c13473e4ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da4bbf05-01ed-4023-9acd-7a69d9163c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_f18dedd8-469c-4162-8b40-2a214c79eb99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_da4bbf05-01ed-4023-9acd-7a69d9163c45" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_f18dedd8-469c-4162-8b40-2a214c79eb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68091bb7-8229-4446-be3f-4684cd5fbbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_09946098-c760-4aed-aabc-481036e816e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68091bb7-8229-4446-be3f-4684cd5fbbe9" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_09946098-c760-4aed-aabc-481036e816e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_72eee5f0-eeef-498f-9244-944a5d7271d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68091bb7-8229-4446-be3f-4684cd5fbbe9" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_72eee5f0-eeef-498f-9244-944a5d7271d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_d4196bbe-37f0-4f20-9cdd-62d7cf1c5bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68091bb7-8229-4446-be3f-4684cd5fbbe9" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_d4196bbe-37f0-4f20-9cdd-62d7cf1c5bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_cf3be349-b60f-4c26-9b70-05db7ebc2dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68091bb7-8229-4446-be3f-4684cd5fbbe9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_cf3be349-b60f-4c26-9b70-05db7ebc2dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_611c7c32-fb08-4357-8f48-928d58136a75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_68091bb7-8229-4446-be3f-4684cd5fbbe9" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_611c7c32-fb08-4357-8f48-928d58136a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_096a866d-6ffd-491a-88a7-91a0cd6ecd47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e23501b9-3f9c-4234-95dd-693614246051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_096a866d-6ffd-491a-88a7-91a0cd6ecd47" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e23501b9-3f9c-4234-95dd-693614246051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_667f2dbe-1a45-4771-976f-05d331b0f1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_096a866d-6ffd-491a-88a7-91a0cd6ecd47" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_667f2dbe-1a45-4771-976f-05d331b0f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2867f0b2-199e-47bf-91e2-eb30adf6c400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_096a866d-6ffd-491a-88a7-91a0cd6ecd47" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2867f0b2-199e-47bf-91e2-eb30adf6c400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsSummarybySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_acb0ed39-6168-4a78-9b33-e9d60dc9fb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a1557562-2a7c-4e50-87ae-ff8e8d98ec7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_acb0ed39-6168-4a78-9b33-e9d60dc9fb0f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a1557562-2a7c-4e50-87ae-ff8e8d98ec7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c06eab52-7ea7-4410-9d0a-d7355c19b631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a1557562-2a7c-4e50-87ae-ff8e8d98ec7e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c06eab52-7ea7-4410-9d0a-d7355c19b631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c06eab52-7ea7-4410-9d0a-d7355c19b631" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cf8ab468-f43a-498c-a905-dc1e00c19148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_CommercialPaperMember_cf8ab468-f43a-498c-a905-dc1e00c19148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_f74a93ca-5854-46d1-b70d-622ece253498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_f74a93ca-5854-46d1-b70d-622ece253498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_61987d68-5f2c-4f40-b8bc-6badc11601d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_61987d68-5f2c-4f40-b8bc-6badc11601d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2db14830-bb0f-42f2-842d-e58a8b6b6e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_MunicipalBondsMember_2db14830-bb0f-42f2-842d-e58a8b6b6e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_9f1b7574-6b50-4ded-8c4f-fa6c403ac576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_CashMember_9f1b7574-6b50-4ded-8c4f-fa6c403ac576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b7d7b728-db1c-4f81-958e-fdfea61dcf7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b7d7b728-db1c-4f81-958e-fdfea61dcf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f5926c33-c6bc-4666-83e7-0ec4a62e7338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4989becb-a23f-46a6-8324-b86ca3e5b416" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f5926c33-c6bc-4666-83e7-0ec4a62e7338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_a1557562-2a7c-4e50-87ae-ff8e8d98ec7e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a1d967a2-1a7e-4e59-a374-9fa16750c2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a1d967a2-1a7e-4e59-a374-9fa16750c2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cb6d1dc7-ee49-4c00-acd1-3be77d695a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cb6d1dc7-ee49-4c00-acd1-3be77d695a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aabc6b4e-9a38-4747-8f4c-7b8d37fa79c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aabc6b4e-9a38-4747-8f4c-7b8d37fa79c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0494e7a7-2097-442c-8fad-9c9bdf5e7bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_d91cb794-0490-4349-9249-ab88af72966e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0494e7a7-2097-442c-8fad-9c9bdf5e7bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_e6c2fcce-f41d-41a7-ba2b-c95b4f54ecd6" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_e6c2fcce-f41d-41a7-ba2b-c95b4f54ecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_a9b711ed-2632-4195-8938-5c944ac46f7c" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_a9b711ed-2632-4195-8938-5c944ac46f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e1be027f-64ab-4ac5-bd98-e0acd241aea6" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_e1be027f-64ab-4ac5-bd98-e0acd241aea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_10aa16d9-fa55-4154-ad65-772d4c43f1d2" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_aad735d4-37b3-4d06-8b03-cbda10c057f0" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_10aa16d9-fa55-4154-ad65-772d4c43f1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_acfa6f78-5ea2-4c2b-8910-db89e9a01520" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_acfa6f78-5ea2-4c2b-8910-db89e9a01520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07ec2dc4-37d0-41a9-8eaa-509e8b52623d" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07ec2dc4-37d0-41a9-8eaa-509e8b52623d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f0b36ee-2e3d-4d76-ac23-810270933dc2" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f0b36ee-2e3d-4d76-ac23-810270933dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_095b8840-fcd7-46c1-8afe-f16e3d7ebd59" xlink:href="exel-20210101.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb962434-ebbe-4b40-815f-5d19fdb5e819" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_095b8840-fcd7-46c1-8afe-f16e3d7ebd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_18ac1ce3-e297-4c83-a76a-6bd5cfa614fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_685e3096-825a-4d1a-9425-97e2e859b619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_18ac1ce3-e297-4c83-a76a-6bd5cfa614fc" xlink:to="loc_us-gaap_InterestReceivable_685e3096-825a-4d1a-9425-97e2e859b619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f83c53e2-3a59-416f-b0dd-326783c3fe16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_18ac1ce3-e297-4c83-a76a-6bd5cfa614fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f83c53e2-3a59-416f-b0dd-326783c3fe16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d07400b0-6695-403a-a733-e18c6f8cfc12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_18ac1ce3-e297-4c83-a76a-6bd5cfa614fc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d07400b0-6695-403a-a733-e18c6f8cfc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsGrossUnrealizedLossesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8b786c32-531b-49b2-8698-8fa888df6100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2facf1b3-5d74-4ac5-be26-395192480119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8b786c32-531b-49b2-8698-8fa888df6100" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2facf1b3-5d74-4ac5-be26-395192480119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_721fc3fb-6d85-4ef7-9a6c-b5f597700a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2facf1b3-5d74-4ac5-be26-395192480119" xlink:to="loc_us-gaap_FinancialInstrumentAxis_721fc3fb-6d85-4ef7-9a6c-b5f597700a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_721fc3fb-6d85-4ef7-9a6c-b5f597700a99" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ce5233bf-ae4c-41e0-8f1a-67b8290deccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ce5233bf-ae4c-41e0-8f1a-67b8290deccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_3b8f704e-2c4a-4610-aa6a-409ff8250f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_3b8f704e-2c4a-4610-aa6a-409ff8250f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_d09d431e-3078-476b-876c-69d76b11ef6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bc9512d2-55e3-4b3b-9783-756231ef6c2d" xlink:to="loc_us-gaap_MunicipalBondsMember_d09d431e-3078-476b-876c-69d76b11ef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a05aa682-721d-4289-a9a3-7e2931c1b61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2facf1b3-5d74-4ac5-be26-395192480119" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a05aa682-721d-4289-a9a3-7e2931c1b61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_28dd97f9-2474-4543-a272-fb7321ae723d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a05aa682-721d-4289-a9a3-7e2931c1b61d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_28dd97f9-2474-4543-a272-fb7321ae723d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_899311fb-b6ce-4669-b0df-558b564357ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a05aa682-721d-4289-a9a3-7e2931c1b61d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_899311fb-b6ce-4669-b0df-558b564357ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CashandInvestmentsSummarybyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0042a97b-2c3e-4560-b6d2-6c390fb4b205" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_53f6a7cc-1b3f-444e-be97-587da1e0f778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0042a97b-2c3e-4560-b6d2-6c390fb4b205" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_53f6a7cc-1b3f-444e-be97-587da1e0f778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1fe9d348-7944-4087-a5d6-0df53b4baab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0042a97b-2c3e-4560-b6d2-6c390fb4b205" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1fe9d348-7944-4087-a5d6-0df53b4baab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b4bf9b97-b73f-4e72-9d60-9237f0901bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0042a97b-2c3e-4560-b6d2-6c390fb4b205" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b4bf9b97-b73f-4e72-9d60-9237f0901bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20210101.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7b7aba49-8a8e-49cc-b4c8-e80335521da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_42e82c14-3d98-48bf-acba-67a9d5c5985b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7b7aba49-8a8e-49cc-b4c8-e80335521da9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_42e82c14-3d98-48bf-acba-67a9d5c5985b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20210101.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bb53dfb7-8273-486b-a213-8ccc8c51c494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7573a3be-ed15-4888-a163-d086a02c61c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bb53dfb7-8273-486b-a213-8ccc8c51c494" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7573a3be-ed15-4888-a163-d086a02c61c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_15792ad5-787d-439f-8d87-0a7727623c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_15792ad5-787d-439f-8d87-0a7727623c35" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_112b1e11-bc98-48aa-9d76-ee237ee9b477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:to="loc_us-gaap_FinancialInstrumentAxis_112b1e11-bc98-48aa-9d76-ee237ee9b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_112b1e11-bc98-48aa-9d76-ee237ee9b477" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f39b7284-7f3d-4c06-8bf5-5d6588f77005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_CommercialPaperMember_f39b7284-7f3d-4c06-8bf5-5d6588f77005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_5570e008-3e33-4adc-81c6-5251b030a11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_5570e008-3e33-4adc-81c6-5251b030a11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_2a15e18c-5f6b-4608-b0d2-afcc4fce73db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_2a15e18c-5f6b-4608-b0d2-afcc4fce73db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_7ce007a5-ec80-4526-9bf8-ab7be424b1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_MunicipalBondsMember_7ce007a5-ec80-4526-9bf8-ab7be424b1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bc49dc7f-61f6-4889-b03b-5efd856e2678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bc49dc7f-61f6-4889-b03b-5efd856e2678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_5bd44d23-faf3-43b7-979f-d4174136b058" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_df593a9c-2c70-4f08-963c-aa3f1539e74d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_5bd44d23-faf3-43b7-979f-d4174136b058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cfbd751a-e01c-4e4a-b67f-10342b150d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cfbd751a-e01c-4e4a-b67f-10342b150d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9794b54-13d5-45e6-99d0-c9e7e00c39e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cfbd751a-e01c-4e4a-b67f-10342b150d4f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9794b54-13d5-45e6-99d0-c9e7e00c39e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5f85c000-53bb-444d-9cca-b37849f7c403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9794b54-13d5-45e6-99d0-c9e7e00c39e5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5f85c000-53bb-444d-9cca-b37849f7c403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_655887ed-ac07-4739-a03d-9bb98df26a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9794b54-13d5-45e6-99d0-c9e7e00c39e5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_655887ed-ac07-4739-a03d-9bb98df26a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0816c2af-bd03-4a66-ab1b-99b1a8de581f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0816c2af-bd03-4a66-ab1b-99b1a8de581f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fd66d4f5-e8c5-4c1b-95d0-5180d6f9cb9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0816c2af-bd03-4a66-ab1b-99b1a8de581f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fd66d4f5-e8c5-4c1b-95d0-5180d6f9cb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0af93358-b213-4dd1-87a8-bae702fb0cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_fd66d4f5-e8c5-4c1b-95d0-5180d6f9cb9e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0af93358-b213-4dd1-87a8-bae702fb0cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67cc8a2d-da6e-4e37-82e7-f092d814a615" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a3e897b-a2c7-4408-898a-9e9cdbaaed17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a3e897b-a2c7-4408-898a-9e9cdbaaed17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d850088f-5395-404f-9289-062ea5f5cb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d850088f-5395-404f-9289-062ea5f5cb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d43f2930-fbb8-4173-bbba-962ced60f86c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5e3257a9-4d43-4849-a58d-85e25eea5fd0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d43f2930-fbb8-4173-bbba-962ced60f86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20210101.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_119e8095-3ed6-4357-89aa-56f3f48df19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_5f36a329-ee17-42ff-bc33-58754a422089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_119e8095-3ed6-4357-89aa-56f3f48df19d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_5f36a329-ee17-42ff-bc33-58754a422089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20210101.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_275cdfa3-0513-4440-a95a-d0653e10721f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6e075a24-d9e6-4bcd-991a-f29ed520309e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_275cdfa3-0513-4440-a95a-d0653e10721f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6e075a24-d9e6-4bcd-991a-f29ed520309e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6fbc6fec-c60a-4f1a-a123-11c30b2ca46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_cc1b4f7c-d2a0-4a58-89f5-51b9c5806782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6fbc6fec-c60a-4f1a-a123-11c30b2ca46a" xlink:to="loc_us-gaap_InventoryCurrentTable_cc1b4f7c-d2a0-4a58-89f5-51b9c5806782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fc436f35-5662-4cf6-9afa-364c53eccaa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_cc1b4f7c-d2a0-4a58-89f5-51b9c5806782" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fc436f35-5662-4cf6-9afa-364c53eccaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f57ef8a9-5bb9-4c99-a680-bbf5b6ec205e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fc436f35-5662-4cf6-9afa-364c53eccaa2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f57ef8a9-5bb9-4c99-a680-bbf5b6ec205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_2911d3fb-459a-48d0-a42f-5d4de058f6d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f57ef8a9-5bb9-4c99-a680-bbf5b6ec205e" xlink:to="loc_us-gaap_InventoriesMember_2911d3fb-459a-48d0-a42f-5d4de058f6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_a020b6a0-3766-4560-8a11-1da36bfe6729" xlink:href="exel-20210101.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f57ef8a9-5bb9-4c99-a680-bbf5b6ec205e" xlink:to="loc_exel_OtherLongtermAssetsMember_a020b6a0-3766-4560-8a11-1da36bfe6729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_cc1b4f7c-d2a0-4a58-89f5-51b9c5806782" xlink:to="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_cde61fda-f25d-442e-b4ab-643ca5a15d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryRawMaterials_cde61fda-f25d-442e-b4ab-643ca5a15d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_aa8517de-fed6-4b32-9204-3ed8a8fbb226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryWorkInProcess_aa8517de-fed6-4b32-9204-3ed8a8fbb226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_fe5e204b-5d63-4fb4-a5f6-4000d842e8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryFinishedGoods_fe5e204b-5d63-4fb4-a5f6-4000d842e8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_63b18ae0-f8cd-4c58-862a-1089828a5098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryGross_63b18ae0-f8cd-4c58-862a-1089828a5098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_67bb7d24-ace4-45f2-b401-e4554e0c18a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_190f29ad-d1f2-4471-9132-0628ae57bf56" xlink:to="loc_us-gaap_InventoryWriteDown_67bb7d24-ace4-45f2-b401-e4554e0c18a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8db1917a-a087-469e-ba81-2403a8f3745e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4d246152-7aba-40dd-b41f-f2d5a85e24e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8db1917a-a087-469e-ba81-2403a8f3745e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4d246152-7aba-40dd-b41f-f2d5a85e24e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b20880c9-e0d2-4dee-a05f-88aab3b2d67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1a007cda-3aab-45c2-bc07-9dae4cceeccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b20880c9-e0d2-4dee-a05f-88aab3b2d67b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1a007cda-3aab-45c2-bc07-9dae4cceeccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75060eb5-6e06-421c-bbb7-ba5b5ea2a610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6be43199-32c9-4c55-b5a9-2c1c928bebe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_75060eb5-6e06-421c-bbb7-ba5b5ea2a610" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6be43199-32c9-4c55-b5a9-2c1c928bebe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_864631f3-2e17-4195-a7b7-0857cf35b942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6be43199-32c9-4c55-b5a9-2c1c928bebe7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_864631f3-2e17-4195-a7b7-0857cf35b942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_864631f3-2e17-4195-a7b7-0857cf35b942" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0f3e4310-6d48-40f1-bd43-5d4459ba8913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0f3e4310-6d48-40f1-bd43-5d4459ba8913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_9a831f36-32cb-4304-b271-6f88f6417066" xlink:href="exel-20210101.xsd#exel_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_9a831f36-32cb-4304-b271-6f88f6417066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2622658d-0cff-464a-871c-a6f93f78795b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2622658d-0cff-464a-871c-a6f93f78795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LaboratoryEquipmentMember_d393fef5-dd40-4df9-b69b-a95350dcee49" xlink:href="exel-20210101.xsd#exel_LaboratoryEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_exel_LaboratoryEquipmentMember_d393fef5-dd40-4df9-b69b-a95350dcee49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_0e1f98a8-af2b-4a67-9ed5-784784be50f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4709642e-dbe0-463a-b52c-7ffc8ff0a3de" xlink:to="loc_us-gaap_ConstructionInProgressMember_0e1f98a8-af2b-4a67-9ed5-784784be50f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6be43199-32c9-4c55-b5a9-2c1c928bebe7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0d03ad46-b58c-44fe-b8f9-e2447b3e70a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0d03ad46-b58c-44fe-b8f9-e2447b3e70a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_138346f8-81d7-4628-a677-6ceca682718a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_138346f8-81d7-4628-a677-6ceca682718a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0931d411-b137-4d05-a45a-dca14d616891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0931d411-b137-4d05-a45a-dca14d616891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_70032315-ee1b-4b87-ae14-b40c2b8b7285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e2920273-4444-4a60-af28-b1fb34a40a56" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_70032315-ee1b-4b87-ae14-b40c2b8b7285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b264f457-f4b7-4a04-9776-bf11019d0f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_614e9ceb-59c2-48d3-854f-6f4c1aa351da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b264f457-f4b7-4a04-9776-bf11019d0f1a" xlink:to="loc_us-gaap_Depreciation_614e9ceb-59c2-48d3-854f-6f4c1aa351da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46d6a43c-9bc7-438c-979c-c8283f082eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7ebc3493-2d44-4ea8-b61e-61976475d268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46d6a43c-9bc7-438c-979c-c8283f082eaf" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7ebc3493-2d44-4ea8-b61e-61976475d268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54984f1f-7be1-453e-8d9a-0642bf0c90c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c011e075-a199-466b-8f73-06f955d82eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54984f1f-7be1-453e-8d9a-0642bf0c90c7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c011e075-a199-466b-8f73-06f955d82eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_6491b035-ba07-4a29-8cea-7494527eb7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54984f1f-7be1-453e-8d9a-0642bf0c90c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_6491b035-ba07-4a29-8cea-7494527eb7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6c472317-b10d-4c2c-a2d3-ab0b049dad4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54984f1f-7be1-453e-8d9a-0642bf0c90c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6c472317-b10d-4c2c-a2d3-ab0b049dad4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_f2cc9c00-a9b7-4c9f-b379-d90c38533f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54984f1f-7be1-453e-8d9a-0642bf0c90c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_f2cc9c00-a9b7-4c9f-b379-d90c38533f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f5dc7193-c83a-4792-b29d-5f437dc62639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54984f1f-7be1-453e-8d9a-0642bf0c90c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f5dc7193-c83a-4792-b29d-5f437dc62639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_9b9872e1-ccf7-4dbc-9774-efef19d283ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54984f1f-7be1-453e-8d9a-0642bf0c90c7" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_9b9872e1-ccf7-4dbc-9774-efef19d283ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f634ed1-c1a6-4bb6-9f59-bf069debe5d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_87e09168-1372-4d63-b575-9e6a6258741b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f634ed1-c1a6-4bb6-9f59-bf069debe5d3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_87e09168-1372-4d63-b575-9e6a6258741b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_966649e0-dcca-4fdd-a993-ff1c31dc4f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_87e09168-1372-4d63-b575-9e6a6258741b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_966649e0-dcca-4fdd-a993-ff1c31dc4f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9c6c5ad8-b8e9-4ea7-8750-36b94594ae13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_966649e0-dcca-4fdd-a993-ff1c31dc4f55" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9c6c5ad8-b8e9-4ea7-8750-36b94594ae13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b72b14d6-4430-40ae-abc4-8e24ec9593e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c6c5ad8-b8e9-4ea7-8750-36b94594ae13" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b72b14d6-4430-40ae-abc4-8e24ec9593e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4f23f293-c0d5-4f13-9518-af53389e46c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c6c5ad8-b8e9-4ea7-8750-36b94594ae13" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4f23f293-c0d5-4f13-9518-af53389e46c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2fd03e7a-7f56-4a92-8a46-9ee0844035c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_87e09168-1372-4d63-b575-9e6a6258741b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2fd03e7a-7f56-4a92-8a46-9ee0844035c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1026907-431f-40a4-848c-55a3f4ffa4b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2fd03e7a-7f56-4a92-8a46-9ee0844035c3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f1026907-431f-40a4-848c-55a3f4ffa4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd602bad-cf92-45cd-a9bc-75d932ab7b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4b79fe53-7156-47d5-b305-936e269ed5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bd602bad-cf92-45cd-a9bc-75d932ab7b0b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4b79fe53-7156-47d5-b305-936e269ed5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3fe8c44d-e618-4410-a785-ae2f8f40dddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4b79fe53-7156-47d5-b305-936e269ed5c5" xlink:to="loc_us-gaap_AwardTypeAxis_3fe8c44d-e618-4410-a785-ae2f8f40dddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3fe8c44d-e618-4410-a785-ae2f8f40dddd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bd03919a-77c2-4614-97dc-6f86dac79064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bd03919a-77c2-4614-97dc-6f86dac79064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d1c702d8-d76e-4bc2-ace4-abd623f93fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d1c702d8-d76e-4bc2-ace4-abd623f93fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3242c14c-afa4-44ea-9e93-7ea672fda8c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:to="loc_us-gaap_PerformanceSharesMember_3242c14c-afa4-44ea-9e93-7ea672fda8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6b419911-b9d0-458e-b304-30d4e3e34760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d455c3-f621-4f52-b269-6757e9ae79eb" xlink:to="loc_us-gaap_EmployeeStockMember_6b419911-b9d0-458e-b304-30d4e3e34760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9af0334-0d38-40fe-940f-d633fd79e1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4b79fe53-7156-47d5-b305-936e269ed5c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9af0334-0d38-40fe-940f-d633fd79e1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f0d74f41-014a-4ba8-a1b8-06e7659ce5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b9af0334-0d38-40fe-940f-d633fd79e1d6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f0d74f41-014a-4ba8-a1b8-06e7659ce5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9d183a2-7de5-46f3-a920-d7b18bc4b2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9d183a2-7de5-46f3-a920-d7b18bc4b2f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_028edc9f-c3fa-451e-98da-2cb7ce0c3a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:to="loc_us-gaap_AwardTypeAxis_028edc9f-c3fa-451e-98da-2cb7ce0c3a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_028edc9f-c3fa-451e-98da-2cb7ce0c3a7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f557fcb9-e3ee-4272-a003-8628042a73b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f557fcb9-e3ee-4272-a003-8628042a73b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8a54c314-771e-4d0d-b863-e53517e6abfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8a54c314-771e-4d0d-b863-e53517e6abfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f75bea30-7b58-4a6c-a636-94bf0789ebc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_us-gaap_EmployeeStockMember_f75bea30-7b58-4a6c-a636-94bf0789ebc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_23917d99-3360-41b2-b538-3a1a3774b794" xlink:href="exel-20210101.xsd#exel_PerformanceShareOptionsPSOMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_23917d99-3360-41b2-b538-3a1a3774b794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_455fff7a-af54-438b-bccf-6f335292e3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_us-gaap_PerformanceSharesMember_455fff7a-af54-438b-bccf-6f335292e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesClinicalTrialResultsMember_5fc4b424-eeb6-4566-af58-d80d418a7ba4" xlink:href="exel-20210101.xsd#exel_PerformanceSharesClinicalTrialResultsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_exel_PerformanceSharesClinicalTrialResultsMember_5fc4b424-eeb6-4566-af58-d80d418a7ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_30bc1a8b-47c5-454f-9d12-f5b07e31940c" xlink:href="exel-20210101.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_30bc1a8b-47c5-454f-9d12-f5b07e31940c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member_155c3e7a-1ed3-4cdb-80df-a0a0f9ff222d" xlink:href="exel-20210101.xsd#exel_PerformanceSharesAchievedBeforeDecember312021Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39b6f716-872b-43df-a455-22bcf4384c86" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312021Member_155c3e7a-1ed3-4cdb-80df-a0a0f9ff222d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_3a75c4bf-f702-4b1e-baeb-8360aab220ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:to="loc_us-gaap_GranteeStatusAxis_3a75c4bf-f702-4b1e-baeb-8360aab220ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_699972cb-a8c8-45cd-98fc-d138144e434d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_3a75c4bf-f702-4b1e-baeb-8360aab220ad" xlink:to="loc_us-gaap_GranteeStatusDomain_699972cb-a8c8-45cd-98fc-d138144e434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_e64915d7-b35e-4d48-bddd-239f4d2db32e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_699972cb-a8c8-45cd-98fc-d138144e434d" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_e64915d7-b35e-4d48-bddd-239f4d2db32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d21a3e9c-bb8b-455b-9a92-656e6fdf192c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_699972cb-a8c8-45cd-98fc-d138144e434d" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d21a3e9c-bb8b-455b-9a92-656e6fdf192c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusAxis_ef61b350-0d6d-429f-8fc7-db41816bc5da" xlink:href="exel-20210101.xsd#exel_StatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:to="loc_exel_StatusAxis_ef61b350-0d6d-429f-8fc7-db41816bc5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:href="exel-20210101.xsd#exel_StatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_ef61b350-0d6d-429f-8fc7-db41816bc5da" xlink:to="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AchievedMember_2a76f5c4-45c5-4c97-84c5-1a0c1adcbc2c" xlink:href="exel-20210101.xsd#exel_AchievedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:to="loc_exel_AchievedMember_2a76f5c4-45c5-4c97-84c5-1a0c1adcbc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProbableMember_3216a210-4e25-4f40-bb8a-8507509f9233" xlink:href="exel-20210101.xsd#exel_ProbableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:to="loc_exel_ProbableMember_3216a210-4e25-4f40-bb8a-8507509f9233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NotProbableMember_6c872e6d-e0bd-4de6-9151-0e267d30acea" xlink:href="exel-20210101.xsd#exel_NotProbableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_6a3de31f-361d-495f-bac3-b1e8abfedba6" xlink:to="loc_exel_NotProbableMember_6c872e6d-e0bd-4de6-9151-0e267d30acea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab6ec294-11c7-406c-8781-0df2c81b5f72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b312f38b-b43e-485c-9717-2490c5a6abb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b312f38b-b43e-485c-9717-2490c5a6abb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_2b0907ea-134c-4b73-8da0-6d06912a548a" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_2b0907ea-134c-4b73-8da0-6d06912a548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_aeba09dc-bd23-4ee2-be24-82b75ef8aa19" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_aeba09dc-bd23-4ee2-be24-82b75ef8aa19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f3a6e929-f0d4-4ba2-8a93-add2c0636c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f3a6e929-f0d4-4ba2-8a93-add2c0636c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19804043-239f-444e-916a-28bc3e9227f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19804043-239f-444e-916a-28bc3e9227f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fea6b3fe-c099-4f21-aa68-9bdd7e941a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fea6b3fe-c099-4f21-aa68-9bdd7e941a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_334ec582-cef4-4851-a0ab-5e41c0cccbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_334ec582-cef4-4851-a0ab-5e41c0cccbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_28db1e4d-f122-435f-99de-e508e54f9032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_28db1e4d-f122-435f-99de-e508e54f9032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_a23ecf69-8324-420f-a9bc-e97f4b7d6f78" xlink:href="exel-20210101.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_a23ecf69-8324-420f-a9bc-e97f4b7d6f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_80e279b2-79ce-4e03-835d-c18297ce0f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_80e279b2-79ce-4e03-835d-c18297ce0f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d7c52526-34b6-48dc-974b-1cd322ee2636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_d7c52526-34b6-48dc-974b-1cd322ee2636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_5ebe5cb2-468e-4768-b8e2-a417f0f684b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_5ebe5cb2-468e-4768-b8e2-a417f0f684b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_5712d44e-4e75-4788-9e6f-cc722c1f8975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ProceedsFromStockPlans_5712d44e-4e75-4788-9e6f-cc722c1f8975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a7b61bea-28f4-4eaf-a463-d144bf113bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a7b61bea-28f4-4eaf-a463-d144bf113bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2e176af5-f3a8-4ab6-8fb5-466736d5f0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2e176af5-f3a8-4ab6-8fb5-466736d5f0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29316c9f-11d6-4833-969b-a2f4907c9544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29316c9f-11d6-4833-969b-a2f4907c9544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_b9cdc9ea-3521-443c-8c44-bec2e6ff8477" xlink:href="exel-20210101.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_b9cdc9ea-3521-443c-8c44-bec2e6ff8477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b878011c-6d02-4ea0-99be-e6228e18c743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b878011c-6d02-4ea0-99be-e6228e18c743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ba9888cc-f422-4ae5-94da-8fe903f51a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ba9888cc-f422-4ae5-94da-8fe903f51a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a1801e99-c425-4617-b209-200b149f2e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a1801e99-c425-4617-b209-200b149f2e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_c9698412-053a-4a37-ae53-9240aba1cf0b" xlink:href="exel-20210101.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_c9698412-053a-4a37-ae53-9240aba1cf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_972eac25-e9c1-4bd7-925a-dbada8767662" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_972eac25-e9c1-4bd7-925a-dbada8767662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_103222c0-d757-4813-8c91-e231475db7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_103222c0-d757-4813-8c91-e231475db7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_dd4cc856-d21b-4dbf-8339-02c25644db0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7a6172f1-c938-488d-aae7-f8e4850abb0b" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_dd4cc856-d21b-4dbf-8339-02c25644db0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01868ff5-1b91-4194-90cb-26c4ae92fba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a29bd0d6-ea7e-459e-8eba-55cfa8ec7ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01868ff5-1b91-4194-90cb-26c4ae92fba6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a29bd0d6-ea7e-459e-8eba-55cfa8ec7ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca64da0e-2180-4ab3-8cd8-ecd576533532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a29bd0d6-ea7e-459e-8eba-55cfa8ec7ee0" xlink:to="loc_us-gaap_AwardTypeAxis_ca64da0e-2180-4ab3-8cd8-ecd576533532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4941bb07-e754-4507-ad17-a94a220c09d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ca64da0e-2180-4ab3-8cd8-ecd576533532" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4941bb07-e754-4507-ad17-a94a220c09d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b00904c9-6feb-47fb-8cc5-b9eb13313a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4941bb07-e754-4507-ad17-a94a220c09d0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b00904c9-6feb-47fb-8cc5-b9eb13313a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_204db885-bb56-4785-8126-3eed2ed15223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4941bb07-e754-4507-ad17-a94a220c09d0" xlink:to="loc_us-gaap_EmployeeStockMember_204db885-bb56-4785-8126-3eed2ed15223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4c331f5-31d2-4a5d-a932-e5720d612ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a29bd0d6-ea7e-459e-8eba-55cfa8ec7ee0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4c331f5-31d2-4a5d-a932-e5720d612ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_464c66c4-194c-4855-a61e-2898a2317605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4c331f5-31d2-4a5d-a932-e5720d612ab0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_464c66c4-194c-4855-a61e-2898a2317605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59d5188f-33b6-4fb3-96da-1c76f950e770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54183360-1eb9-4116-92d1-12a06aad9a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59d5188f-33b6-4fb3-96da-1c76f950e770" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54183360-1eb9-4116-92d1-12a06aad9a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_758a69a3-6cda-4efc-bcfc-e5c6a4ad95a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54183360-1eb9-4116-92d1-12a06aad9a39" xlink:to="loc_us-gaap_AwardTypeAxis_758a69a3-6cda-4efc-bcfc-e5c6a4ad95a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f52343d-c628-4e61-9718-8458f4b91093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_758a69a3-6cda-4efc-bcfc-e5c6a4ad95a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f52343d-c628-4e61-9718-8458f4b91093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1c850db4-d2cb-4277-980b-22bd3cfb4aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f52343d-c628-4e61-9718-8458f4b91093" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1c850db4-d2cb-4277-980b-22bd3cfb4aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_67ff9f3e-352d-47a6-a78f-cb437c61e84c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f52343d-c628-4e61-9718-8458f4b91093" xlink:to="loc_us-gaap_EmployeeStockMember_67ff9f3e-352d-47a6-a78f-cb437c61e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54183360-1eb9-4116-92d1-12a06aad9a39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8defeae3-2c32-4663-bf73-3976ad006b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8defeae3-2c32-4663-bf73-3976ad006b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2acf07ce-332e-44fd-9a5c-dd623ec657b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2acf07ce-332e-44fd-9a5c-dd623ec657b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_a0a623e3-f30d-4fb6-a7d0-6b447620dafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_a0a623e3-f30d-4fb6-a7d0-6b447620dafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9fefd57-557b-4b53-95c8-1bf949392689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39572f1c-2608-4081-aee1-61b88b8fdea2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9fefd57-557b-4b53-95c8-1bf949392689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6c06ff3-6942-4e7c-ad7b-4120fcc7c786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fad41204-8fff-4662-ae1c-92eaccdf6b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6c06ff3-6942-4e7c-ad7b-4120fcc7c786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fad41204-8fff-4662-ae1c-92eaccdf6b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dfb288c5-3775-4148-ad88-e4dd682f523d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fad41204-8fff-4662-ae1c-92eaccdf6b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dfb288c5-3775-4148-ad88-e4dd682f523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3c8bffb4-a2d9-4a3a-affe-536fa511aa3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fad41204-8fff-4662-ae1c-92eaccdf6b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3c8bffb4-a2d9-4a3a-affe-536fa511aa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f5c61222-34aa-41ba-b17c-6697075d7702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fad41204-8fff-4662-ae1c-92eaccdf6b0c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f5c61222-34aa-41ba-b17c-6697075d7702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1e207b07-8733-41f8-8b47-a79d6544bc73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fad41204-8fff-4662-ae1c-92eaccdf6b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1e207b07-8733-41f8-8b47-a79d6544bc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a86e8a1-2917-43b6-87b7-41d65f3927e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fad41204-8fff-4662-ae1c-92eaccdf6b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a86e8a1-2917-43b6-87b7-41d65f3927e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e5967055-5c67-4549-bec4-35cbae5a4758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6c06ff3-6942-4e7c-ad7b-4120fcc7c786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e5967055-5c67-4549-bec4-35cbae5a4758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2c8eea9-389e-4906-a352-3d70dcdf1b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6c06ff3-6942-4e7c-ad7b-4120fcc7c786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2c8eea9-389e-4906-a352-3d70dcdf1b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c4ab8ed5-36f2-48ed-a9de-5c9cbe86e534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2c8eea9-389e-4906-a352-3d70dcdf1b52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c4ab8ed5-36f2-48ed-a9de-5c9cbe86e534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d038fd9b-c530-4373-abd8-ebdeec54d3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2c8eea9-389e-4906-a352-3d70dcdf1b52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d038fd9b-c530-4373-abd8-ebdeec54d3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_57c41d81-9a9d-4fc1-88d1-bb80a9b820c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2c8eea9-389e-4906-a352-3d70dcdf1b52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_57c41d81-9a9d-4fc1-88d1-bb80a9b820c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_02077b6d-cf5c-4e15-a611-e61878ba6aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2c8eea9-389e-4906-a352-3d70dcdf1b52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_02077b6d-cf5c-4e15-a611-e61878ba6aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e91b50f0-5ce2-4650-b700-5021048d4cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b2c8eea9-389e-4906-a352-3d70dcdf1b52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e91b50f0-5ce2-4650-b700-5021048d4cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a22b49b3-d248-4f52-a19f-35143e6303f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6c06ff3-6942-4e7c-ad7b-4120fcc7c786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a22b49b3-d248-4f52-a19f-35143e6303f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9469cb66-6a66-4998-a55d-a38a6bba4fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6c06ff3-6942-4e7c-ad7b-4120fcc7c786" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9469cb66-6a66-4998-a55d-a38a6bba4fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4a3cce36-66d8-44f9-b3ad-f6ea5ff24396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6c06ff3-6942-4e7c-ad7b-4120fcc7c786" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4a3cce36-66d8-44f9-b3ad-f6ea5ff24396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_64144dc0-3052-4bc3-8d29-6781de28565e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6c06ff3-6942-4e7c-ad7b-4120fcc7c786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_64144dc0-3052-4bc3-8d29-6781de28565e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_25dbfe00-a093-4e30-9230-82710c9e4e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6c06ff3-6942-4e7c-ad7b-4120fcc7c786" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_25dbfe00-a093-4e30-9230-82710c9e4e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed02aa56-08ef-49e3-bbf5-1cd102fb3839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84879db2-040c-4e40-8c00-163b6bb66069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed02aa56-08ef-49e3-bbf5-1cd102fb3839" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84879db2-040c-4e40-8c00-163b6bb66069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c97767e7-7ad7-4774-be17-10185aa77f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84879db2-040c-4e40-8c00-163b6bb66069" xlink:to="loc_us-gaap_AwardTypeAxis_c97767e7-7ad7-4774-be17-10185aa77f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda67431-7879-4683-a973-8201fc3ad410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c97767e7-7ad7-4774-be17-10185aa77f34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda67431-7879-4683-a973-8201fc3ad410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_826d5f67-eefd-4321-9d04-4d4b84910639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda67431-7879-4683-a973-8201fc3ad410" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_826d5f67-eefd-4321-9d04-4d4b84910639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6f2203b9-97d5-40e0-83e7-e63123c6107b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda67431-7879-4683-a973-8201fc3ad410" xlink:to="loc_us-gaap_PerformanceSharesMember_6f2203b9-97d5-40e0-83e7-e63123c6107b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84879db2-040c-4e40-8c00-163b6bb66069" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83df1afa-df4b-46f3-89ac-efc9a091487b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83df1afa-df4b-46f3-89ac-efc9a091487b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f31896c7-4bff-4fd3-ace8-d195312d7c76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f31896c7-4bff-4fd3-ace8-d195312d7c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_78030ae3-7f96-408d-b3b0-0e63f1015731" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_78030ae3-7f96-408d-b3b0-0e63f1015731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0f8170f0-41c4-4892-812b-1b05c9ce2248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0f8170f0-41c4-4892-812b-1b05c9ce2248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45734973-fce9-4428-b788-8ee3ae13c186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f2da25c8-f451-4016-bd5e-9216c067589a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_45734973-fce9-4428-b788-8ee3ae13c186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4fee2f18-98e5-4cba-91f6-60e8c4028735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4fee2f18-98e5-4cba-91f6-60e8c4028735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7addd1b6-fe1c-4a37-868a-53c74695e0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7addd1b6-fe1c-4a37-868a-53c74695e0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_c0713dc9-7021-4a65-9cf6-d5f350e6eb46" xlink:href="exel-20210101.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_c0713dc9-7021-4a65-9cf6-d5f350e6eb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4519306f-ebfc-4acd-af00-60bfe07fbd6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4519306f-ebfc-4acd-af00-60bfe07fbd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05312408-4abf-4220-b852-e448ddb88edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8515b9d-0e05-4e0b-8970-6b2ef1ac38ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05312408-4abf-4220-b852-e448ddb88edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_92ab41dc-9bca-49da-892d-c64ef2987b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_92ab41dc-9bca-49da-892d-c64ef2987b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_528b6fad-f678-449b-b8e2-750c097b8666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2dbb88bf-73fb-4919-b4c3-ac5466bbbfe0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_528b6fad-f678-449b-b8e2-750c097b8666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b94cf9b7-66c1-4813-80cf-5d9de18605db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_37eeba17-099a-4537-bf63-1cf3612e380a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b94cf9b7-66c1-4813-80cf-5d9de18605db" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_37eeba17-099a-4537-bf63-1cf3612e380a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c79b5074-7f4e-4382-a6ca-4adf925e55bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b090f927-1c63-4253-912b-1c7a5a59d92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c79b5074-7f4e-4382-a6ca-4adf925e55bb" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b090f927-1c63-4253-912b-1c7a5a59d92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4e17ccdf-957c-43bf-9d1c-365b3d39041a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c79b5074-7f4e-4382-a6ca-4adf925e55bb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4e17ccdf-957c-43bf-9d1c-365b3d39041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9cade610-7aae-414e-b429-5c981078a345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c79b5074-7f4e-4382-a6ca-4adf925e55bb" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9cade610-7aae-414e-b429-5c981078a345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b5bc8c5b-daec-4b2f-b58e-af961f54015d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c79b5074-7f4e-4382-a6ca-4adf925e55bb" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b5bc8c5b-daec-4b2f-b58e-af961f54015d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_080750f0-ce25-4352-bc0c-65bdc238823f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_348d6838-6fa6-41ca-b8dd-56356320dca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_080750f0-ce25-4352-bc0c-65bdc238823f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_348d6838-6fa6-41ca-b8dd-56356320dca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_17a07d85-23d0-43e6-bc6e-169159d1866e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_348d6838-6fa6-41ca-b8dd-56356320dca6" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_17a07d85-23d0-43e6-bc6e-169159d1866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1e1f912a-b2eb-4b35-8309-cb63ca9f598a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_348d6838-6fa6-41ca-b8dd-56356320dca6" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1e1f912a-b2eb-4b35-8309-cb63ca9f598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_725b7db9-6416-4d9c-8cf2-1b8d3882b3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_348d6838-6fa6-41ca-b8dd-56356320dca6" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_725b7db9-6416-4d9c-8cf2-1b8d3882b3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f848ea00-f1e8-465b-b3f4-2ca0a9b331e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_080750f0-ce25-4352-bc0c-65bdc238823f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f848ea00-f1e8-465b-b3f4-2ca0a9b331e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_48e74c15-0625-4fbe-8596-29d0e9e20baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f848ea00-f1e8-465b-b3f4-2ca0a9b331e0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_48e74c15-0625-4fbe-8596-29d0e9e20baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_58b30c5e-921a-46c1-a484-43cf9dd22017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f848ea00-f1e8-465b-b3f4-2ca0a9b331e0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_58b30c5e-921a-46c1-a484-43cf9dd22017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_76674e91-bad9-4bd0-8617-0d224fe24290" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f848ea00-f1e8-465b-b3f4-2ca0a9b331e0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_76674e91-bad9-4bd0-8617-0d224fe24290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_30ff8472-8025-410a-a399-101a583c751a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_080750f0-ce25-4352-bc0c-65bdc238823f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_30ff8472-8025-410a-a399-101a583c751a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8efb110b-85d3-4bb0-84ba-91fd2fdb5a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8efb110b-85d3-4bb0-84ba-91fd2fdb5a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d58ece03-67a5-4c76-b422-1f16bf158c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d58ece03-67a5-4c76-b422-1f16bf158c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f7366480-2eac-4550-abd8-6b33156cb449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f7366480-2eac-4550-abd8-6b33156cb449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_33526c25-4a3e-4582-89cc-ef2cc48c38c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_33526c25-4a3e-4582-89cc-ef2cc48c38c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2f987998-8ebf-4bd7-994c-05987e83aaba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2f987998-8ebf-4bd7-994c-05987e83aaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_87ef8498-c849-41cb-a5ac-b848ff4b4feb" xlink:href="exel-20210101.xsd#exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation_87ef8498-c849-41cb-a5ac-b848ff4b4feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_07f3ec66-3b19-479e-953c-c8555182ab98" xlink:href="exel-20210101.xsd#exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee_07f3ec66-3b19-479e-953c-c8555182ab98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_568b7f72-f6cd-43ce-b5d5-5d0b4ce38c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_568b7f72-f6cd-43ce-b5d5-5d0b4ce38c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ad6d7805-5fd6-4a8a-b238-e24ad1ec2e5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d981e01-f456-4f64-b612-03bc205ce579" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ad6d7805-5fd6-4a8a-b238-e24ad1ec2e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5d7357b7-0e8b-4c9f-b90e-1acdfe2fc2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d7357b7-0e8b-4c9f-b90e-1acdfe2fc2be" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b83be85-59db-4c4a-85b7-77a06d34fe06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b83be85-59db-4c4a-85b7-77a06d34fe06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f5b733cb-92a0-4226-a1fe-b8bffc2537f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f5b733cb-92a0-4226-a1fe-b8bffc2537f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_64e610a4-d145-4b36-990a-ee1ca6f13750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_64e610a4-d145-4b36-990a-ee1ca6f13750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_883da10e-d339-4d5e-8ae3-ea13bfe95e0e" xlink:href="exel-20210101.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_883da10e-d339-4d5e-8ae3-ea13bfe95e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxAssetsLeaseLiabilities_b1ce39a2-a11e-4888-a284-23244448ac63" xlink:href="exel-20210101.xsd#exel_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_exel_DeferredTaxAssetsLeaseLiabilities_b1ce39a2-a11e-4888-a284-23244448ac63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_e73b8601-9b8b-4890-abf9-a0050bfcb8a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_e73b8601-9b8b-4890-abf9-a0050bfcb8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_616cec44-834b-499f-abc7-fe1c11a86966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_616cec44-834b-499f-abc7-fe1c11a86966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_27613305-a7ec-4c5d-8513-dde1a1302c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_27613305-a7ec-4c5d-8513-dde1a1302c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e5a57ae9-99a2-4fd9-ba77-efc2b49a6f69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e5a57ae9-99a2-4fd9-ba77-efc2b49a6f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2377b5df-c28b-4a3b-9324-b7cdedb07e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2377b5df-c28b-4a3b-9324-b7cdedb07e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_88ba9408-a77c-4502-819c-102a501c50cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0ecae21c-e710-41d6-8adb-c3ac426c56a4" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_88ba9408-a77c-4502-819c-102a501c50cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_d8e8361c-c79b-4361-b05c-998d548a8f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d7357b7-0e8b-4c9f-b90e-1acdfe2fc2be" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_d8e8361c-c79b-4361-b05c-998d548a8f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_c779c019-ceeb-4e8c-9b70-278219e2cbb1" xlink:href="exel-20210101.xsd#exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_d8e8361c-c79b-4361-b05c-998d548a8f73" xlink:to="loc_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets_c779c019-ceeb-4e8c-9b70-278219e2cbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_5d86fbc6-57dc-4a7b-a684-7f63cbf14b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_d8e8361c-c79b-4361-b05c-998d548a8f73" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_5d86fbc6-57dc-4a7b-a684-7f63cbf14b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_3125086c-4bec-456a-a2e0-58799e1d25e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_d8e8361c-c79b-4361-b05c-998d548a8f73" xlink:to="loc_us-gaap_DeferredTaxLiabilities_3125086c-4bec-456a-a2e0-58799e1d25e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6d48a32a-af78-494b-8226-54b220144416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d7357b7-0e8b-4c9f-b90e-1acdfe2fc2be" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6d48a32a-af78-494b-8226-54b220144416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_646318f7-a421-4c25-a9ef-0bfe76462755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_d1552e0c-6179-42ea-80f3-0e7398e6ed8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_646318f7-a421-4c25-a9ef-0bfe76462755" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_d1552e0c-6179-42ea-80f3-0e7398e6ed8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_ab17d43d-2284-4dd7-828f-4ca8326cff12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_d1552e0c-6179-42ea-80f3-0e7398e6ed8a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_ab17d43d-2284-4dd7-828f-4ca8326cff12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0269abc4-3a2e-4db9-874d-5d26a888403d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_ab17d43d-2284-4dd7-828f-4ca8326cff12" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0269abc4-3a2e-4db9-874d-5d26a888403d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_27258fb3-b372-4705-a6e8-ac6b305d180b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0269abc4-3a2e-4db9-874d-5d26a888403d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_27258fb3-b372-4705-a6e8-ac6b305d180b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0601d6b0-3aa6-401e-8fc7-007132ef4f31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0269abc4-3a2e-4db9-874d-5d26a888403d" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0601d6b0-3aa6-401e-8fc7-007132ef4f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_257abaf9-af0e-43c6-b19e-6acfcc819e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_d1552e0c-6179-42ea-80f3-0e7398e6ed8a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_257abaf9-af0e-43c6-b19e-6acfcc819e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f1477c38-156d-4358-8a57-792786554ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_257abaf9-af0e-43c6-b19e-6acfcc819e2e" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f1477c38-156d-4358-8a57-792786554ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_43b83e84-dce0-4c11-b87a-794f3c2d4d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f1477c38-156d-4358-8a57-792786554ba6" xlink:to="loc_us-gaap_ResearchMember_43b83e84-dce0-4c11-b87a-794f3c2d4d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_d1552e0c-6179-42ea-80f3-0e7398e6ed8a" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_10a72885-de4d-4fe1-8318-e4653db18d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_10a72885-de4d-4fe1-8318-e4653db18d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_efde9240-7851-4af9-afac-2ee5767867dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_efde9240-7851-4af9-afac-2ee5767867dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3a19460c-b458-4b13-8712-7d27139e2a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3a19460c-b458-4b13-8712-7d27139e2a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_accc8974-63d6-4306-8c63-17d4d47761ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_accc8974-63d6-4306-8c63-17d4d47761ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_3487ddfe-846d-49fb-a2d9-d9a2230ade3f" xlink:href="exel-20210101.xsd#exel_TaxCreditCarryforwardAmountWithExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_exel_TaxCreditCarryforwardAmountWithExpirationPeriod_3487ddfe-846d-49fb-a2d9-d9a2230ade3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8db96b5f-3250-4f6f-98d8-8359055522ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8db96b5f-3250-4f6f-98d8-8359055522ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a203e3b2-0a7c-460c-a1cb-4a561f46eb15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_68148c84-c620-46e4-83a5-d1fce454eca5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a203e3b2-0a7c-460c-a1cb-4a561f46eb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c1b4a729-dd33-40d9-a2e7-0fb0d1e8e2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9df7be63-bf49-4a5d-8877-087a480ed424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1b4a729-dd33-40d9-a2e7-0fb0d1e8e2d6" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9df7be63-bf49-4a5d-8877-087a480ed424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_04918235-5a43-4e8a-a81e-f7543752b342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9df7be63-bf49-4a5d-8877-087a480ed424" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_04918235-5a43-4e8a-a81e-f7543752b342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_883bc572-9379-442f-893c-0fd606681842" xlink:href="exel-20210101.xsd#exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9df7be63-bf49-4a5d-8877-087a480ed424" xlink:to="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_883bc572-9379-442f-893c-0fd606681842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2285317e-87b9-4b90-92a3-90828b585c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9df7be63-bf49-4a5d-8877-087a480ed424" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2285317e-87b9-4b90-92a3-90828b585c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_c02e1243-8cdc-43b6-99bf-f87157d015d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9df7be63-bf49-4a5d-8877-087a480ed424" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_c02e1243-8cdc-43b6-99bf-f87157d015d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7cc03760-0dc3-48cb-aade-c4ce4ee31c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_9df7be63-bf49-4a5d-8877-087a480ed424" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7cc03760-0dc3-48cb-aade-c4ce4ee31c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0e09a025-adde-4d92-8d73-a1e62200444b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2e3730df-423d-4162-8a0d-0ee129c39f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0e09a025-adde-4d92-8d73-a1e62200444b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2e3730df-423d-4162-8a0d-0ee129c39f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0cc95ec6-9616-4e28-a963-6a0acfd5b064" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e19d26e7-7497-4994-8101-acd23d233a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0cc95ec6-9616-4e28-a963-6a0acfd5b064" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e19d26e7-7497-4994-8101-acd23d233a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_53e4845a-2966-40e4-864b-6f2ced912adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0cc95ec6-9616-4e28-a963-6a0acfd5b064" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_53e4845a-2966-40e4-864b-6f2ced912adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6822a616-6e9e-49c2-8379-c9ece57d5489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_d12d64d0-e141-4dde-a640-481b2d6d2889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6822a616-6e9e-49c2-8379-c9ece57d5489" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_d12d64d0-e141-4dde-a640-481b2d6d2889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89d209e0-649a-4811-990e-3dace1cbfb2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d12d64d0-e141-4dde-a640-481b2d6d2889" xlink:to="loc_us-gaap_NetIncomeLoss_89d209e0-649a-4811-990e-3dace1cbfb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_946a8b32-cd0f-4531-a763-21cd2a283091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6822a616-6e9e-49c2-8379-c9ece57d5489" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_946a8b32-cd0f-4531-a763-21cd2a283091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_84e88ea4-20b9-41e0-b736-4a3d102bec6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_946a8b32-cd0f-4531-a763-21cd2a283091" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_84e88ea4-20b9-41e0-b736-4a3d102bec6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c3eca188-7332-45b2-9690-3f410831d7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_946a8b32-cd0f-4531-a763-21cd2a283091" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c3eca188-7332-45b2-9690-3f410831d7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8a693f0-0c97-4d7d-9f96-ce70c15d62d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_946a8b32-cd0f-4531-a763-21cd2a283091" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8a693f0-0c97-4d7d-9f96-ce70c15d62d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bd2b7c27-4b56-40c5-8cd4-856c4fbb4aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_946a8b32-cd0f-4531-a763-21cd2a283091" xlink:to="loc_us-gaap_EarningsPerShareBasic_bd2b7c27-4b56-40c5-8cd4-856c4fbb4aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_fd363de3-085c-4410-b1a0-466287aac895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_946a8b32-cd0f-4531-a763-21cd2a283091" xlink:to="loc_us-gaap_EarningsPerShareDiluted_fd363de3-085c-4410-b1a0-466287aac895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_335cf0d3-5b9e-4a7d-b025-6ee1467556a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fa4609f4-f3aa-4fa1-9b91-293b9ccb9cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_335cf0d3-5b9e-4a7d-b025-6ee1467556a0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fa4609f4-f3aa-4fa1-9b91-293b9ccb9cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c4f25222-10d1-459f-b9c1-4fcefffc65d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fa4609f4-f3aa-4fa1-9b91-293b9ccb9cf0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c4f25222-10d1-459f-b9c1-4fcefffc65d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d22948c-2601-4d91-839b-ab8600be06a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c4f25222-10d1-459f-b9c1-4fcefffc65d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d22948c-2601-4d91-839b-ab8600be06a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_2db0a2b3-e015-49b8-a22d-130dfde30eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0d22948c-2601-4d91-839b-ab8600be06a0" xlink:to="loc_us-gaap_StockCompensationPlanMember_2db0a2b3-e015-49b8-a22d-130dfde30eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_77449eb0-ac71-445f-85a3-2ea6930a6d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fa4609f4-f3aa-4fa1-9b91-293b9ccb9cf0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_77449eb0-ac71-445f-85a3-2ea6930a6d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47a71e46-b4f8-457c-8bd2-977d704d5417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_77449eb0-ac71-445f-85a3-2ea6930a6d5d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47a71e46-b4f8-457c-8bd2-977d704d5417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75e3e506-6a4f-48cd-afa2-98d7358fe595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_54e48ab4-688f-495f-943d-ff890ab57a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75e3e506-6a4f-48cd-afa2-98d7358fe595" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_54e48ab4-688f-495f-943d-ff890ab57a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0981999c-cd57-4d83-b1c2-b99b820fd585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_239af436-4e3d-4d22-8bd4-e6308650e52b" xlink:href="exel-20210101.xsd#exel_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0981999c-cd57-4d83-b1c2-b99b820fd585" xlink:to="loc_exel_AssetsAndLiabilitiesLesseeTableTextBlock_239af436-4e3d-4d22-8bd4-e6308650e52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_f5dda5a8-e8c0-44ff-9703-995a3f94c055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0981999c-cd57-4d83-b1c2-b99b820fd585" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_f5dda5a8-e8c0-44ff-9703-995a3f94c055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_60d1d747-53dc-4680-8f2c-6b60b1e2781e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0981999c-cd57-4d83-b1c2-b99b820fd585" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_60d1d747-53dc-4680-8f2c-6b60b1e2781e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e954ba4-1909-4755-b3b7-a21a29116db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e954ba4-1909-4755-b3b7-a21a29116db9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsAxis_281ce60e-1288-4088-9cde-68032cc7b3ea" xlink:href="exel-20210101.xsd#exel_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:to="loc_exel_LeaseArrangementsAxis_281ce60e-1288-4088-9cde-68032cc7b3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LeaseArrangementsDomain_16ce2f5d-202c-4ed5-8421-83fbc3389ece" xlink:href="exel-20210101.xsd#exel_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsAxis_281ce60e-1288-4088-9cde-68032cc7b3ea" xlink:to="loc_exel_LeaseArrangementsDomain_16ce2f5d-202c-4ed5-8421-83fbc3389ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_HeadquartersLeaseMember_cb322cac-5f41-441f-9fcc-639b15aa1526" xlink:href="exel-20210101.xsd#exel_HeadquartersLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_16ce2f5d-202c-4ed5-8421-83fbc3389ece" xlink:to="loc_exel_HeadquartersLeaseMember_cb322cac-5f41-441f-9fcc-639b15aa1526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_BuiltToSuitLeaseMember_4b8db859-ef1b-49b0-853b-a0444beb33ba" xlink:href="exel-20210101.xsd#exel_BuiltToSuitLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_16ce2f5d-202c-4ed5-8421-83fbc3389ece" xlink:to="loc_exel_BuiltToSuitLeaseMember_4b8db859-ef1b-49b0-853b-a0444beb33ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cab9b398-f771-44b5-ada2-7e3cfa424bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:to="loc_us-gaap_CreditFacilityAxis_cab9b398-f771-44b5-ada2-7e3cfa424bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c055c297-4552-4360-b6e6-293b9a9318c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_cab9b398-f771-44b5-ada2-7e3cfa424bd3" xlink:to="loc_us-gaap_CreditFacilityDomain_c055c297-4552-4360-b6e6-293b9a9318c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_e9684e35-a067-4b78-b135-db30b8fa8e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c055c297-4552-4360-b6e6-293b9a9318c2" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_e9684e35-a067-4b78-b135-db30b8fa8e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fbafc217-997b-4ac2-a2f5-cb7a8d38ce2f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:to="loc_srt_StatementScenarioAxis_fbafc217-997b-4ac2-a2f5-cb7a8d38ce2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e2bc5d83-7371-411b-bb88-bf8b8da12b85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_fbafc217-997b-4ac2-a2f5-cb7a8d38ce2f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e2bc5d83-7371-411b-bb88-bf8b8da12b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_69169f7f-4172-4205-b4a6-902963e6c408" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e2bc5d83-7371-411b-bb88-bf8b8da12b85" xlink:to="loc_srt_ScenarioForecastMember_69169f7f-4172-4205-b4a6-902963e6c408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9527bb7f-649d-4bda-a2c2-02c5313fbc15" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_e3609c72-20d2-49f7-bb4a-a778c6d1fff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_e3609c72-20d2-49f7-bb4a-a778c6d1fff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_e01106fd-0cda-4f96-8eb9-ef787ef060be" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_e01106fd-0cda-4f96-8eb9-ef787ef060be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b64b3aed-f487-435f-81db-fbd4c6bb6892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b64b3aed-f487-435f-81db-fbd4c6bb6892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_85ef0330-6798-45b8-a8b7-d4549e685e8c" xlink:href="exel-20210101.xsd#exel_TenantLeaseImprovementsAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_85ef0330-6798-45b8-a8b7-d4549e685e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_8b1ad3f4-7372-4c99-b6e6-ed5fd8e6e9a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_OperatingLeasePayments_8b1ad3f4-7372-4c99-b6e6-ed5fd8e6e9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ad6d6e7b-cb58-4376-8033-f4c0431a7972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ad6d6e7b-cb58-4376-8033-f4c0431a7972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c63ae543-20e3-4edb-84ed-a9475f730530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c63ae543-20e3-4edb-84ed-a9475f730530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7a8e195b-edb8-4f6c-bc2a-cf728c8bb722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7a8e195b-edb8-4f6c-bc2a-cf728c8bb722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_a7353006-096d-44b0-bc17-679b9493b2cf" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_a7353006-096d-44b0-bc17-679b9493b2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_ab3c2547-5d8d-4866-9281-374de7919aab" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_ab3c2547-5d8d-4866-9281-374de7919aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_c189e7fb-d5bb-424a-8267-f581ee6043e6" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod_c189e7fb-d5bb-424a-8267-f581ee6043e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_94df50ea-292d-489b-a267-fa10fdef4948" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_94df50ea-292d-489b-a267-fa10fdef4948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AreaOfRealEstatePropertyAvailableToLease_01065d7e-ea28-4001-9a90-11a0bd2e4ebf" xlink:href="exel-20210101.xsd#exel_AreaOfRealEstatePropertyAvailableToLease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_AreaOfRealEstatePropertyAvailableToLease_01065d7e-ea28-4001-9a90-11a0bd2e4ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_740c494a-4d2a-4d4b-8fca-79ed72ba29c9" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts_740c494a-4d2a-4d4b-8fca-79ed72ba29c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_e2229215-c9f2-4dba-b46e-fbdc536e54e6" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_e2229215-c9f2-4dba-b46e-fbdc536e54e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_9fc9be80-bb7f-4aa0-a74f-8dc5ea8853ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_TenantImprovements_9fc9be80-bb7f-4aa0-a74f-8dc5ea8853ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dabaa54d-8082-4989-9cdd-b4d99ec795ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dabaa54d-8082-4989-9cdd-b4d99ec795ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b1233700-2d6c-4eb7-b2fc-0a71d438823e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b1233700-2d6c-4eb7-b2fc-0a71d438823e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities_e8baf028-2c38-4c9a-b2a5-3e8df8b602b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuarantyLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e1aa8d3f-12ca-444e-a309-463d1c13d41b" xlink:to="loc_us-gaap_GuarantyLiabilities_e8baf028-2c38-4c9a-b2a5-3e8df8b602b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b1719723-43a2-49b9-ad76-9cf38bbd0249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseAssetsAbstract_6c10f244-3d37-4d39-910c-25b1ee124ef5" xlink:href="exel-20210101.xsd#exel_OperatingLeaseAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b1719723-43a2-49b9-ad76-9cf38bbd0249" xlink:to="loc_exel_OperatingLeaseAssetsAbstract_6c10f244-3d37-4d39-910c-25b1ee124ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f191a1a9-57d8-4b78-b607-bd41eaf2f2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseAssetsAbstract_6c10f244-3d37-4d39-910c-25b1ee124ef5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f191a1a9-57d8-4b78-b607-bd41eaf2f2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4ed96ece-53ef-47fb-8c68-8fce87438744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseAssetsAbstract_6c10f244-3d37-4d39-910c-25b1ee124ef5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4ed96ece-53ef-47fb-8c68-8fce87438744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_893c9472-7abe-4ab8-8cb6-a569f0e012a5" xlink:href="exel-20210101.xsd#exel_OperatingLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b1719723-43a2-49b9-ad76-9cf38bbd0249" xlink:to="loc_exel_OperatingLeaseLiabilitiesAbstract_893c9472-7abe-4ab8-8cb6-a569f0e012a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f396c082-0796-427a-88b4-7cf6d3690d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_893c9472-7abe-4ab8-8cb6-a569f0e012a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f396c082-0796-427a-88b4-7cf6d3690d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3b029b77-da17-48b8-b1d0-13223dea3c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_893c9472-7abe-4ab8-8cb6-a569f0e012a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3b029b77-da17-48b8-b1d0-13223dea3c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_13d9e330-b014-4577-9d70-b4d025d850c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_893c9472-7abe-4ab8-8cb6-a569f0e012a5" xlink:to="loc_us-gaap_OperatingLeaseLiability_13d9e330-b014-4577-9d70-b4d025d850c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_5e13a560-017d-479c-816b-9b921aa941f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_893c9472-7abe-4ab8-8cb6-a569f0e012a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_5e13a560-017d-479c-816b-9b921aa941f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26bb3c57-a81c-4b94-b6d2-a971f6830f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_76b77336-6337-48c5-be25-920282a7c24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26bb3c57-a81c-4b94-b6d2-a971f6830f4b" xlink:to="loc_us-gaap_OperatingLeaseCost_76b77336-6337-48c5-be25-920282a7c24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_63b2853b-7439-42ed-9783-aef4d4ba1f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26bb3c57-a81c-4b94-b6d2-a971f6830f4b" xlink:to="loc_us-gaap_VariableLeaseCost_63b2853b-7439-42ed-9783-aef4d4ba1f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b9d0b1b1-1e2b-45be-a701-f98bc73c334b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26bb3c57-a81c-4b94-b6d2-a971f6830f4b" xlink:to="loc_us-gaap_LeaseCost_b9d0b1b1-1e2b-45be-a701-f98bc73c334b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48145719-0eb3-41f9-884b-b015b6ced51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48145719-0eb3-41f9-884b-b015b6ced51c" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6053a5e8-0c76-4883-94aa-657b15bdd4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6053a5e8-0c76-4883-94aa-657b15bdd4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_aabeadd0-1b66-4ada-8a73-0428ab1ec91c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_aabeadd0-1b66-4ada-8a73-0428ab1ec91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d6790dea-ff6c-4a25-939e-a025764ca4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d6790dea-ff6c-4a25-939e-a025764ca4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_29b2fa6b-a671-45fe-b000-36c331679c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_29b2fa6b-a671-45fe-b000-36c331679c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_33b9aef8-d5e5-4a1e-a8fb-ef80624eb664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_33b9aef8-d5e5-4a1e-a8fb-ef80624eb664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cb47c384-997c-4de0-9b9a-1ab3ea10188f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cb47c384-997c-4de0-9b9a-1ab3ea10188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ac51429-d762-4f52-906f-f0d2f3da804f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ac51429-d762-4f52-906f-f0d2f3da804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_298bd33b-3879-43fa-886f-29dbee2c6bfd" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_8d22ee51-eb41-471d-84ff-60ce59d84304" xlink:to="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_298bd33b-3879-43fa-886f-29dbee2c6bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5ce956b8-c325-428b-8777-30b84f6f8ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_298bd33b-3879-43fa-886f-29dbee2c6bfd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5ce956b8-c325-428b-8777-30b84f6f8ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_e238fb71-2d42-4b53-bcc0-d3d165ef1b1c" xlink:href="exel-20210101.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_298bd33b-3879-43fa-886f-29dbee2c6bfd" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_e238fb71-2d42-4b53-bcc0-d3d165ef1b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a6344ac0-0360-49a3-8a11-9daa196ca3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_298bd33b-3879-43fa-886f-29dbee2c6bfd" xlink:to="loc_us-gaap_OperatingLeaseLiability_a6344ac0-0360-49a3-8a11-9daa196ca3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="exel-20210101.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="exel-20210101.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_929bf5e9-5dfa-4a92-befa-a662a34b1be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_ba1faf60-b997-4ba6-8efb-bfb8d26b0018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_929bf5e9-5dfa-4a92-befa-a662a34b1be7" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_ba1faf60-b997-4ba6-8efb-bfb8d26b0018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="exel-20210101.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b82fd658-a595-4a92-aa7f-d52928ee2e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_93e8ec95-67fe-4a94-96fb-39cf4e187098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b82fd658-a595-4a92-aa7f-d52928ee2e19" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_93e8ec95-67fe-4a94-96fb-39cf4e187098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="exel-20210101.xsd#QuarterlyFinancialDataUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4abdd7c1-4687-458e-aaaf-907b7ef16acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b64af3b-f9ef-477b-b698-e36db7cdfec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4abdd7c1-4687-458e-aaaf-907b7ef16acd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b64af3b-f9ef-477b-b698-e36db7cdfec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_dde4f9f1-3497-4b6e-81b0-ea6dfe6ebba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4abdd7c1-4687-458e-aaaf-907b7ef16acd" xlink:to="loc_us-gaap_GrossProfit_dde4f9f1-3497-4b6e-81b0-ea6dfe6ebba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39265b4d-3434-4d08-9e1f-62bf198a0f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4abdd7c1-4687-458e-aaaf-907b7ef16acd" xlink:to="loc_us-gaap_OperatingIncomeLoss_39265b4d-3434-4d08-9e1f-62bf198a0f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9286a042-38db-48fd-9a56-f1803ddc3d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4abdd7c1-4687-458e-aaaf-907b7ef16acd" xlink:to="loc_us-gaap_NetIncomeLoss_9286a042-38db-48fd-9a56-f1803ddc3d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_588fa9a4-2406-402b-9d6e-1aa4b60b3af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4abdd7c1-4687-458e-aaaf-907b7ef16acd" xlink:to="loc_us-gaap_EarningsPerShareAbstract_588fa9a4-2406-402b-9d6e-1aa4b60b3af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1311fc58-2373-4c7a-93df-0b58251b132e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_588fa9a4-2406-402b-9d6e-1aa4b60b3af6" xlink:to="loc_us-gaap_EarningsPerShareBasic_1311fc58-2373-4c7a-93df-0b58251b132e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ce952dfd-764f-4b4d-bdd8-049322f15cf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_588fa9a4-2406-402b-9d6e-1aa4b60b3af6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ce952dfd-764f-4b4d-bdd8-049322f15cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_MilestonePaymentsEarned_554d5fb6-c5e0-4b70-a4e3-a2e1daa0973b" xlink:href="exel-20210101.xsd#exel_MilestonePaymentsEarned"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4abdd7c1-4687-458e-aaaf-907b7ef16acd" xlink:to="loc_exel_MilestonePaymentsEarned_554d5fb6-c5e0-4b70-a4e3-a2e1daa0973b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exel-20210101_g1.jpg
<TEXT>
begin 644 exel-20210101_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
M]&>.)F4?BP _&LJ]:%&G*K4VBFWZ+5F^%P]3$5H8>DKRDTEZMV7XGY&?\%+?
MCW)\>?VL?$$D4YDTGPW(=$T]0?E"PL1(X['?+YC9[KM]!7@%23SR74[R2,TD
MDC%G=CN9B>22>^:CK^",VS&KC\95QM;XJDG)_-[>BV7D?ZMY#D]#*<MH9;AE
M[E*,8KSLK7]6]7YL****\\]8**** "BBB@ HHHH **** /NS_@B)\>I-"^(W
MB#X=WD_^AZ] =4T]&/"7,0 D51ZO%AC[0#\?TPK\*_V/OB&WPK_:C\!ZZ)/*
MCL]:MTN&':"1Q%+_ .0W>OW4K^K/!?-Y8K)982H[NC*R_P ,M5^/-\C^#?I)
M</PP/$D,PI*RQ$$W_CA[K_\ )>5OSNPHHHK]@/YY"BBB@ HHHH **** "BBB
M@ K@OVD/VA=!_9A^$^H>*_$$O[BU'EVULKA9;^X(.R&/_:;!.?X5#,> :ZGQ
MEXRTOX>^%-0US6KR'3])TN!KFZN)3A8D49)]_8#DD@#).*_&7]NG]L?5/VP?
MBS)?_OK3PQI)>#1;!C_JHR>97'3S9, MCH JY.W)^ \0.-J608+]W9UYW4%V
M[R?DOQ>FUVOUCPE\,Z_%F9_O;QPM)IU)=^T(O^:75_96N]D^#^/GQTU[]H[X
MI:EXK\17'F7VH-A(D)\JTB'W(8P>B*#]222<DDGC:**_CC$8BKB*LJU:3E*3
M;;>[;W;/]&,'@Z.$H0PV&BHP@E&*6B26B2]$=9\#O@_JGQ\^+.A>$=&7-]K=
MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG?BSX%C^)_PM\2>&
MYMHCU_2[G3R3T7S8F3/X;L_A7145G6I1JTW3FKJ2:?H]S;#UYT*L:U)VE%II
M]FG='\]-_8S:9?36UQ&T-Q;R-%(C=493@@^X(-0U])?\%4/V?I/@?^U9JU];
MPF/1?&1;6;)P/E$CG_2(_J)=S8[+(E?-M?P5G65U<NQU7 UOBIR:];;/T:U7
MDS_5CAO/*.<970S3#_#5BI>C:U7K%W3\T%%%%>8>T%%%% !1110 4444 %%%
M% 'JG[$GPXD^*_[67@'150R1R:O#=7  SF& ^?)_XY&P_&OW(K\Y/^"(/[/\
MESKGB3XE7T#"WM8_[%TLL.'D;:\[C_=41J".#YCCL:_1NOZP\&\GEA,D>*J*
MSK2<E_A6B_&[7DT?P/\ 2.XBAF'$RP-%WCAH*+_QR]Z7W)Q3[-,****_7#^?
MPHHHH **** "BBO+?VN/VI-$_9,^$=YXBU1H[B^DS!I>G[]LFH7&.%'<*.K-
MV'J2 >7'8VAA*$\5B9*,(*[;Z)?U\SNRS+<3F&+IX'!P<ZE1J,4MVW_6KV2U
M>AYO_P %(OVYX?V4?AX-(T6:&;QUX@A86,>0W]G0G*F[=?8@A >&8$\A&%?D
M'J&H3ZM?3W5U-+<75S(TTTLC%GE=CEF8GDDDDDGJ36Y\6/BIK?QL^(>J>*/$
M5XU[JVK3&:9^BKV5$'\**H"J.P KG:_C/CCC&OG^/]L[QI1NH1[+N_[SZ]M%
MT/\ 2#PO\.L-PEE2PZM*O4LZL^[Z17]V.J7?66C=@HHJ2VMI+RXCAACDEEE8
M)'&B[F<G@  =2:^*2OH?I6VK/H+_ ()J_LJ_\-.?M#V?]HVWG>%O#&W4=6W+
MF.?!_=6Y['S''([HLG0XK]E0H5<#@"O$OV!/V78_V5/V>M-T>XB0>(M4QJ&M
M2#D_:' _=9R?EC4!.#@D,PQN->W5_9?AOPK_ &)E,8U5:M4M*?==H_\ ;J_%
ML_SA\9.._P#6;/YSH2OAZ-X4^S2?O3_[?>J?\JC?8****_0#\E"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&_
MX*'?LGK^U?\  .ZL;&-#XGT(M?Z,Y.-\@7#P$^DBC'8;@A/ K\8M0T^?2;Z>
MUNH9;>ZMI&BFBD4J\3J<,K \@@@@@]"*_H6KX1_X*@_\$X9OB'+??$GP'9^9
MKB)YNM:5"OS:B!UN(@.LP'WD'WP,CY\A_P 1\6.!*F/A_;& C>I%6G%;RBMF
MN[CVZK;:S_ISP"\4Z655/]7LVGRT:CO3D]H3>\6^D9/5/92O?23:_-&BG$;3
M@C:5ZBFU_,)_;@4444 %%%% !1110 5U'P8^$.M?'CXF:/X4T"W-QJ6L3B).
M#LA7J\KGLB*"Q/H#UXK)\)>$M4\>>)+/1]%L+K5-4U"016UK;1F269CV 'MD
M^P!/:OUX_P""=W["%I^R+X&;4M76WN_'6N0A=0N$(=;&+.X6T3>@(!<C[S =
M0JU]QP+P9B,_QJA9JC%ISEY?RK^\^G9:]#\Q\4?$C"<)Y8ZEU+$S35.'=_S2
M7\L>O=^ZM7=>R? KX.Z7\ ?A)H?A#1U_T'1+80B0C#7$A):25A_>=RS'W:NN
MHHK^SL/AZ="E&C15HQ222V22LE\D?YNXO%5L57GB<1)RG-N4F]VV[MOS;U"B
MBBMCG"BBB@ HHJ&\O(=,LYKBXFBM[>W1I)99'"I$@&2S$\  #))XQ2;MJQI-
MNR,7XG_$W1?@YX"U3Q-XBO8]/T?2(3//*_7T"J/XF8D*JCEF( ZU^+/[8/[5
MNM?M<?%NY\0:ENM=-M\P:3IP;*6%OG@>[MP7;N>F%"@>E?\ !2?]NV;]J?Q]
M_8>@W$B> ]!F/V0 %?[3G&0;EQUVX)"*>BDG@L0/E^OY2\4./GFU?^SL%+_9
MX/5K[<EU_P *^SWW[6_O/P.\*5D&%6<9G#_:ZJT3_P"74'T\IR^UV7N_S7**
M**_(3^A K[$_X(_?LJGXN_&23QUJMNSZ!X)D5[;>OR7.H$;HP/7RAB0]PQB[
M&OD[P;X0U#Q_XMTW0])MVN]3UBYCL[6%>LDCL%4>W)'/05^Y/[,/P#T_]FCX
M(Z'X/T_RY#IT.Z[N%7!O+EOFEE/?EB<9Y"A1V%?JWA/PK_:>:?7*ZO2H6;[.
M7V5\OB?HD]S\'\?.//[#R/\ L["RM7Q5XJV\8?;EY7ORKU;7PGH%%%%?UL?Y
M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D?[5G[;?P_\ V.?#
M:WOC#5MM]<(7LM)M )K^^Q_<CR %SQO<JN>,YXKC?^"C?[?VF_L/?#")K>.#
M4_&NO*\>C:>Y^1,<-<S8Y\I"1QD%V(48 9E_$3XE?$O7OC!XWU#Q)XFU2[UC
M6M4E,MS=7#[G<]@.RJ!@!0 J@    "M(POJR92L?9'Q__P""[OQ.\?W<UOX'
MT_2_ NF994E,:W]^XZ9+R+Y:\<X6/()^\>#7SIK_ .WK\;/$E^UQ<_%;Q_'(
MW46NMW%I&/\ @$3*OZ5Y-\WM1\WM6W*C+F9Z;_PVM\9/^BM?$S_PJ;[_ ..T
M?\-K?&3_ **U\3/_  J;[_X[7F7S>U'S>U%D%V>F_P##:WQD_P"BM?$S_P *
MF^_^.UT'PB_;(^+VI?%?PO;W'Q4^)%Q;W&K6D<L4OB6]9)%,R JP,F"",@@\
M8->)?-[5T_P5_P"2Q^$O^PS9_P#H]*+(+L_H^HHHKE-PHHHH *^-?^"M7@OX
M@>'/!-G\1/ OC#QEHMOHZBUUK3],UBYMX3"S?N[D1QN%!5FVN<<AD/ 4FOLJ
MJ>NZ'9^)]%O--U"WAO+&_A>VN()5W)-&ZE65AW!!(_&O%XBR=9IE]3!<SBY+
M22;3C);/3SW7571]+PAQ%+(\VHYER*I&#]Z+2:E%Z26MU>VSZ.SZ'X9_\-=_
M%C_HJ'Q$_P#"CO/_ (Y1_P -=_%C_HJ'Q$_\*.\_^.5M?MN?LNWG[)_QXU+P
M^5FDT6Y_TS1[IQ_K[5B=H)[NARC>ZYZ,*\AK^*LPQ.:X+$SPF)JSC.#::YI;
MKY[=GU6I_I7E.#R',L%2Q^#H4Y4ZD5*+Y([/Y:-;-='HST3_ (:[^+'_ $5#
MXB?^%'>?_'*/^&N_BQ_T5#XB?^%'>?\ QRO.Z*X_[8Q__/\ G_X%+_,]#_5_
M*_\ H&I_^ 1_R/1/^&N_BQ_T5#XB?^%'>?\ QRC_ (:[^+'_ $5#XB?^%'>?
M_'*\[HH_MC'_ //^?_@4O\P_U?RO_H&I_P#@$?\ (]*LOVR/BUI]P)(_B=X^
M9AVEUZZE7_OEG(_2O4OA?_P5Q^,WP^N8Q?:Q8>*K-",P:K9H6*]\21;'S[L6
MQZ'I7S'179@^)\WPL^?#XFI%_P")V^:O9_-'GYAP3P_CJ?L\7@J4EYPC=>C2
MNODT?K?^R]_P5I^'_P =KJVTGQ K>!_$-P0D<=Y,)+&Y8\ )/@!2?215Z@ L
M:^K VY<CD&OYY*^TO^"='_!374/A#J^G^"?'U])?>$+AEM[/49WW2Z(3@*&8
M_>M_4'E!R.!MK]MX)\8)5JL<%GMM=%42LK_WULK_ ,RLEU5KL_F7Q,^CQ##T
M)YGPO=J-W*BW=VZ^S;U=OY97;Z.]HO\ 4JBHX9EN(5DC971U#(RG*L#T(-25
M_01_)(4444 %%%% 'R/^V]_P2N\/_M%7%WXE\(R6OAGQE(#),A3;8ZJ_4F4*
M,QR'_GHH.?XE).X?F;\9_@!XP_9\\2MI/C#0;[1[K)\IY4W07('\44HRDB^Z
MDX[X/%?O567XM\&Z1X^T*72]<TO3]9TVX_UMK>VZSPO]58$5^4\7>%&79M.6
M*PC]C6>K:5XR?G'2S?=>K39^\>'_ (]9QP_3C@<?'ZSAXZ)-VG%=HRUNETC)
M/HDXH_GWHK]9_BW_ ,$;OA1\0)IKG0VUKP?=2'(6QN//M<]\QRACCV5U S^%
M>%^*?^"$_B*UF;^Q?B!HM]'GC[=I\MJV/?8TG_U_:OQ3,/"7B/#2M"DJB[QD
MORERO\#^E\H\?^#<;!.K7E1E_+.$OSBI1_$^#**^TH/^"''Q.:[99/$_@1;<
M9VNMQ=L[>F5\@ ?F<>]=EX-_X(2WLLL;^(/B':PQC&^'3M+:0M[!WD7'?G8?
MI7G4/#/B6K+ECA6O5Q7YR1Z^*\:N"J$>:6/B_P##&<G^$6?GW7KO[-7[$7Q"
M_:FU*'_A'=&D@T=GVS:S>@PV,('7#XS(P_NQACR,X'-?I;\&?^"4_P '?A!<
MPW4NBW'BO4(<%9]<F%P@/_7%0L1&?[R,1ZU]&6=E#IMG%;V\45O;PJ$BCC0*
MD:C@  < #T%?HO#_ ((UG)5<YJI1_DAJWZR:LODGZH_'^+OI-X>,'0X<H.4O
M^?E31+S4$VWY<SCYIGB/['?[!'@_]D#1O.L4_MKQ1<ILN]:N8P)2.Z1+R(H_
M8$D_Q,<#'NE%%?O^6Y;A<OP\<+@X*$([)?UJWU;U?4_DW.<ZQV;8N>.S&JZE
M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
MK"^)/Q+T'X/^"M0\1^)M5L]%T32XS+<W=R^U$'8 =68G "J"S$@ $D"JGQD^
M,GASX _#G4O%7BK4H=+T72X]\LK\LY_AC1>K.QX51R2:_$']OC_@H!XF_;=^
M(+23O<:3X-TV4_V1HBR?)&!D":;'#SL">>0H)5>,EJC&Y,I6/5_V_?\ @L+X
MF_:,DOO"_@&2^\*>"6S%+.K>7J.KIT/F,I_=1,/^6:G)'WB02H^*?F]J/F]J
M/F]JZ(QL9-W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CYO:CYO:CY
MO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH
M^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@!]K=26-S'-#))
M#-"P>.1&*LC Y!!'((/>ON#]C/\ X+9^-/@S-:Z+\1ENO'7AI2$%ZSC^UK)?
M4.W$X]I"&/\ ?&,'X<^;VH^;VI.*>XT[']&/P*_:#\'_ +2G@:'Q%X+URSUK
M39,+)Y9VS6KXSY<L9PT;CT8#(P1D$$]I7\YOP(_:$\8?LT^/;?Q)X,UJZT?4
MH<"0(V8;N/.3'-&?ED0^C X.",$ C]@_^"?_ /P51\*_MAVUOX?UA;?PQ\0%
MC^;3WD_T?4\#YGM68Y)[F-OF SC< 6&$H-&L97/J^BBBH*"F3SI;0-)(RQQQ
MJ6=V.%4#DDGTI]>>_M;:U-X;_94^)FHVYVW%AX4U6XB/HR6<K#]0* /Q+\3Z
MAJG_  4*_;VE,4TPE^('B-;>W=@6:RLMX1#@]HK=02/1#7[P>!/!.F_#;P5I
M/A_1[9;/2=$M(K&TA7I'%&H51[G Z]S7XW_\$.O#$.O_ +>6GW4N/,T/1;Z]
MAR/XV18#_P".SM7[35I4[$0[GY2_\'"__)9?AW_V!;C_ -'BOI?_ ()%? SP
M3KG[!?@+7+[P=X6O-:NSJ+3ZA/I,$EU,5U"ZC4M(4+-A%51D\* .@Q7S1_P<
M+_\ )9?AW_V!;C_T>*])_P"":?\ P4N^"_P%_8R\(>#_ !=XNDT77]%^V_:8
M&TF]N%'FWUQ,F'AB=3\DB'KQG'7-#ORZ"^T?8OQ*_8V^%?Q=T2:PU[X?^%;R
M.:,QB5-.B@N(AS_JYHPLB'D\JPK\1?C]X(N_V)/VS]:TSP_?S-<>!=<2ZTNY
M8_O JE)X=^.I"L@;H"<],XK]2/B=_P %N_@7X,\.SW&AZOJWC#4%C)@L[+2[
MBU\Q^<!I+A(PJYQD@,0#P">*_-+X7^!?%7_!2_\ ;<EDDMF:X\5:HVI:Q+"#
MY.E6(<>8=W94CQ&F>6;8O5J<+]0EY'[Q:/J*ZOI-K=JI1;J))@IZJ& ./UK\
M:/\ @M5^S;#\"?VLAXBTF!;72/'\#:JBQ#:L5ZC!;D#ZL4E)_O3'TK]G8($M
MH%CC58XXU"HBC"J!P !Z5\#?\'!WA2&]_9P\$ZXP'VC3O$GV%#WV3VLSM^ML
ME33>I4MCZ>_8-^.,G[1G[(W@;Q9=3&;4;S3Q;W[L?F>Z@9H)F/IN>-F^C"O7
MJ^(?^"!WB!]6_8QUBSDD1CI?BJZAC0'YEC:WM9 2/=G?\C[U]O5,M&-;!111
M2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\_?_
M  4&E:;]M_XJ,[,S?\)+>J"3G@2D ?@ !^%>/?-[5Z__ ,% _P#D]SXJ_P#8
MS7W_ *-:O(/F]JZH['.'S>U'S>U'S>U'S>U, ^;VH^;VH^;VH^;VH /F]J/F
M]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F
M]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:C
MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
M"C_AW]\$?^B5^!?_  41?X4>U0>S9_/U\WM1\WM7] O_  [^^"/_ $2OP+_X
M*(O\*/\ AW]\$?\ HE?@7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\"
M_P#@HB_PH_X=_?!'_HE?@7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\
M"_\ @HB_PH_X=_?!'_HE?@7_ ,%$7^%'M4'LV?S]?-[4?-[5_0+_ ,._O@C_
M -$K\"_^"B+_  H_X=_?!'_HE?@7_P %$7^%'M4'LV?S]?-[4?-[5_0+_P .
M_O@C_P!$K\"_^"B+_"C_ (=_?!'_ *)7X%_\%$7^%'M4'LV?S]?-[4?-[5_0
M+_P[^^"/_1*_ O\ X*(O\*UO"?[&WPE\"WRW6D_#7P-8W2G<L\>B6_FH?]ER
MA8?@11[5![-GXC_LT_L$?%+]JW4+?_A%_#-XNDS-A]9OU-KIT2YP6\UA\^/[
ML8=O:OUO_8'_ .":OA/]B+1VOUD'B'QM?0^7>:S-%M$*'!,-NG/EQY')R6?'
M) PJ_2:J$7 X Z#THK.4VRHQ2"BBBI*"BBB@ HHHH **** .%_:@_P"3:?B)
M_P!BSJ7_ *2RU_.I\WM7]%?[4'_)M/Q$_P"Q9U+_ -)9:_G4^;VK:D9U ^;V
MH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH ]-_8I_Y/(^
M$O\ V.6C_P#I=#7]#%?SS_L4_P#)Y'PE_P"QRT?_ -+H:_H8K"IN:T]@HHHK
M,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE_P""Q7_*./XC
M?]PW_P!.=I7TU7S+_P %BO\ E''\1O\ N&_^G.TJH[H#\-/F]J/F]J/F]J/F
M]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]JZ?X*_P#)8_"7_89L
M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
MTYVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'
MS>U !\WM73_!7_DL?A+_ +#-G_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z
M/J***Y3H"BBB@ HHHH **** "BBB@ HHHH **** "OS:_P""RW[(7_"/Z[#\
M5]!M=MEJ;):Z_'&N!#<<+%<?2081N -RJ>2YK]):QO'_ ($TOXG>"M4\.ZU:
MK>:5K%L]K<PM_$C#''HPZ@CD$ CI7S'&'#=+/,LG@:FDMX/^62V?IT?DV?;^
M'O&E?A?.Z69TKN'PU(_S0?Q+U6CC_>2Z'\_E%>A?M1?L^:I^S#\;-8\(ZGND
M6RD\RSN2N%O;9^8Y1]1P0.C*P[5Y[7\18O"U<+6GAZ\>6<6TT^C6C/\ 37+\
M?0QN&IXS"R4J=1*46MFFKIA1117.=@4444 %%%% &EX/\7:CX!\5Z=K>DW4E
MEJFDW"75K/&?FBD1@RG\QTZ$5^WG[(O[26G_ +5/P-TGQ59^7#>2+]GU.T4Y
M^QW: >8G^Z<AE/=77OD5^&->F? 3]K+QG^S;H'BK3_"NHFRB\660M9V_BMG!
MXGB/\,H4NH;MOSU52/T7P[XX?#^+FJ]Y49KWDM^9+W6O/H_)WZ(_'O&#PQ7%
MN IO"M1Q-)KED]$XMI2BVM;)>\M]59?$SZL_X*S_ +>__"3WUY\*_!]XW]G6
MLGE^(;Z%^+J53S:*1_ I WG^)AMZ*=WP/3B=QR?F+=33:^9XEXBQ6=X^6.Q3
MU>B72,>D5Z?B[OJ?;<%\'X'AK*J>5X%:1UE+K.3WD_-]%T226B"BBBO /JPH
MHHH **** "OL_P#X(Z?LJ_\ "T/BQ-\0M6M]^A^#90MB'7Y;G4",J1_UQ4A_
M9FC/8U\D?#_P)J7Q.\;Z5X=T:W:ZU36;I+2VB'\3N<#/HHZD]  3VK]S/V=/
M@=IG[.7P8T/P?I2JT.DVX6:<+@W<[?-+,WNSDG'88 X K]9\)>%/[2S/Z]75
MZ5"S\G/[*^7Q/T2>Y^!^/_'G]BY)_9>%E:OBDXZ;QI_;?ES?"O636L3N****
M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!_/S_P4#_Y/<^*O_8S7W_HUJ\@^;VKU_P#X*!_\GN?%7_L9K[_T
M:U>0?-[5U1V.</F]J/F]J/F]J/F]J8!\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4
M?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>
MU'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>
MU'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U?H7_P &]'_)9?B)
M_P!@6W_]'FOST^;VK]#_ /@WGM)'^+7Q&G"GR8](M8V;T9IF('X[6_*HJ;%1
MW/U6HHHKG-@HHHH **** "OF?_@IE^WM9_L5_"'R]-D@N?'?B-'AT:T;YOLR
M]'NY!_<3/R@_?? Y <KZU^TU^T=X=_94^#>K>,_$DVVST]=D%NC 3:A<-GRX
M(@>KL0?95#,<*I(_!#]H[]H+Q#^U!\7]6\9>)KCS-0U*3Y(D)\FSA'$<,8/1
M%''J3DG)))N$;ZDRE8Y#7-;O/$VM7>HZA=37E_?S/<7%Q,Y>2>1R69V)Y)))
M)/J:K?-[4?-[4?-[5T&(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\
MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
MPX<^-W_/WX%_\&DO_P 9H_X<.?&[_G[\"_\ @TE_^,T<R#E9\6?-[4?-[5]I
M_P##ASXW?\_?@7_P:2__ !FC_APY\;O^?OP+_P"#27_XS1S(.5GQ9\WM1\WM
M7VG_ ,.'/C=_S]^!?_!I+_\ &:FL/^""/QJO)]DFJ?#^U7&=\NIW!7Z?+;L?
MTI<R#E9\3?-[5>\+^%M2\;>(;32='L+S5-4U"00VUI:Q-+-.YZ*JKDDU^B_P
MJ_X-ZM2ENX9?&_Q"LK>!2#+:Z'9M*\@[A9IMH7ZF)OI7W%^S!^PO\-/V1-/V
M^#O#\<6IR1^7<:O>-]HU"Y'<&4_<4X&4C"(2 =N:3J);#4&>!_\ !*[_ ()?
M?\,LVJ>.O'$4%QX_OH2EM: K)'H,3C# -T:=AD,P.%!*C.6)^VJ**Q;N[FNP
M4444@"BBL;X@76N6?@C5)/#5K8WWB!;=_P"SX;V8PVSSXPGF,H)" X)P"2!Q
M0!\A_P#!7C_@H:/V:? 3>!?"=]M\>>)+8^=/"WSZ):-P9,_PS.,A.ZC+\83/
MXWLVXY/)/))[U]W?$G_@C%^T1\7?'FJ^)O$6M>"]3UK6KAKF[N9-5EW2.>P'
MDX"@8"J,!5  P !6)_PX<^-W_/WX%_\ !I+_ /&:WBXI&4KL^+/F]J/F]J^T
M_P#APY\;O^?OP+_X-)?_ (S1_P .'/C=_P _?@7_ ,&DO_QFJYD+E9\6?-[4
M?-[5]I_\.'/C=_S]^!?_  :2_P#QFC_APY\;O^?OP+_X-)?_ (S1S(.5GQ9\
MWM1\WM7VG_PX<^-W_/WX%_\ !I+_ /&:/^'#GQN_Y^_ O_@TE_\ C-',@Y6?
M%GS>U:7@WP=JGQ"\5Z?H>B6-QJ6K:M<):VEK NZ2>1CA5'X]SP.^*^P?^'#G
MQN_Y^_ O_@TE_P#C-?7O_!+_ /X)92?LB:I?^+O&\FE:IXVDW6NG"T=IK?2[
M<C#.K,JDRR9()Q\JC /S-2=1) HL]9_X)Z_L/Z7^Q+\%H=,_T>\\6:P$N=>U
M%!GS9L<0QDC/DQY(7.,DLV 6P/?***Y]S8**** "BBB@ HHHH **** "BBB@
M HHHH **** "J'B?PQI_C3PY?:/JUG!J&EZG ]K=6TZ[HYXG!5E8>A!(J_10
M!^.?_!0S_@D)XA_9WU"^\5?#VUOO$G@0DS2VR9FOM%'4AP/FDB'.) "5 ^?I
MO;XF^;VK^F6OF_\ ::_X)4_!_P#:<O)]1O-$D\,^()R6?4]"9;629O62,J8I
M"3U8IO/]X5K&IW,Y0['X5?-[4?-[5^BOQ$_X-Z/$UG<2-X3^(>@ZA$>8TU>R
MELV7KP6B\W/;G:/IVK@]0_X((?&JRE58]6^'UX&&2T6IW( ]OGMU/Z5?.B>5
MGQ-\WM1\WM7VG_PX<^-W_/WX%_\ !I+_ /&:/^'#GQN_Y^_ O_@TE_\ C-/F
M0<K/BSYO:CYO:OM/_APY\;O^?OP+_P"#27_XS1_PX<^-W_/WX%_\&DO_ ,9H
MYD'*SXL^;VKZ]_X)/?\ !0>3]DKXE_\ ",^);IO^%?>*)U%RSG(T>Y.%6Z'^
MP1A9!_= ;DIAM;_APY\;O^?OP+_X-)?_ (S1_P .'/C=_P _?@7_ ,&DO_QF
MDY1:L"31^QUO<1WD$<T,B2PRJ'1T;<KJ>001U!J2OG7_ ()R?";XM_ +X0MX
M+^)TVA:E::+M30[VQOWN)DM^0;>0-&ORI@;#D_*=O 5<_15<YL%%%% !7YO_
M /!Q#_R)GPM_Z_-1_P#0+>OT@KY"_P""LW[#GC3]M?P]X)M?!TNB12>'[B[E
MNO[1NG@!$JQ!=NU&S]PYZ=JJ.Y,MC\5_F]J/F]J^T_\ APY\;O\ G[\"_P#@
MTE_^,T?\.'/C=_S]^!?_  :2_P#QFM^9&?*SXL^;VH^;VK[3_P"'#GQN_P"?
MOP+_ .#27_XS1_PX<^-W_/WX%_\ !I+_ /&:.9!RL^+/F]J/F]J^T_\ APY\
M;O\ G[\"_P#@TE_^,T?\.'/C=_S]^!?_  :2_P#QFCF0<K/BSYO:CYO:OM/_
M (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\ \9HYD'*SXL^;VH^;
MVK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\ !I+_ /&:.9!RL^+/
MF]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\.'/C=_S]^!?_  :2_P#QFCF0
M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7R3_P5O_:J_P"%(_ S_A$])N?+\1^.$>V)5OGM;$<3
M2>V_/ECIPSD'*U]4>)/$5EX/\/7^K:E<1VFGZ9;R75U.YPL,2*6=C[!037X>
M?M<?M$7O[47QXUOQ9=&6.UN)/L^FV[G/V2T3(BC]CC+-C@N['O7Y;XK<5?V5
ME3PM!VJUKQ7=1^T_N=EYNZV/W/P&X$_MW/5CL5&^'PUI.^TI_8CYZKF?DK/X
MCS2G(C2.%52S,<  <DTVOOC_ (),_L"_\)+>6?Q4\863?V?:OYGAZQF7BZD!
M_P"/M@?X%/W!_$PW= N[^9>&>'<5G>/C@<*M7JWTC'JW_6KLC^V>-.,,#PUE
M53-,<](Z1CUG)[17KU?17;V/9?\ @ES^P4O[/GA*/QMXJL]OC;7(/W$$R_-H
MULP^YCM,XP7SRHPG'S[OK^BBO[4R'(\+E&"A@<(K1C][?5ONW_P%HDC_ #4X
MJXGQW$&9U,TS"5YS>W2*Z1BNB2V^]W;;"BBBO8/G@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF_B]\4-+^"OPRUSQ
M5K4ODZ;H=JUS+SAI".%C7_:=BJJ.Y8"LZU:%*G*K4=HQ3;;V26K?R-L/AZN(
MJQH48N4Y-));MMV27FWH?&O_  6>_:K_ .$5\&V?POT>ZQJ&NJM[K+1MS#:A
MOW<)(Y!D==Q'7:@ZAZ_-&NH^-/Q9U3XZ_%37/%NM2>9J&N737#@'*PKT2)?]
ME$"H/9174?LD_LN:W^UG\7;3PWI6ZWLX\3ZGJ!3='I]N" 7/JQZ*N?F)[ $C
M^+.)LWQ7$^>N>'BY<S4*<>O*MO2^LGT3;UL?Z4<$\/8'@CA>-+%S453BZE:?
M1S:7,_.VD8]6DM+L]*_X)N?L+S?M7_$,ZOK<$T7@3P_,IOI!E?[1F&&%JC>X
M(+D<JI X+J1^O>GV$.DZ?#:VL,=O:VT:Q0PQJ%2)%&%50.     .U87PF^%>
MB_!3X=Z7X7\.V:V6DZ3"(H4ZLYZL[G^)V8EF/<DUTE?U%P/P=0X?P"HJSJRL
MYR[OLO[L>GS?4_AOQ0\1,3Q;FKQ#O&A3NJ4.RZR?3FEN^VD;M*X4445]J?FH
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exel-20210101_g2.jpg
<TEXT>
begin 644 exel-20210101_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \&_X*:_'[Q/\ LT?L1^.?BIX'NVMM<BLH;'2+I/O6T]U/';^<I[-&LC2+
MGC<@IO[+'[ W[.7P2^"FE>%=3^$V@:[K5]IL<WBK7]>TJ&]N]5O)$#3O++,K
M,RERV$SM ]\D[G[>W[.E[^U;^R/XU^!NC2QIJ>K::LNC/*P5?MMO*EQ K,?N
MJTD2H6[*Y->/_ [_ (*T_LV^'_AI9>#OVLO%5Y\.OB'X;T^.S\6^'/$>BW2R
MFYB0(\T)CC821R%2Z@$MAL8/!(!VWPI_9<TS]@J'XN_$_P"%'BEW\&ZK8RZ]
MI'PX:U,=IH]Y!;,\IAE\QL),R\J$4*H0#.P5U/P;_:;U;XH_L2V/[5]WX4M[
M2\N_!ESK;:/'<LT2O%'(XBWD X/E@9QWKRKX'?&']HO]MRP^,/CBPT"ZTCX3
M:OX8GT;X66&L:2EO>:K<-;.DM_E@'$+,<*&.TAP!@HU>/?LZ_MU_ ;P=_P $
MT8OV:M2U346^*.F>#M2\-/\ #N/1[DZFVH[9XU0Q^7A4PP=I"0J+NW$%2M '
MK_CC_@I9XL\&_LD?!S]I6S^":ZQ?_%'Q)9Z4_AG3]0(DC>XCN"B0.R@.Y>%$
M&[ ^?)Z5G^,/V]/VS/@+\5?#/PQ^/_[).@7EW\1HKB'P!;>"?%IF;^T8S'_H
MEY)/&JQJ!*A>91M4 L X#!?(M-C23]A_]AE9$# ?&GPT0&&>0;P@_GS7NG[=
MW_)[7[*?_8Z:U_Z0QT ;?P;_ &M?VCK+]JFS_94_:P^#GAO0]1\1>&I]9\*Z
MSX/UN6[MIE@8"6VE$R*P=5R=PP/E  .X$=K^QM^TWJW[47AOQMKNK^%+?2&\
M)_$K5O#$,=M<M*+B.S,6V=BP&UF\PY49 QUKSGXW_P#*6+X'?]B#XF_] CKR
MO]C/]K;X$_L6ZU\;/@=^TSXNE\*^)4^,^M:WIVFW>F7#R:K879B^S2VHC1C-
MO\LX5>2&4]^ !O[9'[3>K?M1?\$L_P!H37=7\*6^D-X3\?R>&(8[:Y:47$=G
MJFG[9V+ ;6;S#E1D#'6O?OBW^T+\;? UYX"^"'[.?P+'BKQ/XC\/B\EU?7+F
M6ST31K:*-1ON+A(W+NS?*L2?-W[@'XCAU/4M:_X(X_M0:SK/A^[TF\N_C=J$
MUUI5_'LGLY&U+2F:&1?X70DJP[$&O9OVO/C#JVG_ +37P\^"?QR_:+\4_"/X
M07WPS34(?$GA:]:P?6=95PK6<M\J,846$!BH(SD9YD4J >N?";]KC]I.Q_:3
M/[)G[3OP9\,:5XEU;PG<:YX1UOPGKLUQIVH"%MKP2":-9(F!R2Q'0?=Y!/B?
M[!'C/]H2U\??M-ZK\1/AIX4N-'C\9ZQ<^+XTUZ:9H[^.SXLX5:$":V*KM+L5
M('\-<E^S]'^SU9_\%8_AMJ7[.NK>*=:\.WW@S6K4>-O%&J7UXGB#4(X9'F6U
MGO"?.6*,QAC%A-Q;&<$GMOV=/BMX"\%_&#]K?]G[Q9KAT_QAKWBS7=9T;1+J
MUE5[NQ-@S^>C;=A7;\WWLD$$#!H [GX,?MN6_@?X,_LX:[I?P+T/PSX"^*FH
MS:'<QZ3<LD/AR]D:3[%%&FP*Z32*X).W;ACS7L/QJ_:;U?P!^TG\,/V:? _A
M.WU?5O'4U[=ZQ-/<LBZ1I5K&&DN2%!RSL2B X!92,]*^=O@S\ KS]I+_ ((?
M^&?ASH*NNO1^$VU/PM/$<21:G:W<L]OL;^$LZ>7D=!(U:W_!,'Q3XD_;"^*?
MC'_@H1X^T5[26ZT/3?!OA>VF3!MHK:".?4BGJDEZY*D8QL8'O0!UME^V+^U9
M^T)XP\4I^Q5\"_">J>$?!^M3:1<^*?''B*:T76KZ# GBLHX(V(120!*YV-D'
MC!%>I?LB_M0Z?^U)\/\ 4=<NO!]UX9\2>&M>N="\9>%KV=99-*U* CS(A(H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM>C46LHC<*FQ9S&-X7KMW=<>U16NA:)8ZA-J]EHUI#=W(_TBZBMU627_ 'F
MRWXU:HH **** "BBB@"OJ>DZ7K=FVG:SIMO=V[_?@NH5D1OJK @U+;6UM96Z
M6EG;I%%&H6.*) JJ!T  X I]% $4-A8VUQ+>6]E#'+.09I4C :3'3<1R?QJ.
MQT71]+GGNM,TFVMY;J3?=200*C3-_>8@?,?<U9HH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0
M!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP
M_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_
M9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H
M4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP
M_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN
M?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@
M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_
M]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__
M #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]
M^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,
M/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__
M #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'
M_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^
MJ/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4
M_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C
M#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\
MSXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V
M=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#S
MXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_
M ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:
M@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_
MT&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?
M#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X
M3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?
MH4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_
M //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=
MI_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I
M_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]
MG:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#
M'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3
M'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZJQI
M^MZ3JKM'IU_',R#+!#T%2?V=I_\ SXP_]^A3XK:V@),%NB$]2B 9H ?1110
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MPW\*WLWB'4K46MWXBU_6KG4;TVP((@66X=S''D#Y4QG:N<[1CUJBB@ HHHH
M\+_:P_Y+9\#_ /L>Y?\ TF:O=*\+_:P_Y+9\#_\ L>Y?_29J]TH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /"_VL/^2V? _P#['N7_ -)F
MKW2O"_VL/^2V? __ +'N7_TF:O=* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOF?_
M (>N?LH?\-7_ /#*_P#PE/[W_CU_X2KS5_LW^TMVW[%YF?O=O,^YO^3.:Y\1
MB\-A.7VTU'F=E?JSV,HX?SO/_;?V=AYU?90<Y\JORQ6[?^6[Z(^F****Z#QP
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_VL/\ DMGP/_['N7_T
MF:O=*\+_ &L/^2V? _\ ['N7_P!)FKW2@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
MZ#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'
M^Q>-_P#H-V7_ (#'_&O#OV]?VT(_V(/@W)XWUS6M.OO$&I%[?PMH/DG?>7 '
M+L,Y$,>0SM[JH.YUK#$XBCA*$JU5VC%7;/2R?*,QS_-*678"FZE:K)1C%=6_
MR2W;>B2;>B/._P#@K/\ \%$V_9@\%CX&_!K4C-\2/$]MLB>U^=]%M9/E\_ Y
M\]^5B7J#EST4--_P2<_X)V+^RMX&;XS?%[31+\2/$]MNN5N/G?1K5\-]F!/_
M "V8X:5O4!!PI+>-?\$M_P!A[XG?&;QR_P#P44_:?NOMVM:Q>M?^%+?682S3
M2'IJ+)P%50 L"XPH4.H $1K]%/L7C?\ Z#=E_P" Q_QKY_+,/6S/%+,\4K+_
M )=Q?V5_,_[S_KI;]<XVS?+N",CEP3D513DVGC:\?^7M1?\ +J+_ .?5-Z-=
M7=.WO<VQ16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XU].?B)L45C_8O
M&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- '/_M"?LZ_"7]J'X:WGPK^,?A>
M/4M,N1NAD&%GLY@"%G@DQF.1<G!'!!*L"I(/YE36_P"UO_P0Z^,OVBV:X\9?
M![Q!?X(.4M[@GL>HL[U4'7E)57^(+A/U5^Q>-_\ H-V7_@,?\:Q_'WPS?XI>
M#M0^'_Q$M-'UC1=5MS!?Z=?6&^.9#ZC/!! (88*D @@@&O&S3*(XV2KT9<E:
M/PR7Y/NOZ[I_H_!'B#6X9I5,LS&DL5EM;^+0EM_CIO[%1;IJU[*]FHRC3_9T
M_:2^$7[5'PTM?BI\'/$R:AI\_P ES ^%N+&; +03QY)CD&>G(((92RD$]Y7Y
M-?'3]E']J?\ X)$?$V3]IW]E'7KC5_ -Q(%UJQD5IDMH2V1;WT?\<.3A+@89
M"<$JQ!?[C_8K_;=\(?MN> ?^$E^'OBFSL=:LHU_M[PO>1@W6GN>,\8\V(G[L
MJC!Z$*P*C/+<WE6K/"8R/)773I)=XOJO+I]YU\:>'U'+LOCQ!P]5>*RRH])_
M;HR?_+NM%?#)7LI6M+3:ZO\ 05%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8
M_P"->Z?EIL45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;
M_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O
M&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &
MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%
M%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/
M]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_X
MT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/
M^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!N
MR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0
M;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1
M]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_X
MT ;%%8_V+QO_ -!NR_\  8_XU:TJ#7X9'.L7\$RE?D$46T@T 7J*** "BBB@
M HHHH **** /F3Q'^Q%\<OAQ\:/%OQA_8S_:-L?!D7C^\%]XM\+^(O"ZZG9/
MJ!!#7UN1(C12-DLR\AF8DG 55ZGX _L,^"?A3\-/&WA/XE>*+OQYKWQ0>>3X
MD>)M5@6!]8,L3Q>4L2$B"%(W=4C4G9O;!Z >Y44 ?'1_X)Q?M*7_ ,+X/V4-
M?_;;GN?@Y;^7;'34\)QIKDVE(P*:8UZ)-HC"@)Y@CR5&W;M^6O6_VEOV,O#_
M ,;/ ?A#1_AQXOG\!^(_AQ>PW?P\\1Z79K.-):.,1>2T+D"6!HU56C)&0JY)
M (/M5% 'SM\)OV.?BY=_'[2?VF/VMOCQ:>./$'A;3;BR\%Z3HOAX:;IVC^>N
MR>Y">8[2SR)\I8X"CCG"[?HFBB@ HHHH \+_ &L/^2V? _\ ['N7_P!)FKW2
MO"_VL/\ DMGP/_['N7_TF:O=* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBJFOZ_HGA70[SQ-XEU6WL-.T
M^U>YOKVZE"100HI9W=CPJ@ DD^E)M)794(2J248J[>B2ZG,?'WX[?#K]FOX4
M:O\ &/XI:P+32=(@WLJX,MS*>(X(E)&^1VPJCWR2 "1^:7[*WP3^)_\ P5\_
M:LU#]K7]I*PD@^'.@7H@T_1M[>3<",[HM-A)QF-00\\@P6+D#!?Y*OQ,\8_%
M/_@MI^V';_"KX<7-[I/PC\'W'FSWQC*JD&XJU[(IX-S-ADAC/W5SP,2FOU*^
M%GPO\#?!?X>Z3\+?AMH,6F:)HEFMM86<(X51R68]6=F)9F/+,Q)R2:^4BGQ)
MC.=_[K3>G_3R2Z_X5^/Y?OE:4/!CAQT(/_A;QD/>?7"49?97:M46_6*[63GM
MVMK:V-K'965M'###&$AAB0*J*!@* .  . !4E%%?6'X$VV[L****!!1110 4
M444 17UC9:I93:;J5G%<6UQ$T5Q;SQATE1AAE93PP()!!X(-?FA^VM_P30^*
MW[)GQ!_X;/\ ^"=MY?V']F2M=:IX5TP%Y;!>LC6Z'/GVS#.^W8-M&<!D^5/T
MTHKSLRRO#9G24:FDEK&2WB^Z9]EP7QQG/!&82K82TZ51<M6C/6G5AUC..VS=
MGNK]FT_EC_@G9_P4]^&_[:N@Q^#O$PM?#WQ$L[?-_H1EQ%J 4?-/:%CEE[M$
M273G[RC>?J>O@C_@HG_P2;N/&6NR_M1_L7,WA[Q]8W'V^]T739_LR:E,IW?:
M+9E($%UGDC(60\_*V2][_@G)_P %9+?XO:G#^S=^UFJ^'?B-9S?8K74+V#[-
M%J\RG:8I$8#[/=Y&"A 5VX7:Q"5YF"S3$X/$+!9EI)_#/[,_\I>7_ O]KQ'P
M/DW$>4U.)>#+RH1UKX9ZU<,^K76=+>TE=I;[2Y?NFBBBOI#\8"BBB@ HHHH
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M9<79GQKGM3,L;97]V$%\-."^&$5T45][NWJV%%%%=Y\J%%%% !1110 4444
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MS3_K5/9K5:!1116IPA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/VJR./F1LM& &R0N]/K+_@G[_P %)/A7^W!X572_W.A>.K"V#:SX8EFSY@&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M95D64QX+X<GS8:F[XBLM\366_P#W#@U:"V;5];*3V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !KZ,_&C8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
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M3HOAX:;IVC^>NR>Y">8[2SR)\I8X"CCG"[?HFBB@ HHHH \+_:P_Y+9\#_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_M8?\
M);/@?_V/<O\ Z3-7NE>%_M8?\EL^!_\ V/<O_I,U>Z4 %%%% !1110 4444
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M117I'Q84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YE?\
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MVOFCXK_\%]OV2/!_FVGPR\)>*?&%PN?*FCM%L+1_^!SGS1_WZKSL5F^5X/\
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M^%'[*'[*'Q8_;"^+%K\*_A7I>YFQ+JNJSJ?LVF6V<-/*PZ#LJCYF; %?NO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
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MZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DN
MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DN
MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DN
MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DN
MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%<A\0OV?O@3\6E<?%#X,^%O$+..9-
M9T&WN''N&="P/N#FM?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6HG3A4CRS2
M:\SHPV*Q6#JJKAZDH276+:?WK4^</B+_ ,$9?^"?WQ \R:U^$MUX=N9,YN?#
MFMW$./I'(SQ#\$KPKQY_P;Q^!/M!U'X-?M+Z[I$L3[[>/7=)BNV![?O8'@*G
MW"GZ5^@G_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UY.(X>R7$_'0C\O=_])L?
MH&5>+WB7DR2P^9U6ETJ-55;M:HIZ'YK_ /# /_!9O]GW]Y\$OVJSXAM(>;;3
MXO&$Q'';[/J">0OX,1ZTI_;:_P""W7[/?R?&']F5O%-M#Q<WDGA!IP ._G:4
MXB7ZD$5^D_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UR?ZNJC_NN)J4_+
MFO'[G_F>]_Q&*>8Z9WDV#Q7>3I>SJ/\ [?@U;_P$_/3P5_P<+:'8WG]C_&[]
MES5]*N(6VW,FBZPLS@]_W%Q'$5/L7/UKW'X?_P#!;#_@G_XWB4ZK\1]5\-3,
MN1;^(/#UP#]"UN)D!_X%7OOC7PMX,^)5G_9_Q&^!NGZ_;[=OD:WI=O=)CTVR
MJPQ7R-^W!_P21^#OQI^'D^I_LW_!NU\$^,;%FGLUT]%ALM2&.;>6,';'G'RN
MH&#]X$'C.M1XHP5)SI58UK=)1Y6_3E>_S.S+\P\#N)<;3P^-P%?+N=VYZ=?V
ME.+?67M(MJ-][)V]-3XN_P""FO\ P4U\4_MG>*7^'_P_GNM+^&^EW6;&Q;*2
MZO*IXNK@>G=(CPHY/S?=^7_ _CCQ=\-?%VG>/? 7B&ZTG6=)NEN-.U&SDV20
M2+T(/Z$'@@D$$$BF>,?!WBGX?>*;_P $^-] NM+U?2[IK?4-/O83'+!*IP59
M3T_J.1Q6;7Y/C,;B\7BY5Z\GSW]+6Z+M8_OOASAOA_A_A^GE>64HK#*.VDE-
M26LI/[;GNV]_2R/V _9N_P""['[.VM_!.'4_VEKN\T7QII^(+[3])T>:XCU0
MA?\ CX@*C9&&_B21EVMT)&#7*?$3_@X.\/7U]_8'[/'[,^M:U=3MLM)O$%\L
M+%NV+>V$K/\ 02*:^4/^";O_  3I\<?M=^,K?Q_XGT6^M?A[H]\IU&_CA7=J
M4J$$VL&\%6[!W((4'&"2!7[(_#OP!\.OA%8_V9\*_@#IGAR KM:/0]*M[4,/
M]KRU&X^YR37Z/D]7B;-\'&<JJIQV4N6\I>>KM\]#^-/$3 ^"7A]Q)4H4L#/&
MUVW*5+VSA1HM[0O"/-Y\C<K+1M:(_/G_ (7M_P %WOVK,K\/OA5-X"TNXZRQ
MZ'#I2B,]&$FI,TQ[',7)[#%3Z;_P1,_:_P#CK?1ZY^UY^V.T[EP[01W5WK,J
MC^Z&N&B2,]OEW =LU^DG_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UZJX:PU9W
MQ=6=7RE)I?<K6^\^#?C5G.7)PX>P.%P"Z2I48RJ?.<^:[\^5'R;\*/\ @A?^
MP[\/_+N?&.G>(?&=RA#,=<UAH8=WM':B+CV9F]\]*^EOA=^SC\ O@G"L7PE^
M#7AKP\RK@SZ5HT,4S_[TH7>Y]V)-;G_"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_
M -]+7K87+,OP7\"E&/FDK_?N? YWQMQ?Q&W_ &GCZM5/[,IRY?E!-17R1L45
MC_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM=Q\N;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
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MU[G[%POXW\9\*\)ULCPTU*+5J4Y:RHI_$H=U_*G\#U78RO!'@CPC\-?".G>
MO 7AZUTG1M)M5M].TZSCV1P1KT 'ZDGDDDDDDFM6BBOHHQC&*25DC\@JU:E:
MI*I4DY2DVVV[MMZMMO=OJPHHHID!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%?.W_  5?_P"3 O'W_<*_].MG7XR5^M<!^%O^N^3U,=];]ERU
M'#E]GSWM&,KWYX_S6M;IOJ>#FF=_V;B%2]GS75[WMU:[/L?T245_.W7[-_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(S*JEF8
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M_C/BKA.CD>)FHQ2M5G'259+X5/LOYDOC>K[!1117T9^.A1110 4444 %%%%
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MV0++-9VH\^8#_GI,V9)/^!,:[[^&W#NW/F%9>M*C?\9RM\XLR_X6<9VHQ_\
M I?Y+\SX-7]F/_@J=^W,PNOCY\09O!7AFY.6TJ_D-JAC/86%OAG(]+@JW7YJ
M]X^!/_!'[]E/X3>3JGCBPN_'.J1X)EUUMEH&]5MHSM(_V9#)7U917GYEXC<1
MXO#_ %7"..%H?R4(^S7S:]Y^>MGV-:.3X.G+GJ7G+O)W_#8J:%H&A>%]*AT'
MPUHMIIUC;)LM[*QMEABB7T5$ "CV JW117P<I2G)RD[MGJ))*R"BBBD,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBOVL[=&-93*N[XRJY^6T?N1X9\"?^"<G[)/P \F^\-_#&#5]5AP1K7B4B]N
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MX/X@_M/? #X5>(V\)?$3XJ:7I&I)"DK6=W(P<(W*MP#P: .'_:P_Y+9\#_\
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M@_P?^'DS#.5U^+#X:7E_S]JQ?HHO^5KWO+?V&/\ @FM\#?V)=%CU72+5=?\
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
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MXXE'5F9B H]S7Y[_ !&_X+(_%KXIZP_@?]CKX!W4UQ)D1:CJULUY=;3QO%M
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MR1_EAO\ ^!,^&/A7_P $6=3\4ZQ_PG/[7?QUU#7=2N&#W=CH]P\CR'KB2\N
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MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
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M_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\
MSXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344
M0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_
M 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9
MVG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#
M_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_
MV=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_W
MZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG
M_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=
MI_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%
M344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^
MA1_9VG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%34
M4 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/
MC#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A1
M_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%356U;6=(T"PD
MU77=5MK*UB&9;F[G6.-![LQ %.,92=DKL&TA_P#9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H5XM\2/^"CO[%GPO$D6M_'G2+^XCR!:Z 7U%F8?P[K=713_ +S"O OB
M)_P71^%-A(UC\(_@IKVN3%MD4NL7<5C&S= 0L?G,P]B%)]J^MRS@/C#-[/#8
M*I9]9+DC_P"!3Y5^)P5LTR_#_'47RU?X7/N;^SM/_P"?&'_OT*/[/T\=;&'_
M +]"OSL/[8W_  5P_:*/E?!7X -X:LI^+>^A\.^6"I[_ &C46\EC[J!1_P .
MW?\ @HW^T$?/_:._:A%A93_ZW3IM;N+W9GKBVBV6X_!Z]S_B'E' :YQF>'P_
M>*E[6HO^W(?YG+_:\JO^[T)R\[<J^]GYZ4445_:Q^<'OO[#GP&_:M_:%/B?P
M1^SIXZ'A_26^Q'Q??/JS6J%3Y_D*WE RR9 N/E4;3_%CY:^V/@7_ ,$5/@!X
M':+6?C7XFU'QMJ (>2U#-96(;KRL;&5\'N9 #W7G%>>?\$#O^:K_ /<"_P#<
MA7Z)5_*OBCQSQ'EO%.*RS U51IKDNX)1G*].#O*?Q75[*S6B2Z'W&299@ZV!
MA6JQYGKOJEJ]EL8/@CX6?#7X::(GAOX?> ='T6P3&+73-.CA0GU(4#<?<Y)K
M8_L[3_\ GQA_[]"IJ*_#*M6K6J.I4DY2>[;NWZMGT\8QBK)61#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-14#(?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[
M.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]
M"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_
M /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^
M_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T
M_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"I
MJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %* UV?ZG\)Y;KFF<TVU]FA&56_ESZ17S1G_ &ACZW\##OUDU'\-SV#XD?\
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M\Q_\!7^1YW\ _P!D_P" '[,']K?\*,\ _P!A_P!N>1_:G_$UNKGS_)\SR_\
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MO(@[>7XV#9_.R%7(/^"]'A9HP;G]FG4$;^()XH1@/Q-N,U\-+PF\08[X)_\
M@RD__;STUGV4O_EY^$O\C] J*^"8/^"\/PU:3%S^S[KB+CJFLPL?R*#^=7(/
M^"[?P892;KX'^*$.>!'>6S#'XL*QEX6\?1WP,O\ P*'_ ,D4L[RI_P#+U?<_
M\C[JHKXAA_X+J?L[L5^T?"+QH@.-^Q+1L?3,XS^E7+?_ (+F_LL,3]J^&OQ
M0=O+TZQ;/YW8K&7AKQU'? 3_ /)?\REG.6/_ )>K\3[2HKXX@_X+@_LBRH&D
M\'>/HB>JOH]ID?E=FKT/_!:O]C:5]CVGC&,8^\^AQX_28FL9>'G&\=\!4_\
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M%-A(UC\(_@IKVN3%MD4NL7<5C&S= 0L?G,P]B%)]JY(_MC?\%</VBCY7P5^
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M**_D&<YU).4G=OJS[]))604445(PHHHH **** "BBB@ HHHH **** "BBB@
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MME_LCV()G_:=\ G )(B\6V;GCV60\^U95Y^WW^QA8DB?]I/PJV"/]3J0D_\
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MX3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J8&E16;_P )CX8_Z#4'_?5'_"8^&/\
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MQ\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M6[\=],XU/X<[U'5_[+G'ZAL4?ZWX*'\:A6A_BIO]+A]>IKXHR7JCUK^SM/\
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M(_ZUYT^,^&H.WUA/TC)_E$])X_"+[7X,]9_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT*\E_X7Y\4+[_D$_#;=Z?Z+/)_+%'_"Q_VBM0_X]O ?D9_ZA<B_^C&J/]<<
MJE_"A4GZ4Y?K87U^B]DW\F>M?V=I_P#SXP_]^A1_9VG_ //C#_WZ%>2_;?VJ
M-0_U-IY /7]W:K_Z%S1_PB/[3&H?\?/B;R,_]/J+C_OV*/\ 6F<_X6!KOUA9
M?BP^N-[4Y?<>M?V=I_\ SXP_]^A1_9VG_P#/C#_WZ%>2_P#"F?C??\ZG\2L
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M +=IPB'U?%/>K^"/&?\ A-OCWJ'_ ![?#6&#/_4&=?\ T8:/+_:8U#_4Z-#
M#U_T>S7_ -"YKV:BC_5G$S_BX^N_22C^2#ZI-[U9??8\9_X0']HG4/\ CYUB
M&#/_ $\1KC_OVM*OP+^,-[SJ/CZ( ]5&H3MC\-H%>RT4?ZGY?+^+6JS]:C_2
MP?4:3WE)_,^;OBA\/[_X?BU@U;Q6+VYN@S>0@;Y$'&XECW/ X['TKD*]+^(G
MPS^+_CCQ==Z_)X581N^RU1K^#Y(EX4?ZSTY/N36)_P *$^+/_0J?^3T'_P <
MK\DS;)<PJ9A4>$PE54[VC>$VVEI>[3>NYXE?#U75?)!VZ:,=\+/A;8?$R.ZA
M7Q0;&[M2K&$VGF!XS_$#O7OP?3CUKK#^S%KT'_'GX^7VS;.O\G-9OPY^&GQ?
M\#>+[37T\*MY2OLND6^@^>)N&'^LY]1[@5[I7V_"_#&6XW+O]NPLX58NS;]I
M'F6Z:U2\G;MYGH8/!TJE+]Y!J2]5<\;/[/?Q*@_X\OB!'QTS<3+_ "!II^"_
MQPM3FW\=0R#L/[3G/Z,F*]FHKZ3_ %-RE?!*I'TJ2.OZA06S:^;/&?\ A7?[
M0UI_J==AEQT_TI6S_P!]+1_8'[35I_J5AD_"S;_T(5[-11_JE07P8JO'TJ/_
M "#ZE'I.7WGC/G?M*VO^N\/0R?\ ;I:G_P!!H_X2S]H"U_UWP^AD_P"X3G_T
M$U[-11_JSB8_!CZ_SDG^@?5)K:K+[SQG_A:'QGM?^/OX2PD#J?[#N!^N[%'_
M  O#QQ;?\?\ \*81CK_HDJ?S!KV:BC^P<XC\&8S^<8L/JU=;57]R/&?^&CY[
M;_C_ /AC",=?WY3^<9J6']IO0F_U_P / OKLNE;^:"O8:BEL;&X_U]G$^>N^
M,&C^R.)X_#F5_6E#_,/88Q;5?_)4>61?M*^"F_U_@JX7_<$;?X5:B_:/^&3\
M2^&M00_]><)'_H==_+X7\,S_ .O\.V#_ ._:(?Z56E^'G@*;_6^"=)/O_9T>
M?_0:/J/%\-L7!^M.WY,/9XY?;7W')1?M _":3[]I<Q_[]@O]":M1?'/X.2??
MOQ'_ +^FO_136S+\)OAM-]_P98C_ '(=O\JK3?!#X63_ '_",0S_ ')Y5_DU
M'LN-8;5*$O537Y!;,%UC^)!#\8/@W/\ <\06HS_?LI%_FE6H?B5\)9_N>)=+
M'^_A?Y@53F_9]^%<GW- DC_W+V7^K&JLW[-WPUD^Y%?1_P"Y=_X@T>TXUAO3
MH2]'-?F%\P72/XF_#XT^&,_^J\4:&2>@-W$#^1-6HM:\#S_ZC5M*?_<GB/\
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M,LFQ_P ]8_,_]")K3M/"?A:PQ]A\-:?#CIY5FB_R%'U3C&K\>)I0_P ,&_\
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MG:?_ ,^,/_?H4^*VMH"3!;HA/4H@&:?10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'A?[6'_);/@?_P!CW+_Z3-7NE>%_M8?\EL^!_P#V/<O_
M *3-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%%  0",$5PGQVU?0?#'@N9CI5H][?$P6I>W
M4LN1\S\CL._J17=UP?Q-^#%[\2=;CU.?QC]EA@A$<%J+#>$[L<^8,DGVZ #M
M7B<0T\=5RJI3P=/GJ25EJE:^[]YI:+;SL<^*51T6J:NV?/==-\)=6T'2_&MM
M'XFTJTNK*Z/D2B[@618RQ^5QN!Q@XR?0FNZ_X91_ZGW_ ,I?_P!MH_X91_ZG
MW_RE_P#VVOR'"<(\58/%0KQPR;BT[.4+.W1^]LSPZ>!QM.:DH;>:_P SU*V\
M+^&;/'V3P[8Q8Z>7:(O\A5R.*.)=D4:J/11@56T&PO=+T:VTW4=2^V300K')
M=>5L,N.-Q&3@XZ\]:MU^YT(0C334.5M;::>6FGW'T44DMK!1116Q04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %>%?$3X9_%_P <>+KO7Y/"K"-W
MV6J-?P?)$O"C_6>G)]R:]UHKQ<[R+#9]0C1KSE&*=[1:5WYW3VZ'/B,-#$Q4
M9-I>1\W_ /"A/BS_ -"I_P"3T'_QRMSX<_#3XO\ @;Q?::^GA5O*5]ETBWT'
MSQ-PP_UG/J/<"O=**^?PWA_E&$Q$*U*K44HM-.\=U_VX<L,LH0DI*3NO3_(*
M***^Z/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH \+_:P_Y+9\#_\ L>Y?_29J]TKPO]K#_DMGP/\ ^Q[E_P#2
M9J]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_VL/^2V
M? __ +'N7_TF:O=*\+_:P_Y+9\#_ /L>Y?\ TF:O=* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHKYC_;Q^)/Q-UWXN_";]B_X1?$#4?"=[\3]4OY_$7B?19
ME]8:186_G3);R$'RI9<[5D'*E/>@#Z<HKXXN=,\>?L"_M<?"_P ):7\=/&OB
M_P"'GQ7O+K0M2TGQWKSZG-I6J)$KVMQ;3R#>JR,2C1YV_>/)VA?L>@ HHHH
M\+_:P_Y+9\#_ /L>Y?\ TF:O=*\+_:P_Y+9\#_\ L>Y?_29J]TH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "ODS]K2XA\!?\%+?V;/B=XAF2WT;48/$7AU[Z4[
M8X;V>T!MHV)XW2NVQ1W(-?6=<C\;_@/\)?VC_A_<?"_XT^"[;7-%N9%E-M.S
MH\4JYVRQ21E7BD&3AT8'!(S@D$ ^>?V^[B+QE^UW^S%\(="E2?6$^(<WB2YM
MHSEH+&R@+22N/X5/S!2>"4(&2"*^M*\E_9__ &(?V=OV:?$M]XY^&_A6]F\0
MZE:BUN_$6OZU<ZC>FV!!$"RW#N8X\@?*F,[5SG:,>M4 %>7_ !6_9*^&OQB\
M7/XT\4:_XHM[MX$A,>D^(YK:':@P#L0XSZGO7J%% 'A#_P#!/'X%R2++-XC\
M:R,@81M+XMG?864J2-V<'!ZTS_AW5\#_ /H;O'?_ (5\]>]44 >"_P##NKX'
M_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO@?\ ]#=X[_\ "OGH
M_P"'=7P/_P"AN\=_^%?/7O5% '@O_#NKX'_]#=X[_P#"OGH_X=U? _\ Z&[Q
MW_X5\]>]44 >"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\ A7SU[U10
M!X+_ ,.ZO@?_ -#=X[_\*^>C_AW5\#_^AN\=_P#A7SU[U10!\9?LB?L<?#/X
ML_#/4/$GBKQ5XO6Y@\5:E91BR\331)Y4,Y1,@=6QU/>O4_\ AW5\#_\ H;O'
M?_A7SUW/[-?P9U/X&> KWPAJNM07\EUXAOM16:WC9559Y2X3![@'!KT&@#P7
M_AW5\#_^AN\=_P#A7ST?\.ZO@?\ ]#=X[_\ "OGKWJB@#P7_ (=U? __ *&[
MQW_X5\]'_#NKX'_]#=X[_P#"OGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\ #NKX
M'_\ 0W>._P#PKYZ]ZHH \%_X=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PK
MYZ]ZHH \%_X=U? __H;O'?\ X5\]'_#NKX'_ /0W>.__  KYZ]ZHH \%_P"'
M=7P/_P"AN\=_^%?/1_P[J^!__0W>._\ PKYZ]ZHH \%_X=U? _\ Z&[QW_X5
M\]'_  [J^!__ $-WCO\ \*^>O>J* /!?^'=7P/\ ^AN\=_\ A7ST?\.ZO@?_
M -#=X[_\*^>O>J* /!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO_P *^>O>
MJ* /!?\ AW5\#_\ H;O'?_A7ST?\.ZO@?_T-WCO_ ,*^>O>J* /D;]J3]B7X
M5?#+]GSQ7X^\-^*_&37^EZ4T]J+OQ1-+&6#*/F4_>'/2NJ\#?\$_O@QK?@G1
M]9O?%OC@37>E6\\HC\6SJNYXU8X'89/2O7OV@OAG??&7X+^(OA?IFIQ65QK>
MG-;174Z%DC)(.2!R1Q70^$M&E\.>%-,\/3S+(]AI\-N\B# <I&JDCV.* /%?
M^'=7P/\ ^AN\=_\ A7ST?\.ZO@?_ -#=X[_\*^>O>J* /!?^'=7P/_Z&[QW_
M .%?/1_P[J^!_P#T-WCO_P *^>O>J* /!?\ AW5\#_\ H;O'?_A7ST?\.ZO@
M?_T-WCO_ ,*^>O>J* /!?^'=7P/_ .AN\=_^%?/1_P .ZO@?_P!#=X[_ /"O
MGKWJB@#P7_AW5\#_ /H;O'?_ (5\]'_#NKX'_P#0W>.__"OGKWJB@#P7_AW5
M\#_^AN\=_P#A7ST?\.ZO@?\ ]#=X[_\ "OGKWJB@#P7_ (=U? __ *&[QW_X
M5\]'_#NKX'_]#=X[_P#"OGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\ #NKX'_\
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M *&[QW_X5\]'_#NKX'_]#=X[_P#"OGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\
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M *&[QW_X5\]'_#NKX'_]#=X[_P#"OGKWJB@#P7_AW5\#_P#H;O'?_A7ST?\
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MYZ/^'=7P/_Z&[QW_ .%?/7O5% '@O_#NKX'_ /0W>.__  KYZ/\ AW5\#_\
MH;O'?_A7SU[U10!X+_P[J^!__0W>._\ PKYZ/^'=7P/_ .AN\=_^%?/7O5%
M'@O_  [J^!__ $-WCO\ \*^>C_AW5\#_ /H;O'?_ (5\]>]44 >"_P##NKX'
M_P#0W>.__"OGK@/VI/V)?A5\,OV?/%?C[PWXK\9-?Z7I33VHN_%$TL98,H^9
M3]X<]*^N:X[]H+X9WWQE^"_B+X7Z9J<5E<:WIS6T5U.A9(R2#D@<D<4 >0^!
MO^"?WP8UOP3H^LWOBWQP)KO2K>>41^+9U7<\:L<#L,GI6K_P[J^!_P#T-WCO
M_P *^>O:O"6C2^'/"FF>'IYED>PT^&W>1!@.4C521['%:% '@O\ P[J^!_\
MT-WCO_PKYZ/^'=7P/_Z&[QW_ .%?/7O5% '@O_#NKX'_ /0W>.__  KYZ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%?,W[2O\ P44\,?LQ_MF^ OV=O'5I9Q>'/%6A
MO/K&NLS>9I-Q+<>19R2'.Q(&>.1&+#@NK;@$(8 ]C^*GQU\*_"'QAX'\(^*M
M/OL>._$;:)IVI11K]FMKO[--/&DS%@09?)*(%!RQYP!FODG_ (*,:A^TYX\_
M:X\*']DG3[AM<^!O@R[\9:FLD$@AU;[9/% -,&/]8\L%K<X4?>^=00P^7W__
M (*&_#+7OB3^REXBN_!*$>)_"+0>*O"<J)N>/4=-D%U&$']YUC>+_MJ:])^#
MWQ'\/_&3X6>'/B_X95?L?B;0;34;;D%ECFB$@1CZKO((['- 'D6J0_!O_@JQ
M^PTT6AZW+8Z;XOL(WBNHT$EUH.IP2*^"N5_>PS)@@%=ZYP=K@G/^&WQQ_P""
M>?[/WP;U+]EN;XZ^#(]-^'&FG1/%6EZY>0Q2W#B+%P9(7 ^U/*S/YGEJX:1W
M3[V5K"\+?!SXH_L??MTR:I\&O!%_J_PF^,]U+/XHTS38LQ^%-=1"YOL' 2WG
M4$-T^;C^")&]T\6_LP_LX>/?',/Q-\;_  %\'ZOXBMRIBUO4O#EM/= KC83(
MZ%B5P-I).WMB@#QS_@D1X1\1>#_V+M-M]3TO4+#2+_Q%JM_X.T[5-PGMM&FN
MG>U#*W*[@6D [B0'O7T[0  , 44 %%%% !1110 4444 %%%% !1110 4444
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M('Y[U/IOP0^"^C^-I?B7I'PA\+VOB.=F:?Q!;:!;)>R%OO%IU02'/?)YKJ*
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M?#^EV^AZ#I=O965I"L5I9VD"Q10QJ,*B(H 50.  ,"@"Q1110 4444 %%%%
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MTI/_ !46C' M=2C+<OE"BN>2"4+'<[  &3_P4KT73]:^,/[,NE>'K5(_%?\
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MZ9H,UW=*9-*UB2^+RR0PD$[W@ 4R\?*VW)QBN+DTG3[S_@M-%J'@VT2":R^
MS/XPN+<;5N&DU();1RX^](%56!/.Q%[**]6_8G_:ITG]K?X'VGCY]-.E>(].
MN'TOQIX=E4K+I.JP_+/"RM\RJ3\RYYVL ?F# ?(?A'XG?M;ZG^W9^T-X<_9G
M^"ZWGC#7O%-AI,WCWQ,"FB^%]*L[01PL>,S3/YGF"%>N%<K(,@ 'T7X;_P"+
M'?\ !2;7?#3_ +K1OC7X-BUBPW<+_;>D[;>YC0>KV<L$C'OY)_&CXK_X)?\
M@GQ)XQ\1ZE9?M+_%W2O#'C#4I;[Q1X'T[QDPT^^EE.9EW.C2I')T=0^2IV@A
M0 .[_9P_9*M?@]H=EJ7Q6^(^J_$KQG!JUSJS>+?%(622SO+B!8)_L2<_8XC$
MH01J3A21G!Q7L- &5X'\#^$?AKX0TWP!X"\/VVE:-I%FEKING6<>V.")!A5
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MX;LM-34M4N-2U$6=NL?VJ\G??-/)@?-([<ECR>/05JT %%%% !1110 4444
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MGBEO'M_=1W<2XF_LJVM1+>QEASL*E<@\<GU-=-^TU_Q9C]L?X/?M)0_NM/\
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M@<  #H*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%<U\1?C%\+/A%_9/_"SO'VEZ%_;NJ1Z=I']I72Q?:KI_NQIGJ??H,C)&
M172U*G"4G%/5;^1M/#XBG2A5G!J,[\K:=I6T=GL[/1VV"BBBJ,0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;F$88?"X>-X35H^QLOBBW_Y,G\>SNW<_HJKYK_X*]^,O%_P^_P""=WQ#\7^
MO%>I:)JUI_9/V35-(OI+:XAWZO9(VR2,AERC,IP>0Q'0FNP_82_9P\=_LJ_L
M_6GPA^(GQ#7Q/J-MJ-Q.-41I2/*<@I&/-)8!0,8Z>E>>_P#!:K_E&9\2_P#N
M#?\ IYL:_:Z%2I5HQG4CRR:U6]GVN?YE9KA<)@<RK8?"UU6IPDU&HDXJ:3TD
MHO57WL]2#3/^"6OAR\TVWNY?VW?VD TL".P7XK/C) /_ #QKT+4O%_PF_P""
M=/P$TM/BE\2?&^M>'H=9%I-XL\47$NKW<#W,K%&NIT0%(0QV!RNU?E7.2,^>
M:3_P1I_X)[W.E6US-\(=5+R6Z,Q'C;5ADE03_P O->D?%WPE^RU^S%^Q3KO@
M;XD:,D'POT+PW/:WFEWEU)</+!(3B!'E<N\KR.%C);=O9<$8!&QYYTOQ'_:=
M^$/PP\=^#/ACKFMSW>O^/KIHO#.E:1:M=2W"*H9[AO+R(X%4Y,K$* "<X4XY
M;XV_M[_ ?X(_$0_""YM_$WBKQ9#:+=W_ (<\"^&;C5KJP@8 K).L((B!!! 8
M[L,IQA@3\B?\$C]*O/A-^T%_PBO[5?AW6K+Q]XE^']E+\(;WQ-?B<Q^&(PS?
MV;"=JB*>,!7DCP&*J3M3!WWOV//#'[7>M_M%_M'6WP:^-G@CPUKB?&"_?7=.
M\5>%);Z_ELRQ-C,LBSH1;&,L(UQ@8)S\P  /H[XS_M2?#[XY_P#!/GXI_&?]
MGCXA7+'3O!&M(+JU,MG?:3?PVDC&.13MEMYT.T\X/1E)!!/+?#_QMX5U#X?_
M +(5_P#$WXY>-=/\2:[X4LIM-L-.O)7M_$UVVCVSS#4F.?, SY@+G)=B<DFO
M'8/ &H^%/AK^VIKWB']HCPSXQ\1:GX'D7QEH_A/PW<6%II6H1Z;=+NS(6C:2
M1<E]C,=ZMOP>!HS_ 'O^">/_ & (?_4?LZ /K_X9_M2?!WXJ^-/&OP[T'7)[
M/7/A]=B#Q5INLVC6DEHI#,LX\S >%E4L)5)4C!S@@GR'XW_M2_LZ?'O]ER#X
ML:=\9?'7A7PC_P )[9Z?8^*_"]G/:3ZC<QW&P1Q$KNDM7?*,X&TX89RIQ\Z?
M\%9M%E^*7[2%UI7[+OAO7-0\6>&/A]/)\<IO"^HBV^T^&VDBD7396VMON717
M=5P6\LCY9!@)Z!^WIXL^#'C?_@F/\/?$G[/,=M%X,F\6^&5T"VM4"BVA2Y">
M2RY.V1&4HX))#JV23DT ?1OQZ_;=^"_[/_C:U^%^LV/B;Q'XKN]/^WKX8\$^
M&KC5;V*TW%/M$B0J1&A8$ L03V!%;_[.W[3WP?\ VH_"][XH^$NN7,W]E:@U
MAK6F:EI\MI>Z;=*,F&>"50R-CZ@\X)P<?/WQM^$?BCQA^VYXC\<?L3?M8Z;X
M3^+=AX2L8/''@SQ'X?:ZL-1L,[K:4NR93&55FAWD?*#L+$/N?L*?'7QGK_QH
M^+7P6^/OP8\#^&?B+X2DTV\\7^*/ D8%CKJ3P,T,TSN/,\Q(P,>:Q.UB,)M(
M(!]35\L?\%0?'/C7P1_PHC_A#/&&J:1_:G[0/A^PU/\ LO4)+?[7:R>=O@E\
MMAYD38&4;*G R*^H-,U33-:L8]3T?48+NVE!\JXMIED1\$@X920>01^%?)?_
M  5I_P";>?\ LY'PW_[7H ]6^.'[>?[.?[/7Q$D^$OQ&\0:DOB4Z)!J=CHNF
M:-/=W&HQS3/#'%;I$I,LI:-SL'15+$@#-6_V;?VU/@C^U'J^M^$_ ,^LZ;XB
M\-E#KGA?Q1HLNGZC:(_W)&AE'*GU!.,C.-RY\@CTG3=1_P""XSWE]91RRV'[
M-GGV<CKDPR'6A$77T.R1USZ.1WJKJ]OJD/\ P62\4+X57R]0N?V6))+<QX&^
MY&LHD;'L2,* 3V% '=^/O^"H'[+W@7Q7K?ABT'B[Q)%X7N&@\5ZYX2\'W>H:
M=HLB_?6XN(UV*4 );;NQ@CJ"*]Q\!>/?!WQ1\&:9\0_A]XBMM6T36+1+K3=1
MM'W1SQ,,AAW![$$ @@@@$$5\S_\ !'.Y\#1?\$X_"T<;6L3VDVK)XO6[*AX[
MP7LYF^T[NC>64)W_ /+,IVQ7JO[)'Q _9CU7]G;P[K?[.%I:Z#X#NKJXMO#E
MK/;-91R2?:)1((DEP6W2B4@C.XY(S0!ZU1110 4444 ?C)_P5?\ ^3_?'W_<
M*_\ 359U\[5ZM^W!\-_$7PF_:L\9^!O%7B;^V+V#48[A[_<YWI<01W$:?.2?
MD254_P" <<8KRFO] ^%J=*CPS@:=.?/%4:24K6YDH1L[/576MC\IQLI2QM5M
M6;E+3MJSZ)_X)0?\G^^ ?^XK_P"FJ\K]FZ_"#]D_X/\ BWX]_'_0/A/X&\9_
M\(_JNK?:OLNK[I!]G\JTFF;F,AOF6-EX/\7I7[G>$-'N_#WA/2] O[W[3/8Z
M=!;SW&3^]=(U4OSSR03SZU_.?CU0PZX@PU954YNDDX6=U%3FU*^UI-M6W7+Y
MH^NX6E/ZI./+IS;^=EI\OU/AG_@K#\1_VI_!W[5WP1TO]ECQ1JB:Q_9FOZLW
MANWU"5+76Q80I=O;S0(=LY>&*5%4@DE\*02#7N^I_M1>&/VC_P#@G/XO_:-^
M#^M7%D;KX:ZS<)]GN2EUI-_%8S;XBZX9)8I!PPQG"NO!!KA/VI?^4M7[+?\
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M!_AK:^)\'BFZ_:R_;/MO! F.KR? JP73A;9\TRG2Y=H3'.\]!COB@#V36_\
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MP7>7FAV,BG#[[N-"I"Y&60,#D$$@UXWX^LO$K_M=_MH6_P /X)%UFY^!]@;
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M/PM\0_#3X3_#6&*S\1P7!UQ+K5+A[G6))(V1OM%W(SS'<&8;LG9N)4"O4**
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MDWX,^/=/^)OASP1J.HZUHR%- N_$OB.\U,:2A&-MLES*Z18'1@-PQP17NE%
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M8GFQNLHQL7D-DXY)YKHM"T33/#6B6?AS1+;R++3[6.VM(=[-Y<2*%1<L23@
M#))/K5JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
MB5!.1PT*&@H    -24A$4@   @L   +4" 8   "%-W$T     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  %B4  !8E 4E2)/   ,$\241!
M5'A>[-T'?!1E^@?P)TM) @1"#0D!0I'>P8H@B,!YHGA@KQSVDQ//?IR5NT-%
MQ(9GA3_V"A9L@"A21) J-=0$0D(@0$(H"2W_?=Z=9WEW=F:S(;O)EM_7S[@S
ML[.3V4G8][?O^\X[,25.!    &##83P"    6$)8     )\0%@   , GA 4
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MH#!__GP:-&B0L<83PD+@G'988 @,4%;\=Z7_3?GZ5J"3#X5>O7IY-(.9]P<
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M>!T'!E^=,?5S$6W4;TCOX,BU"GI@,.,3NLAY0GFR.N&,?XDC>C>D45_M--8
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M7;^./]JH2R>9_BCS^HG7?WG"_$O43Z14+<G=RZP<V[?#F .H6!P8]A7D(S
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M,37*HGGB]<_.=O[!_/HYG3UN =5HUE6MUX=OYJ:'Q[_<0>/^E$0K=Q9Y]6$
M (#PPF.K<#C@41GY$4T.$-/^F75!'Z-R]_<3:.\O4XPE3]$XX ^/ABCO6Y]G
M,E)B99P7JV.Q.\Y05YGG,93)>6$X-U"1POG?)->P#!@YU%BR%O'#/8_NF4@\
MK7NXO>TT^]:6-+QU35KVC[:6S\MDMZ^19WF/Q0    #A075",-^>6L=72\@M
MJ/4^"V9O_)BC'GWM"P   ,*/ T$!    ?+%- ($,"@>+3AAS    $&XL4T @
M@P+O:^[&0F,)    PHU7$@AT4.!!G_JU23#6>.->I@   !"Z/-) ,(("CPY9
M*ZZ*L18  *)5I%ZN&^F733)W(@A64.#1(9LU:V8\ P   .%&I8)@!@66DI*B
M'@$  "#\J+M.!C,H@#4>S4Q&-)-YOO5KJ-&/$P  HI,#02%T=+CT;&.N\D@X
M0$    #A0%"H'-S11SK[O//T:^JQLLDQZ<<FS,L  &6%+R'ARX&@4#EVY>4:
M<T2=VW0TY@  (IM^ZVL('[9)(9!!8=8?^XTY$.==-]B=LGL,[ZL> 0 BE=18
MRJVO6Z:FJ<"P;"UJ+<.!95@(9%"0?=DY4EQDS$47;GI U3X 1*NXV%@5'#JV
M;J\"@U[;"J''*RP$(R@,ZE)7/5K9D9-ES$67/CW/->:(OGGM$V,. ""Z<&CH
MV;$;[2O(1V (81YA(1A!P=>^HIG^CR*E$<X1 $0WKF78F9L3DI>0@Q86@AD4
M6K9LJ1[A%'.?A5\_G*GF 0"B%=<PK-V\WEB"4*+"0K!K%&K4J&',@1T.#P
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M7"7-WP0C";]/KHKG]U?1I+\ _^Q@7Z[$/9Y+JT7P%P>:0/>@EA#S^YKE" P
M%:BBFUHA<-PE?64%!3M<2/#PGY%2P\"%-7?B"U0A6A9<[6[5L3#:\7TI$!@
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MA;[7'G^>!I\_P%@"  @NA(7PY@CUH,#*$A0R,C+4O)4VS5L9<X&WKV"_,0<
M !!9/&Y1;59108%'8,S+RU/S'_^ZA]+JEE"M$[O5,LO.SJ8#!PY0?GZ^6CY8
M=()FS/^#LE;^J);]%<QOTS,7S*&[QMYO+(4^U"P 0$5"S4)XLPT+90D*+6H7
M4UKB4;7,W^P/'CRHYAD7](M7;:)U.45T0;O:5-410\\]]YSQ;,5"6#@%80$
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M],[3KZF"D:?DAHV-5U6LARY."4A0X!$O;^A45.KOB&6\=KUZ+*OX6.NAL@$
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M8<8?!<92V>W,S?$9)L+%B@VKC3G?RA,41,.&#2DK*TO-!ZI&8?7&=1'Q>P
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MO,6KJ5?G5L9:;\$,"EE96<8S  "AC6L4ZM5)I,8-DHPU$&IBLO**2LH;%+A
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M!8#($<EA8=JT:>I.RY',$8B@('A?$A1V??4?8ZVW8 8%[GCX[;??4I<N7=2
M2HS'>-AXTM4D4-%!@<]%:4$AH<, VO'N*-N@P'A?1=GK2P\*?)OL[YX/^Z
M  "A(^;1SS-+ A$4N$:!^RA\_OD4=U P6C@\!#,H,&D*X)^]9LT:^OKKKZEJ
M^ZNH3D)-CPZ(^K'Q:[@SIH0FOKNE^7E9YG-Q[8O?>C1CR,_<NW<O??KIIW3S
MR-OIW@^VT-D-"JE'4X?J:&@>O$F%FB4[Z?NM,31A>#*E)-4WGO%\#S)O1XZ+
MSX6, \''_]%'']&UUUZKG@N4BNJS  "1!S4+X<T1R!H%+MPKJT;!"M_>^D"3
M/].A(T4^.S-R+0#_3'_.!?=1L*M1J%^_/MUUUUWJ,M*+TD[2R$M=-Y]:OGRY
M:AH1?*7"G%5[:$E>+9I\:P<Z6+!7K3/C<\',EXK*)/2@<&AOIEI7O7IU]1A(
M39-=33H  !!='($("ES0<G5[>0OW0 8%[J/ 30\MFB31;7T3U4B+5O2@XT]0
M\!4ZQ /_>9VNNK"=JA7@Z?SSS_<8Y?&G-?DT;?TQFCSF<A4LN.8A)R='C10I
M-0D28%AIYT(?67+/'M>MJ3MUZJ32KDS7WO\R-1I\+[WSSCMJ>O[YYSV>_^]_
M_TNOOO4>M1]\FWJ]E?A8W,D2 " :69>T3F4)"J%6H\ X*%2K6E45[MS)L4$#
M[UM7^QMTN%]!:4&!"W<QX=$[C3FB&3-FT.^__ZZ:0[CIX>M?M]&L';'TVO4M
MZ/#V5:J&@(>4/G'BA+K\ADE_!SX73$*'>6)Z4.#:B?;M77TS^#(>KA;C:4_M
M<^F\_D-H]\P7Z9QSSJ%6K5K111==1&>==99ZOF7+EC1HZ VTL.0<NN]:-#,
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M[#EX:E]VET=R!\>%V;4HI5%]&G%N+=5\\=UWW]&"!0O4?NWV+1HW\&S* 0"
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M]\7[S_[D835?K\\(]<CX-1P4^!A*"PIZYTRKH,#OT=^@4!K95Z"" @<E\^_
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M_VO,12YW:1G(H"!MZ;Y$0E#@\2EX7\$,"H+OXS#IAQUJOC*"PM47_\68 P
M77Y^OC$7N52)&0E!H4[6=[1WTP+5&= \[=RYD^Y^:*RZU?7B5ZZAZZ^YPGBU
MI[(&A4!==NK/N>"1&;-R]U9*4&!U$NS/!P  1#9'( LTV9>OR_B"$12X<%_S
MVVP:-VZ<\8RG85??2#_\M$#-Y^_?3U]\\86:UX5R4)!]C1K00-T0RDHP@P(
M $0W5=H%HD#SYWK_8 4%*=RYJMY*]>;G4G+\$36_:=,F:M&BA9H7X1 4>%]\
M(Z@&#;P# X(" (0#W+,D?#D"7:#I]-[ZP0X*CSWV&+WXXHMJWFS6__V;7I@X
M41W/].G3Z>VWWS:>"9^@("0P+%RX4-TH*I!!@?<% !!,Z[:DJS$+^!'"AVVI
M5]8"K3)K%%C/GCVI0X<.[K$&%J7GTZCWMJH;67'A?N:9KALG_>4O?Z$++[Q0
MS8=;4! <&/@&47SWR/O>6T]]D_93O1KV!;V_08%#!P! ,/!EDSQU:-666J0V
MIY:I:2HP+%N+RRG#@67)%X@"C?$W7[[!U*B/M]+82QH&+2CHG1D[=>I$[3MW
MIX?&/D^3;FQ)-6*K>&TC4S@&!<'G@F\S_>CEK6G@^5W572:MWB-/S)_S>DEG
M^_,  !!(<;&Q*CAT;-V>YB];1/F%!<8S$(J\2K] %FC[#CO4_0TF7=.23AS,
M557G5AWTRA,4F#1W3)LVC5IW/)-ZW/ L)1;ZOKLBUSJ$<U P-SVT:=-&/3*I
M7>&!F]CIGE< @&#CT-"GY[F4O7L7 D,(\R@! UF@\8V0>%]\(R3>%Q=F7'7>
MMFU;%1JRLEQ5WF4)"GQK:+[\4;XMFZ5T&D#+UFRDE>_^@YY\XG%CK:M6P<R?
MH'#!,S_3\_^X-&A!0?_VSY-Y7WR.].>9.2CHVPA9]G6?!X:@  "A@FL95F\,
MW9L0QL?%&7/1R5T*!CHHF&]9+7@T0@X-AP\?IO=^6%VF&@6Y-333"T?&?11X
MP*6-*^;3VK5KJ4>/'NYOV#)Q_P6N4>!M_:E1X-M9\YTH[90G*.CXV/[U^FPU
MS_N2PIZ'>=;MW)7G$12LMF%<HR##0?-D!4$! $+-F9UZA&P?AL8-DHRYZ*3"
M0C""@M0HV-E'29196(TN:7?"6./-WP*-:R<"/3(C-SU41%!@_NR+;S/]U =+
M/6H4K,@EK+[VA:   *&(FR3BX^*IJ+C86 .APA'( HWW)4'!7*.@DZ:'1Z]L
M1YF9F<9:3Y4=%"JJCX*XJ7\SVK=OGPH!#S[XH*IYD9H!#@KWOS"#_MPASAT4
M7G[Y9??S,B$H $"XX^:(K5D9QA*$"D<@:Q1X7_X&!=D7-Q=8#3(434&!]\5]
M.G[^^6>:.'$B/?744ZJYAG%3 ]=P<(W"X'YGTX<??JB" F^CX^WX\E5?E[ B
M*   P.EP!+)&@?=5EJ# N% \=.B0L>1_@=9XZ*-A'11D7[KAPX>KNY=)4.#C
M%[PO7L_C1.AA@EGMR\R?<V'7M $ 4)'B8Z.[,V$H<@0B*$B-@J]]604%T;QY
M<U4%7Y:@<,45(R,J* @]*%@-DL3/!R,H,*O.D@  @<!#/?L[#1@YU'@5A(J8
M$F[LME#6PC&U09QJ-^?J<"'+?/5!:5<]K%ZWD=Y<7LUG@<;[XJ"0T&$ K7JR
M;]"#@KP7?\8K*&M0X'W)_LV_ @D*W/3 YY59_9JL]L7T;?T]%QSF^+)4.[=?
M-8(>N?5>8PD H&PX!$0J[F<V?OQX8RDR69:V90T*O@I'+MQ+"PI<H#T[[WBI
M!9H$A:SW1U=8C8(_G09/)RC8T8."KWU]N&"W>BQM7_X&!6[2 0  L.)52@8R
M*"1?_AC%I;3WJT";\\-'[@&7K";>EP0%[O!GM4V-9EVIZY/S/ 9OLIIX"&H9
M<(F'@[;:AJ?*"@J#FAYP[\NJ1H$+]UU[\CPN.[6JG2@M*'#3S]?SUKO[?OA2
MNV8M8PX  **-1S-$>8("%ZXZK@7@H,"]\ZT*/*87:+ZJP/4:A>Y-:]&OO_YZ
M6H4C\[=&@<_%,]-_]GG\Y0T*<LYX_Q(4MG\[CM[]OS?H;W_[&[WZZJOJ>=Y.
MCH&#PE>S%](SHRY1RS_\\ ,-'CQ8S<O^>/"ITL[%YLV;Z8PSSE#S,[[]GH;\
M^4^T<>-&-<*FE=<>?YX&GS_ 6 ( *)NR-D/P3:="C=U[B*IFB/+6*'!A)A/W
M47ARU-]HV_^N<Q=R9N;"77^]/O&^N#,C]U'@&@4."DP*1AXZ>O7:#73[RW.I
M<]5-90X*? 4 7[K)!27OB[]MR[D(Q)TT_3FO$A2:%OY* R\\7[WO7KUZT>S9
MKE$=A702C=^[E';NW$E[]^ZE^?/G&\^Z\)@,_H2FI\9/HEM?6TY;,G;0XD4+
MC;4  ,$1BH4_^$^5F.4-"CHIT$HK'/TIT*0MW>ZJ!R[@TUJUI3=7Q-+=E_6D
M&X?VL;Q1%;,*"HP'A>K6K9O[WA7/O+= K0_$N?#GO#+IHU G/H:Z=.FB@A#?
M;IN#BY#S>F6/6*I3IP[5K5N7ZM>OKZY@D$L>.2BDWO!2J>?UES]R:6MA/#U[
M;1M*;E2?&C1HX/&S  ""06Y37=KTS6N?&*^ 4.$(UZ# ]A<<I/]\M\>]+_V2
M0IU=4& U:]8TYOPKW$?<<B===M>3[G/!!;O4<MQ[[[WTKW_]2\WSOK@90_;%
MZ_EY*]*9<<^>/>1PN(ZO1HT:ZI'IG41YX":^#;<\WZQ9,TI/3U?GE8-"X;HY
MI9[7">]\2X_<V(_J)]92^^%+5^?-FV=L 0  X$F53.$8%+A=_OWTNM2]Q@Z*
M.[Q-U2C\]--/7FWNOH(".WKTJ&I^&#MU(6U9^SO=,[R'\8RW1QX=2SMJGT/7
M]&Y&2^9]9ZQUX9$7+[KH(KK@@@MH^.VN.UY*,\:33SZIU@\8,$!MQ_A<"#FO
M<IOI%2M6J$>N/>!SH7<2K5JU*G7OWEUMP]/99Y]-1XJ/J?/*04&_V9:9G-<[
M!J10CZZ=C+5$??OV]0@G  "59=V6=&J9FF8L0:APA&I0F'1C2Z\K%83>+G_[
M-8-4,P)/QX\?IR-'CAA;E1X4V)(E2VC-D9:4E-J2QH^^C%)34XUG//&^WIT^
MB^Z[I WU[WTF39DRQ7C&A8-*4E(2S<^H2IM6+_(X%TN7+J7&C1M3<G*RVH[/
M!3<]6$E)25'OI77KUK1^YR%U7O6^$UQ[4J]>/16*>(JOE4B3OMNDSH4_08$#
M6/6J#FK2I(FJD>!^#[P_5GSL5( ! *@,1XJ.J!M*06BQ+D&=*KM&P8P[_3%?
M[?*#!@UR%WS^! 56K=UP]5A::+K_DTW4XXPDNN2B\U3G0W.3!R\O+TBEU);M
MJ6-: V.M2T)"@NJ+P*^KF5#;W4?!C*]JX'X('(SXF_Z](X=Y'1=O(\^KR1FH
M9KYZC\_SRMOSU282P&0?'#;DY_&Z+IW:&Z\  *AX?'OJCJWQ.12*+$=PK.R@
MP(4[%V!\:/S(9+[3H[]0WNK9/K]%\TVMZO<=2=F?/.SS-M,RCH*OJQYX7WS?
MB]QOGZ."I=.-M>7#^_1U#XU@X)#EZUR4!I=. D P<?-#O3J)U+B!]Q>I4(%+
M)S6A$!1TDF5X7RQN^Z\5'A3XOA>^@@+O2_9GAPOK5@]\7VI0X,Z,_NSKC'_^
MK+;UA9_G[7P%!7_W!0 0+%RC$.I!(=IYU"R$4E PURB,>F^KJD87VF&[^=OT
M$,@K0/S9%Y\+:7H(A0 FS/O"H$P 4)&V9672OH+]JNDA'/HIH&;!*=1J%(2$
M!CTH6$%0..5T@@( 0#!Q0<L3!P1N<N"I;IU$ZMFQ&SHTA@%5DH1J4.#+(X55
M38) 4#@%00$ 0EF+U.;4H55;-24FX/,G7#A"-2@PWA</]VR%:QQX\O>F4"W^
M]J$:).G.@2F6S_/$^[KPE17TW=MCU*VAK;;AR9]]\4VM.O]K%DT:_X#/??$-
MLJY]\=M2]^7/#;)X7S=-74&3QUQN>RY\[<NN"0( (!!X=$8(3XY0# J\+U;:
MOH+5F=%7!T1_]L6=!E.N?I;VSIM2:F=&N=F6'=Z7C,SHJV,G[TN_*Z<5?_<%
M  "@<X1B4.!],:L[49YWWGGJL;*"0F)LM0H+"LS?PKVTH,#XN4U/]T=0  "
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M^O=VC:F0PO>'X'M%\'TC4HSQ'%)NH2D;5M/TFX<X?\Y!54/P@ON^$;[VH\>
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MWZ)3;WBI3)T9_1EP20IW_M;/W]RY.8'[ O R#[M\_]>[Z94K4]WGM67+EJI
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MGC//RZ,^R3I_FS(BD8,+>3TPV'5FU .#U940C.?Y2@@)#$VNM;_TQ1?NOP
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M;RO+,O$Z?1_R<^3UT4A5'9AK!_3 L/_@<<O.C$P/#%(C(4$!*@:G=)GT90"
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MP52-V"K&6M_NN/JO],@=]W&O$.[H8*QU44NF=> IK7\G]9CQ\QKU6)E"Z5@
M(#3)YT0TB,BP\/KL[)([+DHV%D^1&H.QES>EB3.S;3L]<M-#UV8UU#QO/WG,
MY7X-^8R:A?()M9H%U"H @"_^?F;Q#:;V%^2K^:S<;#I\Y+":%WQ?(?/M @J<
MK_GD^R^,I<H7L6&!9_3 8.Z\:-?I48*"-&/PZVZ:ND+U$"TM," LE _" @"$
MD\KXS+*Z*55%!)"(;8;@0I]Q8+"[RL$<&,Q!021?_I@:E(D#0[6Z*73@CQ^,
M9SPA+)0/P@( A)-0^LPJ#WD?OD3DU1#\/ZE5&/-9IF508+PL5TF,=X8&JZ#
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M@6'$E"VVG1DE,#P_,X=&?[:=Q@]KBJ 0H7;EY:J0T#(UC7IV[$:-&R09SP
M0*1S["L\9LQ:2TFH2JNV>UZ3JN/7YQP\3LUJ5S/60*3AH+"O(%^%A+A8[X&Y
M   @LCFXZ<"JHZ(T/8R[LKE[V4R:'B8,;TK_O:*9:I+@#HX0.;AO @<%;G(
M (#HY."F W-@,/=1L.KT*$&!7\^#-$F31/V^(Q$8(LCJC>L0%   HIR#"WH]
M,%AU9F1Z8# '!<&!(?N3A]V!(>VN#XQG(!SQE0Z=VW0PE@  (%JIGHT2&*Y_
M+X.:U*UFV9F1<6 H*#JAMC,'!<'WA.# D'3)0^2H[KK!%(2G(\5%E)A@_;<
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MM4AM[NZ=7[=.HAH<:%=>KO%LQ9-CX8G''^!Q""()!R((3P@+  !.B0EUU.!
M^PKR*[6607!@Z-BZO0HP )4-80$ 0,.%-*O,&@;!HQKR,,@(#%#9$!8  $RX
M>6)G;DY(]!N0P!!I31(07H(:%DI*2HPY (#PPD,1K]V\WEBJ7!P8XN/BT>DQ
M1$3C%4>H60  L!%*!;1T>@2H# @+   V4$ #N" L  #X$!\;9\P!1"^$!0
M'XX4%QESE0_!!2I+3$F0>R'&Q,08<]XP)"T 5"0>%.B,YJUH4^86M>S/9U P
M!Q+JT:$K+5^WRE@J_7@J8E"C8'TNR[&'^^<^OP]Y#[Y^'Y'6P1\U"P 0520H
MA(*R! 6 RH2:!0  "#K4+(0WU"P   " 3P@+    X!/" @   /B$L      ^
M(2P   " 3Y4:%O(+"XPY    "%65&A;V%^0;<P   !"JT P!    /B$L
M@$^5.H+CG"E?48O4YL82  !$*E^C'48BC. (    404U"P  $'2X-T1X0\T"
M    ^(2P     #XA+    (!/" L   #@$\("    ^(2P     #XA+    (!/
M" L   #@$\("    ^(2P     #XA+    (!/" L   #@$\("    ^(2P
M #XA+    (!/" L   #@4U##0DQ,C#$'   0&5H.ZJ8F7[*RLHRYR(":!0
M@  [?/BP,1<9$!8   # )X0%    \ EA 0  *L3662N-.0@W" L   #@$\("
M    ^(2P     #XA+    (!/" L  % A2AO("$(7P@(  %28;5F9M&Y+NIJ*
MBHN-M1#J$!8  "#H^+))GEJD-J<.K=JJ:6M6!BU;NQ*A(0P@+   0*7@P-"S
M8S=:NWD][<K+-=9"*$)8  " 2L6!85]!/@)#"$-8  " 2L>U##MS<] D$:(0
M%@  ("1(DP2$'H0%   (&?%Q\:A="$$("P  $#+D*@D(+4$-"R4E)<8<  !
M9)#+0*,):A8  ""DQ,?&&7,0*F*<W_Z#^O4_)B;&F/,V9\I7:H .  "(;&4=
MZCE4O[GS^Y!C\_6>TM/3J4V;-L92^$-8  " H(NV^T)$6EA ,P0   #XA+
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MJE<!H'0("P#@MUFS9E&/'CV,)0"(%@@+ . 7#@I]^O2A^/AX8PT 1 MT< 0
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>@2 (@B (#8#_ 2IP&$B:A9E0     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_11.jpg
<TEXT>
begin 644 image_11.jpg
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MW2#CUJPU9,1TKRK;5JU;.=?GY];HV*9U&^U'?_"_L,KL@GWI]_[ :O.+71T
M 60(6Q?U\7)8$VV-9L"T+J4Q+HBLQ-7R@F%<EOHH$?0A(2"O+(HO"?JD#+[H
MJ&Q==#D0!MZ%A9=:3?X8/BI.4.ZE#WD3>E;6LQQ#WI"?/D5ZZ<?ROJ0*>2S0
MQ=B&MQ.P+IL7Y)&^M*WN?*UH0D(L\M: V'<)1HCZU^V3KB-"G]]G40\:Z1/
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M; NV#W\$=OOB,JA\":2#&F0O3D[Q,P"^E-[E)=1K1M9:7Z&DU*R"+9X<YA3
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MI7*?8U'\XRD78QEL+[;AC:$' *+'WP?-40%*G_J2E4S":RFLH].=\#\OWN-
MR8L,(9_LZ1WH+WM #H^!:+_0[7J]:;?==KMMW+A)CJQBM]UZN[?9UU<2EMT1
M1J1__:IK>'A0_)"S5O^)0$CGW(,+YQN!$0VI+\+PM"RQ 4HO]+%=#2/ >!-@
MX219< @3+.KV>G2'NN@7&'1#(BR,:2 \]T!%4A4#9^B"AGGI5K6J8*BR:$TF
MW<B6V@B3*TU\I+L1?:*E(\X<^8-6KTOT@2X.;Q ]F!.%U.?7C(_0)ZBDJ6_8
M@E4Q1:-?B\XZVPMT'NH./((_R Z!E ?*R?%*&"9!@7=<HY.<,R[H)+9M47)?
MDSZS<!&Q6EGPL>5["W&""3ULP2/8A,X8R* _$=,!#D$+:1Z\J,V6!G=6?G2:
M\5*?VJJSH4H;ZMLBDT'=W[%WK_$S6DL!9>!KQ#"!#[*$;:[)]J$+T!<6 C@&
MWT2$$)^<\;3*4LC6TI6(S"*3(*O=]>YJ*<<$U68Z2&;L?4+5;-O%\8L*'*M6
MD.[Q5"IBWI\^2+#AM^IEG!O(*GK!DU-=QT TC2'03)#KB+IV^RKLIB7I<=49
MO>"(_HZL76.C:]>Z/P"0) #V1HQZ[7Y52+_8]C>V;IUBDS4:=Q9F+D6WD;(_
M8+ MLI>I\TNPF,*"\NI84CV\V8<W45$6W\38,Y;X@S0&.ZQX2_9R>'C(QM2W
M-:,C-C(\;/T#_;(_HDO(PFA1=?DU<5'*UET.\3^13LYIWWV2ZL&NYG.\7KFD
M8514U-'D,M,GF2SX6XJ88$!SM,/(?0\D5S($;XH3Z9E.-#(QC7-F4:QVLR>7
M5:LS)T]+@$M6E3(4\U+43E7!G@*N/AQC24HQ),5C0*LV.W/6-F\<L(G9$W+R
MH_:KO_R[=MV>V^R__UL_91<NG/&5H<&!LJ^V/O30-^P?_Z-_9'_[Y_Y'V[OW
M>EN4@80*OA X4!JPII5%#S1!<W# 7/#X32?NQ'1#QB($$/[X1W>D=[ZB3MZ*
MC(M*T+5E$!Q@2.=(&W$V[ZFA4;\+;^3>2'7P1V 1R)< ^4*=."_1F@+G+W\0
MY]=A!KIV[9CMOW%OZ$L7@H%GI6]5$'\B>*"8@+?O_)'A@09=,XY-9>&=TB=.
MGO!7U)'.I"8'30(OHR/!*\$8!IE9.<8* \(7\DH*9/A1CE_[M?_7_M6_^I=V
MXXW[=6^-7;RH25>_QDKTPHL3)T_:/_MG_\S^PH__!=N__T:O"P5F#R+-R25Y
MFP!;$]P)J@^\5N_$B1-V_ORX&PB0E0PQPCE/'8Q87A,P K9J58& /B/#(^&'
M;$3+P/" G%2H.PWN4)-SC##]]30=(Z0YG:["QTW F"_.+]CITZ<EQ^,BBQ^]
MP3D6NGD 5C"B(9^:F?:]CKR:DB^%\>4P^A'W0L:&*,\.B6PD7M><T;]PEH#2
M"3C<^>.,$PC-9V0T9VUN=D[T7?#O!>"<"#)Y;29/GP($>49G") '!P:E=Q7;
MNG6+;=ZTV1U5@>7XE.PY[Q-^I?M*F_X_36**WN5Y!;ID]>C95U_TU\_Q0UC4
MC;%GY1JGWP65Y>D*<MR7+=HZ.4WXQR3EQ9=>ME_\N[]HW_/Q[[._\3?^NLN6
M/S50 -3IL!>?0+YD_^0?_Q.;D;S_[;_]MQ0\$FQC0[*R:X1#0<=^^]/_SG[E
M5_ZY_96_\I?M@Q]\O\8M;U__^M<D_]@2MJ9(YC3&35TOUA0D!.J\;] .PK/U
MZ];[CRL-#0WJ'A/MP&,"%P#]@!L^=E79I$3?R1=YEF1UB+P>&AKJUL=**H'-
MA'3E6]_ZEG5J8=+GJXBZWP4_5:U*BS(^),>^9_\-_N-/[,-'_PDTN!_SA(+A
MNN5IPJ0.O\,QU4Y\0HA,%C)LC9)-TUCPRYIGSIZQR<DIM\,LB*BP5\\31'H.
M;V(=@1<9&QT9MAL4K/(4Q.V6_)#3IW*^-=!S)?_UYW1'TH%NGG1BH)F57;9D
M\M0+648G^$$K7VEMQ%%56=6!>_65_*0:YX?&#9OTKG?=*;WI3VZ$>TY'"J@?
M>:0/#;7YLS__M_W[$#_RHS_B=H#[K(8.#@[9Y/24ZBW8:P</VK<>?=3>^^[;
M;>V:M?Z:8FPU=<.'IGC,=W*"7PCV;%AV!1J]'07OZ#*O=.1M1\A_A#AFF SL
MC-L5I?'A/&X)I4ZR<F0ON75D?V/?L E"S((DV^J+LNO*.STY:4\^\80'PRRJ
MS=5F0GZ!MR'TP"^1#?1@H+_?-FS<Z&]C0G<<DF9"&=I(Z,$G)S+&TP\R\IVS
M'$)!1JXS3&AETY47SM"?&8WO],59^;TYFYR8M&G98OQ;Z'O2F( %&*"H@+8I
MOTJ-Z,BZ]>O\.W3XMJZ_C\64B7JXY'^49<;5)XA^%8!^..A>O(&O)_!&]N8T
M<4.?SR@>FK@XX?J-SV7K9H3HLWA:A<\>'1JQ#03WTI,^?RL0\4]B.YU_^(FP
MTI^FY5((=\E/L,[V/Y\(2<Z@'%D[?_Z<G3YWT5?M%Q<7W 81AZ&S; '[P/O>
M;_OV[_->(@\L1/H7[+_#X6W[Q5$,4S1(S*H(RO[:7_MK-B@CPG+QQ8669G#]
M-G_QK/6/#MM,;=[Z\GV6[PQ;J\;*(?M<YU5_S<IC_ !.Q?HJ&^1,?]BN?_ Z
MFYE7N@*LR?%SMFYTT X=>-G^^,M_Q#-PJ]87?.!1P*)F:;EVUNK>2_Y)$5PX
M"&PE0,H39;^F3+E<ORL[*R$N+/I//PHJPZI.E-]EH-F\K)V?(N"TC3$I%'&$
MX0LNS"C=^0D#+0&@(P*K]6F@76KMRBGEO J,C8P *Q>ZZ8Y7QFZ-#/+>&_8K
M6R@0E3X:X]5(S[#_M0M+YTPR4$Z3,A.<,5M?4'!>EU'"<9Y4 !V-/H_$8I .
M;6X$A/X*,#=ZX4>FAH>&;=/F33XS)T EH/NN[_J0@J8Q-R:,L7\?0#)"GTZ?
M.6W?^/HW% "PWW>]CQNR1'^\3QJ/"/"7-!S*Z=-G9!#.N_.$OY1IR(BU-0ZP
ML(^52M5%_PB:&O).&' <$RL+@PIF!N3TNIJ1] V(8PAX/U6'?X$O&7\@'>0L
MTX_DO$^R,3Y^P0/@V=D9=PJ^>H6!3F4G ,?P<X]'IER/*/C8I !X6$? @]ZD
M?=JB;6\SU6X<CU35WJ9?*U\;.8J@='AS6D%'98[5P? $+-;!%\^B/'J=*D]P
M!^WP$'IP3&-CZWPL^OOZ)1O!\2"/&&:^[,4CY"5Z=!;K1.82P*%&H*T(]!&G
MP;[/8Z>/V[3DD8 "6N 3CX'1)>CTMR"XQ4=#<E84XI#6*:@/*^4U>T&!^LVW
MW68?^>A'O?ZP):8E^12]A7Z_YL>VV%;'JT(')"?H!WU>D,.A9_3GU+$#]OCC
MW])$;U2!]EKE*]OCWWK<J@IZ"NI6P?LF>5&$TQ)=?!>&7KD,"9V7ZC/RQQ8P
MY)&Q0,>82$93#0_A,V/'I\M(OQWRL-J8AK!HP*0BZ$Q).E:OAB^^CTM7*(;^
MT 9/%P"G+>$[-BVVCR,?V[#1)T;8-B!\25:\3FB!/LJ&8".,*?WS/HI^UU\A
MU]Z.CLAP17:W+Q\FUDQ*IQ2XS4S/R*E771=*R)GTE?-%5D_53C>H4$7>EFB
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MU\<-7JI][GIV&.=T!CV*8YF&&-SXN>Y3ACXH9G.Y@%ZVUU47*S:HB9\_M4F
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MI6"._*)=;1 HXPO@,T2A4N@>? (:P;P[Y%5WADF:QF.$;1H+<W;VY%$[>O"
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M@L#W_1J+LXJY#OE."B:31?'[QW_LQ^SO_6__BR;5?6X;?-MK+TA_>X-T!)@
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M[MKIJ]7^94(95>J-C@QIH!D,BN(1M1L> 8/(@6]ED6/'"6! @U&/ADLS9Q&
MW&#P6=7FG+?U^.S<C:.<.\8*0U)8HAU#",WPT_N<.% >'^+P'A/]SSWVJ-55
M]H,?_*#=<LLM<G@UZV=_,6_PH2U]?-5:>2S+%XU7&>L41%HC1G!^KP+D21OO
M6,[I%;*-*'#0,[O3YA)>$GCZ'D\!O"2-NFC5ZU5]E(2O!#?1$7,-+]R AJ0
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MLJ<>?41ZTK8['[C?[KC]#M=M:&!+&\$YXYX>_[X23R5#8.KRI0^K7N@U>NQ
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M 8SH*DJ)<II(\/I)-UCHIY3,?[1)["AH$L:$K2F#@,-@&X$;<RDXP29TDQY
M;:M]TA!+5A51>I3=#:Z4G'K8<H%1Z.27Y(U@G]4)OHQ*@$+ SS8@C&).^5YY
MZ3E[Z'/_R:HS%?N^/_MG;?^[[[9IOF$N>GC:,6 %T9RQV49-8\EK(/O4:HI?
M:@IC*S8)8GJ@,XP%1BF ![()8-C3H"9"L* Z8E ;QCF9V"954XR\ ,%Z7U%\
M]B ]_.H>0& *KZ@/GG)..1YA\L4''#PTLSKLD X@O#\<"=*7;QN"UTQN((#
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MKMBX8=$GE _U=E%MA2 VJ4<0VPY5+J4#L3_Q?K>/W%16[X>,'F_]X$LTOKJ
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M<K9V8\.JHUG[@V.OV1<GSMK+]6D;NZ'?[MB=MSM&LC;6*=J1XQ/VTO$S-J/
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M;V4J\.M>!6M463X7NS331G81)!XW-3(8EC !\55SG@BD90O)Y8#B2=!=D*G
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M:*XT8FF GHAO%*+A6XG0_U9 FL8NK?I#5E8B'','%.5!>8LR_MVW)21\)U#
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M!A*Z?0??:D"&XNIS_!)BE+MK!>CSH%OE(ZW.CP2[D)PZ;R5+GE^?R#?GW56
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MG<K9N6K1*GTC5A\8LB9&YZT&%%B*P&,]E#4:$!YW^P^D(, 17"^"XI _&@.
M&2J&F_*DDQR-2E2H:X&AH2$K]95L:'C(A@:'+%\L^!87E([5<YW8P." K=$X
M>GOO ( .>.:!D^C#",,/7VU+^!0 Y@0#@;'D'GF9_ 0Y#0;Z3QN$?BP]6@88
M>_KIDRD7MB0 D2SS*/Z-R$8/WC@P!HR'/UG46"&?C URAYSZ1%'"QS4K7"[3
M?P+.RVT2.H&LH S\*2T&#6\U\,YD9)&WY30;-3MYXIA]\^%OV#-//ZG)3-9N
MW+?/UJX9T;EH D5'-H/NOK% Y:T& B:W'4)7J43/TKKX1@"=[LJ, KFX]2,L
MZ@1]3O[UX!H!?^F388T90+".#,9Q!(-_^,\($$[U<VAHT$9&1CPP9_MJ#]ZY
M\&V)KC#J'H#**0'SL_.^(GO^W#E?.;GAIEVV?ON8#8Z-V@W[]MA'/_0^^_A'
M/V0_\L,_8O_=7_LK]M-_\[^UO_.+_Y/]]9_^[^V][W^W79B8L--G+MJ&#9ML
MSYYM,MH#4J:B34U6K97ILZ'UFRPG(7SZX '[YK//VNY;KK<U&\=L(-.R/1M+
M=L]M>^S8^8OVT(O'S=9MM#5[=XN>1=L]T+2M.[?8,\=J]OBK,W9FOL\*ZW=9
MM31DTQC*MR-(5Y4^FT\Y15:Y/;@4ORYQB.3'0;G#7!H^7T&2 E(FI >#D\9K
M@>/'C]OS+[P@)_F,'3M^S&J5BHV/7[#3IT_;\6/'[(R.,],S[CS /W%PVQ/X
MTE?L"Z_&TV3'@PSXD>:C3H/C"\ZO.P;*RS6K&LOR_RD"EPMD()G<,>[!P;._
ME'X&^> 8 HIKDXL>O'EP?=28Q+VZ(1C0Q%#7/LE4'@\2V&J2R"5C]^T$]*$;
M8*(OHI<OI/N^=&3I+08/D/1A<>*L;,M##WW#C_MNV&<?^N ';>_UNVW[UFW^
M= ]F!!GVTS]Q\$ ZT3.W'_I FM/H="[9Z3<$ZF.H.SPE<'WF"< ;7$GM0= O
MG@2SG9/59)Y<MWAKE.MB>%+!1.@_-QZC+LAK7U_)MZRZ?_Q3ZNN^4^!-6@\!
MXQLQ.?"-Y)Q088#.&Q(,"3^.*=-ON?8Z&9@-]M4#I^RY<;/-6VZSVP8K]N'V
M07M7:<'R.]]C_WY\JSU=&;.[;K_>/G;+5OON[3/V7;?/V88']MD3G1WV]5>;
MEA_<9K?L7&/7ER9LU[H96[\U:^/5:1O,K[%6-6>G9C,VT7^=G5DP&U# NUU$
M#;<OVD#VE/65%NW\A44[/3-@M34R^/EQR]<;5LHTK;]<L'(Y*VQ8/E.S3K5N
M)>NS;+5HQ6;1VA+H>IZ^-:W8J5DSMVB-?-,:V98U<BVKJ8ZZSML%]3?;MDS!
MK-YN&J:[2>R7[[-.OV;PA;I5LS(0F46;;\]9=D"&N-2T)NFYBE647LW)>!1H
MHVIU7==LP:J=!5ML:Y)CBU9ISGE:I] P$6>M7,VOZ]EYE5D0#57K%!,LR*CG
M186C'(J.A?Z\Z%ZP9I:WVZCNVH2-GSUM!UX\8,__T2/VU.]_P5[\TN>L<NQ%
MRRU.6463JA<>>=Q>>^$)>^VE;]JQ0T_:Z6.OB=\MRW<4%.=YO5[!^]S*U:V9
M$=VB,V(C4_&^-#-UD[OO?EKB5ZU=M6JK$J[%QW9.SBC!9E:!P2K(FWPBUKU.
M'<6!EMIJ:AR:[%Y1/XOYN@UIG/A!XKG<&IO.E&6$J]:O?$-MC6\C:Y7LB#A7
M,)&O"1*/KI>\OZ]0$]RNP+#M*&P!*&1TSO-2#7*GH0"KU@B_&I<"=^0R^B'X
MX5$X$/<S2U;DT#&8$0$/Z-*/"),Z@&X00+EDA3,$@.*?] [D6_*9#(_S$3[*
MZ9HW+*C?(EU2>>6 BSJ="ZJ?P%&%+:N^T8.B*LG3ONCW'^%0$QP#/VA>[;$:
M!2]4CC+1/E"6ZX[J]'3G%_2LADL /^BO.U.=!R0T"A]5129'TN$// <B;ST_
M]:320 ^"W#F')RPQ_7(0MY?X%I.D37!9>AJX3[T^9D&.J!]Y@$;OBW+$(#D\
M!5(Q3PW@=.D8QN5RL,0[QAY9R(KQS;8,HJ[]L3;R*CW)%"6OF8XU.M)#Y:]T
M9,_R&NM2P9JEDFQ0P6KR%)66M*LEFYC3O4[1L9TI=8_-;%EZ6);NE73-]H&"
MV@VRT6G+8LI&--K]"G[ZU*S&OE/2!*0I85A4/MF_5LDJU:9-'#MN[4;-MMZP
MTW:_:[_L:ELVNV!9Z2;I6<FWA,86&K(ILAT^AL*XV.'CI?K@6?S 9W(Q'G%,
MNQ^5T:&;%TC=%;UL.U2;L2$.L0YA' >.029#+:Z3B5Y&H#Z_)H.0TTM0MUR7
M'$4[*+VB&9?/I(UH-]!A?*R/M_2]R9NY^/T.Y=>?YW5YTSFP5/=R1"=7PT #
MYZ)=N@%RCKZNQ(SXE)&_NP1Y4T^"1?&S@%U0O4T1U<GR^R.2?<>\'[G&USJB
MZ\I'+X/E4SXA>9KRQ#71QH8Q2;7+D?=7;6;;(?9H\J80R796:85"5GZF)I_;
MMOF%&6O,C_MW'UH9>0?EI[U<:]Y*]6FY#K76+EE._@'9@M> CZ[_B?.B*_WV
M+J=1Y\YLH;)YOE F\!&U(P]O:9'JJ1W9ZV+;YN3!U)+)BRIF"!F:\,CRUM<H
M63^!A^P#/K&C@0'YU?:6^M<BUDALB?[$!^Q_777(#_'+09*'A&MB1</.GSEM
M$^,7;&9RVNH5Q0?88"<L]!$(,J;\SM0D,07P(Z/['N<)0]T:";45948UZA]C
MHRIRRI54%4:2'[5#7A<UI!7+U6KBO<94MD,CY6^AZX'T+SF^3>!#)&!8-"@$
M#!*F6KUBX^?.VOS\I)45*%9:O(9KU$I]P[9^2(9\:M+:M8H-C8U8NS)E69QF
M:ZV5"YMM:L;LS'S=1H?*-E"6<Y#E7I0,^B1 G[H"QIES$Y:;;]I'[[G=ONON
M>^S)AY^W"]/G;+Z>LZ=?F+:77YJQ_7OVVX]]XC9K'9ZP5U]^U2I2DJ.5!7OY
MP$G;LWG4[KYIAVT9&[#*U%EK+TS:N@'>CL%[NR.H;_PP@T23[M'3E7@Y*,D9
ME>2H^G!6BU*JBG+K6*@K2!3F:W)@2@/SU;SB;P7 PD)#,]\DG3(@>9D\4!?W
M"U+DHH[4WR]U[T\^)1FAH@P@F)<!4$W6J;%R4)$.-6QB\IR]].(S]M)+S]KY
M\Z<L7QZP[;NNLSDI\.3TI#N_<G_)YJ8NVL:UP]8G0W'FQ!%[Y85G[#0K[=6:
MOZ4"A<8=]/'&"K51;*C=E=A4NL8<+,A*,\<H--0O6=ML50Y Z/..F$?WKH24
MB]A:E(&2L[>ZZI,5S2M @!8&R@-8&1<WY$IQ!RU@C["G>0".H5M]!$GN.M\$
M0P"P!,UF>+O.Z[U%):P<BB)H21 C?BT0#'+ &.S1A[@O%R#0\Z=8A;P'&^Q_
MY@O!<1+BWQ>Y H0V0K]8=?+O)6"<971Y<D,;\"T&0%PC+T#\K@5]B[0ZGW4_
MMLTU8Q/'8C58QG/XK2+4RVM. VK2IHEVQ+ *MH*?NN[RFDNA;QV0@R(PY[Z/
MI<BB;'!05S\V'C0EN#J03B )AB<9C!7?^Q@<''#>=!^]$Z +?8N#,/+S:@'>
MI)'^4$=#X\\ON-)??@V6K76 OQ9/DZ;%NL88?B@ :M3E0&4C.O*L.5V7^LJ.
M!!*\]07ZG#?BES\5$$;=\3YR%+;$QX8<=YU)@(Y,"#J:"+-EA7WG.?*(GJ9P
M_,*DG3QW3K9_S&ZYZTY-ZK,*P$2[)@M#Y4$%4LJ[6/7),"\%:.NX) -"C3TR
MSHH_.@W+7>ZZLN.#Z_WW+Y=+%\#XVEHD$C[1-Y=KE6$\&2N76Y4G'4#>2:_6
MJK)_5965+<J++TS E6])UI"KP N:CX"_2LM,Q$OD-@'*QGJ6H>CU]E0NK@1S
MC;[#!^C%-E_+$YD0\$6$:-&F>J,\!KDB;3E>CG8FG^B3ZQ3?)=#1^8(,)!/4
M(/-+O"\D3Y-%@=<;@T5TE*?-W.>I:;E4UOV,![9-^3=_G6>^I*!0_A595=FR
M9'M /"A H\;[PM&C=N39I^V%1[YA3S_R=9N0S\OVY>W4D4/VA4__ACW]Z,/V
MTG-/V87S)]6N@D<6%$0G=&#7.4('LJL+]5U]@R_(E<YGY!]!?LU\KJ  7#A?
MZ-A\T2Y! OTL.D:=PKRP*#KKZM]\J6BS8+E@<SHN]!44#@]IDCOB:!Q;H]UK
M/V^-6"F_03YOC2W,R(=*Q]>,#/MQ9FK*GGWF:7ORR<?MC[[\97OFZ:?\[4GB
ML(_'U8"/A1#=8/SX,#;^W3C9#A^G%8!MKU0JUB>;H]*N^TR.ZM5%7^2!EWPO
M@+JP%Z&&E+)\!\.U6?YK AB<,)DI([/9#"OJ"[9NXXC=<=LMMF?W!KLX?<H.
MGYRV:G;,CIV>L_.'CMJ#^\?LGILVV_$S9^SXU)Q52EOLY>,9>_F)T[9G3<D^
M</=6S8HK=NKT>1G:@C4TVSU^9LX=1Z%8M7SC@JW+SMAU@UF[==N0K2VW[/B)
M27OIH(RQ[;>U8WML][9^NVZX:;<-2LGGUMO+Q^;LY8FLK=LR:!L&&[9[K&0;
M^SO6WUY0X#>M('A1"D30I;ZX!&&H,7H%]1(S(F;2S11>%BHJ)\Q493S;FC>W
MRM:G8UX!;%X!=Z%9LK[.0$#N)T%Z<5EZOY<M=12 Z[JHP+_0Z/,Z.%)'OEY4
MX"NG(<S4U&Y=AE&89W5+79FYJ'X5Y 2KFIR\])P=.?RJ34V.V^CP@'W@0Q^Q
M!]_W?AM9,RKE6K!:LR8'OF C_7UV^\TWVLW[KK?M6S9H6&O^9:[IR2EKR%%5
M%A;E*.569:A@5X')PR58$+T$ZC*T"MCS31D[85&\5"],/57?-*%(\G#_2ECJ
M%%56DQ5AOI-G3=P_.07Y.5WG_!VLP<!@4#$4\C[NY!@JG&-(PI%>WCC@!''H
M2Q@<81J"PPG.YG* @0/<*>L8\9I 541ZG6:J5"7>/_JC!'>>[EA;@2YWZ/ !
M)QG*7PFB42:@&U! 62J7O![GA8PRP3OG](3Z,+C<IR%WSJ('<#I#A>%<^<(E
M];\^+2%_@@GO*.<.7NC]PF%P3W^!!YPNU0E'2 ,CL\D7MHH%&IG,X/CI*V5C
M_B3[ZT+D$[@:A%3Z'IQ2".)"  ?_:(@V^= ?$/K =#^N!M*T1'K@'>]YIV^1
M/QYP25^S"@B&1D9<WT>&1JS<5[(VDTR"/.4I*@@:4 #:+R3HZ=/0%;*:/+0;
MTC?5F='$6C8^#RJ,Z*+248.<Y@**<^2D"7QY*]2BM6H+)D^M]JM6E+[P+N4J
M/R0G.G;OWV<#HZ,*ZD6GQN3\]*15YRM6KVB"6).^,9=18(.=72D#\!9V(?O.
M;SZ)[$0VAO%F+(*,+ 7'2_+K]9$!/HE? 'E)!Z)LDT9))CU!QT);5!<Q!KS>
M8 2_MWR< @VK ^W$>I9CJ).R85Q#'7$""F^0:R915P>!_C12993%T$;@WZ6X
M.JAG*D-PCIV@/ /(9() ?8G?SO/D2"#.[WLHQ?Q)'/R1GK0DDVW9'+8ELAJ/
M#&"'&K+Q2)T'Z3D%@WE-3)(@O:1Z\JIC9OR"O?K"B_;LHX_8W-E39G,35IL\
MJ_HTR5)[BS-3UIR?M=KLA)T]<<2>>/R;]LPSW[*IZ2D;E3PR(? W,=%N(FON
M[U4WM#G*GDBQ',-31.X+E8\883EJ8J<\>0_2I4_B"<%Z47W+JS^ZJ_[D-5E5
M?]0OKAG%^'24%6Q0%D2T+%W7Y+.9 !<+.:M+QTZ=/&Z/?/,A>_BA;]B)8T=L
M<7[.)BZ.V_ES9\+3*8T*;0=)OC)X__EHG'3P\<6&+<G&<D"&F!3GBS("T*EB
MO)VII0D"RP09%@\U7IJRR5]1@EY>WG]^)\'5:NT; PE@<N*&N:F KFD:J#ZS
M/;NVVH[M:VWMNCX[=6[67CI>MZ/'IWW[P0/7K;6=Z^4D<BT[H*GFU\]D[-4)
ML_6:3;YO^["]?^>PK1TJ^+[H5XZ>MFG9^H5:VS9LW&BYP6D;'9FU]?T7;:!]
MW@8+%;OKCLT2QJ(]_W+5.N6UMF7G6AL=G-.] W;;=:.VH;W3'OO&E!T^6[!M
M.X9MVQHY)3F1?M&ZIC]GY6S+Z@O34@($&$0J01X_27%T[HKJ2A>0GJ>#"6;Z
M!&[^5A0I94O*C?)QWI'W8O6J(=E&Q7C\)ZMJ&0DMC_/(&[&IN@-F'!O)D8=-
MK4Q RGBZJ.C(._HU;5*_L*&V>%]]5NVVZDT[?_:<G3AZW+\H>LN--]N-^_;;
M\/ :37A*,EQ2GKX^.?&,+53FK5*M2Z&RMGG+5MNY\SJ[^9;;O$]'7WO-CA]3
M'00X<@IS,[-J/:$+Q1-=_GA2$X28YND8(!W9!@3Z#T2UZ9=FWF((JR,8W8@8
M7X[D2]=#?RE#63%/_&;5 R67"= QAP' V>"X,)[J@P?H&)O$$?FP^EB)P6E0
M.L;'5VOE'/Q=KPGRFD>,$O<(]LB+HV;ERNM,@3L@I7&DB=ANVODUJ3_!L+I_
MJ<'K@NJ(]/*)X$%&TC_/I$-H,Y4'*RD@;2G_<HP0Z?2\K&PE_8"7_@N@HI6F
M&.]0(!XX"1>T['DHZ[2$_EXM=/LII&T@?,E2)^$R!"/B/7G2X/E)6I[L]$.[
M[[-60$I01[^I-_:W"SHEH%YME2C":KQ+ _Q [JC,5Q555SC*L2G5K^%)TA_N
MQ8E'G$1<+3!&:>R.G\[KDE6W3;%_M"E'?N[H83OPY)-V]/GG[= 33]KIEUZV
MTP=>MO'#!VWB^!&;/'',IH23IX[:U)G#-GWFB$V=/BP\8A.G7E/Y W;NR"O"
MEQW/'SM@%T\<]#PS9X[:[#F5/Q7*S9T[8;,J-WWR-4\[?U1MG#YNIX\<LJ("
MH35KQV1S9 -E'_KZ^FU@8,CZ!@:M4"Y;IJ^LH%\!&*@\:1F@?^@?O []#GU?
M^OA0.G"$!6G=X=S'Q/F=V :",=7%V"-*O/$CCADU<H^G54R&@XQZT640TKTQ
MIY5V^%P+>/&D'B^;ZG<$IS=!GS!(7STW],9RJT H$_@%Q""<_@(<PQ.@@#'O
M);B2H 1",$X=X9P O:U O=5.[*EXZD^T7,>"3C!)[,!K[(N*,*KM!H&P[N'#
MI+?U:LU7@L/WCZ!!5:N?_()XPW]DK*'Z6C8W-^-?1G[UX $[>^:4#8^ML1MO
MN\GV[=UEPYHX6DTT+,A^+]1LY^;-=M.^?;;G^MV2N;*]>NRP'3Y\V"8F)YQ_
MV!F>4D!G"+[5:Z$TS3^E5M;6U@*.5LR&%SLV4NG8FJK9:!=#VLABV_KK\D>J
M+Z> FBUG]495?=7$HM*T@6K+2HIM^I2G+!J'*IH,=V8DDQ<<L_D)QUP!VLX'
MS(R'Z\QY&QI>M OGSMKSSSYKQXX<AH-V\XW[;>^>W;96D^%B7CY8;2(E!6R[
MCJL!LN-CDL@1\A+3_%H?MYW2 P:!M C("_FXQQ9@?N6<,<E*QGC+7E^B6TRT
MF"SSJ_2JQ--Z(+G_A5_XA;^;G+\A8+#2D!X\C 2OB6)07GSI.?N]W_N" K&.
M#:X9M>_[OC\G1>D7CMBQLTU[XMFSMF_/'OO [5MLK$]**8'M6[/6CEZHV^>_
M]H("PO7VW7>MMW4EL_G%JHQXOX0B;U]_5$YEHF:WW['7JK-3]I]^ZU_:NF+=
M?O+/_X"5!D>LTLPH^#]NU?9:&UBG^L[,VM3$>=NQ+FO#Q:J-GZE;]6*_C>X:
MMOE2P1I3Q^R&]0.:<4_8'WS^<S8_-VMCF[;9V):=UBB4K4&PJ&"ST%&_U$_V
M7R+8.1?TX$C#OKJ\E">\N<&J<_;J4]^T11F4L<V[;.VN/9956^SQ[*B?35:6
M%&HV%=TW92_:"H@[!=564. I*]"48?-[:50^V8)+TU/84IZ&URWE<J.H-% *
MP#,!'%RCL6#//_V<^'#6ONO]'Q8?[Q%O-]KL0L-F+IRS5YY[PMJU>?6M::52
MT09&QFSG+;?:8K9HQ8%1&QA<:[7%AHV?/N./L[;MV.H_F+*P,*^Q5B"M(-_I
M2>AM.&W0K1J%#<E+B\ *)R>#T9*A($UAA#_F)IVTF)_'\DW==Y3R=^O1>0OC
MB:%6W]KB?UO7])L5I'G)QJ&7G_?5N%V[K[?MFF!DBYH$N3.BA%!UQG.-@)\!
M?M0_#\!45QH)"I=6X:@B..W@]%1+K$00=<//?:M42 L0#5[B3'%62N6VY^GF
M"Q#K[\)2-?&?0ZCE]6%9/2F(9>$& %W.F92A]H T*>[7]-V=>##,K-3&].#@
M)==*!^)YM!7DN]RDA'M=<,:$M%AW]ZA/F(0MI8> E%ATJ>YNWP@LH L'I?SQ
MB]?TSR==;S5 2M)G#_I($"WA*!HOT_\TQ+RO.[(>"%T*I.*,:YJ<HR/'7GG>
M@^1<9<%.GSPK?7_)7GOA13OVTHMVXN7G[.C+3]OAEYZWUW1]^)67[;677[!#
M+SQCAUYZV@Z]^*P=?/$9.ZCK@R\\K3S/*O_S=N3E9X7/J=RSCJ^]2-[G[?"+
M+ZANY9$O.'G@13O]Z@NJ\TE[16DO/O.B'5"[)Q3<KUV_T7;ON5Z!!C]8E+&!
M\J#U:9(]/3]AAY]^T2H+"D!D.P>&98L>>%#]4;"N,7-D/ -[!-V390 /7,<2
MC&73$&4K59D#^5UF=?2*=-O?M-5M=_4VE\$5LC"^<8PCQ.:ZR3HZ?0Y^IPM=
MVF6U5P(YT9(W#[&-E: 65JT^ZI)X+O\II1-B1Q1TRT=>.#]N)P^^;)GZO&W=
M=9V-;-TEOI;"Q =^^U$!G,:)@#C81_D2Z3KW"  90GX-G"?>F5;#S_/R-]E<
MQ@Z^=M">?N9);V_OOKUVPUWOLCTW\LKFJKWVW'.V.#%OI>R@ZN[8=?R@X9WW
MVM"&S;;YNEVVH*#YPOE)FYF9L5)?GXV,CGA/>%+!2C_=32/[^ OJKIKV<[E@
M!=T)ZCS+DVSUH:#RK<4%.Z?)Z9DS)VQDXP;;IABH,- OKR5(^JSI@"-[RPO"
M3'9!O&>Q##L'7UF]ET<7=M3WCKRGHE^_5ZW.VPO/:<)\85S]WF=WW':[[=FU
MV\K%@DU=.&]3%R]8:_:B#?<7;,?>?=:_<8?\J +M%"S)4P+):;!AHA3A%)#'
M;3RVW&4OE@E'[O<IAE"DH_.F;,3SFL0?L[+*%Q17?>3]'[0;;KI1L0+R(?[@
M/%/-?J?"I5K\)@$CM@2<XZ2E3K["R>.G?NLK#FI&)0<M^9J4<G0T2RP5\G;X
MT$&;G)J2;(;M$M-S=<O5*G;'=>MLI+]CT_6J3>& !P9LL=:TTZ=/V<CP&MLA
MA9Z9:5A1QKS9+MCX9-6.G:K8Q<F2C4\7- FH6GEDTO;?,F!;MF5L>GK&5-1.
MG!VQQPZ<M;G.>;OWM@&[8VO6%BZV[<*T EL)S;QD_=2%*9L3?<6A-0KZU ?U
MC^#<95;<(PQ$&<&,^H@"=IH\^I6@2L$PWCQ$DCBKO^Q[K%E%GUJN;I5,S9J%
MIE6S=?_R:3W7L(:0M&:Q%;Z0*B1OQ'J^D4*E"3DZ%I;?)W]5RES-5*UJ-:NI
M':\GRQ=,:Y8IY:TV7[>9B5G;N6VWW7S3[0I2^FQN=E%*W&=]_4-A1;O"^U15
M=T.S_%;':BSYLZ+-9$0*O4?*O7YLO>\Q.W/ZI!C3M#%-B')]JK\@.H305H,^
MCO0IWW)L%-H!BYJ,%-B'UQ:-;:OFX$O(1UI$OU:^6BH-;,2RF@3691GK.28]
M,N":Z/!]&X)X>5;1)NHD0QCN9 A]3+GB.ERF93A(<31 _CYU.80N%EBI5]6J
M,Y8+=24U8FBZF-SC/ 7435%6D0@,'66,PU&2DZ+'S^.EGX=K8C+'Y-;; ;3-
MI+LII\HY@35;)YBH(.>0XA2H?_&<OH$!0A >^K-$:;SO1E_W^$1PWJ2N ?+
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M-QV$+ &*D)PF0!D4WU>QI" (OG_)!@.,4L@(Q"$E7TYCX#-WKU]*W4GVO<H
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MR!LO?2>>>>+)./K$5^+N/=OCXS_]"U[NLI)GTF\$+I/XD%+ ;A]0YM0N"X\
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M.V5Z#JJ.W6J26TYTG='!*I2&11A\VD@(]<\QF2DA+D=LWS*/')TOC3GE;Y1
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M:CNGY8D1'67*Z1K@#I.SO'MBS.?8,ARCFT8Y5\QH<L3*01>+MRE4Z]#[\)V
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MHQJ]4>-R!=S1>!]/C*7R;&B$R4S/<*LM?GG9DX\XS,;*XH)'SFJ2?HZVHE:
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M61_747P-C$1SI16CJ^W8LCH:XWPMC,>5RG>NL1A#4X,QOG,T)B='[+0OK6H
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M-Y,?))*MR $U6,>W_WB2P< S1ZB!HZ!G)4T)S^@(UP%2F)<Z(]#4CSHIL]B
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MYN9T+D=^M1LS\W.Q+!XM"\HEOHN7^'Z'3:KJYN'^^^\W7KAPP>N5F=W#X*'
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MZ&,?\M[!)]\Z%5=GYTUK#AVTWB^YX^2="JQ-4WK =T4FQT=CV\ZM<I;Y2-9
M3$YOC8/WWA>'#M\7=Q^X)Z9TS=<&1R;'HCTU'B-RTBG[PMQ<>F)!W;#-H^BR
MW&5Y:4'U2)G78ON./:JS:7]*>7!Y-:;:$S$V/!:S5V;%"[L2M?U%.MK42D-R
MU,!Y7/785ANH _*PG*@WB0BLJH:#Y&*=5)P"B*V2G2#I8#JZ#:DMN#T8DZ/N
M,-T'JSRI&^A7YSTTY'Q I\L#MP+0(8RV@!XXGO+!0<=1]\QESE/_[#A[MD_\
M4$:'DX=HF([SSGFD6PK3_QS7T15/9[UX->"^Z4L'<FK]SQ:/,F7CDUX>5V2T
MVHETKP^MSTJ39K56U)YD RJZ"8IL^GGA&CY2./GDN/HAJQ1$IR^B^H_,5##%
M4=X%8,MESO+; $PSRPY40+YS+7#'S^ T8'%]*X3'Y8,>P/3S3YCJ2\']B B0
M?_]O'1#'?-?.\Z\X[750%.L*9Q2!<JU?A[YQ^0TD+B@@+P;IUC_E@UQ8>L7
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MMV'E?M9MH^[?"(I\B4L=N2.JR=^H.BOE=F89J0ON(P/S9*RUA\22>;$SE74
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M=KI&7L58L1]WX='.,SS?Y$QZ#WIYIMF2;" ;N5Z$ ,>RM(4R@T4_D9EG5#:
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MBZ:/1%TV^I=#U\.-\TV0<H3>^C2IG]S<[M\V*,.>7509,G+MFWWE-4\;Z =
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MI+1DD@,$J)_K6R@2%9!VPU^F84P"-6])SAP3K7)>AY2'T#RD,A%6G-KUL7M
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M0%\L5YV[#&2EBR2C'A1[Q7T&2GYR8CU)3UO*3#KWH5F>2)"&^] L#GUIQ_U
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M4K?NVL8P\$CU0;V@IQ4O CNSND?[HW,C'8X?&;FCK96YCJ0I0!FAL\Z9O$G
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MSL5E;*,T=TF^S4+:IWU9<I,DI:8*EYQXQV1(<='<.T +O0-WX [<@3MP!^[
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M'NOK(,4K!+C.='M!FP-I4>@-:$/#O-8(44\4HYY?'?BX3+EEOD3;.I>"$HA
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MI>79./G&*W'^Q-%8D(YOFYB*S_[T9V/+MBWF@YZ9>KCCI*M>\_&VH3P"0:
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MWVE2.W94_Q,H&)_'OA1AQ,^_.A0:ID,T';U,-T]&@$P,^#L&]'?U^!D2CS<
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M$0<>>C0NSRY%HZG17J:%,I9Z1PE3IZ/&PU%*2D<TY$XK ?D5]&Q:AGK1L%D
M<:!-5F[LO>@54(92KD*W'VA(--="C\=*YM.-:-!..9E0%AH9D8C+7J&D(\S;
M1M5HUV7I<]W#,/%XZ,477HQO?/,;,7OI4AR\[[[X[$]]UGGV R-7N.N':\N$
MX;ZV7'4GO0!U4)R0.H_O"E!,T?8@0^=E<(-1X@F$';=-\JP&-1F*<\F.(?W
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MDL6J=QMAV0=/ NQ,T>>K3Y*6F?=B_U*[]HFO =MMX8IG4%-]4\>.*YF7IS"
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MY3 -RK$?D/,WB ,^/"9GE6NV$)0SC$,.,G.,$RYGDJ4(?'T4IS0YIJHO[JN
M"=$KWI%0@==8EM..8>7=$NV!)DZWG.N1Y%@/"(?:HW)<Q_QAGD$<8I41I+Q\
M](VRK^)8N=Q"Y>4/PHF70=$;:HF&T#2&1YU'^6"</QI'?-%2!@E%S_+,Z9M*
MVU+>3:5MR!D?U'&MA2/<B 7=[XB_1>GWTM" PN38HJO,@,MU'&@NBR>6Q*C>
MI+=%!I0?V7#.'N?^ )&N6QJ0C$Q,QJ"<[D'S0KE$&X=43O9R8TR.K>I-]=4
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MX%<%"*C?C7AQ/=308:)'W6#0./JO'B=%NWT0#?B!%G4.%G[MI"J\\-HKQ_4
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MQ1[M8'IBY6U/;:2O+24'>"/@D_9]J.CE4R?YP("=R/;D3'@\#Q\.L,L9/PY
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M2>F*N14I#:--!(P,]9EGE# >.%=Y4!5&LDAU\]!U A._679>#_K!#_EG'.I
M9Y:5/6ESW7D'F#K"01DY#+#L98=&EZ>3L0B25LA,/]WM_A3H?'*O+ZW?BC09
MXCQFNGU+M"2'D'<\S2I"Q _YG Z<+^5)7*^O)$.GK<[3!T+#Y)D@\^K(3W'1
M >23.V)^@P,FKC,6(6+'#WJ#0#B\YKKG![B$]"\P\<-% 9R>ARO/;MQ^+$*1
M1CB2.6U\\&B0/H(DQ!U*9)ADV=7_0OS@6]?.?I3!PQ3D98-6RA]T?4_U7@3J
M*3L]X[6JC54KHM*QX\>/VN+\K&V9GK*:TDWB5,G&EE2?6^5PE77N3V42#2]+
MRJL?8I<1Z'/,O'"D;/D($L[1(8IT2G!9*AYZ[^GUR[R(5#\-XNF'#"(?\H5?
MA;N\-L8@E)!B^K]B.459-+M(6TSGQ.5(OLY7CDM;%13O0Q,9Q=[C<1^(^.(E
M\=[CK1<'X!)TUO3/99N.&7&$7<8Z]\B>D+[@9'H;09=? ?P").6<_I9\EI>7
MA2NVM+1DBXN+-C<_;\LKRU;7H&YM9=61)WO-M;H[0Q6EG9 3[[/OXJ]:4O_-
M;'D!W#;H/M\V\%W25'_D2;_/I)S;@E0MR)4B9BQ"5QX>)S#J)9+G]D>Z;E+N
MB7[1[F3<"+*=<42^3D0W$E'R)5,&?$"VX44D21<X=SZ"YPS41RR=XSRN.4DE
M]%_<C/C1ERHTY<\-/YR'/CC96IZ'30/*Y4ME,,@HG.M:&(XP'J&0^=/3_BE>
M-00:7A?I^ J*?AX^7L"0>.<AH"Y]MDIUF1T_-SQG&T32#6U1+QS1*0SWR0!/
MF;<XSYW;.>#OK +M@PXA\RN)JZP?M@U$J7&Z-I;C9F3C''F[CC1=.:N#P_&B
M27\:H"A'ZB>?AQS/#83<8]G+KAW;Y4 MV]._>L+N_]E]]C=__0/[R0]_:#^_
M[S[[Z8]^9(\\\(#M?_--ZS2;GA9=(OW:JIPO.6!>5UV(NL]M!20^<;J._7DX
M^Z!Z1+1%/<J(,]>;\/AP0/VY<RB@/GD:,S<WZWI ?^L30*IO?X)!/&7+C'E5
M S:P/%+RF?462V"$K(GO\.5R?Q*Q>9WW;T_0QTN_/C @,QW@,R86N(KEF3V;
M^>%E=AY^?>"\D_X!06.^, XR"KU9P-2I8QB$S*#CG._?O]^>>NHI>^*))VQN
M=J[;.63T3N)\N_OX(=4!@RXL)4;19][DI/E6<C*:9[^>@B#&.&_UV$6,M/</
MO4P91'"5'X?Z,>E</$[T2)](\)D4\>>/ZFDCXAM6\TSMAX,H.,YUGPR+<NR)
M<6.@$U1<3Z-+>.1Q/;K@[UA\"@ QN9,P3(X>83."/%/HV=.EQ05;7)BW]]X[
M8$\_\;B]^=IKOL3EP-MOV^'W#]I[[[YK[[_QNM7D$%U_[;5V\267VO3TM%-A
M5CT_!<N0Z][K4FGR/?+"/G]XW3L/&P%UFI=TYJ\F@UR?:O9WL^#TL1^B!_!5
M[=G9$_;\\R_88X\];D\^^:0]_O@3]NBCC]K##SUD#S_\L#WRZ"/VZ"./V",/
M!S[Q^./VT(,/VLLOO6S'CQUSA1D;J_G[,SCJ8M1IGPYH'UZN3<;?"$)FT?XH
M&]18PA.3!5+D<]'\SL,G%D:D!!]*HV)D%^#.I@#%PJDIE34Z'97AU>_XD2/V
M3__1'\OH/FV?_])7[7._\SNVK/N-TIB-5B=L=)T7\=09BA[*R5?E<#[RT@ '
ME%?H^?"J=@'@PV=3&#4GP C$$AN-C.ETO+,F+7_QY<5<>,))[\Z#CN33;22D
M$<").%(:W=<9#S:1'LVH,MJQV@@?S%'^I9JMM4>L61JW]=4Y^]%_^-^M?O1=
MFZJ6[#O?^I9-36RUUO2,K8Y-V)*,0(UR=UHV7MYJG=&FK=8KUNR,:6BNSJ:Z
MK%Q/W2ISF0)P)+L779!;)"H]68:\Y-QU>F',%D*+LJOK<C+DS-%?J!$TRF$,
MG2/%'P2?@9.! 7B#?B+7DVBZD^: Q/03$4+\*.PH(W:;"$FSS(07F<QFB%M!
M5BJ%.MFQD995.GR,*7@9A-9(4^52^=9')0W5@^JD)0.WSN?/75:4C:\[DHOJ
MG$Q'&U%0I6FUE#\&,3F3K@>I3'3P19T_'10[(AQQ?WR8TG.=[W/.+]]3K*'Y
M>!Q^HD-]#6,E&_9S#>@*/ "^-"3SKF,^+[8?(/-.V^ZVL21;TN 09XA9I$V"
MLH,V\BSFE\^C7??T->0(A'/(ST$'OU(8]/CH$T?*QWI=Z RK%\ _FS\$<K#S
MDOB)W3%Z="#I2QI@L4#'>7,D;N98OPUXR-!9[PTHT%FW?Y+UV-BTE=?7O+T=
MG5VU9^_[H3W[D^]:1;;H6W_\#^WJSWW>CB_5U2[&K685Y[>CMM$6=DKB>80=
M.<I65>L&BO6;7W(F'P:<N2Y;+;6M)-^L&Z#O#$*8ZFP45/O#)MO2@J=]Y?77
M[-$GG[";/G.+77+9I59>;5F]M&YK:KN4?JI4M?&*ZF>L+'NY;HMK:M.U22M5
M93O%4W68?: -)GZ=;_%!G8(^4%8?05K" >P\$A\$WS^^ +FO*,OV^UIBR8$U
M_Z'#ZVYG>I#.=0A[%[SDP0-T_)RDN@]MY%74WS[ SE&_'=;:4^;(LRP:%=45
MB#UKZ1K3UA9/G6;=GOSI]^SIGW_?=EUPB7W]'_R?;'+;5M=QEF62<:-15[XJ
M"^D'8$0*A'T%X!UQ>9TZ>C WO(US_V0[P+\H4RXW0-M#OSF#WB!P?]#N0WMM
M;=E^==_?VG,_^&OUIRKN!1?80DLG[-+2$$]K]&VS-E)E>4K51NNR%3RR85ZC
MJ;IL=6SG%1?;W?=^U:[]W!U6ERZ.-MK^KD-[HF:U4>E4 ;!?] _^5 !]IWS(
M-=D?RN"V CM-7&0OGR:7E?M1SXJ''U*0#>'QA%W]E.*[<RZ=(H[+,MT#N"9]
MUI'305&'<O1"U@Z^O&4 G+\<+Z>CO.*U"-"$9\J9^2&MZZ_"FJMKUBFK?.JC
M7_C5H_;<+W]I<^\>L._<?;?]K_^?_]5V[][I-$J5E'Z0N4\A]&KL+ +"I7%[
M)4JAJ,BVG% >):&H_N(.BBC,2T%RQ9\KR,X1OZSLY[K^FVN+-J9.96GNF,T>
M.6@G#A^T1QZXWW[UY*_L]=??L ,'WG,^=NS8X2^55BJ\+8X3$(V);2JQ> Q@
M3H?XEXZJTA$YQH.((0_#VH\^0D\8!I:*T#%A5$POO*Q>!<2Q92NTDU'WE1=8
M$GV,M*-29YI!%]5C)K6(.5R\)?UIJ:/H=-3!R&!"#V-:5>?<:>/DR: -0<^#
MLGB><4W^S ,Z2E!TCH&*(:=?A.,H'"WA,$1B-T)$07^&&*\S@:[1$I,@Q:6>
M72]%F\%AQA3U9%"RGOYN@"GJ1P/4+YU*."EB((4'4+9>F:)<\)@[-8I)9X93
M5G30@2SS36&B[YV^'P.AS1,M?Q2M<W\<+61'CZH0R#-@T=FFHYQ,^!P&1?I%
M/!V(0_%(?:<Z[\->6!%R9U?,9R#*::&H&RYW[^#[\RT"83@/19[BNH<9_#K5
M@0AWVTMV*@!>H,_(DZGLJ'C$!/#%"V1CXV/>1M<59T+.XD477NPO^HW7QN6,
MRUF:G+3=<L!V[=UK59TWE4>C*:=MI&13DU,VICKUEQ0+/!8A^*=<&64G$M_=
M ?4&:4\%T,GE\L&GZ'5EXUI>!.HBG#OR)?^(%;SHG\?R"1\!85F6PX [Y(4S
MAY[3A_#$H#OS2IR4WNM6-H]@>*.]^(!117=^]<LOU^:Z/!UX.L>D+PHC/R\;
M=B[%Z==A^$CQD_X$/]AM;$J4>3,(#1W41S3\NL8.0!/C5AJK6FE\TFK36VUR
MZPZ;WK%;N,?&=2SOV66UB_;:Q"47F@R$K:N?69N;L\;*BOA(?85H^0Y8DN,@
M>)_F]J)0?UZVL#_.$S^5'UM"7'_223JE89DL;02=\25 "G?LRHOZD7ST@XX[
MYND>H*A)QR(_\,P@Y0<AG9]UR.6!OOXH/WJ5[0@#6-;Z2T,1IE5&=4YY58SL
M,YP#KGXM(5O+LPJNK*H,C%XV1#R&\ID%"9_&2,<Y.3'AAKLE)SV4Y=Q!-*!0
M9%<>*<:Y5H/Q\HBU5I>LN;)@[;5E:]>7[*5GG[)WWG[;7GKY)7\4]_SSS]F[
M[[YKJQIAKFL@TVXW_(U[E+<L)WU$GN3HZ5 .<1<[PQ&''(<?# <]#$!3CG5&
M3(VCY)2/,@-]X66<<"'.>$D^[2 RT5X1;1!^%.3(W%=;Z4%FI_J=\\".2@VN
M:U AE7'C.#4^H7/1D9->QBA)A^:.STIGU)A%=Q@&OT7:P3^;<+5PT'64V!S7
MLY,^PNQ,'$?]*XOH2AA4 /T!1>8# WHODMXNLKY[YY1H%W&CC*@E3X_^BD8V
M:$7\*('<D!%OZ6=9%<%+DLI$!Z:3X)OX> :*P3$/YHM0E,<'1OW(#^>;V7!?
M4B1D<H 7Q@ Z3W?@P7PN)X?TP^"D/!*>%A2E&W^#>B]2&7I?Z(3. -S>):2S
MY A *W>:18A\D@,U@&%#"_%UFN^Y_GD=JM6Y\]'3Q9Q_CIMYR.!/5E1'K"G'
M7G24_\34M*VNU>VY9Y^W8T>/6UMU,JZP-84M+BV[@UYBQZQ*37G#;]@T=N2@
MG!M!YB'7@9CID\L' <J+WB /RHT^9V?-\Q@ ;S-"EY>R[<;3.7(D!30YNNQ.
MV5\AUQX//A#5$2<P\@[9 Y$/\7-=J$VJ/Z I>ES]U>L%)WT3X,F<EA ;1QTH
M/R^?MW%"TOU!/*D=A$M"^J)-R^BR2 A_'%,"7U.N2+9MZS:[_L8;[=8[[[0[
MOO@EN_-+7[8OW/LU^])7OR[\AGU1^-FO?\T^\[5[[<:[[K2MNW?(L:]:A8&Y
MG'4&,>T1^2R26[FL@>5()?)(("X]7R\?SC,L((-N621WEP-L81M9@A4O1GN8
MTI&6^F)@ZN6B?M$;Y*5KZ&3]B;)*IY,LR<O#E#?W]2^.9P#PW)-I"CR+ ,U<
M)G[T#SCI*K!XI3]O^$NZLK(VJGM^GLNK'MK[Z$3KTPYGU4E'P%FI4$ :>K4:
MLUAH%K,HDU-3[I3SIC6/U28G)T)YSX6F% ">7'&DZ%W#45!L<:Z;<B:9Z1=B
M ')YX)LR>)S30"X&Z>1NNNO)XURU*&O)*9#?;I===IGMNV"?SW8<//B^/?3P
M0[:TM&C+"[.VWFK*.56>+,V0<UJVBB])V3QJ1)JQ79+3+ KKT"@7G'EFU]58
MY&C+-^]BH]5Q9UT'V>WDX.I(AXEC#7JZ3,>'$D,PW4>].A@A85OZT!8=D$])
MJ%DZ:@S=/>^,5-.Y]$$>-":M*EGX-DT:P&P=&[$]TS6;K&GP(ODR@!B&ZR,X
M^_"N&E#>V5''(+A1 %5>]\^%?1!*PHE^ 6YF7'^XEP(_ 'AZU;]WOETCGCI+
MOZ+M$.870X&8/@-%^DCTL4%N'XZY//Z_ +K7Q024@31Y)BV79W V*,O<9;29
M'\D=4WZ.00>;PY,\;)*CSM?4'K$'3!ATOU#*SB*U,7?6J?<NI%/G<0,LRF,C
M@*;3U5\Q;J^L?MF%7GC<&[SO YPA6(1A?(E:.A,0+L+HI3L^_,A//Z5*Z?PL
ME3.2 1$:OYA%I$[5WI2>.N68)VJ*. @XE !I?&D:DSA;MMJ.7;MM<7[)7GCN
M1=M_Z)"MKJS9:&O$E^)4JF,V(JS49FQ\<HMH5/UC.1TY .4BDP,0)1LH_RGB
M9T"N+I-31'4YJPRY["%'PD,N.G,Y\^0RLQ#<%/A!=H7X79KZ#8-<MX-\=?,7
M.J3[LO+*38.8=>:+X1-^^."7^@QAS,*K+H6D&:P[L$M3P(K9WJK9R"2XC5]W
M@ &#78RH'/KX5(#+1SJP$?3*&^C\@+STJ?O;MFVS6V[]C'WQWKOMKGONL<_?
M?:_==2_X9?O\EQ2F\SONN==NO^=NN^R::VW[SITJA(:&S;JT"KG(J58'T:GP
M=#GZT")X61+DNLZ\>)G\D'ZJPW(Y[ OWW#&6/(A+>;VM]LAY&H_8Q0B#3G;:
M.3+I$&7/@\N(>SK(]J%8!LZ#1O U# @OEC5#-TQX2A9T;V)\PJIC-1]$XD^M
M+"S9XHE9^2<C-G]\UIIKS+2KG+HGUT1:>K*=^#1"6,9S -0Y%4]CIT+H)%=7
MV>ZH8<>.'K.WWG[;%I>6U$'*,3L#)3MGH.Q15C="<@HY4@CO>%2&#73WE("#
MVY:(<7K="19=::A=<LDE=OMG;[?/?_[S=O755_OZ_==>?<V.'3NB1&VKJE%+
M[:W3E,LIQ[OG7&^ .+1=E('KR,@*1T&_'\?L8*N9BZX:K)B"I1YB-)"##(CB
MN*.;467I'L\ W<$?0'>>94[!3O'<G7?,;.J<_&S=RI51D^^D$?>2RK*L$7<#
M,>H.=T_&<-03ZKQ#Y<D05%1&/B\.YD^-^WKT=8@IW[[C!ZCP\_")A3P0R)T4
MYTP.8'E4V6%^A+1[.L#!SO,\G#FX$X(\Y:07,1R"?@C')?:R7E>]S,[/6[E:
ML^NNNT$V\EH[>."@/?7DT_;NZV];13WXUO%I6Y=]K#<T^&+2?(3'Y3&1XM9C
M2![G(0'&/SE /%5ES3FRHZ\.YUS]!7V>-XI//F2G/G]\"#_#OU&B3F.UCL^Q
M8G4=ZVLKUFBL:H"^9F65NZI^$>5IKJU9BP]GR3&G!Z'A%]^/XDGT9B'\A9!?
M%QF 0NM3K)(,+)"#+]&AOM3&%]7&FRNK7@<GCAZUPP??]X];N?V5L,ZWX(!S
MYJ2[7R1#R:STBAK'FV^^80??.VAK:ZLZ?].>>_99.[!_OV^3Q$@[K[_[N*';
M2>.D"^C,:7C F:H-#BB.+I_"5=]DC9;2ERH^DT>9]^V[T&Z^^6;;M6N7O?[&
MZW9<3CHS LSLX22R1(AC7C^^$?J:]/SKNY><<IUC)8H_^C &(S2:(O:<=*5)
M3FX7=9V7K&P&<8[[TA<0?OPHWGK7R#D<;2#/=(]/5*4?+9L[?M .O/.JS9XX
M)&.[XNF&(;2Z]!/RO^>8]YQU9.=..2_"]1U)<1Y^[0$=T@_[PF1!GC'/'QFC
M(=#.?)9=Z+OX;.!(GH?-@[<XB1 [.@QSK PXA\B=/:PKM9JO25]6![YUZS:[
M[MKK[++++O=UJV^\_)J]]-2S]NIS+]F[;[YM<[/SMKRZYLXZM@O 03_?>D\%
M_;KML[1RFO(:Z?SBJPOQ$]X,?(97Z$_IF:E5WXD>+2XOV<+2LOJ)-6O(_VCB
MH,M9!]O-52LU.C8F.S]3F["IB0E_>H!K*(UU] D[5R(T>9/:)%FYOX#\BBA9
MQNSS)UR8YPHHMLJ/'/P)@(Z\-]%8J[L/4I$=/G[BN!UZ_WU?R8 ?@OS/M^*
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M2)L[H2ROK(.4VU&_+L"+[N<XIP./6^@@ \*A0"9L74>^["/,-2]8T?'E.LB
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M'^F+].&:/ AO-3LVN7NOW77/E^T+=W_%)J:WV/SBBLK(KC)15B\C9?8.CV,
M>IX[1.3E^N.RDM,K)YVC2\C_E*?R&^8 PV=^C UD'22>8U^F<3_'V2STT1 $
MVR,?PDD/YX=?W$_.>D'.18C\E1:^!UC/O!#\F^&DTQ1DJVAO.$8*\%_*?S /
M[IU+)]UG3=$OV5W"PX&*F7WT])/@I&?P%^KA5;*KZ#YFA*=D*_-SOHW>PN*B
M_>SG][N>?N,;W[ *RRY*53MVZ+#+>W+;%O&&'<1I##T%79]45GCAFGL@UQ_6
M2?>C"STF'#*X;@DVZZ23GZMQ*>HH(_RRK*,KQW1P6U/D44"<;),"L"O4/3V4
M4!F7.CCI<DO5)S5'FM80(O)6\[@]\_,?VY,_NL_V7'2E??,?_"/;OF67U1MJ
MD\J+29:F["KEXAL>/"V<V;K%&G+"<=9'-5 :'8VEJJ%CY]A)!U1\2/"N1^S>
MI?+1;\F&+2S.V<-_\Q?V_ ]_:/LNWFN_\]__MU;:<XEL7L5J<K8GI;,-.7]U
MZ7%%9:JH_VY)Z=[9_Y8]_E^^:X>?>L9V2)_N_OHW[,9O?NTWUDD'LAYE.\9U
M4"0#/^D"E^>=](\7SIF3'OW02'P\1AW&O_NW_]J==+;-4A=@VRZ_PK[SQW]B
M>RZ_)IST :?3#:3HT$G3">0=47 J_+[_/QGDRW6AWTGOW8!C;PA%(H5S/QVB
M&T4G/1QTCIA#.<"=EIST6/[0D7+AI+?E%"TO+=I?_N__BS7V/ZNX)?OLU[]C
MMW[I&[8^-FV=ZK@ZF5%?CK)%H_KVL5G;O_]-6UYH2&G'91AD4%N+MG1\W@X?
M.F3'CA^SN>/'K<F+E3C@<(H#0^^FJ]K$I.\8<_'%%]OV[=N]4>.8L:/.^-24
M=VPOO_**'3SXGDU/3;N,5R3CK5NWVH5*1QH,+N%TK,@',T&Q032EW*C+><I+
M'%J.K,?U!@KHP*"*;3;?/WK(+KKJ"M]RLJ3.E/6$Q*I5Y) I/K)S[=._Q?E%
M>_/EE^R]UUZR:ZZ_UFZ_^UZ[[+;/VX(ZK*FMVVUQ<<&6UM9L]YZ]]N9+S]G1
M=UZW[:+)XS,Z!IQ)\LV&@KK! :@PP%M=L>>?>\X.O'/ )L:G[/-?^9K=^L5[
MK#8U(R,"*Y*?.GH^F=W"41)+OD.$9.  287S1CI"S<X ^DA^/,$@IG=6<@)\
MD$)'AD$2T$;<@(LP3CK.C"<0<'!5T[^4,U=>=X"WI20K;VLI099W-MB*X??)
M$R/)[2R+' <]X"K/\/.$@V-?,Q&$D2TXZ=(;^ #)GTXW]E1FC3)Y$3/X 2(_
MI74F(BP#18A_EMHT@\N2O\Q-,$O?/%QIX1-YN@P&"0U<]D&0[T*V42Z/G$Y!
M.9RP@20.'G7(C:)=\9(GNB79.9=%PCQ#ZO<3()NX!H-.7"-SF/(@C^='';@=
M*3(S7 $I?@K.M%V_Q(OKHV0+$LZ@9WYAV;9-5GSGB[9LS -_\1_DI'_?:N.3
M]NU__(_MZCL_9[.K<F1&)S6"5QF@RC9(595)>MU47;1\.4IVTJ5O"G=[H+IS
MA@? G?1T[J50''B+CZBI+:G]5N2L3LJQ'A6=NISSZ>EI>^NMM^Q73SUE%UU\
MD=V@P7I' _(U.>PLPV -].3TE.N*2N@?GF'K1F2  \;3PE8:8':8I1==6/,Z
M45MW3B03>''TD 2I#*[SQ,WUS6GBO6L;!-#)F/L(@.L ZJ670R+O]3FB<KO-
M@*;:%77'Q^R*(,IA:[CHD0E>X,UM-=0H#\<H)R]MQC<QF(10J#RACD812\L+
MNE^W-YY^PA[YX7VVN+1JNRZ_6OW +@V0XPO@M'_LJB^+:;?L\BNOL-MNOUV#
MN3$Y\G7Q797ZR@;(OL([?/A'>^2H]R!DB[W ?@T#R@3?N6PNLR%Q$;<O&\'.
MEYA08B*H+=X7_?V*DLKUU"]^9,_^^#Z[](I+[=[_^N];Y<*+U==LMU)]U"J\
M-Z)?L\1[2[+9*M=2?=6>>?(Q>^EG/[?Z@?=LZ_2$W?.M;]F-7_NRS2G/]59)
M?;K\$IS%X/!D&&15T3QF,;KB$"V*%@FR;OCED/)2WVYONY!T%3T9DFF1]JD
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M:D7=BV_%XMBEJH B+V#6BQ$=D(VW?96E);FS7:$O=1$%VGY3?</LW)SM/W!
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MWW_?<?N.[7;555<[$2;.F+UGDHFRA2YMC*<";B,NC^;%#&DA7[?S;J/CVB5
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M8Y*)WX&6D(F!;.^[S.3D@Z#P3"^7AX&#\Y>0O#U_)]?[.>-$(0[E([Z 8!]
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MNNGM')),M2B]\O$\^B#B;P:&E1>(=I!IP%<@.AY]0Y:':F"D+$**BXU4.49
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MN9Q1UN$ _8Q>1\)\'N&]N@T,>7+O=.#ILPQT!+*<AK49\E3-:6 7,W >IK0
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M/BXAJ>&7J[8H \<CSDJMXLZTEUL-LU.IVGJYIC0L1*%3J:H1JJ&I4;;HS&7
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M%-0/YYQWH.(]J-. ^ "\OJ@W)LY$Q[\GH?J!MQ3EK( [Y0G5?3GO'"E(;![
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M-M>LWEI1^UB#FG XP,D@.FW555]].;B$$D)31YC>$+C7PRY-+P"8Y*/ST)W
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M+_XHZ<RV;38S/:,.BSP$0PRK@^M? '3HX/+,8>Y@HY/G"0$TBG3"0$;GE-H
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M"$I=O-5'Q_RQF]38GGOD?GOLY_?9]-;_/WO_&639<>3Y@IYY9=[46965I26
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MY*-HGI_R]QEI B*05M=1C[A>X*=P73J]3KATA>Z:L8Q((3@^#$;2LB?NPI*
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MWOF0-:MU._G!"7OM]3?\/1R?;5._8$G(/UH(JL4!F^''<.#6,O#PE8$?)ZA
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M0\%P@:SIYNBSV!+@+EX&P=E,(\0YGSEFV0Q+-!;FYT0O'TM:L-F%LG\0*</
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MK'OT$90?HHHLQB5#X7%U4,3$Y\D%RQE8UL!]PE:#J #]-D8G07;""48H.,"
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MRM)+2VH3'SA(3GT2H^JV(SRM8$9?%+BNY\DE4W)W0K#-X8Y3*/I F6D'IU=
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MI#M5OG1V;Z;'\N*9K*HO&6GE[?E'I*ZJ8X+PES;,N%/?UT8-#@ACZ\-<5O=
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M+]D[[[YO)TZ><AYNV[+%^+(<VR"RW2*?\F<_<QZ%#0\-V=[=>_SSR;5RV0<
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MT8_SN;EY=]K';X_;K!1;K5JSFNBKEZN6DV,ZJ!%WGYR4+(\E'Q!\-IB!F8Z
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MY7[WAENI.#Y:6+W\../MBN,N@,&J%,M2(&E;OWZ]'3YXT';MW.6.Y<T;-Z0
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M[/7KPDU,3&\Z2@@#G1.S8$"QI#^71>/"A0:)=$!)LR %HX=]T,$M7B^YD;[
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M81H-54EX6G[5[WI#R0628/2B1&0(JBSTP+JS1,^XZ(: :<@!KR_HB)&3DJ'
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MTQ&CGK@G3L,A] X#/:-=>R]F8SJ&4P?>T3LW;I:0;-PH#?BNF8HA3L.(;+R
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MEI:Q^LH+S]E[[QVWF9EI/^PHD\U)'\CH4H@@JE-X+L)^^0X9H-\J.WJJ)EK
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MB?3BU[]N)U]YU1[\[!.V9]\^>^WMMZQ#"NN._?LME<U:@7W+I70QTIFW32_
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MHWD THW*&IP&(C0,8640*,5.7V&WKQL#J:G^]0F!TUB9$L4!@>BC:%>7"'^
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M<-6NR$AA[V^TB!M;<1DPB;RE4SG9FZ$!NJ$IJ4)/%8<G"1OE'T(")P'!C0"
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MY3^W#*-[:@LX Q_W'O0(;M ,?CL 4T!T'U9W R H97B2T&S,?! LQ8F8Y@:
MD X-(Z0;,22-'B$;-0('Q0DI79<>48BWE!^_^=GT+>#?(T+%>$I[<GK:IF>F
MD2*VIK_?=NS>80\]_*#MV;,K# 4I3DG*!D8G*92BX^;" 4$<&JO317]1+YUG
M"PX--'GO*#7P"8J M'@7Z.H&@@)*CH PK,CXH:>_.C=O15V'KESQ8\OQD(6
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M S=PA"TT7*B5+9>3DZ.T2S+DJZ6R=:C]PL/L@,("2GI3V*Z47F8LAZK:!*D
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M-G%YP":O#-G,T+!-*TP.#]OHZ+#-^2Y:R%BQ%T:Z[CG[ L-Q9&C 1JX,V/#
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M)D8F),64":5578C;H:,G[,7O_'M;G9BWNS[].[;]]@<LFNZ2DX>7JA<45PI
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M-G+RC"7F2M8I!;X@@X6%XI0' XT#DC[(^!5*(430J'LW1EUIA4";X#=I!.,
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M ,@QY,#U\NR_5 C2]+<,$;$1_/0 (/R#L ]$_TT Z;DBB12*KM'<VN;*_@<
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M)L<OV_CX@,T6IFQX8MA&)A5T'1X?E+"\8H/#EVW@:@A#(U?T;,BNC@W:T/"
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M9S7^>T>.6D$&>[4P:Q-BD'-'C]F,O+<IW1^4(!XXQ]S LW;QS!F[</J4792
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M4YF7RN__0AG#N^;TKDV[4>M+$'WC?_! ]-O368;H][7OE\.US^DG;+SAF:Y
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MWSMFAUY_34RU8'?>_X ;ZK@(I+6H1L_P(NF0;S#V]=.S5SY2\2V+,DL)=1E
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M'KARQ<9E:+ =85BL1F4T<U.X]_V6)4A(#V9FWG8PQJX%\D IT<M('NSAR=2
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MH;.M+/CJLI9TWA:2.2NKK<VI*17EX!(*8K00;"G0:5<MB^?IO%.<>BV$:IE
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ML<J,T#PM;RVIZ$_^RI'>O,8R,[3&G*MW1T=M5A(*1U!76X_>WC[T]6XV'LA
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M'7A0><'2\.J[REIP4]TB(+]<C/JO!LZ!Y$=/3)=4I%D)_IL&/'5#]O3>S2'
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M"(X]^05,T;C]YE=^$Y@;LI[I$@TWTSG489H0K:^-JG\UT0CVLTTLY(NXT#^
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M>6=&Q1J995 9^F#/+7[Q<"T>2Z\,Z]-TH+ N'IT9#:+%[BA*ISOLF?2#SBC
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M5R(=0-U3SX;WS#:9D--%8T 89B,6HG-5I?D+1H<+[\='DX9I,QZF9SVNS&-
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M$TIQQEU=BZIX$VI;.C'/=/,RB*F#]94M7E.+& VW*JJ#WLXN'#UP$(?V[D.
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M_P!J:307Z=AH8J_:O>5D$AU=G7S^*#9OV4*^%9B>G!I@;GH:$Z.CQA/M)=+
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M$OQW'*EKE+H&06&,(.]:X1VM:[QUSV^$#<14@$^K2]LU2FYH3<X;7N.&VBB
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M1PZV3:B7LZ)(6/;:U79R:A+34U,W. $"TYUF4+IKW_'6<S^, R^\RHM!E)Y
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MPGCGWK6/E7$)*B]9<[VS6X&>"_F6Z43J?&T$0QX9[6R#B[EEYB_+4@M@X-H
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M+\TY7)Y'-I6T84,4$Y-Y1R-!YSX-/*JG1+5>O:E"I6\.*-'1X:$3OO77!-=
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M:0U]+6B12M&.(#K=_@E40O6O_NJO_IIW_D.!\\36@XPS&1(R5-4H:4QK(I'
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M^!_R0_?5)O)>BJ*LOHSW#=0F*FT+[;IMF"C:)3>\R*Y_]7=:1P,GP!=A 66
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M0ZI49\B0X9D"&M% :').?,\ZZZS^6MAV.RR#X1X-+]<0]K@,)Q(H;Q]'R3&
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M@^N&PJ3^2I^C>'\J(4N&#!E.0=!@Q[7#:3#KF9X-?3+ [[CT ?\0&GK,C]K
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MX:2A:_1$WT!<1>H3TGJ"(080#.0SD>-"U NW2=Q'B:>#=$W+L8 -W,9W!A@
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MC;JM-!M!ZG41_!6;6YBWED@Y=5,C&-<1HMZ5,.!8*U].=60D/4.&#!DR/.W
M+&&7&=-.SUI+*[8R.V_=>LMZS985Q8(K(AIE$1JD!-$H%ZU0R5M7Q/H(J8HS
MB,<@;1'P9E&D7M*IB/PDYM@92$[N=*R(,-4*?MXI]VQLO.9$/<RBLF0AS+@R
M<#A"_,YQ(B%G:<&#_GF"8)Y<<X@"_%:\&""ZD4J!XR48]CO"B:L3V&3V7 31
MEU] LH:(EGQ8TY^1<#_" 1=1^ACISR!,MY^$Y^0UZN0>!M\&MH<QT'6UOJGS
M>&_5_=7P4%)^$![G<38>>!KV9^=32.N["N':9]W3 NEW/R7!Z\0I%\2?Y6 %
M:^>+MM116)5Q,Q'WALASN]E,ZE#'UDU/V^+\@NW<L<.6%A=E+N*L?%UNBF"W
MFM90/:NK7M5%LA>9"==YI5JS<1'V\8F43$Z[3,U,V_3,C$MM8D+W)JPV/FX;
MUZ^WS9LVV>:-FVQR?,*W?O2!=H8UD5,%&RX-)X18Z#)DR) A0X8O&V)/I2X'
M\O6N]_RKO>E[WN1K9Z]_P4MM_/3SK#2U+MDMHB!&(Z+,HO&<R+*_Y%DQUL?F
M_&72U1B>V8X[;JQ%(/+=LO[C0D3(UP_SJ-ZL/#XF8K).I&32&BV6!: N\Y(5
M$T?R-=T%>5F20-13'U],(;GY9<)PG,(L=7)Q-,#^%$E^_$42W"?#(^"VF24^
M3IZ ;G&+O[03O(]+3*)?'N8:X>(X^"%)C-S#Z$]_+?IJ^'KHQ-C75HL(,^OM
MRU>D&T*YZ)/D:%GHZYC2R=-&QVA_%73#[V(_\6=UW@QTA*81%_S(Y?$1"7<'
MZ5^2=%3&VBI!;'7(QX.*J@MF!Q<;MN? 87G4LG4:8*ZOE43^.BJC+:O6:M9<
M6K([/O4Y&R_7[(:;;[*)]>N,_5Z6Y%.=.*GP%MLJQ[V"%2@O/6:_==?KEBP"
MCX;2V_,[/)&(*)5*KF.ET;9*K6P+"P?M0^_Z)WO@]MNMM[QD/_0]_\E^X:T_
M*UU8IH5#Q47AA-0[M9&1] P9,F3(</*#_:-% 'Q]J\C,1S[X(?O.;_]V.[RX
M:*=M.=\6&F:M;LGRY:JOE^T6FB(5+1?G,+F2K[%E 4 :W.N(^+B_(#D$XJ.+
MQ)S=,YRDB=R41-)S3LA$ZL19VB)W74E^:LJNN_%Y=O6SKK-\J6R-=L]*E:H(
M$Z_C!<J!;WGID00S I"N%%E3^$>SK<08TOE(>#^M6Z[!D)T3)>G,"..@JQ&(
MKY7O,.A)"&3J$0&Z.&E+Y'@PL,4,\T!/W)/V,7[!'O^#3H[D'O\Q\>4J(\(-
M?D TC[P77"?0;5\N)'\8B#E))[XZ]DFWK+.LB7N$UVEWDC"#WX2%CV%MN^SW
MH?OZ(_TH0XGUH!MN7,=!NG'-%H7NAYL%/3GS%S85?AC8D6[A!=]F2S1;9L7*
MI#WVZ.-V]Q?OM.7#(NK+BY9OLQ1LQ5K-IDU/S]C*XI(UEI;MJBNNLJN><X.M
M.^,T:RH^+<6MP:QZ2^%W"_(NE$6>3(U5R]8K*&S*GX>LL*6+QTE@0(QX!2F&
MNE#H-*U6*5FWL62?_/#[[:[/?MKF]^^S'WK3?[1?^L6W6+42E@/U\JJE<D=L
M3G5D)#U#A@P9,ISTZ#7;UBNJPZ<3%Q'XMP]\V/[CF]YD.PX>L+'Q:5M:[MC$
MAC-%2B;\I=%<L66%;DN$.'R5M,ON'4S\06@2.(E*"%#LRSC&/:P'-N549(4/
MKS!3OZ(!@Y,K^=5J+DLOD9GZBA7&)NW&%]]F-S__5BM4:M*A(G(B>W+GWNN?
MDQG(A_Y\4G0(@:"E;\C%4?M9^9_,O >W1P*R&>*:CE' \9-TB>R%ES0AIH$<
MLG<W&)#T@2X>6Q&]HP$[$>EHQN4T@' \;AX'3[UP+81P T%,XZAIML9,>AJX
M#U[H'UMZ2H>H1R3IV.'89MF5X.]%%(KR/_@== IVPH>&(H+?(>T&^2<'_/F,
M/+9C'+C+K+WO)9[V)H&'DV,'%?)& U3]VMUEG;>M6!BSA^^_W_[M_1^PV6W;
MK"CJO&%FTN;G#CA)GQJ?L&:C(>Z^9.><>ZY=?,TU5EL_8^VB!@75FB^'Z78T
M.!-Q)J](N4ZK8\UZ7<G(X"0HA*ZA/#"04=[S\G2O;<NRU\E7;$G5L--JVEBE
M8N-*HD?OO]OV;G],*C;M^[_S.^V71=)KO&RM].L5&  H?3W]3FUD)#U#A@P9
M,IST:-<;EBN)[#*3*S+PK__PS_8#W__]MG]AWB9F-MAR,V^77'V]G7/!)2(%
M.0F[KC2=*-#)-;LB$4.]';/"99'NJHB-^,8J0 5].4/2Q]'7+2\OV\+\O"U!
M2/B)3+&]W.RA@[951*@R/FG/N?GY=OUS;[+:Q+1(3-&7O5BIE!"U0.R<[$E<
ML2,P; BA.UH_FR)Y:P!R!9%[4B1]%>1&1#02X[YZKD=BYIX&TNEF:\2! <0
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M;GW9*ZQ4';-VHVNE<LV:*<*1;IU\+_8$Z,)2%6RDF[#8MH5[09G52P&2?DO
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M7TH>2ON8-Z/!383\P:X&HY)\5SG&8"O7%O%5_=!@CTE+=G0![/*"C!HP/O5
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M=L=R'9TWFM9M<MUUTI'OJCU0F\ /0I(OAR>HD',DW<ZHX4C\#:"MX1['. %
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MV-91OHK,,\V8LU(WU(0P>$Y*G&<X92&4E>"_.PO'#"<O28_KG')J\'@,XF]
M-Q:LV&E:N3CA!8//O4V.B5BK@%#RL"_F*P)<M':Q("*N3"\7K,S^YJ5B7RHJ
M-;Q@H99782$M%42V.E0K[@6+8L0ZL6&1'CWY[T>-6667+V/Q-K:_:(J^:KP1
M;^%\5I^M#7NVU.A8JS1FG?$96\K7K%.=L 8U0[J45)E*O(6M,%QZS%:$G6%B
MQW,J@H8_W2 "[S"4MJ$#50.@<\PR9,AP:J%0+'G[6QJO>7< %8!0Y,7&\WF1
M $@B[8/:6/_1EJC=9[<51#3<CSE>!BK);C%(5TUNH2J_U SW"EUC8J_>6K;9
M^8,*IV%GG'6ZM>5/4^?LG#$[N]<6YPY9<WG)K*&^A+9)7GK+I7-(>4_A> \B
M=P7Z'F<AD$O:+]K]V(;ABGNR@\1SN76)YHDP TK[Q]-BMPHC G@3^Y,C)  K
M<F4=^8'X+C02?_=*=ZKEDA_]B3=+B"!@2FAO=^GKO-T-X?G3:HGO(J(P>(+=
M8W"D_HM?,5_L"U]:E67/#P6E<_US$HA+^4@^R7U._7&4L'*;O.4[*.&<;&.5
M#GUYK\,R"]9!LR9?YMPC'OA%TA!1 ;WY." 4\<G"^R<=^T)8Q_*6-(N2 %_2
M+".*?VAQI"0.!5(8>-"^5%;Y(#,_$_]HY^I*6O*,OA1>H0%EMVFM3IW2KV26
M'7ZR0QTBY,!=5DM/TO4C:1=Y3]"E7PZ2>'F?K/!\)R1K6;O 6G?E5TM^B+_U
MNF'GEQ _W.05JLJ:],M!Y,6M%*I+AJ=9.L3M]R!HO''/)Y+Y8)'OCROS=C+S
M0:'TQTLI),VT%RA_S*1"32%R=XG0R'A%\T)W)+@7_0X%G^O5%3,IITG94S@Z
MAM%H6)^(_JQKC(.0_HXDHX/,,(3X&-?S*4.&#*<D:%/+(ND],8OZPI+U6FT;
MJU35]W>L+")(,]$MJDUW$9U(I).7B,P@D!..$/&>"$TGQW5;/$:DJ9RW8K4@
M<KYB4^NGW.Z^P_ML;GG.[KKO3GO7>__%_N4]_V+O?/<[[9WO?;=]^!,?LX]\
M\M_MWS[Z,=NQ;7M8:ZO^"3+C:V[I5J2WDU*.X=!'Z#-"_S18(TQ?%6S2KT%_
M^W#_9%=]B%_2QR@<^I2P3.4X(>\CP?:G#P)MK&]3*;_0H0=!E]_T8>C&DP*N
MZ3/1"7O-AOIFQ;G9J%NM5O4G#QU=RY%\[+EYE,6%^=!_ZS[+/)5 @901EL*
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M?/K3G_;\Q@_N<1XK^:BX9\B0X1F$I(H_MNUQ^\NW_Y7:I0D[[^SSU(:<K[:
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M_3X9">=J[!5J$'_B"DF)1YFI5]*U6;' EG)%)TH0-@8/]%\0<B=,V$S:1>(
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MIJ#Z!DA+,H8%ZK<\%-]G@O5W(DL:G.<:5^IW];D"-"%R$V5W9R=@>>A_I8"
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MB7/A:@_Y['?MC9*S,[,X-W/.7NHD-PIO@V#M,J2 )%8)[.Q"Z"5QF7CMZ\>
M=)T526*FH[=S$+TP$52OD'!DNW_]DK""NC@+G-C$PO)T45U<Q,RY&9PZ>9(D
M5RX>?B*5%HT295'>1$R7L]\F78GXYR"\;[LF)%Y43ZW@J\ULSW^.K_GY>9M@
MY9DOIX>:J5<$.V89U$!]S->NHE+,8'2TQ+')[TV6Y+K3)-%N(\\)9I3IH$)&
M7\EG42;['BWF4>(7:+02883G8R3M%7[7RIJ49)E.PK05$OB18HGI*R8CA3+#
M2DQ;PDBIC+%2!9-1&9,,GRB-V!N!]3"UZE&O5A'+[IPF--84 <L@K*0'! 0$
M!+PB860Q@1ZT%"&.^=$V<1_^Y0_CMW_[/Y$4E9 M%#"Q=CVNN>4VW';'G<CD
MBHA*$\B4BFA2QV*M 7&30H&D('EB4V]IE'J1JL'?,;^2SABW$FSHDM"V;"53
M)*1)$C4S-X^X5<61?<_BV_=_#3.GYO#V'_HAW'#++;:3BU;SH6WP,F[_=JL/
M16199EB=DCH:X30S&)_8J+]:5=6#@8H7B=.#JSYRD/0)=DW[Y<[BX<+TT*U[
M$8Z(Y>G3I[&PN( K=^W"R.BHD427F+;H0<^$.%[L%]YL3.S@'Q=(Z%KU-+UZ
M+J ?97!Y]$"H6R770Y%&1JT=G'@HK7?1L;L8ZA\*$R4I+@ZSC^CIMROV]:!A
M"7QZ(<O)5@^RA613SQP</GP<^_?OLX='MVS9@NFU:TUW5^XJ":3'M@ME7=/6
MF@V]]DW^\B![XL0%J0>&:95>=T :G& M<-R=8Q]6JXN8G%S%LC>S/9IH,$LM
M9M^1?'.$8J((DNP(#S_\$+[TA2_@Z+Z]R!<+),R:2+8XL^R2I+-_]+ KQ_:>
MJZ_&U;?>B&A\%$V.LP;#[<Y3E^.W$Z' 9LBI66@GBZ&-_),TDWV/5&]>QTR4
MYT2LV.:$@Y5JE/,XI]V59!O)^9-?_SH.//D8,BT2]7P&5VT)[B[+(?>1CWSD
M5Y/SEX3T%RD@(" @(.#[ ?NM27YN])#9GWWES_#X$T^@+@).@J =-K;OV(FI
M-6N0S^9)&LA02!JTJAB3Y+:U[S.OI<<14)TGQ-14]W_+>N2 )$80,==.'LH7
M:X6\U<;!0X?Q_-Z]V$?B,W/J.-J-*L9&: -)[]3T6GMS(S-0,4D.Q4A9KVRW
MPBKR922.!%I'\_U-3/*0549VK?Y:B:9-$EV*%-D_I]N26"9W[:&R1/)B$DN]
M?5([XGSVGGOPW$,/86QJ"N-L.Y$LI]NE]_;VM5P:K&V3S%I\7HI^O0O%R%:(
M599<6'KE4@9A#]^JK63DD/B5H*<_N::FH4C;H7LV_ESIY>:BB<W!@X?PE<]]
M#L\]_CBBR@@V;%AO[6AVFJTBYZZ$M+46QZ/"='0U<ND4IW _P3%AN2Q<D9@8
M&\>I4Z?PN<]^%H\_]+"-[VW;MJ(R4F%[DB"3X.>9IT1"W^6XFV]F$(U,8L/6
MG5AUQ19,3&_$UBNOQKK-V[!VTW9LN_):3*W?@D5R]O5;=V';M3=BBFG+4QM0
MFER+$<FJ#1A=O0%CJ]9BE%)9-8WRZK4<.^LQ-LUP'DL3JU$8FT1$*8RO1F5R
M#?-.H;QF"B6.L<+D!"8Y]N2#ON_IIW'FZ!%V:)OME<&:B7%\\"_]"-9,K7;U
MS#@_^ !^%Y-C0$! 0$# *PY&:"@B*(Y:.1(CTBGRTNVVT6S4L# [@X5SY_#T
MHX]A\=P,"B0J9'UHDI#F<UE[F5&KU30W 1$93X)LBT#3N!0B@THG0JL57J45
MP6TR_Q>_]$5\Y:M?P?$3)S ]-8W7WO%:O/U=[\(/O_>]]OIU_V!A']*?E$.;
MQ4/<43_!NG!437!5[==9Z51/$40/ES+1J#C5P43$N)_.0ZNR\I4NETI&(I5F
MZ_;M6+=S%U:O(KEB6\IFQ6FEWK88%);4H0]O7\].#Y6=B#OPSU =LE$3%F>_
MTJ3K-PS2XLH[C_%?,H;:OD+(SH7Y>1P_?MRNIS9NQ&I*I<))&>/Z=DK<N9T,
MHI>F']<[IQZ5H[LXYJ:5C%7%+RXNHLQ)PM9MV[%EUTY,KYVV.*UY:[*:SW3=
M]R(7H9DIH(8B,I55F-YZ%;9=?3.NO>TN7'/KZW -CS?=^2;<>O=;<?4M=V)T
M>C.ZQ0FT\EI%YT0N4W+G>8[Y?)EA7A1>0;LXQO 2]>>PV,Z@1F+=X'4<,:Y0
M04QIE7A>*J.K%ROEB\A'>8XUGM,^MU6E)*FS'2X\!EZ-""OI 0$! 0&O2.CW
MQ?^(D[;8;[@(9Z-9QSV?NP</?/-;N.ZZ:_"^][_??O3O_>K7\.+S>S%[;A;Y
M0@FE49(%YM%*^OCD! H1R6A.?KW]U6+2)+M.0V5*Y!+3DHM+DE9[L3_]S#,X
M=^8LUFW8@->\]G;<>,-U*!>RF%X]2<([;2X)+=JH-S9J.N%>^M-W/7'UT%\[
M2^HG<:OL%IC8I-/T;ZQ=)V(Z4G&"OY;.=)RYAS!,ONAZ"8[\@S7AV+%CA^VU
MK95A/^D1M JKMU[J<K ,C\%64[JT\(^/H+VIE?F4N/JRG9/V[ME-Y79,D#[G
M17)R:?!EOA0XZMV'].3S.4Y\"EB]>C6VL1TWK%_/=AQAG5B&GWPHK?U=BB6V
MI,\3].(5K //;7)%U-F'%9+?LK8R9'E34VNL+SL<URHZPS$KUQJ0%+>S).DM
MMBO'G[X/H^.3F-"DK%Q&B7DG5DW1W@AG9^8QOU#%JJEU&)N>1J8\@@;';9OY
M] !T6SL4Z2D/V\XTQPD ;>%$KLL)G28'^HZU=(=#DTY]ORC:BK2;9WJ]7(S)
MV^VF39RSG#CO??))G#Q\B%TOO_D,IE9-XH,_^@%,K5UC=0PKZ7T$DAX0$! 0
M\(J%(['B*F(@<GD@ >'O][WWW8MO?_O;N.NN._"/?N$?X=IKKK/7_[<:+1S<
M=X!D^GD<.G8$5;TXI=O&V,1XC_QI==+>K$ABX>%_RT@UK"P12%O)9%BKV;15
M]?W[]^/@P8/8LFD3]EQ]#=9,33&NCMDS)VE8S E  4U;?6^0O%"??-*S\H-?
M2M)5EGU8O">GPL5(^A)(QT"<KI>0W02Z*Z"5=)%A>XF-K:J7;64](CG7427*
MW42$WEQC+D+2+PW2D=8C^]S+F\Q//K'9$]%!^_^B,4C2Y<:B!X5+Q3+6KEV'
MJ>DIFP!:_PEBRRL%Z[F2NBJ-^J=>K6%B? )C8Z.8X)@>GYBP>#T*JHU;"EGW
M[ 2*(VCG1^SA5KDYJ>\UAG4G2<\X1(7(7,6>>/P)//W4TQ@;'<=&CNO2^!C:
M)-\MEM?EV'6U-X<?\T>7J5W^D3NZ>S!:=S;TK=%P=ZOY]@ L"7KR<E(V1YM?
MHKI-_O),N/_IIW'LP'YD1=)S*9(^'4CZ($(K! 0$! 2\(B&RUH.1 EV3K,1=
M<6*R2JW1%C!:&<?;WO)6_,:_^[?XO?_ZG_&O_]6OX::;K\.90_OQP)>_A&]\
M_O/X]E>^BA>>?!R+9TX!<=,(<JQ;[B0$;9(0;:FHE4"]"EWE1%$>Q5(%I<H8
MKX&S9\YBYNQ9E$AN-FY>A]&Q A9G3^'<R6,H1R42C@B+]1HZ)">%B5%D2@62
MX1P)2D+ J$-EBH;JH;H<RY"KCHDHO=YNE-&#DZ)#5MUEP90)DC.UB^FC:-7<
M)A\B3T[R8F_46RS(Y2>VAQX+1>>CKCQRYQ%YL[=9,DS;^O4>4$V@=&H72;]\
M%^[*3%P7%&F2G!OZMGBQ>K*2*L^+38PH(J2F-R6F;QA\_" &\O3T#,&P]O9A
M$JT6>]'$2YL7<NB02^;0XD"L:AO+-LFOZD;[TV7U79KZN) MPV#IV;XBV3F.
MRYAC9J%615X3K$J%XY8VMJI,R+[.%^V!Y;C=I(V+''^DV$R?[="^QB)RF28;
MO8[ZW R.[-^+8X?V8?5$!5LWK\7J56,HY?+(<XP4))Q V0XPK%N1D]I<\J*B
M;*=.%;,FF?8B)P=-C): <D$O-FKPNL[)0@.%#/.R31S5S]I#JN4BOROZGC%,
MZ_)JR XKD.&$0!-;36CU#= H"0@D/2 @("#@%0P1-EMI3,BN2$^6/^2UQ;K]
M\%?*HRA$SCU#J\2[=N[ C__E'\6O_-(OX._]G9_&3;MWHGKB&![]ZI?QZ#>_
MCN>>?,P(2K.ZB%:](99H)%PD/4L](@EMDH9&W$&]R7CC97J[Y#F2I ;6KYU"
MJ:2=HULD(C'6KY[ U,2$O4U1*]1Y[2TM@JM;_69S0M:\\#)#TJ6CXL3AY"+A
M_+.3-$F=K=[+@3J,,--X\3T3$67%63:=.6DTZEA<7+#=7.27+[U:^2T6BXCR
M4:\<3Y*UFGY^V;1GR$>KIO)G[PE)I$0KJCT=.KB*.R$T,7%[=?<_1ER59$B]
M;8*03 2\^.MT:A]')2:]C\X32<-,\W'I3SI]2K2"7JZ,V$XNQ>1.A(YR<]*N
M+^;NDL#KX>$\N%9(XE< JVO2+WHN0A,IN7&UDAU[:!GCVS;QU!VB5JN!9K-*
M8MS&F@G:.U[!U'C9QNS"_!GLW_\BGGSJ<<PMS&+-]&I,KY]&H139=RCB&"A0
M8YZD7^XS.A;8IGF6I*F*=H;1VT4ST-M]]:"JGGD \RE>?=JR\)Q6RM4_Z@Y^
MC'AKM;T8R5K;^25BNZF[]%W1T2:..E?:@.#N$A 0$!!P^4"_.2*2<CUYZJFG
ML'OW;KS^]:_'!(FR)VZZK;YIPWKLVK$-5Y!43XR6<>3P?IP\>AC'#QP@,9G'
MQ-@8RB6]G*5#<EX@V9&O>Y/D@.2D4"1!%^GOVBO1F\U%'#SP(HGZ&98SBLE1
M$@L2]G:]ABZ)O C_J>-'$6M)DT1UH:Y5SJ*LI4TB'-K,D5<]PN*@[2!%7OSJ
ML<?%?E45;V14!'W)1Q$N@=_&4? /A4H*Q9+E;9*LRS]?9?N',17OB;KL43IO
MEPXZ'Q0KRU(HGC..Y,+B""/,DN3:X$\3$WNZB*06O;"T'I%4?]XCK69KOUQ!
M\>:J1.GIL4E0*E$"A?AP'7SZ-/HMZ>+MKD.U:C;$(LM:X>9D)6V#Z;!_ZO^T
MACZ&E34,Z@^5H6;,D>3: \*$+U_QO&)]29MUIX17YB_.R>7T",?RS!GL?>)1
M3E ?X3A^'L_O>P''3I]%H5S"SBNOQ,8M6U$9'4<V+Y<=CE5-L*A35JL,MJ3M
MF*1FUIT?FUS1[!PGHAI#.4YL]:(IM93UD;6_:JY)'.VE(MEI3)[)7N0$X<C!
M_>AHA;Y8P)KQ<7SP@^_'ZC6K4&\T.?'1&-44/""0](" @(" RP+ZO?$$4@\]
M^H<@K[GF&HR1=&MEV/DUDR20>*Z>&,<U>W;CK6^\&]?NWHFUTVOL!3 'GG\6
M>Y]_'ON??P[S,^<PL7H5*B,CYGMN;^+4SABZW4].42AD<?K42>Q]X3D<V+\/
M9\^>QMYGG\8S3SZ)IY]\ OM>> '[]N[%4X\_CD-'3V#-VK68F%I#XI^WE4(R
M<=J3D/2$N.A<!-U(NL@CKT5L[$CXXX5A6HQ(]7Z'Q>(8[JYU[F!$.3D:^6$;
MJIWL.J7#V9>4GYRGX0AQDBX191;)E[N*GA<021.Q,Q*M.'Z\OO/ !)X\.UW,
M,"2=0JP.BG9!#DD^E]4,28)91R.S?=VF7TAT>!%Z<6DP3-I\VZ5A^GU;Z)KG
MKFV=#;UV8EPOMZX3L7-]+/.0L@>@/&I?P>[6Z,%,UDW$5WK<Y(KIE( <.<LT
M>K@S*A61CZMXYL'OXFN?NP?[GGD2A4J$B;6KL6'K=NR^^FILV;P-H^,3NJ%D
M+CSV(B6J:>NH "+'\K7";B\'ZVBR(-<DAO-/3I,A'D7*-6E4'IK6"]=1[E2=
MF..#$P#M(7_JS$D<UZ2V7D>GV<*6]>OQ 9+T,4Z ]:"VW,Q4FT#2V8Z!I <$
M! 0$O!+A24U:!!% [4AR[MPY(]VWW'*+[?4M4F PPL2#D8:6O8I\VY;-N.F&
MZW#+33=BI%+&"R3H^YYYVE;7Y4M>*1=0S)-0D/B($(F8:.<)K7[/S\X9>9 ;
M02Z;MY?!5$;&,#E!<E\:L;=WOO#LLYB?JV+U^G58N^D*6U$7Q1$ISG03DD[I
MK>[*3F^N.QA6](N:M(/@V\2@\]YE7VNZ_?22&(]T> _).4-[YQY+TJ7!-O+N
M*&HC$W4 <9[^- ;#+Y#./NP/6Z%-Q)\/0B2Y-Q8\;$#HGYLT>!W#\@L*3_?+
MQ=#317&KR'U8GP_8KNN50MKL94C2S7J),-L89WO;@YHBZ0Q2.5K1;S.NI8Q,
M.SE2P+$77L3SCSV.T9$R;GO]:['CVJNQ?L,6VW,];G:P.%?CN-?W2F\LU4NE
M2*BI6\B;3DJ>8Y@F:Q7=9@(9MW+ORO0D79,TM:];07=N7)S R 6'DL\7K&\6
MZHLX>_($ZOS>=.:KN.WF&_&^][\;(Z,BY["5=&LCNWIU(Y#T@(" @(#+"EJQ
MU"JB=EJ1W';;;;:2[HF%'O[4@V@B*2(%VD%$N[F4BA&VD$#OW+$=4ZM78W1B
MG 3[' X??!%'CASD^5GRYBX)>YFD?Y1<1 0D0KE4,4*N5<>M6[=CR_9MV'GE
M;EQUU1YLV;H#)TZ<QM$CQY$E$=FV^RJLV;#>D73]/'9I@T1V473F?S7]VT\O
M&2OZW5U.]\K6)^VW?:"897_O11A%@@F1,D] 55,C6]\K3Z!N3_ALE9KBSX=!
MY2E^&-(D_4)0_$OLG?-TRQ81Z26V2[_:3'(Q6RA**P(NLJS5=$$3(>DUEQ*V
MCZU>:T*0R^N9:G1S&90*>1S;NQ_//O*8[0AS^UO>@-&I-<BTLVC6FXCK,;*<
M1.8A?WH2_*R;#*A,Z;+=@/0PJ1Z"9I.::Q0)NHY6GCY6KEM)EYW*KSIZ$N_O
MKF0[U*]S$OVSQX^ARN]-OM["N][Y-KSUK6]&J5PTURS[[MKH"5C9MS4@(" @
M(. 5 B,1%&T5.#<W9S[":7)@1UM95)C>92X_W3I__$5 @)W;MN+O_/1?Q[__
M-_\__,YO_P;^R<_] VR:&,/^AQ_"?9_^-.[]W#WXVA<^AP//OX#:W"(*^2)&
M1R>P9GH=QE>O065\'48FUB%;&,7,7!5'CY] -XJP_9JK<>75>S R,FIO..W&
M\N<EF6*9(ASV2G4C*1U[<(Y&FRA.-BM:<E$H'^%(C"8FP^2EP^E-[$LCL7>)
M$"*>VN)1_9$6M_I*;4FZB\&15G=N;9*(.LT375O53<3Z6BF41^5("!%"$49#
MRLX>F,Y6_1FNF(%89_/+!#\FEXB(-,,OI1R_,BVB+O)KON!L#R/1;'OM=YXE
MN1715KA;E>Z@-5='A^.P%3=0K2V@06*N;4K;.;?#S^3X)">@$RB-%I$K95#D
M."Y0]$"L?P!8?O#.=IVSG(P3/2;:85TTRDU$R-D?MOL-1==Z"+MKD]0LJLT:
M%NL+U)VXY_ [FHFRV+1IJSV,JX=&W8.W@SWRZD4@Z0$! 0$!EQU$&D2TS(><
MYY[TN'/^^#.-<2 2=1$9O39=NV]HE4X4(,IG,4XB<\=K;L7/_-V_B__MUWX-
M/_V3/X$-DQ-X[J'OXI&O?1E?^]//X+$'OXTSQX^B55M$?7'>?C3;S1C->L,\
MS>6O?N[T&6S<L &WW_%:K%J]"O5&G<2D8ZX"(IY&!D44S15 %$1ACB1ZL?A+
M@*N?J[/5]SSQ<0,RY#,(I1N$K$O;ZT4P'3Z/PM+AR=F*D,J7MMG"=)X*YQ\+
M-]5VV0]7D-K?$W$O^BB-VMI6="F)%E>71*=V<'E9T+.%Y;,LO]6D=R=Q?>XM
MN##\&#?_?ZN76_&6!M.C?[H@]!(N"^#8SW&&6"D5,3F]&N-3JQ"1W&MGGT*9
M0I(N]RUK&4U@.;A%_OT$0 _D2J?<8)SM;O)C#T/;BXWT;>"Y[#!;$N&Y+)#;
MC=^CW1[NS;&N).':8:C=B4G2F<X>0M6D*V=WQY(J!"0()#T@(" @X+*#"(J(
M@QX6U7F:J'M1F$A(UEZ.XE8;/?&0&XJV<FRWN_8RGUMOOAE_ZV_\#7SX'_\"
M?O(G?@QKUJ[!PNQIW/]GG\=WO_%5+)P]A6Z]AAP)QA73JS!9*>+LR>-X\K%'
MT:@N8MVZ]5A-@B[2HI5]0;?NC9R1-,E6D2G99<2'?W1M(A+$=&(H*Z-L?0S6
M^:)"DG2>,/RB2-N;$HOB9PD)3<2(I!)<:J6^![ VK(_K8^]^T;.5HKKJ7'O%
MRT8&],+L2!TBBR\'7-VI4VVC9QU2HO8R7&+;:)S(/HGU&PU677S]K&X4C4&M
MV,L7O%:O\SJV!ZT7.5:UA:/.M4--K5:U--*C?NSUG0AY\M'XE3Z)XE2&+V\X
MG%T]7;19_2*7&4FCV;"^T41 &F+JU5%I Y8BD/2 @(" @,L.(N""D84$/?*P
M!$Q',DZ*0%)#L?5ODA<FTZW[8J%DV\N5"P7LV;4#?^D#[\4__KG_!1_^AQ_"
MW__IG\+FZ7$\\LU[\8G_\=_PQ4]_$L\__BCBA1G49\_BT(LOX/BA0U@[O1;;
MMFS!Y.0J1YQ4:M;MGJ(K]S"E6_GLL;*TW:(H]L_.+@VF9^4B&[P(GFQYRQ+K
MAB*=II<VR>_LX"$1P>*3XY(\@F5A?=DN7I:#")[O6_]@JKFSI,KMH5>(PE-Q
MRI^<ZD1$WMJ YYXP>]N44D37_*R5;P4V"K)3>98@5:Z.7LZS>PAZ54E#^=)"
M;?JK.MC=&=GHPWD4$1;D>N0)L^KATZHM#2S(XACNQ?10!NOO[;)2%)^(P>HO
MFQ3FQK[:V4W8U#YNXN G<-9>23LK+F I0HL$! 0$!%RV,%*2@G[L'4]*2 -_
MYC*(*$5W%&$G6=<#H;E<P43D0#^&&1**7*>-J[=OQD^^_]WXT-_YZ_AW__*7
M\9?>_79TJ_-X\IOWX:OW? 9_^+O_!=_XTN>P]\E'T5R<Q[5[=F/S%1O-#UM%
M%PIZ $ZKA-X&9XU(2@_.R#X&+O_<0,/,-MJ3)N^#2,>GQ2-]+NAJ,&U:#)[8
M70Q,+M+LW$2<V-T)(Y6*7EJV067X<@P\9UJ-%P7; YA:R:4"%Z:TJ?2F.)U_
M!3 5Y^?Q(4OJ?Q'=3M5 >Q%#PY)C;[A9G+LK8"O?29V]+[P'M?@3=\XZ#]6_
M)$R)$R%\D3I)8I,_'DZG.R-2>061=!_OCP%]!)(>$! 0$/ #B!Y]<.B2  P&
MD928'RP)G[9:)(7CD>>=V-[4.#E2Q-O?>#?^CW_]+_'Q/_Q]_,H__V>8FAC'
MBT\_B:]]X4_QY,,/8:1<PI9-F[!ZU:21/;T029"/K4C'0)$!+Q$BFB*<\G&6
MV*JP"*B1Z231A6#=3T+./"*)ME.*W>WPJ\])NH" 5Q "20\(" @(N"PAHM9_
MH,ZQ++<:)[&U<;LV<9>6SJ<5E%\?^>S&)&QQ#FB1K)/^(=+;C+HM3(P5<?O-
MU^#O_,T?PZ_]\P_A1][Y+NS<? 5*Q0ZV[+@"8^O7(BZ-8+Y%P@?FZ6085Y(_
M#;*Y#(K4F\MVT<JX736ZG #H3:<>9C%M]'49!EF<ECY8L2Z-EJAL'KLI.?^:
MN5.BXK)F@,BKLZUC>V6S%31AD4V):Y%6L\W:Q$9=*<Q<4*2+UUH93:^.#H7I
MD0R#.4HDYWVH#+<JS%B51V)M]I@YP\NRODZE%]%W==#S F[7$K-=<?R8&D8K
MGW9,L7&2I/?P;A^2-*S..AE(?ZF0EL$5[Y4AHBB/<R-I<R!G.B-VMT"[&G6[
MG#SJV.&8[)11:)>0[V235_TS5UL3RLCUI\2WE>Q88HMK$VL#[>&2C)N^L'Q-
M>CG1!<>17H 4\SO4U=9&[#_=:RK$+(G?$8WW#@=?B[9UF$\/NJJD+"?4MA-2
M@/5-0$! 0$# 985!LBU2<^G$QL$_1-AHU(V<+"S,V]:.6F6G9B-->MANS>HU
M^.$??@]NNOEFM.(6UEVQ$=?=>"/*(Z.(F4_[LQNA(<FH5>OV!E/ILXF B"[C
MO,UFK_\DI&P8*?2P^B:$<[DT%DX]1O;Y$3SA<KJ3ZT0N!N7S#PQJ]=KE=RO/
MTF>$2F49R[\4N#L,]K"LVBL1MVO)$+L8I/:Q[0>U'2#%SGT]%3_D8VY,O?3J
M Y?'5#*/1+8K3OI5MC[F!N/KF++O/'F%PL8*^XF];-?:E45]J##;AYRVZ]D,
M;=FH<YO\,*VZL==ZRXQ).V.X?_.IVM3T42QW<IX606.&%Y9&[:R'1663;=^I
M79<8H_W8 Y8BD/2 @(" @,L.^M&W'_X$(@.V:IB0@F%0G$B:D;M4.KU&O5@N
M&TEHDEB/CT]@<G*2Q,&ML#?L;:/*G\/QXR?Q[8<>PMF96:S=L %KUV] 5GM+
MERK(4(\>4A5]C5M:3<P@;_[OSK5"JZV>^&D_Z,$=5ARYZA.B); X$<=^G0>A
MG-+C5D]=_43JS34D:2M?QK+EI"!=7LQV43GI$JEC?BLK3997"B95?NDQ(IU(
M3V^2K <&J(S^?MV4A*C+!L4O:<M$C*#WTM-.Y>%1L,D&1=>VSWBJ?)%V/UFP
MEP^E;$S+*Q6JE[6O)G1L'+W,JYGLJ!)%(L)L'XU+CG>U7QPWF=Z]ZG])&ZK/
MJ4?2 \_5/R+6$OGVJRULC%"!S^?%PA(].C<5'(OZGC4:37[W<KT=F@H%W0T(
M2".0](" @(" RPIITJ#5;D^\+@72X8F$5KS/G#Z-QQY[#.?.GC5"H[V<12**
MQ3+*I1%$>J4Y"?BWO_5M?/,[W\7DVG78N&4;<J4RNB0[=>U8(8).L=UD] (7
MDG3W4E']<3:+X$@,JD=*!MU$1!2],,((HW<]&09/J&RUW4,$EGF];AV]#(-"
M1::TXBI"IY<4273MV]FT*W^BP_X.5S<4LD,V2J>(LUZ:H_Q^5=;K]="5"UYJ
MOPMS\>EV%$S/ !3F=9B[2I+>M86?=)" JYV5W@O_#).T+:\D^/X3^;4^-$)=
M0*E42E*(-(L\YY/)B(03%+FJL"Y>DB%['BP'\_6$'W^'19'*ZG4H7O;HH6K9
MHZ/L\;:Y]"[=DG$;8 @D/2 @("#@50=/#+P;P'WWWHO?^:^_@]_]O=_#X2-'
M2&,RMCWCXD(-ITZ=8;HV)P1M?.<[#^+HL6/8NG,7IJ^X A&)CU;2R6#1ILX.
M121(DDV(^F4+UL6M0&ME_N6C"VIW-9'(F\038\F%R&' I<,F5\DDJP^U,2=<
M73\VU1^ZT[+\79HTU'_^3I:Y!?ES]:MA^)B7#=Z>@)4AD/2 @(" @%<=1"CJ
M]3IF9V?1;#3QXHLO8M^+^_"5KWP%/_,S_PM^]5_\*K[RU:\:^5B[=JVM_#WX
MW8=P[[U?Q_I-FW'3+;?@BDV;^"N:0TQNT] N,0DY]Y(A"=+G<H56-G6G0B)7
MD)<3(N-RM]#JO+UZGNUHYW(CN7R;[!4'<W6BZ-A'>IQZB&"O?':D[X5T]G;;
MX01681>"TGM[ E:&0-(# @(" BX[:-6UOW)WZ5!>W78?'1W%V;-G<?K4*?R#
M?_ S^/5_^6]PZRUWXIO?>!#_Z!<_C __\D=P[U>_@0-[C^!K]WT'AT_/8<\U
MUV)JPR;DQU:C#I)T?@I1!SFM/%-LE5XD1BX  \3'/9 G(IHB2#I7'JU0IL2Y
M4IS_,RV-Z72]]%J-3NL5DN(MC:UVJN[GBVP2:=:YB%2SU32_8?^&S)9$=QVH
MRTI(,KJ/3O67QP%94L\$TJ_5<RE2K-I*_N9),SCZJ%7U1%S;N#HDQ0X(IT?:
MB2;9/C,'ZM>#D+1 <19O.MRYH5>82K. )6VYG*1A1)62;M=A>23*Z5UCEA/!
M4EH#I.Q+B?10G<ERT,10;:RWBM:;\V@T]9;1*NJ-JMT-LJDCU7719&*WDT^W
M(]>3HK7/DG8:@-I1'XOG)"[33D3G=JW=7=RYC+3V84GUN(D:[;$)0ZV!F!/C
M-N,[1?96E%/C(,LLV=CI5?: 0-(# @(" EZET,JMB(Q(ULSLK*V8WW333?C5
MC_PJ_N!C'\.__\W?Q!.//X&?^JF_BG_R3W\)_^5W?@<C8V.X]H8;,#:YRAXX
M[8KMD+3HYU3ZO R#>(>1&R87*?.$7<3'KD5*+=P)_[B,*T2?8/5=#_0@G[F3
MF+YTFI3PTRN34!BOF,?;M]0N7?./U4=MUQ>&*"_CO N+)1J 6RUW1,_(?R(7
MA:D?L'U C! SG6Q(VZ>:]1YR99P2*5PKP.ZE2"MS]4A#^:1+=P)\^</JNU*X
MMG7MLA)9"42*I=,_)"H#[650[=BUB\4Y^S494Q@OK+V&P4IEI$T(!\3T6Q'#
M;=2S'[5JS>[,^'IVV/X!RR.0](" @(" 5QU$$K3:*,)0*!9MU5@41#ZS(K;3
MT].X_36WXY?_^:_@W>]^#QYY['&<.GL6&S9OP>CJU6B0Z%2UZPM9B:,T&>1)
M=KP,A8B+3WT>\3U?+A5&>A)RY F2])A/N8BQA3M"FA:?SI>IO'8]L%-'3Y)P
M*T]$E^VHH^TJ(EV4WD.@5N.E4'Y!^6/M3Y_(Q2!-P^QWXNKLQ<KFT>Q*R*C?
MBI$79I/"XX2LJMTN%::7'T=R$SO.J^W*86W+C]6!$Y[!.O7%E;42:"*A#G%W
M*ASED]VNS]S=&HU7Z=4JN^*L!FJ_"T"D7#K5GEZT8Y$RIVU= D;K3;'*JX=8
MHT)D8S-@>022'A 0$!!P6<$31']NA.P2H?PBY!,3$W;MB(LC/G+K*.0C%*,B
MWO3&-^&UKWT=QB96X=8[[L0U-]^,+@E&G>EJ)#K-MHBQ"%#.$63+OPSA3.Q4
M.3URF(A;S5U:ITNO%2&2Q(/R>DD3OK0;29J8BK2IWH);&4U6]ZG A.'IMN[I
MX\=(&LF6\ED<163,'BJTD*4P78E8.8GX]K,"4[ RDZ"T_3U)37B\#6I3P=4E
M:^VK.OH)A;/=Q5M>7\!%8&W&]"*T!F5CD()5QJ![DMK0R\5@8\&3[V62FZVR
M6752?:PN2>00J%]LTL@TVK5(Z?567$U*O:C??7OY?I78-<>.M5TB-E99KI[G
MJ-7J=K3S>LV>[?!IO#A7J9;ME"0;M+>ZZJ [6-*MATBUC:/*TUT-?V?K E5Z
M52&0](" @(" 5QU$SD0&1!@JE3(V;]Z,8\>.8G%QT>*,1)-,GSE]#D\]_0RF
MUJW#.]_];FS>OAWYD3*:)!5-D?HL"0895<+O+PJ1$2,O1K 228BCF,E*R>++
M 2/A(GP\][;(/JV0RI*5$249W7=O47M:'54G'O]"D)0O^#L;1@+5YNPH(X&\
M%KFWR86(=4*V?Q#@B;[JI>TS[:X&)T&J<\3)9YF3S&*QA%*I:"O:18JV1M0^
MY;HN%1DNL7B71F_0E?@M%,\3ZLTGYTI?+I=-(MMZD=?\CNGA:XT130KD]J+G
M'G1'P,:^1CYM5']H# 4X!)(>$! 0$/"JA"?IY7(%NW;MPJ%#AW#JU"DCK]JQ
M0L1S__Z#>&'O7A*9LKW4J$#B$7?TJG,2'A(8L@XC=[R\*#SUL#VE$[)HDIP;
M_ASYB5^!%LP&BB>O*R5*JK8F%B+[2T@ZZZ.5=.$O@G+Y"8)?=58'65NS[;U=
M,LQL)CET!'T%G7@90.TOJ"_Z=S@RJ'$"JK?JNAU[],9/]S"PWOZI%?5:O8YJ
MM8K%06&^Q:H3K9IKM;M)T5&K\EZT4J\PZ:G5:M1%(IZLU&M%73LI5:E#84;8
M.<ZT>N[&G/K*C2.[^,'HBN\9&0[:[ZDI5OI%#@@(" @(>#D@LJ55T4]]ZE/X
M[G>_BP]]Z$/VT&?Z]^ABOTT](LFC=-U___WXS&<^@P]^\(.X]=9;71G-#CYS
MS^?Q/__X4[CRVINQ=M,V=+(%+!9(+@H9M"/=MJ^B&'>1IYYL5$FTPU8)98-)
M$J8?6Q%AOV*=ME$3 ZU$*K7W-[8?9]E)$9;4B4&)<T@OO%\2ST4\/51'$51*
MVAU##Q"*+*G^(FZ"N4?0#H5YLB>X>L@E)2&X'JH'B94>RI0]MGM'TC^:Y,BE
M2%K2NB[D^N$G"+YN@N\C'1WA7!F45BN[0J,N5P]WQT+Z_9:/<K6POF;]5>*2
M-AZ"M.UUZI1?M<H0.;4[$VK?E(IA=4TUA;6GKY.WS27@,<EJ;><S61E]G=8K
MZNM.@5=*0[$]S]E6N0Q*I0@/?>73^.JG/H96HXE-NV]"MC*%=C;/SFXCDV.9
M7?9K73[I[+^\NRNB?A-D$PU$U\9-VW1GI)^2Z^:9-^D/,YN]1DI9H#Z9U.8?
M/;6!*(\6VWZT)EN!5KR(XP?VHG[N#(K4_QN_]J_P5W_ZI_C]<=^);E=]1@7N
M36"O:@22'A 0$!!P6<%(%4G;IS_]:3STT$/XV9_]64Q-3=GOD9>+P9/&N;DY
M(UB3DY/XZ$<_BB>??!+O?>][;9>79Y[?BU_]M5_'U,9MN.:FV['0(@G)%1%'
M)+8YVI$EL6FW$)%HY?132L+G(1L=:9,M?7N,< XAZ3H7<;2DO5]E1U5MY7>@
M3N9GGB3T>GR=A#095SJW6B^2M=06D70=?5[I$FFT:X5;J,QR^<XCZ83%I&SP
MXNKD[.A;EJ1?!LN1=&</+RZ4>0A$Q(4>";<K@F7HHX=)I=O(Z#*PLA.D2;?N
MMJBM;$6X'=MDQ?>%QS!SK;Q$I])[0FS/!##8'L!,Z>G5W2.EU&IA)%WMK$3L
M9Y)IN:ZT-39Y]=C]7\87_N2CZ-+&_,@:=&).+!JZJ\"))(EZCH2]48OY/6@C
M7RF9^GIUD7'N)5;6-F:/TV\BHDXRWH.B$INU!::44!N/>9N\DMKK]<! D6%9
M'FOSG,DV,%$NX]__^K_!3_WUGV!:VD>[ TGO(Y#T@(" @(#+"IZD:^7[X8<?
MQL_\S,]@S9HU%N=)V4K@B9E^QV9F9G#DR!$\\, #=MR]>S>.GIO%-[[[$*[8
MOAOK-N] HYM'4V]J!(DM/Z)#MK+(H_9X[HI\))!.(^D)2>V!Z8:2='U(MO31
M/P^E\R3=!XO@#27I*:*9+M=(84+2!W_P1=*%)61:I% Z=4Q!E\-(NJ&7MF^_
M#MZ.),A@I',9+$?2T_E7"M$;?T=!.D2F_0.J4J\RK.V2<V%8.;HSX#&X,NY4
M.7W6?XSW*4SCD+I:?R0ZW6J_5L%ADT7ID@]]>FQX0B\,MIV-&-71^D5&N'XN
M5XJF;XP3QR>^\PW<\T<?Q?SI4RRP:"O@I5:;$Y<:LY 8%PLDQR,HC4Y@\]:M
M*)=+F)V=0Z52,;(?TU;WEE!9QX_90/%EZB\/:EN[DY!E/6A2IUM"*\XC*HPQ
M/L)".8MFJX[YF=,X<W@_VK,ST+VGW_PW_SM^\J_\&-NY@6*E;&FM)P))#R0]
M(" @(.#R@@B.B,(G/_E)(^D_]W,_9R1=89="TKV+APB_?'''Q\?Q_///FQN-
MCD\<.(CIS=MQU?6W8&QJ PEZ'HT.262')$JD1"1%I,B$UYEDQP_"K:*3L S\
M1!JYIIWZI"&RMMSOJ9$B20*=#2/IRX+)S!<[I4-0+K772K?!4YG+DO0A\ 1R
MT+[T9&(0PTBZQV [G#<!>BF@/IOT4&3ER\%IO%V#]GHHW(=JXN G$CV7'FL#
M"SH/:<(^.&&@9HJFCG*AT?AN876EA(-[G\>???YS.'/RA.U8I%PE<NX"!W$W
MKJ/!<A?(JK=>N0>WWG(KOP<31O3]!"[NW8&1*XJODN^COCV^[[12;G$DVYD,
M)PM-W54J(!HM\[J#?<\_C>]\Y<LX_-23&*.A__Y?DZ3_]1]GCB8BN[,32+K'
MRS#" P(" @("+B\8&2)!$%&7FX$G)#MW[L3[W_]^>[CMB4<>PZE39U ICS#&
MD11))Q/S;PMYK4)2,KSN9MWVA:]4B/B)D/O=3B2Z-E*5(GX!?PY@FZO=_61$
MDTZ)KNV.AKHD2;IB< +IA 271Y'B7+:()B>5I<FUN/Z.-^/-[_Y1O/E=[\6;
MWO%#>--[?@3O?!^OW_E>W/2Z-Z(XM1[E*S9C;.-V5-;KN WYU>O1'5N-S/@4
M,+Z:LH8R35D+C*VC;.3YEI1L-LF,;D>.DF=\;G0-1M=,H[QZ#(61,HHC%91'
M1OA]*]CN+QG24+6!)C;:"29@*0))#P@(" BX[&"KE F6.[\0?#IM*:<MZ"2M
M1AV-6A4G3Y_"Z=E9\X_5 ZGED3&FS*&MA7/F$RD']& H1:]6-Q_<I>5*OUMI
M7 :*DD] (F:.SL70!C&H9H5U[,.Y?9C_=%:[?21"DLY*7,C*X1A6OMG//\.4
M65R_KJZ.7EXZK(V'R/<35I5AHK)Y5'M>#$JA57#UA]".]>"J5IO5+WG&,X4I
MZV-8W7R8)-/5W1T17O5GEB,R0B=;QKG%)K+E">R^X3;<_-HWXLJK;\+F;7NP
M8_NUV+[K>DRMWX%,?@*Y:!+3T]O0;!=QZFP-I\\U,#,?H]Z*$'?+:,8E"DD_
MI25ANE9<0;/E982374H\@K@U@;@Y@79S!)UF@1/9(J)V#@N+5?/CMP>D6<]B
ML6S5U$XPVF'&[2[DZA;@$$AZ0$! 0,!E!:TX>I_>-'&Q5>%+@,B!MI3KDBSI
MP;]2J8 HE\%G/GL/OOWDDUBS<0,V;=N*;K& .)]'JTMRGFT;R>KPO*/;^EGY
MI)/\=B)'O!+Q=AGA2D.7)OJCGV GW8[R,(S9E,=]")$P^_1AYXSTJ[$712J-
MSY/.ER9[%Q)G$#%0IMEJ0?RC(Y-:'G?"?ZYN7M+UOA28W>PK<R=1@;)IF S!
M8%UZDL2O&,HP1'00K!E6 M6%(F).,TST0BQSD>*$<%"3]'M?>@^=>LEU-0XY
M/C,MM',=U)FVCCRZ40697!'Y?!'5:ITD&R3=><9G,,M\1UI-O'AN!M'(*DRN
MWH#<Z"A0KB W,HI,F22[4$*<*Z";KU#*0%34S)8BW>S/9 %?SXB:EPJ/<:%#
MZ=KN1QDCY-H?O8QRL8)B1&+.L3X[.T]"WT:;QI\^==JVA]3=*ZL-J^[&4\"E
M?4," @(" @)> ? N A*1K4N%")*]R*6H_9K]&Q [>.&YY_')3W_&WC!Z\VMN
MQ]BJU:@UFGI$U)A#CB3>OY9=HMU!1"@&Z9XGPKV'"1/Q)#X=YD7U$!&3W[>3
M/IGDGT3S]X:^;M=NJK,[KD"8;M!FJPOK:&^.M)<@R=1$)\75H=]>DK\(7*B.
M@J_/Q9!NO[1<"E2B;W?!W]FP]F*XD#9%J62;N2<-C"<OZ=&AFSH9U4NO^=?;
M<$FR8ZJ=6:BBDXLXL<RC3:)\YNPL]NX]@+G915Q[]?58-;H*N58&Q6X!!4HY
M6T)$!I[O9"'^/2@%M%',),+)*TM!OJO=CAHF^6Z3D]<F[:%T6G;G0/73?NH+
M<[.4.8Z?+!Y][#%[8^E*GXUX-2&0](" @(" RPZ>T/1)39_5>/)S(2B-?UA3
MNZU4RF6\N/=%?/0/_PBU5A>CJ]9BU?I-R)0J9"0ET@\2(2-(RJL'_/20J'M
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MI"M,9&$)N^%/E.B+5GGU:R6*V2,3U".2_]?^YO\+QTZ?Q,UWO09-DH\7GC^
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MS.Q[$OGJ&?QOO_[K^*F?^BOV%M(L^Y%*K8'#2CJ;ZR,?^<BO)N<O"<MW4$!
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M_/5SE$>ZC14W64SR2*W>YC,)$M@LE-VTS^>'D$AG._ALG0>+(G8_X>D4V<V
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M3-]^7)WO3=F,'ZS"EO$D8=WB!9@[XRU,>NDI/'K?8%PQ^!4LM;8'":>E+SR
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M-Z_ MK#.Z'E.M.7#T *D;5Z%-7LS#6'N;("./;L@/M(4C2>+8CM8=/Y!90;
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81@'\/\R+D5;H!\@6     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_21.jpg
<TEXT>
begin 644 image_21.jpg
MB5!.1PT*&@H    -24A$4@   VP   +"" 8   "B#5![     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  %B4  !8E 4E2)/   /^E241!
M5'A>[-T%?!37V@;P-R3$( 1"(! "P8-[%:C14B]U]]Y;N^VMZ^U7N76]U5L7
MZDJIM]1+N11W=Q(2)(2$0%R^?<_.&TXFLY:LS.X^__ZFHWMV=G;9S+/GS)F8
M>@<"        VVEEC $      ,!F$-@       !L"H$-      # IA#8
M    ; J!#0      P*;02R1 A(N)B5'C!0L6J#'+R<FAI*0D8\Z]\O)R6K5J
ME3%'-'+D2#7&5P<   ! X"&P 40X"6SZ/_6%"Q?2WKU[:>S8L<82:S-FS* V
M;=K0B!$CC"76Y0$   ! 8""P 40X5P&+:\ZF3Y].X\>/MZQMFS9MFN4Z!#8
M  " X,$U; !1BH/8Q(D356@S<Q76     ""X4,,&$.$\U8AQ3=O\^?,;FD>N
M7KV:TM/3*2TM3<V;H88-    ('A0PP80Y;@6K5.G3E145*3"VXX=.UR&-0
M   (+M2P 40X;VO$K#H8L8(:-@   (#@00T; "@<U@    # 7A#8 $!)3DZF
MRLI*8PX     [ !-(MV0IE_NV.WP>;//$)V\^:QR[Y#<<Z0[^(Q%+_RY
M"#X$-C<0V.SEX(,/-J;<XXXS:FMKC3GW>+O8V%ACSK/X^'@U!(,OK\,5[E!D
MUJQ9:MJ;SRIW/.*IPQ$$MNB%/Q<   #!A\#F!@(;1**%ZS884\TWHD\O8PJB
M"?Y<    !!\"FQMZ^ GWP\2O9>3P$;1@T4)CB7OKI^W;KO?$?;T&ZLN#B?<A
MI4U;*MV[QU@"S?7@1U\84\WWK[,F&5.!Y>]];6EY_GS=_GAM_N+MZ\*?"P
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MP(%+IGD0HY<^I,8I4R[>%^@FGT8/Y:QR69.F!S]]&Z'OLXZ7Z\OT:?WQ
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MMF6R7);QP&%,ULF8!UDNY7 PN_C7%.H_\PYU_=NH4:/4<ME>I\_SXWA>@AT
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M')1DO7E:MI<>(&5>@ID^S6,N5_:'Q_(X"7B\'9-U^K;Z,MF.R?/HRQ#.
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MM4])-98"       X(;"%$&K7      # '02V$$'M&@      >(+ %B*H70,
M     $\0V$( M6L      . -!+800.T: -@=WS1=OW$Z;IH-   0&@AL08;:
M-0      \!8"6Y"]_L++M'SU2M2N 0    " 1PAL0<2U:WTRLNF$PXY&[1H
M     'B$P!9$N'8-      !\@< 6)+AV#0      ?(7 %B2H70,      %\A
ML 4!:M<      * Y$-B" +5K      #0' AL 8;:-0      :"X$M@!#[1H
M     #07 EL H78-      !: H$M@%Y_X674K@$     0+/%U#L8T^!'7+OV
MUC.O4+?T+G3N"6<82P'"0^^)(]3XP8^^4&,[V%U41&L6S:>:FAKJWK<?9?;J
MHY;_ZZQ):LST_97EO$S?IB5:>CS*]I12=545I:9U-);8$Q\O>:UR[/"G @
M(#10PQ8@?.W:B8<<0\<=.M%8 @#-]>.'[]*K]]Q!,[__FN;\^#U]^,R3].,'
M[QIK0X]#& <;/1CJ\[S^LQ>?I0<O.Y\>N^I2Q_X_3MMR-ZMU     .X@L 4
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MDMNTH=8)"=2]?PY==.=]#>M#+6?4&#K_UKLHI4,:M4UM3Y?^W_UTR*33C+4
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M.QTQ7^>'FL:6"V0-F[GV!K5X]L/O4<>N76EG00%U[=6;DA,3:=V*Y:AA P
M" '4L'DP:C Z_0" Z,-A3524EQE3    $&P(;![,7X;:&@"(7@4;UM.6C1N-
M.0    @V!#8       ";PC5L;N :-HA6Z"4RNO$U;-UZ]Z,MZ]<82YSPYP(
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MZP      @@V!#5ILIB.@Y?090$_=]B#=<MEU],XC+U./+EGTWI<?&EMXCVO
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M3]&4*2_0S=\<0D]<N1^E&*NI9@F]=_E7M/_/.ZB^=@4]L/5^NN[CU83(!@
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MP 8 (<'W^I*!0YH,Z9G=T P2    P(# !@ AU[5GKX8!M6H     ^R"P 0
M    V!0"&P      @$TAL $      -A43+V#,0TF,3$Q:KQ^VD(UMJO>$T>H
ML=WW$\*'?*8>_.@+-0X$[FQ$!/)YO*'O2TMY\UKD^61;?SY_H.!/!0  0&B@
MA@T ($0XJ(5#6 ,  (#000V;&ZAA@V"1]]!N4,/FG2[9/6GKIHUJ&C5L
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MQ[5LY945:!H)$ :X*WP.:KC/&@   /@+ EL8&-0GAXI*BE'3%B40S@$   !
M(+"%"0YM28F)-&_90BHN+3&60J30;]&0F)!(R]>M:A@     ('HAL(61+ND9
M-'KP"-I54JQ.Y+G&C<>])XY0 T0&;@;+ 9V'WED]:?J\F0CI     %$*@2T,
M]<K*5B?S,H;(E9B00.-''T3YV[>BJ20   ! %$)@BP#<C XB&P=SOHX1H0T
M   @NB"P 80)#FU;MA48<P     0#1#8 ,+(X+X#T1$)    0!1!8 ,((WQ-
M6WE%N3$'     )$.@0T@S'3+Z(I>(P$   "B! (;0)CAVSOPK1T     (/(A
ML$4 W(,M<L@]]3P-$RZ=9#P"     "(9 AN #4@0 P    #0(; !V(3<3X_'
MW@P     $/D0V        &P*@0T      ,"F$-@       !L"H$-      #
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M:>GU</5U]=0Z(9YB6KD^=MYJY2@CKG73(+IY]4IC*G+ASP4  $#P(;"Y$>K
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M:<J-K\^C-DF)=-^Y0U0-I'X_.L'-2UNG=5/3')K2NV92UYZ]FAW6&)>#Z]<
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MI09T, (   #0& (;1 U?PQH'K' /:ZYX6Q;O?V+F0*HI+326^%]RVQ1C"@
M  #,$-@@*C0GK(5C,TA_EL7[OVASF=O@!P    "!A< &$0]A;1]?PYJ[L@
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MEY79N:.Z-]J($2/4LO'CQ].T:=.HJ*A(S7-9$M8\!5=OPAK7,M95E1E+
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M-X,T\V=9$M;<E974?1AEG?\,E2[_V>NPYJIY*0     $'@(;1#2$M7T0U@
M  #"#VZ<[88T.<.-L\.+W#B; \IE#TUM45B3SP"+YK#&-\ZNW+9&31\Q=@R5
M5+>F#O&5:M[*3W_.I]BD5*JOK::ZJC)CJ;4S!U7CWF(^BME--/G[Y;3S]]=5
M1S$    0N1#8W$!@"T\<V/(_NDT%E+<O'MFBFC7Y#$1[S5K*X",I/CV;6L4G
MTW%G7T<G#&I'([+;&&N;&O^/QRAUQ F.??^4:O84&DN;2ATUB4[NO :!S4<<
MV#Y>WIKRWODG AL  $"$0V!S X$M/!WUXS9J%1>O DK!U/N-I4UYTPR2/P,<
ML&X_]?"&'ASY'F7<R0CW!LD=@[S^^NMTRCE_;^@-4FZ*;>6!3U:J\0G]*JA'
MCQXT=^Y<&C]^O.JZG_'SY156T#4?KJ?GS^[=I"R^50!W[\_;??S+2BJJ;=>D
M9TE]&V]J&=7]W2BCT;'0RQ 2_#R%8.[-DCM(\10V<Z[Y@.JVK:(31Z4@L/D(
M@0T  "!ZX!HVB#BM$I(]UB;Y>LV:A"*^%QN'M+_^^DMU\3]]^G0Z_+@SO0YK
M\7%QM'_J9A765JQ8H;K_E[#&N&:-RY+>(#DPR;!DR1(5$AG7ABW?5MO02Z4,
M2Y<N5?>"8Q*P/#4)_7[!#GK^ERWT^ITG4W)"K JD4H:0X,?'U5-8X_U_[<0.
MM&O6QPWW=C,/?%Q+<I?1FD_N-1X)     %80V"#BU%7L\4M8DWNCZ<T-.W7J
MI +6A1=>J.:3.F;30S_O]AC6I*Q;3^FK[M66EI9&HT:-HCU[G#?+9AQVN!DD
ME\5A)R\OCV;-FJ6"VK1ITVCHT*$J)/+^<S/(>\X>I,+/;[_]1G/FS*'??_]=
M[1N7SYVM2#-(3TU"UU1GTI7#RVCQ+Y_1CS_^2&W;ME5E"#WXN3NN$M9X_U-B
MRXVE3?&QJ,A?X;8L     '!"8(.HTI*PQKB&BYL+LF7KM].#TZN]#FL7']16
MU="Q\O)R53O'S0Z9A!UN1BAE<6W9_OOOKVKA1H\>3>O6K5/[OVAS6<-^\3(.
M<F/&C*%##CF$MFS9TM SIB^UC EQ]=2W;U\Z\L@C51E"PIJW-6M\+';DKE"U
MD%;X6 SOD8RP!@   . E!#:(&KZ&-?.U88QKN-+3TVGZO%5TS_>[Z/4+^GD5
MUKBLK*PL5:O&@2\W-[>A%DL/._HU7QTZ=#"F2-7(S5I?H<*:OE\<_'B=:-,N
MK>$V!MZ&M5V%6QN5T:U;-RHJ*FI42^=MS1H?B[U[]S9JYBDDK+D+?N"]F-C6
MQA0   !$,@0VB K^"&NBO+X-O30_EIXYJZ?784UPD.%:-7/-FE4M'8<Q,6U>
M/FTLB6NR7YF9F31[]FPUS0'KL1GU/M_&@,O8N7.GL99HUZY=E-2VO5>U=.;]
MYS Z<.! 8^T^"&O^USHMRY@"  " 2(; Y@7NA5&&3W[XPE@*X<(?84TZ]>AP
MP)FJ!\1O7[NS2:<@^M#KZO?ID2F_-ND41!^LRM)Q4\<??OB!WO]Q&7TS+X_N
M/+UI,T.N&>/KV'[\Y0^ZX.6E=.:01)_"FF[QXL7TU5=?4:O625[5TIG#&@?,
M'3MV-*JM8PAK@5'OX?YV    $!D0V""B^:MFC4,1=[=_W-\>HE^N'>FV!\27
M?LQ7MP'8\-]S+=?SX*HL'0>?U%X'4FE,&CUS^?[&TJ:&C=R/OLSO3C<?G4VG
M'=K/6-J4NV/!U\H-&S:,CCSZ>'IK:1N/M73FL,9-*/F:O+%CQQI;."&L!4YU
MR39C"@   "(9 AM$+.[ZWA]AC;EKNJCS9UD<L/1KUK@&2VKGA'0PH@<L;I9H
MKJWS)KA:E67%JAGDYLV;&_4LR;P):WP; P    !P#8$-(A*'M91!$_P2UN3>
M:*$*:QR(N'=)[JA$IP>LX=WCU39\#[7NW;L;6SCY,ZS)L?CW\9U4;Y#\G-P)
M"W?&HO,VK/%M#     # -00VB#A\XVP.:WGO7N>7L";W1@M%6.- E)R<K)H:
M2D<EC+O;EX"5E5Q*\^?/5]MP<-)[:/2FEM';L+8NOT0=BXL'[J7:/=O4<_%S
M-N>:-3FN?!L#     ' -@0TB3UV="FOEN8N-!4UY&[ D5 0KK'' DK#&M679
MV=GJ=@ Z_4;6_=-KJ;"PL,FU8\R;6D9?:M;N_F:'NN;NJ''#&X5'G3=A33^N
M^FT,     * I!#:(.'75%7X):QRP/(4*?X8UKEE+S!RHRI(N_5V%->YNGVO6
M5JQ8T:0Y(I.PYJZ6T9>PYFTMHS=AS9OC"@    !."&P057P-6,$,:URSMO'%
M\]3\JE6KF@0Q#ECZC:PK*BJH39LVQMI]N"P):ZZ"JZ]AS9M:1F_#FJ?C"@
M  #[(+!!U/!GP I$6'-7E@0L_4;6=75U34(=E\77K/DCK/'^>]-TT=>PYNY8
M@/=:IV884P   !#)$-@@*H136.,N^4>.'&G,-0Y8^HVL<W(:WTA;PAI?L^:/
ML/;2;]O4-6L(:S85$VM,    0"1#8(.(YX^ )?<U"W18TV^NS<P!2U\OVS ]
MK/$U:_HZX6M8N_/$+(_!%6$M=&I*=QA3    $,D0V""B^3-@!3JLF7D;L,QA
MS4ISPIJKLAC"6NC5UU8;4P   !#)$-@@8O6\ZCTU]D? \F=9"&O[R'$%
M &L(;!"1$-:<]!ML(ZP!    A!\$-H@XL4GMU%BZR+?B:ZCP1UFA"&MR@VV[
MAC5WQQ4     $-A\TJ;/ ?37UDHJJ7)V0 'V5%N^VR\!2ZY9T\OBSD?TH<,!
M9](1SRVP75CCLN2>;0?EM&_87S.KL*:_/GD,!RQ_A36KXPH     UA#8/.!:
MBF[G/DD#'EA G4^XC?ZJ2*23/OB9COMD'IW_P>_TV?)M5%EK; RVU]*PIM-O
M*IV5GMADO0A%6..RWKYX)!5,O;^A1\G<W%PJ*BHRMK(.:SIY'(>UBOP5"&L
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M6;OVU- IKZVCF\=W=%O6Z[\6T*?+2MV6974L.+ MSRNC2?MW4O.^PM<^  !
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M<'U6!UX)1%AK2:A@YYY[+IUQQ=VTWY%GTF_7#:5OWGN&CA^727>?UX\^_>=
M.N/8GE32+I5>WI)$URR+IZ^VQ$9T@&O)<>6:(!XXK'7OWIUB.PVALKATNN:8
M[L8634526'/U&6,M"6N,.]?IULU9L]9ETEV4,F@"Y;U['97G+J;XMAUH5*\4
MM8[Q/G'7_1^<GTW35NY6Q\X*+^<:K-?/[D%/_9"OGM],CND]$S,HNT-\P^LP
MD[(^."];/3?O@YD_RV+\^.RT>+IR7+K+LOBQS_U92.V3/-SOPX1_;.!:30
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MSE:?(?XLF7E3%N/E7+/VW@4]798EGU4^%H?T3W%9EDYZ,TU/3Z<1(T882P$
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MZJHL\V?)F[*8>9E56:[*Y\_EA,&IJDED5]J@_@VW:^>L568]>O10/\    !
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MR^'!ZMB9]\G5<WM;EKZ<R[3Z3)J?P]7^Z\NY+*OWP;S<U[*:4\/&?/W^ P
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M!#97Y>B? 5?[9"[?55GZ<O-CA+=E\3[HGV%]/W7Z<E?OCWFYKV7Q=Y($-@
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M^G?NW&G,.=\;OB&V7A:O__[[[XTY9UFGO;A:#>Z.!0<V^1$)    (IOKBVG
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M5?-&<Q-(':^;-FV:>CR7Q:]'RD5@<T)@\PX"&P! Z""P11DY\<P\\V%JT^=
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MX6:ZY,*S*#VA@N[^U[[:HI>??XKV%FVEN)1TVKWX.[6, Q:'-6D2R<&+E_'
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M-]2P<>#2 Z@>2JW6"7T;ID_;]3M _W<:['U<N[R *LJK**-;>^K4Q?5] @$
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M]V/&5HT=..XPZM=_(/7JVX_V.W"LVE[7??CAU&[X<90R>((:N,GFSKQUQEH
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MJW-:]!(9X?B+1A\BE?EUR@  X$F_P9EAV[,B!S6N)>2:MAT%)2IXAF-8 P"
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MQPX;@4V[+5>^M#YN%JTUPAC8B(J)548IT!C6\C&LV>-QB(ABS;Z]AXVQZ,?
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MULSL@IHBX^;!7,H6;1C8B(C"U%MOO:7?;LK8C@7[&NCMV^[JFNP,768C1HS
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M6B>_L-F5XMI1P<Y\[;=P"$/6[Y(=[A]$1!2K5,VLU3]NTWOCEG/'JSI=K/=
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1Q!9/:H8     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_31.jpg
<TEXT>
begin 644 image_31.jpg
MB5!.1PT*&@H    -24A$4@   TP   +F" 8   !Q;12+     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  %B4  !8E 4E2)/   +QJ241!
M5'A>[-T)?!3U^<?Q)YQ)5&X$ L@-RJ$B:&W%6]&JM=[VKU5;;:MM/5JU6JVM
MU5KO^[96K5JUU7I4JZTHWB>"J%QR"$2.@%P):,*=?Y[)/,DOD]UDD^PQL_MY
M\QKFGIV=G9W,=W\SO\FKK"(     @'I:^6T     0 "!"0    #B(# !
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ME+1;PXZ%J""W!,<-1=IH6+'YW&YM!]D\UFWLM<U/W^E2TZ_A26F->"K6_
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M4    * ^ A/JL6 2+Z D.ES[F[.,6.,2F=Z=)M[T:M);<VJ:1$V<=[7?!0
M@%Q"8 (   " ./(JW:=])L NP[)?W/6>D*C^^KYXP4JO';PL*]M+$[0J[0T5
MFW+N?2>#>P]4-FRO;'L_RMY3E-Y/\#AJ[Z&)AV<  ) ".5?"I"%IWLP2K^G>
MJV/./+!T;6FY3)]2[+WO]OEM>5!KCMFP?E/-?J^-?@_<L*2T7QMW.MUO
M<EG.!"8]8=3 T+Z@K0P>WLMK-#AD.WO?:]>4R\@Q_;SWS7.'<HL&G[DSEM;L
M]]HT%)C=Z72_T?U']R,  (!<E!.!27\EGS9YH1<8NO?LZ _-?GJ2:^^;$J7<
M-/F=N=)W8#=O'V@.W6]T7MV/"$T  " 797U@TI.\+[]8(6/'#?&'Y 8+2[GV
MOE%+P]*HL?V34I*J^Q&A"0  Y**L#TQ6PI)K"$NY32^C2U98,A::    <DE6
M!R:]L7WHR-Y^7^[(U?>-:GH):J<NVZ3D'CT-87I/%   0*[(ZL!4NOJ;G*S@
M8'W%)BIVR&%Z"6JJ[EG3$+:^8J/?!P  D/VR-C#IK^P]>G?R^W(']YCD-OW\
M\PO:^7VI,61$$:5,   @9V1M8/IJ:5E.U8AG5I24>=5!(S<MFK\RY9^_EC+E
M%V1_E?P    J:P-3KI[0Z>5XR%WIVN_9SP  0*[(JZSB=R<D+R_/[\J\B?.N
M]KOJ.W#PI0V.=^FT49*J]YWH?+G,W69AW%Y:X4>B]R_%V^\3>5]->9UTL_<5
MI?TYWF?1Q,,S  !(@28%IC"%I40T-SA$77/?=Y1.,#,E"OM*2_?[1.;/INT0
M!@UM3T(3  "9%>G U- )D9Z M/3$,:Q2];ZC=(*9*6'85U*YWS=UWGC3AWT[
MA4U#VXO ! ! 9B4E,$7IQ 1 =FLLS(41@0D @/#*ZN<P 0   $!+$)@ 9!5*
MO $ 0#(1F      @#@(3     ,1!8 (   " . A, +**U3BW8EF9UP8  &@)
M A. K-0^OZTL7K!2YLTLD>E3BF5M:;D_!@  ('$\APE 3M#P5+KZ&QDRHL@+
M4V'"<Y@   @O2I@ Y(0^ [K)R#']9.Z,I5RN!P  $D9@ I!3-#25K2XG- $
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MJ]@Q($K?_^!QE!(F  #"@\ $(*NXQX!$9?I806 " ""\"$P <EI8JA4G, $
M$$[<PP0@IZVOV.1W 0  U$=@ @   ( X"$P <M:\F272=V!F+\<#  #A1F "
MD+/65VR4]OEM_3X  (#Z"$P <M+T*<4R9$21WP<  ! ;@0E SM%+\7KT[D3I
M$@  :!2!"4!.T;"47]!6NO?LZ \!  "(C\ $("=L6+_)NPRO8Y?"C#]W"0
M1 >!"4#6TI"D)4K:+)J_4D:.Z4?)$@  :!("$X"L<N#@2[UF\8*5LJ*D3 8/
M[U73    -!6!"4!6F3CO:J^ME]UQZ1T  &@I A,     Q$%@ @   ( X"$P
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M*-,_+O9^5.C5M[-T[KJ-+/URE3Q^SQO>>    $0/@0DI5[KJ&UE;6B&G_>I
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MW!CYSQ.39-(;L^61.UZ3N3.7>K7E(7VL)+'/@&XR>'@OKUF[IERF3RDF. $
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M]7>YL.BUZDORGCY%IAU[F7QYR</R^%4'2Z\,WJU'"5.XZ8-M]5E-F40)$P
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M 8,N\;MR"X$IO0A,   @F;B'"0    #BH(0)0%9I3@E3IH\5P>.HO0=*F
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M"P    ":CWN8 &052I@  $ R-:F$R?W#K2<C83TA"?.Z 4 L=MQRCUV$)0
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MR#U<D@<  )*IV25,^@?=&@    #(1DT*3,$*'_H/V=[O @"T1*P?H:)4R0X
M -FJ1?<P+9S[E=\%     -F'2A\     ( X"$P    #$T:1:\N)=3Q^FVJC<
MZ_^I)0_(/5&MB&;$Z'ZRM7*KS/IDD3^D&C7E 0"0690P 4 (S)A:7"\L 0"
MS*.$"0 "PE1*10D3  "910D3     ,1!"5,.LVW%=DJNJ-Y#DVEA/8YD&B5,
M  !D%B5,0 KH#?P   "(OF:5, T=U5OF3%OB=2M*F**)$J;4R,0^&"P1B=)G
M&L;]T-V>0T8425ZK/.^8EXYUU-?6U[%UH(0) (#,:E8)DQN6$%UZ4A:E$VL@
M$^;.6,HQ#P" ',8E>4 6L/!+" 8  $@N A,     Q$%@ @   ( X"$P
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MBT0)T^(%*[V'TB)YLKT4I+DE!,G8%MF^;9/-MA?;2KR2]$EOSI$__O(QKY_
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M?<5&OPM(G#[P6$LH5RPK\X<     B8M,8-IA4'?O ;9 4VD)9=GJ<O8?
M-%ED E.'3H52NOH;[F5"L^C]3.T+VGJ7YQ&<    D*C(!"8U<DP_F39Y(:$)
MS:*7YVEPZM"Y4*9/*?:"DP8HK9',&@   , 5J<"DQHX;0FA"BVAII89OO52/
MZNH!  #0D,@%)J6A2:N+IO8S     *D4R<"DM(1 'TJJH<D::D(#    D$R1
M#4RJ?7Y;[Y(J:[2?^U& S%M;6NYW 0  1%ND U.0WIL"(/..'GM5G1\O&FH
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MDE)*E@  0.01F  DG3ZH=H=!W?T^  " Z"(P 4@ZK3Y<:\$#  "(.@(3
M ,1!8 *0=%K9 P  0#;(JZSB=S<J+R_/[ZIKXKRK_:[,.W#PI7Y7N-8K;-A.
MM9*]+=BV=;=!HOB^UK+MUX3#,P  2)$FE3"Y?[SUY(83' "QO#3]BIIC1&,-
M  ! F'%)'H"D:Y_/)7D  " [$)@     ( X"$P    #$06 "    @#@(3
M   0!X$)     .(@, $   ! ' 0F     (@CK[*)CY+/R\OSN\*/AV+&=^#@
M2_TNME.RMP7;MFEL>[&M:MDV:>+A&0  I$!6EC -'=7'[P(   " YFMV"9/]
M&JR_A*;ZEV'W%_NFX!?K^"@%J97L;<&V;1K;7FRK6K9-*&$" "#S(A&8YLTL
MD<'#>_E]2 9.ZFLE>UNP;9O&MA?;JI9M$P(3  "9%XE+\O(+VLJ&]9O\/@
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MRJNLXG<WRKTDSS5QWM5^5^:YEPF&:;V0.YISJ6HN[ZNVO?B^UK)MTH3#,P
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M>19B7!9HK*WCM=((=[AUQV/3Z.5_[NO8?.YKVG";IKBX6(YZ=HO7;_<PV7P
M  !A%YG I)>'4=L5PJRAL!1/\'E+"TI;RYNO_$_^<.D%-47)P2)E-Z18*-&V
MEN)H:4ZL\6;.G.HGG>OE>\;&N]/%H\]JLM=QV>O$>DV][$_9,"NQBG<Y'@
M0)A$)C#I+_]Z7XT]DP<(D^:$I5AV[M]91@SJZ?<U+!A,A@X=Z@4:?:Z2LO':
M5MJM)3TJ.*\[G=%AL2ZAL]?1^Z:43N<N2]GR;1IERW=KRE/N)6D   !A$YG
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M28X[[G3Y](_[R-GCBV3CJB_])=6&G&#0L1!E!V@-1B^__'*=@*3=)E98 @
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ML[S[Z&52.NDI;[C[+"6M_<XJ=X@5CFR8=0>GNW_<ZIJ:\PRUY-5E^T@N;P,
M2*<H'G>#YQ,F637E13HP!6FM8:<=?+/?QQ_8AK@[5JYOIU1OBW0<>!IZ#QH8
M-FW<+-^L6R^CJD)+K!\5=/[@?!^]/5>Z]=A.UJZIJ!>65*QYXM'[KTH6K:XZ
M<HD4;IM?4T+FKK=*U3:RT+3[/D-EU8:A\M[LO:1\TU9Y\$<#XP8F+5FZ\.E%
MLDW;5O+BOQ^29?^^RAMNA\R*BHHZ->&Y)41N.'+#4+!?Z3.:M IRO?Q/Q\_Z
M;?U F\I])^S2\?T! -2*XG$W>#YADA68(G4/4V,2O;0)R"4:3O2Y1&/W;KA&
MO:#=JZ;7DJE88:FIM**'G7<?(#OO,2#ARPF3R2[/.WKL5?+KGSWBE2S=>&Q?
MN?J%Q5Y)4I"&I8N>6>1-<X>60O7?S1]3>YG=VV^_[;55, @%0Y*U+439,*55
MD.NR@LL   #AD%6!"4##]!(]+6W1TMAXO\;$TIQYPL:"VKH9KWJE2KV[MI>S
M]NM1+S196+K^F+[>-#KM@MN.\<=6AR$K%;( 9$$G&(:4C7.GM6%*NW59^OPF
M   0/@0F( ?H?4C3IQ37U,B7:&FLSJ-AJ>_ ;EE9@JN!Z/!1'>6B)XN]T!0,
M2[$$+Z%3UK8PY/8'N8%*N[712_MTF>XX   0#BT*3-ML5[?J80#AH_</:>4H
M(\?T:U+HT>K[AXPH\@)64R[EBYH]AW:4D_?HXE7PH/<L-126E 8;#3ANN'%#
MDCL\V!TO4&E; YA6(J$&#JNNI&/P\"*O'>62/0  HJY%E3YT[+*-E*W^)E0W
MA;DG%MPD'!_;J5:JMX4M/Y7;.=Y[L)HD-2P%Z3PVK=NM-"SI,\^"0:FA>9K#
M76_5TN4U)OAZKMXGWR);RDMEV;-7^$/JVGGGG>6SSS[S^U)K].XC9.I',[SN
M03L6R1>?+Y6W%MSF]==7*965B3U8N&I*R:OZU[A65<?[<%R L,^ \[QV_/<?
M#?8^5-3?"X#LEHGC;N76YC\@7^T[Z'P9/KJ_S)RZT!]2+5F5/F15+7G*/2$*
MTWJ%#=NI5JJWA2T_E=LYWGO0X*//+8M%Y[%IW6Z]5ZE#YT+IT*G0ZW?%FZ>Y
MW/56+5U>8X*O%P5:RC1OYM*4;YNPLL\LZN_?W?=R];/,-MFR;Z(:GV>M*&X+
M]QCK2E9@XAXF($WB?9E312MXZ#=X>[\O<:6KOXD9EK))S^]?)D,N?;.F.Q8]
MR/[WU??DZ!O>E>N>7R3WOK+4&Z;-M==>*[?<<DN= _'9C\Z7O[ZV5'YRS\=R
MZ^UW>N-7K5KE33-Y\F2O_Z677O*6TQAWN1J6  ! YA"8@"SUU=(RKSKOIM!+
M^#IUV<;ORUYE'S\O [IU\;KG/WF%7''%%3)X\&"9.G6J-TSI<Y;>>_._TF;1
M^_+2%]_($:.KIS_XX(-ETJ1),G'B1#GEE%.\8>JXW3K)@U/+Y,O_7B__?O9I
M^>BCCV3\^/'>N#///%-6K%@A/__YSZ6/+/"& 0" :&A18&K3AKP%9),5)65I
MK0TO4\7]?7YXFUQZ4 ^O6VO(>^.-MZ5MV[8R;]X\;YCZ]:]_+1\O^%H*VK:2
MQT[I[]6>]]R+K\O6K5OEZ:>?EB>??%+^_O>_^U.+_.OC4OG+X07R\:>?R6^O
M>TC^^M>_RH ! ^3^^^^7#1LV>*5&Q<7%<L3!>_ESU')+E-QNPR4BT:>?H37(
M#GR>V87/$PWA'J8<Q7:JE>IMD8YM'>]ROX9>+QGS)./]I&/[&'LMO0ROY+D_
M><>T\Z]Y6/YZ^Y6R]Y@1,J#_#G+GG7=ZTW39OK<,V7E/.?.DP^7'/_ZQ5^7X
MJ5<](3+]GS+QE?]ZT[C'Q/(-6V31PGER^NFGR^BS'O5JWOO[[;^3N^ZZRQM_
MVNEGRC,OOBR_^=6Y\H=+SO>&&3T,V[*T^[Y72^2L@ZMKR%.IWBYA9I]9+F\#
M $BG>.<'4=2$F-,@BHB +*,GEM8TQ)W.;1J2Z'1AM^S?5WF7S*F2S_XG?8MZ
M2GGW/>2IIY[RAJFCSKA4/GSU:2\ :9C1JL9O^,E^,O7S8OG]E=?*Y9=?+KN,
M^;8_M7@/N!TZ=*BT:]=.\CZZ32ZX_%KYWRMOR'///2>C=ADM2[KM+X<=N*]\
MM62^-[T>Q+71>YHT(!GMWF6'[+Z'# " **&$*4>QG6JE>EMDZ[;6]Y6,]Y/.
M[>.^ECKDD$.D7[]^\OWO?U]FK=Y&;KWU.ED\I;KT2 ^-/_K1C^3AAQ^NZ5>O
MO?.Q''7LL=*C:T<9=]8]\K?SON,--UK1PPDGG""+%B^6D<==(3\ZZB"YZHZ_
MR)>OWB7#=QPF-]QP@XP9,\:?NIJ&)BM1>G]VJ?=L*/=XF\O?4?O,<GD; $ Z
M1>6X&_R;'DL38DZ#"$PY*I&=+!>E8I]ISK:.PKZK[RL9ZYG.[ZS[6EK!PZZ[
M[NIUKUZ]6EY__75Y;OE@6;FE0)XY<[!78A3/?Z:LE"O?6"E/G-Q/!O4L\(?6
M]\6R"OF_OQ?+[_?K+M\;V]4?&MN/'OQ"BK9K(U<?7_W,+ )3-?O,<GD; $ Z
M1>6XZ_Y-CR=9@8E+\@#DI-&C1WNA1)NN7;O*U(JA,F[H]G+Y(3V\BB J-F[U
MIZSK@SEE\O*L=5Y8^L,+2[Q[FV+1X3K^B1_VDPF?K_7FBT5??\ O'I>SQG63
M?IW;U;D\#P  9!XE3#DJV[>35H_=/K^MW]>P5&^+1'X!"8K"9Z+O*QGKF<Y]
MT5XK>-BSD'+F0;V\MH:;QR:MENM/Z%>GI"DX7$.1UIYW_3%]O7N<3'"XAB\-
M85H1A%YNY]*PM'[I+*\2"F7K0J4/U>PSR^5M  #I%,7CKGLNX4I6"1.!*4=E
M^W:*]\5I3"JV17/6)0J?B;ZO9*QG.O=%>RV]3VC6N\_(VV^_+=\ZZ<\UX40/
MA_J 6:V\X8@CCO"&'73P(7+;K3?+VC:]:\)28?O6WCAU\>^NE"^Z'R;?O/(G
M^7+A/.G59P=I_^USY">[Y\MC#]TMGWSRB0P<.%#N^<L#,JA_7W^N:GKOTA_O
MO-NKA,(]%#_^SE=R\M[5U9ZKMQ;<5C5^2U57XX?KRJI_>57_$I&7I^\CL6DS
M99\!YWEMW08 @-3+Q''7^QN78"+):U7[-]C8.@=E)# I"TUV8I.LDZ9D2>?)
M5Y1E^W9:L:S,*V'JT"EZM8TM7K RK<]":JYD???3N2_::YU\SPR9\=#/Y8NY
ML^2/#[PA%QPSPAO^G__\1S[\\$/O^4E:.YX&JS]<=HD4SWA/QE_R;$W)DAX'
M]= Y;=HT^>,?_RB]=A@L+[XW4QZX^R[YV:\OE)'=1;8K;"^M6[>6/__YSW+)
M)9=(MV[=O#"F=+F??EGNU8;W[6&=O&'!0['[ U4N'\OL,^-X#@#I$<7CKGM.
MXIY7)"LP<0\3LE+WGAWEJZ6Q[QD)N_45F_RN<-'+'.?-+/$"G391=OW1V\NL
MF3-DAUT/DEDO58<8=?'%%_M=U?3RN1-__GN9,_/3>I?G::#9>>>=Y9EGGI$N
MV[674X_^KESX6KG<^,?+9/6*95Y%$I=>>JGT[MU;3CWU5/GJJZ_\.<4+25JJ
M%;P\#P  A ^!"0B1M:7ETK%+N$K%=)VF3RF61?-7RN#AO;S2+VVB_(O_61=?
M+_T&[R1K2KZ0S^<O\8>*]._?7QY]]%&_K_J>I4<>_HL,V6EG>>2MY?[0NHX\
M\DB9MV"Q_.VI%^3.P[K(;Z^^65JURY?"PD*YZ::;I**B0IY^^FGITJ6+/X?(
M&S-6R]F/SH];$00   @/ A.RFI:*1,F77ZSP2L?"0H/2VC7E,G),/R\L98N5
M)<7RAPO/DGF?OB_39\WVAXJ<=]YYWF5T1DN"OGSK87G@OCN]R^?<&NRTF/_5
M5U^5;RHVRM9OGR]=*E?*>3\Z7$IG3)"V8W\BY__V2OG@@P]DW+AQ\NZ[[WJ7
M[IE]AW?V2JSTGBB]/"]XR0!!"@" \" P(6OI"?[<&4O]OO#3<)=?T,[OR[S)
M[\R5(2.*(G$_55/][MQ3Y>233_8NL7OPGEO]H2(''WRP]V#9G@-&^D-$IDR>
M+'OOO;=W^5PP-.VXZSB9^,K_Y*83A\A[[[XEUUQSC<R<,5W^]IOORYT?MY5G
M7GK3NRQ/[XMZZN.ZU8_K:UMH<@.2=NO]30  (!P(3,AJG;ILXU4 $073)B\,
M32F.EBR-&ML_X:K9H^;PPP_WNT2._O[WI'S#EII+Y/;8YS!Y>DZ^K"[]VBOY
M<2^EL]"DM=M9U>&+5Z[WJ@XO*"B0@PXZR)M>^[5*\3^\M%+VW.\(>>3=4F\^
M79Y;FA0,31:6K'IS  "0>00F9#4M'2E;71[ZT*25*0P=V=OORRRMT*%'[TY9
M&Y9BL>#RUW=7R1]?6")W_&B$S)S^B3^V+@U-19W:R<F/+JSW_"67A2:=KG?G
MMG$K>+#7ONV-%?+\)Z6$)0  0H; A*RGI39A#DT:EK2BA[!4@5ZZ^IM0W4>5
M*C-FS)![[KG'[Q.Y[/=_D(__<;G,?^]I^73A.BDI*9$33CA!+KC@ J_B!JT5
MSYHC=^\F!^_06D[Z\9ER_/''R]*EU9=^7G'%%7+LL<?*<\\]Y_7_9^IJN7#O
MKO+$QZ5>B50\^GI[]2N4=1NWUKD\#P" 3-(JNO4\Q1JM""H7$9B0$S0T;:C8
MY%UJ%I:*(/2@H_<);5_4,30!14/E#H.Z^WW9[>:;;_8:];O+_RQ/O?"*'+//
M<"EY]V&YZ;%7Y?S?_%:Z=NTJ\^;-JU-A@UGSWKVRYJLE4M:JNW>)WX,//BB3
M)T^60P\]5"ZZZ"+O7B>]#.^(,=V\DB:]?&_UU_7W/;L,[^Q#BFHNS_MLX=?^
M6   ,DO/H:S1<R@]=\FUX$1@0L[0R_.TMC>M'MM^*<G$\X3T-:WVN;'CAH3J
MX;I:$A?%A_TVE9;VO/'&&S)TZ%"Y\[Z'Y?DWILCU?[Q0+OO=)=[SF?YUY7'2
M>>A>LMLA9\CSSS\OUU]_O3]GK=&C1\LW*^;+*T_>(Y]\\HF<<<89WH-O?_:S
MG\G<N7.]YRQI+7M:(M6G6[X\_K,ATG6[=G5*JK2Q9S)I=V'[UG+G*0-EEP';
M^:\" $!XZ ^\>NZBYS!Z'I4K\BJ#]=DV0O^H*_=INF%Z'HO[=-\H/R<FU=A.
MU?27DL-&7N[WI69;V+:^[_ES)+^@K73OU3&T]P?IP4]_04JG=.Z+]EI'7/"
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M6OG5KWY5LVQMRC=L\2J*>&/Z&J_]_NQ2KS:\PP\_O,Y#<VW97O7B(P[RN@$
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M"SFQPHZ5%+EM;>S2.VUT/NO6)AT(3$ *;;M=OK1KW\;O Y)+PWA^03N_#P"
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M\[UQY5]OD&T[%OACJG6K"DCZ0$Z]=^F3#^=[_4;O;=+IUY6N]X< 2#8"$P
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M:*DHUE"4*GR? ""][+C[\"OG>^W2U=](IR[;2)\!W;S^,'+SB*T_M>0!
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MW ,+WPTTA^U#N;C_Z'NW]QW\(\WW"0#2;_&"E=)G0#>_+YSL;T?P[P8E3
M  !2:GW%)K\K=Q&8     ,2TOF*CWY6["$P     ZEE;6BX]>G?R^W(7@0D
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M@P=Y,#H ("P(3      0!X$)     .(@, $ 0HG+\@  84!@ @   ( X"$P
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M,..[ 6/[A;M/M*2V.UU.+NQK?)\ (+FR\;@:[^]ILI[%1 D3     ,1!8 *
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M59<Q1.E8E O'W-9M]$J,ZO?FOJ?YGY=X[625,'$/$P   ("LDZS 1"UY
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MC6?2;H>EN!J-"F&N"7\8Z_BZ[D9N_@?HZ++BCR^7L^.2L>+)B0$:^.Q^C7P
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MWBY"'6H?@B (XOI!,QYII1N1&J/M^P>JZR!*<W?S1LBS":,#^D'31*:B--^
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MU;VW]P<TES[.&O,UE :<NTAXA34L01 $05QW.-<B\;(FBJ]]:NO">*Z]PA'
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M#CUM,,W^#&_6G?;J9>J[O :AO#C] "7E'4CFVIK?'@A=:*FN0.6EQ[ @]D*
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M$ 1!$ 1!$"I02!Y!$ 1!$ 1!$(0*))@(@B (@B (@B"\ OP_.59?>MRQ?8T
+    245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_41.jpg
<TEXT>
begin 644 image_41.jpg
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MV[B&#K^W(#(>[1>OQK2XLH46$I4W_QSS^TTOOS<142((@M^ "( PX,"8]UE
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MB=6[QLH6"Q)^;\&669B8;0'$=6%B57ZKNO 67A$E6#>!@R (@AUHF6 !PL(
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M.6Z%?C[BYOQ6YYI%CAE\;>I4+U(%_H)E!LWI3TW?39_?E$A+=APS4@7!=_"
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M OKY$V<MH^O[=E#[9D24B"@)%$24"*4-5Z)$*#Z>%"72?<L%.[*.T/H#!U6
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M\$L3KEH@_/DUT:HL=N4,=/Q9CX$,UPN0NA%\2; ]0W2*:BGQ9"L)\%I+B2^
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M/I_0QI^&4/*^*?GGODTMEWY.5Z:^0W</?)%^S;=0Y]:Q-'7TG=2Q3L4"D\5
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MW0H1)8(@!".E791(]RU!$$(:;PJ2HGCFG='J88XPXI4G56N$70@E0<+X0Y#
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M4SI7$>%)08(Q).BRU:!N+-W9+5JMO&X%KLF"RAU!XDK<,".>?Y^NNZB):N5
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M"-Q_[]Z]C2N<A:?]G?S"C71>N[/=O'309>OI%=$.LY?I0%1@0<BU6_<Z"1*
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MKQA'S]*JSV#Z>]:G*HY9L+"*N_DW<D>0 *X?\_E(AUT,@*_?I$.AK=Q#N]2
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MK*!#AX_1J.EI*I\@"(+@/T24"((0\GA+D%@YSFF?WZ]:%/B8+DQ0#HSMX'+
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M6TC'M7!-*V<1<90594;9=<<98RIFS9JE9G_JW_L")4C@?"_;FJU:!8 O! G
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M',?9EX($K7 0)/IX% C#D2-'%BYHR'7Q;Z-K'X-9K<:.':OB=G4!&Q@? IN
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M=N>#ZKC5&  ]C>/ +@^CYS5CUUH"=%O#GGN(NK3M1#=?<:U* \.>?9BZMK^
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M.$CW+4$0B@0#W=GQ9"===_!UL*^G(1^+ #[&<6"55P?7?:/M+EIP9VSA/@?
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MJCN?NJ/*Z&E6CBK#SJR=XXQT\S%]G\^WBV/+^3FNIP'DX[Q6MG18D*1]?G_
M"Q*&[P,/<KY/':O?#KCZW0#;=97/55U@G FZ,B&@*YR5( ']^_>GT:-'T^MO
MOD-SLUO2=S\OHO\^]9A:ZP.M)UNV;#%R.C)_]G3J?$%'-9[CRBNOM!4DJ%>4
M 9,70$SHF.L50BHQT7FPJ/DW@KBI7;NV$BW+ER]7\;2,/'IT^@%ZN',P]-T1
M!$$(?424"$*0 V>4'5?>,F8'57?L6:@@F,]CS XSSF<;NBT]SNCYS.=8;3D
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MSGF ?BT=_9H0).B:H[>4>$.0M*X7Z35!8KY?8*X'N\ @;CX'=:O7KRN"59
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M<P,P&]>F;3OIQ1EI:E\0!$'P+R)*!"'$T)U3/; 8,,/I[/!Q?@@"=HH!.\*
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M?GK[VOC">DU*2E+" <<A3E)34VG9D7KJV/9W;U);'0@6#A!X7][5V#CB#%I
MOE^:01-_WT+W]*I5*$ 8GOX7=7'Q1=UISD>/N:P+01 $P;?([%M"2%(:9M]B
MXF]YRXAYAZCFF!*5*'OM+VI;7,I6C*0*U>H:>T05:R30/Z=/49ERY?.W)_,]
MVOSG!^+YCR*U/7G<R)E/V8+!U2I_!7O!0/^<H9SMR^AT[F&J4#4V?YM-9T[D
M& ?/@NF33V3L*+PG=\"X'2M;N,[)P_M4G.T"=VRS>-"%"#"+"OVX?@XPGZ?G
M =A'5R[NLH5![1A#PJAZU1[_&-2.,23<9<M\'"!-GQF+G_MZ/G3+^F/E5GIO
M105Z\_KZ3D(/Q[=LV:(&G,_;&:726.BQ/1UW9^R"4 V/:^JRM06B$>)L\XL]
MC13W".99<TH#/+N1COQF@4MI^[UD]BWW$5$BA"2A($ITX1%*-!SQ$VT=<ZER
M-C%NX4R^D/CGS&E;9Q)C#2!LRD?7MG5,:UW^*%7+MW=\ST:J6+,!'?KS:TLA
M$=F@ U6H48_*1T;3"Y<UIC:)SK,VY9W\A\;\LI>:U*Q(&PZ<H!^_?M/>EB:V
M#B^?9L3.@G)7N^ &.O'_[=T)?%35W?_Q7\*2L(=-2-B7$@&M0%!K0450J%6K
M!7<%*5B7%NOSIR*51VVE+19$6UMMM14>Q*5U@;JU"HKB5JLEBA70($N00()
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MI4VS1B&!Q-#S?V=ML;RW\@MY^:[SW+45U61+B?[E;<WZ',DXH;.D-DTEE !
M@O&V;%='YXOOE,:M.KI+5?._O0^[<Z'6;\Z5ELU;./.=VON7'Z[U)B<G1_KU
MZ^<N50^A!+#8E7W4K/2Q]TC:T+'R]:L/R,YW_T_\/GHT<$Q:L,&9GS^QMV_8
M4'J7+1T@K^-1SAZ8YJX-->?E//ERYT'Y_=4]PY:E@4.?U/[=OBWD]@O##\K3
MLOZY?I\\-;ZG;W#1S\"TTRZ33A?^3/:O_[=L?OS'[I:*CC>4U.0O-M2L:+ME
M &AX]+-[R(!3Y.,UH7^(.Q[]?[-&/O_9 '>IG'>=+BM=9^;_,23\0WW?S?Y
MSLPZPUWR%^YW4 W%"(?_;VD J&'-NIWL!)*TTR^7JVZ^VUU[C&D!N75$1V?2
M>5WGI:T1SW]<)*_<T%>>_V27L^Q'6T#.RFPEO[BHBW.[8+^R3 N(!HTVJ8V"
M7;.\=+VVD.A^NK\>YZ6!Y(3SI\JV5WXC!_)6NVM#;=NY7;)7E[=PE)3Z#Z('
M -0?)I#H'S JF_0/5^'TN>V?SJL&#9TT$)C08>9U6C.]?W"=-\#XZ=BV@Q-,
M=(HG6DH "RTEL=%JX+G2^7O_*WOF7RE[FG:2<W[\)_GS]5G!%@<32.PQ)!HV
MO.-%O.O\CE,:(NPQ)*8KESWXW002N\N6"25V]RSO.K_C=-W(/WSBA*ZBCYYS
MUH7SR,S?RICAY6-*UJS[PGD=T/=$Y[4"_6BV/E=[C3Q9A@P<)!\' @T22VZ4
M?<4!Q(%3S:VYO^975<^1WW3GHONL6+3D)?GI;_SK(AI*UMUWO@R8_7DP>-CS
MAG>[BM12HO2AC:I7U_)QG5ZUT5)RW*%$'XIB-&_>O,*=9@@E &P/_:VS?/"?
M#2(?/N;<M_R=]S]T6B_TH8?M6C7Q#1;*#B&?YA;[#FKW!A-O(#'L8%)8?"@D
M6!AV"/$+*<H.)DKG__G8C$H#B?)VWRHJWBV?K5U3I:9S_6M:0V6N@WT-=%T\
MKHG?N0" K:J?W;]Y['?RYV<7N$L5Z?B-2_Y^Q#>0F'D30KRA1%M,(KV_MMX?
M*#G@>R='^VOPJLE04N7N6QI&]#[$&D(&#1KD3&: R^.O3R60  B14]([\(GW
MFC,_<.! )U1H.'CXS0)G#(E?(%&Z3K?I/@O_'1I(E"[K>@TL,P+AQ"^0* T?
M&H+^]_FOY+9%_H%$F0 R<?YZY]4;2)0>I\??^MQ7SJ3ST002/VFMVLBI)PUQ
MNG0! !")"1YV"#'SACT?3?<M-:!/9MQO+1]U*#EPX(#SA$8-(\.&#9-FS9JY
M6P @O/]\UDY*"K=*TMXM4E!0(+?<<HN[1:3H@/]##GU%N(NE!I/,CBFRL>B0
MNR:\K_8<DO26C9T6FD2A=\WJTBD]V'P. (!7MV[=0@*(,LMV4#'+9LQ)71!5
M*-% \NZ[[SI/:"2, *B*19_TEL(5?Y=#AP[)>>>=)UE96<$N5WK;7[W+EK9R
M^ U8-]VW=)\)I[=SCO$;L*[=K/2VOY'*,EVN'KRLN_QT3'K8P>^FR]:"27V<
M5[-LL\O22>=UH'MU=.[020IW[W*74!GM3F FOV4 J&_L.K@)']Y 8K.7-9Q<
M\''3XYK, 'HSQ4JEH<0.) !0%<4'6DIQXW9RPJEC)3T]W7GJJW<,B-W]R@X3
M]G@2W<=TY?(&$PT-ILM6N++L,2#:]<ITY?(&$^\8$O-J!Q._LG1>[[Q5W6#2
MIWLOIU\O*J=]H\UD+P- ?6=:0KPA1'F#BG;?,EVX=+W9YITWK_9DUD7;!:RZ
M*@TE'W_\,8$$P''YZZNMI2C[!3ER]*CL/_,.N?:ZR14"B>$-$]Y 8GB#B1U(
M#&]9WA!A>(.)-Y 8=C")5);>><L$DRY7A;^E8R0ZO@0  #\FC-C"!13OOAHL
M=)U.E>WK759VN(F5B'??RLO+D_W[]T?UI$:]); .=._:JX.[!D!#]Y/'ORT;
M%OQ$.B852:]K'Y:V73/EH<N[5ZC0VS0<1//P1 T;]RS9)C\;U5'.'M#675N1
MEG7+4[E2L.^P/'I5C[#OJ4%CRK-?R:C>+63*F QW;:@YK^3)/]=5_O!$?>+N
MOK7O'??#$W5<B=\M&>F65)'=*J+7QBS;\[%FOB>TT  (Q_[LCN:S(M+=M[3*
M;H>*RN:]X4)#A7:_,J_AUAGAMNFR49-WWXH82O1.6WIWK6@02@#8=(#[GU]O
M+2EO_5*26G224R;,E4&].CD/*?2[HY72L*%WV=)![3J&Q&X!L6FK1>-&@<^H
M+24AK2F&A@V]R];@C%0YJU^KB&7M/G!$B@,AQGZ.B<VTD)R2GAKV_/4SL.?-
M3TERT^92=N2@Y#YTA;NEHLI"B7;?TKN@>%7U%UM]Y1<$["!BSP- O%7UL_N.
MW]XCS[SZ=W>I(A,,_ *'O<X.)W:@,.L->W_]'68B@:XWY9EMM1%*PG;?TK$D
M '"\_KXBPQG@GKNWB1PZ9[K<=_5)<ON%79UMIJN4S739NO_*'G+_%:'C0@P]
M5KML33XGW7>,B3(A8NZX;LY[?OK5_K!EJ=L#8<1OC(FRNVQ%.G\-)&K#@]^7
MPG?^SYD_'A?>?(7S2\P[ 0#JOW"!1-FA0N?-%([9IB'"! D-&F8RQ^N\8=8K
ML\VTEMAA)!;"AA)]0$NTK20 8-,![KNEM:3LVB@95\R64<F?!;L\^0T>-X'$
MM'IXQX48)I"85@_O&!-EAPC[/;W!Q+R_.1_=UQM,PI6E[/,W\QF?/BS?_O:W
MI4^C;<ZRKT;)DM2XT;')LQR-Y":-&^QD>-?YS3,Q,3'5^M0XN<)DJ["M2:/0
M8P-3-$R(,*\F1!AVR-! 85HYM,5#V0'%K%/F.%UGIE@'$5O8[EMKUZZ-:BR)
MH2=.]RT ZL%%_>63-?G2[(3><OBC)V3IO'ND3Y_R6^P:IB*O(<,.)#8-!V9@
MO(8*[Z!VPX2:_SFWL]S]\I:0@>B&"35:EO+KAJ5!1)_\/G%8QTK+LMUT7OCQ
M*+;*NF\A,M-J1/<M '6!W=(=S6=3N);QZZ^_7O[RE[\XP<$.(=YEPP0,.U3X
M5?G-\69_FUFO9<2U^Q8 '*_U^SI(B[YG2-&:-Z5%X7]# HG20+!IUT&Y9^FV
ML.-"3(N)#FK71H1PXT)T_>@36\M53VZ2F1=U\0T12M_SD?=VR*;"@[Z!1.FQ
MEPQJ*]<^77E9'P3"C4[AR@( H":T;=LV&!STU0X19MF>3%"Q6TJ4;K-?E9G7
M8^S)WD>#2*Q;3<*&$GURN]U\4]FDKCOO 1G5=X8S#Z!A^N#33G*D4:J4OOU'
M:=7_'#GSP@GNEHJT=:.XM$PNZ-=2%KX3OKN3;M.[;.F@=KO[E4U;-_[VR2ZY
M:T1'^=T;!2'C0@QMW3BC>W/IT:YIQ+(>>'.;/'1Q%UGP_O9*R]+)VVH" $ L
MF,!@F'E[O?UJ!PD3,K3>KNO-JYET6?<QDUEOAYI8"AM*M#FF*A, J,6?]9'"
MCYZ3XI5_%UGZ*VDS:)Q3T;>9[E;:"C)E='FW)[^*O:[3[E9ZVU^_,2;*'O=Q
MT=#V80>_F_*U54,GO\'O=EE9?5J%'?SN+4N9@>X  /@IV!%AO&$5F>!AMV;H
MO*XWH<+08&'3D&'J[V;>K-?C3=EF'W-\K,,)W;< U)B#AYO*WH-'I>S#^;)C
MQP[IW:FYW'5)#V>,A@DF=B Q7;9,Q=X.)B:0F"Y;?H/?[1!ANEGY#7ZW0X3A
M#29^9>FK-YB$*TN98)*:'GI+7P! PZ/C2,R4FI+JW/8]>_5**2KV;ZT/9_Y'
M.RL$$3.9=<H$$C.O[""AZ\QDAQ;O,<K,ZS8M(]:!1$5\3DE5F"Y<:MFZ6>X<
M@(;DD:?3Y-WLK5+PXJ_DIIMNDBE3ILC @0.="KU6[$_OV5R6?%Y<(9#8M,)_
MJ.RHY'Q=Z@0+OS$D6I8&#AU#HEVVP@U$-^$GLV.*-&F45"%$V/0],]*:1BQ+
M XL&JTXM&X<M2S\#G5"2W%CD\$')?72\NZ4B!KI7#P/= =0'^J#<PMV[)&O@
ML8'M):6E,N"BT]VEBMJ?/4E../^V"L'!CQTV;'8W++\N69&Z:9EM]JM10S'"
M04L)@!KS^:$!TC'_7\[\M==>ZP02I0'DW/ZM9.Z[.YT[9/D%$C7AK$[RC[5[
MI55*<MA![7JLEO'+Y=OERL%M?4.$TN-;!?;5\K3<<"X<W$[N?V]'Q+)TO9:U
M;,.^B&5M>V6VI';^AI0=.>2N 0 @5*^N/61@W_[R;O8'[AJ1_.T%[ERH2:>U
M=^>.M938\_8Z95I$;&;9! FS[+>?F0P[B,0*H01 C7CWDPPY=#196C4ND7'C
MQLFP8</<+>6M%L]_7"1_O[Z/,WC<=.6RF1:0GX_N)#W:-@UVD_+28_56O7^]
MMH<L_6)/L/N5EQZO ]I_/J:3[Q@39;IL/36^IVPM.ABQK#;-&LE#EW?W'6.B
MFG7[IG2]]D$I6K%8CNS;Y:X% ,!?:DJ*G'K2$*<[5S2\X4'9 <*>_&AH\6ZS
ME\VQ=KBQA6M)J2DQZ;[54$3;3<V^(QE=VU!?W36OKQ3L;R*MD@[)59TWR/3I
MTYWUIAN5Z;)ENG+I6 W3,F$"B=UERX02NZN4=]R'WW'*>ZSW')2W+*7'>9^%
MXBU+C].N7#,NZAHL2\_CE%^\(\5KECE=UR*A^U;UT'T+0'VC ^ /E)0X\Z,F
M7>R\>CW^^./RF_Q3G7EOL# AP@X4]KS=RF&"A5EG=\NRV>N\Q]O+-=E]JU9"
M254KXJ82?SS')=I[V8%$5?5]@+I ![C_OR>&RA>_'B'?N'J._.3J2V7*!;U\
MPX"R@TF[5DU\@X6R X%?B%#>8.(79I1]+H7%AWS+4G8P"5>6'4R4OO_SS\^O
M-) H0DGU)%(H\3L7 #@>VEK2KDW;L*%DT:)%<N>7H:T@WE8-LUW7Z[Q=/]<J
MOQU:E'V\]UC[59F@4F=#R5OK9KMS%F=7K: $WOIH:#>(NF![P6Y)26TBK=.:
MNVO\G=/W9^Y<N;?6_<:=0\)):N3.H*J*#[20GSS06$HVK9 SV^V243<\Z#P8
M49]#$FY0NX:)7[ZX6;;M/2(_'-8^)) 8&@QVEQR13_-+P@Y$-\%$QWUHERUO
MB# TF#SV_D[9=ZA,YH[S+TOI>^H#%B.5I<'DX3<+I.A F4SX5CLY(S/-W1(9
MH:1Z3!"(A% "H*[1NW%]F;M>KOCI)'=-1=H]>/,3/W'F[6 1+D#8\\IN^? [
M3NOQ)K1XMYL0XM=R4I.A)+2F4,/*Y$CH=%2G0X'I<&"Y;O[7OG,K*=BZRUKC
M_Y^7O8W_$NP_YV>2Z7BF%JE%,O+TKO+TO3^5\>/'2_+>+9)=4"*9)Z3X!A)#
M*_3)22+=VJ>Z:T+I0/1_KMLGIZ2GA@T1^AYZEZU/MI4ZK1SAZ/L4[#LL+9HD
M.RTTD6S=>SAB67J\!BJ]6]@I/5NY:P$ J+JT5FVD:.\>=RG4@]_OZ@0$I6'!
M#@XVLVQO,X'$'*?LXW1?O\!BE@T[C,1"S$,)@/I/NV]MW-M9SCFUGW3,/$O^
MN[>]3#]EI^S?MS_8!<IF6C:TA>'W5_>L\!P3F^FRI0/1VZ0V\BU+Z7J]5>_B
M&_LZ7;2T1<3+E/7H53WD^F'MG??7\_ R[[%@4A_?!RPJ<_[:PO.+B[HX7=%T
MH#MJGVFEH+4"0'UG H*&!A,<['FS3>?-L@DD^JJM(69_,V_VL;>;>7L?$UIB
MB5!23:4EW/H3^&!5AOQP:+,*XS9&GO5M&=UKK^PO*:T0)DR%WHP!T58.'9OA
M#28F1)@N6Z8;E3>8F&7=KF7I>WN#B;<L?5]]?V\PL<LRK]Y@XCU_+4_'QF1<
M,9M@$@?1=.<"@'C2SZEHIAM__C_N$:%N_7N>.U?.A X[@&B ,//*! JEH4*[
M6IG][983TP7+O)I]S3[ZJD$EU@@EU=!W0+I\N7JKNP0T7/_)ZRT9'3H% XGI
MLC5HT" 9V'2M,Z\5?F^%WO &$V^(,+S!Q!LBE#>8A"O+&TS\RE)V, EW_EKN
MSG?F!X-)AU$_<K<@UB:-O=:= X#$HV&C)FCW+2\[=/C-FT"A-%28]?:KF=?]
M=%Z/L9GMRI05*S$?Z%[?[S:5MW&'I#1K(AT[^P_2Y>Y;J.]R\SO(0Q\,D\$=
M4N6A:WH& XEQX, !R<G)D?>^/L%YD*$^A\2NT-NTTO^_SW\E7^TY) ]>UKU"
MB+!I@/@@$!3.Z-X\)$086M8M3^4Z8TBTRU:XLC1LW+-DFUS0KZ5,&9/AK@WU
MT-*M\G[N?KEU1$??\]?/P+33+I..HW\BAW9LDMQ'_"O+?[KGM_*=,\_5/TGI
M0<ZZ\A?_SU!4U/.<D]RY<KEOK7+6F5>SKC;4]OL!J'N\GUG588<"#1G>D&#6
MV=M,"X=9[YTW_-8I4XXRY=K[U5",<-!24DU=>W60W87[G;MQ 0W1RRO[2_^T
M%-E_J,RYU:Y7LV;-I'#/?LGYNE0&=TIQ6AW"T>/S]QZ6[JTC#T)7K3WAQTO+
MTKML=6[16#;O++__NQ\]'SVOG.VE3I#QH^OU_'NU;2+[2L/?,3 U/=.)%F6'
M#Y:O\'.D3(X>/B)'S6M@*CNDTV&F*"8OL\[>9N\?R\GPV\;$Q,2D4TWI]9/%
M(:%!E\TZOVV&"1)VERR=-Y-WN[U>]]5MWO)C@5!2 [0;EP83;34!&A(=X+ZU
MI(T\=ETOYQ:[VDU*NTO9M$+_S/J.<EYOD5F7]7#6F:Y2-M/-2LOY]:7=PPY^
M-\?^_MI>SMVQ*BOK#]?T#!EC8IAC9UW>PW>,B=)ETV5+SW_=MA+?]^Q\\9W2
M:L HV?SXCZ7HHV?=M8@UTS6BIKI( $ LZ,TX*IOTEO'A)#=-=8*"A@03*C0T
MZ/27X87!,*';S'H3),RKW15+>;MO*3U>^77E,OO$"J&DAF@P:=VVN:S*WB3K
MUH166(#Z:/G*GG+'L"9.ERWM'J7C-NQ@8BKT/QAV@G1O7AX*O.-"E D19MR'
M=XR)88XQ96@W*F\P\2O+;_"[7UG>8&('$M-ER^_\M5P-)'E/WBH'-O]7]OSW
M-7<+  #5MW[N=X-WPS*3:<'XX7OMG%>SW:PW3)@PZW4?W=<LFTG7V668]XEU
M&#%B/J;DG8T/NG.)Z^C1(_K_\H4:H'?DVKSA:TEIUE2N'57Q88EO;PB?@M%0
M)0?^_=3BWP>.ECE_3?%S-/!?X"/)7:K(^3?NGF?Q@>;RBR<[2<NT#O*/6T^O
M,([$A(*9%W61W[U1$*S0KUV[5OKUZ^?N=:Q2K\\AL4.$34.!>?+[*Y\4.NO\
MQI!H*-!N6)6590*&Z4(6KBP-,#,OZ29WO["Y0B"QF?/74*3[SYMQB1-(*L/#
M$ZO'M(CH7Q4-76>6[?E8\SL7 +!5Y7-BR7O+Y.:9/W67*M*QF>9WJ 8%0\.#
MW<JAV\RKLK<KOWT,>YW.&_K[7\LP9>FK44,QPL% ]UIB!KQS/5 ?S/I+!\G?
M>5A*O]XHF8=7RPTWW" ]>O1P[K:EUA<<D*N>VB1WC^@@%V9U<-9Y0XF:\TJ>
M\V!$?0Z)-T08&B:NGK=>SNC:3&Z_*/3N(\;+*W;*_>_MJ+2LL8^N<\:0:)>M
M<-Y>720SEA3(K.]TDK,'M'77AIKQW";G@8V+;^@KS5,:N6LC(Y14#Z$$0%U2
MDZ'DDK_K']$K!@L3&,QZY=UF0H16^>U 8N]O H=99S/;52Q#"=VW %39UI99
MLFO73EG_TGTR<^9,.?/,,Z6PL%">>>89>>WUY3+GU3PGD/SUXZ(*W:]LNO[3
M_!+Y;M\6P580/PO?V2:C>K>0XD"@B%36WS[9)3\=WJ'2LO0N6UJ6WQ@3I<'E
M^4!9DP:WD><#YZ_+?O3XXM(RISPM%P" 6,G,S'3"@$XF))@& 1,2=%DGLX]A
M0HN]S1QOUAEFG>YC7FL+H01 E2S_=RLYL/4+23FAMPR??)]D965)NW;M9.3(
MD?*][U\F3ZX_008V^UKV?OF&3.R_3VY;])43&O;O/W;7+5TVW:QNO["\]<,>
MHV&8=7JK7K\Q)LHNZZ*A[<,.?K?+\AMCHNPN7I//27=>[3$FANGBI>5,&5U^
M&^&>-S_EO ( <#P^^>(S=RY4G]O^Z;1*Z*2M&69>F18.7=9Y$T*4'3C,=MU7
M7TT99G^SWMY'7^TR8HE0 J!*_K&JNQ1EOR"Y?[I&.O4^)5BQ-Q7Z*2.[R$^N
M'":C1X^6YDE[Y>QFG\L/'E\KAYNT<_:S0X3I9N4W>-S,FVU^@]_]RO(;_.Y7
MEC>8V('$C"'15V\PL0.)&4MCRC7!1&\-C-C2+A%FLI<!H#[ZYP_[.*T6IN4B
M7 N&A@B=_-C'ZCYV&2:8J'#;['UB@5 "(&K%!UK*OD9MI.BCYZ1/GS[R_(SS
MG$'C.@;#6Z'7UI-APX;)3>._)Y=U_DI^^Z^#DKV^..Q =#N8>$.$80>32&79
MP21262:8^)V_80>3M]?L"@DDAH8TU?/'STCG[]WIS"-VM'^VF?R6 : ^N?C9
M?<ZKZ7ZE[.#@[79EV(%"CS6M'KJ/*<NL-_/F>'N^-A!* $3MX:>;R>Y5;SCS
MPX</=UXGG-5)?O/6US*H2VI(A=[XX=47R-21G>2'B[<XK^$&HFMPT">UZ^0-
M$8:&@8G#.LJ4%R.7I>>RJ?!@I67I7;9T4'ND\]?UNGW&:]N<_;V!Q-CVRFQ)
M[?P-*3L2^A!)  ".5U*35*<%0[M;F980?36AP]LUR^QC H=.NMX<;^:5*4/7
MV]VY=%XG/;8VQ"24Z!VFS 2@_LAOW$\*7OR5,W_++;<$NSS]?'0G.7RDO&N3
M'^UF]<";V^0O8[LXKZ;[E9>V:IS1O;DSF18.+SWV[I>WR)-7]Y 75NZ*6%:/
M=DWEIN$=PI:EYZ^W_=6[;*W<4A+V_'6];I\UIK.SO^G*96O6[9O2]=H'I6C%
M8CFR;Y>[%@" BEU.PTU_?G:!NW<H#0QVRX@R+1MFW@01\ZI,P#"O7O:^?NSW
MC'4XH:4$0%1>?K>;%&_;Z,R??_[Y,N#DP16Z/&EKA';E\E;L[7$?67U:.:^Z
M[ T3=C<KT[+A#1-V67TZ-PL[^-TN2\_-;_"[/89$;_OK'6-BZ++ILG7VP+1@
M5RX[F.B\!I+B-<N<T+;EK_ZW= 0 -"QVU]+*IBO._[Y[5"C3W4I?[>Y5YE4G
M#1 ZZ783)G2]!A*SC[W-E*7KE3G>+)MME06;FD(H 1"5Y5_UE)2.O9T6@:'?
M.KM"(#&\P<0.$::;E;YZ@XD=(@QO,/$K2[M1>8.)7UG>8&('$G/^6I8WF-B!
MQ'39TOWM8&+*,H$$ (#C<5B['(2A@4 GT[U*6SC,.C,9WGD3,G3>=-E2YC@S
M&3JOY=M=N6I#3!Z>2+>M4#P\$35I:V$G=T[DJ^T=I7O'[>Z2O]W[6HK^0T]K
ML;=\11CARBH]U$3FO-A1]N2\+VU..D]&]NLF$[X5.BC<T,I_1EI3Y]DA=HBP
MF9!Q2N=4:=.L48408=.R=I<<<9YI$JXL#0;ZY/=6@> 0J2P-&2MR]TG.UZ4A
M@<HP(4/'D&B7+;]![4K+6OAAH>B%U6MQ1F::NR4R'IY8/=K%0>E?%0U=9R_7
M%K]S 8#C->V^NV71ZR^Y2Q69H* M&7:7*ZU_FVV&V<>TB)A08JK\WC*4EN.W
M7>?-\4K?RUZNH1CA()34$A-*:D,TUS_1SR?:GZ':^#H2Z5R,?C__0/9O^(\T
M:==54COWDY*"M7*H,,_=6E%2HR;2HL_ISOR^]1_*T3"#L"LK:V_.NU*:GR/=
M)_U9!F>TE_D3>X<=\*V!XYHG<IV'&>JS0\*9$P@2_UP?^8GNIBQ]R*)YIHF?
MAY9LE64;]LE#EW</6Y8&CDD+-DBOMDUDUF41GNB^9I<SJ'W6F,Y.ERT_IBRE
MUX(GNM<.0@F ^FC-^ARY\.8KW*506EWWA@6;"2%^8<*T=NBR-U28;49EQWB/
MK\E00O>M.DHKRGY3//B=AT[1\JO,5Z6"[_?>.M641#H7X\B^(N?UZ,$#DOO'
MJZ5Q\[9R>,_7DO?$3RI,.Y<_)JGI)SJ#KW72>5WGW4^/U3)T/EQ9&DATW,0=
MIZ7*K2,Z!KLO>9D6$ T:6XL.!KM">6D+B+9JZ'YV5RZ;75:;U$;![E=>NKY)
MHR1Y>G(?WS$FRK2 Z+E_[Y2TL&7I^>J3W%^YH:_S9'>_\[?+,M="N[4! ' \
M#I0<<.?\>0.'SIME[ZN7'2AT'WW5,*&3.4;WT7E=9P*)V=<$DUBCI:26F(IM
MK*_-NC7YTG> ?]<5FYZ/GDNLSRMOXP[IVJN#N^0O7*6_LG/2LCNFMY&4U";N
MFIKC/:?*SF5[07G%M6-G_^Y,->U'3YTGI05K96,@D"A32;:[)/FMTPJV=XR$
M=UUURC(APNYFI95_'<]A=Y4R@<!TL_([+EQ9RNZ>Y5VGYZI=N6X:<>QVP>'.
M7\>_V&55YUI,6/")Y#UYJQS8_%]G73BTE%0/+24 ZIOLU2ME8-_^,N"B\EX-
M7M=??[V\WW>J;^@P 45?E9G75].URX0*<[S9U\LN1YEE;R@Q(4?54(QP$$IJ
M26V%DF@KZK452J()2<<;2J(-8,>CJJ$DEN?BY^;'SY:UOQQ6X</ KBR?TK-5
M2,79L"O>G^86AP0+=3QE%18?"@D1AAU,_(*%LD.(BE26TN/#E:7G;X))NU9-
M(IZ_"2;>0&)$>RW2+[E+6@T8Y023)FTS9,]_7W.W5$0HJ1X3!!()H03 \=)N
M6^W:I$GG#IW"?KZU/WN2G'#^;>Y217ZM&'8P,2'#!!+EMRW<F!)E]C/O%:M0
M0O>M>D9;)39OV.$NH;XZ<F"/.W>,5J2U0JV#KW6L@U_%6>DZW:;[+/QW:"5<
M5;6L6Y[*E=L6^8<(I95^K?S/"%3HS;*7'J?'W_K<5\X4J2PU<?YZY]6O+#U_
MO2O7PV\6R)3 N44Z?PU+,Y[;Y!M(5+370N^\I7?@ZGK='R7MM,O=M0  A"HI
M+75:2$P@B88&!3.99?/J7:?L<&&"A=)U9IN9-\$FW#&U@5!2#Y4<..C.)8;2
MDII_NG4LRCQ>B70NCJK\T>)8 Z>_*,KJUCY5"O8=EA9-DIU6B4BV[CWLA(#:
M4G2@3)(#7Z.>8R0;=QV2S!-20@))!5%<BY+\G,#_CTIRXZ;E*Q SVCH1[PD
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M=_O\+\SJ$#+&Q+"OQ931&<ZZRJZ%Z<KE+2O::Z$/L]1GQ^0ONDL*7OJ5NQ8
MT)#U'CTHJFG4I(O=(Q)#T7^>=\+-SK?G!R>E0<<V9LR88-!9OGRYN_;X$$J
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MP63>6_DA(<*(]EJ8\YCQW*:P9>FR"29S J')&T@,O?.6$TRN^Z.T.WN2NQ8
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M%A,-, Q^!P"@?B*4 *@UVA5+PX6V?HP>/3JDRU8XVI*BMPC.R<EQCJ=+%P
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M47VZ]Z*U! !JR5=??>7.'1]""0 T,#HPO::Z;7GI^))$:2W1@?B%NXO<)0!
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M#!EPBGR\YE-W*12A!  2#*$$0"(YGE!2&T' : BAI*Y_[D<3KJH;2KC[%@
M (*TE23CA,[N$E [""4    (*MR]2]):M7&7XDM;2?3!@JC_""4   !P:"M)
MG^Z]W*7X*BDME0,E!WBP8 -!* $  ( 3 A*IE>0_JSZ6K(&5CV5 _4 H 0
M:. *=FR3U>L^3X@0H.'HW>P/Y-23AKAKT! 02@   !HP';=1N+LH(0*)=A_3
M<'1FUAETVVI@""4    -C+:,:!C)7KW2&4@>JUON1D-;1LRYM&V31I>M!HI0
M @ UC,<_ 4ADVAJ1FI+J!!$- /%ND<C?7A \ET09SX)0^JR56#YOA5 "  #0
M0&BE4I_4G@B5?U/)C=63XU&W$$H     Q!6A!    $!<$4H     Q!6A!
M $!<$4H     Q!6A!    $!<$4H     Q!6A!    $!<$4H     Q!6A!
M $!<$4H     Q!6A!    (B1#4M7NG.(A% "    (*X()0    #BBE "
M(*X()0    #BBE "    Q$COT8/<.41"* $   !B:&/>)EFS/L>9BHIWNVMA
M(Y0     ,:"W ]:I5]<>,J!/IC/MVETDV:M72DEIJ;L7%*$$    J"4:4+(&
M#I+5ZSZ7@AW;W+4@E     "U3(-)X>XB@HDKZ6B .P\ J"%)24GN7"B>[@N@
M-C'0NG+Q_%S6KEP#^_:7U)04=TWBT9\A<XW"_3Q-FS9-YLR9XRY5'2TE
M0)R8KEP-':$$  "@GAL2J/@FBD0ZET31++59@Q_X3O<M (@!NF\!2!1V=YMX
M?_XDTKDH<SZ)<"YZNV"].U<BHOL6    @'J/4 (   #$6;.45'>N82*4
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M_,B /IGN'C ()0   $ ,:0C1J7.'3NX:>!%*    @!C9L'2E.X=(""4
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M ! #M)0  &@IB1XM)0    #BBE "    (*X()0    #BBE "    (*X()0
M  #BBE " +6LJ'BW.P<  !2A! !JV:[=1>X<  !0A!(     <44H 0   !!7
M/-$= &(@TA/=E\U_47IU[>$N 0#JJTA//Z^/>*([    @#J+EA( B %:2@
MIJ5DP]*5SFM=I5^'^1HBM?[04@(   "@SB*4     (@K0@D   " N"*4
M (@K0@D   " N"*4     (@K0@D   " N"*4     (@K0@D   " N"*4
M (@K0@D   " N"*4     (@K0@D   " N"*4     (@K0@D   " N"*4
M (@K0@D U+"DI"1W#@" ^J'WZ$'.%$E>7IX[5W6$$@    #5MG__?G>NZ@@E
M     .**4 (    @K@@E    0(QL6+K2G4,DA!(     <44H 0   !!7A!(
M    <44H 0   !!7A!(    @1BI[X"#*$4H   " &-J8MTG6K,]QII+24G<M
M;(02    ( ;T=L Z]>K:0P;TR72F#7FYDKUZ)>'$@U "    U!(-)ED#!\GJ
M=9]+P8YM[EH02@   (!:IL&D<'<1P<1%* $   #B0%M-MFS+IRM7 *$$
MB!/3E:NA(Y0     <=0LM5F#;RTAE     !Q9.[*U9 12@"@AAT]>M2= P"@
M?C"W-XX50@D    09\U24MVYABGI*'_2 X :EY24Y,Z%6C;_1>=!6@" ^JWW
MZ$'N7'1BV1)1'?IUF'.+]#7EY.1(OW[]W*6J(90 0 P02@  50TE=5UU0@G=
MMP    #$%:$$    0%S1?0L 8H#N6P  QI1$CU " #% * $ 5,7&O$T)^[NA
M-D()W;<   " .#M06N+.-4R$$@    !Q12@!    XFC-^ASIW;6GN]0P$4H
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M?I[]T'T+  "@%APH+>%6KJB22)5X'$,H 0   !!7A!(  ( H,)X$B!U""0
M0!3T:=R]N_9TEP#4)$()  ! );25Y$#) <:3 #%"* $  *C$?U9]+%D#&; ,
MQ JA!   (((UZW/DY'X#W"4 L4 H 0  ""-[]4IIUR9-TEJU<=< B 5""0
M@(>.(7DW^P,9V+>_=.[0R5T+(%8()0   "X-(]HZHG?:.C/K# :V [6$4 (
M !JD@AW;G->->9N<<2,Z:1C1 >T#^F0ZVP#4#D()  !HD+1;UH:E*Z57UQY.
M"#$3@-I'* $    05X02 *AA24E)[AP  /5#[]&#G"E6""4     XHI0 @
M ""N""4     XHI0 @   ""N""4 4,O6YJYSYP  @"*4     (@K0@D   "
M:LO-S77GJHY0 @   *#:]N[=Z\Y57=+1 '<> % #>'@BZKH-2U>Z<XFAIA[8
M%J^O*Y8/G ,2R:)%BV3LV+'N4M402@"@AE4GE/SI[OO=N<1P\\R?NG/5P]=5
M._BZ(HO7UV7.W_O^?+\BJZ]?ETJDKZTFORY""0 D$ TEG=J?(-MV?NVN 0"@
M_JM.*&%,"0#$ ($$ (#H$4H     Q!6A!    $!<$4H H(;I4#WM5PL  *)#
M* $    05]Q]"P!B8.W:M;)JU2IW"4"B&C=N7-0MFSMW[I24E!1IV;*ENP:
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MT;]O_%SN#G;C,EWN H(W ' %QT_9XTFL\6^^+;56J'KJG6/A!W5:TE%M!P,
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MDW;(F]/OE-S)OY-)SB!V *A]A!(     <47W+0    !Q12@!    $%>$$@
M  !Q12@!    $%>$$@    !Q12@!    $$<B_Q\</#)45SZ3J@    !)14Y$
$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_51.jpg
<TEXT>
begin 644 image_51.jpg
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MTT3EQW26J#@AA! B#F!T5^*NN>VR\,A\(#$AA$@<*P#HTP$:^];H9]BF97J
M_=CVCV$Z_WB&;9<K(800HM:TM^T)0^D K0_658K$A! B4:+&)_@"@+YO^ ,_
M+9V?SL<>SSS@YV6\A!!"B.RQ8UNK&SI\0+A5?_Q6DVJ0F!!") J[.5EGL:*
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M0SHX#,!&'&#^-E\<KY8)(800(CXD)H00B0*C'D ,H%L3?;JGGGJJR\!'&'&
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MM^UPV]IWAUN=;-C9&L2+TK3OW9?:.J00L-V-X-.XM]V4Z#,-'( /06"WK3A
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M/8K&&D:J(R%*D]??"M^5$A-5D#;C.(HTU7O:ZBLOSZ0M1QK*Q/N<!H[X^N)
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MZCK/^:=\(]PCA!#QTW!B E]5QPT>%/3W%J(4-.3AEFW9[CY\_-'NPW./#D3
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M[SGEX##F0"#V/OV;->Z;;YT8^5P4ZZ)6:_RN$6GH*L%K2,.U")$5\O)[L>5
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M-5LDH@SV6@D)&,<;-FQP9[[ZM>Z+-S_OWG[T +=[PV/!H.>H:RM6%_CRCRY
MZ$[TNT=WN2_^7><,387JEM</4?7^][\_6/\!JW<3+ SWTDLON<<>>RS8+I0/
MH)"X]O/O+EH7G[S\1O?B[E;W_7]^;[ =)28X1N*<B3O<07NV!^,C-F[<&/@C
M1X[L6J-"8J(TUHBH][4(D2=V;&MU.[:V=NNNFS;\WS]\4.Q=+C$1 0VHO)6+
M2$R41[V?\:2?PW*>@ZAK8%P]C8Q2+[<XA02,9W9M@L%+0]TWV&LE)!YZZ*%@
MX/;@H</=7;N.ZA(2YYQS3N2U%:J+MK:V8!T(&-LPS%D7)\UH"?9'U:V]_N9>
MN]Q__,=_N(]__./!:M1D_OSY[O>/[G!?O^3UP794/N")9>O=)WY\C_OO3[^E
M:%W@NK9M7N]&[7K4773114&<+R;L8.M=FU<%^]:N7=LUI:RM"Y1/8J(XUHBH
M][4(D2<6S%]:=$'6-.#__N&#0N]R4/BOK,@M&(B-[DZBL<%SD$?B%A(PGBDD
M"E$K(0%...$$]Z;SWN%NWWJH:UE[B]NQZL% 2$11J"Y@:$-(H.N/%1+EU 6O
M'U_ZO_SE+P<^_LC085S#E!G'=FU'L>#QY>Z3__W7LH0$^-B;CG#//_]\$/:Q
M0L+F904.8%T((40]@) X:NZ4<"M?2$SD!'PM+M>]]KH;W;$__)_P2-&H;&EK
M#T/Y(0DA >,9+1.%J*60(.C:=.$IX]RLJ</=OGW1'P8*U05:)+"V!<<0%*H+
MM&[0E7O]Y=;%\4<?XF[]VEO+S@O7/&;,F&#;4DA(H.4"8@FM)(\\\HB[^V_/
M==6%$$+4$G1MHI# P.L\HFY.$:!,($OEXC570M[N&XCSN;1YU0I[S?YYX[Y?
MV]IW!Z[88H:\AJCKJF?WAZAFUZ2$!(Q4VVV(8?A7W;8NB*/QS'<D8/HXA02,
M9RQ(=]=C&X*N3:>>>FH0?^^]]Q[0S0DS7475!:9194M&5%WX9<!V.8OSE2LD
M4!<8;P%81SY1>4%08&V.8X\]-A +$Z=,CQ026+0."]-A9B>,E7AZ4V_W[?^Y
MS5WW^;<&=8'RH)L36/+9F8&?-NK=M<COYI 6^+LG:;HV(7P@(E8_L]&U#!^8
MZC$2/O[OG[^[0N]K(#$1090!E79*W0>[/XOE*Q>6LU1]E$.<>96#?QZ[G=0U
ME)HJ&.<%_G6!>OXA]U]N20H)'[P'<5[X$!/6X+7[X,<M)#C]ZZVWWMJM:Q,,
M;0@*#,#&#%<8%X"5L/VZ@!'.P<B%ZH+O>< I<./NYL66GJ@_/\7RPF)T$!./
M/_&D^]\G!W03$JP#M& <??31P2#UWJ-F!<_%^V9L=4?/.B*8V8GW9N8WEKC%
MGSDB\($?!OX^FX84VE<LK05Q%EQ?O8UDWYA("_9ZJKFVS6NZBQ%1.2,FEE_G
M?$^3-#U+<6/+B@7IL([$T.$#W*@QA?_6I!7^MJP/HM[7)!8QD5>2,-Z2HI2Q
M:??SGF6I?.5BG\N>EB_.O,K!/X_=3NH:,'9F\<;-!04%S@O\ZP*E_C#L;M_C
M-C__@ALW*?[!_O;E5HZ0@"'^GQV&_RF'#JY*2-  91@BXN*SQP7;:0,M$EQO
MPH?&>#%1Q?<\0(L$I\(M1*5" O7*<_CYELH+US]CYM'N4U??ZS[WGE=TW2.(
M),S<A*Y;"(.5V_JYFY]^N>NYX/2PO)>^44_06H&6"_I^G,7&%6KM\(\KE*>-
MK[?1Y1L3:<%>3S77)C'1<RH5$SVY7UD"Y2-9+R?OE?5!L;\#A3_AB4P#@\\Z
M&R<JQ]9EW*X8Y:3I"4U]>KMQ@P<%,SO%S0??<(6[X*QO!R^B*'?U-_[D+O_\
MC9'[[KGUB3"7XI0K)/!%OUHA40B\6 LY?,GW5X:.<FA%@#")VD>'%@8(!*2-
MVD^'_>S:5(QB0L('=5&,:H1$(<K):]+40]VEWY_GSC]Q1%=>$ E8D(YC0,!=
M#Z_L)B0 IKY%ZX4%ACL=MVG4$^XCV.\+ G^;(,R6!X1QGPC#O'_ ;Z40!\)W
MA,@&C7*_*"#R+)B*T5#=G"HURK)2+N#?AT+W)4OWJQI8OCC*&6=>A;!Y^^?!
M-DCJW)8-.UO=NA=VNIFC1@0"@T1= ^-*O33Q!V3JX6/<BB<WA#'=.>FLPP/_
M_C\_&?B6C_Y_;W1ON7#_JLH^_.-4:%P H9 HM4IV*8.77[-A\*)% F'[!3]-
M\-K\5SN^V,];VM?-/;1X7=AR%<H+]$1(\!S,MYR\<"\Q1N+4$1O<E'$M07>M
M!0L6!.-&T'V)?/W*_W'/]#G2?>^B8PYX+B \,)X"Y_6[)OW'<6N"KF.,!S9,
M2L5%A6T=%CH>,&V]#1+\OOA%,D_&D5HF>DXE+1.-1EY^+_[O'SZ(^CM U#)1
M@%H8<$*DA3&#!@1=G=#E":T4<4P=?.3L22[*W/[A;R\)_.E'CG.O>M.Q0=CG
M^__V^S!4G%H("4*#UX*7JW7U;)% ^F+\\B\;2PH)U$4Y]$1(^%0B)#!&XN"6
M?F[1HD5N]>K5@?%OA01:JNY8]%RDD !84P-\]']6!#Z->+!UZ]; ]X4 ?*:S
MZ8&_37@,6BH*'0MLG$V+/][U=$((40D-U3+1"(NUD4+W)4OWJQKB?"[CS*L0
M-F__/-@&29V[&"NW[7!M>_:Z\W[9N;)QU'75\PL,#9Y"KZ^XA03>?1QLS:_,
M?!^FC6+75NQUS[K@3$L@S>7L"1!@%]VXKJLE -CN28!"POK CZ, \.-N?GL_
M=^X-+QX0#]_"N+0]5_;+9%Y0RT3/4<M$8?+R>V$YK ^*_?U0RX00X@ P72R$
M-T1$3\4,7D1P&)#]P%U/=HV'8!CQ*Y[N[ K%EU9/2*I%HMB7\S11C3%JZ\+^
MP<BCD !\+F#(0T102'QQRM\"WS?\N4VXSZ8!-MUMM]UV0,N$W4\?V## '_ D
M7"7$\5L40C0&$A-"B)KP[Y_\7_?S'][M;KKV+^X'7_V]N_;*/P?A7W3$??]?
M;W:W_M_#8<KJ24I(%/HB@_AZ=VV*VD^'\]F\HHBJ"YL''?(J=?WEUH7-JU+\
MO,JI"UNO%ACW,/CA$/[2RJ.[Q %]&/H4 @1A&V?3 FP/&S:L*VQ]"_.(VE=O
MJA$@0C0J%-^-*L(;2DQ,'38TF%=?B')AEQ[1<WKW[>V:F_JYOGWZN+9=>UQS
M<V=XYPMMKF^_/NZ&G\X/4U9'DBT2A;[0EYM7)>M(E+K^<F:P KC^GJZI0<II
MG8DSKT) &%@JF<VK5+T"M$QLV;*E2T  W]#WQ8&?%NZAAQX*A F!6"'8;T4$
MCZT%5__NH]U:*HHY(80HEX82$YBEIKG#>(EC<*G(/^SBT]-N/J*3NW[_-S?Y
ML(/=N,G#W25?>*.;=OC8(/SN#Y_NWON/9[B_^\2KPY254Z^N35D0$IC!Z(X[
M[@A\B"+K/G+U?'=RK_N#1>3>^M:WNO///S_,83])"PFL:NVW(GS^AE61K1N6
M.(4$NCG!J(< 0/<DW]!'F"".SF+C+OSSH. 8Y@L*^3R/39L46$0+J_(*(>*G
MD45X56*"7VNS^-46_< 7KGLNEX("]X-.B+1@OW;^P[^\P5WZY3>[_DU]N\(C
M1P]Q1Q\_U;WRU=4MUE4+(>$;LL@+I%U( $P)^_&/?]Q]_O.?#[8MS__^B^ZV
M/_PF",.H_]6O?A6$2=)" F"*U[5KUP9AU 5G;2I5KW$*";8<P+"'H(!1;XU^
MZY"&#E@?CL>!8BT2<!9VM4H2K,:[^IF-X9800D13:;>MBL2$_8.:Y2^V)T\:
MEUM!P7NBK^FB$:B%D !^-R?D!=(N) A6AW[QQ1?#K?U<>,%[W4TWW12$%R]>
M[*9-FQ:$02V$!!@^?+A;M6I5782$#XS]:\[:&6[M%PA1QC^A0& 87:7F?W!T
MEZCPCV,\L=O^OJ3 I =""%$(?@ D_@<UGXK$1)Z H."<^D*(;%(+(6&Q+1+%
M2).0..RPP]QWOO,=][G/'?B%Z2,?^8C[P0]^$/RA^/K7O][5S:E60H+TZ=?L
MOOQ_RVHN)&B\HW6"@N'XXX]W'QMZ=U$1@'"4X<]C3OGQ<UUAI$/^Q,83QOGG
M3()9<R:[QQ>L#+>$$*+G-*R8 %BD"X.R(2@P,!MSZV,E8"%$-JBUD(BS10)?
MX2]]U>A$A00X^>23W7O?^UYW["M>?<!,2P"" GSF,Y]Q7_WJ5VLN)% 7OU\]
MTIW8LJYF0H*B$*![D>V.!",?,S'1V(?/L#7ZX1!O!0 &;]N!UQ:F95Z 8=]/
MFL-FC7?+%G?>&R&$Z"D-+28 !F5C' 6$!>;6Q[;&'0B1#6HE) #S*D8E0@)?
MX:>/'1#&'D@U0L(?8$UWV.&'N]ESC@T6I,-@:[OOGGON<7/FS'$?_>A'W3__
MYY_<U_[A-6[1;[_F?O:SGP5C*)B.Q"TD6!=SCYKN'GWTT7!/=^(4$N"JNYX+
M?!CW:#7@X&<:\Q $Z.Z$;8H%"@&FX3[&P=D6"< 6#V#C>6S4OEHPI&5 ,!A[
MT<)588P00E1/PXL)GY:FPG\<A1#9($Z#EU^Q2^55J9#HZ5=X8(5$,98^]91[
M?M63D?U>/_SA#P<S&/WQK@?=3[[VC^Z1O]X5C)^ N^&&&\)4G20E))#7A D3
M@L'8OJ"(4TA0%'WNW F!3^S@9QKY"Q<N#'PK&K@/8<(X.,(P\K5IF0?#(.JX
M6H#!V(<>.2X0%&JE$$+T!(D)(42NB%M(("^0%2$!P?#*5[XRW-K/44<=%8;V
M<^JII[JSSCK+'7?2F6[/[C;WCK>\SIUSSCG!@&W0TM(2^"!)(4$@*"9-FN3F
MS9L7=!F*4T@@+V+SLEV<K*'O=W7RC7[?\$<:MF;P.(!T/(>?!V!Z.ZZB5F!6
M-8RAF#AM9" HZ#"#"YT00I1"8D((D1N2$!+(*^J+/DF3D"!_^<M?PE GCS_^
MN+O^^NO#K?W<>^^]P0#LCWSIO]U3CSW@_O,__S.8W>F!!QX(6BR^\8UOA"G+
M6U.C)T*"8'8G")K;%ZQP5_QZOGO?C*UN\_/KPKW=J41(H%ZCL-V<+&>??7;@
M^\*!QC_3VS &;]OT40*!:2TV_WH 43%]YM@N)X00E2 Q(83(!4D)">1EQPQ8
M$'_2C!9WYJ07"O;WKZ60H.C!(&LL_(8%X! W:]8L=^211P;[L$UWU6WK O?9
M\V>[YN;F8#]:!Q ^Y)!# L,>>6'@=BV$!$%=W/O\</?3?WJ=._'XV6[ @ $'
MC-VH5$B@7@MANSD1E-U"T<!T-CW#% I,R[ O5I#>;B/L=XFJ)YP2LIIU7X00
MC8?$A! B\R0I),H!TZ_.F#$C$!18:;JMK2V(KZ60(+A^###&N(!2>5U\]KC
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M &PA2J,!V**A@)"8.JSTEU)1/HLW;LZM.*LU:-TIM^4L+B$!X_,#URROJ9#
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MI6?4^"GNBL^>'QCX[-IEV;*SL^L4C'@8_#3Z:?C#AY# ?H1I_-/9.(:Q"C9
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MY+KED7E!))QRRBGA5G1>X-IKKW477KC_^8X:>^*?$^MS]$2@H9RH7QCRME6
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MW+O?_6[WQ2]^,1C4?/1Q<]P?E^QUM_[GQX(TA:Z_ED("8+&_!S:-#L))"@F
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M1C8%<:QS2[E" M=_Y073@CSP;$E,=()N3VN6;PK"3<U]W85G7QZ$0:VN)<J
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MW0&$_>TH'R!?^US60DB 6M8KQD(,&#3477O?)O?1UQ\:Q%' ^ ZS4F&]#"S
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MQ]%9>(P-VV,)XX!-#ZP(8)C'1IW3"@"",.O.!W%10L&/I]'LDU8A@2_G .5
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M\6>."/=$D]N6B;P:6)9&*&,]0?W2B?KPXM[.;QU9$1+%L/.*3SGT8 D)(4J
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M%KLV 79M:FYN=L<>>ZR;/7MV("@@%@H)">QO;6T-TD^<,KVK:U,QRA42:)'
M;$YY6YQ(B'J"E@F(="%$>LB4F!C6W.2VM7=^J12BT6D$X3QS=.&Q#W:,1!00
M%2>??++[\\*5[NI;%A\@).;-FQ<(#G2)BGN,!&:AP1@)"0DAX@4M?%IA7HAT
MD2DQ,6;0 +=\Z_9P2XA\TRBM#\48%K'.!+!"HM1@ZX=>&.\N.&:?<_OV?XA
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M6Q;0_0B"@,8]PHP#B,<V'84 CP<\!O$,V_2 ^7 ;Z7@.^I4@,2%$2D 7I;A
M7A GHC'!6 ET0]"8"2&Z Q$0QP!<Y)$G00$!,'3X #=JS- PICH@MI!/&KL]
M62 DGU[T;+B5/#@?9G,J)"AHP*/[D>V>Q&V(!;8XP+?IX'P!0'%ACV7Z>>\=
M'/C<]M/!4624B\2$$"FAV*!KB]9Y$5'X?9J!QDP(L1]TPXES;0$*BJP# [>I
MN6^/A01!/MNV[$J]T,*S@&>B5D!0//?LMLAZ@0%/8,C#T= G% R(I['/M%8
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M0&B! 'DKEQ!"])19<R:[I4_$UQU6"%$9:)5H&3XPW#H0&/%P42T*A&&;Q@H
MVUW)=FU".CC"+DZ(0]CNJY2&%1,$1C<,34RMBH',>1G0&%4N6S9N8S]='K[:
MHPQY+)<00L3!Z/$MP:K$0HC:@E9!M$I$K3@.HYZM"]:HIUBP8!LN:A^Q:8@-
M%]L'"N5;B(87$T(((42C,&K,4#=T^  )"B%J"(3$XPM6!JV#44!(L$6!ACT%
M <.V*U,AXY^M$ 3Q-C^".&PSCNFLJ*D$B0DAA!"B@8"@P #0!?.7:@R%$ F#
MKDWH7CCWE$/#F,)8 Q]0"-#09QA0 /@P/FH?8#Z :>#SO'9_N4A,""&$$ T&
M!H#"N,$,3XL6K@H,'B%$?*#U#VYWVYZ"+1($!KPO#FP8^VR+ 0U_XA_'_38>
M^-N$Y_;S+1>)"2&$$*)!P92Q-'1@^*Q=L2GP[5HE0HCR>.KQM6[!O4O=G;__
MF]OSXEXW<=K(R#$24=#0MP8_C7P P4&#'[Y-!R@$K"! F-L\%M@TP.Y3-R<A
MA!!"5 RZ/D%8P/"!+X2HG!E'37!S3SW4G?G&H]T1QT[L:ODK!0QX&OYP5C30
M)XSSTUIL>N+G Z+B0%1<,20FA!!"""&$B!D(\T./'%?6^"0:\/!]D0#?"@YB
MT_K'VW1, Q_YV/0V'6"7JTJ0F! BXQS^_6NZG.@9MBY]5PNBSDLGA! B>_1O
MZAN,3\)L3H4$A1TS04/>&O0T_.%SL3F$(0SLPG,,,PV=/=Z";3\.1,45H]?+
M_CQ2)>"%<LT"_)&SZQ?D!?[QSEO95*YLP=]7U._,CXM*(RJ#SU$]*74/J[W&
M>U;\AWOYY<Y%'45W3I_VR<"_>_EW E^H3D3E].J%-9TZ;401S4/W/NF./^6P
M8 K7P)[N=9 [;>JEP3YKCM.8I\ @=MN*CRC?IF'8PK0, VSCNG M=C_C"B$Q
M40#^P<Y;V52N;,'?5]3OC&4&A=*(RHAZCFP]9Y$[EGTM&$@+7T3#@<:JH_VH
M3H2('[1,8!R%'9>$WYJ=CC7*P/?Q]W$;^.FM*"!^'+?AHX5#8B(FHHR*/*!R
M90O^OEB^0I23IASBRJ=12=IPW[&MU9TW]ROA5F7(*"R,#.<#49T(D0P8D&VG
MBJ68\ U^'QCWA(9_)<<0'N,?SVW8^10WW%]*3&C,A! 9 $9^,2?B(ZI^K0,P
ML*)<TE2SP%BMKDT((41I)ATRJJQU76#<TP$:]KX/F,;Z<$CC.S\_P+11^\I!
M+1,%X-?9O)5-Y<H6_'VQ?.503AVLW+;#36D9$F[EFR4;M[@C1@T/MPI321T7
M D9[DBT3 .L E#MON2@/?84_$-6)$,F!M5S8U8F_-=L:0..^%#3^?6P>OE H
M1M1Q0"T30N0$B(1R7"D@),8,&AANQ4\<1GF<-/?M$X:*$U67OK/ R+*N5K2W
M5=XZ(800(CTT-?<-0YU$=7.",4]7:)O'P+>.:8C=]M/:.,"I8RM!8D*(G  C
MOAQ#'BT237TPZT8R^$9WO2FW!29M(J@0[6TOAB$AA!!I *T+E;@+S[X\/+(3
M&/!1T,BG<+!&/[';2.<+ >[WC[5I&>:V?XY22$P(T6"@9:+1R%.91X]O"09B
M"R&$2 ]LH?9;K0LY'QKRP#?\?>/>%P$,\[ARCO?3TMF9I<I%8D*(G!#5%<<'
M1G5+4_]PJW'8TM8>A@J3MA:50HP:,]0]]L"*<$L((42:B&J)*.8L7'B.CF*!
M8<8S+1WCN-^F91[^\3:=]0']<I&8$"(GE-/-"5U^&E%,S!Y[<!@J3%:Z.8%C
M3IP:#. 30@B1#Z*Z.E$L,$P*I25^F(XP'.5;5RZ:S:D -"SR5C:5*UOP]U7.
M[ZQ4'90[JU%>:=^[SZW8NKU@'512Q\!OIL87)L313QK,ZM2_N6_04B%Z!K\.
MUN*^9075B1#E4^OW?Y+8LE BP/;7;$Y"-#CHWC1U6&,;G1AT/JRYR6UKWQW&
M9!M,#[M]2VL@*H000HAZ(3$A1$[ 5W7_RSI$!(SGI&=PR@IC!@T(NGFAE<87
M%:5:)=((YBE'ZP165*UF03LAA!"BITA,")$3T 4'#H8R@+$,P[D1QTB4 EV=
MT.T);-C9&H@NVX4I2Z";TZPYD]V:Y9L"4:&9GH000M02B0DA<@);)C@F0$*B
M.&BEH(^6FVI:)M"GE*[>H)4"H@(M%!B<C>Y/:;J^-( ZL74CA!"BYTA,""%$
M#\! M30-N$-+!80%QE2 K \&["EHJ4&+#43$J+'=ZT8((43/D9@00@B1.]!"
M$W3[VMH:M-@$XTN:^H9[A1!"Q(7$A!!"B%RQ<<-VM_2)=8&(4"N$$$(DB\2$
M$$*(W  A@2ES(22$$$(DC\2$$$*(7(#Q$1 2Z-(DA!"B-DA,""&$*)MZS0Y5
MSGF?7O2LA(000M287B\76Q\[ BRI#3B-(N9FS^)B3Z7@G/-Y*YO*E2WX^\KK
M[RQK\#FSW+/BBL _;>JE09A^&K#7%#=)E/'EE['V1_2?I-.G?3+P[U[^G<#W
M6;;X63=QVL%E#[)&?LRK5-Z-2!;JY.6.?[TZ_@E1/AU/3*_X%W!-X_O?\O)+
MG>LJ%:7CIX2ZL66A1(#M7TPN5"0F*"1\\FCDR.C.%GDN%\I$7]07/F<63KV*
MK^8(TT\#25P36P=J7<92Y\7,396,D[!U4J\RI1G5B1#EP_>)?:]D%5N6<L5$
M5=V<:-3(N!%"-!)XY^F]ESZPAL2D0T:%6T(((6J)QDP((40#@*],OK/Q-NP[
MNR^M#&GI7-%<""%$;9&8$$*(!@#-UKZS\3;L.[LOC30U:S$Z(82H%Q(30@@A
M,DU[VYXP)(00HM9(3 @AA,@T:ID00HCZ4=5L3AB F/=99CAK2][*IG)EB[S_
MSK(*GS? KC\83X!PVL85I/&:DJ#2+EA1=9+6;ESU@/6C.A&B-/;]G_7?C"U+
MHK,Y"2&$R 8T"D4T^*,I@SD;X%FV3J2;1KM?C?Q,QM(R(81(#K5,I(]2+1,R
M3N.'?ZCCK%M[KW3?NI-$??<4W:]LT4CWB[\7D/5R\E[!+[=EHL=BHAS2: C%
M<4TJ5^UH]'*E\=H;&=P/XO^QM']41/S$^8>:]XQA49@XZ[U:_/N5AFL2A6FT
M^Y67,K(<\"4F2A#'-:E<M:/1RY7&:V]D<#]((_VQK#=QU['N67FDI9YP'1;=
MNW33:/<K+^\3E@-^3<2$$*)V2$RDAV)BPO\#*N(ESC_6NE>EX3,=9[T+D4?R
M\CNQ?\L2%1-"B-HC,9$>2HF)K/]!01E FLJ1Q#6EL9QI(D_/M!!)DY??B?W=
M)R8F[G]JF_OCX]O=@+Z]7)^#>KFVO2]U^)@4ZF4'J8&X%U[<YP;WZ^U:][S4
M<9!S7SQO<G!\VCCNVT\&/JZ^XTHK F5]^%.'=VZD#):K6AY):;F^]MLU'?_C
M.>L5/%O0MGT[;AX>,_@O[GNYX[D\R/7N> ;;][[<^7QV['QA]TMN8+]>[JOO
MF-*94<JX]'^6!]?<]N++KE^?CF>QXQ>Y=Y\+PKOW.G?5^Z<%Z20FTH/$1.U)
MXIK26,XTD:=G6HBDR<OOQ/[N$Q,3U5+!:6I"7*TL*E=M4+DD)M)$(XH)&\>P
MC]WGIRNVSU(J'>+BHM#U^?3D>DFQ=''D82F6KM(\K"^$*$Q>?B?V=T^;";9*
M,?NI(C$AA*@]%!P2$^FA4<5$/<L5=4T])8D\\P3O>;WOO1!IA^\2</7O/AJL
MRC]J[%#7ORE[J_/;WWVY8D*+U@DAA!!""%$E,+[IIL\<ZR9,'>G6+-_DEBU>
M[S9NV!ZFRB]JF1 BY:AE(CW8%@ERSXHK O^TJ9<&8?I)\_++^_!_YT;,G#[M
MDX%_]_+O!#Y G-VN-5'7U%.2R#-/\)Y7<^]?#L>W"9%>.I[07KW#<'*L6?&\
MV[9EESMJSM0PIDYTF/LOOQP]0KA7KX/P7Q#&W[ HBLD%B0DA4H[$1'J($A/L
M_I&G+B%LLK?EL.7B_GH09]W6LQQ9(2_/M!#U9'?['O?X@I5N[BF'AC'I)>I=
M7THJ2$P(D7(D)M*#/U;"?^GFQ?#B'Q!;CJBRUI*H:^HI2>29)WB?ZW&_A<@;
M$!1+GUCG9LU)YPRGQ/[>^8XL)14T9D(((8000H@$P6#LT>-;W-H5F\*8_" Q
M(800HB3Z,MV8\,ND$*+GC!HS-!@_D3<D)H000I2DWD8EQ$S<@B:)//,$ZT=U
M)$1\H'5BQ[;6<"L?2$P((8000@A1 ] Z\?RZ?$T7*S$AA!!"""%$C<"B=GE"
M8D(((8000H@J03?02MR%9U\>'ID/)":$$$(((83H 1Q;9,<:%7-Y0NM,")%R
MM,Y$>M Z$]W+*H00HOO[/R_8\FB="2&$$$(((40BJ&5"B)2CEHGTH)8)M4P(
M(81/7M__#*ME0@@AA!!"")$($A-"""%*HI8((80044A,""&$* F;NX400@B+
MQ(000@@AA!"B*B0FA!"B"O2EOK:@ON.N\R3RS!.L']61$*(8FLU)B)2CV9S2
M@YW-B=RSXHK /VWJI4$8_MW+OQ/$Q<W+'?]Z=?R+GX,ZGK/]WY90!L"R 9;/
M#]>*J&OJ*4GD&1LOOU1R!I6D.?V0R]S=SUS>Y0OAT^N@WF&HL>$[L1[OQKCA
M>]%2ZETD,2%$RJ&8>/0C[W,KMFYW8P</="U-_8,X45NBQ 0')N/K;1ZG!B2V
M7/4H8]0U]90D\LP3O,_UN-]"9(D\_5;X7K24D@KJYB1$1MBP<Y<[8M1PU[YW
M7Q@C:@U:A]1")(00(L] $%4BBM0R(43*8<O$7S]XOEN^=;N;/?;@8%O4#W_Q
M.I#'+U.%RA'UY<HG[CHH=4W54$XYDB KSP>?9?I"B&CR]%NQ94 8E)(*$A-"
MI!R*"9%.[$LW3W],@"U')>5*H@ZBKJFG))%G*9*HFZ3@M6;IFH6H!WGZK=@R
M( Q*205U<Q)"B!Z ERU?N$(((42CH98)(82H$K0:\16*<)Z^3 %;#AM72#S9
M?7ZZ8OLLI=(A+BX*79]/3ZZ7^.FR *Z7UYV5:Q:B'N3IMV++@# H)14D)H00
MHDH:24Q40A)UT--KBB*)/$N1I>>#UYJE:Q:B'N3IMV++@# H)174S4D((800
M0@A1%1(30@@AA!!"B*I0-R<AA*B2O'=S2B-QUFV:RYD6\O),"Y$D_(WDY?W/
M,O =J6Y.0@@AA*@*&A-""%$(M4P((425: "V$$((OO?S\OYG&?BW0"T30@@A
MA!!") @-[T9$8D(((8000@A1%1(30@@A G:W[W%K5VP*MX000I0#NP4U:M=0
MB0DAA&A@=FQK=8L6KG++%J]W&]=O=Q.FC@SW""&$$*61F!!"B 8%(F+'UE8W
M:\YD-WWFV"XA@:]KC?J%30@A1&5(3 @A1(.![DP+YB]UAQXY3BT10@@A>H3$
MA!!"-!B/+UCIYIYRJ.O?U#>,$4(((3K!S%1V=BI,?5X,B0DAA&@@T+7IJ+E3
MPBTAA! ]A89W7J:'K71 N<2$$$(T".C>U-3<3RT20@B1$)@1#Q-:P.&=VPA(
M3 @A1(.P9OFF8*"U$$*(^."D%7 8AX;W+!S>N6@-SCL2$T(((8000L0,! 4F
MNL"$%WENI9"8$$(((800(@'0K1037F#BB[P*BEXO=Q"&A1!"5 !FN. K%&$T
M<6, 7KF#UFI-)8,#TUH&(83(*FBA@+!(,_P;9GU03"ZH94(((<0!5"(\A!!"
ME 8SZ6%@=MY0RX000E1)H9:)O*#6"2&$B!<,R)XU9W*XE3[4,B&$$$(((41*
MF73(*+=QP_9P*Q^H94(((:HD:V,FRH5?HM0R(800\8.N3FF=IELM$T(((800
M0J28IN9\+1RJE@DAA*@2M4P((83@.[,2TOI^M2T2]$$QN2 Q(80052(Q(800
MPC>\LX[]6\8R24P((40"2$P((83(PWO?1V)"""%J@,2$$$((W_#..O9O&<LD
M,2&$$ D@,2&$$*(:$9'6]ZL5$?2!Q(000B0 !$04$A-"""$*L7;%)C=AZLAP
M*UT4$D;%Y(*FAA5"B"JQ+U<8WC*^A1!"E**];4\82B?^W[-2[0X2$T(((800
M0M2 '=M:W=#A \*M?" Q(8000@@A1 U8_<Q&-VK,T' K'TA,""&$$$((D3!H
ME6@9/C#<R@\2$T(((8000B3,TXN>3>W ZYX@,2&$$$(((42"+)B_U!TU=TJX
ME2\D)H000@@AA$B W>U[NH1$_Z:^86R^D)@00@@AA! B1C ^8M'"56[-\DUN
M[BF'YE9( "U:)X00/8 +UW%.;JX:FF6T:)U( X46SZJ40L]QN;_5J.NHY+AB
MYZ\GI:XKZ;I)NE[*N8ZXL-=\]>\^&OB8_C6+LS;9>\-RE9(*$A-""-$#)":$
M2 ;^EO@\)D$YSWBA\Y<Z-LGKK@75EJ\G=1H'?&;*N8ZXL.6IY7F3P-8=RR4Q
M(800"2(Q(40R\+>4U&]J[8I-9<VL8Z_#4NJ:RLV_&I+\C>*Z1XT=6K);3E1]
ME'NODJH;>Z^2J)MBU..<26#+@3 H)14T9D(((800#4=[VYXPE Q)YY\4,/(W
MKM\>;L4/!B2+?"$Q(8000HB& WW:,4A6'$B20@@#DO.XUD(C(S$AA!!"B(8#
M@V-7/[,QW(J7K']];V][,0P)41J)"2&$$$(T)$W-_1(Q_)<^L<Y-GSDVW,H>
MDPX9%8QKB!NT!#4UYW>*U$9%8D(((800#0D,?AC^<0*#N67XP' KFPQI&>"V
M;=D5N]!Z>M&SN>SBQ('*]!L-B0DAA!!"-"RCQ[>X98O7AUL] \9W7@SF67,F
MN\<7K RW>@Y7@1;Y0V)"""&$$ T+QDY@,'9/!05:)&!\8[7CO #C'R*@IRT4
M%!)Y7@4Z#]/"5HO$A!!"""$:&@B*@\<-#8S>:F9X6K1PE=NQM3570@+ ^$>9
MT!6LFC$4. 9UDW<AT>A(3 @A1(,#XPE?9>&2&'0I1!; . $8SA %Y?P>F ;&
M\J%'CLOU=*?H\C1D6&?K#<I;K%ZPC^EP#(Z5D,@W$A-""-&@0$2P"P,&HL+!
M($)S?2,WV8O&!K\!__=@X>^#:1K%6(;88GD+O2>PS?H+!$C',2+_2$P((40#
M@B^'[):!+AY"""%$-4A,""%$@P$A@0&G^((HA!!"] 2)"2&$:" V;M@>+!JE
MU@@AA!!Q(#$AA! -Q'//;E.+A!!"B-B0F!!"B 8!W9LPZXP00@@1%Q(30@C1
M0&B*1B&$$'$B,2&$$$(((82H"HD)(81H$##P6@@AA(@3B0DAA&@0+CS[<O>J
MZ9\KVPDAA!"EZ/5R!V%8""%$A?3JU2L,Y0]_=5LA:@D$+9Y!^O6& EO7TIVT
M74L]GIEZG3<);!D0!J6D@L2$$$+T (J)K/\!\<G#'T61;=)FH-&PTK5T)VW7
M4H]GIE[G30);!H2!Q(000B2(6B:$2(:T&6@TK'0MW4G;M=3CF:G7>9/ E@%A
M(#$AA! )XK=,I/F/"?\PE$O6_RB*;,/?4EI^4_S]Z%JZD[9KJ<<S4Z_S)H$M
M \*@E%30 &PAA&@0KKGMLN"/1+E.""&$*(7$A!!"- CM;7O"D!!""!$/ZN8D
MA!!54FB\1%J_ZB];O-Y-GSDVW!(BW:2MZPB[?.A:NI.V:TGZF6%Y?7C>O%),
M+JAE0@@A>@C_:*7ACVDQL&C=CFVMX9800HAJB'K7YTE(5/HW32T30@A1)7;P
M=2V^B,7!HH6KW*PYD\,M(=)+VGY3-!9U+=U)V[4D_<S4XASUQ"\??*"6"2&$
M$ &CQ[>XM2LVA5M"""$JA08V_')<WI&8$$*(!F+4F*'!0.R-&[:',4(((<H%
M7^LK<5?_[J/AD?E%8D(((1H,#,+>W2$H,"!;""%$,NQNWQ.,5<L[$A-""-&
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MA$ 503+/WF?.F9R9S$QF3C*!)-_/6F=E<N;,F;W/RYS]/WOOLP$,2/9"Z9\
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M71[Z,G^^O'U!, $ .40P 0 #A_<;WQ]^ZY/QY\N[%G05*M !&P   $ @!!,
M     B&8     ! (P00   " 0 @F      1", $    @$(()     ($03 !
M0-X8$Y9]'K?W3&X  /JJQ.N9_UJ7#,$$ '23-\ /@[P! /JZ;*]I!!,
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M^9\JZ%-/;^H)!!, ,(#83H$ @.ZQP8.=;),F&T0,_?#ISI.;3AT\\ 8')9@
M@ '"/E7DU;^VNO\! +)E^Q'8:>:5RYT^:/9WU081 ZE94R*""0 80(:?^2&]
M_=8!]S\ 0#:\SLDGZH,VC@>""0 80.R=M /[WB6@  #T"(() !A@;+6\#2AL
M>U\  +J#8 ( !B ;4-@.@W9@)6HI  !!$4P P !E.PS:$5KMTT?L$TGL9&LK
MO Z&  !TA6 "  8X&U38F@H[,4(V " ;!!,   ! !KQ:6VIO.Q!,     !GB
ML;#Q""8     !$(P 0   " 0@@D     @1!,      B$8 (   ! ( 03
M  (AF      0",$$    @$ ()@     $0C !    (!"""0    "!$$P
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M0;[2ZT_Y2I<7@@D     @3#.!    (! ""8     !$(P 0   " 0@@D
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M>[5IP2+M*O^_*G,Z5P,X41!,      B$9DX      B&8     ! (P00   "
M0 @F      1", $    @$(()      %(_Q_B>] PY,HJP     !)14Y$KD)@
!@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_61.jpg
<TEXT>
begin 644 image_61.jpg
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MKE>4#KPAGFUM38I[F/P??: WIZ]O0,]"G&'>5Y0'U!5B"O@.H?*#/&ZK-@8
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M'X:'<>FIC.&H990_7>H8'*Z1O656PV6UXDH"/A.986OIS$D!CEA1BI"N"58
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M=Y950Z<\K/1T8;SLNOY@^-W+_52NT$,I'F&H5NE74IDHT1/(7D&M;3:N2$X
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MZ!);N6:=+5BTU'*L7F-H1,:B4F+_(4"9XL'<"^33/X $A\1RU6,])YVGYUX
M/@ BI8\#HE:Q?BO-:CG+,$H- X0JDCLCPT8*LFOOP."P[=Z[WT9]:3O&MR!#
MSYX^84Z6;%I=KO@0=.#2>#$83($ >H@FQB:LYVBO]W 5QP2] +.\DPP,"1_N
M.6"'>P_(?V6P#[>%(3\?2DXF%L/UB.I9VS/$,#=E8AH32Q(TS7H6AOBF<D%Y
M&[E=Y9C=PD:'!A0O^5*D] F@EY7NE59KR<^SX>&2'3HLD%16WBK.7M2KI P&
M",T ADI*6+1/5N"#?KZ,TGI@9-1V[-YC?</#UMS6;GF5+4 3O7E*%+E2'5'Z
M!<8?ZDP"O,BH1 =%(!!U %11@?--#/4[YE_P+_H;PJBRRD^X#SJG&F;R++!B
MXGHUA!6)9W$9?Y6F)HX3FROFE'99%C7PFG04&*9'E GZ.>6?4DJL<J,ROVK9
M:ENY88.M6;_.-F]<;QLVK+*!WJ.V>^=SQF[<]/X2]WB%ILC0H :=111JSO-
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MEU<A_^G]G(R/'T\R-"3 U>JK\0!'18%4/R@7\T_>5SD\FL+RU],LQ<0+,.
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M?MQV[MII!P\>\L-%!P>&W+ C SP@PQ>Y?T#/Q?C/V7*4$PSBP8,''9@<.'#
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M];D.3/IF919NV4R.X1*6AF,8GGC\";OPH@OMPQ_^L*U;N\Y[F>(>/?FZ[0E
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M%ZH#-UA;=I'9J.+?!H!7W6A,H&[0.48-,"1">3&WY?X''[!/?_JO[,UO?K-
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M&&J?ISQB)W2^H"P3"2H3#S)6G CEB]Y%XLF]SZ]3?C$\RX[MK#);LFB);Z=
M3V4:E#"',NX0CMB4>.H"D\G1)?12QCEV[5WSO0QZ.8CID40UA#O9XYK/3NU1
M]:O^8N,DG4+W/?PS[UGM:&VSS>PKUC7/!H;'K4]A'AT[8@]MO\..%+?::.60
M7;EZO7W@FM^R7.5Z:\TLL,J8&E.M:B0TP%"#SD&:<S#T]'-/V2?N^T,;G_]3
M:^LHV!O7OLTNZGB)*OU"&\U+J<HP-*E253)LQ!;VXS@><6;S[*F>V]":W;)E
MB_W9G_V9??"#'[*KK[Y*AJE.*U;B3)-)*3C;:D]J8\I.A68/AJ1 U5K?^NS6
M &($AM[^MK?+H ;E74O,>2#-4<*L*'OTT4?MOI_^R)8L:[6"K;.GG]AKNW;M
MM!>_?).][>97"C"UR80OM$I)!B0S:D6?_#X[2K=BCT44SED;Y1,DO!T9&K%G
MGWW&MP.X].)+I<R;?349![/69C-IP^J9>+ KQ&GST\CGM(3GZ=Z@>KV:1+!L
M8_X-/4/9;-[NO/M'=NN/OF&_^>'W"X1U6&MKEXPP^1)6AWFBI*C>;L21'!35
MN)\-(?5LTYV>1B]K^8(# <#0U[_Q-7O\\4?M92]_F5U[S;42$C?LSQ/.ZL)]
M!(Q3P)#"C&D[<V,BW!^/6#$W2Z=*?K2(\L%!::?W$/WT_COLBU_Z>]NP::7]
MROO?8QWM,O@"K#XQ&Z$]E<2 (3VC9PC \^RSV_#1&Q?#(X.*<\Z/*F$CRJNN
MOMJ7H=,P8+^A  Q#/-DO*>Y?A>2D%WJ)W>(!],S;81+_A !GY_P%?A^^#V7,
MP9W<U39TLGYHK>+GZ1Z>D2X _73X#),]]<S3MF_O7F\D+%ZXR!LVPZ,J[TU-
MUKFLPX:;#EIV?J\-%??;%:O6V_NN^C6Y?:&U9Y4VHV9-+9*_ 88:= [2G(.A
M+3N>LC^^_;]:;]./;/F*17;+I1^P2[I?9N.C;=9?+JHR96Q!OET5M-7&BN%P
M1!3IL>C4P1 ;TXWY65S_XT__QR\M&,(]QMZ7)TLI__2G/[4G'_^9O>JUU]N!
M77G[^!]\4@HT:Q_\M9OLM:]_D<"!6M "L><R&!H?';>]>_>X$5^]:K4;', @
M;SW8:M@8&:5S8LCCBS,!ANZZYS;[VM<_9__V([]E"Q;.L]:63BN.4Q;#4G 7
M+T4-,%2?YA(,D<S,&>(XCOL?>,!7E0%:AH8'?$X:\\S8[),]H0#>I %I0H]T
MI'R>HUWDH]ZQ^HPKO9(L2.#WRA4KC4-0\;=CW@+7621(**^*;^SI\?(Y21/)
MN76\C^J>)&:7=M(ZEA_%PACL]ND!2CEDI7\4,#0A=_-7=IMU#]K\M0)IA3Z[
M[+RU#3#4H%\8FF,P9/;,SF?L3^_Z?^UH_H?6-:_-7KWR)KMAZ1O5\EAN%99F
M%X:LM4A7.I-%I9KBG!T1E=XW:>,^5>&E5I.[V="D<4H3"NJY[=OM3_['G]B'
M/O0A>\&5+_!EVK5$$LP=&"*.D_&,E"3!%/(TJ),_C/T_N_U9^^S??S: H9O?
M[DJPUFTP2&R@6/))S"C&']UVF^U\[A'[K=_\5=OR]&'[R/_QAU+*6?NM_^VM
M]LI772T%+V596BJCU:&/AP2&IJ_"JQ\#A9<N=E51TGF3DB^YK57R58J/<2?F
M9W5X]1AEEC@7!/Z.]ASUE6ST_*Q9O<8Z6CML:'3()UICP G6C_)(ODO[&0;3
M"%..$CD(N0HD4C+7!T.\U]<"0^42>S(UV5UW_\0^\[=_:K_S[_^5K5VWTEJ:
MNQ2A=D$A-AL,O07I,GA<,!0I=7L\FLDIR[9K"5R+X08$<;H[2ZZ_]>UOV<./
MW"\P]"*[[IJ7>6)7!#88?D+E(%:(@YC[X)7BXO_[_4Q@J.KX.'1B8$@PH#PN
M]^R#UF)-N5:[][Y[[(M?_JS T I[__O?%8;)!%C)W$JUK")1B$\ND[,__XL_
MM_W[]MNK7OUJX_B/D#<5WRR2*WK&P8;*'> D@*$@Y01#K_*'R?D<44)OT*%#
MA^PVU4. Y@M?]"(_:H6ALK;V+N]Y(@WC/#(?FO:T5:,&T)R0\*>[Y5D:,!$.
M:3P)AL1Z#8"GW/,-?K(;^[CDZAGOLX=WW6V]F6=LJ+C/KE]]OGWHN@^K<7:]
MM106"G25K:UE<LY0DID-:M Y07->6AE^8/\6=HAE?L'.W3OMB2>>L&>W/6>]
MO?U2""BE,)\C5MPIA 5SQ3KY=SK(%8KK!'H$4'9G ]67 D-;RXD^G4;X$%K@
M,4[U'?L[I7ELL?J&=X6\[=F[U^Z\YUY[XJG'PX9\!2E9^<?>0M@R0%,H1M'?
MJ5P%:;6<<H-\4<9(*/DJ3_E+?YFP_G,OL4B) >5GO,[(^H_RTRE#A;%BL\@C
M1X[8*#V2^F-.AAL8,08,PQ&6P.M;!0-33AUPA&"=0JE,_@@CX>I'*?:-\O0*
ML9ELB^> )G;Z+;+C=2[9;1GC))<^EPJ_9DGI=#RA[V;@&9_*?V)25#KYG"^5
MHS O+,0I4 00\4%RU:6:3LGO*<]27/WT-)/G 5U.E$/RI!(:#)ZUR@"NR8_$
M=20$"N67>-.3PZ3[BRZZT*Y4@^J*RZZP*Z]X@<]'.W_3!7;)Q9?:Y7IVR467
MV 6;+[!-&S>+-SE?<N$E=O%%%]O%%U_L[\[?>+YMW+#1>Y58ZKYJU4J[\/P+
M;>/&C;9._FW8L-XVK%]OZ]<%YIN++[Q(?NO[\\^O\H;U&VW3ILWN9NV:M55>
MKV_7K5_G5QB_SE=X%U]PD5U\_D5V$5?Y=^DEE]BU5UXCMQL\?=B+B//MT,]>
M&SQ-R-U4NIRA?&I0@\X4U4$;9Y@P JHT*/XQ-M\;&5:]84GUN!T\>-AZC_9;
M(=/BK4R43U'*M4&GGQ);G.**3T3W'A4!0\XNXRRKX>$Q>^+QIWT_H#5KEUMS
M2]8/?9W@" O+RT#IJI8@1R;4(W3B]+#"N]-%DV *T"#/ 2U>JE#4>G@,9C(J
MQ'$/&!U:XH?%M,0Q\,S7"$=(R'^EBQ]RJC" )E/_>!;,/5[/EL H+G*9E8L
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MV=),WZ2?UWM_7")?/*<34IS<"^H[\T=\+AGE@QXAYN3$WJ'XC3YXOLF!$!S
M$'HJ@#GR*,A=T=7S; :P2WEBT\5%JA^ (LHW%/401+IX&M?)Q\C41?*:L/E-
M?6_BG##I"\H08)-ZXZ*YNSKDZ1\X[7>DR=^3S_ I+,10^+IR[[_UY_K!'87P
M2(>4=PUJT#E/B>:>.RJ5:7&9MQR;6YJD^$NN-'PILY3&ZC7K;,'\1;9G[Q[?
MPAZC",>N98QEK+_1H*A:3_MSHZH66NR./A9C?"-HH,<%P(!FH.NZ=Z#7Y1@<
MXN3R07\7#7<,"Z-,#T-[:[O 7(>%T[+;_5FQ6 Q[@["B0P9O9&S8#3>*R..2
M$.X()\KC@$#/Z-6IY;%Q 2^!!, 7,L,8]5K&+UKJ[&>"G+16VYH%%EI:I%3+
M+C=)":/BF O :=6C$P$@L&ONT."(%*%:KSD!GS([.7,T!Q.M27LI>31B=1AD
M.GE/$-<:A@"#R.>'APHL$E_D=$ C&2-8Y+1YU[Q!#SMY#YKD#7D7>A)X%M[)
MD(E=X>NWAZ=7O"</B^-JN0,J!60(DYVF24_.,4..!0)%Z]:M$Q#<X,-GCSW^
MF#WPX(/*.X%T?4-9=7G$E2EB):$1[DS,7[SJCV$7#!W+K3&9Y0I#&O2FX#%&
MF)X47?E]SA%U58#"F0P@#N2IV._/ICBEY/%;<C7FK!YX7H3R6)<2YVUMK=;=
MW1U6@]$#F:KC)TNAYRG( C")O=]1]YTN(H0(@-(<4Z%!#?I%IF/4[M-/5-TQ
M>@+HAFV2DI>1HT.V7!;8&15HF!BRCO9V!TR[]^VR;"%C3:U-EFO.>P^$5( ;
M$LC'[J,!1-^(N0>HP"@)C'WL9:DRSVJ8S]EQ=ERRE>3]L$ 0[4)Z"_@F;<SH
MC2D7]07_=(4!:OW#@U4>$&!R'AFRT>0=*T5R,ORT'//>8J35F0@NIIN\NZ.[
MVET>A^$PT## )@(?[R61,9%9#IHJX9@>DURVWKXC=NCP?J77A,)6FF.8F)NB
M>&;EAMX3/D?I->6:O6>+8P0&^A6/@0$[-'#4GM[QC.W8M]N>V;Y#X*,LL*(X
MR'TS\6"2;SDO?[*^Y+^60VY-IV)I3 !QT'EPJ,^.]AZ2G <=@+'/3V]?KP]5
MD0;D <,#M*;CD 0>TVM'/,.NTR,^>97?)1DR5L44Y8Y[%DVKY%@FUV0CXT7K
M4=R&1@0Z.9A5H*O0VFPY&2_F3)'_]/*T=7;8@D6+;?'2I;;DO.4A'Y4N *<1
M@59VMX:+(V,V,3QJ8\SI&1(X%?.>_)H.4(ESTH.8<#Q.!!#&_*7>GC[EK_).
M4H=>%7@ZV)R:SPDG!O/YI-A H0S3(U*DKG@O$._(MS$]#X?GZH<8H$3\9D=@
ME-PL>::R5Y?DF(80@ZN <&H7/3'TZ(;A<F27I^[K=)\IFP ?= 9QIP%$P\D[
MQY0W[-M3[1F5>^_9)IQ$G\U$01>(U0AR^?0-.H(AL]G2E'3A=^VSU+L8NRE<
MRBOJ]$1'7:$T$=, :5:]'U>ZH(^(5X,:=*[2G"ZM9\'VEMU/VY_\Y+]::>'/
M;$S@Y[KN%]F;SG^_-;5?9*,R?$V=&=O[U&[[V4/WV(+Y"ZQ[7K=/'CQP\*",
M!'-Z"EXA@RA!'I9^^C51PDYZ%(=2TG*[D:DAW]Y?_.RV9VW+TT_;A@UAM88/
MI_C&:(E#ITIU4[Z@) -AM-T 2%E%HL<+(\6[C9LVV@477&C+9%QC%SE"1MFD
MYQP < X6R[SI\6AM:_8Y*VY@^$L$P7A.(V^U3L;324JJ5&2H:<2>?NIIN_%E
M-_H.U!6%59#J:Y*L^ @ F)#;YW;MM*]^[9\$0O/6V=UE3S[UE WU]SI )2_Z
M>WIL[^Z]]N8WO<E>]_K7>0].6'Z>R 4"F265!,HX59Z]C#C0DF[XG P)!I,T
M&1P<\OU95JY<Z3L_+U6ZD9\Q+-ST2)[''GO,'GKH(7]&7EU]]=6V>?/FT!LF
M-S%]29\1@9?[[KO/#Y%E'@9IRE"<NY ['XH58\@P:L,"/LPAVO+T%C^C:?/F
M\Q5&4_ ND:/N#M3RD)Z!D!_!'13+1CHO"8][C"[SU1@R/'#P@.W<N=/^S]_Y
M/VW9\F76U=7M\\<J*B3T9D&4JVFDX*KQ/0ZEOZ<\UE)=_T6E5/F.A/SI<@]N
MN.W'/[([[OZ.O>:UU]LU5[U,HM$;V21#WJXKWX@=\(V*>1#2]7@$'IE]*9L]
ML>$@FVD"2JG' *&''OZY_=,__9.?)_:!][_?)]*C+IE'%/,O$M_P[!O?^(9M
MW;K5=YJFQW/!_/F2-^1Q.IVGI%="$_22ZSD-(71':U.K&H6[[7.?^YP:BV/V
MH7_Q(5NP8*&U%%H$Y('N2:]XG?Q+4XX$%]7*/-NR4BQ)AZH1M^7@%OO6O5^V
MO>-/V'CNB-VX>K/]YE4?MK[BY=:=7ZJR6[2V%H4%@*^TZ,LSD5,-:M"9H=Q'
M/_K1_Y+<'Y=F6WEFHK+^>@9[[*YM/[*)PD[]FK"-W9OMHB4OL*[.M:$U;V-6
M&2G;P</[_7PL*C\KSICOPK 7%(&'MYBD%$*7>ZCL4484!+]I4>$^,E+PG8,F
MO4?I,P;/D!@'*6[<N,D-$" $YAMZ8R8F)H?4HE'&@ &* "<,ZS 1%[#&L ?&
M$./<TMKB!Y)RFO6R9<NLLZL+FQ44DV2MRBO%0<N2>/;T]GBX&%Y6DZ#T"-,5
MG]SS;52^?.D7]S60NW5_<5?R=%RV?+F?K[5R^4J7T14T/4QRY=WA<KMSSVZ[
M[?;;;=Z\^;9:8)#N_K5K5MN*\\ZS94N6VJ*%B^SBBRZT%[WP139_@91\"@A!
MV<JD#/5HBELI>]+R&]_\IMU___V2D:&Q9D]C\HR>%(8-R5_D(.R8I_Z]C 83
MG3GF #"T=^]>[QGB^^7+EENW $0T$A@X#-W! P?MP0<?]+3M.=ICV[9SFOYV
MWQT8 .HL?_!KYZY=OA/OP0,')$<X9B0LO3]JAX\<\<G5<$_J/C+@[JC<<<_1
M'O$Y*]4"'Y:;0][S=5 @?^_>?7Y]6D \3MP>$AA\U:M?Y9OW48Z\O*JL'K,.
MZE5\GT[KX]$Q_:PA;SC44"R7$&E+.7[VV6=M^W-/V>577F!+EJQ4HT1EV2?=
MAR'Q0(I3ECJ)K'4 ?ATBE-E+.WLB7C2</-64=D1G[[Y]ONU'5U>G77'Y%5[/
M25;J5RWQC'+VXY_\6.6Z:"]XP0M<GXQ+=S D&W=[AM+IE28@BY=Q\EE7AJ;[
M!_L=\%-?KK[J:M<K+%KPU8WR#MV0)ORN32":/"'L2=<SR1 I77Y\.%QQ.#)T
M1(W9)VR@=,A*V1%;T[7 KEI^M8U5EEE+ML/U:B&O[WQN*//"9O:_00TZVVC.
M>X:>W;?5/OZCW[7>YMMM\=)Y]M;SWV'7SGN-C5=6VVBI:+E65:B1G)5RK.@2
M1$@4#\: W[204;:TW%P;B%CVBKLXCNY7_55;7RFQ2\4 +G!754Y2-/D"NRCK
M1TP-A5%26!#A1K=I)1%E\T>IYY'H5:"' 3]19BA3%"[R,6\H?!^$*Y4"<.,=
M<V$P*JA'>@L\W?$^B4>,UZ1J$Z5ZAMQP.E4$*IAW510H:W6P 6C+YZ10U8IC
M& LJZM.2^/Z?/VA?^LI7[*TWO\TNN.@B'YXK9"O>PD6I%\7-#/4)]!&WH'@3
MH43'ZQD"4%1)2I/O/_8''_--ZG[S-W_3)YX2)T\CQ0$0 IA@8O/JU:O].8"8
M^#5)!H#,E[[T)>\A@GRNAN2[Z;6O]=ZDV,O4WM+NPUP# X/VH.+(R?/0WOU[
M!809@@3@$H\0%^X)GSR=--P2608-  AYGHA(!8C?GA[)?7([A7Q>DV3R;$O>
MXY;A2 Z)I4>*0V8???01>^211^P__^?_[#UBG9U=H6>(^I&29QH1;"+73#T[
M]2B"QME0<0; &\NDEUL%_:/;?F0_N>O;=LO[7F^;-UUI^8SR8%3IE6M5'-BV
M , NM]E1.1=(*D_?X+0>G;F>H<FT<_VB/^:)_=,_?=56K5IE'_C !QR(A)XA
M#/U40B\TY0OV=W__=UY&W_/N]WA=FQ@;]W*#ST%GS4P,Z2(#>H \B3U#7_C"
M%SQ=/_3!#WF/)F4\DPFKU-+Z".)[.*T;F A >4@_\]*:Q+<>D0:1RF65\N;6
MFIZAH_:B%>OMP]?\2QLHO\"Z<TM4CTK6ULRP9Z-GJ$'G'LTY&-JV_UG[[[=_
MU [G?FA+ELVSMUWP3KNJ\U56S*R14<Y:,3=LS:-2E@4J%4J&<+D-8_* !8PA
MRC=6[C08BD"#RH\R<A"54O;91.%X7)+'](I@^/&MZE(_\O(3XU-UGSRO4O((
MV28_G"3"!MC$]_B%G$7)B$=IY9C)!*!$O(@GWS*9EM8F0:>57I2%1QB2\$-^
MU1@JWA4%_@B/2<B ,;[5G54F2L9F^V1_!$,_?^1A^]9WOV-O>LN;;?W&C=Z:
MS92+ A-M\D>Y)R5-FA '_)F4*81[(F!HK#3J+>B/?_SC=O3($?O(;W\D ![)
MR%$@*'SRE\-BZ1E9LW:-SY7 *#A($QBC1^<[W_F.#V=![/B+(7KM3:^U]1O6
M^Y 3<>AHZ?2PMSRSU7M>+KGX$NL2P)@H"1BK/+!4OIJ_(M*>U OB!IGYG^7Z
M\3ZNKO%Y6TYZFGA!?D?_IE8OY8A[&H!@)$ 00X[,NQ@<&?3>N>\J'W[[([]M
M2Y<UP%":SEXP5+;60JM]Y>M?\7KQQC>\464Y+V SH?BJGI7"'*IC40,,-:A!
MSQ_-:6FEBA(@1L4W\BJI<JK.42G=:.@9E=25#7BAI%_42>YQ)XWEO2MB%$OU
M7H;1F9:[7_.6:RI8OKG)FEM;K"!C&CG?W&*Y0K/<2*'DI)1A0$CBIU_Q%S\*
M!6>62U>DG)QEBZJLR,!E9D7.0&Z\$@6%D<58HX-<8:44&;]1>("G8(R#@6&(
MD(F8S/M)3[R-S*1;9U:K)3PT,N0\K.<LD^]L[_)-_'(YQ9GA"'FO' C)BBR$
MI?3O9&?P]@X'#%NW/6-'^GJM,EZT<?E)%#FK"(- FM=3I/A5R^F4T<\J _+\
ME/F)B:1')*Q^(PVXIV<F ,*RKP"CEXC]=UA^GA6SH9]"\-]-31GG0A/;$7"H
M)2O% %/$4L!/\64%7E]?CW5VM>NKHHV,LZI/Z9TL4R9?(A,F<GL40V9Y?,$!
M&!3>>^\=WPFP.@M0,0$?=G\4+YAY99%]0K="I]]2N>Q,/#EZ 0 _6ARU%I7/
MA0L6".PU^;,T,92#9/A!":G'['D4]CVJ_[X>NZ&<)=<E'HLISUXN2#<]\%XP
MY4&E3'E1/4K^Z'EC/Z50N:E$*I/^42U/)X)*RWXRG(CK/!G4I(L@-TQ/<U ^
ML;P%943</,*Z#^0-&_VDOI/OG$/&T+M>A#SA&\7;ZX6'S)/@MZ>#&!U(^@1*
M4HNR5WV6A.,WX9(F'E%/?<L,>1E9_T)=%/M]\KMZG[ D3$21#M2]FFUB/?!H
MJOSKN9_+YNE3DM^Y,(>LS)ENE#GB@WR1&]2@<X?FN,0FU9H*"_N34-?2QI55
M4  !3!G_^YTJH2L&L0.@G)X"7L3AN:XI,,-SC!8M\?@=C,+A["U6]L256CSS
M3?J2GAE83MW8C3%7",-6-9;AFS1CP"??3S+DO2OR"^7I\BANM:TY" 4*&(B
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MR1_* &'I:V?^][E*GG<!L,4T\@GA'>U>/GV2=1*F__'C.%2;7O )41!Q*I\
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M::V\4UD$[_@T !YR\7O1;(%0\ND4/B&J+7.3:94F2EDQ6_+C.]#!^E]/TTS
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M]G:[^>TWV[O?]6Z[^>:;[?6O?[V]YC6OL4V;-EI+*_L,97Q8EQ+/4.YLAZH
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MN;^WO_Z;O[&[[KG;AL?&+"?0U=[1:4VM+5;BV(]L7DJXQ5>Z4%8\?11\H4D
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MTO-+_GD>RJWWJNBO6D:2,"*=*E"9F8A3+4\GZG_0IPDG]RX/OZ4'*(?N#IU
M'-RKI%3J/YS62Y<&->ALISEO9E*!4$X3/G&6R:YA!]CD;7(-[D(52S\+S\]U
M\K@EO&G3)GOO^]YG;WWK6WT5C"L:*43>Q4F7T%S$&B4-$.%,)\(//2XMUM'6
M82WY5M_'A3D43"1EA1-N3D5QL](%(+1APP9[Q2M>86][V]OL7>]ZE]UPPPTA
M+>0UH,GG3GDXZ50(Z0<QCPEF3Q[DB7)5)3MY$6=%A.=_7!.93HR"S/Q%6K!@
M@6U6V:#G#&-*WA GRD:#9D%*2H9*23=/5O\]-7_\-PV.Y!G%)%V>N>_H[+1+
M+KG$RR1YXLOB^4:<RJY ^M3+'7FD=UQ]>,H=NN^XFB9#+:5*[DF3Q^TX7)\F
MY0P4?Q.O$!-]S0L]"N[J^51UTZ &G2,TIV"(JD,E1+G'RAB4Q2\7T<)DKQ)Z
M74B+[NYN[QGREJ%:7,\'H<3C<0%,[F0("SD/'3YD#S_ZL#VQ]7';LW>O+5Z\
MV ^TA'@_LU(]-O$M!!CB,,M7OO*5]L8WOM'><?,[[(HKKO ]7<8GQGPH T#D
M90<#]$M U(FE D&DP^K5JWV>%H P]&3^\M67YXLHHTTJ>VO6K/'#5WW83(V%
MAJ%O4(-^\6A.P5"F$GJ!RFS?'C?1RS(O)IEP-X5I727L$_/@^H8@IU>SY9)B
M/!MFRZ,S0\S]J%A&S$3?T;$A&Q\?D>$?D;$7N/#S,B+//KYAVB-IFF:>S8Y0
M\&SLA]'M5&N88:H]>_?8KEV[K*^OSX\EZ.SH\-.X+[WD4@<KZ9ZKF4G"U6%
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M2_D&N:6VY8CY0P4<!U\R4M;L2.V[4F. ]/@<)V+&$0[,WR(/8GHW -'<$OG
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MJ"3/R1"&KLH8/Y3'C$KOV(0,I)VW5$^1Z!G"ERF<I"V "'D/'CSHH(AT9\@
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M(H=6LJP<0\'$4HZ>*"43<2<GD(HQP#7LQD3?H)B1.4[N)FU"^5+AQEW"0<Y
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MVT$!8<NO1/8X%,@UWL?G:2(\TH,K;MPK^<F&E!CQG/?&\3[,&\/=R1)?(D4
MH ' A "#;#R+<I!6@+VTO#SGS#'D<L"C=..*O&Q5 >#U2?^ W>2;LY-(B82I
M?P Z_5&&B5.^ &@/@#UK37+6++=BSC0[:^MK@QIT?%*C1K5UEG0JR@9"J1_H
M[[$_^,I_M/XE]U@NWV^ON?BU]N+SWF+-Q0TVFBM:4<JDH&9DDUK>"$;]\A9A
M\$&MT1,'2NE=7^NVJKP2U\1-+4EX-G%V9<X_KJ)33:<JU9-+1"B$D0['6VVS
MI'0+^WA$G#"6+'O?O6>W_?[O_[YMV+C>?N,W?MWW_9DJ7S34DY256/6"*DGV
MP<$^^^SG_M8.'-QCO_JK'[3SEJ^204&Y<M0'Q&1J*>&R@)$HF.I KJ+KIK/<
MS!),>W8EO513: 9OPW\PD2(,#+3B7)%1+F5MS]Y=]O5O?-D6+UMBKWS5JVSA
M@H56R!5L:'3(5Y-AL <&!^W11Q[Q.5>K5JVRI4O.\_E#@(B^_CZ7A3+*=@;?
M_-8W?2-)#OD$"+'DWH>H9)A<'!&BDBX.G%*"AV,_@M&NE@V]CG&-914"  0P
M$5K\D?@=AOKD-G$^.CQL.W?L]!W"5ZY8*1!4M!$!8^+ G"FV7N!<.88%&?[#
M7P#"V-B8;R!)#PGR!M V*0-SIMBN@2=1!M_I?'S"A]^(-X"". XK#=>M7>?I
MA[^^]8 *&O%(QTLEAT@DOXY'Y*D O\($[)%N3S[QA'WBDY^T:ZZYQFYYSWO<
M%:LL1P5LB4<M\:Q_H-_WSL(=LG&VWF<^\QE[C[[G,&+B%H#N)#BL$@V YX$B
MJ,NH+*L4Z";II?*SQ0JJJWD;4WD_/'K OGW?9VU[_QU6;#Y@MUS_$;MIWO^N
M),Y7]?1T#="@!IT;-,=@J&+[^H[8GW[K_[$C\W^L)SWVABO?9#<L>8,UE=;;
M6!XP)*6BNE@HA0FZT7##=$4'B#0+PGT=>>N"(?D:)PM/DMS-VJC*[2S%.B%*
M@R'%Y5CI?Z; 4#2P&"9ZA/[@#_[ +KOL4GOGN][AJZ72QN?$P%#.P=#G/O\W
M=OC(/GO_!VZQ%2O66"[3;I52,ODVP^G910%@NN*G$G+53X\3R3?^PY\$$"7>
M$:=03@##,4XQGE.O)#MW;#S(RK!_^,+G[+R5*^QM;W^[[Q$4TX=C#&A1/_GT
MDWXJ/3T\G*>V;-EY-J][OL\=BN=9 7;NO.M.^_SG/^\&G^&G@8%!!Y_3MC20
M]_3"Q.&U1*QJ7*#)/"*NX2[MEC C\)E,4R:IZW>J(0$Q-#1O_CQ[Q<M?;NO6
MKW?@D/7Y8^:3P1]^Z&&[[V?WA55SBB,,2  (<<8=H,=[3!3^I%P*36&%>6C(
MYA</G_EJG(,%T.+ 8-)FJ'_ 7OI2CFEYF4!ED\M=KA2G^7DJ8 A?.!CX4W_U
M5W[DR[O>_6X7K+6EU<8$AA@231-QXBRY)Y]\RH$L6PX0=WK)MF_?)C!TB[WJ
ME:_R]*17%7D)9PH]3V"H2JH+6< ]0UZN( (84@VT<57DPV,"0S_]6WMN\ Z;
M:-IOMUSW.P)#_TY)G)-SE5M],ET#-*A!YP;-.1@ZH-;O7WSO]VQ?^ZU2=(?L
MK=>\S:Y;_#J!H74"0^,"0Q4K2"\5BBVND!I@*(F#XG*L])\+,,3RZ3_ZHS^R
M*ZZXW&Y^Q]O"3LDIXW,B8*B<:;*!P1[[7W_]EW:T9[_]VF]\T%:M6"NW'0)#
MK22J/A[6Q^-2T--;X<A5/SU.)-_X#W].! Q%"HY)]@R39_1^S^X]]HE/?,HV
M;MYD[W__^SV-65H=>PD.'SY@1WJ.^HGT;"O IH6# T.V8,%"W[H@@!)Z8LSN
MOOLN^^8WOVE7776577C!A1X6O4ECR@=$3<_UP.CR+7+'-(GYYI3<>IHEX(9O
MHEO\XEOO12)PI^"7<\JOO-S24[-HX4('>RS]SQ5D-!._F"R\=]\^WU4<<.-@
M2'+C#A! 3Q$]/+SC?I+T?0P[!J>?\4P\P!2 <5! Z,X[[G" R)$L "W"R&&W
MI\BOO*$\)G(=GT)!/5DP! '8GMOQG#W^^..^G)Z>/,I1FT#L11==9!O7;K22
M_D9&AR5SR,^TO,\_&!)X=1F2^3])SQ"]]0$,[;-OW_<9>VX ,+3/;KG^MP6&
M?D?)IGAD2E:6FWH-EP8UZ%R@.09#)3LR/&Q__IV/V9[V'\A0'+ WON!-=OV2
M-UE+>;6-JC*54)Z5"8&AL!OQ5# DQ1V\FIE2(M:35R),)U7VZ6X5V"\H&#H1
M49FX"@&&!@8&[+__R7^WRR^[S'L^V!#004-5K.GRS0B&LGD;Z!NP/_O_/FY]
M@_OL7__K?VTK!8;*);66 4-\E&55TI@4K'ZXDHW&@F&BR5BD@8''[E3!D.(4
MC=1DFD^&EXX1[ACV /0 AC[^QTJ?*RZS][W_5_P(DWPVYR!CAXPDFQ->+*,(
MB.CJZ/)>CB>W/.URL+$E0Y&^"[<>?.6?OF)?_O*7[4,?^I"]XN6O4!AJ?2N/
MZ07"^/M^1B+$\[E$>C^U?(1[AF6JPR#ZX]M:2L_;J?JAGY[&^I>>&Z.4<B-.
M^/Y<WQ$VLC7EF4,2PB'+B#?SB12JIP^ AO"1%XIA$0[AT[M">/@!$19^DTY\
MV]71:0<.'; ?_/#[UM75;3?==)-Q] KY#T +/4Y15LD@1KT1#N'&.-8C=!/S
MK@!?Y \3P=D7ZA.?^(0/D[U;8(BO.8YF;'3<YRO5$N6 (*@KI 6]?^17L^['
MB^,.BGU^%>^;5'>2>$^F^?,-AO@OD86KRY-U4#DJN7N*A^Q;]_Z-/3=XIXTU
M[;5W7__O['7S?EOI3[ZK/(@;8*A!YRH=%UN<;J)+FXF&KC"E"(K%HI2=JP6]
MI2(BDJ[<1CX!0K%$KD]ICR/_<E&]%)B)TX1!H27.I%D_GTP6+YB7>JZ/31@?
M<-20P#$GH*.),9IN3?"5:\(RJ6+]"1D[QW=GD*:7H1C'J?'TH27]!1N<L>&A
M09?55QCJ(<,EAV3 66[.')KN[GF>CH-)SPD]0LQU&1P<DN&<<( Q-C'F/1]L
M:CA__@*?2X-A9?X10(0\:&H*C!^D!-\Q3PB_ H<-+#'J@ 28^\GWDTQ2AF$R
M,5? H>X]_OH7G\' T%$!DZ&1(<6-84PF50>WH^/A<-GAT6&/+Y.JV7*@*4N9
M"7M3P?1.D4;('($685.NB ]@R5EEC(T+.6*EA33(A"$VCO\XJ#2E=XW-'XLJ
M2X E]TO^>'KX_X@7\BL )84Z Q-?TH?X^&__2C^3N/'GD]SUC+<5_.6W+LYZ
MSJ1YTI.X  R4^KXGUWAQS'M5D9'TP'.%&OS'G[.%*+,T)+@B9/);.24Y50N9
MAZ8W)'.%NN]I0/QC'$*=B=R@!IU+-.=@B$J"8H1HQ865+"6T0X/.<B+?@M'2
M5:W@4R&, 4:'X2,,%<,.^!V)LL%['[JAI\:-6>1H2IY_PEBR*67LL0'< 028
MZX)AYP@.]A-BU=B%%U[HAKVUN56&<\)&)T;]F!, 0G]_GP#10  (BBOU!$-/
M?-FC!E#%O SB[IM@D@9B*,SU2< ,DW-3[/M# 3"<0[[5<O2#W@Y?$24&X !X
M0UY/,CU7#"/1RP$8"_$/  "P% %/W).*'I&1XJC+3"\-<8,QG!%@0<0%&121
M*B,[Z02HH]$T,C;BP!!@P81MTJH9>?2LT,3<(?F5I EGI%&V*"A1IF.Q][J-
MCUN;\@901/H[6%2XS,<B#WQ.E]Z%!IW2G&L2!\(&^,"D*=\@,_$BWO,7S/<\
MP!]]Z3*>*T0<2 _/@^3(%=*,>$\.(S>H0><VS7%)#L8-1>$M!S&*@Q8ARL2?
M'8OX)%%",_'QR%MZM7R\<(]#?%]/EGI\TGI0Z>: P W)=*H;KV,P)H.\2//Q
M".. @1D:&G(0"YULVBDUJD8.Q8IQC51K.*M,&NA]E-3!@/^K^</=,=CSJ\JA
M"N _<8(]3OS3U8W\,1@J)D=FT'- KPWRN;P393MR^+ ;;X9>?(Z5WI8%:@!'
M^$^:+EZTV.>8L!$CZ0&QBDK".O# T.,IZ3(I4P MWLN:Q$'.3XKQD_3&_TE6
M6GBZ3TV[T+LD0"!@1+V%R$L *W)YVN$O^8?G)"3_2T; P*3<DAFW8M[![CQ%
M?!_"R#CP(JU(#X:R #N2R 'ET-"@3U[N53I3-MD!._9$D0_T5C$!G7SHZ>GQ
MU5XC2F_R#%GSF;RU-+5:9WN'?T<^(B/N20>/D\L9XN+I[S*'YU5.")F9%P5P
MI&>+A08MA5"^(S!%+B^+2?J<"E7UBV0@36)O6R1^\YSWQW-;CSQ?77=%\!>^
M]_B+^%^_3DM<&M2@YXOF& PUJ$&!4*3T?*Q9L\;WK#G:<\1[5WC.4NDF3K'7
ME27G?B\CR'UD# IN?6@H 3%5QI ?@P%T,#T!A D' !9 EP.2Q(Y[3\TQ./04
MY*RSH].-.0:&>24MDG?'GIUNG%EFCE&=B3HZ.SR.@X,RZI(K L39 -1?-L(0
M UA&!'XXS@0^),!YX.!!&Q'H(0T'!'8&!7Z8Z!SSF33E.C(\X@?C'F6H[> A
M/T]MVW/;==WI<[[V[MTGWFO[]NUU$,50'&" _* 1X50G6P V/ <\,H]I8B(
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M[N1=*HK:V=!0TI'\") 0,Z_8]:/!.NT0HNFEH7GV_,"TY3_598:<]76#)&M
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MI@NB80=#,#14Q/&?'_X7,2\8Q1D4,1$$0WQ]*X@X 60#VPN1%/U%PJ</PQG
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M0I%5<"R?YP@(]JA!@X3M$Z O1:ZZ($*POA<I#)*"]@LM6FWM" <=S:H#-'0
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ML]=Q0([:PHB:$5X/M%-RF9I7RB0K(TOUV:D\9'F[RY7?DR>/NP'UE*E3?)&
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MC/P#C,K+RJVLK-2G;CAQ'T%#'&Z4K6_)X^^B[$$;%LJ;C1'SW(XGM;T 7F)
M$#NF<=BH4C_<CXMY_9?J)W9\R_0/JZ0 .AC14^<<Q4%;8?=J;ZOR@\$_[SS
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M7G?77GNM@Z#3#:>5WBS_%C]Q6:%%(&^T!]5*R,]9*+7-O]LI"/?0/E/;'V6
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M$'%=M7J5/?;83^RV#]]BM]YRBX09H^!,WSDXC*!SW(8D+[? 6C4ZW[M_K_+
MV6*3!)ZZ!5Y*[*57GK:''GK(!>'?_NW?VN$C1WS?&4X>C\GKAJL<>]$LF+_
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M[*:\?-D*JZD987/FS-&WL5 >/#V!249Q>&4&AYT8FIMUZ];;GCU[_81Y1IL
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M5<%6!Q#YDY\\X)JAN^[^A#4UM5I)486U=R2\CFDV\<K! =,%#: 98KJ*[1$
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MQ>H^7WZ8,F-_&1SWK PC#MHNHWH<:</(NZ&UT8UD,?8%++'YXL$C!ZVCBTT
M([LF1<'T"5..G*V%:VUKL:[N'NOL8JI/S]N;K$5AH3GPD\Z]$<3=-"6-OZ-$
M/5&WU"7%$59812^=^*&R]K;TSI<7;= U2/PIH6@O^[2U82!VE<;YP.HL[ITO
MK32EZ9VCX05#&K&Y$,DJT17!!M-"TQ!6B?@42$^^7%!W#Y70-#%*#$M3T6 $
M+<;%D5@#Z3G#,>H<R WD=^BN*_-,IURYJKJ_NWA2G$-U*DNE0FDA-8"2' D@
M7-!<! "K:P\:#,J<WY0'&K[V$,8 Q%8$W:HSPNE6>(31U4F]<:\+ J2;]P(T
M"!&5<8[*)$=QYF04R'=T<&DT8DTZ"9L< 9;@!+SU#)?#_C3XE_#D.8X];#PN
M.<)!2.'\4%#\Z<H]CM&\8O*IK,[.'H$5-F"4?[4]VA]3;SG9^5X^)45HG,)I
M]81=5E)FE>555EI4I+3D6%ZVG*XY #1]DY6M_.6H;V3F6VYVD?<-IB#)#VV#
MP;CGE7K0U0-]I^B,=H\[CP3)JP,8N2$3^=<?TY'"02HOIB5I-X#(=NOJX4RW
M4'>N14.;!A^AK 9*;Y)']#K"\K+5/P@ &[>)^(I-$,[]112#;>\+*80?MH10
MX Z^X7O8P+%:DNT!%* #:_PQS378P@UB&H@'#!3O0/YPE(@[[L_B!DX!::"-
M*R_D6_["0\J#LN%!R.=@?3U-:;H4:+#V_S81G4?"18S!1^TQYTG3[QPYDQ=S
M=?DE@MDB_!$.89^A("BPCV%Y->^2PD-_?CI]]#P\"7^QL!K((="()UZ>G]RD
MKI\@<C]ZQS5V_$:8(33YK1#]GB7^:#I+\DO\X-7\W'R?4L.XE>,W=NS8;L>.
M'[?FEB9?881@].F2O. /VQ//F\*C7[!_35E9N1M:$S;+N"7F/<X@[-,4$X J
MKI^X#B^FC.+VX<!'X<5MCA!I/Q="?,\*1:;V5,76TBR _';5(^W\+'^AUUT(
M!4!(7D(_HH^HK!SLI2E-[PT:9C 4!&!8ZAPZEG.:-/W.D0N82.#DYK(18JNQ
MOPL @&6_OHR8]B$"B/BNT>+"/'.#T11!Z'Y3'7[Z._WQ/6$1ASN!&\B9O/ZX
MXF(@%.(-KAN IC_V0G+MD](<[W2-4.CJZ7+0ENALMR8!'TZJ'U%;ZZO)=NS<
M;H>/' YGEQVMLW:?#N/L+ X#[?!\M[6W>9I:N>J9[ZDDEY _M!1QVM+42TR9
M)@&QZABZ<*#1VSZ*"XM]PTP,W0D;+64<_OD2[0@ 3(MG ,A4:[P$_JTF;^?]
M^T*JN\ \>%_5M\ZS%0Y$?X@W<$Q3FMX+-*S<E4[%OB_L%X)A)(P&Y@#Q&\*8
MEGMG0/IB*-W7M0&ZAJF5X :C6"6=ZLY&9V,H277_>?!?&&YL-X!P8P.VC9LV
MVIHU;]K&C1MLPX;U2;=^G:[K-X1SLC;T.IZO7+'2UJY9Z[_7KEUKRY8OLS5K
MU]BF39OT+>%LL/7K0QA^E5NW=EUPZ];IMYRN:_4-;MVZM>Z(%VT&2][7*=P-
M2M.RI<MLUZY=OJR>Y?5H-+P8+I"Y0F[;HUKC"(JRTC)[_?6EMG/73CMXX*!O
MMBC1[Z/IN+P!'@@J-/$MS<U>[O'^/3$H"@"F]SY5,'*/UL:%I\K=5V1%WV+<
M2@-",T-+ IP0;JIS32;UKS^6\[,G##9";&K7UMIF+=C^='99KM)\Y/ 1JQ<(
M*L@KL+'CQCDH0BO$*C,VRR-' !PT2AQ6R^" WZ0O[%.3'\"6XB4MGF\1[<6U
M1(.-R!5PW$XOE"[V^_.AN/^DNL'RP&_?RJ$G#*8PGF?E%]^PWPY&RMQ?#&"D
M+;!B#)"%H*?<^3U4H4_;Z$,T/SG:&NU/U>EU2GBT0^+SAQ'A#]<_G/AYJAN0
MHO@&=1=(I"?^\WJB_7EXM,6+"#A-:7H7T3!ONMAI]6T=]G]^^0]65_Z"]60>
MLAMGW6 WC+G#<A.CK4O,+2&A8]9A!1T23&)^?J(RGRIJIJ<'9 .L6AHB#01^
M!@9/BHPY\7Y,.96<>9\GP11AXF@!,+;]Y2]^8>L$5(I*2UR+X$:S490LI\90
M-!CYAI$KQ!5&#>-G.3&_&6W"Q..=EF/B'M 0"U2((D83D[HL'6($RV&AS4W-
MKI%P$&#Y5G?TF)6752C-;=::.&4?_-!-]LG[/J7W,$9]WZ.1+\XY)&4)DP_W
MOEPXSE *L85_7=UQ^^Z_?M=6KGS-QHRKMC_]TS\1T,H7,&A7&>5;5>48*R^M
MMCP!YIZ>=KF$;=FVQ39OVF;77'^]K^0B?_PE2;\S/0U*@M*?;+.^\BAHEA!$
M.5DYUM32:%NV;O+SR=AXL;2DU%I:6T)Z]<]!:Q0VL#P#X:OP3Y\Z;945E;;J
MC56V>M5JN^+**WS7Z6W;M_E.OR^_\J*-&3/:;OW@!VW"N E^OMF&31OLN6>?
M]55EUUUWG0M9C+1;6]E#AP_4^B@  /_T241!5/R%322[VWOLV1>?L9_\Y"']
MSK(__(,_M 4+%WC=9*JL$43X'5 @DNPHOQ?2-J&X/0SZ/38W0R':Q<"]]>R4
MD@>*GC9.VZ6=,^U(W?WK][YC4Z=,M9MNOLF].8@1F*2,>'].PDZH'_5D=KL]
M#W$5%15;DP ONSG_S=_\C=UZZZWVN<]^SML"0)6E]?1+M'=*; A Y<56#7P/
M".8($?K29K77;WW[VW;++;?X:D+7"NF3G!SU"WV;RH\ V%#_-CU076,0W9^P
M#QK@\9 )(VK")0SGM7$22)?:Z,'Z_?:;UQZP@RW+K;NPSCY_ZU_:U;E_*<],
M5>/@72PJ"$0^TI2F2X6&==-%^&-"S&+YEM>L,7>/8F^TB37C;6+)##^. P')
MV6$9&9V6+2$*H_%EH# -_]-M"*H?#3U= V=AH$X;.,M9\WR!?9W/8. ,L%:O
M?L/!QW7ON\ZNO/(J6[QDL5UVV6616V3SYR^P.7/G^ 9S\^;-L[ESY]I<71&0
M7'D_;_Y\6[!@H<V<,=./M6"G6W>S9OIW"Q<N]'.1N.+8ZX9O%RVZW!8I#ASQ
MS9T[ST:/&NU[Y0"@0A%DN^:FNKI2 BG#2LN*;/+DB7Y$ =H2EMQG],  8>2
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M/Z-]PEFY<J6O\F*_(@>T)#@J)Y]U&Y3(<5_BB6(*&A4YGC"2)CS*QC4J*D,
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MAV5D-5A!1Z9U9$@8RL$8V(@QQ'YF9V/$>C;B^_,FEP87U['9&*X_.</3'U-
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M,23"'R DI[P[L/!_H2Z@V :E#ZF< 2A>']&K@?HUU9%L>BE5AV:&:49LG2#
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M(;^D2W'SO?QY0BZ"*,\8Y! >]P/UJS-(KVD# &]66XX?-]Y7*M)F >S8AW&
M[R?NO-/^Z(_^R.[_XA?M"Y__O-U___WV1=WCOO3%+_GO\(SK%^WW_^#W;=+D
M2=[6 'FA3:#YB:(=)%UQFL^9[K-0\GO]HWZ(ER+FGO;)"P_]XHH\36EZ5]"P
M@B$Z%NIP!!@C*WH6C)L>Q;NWLD\Y,X7A]G/O!(6TP.P#PW?FKK_ O$/>W3;
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M*WY'("%-;S_!OBAK5B/%Y>ZC\ZQ,8U- F*^?Y+YQ@^W:O=/O 26C1HWTJ0#
MAH/9BR$E H&?6N4  :8\&AH;7!L#X*BNKO'G ",8,%.*  KV/KI80L"A@>+<
M,4[FYS>V0X##G3MVV"$_<#3#P;NO6E)Z*RK*[9EGGG4M&<_1)&'HO6#! GOZ
MF:=]EV2^]Q5A"H\3Z'?MVNDV'V@)_ #6U&:N>[1WA,_2;?;JX?L@F$,:T_3N
M)W@96BP :EE)F;%RD'XT9I3 3&6U:QVQ#83?96>&'>&Y9RE]N,JI#<3 /KX/
MH"--:4K3VTW#"H9< HII<%Q"#ZO&,.[+;'=A '-@#Q4W9@0<:>0L<>!R@_UV
M,GV5V7DD5]^$E6G]W#M,Y <&AY ESWZ-1O7]R:>B,O2_7'>*Z^E!VP$8@%%&
M3@&'T2(Q!")4-Z;FZJY'OWM'V:Q&8LK204AT97H,$ )39RFZ&QB+L4\8/\&*
M"XO=U@G;)E:V0/B[4$+5CB:%O6C02!'7P<,''$@@6&I'U@J$%3KP0',#0, N
M9\*$"6Z;0YHO1EA0]N2YHK+2KP<.'G1@M'#^(KOJJFMLP_I-UM(<]J]Y?=E2
MFS%KIMUTZZV^:>#^0P?L<%V=O?C2BPX,;[KI)M\"P ]BW;_+5JU9;3EY>?;1
MCW_8YE\VUYI;VRS7[6=HSSV6296IK;-/$)L3$@>&P47%I2KK23[=1_V0O]!.
M\$^'55_0MRR^Q/76]CM 1/X6)2#.3ZJCQ;+2U-L[*T][T/Y%4W442.3';^@7
MM'"5%4T"_M(##Y!?/0I>(R*LN$?$!L?QMZG]QZ>8N8:WD1,I3=V^PSBA]OK
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M5_G!9]H[ $@M?N9=2PM;-K3+;Y.O_*MOK'?'.6),1:$1HLPI>XSV^4W[9U!
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MY(GRHTU3GF@%<&BUF-I$>X&VHKIZA("5@)-&WMNW[;"77GQ9W^3:]!DSK5B
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M?0/XJ:@0 -"H&L8+\(#A,1*DC$*Z<@6F"MT%@=U;=CZ:/(OK0_J,LB%\;"L
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M''_YRB;[(F'[06/J4*X%G"A7";:XC;"+-P M/EY#J0R@2FG-TG-&^WU(;2^
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M [1B"FW%?%D]-C]HD;R/Y+(?5=B9/!5 \1M'VTKFW0=)P1"<O:SHLVT"':P
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MLMV[=GI<38VMMFK5F[;FS77>+EK;Z@5R"VWQDLM\M XPR,K(5:A#:Z>#U\5
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ME@2@S9HYR]7P,&:$ ,PRG#[?9ALW;0RV3H4%#LP $<2!S0Y,F"7_&S:L=R#
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M]1S;G-*2"I^>(/^4#<0]P >P1#D0/L245PR$@F$K2>2]WT9E&H@P("_KR$,
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M6.%Q_ QMDG8&>?M4W0.<O<W+\8P5G"P59Y^I^?/GX]%!#E-6@"G_+N9'R@M
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M:'*8VL)&!_4Y!X1R6C5V$^6EY=;=*:$B09HCI@4(X$JCB%DL!!B%J<&4T?8
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M(2=A>8DX-@TA;LA3AQXWM-X5]+VP<&L8Q%P1L8:,\;TP0\P+ H?<2-(DPF=
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M2@ENK5RYRC9MW.BS8RE[*!N)'T@X,Q:91;MDV5+/<\Q<A5A1?KW[IG?;0.^
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MQHOEY89O0X!S*M0A-UQ0XXW+#M %MF!P@;?^($SY9>L16H78>H1!S,0!M7R
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MO]46J0 [-7^VU7?VV(0^GM'RJ-7S->NO].ICHO9"WW_X<.D*XOMM_\@(@I,
MQN[@QQR#M%50,9A0OVHE-'NC2#9OV>";8"Y9O%2%4K_MW3.B=YIZ3L&A@GL&
MR<A)2=$T/QUNIL9CGL(EU-#-7G[Y95NZ=(4-]"T-A Q_,FM*M2P*AYGQID*#
M@D/V4_A24+(9*!L\,BV;FA_-X13^YYYQC@JGT%^/>Q$5_$N!6BIY^(!HC<+/
MM'2:Q_&SW&< <RZL1OOSQQ[S#1<ON>02KZDN6KS0B5<L'*/]%.!IWP+\[P,T
M4WZ(2*<%SWW36RGQ>)<X#^,+$B*1F"_62S96WVOW/O!M>_SQQVWI@N5V[5O>
M9>^[]7TVU+- 9$@$4 4Q\47Y>J*2H9"/V ^JZ(.FNQ7&;WW[;OO>#[[OZPZQ
M.>V-[[[1QZ$P6XUU7KQ5M(/]!X59_'@@= Z[\@5Y/@5/9J7%?"5#?(<//_R(
M_>5?_Y6WN%S_KNOM Q_X@+ZA%2(ADYZ/(27IO">?VCWWWNLSR-[[WO?9XL6+
M1$A*^OXFW0[>\596A8=!]US'[P- _>D2C;O!LY[6]NW;[3O?^8ZO3G[]]=>K
MG.CWYZ52CSRM$*K\X/OV6:*J5.$.]O,=A];DL)(TYMQ]TD((%<P ;PU.X&,N
MK6R3A2FK%$++T.#4@.ROV$_7/VB/;+C;1B8WVD5KS[)/7O$Y6YI_A]5RO7HG
M(T,9YC>.+1E2S6>B/F(/OW*GW??\YVUJX2XOK!;N&K2!D<4V4JK;[KYA?5 3
MUF.]3DR\,$W>Y^/WV5EM_FCX$OGZD)-"Q*$/D>FJ-14N*!RFGE) 5*KC_IAN
M*>^F4B&K6-"SL/IJ+-QBP5'4.S/<TRF%'@451*17)*M:94-5IGO3T@,QPQ_4
MT,(XAT $@AW8B3O8[X48?I,;-&G3&L1S"C10%IFK8[?\WO1UDK!3KHLL!B)%
M0>I& UUDT"BM8B2IE 1QQ4PNS$VJILE4<\(S.5[Q0G5J:ER*&,4O_V!1+FD%
M\L(Q\2^U54^'0.  _S%/(1JRC_M*9@NR7\(B<@HRA:/JFK)$_L!.O.4VZ-BH
M6KXT:;NWCEM5_LF+S)Y^\AGVUBMOL*7]IUBW_-]5[5?-M%?NJ,"OC5E7-^,Y
MZO;%O_\'V[!QO7WF,Y_VS2-GY$LIM<,F0RE$<IS& <E0"AW?)QX3*SCGQRP@
MTI_T0?D]^NBC=M655SEY7<,FFCU]BH-*JR6OI73<G@[A55Z8*SKY<38<3-B!
MYQT=Y_K6_L@0VT@,[QZVN[YYIZT\J5\D\9V^9EEO:;%-C'=[A:9:FY1YR!GA
M]Z\"6Q))D"*[$4V1;PA#L: R2M]%;\^@/?C@#^WOOOAY6[UZK7WL=W[7ETLH
ME8H^>)F!\M-K/LEN'<B&=WWSF[9Y\R;[V,<^[BM \PW0JM//*M!)VI'>M'[[
MN;[-^%TQN8&PLBFQM_#(OC=>?]V^\(4O^$:J'_S@![U+#+<*,H=_R3?$L5>8
M5"90MM""2 6+LLQ;D536A?%RP9UVQ/ON(^4KT2B;RD]8582IT.RUWBH30_+V
MV!L_MOM?_WM;O^L%.^>D,^V/WO(Y6YZ[7I77?NO"LUX)G([GV=S+D.'-B".G
M->8 /I/JE!1[=:TM6W*U+5I\NI7[%]K0PE-LT:I3;,FJ-;;<9:TM7+;,>@>'
MI ![K-C3ZU+HZS-;H$(%68@,NN2'NFVB*")5&[7=U2"[I#S'<A6K]<C5_BZK
MJB(U7JQ:K;=NDZ4IVUG=;;OK>VRL,&[CA4D;;8Y:M5RU2BE(M5QSF=2S\?RD
M3>B(3(J(C#1T+@4](>*Q<W)$[T[:KNHNN;O=]C1WV'!SBV23[6GLLEV5;;9]
M8HOMF JR?7*+FYOL&K-J]X3LWBM_[["MXQMM++_'[]M S66J/"[_3LB/>VPT
MOTO'W396W*7S86OT3UEQL:C&0M7&)*5!U>?Z\E;LU7E_S4H#>CXP85U#$U8O
M[[:^9:HY#HIX=.TT&QJVT<)Z:P[NE?UCBB,IV>XIL:]AJQ5V6L6V6R6WS66\
MM-G&NX+0K8E,2JJ%339E&_U8*VRV2EY'V3U6WVB[)U^WG6.OV/#$:Y)UMG/T
M%=N^]R67'8EL&W_=M@^OMYS28F@Q^R69$]6B<B2U4Y,P;1UED@:*A (WJ-@3
M"]Y"H."AQ!@#<O4U5[L2+)7+5JDK[T+L(<&2WS8X85/<Q%:QG"H'S":#D-3U
MTT'D(%0B L@?40"*.4H'R!C3W;&6^*>K.9^G5;5JJT2XUZPY2:0B$%;2J:M8
M<N(6_*)W]*Z3'!$4A*[WJ0K=8&$U:"H.M/Y%85L9WUI&I(4M,1!("UVCY'DV
M&(8\,1R E=0A,U1J0,W=H((36J@0_('['"'4=+W32DOK,96KEE3VE4"@&&J
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MNE=?\Y8FR$]L84.YT-+%[+#++KW4>GI[_7X[TFN]0&+V@?S6B;20_R/IBV!
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M6R]4[<<B0P^)#%4+=3MWS57V@7,^8ZOTK8I%9F0HP[Q'!TV0X5B!0C!*AMF
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M?!"GMY,>(*0)X[OF008[PH@SY3AZQLR0X01!1H8R'">@X<VW$VBM\BPB,TT
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M#PJ$=8<*#2FY>JQ54XN=+G@Y9Z/+0B[4^/<'WLU+8:85QT$ICT.$*PM:?2!
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M-'29B;BP,)Y^C1SC.YJ^P_OZ]>OM@0=^:#?==*.=<LJI4D0YZ^_M#S/39M,
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M!P.]X7Z#Q.%/R!UD8')JRDD>X6N)'(<<T%1',-F5'G)4;524IYE1!EDCW,P
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M?=_M[.OM\[VX%BQ8T$JCZ)['OTXI[&.8H[]<N2?Y8E_$.-9[B9FHN("_)^7
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M7.)=<$OO5#G9U1&4LRIJ664.%2H&,2\S[?HI1=RM7FA5O=Q1[Y7UE3*2'@E
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M0PUT4MT%(97??>5QA@QO1/24W V >?/GN6*@)S1,%9LA7H:G&7+GQ&B4A.\
MZI=@7E>YP4Z50G>7>M82KOV0? $"(,6F!A'[^4*'=>17)2%] Z-_>NTM ]0E
M.AD5GZ_NMBXU'OGJHA^,5Y#VSNM=00JV2@T>OSME<N)66]K;]CW A@\=H^2J
MDW)N*I-&EYI:76L:$FFRFAPC@#1*46C(6".14R,C$5OO)6H]Z?CW2%@'H^(I
MX4JCSGJ/W@)Y9S0T5]U@];5-:Y2&>KX7UFBKVCI]%)7O6>V\TVYVQFGOL;WV
M>)O5RHV<XIBKJI.;.6]@#S_L,!?6$QU\T$%VVJFGV$<^_&$[^ZR/V$<_>G9)
M/ORA#]HAAQSD4VI;3IIDVV^WK?A8T4^S]I3WM7PTXDIDU=O!@P=Y@QE.?6:1
MKNJ=I!N!3" T_-X0,\W&\0:5A5UGG!R=ST,.NF2'-4H([N >(U/A?5K<O^1]
M&#W)6WM'FW409C6N#&P,;!H0IH@4AISW9"@]['#+65-C0\D<8:1L88+<;M"/
M1DFMU%Z0G-57U[CP_;$B)$C^U.F^0>Z/D [;9LNM;)!(%S2)$4<D)^]J$N&^
M)/*W602FF8^[ZC[/65==>;F7LVKU ]@B@K#_M48)72]BTBA_!HO8C1@RQ$8,
M'6I-^CUJR% ;,V*DC1D^TD8/'V'#1(0:1(2@TJ7OQ"F,N%'ZW0_A'"#U?H.H
M0,=[Q3R1;OG1I6?M5J..1Z,B5:<:5^A:Y64@IW0JJFP7\NI 5@]4:!J53_TG
M8QDRO)'QZD>&_G*A[;7WGK;[3CO873,OM^M>^),42[?M.^%D.WK;]UI;?H4J
M5NA-H7SE0G!LK9 Y&A9549>D%]/?D2'?CEU Y;7)JGHN]37VS/3)]H]IO[(N
M5>B#MSHQC S5<I =-O"G-XCKNHS&Q*D)D.ZE ][1*XMN(NEG@&=Q]"1MEBN_
MN5\3TOZEP7/\8IILPH0)OC.&W[YX4^Z^%HAAB.#WRTNFVZ\?_:JU5DVUH=UU
M=M#NA]NVHXZTNL)$$1<UB)PUQ,@+HX,0DWR+&B.1##4$*&YZ\^CAGBG5B/"[
M9URH)S]HZ$NC-2I3<3T;[]><O+*3D(=T.@=RU1NJ(5[.2V<!1<31S5X@C\-A
MDMPS$I*GH:H)HRJ$B3SB/>U^7B1%?,A) &2C@2_1RQXC$BR43D>!.*U8P6=R
M6OQW76V]3[D1>K:5DQ_!OX*/1$!R.,7;RY[;2)"*;ZQ_GK:]#/4%1D$2\P[2
M(.3%FM.;\"L<Y%<B<5J*_&-$BZWSP//#W=/[Y,IOLA9[-9 1J3E?VR+S>96M
M8*\G7.FI5M*:Q>ITRCBLE-.K^<AMK"OI:)-^Z?(0X64M"0N23B^,,R*)>[C/
MU"?A'"D"-$B$-)B17?T%?8#%,-7O$>"7.GMT/#U,JWM?Z5&?\/1R4))$(.5G
MO<I50TV]K6IML7;5,S;%W/GT#?;"HML5A'8[=K^S;8_1'["FPG ;0#6,<W4I
M/5HI73)D>*.BI^3V$Q1P*FXLZ+X]ES^YQ'-Z<_Y.0N^0LX>ZI;A=>(=BZ)=(
M$5+/63,B!5QD5U&.J_SNETCAJ6=310N"<J^JL<W&3O(P P]W5&Y2*GR1.2VA
M)\SS_E5HS**X4*1('"Y'XKOXC+4AT6V>\9LPT(-F%.OYYY^U^^Z;[ ?OL<,(
M.P#S:Y)R,]$/K@C^N$)-S/4HP8V/M'^$Q1M</:MKJ#>^5-[.Z('O'HN+["7>
MDY6=[K!6K$[*N5X$KE9EBD6Q-/XQ/CT@'2!=$%//>A>5J/!.SVK</L<*<#IS
MM0OW$(PUBLHO4B<_Z^0W4J/GY>+?YI(0VUZB_RJ)J0'"_QHG0#3TR622RJ%:
M?^M6/0J_16#5,$,&U>K[2 BCH$65F5K9=3-19!9[30UU-FK$,)<A@VC03?&E
M 6<="V6#A=<<P-E@S0.:_!GOU"+V2)*>+C$9G5BLZ4]F/"Q)7L1P^;WR7_[T
M/*LLQ"?&2<DN/T46"3]I3,(EX7,WY1[^!'?#;[>'1?U&CW!, Q)"H+>> 10.
MZ2B9[]:[/$26,M$D,M#<:(.'#[6&@<U65%IWNRZ3^5BH)/Y]L^"#I.>/90$*
MO*Z>:B$6\L_]5)@PTREB6ZM.VNBQHZPSWVE+5RQQ>ZP/ZRITZEF'0B-]I&=,
MMTF[R#\]D5 MBOB/^[A7+CQ?HR@$B>"'_^F>\%93KQ3V[NX._==I*EHJ1PTJ
M<NASA4=DLK.[57%B]$Z1BR +,F1XDR)=E#<H5*?\OZ@,J+2N1Y-G_1<I B<W
M*(6\DYS^28>$-2=2F-4<4";%88V$J@*".NLM_:_9-.XT])SR>_+))_NV:#Z*
MRMH&Y)WO?*?(S7UV\\TW^YH,Y*JKKO+#[EB_PT%X3"&@)Q]ZZ '[^,<_9B^_
M/-V^]O6OV1577.%^0(@@#WW)FQ'TXAF5H('(Z[Z]LU4%LF!JJL5C10J4#372
MW#6%&HF(1[=("[\57?69Y0(]? EYW$L@5'U)9^H>N_T4%+]!2H+=JBA,*Y2+
MVRD/D\3#7"YE_DBP7UU!( -QJH:*VW,O$E F$ $:-"=]:K%<=%\M(N&$1V:<
M=$JJ19SZ+RE_UR@0&9DOEXIN5A:Q.<6#[?6! "$A+H$L5K*SFL@^^H,IV'85
MJ-9:[I7J9=*I]UVYHK7DVR3MUJ'TSHN46GV=53?6ZYV95$A)5G=#95F=K]6$
MYQ7-\UZY0+Q$1 <.'VS+5JVTYU^::FTB(.HV67>M_*]3C:A129$$MW!31$KA
M<9%;'K8R*;WO4]014_AZB8>K1F2G5GJSVCI\NE-E3[FP2IVR]O:5RMAVO5]E
MK5T+5']7J%Q2?]&7&3*\N:'BOWZ(#7!<D$I':&!NI%6+&/@D@=Z[Z ^H6JN"
MJ5)+N(:GZPHLRK\R271Z;Y%I*FEW58TJ;4$]9_8DU2E,0<'2(Y:VE,'>(;G^
M^AOL@C_]R?[\YS_;7_[R%_OC'_]HO__][^TWO_F-_>YWO[.77GK)1WX@0!$^
M#*ZXLHASUJP9UM'!MY+R?JHO,F/&##_1EMTN<^>^8O/GS[4_7O![:QXXP!NF
MA8OF*[#!G>>?>]X/V'MRRI/VGC//M-UVV\46+)AG__,_W[)O??L;]HUO?ETD
MZ2LN7__&5VWZ]&DB7U/MRU_^+[O^AG]:6]LJ^^YW_]?/%()LI<%H11R528?_
M]0#I19/6V<D(!4TWHVEA74A.++BVN\8:"K56GZ^7-%A==[U(DLA#E92Q\H]L
MZUO4X$LXC*Y:! JAJ.,?US!F0 F)3[!#&5Z#N'FF99BR$UT3.4,XH\J;7)5#
MA=PE3 4EDBZK%8"[OGA7PBA8E!CN*M\$D)CI":W<<^L*&V9K5A-BQH)>SKEA
MK8<+6\"K<U[L750$D'5!2+6 ,*(J!Y0^(4"D4S1#>C-M5R;*ZRAI]'H6G5.9
MJ%)CFU,@JZ.H$:?\,N+3VX4>1+<8729O"HCN"[*7EZ ?2@NFD[+"%&8WZV&4
MMUTJ9EUYT=J\2F6G.E9\GT)V\-'_Y!;37&'Q?<P3XA=6!?5L^F ]3=I,$(^:
M;MGIEY<>:NUHLV$CAMG0X:-MUIP%-NVE6?;*W(6V9,E*:VV7KL'-ZGKI,DA*
M$#J)C"[Y'_?^&\T6X@P5+8DBO+HH>)Y&/8+]O,);D/N="GN7_.U066K/%VSV
MW 6V4F0-[>Y3JR*,J!#JK4^1A5AER/"F!;5SO1#)$,I!VD3_%VW\J(GF)]:J
M8H'$""8<5,!(A+CO/S <I;=B04I**O47/"!4,L//8B?!U&_]Y[]#[SD)JA#,
M,WH#^6'GU0]_^$/_N.G/?O8S^_G/?^Y7WE<B$D%!XQ<+MAD=D')*B$=:T7.%
MG'%X'.L>.#V74(4P%7T;[ZB1H^RZ:Z^SG__B9Z[T.6/ETDLO$2F:;U=<<9E=
M=>75)?GQCW]L'SGK;+OVVFOL"U_X+SOPP/WMZ:>GV.677V[_^,<_W,\(;R!H
MV'LB_?K!"X>4KQH<IKRZF1KHZ/(" @G(Z9H3$4"JF283\:C2<]I>B(?^TV\1
M*1;1*JU[A!(1F@']#'GL]_B77,F_1$J+2)-1A#Z%\I*(LL3S!2$O?;K&B5H0
M&H?J1$(3$X5N0IFDW(W3<+BOP+G$Z1XB#I$W'T'4NU(#Q'OB62[4B] 0.PEQ
M"77%28#^*MFJ*,%[EQ+T++A''4R;3R&TN+VE&S+)1T YU"\ER;,J=5FJ.27>
M3XH?JG3A\RI#_![)V6#E<:.;#8=Q5I#HEI-,Q5P21AA%5>B-B<R0<H0W$!N9
M\_?5-KAQH UI&&B#Z@=84TV#U=3RX=9 +F,:L,R28Q*0-)F ,SEO<J%L(-Q+
M%Z2$,I[+R]U\K?RLLT*KZ$YW@TT:,\'VVGEWELOK69>M6+349K\TTYY_^EE;
M\,H\JU%\HM06U+53!X%K39?<043@^!"UB\)9$OFQNLA>F=0IS<@!3C1GW5J7
MPE_=T&BKQ ZGSYAORU=*AUJCY3OJ11(A>G0TE9Z>E(I7A@QO8J#)-AA\;4M2
M-]ZL^,I7OVJ__,4O[0<_^(&3H?///]^^\YWON$"03CGE%"<4?8VL!))89?_Z
MU[]\.0(C.X%[\)S1LF!ON^VV2YX%L'T8O/CBBW;.Q\ZQ3WSR$_Z](\@7:U
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MI?ISC"C,-/H=[9WVH[O/<F5XP.:GV6G;?505&(4IA9(X58*[N6:B4$GI]5(
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M6:GD;ZU5'1VZQ-H7M=B!.YQFAV_U:1M6M9GJ,NG%E#-3D#UQ+X4U0X8W 38
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M0X8,&39I9&0H0X8,&3)DR+!)(R-#&3)D6 ,6V)W?_;B=??:'[-1#CK'S;G[
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M^6=\ 2?3.C1H3#\RBK-<O=\A0YI]_51#(XO(BTY:&P<T>:\9HH,9&D,:!LQ
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M$Z1$:0@?>. !VV6775P)$L@UC0RA$5"$D"D4,"?1<EX-N[WH9;(]?/KTEZ3
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M9EVQ2+$AD(ZH'%%4$ L:8>PSNL%SB!+VX^&)O$>1^F&-,L_Y14Q[^#27[*#
MF#Z(! :"@. 6=IU0*/HH9I3ABI85B5++E]R!U#"" ?'R;?B* T)\<-\) .L5
M1#H@ @V)<!X1Y&_$T!'^O2[<981DV;*EGAZ00LY>@F"1#IPCY+NV]!SAM&U?
M Z'P^6G3BB=3!RC0I<N7N.(MI2.-@\)&'K/N*;T^BFD]E'OI@$G\)3UKJGW$
M#F%T"O<B2<0=\@ W&?$B;5SAJV'B1.T>29Y)HEW\)$P@7AD5PDT(J8\**3RX
MRWON*8/1'M-Z?8'WY;(NP#QY!D%L;(+LD?;^)I%7"7=&#JZKD,DEJ8#D,>4$
MQ+CSF]'.THCG:X#H=R59$SRL,E.*0T+\O5XG>5^2)"]X3MUB:HIOYG'T0ISV
MC@3%W4W^8IWN)7J/#O!IQ,1O0*<!OW&#*5ST#.^9KL=?WGFG2.4UK[*+4"=X
MA^!VNF. 8">6I'1J^.\D;F*N1,SK)7ZR>:)Y8*/7P?!IFHAR5S)D>&MBHY$A
MZ W_%_+TPNA=A</-:.!I>"/<E"IF5%(1*!54*X0($- >%;(&Q+J;.!64'KU]
M1@3"8EH0%%00&L'X1QC2BH:1">Z92L(M'RE*X(JH)B@K>FLH2Y0:SXB3*RU&
MF62_=W@"N(_BHQ@R0Z\,4N330DHWWD% ("V$Q7N+>L8(%NZ7E*/"W47/$N(@
MAT@WQ(F$I*5ME9.:B9,FN9N+%B\.C8#\K:T.ZZ&0SKQ(B2M=W);([=A;Y3UQ
MZ50ZDC^0+4:;0A.@O\0,0"'[Z(Q^$WX$N^%<)=*$,$-((90AITD 3PO9(9X(
M[I FW/MWR)0V46)#%-9T]9A'HK]<<9/T@C"RZ!MBR7E-$"&>$2X(%>:QBYO$
M&;OE@EO$LUS6!9@/_D""= \1UU7.!TG*I9>)]0)E#+OK)GP*HR2I.*?C7KK7
M'^F&\%Q9Y_>O)<KS %D;,$/XJ3-</:D$CT,9>(8YZJ+'#S_TY_4MB6O)GB[<
M5W*G!,(7)8'[01J2IA(?79/$]([HM[N(@.DH_G]BG;=(C8*?TTUU8C[\'T>4
MJ)-8H%S$NIDAPUL;E/:-"E_X!QF2 H$PN')94\7>"" ,3-7U9WE44*KT$->N
M /RCAF7BY$H2W%B[?QL;<?W!2O4Z(4[#63,S<J3O8N$CLZ_,F^NC/(0[?&<L
M4?YO(9 /D _28<B0(4YVV+'#;B*..6 4B*E)/FU".D"JF';,D*$$50DZ1)!F
M1A]+)/!- /'LU21#A@R]L=')$#T-. &C)B@/&B9TB*^K>2V\%[R7+?^])]@O
MH.1Z*SI&>I#^8_T5);WN\K_U1A)D"$!(^T (.%!RV/!AMFCA(IL^_26;]M(T
M>^3A1WR1*/[YVJF$T$6)J?(J0D-I\(:$:R7$,I*&D]E$*D*/>16D)[SE0KP8
M4>(L)=( 8LXQ"W->F6.SYLRR1Q]_U,__(9\A1!L+L==/F%Z/SL$&@8),N$MA
M]X+Q^L6C5UC6 M*=/'!"HS]^@W*"4[I+BAU3XYPY1IX!UPE)V8INQ.N:@!^Q
M++L?W$OPG^FT_KC1"X0Y+2GPRT5.NB3W/0CFV3&G6/A]?],Q0X:W$EX#-A(J
M620BH9I1X9,?;["*%Y7JJU4(K\:-=!A>C3L.["JM69_"*<Z<7\(HR<A1(VWK
MK;;V0Q,'#AKDN\WX<"KB9Q9!("6^ABJ11&>'O%L/.+E2 \+($W_EH!%(-TBQ
MD:&!"$(9(@#^,KF&]()LNRAN2"0<47 WDCNF"_F8+EN9(4;T]E^>_K*?C/W4
MTT_YU":D:6.!,! FCYO"R?3<FQ'$@6PLI77R_/5 S&</TQJ0?D\Y\;1/RA&_
M*2=I8-[CE\2N/=FD0-[%S1<(=F.^KA682<Q&>SS#9K_=B,!>F? L N+#SCX7
M_8[W/= /]S/H9_SOSZAXA@QO-;P&9"C#ZPGT(F24'5>N)WDF,L(Z'(;[4<9\
M8VS<V'&^BRNNAZ"1*)>@*(.L#YS,* #L)&,=4SE0Y+C-V4F^TRI9,.H2P^%K
MF=+7U#M_WR/$!8GAY3ZZ2QO XE4^:[+]-MO;Q(D3?33(/Y%0(6P;$A!"WSFH
M^+)FB3"M;YJ^WJ )]T98JL0;XC<X8AB]C*L<0&S8]$#>0XHA-A'D".:I(TSU
MLY&!Q=-,,Y-OD0A%.]BG;*\+" -E3DS=W>=\L7)"]FK@]3V*(A3O(RAVE#WB
MR>@QG8!<=;:;+,.FAXUVSE"'=5NM&K]\AWJ_]7E[>M:==OV]?[9Y YZW$4,:
M[9CMWVF;#S_(.E9)L;  MK9%/?(V]5H:K*HPT*HY;ZA:SZH[I)3JPA(^3E%-
M?8>L$OJ[WL4;GTHQE_5RI=Z7V4I^I<VZDI$9&KNZ&N(0ML _].@CKCC=GS6X
MR^M"=]A]EPY37_?NM\""S+BSQ\,@,YQ#%,\F<8?U'*6+\)YOKSWPX(,V=LP8
MVW&GG7PZ@'<#!S5+.5991WNG31PWT;;9>MNP*ZZAT?+%L&TXO2"^'-%_W&JL
M;_2/O#[QQ..V^<0)ML-VV_LZC+B5EQTSI,NCCS[JC03V7-0#C_>,;)4@MVF(
M:,AB@Q33((W8"(#T^WA/(\"G.C@ CY&BG7?>V?,I/55&^ %A2 -B$T><@$_G
M*5,]O I3-,_.0^+$)@+RA@/\GGGJ&7OWZ>^2?[OXR%NO5FHU$(DU-Y(]8>.:
MI,<Z5&_BL4:X4X2#^'7;[;??9L\^^YR=^>[WVO 1PST-8CZD$=.N/ZAD_]6"
M<)7RG>!3OW1]<=J+=OEEE]MNN^]F)YYPHBU;OLP[!#$=HQW"!&%A%R*CAVP,
MX$.M >),\0  __1)1$%4E)M81C#C>:X_B!/ =K%BGNJ]7N#^[7?<;A=??+']
M[[>^8T.'#?&Z4"D=<7M]TB:)=1@-4CZ4Z@)!D%[MRG79C&5S_9RAV:WWV:JF
M67;V8?]I!]5_,9BK2NI 3+\,&=ZBR,A0.62]IU$)Z,OL.I&A7*TWDGS/['=_
M^+TWOCXLG^QN"YHG(.H=FE5CMQ7AP:TR)0W2]Y40PM"[!XLKI3CJRE9ZS,V:
M/=L?#1HX,"P@UKL!30U.R I=W7;(@8?:61\\R\VNZFCS1@&LJ;%S_^4.9F@\
M;K_]=KOZ[U?;A GC[,03W^D?OR4=V/Y/+_WI9YZV.^^\TUYZZ:52 U.M\N%N
M!0?#O:Z((\9%B'?^/KFO4A&G$2@A,82_["CC^ *F!FGL&"VB=\SWYF@8(\K+
M1$2O< C<D<^>UF5V(*-.EI063.DM6KC8_OUC_VZ''WJ8WO)N3:1!+F=D:+W0
M*X\(?D*&^#;9Y9=?;KOOOKN=<-P)?OZ6'R.1(-HA3,2!-4-3GIKBNSIWV&$'
M?\8[)\3<BP1!CF)\L;TV,L3G82Z[_#+[^E>^9GR_D-$A\@%2E8;7@_5(FR36
M&1G*D&$MV.ADJ*M#2J(N;\_,OFLU,C1!9*CS+4R&'#+"T#D[EE"62Y<MM3__
M]4)C>_D!^^]?\BLVW=AW-P1>H?\8Z6$$I@1>8$ZW<00(=TKACE<@<_Y.#M$
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M96%M9&C-Y>?5HSQMN2>MYLR9XR-#3(N^\[AWVO*6Y3Y"23S*P4@IHX@///B
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MEBQ98M;8/7MVVQI#=,82+&6 /YSF-[OIXP1-^,PHHVZ/VF%_''(=.^?S1:?
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M "CC155P;M=\%B-A ($ DA%;&([UA8:&.$\&1[?/$D0>(9@-$)&+""D<2"?
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M7X_Y89TX?L( 4C1Z;IN%3C>B;N&(CHQ@F-'R5(&8!S&>N4:]-=8Z[.LOVM]
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MA;+_P'[YR4]^(M=<<XT\\<03A96\CY>!@5QZ]5=PEB,;&C B=QP!(K.$;T)
M".M\XEF4 $*^))*0/?OVR,D3)V7NW+G6 Q\:&)2H/E.EP(@>-,,"* +>&TFY
MWO*H[YU!&JM@44D4QN]^]SOY3__I/\D?__$?FR^2!PH095(HCI"E7?\1!C2F
MP,:7PE.072QDX/U["#__70^X(#[O;_MK4#H]8L?PLV$BW+?>>DM^]>M?RQ<?
M?$#FM[;*G-FS;4=Z5IIF+1KJ"^4%'SMV3 YH7=BT>8-455;+DT_^GH*D&@U)
MPP]%[^QY._T(GY4=NW;("\\_KV _E]?Y[61H<$BZ>[KMG/+T90JHH9X"<"HK
M*\V/ASIJEC@E7WZ4%^6P=^]>^<$/?B WWG"CE0_M-%>^'-UWL0S9C$J]CYRR
M=J>?I*-B=4K;-D"*SL70\)G3Z_EN?AJ@L>I[(<K&*T,X$ZT7M'_RAC3SVZ4I
MGM2.B<9G,#HH>WLUOS_XA0RECTM-R2GYVIU?E^L;_K4]A^2%W&[V12K2]*4I
M T,J'I0C-$$94&6[Y?"'\@]O_%]2,O^HQ,JC\OO+?B1-C2LD.1!5 0(8BJN0
M&52!Y,"0BD5M@'%CM!.+Q)NZ'P<,!;)K?+H0J0Y_"P%E"A>)PQ'F ?<0RAQ!
M>_CP8?FS/_\S QMWWG%'-AHFS(,?# ] X"I?/ Q?I0+!&5;F"'THK!#\SOA0
MBE6NL^3?RT5\9"1IIG[ D'[8XK=KURX; H!*58F7JH!G#9)[[KY;EBU;)C-F
MS"1@%;,I4P)>R.=BQ;G_Q3%W_IO?O"*__.4OY5__JW\M5UVUV*ZQC86/OUEA
M@C#MMPUS.# )HW#<=6_I<=LCZ'_!)WQ<]"_(.Q<7=XY"R5=*A(?"Y+I;.L I
M+JYYR@8??-O.[7]'S,+!VO"7?_57<LMMM\H]]]PCM;5U07R=<S6*GC#);V:9
M;=RX03[\\ .Y_OH;Y$L/?EG*RRHT)/TV"0[(0& !RD_#YT?A7,BGH"Q"Z0E3
MH30,#0W*AHT;Y;>_?44>_/(#TCJ_U?(O/PA\A?;OWV_#D>3MB )W")^T^OHZ
MF3EKELR>-=O:S<X=.\V/B^=@ZACUGDUUMV[=)G=KO;[OWOMLR,PZ+=F/D?N^
MX%V[C&D9LA1",IVTLJ1N ;YXCW#MT0+I]74JG\8'0^X=B\FH]R<.AI">M(L2
MC1]R.:4R-)*)2$)[K&F5M=M[MLD_?/0S24J[-)1TRE.W?4VN:_I7^BY@*/A^
MX2(L4I&F#4T9&+(>22:F#2\CW=JKWG+T7?G5AS^5X8IMDJ@IE6\O_Z',:EPE
M(V$P- (88C858$@;NP&AP')00L^<J$ZQGXFV_7RA9<)M$KE4R#KEG,=+I:^G
M3_[RIW]ISK4H2GJR^106D%EA'"*GW!TAW/,IKN&BU*%TQ"ETTA 6\J+"$$*@
M W3"E$R.F#\2/5SR NL-0SI?_;VORH,//"@M,UIDH+<OZ^#J00.Q#K"(?JNP
MD/_M*[^5M>O6RE>?_+HLNFJ1^=@T-=1KBH@'PPPJL#4\FVFGOU%ZI)'AP7B4
M65K@, W;XLQ:/?B%^-]<<A%@S91"4X3)NT+*BBMNG14W;$"ZO8)U% !4>]6]
M'TXOPRWKUJZ5?WSF&;GEEEODIIMN,NN!+Y_P-P%#6!".'CTF[[[SGEQ_W?7R
M^"./2D59^1FE[15LF*@3A13KYT.:KD+;R5C]<G&<3!JPA&W>NEE^][O?RI<>
M^;(L7+# RC&_3?$<OFV H1(%*<-8:I0 SZSRC9]6:6F9G#AQ7#[]^&,9ZA_4
M:[7VG+>$,ER)7Q=66JR4UBG0S@7U#P( ^*\">%AUFJ&WX\>/&^C"6DK=GSU[
MM@+[J^PYVFZA-DE:"Z6W$!@:]6S8TGD.%*%]E,2L/**9?@4_(](?*Y5$,B:E
M23H&2=G1MU-^^OX_2'^F769'NN4[MWU=5C7_S_8^Y005:#)%*M*THBD'0TS>
M["])R8:#;\JKZY^1KLAG4EI;)M]9\:,K"@QAUD=P,KUZQ\X=-KT^'D_84!04
M5@Y>F/+3^^4@-+U"#4?/@Q[(?Q>_'P]0; =&)=Y'.3O**2IZM/E#,?8M_;,X
M:9BFZ->M,Z%_/F (I?;&FV_()Q]_(H\]_H3Y)8V,#&E42)MC3S@:$Q1Q(5_(
M$QCG:U)$7KAR<;."<GF6RYQ"2BFI<<6:%";+(0V'I1$BJ@%),\!HE!+W2DFO
M^V]8/(+/83%X][UWY?4WWC"KT+77KM:X#EO<('LL>)8R [ >/G)47GKI-]+2
MU"1?>?1QJ5<%GHN]HRL1#&W=OE5>>_TU><C T$(#+]2#,%&VM"%\LR*:E\,*
MX"'J!/6TUJ;-I^78T:.R;\]>F3=[CLR;.U>&-*PA!=CX<S'T!>"MKZW7,G?6
M)J[[^AP&0WR?;[VAY8NO$<0L0:Q3:]:LD:>??MK %=\O5.](:Z'TYJ<+&O7L
M%(.A:"0M._IWRG]Y^V\4#+7)W%BO?._VIV5%T__3WJ><()I:D8HTG6GJP9!*
ME$'E=0=>E]<4#'4K&$IX,-2P2H8'(MI+:YCV8(@-$[NZNZPWZ:?[ @ZRBB(4
MOGTO($ )9( E"-8+J+$(2XX?:DLI'#V#3(.[^_E6(0C+D <A6#"8_OV;5WYC
MP.<!!4,S% P-]O5/&@R1+GR&WGOO/;G[[GME0>L"1N:T_..:2GU>[Z-(?/Y[
MI4!<DH&5):QL['?P'.]"_KZW%O';,^3#A'PX*$&?!N+#+#G*$+!J8>A?).*6
MA#"0I&%;:)QS5].*I8!T;=Z\6;YP[[URQZVWR\#0H$W;MF_#^KSEBYU&I*V]
M7=Y\XVUI;*B7QQ]YK B&E"CG;=NVRN]>>U4>>>QA673552[_\B@>B4EO?Z_E
M(?5]* !#W=K&YLV;KT#%^5\-*W@^=." Q$JBLF!^JT3C,5M'"S#*]ZF_Q 50
M1/ERW0.4,!BBKF,YPJ)+.V9XFN=>>^TUJ:BHL#6'B ?7:#-0.-[A>A<F_ZTP
MC7KV H*A6&9 TBI?^Z,*AE(.#$6TH[I[:(_\V6M_*3VI$S(OT2<_N/.;13!4
MI"N.+HIE:#"2D?4'WY#?K?]'Z9)U4EI7(=\-P-!0?XF4EDU_, 288:B,L+PE
M8ZR9<H4^Y8721(AI\1[DI ,':I2OMU)8(@/48E./\ZH 2L%8[['&T(F3)^3%
M%U\TY^D''GA 9K3,D$&&_<YAF.P5?(:>?59FS9RM"J5<DJEA2:IR8M=W\@2%
M0FQ08I0#OSDRG(BBA!(X>^N1Z[Q#3W]$F=]6=EQ7YETHK)3( UL<4PG'9CL"
M<O0::2$5 $E\@+**2E]/JS+A&;X#>+(0+1N)0XDJQ$I;E;B]K4U:%RR0A0L7
MVA @UB&(L%P\6$QPR!QQ2Q1YG3C>)C?=>*,\^?A7I+:ZYHQ2OM+ $&6R==LV
M>57!T&-//"I+%R^5E"KT?*+.MK6W.<N0YN5PRBU5 6!I;6T-P$I&JLHKY="A
M@])^\J3,FS/75@&GN@\GAPWT4A^H6SS/N:]C4!@,<9WZQ% MG9BAD2$;1@8,
ML:3"DU]]TH;>:!/^)<K;U[ULW<RCBPF&X@:&DM(72Q@8*ALA_1G9VK--?O+6
M7TOWR#%96#XLW[_K&[*BX?]A[U-.4*@)%:E(TY*<5BC2E!-+^#.[!=D"6&+Z
M.P*&E8CSV5!%'GO!.A%F& 8?!V-5\-;[U>_B3.K8K7,$(]CIR8:YO*+<>KN<
MQY5K5$G7UM5J1,Z/$/!EY>76^V;+!7KQO3V]JDXS=@\0@D+!MX/O,V3!;"S6
MZF'8K*N[VWKFQX\=D^T[=IBC]Z%#AVP10];K01&BM-@+C.$T_$$82F&8C_R'
MV4<*P )W=749@,'OA.&S/@T'2P..M4XQIJ2WMT_:.]IMN*5-%2K B9E@>W;O
MEOT'#I@/R;9MV^633SY1Q=QN('3GSIVV?]4[[[QKU]>O7Z_LIH5_]MEZO;]#
M/OKX([N.3PME5B1'MC>6M@];-D+!!X[*5E>U7,,,,2S%4%5E5:6!4::XXVOF
MZG2I'0$]+<TM=H^Z<NSX,7TS6"!3P1!@A'I#?82H-X7(@+#%8T0&A@?L2+E1
MOX@OX5245U@'XG(CVH>3$0J.--]):Y&*=*51](_^Z(_^37!^0:E$NU\EUCL4
M&=1>6]?@,=FTZSU)5O1):30M5\^Y4>I+9\E0*BE181E[U?DJ^-@6PDT'IT="
MKRCH&65[GV=OJ/1"4:[A/ZA0KVQ,XI4P3Y;RWU=&8-K0&!8!C0O"DR._$3YA
MYMDS6)\]&^M_VOG3HW)&N[18:& 7 9=^OI7CW [KQGG$NBJL.#TX-& * @7?
MU=4MUZY>;7&O4>6"OY-].R#[4O:G^VZ8> \'5P %?AW+EBVQX8Q9,V<I\*F0
MI4N7R1>_>+_<>>>=<NVUU\I--]\L-]QP@]QP_?4&D@XH^%BMW^<:R@OK#P#S
MR2>?E$H%3TN6+)$UUUTG<^?-DY4K5\J,&3-D\>+%QLR"@]F"@6^S/0;/LUT&
M .V.VV\W(-7>WJ;W9\E==]TM-]UTHSUO^:29R3NK5JTRX(7R8 AG]IS99BF[
M2K\QA_,9,\TR,4_C,%._3YCSY\^7UGGS9>E5BV6&*F:4=&]WC\3C,9NNO63Q
M(EE\U2(I!2"C3#5=X;J;3UKBH_+]K$3Q!O7'!V>@>1)_9_\6]VB3^9Q[A_<+
M<2&BCF#Q.7C@H"Q?L<P #^2<VW-,6P+,PM2%3@6^Y#6S]+#R5&F]R"B8Y2N
M^LKJ*LOK_A!H)DPL.=0AQ Z6(F9/NEWSPREP:0B#!,Z)*VL6D9]+%B^Q%:J]
ME1$*QQ<N1/G/P%8^GC46KA0*ET,A>1?^DS3OJ^PLT?22(@UC1.5O5*_'T@X
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M51B<ZC\JF_=^*"75_1*-IN2:63=);8)ALI3VVLJT,3)MNCA,=CXT)<-DJD
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MS9^#&5N_^.4OY)7?_E:>??XY>?DW+\O'GWR2M23DDU>@6'O,@J!5W;9Y.'C
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MN/*_D3FU-TG?8%*53\@R- H,*1#*@B&$!E&]<(VRD%6E$#DE&?Q \ ?=I+"
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M<R"4D@$@+6>F17N%B$)G.(=I^>Q:SM1LE!H+2:*$JFMJ;&%%%G#TB@E%#Z.
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M*H*ABT[X$" /\5E@E5NV15B_8;V\]L9K\LZ[[\HGGWYJJP6_\<8;MDT":^@
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M?_,;6_!Q<'@PJS0]>[)X!.S)>OMZ1)&B6-E[[(,//I CAX^<\?Y8Y!4C2PT
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MC;6.3IPXX:Q'"CXV;E#0\O'']CQ6'0 )K!$RZPK6F:;&)EF^?+G,F-$BGRC
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M65PPILIBWIRY!CK2FEZ<E $QX_E)9":8YX /MK1@^ PK"\ !9<-:/L0)_R&
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M,T'*6IW&IGR!./I;%DEW'J8)A#MIHAMW+GA57\NEP<5K5!K&H)0MDZE?5.7
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MC<J@EO\(>:69/^&^"7K56#/V#*;=!/?UU$]Q]\RU@I0-$W9AV80%#0^VZ^=
M!J+R_L)D00?,0I05"D;K-*_+2Q7\:F2=,Z_&Q3AX5M_+ "[P^M5V8$!,&<!!
MW82IF\8*D#R;)2BFSRBS-T8DKN]J@-I*-"@%#MHFD4LE#,^'.!$KT_*OD_OO
M_Z(\_OCC\N4O?UE^[_=^3[[VM:_)33?=9)8AMHEA[[XP6=-4QC9$'7>LTB[@
MW#8C^E!!TG(X&X?+O1!I?I G!L0*?((\LPD5FH^9E!XC*H=-]G)$&@3?*5*1
MICE-N64H'4E*O[;"+4<^D5]_^A/I3.^0JIEI^?;2_TZ:Z[37)Y7:RP88E6E#
M!"00'4 3#HLN:H5Z5+F>HM)D>D\7@0HY40[T#YBR9$CE5.<IZ>[IDLH:[9FI
M$&*/K)2")> ( I7IV2Q#0,^V;Q"K0D1!0T2J*LIDSNQ9JL0;I+]_4*HJ:TQX
MYT -WR5?O'#DO( $#)/>+IB_6BT .UAC.D]WRK///J= 0I7!??<;&& EY;[^
M/HU#E5E@\@D@E$_TNE%2;DK]B(PPO5W3!;C"<1B@A0\/D<)!^3_^Q_]H:PTQ
M*ZRIJ=G>9RB*E:H9MA %V Q; 5A@R*>%(ZEGH4<<O>G%6^YHO2G3[S.C"^=L
MK%ZLO,VFL0RA,=V=X3#\D@"3Y $6'ZP&Y#6@AZ$Q9H5AM6(!R-/Z'L"4N#"S
M;<^>7;)P\6+IU=])U82#&@:@LDN?HWQQP@5L=9X^+>V='?+MI[\I#S_P):FI
MJ%3 Z#8.]530,C2JS.A$Y!/WW'L&?B9(H^NM"W=T._-UK##Q+'_Y5"@-A>H'
M-#(\DG5D?^31AV3.G#G!G3.)//#6'T /?EHXX?MK?-?GD_^>MC2-H3NG+OWT
MIS^5%2M6R$,//*A ID(&A[03P#YRELY<6@D3YEV*AZ'DN,HKO6IAFV5*&2ME
MKFS&HEP^^C5]J*U HG.ALWT/RY"SS"JD&U'PK7]ARY!&7#:=_D!>V/$W<K1C
MEUP]XRKY^IH?RK+:1U7\5DDZZNH!>TP6J4C3F:;<@3JC]T?TO*/ON.PZNDX&
M,NV2J,K(ZL:;I+*L3I] Z=,38_C!@QH5J-;;<;\F)EPN'2H47Y020RGXDGSX
MP8>R==M6V;!QO1T_6?NI?/+QI[)A_7KS4]FT:9/-:/I,?W_XT4>R=<MFMWO\
MR1/2W-(L]?7-%B9^)DY9\3W/$/GGE=(X>:>W"^:OOH[P!P2@Y)E%Q<*+BQ8N
MLG3XV32 D$**K9!2M/!48?$._CPV:XBI^AH>3P,\3AP_8>OVX)>#(S*6G_OO
MN\^L/FUM;:;T%BO08,^T-==>*S?>>*.L6;/&ABI0:LN6+S=>OFR9@2:<<0$Q
M+.C(QJJ< ZINT/?PW6G6\+'X,%0"0&(*/\ )WR'6/V)Q2!0R[P**R.]R#?<&
M_4T^,-4?X 9X!4CQW>J:*OGB%Q^0^?,7& ">-7.6U%156Y[6U]:9-8EE IA.
M?ZJ]0Y9>M5B6+5DJ90J8] .JQ'/E4;!L1I79F?EL#_AR+W1[#!K]K7'"G005
M2D.A^F&DZ3^( _S^?;)JY4ISH!X%R (B3/ZH,]QGVCM'[_Q.\( [/UW>A^&^
MZ\[QV_KXXX_,PDB]9B:@BVN8'1G@T6\!@.FLV!I#:?VM96A ">N2ODM[*13?
MT90+V^>-NS+>>X7)AU&(P@[4$1RH]2_L0 W^.CEX6+9W;)">@5/2HAVM53.U
M\U&V5-](*/YU<<JWYA6I2-.-+LIL,G:M;^LY*CN/?"I#TB&)RK1<TWBC5);7
M2[2$/:.F/QA"<2) L0P!=N;.FVOIFS=_GBQ=ME1NO.%&6;%\A?G&K%0E,+^U
M598M7R:M"UI->1_2][ 0K5JU4H7W7!/(&/7<4!G?\PR1?UZPGAF7,XA'>24<
M;_V-D,=BPW3Z[=I;1^$LNFI1 &:PE"1MT<%"PK^0LN,=H@,@X5.VX[TJ+*H*
MW\8RA-6$YWI[>VSJ.X"!-7RPR& -8H=XP MK#+7.FV_76YI;[+K?M@-F=6<<
MK_G6O/GSS;\(L(.#*P"%80ZL1NPS1GB+%$QQG[SG-^L8L2?:;7H?2]%2P)5^
M'Q#%=3:NQ7?DMMMNL_< 9+-5J;*F$?G">PL4#"U?NEQ6+ENARG:AQK%! =P:
MFPG'6DA'#QV6DT>.R=+%2V4Y8*B4]8<F (:@;)F=F<^6R;[<"]T>BX(P)Q3N
M)*A0&L8"0PRG[U<@M'??7EF]^AJWR&4!:PN_R2ON45]*XZ5RLOVDK3S^VNNO
MR=IU:VT[%Y@M7IC1A_/SI]KQX-[:M>MD[]X]VLG8H<!TF8%1ZB*+*-HLJB!Z
M_KOEB7*KKPD;#HNZCHC^T39]9\"LFR41:^?Y-#K^G+O?K#?%/2Q*WC"7G];S
M(>0PUB#24V@V&6"H??BH;&]7,-3?(4T5=7+U[.NEJ;0(AHIT95'1]GF1R "#
M"AX !LKXCCMNMU68V>L*ZP9*^>Z[[Y;[[KO/%.P==]PA-]UXDRK9Z\SB@<^,
M2DE3ZC',^'I^(69R74Q"<9WN/*T]_X,V39Z]R/SV+%A64#" &[8$88'$>7/G
MZ9T2.7;LJ%FG6/<(2PR6&X:W4!K,=D,I^:$RS^0SJVBWS)@A5Z]:9;X^?+.W
MIT?Z]7TL3/C\L( CX70Q9*6@IY]A-;W.=P Y6)28F=:IP(=P>9XA+I08VX%0
MKH UP"O6*W:X9_L0AD7CJJ0KR\JEH;)6ZJIJI*JBTH!4DP*W4VWMLG?W'AG2
MYQ+Z'&"Y2$HH:ZT7Y!] 'XMJ(7! OF,%HIRI-T/)(;,F,H1)>3$$RMI.ISI.
M&6C%"H@#=%=WEST'4Q\ NEA[;%H\372,8<7!X0$#2H.#;OTC  \@#- -2+8%
M&14(%;*2>B(=^6Q^3/H>83D@EAOZNRBD6<OW8*QHKI-U><F5(A7I0M!% 4.N
MM^N<'&GL!@RRQ#GJ++AFA\N[%T+Z/.-T#.,LG50!BED]&H_:"LFL;U)?5V^]
M-YMQI$(=_Q7\4!"R9 4.I0M4T?(L[XYH."/I87W6;5G@\R_(N/,B'^=P4/0(
M^8-03@ :!+CSC5#A/PG!2:^?_;F8*43OO+VMS90'X1/>X2.'Y<,//Y!?__K7
M\MQSS\JAPX?-0I1.IFW&%M8QMN,84#!C^Y$I^_5^&%H),PL;$C= SM:M6]U4
M^OY^Z5#%R# 70VCD,?>P*D'XD)!^_'JV;MMF"FK/GCW2UMXNS0JF &E;-F\V
MX,+0V$E;/''(]B=;MW:MU>V.CG8Y?NRXFX46B4J:[1KPB=*XU%162:<J:/R'
M $FIH1$[LJJW:E>M!SCR3J[N^S(;B\^5>-6]KO'!G !?0!J=3C[D&&=>RF9H
M:-"6(6#!RD*K.E,78<K"64?=-8:7&>K\@S_X _G1'_Q(OON][\IWO_M=^<,_
M_$/C'__XQW8/_L8WOF% UA;0U#\V#,81.IQO/A]C468;EFA=:+.E&!@VIN[X
M(T.ZK%S.<+:OFUB! 68PY^R?9QS<AZE?^P_LU_KA9BC2ML+?#?.XY,MI% ?W
M"A(IH@T[$%@2B:MLP?<)R]8$OE>D(DTCNB@^0X.JZ+J'3\FF?>^+E/=+)CYH
MBR[:,%DDH8V/1LOL(@2!"C9>9<YG8*I'R9R=+B"FTT]A+N>;X_%X\H*<\?((
MQ8JS\-%C1VU!0Z9ZXTA<5UNGRC)IZ]U4UU2K(HY;<ECKYK@J<&8GU9C2WJ)"
M^[3<>/--YG=B/4D%1Z8(+'OXS^>#?G$RPV3Y%+P"F$ XH_!W;-]AX &K2$-]
M@TUM)P[.S']F_A?*+X#/KIT[Y>677C8@Q] 40U(XD4=5V;"('4-;"/[&QB9A
M&GR']NQONN$&N?...VUJ_^Q9LV7IDB5F70$T8KWQQ#?LJ(Q%A^$R+$-8A;#H
M,%3%XI'D&3. ZC4=Y*$MZD@=[>Z6U==<8^6BD9!5JU;9,,C^??O,/ZFYJ<72
MBU4)@(L/T3577VT@B7C,U&^UM9U4P'9(OG#W%U2Y)B2N^5>J1ZQ*G!-N@Y9?
M^\DV6?OI)^:DC06,1?]P2@\/D4$^36-2H>$L:WOCO#<N^3#R>6P*EW68"]&H
M9VS&&M?('@#S8047.^7FFV\VJPN 9]3S ;.T W70'+3U7<J/A3%;M?. M95R
MH<YBB27_ :BE9:R<3KTI-?"Q;MUG"HAFR;6K5Q,K\Q-CY7!7IW-YR]((+*[Y
M_///R1MOO&Z++6[9LD4^^=@MJ+GNL\]DP\8-!HY85-,/SW&/HPW1*:^UX[KL
M;^X=.7)4%BY:H"#0K;%%IX?TY5.A:Z,)T,@S.78^0T@B;6.CALE*))XJM?O'
M^X_(MI,;92 ]*-7Q<KEF[AII*6>8K,Q5)<+1OR(5:3K3F5KL I,)+54T].XP
M+9NP+R"_ISLAX$@WBA0_FV0R:0(:JP0"'_/]<04#;"#*+N98,@ /+<W-]ISM
M;'Z9DQORP*%5\T-[_:S+0J:P@SPSRT@G0X>//?:8?/UK7Y,;;[K1E ,SVN9K
M;_^:5=<H7VW.QRB\&0IRV+N,J?4&>I0!-C!.SSS'$!E^0->N7F,K&J,<J8\H
MPLIRY]P\HVF&6:WP(0*0X. \=\Y<&WX9'!BTX104+5M^8"'"@1L0 T@R!5M:
M9L"K6H$KPWM5"FJIZY1?2L.%L#JPJC9K- &:: ?$@9ENMLJW/ELD1S:$F7#K
M1DV6:%< 6  \1_/IT;*B;A7BZFHWS 6Q)0OE6HBH,[[> (*I#U@2Z3CYL%B*
M@;J&,SY\K0)H?,]@P#?@#K[UUEN4;S6F_6,A-0NHUH%B/2A2D3X?FG(P!(%]
MK#>G?V;RY1K'@*\$0B #B$AO4@4JE@@$*R"QH:[>?&40B%A&\'? 7,^&J0R=
M(2"QI! &0,+3Q<@[[^!Y(8AT4/HX2@\/.ZL6YGEFE>'7@9(!K& MPF$5Y8-#
M-<,8O7U]TMW7(SV:1_@"T8,G]2A.K$ &,D/,4!=',@P?HX'!_NQJT5PG_]]Z
MYRWY^)./;3@&GR16NV86$T-DGVU8;_Y#[1UNMWZ^N6/7#GGII9=L04CBOE?!
M$&7XSCMOFP4 JU"%]NX-Z*@21C$SS,F['#,*C !%3)_7A)NEJ$(!664%/B?G
MO\?;="#J-)8>G)4!HUYNC$M!4Z!<> \@Y9EK'LPX=B 5<([/&F"6[V+MLSH#
MT;9"S8LZRJRS!Q]XT(;7GGCB"7GXH8?EP0<?-+[C]MOE]MMNDR]]Z4ORE:]\
MQ9CUB!YYY!'CQQ][7+[RN%Y7?OPQ/09\ZZVWV9(5Q!G@3_R(R\5HVYY\\[YX
M7RQ2D2X].G\P9*M$%^ 0T=8, G$RJN5=.<T/H0N80>'3:T5AFK+4WBAKELR8
M,4,%=\*VC<#'@ U'&QOJ;287BIKW$9!>,?ALG&JZD"5DEB$]HIQ(-P  ,SU@
MA[67^!I#&Z2SL^>TIM$MG$=^ 288JJ 'CK,U%ADL. QIH42L:O$13R@4_1[.
MY@ CE T^0]Y:<.+X<06G#H3MWKM;E5#2PF([#<KED/EZ'+#A+\ 9<:(<*+=/
M/_G$ !86**;N ]0(<_.6+;;M!D19FT+32'&>#@ 0DW,8V6IN:)*6IF;]UHB]
M>^6TA+,3>84SLY5I,+UJ(M82#QZH6_Y]S]0A#XRPR@*>8;X%^. 9WF=(F#98
M"/P#E"K**FPVY0TWWB#WW'V/W'///7+GG7?:3$+6G:JKKY>JRFJ-0S1@Y]<$
M$SMO^;%UQ0*F_#M/==IUXH>%TJ?E0G5"SDX7XQM%*M*E3Q?%,E0D-TR"D,.T
MCJ4  6V^*4I#(VY%9WZS>2>@@&FZ967E!AA0E@C-RYU,J:F M]Z^,OD V,/Z
M0T^=5:3K:^K,UP9'6@ *8,3 D#)#6  ;  G#&5AEN$Z^AA4/C.6'12%'4B/!
MT(?;V9YO4 :L672=*C%FZK'4 =8@VSE>";\AAC V;-QH#KD0 !7 ^ICV\'%R
MQU^$82]\1VZZ\49[GAE+A 58<Q:&$ILN[ZT3WKT']<,T?"P-205)@"\4<Y&<
MI0_02;E3OH!8#PXF0N0C^1GFL+7%./AC>)*RL?:F=8KOT=8*$5/W::>^[F(I
MPJ)765YI +VTE#H;L6%N6^5:V0,QQZ,!FF?25U5=E742!\@13I&*5*2+2U/7
MZEBQ5&48E@P$0T9&;!7EX9(>*8NI<LNPBD6-I-)EDDFIL(B66H_)5K2VO<EX
M>5!CV*L"C'VB4(!Z-<UT6Z*-DR-K$[FU:L[&XQ-*FF\KV\J[GL^/+)::#)AS
M9A%%&!92P%-=564S94I4($94(+)Z+=-\Y\R9;8(1RP-"O$>!0G4U"\]%)95D
MZBL[2<=L9>,T IS>I?ZE(L.2B@XJ#RF/Z&_M>4:TYZO)/Y/UNMWGW9$SV$+4
M<O#G(QD-6W_#F5A&CX7S!G5>^'N.5<K+H"J;8550E36ULG7'+MFT9:LD1S(R
M?]9\:6F8*;&(*A:M"[45]5(6+9?;;KI-;KSN>FFN;Q#F\\23&2G3P,JU#I1K
M'8/Y'>926.L+FSF4*[!JK&/_.WRT*F3ERFMDP8*K5'E52+WVY&VZ_E57V0PF
M/U2%PER\:+&M9=30V&B.U%@4<,2MU7CC-(VO!S/\\%E"V3$K$'^0TD29E.EW
M>GK[)5Y6JF6A^153X!9/R[#R4#0I_5J_2QLJ9=;".9+6,BBM*K5*PGEZC+P=
MDVP+ECP.-VO-]S/: V4Q"<I_W\(H0.1;SOJ1X\F0AFZ ALX JSHG%4&F]7M:
MI*X.A<C"UV<]N+$IZMIVL C:[%5]#V;-Z>%TRCB98F5U?(OT6R5Q!=B5"DC*
M]'F D?-3 HM$M#R,V;(#<YZ6353Q;;4"8>H '9?^P7XY?N*X^??A?S9WYBQ)
MZ/=+%-C3S@&_^L]8/V9I,M:X>7:@20/6ZVG6-]*VG8DX3CD)DN-"91WF0F21
M4, 'LZI_A/W4AO1<9:RM\D]&6 PU0U6NC"!?L92YS%9)85RD(DUW"DG-J2&:
M&3T=A!9*PZVEH0U.!2<]?.L1ZQ'62].6S%](!:0FU-(.T,$IVCF51URO5+FY
MN<6&7Q@Z.MUUVA0TO4?\C'ROU"D=%?^7688!*,HKRF7FK)GFW,P4:!R8JZHJ
M[9[E"ZOZIK""96Q!2H8B6.BPKJ;>%"6$G#:VIPHS2H=>-DJ2X0AZX4R!QX+S
MT)<?,@=LMA)IK&N4E2M6V' ':SM=?_T-,KMECM75UOGSS?'U@0<>L UJ6UIF
M6!SFS)YCZT/=?__]!H!PGL;*Q8*+.-#B_T5:XJP'5:3+@FA79KU#%A6@I**G
MN (FVBO63*R+#)&R5 1E;X[\#8U6SXI4I")=?C3U8$B5@LTD4^7OE3GJBNN,
MJ_L99E[)3U?"H=: GQ)'I@6SP-E ?[^TG6HSX5JC2I2AF-;Y"RPO3IXX:<-
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ML1[[U%(A2]!YMYU)4'@X*?Q=ZCY;FZS?N%X>>>QAVPN.^IP/9OA-60&: ;P
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MU;K7T]-M\?%[KG7U=.F[/=+;W6LS-;O8XZ^_2WK[^F7P](CT=O;(OI,[Y,C
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M6^\0JP1'%#U'FQ8^,&B^1]Z_B-XF8,0M7MAGX4 (5D 0_CCSY\W/]9*5,%9
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MV)M,>]^J2$[U'Y==AS^3_OAQ*:LLD>5-UTI=;(X**Z:9(_SU:5KW* =J!$$
M?O(=J,>@4<+G7&B*VCSQ0J"R >N>?7ML6 7PP[8-]#(16@@[-D3%3 XPX/G7
M7W]=?OW2KV7+MBWF$W'LV%'9O_^ ;>B*21Y_@P,'#Y@I_I J8YQYO7F>65I[
M=N^S(UL)L,OZX4.'[3[7.![6YS&3XS/$E')\=E BQ-<I(GK1E@(]DO=62..4
M0F$B3!BP-C@PY*Q "M+FS)VM/5RW;QAK&R'@L; XT_V ^43-;9FK0+%-/OUT
MK<T(8QHPSN)+%B^VJ>\,.:+(PE2H+O@9-0: 8@E31A8GE(^25SXH$M+O6;6>
M72?M6"98"/"##S^TV7D,@:&$"*.LK-P =6?G*3EXX*CVX@]*;5V%M+342W=/
MKYSJZ%(PI&5W_*3E9WEY0A8NF"TKEZ]20%;.A^WZM"?-3E\^OC9E@BS>N'FC
MYE.'7'?M&K-NXN@/,T& ]M+4V&B A7)A8@!.ULSBXYR) ?B[X7]#/0(\ 188
M7J;38'5*VQA6%;Z!E07G:=X!8&3]DS1LHN/C"*CB>UA?J&OXCT'#(T,&S&FK
M@"!OZ2E$6(OX/O7$9G,I0]2U,^J;$L=L'G'4?]QAZ-=F/FJ::3/D$</*Q(FA
M=#<K3.LA[UE]BFFZE/4"#NH:6^L(1%-E$BV)2]O@"=G>OEF&2_JD/E8IU\Q9
M(]6)N?JY"O=!R$6C2$6:MG11'*A[5$#L.KE6?OW!?Y6399])?4N)/+'\RAHF
MH]^(->+]#S^0-]YZW1Q#$6#983(5UH B? (0U  3P.1++[\DGZ[[Q$!E2;Q$
M$J4)#4?3J<(1!VG\;1"J"$[O;(M 1JGSS73*33?&7P5?%Q.H/(O0U[26:J^1
MG=RW;]MFJS"SQH]M69$<MMS6A_1;>G8!+$-.R"/L<2[ND\_6K]?O#,GR5<ME
MUMQ9IDQ(,T(=_P?RPM;^F3?7K%='%,C]W=_^K6S;O,6&._#/>?CAAXT!403L
M%0E4R#*$@J0W#_!D=6HL"?AMH#S(?ZQI*#X45KA7/J)Y[!430R\,D[WQ]ELR
M:_9L<\)&";<T-6O>X6_!4@H#"M[ZY,TWWY+*ZHC<?.O5DHB7*0CJT+3MDE=_
M^Z:6N::AME3N^<*-\M17OR'U-2V:AJ0IKVE/FI5911^R#'7W=<FSSS^K=;5/
MOONM[QA(8-9D;V^/E4MU%<-AQ^2MM]Y2D%EGVYY0;K0#RIOA9YR'F7@ J*<,
M83H/#%_2%@!'?DVN3S[]5!Y]Y!&YYYY[+"ZE.$4'=4AK?-;R@[_1Z:[3YMO&
M[$8 ,+,P-1'ZN ,RG@R8YQ%M/_<,M=Q1(<N0!T:C2'^21S[/J,<\X]JYLUSA
M5X0O'7NS 0:IPQFLF "A2%Q*53ZD58[VQ@;UW814CM1*0N+RX<'7Y*7=/Y.!
M2)?,3%7+C^[^%S*_]@Y-?]$R5*0KARZ"92@MP]JX3_4=,\M07^RXE%^!EB$$
M',(9 7SDZ&$3X/3LZ)&:94B!@%F&5% #AKA655%EO<X9,V?*#3?=H,!@CBQ9
MND1:YRTP@<>NWOC9+%JXR-;*N6JQLA[97F+YBN5F,5FX\"KS!6)_,0"6/:O/
ML1_3LJ7ZG#X[<\8,6W21-7>(#TZ_"%F4BP$A(\J'O+="&J<4"I/UB)4!K#C(
MMK>WV7EC<Z.MW8.UQP_YH?Q\/M34NBU(4#K;MFPU_R9 *XK++8@86(;RJ%!=
M(%V4 ^4QJ.!PPX8--AL,8.IG!U$.$''E.9BA-<)#T;(.$KOM+])\O.<+7S E
MR] %0YTET1*-EW-ZC\5*9<^>?=+=TR%SYK0H(*W6]*5EP?Q%LG;M>JT+I_2;
M,2VS>;)\Z0JM#Y66WU>R98AAH"U;MQC88/@*GRR&R !"WF+I.PSZPZPZ./P#
M2'&TQ^**%:FAOL&VRZBJJ;;RF:EMR"VFZ?;!H[P87CNM8;&,!>W)@R=/R"\?
M1X"'G2M39XF/OV<4W(/-7RB?]?T<P '6^#\7=C[K?^[1@+C&,![QX]O40ZX!
M[@!^^!#A$XCUC+3K%^V]1)0)!.0?EB&]IG(T%<,KL$)B296]&LZ)_OVRIWN#
M= V<EEF5S7)]ZXU%RU"1KCB:<JE+@XT$UII,&I\5[?FKTDMI3V.X9%B2"GQH
MT @6$P)9 OS *H1,*:L@9*:1AG4V1DF>#X]%A;Y5B,<2&O0L4:[>K)U-KS*F
M<RP;?)W97BAEA!XB"R'?TC)#%66%GL^0YD:$>8V4)BJT%UPK38TS]/XL#3MC
MBP-BV4 9V.PF#:.BDK56 "!I:6YIT&<J9=:,%DF41&76S!E2IT!$RA/2E1Q2
MT)J22()M4YCEIY5#\R.1BD@BJ8H("Y-&,*J ))+M+IY)I(%2&]'_AP#">F3^
M(,QV!QD%"['2A P,LYW H&TUP%89IWLZ)1IW3MWX<C ,<//--UEZ6&2RH:Y!
M[RN(T?=+RA(RHO6';1.PV+!Q SX]+$_ %@,HU:CF;UDF(I5ZH2(3==MT*)?J
MS6A2ZUY/OY3'$K)_SU[YY.-/;(TC]@DKK:C4WG-4OQ.5'K90T'BG-$X1%+(^
MS[8*>P[LEUGSYLI==]]MY<G,-, 4CNO,$F/+%;;CB$2'I:/SH(&UXR?:Y:5?
M_4Z20Z5263Y+CA_MT;16*#C"XJ1 2_/!Y5[,?)<\?V[D.R5AMO@YFDS=+T@:
ME&]SZ8SF<F98F\*(YIM;/@++!PL!TCYH*S##0[S(D;6!&"+%(M)YNM/:#WXR
M.!1CO;&5WK5>558H,*U(2(O6\T1I3-H[CBN?E%FS6V31HE9]+Z[@5;_'?H@:
M/"!#*X#6<ZS23,5W,DLKKB3B"G C"7U,W]%.',^4:*6&7>5VG"G =.JP^.6S
M?\<J;2 /R$:?YBQK'33_'[W+5'GJ(]N08-4\=D0[!]JYJ-'.4VUEE<8E;99;
M.&G% AAS+;%\I$3BR5)MR]0Y@%%&AB))\^TLT?H:85^\5+7& PNG!D G--L1
M+5*1IB_12B\:J>C31NGX2B/?X\2'P:\%0CZ8TZ:> P+H07)$P3J+1"Z_+,N4
M]2SWI[\!6/1H;<=MAG@4='&/:X!,ONM[DPSOV'6F(:M@/:D@@^$"B'"FFHB#
MQ4?_.,>LSS3?K=NVF4\'8(*-6[F.,JNIJ;5>/:;__0?VF37 Y^,(*QHJ\5RI
M#1TZY6G.T7K$R;E'04EW?Z\=/?=J6"R"9V!#\XFRX!U6X]ZR?:OR%ENA^O"1
M0V;%V[5KIZV%=.#00=F\=9-LW+C)AES*R\ND5L$HEJRAD4$%F+/,(D?9G>H\
M95.O6><(JP56!^*&XL+J! -8R0-??CBX%VGBA,4(2P]MAWJ!_P\ RJQ(6D=H
M,]0#?(NH[UCMVMI.&M"FKC T#8"EG>4V^;UT"8"$)10+\F>;/Y/7WWC=K)/X
M#)(&LW[-FIGUE;+V/ $Q:S)(.Q0\SSE62>IED8ITI='% 4-![\9K=&^!L9^A
M%LOOK/*?2$N^6(0D.D\B_?CTX."(4D3XF!.FII4U4/QP#,-"?CT1AI'<'F(G
MS R.PF8K#2PE_(8/'CP@1XX<=MMLV.^#IL095L)':$1! 2##>I"L6W+LJ#E9
M[]JY4]:N6VL.I.1W+.8<1,EV#E-!6@LL#P@?AT[BN7?/7MF\:9-\^LFGLF?O
M'@4*I38MN+ZNP=[!PH4_#G5HSYX]E@X<F'U^,=Q&?:)';T!(01)#+72TRS0O
MRQ0DEE:62UF%8S;8C"5B>KU">\+:VR\OE9KZ6CEV\H2\^_[[Y@OTVFNOR;;M
M3),_:C/>WG_O??GHHX]LP<PM6S:;TSEK.[$8)GE+//H'^BSO *0,\5 .;1TG
M+4_)8T#2W7??;>!IAP) CM0!A@,)8\HR_7(D9$5 7AYX<G4TXT"HYMM5"Q<9
MX*0MT5:XAC*O+*^T&89T""#J6F?G:;,>,92,]9.Z1+ND_'S=#_X[@WP\?%S"
MO_TUUW9&7\_>"GZ[<_<[2_8[.%?*O9MCXAE74,>JY0SK,OFA1=,"T*9],"0(
MR*:-\;S1!.06SP(:LZZC^DX6#-DE IE 0$4JTF5.4PZ&# 1H8V*HC/.</T2X
M@>FY_@LW_DN!LD, (>%\KH0YGQXJ2INQ?00P2M/RQP""2[<?YK)M-[271P\8
M*P1#:Y[]7EF<,WO)%G.T/-9>'4-<&B;3YU&V!KI4<1 VSM?>"L$6%;P/^.!Y
M[M-#G$JQ9\,^6K3,P $ LB D>S:Q1@H  0%O,V$T#U@IF]ER.#B3!Z2MHZ/=
M\HSJP6_2Q9( K!>#(@2\G##P>%P.'3DBVW?OE"V[M^MQEVQ7\ ?OW;]?#BLH
MW+M_GZTDW=O?;\-CY0J.9L^=8SY ;,A*OI$_S.I;H KGAAMNT-YWO>7K' 5K
M?)^UCQC2H89CX8LIP)O5/-/\L4@'@(GKO3T]LF!!JZRY=HU=9QL2E#8 B7#<
M,#'M(J3(KE"R20":![X]:,98_;1C\(PGE#;UW9S?M<Y@=659"A8N'-(Z!E&/
MVMK;;0TB@#76I#)M3P: [(EPGI\M[[GGV,5+_ZELP,+KY(->US\[SP;#/?T9
MA,\]Q_8S!\*4_#6((3'J19AYCEWOW??=?GLM,V;8<&&"'?2'!FTA53H"M''R
MAO?.R+0\XNOF *Y_]KQ>"+_GXURD(DUWNB@.U$EMO>Q-MN/ .G.@3I2G9>7,
MZZ0F.E,50;E$,N76V&F4?F\RVA^CXQI%/4=1:"LU9]X)M.X+1!=2"+ "-+._
M6+1MGRIBA!G#/VO6J()404[Z4< H2  1#L$(-7JO*AV%?;5B*O2XA^ "6 &*
M>(9K*(+:6OT=BYO0YWDVQ<69%^$&P++G]7Y-58T)<7J4S,A!R&[;MET6+U@H
MBZ]:;$Z5)N3UCYS/D@I_(RN;47?.(.*(=88W?"Z2GYCPF0F&%6?MNG5VSDPY
ME@5@>*RCK5TV;=QH@,$O$<#,L@\^^, L,FPW@D\.0 @@PE :>8DE#08\L581
MPW^G>[JD2X%(3W>/S01BA6XL:( JK&-'CAXQ"Q!Q77[U*K,>,(2R7[_++#96
MY :0$0>^";BITWST*P,SM+=[]VY;I@#>MGV;[-BU0YA.S\K ?E5@0.W)-JQR
MQV7OGD/*!S5^G>;?4EHF<OT-JV3YTN4*ILHUKX),"^AS4T19Q_DPY4KSPL8K
M^)8&R0*)FS3/Z#Q<?]UU!@Q8 XKV@8+G""#&>DH9,=QK(%Z?XQI#9L3-MQ.<
MI+',L0@F3M05Y97"0IN +NK#ELU;#.S.F\]6*6XM(NJV@;(0\=O2K/\ ];0M
MVBNRR3H>6I]I9P!;6^<K@L^8AJ'A\3SO,AS',YP#A*C#O.\[BF<37CSOA]89
M5J;-8A6SC8'U-6]M!QP:F D(F.,G@G&,:W]D**;7];O1=$+O9N18[S[9=WJ+
MC&0&I#G>(M>WWB;ET69-JK,T%:E(5P*=7:-=$,+BX/U?W!5O;:'1TA@S&?P_
MM-$J]J$=<W2")^ "9."),//8VFX^CT5CW1_OO8 *?C](8SZQZ!M#5JPC1$\6
MPOJ#A8!>'7F$<$7(H@@0?-Q#P#N0Z%:[Y1I18UB+<^\7A*-U/,Y:*[425^5!
MT0(44 J ( @@@B*PF3@:3]ZKK:LU98U"8<B)[Y#E6>&OX0!*;5J].8(BX'/5
MAG) V"/X45:6!OV&^2THTU/E''8.L6Z3UJ[>+@U&E4HZ::M>+VA=*$WU39H>
M5OH=EMU[]ACH8*%%X@O@81H[^WNQ'8(;UG,6-];T04%Z0(03\]$3QZ5' 6C/
M0)_T#@W(,/%0U3"D<3O9V2&]@P-RI/VD]"6'Y)1^(ZGAG-#OO?SRRYKG;@7A
MHPJ6B#?#CQ]\\*%]APUD\1EB7:9_?.8?Y?GG7U!^3EYZZ25YY957Y)__^5?R
M[+//RFNOO6JSSH@7^VR]]NIK\H__\(^VZO:.G3NM?C&K"0L=@,O*A,P9H_Y<
M$*(XS\9ARCKVACA$V3KO&_4%(NH/]=U;-P#FKDZZ"/IS)U/2MMZ361.U#K/^
M$%8[.@8L7DH].WCPB'8.ZF7VK+D*4.(6OOD(:1A$/6OY-;9/%"1-J8*780O;
MAI^U'CD?M6 /,*TGU$76Q3(@I>$!DGR[@&AC/M]H>\@$#W"LO6C<8(;\ $IA
MYAL0OG!8EA.1F'6<B#N+0#+<F]!\R.CO$<+1/(0IG1&-#I,-*,$4$Q!(JZ8[
M$V$)#@5(D4IEK*^:IQG]EKYG/1E>]ERD(DUSN@CK#(U(KRKX76WKY)_>_2_2
M5KY!:IK3\K75/Y YB37: *NUAU*C#12!H8W0UAER)FY;8RC#-&>:,?=P\G42
MRX!' 4*XY=-XSXZZKY=,6$R Q@JW$ $*2,)+O_FU;-JZR4 *2IUA&38D9;@J
MI<\PY 4XHI=Z^.AAV\]H<'C(!%YW;R]!Z(=SWT5QN&/N'*=1>J:6OHQSC/;
M!Z'+9#"VE:!WB> $)&S:M%F^]7M?EWMN9\L(MX8)QH$8LV7TCY!-/L)Z/BJ'
M](?E61 M]EUCEA>3< B#TH/P8\('9_?N71C\9.>NG0H\^N7::]<8R" -;*N
M\S%^4(V-3=;[]S2@B@@+S_Y]^_7=738$XH<*42*$CU)DME&_ J!8@IZO?DK3
M;JG0(_$V!:[Q'=3T$V9:ZR=K! TI\.0ZPY( 2)0I@!,%Z,HF:M\"H+*/$WEI
MRBA0;'R+Y_WB>]RCG&EBD2C^89KH=*4,#Y9H.&SGD)&^@>.R^MI6^=ZWOR^+
M%USMJKDJ+$_Y%HKSH4)M(TR3J<]ARK8CJX1V.DE2D*#_4[?Z!_OEY[_\I8'(
M'WSO^P8"ZFKKG#5'\YGG6"04H,SFIA = @_*2 -[<;$7&/4 *^EUJZ_3C'3W
M6<L,T +C@_;BBR_(/7??(S?=?JN4EVJG((DEA<V+W40$3Z6Q4IL!N6OG+K,@
M4A?PT:&\ >JV*K7F \-6LUMFRU!JR#H_Y17E!M !N\23][B.18MWK5YI6P54
M,:L0(LT^/=19B/K-SO=]6A???><=6R[CR2>>M#P#. +>"Y(&PS,DOTP;9$1_
M#*A8'23^(VYMKK5'7I??[?H[Z1KID,6E2^3'=_]/TE2V2I^M-1ENP12T%!:I
M2-.'+BH8^N=W_ZNT53@P]/75/Y29L=7:V"M5X=:JD #XJ%"<IF"(]8+*XF7R
MRFNOR,NOO*2]KXPI\MFS9IF A!&""#:4+<*/H1X$-KT]G']1WC:].!"44!)P
MXRF(-KUE !&*5/N<=@WABO!EV*"ZLMJL,?@OG=;?L;*$*8?O?^-;<O>==ULP
M[ ,V$3#DP0#*BALH")[!*L,[/.?E*"#O5[_ZE;SYYIN:ED%[A]YVDP(1TH&R
MH)</T$"!8-EJ;&PP,,%P "L'FV.X BB&F7B';YN"4>4"""DO9XC1S98KKZK4
M.#"DJ(K*XL!BBVZM&F:4F;^)@J?DT(@</WI4*A3HX)_$??**(4KRC?5K&+;$
MTD6YL"6*7Q.)^X!0LS;HN1NV<58^#X905)&X_F:Z=KI"@5.M,FL:I:57P= U
MJ^?+=[[Y75FY]'I)IP!./G>+8&@L,(1?&&"(=F1@5YFA8S8:[>P^+>L_^\Q\
MA>ZZ\T[;GH*RH.U0DP'1E/^^?7L5#+TX(3"$E8=AVP\__- L@]11AK@,@&O;
M[.@\)575-7*O=FZ^H$R>4"\)8N.FC;)ERU8#317Z++X]M&O64P)$,Y3M.C(.
MT!!7&*(>A8EE [!4WG_???+UKWW=K#A8=O4%"C!XBG?=^RR/P2EM$##$CT&M
MA@-8DX;K])TA67OL905#STC7<*^"H<7RXWO^;])4NE+SH4[?TS0H%<%0D:8[
M712?H4'M_70-G)#M!]=*?^RXE&JG>-6,ZZ0JHD)*$@IUM#>/,D%R!#Y#CK@&
MTXBY1X-TC3PDIT:1%R*C:*QVS'4?I&<.A<(H1&.%.P:5)<JD2P4U%A]  PH>
MA8M QT*! D#XLYHNU@B(K0;FS)DCS2TM-HW<UA"J<U/.81RIZ?V&N5J%,D-P
MY@!<@Q-PM5DZ^"8^-8!4+!RLS0(@,%\B5?#+%B^5&GT6H8V#,S"(GJ25(Y$)
MYY$[V#W"H+=+AJ"44&@(9S>$I_<#907 6+=VG?G3]/1TFQ(@O0"T[NXNO3]L
MRH7TTPMF6(%>>%M;NRDO>M< 1;[-NVQ4"WC"LF;6,&7R-*X*!NL*0U#$P7K7
M081YCN$#?(\H9T",#<O$L,XY1VVFZA,NJQG;FC4*:&PJ?9#O#.61IR@VP!=Y
MZ8=JF,$$>,(?B&=PP*ZHJ-3[&F:9AE-6(WT]#(T"^@')W=(RHU967[U:FAIF
MV?=]7*$)U\4)D \K"UKR^5SI?-_W+VOT )/;=FRW>K!F];46Y[#5%(!"F\%Z
MV-S49&7.4!,$..9]?,OH5. 31]TRRXWFJSVE_Q$&=8O.!I8>%EW$9P@P56)#
M@EHO\D H]<A9;\3J $.V+/C8VCK?K$''CI^P..-G-GO.;!O"HDXQI9_M<_C>
MTJ7+9-;,F5+?4&_QH<W@VT>;K:FAO;HZX]LVS/ W;9YS\H*VBFS =PWK$/'R
MEB'6#2)]/)<!66H+9BX=O_E>5&]S>41%*FMG15/:X=%WCO;LDGV=6\V:U1"M
ME^M:;Y+*6(L&A>6(< C$'8I4I.E*%V4[CBY59 <Z-\KS;_]%=ICLJ6M_Y"Q#
M)942SSC+4.8B6X:RI*]X13$9FDQ/&BL"*TKW#_7)H:.'S-* XL0B0X\5H(!_
M!,J7F#A+1Y*(V?Y=*'3\7ESO]NQDO@DH/,[-'\NE#\6 4^^Q(\<EDW*+UY7$
M(I)0)8XSZ8+9<_5Z6E:HT&9?* 1L@L4NM1SI<R(7C0G/0G6$0 ;( 4K8"'/_
MP8,*^([*X#"K1NMW@J?Q2=JJO6'V1ZMIJ)'5UZZV7BUYP+LXDA-/+##X3:#H
M4#!8CTJUUPXP6K=N79 ^UVOF7?,OT?P!S* \R$,68"0,+$. 'ZHYP L+0[N"
M*\!08UV][34UV#>@B<I(,A@6HVS\3"_S?QIQY6# 2T$C<0(0\0[*%TL#BMJ<
MSO4=5Y=<+F7SR;:842V45J 9J;+ZSG.=70?,,O2-KW]36N<LTS#TF5 O?"HL
M0^=NP9DJREF&^C0O?_'L+Z57Z^H/?_!#:P-U-77F6T;LR5\_3 88<.7$BLQ)
MJ]\ :4#.7.U U-;4FE,[Z06XV,S,,N0)2S$D9?OV'?+<<\_*77?=+3???HMV
M5IC,$;&1Y7S+D#\%X-CV-US0?]0[@/J+__Q/\MF&];;AZRVWW&( !R(^6#FI
MYS-GS'1YKP2HIPZR7I9SH-;@@B%MVA-UG_KAG^?HVL*(///,,U;G?_2C'TE+
M4XMMG4,>I#/:42#>:8:<M6V7Q!0,,5R-7U-&8@$8ZM>J2UU,I/2[Z;A\<N!C
M>7W_WTC;P Y94;E:_N"N?R7-B=5:]Q0,T? A[X5=I")-4RJ"(4A?<0IL<C09
M,(3U@:S&>C"0'#"AAJ6(;S,ENV\(OY245)7C2\(PSH I9@ +2CF%@M3K6)'"
M444)GY4"*QMJ&>#0U]MGEI;A@2&)*,C"UP'N'QB4,A6D!_;OER6+KK+5?5G7
M)*(X  4]%ABR?--_S(RK**LPJ]!G&S;(B7:W"2O*G$TA(3^K!L$^>]YL6735
M(BDO+;<U>D@GYYCCN8]EB(2B?/@$T^^9F84%"<4".+)A""44"XP%@*U%&IN;
MS%\((,0NXTD%0>0;W^]H[Y -&S>8$VKKW/FJ,*MEH*]?2K$F:33=D!> ACKG
MXN*;"'&'R4= %!&CS"A+ZWECI= C[QF((:_T??>RUFL;)F.6GQY5Z0YI&1\[
MN4N:6A)RQZUW2&4I>T%I^4[Q,)G%*8C6I4$Y,(2OUS,_^YF!Z^]\Z]LV7,N,
M0\ %>4LY H88JF)E;P J^8ZUA!E^O,>P& LJ$B8 @N46J#-<JZFMUG:;,HO-
MCAT[Y6<_>T;NN><+<N\#]YN\HI. ,W$^& )(T]XI?^(! ZAHP[U]O?+,SW\F
M[[[_GCS^V.-RQYUW2%-CDX%QAO.H(\U:)YT%AV%07Z8.++OO\'^ /"@?OJ/,
M=]VEC"1B"1L"_)/_\_\TJ^__^#_^3R9/F*D*.#S5>52:FF=*0WV+5%7622Q:
MJNGLT6I'FK3#H-].:B4'#,7242G-Z+V1&EF[;Y>\=N"_R)&^M^2Z^MOE#^_Z
MM](8O4;3J.W+9T$1#!5IFM.4@Z&T:M-N[7'O/[U)_OGM/Y.3I=NENJE7OGKU
MOY39B:7:X.JL=Q4M87HY>T:A@%2!*XC*[8LU#H5FNGB'PS"-<BX,+2U?"#@5
MHK&41T'@=0$4C<WFR*,P\ I_URM+[II+ .<%WN<!$[<  V4$-'X0$.NN,'VY
MXY2;DDX:%B]:[.*A MD 3QZ%-VHE#H"@RC)\=-*VBO2PEOF<.;.E6GOG0]IS
M)0R4@?^^!IP-UV_7$B8 !L0P%):BGMX>Z>WM5L4X)"TM3;9,P="0>\:4#/D^
M!G$'10OQ369O,<7^JM:%SJ>'=WT:K2Z=&9^)4OA;8Q&6K:2FB;@</G)$DL,C
M"D 7&2#3R.CU,^LPE 4SDVFR^DI^^4VDCH[7-B83AT+U&1@0CI?EFW)/?Z_\
M[=__O17'M[_Y;5OZP=:E"H O-LIC)XZ;@SU[Z=56URD8Z9']!PZ8'\^,EAFV
MEQ\K4<<5T "DL-RTM;794'1]0X/,F3E'XY223]9^*G_[-W\C]]Y[KSS\R",6
M/NT :R!Y% P4V_5"1/S9(H-X_^+97\BZS];*(QK.'7?<:?=/:#P!9_B^-34R
M Q)_- U3\R,8>,X2O\[6?FDSW=T]!I!^\E]^HIV!N/S^[W]?04^SS5#]9-V;
M<N3D 5E]S772.G^Q J%*38MVK#2_DDEM-\,]F+$D%:V0896U4>F1BM20Q)-5
M\MG>P_*;_7\A'?*.W+!PC3QU]9_)C,Q5D@"4!S(X$_@.%:E(TY7&;NE%FE8$
M$$+ (\ QPY>5EIF_@EE95 $@C;&:]/?UVRPWVR5?GT4IG8TL7/TSQ<:SREAH
MZ+&;&+5P&&YR4X]]'.SYLY"_CV(@')0APV"$P= #0Q6 (/AR(]*2S^/EQY5"
M6%P8BL1!?0#KZ+ ;&J+^P,R -* 2<1NW I)95PI+'T.D#;;%1LJV76'HEW<8
M2F.6(A,&3BH0/M&F($6!D]\ %L82:=;(21##VK:^D-9OODE;PIJ+]9*UQ !@
M7,/?I]#N]),E_-8(!VLI[6!P<,B&EVG/^-/Q/>+#<#PMDR4FNDZ?EM1P2LKC
MY5*>*#/K4FE4.5YJ5C?:E&U)HVEA/T!\DAA<*U*1KC2Z*& (91D^FM*<(D)0
M>IY6=+YYIMGA@8@I$E4XY8ER,_.S7@I6(?QIS&&X'&N)?M*L ^-\6)^CU^J<
M6#5\_0,,X?"*#T>?@BNFS:,4$-J0 T-V.B:A8& ;FM#?*"P$-V'A0,MP'X(?
MXOL3+7?JX$2>NS#$-\YD/\R"%9.) ZR9!& <-^X7+=ZY;XW%4T4 '.H*^8.R
M!\Q062ACMVT$,R[=K$. !Z"#Q3JQ!BU<L%"JRJHT/QU ( RK-QHF,](6+5PH
M[.^U=^]> P[<XWM8!SEG2 VK4*YRCE-)]3F&N(D3<2$LXLN0%744$,3DAYJJ
M6GWT[&%IKIXU;XD?LT AAOB.'#DJ;>T*?A3$,$2(_R%#B<R<Q(>HH^.4O/;Z
MZ_+G?_'G\C?_\+?RSR__L[SVQJOR^ENORQMOOR%OO/6&_M;S-]ZP84=KPYI?
M3-W'Q\@G?:K+NTA%NE3H(LPFR]ALLNZA-MF^_Q/ICW5(:>6(K)QQLU1%&U3A
ME9LBM=V2A9D]O*G_E>!?POE$J/"#60$4;LRAH;?S[8V?[_MC$8(QGQR .-.B
M$OZ=R9Z>^3Z$4*-,?'9Y(==^JEU.G&2[@CJ9-6NF4]3V6"[L? JC:'PGO(\-
M\4$IL#@<YGL<C'%<I;<*N ' 8.TA;$(WSDN3$=_WPT(:38;2  TI]@-3I34X
M1"_>?8O(^KPA[@7)?T*?8>@"!=)8WV  R])KM_!GLC-[])PI>#U;E_,HCG^<
M/L-W49KLIU;/;"&]9\,H&H\+1AK4!0WO',B739BL_ O$"Q^O]1O6!V %Q_Q^
M&]8\=/"0[%?@P_ 8L[/V[MEC4^</'CA@4\TI4T#(P<,'5+D?-Y\B=G/GVB$6
MR=R]V_QW> \PQ'VFM^_1<U:Z7K)XB>75_Y^]_X#2X[KN?-']Y<[=0"/G2!"!
M6<PY4\&BJ&0ECZV1K+'',YYW[UM^=]U[YZZ9>]^=M]9;SV,YVW*2/+9(9<FR
M(I681%(,( F2 )%SZIR[O_SV;Y\ZWU?=^+K1 -$@T*A_8Z/JJSIU4ITZ^W_V
M25B1/!S!GR+O^)YPH_^VO?Z:D:IKKKW69I=!A!BCA']N849U9F63E#N"'P:E
MI-9W'P;EA>_JU5=?L?%1$*WZ^F9-_TG)YH<D4Y^2IJ86S8LQV;UKKSSYQ%/R
M\M:7))\;T7B6I$/S:]_!([+OT''-Q[W2<>B@'#MT0H9+2C;;>J24.2GI8E*N
M6OH!:8[/DP1I"^H(C;P[1H@P2W$>Q@P5I4\5U^'^-^4[3_RE=-7ME.;YP_*A
M+?]!%J76:\MXSCD=,Q2&'S\T&\8,308(!B#(J<8<^'CA-^>T!+$(]?:QA46_
M3>VU :;-+59Y8Y%Q\:BMM/R8(?RA-4S+%1,^53TF>/:&8E/8@<%!6QY@;CO$
M-^[<J'^$[2M_GJT)HJQQY3V:SM'RP*!C=I2GJZRM=:YMO,D4>F)HT^:UI8P2
M"\>94*I$46R?*A3HFI6K;/H\2L;R1U$*UF(Y6X3#\GD]$717Y)D=I7%$J>6S
M.5FU?(413/*H5GZ?-=2KB?[YLG"^0;C^G5-.3GE'*@R@_J=__F=YXJDG;?P/
MI-=O*T-76%G<#$+VM*.K%W*-I0@?*8N4?=NM7OUF%B-A\'XAO0R^Q@^>]Y8<
MXO2YSWU.[K_W?NLZ8\T@(^PJC!D:5W F@&<)$WSE:X_91(0///RP#6ZVM*JX
M;XEX..N?OF&):QQKC1D*EYN)\&%!GA][["ORUEO;Y=[[[I$M&Z^S/.H?/"9]
MPUVR?-DJ228:I+=G2+[YC>_JMW)0'GKP3KGVVLV2RJ0E*TK.$EA_\]*J]6QN
M,"8O[3HD.^3'DF]^3>9(BWSFEG^6U?572DKSSL]PDUC4=19A=F/F+$.,%=&O
MV_8FTTJ@>_"$[#W^L@PG^B35,"(;%]PH38D%6C>DE C1)4+%%)J]<$:6(5^5
MAL6?!N<>88+EG4XBIU5*-9Z9%.H5E1ED@('+_IR*F@IS8EBF+$)_DV&<0JF<
MGAH1W+&-P.O;7K=N!69G]?;U69<$),CV-5/E4*V(G6>N^G8QF"@>I '1EVAQ
M0.G0JJ?RI5N+Z<-=W5W2T]MCXS]01HSI<)N<4N&J?QH_3^P OR%,^,78!E4%
M1KKHQB"NM+Q'Q[)&:E@["<L 4^_SZC=3JB%8IHCT>?-+?2!7L&*A4%BXL3[3
M*$V-JK@TR>RB3YP)CV<83Z(/NLB$8&G7ZXB#RVO2[Z\[2Z>><XMN/M*'&_W?
M\E+SB4U>Z;YA(<E^):1S6IUEB&XS1QG<7S6<:< B-T$XU/)CHKL:3F8"O&_^
M[+Q&O$98E^?0(26L)^366VYQ:P M7VXKD:_0XYK5JV3MNK6R;MUZ6T=HY:I5
MLDK=K-)[3)]?M6*E3:M?LVJUK%FSQC;-9=89Q]7<M[6!5MK.]<PZ(_^ONNHJ
ML[) AB!-&C&+2_"V*O$%O%(O7#;2HZ=L-$R9VG+%%4;*^;YIV$')Z)8.IQ4B
M5/G%B8K=UG(QU?NF_//ML)\:&Q1?=ME:F;]PD10U#B<ZCME <\;\X%]V+"^O
MO;;#K&2;K[I<UEZV7,LA8Z;Z9-^1;CT?DY3DI3!2DOZQDAP=W2[YNH-:)[?(
MU8O>+W/32RSU=)GQ39.."!%F,V;.,J3JA]5+L0R-:@@[CKPDC[_\MW(\L4?J
MVT_*1Z[X?\BBY"950 W: H$0-:CR"V8%F?6&OONW$35[M*I<*PA9ADZ':C>-
M>O8VHE)!4,]AID<AKUB^P@9]HJ##1* 6:K46P70M0U3.;$[*'EKLW,TN[)CU
M6;21Q1<9#.KC!UPK5OU7CT.7IP2A>D(&&2#.D!\&93.8E8J<*?!O[7A+E="(
MW'[;[::H7#>"LZ(8J3)H]:M$"@L5 U]M(+56YFP5XK.JD'=C-1"Z0UYZZ253
M@/?=<Y\J"'T&7S0>B(\7YQV=G3:>:?Z<^38%&I"/O >_TC'6+7X[5:?I"G\F
M/I]#UVI9MX(G[7_@E2IA$.>6YE;I[N^1X\>.J_)>%4SO]R$ZG*Y<A#%=2^=D
M&)?&\PQ"MM U#;]\_EE;#^O#'_ZPS<2JJ\OPXM0!>1.LFZ5_-O7;SE4J45<W
MF@XC%2KD'V61)RE?O%-(!=:?HT>.R#_]TS_)#3?<( \]^)"]%]_M"N+!ZNO
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M9(V<@8$^ZRZY\<8;+7&$1!CX"SR1H'+F&I8/NZ9NK&)WT9P \LHI.RQG$ ^
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MD>O>=9V2H0=/(4.L7>0-E4;L]7=:R0@$FNCX/0\A2G__Q7_0:R7Y[&<^:^G
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M+)K5R<H'94K+EOX=.GI(7G[E92-R-UQ_@SSR@4=DRY8MUF6*Q8<Q0?6:9OR
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MU\S<"!%F%]Q7/\.@\JE *R5^C?N^@E:9*0(]K_QQ'I*P-U9QZ:6E2Y=:%\[
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M##?\.X,XA-TRN-579@R09258SIV;,ZDH@LI:_YVV0KS0$,29-590<! % #G
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M*[*XF3@%.5U WB;*I%'P67,. &\F?\E7#=(1A00[XF.=T73Q3GB->D11<(0
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MEH"RT-;F]A:C!<I,(2IS6J)4N&$R1*7/=<9:[-ZUV\A0=T^W5=8H(BIYUU4
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M62EH.O*B#2ZMDS+E/DUG4IYX:YO\X."79*SQ3;FJ;;E\[HI'94YBC=AN.MI
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MK0Y4&2F1J+2C]3E[,E3I@XF_9P8^SBJ80;R<!D2-+4;83H)TV%!BTA%.UVE
MWH9E6@C'\6SD' *K"4H=0L#Z-A "9D)A(=JY<Z<L7K+$9@UNW?J*//W4,[)C
MQUNR:^<NV;5KM\GV[=ME]^Y=LO_@/CEX\)!MQKM[E]Y7-PR8/G3PH!PY=%B.
M'#YB&_3NWKU;3G2<D'W[]\F++[XH3S_SM/ST9S^58\>.VPPJTL=T?&:4Z8]*
MGOK\Y9U1IMBU'E#JB#MH:*BW^"-TX3*+#4)2T+1 2DQPJ\];.D.2H,M+_:?K
MC2!/%1<^?NA/(S@N+&913I2,$\U/(YM82?59_^8L'/9H8\*"WH*4LT$P\6+
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MO/[::Q@Z="AVW657LPQ>!%;?S],^48IS@N\B23]T;N)&$90G9I4?SW4M/UJ
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M:0B0[[Y!5'\;)><?_6PNF2!#IAZ6.(8,B1RQ3C%MIMPS;/>-L'"Q3I@>(H;
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M=.S:UE4R"*.DN!:?OO(R51E0=,)YN.S4HW#HR.,QZG?[&#?IZ<]ATK?=,'1
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"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_71.jpg
<TEXT>
begin 644 image_71.jpg
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MD9%\+H?G7W@>S^UX!LN6+4.&1%/^:)%4@J0E3O=TOK^F&O0-]"-#DJ)Y?EH
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M.TY[53(M=23B61%E$ME*A/[W(MW931Z<93@2)(I:H<P&F.0X)M*LV9=J$'6
M*$DM%#815Y%KS6=5C+6(16D0)H+=$Y88+3(+PD?2"/7U]IKF2<>MJB%OO-;&
MG;;EJ>FY!4D(S8VXJ%EGLM#,91_?HWGS:]/ 9R(Q\233IUS"T2-'<(PR.3&.
M7&X2P\-#R.5S1FRL,R=/Y=^YAIP,)83"SO)A)(GY8=%D?CL[KN0T6V\+>ZE%
MY@-95YEOE;8PRVUD/FCWOJ0-9@M& U,6K/R(0#*?=:J8GDCS*6VY/6_UXW1N
MJZQ)"'N3M[$(\TI&)OQ/G0FY++\#F8H/I6$W%)DU23 -1>N0.]+LT/);K92E
M7:_9]KC\9\[P7_"?AX?'V4!UJL=Y %6F&@9S]S[;3@LU3N'")1U!*=$]26"I
M4&9;Q09*FLM02&#UO%:+D$RJ+5-+HTW'TRC;WJ,)([2C0V-LI^ILC!R9;0@;
MJQK]C&4[2#QKR!>*B*5).DEB2\4B"KD<\OD\BF5WCGVEK.%)1TX5MI(:.DJ-
MI)4>LT%D'IO&2BV=KH$H7'9_]@BUD!KV7[)DB8FT4S8'4,'X&;:R(IX*@D@_
MDQMC8V.VUV889FG<;'B78A9?3HB4DJ2R<+%\, \U3U5F'F>&($^5CRYO:]8!
M,;,%"%<&G6:XI'G2)-;AHD2'G]UWX^'Q2H2O7<\#J$*4!D 085VH%?C+ L:]
MQH9,J\;;33NPDV!$Y$7LD2"O$T%-L@UT]S5I*:,I(Z 1FQ8@,IE"E>:%DE;T
MDZC17J460[D6Q>CHI+TKS6@\U8%,9P]*8JPDH#62$].J4G3.32R51J%8,L*J
MDW>T.T"!#5D\W4&>FT(JVXF.[E[3CM88IDHU2A*L>:$9I#MZ2'B2#'9 KJ4E
MMRNE05H5+ST7,9(T:X/. 'S7B"G34//Q>OMZ[5[IZW#VY4Q:)T?BW-4(*/TP
M!:"TPY(V4(QB,=HOE2QLTOAJ7TW-%^SJZL*R9<OL>%7]%JF)*L_EKMX4>3W3
M-)D5ZMC037U_BDM<Y81F@3900]2FG3.KY]KO5QX:TP"L/-3LM"K=:^YRDND9
MY_?ER@NA]%09FD>Z6DXH/RB:$F!Y(W$Y) NNG 2B*1NAG X*ESJKZBP5BP7;
M=4+3"BR\+(.JJ\T=N>WAX7'64 OBX?$*1*CQ)*&P:W!/PA=/IC$T-(8GGW@&
M#S_T")YYYCD<.G@4D_DB7XO;<Q'%\?$<_N4[W\.APT<Q.CR. _L.&IE,IC6$
M7V/#1+):)R&FB"(=/G8,M]YV.U[<LQ=%-KR//_DDOON][^/11Q]#+E^P,_4?
M>>11//3@(YB8S&//WOWXUK>_@Q_^\#8<V'_8M+:V"MY:T7:BSS64<X&(:0.E
M"=**9S6N.GO?%K#8G,*S)ZJM, )BA$'M>$ 4VB DS"(P<1+556M68^VZ=49.
M!P8&L'CQ8M, BZB**,B>B,E+!4>H'/G0<9LB);IJJH3=AR162?82I-LK%DPK
M[>B@M%5Y$/G3\;3JG$BSK[(BDJIGNK=-^N>:S\PKE6VG\0S*&=\U-TWD5B#S
M ;-7Q%3E;G)RTLJ>.DI&@^FN%0']KWM>%#?ST\/#XXQPKEH\#X\%!1''*8(:
MBAJG&,J5*IY^^AE\_>O_"U_]VM=Q^X]_BF>>?0YY$M4R"6BE6D>A6$:Q5,'?
M__WG<<^]]^.YG<_C>]__ <GF<3NC7II3#>5; RNAGX\]\23^^F_^!H\\_AB.
M#Y[ E[[\%7S^'_X1G__\Y_'C'_\$/[KU-OS/O_T[?/DK7\&SS^[ ??<_B,]]
M[A_-[/MT>VQH!'5I:^VS5,/6(B3$#N'U+$%G1+*D]=2*:NUA&4TDH,W0;7[O
M.6Y<118F)B9(5M5YH)]&5)5R,Z$T%6G1O-\ZB48VVV'S6[6-5I5FG9V=IGT3
M4<UD,D8<9G/KG$!YS'12N)3_E6 >98I^7WW]]5BV<B4M*8]>PC"\(D%RQ_*0
M(#E5J=>P?X+D7_.F=1Z_3;%@AT C*%8>152%TR2S?9',"[T73A.QO)$;)G2G
M<4^9!T1\14Y5!LLE+>9S[N5RA<"/P"+-7,W@X>%Q-O!$=8%#U9R;BS=5X6D4
M6,=<NM-<^(//HD$CZM!4\<I(0[FM,@^8=BV09CA-4HLH#.W\FX^TA>)$B2K>
MVL]40]\TBBI<DT!E@@G%1D.*M4J*]UDWU!\AX8F44(]5+-TJ]2H*I2(>?/1A
M_/,W_Q>V7K@-VR[:CK%"$7_RZ4_C__J__P!_\N=_@7_S^[^/'7OVH)Y*X8''
M'\>??^8S^.,__S0>>N()_.0G#^!??>+_@^]^_Z<DLW&,3]10+,;I?1HO[#R"
M1+0/^_>>Q%T_?10?_ZU/();MQC>^^T/\P1__%ZS=M TYAO'S7_XROOXO_X*!
M%<OQ"Q__./[Z[_X>>XX><AL:V+ AW=,4A @;[)BF)R1HQ#R.%E##*+.5I+9>
M9MR5"$H:.CI/5%FNPB)38+KHS/_BR5'4-"=7YL%Y_UIYKY_*?S?E@N$()(0T
M1C85@5*/\P4]DSNZ)I17453*%2/#VM)'FELM0-/\7<%-YU!>.G>CT'!JC82%
M[]<+*%4G,5X81ZY0QHGA,:8YKR=S&!HI(E^.H2)-=)+^QDAHF"3RSQ60(/!G
M +[96*/$DFV5I4Z[2E3JB%/TS75T=6+M]DWH7[>":5 AZ6+YC8A4G4J4[FU$
M06TC\T);_V:1^4#+W.?L!E/*%OM-ETBMO51+-5Z9PKS/)K/HSG2S[).\]O3P
M^TO;%)IRD7ZIB#.=F%C\-U4&FZ49*MLRL3(>WC,?5;HL86UZ32!-:+BE%]H@
M3OLBJQW)-&*9E!W$Q2_1IJJ$I-?J8GT+=9VDISHM<$R76=SU\/!H#]6]'AZO
M&H3[=MYPPPTV=/R'?_B'^(,_^ .L6;T*XV-CV/WB+NS<N0-/D)QJE?GS.W;@
MZ.'#MNI\T:(!]+#Q_,]_])^Q?_\^W';;;7CBB<?1W=U%=R-8M7(%LIFT-85'
M:'_OOCVX<-LVFU_YPLZ=F*#[99+D)8L7X9&''Z8_.]'3W6VBAB]/$B=H"/'E
M@#OKO(XN^K]]^S8,,'[#)T[@Y+'CR V-H#PR;L>1:M6T:^W5#K\\85-'S+83
MXE6-OYL/6+0MJQ+)I-L-H%)&@6;V+%] F9T-;4-4*9;L6$[K6 7A]EBH8/XP
MC\)R%0Z=CPZ>1&E\$I5<WJ8&)'4"%#L\"P&DL?;M:&2@E]^V-/LBH_&X^TY>
MKN_7P^/5 D]4ST-,:4X7(IHT"C]#2+,;K6O?68K6Z$NS09'6-4*SX1.#^+6/
M_S+^\L__"Z0 _,N_^*^(U+0BOXBEB_JQ=/$ EBU9A%JE9.\G2$27#/1A&<U/
M'C^**R^]%)=?<A$&^GH1BT8P,G22=J)(LK&2K%RV%!VI%)Y\_%&4\I,H%G+8
MM&$=)L='25A'T-.9-;=T L[XZ#"Z.C+VODB7#7>^#!"1TX*FGKX^7'W--;CX
MDDNQ9/ERI$FV"V/C*)"HUB<+MG]7J$V?\XX31CQ$.O@7%@4:N9&!P"P@)>V@
M\_RE;:WP*K]%!C+9#++L% PL78(^DOV.KB[;R%TG:B7C(K84$=R8]M*,V7OF
MF_SY&9='CUD09@O+OO)+G1/KN!5*.+IG/TX<.(P*.R"1I/8;IIWY9&-@626Q
M,?1_+D!W-"=5B[0T9]HM2&04^-N5,Y5O7D.Q5]Q4%U\./3SF#T]4SS-8;SVL
MZ]@ ^TGZLT&:#1(QK<=G(Q5NTBY2F9L8P]UW_@1///JH$=#++KT(V[=MQ=8M
MFW&2!/:1AQ_"X4,'L7?/;J2327MGZ9+%F!@?P\$#^[%\Z5(<.K@?_3T]R*:3
MJ)8*Z.[LP+///(TC?&__WCU81%+[YC?=C <?N!]//?D$?OW7?A4?^N '\,3C
MC^'$X''\[B<_@0_\W/NQ?]]>?/][W\5%%V['Y@LV.XUORQ#F2P61XHF1$10F
M)Y%*II E$92F,MO78_,&QX:'30M<JU9LFHG*FQ:GJ,B%T@Y6)BEV#1MFWH>;
MMO.'O:L[]WLF1%H4/HD:=_VYX7SEK","XR3Y(V.C=BJ0%MZ("&B++PU(APNQ
MC!B(_%LPVOOE\;-%\TX=O0/]N/;::['MXHO0R6\J-SJ._;MV8_C8H$T+LJDE
M]I)9;Q*6*3YK_BU[9BZ#H!@:0DMG 3F72B71D<U:O2(-JQ%6FFM*C95[_I-Y
M2$[#A6 OT^?MX?&*0>Q3G_K4?PSN/18H:M)HD5"5\A.8>/@GZ!G>BW2D;,=K
MUM=N06355D0JJ@3=BFK>N!=/A?EH[8**MA7.KQ8T66W[_(P1N-70Z,DCBHQ%
M1.E7W?9#3042K)YGV-5D*;JZZCSP5#J-;5NWVF(8G?NM8Q-O>><MN/+**]#5
MV6FD54/V%UZX#:M6K,#K7OM:O/'FFS#0WT]2>PFNO?HJ(T:;-FW$\F7+U/:@
M7"EA[^X7L7[]>JQ=LQI;-F\V/PJ%'"ZYZ")\@"1UW9HU)+#]6+]N'6YZPQNP
M8?TZ\V_+Y@MP]5578M6JE0QC#7%K<-G 1=3P.7*F91FHE4SJU1(B(HQ*ACFB
MG=TZ_;'5U6PY'9&GK00;W-Y.5"?S&".)C21B2'9U(,9&V=R0O:#!-6D'FFM>
MIX+LI@*2?%>J&#IQ D\_\PPV77 !5JU=8V34;9@_I2D+RTR4X8BG@H5=#*>&
M]L?')A 3H>[2',8H?OJ3G^+XX"#Z>GJ1)9&.1IP?@P</X_C)DS95H)N="4T?
ML/)!_X2S+I=!6%LQJ[MGZ=U9OOX2(_P>SQ JUOI^8U&4"P7$Z%YO7S]22_J0
M3J10*Y80K;I%42*"UF&RLJ7.BEU<V6$BN<,P=.](JPKA!(GNTT\]B=7\]C9M
MWT;+ZBPQS,$[#>CW'!%E/:MM["KU212.[L?2@P=03H^B<K* Q.;K4+CT6J0K
M*205)WVO]$>+Q(H%?K>,G^:RGFT1]/!X-2%2LY4;'@L7K)#+=12C54P.'<71
MSWX*J_?>A9[2"=0'!E![_?L0O?9M9$H9:$_0L/?.JMJN0KLZ497GG#%+K=JV
M80[\UV7:XS;%;%X%+W LPJ;,TL3IS>Q>BSK42-7C6:9!)Y#L8,.79.M <A)J
M-YH"4RZ5;(A8FCAI.8K\W=W=8\]R^;R1MU+9'8M9+!5M17(JG2)1&B?QZ;;%
M$Y.3.23IAK0J-J2G=XMLJ&BF^S3=4&A'QT?-+$F"I1.6% YM:R,_E#':Q%X-
ML-(RP<8UQJO]D73;/K"BJ&S8V"PRFCD&?@+U4HX=$ZTPGN-PIJ(?W#9#JZI%
MUA/9+,8'3ZHU)0'4FA4=;0J<.'+$&M@5))6= [W0N>G3P$*DAE=E2?,(P_*@
M$.G>MA<285":Y(LXM'<WOO'5K^%U;[@15US_.I1S.3YBIT)$56FH< 9N*$_K
M$8:D5F%>)9$;G<#(\ 3Z^Y<@3?*I Q+^[ __&$\\\A@2S(--JY?@36^Y$?%L
M!U+Q% [MWX=E2Y=C.SL66>:9.2[-*O/4PG06"+^Q5K3['MK;G!_:A=;"T,;Q
MLXW;O-&V(I'9W,*A*-0M3Z*HLF-1+[.<LZZHLDPD2$I+P4KZ$^QX:'[RXN5+
M;9<'2^LPO8.Z1?]/E1_5$64<VK,?7_C<YW#Y%5?B3;>\G?ZP,V]_37:)UH58
MIP0[D)5J$I.Y0WC^_N_A<G:81KKW()WOP,36#^..:U^/WD(W.OFY%"IYU/C=
M7'+)95B\>"D)M]O-(ID*MFEK"L.YQFSEU,/C?(/7J"YP6#56CZ(2J;%AG\#D
M(S]%]^A!I,MCB&1(S-9O1W3%!E9*TB(FK%)O5-A!'=BV*IQ/_1A4J*W2%C(/
MGS?+;)4F'\U)W']T2MH\W<D]2G#O-H\G(1)!U5&IM&=:PL".K(7BB*$[.M3F
M/J;3IG&5I)()TW@D$W$2I!C2F13MQ<EO(FP@4^(YID-*I3074G?T(WPW'D.<
M%A)J>$F\),E,TMECPREW0[?EGH:]S1^]IV>T(W?4$$H[[JY,2QIJ7FU4\VQ-
MJ^KFV2I^YOD<T,Z6-)U1NE&8F,3CCSZ*YYYY%D<.'<*NG3NP=_=N'!\\CHF)
M<71U=MBQL:-#)S$Q/(JQT3&,4R8TCY6$O5@LH4B"KS/5[02NW"2O>4R.CZ/$
M9R62<=T?.7+(B.6FS9NQ8N,Z$NXR8B0.06B"J 0AM80@L21159I52E4[42R=
MS-B^JCKAZ_Z[[\7)HR>0(='>L'XE;KSQ.FS8?C&6+%N&*CLAZ40:BY8L9G%(
MT%6FE?)$&3C'-)L-K=]!*.T@T[.5ME#Q;X/9PO&2H36PYGWCYO2@-=L*C214
MNRA$]1W3+)'MM/*I3DJ\N]OF+$_F<S8O60=G&#E5&DB".H&?CR-G)NKX5%AF
MA_'X8X]C^<H56+=A/:W-DF=R9Z[@>_6Z=BL8P[$C+V#%[KTH9D> \0H>?N($
M_O;081S==1C//OXH'N5W===]]UI'>,.&C7Q/?M;MFY\1!@\/C[;P&M4%#C6P
M]4H$A4@9DR>/XMC?? JK]MV#GOP18& Q:C?]'*)7OYD]=5;L;)A-,\7W&G/_
M^*-=53A?C>I95ZA5-^S:#"MX<W;66=2I3'JS3J+&UHH&=$4$CH2G'LN@GNA@
M*Q=H5/G*_,--^T:29@]?I"*_[6[JN2PKCFHDA<!?[1YE89A3.!0?7=58NU.T
M9$#:2[>+0"6'B#2JY1RMDJP&>=WP<S;P<3O?ZX$F]^"NW?C*E[^$7<^_@)Z>
M;I3+3HNL9\E4DB1P WI($'+C$[:'J,VUT_MT5:OSTR2Q(M[2+$\A@E+):8NU
M0$::X^-#QW"(C?H[W_L>W/3N=Z RD6=2!V3<TJ<IE%%UN$HLUR7$V:'(C14P
M.C*)[HY>)!F621+@O_S3_XJ=3SV'3%<G+MF^!K_PBQ] _QIVVJIU/$URD(RE
ML&';9L0[LG29B<!\LVD(0?Z>SYA- _BR:U3;P4Y1FULXM+A.?^YT)W8223HG
M1T>91PGK]*C\=/;U86)H"(,G!K%TQ7)T]?38M]8HA_3*""K31 OGA(CJA6@-
M1_;MQQ<__X^X[,HK<..;;A9_92<SS>>.W(:8GT95BQZ3[)@=PM,/?0]7W?93
MC/3N0;;<@Z&!-^'A]WX0JZ(K,#ET'"EV;K_RO_X9-][P!KSC';?8-"/[7!D^
ME7E7[E\:>(VJQRL%[DOW.,^@'CTO^B^\JJ(-*KZ7LO);L C30(T5&S%W7KU$
M9$[:E?!WD\A\AK2QURIL9$QD/S"K12A2:"?Y29DP#RBF#>5MA.'0_-/3B;2(
M85@8&7>O(?EJA=<R13L72-,HOQE?*PAG!KG+UIYM?I5$H6)S.J4!K9",RFV9
MZUZ;VY>EV62CFY"&.9LV25$R;/0U74%D.AZ51CGF5N#3W40LWA!-DU"YM"VF
MY+[\5KI8^KCR/*UAI9E*L4VKL&P-GLF0::E]6$NEDH51Z2O2HBD=Q?%QFU*@
M0P$$(\]Z)X!R[9Q"SH7B,6\H_V.9##M$+$<L(R<'C^.'/_@AOOP/G\.7O_ /
M^!+EZY1O?^/KN/O..[#CZ:=P=/]^'-R_%P?V[7&R>S?V[WX1^_:\B(-[=IOH
M?M<+SV/WB[LQ-CYFTPA$>HT8GW5>N0*E\FIDV<HDRQK+W]*UJW#5%5?;7/;7
MOOY&7'WM-;CDDDNQ?/ERO6"' N1R>1O^#]WP\/ X-;Q&=8&CK49U_[WHGCR,
M2/\BU&[^ *)7O9$57Q=BZ:RK^)HK/]XVM=,-O*(TJB11-E<RF@82G:99!<F1
MVVC;X4P:!-/4!/?-T!S5&1#9BHE<\:6F.(DT3\N/4R!B\VZ5X],UJGH[4BTA
M6LLC6IGD?=XTYWHV)]"!=C8M5/S\BX4\'GWH89*$$^CHR&)\?-2]0Q*A^8 7
M77PQ>I8O931(&D4<I8VR=VG'@D&:JF@W1;-. EDC^=6\UD@BR4:\B!=??!Y?
M^MP_XN:WOADWO?-MME F9<?5NM.QA+"<14RC6D:YDD<BF4)NO(")T0*Z>_J1
MZNK"\/ H_N0__1%V//4L>OK[<,5E&_'1C[P/_2NT2 O8^=BC=#N#=9LW(=Z1
M<2,,978"E$>!)NY<0+L+*,P6[G:)_!+AE:)1M8X#":2FD&BKL8,DEI_]Z\]B
M\/!!F\<]SHY'@N5'1_PN6K($*U>O8GE(,#^G\E"=$>VIJPY0Z*OFLTK3S@=X
M\K''\0N_^(MXXRWO0*54,<VM[#67@_EJ5"N5!"8G#F#GH[?BRMM^@N'NW8B-
MQ=%YT^_AX"_^)A;E>Y!(1W#\Z!%\_7]] V]_VSNP9<M6QJ/,3ZZ&=#IIQ%GU
MTEG7K;/ DV"/5PK\'-4%#JO":A$W1S4?SE$]@%1YW.:HUM=O1R28HZH3F]JA
M;34XG[HQ;(C/!K-5FG-VUEFT(3N#W*/(N*KYFOI%8A=-LIT,%DR8%I+"!HPM
MB]EK%A$I/9M-M$. :3);S-7XV;7)+<VWU(*AFB17<%=*47NST@UI4.26NV\O
M"J,6D]@N#W36KI2*2&F]3*)*J9?H7]E%?QYYTLZFG3+%1E,+O5:M6H5-ZS=B
MP\8-V'SQ1=B\=2NZ.SKLF$@=6) E84VP84VR R"M:4(2=T==)DD<1!YT]*5)
M*NF&<7DO+9D6HDGSI+FK+^Y\'ALON !K-VU@/&ILK ,R'A2/J7+&.*M'P/!I
M3]0JTZ%0*"&92"-) I//%W#?O?=A='C$_%LTT(W++[\8R6R'I=N!O7ML7NOB
MI4L18QC-79&10(-[KF#DB.Z9F^?.V=,C2*]6G,NXG3D4AKF&PZ6;PJT='2K,
MUP)):8W$L[>GQSI*&B[7X1P]O=W8N&DC+KKP0CM<0V56.V6L)GE=MVX=-FW8
M8#M*;-RXT>RM7+T:2Q<OP8N[=I$D;K%YJB*](KE&$)L[++.D9UO0;K4:0:DX
MAL$CN[!B[SY4LF.(5TD^UUV#R8NO1C<Z<>3X87S]:U_#MFW;Z/\VBPL+H'TW
MFJ,J+(S\\O!8V/ :U04.:?4JQ1I*4<K$$$;_X8^P^,GOH*,RC,BB/E1O?!<B
M5[\+*"403639&)/<\+VI"I"_FC2+#>A8P[E"6IHY5ZCR:VY%RLA)&]5NLV9N
M3F@3OAF:Y1 T:AN36%.C%6(VS="L1T<N4"@=VGSF(O&U0I&M+I\Q#6M)-N )
M$E VYJ63HQ@;/&':S&Q/%R(DFS&:JP/0 #-*FL\9$*].,.UTA"I)8RT=MRV&
MCAPXA*_^XS_ARM=<@^O?\D94BR4F._WD*])X-KNDPQDT"2*:))'E@PI)_^B)
M$:23W<CT]F!B,H___NG/X/EGGD.<1/7:UUV"7_C8AY&*L?-&,O#"LT^A5JQB
MZ_;M@!;#4;2C0;VB R 8"Y&4M@7A]"@QWIK:4*-;TC#'DVFZ6Z:;;1QDV,_0
MFY<<S9]>HP,XVW<S'\Q'HQI,W1#4<<I-3&!D9 1CMG^O.G?:!YGV>%^FW:5K
M5]LPNNWF$?AA_[?63_RM*2LZX>K__<N_PO4WWH!K;W@=4B2+LAEJ,\\$5=6=
MD2QR8_OQ[(/?QU6W_02CW?M0+Z;1>=7'<?C7?@^33XWBA_?<R8Y5&>]ZQ]NP
M8L5J$E1IAC5=11I5+=IT<\1?*GB-JL<K!4'MY+'0H;E5TDI-G7[BX7&6B).<
M9A*H=:> WBRB'2E;N#3!QOW$X"!2'1WHZ.]!HC,SDP@L($A#IET(1D^<M)T'
MBI.3&-5!!H4";"[@.0Z[7 M=U&X(IEWW.".(J-DT$1)]D?YL9R=6K5N'K9=?
MAO6;+\"%O%YXU178L.4"+%^UTK226GBEA7RJ!27:8+_"?&X6C5#HB-.N[A[;
MBU?O2$0.58^ZJ3-G!NWEJGI8$D^XCE2U7$(D7V"$ZGC@F8?Q]>]^ ]N7+L=[
MW_IVK%RQRL*BN&J7$6F(;6ZKAX?'G."_EH4.5H*JX*1YTF*1R8D)JYP;+:6'
MQQG"]CYE(Y[HZP;2)*RE*L8.'\?AO?MMSE^R*XM$5P>02K"F"*J*^9:[T+YU
MKJSD.DPS;X.@W*M39F_JVFQ5Y#-P0_&0AE,A3&<9YDS6]K'MZNPRDF*DQ.PW
M20ML[JT\:!,<Y_?4 U,B4[3?IX:J#^S>@Z,'#YF[]FA:0,\=PG"<2LX4#3?:
M)<!+"::9.T6L:O.9PZ-O=5!&A"10!TZ(=$X6"Z813V<S2)',:CJ'.E621#J-
M) ELL\1I)C*;FYS )#LNA6+1>2<WHZY<G2E$K+583^$.%^TIG*EL CM^_%,<
MV;<'[_VY=^'B[5O0W]_'3R?TK\[R&+5M[T14P_+MX>%Q:GBBNL"A:LPJ-59V
MVAI(>U:J<@^'8%79>7B<"30?MC V@<+@$'8]]A1V/?6,D:YQ=H8Z>GN0R*9A
M$TG8&&N+*6M8YSE3J+E\NONZ6XGO#%P!;X>@ ;>&O-&8!V2,(I?T#=@3_IX<
MG\"A_0=Q:,\>['_A!1PB<=2N !9>>W_JFYD=?&YA;!*]VA#GEJ:F5(IE/HV@
MP+1ZYJFG</# 05H01#Z"VY<"C;#,(F>,P(&S<N,,P,02.;6#,D1822C+%&V/
M)BVDTG-B?!PCPR/6^5 G(3\VQG37'KXDH)()"<MQDTBK7B:YK9293\Q3:3%M
M:H8T['3CK!:=\7V1YT8YIELZ>E@;^Q\Y? 3%D0EL7+<1_:M6&)'6SA2"E7^^
MJ]EV>E=EN?G[\/#P: ]/5,\;.*)J"PW""M+#XRP022>1[>A ?F0,C]Q]'_:^
MN =]BP:P8?M6-K++$6'C:]M(E:MLV$D:V&'26?]GBK"A=F13)9J_9VFHI=G3
M$*[9HAW7H#L-%%^U]S0'4;]%:C2?<>>.';CGKKOQZ,./8)QD1L.\LJ>.GBV*
MLWF-@?\MWH9S-%W8ID13!_2>]E_5;@<R5@"TT$X$2Z>5/?WD4SAZ](B%00]G
MB9)'&RB]I=77?KQ&W@(S;?Y?+A39D1JS0R8BE9IM>Z;I*&E)-HMT)C.K:*_4
M5"9KFM>>GAY;@*=%@U4MA+3Z\\PSR8Y\Y54=(><,RZ6.>:U%L?4UK\%DL8*[
M[[@717626$8*F@=.B*"6^2TIGN'V5!X>'J>')ZH+'-+>A%6J*D@-R>I82]LJ
MR%I-9J&M-E %SPI8EO62J_*=:-5$J[1!RUO3Y*RAL,X0F<^4-D:G%O[GTL)C
M/JBHG)"LYHM%C(V,HG_Q ):L78U>DE57A%A.6*14K-2XJ]1H7MZ<$&2'G!#)
MU,^*YO'%(C:O3YI.6] D8=XU\L_\55FGL)S;PB<[%,"-*D03,9*/A)$;::KT
M371T9G#S33?C^NMOP!O?=#-NN.%Z7M^,=9O6TQ[?YSLBEB+=41(7[8[1T+0&
M(N(@[5M5<R6#\)C0GJR 1$ID2D/'8J)N:!FV?5)O7R\6+UK,M-&V1_J^IN)Q
M+A"&92[NS=6>0?9:90YHI$V+3*'5T=G%AN&5-\S'&,FD.N/WWWLOGG_Z68P-
MGL3$T"AZ.KNP8=TZYG.7FP\L^Y8OLXOKS+.SPSR-Q^*6OQH5L+K359)\W"3S
M0#2F'2V2J+'L5@/B62$YS8\7L>+:J_ ZEL4=+[R(+W[ARWA^Y_-.$\QX:@]A
ME=>XAO^#[TAA]?#P.#4\45W@$ <UTL#J51H<-=2JI&MU;5$D[4V<YK1@%:YZ
MZ204JG>UTK^QVE_9W"JSP-YMD7,!5<@MXHXX;>-=.\-3B35ZTV%:.)$@K]Z:
M%?$*RQ$;SXH('Z6WLQMQ$<(JTX[%*U+6 CZ1L^14GEFZ!C);VM)89=;:?Y%+
M$DW2!YJQ/)(XJAQ'JJ[L&@D5J6"9UCMZQ5R-ZI" %.]):EFL2Z4*)@L%%,L%
M/J-=NJ/M9J.)"#JZLQA8L@Q+5JS"HE7+L'C%4O0O7XYD=S"_EJ16\Q]K?+^L
MU>3% MWE^_H\ E&81!ZBVBXK#(2\8!FRQ3<DV95\GD2V8F15>\_JN>)8(@DJ
M2KM&$B0TO6YRUE#QGEG$VZ-A[_0^MX8SE-,B#$^KA+",9%K,26B7Z1MANM=(
M*D=.G,1S)*D'#QY$7W\_>M@)T+Q4FUL:!,[*H&Z",ME.;-]<WEIG1_FGCHDY
MH+(KDCB]/FR4Z2:9/3'XO!Y%7G4Q"Z&VPZO0;>NHU"JX;.-6O.G=;T4J&<>M
M/_HA!@<';0ZN J2P*%PA09WU&_+P\&A 7ZG'>0)5OAJB]%6;QRL=:M!%&FWJ
M 0FN?IL62ITTDD+-31P;'L$0B<W@\4$,#9W$L:-',73L.$X</XZAH\<P2ADY
M>!C'=NW&V+%!C)X8<KR(Q-O<;8*1'W4$1:)%7*QJC#BR3:*K8=OADR=Q],!!
M#%+&3@YC;' (D\.CJ$SFFX[5]3@3V#953/M,-FO[[BY9R8Y&9Y:=C4[$LVG;
M8JPN\K@ $ TX=HG%L2)E?X5"XAECF2I'JABKY;%NV3)\X/WOQ<I5*W'GG7?:
M=EN:>J 8B#-[>'C,'9ZHGB=@,^K^9X/:J.<\8_58@#!M$<6T6,U@>;6A695@
MS?=4^9V%?)@;9M_-#]6<Q!0)IHYK54NO,^&UCVFYX(Y\_>8WOX4O_M,_X9\H
M7_B"NW[E2U_&E[[X17SN;_\.__S5K^([W_HVGGC\<5MD8]HU:7)#?\H55 M%
M7JM&8C75P>81QJ5MB]K^GH\\]#"^2+?_[G_^+;[\3U_$Y__N[_"][WX/1PX?
M1BP:<W'3.W+[+&%#VX',"PVOY_G>:6!Q.Y/PG YRSK2,O*$4\GE;F#8Z/F8=
M!/K(_ \UGJZYFDL(++S2X)L+>B-X2_XHW^>:1[+68E6[/<@=[0VLP2Q!UU*E
MA&1/!U"MV)2##(GV=:^]SK3#P\/#9L\TJ+0;:E*MG'MX>)P2GJB>IW#U9TL-
MZN&Q8#"S 6XNK=9.BS#,@I"4&$A**Y6R:4QW/OL<B<P!#!T?M/?3P6*918L7
M41;;"4:2I4N78LF*Y5BTE/>K5F#IRN6H1NHX?.0(2L6B<S\D*PRJ^,+DZ!AR
MHZ.H\KF&\:.II)%DS5L=&QG!R- 0>KNZL?7"[5A&-[O[^[#]DHOQYK>_#>LW
M;33"I45G/\OA7//[I?#^)>13"K."'(G'S1OE=4+318IEU-@1T8$4TF V$[PY
M0>X&]J41%RD,?TNS?CI8N)K<"%$E::[&@'[V=SH5O%0$29;1[))>Y'/CZ!QG
M^4E%D4<)W=W=6+%R)?(DX)I>$XWQW5K%]G3U\/"8&SQ1]?#P>%D1=K!L]?4L
M9-6(),F$"$:U5,+$V!AV[-R)AQ]Z&$</'\&#]]^/(X<.(Y-*V[#KS3??C)__
MA5_ !S[\(7R(\OX/?1#O_KGWX?T?_0A^_F._@G>\[WVX[L8;T$MRJ=.VR#Z<
M)D]7AD$KS(^0Q!XZ=$@KQBQL(JSE8!LBD94>DM2WON6M>!?=?1_=_^!'/XQ;
MWOMNW/R6-V'YFM5NU3_#XE:5>\P76B@E!?MB=C0RB:0-L=N9_IK[*YFO-K>)
M9(:[5;@.4(39=.9Y5!-134314XH@0[Y924:-6-?2,3R_ZWE\_Q^^C/_V/_X:
MG_G;O\$WOOD-W'G''7CVN>=0TC'+C(+FJ[K%7AX>'G.!)ZH+''5V_2.H(54O
M(%,90W=A"/$Z^^KE.$JU+.K);E9Z'8AH#4@LR?]XHR,,=<R?'9,Z]RQ6E2Y-
MPPQQC^<(^2=_IXLM.I@A[</6-@RGDJ8&*80;JF1CH):A&6H)=5QJJZ@19 .B
M(S;#AK%>KS",FH"FX=PF:6-W-E$80CE3-+MQ9M*2!@&T4$EE)!(+%BUI1W7F
M2UO0B7#H=TIH5HW.$+E1UX(L7K5ECW9JK_,:J<=1*]50K)112["Q+Q5HKVJ:
M-.6!I@*$@@I+/<MQ6?Z2!,2B.KXU9B=E;;_X0@P/#R*:JB/9FT DHV'8,E*9
M#B32G4B2O,:[LHAG.Q#O[*)9%EJIW9'M(O$,-FG/E8 \B0/) W/2/IFAL5'D
MF><ZKKC>D:+__/:J?!:/V198.G CWIGA.Q42DRBRF0Q)+\/%\&MH6C&?4=[:
MH'D8?39I1O,"G]/)2P?&+JQ39I&I,L"?85Q.EQ[\;G4JE:6;TH7"F+@T8G3T
M72MO@F)$-S5_N,7O&LMP*"IW$K/LWA=T;*GSPWX2T]-JMK0/T9S&"<8OQ<)?
MC,:183$JQLI(1Q*(#@]C[,1!.P1BXL0X#A[9CZ>?>0JK5JW"DL6+689CMLX@
MDTXAE6)GR</#8TZPNM7C_$)(S$(13ML@>'B<1ZA7*ZAJ>)3%.I9((&'[8":Q
M>/$2(QW:P[*L>:4DGM).24,F8MF B(Y(AZ[!O:Z:5VA;'"5(J+1[@#1LY2HJ
MQ1(ZTAETD=1.#(U8!RB1$#GFU78#4%7I")2'A\J5M+0JBU;^*%V]?;CV^NM-
MB_]KO_YK^+W?^3U\\I._BX_^_$=QZ:670J>D:?>*2N7,.ZT>'J]&>*)Z/B(@
MJ#8L)E%SRHK2P^,5 QN6!Y*:)\JR7B:1S.=S>.ZY9_&-?_XZAH:&W%Q&:3/Y
M7&2AVDHB]5O?14-(3$D2;--WDH9(1X8L.(;\Z#A.'A_$RN4KT-O9A1.'CZ(T
M-FF[#L3C";['H- ID=:S&3+V>.5 Q%0'4FBZAT2_)T9'K4S:?L3+EV/5JI58
MN6(YUJY=A_[^?I:EF+WK.CT>'AYSA?]B%CA,8ZHA/2.D#JH4[5QL-N9Z7.<?
M^_1F;O:\UN>5!6:R-'G3-(;*^%#. <*.CY4W.1G(E#<RD%9292QX/@?8?I8L
ME^Q:V?92+AX!V>-]1&5V!EP\%9YHL)J^6"S8:4,ZO[^CHP/777<=UJ];[\+!
MYY8T=,O-_0N&CLM5FZ)ATS0T%<.&=MU\4T&' )0*>5MI7JY5T;=L"3J[NI!*
MIC!^<@CYXR=1RQ7Y/HDMW; MLK3S@([[-!>F)T)C>#AP?SX(-;5Z]TS>/U>P
M=+-TFB[3H."%$D!!;L2]R?QT4'D*3P4+%]!9].6EI<F4W^:T^X\2& IV3WO*
M>[DEH5M:!-=P6Z+7^),Q"LK)=%C:*PRAMZT2P,JPIJS0?KA(2YT?E>\.DM1(
M.F'3%$R10)^UV;\63VEN:B+!#A*?->>WAX?'J>&^8H_S"E:A6F5LU:]J/=NJ
MQ^TYJ0K05WZO=(1:G'.)$AM3:T#5>%IKZAI4)\XO5_;F3T@$$52](L*G4Z54
M4K4P17[9$:7R@WZYO8+9P ?$5J1#*_LON& 3WOKVM^'-;WT+7O_&-Z*OO\].
M^]&1F8+;9[A)9&C1X;WB(&):JR"22B _,HI#+^S&P?T'[/>JC>OL>XIW9+%^
MVU:,38SCP)X]&!L\X;:M8GJ+B(BDVIQ4.MZ.[)P)&FE,]\Z5F^<<EB],1W:0
M&^G;]#N, W_0LJ7\G*%\UT$*>E]IK Y9N5RR?)=;5AYX[TBG2R?S+_S3;Y'I
M)F_UW$Y1XWOI=-K*G()GQ^#2HLV#G@5Z5]^7MB>S[TPO3D/$GI6*);>%&>,L
MOW*Y',MCWDAJOE1$N:*MT_A-,6R*5R(XU:Q:J=&\$KCEX>%Q.GBBNM"ARC6\
M52.F"IOW:AQ4Z=GB$_VIXC8R0=$XI;T5RDRTV@BE+:R&GR[.O_9RMJ K4V&Q
MR(9FP1]_B_24V1C87$8V!G:6N^S1W.8@GJ+!GS7,09J&?IX2+7;E0CLY5ZAK
MN- :8Y?G:KBCJ10B(FEJD!66>7HH0J RI=.7,IV=)(;T0Z<N%0LHJ:&MENW4
M*B<5T]IK7U%MO&Z;KUM'B0C3,!09!6+AU95V8^D4BLR? AOX>"IM)'5T;-2=
MC,6_"M^MTDF)W!=YE7LU$L5*J<QDCB W,8FNC@Y+BZZN+DQ,3!A9+=<=L3#_
ME%;TM*&YI9GMQ=K9@4@R@5T[G\?Q(T>1C,5M2+9GR2*D^*RJLB-_&98U&]9C
MW98+D&+Z[MN[#[M)6C/9#"J% MW6B$;,$:$005+,#;3,,"E.2JY"OH#)R4G4
M28(M'UV*+2PH3U2W*,\91A&X2HE$C(0R_/8L#93TENYSCX-L&GGD35P+CGC5
M4:IF("%<E:9RQI)"O_7-5^FWB79F<$OBK!SI3RYJZD:1SPLL'\I;6QRG\L&R
MHE)I=44@!I4;"2'OU&EH=!P4MQ"\EZFFHXB(&HFF09Q_L62*X:FA,YE%/):P
M><XBJ8*^$25?/!&E.3L\EM<>'AZG0^Q3G_K4?PSN/18@I ERC4,5N<&C*#QU
M)WJ&#R$MLZYNU#==B-J2M8B4JXBJ\F.EJ8;43:ISE;S5K*V04:M,76;"&HH6
M:0=6OFTKX*#!:44[_ZQID#N*H^(C]V11UQB%9&GDY D\_<03.+!OG^VIV='5
MB61:\QGI%1LYT7FG^7+A"676<,@?^F=^RE[S.ZV068O=1D1T;1*G"9K%G;F"
M0:ZQ 8UJ*#O8@'X_B=/]]]V'YY]]%H/'CMEYXAD2N-E\:6<N36(LG49N?!Q/
M//D$JB1_RY8O0ZZ8L[TBBY62K= W88,O;9%.A,KG)BB3*$B#E"\:4=3>I 42
MRJ*$Q$O7DMWG34HD>,/C([COP0=,.[I^S3I;7&($E_'1XJA4-FME6$1$I-B.
M#"9Q8< P/C*"X\>.&]GH6[2(?N5M\_[GGW\>V4P:%UY\$5:N66-N6AFA/;FI
M/%*.1TE0$R3*72PGVF.ULZ<;&=[K>$Z=!2_B:QI92QAI<TE$2=JC%!&-)-.I
MMZ\/_;U]2 0:7/D1#G?/*W]I=9($^\E''L4+SSZ'(X<.6=CZERQF7+7+A"-+
M(<ZJ[)Q+L%Y1?&LL"P?W[L6S3SZ%'4\_A4F6G][>7B28GG5U:/3]S;7<\[GE
MLQ:ND;B7)O-X\;D=Z.KKP=+ER]F)T3GZZJB4;->%DH@IW1<Y5<=$HDZ4.CME
M7=6YHFAT0&7N!.N&QY]X'/T# UB^;#G&AH>M+.4G)]CI&6<^.!FGY%EN3_!;
M4ICT+;G@!?FK3 NB$D$")9:J@\R[DSN?1%]M&#U1EGF&/W[UZQ%?=ADJ$7Z+
M*HHL5S&6+W,AR%=WOT#RU,/C/$"$/<;V+;?'@H!.09&6IU9G);KK:0S_PW_"
MJCT/H#/.!GCY*M3?\B%4+[P>&"\@ELJ8%L&TB6$]:*J.Z0V?8,:M8$F8:_5I
MA::=Y:!B;X5I@ULQBW_2C<@-F]\8N&7:'$(_56(?NN<>_/-7OV8-_H;5:_%S
M'_P 5FW>2!*1MOC7*VI4FS1> =J&@S"B>A9H:!1;<+;N"M88,P42M8@-7:<8
MQ_MOOP-?^*<O8()D\8)M6_ ^QG_;99<BDBL$;S5AMG0F^8TED]B[8R?^YV<_
MBP3+SI577HF1T2&F<9C>[LUD/8JDM(BT$VJ9I 5C@6N0DE S;?M?VIVR8BJ]
MQR9&\, ##V#YBA7FCYYI04H\&<>2)4MQT267D+"E[2S^JK9^$GDA <^=',(C
M#SYHQ%3O:&ZJYFC_]*<_Q9-//HE++KD(O_B+OV";[\<UO"IRRD(BHAQCF!52
M:3]%AE0V+#5T#?+,-&KM\HG/M(&_-'6:HRIR%+>A?VEZ SM3-W.&XK#[Q=WX
MQ[_].SS[U#/H(FE^_T<^A+>]X^WFG&EJF\J2=8A>)KAR'/QH@M+ .@U,UP*_
MN;ONN!.WWW8[!D\,XN*++\;/?>B#6+UU"ZHLCPJOV0WC<)K@FZ939*Y8QHE#
MA_'YO_^<$<4U:U:[YY9G+EBZBTGK&91+(0RNPAZ603V-,T]U(M3]]]V/ 79N
M5J]>;655\T6U 7^HZ3303<U]+I#<7L)R>.UKKW,=$I8--Y(U5:_5*RD,CHSA
M\=MOP\2#M^/JU"!69R8PS$Y<YC?_OTA<_DL822]%.E)%DM^KYC6KPC6B&@;V
M9<C2,"T\/,YWG'TKZO&RP54\+T,-MP"AJ$LTU*;AQI&1$1PX< !'CQYU0_U5
M-BA:,"/"0;)B0].O$"C>-DS/AE)DJ<XXZA2EP4-'<)SQ'QX:1IGIHO/2YP.;
MMUDJ(4GR)2UCA@WS\6-',<K&/3<^09G$!/V1#(\,X]B)$SA\] B.'C]F<DQ7
M^J\C(O?OWV^;Y4L.'CF, X$<IIU0QG*3V+CY G3W]>#PL2,X</B0N;=GWWZ<
M&!Y"4?NJ,@YUDLNX&G626&:X:="D65/G2L/DQXX=P^#@(/*Y/+^&B)$+$9!P
M*%[II0Z"AE=%5(U<LVQ428!%P#54+8VMMA>R8>(FTM,,?6WJ(%FGR32L;FC>
MYH.'1/<,H+ I7-(DBM2),-D\2@OOS"HY)& O)?%HN'\J+QANQ5ME401P]^X7
M[1O<IU&-(79NF _Z/ADI2O!.DX/-\6@(B:]-@6 >\Y=-#^ED^1AA>;C_WOMP
M]UUWX]Y[[C6YC[\?>NA!._1!Q]F&\JBN#SZ$AQ]X$(\^_$A#'G_T,1P^< @=
MF2PFQ\;Y^U$[V>S WGT8/'H,AU1F Y'9"SMWXL2QX_8LQS)O8)Q;JUR5(>T4
M48M%$-.H!(M"-<)TT=09Q8)YJGFJX70%#P^/LX/7J"YPA!K5.HHX_OR3&/W"
M'V+%B_>C*_'JU*@:D6'E?_\]]^"K7_JR#3%OV[ )[W[?^[!J\P8DM.60&L"R
M5N4V:4P"G(\:55M9S$91TSLTO)G(9O',7??C\Y_['$9S$[A@ZU:\XSWOPK:+
M+[(SQV>$A;?MTEDKW468:@QC@0UYC>['213*I3RB;(S=.T'ZJ_%5NLK=,']5
MB)B<(H$RM_PBE'_Z$Z:7!4>D9<\TG>I,D-1H6D':"$H?HM(>%TN\1MT<5=J5
M-^/CXQ@?'44B&D.2A#H_F<.M/_@![KO_/BQ9L@B__,N_A(U,!T56Y--V"RA7
M+/TC)(":6ZHI"B*OMCU0$"[][Q9OM8%[Z.X5G88EW@1I?$;:3KJY;_<>_,LW
MOFGS9;NZN_'Z-[\1KWW=ZXRTZA"!:?G7A)=*NSIC97\+E)]*RR+370<J/'CW
M/?C.=[YC<VO7KEN'M[_S';A@VU9;)*0D,R)N99\_@B#/YH<TIE'FJ8;^-83_
MW!-/VGZW@J5%4);DL,J$R/RT<J7'3"^5S[ ,RDQSKV6N?,]V=-IT$>W%:V6>
MY4QE(42%KTW27I3VD\R#WIX>EL=>F_K1R(O0Z7H&A>%)=K+V(G?_;=APX%$D
M4L<PD:<_/__O4+W^5U&*2J-:0:Q:=B>AL1![C:J'QYG!$]4%#D]4G8UPP4.H
MX1H9&L:>YU\P=[6ET*HUJY'JZK3&2:<-135!K*DA"G$^$E6FAA%5:%@_I=/'
M>'N"\=^[U^:&ZH0D#:=W]Y+HI8*5\LUAF26=30-4(:%/)%'.Y8RHQC3/EVQ7
M0]SF3IA>+(>F(:)#80I:N*QL!7X%%Y=O[CXT$R+U8*4SW;*I!;1G)(7$0]K%
M<#LATXR6:(_F9<9/>L\DR;G-UU8'A&FJ!2M[7]R%7;M>Q(H52[%QXP9D%PV8
MAG@&44VG6:BJ=B2JANVUFP#9"FI:C$<W);$V'X3[=)RYRHW"9N1+A(/NV:E:
M;32@IX/\DV;XR+X#IJU.LW.U:,5R]"]?9AIDS?'D5Q38GHZ?%5%U^11#F80_
MGLYBY.A1["795MYU\/M;RO!K"H."76&ZBTS.B:@J3UD.-,6CPC*H><&5<MD6
MV]E("9]9.13DCLI6<-]((SU7/<EK<]VCNE-IJ>DE*C]A6=:6:(J/Y6, G7ZE
M,*B,51E'D5YU&N2>N3GE+$J5))+E& JU<>3OO0W)._X9DXG]2$9H_I[?P>A;
M?Q,]E66()S7*4R;Q]4/_'AYG T]4%SA4N><C;*CK)8P__01.DJBN&GR4]*"$
MV+I-B-WP?M2V7.](1M0MIFJNK!UFUHJS97K;^M-:[.E/3&.FY;EG [[>SC]S
MFT_L66!AJM)US^P7&R C)"(+(A(B],$4 $N'-B1BMKI[1I(1(2%K-%8!9B.[
M+E#3T<[=V=#\^C2"JT:8[MA>GB1:2@O=2[MDP_?-G["]UQ*06>)LQ_-:8^VN
MMKT9 ZST5T,^+=YTP_RBA&$S9Z=%T-T;H0S0W%C.2(OP6<.<-[IW#ML+1MJ4
MCWI9?KN'_%_7X$4]JKE]3@4]<Z2 =B0RY[41%KKEXB:[>B1W9X$L$6:'M^:N
MI?>46_-%(PV5KU9NHT:,9G4J\.IG":V:MPZ$XJYR8FG@2*1]:]:95G+(S&ZF
MPAW&*_S=!)>/[GMR^3;U7IA?4^G"&W5 6V'6^)^N@5U=K"2;&^Y9(]WUK.&F
M@X[KM;#S+_PFU#G6K=5$3?9K.GJX1")=G\3P(S]!U[>_A..=NY B4>UYT[_!
MX'M^!0.5%3K\#)4HB6J,];+<5Z=.P1%<,%Y2A.GGX7&^XV7X7#S.%F56F)J?
M6"^4V-LO(9&,HTJ246=-J&U1-$PF;8?5IE8WN6IZ2F:BU48H[='.IN2E@1J&
MANN*#\69Z4\5OOO?M,=,%VE.9&;MG3076LBAW\&[S1*&O%7:V65-/R6G ZW,
MW=U32#NH@64<C8@IKK1G\QOU3"UNLUAX]4Z3S +;X)]72SOY$3;B3,,8"4%4
MJ:STE,B.[(=I:R9Z)ONA*&S3/72$T(G>F2;& N1G*#03([?G!-UR\0S\D5G@
MF8NNKA1&,B2I@NPW\BQ,$[L-PJ(?H1E%&N#F<$Z39CNZTWMFR/\D9P"Y&[KC
M2#C=)]&;X7<@"P(*A_[9-1"FNR-V@17]9^G*NT8^!O?-OYO$_NB Q)7'X)[Y
M*0G=#M$HC\UB?[*K]YTX]_F_W+:_, ^=F7L^)8Z<ZCFOBH+<E7NR*RO3H/FT
MSJVR'M?8R>.UPLHXRGNCN^S$:U&A8"6M-2(>'AYSQE3M[K&PH0; _O$O:&0-
MP?U+-23HX>'AX>'AX?&S@B>JYQ&<UC3HX*LGW_AQ=M#0<2@A\?4X/Z$.BW5:
M5"Y".1>0DX&$FZ2?U=!B&#:3P&%*&/[&D"V-I_G7+,T(WI]/V*:7>QE,-W-.
MT,VFWW*WV4X#>MADSP*N=^T=)PWHOED"M'6W"2Z*+FT41SDJ7V9#^V=3;EM:
MR]$6R,3YT617_BI<[1P-M=DN@";F;" -?X)[YX;<IA]!>,RH"9IZXOQO?M)B
M2S^;W'(20.&7&Q+]I/\FN@_,I]YQ6N&&-)5!MU"05II@[RK.?*!XR0>]IWG7
M>L:W[5V+6\N['AX>\X<GJAX>KT"H 0VEM7T_(ZCA#63*[>#9/&'NJ+'GU;DK
M,L#?@7LB1+8RGQ!1F(J'6X1EA$!_07A"]XPDV'!M,&3;#H%;K6+O!\]#-_F?
M&--4^O%>X6F'D(_8?$W=*#Z!A&%K0!;HC][27XCF\#3#W+1PN=]NFL-T.[/!
MW O>=^+2-0R/XMD\'UDR']C".:67S5M5?%VZN?2CA?!JY$_G[U?,/]O)@L:.
M%,YLAN3LE 1YVAQG,P_#',1)?H60N19#J7/?9-?N-9U$\VW-/2=AGC>YX.PE
MW(*JZ4[K'6>_>8F'S$-E@H>'Q[G#S!K"P\/CE0%KF ,Y2ZBA#AOSJ4;_S-RU
M]XT$)$PTUUCB"(M(0<U6?LO]6))V O\T/U8K]B61.-_3NY+ S,P#NZ>$GK>(
MD1J%)YELN&MD1E<=/$!S_0X)=#M(8V>:-KT7B#:R#\,V!?D9I&FS]I1FC3 U
MP\A6DYG\:+4S P'IDMW0?I/;RD>=(*:]9,/]89W8X[F#;HOT5K0W;4!^E4[R
M6\?P5K3GK'[1;>W_6R%1->).?_2[KCG/NEJXFM+")89)(T_U,X3]#L2TM(YL
MAM"]=I&P$ZV*.E7-G:!FQY[2S @S[802ENUF-W1$<R&7IQGCU>HWK34Z6'RH
MMT28[: ##P^/<PI_A.I"1ST*-B=(L"8L'3V.B<?NP$!EA"9E)!;U(;)Z"[!H
M'1MQ-J3Z4Z/45*M:M9M*(I>;M$9?VQE561EKD^UR60<!RHXU)7PW8F=LVST;
M9JVXKI(P:&% )*D3>JIV?**V=S%-@]QF0ZP-^'7NO&VTSW=,P\$&V,(CMV1/
MC8G")FDT,*"+;#"T0(;U>[E*=^A&K4!_V:!,3DZX1B\10Y'N5M@H6/SXJIW]
M[@)O1WFJP==OBU>AB#CC',DFV #64"P7$.M(8VAHT%[0,_GL L>7 F&319GZ
MK>;'FB!ZR0CQU4#4-M&8EASA$LE2.-7(!8UUB%J-X8S+(_=N-3CB$30S<_FE
MW1,"41@4+J6U"X^T<4QW25W[D+K&T36J_!FF92@R;&BI^%LB/Y1W?+_A)D4K
M\5S.NWMS6^F@?*DSO9FOT+GHBC/-"L6\N:7GDDJYR'")H*C15[D)PABFD\*I
M PH8]E!H:.YJT_UB(<]R.6$;_9L;%95'EFS^+E583FG'R$:09NX]NLDT-G.*
MSGJO,1Q\F3&5GXR/_&8X578++/>AVXJ+TDU:L%9R8H1#;LO/<L6^#6V-);>4
MBOH6I#44&:M2M/A)2:=\,>)%.R)E)<8I/ ,_//93>2%B)I*D4\9,R\<7IK2)
M\H&@I2K+KOW4MR12K%.P&!X+(^W7D_P^E <,3]325N%S\37%(O-!88]%1=I)
MCBMT<S*/*DD7K9C(>HWA*I7R=%YA4ZKK^W+E+,IX,(%IB6&5IC1<Y<_TT6$'
M)C13.J@<Q/@]B<!;/&G& %@=$4V3Y#/XJC.09[SXCHZ*C2C-F+9UAHD>FANJ
M%ZRV4+JJ'-,9N:5TEU], !GQ$6V5F0>Q""K:7DUY1O^4G].TF4H/BCH((N(Z
M6E>[%MB]ZBZ%U[Y=74DPE;X)N<ERHX50#$<\D6(VL!YAODCL(Z!4M'U;)87)
M&,GOH7W([GH6H^F3K,)BR&Z\'B>W;D>FVHD8,T3U3X*)8'6BXB7H$MQZ>'B<
M'GY[J@6.>BV"49+2+!N1R<<>Q]'/_4=L+KZ <GT<J0LV(GK->U"_X/6L/TF^
M1-:L,I2X;+7_64D/GSB!I,ZO5G:S$DZR[E<CRNJ9CUU%JH9&E;:V=[+&@; -
MTE,)MD9\%N>5YN6)G-$HM2EJ'-1XV]&EM%,9FT31M!"J[%6Q!]#[82,4P)$:
MAH!&:OQB?)[MZ4$I5T1*Y];+;3X?/W'2PF50&&FFC>VU,;S.N$_T=%F<+-IJ
MW"S\)"XD&2(+2H149X>17Y$-A<U",144WK*YI[DE6&!N0Y1R2PTV?]LFYFSL
MV(0Y<B+[@3T1G; Q:M;^U$D<3)M&NW:&O83VM9^GW O=$$1BU!A/2S?"5M_+
M/5H-5]4S=5U86V"->Q"V1IKI'3:8CA0%OXDR?VJ[J^8&7H]$@M2HVZX*O!<9
MD%8OR@Z#^)PT37)?>]8JW2P.BE/H1G U!'X99$<;KM-MD0NY*^(B.]KK4GMO
M:G_4..U8^BJO%)_@==FSM&$Z*W_MQ"H1&9)0A44DQ(:@!2:8PJ5\D99+[RF>
M=9$&Q:4E[>5VL5"P:YA/1DAEU^+)SXCN2RS?&$[E2<,%ON<(47#$;) 82A]I
M\M1!-'/^5H<QC)^Y2_=T>I;*?Z58MN<Z>$'?IFD"^;UIND,'OPV9Z;S[!#V/
M*GS,/TM#Q=?^F*PEG;4?YY7=0-XG5/ZL8\;0\%[EH,;TKQ1SUFFS.-#,N!CC
M87LW!\V"JT\43Q46E4.7]A9Y0AOT*QUU:('-ZV28:@425:5W5X<]J^L$,49]
M@AU&I;UU9FG7RI?>8=RJ(L="D&ZV_9I^\)_R+\%P:N/\&DEJ+5<PPJ[.LN)7
MR[,CJCC2KQ!*#7XLYK9U8E4_!$]D3^FILA/"R@/+=ZPCBP3O2;%E2KL,A?)-
M;H=QCK&L%KN1JX]@]*$[T/O=K^%XUTZ&,X&E;_S?<?26#V&@O!QI$M=:3.E/
MUVQ;+?EM3MCM2XUIY=O#XSR&)ZH+'*<GJN\E4;V1]:EZ_C.)JC \/(+;;[L5
M19(VD2&=<YVHN$9?)[68EB(0F>DL;#6JRY<OQ[9MV[!TW1H42092;(C'AD?Q
M])-/XNB1(]8X7?.::^VJAE4-67%X##^][78[XK09IF]3P\"@*0R"#3O&(B@Q
M7/+SHHLNQNM>?R-J;*@3,9)B%LVG'GT,=_[X)Y@8'[=WM)EX)I6FI.PL]V5+
MEN"*&U^+3=NW6H-F#2'3871P$,\\]AAV[=IE!*A(DKIHT8#3>K'Q=Z1M*HW4
M:!7HGK11VB8GA*4)W]?FWRDVE$DVF#%V"A0'(Y9,)[TK,3)$D9G+!SE XJ4P
M6?P#^P%!D9:GJ?TC(5.#ZMR0A(BRL0RW+VJ@3F+!=^5>,Q0FA65:&.ANE.FL
MHU)M?F?0@%75#HN4J-P$+:?"8!IGFDLC*0V<2* (42J38?J742B2T-%^FF6'
M=);QD<9/;SNWI/EVE"Q(X< _(T"\3S'OPC*09II* YYD^4EG,Q@='T.:_JBS
MHS177BC,(6P+(Z:%RHL10):=6L4='RNWP[Q3/*SC05A:,C!RK\ZT%&F(*^V;
MJCZ%9V)BPOQJSELK4WQ7'19]*]EL%IU=G>CM[36SJ7R&E9^)"5=.0W/9&1D=
MP=C8N)4MI;,K0PJ#.SI5[O5T]]@1MHJ#GLMO'1&KHTG'QD;1T=GI$I/.BBBG
MV'G<=,$F;+_H0G0/#%B:B%Q'^6T,'3F&!^^^#WOV[$&9>=/9W47*Y+YM^2E1
M&=$)9'9*D\H*GREL"C:3R/Q2F9T"ZXI$RN)EZ<[T5QZ(:&[9MA77O?:UEH<Z
M84H'+;!06+[K-+%1BN:R/O+8HW;\K=(PK0W]^=Q&>#0*PO"X%'.P\LA_ZB@/
M,'X7;+H *]>O0U+IP'PKL@[;]?P+E.=1G,RC@VXJ?\)RI=!+DZZCA8T$!X[+
M3\M;=8A(=$,4589I1VEU\6678?W&C23%+%,5YKL.C"#"\%5)5%'JXK<P@N%'
M[D#V!_^,\?1.5!C6)6_^WS'ZU@^AN[H<&:9Z)5YA>GNBZN%Q-O!#_PL=K#V+
M;'83K.'*1X]BXO&?8J Z1),2X@/]B*S:"O2OI34U1:S_K(&<J@5561T[>@P_
M^L$/D9N81*>TJC23EL4T:>XE(V.2L')+L7+.L/+O8L7=MW0IS1D&_CY^Z#!N
M_=&/\.@CC^+DB1/8N&$3!A8O9J/O&NUQG<&__X U9$:*% :*J(8(CAH_>>',
M:G9TILC&B[MW&^'=O'4K&YRT(Y)T[P ;VY,G3Z*KM\<:D717%GV+%J%,_YY^
M[EGL/WP(*U>LQ*KE*Q!E Q81>:!G$R/#V+]O+\;82)X\.81[[[W'XM;;UV=A
MT;W(EQIXB1KL! ER.ITQ0I;*I)U(8TOSI$@JTR2IWVRPW5 B"34;1S60*<9#
M=M7XB6C(GJ[IC+L7(3&[M)?)2++68&>S'78OD?LV+,EXBTPH3!+3N,D_7DW#
M9[\3[EXD,GQ.,3\:_KOP2K(=&>9GAN%AOII_&72D:";2S[AE&>\L_=<I5RG:
M.W;X"#LD3]GPMPBZCC!5!T=Y)TJC\A.71BPH:E9^%!:&P32/ 2%2V$4VE#8I
MAEFD2*>*B: ,\_K\CAWF3Y;ELI_E*"<23#=$1)26ZGA8O.6VN>_.R9<&3?ZX
MM$_:Z63*6Y57DYYNI!AG:8&3C+-(<*:#Y;FKQ_S2>R+$2@^)E7<^5QKIN,T.
MVNDD*>JF.W);9:*CLP-])$T]/3V6'B)7TBB*#(JTJ1QE^8Z5(::KW,S23;UO
MWQ'#U\]O=C'C*7M*.U=>5*9(9A@WD25U9$2N]%THP:4Y5)P/'CQ@<R:[Y ?+
MD.(D]^26M.>F^>>W\^)S.W'[]W^(%W;N8%ZF+(R38Q.-=!0)5.="Y]-K&I!]
MB_QNY)<M<E(FJTZ@7>NDD/QK7UV1:XW"Z-CB<9+GL=$Q2P>17I%53=O1- !-
MORE-3J"<+^+@_OWFGK3$#]YQ-^Z[ZVX;V>@C,>]4.K$,I2D=3*\LRV,'TTSW
M(K+JV,3IOS;,5SE5NK.WC"C=RC$^#]]]+V[_\8\QS&\]RS)M^4!B*HVSI%PE
M265Y4W04!HGJ%1%'?:\J0Z'H6U>XGWOZ&608AC6;-UFYER):G41[EVEBX*46
M(2DO%9 _O _1O<\QC4ZB1GN9C:]%?</%+,)=##O?8QJ[SHXZ4,'[0M.MAX?'
MJ>$UJ@L<I]6H7OM>U#?=R(HS:?.LIHBJRU9IC:3]_/(__1,NN& S;GS#Z^VY
M&G"1!FEA;-B1C9AI9=A VO _W3EY_#@;X I6K5]K&I$$&X-=3SV-O_[O_QT'
M]NW'^K7K\/Z?>S^NO/8::Q!$E*0!BHL8L2&2'C&$[D1VU0":F)D:QQJ>??))
M?.6K7\6Z=>OPB[_\2^A,L!&G6XPZGG_V&2,D:]:O=^\4R]:H[]^]!W_]F?^.
MP6/'\9%?^47<^*:;;3A6K9*F#4P,#V'DY DL7KX<!_?LQ7_Z?_X?7'W55?BM
M3_PKDAU'!AO#Q(*"9?]-A<] ]R32SIDIGY'6THS_PG?8^$FS9':9#C)UEG4;
M:-UHQ_Q3PRFIR#RP$UBNT5F];8UJ4QC48(?A:+Q$SY6WRC][/S!6>,R_IO?E
MJC2J3HM,!,]TVA =LOM&5MDU@CTDD'?]] ZL8 ?@TDLNP60^QXY&$;T]O>AF
MAR)!XB8"Q4@9H5%9TJLVK,X;TW"JT\"T5ISUG(P)0RQ3TK;W]/8:"7KZF6?P
M!//_-=>_%E=>]QH[*C9!0E@>G3 "82%5O)O!M+9TMWCHCFF@.:LDBRK+@D)3
MY6,[RC/(;]-6*^\L&_A?D[M6'G33,'/$QH[B)8J:[L XB'!+JU<BD18IU_=B
MX/N.!#JW+ ]T3['A<.:37):_(O#,$.=78-?LB]C(3.EF?X$+J;AIG1^X\RXD
M^-[E5US);RS.;^!%"\-J?C>:OVIQRG3C@5M_C#O9,4W1SMO>_VXL6;$,PT>'
MK&,D J[.48+Q*"4J[IN1?PI*4,[,;\4EB(,0Y<<X.3Y)8CIF^5+0,:.,UZX7
M7\3> _OP@8]^!-E>-[)28(?XZ+Z#2$MSS6^UN[\/9*'XVC]\ =_[WG=QTTTW
MXWWO?[^1?OF@J01&E(7 3\V;-<TGPR/-LC35 XN6($.R&DG&41P<P3T_O!W?
MO_U6K-^R"1_XX <=D6V"S5%5/,)T-3BMN\RGS%1>(A@Y/H@??>=[6+%V-5Y_
MR]LM7>*1N"O'+$=A:M2B+%W) 42'!W'BH9\@=N<WD*[O1)'ITG'+_XGRS1_B
MM[Q4YU?Q6Z@BZ36J'AYGA:#E\EBH4+V=%"-B(Q*IC;'RF61%R4:/E6VEFN+O
M+&VE6!F[!E50!65#NFIXU."RHM6\M9ZN+G3V]:.CM\L:JZXF+526Y"#-1BS%
M1CC3V<W?W:Q@V9CE2S@Y>,(-%9I&%#AR](@1VX(:ZV0"-38<6JPD#9,T+"I4
M,39B"E%#:*BY7]*0:'Z=$]Y+6Y)(HY8O(S\ZB4JNC%S5S24M#8^BBV%8U-W+
M]_0N25 'X]J9)I$E.6)H=!)\28MEE#[F#WTC(:H5*_R10+*W!V62\MQDGJ2;
M#;D:'FDWF*81+3@)1>8,N;75;#,EXE8:*F8K15X1VB/]5B.GA1RZ*K+6Z.A%
M$4S];FX@U$CRD1IB7>6W.@8D"M%D*.QD4&*QI VOIE(9I)DFH:22TNQ*2Q=H
MZB1I:0*E)>PP3:"TA!)IV5)9IR5L: MI3]I5:8*E38HS'A)IKE-)VJ?HF43:
MO90TLHFDD8<5JU9B^89UV+AU&U:O56<ABO&Q"8P-#J$X-&IIK;*G]Z1-BZ7Y
M;F>6A"7-N$90(FF9&!I!872<9&.2Y#&*3=NV82T[34M7K48?R^/8\(B1ATX2
MX"S#%"^4T<DP9Z7U9#@TS4.B^<@F--,TE!2)<IJ2BDNK2A+6U<.RVV6B\MM%
MR:1(RJ()2I+EC?%F^./,.VE4G>;9B3H_26G.Z;X]8[Y8FM%,XK2B_"9(Q#2_
M-DE2(@V^IE.8\'>"A5R+D\B+E.LFRGP1/I$[$=0$PRX-F^:CFA:<5]E7@0L7
M;*F@V-Q*$Y*UHA8PUFVJBZ:PJ.SK>\YF.OBNAO$U[8$YHZ,Z2=@+N0KXF'G!
M;ZLCB?Z!/I*X7KJ=1#$716ZBB,G)<93Y36BQ4$J:3:95@A)A&8NS;HAG.TF"
M609*5>38:1@Y.61:<'4&>KJZL73I,JQB_J7X[6>99O:-:\@_5T"LR,XOPUNE
MX<":%4AU=UB<--JA:2PBS%T,4ZPC8QW2&,NX.L$)AB.N_*=H3FJ&=5%7?S]Z
M%PW8O&4M4(N5RHA.LA[B?;%6POC$J*69RD4'P]W9T6EBA)S?A<J_\K3Q/= /
M*ZO*#^9;*$F6(TT?D$9=^:2\K4JCS<\UH@GQ&J:Q;J3[CJ/ZQNLL]SJ5BL_I
M K(U4M-T!>QK&?&M,=^M4ZK8*X,\/#S."&IF/18XI*%2;1>I%7E3)@%@9:E*
MD!4EZ1\?N:&E*0U(4Z7(6U62:@PU#.L<X@]C8_8PL,<K*V<;HM(]"4@'&T(U
M2B4M5K#&-68-ME:S]M)<9*&'C;<T:YK/.#D^87ZD1+KH8:@I,N&?$(90L#"3
MM(F,94A(NT@VTFQLTFQ@BI,YC(^,VG"Q&J#0'851E;_"D!+9XOL:HE-;DF(#
M%>=]?F0$DV/C-MPN#9^T5Z9+XU71U[U"XM)L2AR!8",E^W;OKO:<[S3LB8R0
MI+KI$DX3[2*D.-E_=N\B&][(+' C\+]5+(W4%E9=7C2$_UR6\KF8L(E^TR1,
MEP#V6_::8+^#=Z;%0\4H$*602R794WE1^>)5Z4>C$DE4__+E6+-U"Y:L6F6-
MN^8>'MJ]%WN?VVF:;G5^-&1;RQ<Q?/0XCATZ;-K\R=RDY86TVQK>3S*?(LRG
M.$F#AL.[2"HLW/0OQFN\)O*FD.CJXM/XT^]0^.<BR"OM.]&]>^96:[O\-M>4
M!H*E)_^S:R!":!X@L.T0FO,2FINVSGEG$J(YC*V89M;L%\T51A?KX-U0Y*GL
MJNSKN]6W11'IDMTADL@JO]<HOQ7V+OA]\!V66SK&-VE.-WK9(5BQ<BVZNS5/
MNX[!8T=M5&+PT"$4F5]:Q*7%D@E^\RH;%7[SDZ-CYO:)P9,89E['4PF7?]81
M2;+0:/$;R2G#I-T!1$0A32O)JJ88=??U(BIBK^^#84A*PZH\4IF6W0 67^65
M\HG/3?A;"ZK8^U4T3).L^F7X^'&6-1TCK6W)]$2=!78T+.Y*)S-R$D I.,.,
MX6D669+V5M,'E-9ZQ\T+=_:MOE1A,H+*BZ4SOP]^J^I,R.](60^8CO81R\WP
M90\/C[.!OG0/#P=6T&HDI/V3=J>CIQL]_7U&"B>&AI$_.8S"R!BI<=2(I!8;
M1-B85,<F<>+@$=.Z2)LAC855U*>#&@E>-.]-PWQJ(&U+H$(%HW2+30 2)*WQ
M#C;(;)@D:FO4H(@H:7LB+>Q0(Z&YG762JN+D)(9)5/6[L[/+M"(:=JW4M-U2
M&27-@90C$H\Y(Y(@\:%$4DFD251ZEBQ&ST"_E8]E2Y=BZ/@@]C[U+'8_^B0.
MOO B&_ :!GK[L(3/%BU;BDQO-V(D5EV:$L+.A4U98.9G:"9MIM<XG0I.,V?3
M!Y1._&ZDK=8N -)":Z[O\,F3_!Y%LMC'Y+?K2+2;#J#O2$/7&OVP>;.='>A@
MAU.+E$9)1@\=.&"+GO*C$S9L/SX\C&-'C]@T'LUO'5@T@)4;UJ%K^5(CJ9%,
MVD84*B1M\D>C*YH&$&79$'F;8,=$6GP1:=4ITL2*<(I@Q^T;#J:L*#X:MF@#
M^T3Y;M@IU?Q@::LU%UASI;4P4_ZJ[,CVV9>?B)%NN:_TLW#-YJ32G_&4)E?Q
MUK2G\*I7/#WU\#BW\$3U/(%1NKE4QK+38LVT,/:^^ZV*=C9HB%%#OM;PI%-(
MLT'3PINA$R?9( [AY. @^GIZ39NF8= 3QP91'L]!>P7*7G=_OYN7.&LM/P4U
M+O(G5\@;6=6\MZ.'#F'DT&'3 G62*'=T:]&)MNV1UL?-$]1O-523),MJ3(\?
M.8K<Z#B&]N_'L2-'Z'\,/7U]I@VT?6'ICRW\(33GUAI):7D\9D+9UE3.0HV3
M%L;EM2J>)('L!*GN+O0N7H1%*U;8,*H6UNUY_@7LWOD"\_"P+=Q3WHI(B5!9
M)X,D0-#\U8K(AO*<'0>W"ELDC ]9_LY%2R\R=/;D918H?*&<#O.Q>PK8MV+?
M,<'\L/U!V8G+='4:81LGX<R/3UB\1;;">>?:[DL=.'7<],WHV\@R[Y:L7HVE
MZ]9AQ<J5Z,QV6"=SUXX=>.;1Q[!_SUY3'&IJ4'=O+S*TK^WG;$<-$E2;[D+2
MR"_)2)T6.^[;LP<GF._[]N^SG1OJC*]&'+0-EJ8(J5QI49LZF*XS+"TDHZ(L
MHEW%STUU"/--HSO\7]\[H;I%TQ>$8\>.XLCAPU9?J&QJ2DFQI ,B[/$901IJ
ME4/%1U=GZ"ZML+RP\NJNZ@RX*\.J.-".O=J(BX>'Q]G $]7S!:KY5.FI]IZM
M0M:S6: *O8%9K(D,2YMJPZ\DH7)/BS4Z>WO01U*R>.4*K%BS&M?=\#JLVWP!
M+K[J<ANFUX*5_D4#6+1JN0V7L:9G6 -'3P7&1XV?%JBL6[\>%UYX(?H'!DPC
MV]G7@PQ%<QW9"J&N>6D4-2C2XJB1TG"R&E,UP%KX=?S8<0NOAIA3)+FR*TV2
MYIRIH=/<0X55\7>Z7(]9P>2Q+ R224.QF8S;,:*D.:I'CMDV2$?W[L4!=A"D
M6;WXZBMQV6NOP?IMFS%9S./PD</8S^=']NY#;FC$-L.7J\ISB>85BU2I,R%M
ME,B/#=^?R\:=97A:V3\'D'NAG [SL3L[0D+D%AC9"G_^%;45%M-J+0EG?V\?
M1MB9/'SP8$"TE(:.*&ETQ$X 2VEG 9)-AJ6B0Q;*)3=?,QIC)V02$\.CJ!7+
MIIG5?')I1/7M)SK9691;=-?F6E-$,)F+%J\#!P[@1S_Z$;[RY2_CUA_=B@.'
M#IIV5?-*M;=L9R:+%,EP+SNQTJB:=I?OVJ$%%DQ'2ETZ69;)92.TEFY\'D\D
MV6GMPN(E2VRZB.J,);S?L&$#^M4I5?*R7CA3:)<%ITEU:1:2YEFA,-(_TZ1:
M>C.8QJD9+[W//X7=--OVU,/#XTSAB:K'=(@PJ')EPZ#3:[3W8ZJKPQ8_Q-E0
MB$!NOG [!I8MQD577(ZMEUZ,-!LS+?#0:FVM)"]K<0?_3@>KT-DHYG,YF^NZ
M?L-Z])*H=BP> #24S];'-"JE*N(VOXU"<JJ&=W)RTH8N-VW:A'5KUEI#HX4_
MR]:N9:/F-+K2.DG<%D;:9DI$57-05>Q/'[Y7.]3I$(D1J52*Y4?'D!L9LVD9
M(D6:!RS"LF7;-JQ<NP:]RY:@?_4*+%V_#A>PC*QF7B28WH6)G*T"/\:.Q,FA
M(10F<]9AT'ZM6ARDQ4A:#%-EYZ.BTXI.11!>C2!ATV;WO3T]&--V4%I0%)!]
M:4J3[(3INUDTL B])*S:*DH+Z[1P2V7?:2750>!W0?*D[VYL;,RV(-OYW',X
M=O0H.D@FMVW9B@LONABK5Z]!CGET^/ A[-N]FWE]G*^3;I&@EG7L*O-,9%9S
M2+4;@CJ+5UUU%6ZX\09<<\W5V+!Q@VU5)?:H;U5;J=4+15QQS55T_R),3DP8
MB9.VU9%"1^JFB>J@0(SIF3V28Y85K>Y?OG(E+KGT4MOJ:X)U@4T!D(4SA-RU
M+=0HZMBZN>2S4TR;XVV=+6F5-6W)I:NN5K50PKBX"'AX>)PI/%%=Z& =)\(@
M<J5]%>V>'?BRAM/X3(V5:3"US'<6B)RIUZ\YFQI^%9&LDO0AD4(MR@H^%-J+
MI)-.ZU(NLI+5M$3:*]?9$*019>,D0J&C%W7JT_C)8:2S6=IGI<V*7HV1PAG7
M7$:Z81JR0)H;GE#"A3K:-Y)-E@TQVBE8K/"U$7R$!-6&@C-)VZ)'$LV7$"_5
ML'C18B0R*5QUQ16X]OK7FA9/PY1Q-58:[J2;3"HDZXR+MK1BN#7?SH;GZ#>;
ME"!U'$2MM0;%7@K"K+:YG<P'(G(S)'CV4L((@+1#%-/$,7X6]J8\:8V7Q 8N
MF?$BJ"E;15Y#K< .R_@$:KD)5%DN,ET9+%JS#$NWK,>B;1N!@1[4M+([FT9=
MY4"G!K%SDUF^&,LNW(*5%VW!$MKMTR(<$I?2^"B&CAS&R8,',#XVXO8Y):'2
M CX+.\.F/2EMJ)O7,&QS2;@PSHI&,TR[KKR=#V@]?*]9SA2G<Z/Y>;,H,M)^
MJF.P?]=NC!\;1*1885K6$*5H<9%.3])4G(ZD]G[MQQ#3^-#QPYB8&&$E7T,U
M5S0M^."!0SB\>Q\*H\Q+E+!FPUILVG8AUFS=CMZURY%=UH>>)8NP>MU:K&.'
M8U'_@'5,GG[L89PX<<3F*4?9,8UW]R#2T<V\2F#5N@VXZ-++24(OPX477X8U
M%VQ%.MW!,-%NE=^ZIJ<B9CLZ9/E=:RZHB*RV(E.Y5%W _RA*<"=UK:8/!'5^
M^UHXJD,NM$A,QYK&=%"),U<GU33-+AG;HEVZ-HN.CR7U=ONO:HJ1RCRO(MKV
MOL(50(L06<JL,UUC'#3%(LX"JF^N%F?]3#O:]4#NN;BY]SP\/,X,^J8\/.8,
MD4M5S"+,1H;80-A\LP4,A;/"!D>G6H5SWCQF@7@"\U>+;G2*T+WWW(-_^>8W
M\>UO?QOWW7<?GGKR2>S9O1L']N[%GF>?PPL//HIG[[P'S_ST'CS]D[M-GJ+L
M>N 1['WD";QP_\/8P?M]3^^PS=_W[-F-QQY[#-_[[G?Q@^]_'T\\\:0M?M-V
M4#8\+6V6Q#HQ+&-!L%[-$-G1WL2"IKQHWFE4AQF0^"/-CIUUXG1E^I$\V9 [
M.Z+:#2.39D>2Y*Z0FR31',3$Y#@[AF5V6CO0QXZ=#C6PQ8_L%&@C_I+VRZV1
MI"79P6/'([ND'WTKEJ%OT5*,#([B\-X#R!T^@L*)XZB3!&=(&*5E%:+LY&I>
MN[4JS1DGHA:0-<7%=M9@_IJFGIT2IX6<V;F8"6=![]J0NLH'WQ-)M<[)64#3
MG;1H2QTTS:/53B8:@3'-L,*N\'EX>/Q,X(FJQ[P0:G>EI0U/#M(PV$*&$=6J
M6R2A>X]3@,DC+9+.O3]Z]"AV[-R)IYYZ"KMVO4!2^02>>>89//[XXWCPP0?Q
MTY_\!+?_Z#:3.W[\$_ST]A^;W/'C']MA 3^^]78[3E=F#]QS+Q[@.\_R_1=W
MO8B#APYAW[[]V+%C!PX?/FSY(A)CY4D2$)$YL)=7/#0*$.Z3K#F]A4+>#;\7
MBBCG"G:$:#&7,RF3B.9&AFU?T&0\B0EI85]XD9V.P]!I5DN6+,9:K>#O[[65
M_S'3<%91%='3<':2A#>;0BV30(4$N!"/(-'?@Q6;MF#=ABWHRG1B\N00#C#?
M1C47E6'3JG[3>,=CJ"5<71#PT@;T7&96?XB<6OZZJYY(0VE:RE/ GK),."TH
MWPN(JM+'+1@]<VBD0UNKZ:A:==)T%*SV<K51)@N?AX?'SPH+FV%X3$.H06B&
M-?"GJDC5V-..MG$R/LG?VFA<%;T61K0V**>#&DSM6:B]4J6Q,6VJ_ B@,#8T
M)'. [)IVA:^HP;&A^5/ #>NZ;7'"1B[T4PW8-"B.)%W:Q2"?9X->*@7$6N&;
M[H_;KU-.O\J;I" M=7J4YA)J$=K6K5MQQ>57X.JKK\9EEU^.BRZZR,RV770A
MME]Y*2ZY]BI<?.V5N.RZ:VPQU:6ON1K;K[H,VZZX%!?1_,KKK\.%UUQ!-RZW
M>86777X97GO=:W$I[[/9#,JELB,;)&%D3:;UUOQ%(VA!L%[58)G75)\<B>C0
M\!".#P[BV-[].+[W $[L/X23!P[CY'XG1PX=P/Z]NS$Q.H9C1X[A[CONP?>^
M^WW<>=<=N.?NNW#__>PPW'LW.PYWX6YV+G[\O>_CI[>RL\'K;=_['N[Z_JUX
M\D=WXHGO_P3W?_T[N.M+W\"]7_LV[OG.]_#X0P_AB<<>HSOWX%O?^C;^^9__
M&?_K6]^TN>0V9201LQT@V(MU=8(^)5ZU>$MC+OK&]-U:G25S?<.!^G5.^4SW
M0H(;?J>Z:K3$ZHU3?+KAE)!6T;08O::K:H0XZT8[L8W!LAJ"[MIN"8I/$Q0/
M"[?BQN<N/$P'33O276#?IJ\$\?7P\#@SZ&OS>,7#:1U4B:K29&T?:*U4>9ZB
M=F\'5K@BNM*F:D',^5 !J['0'JK:=]4/_9\:RDV5#<W[4^.[9<MFO/&-;\3U
M-]R *ZZX I>2;&XCP;SB-:_!3>]X!][\WO?BYG>\'3?2S@UOHCW*#6]^$ZZC
M??U^_9O>9-=KKGL-+KKT,ES$]S==< &NO/)*7'_]];CHXHNM/&G^M;1B.I*T
MSGN/*>@[C9/0Z^C:+#L.(GQ*+VE"M8A(NU\T3NU*)=B1C-N<7YWX]=PS.W#H
MX"&2W D,GCB&IY]^"@\]_"">?/)Q[-KY/$GM/KS Z[-//TT2^CB>>NI)//3X
M8WCXR2?P]/,[\.+^?7ANUPMX_/&'\<!]=V(GS?8</(CA7 '[!X>Q[]@1'!\9
MPA@[-77-DV?^H<"\U'U WL)YWT98&>9&)].JCGG6/W332"'?E1O2T+HZ2 ;.
MRND@^RKC1I1YU<*PR;$Q#!T[SL[9I$UMJMK^L_2.]88ZTB$Q-M ?_599E5U;
MR$4W$YJK;P36P\/C7,)_50L<ZN]KH9'HE9W<PPHT4BLAIM-0(NR]:W\75ISJ
MQ[L*O+G"YF^:R3P2BZ!<8^/!!H--AC5^5L&;Z#U5Q+)/E^B'- FAV+Z7TG:I
MP9'4V7#&$C:<IST5=2ZWE23^GB9R+Q2%K54"TNCFAFDZ07,#)M!. -W9K^"9
M'2W)^-BI,(&]:8V)^4GW@[AIK\,HGVLN&EL>[8INI-7T*3KSD V.I47PJG.R
M$9!ID#^MPO^"I],1.C57>4G :#1B$H;U%.%5IT;#L[9INT1'2_9T(][=R0:\
M@MS(",8&!Y$[,83JT*@=FZEBJ&,G*]K3<G3<TKI.\\+PJ%UK^1(&CQU#M51&
MBNYIIP@=V9M.9VU_S((6XFGQ%DF6'3-+J'S.$LPY0"].B=MN2.5!SW[&L" Q
M("W2G#7-(OM:86\DCVEC1WQJFR>2T@J3JL1XD1J:"/%(%;F)45RT[4+\WB=_
M#[_YF[^%-[WYK7CKV]Z"W_B-C^.3G_PD/OZQ7\5[W_<!O(<=C8__ZL?PRQ_[
M9?S:K_TJ?NNW_Q4^]BN_@E_YI5_&+_W\+^+7/O9Q?.)W/H'?_-6/X^<_\D%\
MB'+3F]^&7_C5W\+ RC489;X=/'X41P8/,PK2C++3D6-(1%A95U3K_,X8/>W6
MH2W("KF\3170]!+M^&':R.!/$6WD4_![ANB9[+#&LSUA2>"[.CN08EK8NU83
MZGW)3,@?'1BBD$I376)XCA\_CI'!$Q@;'<':]>NP?,4*>E%G>70G[ME[>B<4
M&5B]R#"PWC M,A&.5(6@#[3O[CT\/,X<4U^5QX*$JL4"&X J*WVM)(WK&-5:
M#FDV2XB1K"58$_*9M(:F+926@.\U.)>(+<F<YJ<5RP56K#0K\EIF8U)E)2RR
M5PU$]R*S?$<$,&PT]*Q4S+F5_'2_HC/S___L_7>47=EUY@GNB.?#.WB;%ND=
MF51FDFGHG2A2)&6J1*FJY$I5-:NKINJ/6C-KIJFNZ:GNGAG-ZEG=JZN[K$J6
ME$21(I.>29?>^P02)N%-!,*[YU_,]]OGWH<7@0@@@$1F LC[!3;N??<>?\X]
M^SM>82G7%); 4,(U!0$^)<&-()A?*AY>:3&(:GR4I_-*)\\A_$OA\V'U#Y):
MJXD +2@,J(XHPF'^FH1[A;U-#J;2(L%Z4)J:LD.[=MF>9YZQW<^_:&/'CV%(
MRE[FLM%V6"UDU7M>2,\EH@B=+BO! [)*N8 (80_B0Z[R@+1M3?_EXH8TR"^(
M:@=GKH?]=#G#G]T<V#>WJ[O+CZZ=&9^P8T>/6(D%."*HK)C.Z5V![<I$.MEV
MK"3!'',J"YU=UI"[:;G!V>X<V2D/S<^4YRHW*: ,^,?#Q$O1S-\59!&:A4K2
M)"_$>WF[IXG"\-8 =XG;$F&%^S+B/%;?(.&AX< 62LHIRRC-\IFL%?2[(Y=W
M\?F5;57KRJ5LXYIUMGGC9MN\=;MMWG:%]?9WV]R\&AGC8]963UM7SZ#U]@U:
MOK_7>M?T208LV]MM.?WN6CMD70-]OI^R-US:.:8T;;W=W3;8O\YZ>F16_J;;
M<BHG.5O(RHSJ(E;B9U*<[:^Z0A]=F[*8/35HO!S:NT]EI>3'H7),,(>+T/A6
MY&2F-8\DK7D7B=<K*L0^T4!US4)*SZC?2!N^=;=+3ZCJ1>PL W]*\HM@3QT?
M]C!-J^'%/K37WWBC_<*]'[ K=NQ0U=KP0RGX9)R08LE_!/M>3Q%TW))0_7EY
M51YYPY5GRI] NA,D2/!FH"\KP;L%7H&JTN7:5CM=4!YL"\2>J*QZY=A,A$WT
M(3 !*' 3<87H!@+J.J&% ,7B/9:1+(=0^8=-WYE#RW F/2V^Z DW>'^>0*G'
MO1_T#&[8L,%F9F;L.]_^CGWE3__,-RAG$0]P<PPYDR[^Y-V-=A$)AI@YK]WW
MX92RK9;8(%Z$0.4@*Y+9T=-CF<Z"F0CL@LK(B1/'[<#KNVWXP&';^]R+-O+&
M >^][NCJLC1';N8RUB,RP-Z>#F]$J $A\D,/(1FEY$^P B"+934$9N9F=:UZ
M[UU5WTE1^5+2MU-4X]-%OR>F1$9G9VQ.1(NSZVG$%I1G0_H&!M8,6KOR=$KO
M.6UN:F+2*FP]QE!]S.*4SV5]*],3$S8^-FJ3DQ-6J:E1JT9&5GF^=OTZZQ!A
M9?];PL$N!&41O\I\R6K(W+Q-CXSZ=EBS(_+CQ$D[L'.W_>3'/[$)N1GRFSI"
M))/ZYNV$O&M3_)GO2U@@E^O6K;/.OKZPYS+E-:>&$W6;"J7/7:?"2Y @P3N&
MA*A>,J"WC__#W[F BI9Y5%P96O4Y5QFU]I>($U0J9:^<_1($<B+[=7IA]1L=
M4RS.>Z_.(D+*0H(6\1Z32%"T3I1;(<>QQS!SV/(JS/'RGCT\=IJY/.)P,HRW
MDCG,X#X;I3_PP/UV[[WW^4DVUUQ[K6W=NM6)F#21^^U#_PE3\C0@_=FB)YW.
MA'*C/X;L641'+Q'IS;8]G%:V^8IMEL[F_'0IR,J4R \;R4^-CZL!4K.<%'_G
MVB'+]_9X;[4/E:;2*@_R1UG(HKSXM# D9"L_ED=S(<SEF%=1&BP5?3F6$GGR
MOD((OM*KH[O+^@;Z_42X?F1PP(6C@X?6KK%N3F:+&IP04[Z_^>DI3_^NH0'O
M+2WD\[Z[ PNOCA\^8L-'CHA8GK0Q$<SI\0DU7!OZ[K.^A56G[*39!U??#%,W
MO$=1P:.AP='*'%V,&\=8Y'7DF)]R-3\]XP=#3,FML>%A.W3HH$US]'(NI_R+
M>BGI=90[GILA\U<4KWO\R@U5C^H.V??%5>Z&WD5N43S"$#]VHF>24+;:?/I!
MI5*VP8%!ZUNWWAO=2$,$=D'OJ!-\2%_F?4$4UB)XPSOR\Q3"E (:V1XOO?2\
M<O\2)$CP9I 0U4L%7M^%2I;*<]6@HE7%&A,[Q*W3D[&,,(K/X0%LDK]0YEJS
M!B?AJ&)F/IF[IPJ8DVM09*X1N"+X@T!2D8BD(FX.:8%\]&<0HF:%SC4V%S];
M <&^WRX/Q0<S#)7><,.-=L\]]]A]]]UGG_FE7[(/W/L!V[!QD[R0PI%_G#N?
M0"#!E!ZD"8T&5D'[Z4<B+$Y.R!,]8[LO>L&G1L>M*$+"*6%77'V5;;OV:KOU
M%^ZT]5LV.7F='!FQVM2,M=5$ JI5)TJX@;)'J4,(O(<MAMZ]6Y4[\5Y.?'A9
M>;%YZQ9?S';ECAW>4PUAS'5V6%;76/+=G;;QJBNM=V# MU?RT0G]>>-/:<WT
M%A^2SZ9]\_VU:]9:7HV1&1'(7>R+N_-U.W'HB+77%WSN<#<]C,I_KQ^8/Z,K
M\[VKY9*/JF2RX:2H[LXN*ZB,]!0ZO0$(:>[J[K9,/F?=/3W6(S,L^F(?6,"<
M=R=UJDN<^/'-Z\K]2L*W[F12#2 GJ?+/1T$4K+CA0E*YZ#^GK>YN=)5 )MF^
MJZSP#XBD9I5&+-ZCK*<47GI2*=<>MO9P\A0C#(OK&:4?%[GE_I)/^@O$.(0G
MO-9],)D@08(W@82H7NY0K<G)3[-SLW[L:%4"R:S,S)TFU>E9'[8[15*Y5JVF
MBIP*F%XPW*-'RS<>%Q'Q>5HQ8=7SN+=KJ2P+:G2]JTAIX)XOLD"!R5W9<N7Z
M9A#WS :E*#>EW% \N,_F__0LHWCI'9Z?GY./6'JW*Q;R5V1 90;0HTJ/'(O=
M6%CB9%,$IZ9\8]/_?:_L](9,'YO']_=;.I_U'KN.@7Z;+\[9P?T';/R$R.KL
M?%#^<@_2Y6[+W7!D94M#)<'I4'I!S+9NW^['E-*;RC \',B_+;V+A=\%I7%O
M7Z\?I,"\X5HT32?T7(LZJ6&04MH#]EX%])JN6[O6!D5PF?;AWV6QJ&^CZ-^,
MSW4GWR"LE!&]YSEU"E>.9!T?'?4%4B>&A^W%5UZV/?O?L+&)<9]F<%+7(T>.
M^#0%OG-Z*S/RAVD#N,NP._'T;W8E@6C+;](BG<N'AM#4I)/,<%"$&D$JF^TJ
M4^P/VX[HN1\0H'<(&_HSSY<Z</_^_7;HT"&;'!]WF5?XB0_A2HM84R8AM( X
MQHBG*SB!)MTCD"9>CI.RG"#!!46;/L 56$2"BP%4@Q-2$IVJC(L_^;I-?O7_
M:=LJ^ZU1%J&\^3V6NO_O6_OF#UA5%7XZ)672)F6"\G*$Z_Z]^^S/_^S/;'!H
MT.YXSWM\KB9S4AG>98$$! )0T=*[Q38WW,?.</0HE3Q*#V4R?.2H/??,,W;=
M]=?:+;?=YJ0&11(@Q>-U=5!F,:CG492JVCU8KOP6%*?YDNW;L]<5QC777&.;
MMFYQXH@R1 $Q-,F0<[Z0=W?FYF9<64Y/3]DSSSUC=]]SCWWN"[^B\$GQ*AP^
M;U9^MV=$0G,2[$Q.V8G]AZR[781+X?"X-&K6MV&=Y0;ZK#0_*P)5L*S<A6BW
MJIGE5$Y+M%H M0[Q]@2(P4,L(*W/8RQQS$TL,;?8Q"DLXYIP2G$N1IP_I^ ]
M=4M +!KUJAW==\#^X[_[WVW3YBUVWX<>L+Z>7NOJZ/1AY[+>,_0/B4VC^'M[
M/!Z\<X(KAYDJ@")G(WGVLF7C^9+*'</2#/TZ,1$>_>G/[?$GG[(/B(#=<__]
MWJ ("YE6BD<$A7TY<DO^17?1=0ED9SE[;Q:+?"-L4>ZT?@.M:%LN\5> '^U;
MESLT" F[$R5(D;\6PN\8D,MO_?7?V,$#!^VW?OL?V9"^*18Z<M0JC0J*"#VB
MI=F2$T9.J2KK'?,Q<_F"3]OPH6_RNE3VO70AQ@OM%>L8'%#=D[?)Z;+]U5?_
MPK[S_6_9MBO6V3WWO,?><\-MMKEOFQHT"S9=FK6.O@[?E830'=Y_T+[UK6_:
M?C5NMF[98O<_\(#7/5,BN/38\HVWDD'FRI-/2/S<B:"N]'CF5!\PM_WG/_JQ
MI;,9^_@G/N&+_'Q?U&9RZ%Z_?>@^@@_/JSQ2YQP[RAQUS+?Y;@0X3H.+K=AN
M4SU);S"]QZ21[X02YZFN[9D>*X].V.33#UG;,U^WH;G]5FZ7N7_TSRW]OB]9
MM6VCU57$<RK/66^(41?)?IQ-P:FW%"N5O00)+C4D1/4BAVA?DZB6?OIUF_B*
MB&H9HCIG=O,=@:ANN=<J4F09$=6E@"RPC^(WOOZW=O+D25N_?H.-C8WZP@=Z
M).@1"/,.!56>$%6D59E#&%E4@P&(!+V?[$F:$1ED(0+F3RF9AI4K9>^)H*<L
M!NYA#E*,V7"5$E*02U*L)T='O5<'!?G,,R_:;;?=:'DI3=R!$'5V=+@[Q=*<
M%3H*5E'8][RQSS[TX0_;K_[*K^E9IZ5DCAX_P/8]"_(>XL2"$39&7]/18RE6
M&T. %VK6*9(*R2J5BY;M[K-VF26]FG'7E[%:?2)UYQ31%U\T2;O YR6%X4JV
M)4UCN#)I^0+="/9;E,RRG&:EL+6=7@:" ZLCJCC:4-X>>GVO_='_^#_Y$/.M
M=]QNG2(KV[9MLT)GAP_KKMVR588;85J(TMV=BL.,PB9\RN\0-Y$#AGS5T*$'
MGH:2]VJK+#WVV!/VTBNOV(<^\A'[P <?\/+E/=V^1?P9( ^73<^S56<KV'NS
M<%^;SIXBPZT];DV0-M'MJL#*?R6HIVDS['*7Q%P"&FIC)T?ML8<?L<,'#]G'
M/_8QY6&'M>73UMO5[5;H176K^J8ZF#*@/&;J"VZWY_-6FU7#C1.9]"W0R&-E
M?JTHDKM0M.[!/IN=35E[1[_]S5?_TK[VC:]:=W_6OO"%7[0=VZ^QC@4U:-3H
M8WYL+;U@\VI0URE/^_;9=[_W/=F=]:-;UZY=9U-34]X(AFCRC4<1#!'A2IQ)
MK"B:7,("KK2*4L7+$?42#6[J!^JIYK?GZ172#)MQNG&-IR#,SLVI<1_FQA,N
MZJ?^_GY[W_O>YU,L.GJZ^:"5U-Z\;L*):K;7RB?'G:BV/_L-&YR%J*9$5/\;
M$=7?$E'=D!#5! DN$!*B>I'C31-5247D;7Q\S(KS1>L0T:B)7*"86,@2'\T8
M V('D81P->M4W;/M#<H$@L%FV RG5]F>BBV%])O*WLU*XCU1J=!CL,=BZ)F0
M@I7#3E05YG2:WK64S4@ALE_GT<.'[4_^RQ_;/_FG_]0ZNSKE5T/VPGZ)H%22
MDI7[K-C]X8]^:-===[U][).?]F%!%"KN<[!!>UI^^_ZH[;ZH8^3P41LH=%F:
MW0T4GV*]8AW]O5;H[;;Y4M%R7;V6BI1;DPQ@--R=%2C4RX*HRN&:&AH'=^^U
M_]__^X]L<&C(/OC1C]B&#>N]U^ND&CGT;F^_\BH?(JZ6RQZ'./^!U+A5*N&T
M(.+,/-=0IA:<6$Q,3C@Q@"P\+J+Z^NX]]HN_]$MV[X<^F!#5Y7 .1)7H\XT>
M.W#0CAT^8CNNN=8.'MSO>X0.K1GR/4+[1,9HR-64SJ074S!86(3;;$?&D']&
MWSO.5V?G]%QY6ZXKOR8ME4O9V(2^?[4"_^IO_LJ^_N W[*KK-MI_\R_^B=UR
M_2VV,*>&;HWI-F6K*QO3'3G%MV[[7GO-OO*77_%1D_?>>:=MV+K5YN=FO(>3
M;]?GP<K_.';M^FNH+!"7^'N*WU)/S(FDEM2([1\<5-E:"%,8]-KGDPHD$_'Q
ML/L/?^SIR)9I],IR9&I6Z0#1Y8 +C%'V>@<&16##5 ,?YE?9;4WIA*@F2/#V
M(O7E+W_Y#Z/[!!<A4'/L%)I6I5,_^+J57GG8>FL3XB-5:ZS;8*GM-UM;[S8?
M&4RQF=]I8,5PQGKZ^[RW@)Z'WJ%!Z^GJ]D4.73U=UMW=[0L?$%8+]_3UZMKK
M"R"0+CTKL*FV"$J0@O>L]>AYKZ1;;N-6<$\B=PIRG]Z:CLY.E[R>L:51OD/W
M<LLWD2^P)Z?<EGM=/=W6LV:-5ZZ[7GG%[G[_/;9^^W;K'>R76UW6*4))&#B=
MAR$^-/*K+[WB^Q>B?"% *!GJ?Q14N5ARTLW^LV4IWLF38][[QWZ?;.'#HI).
MN<V>GBBE5"KT_B[5'^>B3TC]H!Q;;+5DR:+G*\"-+#6W@K5E'R]#7H+)%M.X
M?X:P0+9)IZ>?>-)[3Z^[X0;;N&6+"$Z?IS'S^^9G9D5RZKYRG#G0WD"(A.%^
M>L9C1<D\Q(R(2'N:N80BK7K.&PC"D2-'[>3(2;O^^NMM\[9M;B<0D^7BP3.E
M;S0LW$2+T?A=J[B;Q)][A8TI"J'G7/[(;O-]"V(GFT\7O>;'$I';IWYC.Y;P
M##)U*LQZWLHS?41#[YQ4Z3:V%J.E1>%I0SQPH(4$QV[36*,12H/O]==W>3QI
M5*X129V9G?%CA&E$,M_XR/Y#5IDK6E;^%J=G=3_O(PZS:C2VLZ"R6+&9\4G?
MKJI1%1FL%/T;G)VKV/$3P_;ZGIU.@/OZN^S.]]UAZ]=ODO\BJJF<-SCR[!)0
M8+YH6F$JVX&];_AHR.WO>Z_U;]Q@G?KF^]:MM4Y]@]TBAS1,._5]\YPS]Y%0
M)ZD.XCEUE!J7]'QF5:?1B,K+/7I98W/47]0EV.W /=45+I%[U$7LDC"X88/"
M+7=ECX87=:#[*[-^VI7^0BE=#B*Q;5EK,-_V^ &S8SNMJS9M%>;;ON<>2V^^
M5<VL;F\H4ZO$B[%.Y;_0FK\)$B0X(Z@A$USF<!*A*W/=JNR'2"6IRIC?-=W6
MI/#.*"(DK!UNB&0L2$FTY[*^78[/ \4M*4>OB1']DW?>0U&7 EPJ-?G+X#Q"
MYR9[0E8@E'*#WCGFG0T-#OG&X Q!XV]5_E<B(?PLA/*Y=5(Z@VS'(Z4#Z0F*
M/\QIHR=FZN2HO?+DT_;",\_:"\\_;SMW[;*]>_>ZG#AQ(IPZD\YX#RR]+,0C
M)E>7+8@?&82LA$B)HJCI^89DLKH[*X6^:?-F$=<;G:"R,"7;+3(PT&\=:MS0
M0^TBA5\0J>U9MT8$I-_)15[/F&;!4:#=,CNT?IT-BJ0P;QH"X4"1JXSX=5GH
M.7FD_()PDE<(\PC)\Y40;ZG%=\"5O7KQ)_SF-MR[X"8/<1<"SCWO([\0WITF
M+>'A9RL@*!#T)O3[%.'D=Y 0AB66%P&_%&8)]@.A/QTL?MMZQ15V]UUWV[77
M7>^[,6RX:IOUK!VTT<EQ[\G.Y]0X5".1OL*:_$7PV>L'N<O\3'I7(8(T3A9$
MEMG,GZW%:("F1,*ZE?<W77V=_<.__R6[]NIK+*-W2+O<H@PP%<=37J2U2R22
MK>&8WI.7+# -1'4!\?7%="+0[8R$J-Y ]!5[FJ44#JY^KS)(G"'!?/\9^<^T
M$W:E8(>#T"LK#R6<Q$=CR1=3N9QR S1$G./1(>_5E5V?JB([Y(L_5SS.!:&1
MU"Y[E,ESLYL@08*5L7Q-E^"B ?4NQU&B_5!D?FJ0&%F#1CK,# 6G:Z3R3@-6
M?3A?E;]J3Z] ?8]3E&6D,&GQ!^'^=$$IL'E[NQ1$.TI2?GGO  1 [V.EZ:**
M'@7%D8E,%6@*B@5BD\I8+I.U?#9G!>^=S5DNGY5(,4J1Y+-I&Q)Y\:$W$6$4
M$.>79_4>02G%BW98/<P\M<F182N76 RA-$+U*HS(_GW[["<//61O[-DK ESQ
MS<\Y<K(MF[*TW$11H3!=8<D]TD<:JBDQ<7%X?"/AJT%T>TI(2][Q SNGQ/\4
MGD"H@L1A=#.>CXA^XGX,]RNDL;O;\JH9EM,0!ZY%9(Z0H)!;A3@SM:+I%B*_
M_ A3Y2.;NN?HL9(4NKML7@2G77D&X60[*J9DL%"%_ B'0RAO).UYD0$1!2^7
M.94KY:DRW\W2"\O<5(@ Q %R00\?;D' F,]8KU=#^CB-0N(_&EPTGI3W,L?B
M/@2WL-LJ<=JZ?86#H6W"U% <G91!*D3$9,#J+#)R.S)/&@C,L\8/%O4LR!Z]
MPNP+2R.);R@VSS6^UXV72R]'$$Z7<,_:,#]4PD]UTWV<WLI4OLTZ[F(W<L_]
MB"0N.R%\D5TY[46FI;PBX9CD-NM9,VA7[KC6^@;Z?+_;;'^/;;WF:MNR?;L:
M' 4G>4/;-MFF:Z^RKO5K;6C+)NO?N-X*,M^]9L#:.W+6*&0L/]AKA;7]UCG4
M;_V;-BK]VM70Z+9MUURAQHI(HO+BBDU;K3.KQD95Y%)YR2)&3KBKE(M*9Y)
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M?AI8(VQ1E5=^KMVZR?K7K['!C>M=AB2;MV^W:VZ\T:Z^^FI;OWZ]Y3J[?+J
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M5P*-ZOF9&2LJ_WQAE-O7A;1CJ)S%;6R27U4#Q4EIT8KS<SZ7F-.=V$^WN9.
MQ'O=EY'ET'R_BO"VNA7+:J+)@17MM89+2I(ABOHKJ7 T5(2()H>6^/-W4WE)
MD. M0D)4$R1(\ XBZOURDA"V^YF<G+1#(\=MNC3OQ"67R?K^P?7YDE7FY[T'
MS$G%*L%9[/3:0H:ON.(*'UYF6'EAH1Y.*E,8ZCZC,+A+[UA/7Y]==>VU(B.!
M'B=8/4@_%J4QE:,UGU@8"KE;4%ZVU93V(JNEF3D;'A[VHW)[E>89-1 @L"Q,
M\OUJF>KD90.)'#H3SLOL:@R? D35MPE4^#F9*MUH\ZDKC8(:6CF%6XT:)ZH4
MZ\A.@@0)SA\)4;W(00N]H(JT0XJVI]IFQWMSEB\5K) N6'9=CW7/JN+/2MEF
M*ZH5)7Y&(M4C*V9UOY#&F=-0E_+UN58,5=&;A%) Z#E:A:Q8N;>XURKQ(H)6
M::C&KUM5A$&*R^>QU:W>'N:ST0L6]@"(T+2D9Z<==\@[AO!DIT7.!4OMNIQ+
MSQU*:1DY9W=6B>7R!%D)I\5-$LI*.!*UF9;Z[:OAE]A9%I[NK?EP%ED&' '*
M8I39D^-V8N]^.R8I3L[80+;#>CNZK'_-H.5[NC#H0\40H'C7BS.A36%KQ\\4
M*['3UEX1"56![UO'W,A-*J=\%WK>EM''P!'$*9$+GBD]<GGK'!JR-2*T:1$E
M%GRYAR0+LC1>+BNG_:KA2\1/=SLN^@A38UPN +S7<HG09;R@;W"I^-1XI?MJ
MRC+NI#D:EU[KEGH"FS758^5*Q>9%3.>+1>]UK<X5+;^VWQK]'8JNPE%6HX1A
M?R5V*'O87-E?=HEP4_CE<9"T^-L*=TFO0EI&9MT\+E!G*JYBU"Y\P,M">=)>
M5M5:L9S*4+Z1MQJK_MMRLJ?RMI"3F;K><.QO5<95Q^G*A "2\<+D7H($[QXD
MW\PE!,@;E;*J<DNGTGZ<JJ^>=N5%S9L@P24&%5O(R.34I.T_>,!>>?45FYV;
MM8[! <MU=G@/FR^J604Y37"10UDX,3EA3SWUE'WWV]^V)Y]XPJK5JFV[YFKK
M'QRR#-L[R5B]J@;W10W5P30,(>.J?U.ZIXR&HZV3>CA!@@N-A*A>*A!!I3?#
MQ;=$4>O?%P&H8HQ[!1(DN,3@0_)J<*W=L-ZNOO8:VW'#]3Y'=.SX\;!0I5+U
MAABE^]VWD.GR@N=A>\KWQT68*\QJ>9^3K'+0Y@N;&I[?%S?:O*>8(7[B T%U
MLMH6RFG2H$J0X,(B(:J7 ""GHJ:^+Z%O@LT</?Y4.5+!LUK>A[(N<1 KZG@G
MXY!P=@%(</FAI='%HB;FBM+@&MJRV;9=M\,V;=GB"ZMF9F=\F)C3I=BGTHF!
MCR"HL)]G>8=@-(>Y+T'XM^[38BY>A+U%]>TJ?\,''83ONZ^_WZZ[X0:[]_[[
M[;;;;_<%:X<.';39\4F?F^HD,)/RD2(:*I21L\'S-&*(S?19A;VX# :S$HK5
M:LH%1B"E3 G!#O^I;/J4)<*,6PD2)+A@2(CJ)0 J/Z_\N5*ITNO04HDWYUPE
M2' IP,EBZ'WR,JS?M4;=RK.S5B^7?4_3#5NWV.S<G)/5^?EY7QV>Z/]+ SXO
M51*V?H*X"3$!U.]L)F.9=-HR:HQT<0)89Z=-CH_;_/0,K,_:LQD*AKL3%KN]
M-5A,5,\-D&%..VL]F"2<I(5;45P3)$AP09 0U4L OKV.*D,J0EU4(T)4@Q+@
MIR_:P2"5KM^=>\6[%*V5^/E4Y*M%J.)/1XC'.2".=BQ<EL3AG..QC/US=L,S
M[!U&:[JTRDI8SNQR<EX0@5'YK8J0EHHEJS ?420FF\M:5J2%;:2<E*;:;7#-
MD*5%:(KS1:MQDE3LZ:K\CPTM)^<"Y9];XQK)VXVEP4?>,KSY^,5%GOSRH/IW
M8[YC T/][1Q36RA8*I.U7$>'K=NXP?*ZGQJ?L%I)Y4%YSF(JQ*<XK0:M:>.>
MG@%-<_HOEG,"Y2!T%M1J=9<ZNT/P3$ZQ: K5&H\0A3+33)0@"1(D6#42HGH)
M '+$UCHU5=PH;C_.T;5!.'*TG7HQ,G?!*L*S5.+>BT"OV%)9@9@M9S;,\=)]
M7(F?"7%=OXS[S5<M$M*A)0ZQK!3N2$YS?SDWS@&>3BNDR5N!9>,@Q.G2*LMA
M.7-GDG,"TSD$["FU+2-2ZN59I-1U>:5J*9%8YOHQ#,S65 V1@*FI*9N?G[,%
MW?N4D-44< ^@/HS3)+P&\12 %86E[AR?ZM5DJ[R]\*@L(V\%*#K^+42_SQ<>
MQO:P5RU@BE*NN\MRA;P:(A4KS<[:[.R,;TO5KCSMZ>KR5?(U-6!H@/M! 81E
M%2%QOY:1Y=#ZGM[06,X%\3>--<H(]PMM(N.JC-UMIK(L<-SNTG(3TB)!@@3G
MAN3+N50@@N0K_J.*,4&"2PU.,1D%$#EEZZ*42$M[-N='3Z;3V3!*0-GV7E5.
M,<I8/IWQ/2FKQ9+56713%UG%H>03N&@1\@>RK[J*.<7^K"$BIYN.@J5ZNRW=
MU6$YETYKIT&B<@%IG9N;]U[4-M]'-=KMX6*#!XDMW12A-GI\$1[J=[/'G410
MP^B"]!HD2/#N1D)4+R%XZ[_][!5WZS"U*XU+!5)F/N=+?^>ZJ7N"2P#*SCK#
MHYFTJW!C0W@5T#=V[;$G?_ZPO?#<<_;*BR_:LT\^84\\^JB]]-13]J)^'SER
MQ"J52D1<9$_71/V_E5#J+O?I\6PUGR3?+3WENOJB*JZR.'KHJ.U_\64[^.(K
M=F+??CN\>Y\=U77D\&$;/3GJ/>>05>\UA^3Z_K7GBM,#Z?4@C2#D E2('J<&
M86.?6!'PMIH>4F>IYH*H>KV%/Z?\NQ#^)DCP;D5"5"\A.''S2G U4,5XJ=6-
M"B\DE7^JXI>HFP27.M#AY"L96V%.7[5BE9E9V[MSESW]^!,^S,]+5OJG.PI6
M3[=9NC-OW8,#UM'78VW9C#4@,?2J-ISJ)GBKX'5-= _XJ6>K;3SZ.??*HS([
M-C#\+SF\[X ]_^33]OK+K]H!D=03(JY'#QZR@P</VO#(B,W-SEFMSBXFRN,X
M?\^5X&'>)?K]5D!)L-#(.#&M-\IZP*$E>$N/*@86U*C"7,/W6>5=TNA.D.#\
MD1#5! D2O&WPD5%&!20+K/0OEVUN9L;6#JVQ&V^[U6YY_SWV@?ONM[L^\B&[
MX][WV]T?_I#=\K[W6/_&];Y%&^9!HO@O8C3)XH*EF<:AA@<]YY/S,S97+=M=
M]]]G=]QUI[WW W?;+>^YW6ZX\4:[Z=;;[-;WW6F;MFX-_!BBNL B4G=Q]8C]
M?@N9JL]=ENID<*!6J\@[2#4!C0*KL$-0.7>/.=BKW2XK08($RR,AJA<]J.!4
MT358]5QGW8DMI-5B;UNP5$WO.%+4V,Z%.7Z%8)YY4]29K+)JIY?J=#3K?U6@
M]'PLE;."BA=S;TKDAD=/]PRG%;(>+A92L(\FSPA+/:,X,NR+TO,YBJL<PD/+
M+945XNON(<O968U$Y&NIK.C7LE :1,*QLF<4E0=;5EK2-9:6VU:BN+SP7B:7
M"@N16L)W1HG,LC]JJT!6.(Z415&<0L10+(MK*LK3.@NER-LR0[^ZEHK6*!;U
MNRSG&B([506OS3H[.XV%3BOA0@[QAA1;$K<SRIO%<FXB[R!(ZI63>WE@7NE/
M6><PAQJK]W7/S@TT,/)=G;[:GY/'<H6"=2A/"YVZ=A0LF\WXYOD>;9_4JN_>
M>RJ1Y0/B]4&<[_SV9Y+HF3\X+V!Q:5ZH7%.^]4W4]1URS*K7Q2*OM7I:95S$
MM+VJYR+9"ZJ7.:)7'U72L$J0X/Q!39#@HH<J7%?V#9^CRD)DYT9>(_.>2ES$
MC@G^ I4G%2-FF!VV'/Q]='_>B/T_;^&_EOL,XV6*C0BI+\*(GB]P'Q&IU1(0
MC[NGP6)9$9&[F%C.WFI$_YTNR^&,<?!(G[_H'[ZVBJ/Y0/^=55K-1^(.KU(<
M7)>(_OD*:Y&'^(I_"YZO*'_N>23%CEEYC-=<J:A\_C+E0/#T/A/P\LT"+Y;&
M;44)5MX45O+O'<)IY7O5"/GFY1Q[^L=W6Z$W7'F.6X%2!KA9_DOI/_*W^6 Y
M609O51*YEU$>+!'J6$@K,<48.U4T5'@IJ4YD_1WU,26W)>PMMPD2)%@=^(H2
M7 I0O4AE'Q1&4M,E2)#@$D!47]$0*1:+85/\<R*]"1(D>+<C(:J7"E2WL^<H
MN###FA<OZ#7F)*Y4HM N"$A&WRH(.8<T#7/K(HF>76@0'H9ZXYZI-XO6?5 3
MO'UH'7[7#S^TH5JK^3UY#$%E?G&](:)*[SG&HFDPW@ GOW0]'[PC>8Y_BI>'
M77^A3@YQ.,]H)$B08 4D1#5!@@0)$KPUH'$=$4B?>PJIJS/P+X*72EF*N>>7
M(#C  !!^""N-P#3'O7ICT%\E2)#@ B$AJA<Y:)S320'8\-_WH:0E3Z5/C;B@
M^V9?% 8CPWY[@6I,[R4($B/V:3E9-638[1 ?[XU@9I<DZFD)+Q7-Z(IP\9Z+
M%K2\7B3+8B4MXF&0O9:XQK(<5FMN6:P4!MQH"K_/((#\72*+C. -LB2]SHC8
M,AG1ZO8YP7U? ;BG]Y&1ILMQ;QB]<KR,\R,\3? .8[GRWBHK9E2=171FZ6S6
MNCE]B@61WJNJ=Y \]EM].T%0XS"?)ZB/V28-<MK.]E.*X((^&(@X]7*844UY
MQH_S]R=!@@0!"5&]R$$UYP.OJ@!KJN KK*!5)=B@@F^7-'3/486^0M;9!=8$
M?L=R >#*:$FE2UV\5,X)(B,L0J"")YR-=JOH*>>!,RP83$B?R5N472"LW/!O
MB6>Q_[&L@+CWXS2)R6,<S^7BNQ2K,'M&OY:BQ:W6J"PKGM_+2*LA^=7:H[4Z
MR*S*5&@Q**U8(.)R+FX(,MXZ).O#LL1;USBEN.(JBZ18,,=]&SL]\(9P8]X-
M1/%8*=T2O/4@L\XD9X+RS;-1A8H5\I1O_][;Z(W4%7AK_,WG[ZFR%CU8#JL)
M\YF@^C:5S:GZ5?V;:K.Z_FKUBN\+S.?;MA#%ZRS!2) @P>H0U1()+A4T>QL3
M)$B0(,';#E;XTQN<SJ1%2 ,5I9>X%FW#E53/"1)<6"1$]1* ]S!QU>7R(ZI)
MG\.[&BK*<6F^G$KUY8!XB/S-U#=NU]V('@!]\EZG\3S\]&OX=?&CSNE93DH7
M(J+*"$A;F*_:?H81DP0)$IP7$J)ZD2.J!QU4Y%2"ETU%&,7%]\U,ZO9W+^ L
M<2%/<'$A,,@W 5GF&]>5W3P@KOQJ.LHEGM;QIOQ9)>1-<WK >8+ZJEJI6+E2
M]MT,^)W-Y2R7SP5BGB!!@@N*A*@F2)#@'0/\!-+ <&H@, DN)\0-:\A<)I,-
M1$Z_.:$L& CY?]9YI1<1/#XBUUYF*<""CW1%/:SQLP0)$EP8)$3U8H?J]70J
MZZM,%QKT2"C+:FK%U]BGL*S?-6OG^-&T*L@4VZ.\M96DS\&2R./0 [)46F\)
MRQDDK/^J*2XU_98"X A0[E71IZ4$Y!.NA*-4907QHU4%[+9X>>&P5,DP/!G%
MN2EQKPEF6^4L.,W^4BC.X=BQ58@O,)*?2Z4E/&?U;UGX*BK9CR3Z'58V1^F]
MROBN!KC.D&G&XZXP<SI1TZ/HJCBXG%,\S@VQE^Y#'+\XCI2!M]#OBPNDO_*"
M!77^D47BJF*5(O-M[6D547VK'"'*AZLR6^>;)DT9(L^DE*8,G[,X5-!_BPG>
MJ;*W6$X'>1/OX1I+<+0%.-WJ_)L 1P&GV]*627?Y*7J-MI+5%IBC6M%+Q9FC
M4Q?TC0*% Q*;($&"\P<U2S\:1G8  /_T241!5(*+&FVJ\*G4HY_Z[>?=0TY#
M[>X59UV5.&>EN\$+5"&?$9$W2\71?*#_SB@RH_"V+33\IS2,"_?T5C2CC.*)
M[$#&FPO0N<9R ;#JGA#"K$O<>Q++JG$J,Q?#R=IJ1?XM(\N&927_5H)OL1"<
M#/>1??^-1"^7^G,>P&7"ZPM4(K?Y U$PWAZXW['H/X];)%'TWSV(X]V2!I(P
M1>?LHO\DNBK=()'^3/;+:H2VIS/6GI70J!*!8^C<ZS(OH_@3(2YWBR1ZMQ1Z
M=3;$W\5IW\9Y01[RKQ'5R^UU11>W"6+4F>"J-?@5TN!"^)L@P;L3?$T)+C%0
MY;6G4Y:.MDBA(JQ5JU:I5%1Y0F"32C%!@@3O#)P0.F%;\$5'?J*>GLW.SGKO
MHM=.^LU[;W3K&?=)M94@08+ED!#52Q#,CVI4:U8ME_RH0A1#)I.Q7$[$E>'_
M! DN0CB!J=-C'DB*_O,-TR$O;):^:(B4>X@.O>EO,UJ/CM4OU9+TEEUL+$KA
M(4Q+Y<TB3FYW+[I?#:+\1$)C&2?:O<>4:2H\XPC5DNJLNLBK$U3]46]1G[E?
M;W]6GP8GU_$4 N*S#+P<*\S$+SY9"_,IE67BWYILN."$O+5L)TB0X)R0$-5+
M$.@0*OZ:R"J5/M6AGY>N2M^'W"Z&&C]!@I6 ,D?92VK5NBO[AI/"!*L&) H2
MOU3>*3BQ#1(33XB^-TIHG*32/N)3G"^*I-:<O''0@R]*RF9E''KW#H;_'$'<
M:&11_WH<R0^@^I>[NNIGGH4D"64]08($YX>$J%Z"\$I>RIWM4-*YK)ZT6545
M9K54"O-4DTHQP<4,5^!!>5>K%4NGTTF/TSF".F Y>:= _C']"/&\5*,YTQD6
M&Y6*\^+0#>OK[;/^_GZKJX'M/>8B==ZS*CN7#D6%3C-E0>0[G;%*-*+%\=8>
M!^;>"C61<9XE)#5!@C>/A*A>Y& -04,D%!WDJ_I9%:T*OHUAIJZ"M?5U68V5
M\WI/#\5J.R9\Z&J5<B[ ^WCM ZOUSR1A&%@&J>0K4G"*4V>A(.*2D1YC@4*+
MWR0 XO:D "(_5I3(VE+X?+@SB/MQ%GBXSD/YG&^: B<BK6%M2<=%$L$59.R7
M[A?9C60Y^S[DJ:@%T7_8QQW<C-+620:RBK1:C) Q]$;1$Y7*9FUV;JZIR(FC
MW]'8.D\TAVWC'D8/8G#_3%A4=F*)WKW3:(U3,VXK(,SYU/N5C:P:H0P%D<O*
M'^JAQ5(W7=/*MZS*"2<ZIT18%ZIJ@,Q9(RL['2G+Y/6B5'1ED]>WS9'(E"C^
M*,?-H%Z ,+<B#GL(_YG13-?6,/ 1-!1J5O"W2 -A=;^DKI@LM&=4!R](*E9/
M*3V4)BD5H%JJ;G65=3\(("KC"1(D.'=0=R2XQ !)+16+5IV?MX6J6NY2^BQ8
MH/<B5(@7N,9/D"!!@F41D3M5._2,9S-9GW?:J-)3JGH)2JHZB881>Z?Z?;!X
M"8,&%;%0HSFZ#[^I>V-"VGJ?($&"-X.$J%YB\.$]28X5_RB#F7DIAAS]'5Y5
MNO#?)8XPC'D91.02A_?D(M'OL^&4V3,I:JGUA= CZR;HN8O,DNW>DRM7XK(>
MRL(9P.O82(N=$);H96SF?&4I]*SIQUDDMM_\[?>B.?1L^^\X[IB-A0>1O-V0
M_\VPQA(A#G^,]H4VJY7*5ITKVD*MKDCI?5N[U2M5*XY/V>2)89N:F+2%=+L3
M6;<=NTFT8UD*#"Z19IA Z[NS('AW*DZ+W#D3F.\?S3EM-=X>$52Q;_.M]1;"
MMH!M;6Q714EF@14]L:C7Y2*7($&"<T%"5"\14+'2:\J57HE4)FO95-;:I>^9
M*\6T@'JMZD.6,NUV+EU(D3 4=ZE'XV("Y&^IK @I6U?2T<]50Q;(,Q?]MTP&
M\@AG4ZFT:I]HI;\>.FF3^)26%K@+*[C5"B<?*C/-Z17-.$97/7M3XJ%N%8&X
MG$5"!$"PU_J,-&[S/9(5=M[A3QSN.,Z2,$JR/,[PZLTA#G<4GI">T:,6 6G5
M/1F14,Q4BB6;&!ZQJ;%QFQF;L(-[]MF)X\>M+9.V3#;CYC'G1!$_(O'I*#R+
MP/S.6&)CL8_Q;T^W%CM+<6HXWU/7_UK!TUABX!YET85YIDQ!(OXMTP?8MYJ#
M2M">3EI%5KV$B*@V2:J[N=B_! D2G!_XHA)<@JB6BC9\Z(B=.'C(%DHEJZM"
M]4W3F9.%4DF0(((KVF7D;(!$.7E:!9PT0#1EWMUN$KP6,,=:[S!;JTG12\$S
M3.QP*VILL= &(N DCL,N"&=;1!Q$:E>"[+ 54I/<N 02' A+(,+G+;BE*\)O
MX&ES%HG3#SL^QUSQC\DY;E;+G"X7R%:CIO KCBYZ%@O OMN+$).IZ/6%!>5#
M#88P)SX2XJ(\(3\6A4UA]3Q78[DT-V^C(R,^+:FCT&%=DFF1U0/[]_M!5QF9
MH5>5N<GMA0)S!0+A5#S<OQ8RR/[0L33#P+W<,)43PMB:SLL+9B3Z=RHM*?LA
M+LO9:<-/MOESR5N[RF=<MIM88*>*=BM/3EB9A6(BM&GY4Z\O6(I. ]1JTIN:
M(,$% U]3@HL<#572-91$>=HRC:HM5-MLLKQ@^TZ.VM'A(U8MCEF]7)+24*5:
M5V7>4$7.0H!6Q!5[K"CI:6@5KXPED 'J<Y?P7!K$E:=OA155VEYQ*UP8<[>;
MX F5NJ2E:VFA38J5/U7R4ADNF&+=C-245:JZ*=>\LD?YU?2B6I(2ES]UV2]7
MRBZ5JIXIBI;/2O/1GQ'<Q%_?\4!*(P@.RX>6^+D +AZO*$U0?"FYQP()>D0X
M^M&/?]0]RL875<A\)+X !,']V-W3)/(G,A](2! ?(EU&_#EV4:*Q?02<YCY^
MGRYLL"Y/HM\MYHG'4N7,XSA>W",Q> ^)A"#(ON<Y5W<K()0#_<9LI)3]+82"
MM$7(SQIAT7.4OA1Z6S9CQ8H:5TJ+#A;/4;;3*9>B2$XMC7LA_$X0<1I_?8@U
M^HT03U[)384D$!TW)WO\Z380.J6MN]4BV&L5K"X1COML*&[(@LI(0_%"B!<N
ML)*=.)Q)R'<O)X!RIO1R(I\225/Y*HN8+]"[G,U9(R,_<FG%7^XK#3AFE)[(
M1BXCR=J"TFV!*SM]*%_XM&J5JLA]-90O_*K(/03"SS>U2&K6*,OL&:1>J?A1
MH/4&WV+5[Y%F&A)V@?1&:BIOGL;EBLV.3]K<_+QU=759S[JUUK-AG?4-#=CL
M](RG04;Q9U> LLR49F:L-#MM4]-3-CLSK7C(#^J8*-W8P:0T-V=ST],VK_=(
M46:1N:E)N3E]5BF*.)>+):N2/O2.2JJJ0XKR?VYNUHH*0RR8GY';,Y-R>V+"
M94Y25-A9 ^!Q5OR),W4$)\/.S8XJW$6E==U'MCCB6H5<=36+K;B76?WS% NW
M34F0(,'J@49(<)&C+M)45R7?5IFQ3+VBBE$Z)]=MI7Q!"JYAJ7S#LE*F;36U
MYFLHPXA@+0.4C?X3EY-"B,3-QB0&)0P!P5S,")S,0"?C/WH_9!82@WDWBAO(
M*6N+!.=%+-NDB,5,7%P1TP.1SRL.DFS!VA4G%%I61#1-G/$G*Z5.F"2$HS9?
MM/KLK"U(.7JXY!R$M::T\3.W$2E6>N=\RQR4N91W4U"NQ%WV4; +4I*NR)TD
M2ZKR1^(+U21.!" =$$XGG3Q;60)IX"J)PNT"N<6^[MEG<:GX<]FOE<NZ!@+B
MXF1DB3\UQ8OX+I&&GM-HJ8GPU4M!:E+Z2%WNUJ2X:_.12'$COK69_$$@#$X0
M)J>L/#%I-2E[PDRNGZ9E(5Y*?(9[J[*WX(2NS?WA64F$8&9^SJ9%"N;D9G%V
M1L2AZ.4AW]%A*4B7TJJL_"R3%TKC#CU/BY#5JQ6Y,2>_ZVHOR'?(*_FLYPN*
MXX+"O< T ;$UTHAPI%1V_'A.";UV+B)Z]-1"8ILB>RP\] 6(L4"6EXKLM;=S
MW">;TDO4D'&!K"HPI$M,L-V]9<3]DUOZ856E _FFAR+K.4MU=8N?YA4I$4"E
M ^?CMXDAMU5TKW+8IB+9MJ TK1%QV>$,?:Z2=I$AW$_3.\DWY#V@$I%:XQO3
M-]-0N%P@P+K622^E!^]6DC9)*HZ3A)Y#1"'P_*'LM2G?TOI>?2H205,%,#,^
MX>6FL[O+\EV=F+:%O/)!9BO*VZ+>550NVA37C,*<[RC(G AM7Z]U]?9:6NG
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MW)-/VYJ!02MT%)QH;-BPP<M,0803DEF7/=)K>GK:C],$I#D!ISQB%J%<II1
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MDZC.3=OX?_J_6>=SW[5UN3D[4:S:0_LG[7C_)OO8/_@7=O65MUHNG;5<CY0
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M*>B"50BWPCNI9\RKFQ'!#J0%XDE_3TIV4TH*Y3/]/^F<E+DY66<;(.:_^G9
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M/*+?$^/C-C<[9^E"P0I]/983.6?+H:'!0>O,%6Q&RGM4Y'IF;L;ZUPQ9]^"
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MC([9\)&C-C4RXL=)NAW<PUXD9P4>+)$FF9"<"?%;_&2NK?OMO;JGOAE_=B[
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M$#[Y,2UR2B\@4T5>?NDE>^+))_S,?!I_"B$F%4Z% O&X!9+F/>L*I[M&H%>
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M417SY)CCFBIT6K<( ,/P]!*BM#BU"0* ,FOVX)P%"^U2F"(6''?I\_1T90H
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M>T'OE6CLO5.%$F5UR;+E;L6.<^V;FS]QXI0;^]XX?QP[<>)NV>J]6A*I1K&
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MPNSCIP]Q)Y99C$2R+,/^[-"5)Z=0FIA"63*5=C8:2*N#5[+R'!H:LN%_63P
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MPX>/-P;NE\K'I0IIK[1LJI";QMCH*-M4?CRK:XW,D$+91[=4<.9(!:,)(!)
M$7E(!Z;!U8I6 Y?8^!5+J-"=C&Y+[+<KUHAZ(EB#Y9*06>)H\%S1BET2%EM6
M*\/6E:*)A<M;FO-E6AM71/Q((\XNL+A L59'>2(S,M&HF9+1N2T:F0-GP94P
MA\QIT559BY#F2DD2+"&JN9=LRTNY##*9-'),8R57F+$!J49>Z;<I :[_%P_,
M.\8A4I?"ZJV;L7KM>M37-*!UR2*LW+H>'1N6(]H8Q^X#SV%HJ)_QDDU'1^NI
MF)BF\U7@#:-*RI02,[50$3EC'6-CG$]GK:$NL'X5M6TKZX>DQ/-R.H<*)9 I
MV%%;NN;2$\AEIY#/IY$O9%Y9BEFDTY,HE/AL.8^<\IC/%OD;LJA "3"_)8((
MFY,V)DSUA\1<99IGNF4>2$=)(9=#@?'.,]Y:R2[1W,SIZ4GD9<6!A%LFOB3E
MB"LL1[,20/^D290I(IZ9?5 M9C-))&P[5R.?<J?RYO^2=B"2P8TX_67UENB]
M(XN![?<O B^-M.JEZK[JRNRRD3^L3WK?9M=M696HA'F-?D48QPCK(@^\R??+
M$]8124!YQ7=/HO=NYIC7D4&3<%;5U:*ZM1G!5(*$-8G2V!1*HU-F:-^^"?K'
MN)7U?C ^999Q:3IC9M]$V$T3[,K+879]6E!FOWNO!4XR+2T*O41O=)R=7Y[P
MO]7]^:(.B$B[+09C^B)%U23^4[[S/,PZ)1-OR<8ZU"Y=@L:.3C2U=2!16X^H
MM*YU=:AJ;T.BN1GQID:$:VL08)W0MJLL?<:)[T,HCE*$WSU>"S.^MB&5*_._
M2#Y\^+@P^'O]7^+0!'U]%DN9 4SM>ABUTZ/\^.<Q5BQC-%2-9/M:A*L:V=#F
MR"5)NK2+$3^8UJ[I:ZT/N35V_$"SH;8=G-1P"FI$YHD:%FN8^(&?+W0Q S5R
M3DO!9_3AEI\F&KI6<^#"&G?*Q03#R:8SV+=WKVDX5J]=@V15E=V:&T=%STF3
MXNE<9%H6@*Z*!,F0OHBI2$SWP2,XW7<&F]:L0WUGF\W_DR_:0O2BIXD@%23#
MT$Y;8:8G9>9R&ME0UBU:C+JV5C0TM[!Q#6&@JQ=+EZU =4VU;75IL#3:__.&
MB)>MQ&:9:5&(1!HY$7\S*43?0DRSN:%H&D18\_+<SH$CCGL3YMW<>_,E:N45
MBL?H%W^K<7>O&R'2T#/CI'/Q+NL84+1=K(05C=5+FMXPRXE^:6H&GY>M3 UI
M:Y%7.$'AN1,6K_,%LDX&B9GY1_]5;64]PSII).@BX9K2H#1J =+,D+W(*^/D
MD2TCSIH*P.MZ@U0;SA(3_F*<=4_AV#N@YRCVM.J+5S@ZU>]Y$#D4+*VSH YF
MA>^[XN:]BS+*K[@YP_7*&CZC.//WR. 0]K_T$D[W]&!B?!PC_0/H[>XV>ZE#
MO-=UZJ3MU7_B^'&</'8,)XX>10_=:M<S[=>OU>^>]8!7@Y<W%QU>]LC[V4&<
MFVV.$\O3N6+0.0\JD^Y3IS!.$KYFS1I$M7A,9<,Z+0L7JE>R:*#ZJ3JI=] L
M<+">JC-L]4S?3SY3+N99+4,HL'-6/K(;\9$C"!<J*+6L0GC;7:BDFNV[K?ID
MY:[PWZA\\N'C9P"!\L_:*IS+#-)X!4E@LH/[T/O?_ST6#Q[GKRF<(B<=;5V/
MU7=_' VK=K!GSP8U/H4R&[50,,R&61])?E1U4!NOCS(;0.][N5"QZY8^Z-9(
MVP?6^[BRT>*I,S?/N5)FJUPQK8ZK7?3<FCU''MU&U\.,;PLTT*\5:D)E7N<+
MG_ZTF:=ZU\_=AY:.=D5P5HSU3Y<LXLY1<&V$SH?T:852$1$2Q/+XM#4TCWWK
M?CR]=S<^=.][L/RJ+6:H7 U@,!)WTG$QTC+;#YZ3*CED1R;(1)I(YLJQ%$F8
M5'@!G#EY$@]][WNXX<8;T+%XD6/ODF[DBS6.L[/];&8XX._9X>E4.^UDIJ>-
M'(D@BF#I 0WWFUO7N75V")%Y+R^=/&:]<P-R8C$;RG?WU!"PJ141$DO5&5E4
M*!8+SNIIA:<Z2??R+U1VY[ 2TJI:_)A.FR/KUBWOOM+MA:5[6F!7DBU1YF&$
M1#H6BSLDU&+K0$1,:1?!C)*05!)1<Z.=BJSC1<A[I36B^_PMDEI@?(.L)T9B
M2)3/YB?]Y\NF_>)MR@B)C<AC.IOAO8K-=_;<RG>/2)U]GJ#[8MG1[CKOJQ,/
M$6T[6AJ=7-8"(#VKM"H\[:*D^"G\74_OPOWW/V C, I70]M:X:^\[SO39_F@
M+4/C?$:KX.67\E]S-^^][]U8O6&=A66=(,6/HK L/OQOY:3X*(ZJ>_93==>)
M[PSF_33(._V9!7M._CH>&2PL_73S0-!<TX5&2>QLGK^6OXRG[EE\62^>>'0G
MNDG8W_G.>\W<FW+2%E+QGCHM*C-UVF3-POS0=\W23%&XJENJ>\$2BI4XTM.C
M*#SP]Z@Y^@#BF3)R&^]"[%?^&RHMZZ#=NT)\3M]2P?E&OKF84[=\^+B,\>:_
M/3Y>(_BQT7]]="C6.-EPK+/H1Q]6TRBI(72'-6VH4]MOQL+.O1 ;37TOV5"9
M=H;B:)GFBHB1PG#()_T-28-%T9P_&;/F?6V'*#&W1<9)FAXV=J9]DK"QM'MJ
M'#P_]1RO>Q_MUP619?IEA$3BSB/T\N<LG$;=,.?Z;.B^(];HTF]O6-\:*=U1
M8\/G+0R&-U,..K] 4=P]L9@I#![*;%W5P(&DM!PE:9$$21XS>92GIE&<GD(N
MGT96TQ7H3AI,RV=+@PLW?OSC_)Z!XNQ<$S&P?R0G5K=8/NJ@1)G^!!OK&,L[
M&@HC+B/G)#D2&7R7)$GZM,F"),'[25[3_>0L-PFZ,7%_>Q)A>'HN*O]-PD@E
MDHC3K3I8(@**A_*EJ'I$$B2R)&V7")^T@\.#0]"\80UMJY,B2;'CD J1D"&$
M&,EB6$/;>=9%DA"G+COYXVAF7<VPB"3_I=-IT[+ELUE;@"2B+I(CB:@.,"Z9
MZ;21>84_.3:.D9$19#(R=<1W4'6!8MOX\BC_3?/&.-N4!/HY-C)JAO73],.$
M92G18B?)U,0DIC15@?'(\+?F)\L(O^J>:?885R-1VEB!?H=XC"@_F?_VK)ZC
M?TX\*5-I*\.EBQ=C^]9MV+9U*ZZZ\BI<==556+IL*=:O7X^/?.0C^.?_XE_@
MM__Y;^-W?_=W<====QEYK:NK0SB>L+"U!_^,50=['YPZ9.^(Z@[SU=(M,&]5
MNSPQS+[@BO?^S+G./U8W9UW3WOQZYVQG*RU<4GW@=:<,F;\*5L](!!:Q/<IG
M/%'9>],[^!$T[:G<S(P \;=&1Z1%E=94_C(BIJV6J.SM^V7G?%+E0?<J$YMV
MI&>-V-*-\DOA"/2>/YUP??CP\;KA:U0O<4BCRJ\TIOOVF$9UZ?!)?FRG<8*-
M\5CK!JRYYY<<C6J0#4IT'"5>#P=(4ME@V[^*,SRI#[!]I5\!HDW23HFD>EHE
M@WUU>90?,V!#P-_V,9[U0:Z0T*J!4".F?Q[XZ;?K\G>&0+X&S'ST^:RT'R(+
MG__4IVW'F'>]]SVV5[E(C>>SN9Z=!)=XSM&HSJKZ1=X6.8I42Z,ZQ>P+X/%O
MWH^G7]B#][_M7JR\9BO*:M@8CT X9FE^/0W13!ZX1R/X1JR<:Y;_\E^''.]9
MZ931VW4*.W_X(]QPVQU8M&*E^:,YD8J+:1;9<1#DSTR:"1$!:^QY;29L_IXD
MT3EQY*@US#'FI31K8:93VT:*)'A)5/E9 RV"YSYO])KUT\)V1=#1(1AZYNQ,
M/5NLQHZ%"('"D?:RQ+HMHKIBU4HD4E6LJ_2#<:R0!%C\&98TC"*2@_T#F")1
M%+F<'YY6=,O<DCIPTA+F>50,FYN;L'2EFT_, S/?1+*G_)@:'C'+"B-#PY:[
MVGE(?FD*A)"774T1$I(^Q55IF9J:HA]EK%BQ BWM[4J4N57F:X<HI5MS6]4A
M*9*HRL!^U\DN1<7\$91[JD<>L5&YB/B)^$RGIZT>-[>UFO^Q9-S<&)@&Q4\$
MN20C]DSGOKW/6SYK"H:*(YU)VS"^W*QDNE>O76O/R$:H#-X_\L@CS-X@;KWM
M-M0V-AJ1CL3C>.&YYW#PX$%<L74+EJ]933<62S32C;8=S6=S%D<K3^:/K$YH
M+JOB),VLME]5I]B(G9[4MX'G7AD).K-RH,R'\L#N.S]M\5Y0'1A>!].:(\$W
M!Y[_L_Q1N?*7O3/Z=@DJ3\T/SN>R5C>TE_].IEU3(#9OW(1J$G(M%F2-,&\U
M1821-5%]$TS+SZ/*U.F .-,#@DSF1+J,;'H<[2_]$$W=/T%XJH#TACN0^HT_
M0Z5E/4KJ8/)A>T<(7Z/JP\>%PR>JESCT6<ZC@,F3S^#HG__?V##9@V1Q&J/E
M$'(-*U&]_F:$FUI1"D_QPYJS!M*V5;1//DD)/U;Z=-L<*Q%([\.IH64/;A70
M<'XY4+ /LC[,,^T)/]QJ%&8^[+I.?]5 R+_9W\,*XRKM:P R(*[YD[I9-L(M
MXN&(V\#PGIWQC[43[KD->\M3RLS'UHV,->IL$/N'!_'DKJ<092.Z==,F=+!1
MMSFXUI"2B-!=6?,2H:'QF.4#/:;03^:1&G<U0!Y"^9(U+H%47$YL#_0#NY_'
M21+#6V^\&76MS?37B0,S@O%B[(V0B]0S3,9/_I[-#,=M@7D:"&A(,6'97"BP
MX23Y*2.&8BR(B/(JG4=91OSY.U1AW MT6T4R1B^" 1*2?-*&PB.I /K[#^#9
M9Q_#MHW78-'*JX HR1V?TZYDI%J,0]X(J)%VQM=B8VD/6IJU""\6I_\D,L&:
M%+H/','7O_I5#(X,F[94)GH"T1 R)#""1P94#FJXI<7340VO-(?*$]-X6;US
MTLY2<(B:-%.S.S<5:?))T%B?:JMK,$02-T5BM77'-MQV_4VF8:UO;D95&_.:
MCV4US$ZR(=*A.'_]LY_#0]__@>U+K[PI,%R1+\U5C<=8WQ0'9K)J>9+N8[R^
M9.E2W/W.=Z!]V5(42%I"R9@MQ#J\YP4<VW\(?;V]Z.GN,?]J:FN8[AS#BAG1
M'1L=LU7B2O,T"6IK:RL&!@90W]J$#W_D(UA*O[U5X*II[!O:])%8514JVFJ4
M:=#J^R]\_O,X>O2HS:-6WBF>S$5,3DW:7&1=4R[%&:XZ#O5U]6CO:,<ZDLS5
M:]>14-;;=K7*RTF2ZS,DOD-] Q@?'\>N7;L<\NSFO<HK6\CQ&$1K2PN:Z%<N
MD[7%/DTD[4>/';/I!<M)M#4=0%IDU=V!_G[S1UNI-C8WF@97WXS-6[2H;ZV]
M2ZJW89+M'-.V][G=>.FEETC&\\SC)5BS;JUM'B#R+1NM-BU"!<&T:N&6RMUV
MSE,<73)I8)ZI[JCSH'JAJ1C(L /#EU!:XL&^?APY<@0#K)\VQ8'OGEE"T#,L
M:[JV]U5U7'E@B\!X5-VHA(.8SF1L:UB9[3IQ\B2FF;]56BBG=U!^R ,]3@)L
M(REZCV?E94F=*]8%?2L<[7R0?N506]N.U2L6XYJ)@U@^]2PJ(SEDM]R-JM_\
M$Y3;-MH&'2+/$;UZ#,-[C]Y,>.GPX>-RAT]4+W&42OQ8A@N8.KD+^__VC["E
MW(?JX1ZR@2ARY5JD@TW(L4$IA2>0Q(3;"$C#9I]PAP"RQ70^6NY7DRBH$?'@
MU@!]\$64!+OD?NC4 'LD4*3!O.8MT]2> WWL10P3E(CC*4B<5,WTGWYZ'U#M
MD5VFV! ^;ZJQ5L.1+#J-Q>P/K6,?DJ2=R5/CKH8HG2,QI_NXM"]LB'/Y/,(V
MEY/IUQS%C.;[::C0G1\8*-K*7-%H1[,[.Q/R9GXI0O(F[9 :S?3X)$9'1U'/
MAE<-L)-S2H-R@>30B*H(H;,024/%NE>RM#IQ#["Q5!R*1;F)D%A-(9&((5/(
M(U2;%-M"-%^V^6R:AYHHT;]\+:;B_<BPE:N$TDA-5:&4"2 >+6.Z> :#DP-H
M7[P*:-Z*,X4:VPP@'%.>)=#4WDRBT80(B8W(N96_XD[_3W=UH^OX"1MN5UH*
ML3!.O'@ 9TC6UFS:@"4=G:CDB[:%I.8ZFL;/38?JC0B"$4,2!B.KRF=ZI 9?
MXC7&7F-OG2:[XD!]")$+$>D2P_GQCW^$4]W=N/.NNW#//?=8YVAL;(Q^!M#(
MSE>DEH2/7FI>:(3Y_*VO? 7///4DUI(X2;-[\- A'#]^#'4-3;CJJJMM&%9V
M<)5N#7UKND&>Q'$=T[9J_3K;%C/ O!_N[<,W/_]%G#IR'"TMS5B[?CWJVUJ,
M=(K4R:23-*$'#APTK:I(BDB<M(LBAS5-#7CGN]Z%921[09$=2Q;3)4L"?$]"
M)$)EUAWDBA@>&L(#]]^/_?OW6[Z([(G 9+,9V\ISTY8K2"";C1@K/]41&^H?
MP.,['T-5*H7;;[L-U]YZL^V8I$[!X.E>O/#T<U8OU4GS_//R7O4O[!)MF54:
M[NVW':D6DTQNV['#B+_R-$&_I1U4>!F2.3TO;:GF[6K;Y0F2Z$EV:CH6=6+C
MYDTD=NK<\/UAG@Z>/HUO?OT;>.:99S0,8:,96[9MP^HU:ZS>-=?6\QV*HX:$
M5P34RIS99#N9,7[: <Z#ZD>%X04UQY9UKCB91FDR@_'<- KI'(X?/HR''WX$
MT_DLJMB12$1BMF.;%I>IG-T:QS@[1VGL54?U+9 -$FE2-8U \5!'V]X)(Y]%
M)_ 9T"_FA_SP;J@.*X\T_U?YHU$&22"L*1XI;%B]''?B-#;B((J#:12WOP/Q
M7_LO*+E$54Q=&SRSV'XJF/W]].'C<H9/5"]QB)^50QGDNY[%D<_^,9:FCZ)J
M\ Q"D12_@W6D5PTH!2)L("<1!1MY#8UIA-?4%]X7TB$,MDC *VZ9CW+A$39]
MQ,/2?#!0N^8V?B5^K,UXNHB)_9-CHZ1V?S8JTIKQ66DR^8!WU9D#R\;!6Z@@
M:&&,>+&V.;0&C5 C*C*I./#/3!QF0'>:WR?MFS1=<B/MJ;1E,3:^%3;$(M6V
MM6>>&<$  AJKLX^V,H8DBF<B46?UJ0PF5D2F5&!>L\'6O%Z2'M,8\[E<CHVW
MGG+C$A'Q5]KUFVG5N>Z(N(NPR7\/TF(724;IM6G]LIEIVWYQ*I.S!1W%=,8(
M5C N#4\&D2Q)?;86I=0(LM$*"I$T8E/-?#["\B'YCDRAH.OE$/:.5N%'Q_/(
ML>'7J"MS#LLVKL.]]]Z+1<N7F?9'^6G$G03NBY_[')X@ =(0LTAA(1+$P,D>
M+%VR!+_RVY\@T5B+\G0:D<9ZLD,-G<^"&G&F301>\_IL?JO*C/[;M 7>\\C2
MG#*;=<H$F#N9*QOO'\3__A__ P=>? D__[&/X<Y[WV$$:V)@"&.#PR1I-:AK
M;4&()+RDN+#^?.=;WR0Q/8J/?O@CYM6WO_DM//WT+BQ>M@(?^]@O8 G3(8VJ
MXF.:2QY'2.C4T6JD7S(]I;FF8T/#>/A'#^+0_@-83Q+VCO>^!ZGF>M9GUA42
M+\WA'CW3AQ,D]2(^0I8D2ATD$?@4"9,TDC6UM2QSI[2-F#,_I G44+I,=X7X
M+LE\UA&2K=&1$9M;GI!FE'DP-CYAQ&G[E3O0W-G)-.9=#7487<>.X?.?^8P-
M[;^-!'[+M5=;G1:YTM0'VP*5A+N&:8JR7/3F>*1$QPC3*:VIIH$<VO<2OO^=
M[V+UJM6X^YZ[21Z;+9[2J(N86KQ5=GQ6MF>UZ05+V7:SFIP8M[)L:&HB*4XA
M/<E.%M^Q?G9XOOM/W\%QQE/3<#1EYK8[[\ --]W((,O(3TQ9NA>O6NYL+F#U
MA"'(FL8Y1)7Q5MUB7,8'AS ].HY4-&Y;EA;XCCS%^OJUKW[5K#K4-3;8W&9;
M\*;T.DDVR*:I.E#*([VO(JJ9?,[R3?/8]8Y&^8Z%^$TJD<3;W-]9\;!I ^YW
M<):WYJ^C25;>. 2W4,[R76[ TLYFW%(XA56Y%X"Q+,I;[T7HE_\0Q9;U/E'U
MX>,BPB>JES@TE%XN3R![]&D<^>*?8G'^!$+#PR1I"93#=20B#?H$\V.81KSH
M:!K$\8+2&Y*EB#;)/J,^S'/F+/*?LQCI+%V3)D5/J$VQQ0WN)UNV6'6FJC)#
M1M3 .6<$S]V/HHYR(G>>4P<D  Q+C;1(DF##M(Q3)!;C4228SU$*6KHNPF'^
MFE,+3]!]^1.3Z2$Z$RF6NSP)1$$-+DF0"(#FF=E0(AL:F_9@#_-I^<OGU>#,
M1B'$QB>><)YE!M)KTW+.GE?H1258=A;1Z(I=U[G);%<.*B3)&CH4H9%V)L_&
M-YJH GFCK7:?(F%)L%%6O*<S8XBSW(+C"83B(\A'2":C:21R323@U2CGTLRG
M292JPF;O]*5L.YZ8;,+ID2GF1\F(]Z(-Z_'N^]Z-)212%KE9>?V];_\3GGCL
M,908N%;<QVNK<.9$EVDG_\U__@]8NGP%2I/3"%>GF%],&\O$PTP:":M')J[?
MJG#T?W:!JTST7T1!S^EY/5(@8P\EXY@8&<.?_I<_QO//[,9O_N9OXM:WWVT:
M3Q'J\=X!Y*9)#!MJ2<9(K%BNNG[_=[^+WMX>?.C#'[8=A+[YC6_@Q7TOHJV]
M$^_YN9_#^@T;G'K.>%A\^2YH6L+4]!2BR002]?4HL6,P-C"('S[P?;SXXHM8
MOV4S[B51#=6F'+O$)#+E;(ZD:<0TS=Y^^%K(9*O@F69;"$8RZ"R^<?)$?UF[
MG<X/LR',$SZ!$K-06CA&Q$AR(I$TTBVRV=7=Q3Q?CJ;V-HNGZJG>CR,'#N);
M7_NZ61L045UWU3;6Y9+9M]7B*Z&&G8D$.SHEUGO59Z>KY,#F+/-GD._(H;W/
MXY-_^=>X8M-FO/L]]Z&6I%-E(^VX#7539)[)C-_K6:8O$ ZX<U!EBW8*2<:Y
MKJ75M,VQ9 J3)/H_^=&/T-_7C^Z3IS \,HR/_\HOXYK;;T<QF\$T.QOC)-3U
M38V(LFY'V-G0 L]0EN\<R\;JC_*-YS92P;@J/OV]9_A^9-':WHY$395-3]K[
MU-/X)W9(EK(^KUB]TN:DVY06-]\%G=F"* WG,R_T3;/OGAN&_::H\^)\EUB&
M=#L;SG?-^68I7V9#92(1Y*Y0UA0KOJD\MKSP?;0./8YHEN%M?CL"'__/*+5N
M\(FJ#Q\7$3Y1O<11">21ST\C.'0:(T__$%6!06#D#(E/&;FBZ 0;T4J,!9E%
M,9Q!*,IS?;!G-'T!A"OZ4.M#ZQ K(5(^.SSK@726I-:9RZK&1,\*^L!+0UE@
M(V)7]0WF=>-EA#[>(F'.#S::P0()BN:JNB28'^P"?]O<5S6$KK\!^<;&2$.4
MTLS8'7H<4=SUD96X7WFS"4N0CSD-1RYO!N\5MO:_5YJMK2$Q$J$P_^1O15H5
MIE$15OJL):+P.)>(E:QA=%;PDDL8:>?)K#QR&C,[,>)!]D A >>S>FZA5ZD<
M5(-89+18!B05N8DT&^\4 O$ LEJQG<^A47N/3V8P>.H,VI:O9GG6,Q_ZF6UL
M9*,9Y"N=S+L82J=/(#9RC.DEJ6##GUEQ,Y[)M6+/\X=0FXJ9D?*FS@Y<?^.-
MKKDN)\X6*\9MSW//X?GG=J.GJ]M6F6_:NA5#I\_@Z+&C^/W_Y_]&VZ)%".18
M;EK 0^)@Z?72++@-G_)?]XR$LMRM'KGW!%NT1#>6E[S,7W8]Q/PJQDCVDC&,
MCX[B+__;G^&%W7OPD8]\V(;21=P5FH;OQ\\,:S(&&DA4I2&4G]_]^M?1U]-C
M)I2D]TLS[Z0YC)1#9E]6\U&EF0Z*A%CY,%S&[_2)$Q9?I4^D6H3KA]_Y'HX<
M.8RUFS;B[G>]$V&F677/%E+QF"4A'#YSQDBIRD?6WN"25>M'B>A):ZMT*X]8
M5HJ+M+8B7:$BB3EO%:+LB-56HS25MFTX961><U>'2<IDR:"QN=FFFFA:382$
M.#LTA,,DJC]XX '3?%]]U=78>,-5J*UM0)H$6U,)JNOK4"V2RLZ6D2\^ZV:Q
MY9_>2TDH%L?SCS^)O_P??XZ[[KX+[_WYG^=].:3H_5;9>23.)6XJJV(^8_D7
M"(8QVM]OE@HZEZVPN>%ZKW+L)!P^>,CJP>.//(KG=N_&+_S2QW'+G7=:1T_/
MJB.DN;2)5 *-'6TVY4)YHGNJ*]Z[9-'FZ3C)K2PCU#4WHJJ99)IU)3TV@<<>
M?!@/?O^'N/==]^+:&VZP#H+2ZWU[+,'RRSSB'_=<Z9CI0-&1O0<:95&=U3GK
MI@BOA]G?P;-3@E2/17CEEM\5-\\"49+5?!CIH3Z,?>W/477B1ZA7AW3CVQ'^
MY3]$N7V3+<[TB:H/'Q<'/E&]Q*%OS13)0Y(?N\!$'PG.)"K3:2.D"&ON90T_
MNFQD2AD$"T,:7P9BO"YRJ0\R/= \.H]<>M"J7(^PS05_\V,\%VQ<B@5GWB?)
MW R\+[ :'N^C6"')44L>8F-'PNJT*&R\2%1M6):_O 9"%@(T+BN_ S;G3/%R
M'Z%_UJ!Y_KKQU%\UT+HL+91I/RILK*4S98-K*X\C)$-R4R"1#5$B;B-4B3A$
ME6FWALKQTE#2HBLM:!+!T%Q#BAQ8?"P*;CR$D(@0&3,)JORRHTB9]RKI.<_O
M,LLCP'S(C:.826.@NQ^U3:U(MC5;_#176*:&1E\ZBCW?>P!;;KL!]6NO9!S8
M(>&]<C2+4F@Q ODB2GN>0."Y!S$^?,P6/-7?_$%T)U;CR2>>15M3 UHV;$0#
M24QS6YM-7S S28H(1>F='!_'\<-'<;J[&]TDJ[?<?IN1B?N__P!^_?=^!\N7
M+[?AT H)F?)21/TLH7"(NVG#!)4ASYVL42:Y>2PP.S2$;M,$]-OR0_E)=\D(
MTB42=G8B/ON7?XM=3SZ%]W_@ WCW.^]UAH9%!DDV"T-3.#,R2.+2A)JF1J8E
MC!]^Y6LX^N)+V'+UE6A?L00=*Y<AWE"'TF@:7?L/(YY*FA8OQJ-IW51722PG
M2>X&!P905UN+N$@CX_;USW\11TBVM,K]WO?^G)%DBRJ?$VG+DP2/G"%)&Y]$
M*\E_K*:*9"M*$IIGQT]S63-(U-2@E)XV<BN-N-XWK58OL0,55$>)=:D8X342
M*^M8%<I&/J61'!P>0A/+24/IJF^":5299R>.'L,#W[O?ICS(;-2JZW9@ZLP
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MQT3G\R1+9YE@&9D A0VO"1O##,MGOJ0K$618)I5J=BX2=6A<M0FGQG,X/5G
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M%/JZ>W%D]PO8^\AC>.XGC^# KF=L!7R":?*VJ#3"L!!('DW+F(C;E(9\H8!
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MGLMH[WSFO4QD/?GDD[CSG6_''7??C4C,(9D^43T?^$35AX]+ 6_^V^/#QP7
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M).(\S/0%F">J$U4-=6CK[$#[JE5H91Y)\Z[=RC1_]LR9,[:SE0BM#==;G;D
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MX#O?Q7>^]6T\OV<W]O-Z]T ?CG6?PE0N@_K6%A2R&83I1S <-$VM-..G3IS
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M9FR\[DHDFQK)H$C.M6I=#?3K:2N-$,R3A4B"77,ADF=3!L2XC+V<*[H_,ZW
M]<_(WP)B]T@ M#*=1$ZD*TR2KL5')9*?$N]7-/>6<7!\5_E'$ R1V#%O2'E0
MRI=,HB2O(J:24"QIY%7FG;R]^V6$7RO[-11?+M+O(DD/_0B2<&H5N^H169 8
M"-TRI&J2.A)'D%26HR$4XPPO0<(9(?E4OBMKBB1S>4J!%PI,3XYUD6D/D2B'
M(W&$$TDCM#;87];",(:A*0$%AITO(L0R]B3(- 3X?"#+LDWG;'I'A/$&R?+:
MJ[?CS@^]%U?>>J/97E7.F<:8A%7^2KNI,,8G)Y#/9A&+Q]"XJ .-K#M5-36,
M2\1LSIKFF,1=':")L4D,#@QC\9+E6+IV/2*U]5BS=3LB),!:Z=\_.$"27$$H
M%;<I!.I *7NDS50GRNG B+R=ARB.WKDRSDV!U2U/^^F*$586]CFBZWIFEE^:
M&ZO.JXGY>?%@OO%=##)OE79U*KV-"'PMI@\?%Q_^T/\E#K]W_NJ05D,-Q/3T
MM-G%[.[NQG///8>KKKH*'1T=EH>7!6%56\L_&OH/BV"52;8B 4PQ_D4VVLFN
MYU#XYE\A\/Q#2)(TI!LZ$+OR5H167@'4-"!8S"(7KD$\7H,*R9&T6:;*?$U#
M_R[)X&=A3@,ODC:_+NJVD4]=%T&5GQ*I3Q?ZK"@^KMAPK\B)GIWGKZ"%5X1Y
M39)J<1$A\#Y7+'/Q%S$5:?%$4A%(V!:DY7*&3DOLM)"4LMR]>:2"5J\;P=5]
M$6#+HPJ?(?&@&PT[:UJ AN@#O%\R.U\D)$R;,Q5!UT5,2$KIUC2;(IC\'231
MHPL&(FKHIDOS3BT_5;)N'FH:@U21BI:(#45$R]LJEJ>\I'@Y"#$3-&2M^WD2
MWW(YRC(FT9T:1ZXT@7!2=84/,=QB=8L]HWF]BHM\GIZ8L#A6U521^ 80BD>1
M2S"^DU,H:DXSZUIV.H=D(H7T5 9Q$ND(W422S$^I-[4XBAT&D>EB+H-*+H=0
M@B0^&H"67(GH"V[L+3WG#[JUNB HOQQ?F*N65Y9?7KY8"$Y8<Z"T2V;EF>6H
M6*PJ$(_:LE;G%V7HGYV82GH*V9<.8NR);Z)^>#="[$A$[GX_*F__700:ES/V
M_M"_#Q\7"SY1O<3Q9G_<+G>(M,H^Y=Z]>VTU\NK5J^WZY4I4BR2JHAQ3E1Q2
M@_N1_M*?(?[BXR@6LAA+=0*+-J%^_594KUJ%8FT](EJ<$R;!*,HS-KY:P$2B
M:G94C?4I'YRC]^);#6.C9M,-!%X0N9M-5(V@&5&;GX]T):\9U\H,:3V+N7,&
M23]$VD0*C)S,(BCS$<R[)SSUWH&9^/-48;KQDS;5#'%*H(5ST@[2+=.MSYM(
MGW1]01*N$NN!%D,%2FEZX,PUM?FB%B\77K*]\(S<Z%0W)"(A\Z (&6&2"U%$
MQ45Y(G\]#QUX!,*JI$B3Y86N.<_,AQ%M><PT54H1Y+-,I33KXV,X^-1.C)XY
M@8Z6!G1NW8!(^U*Z=>*M,ILICQDR. L*6_<I*K^ N:5(,SJ3YV[<K1/":T:\
M1=X5'R?.IK7TW+DP,U'25.O'W%OGA3S#T3L;8@=@@2R9"\;;(_RSX\'NAGM&
M6'I8*GPGF%KGVJO"2^-<6+TCP9]ZZ3#&'O\&&H=V(9K-(W#WATA4_P^$&E8@
M%XPAS'KGQ$!YIRB\6D(N+GRBZN.M N<-\N'C+0(U!K6UM5BW;AV:FIK<JY<W
M-'JL14-1$H_LU#1I7@GCDVD\^^SS^/8WOXVG'W\<Z:D)A*/.%JME+=PQ<O,J
M8#MF[;#;GFD84Z:%-#<S&(TC%$W,2# 21X "S?\,DPQZHKF<%*TPEZ'W4#2&
M4$S"<TJ U\X*KU/.^JTM7\^&,4<BU3,2"&F/?$I8\T^=>,R.7\"$UV.,G[1[
MIK&4YE3G_,1I>#\2X=>.OXWX\)J7;F63"<FM)[91 L5HAD-PYKKEG_GR!I("
MKW-@'0E&Q0SVV[!S$%TG3^&K7_TJ'GSP)ZP#4TR>.A3G1XA*3)^T@PBS3%DN
MB"<12#*?$U4\U_S:)$5'2IR=GT2,Q[AS+HTN[Y<C/$93Y.[5<R5*/\+>/9Z_
M1HE$:YRR5YF'7EGFA*-P333-(^)*V.8YVZX.YY<U/GSXN(3@$U4?EST\C8Y6
M:FL1E59K:_O)NKHZNW99:J7=*"OJ,DQDBUC(A[3:/91(()9,87*B@#-G1C$^
M,8;IJ4FZI3LMSI$6\SS2;"[<O!/-,G+'YRNV&"G!QIZ-OS7Z+O$@*3$)\YZT
MMK+5JN%U72-9A(@BR2ED#DS$1Z*%/9Z03)H[DHA*I(I238(AOQ7.7*F$ZV9)
MK2.1&H9%]S.BWS6\[I(J$5;F2T#FH)(DK@F9C"+)EODDQJNL*00DK38L+.UA
MV9% 21I%7I^1B",5$E[3-DIKJ*/+1TUSNH!8+KXZ5!]?2Y74D+_Y;H&+AVLW
M*G9(\D4KP['Q<8R/3S!;F4X1=9?8OAJTL*P<B* <BJ 4BC+_2$1%1I/,@P3]
MH5223+LDH45A+'/E<YSEINDE\5JZJ4<PU8A@=1."-<V.Z+RJ@650SWQGN<7H
M]C5*(%K'S@7+EQT4A%G6KR#E<!7+ED>&56:<)(J?%M99/5;GAFF4"ELUW?+1
MS<L+PNQ'50#\K4Z#5SZ. PMIUC4?/GQ<*'RBZN,M \_ ?[%(:G>9-Q!&KHW0
M.*NL/;(=(>$2:8V1#"82021)*K3=)=M)FPX@2.-V7IC)(C:H\EX$5T1'A$7:
M4Q+*LT15!)(D):1[+DD-Q9W?81%4D4&2T?@\,=+JBA'6) *V,I]'$DR)KLV7
M@,(S(JQ5] S/(\=AD5A/&)\9HDR)4T1*M<"'84F#*RUK4(;J1:*U=[U(GK$+
MBA*MN:<VK#T;#M%P#G+C'2DDJPN25*^^T8E;5 8CI=)4GR,,<[;#5X"1(!XU
M'U;U03M$Z5G9@M#BP2@)N&P%TU<492K+W+VZWS(V(+NNN5P&^6(.A7+!]OW7
M'%Y( RFQ.:K,(^:=::V9ST'F=Y#Y'R1!E'4#D.3R(N/$3I)$=F&#)+:Z+I)H
MS[TV,6T]_3"1/_-%X7G"WPJKPG/%Q^)D'2EVAD1T0ZP70?IKTT+FE_5KAPBH
M4\[,<3>?];V1V!0CU@>G-KAU@CB?\O#AP\?">/UOK0\?EQ"TLY"TJ!*;XR;B
M=9E#^X6+F&B%>44KRTE&TA/3)*:R'5LR^[%A7@\GU!"_!J@=]410(RNMHPWK
MJ[$781 A94-OY]XU1T10C:3:=3TCT5"RA 1B02&AL.=$.D4T'3(Z7RJ,!PO3
MCC-B_CN$=;9X\=#]BCTS[SF*I4O72>(]@TGV^?,(J.;-GB/*&-USW7GG;S+,
M1!F/(J+:.M:)%DEIOD"2F45>FE41(;>3)G-)Y]-/"U4*"%-T#%(T&UIS:P.5
M6@3*%-2Q[U)O$H"(GLPOR3P:R6! O]D)X/OEA>VLM'?4SJ+1)A9Q_GFM8B:[
MZ(-[/$>TP,L5L\3 9\SJ (\6'Q+F4H5$-<A.5DCB314@X1;QMWK//PO):T ^
ME[>%=_K>2.7N6$]P;[J0N3S-G??AP\>%X<W_ZOKP\0;!V?Y2MD:E872JMC5:
MEPD<&Y0DIF4UNA640VSX>2E:JMBUL5@0HVSOBODPPJD4T%J#:"J.NJI&Q$C4
M9'B^7$[SK<Y1\A0^;,/ $90K)&E:9"3"I4:S))N7,D(OH5O3"I+H51(.$>$S
MQCG*(CW25'L$Q&F'35Q28 2*_E9L")TD@''5?,ISQ.XS')O3*2G:46F<+\X)
MW3"6*DJ)DA((2%LX5T0J%;\B2!B43F]AE<1LMXI\:/J$XL\.C%DE<!:9F6A.
MA;9"6E#D1D?Z802(:3#?Y@GSQM)F1(?NM8C-1(GA[Y<1>Y:G3I[IZ/HS&[8
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M#4.,&#%BQ(CQXD#\ZI^DK8(R&OP</O')3^--[WT[#M]_-C+57BRZZ&HX]U^
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MM^'?-]Y*^3=NOO$F'M^(FQY8AL[RI@B>AYX[_X1OW\CGZNXGL6!]$Z8["_$
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MLX;,JX_$0?L?@&,MK3U8OU[U3 :S#ML#XY3>%\1F.PXO::+ZTD! 5)75]H$
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M)(./ZV7PN0CU;B-QK\=0YZ(>DNB<R*W<)/6]L3%B;&MHZ$Q^X@SLPWLHD9J
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M)S?-YL_0W@U\:-':O?4$..$UVM96;-"QZ<R?L*Z(DB!(3\L#"G/:SFE?I#P
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M+R&[E-"0S'@JS'C3O*>R?("R-9)YKZLW-LOS3"5-IS==O%)EBI=YO$<\FQ?
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MT9C)XMFG%V/NPX]@WF-/HF=MA_D3&:A?WBC&BP1JC]G0BIS:$EAL;47"HB$
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M_8XFVJ32(#0D&$AW8]>_-&2L: D2,?P'Z2 1XSG'%$K3"@*7G9BR'W[K.]H
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MI9]\"7#AP3&L#0WEV<8]C3/=S_9]PK-CGBR&4Y[/Y9]F--_UO:1#4WX+$"#
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MM];DY]/Y?2DX'W9<##3[L^'?#[:7SRN8KUB6,L]Q?'8;UYR.1:U4*NHZ0(
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MD%@)GN,1\R_S)DL4YDS:SE %"!# 8;&O/\ E"1:!-2V44D>I6(A4+%;.:P6
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M7S9:I%JR4$?6BN4I%(Z=%JDD8 -JI59Q@9)4M_%O>GS"OO?-;UDO2, G/_V
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M6\?P7KLZ7;0UPWLLN@KY\Y]]PPIK=EC2$HCC3N^M^3AM^7<>L5C>#Q#@@XJ
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MA?#"QR7Z%(_(%\S'%>[B!_?J59#:<!QYLAV5;1OBX=2QW $"!#@]O*\MP$H
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MBIJU BJB'([4?A4*157@[/++9;*:_,1N9%6L>)^3>N PS*"BC[HQDM0$.?_
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MZAPN$$=E24T0*L\4*E6NAYK)3ED4X4IUIFPZ,V6U1%@;!62S><O.Y% !]X+
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M/G'*[X8K'+0E0.J1;EQ6BOF&3I*H:<PSOD7V2N1 5D\>/VXY-!;BZ21\A^\
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M9[SGF</SCO9VC>OC5J1<^HJ[>W'X1'MO#\+B50X,E,=@Z ^N"D"-ZL&]>ZT
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M7,">0K.<T;Q0_.<Q/&=7)>WE=I*<Q<P)&M1$:RO)!22R)5#1DK"Q@EZ2^3.
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M0MY*L$L/!(25M<;=LBL1E8XCE+AF/8&*F*LBN(I<KTKXV(DC2A+8WQ"27%]
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MF?)UC9T='1FQW_JMWW(3S7"7Y(O9;0AI2$TW20YW;/*'T<BO_@F$6WW*CV)
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M<+D\2W]0.-SBO__;OV\//O@]^_W?_WU[ZZVW-*;RE9=?L?Z!?A'/KWSE*_;
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MOR,P?"3-([U%T003WEP(5KX$B >[NQE.K<_)51EB;C6 2"R)>RF08RX'!C+
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MAXK_DD,3>7 $K'5J^.3LO +Q=_3P85N]>K6[]IR>S6:E!;J0L1E/).1^J5C
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MB+V^V\W2<&]1.3LTQTN=8:5=\%LTCG1(1BS/24:QL-4AG.Q2!U&KXKG"P^"
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MHZU=#9V9J6F;&9]0OM2N:8 F\C%NEY,W85;#JQ#/A/*HR*HN P0(<!8(B&J
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MH"JZV8!JM=QDM7S91@_\C1WYZ_\8 M6:@.J/+ '56%[*/:.\"ZSBI/I& ZH
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MXK)DW"VS[A4@SSS$^6 86X""_ )\:@(Z^)RLPLH70!/FNK2RXJ >)AUP,JV
MN:8,Y<<$6.<*BS93S(L7+993SZFU.;"^5B3/DH 7,G59 J:*.@JX)FO6TQN
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MX,/G C@L5AL?'[6QL1')K4FR#:RMY'=B9,*ZNGML]]X]=MOMM]L&=1@Z! X
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M >5RS>$991#<1^$Z4%6>D"M#[5A.&=XG8<QWS*45G_XX?^\CC]@]]]WC"A+
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M555 1@#,+4B!5I5*][@N)>03RN@*;=Q%&2K 6RC.Q;E9@8>R*["*%-2H&F)
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M7%=_OQ14D^*:LY+2D1>HQ5Z!Y:F]H\/GTYT_=]Z'55E0D6A*>YY1<&T,SPI
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M#>MKJX!!)I6VZ<%AG[L&B.OJZ[%:(F8S(^,V-S8I(*7GL'2A\"Z!JH&,)>2
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M3<+4==57SX_X,LC[YLC?J6,$D#Q=^O/?E)M^0TN -J2E](3WEU/]_27V.B8
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M5^T;7_N:??.;W["GGWK:GGGZ&7OUM=?<VP+NLYI""VC0^0JLAM=#E _ ;UX
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M[V&KW/=#EN[&HIJ]W*(JV'J]DEC)TGIQV/%2NI:P]40QN65 ^8P4'&47E1\
M\^TF?3#AF9(@:4T+,/_9'_VQM0HP_N /?=QR[8&UT%.G_U:2Y\I6*\4;:GX
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MHD5@6&TBQ<K1%ULIW5A8&>Z'"1,-JWHX(@" X*F N9&2@="H%&+:+6ANUP+
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MV/6+=+(#&$?G&)8VI5'/1&EWUM6E/V0#^U5W:!2<*]W^#0J L<^_@]RRRE*
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M-6DESS[GEZ.8\D\IOVTJC[* ](( )N]A(X?SY\_;Q@T;51>G;/C"D&W:O#D
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M^_=_]3_:%__XO]K?^P<_;3_P2S]KE33O2UJR),!530NC9HR5_BS6B>.WMA:
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M:N4-6%35+GBG];M'D3P;U* ;A;Z[7TR#WEJBH0\YYD.<S$5CB UK&T.\*(C
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MYU&*^.U;JMX %("2B_Q&!'!QH.A@966&HKKA]2,J+X".RI N#WREZ>'!G,@
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M7U%' *YZAR#@^@CKOPMDY$PNL;)?QGI.PJZW>CJ+ZJV5SGZ/<"H7A8\XJ73
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M8NYY6ZS_6#Q XUQ+Z=DK<5JL,&K4%8'X^AMRZ8XE)IE"(6*=,*>S2N8*2I9
M58QC, S/<'Q-^8M6*OLS*,<K,/-(?2&*PLWGYZVMH\4R":6]7/+G\-O("%^@
M,<E:PHKX.#4!NUA*S\?LEW[^Y^W>N^^VHP</VJ/O>\0>N.\^>_'YY_3^LHU>
M&/%A_ WKU]K'/OQA6YR;M@?OO]=+<^>.[8H#"ZC>9Y(;5WD-8M-[2XL+#A#G
MY^=]:D%O7Y\]\NBC]LZ''K:'WB5^Z-WVR"./^)[M6$ %*11'D,XEEKBD?X.\
MNB)69FJ27<BUNO/*W)SJ3-FR['I47#3+SUDBJ5J'(WJ?0TLA$"G_2YD[<X[Z
ME[R9R^?E$[VTCH,"U#_"A+QTKS[!XL \*@Z>X2W1E26BS*[ ^G>1>8VSKBM=
M/A]8[%O?+N4]#!2ET7D%\L)9@>L?BSA*,!R5BW-= +^OW*D2ULI*'_,@2:/2
MHB\ZX%AD:5?M$+*JYP K!O%1!GZ.[/F^)=?@6I@(%T9PW<^C6_Y-1=\"]2-X
M+HJ/[[^F]B7(JM+I3#W5A8CK2"40L(</XHSBNOC2D+VSQS'X!N*QI)X4\U%6
MV$4_7!!5U?O4WO%X/ XXE#"<+[X[LBB7]<W%*%_=;A%(K574*2P7K5(J6J:I
MR3K:VBW3WJ$ZK6\8H:8%CA,5BU<*EDXG+-62]:'_I+=S";4P>8ME2[JGX&IB
M4FI[,_KNR5,DK08UJ$'71GR]#;I)"'T-$&*1*:Z+4-DMZLDW5=2XE@L63PB4
M.1I%T:EM+U<\# J"N8X7E<-R5D,><J307)F$BCL '1=!3* \ V7F2I65KBNR
M -<22W&\ 4A\0W9@$? 20'50$:3+ 6H\!*EQMI;5->9YZED .8 U2(,N7X%1
MJ*@[GDED6%FL]Y4$?HN*KU!4E)*3QQ$HQ:I ;$E M29@Z4!5G]R>73OMIW_R
M)^V__N5?VD<^\A'[Z(=^P![[\I?MB:]]U9Y\_#'[XM_^K?W^[_RN_?+_\;_;
M)_Z__Q_[V$<_;%__^F/VS__G_UE]!62=4!JD"0&L#@H<3KH(W<(DA<JN/:EL
MDS5W=PM,=UE73[]UZMB<Q5JDFTIGL% HS$_(GFZ2CSS#<O8%(2$X8P5SC(JF
M\X3"H.23*DJK*N\"2G&W\J+XPW!+1"#%K7=RE=CUL,X"YBKA_9DZ]KH5,D\M
M<93@,%J.#I+\GO[GFM\*_X++*W*0YY ]PHAUWUGI\C0J7ZK_2^S7 UZ9EL<7
M\$5W4I?RRFGP!(JAX%[,01IS3O4<'[MW$O7=J1-*9Y'?@6S#9Z.,$C8\KX;G
M]7G@&E7#.2P_9^YSC23H?.E[TY_'QQ% Z[]UX)HSY_Z?_BDO4>27$%VP* 7Z
M"Y_U(U=)!X\Z2^:(1%'H]6).) -5?++K54\ 'I==<>3$?9+E[P\Y(IV3!^YQ
M&0SJ;1J/"*R6*T5WL39ZX8)-GSUGLZ-C-C,^9E,3(S8[-FP+P^=M:NB,#9XY
M:9,34Q:;$T MZ>M6QST67U"WM*AV-VF9<M+BZE"8@"T)].)M4(,:=$W$9]^@
MFX1H! 67I*QT5 -?5L-;$C"KI*>EA.:%P; 6$$B]_-E6:YK+6C(?N*JIIDI6
M:Y*B2ZL!7\;53,"<8YF,%05*\FJ8\U(B\&)X%%M!\13SXD4US@I36Q0OJ*8)
MS%W&"J-&G6,MIF>P;HICN&&Z#HX++$5<53S*O<";))*0!H-Q+U1-24"AE3=B
M:3]7^I<IT=>G7'.S^PYE;EP:'Z7SDC$ ^0U(;Y-BC/NB#5;/LV?YEHV;;?.:
M=<Y;-FRT53U]UM;4;-U=W9;+9FWUP"KK%NCT>9]72*;[NM1]=I\2DK$REJ)$
MW-),"\CE+"?V5<ZD\0IQN"(5<P#+!-9YB4UU"O;[M!IU3'U37\@9L/Q&Y%9A
MI0]T$&T%6A/:K=:STKF<E[_7WZUH(D,\[.F\BC3<*.3]-Y@?+@/)BK*MDQ4N
MN9 E==@[(3JO[P<&%O=01LA<[&$47RT5,/%X_%C#*0_N1>SO")A=L[P>D!PE
MBOKAF/(ZR>L3+**^$6=$07I)2\!T^G ]QD!-10$K^J8K N7!^:4<2&PYKYQ0
M3P)U'=8[$IDF?9O,^R[;A:%A.WGDJ V=&_3S"X/#-C)TP4:&A^W\X#D;';]@
M"\4YI4UMC3JL3>KLI@66$RHTM8B!; 14 =#)9?EK4(,:='6D)J=!-Q-%33'S
MM_#[MP!@3-6LHMX\<RIC,8&TBEIZ@=58)6,Q!VYQ8SYD60#FDA'_.E8[&QH;
M(\U"U6%8C>&WA!KD@+F.KG3+&$$2.M(Z,^W@B@R0K"H98H_>([AVEE*[C)?N
M*5ZEM2:06JN*)8.:SWN E49_K<)!_ PNO2X!,A<6%I;V 8>PTB![!X/A[^7D
M( U)ZGTP<@5& YA9U8\]B/F&@7]3@0-_R*6L0KA4TS%7,C0,27;Z+RE%*[!:
M49GFV>%'9>[;=@JT>EJBY! V8B?NN8W,22ES$.) 1&&B>7\>0FGQ12S$Y_=<
M)?LQ"A?MU*,+'IL_%[Z/6,AK$)>.NNR 1"&Y%\DE2AGG$/>#-)#OX/U1GMPJ
M+EG@VY7??ET4[+\>Y-V'H8D#YC<!PKBAI>M^3[^X%S&IB>Z)G<A?$(NNA>6R
M%!X*PQ';)<^&\2WE,**+SQ+,F7.8RRXKY0&@"'CCF@)YQT>G,=W@S,$192#V
M.<,J"SP]!!]P(-]H:]&H@X'O5??/RK.0PD7Y].@<#%,F>J_BBQ./WPCB]/#\
M4?[\7I)#R-P7^YS@Z)XXFB/L=4SQ^CQO+)!EE1DC/AP)YW$3#Z&IE&X^=79+
MNIB!=03!T<.'?R24ORJC B%%:209@'O>K5-_'WE,I9NLK[_?MFZ^Q;9OVVYK
M5J^V@=X^6].W2IW&U;9JU2I;MWZ-[;Y[KVV^=9NE>EOUZHKZW7E+%*M,] G2
M[4DF7XRE1.EO4(,:="U$$]6@FX10'$!%/XHK^:(5%M5HQSK4A.)G$Q"IQI*A
MXDS%RFDUH2G\7*8M7FJV>#&G8^8R3A8#MG+&RO&L%5(YRV=R5LJDG8N9S!)7
M4EFK)G/BK#!@2@I5\6.MD9);D1W;ZCX .L9P=EK/L&O3]?#%[4E-Z;2XCC']
M-AS;ZS[6TZK.*RQ\"JVI+')0,EQC17R5Q+[^M^Z]U?IZ>WU>:"*7"Q61_G,%
M+ 7(_RO$B7*L"D#B*_4O_^+/%:YFAXX>MO_XZ[]F(V,C#@P^][>?LS_]DS]6
MFE%RB"FPF-7'M@0,]"\FD%H3-S5G+9%.^+[J> 3 <NM*7_$$:0L.GD:.2Q'J
MA]Y!>OES[,7<YM BY*!5NKZJ>L7PJA4%(@IEG__,.49KK@=1\W]P)(W!HA:=
M,P\XO.;O !B$R6*N).\ I/!>>D>^(46I'%BBPK1PY#K6^YC>&\N3AJJ_/[98
M#(SG'HW")0!DJO>\W_,?4E0F83KY[>%TV=EO*9UT! ![/*N@T0Y-2\1]A0L
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M_?^M8_R@U6;/6$U8;;ZY3<U^A_"HE*M:S$HJ(<"5D\)HL71*#:W %]8$&F6
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MBP>6*=S2,)09$YCUE=3X6X$4%A=-4"*>-K8<9*XF%K94%BLIP^5^VY4YEA+
M9"J5T;N2EE)C3QB&^LA!@A>%A-($U.(:I^ 6Q:"\HC)+5U@@HK3HG<3)T2V$
M:26KTJP0)9N:/F<I*9'YMLW6?O][+;?[7JME^I2QK$T*6+[VU%-V3 "-Q1AI
MO0<+)7^DR4FO(O]019HJL*C6;*&T:,.O'K3Q_<?L/1]]U#[P]W_<TKWM>B[M
M<WZQJ!9:VZS2W&)I@8?E0/78B9/VR3_XE)TZ?<;^^3_[GP1(6NT?_S__D=UY
MYYWVS_[Y/[<_^.3OJTP3]A,_\>/6*24<\RD82A/)4G(BBRKR*T[/6K4X8UG)
MZ#._^>L.9*KJ(:Q>O]'ZUVVP;%>[=0B,30H$]G5U6W]?OP^-DT\LTP "P-[@
M\)" \[0U95)V^)57[/SAXS:P894]\M$?L+O?^:"U=/?JU7$!C(* DCHJ/GV@
MZNZOOOC'?V2__1M_*&!RO_VW__"7K'/U:M_:=7YZ)@!? JH=?:LLUMQD+SWV
M1?L/__97O4[]=__]?V</_L"C/O4@O[#@=00W6U@C0['[4&VZ*:VR3?OP*]M;
M,@>S+."2RC7;\)%C]BO_RR=L[/R(_;/_Z7^TNS[^,?OZ9SYCKR@/;6UM/G1\
MV]UW6HM " )D2U%5+,O/SEIE5F!)^4U+_DQ[*0E<O_SL\_:$@/>N/7OL@Q_Y
MB.J]TN/U0;5#SXZ</^^[?"4DNV;EG?I)G63+3H:KVP1D:GJF(F#&0C"FS+#J
MG,5N@9_=(&M8^)AS.SXZ8FR4P+/,MT1FS*_L6C.@NJQW"Z"JYZ%O*V9?_?SG
M[#=^[=];KA:W7>IP_.-_^D^LM;]3=4YA1F;,5"Z5W@Y+]JF.+Q;T;%X?2L9J
M IX1U=0YC*O#$%.^\11153B&_5.(W$&@:BAY9LH$)2ZP*D2I<'D'E^2UK,X)
MG8Z1TZ?L/__V;]K$R(C]W9_YNY9L:[%GGGW6BN6*;=ZRS>Y_X$'KWKS)RM/3
M=N',.0=W ^O7^FA..5]P"_?Y@X?M5S[Q"1L\==I^XF=^QC[XL8]9BX!T36V9
M+RJ3G/D>>:^^3&'40G"=WGD9_]"D.RX9JKU1B-.O[;<__+W?MYF):?N%_^%_
ML"UWW:Z\"NRR\HFV0F7(0D^\(I0%7O_@UW[##C[]C%7R<[9^XQIK[=9WNYCT
MZ3=TE+#DTS%:G)NU*0%1[SPI[RG5QRE]4Y6>'NM*MIA-+5IGKLEZ>EKU71]W
MJ_RC/_:(_>3_\J\MUK7+8O2J@Q[G=XT:0+5!-QHU@*HH CTW.N$[E)7M\6+-
M1I)3-G[B-3O^!W]L3:-G+):?M6RG )3:]NP"5KBTP$NS<U-+JV72;:X,8[B)
M0HLZ!7+!SZ4><(5;*4IQ "1T+Y</Y2;0P/PZR(?N"WDKYA>D/Q9T00!%@,I7
M>XN0-</H@$^ :CS!_O0";M6RGIDG!@&Y<.&+Z/]F[S_ ++NN_#[T?W.J6SF'
MKNKNZIP3&AE$(@F0("=0HY'&DD;?DRW)EF3Y29;]_&0]R1K)DFR/K4]/3UGC
M&7&&WT0..<, D "1T4#GW%4=*N=<=7-\__\Z]U97-QJA24HDH+.J5Y][3]AG
MIW/W;Z^S]]J"3QM;QWL'U!I1-I87T8]_SHQV60?7K<'%''*KC&MF%J$2(2!3
M(*CV(/[$YQ ^\CA!M1W90@B+V132,W,&>[)H^0FB-H:2C2(9L2(;'A$U\/;(
ME+"XNH 7?^.W<>J/OX=GOO0YO/ 7_PS"'4U*P<<"5364!>:Y++=J7HM%C5%4
M7A3-2F<NI3P$#/[I"L=1%>^MVS,+!*KJ#'B9]J69&>9Q$HW1"+[UK_X%OO5;
MOX6.CBY\[H4OHV?G3GOU'V]I1)# (KBRUYC\TX07LQ828F1!"_H"C"-K4CZ#
MK_[:K^'BR5,$B0"^_ M?P4-//8DP@;E$(-)L<T^!><7RD2I.W_KJ5_%K_^8W
M<?2! _CEO_R7T+%C!^/I,^MK9I50%XJBMH6@6!O%F>]_&__T5_\/A'GO__JO
M_A7L/WZ,^4'X(4!X9'$G&-G$HDI9Z[.@7-8M=8HTG$3PMS0_A_KF%LP/C^/_
M_9?_.A+3B_CO_M)?Q/XO$WQY38(@*\N>QD7+&NJ/J'/D=<)CO1*0):;FL)Q<
M0_N6/K/@9A:6<>G<>;SX\O>Q_^ !?.DK/\]\<BS[&HNM[)=E+[V6L'&U(<8U
M7!-SX%IUAZKP9;&S(2,"2$$W04H='?&N5!U!A1/@]8$PPRWGF2ZF.U_ ZL2T
M/6=1EIDF*6E<9%;02]AZX_77\,_^R3]")%_&GAW;\-?_UO\3X?9&IH7WG$\0
MM-GA(VA%&KF/UR@NH?HZ\_-;S4^%)VNB?*EZU?E4_++.['<-<9";)E82LYX*
M"#6V5YTUQ:V8XS/-M!58:S4N<_[F=?SN5W\=K[WT73S^Y./XY;_^UW@'KXVM
M#;$3$8G6,'WLP/(W(K&T@M5DPD 5[/ ZK^VC9E']VW_SO\?"Q!1^[I=^$5_X
MV9]%$^%/$Y[LK0[SEI5%O,K\9_W,95@6?,Z4CTRCWMIX>0\-4?%R_^+8.+[S
M.W^ 0 [6T8ATM,+'9R.HB9[, _U>*5^R3$L@WH"A:S?P]M>_3CA=P;%'CZ*K
MOY>=VT;,\+G2T)2VKFY"K@?IY I&;]W"K5LW;=RTAD>HO+?MWX^=>P_:\[PV
M,XN%X5MX]3O?Q;DSY_',GW@<?^97_C>@B:#*/-/"'S])<4'5E4^:N+/^*9\6
M4-42BL1)@X@\ 2$:B*.[I1?=NP^C==<Q-.U_&,W['T/]C@<1>_!)U!U_$C7'
MGD!DWT/P;SN"X.ZC\.\\@,".@PCN/(S@+N[CUK_[$ *[^'T'M_T'$-Q*W7$8
M^7U'4=I[&&5NRP<>,/7N/P;/GH/P[CJ(T+YC".T]@O#^XP@>>! A:F#?<>HQ
M^/?R/-[/L_<XSS\*[U[>>\\1[G\ 'I[GV<\M-7#L402./@;O\4=1?/ 1X(%'
M4#Y.?9#?CS\,[[&'$3SR",(\)W#X$7@//XP<PXGT'4&T:PLR!,3BS$T$V:PN
M$!!CV[<CT+L%"-7).P_FEA80#X?1T=6.<#1,X(B:!J,A QM3'J]^EN4MS$93
ML_QCS0T8N7H-5TZ>P8Y=N[#KT>-L3 D:A#TUU&J0RFR,98$VOY,J)/XGBZ1:
M7.W1GR;VJ-&TS]SO(X2)ANRHMV+=8AUU:JD"T"=M!40%PD@.&8*6C] :)DA=
M//$.;@P.(DXX>?S99]"R91-6T@FLI5.$AIA!L(+P\]P0 4O JE6L_&KX>?_5
MM34L"<2R:9P^<0;M3.^1?7O1T]L#7R0&3YXI*##.'B<<-OO(\IJ9J1F<.GD>
M#;5Q;-W:CWHM4$"0T<SQ)(]K:$&&<%=+R-%KUMF1,00R)3QPZ A:FEJ48P:?
M&I.I.BQ75=KG)84(2/3&5([4_;ROK(<ZEDEG+"]D13_[ZNM8F9K&@\>.HN?H
M7GLMK2$H\D 0CCJ+'9@PC0*;?$9+91)^":!> F2*<2L2UL.$P1'!"&&CNZ<;
MO;V$%L6+4*IRT,QRG9-,.&-<!?^R"NJ8\E) )IC6^8IW,9LC0ZISR)NR'MAD
M-4*/5.O*9Q-K+(<:RR=U@A+R<I!*,_^:;:B-E_7)W'ZI\\*T3@^-X/I;)PBJ
M1?0T-^*AAXXCQ+HH65E:,@MLJ+'!7H-K5GV ("K1_6S<+U5CAP-ZF\&ZQ]A0
MN67X>I<N[P=V#@%:T"I0E353@$AZ,ZNPC\\**X,!;8%QO73F%,9O7&=^M>/H
MXX\A4EO+?*]#F)TTI5>NJM2Y58<AS3+3I"L-W0DS[_0\).;F\>(??]N\.^S:
MMP?;=^^RL;/JL,ARJ7CH>OVIDQ50'>&?9M')BX:&HPCR,RI3PF)=32,"R0+B
MQ0"Z6[L0(?1:YX'0J8<KJXXUTZY)6\PD-$7KD6<'!:44CCQT&+%67A]6'D81
MJZ]'0ROK)_,@WJ0.@:SQ/AQ]\#CZ^GIMDEU[6PNZ]NQ"B!V$:%T,:U.3F+QX
M%0N3T]BZLQW[GODL.ZPM*@6&XY2'*ZZX\O&D\LOMRJ=!O&##)),#.:=>DUCB
MS6@Z= P-#SV-EJ=>0,M#SZ/IR&?1^"BWAQ]'?-LQ1-KV(="X X'F?O@:M\#/
MS_ZF7?R\$]Z&[:;^.+5F&[RUV^!OV0-?UWYX._<BU.9HL'4/ BV[3?VM_+'N
M.83H]D<0V?TD(@<^C^#^SR.T_SG3\/[G$=[W/ 'V.03W?HY@_!2\VSX#;S^W
M.Y\CX#X/[_9GU[6\^3,H]ST.3\_C"'0]CF"G] D$N"UW/HILSR/(]_+XIB=Y
MSE,H]3V-[-9GD3G\612./8(;'C;VB"! 6%D.1) /QI@_$6<F-N$I1!BKU4QW
MK>&M=;U*6;9C;,S*@G["!15ZY5Y1301REI8$LH0_65WE'4"-+;PAK))^,X01
MQ]J90Z"<0K"89$.OF>'"#-E.91L5M/!:;IQPO0Z \4^SNPW4U.D@1/D9GEEQ
M15=434J2442P)@\$/L8Q%O+9Y!)9X12'B;4DYO)I>.6(O":(NJ8ZU-768'ID
M!+FE502"$3;L 2:7:<WED4^F")M)+"[.(53VHZ.E&SU=?=C1UH:Z7 &^3)(\
MG&"$V4@'9"V.PY\E1,F3 N$CU%BO<1JH;Z[#\,U1_.Z_^RI!, ,MXO#RRR_A
M5_Z/?XQ__VO_%M_\S?^ [_S[7\>Y[[V!],RJI2<<%D2R\=8K;H$0H=%,CG[F
MJ;:6E\HH?9<UE,A$9M(RP;5!QB/O16J%8+W*\E0Y>?(L3\(,RS5"4#9/#H0B
M ;^W:LWFM7)C%?(%>?\@:@B:4>9?9F45B]-3!.L5YF^1QU4FPB.9UYTRT5KR
M3!BBLA0RC/F%)2Q/SZ)( %/<!'KJ!(!09/XXV5$):**68%66/ UO8'Z7]0J=
ML='KY.SR,E+SJT@NKB&52*.&D"?+LEEE5>XYU3DO0JR[@J]Z EXLYD7!FV07
M+(G<RBS6%F;M#4.HL=:9N2]7",PGJVBZMS[JLW+ >@'**ZKJN,K5Z\"CXF3U
MTN!:J68]*Y<J=9^PQVND*@N-W?!Z")/,EWB8&N'5?(;DFJ[$/%8]56$Y><BP
MF!ZMXA;@M<5DAFE>0DZ F,FC+A)!E,=K B%[>R++GX942%0-G(5!&$\ERJNZ
MP+*HP+64EUCG0)%>FYK'S:O7<>[D:5P^=P;3UZ]B<7($*=9O+<L:C!."V4GP
MR>\RZ_?X]5%<.7\-2XLS[,#*$PB?:()L@7F_N,+\36602R:082=BE<]/DF4W
M.CEAOH\7Y;XMQ[0L+=O0E974"NM^$L%"'NUQ']HBRD?F&_B\:($15UQQY;[$
M^15PY5,E^H$W"YQ4/^!L\&V)2C;8:F.E-I&)C:T:?#7"'ZEJ%'0-O]W6VU*]
MGQJO]7/YG3%YOPHVI-7&J*)568_[/901KYSU\437R-6/6;D(98GY161GYK P
M-H'%J1D"63MB=74ZDYQY^[6PW>LC1%%NJ*]'=U<[:FOB;.\+R O\!$1*IS)7
MKU#S67ARA))LBEMJ_OW*EI#GO5_+^>3[5*Z=G&-I&Y\G\<MJIM>YU C3(4\)
M.5F7J![&H:ZV#FW=W6AI;T<JD\;4\#!69V8-,K5008* -C,];6/VXDU-J*%N
MV[X=GWO^.;1UM-O$%EGI!"#KHH]2P0WA(UY;:[/N=<[""L&+H"I+W/3\+*Y>
MNFH3D$Z<> ]?_\8WV, /6CWT1X(\AX%4\]OAJ \5&T/-DY2_LOSI6KU^W]RW
M&:VMK>1HS:QV]OO#LDCRLY7I[9\[ 9DMAL#KE/Y0K :1>*T!ICQGR+E[8V,C
M+^,]%-8]1-:U#N9I?4,]TMDLEI86<?'T:9RGRK6;S?AG)T!C3DO<:IRG5Z^O
M!9^\7M]3+(/!:P.8&AMG&!EDJ;+@1ROC96WE)L;!ZA*OTK7FNY7?9'&4>ZAY
M^?9DIRL8<%QCR;K[GUI65E>QNJ:A1^Q$$/"K0WULG+N>;_VQ/ 3Q=0T-B+'C
MJ')93228;P2]U176LP[6GWHTMS2;!=RI!Q]1&38*[Z,\D,BW[LV;-W'UZE4,
M#@Z8*S(-]4AI2!+SV(:K4#W\353':&QT!-<'KF%M=1E:B,,ZHWZ6.^N)<CZO
M-+'0%(YYTF4G8DY^:5,Y_K[$44R5",+S2,XOVS"C4*%,0(UAL]*CWQ66OX_Q
MT^IAKKCBROV)^]1\"D60506_.\!0$,;&06KM'H\YC;":S0]760Q-*Q#J: 4>
M[Q!^%Q 8%-Q#%0^>(^7%O+_7M!K6W>&M[[/]%;7OVNC[;5%C*%D_76,0N4OC
MT3+)A'U.)Y*.:Z%\@9#9:%"@\9EI-K2ZR)GI[X3S41*-1G#@R&$\_/##B!)
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MQM@N$5S549 E.Q@CZ!'<%%?52;E%LM?;O(\@3; J-U.-K,,[]^U#_]X]MK"
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M"V^\BC/L5)Q[[54,7#B+7&(9R^.C&&<Y38W<Y#WE88.033@UZRS%.GC6226
MLJXR5.[5L\8ZQXZB!TD6BJSF>>LX\F1;[$2JY7WGTV5NE09!-M-L&>:**Z[<
MCSA/HRNN? I%H"HKC\$(/UNK9XVT7NM5SG$V'U]XG1H;76^O@+,Y-F9.\V7.
M^MD@:UQH@?"1SV:1E=L:;K62DF!#K^FU(I!6+3*_F 0BJ5Q;0:OF2'U1MK2.
MVAC+NQ1ZI1V(\'C8PC +L%F<" ;%/-*9).&8@$KP+!3R2"VO(C$[A]G)*5L+
M/1(.VQ  .7J7)5.V(CE#MW7?>2R53"!!,%TD/&7364+I)-Y]^P1>_J,_PF__
MQE?QQ[_S!_BCW_Y=O/J[W\#W?N\;^-;O?QU_](=_B-?>>A-#;/@S>G4J&'6R
MR_+?/G,CM6," 3;<9GRVH_Q:R=N/(U:F@DKF.2G5\E88(3"54_ZHTAF3HWGF
M4?6^ND[AZSXL>8W35ODMSB]@C7"?98=#DZ 6-89T9<6 4^(,$5#HO%#Q)@SK
ME?_F+5OPF2>?Q%=^X1?PE9__>9O<])6O? 4'#QZP/-8RM5IE;/_^_;8L[N>>
M>QZ;-V^V)5;W[-F-CHYV.^>AAQ["L\\^BT<>>Q1??.&+^/QSSV'G[IT(L:,@
MJZ\831.+!'T"57OM;*_X*_7;+(Q.NCY,G*$+%7C< *K6B5">?,3U=XOE:V6K
M_)]=6,#(Z*AY+K!ZJCS3O51.2L0]1'N=9Y%U@>FRH1.ZCLJ+G1,^KK!.Z/'6
M?SU=+3BT9SNBC,;E,Z?Q^U_[+?RS__U7\7_]HW^"7_U?_Q%^_S=_$Y/L8+W]
MRBOXG5__]SCSSIMHCD?16E>+B/*4M]>];8@(Z]3Z>%OYHY/_/X&XCV7B2_'Y
MU41,EH?41] -$<'#K%MZ0R +<[06",=0D%_E^TF/*ZZX8J+VU157/I6BQD[K
ME,O"J?%N:F)L#*0:'S7TUJH)\)R&U!K>2B-I#;K"L/^TU7_5=K/2VO \/\%%
M]EJ%)U^H<GNC,:^RN,DJXV>C%Q!(\5I[%1H(.4,-M'RL7F-ZN<\71#$<1"X2
M,,VS=<T$O<CSLX?'/.8@7$#*[VKLF!Z=EPVQ(23?YOPYY+P9E#-R@Y5'F/?6
MZW:-O<MGTO"DM2^ ^F@-&CHZ45-7CWPJC9+.5YJ8#KW>U)A).9FOKZTW+P+S
M,W.($;A:.UJQ[] !//;$$WC^^>?QW.<^AR\]]P5\]KG/\_MS>(Y@]<"Q8P9A
M6DW(&G&!B:R;]HJ?6_W2*)]Y3(AEPPMX2"L)Z;C9.IG'U4[ .E#=0[1?/F"M
MW'0/A<UP!=_J$)R[< $G7WT=XS=OV6MCEJ8-*S"@4O@\79X - SBXMFS^)W?
M^AI^X]_\&WR5^MN_\1OXP]__?7SWC[_EO,9GN=H86L618=GK9<99XS [>KIP
M_.&'\.333^%1 NO6/7NQ8_=N-#>W8->N7=8IT,I&\P3?5#)I$[3TFG]Y><4F
M$G5W=QO\-#0TH+NG!X>.'L&SG_\<#C_R$/H)MY%X#1/+K@3CH/HDKQU63YD&
M,;2<U?M4/Y@!96:FH-VQ5ELFZ3\[7V(YJ6OY9^-##0HKJF>!)Y@KJ8\2GJ*X
M6$@*QS*4]^ ^E8/R6L=U?^LH,K\L#J;<+]THNF7EWO%HS'P::Y:^W4?7ZGA%
M['X\3W].>%(G"(V?=MR!Z56#!\&&*'JW]6'[GAW8?^0(#AT[CB/''\3>_0>Q
MI7\'^K9L17U#$SJZNM&QJ1M[6+\W;]^.D-S,L0,(7]BR44,"M(J7C5-6'*0,
MWWXKN%5Z5><L\7R>"[J*STR!H)[C\YYBN63UJH"?=:XKKKAR_W+7KX8KKGPZ
M1.V*O?H7)%8;-8D:.C;.@DP#56X=2XGSJE'7"*:JLXV=:W6Y$X:U5W:=,^%&
MZ[%;R)6&4BI+JEE:J:54EBH+*\&0"@*B?*N7"(_9M13RB32T;GZ)^XNIE&E!
MX^:R&10)-84$M^F<:9[72XN)%#QK:_#QN(_GAG(,=VD>A85E>/1:GW&*LZ%,
M+2]CX.(EG'KK'9Q]]SU<.'L>U]X[B9/OO(T+9\[BZIES&#AW@=OSN/#V"9Q^
MY55<.7L.8\/#N#XPB,GQ<1LVX(^&T$HHZSFX'[L/'43_[EV$@'ZT[MZ&CEW;
ML&7W3APAJ![<NQ\U<M-5<GQ."NB(*S9<0=FF?8)3YY@:;Z]9<V75=3B ^:T_
MRW?+[GN*G6L%S!,,0'D^PY(U-9G..!.<"&VS4].X=?6:61\-BE7F+'N;[,2?
M/G4D5@B-2N?<[!SWLTQYG5R8S<_-V3A>C;TTZYY28O=SXBT+8I#Y'(C(+ZK6
MK,^P3%/(LOPTPWS'CAV($)RUA.OJVJH-^5"UT9C7E,9?,F\T^:BIJ<DF92E)
M<D OU>I86JU*%ET-(='2K)HLI;(0D!NL*3 !JFW8B:&N@[TVE<S39"I!ENJU
MTP'3/BU&JT4IF!T5K0RK_FAAL,ZSP/"XJ4*;QB-KXED-X5H3]VR)ULHE[Q.[
MOJ(5$61KE2IYJC! 5;B,K%3P77V.'>L\CUD>L%RJ::;(ZJD\T_6EH!^Y4  ]
MK*L_]\M_'K_\U_\F_JN_]?_"7_\[?P?_S?_X/W+?_P/;CCV(S_S\+^#/_I6_
MBC_WU_X:'GSVL_#6-B)%2"T%:RP-]GN@J%;N84M,>Y5[NJ\Z2W%6AR9N-9F-
MY5AY*Y(K^Y$IE)%CG#36N%PNL!-F&.N**Z[<I[A+J%+LA]>5GVZI-D@L*L&/
M&C!9YB1L2DP=WY&"BB(AA T#H6!F^":"X]<05>/7T %OI(;G,0P"C5=.]G/R
M52H_IBO<MXS2VA+*U-+:HGVV[PEG/[@M)YSO4JPN8VET&&,# VAO:T7OEAXL
M+,YA?.@6A@<'"'L#&+IQ';,CHUBC>F=FX=6" XN+6!L:QM3 -<SQW,6Q421'
M1I <YWGCMY ='T9@81J9\9L,:P3+D]-8GIK!PM@X=01KO&=AZ"8P<0,EGI^X
M=A6IX5&D5I:PR/0.#URUM?^C IR"!Z,W1W#AW$4,7!W JZ^^CO/GSN,JH?7*
MV0NX=OXBA@9OX.R)]_#V#U[#F9.G<?7\!9PX<0(+\PN8Y;WC#77HV[/+G-M[
M@Q$C&X%%T4?HT^023=HAY"U.SV!\9!Q;MFU#34.] ;_*2TQE$][TA:*RT[C=
M54+BE0L7"6Q;T=S4; !I_D\-J A8 @7!2?6Z"DB9Q4[A"3H9MGQR)I:7,'KY
M&N8)G7L/[L.#SSQM,Z\OLPRTA&=#8Q."-7%H%2*Y(1+,^B(A\S,K9_F//_ZX
M^?'4S/KJZWFY@9*E<U-?GS.3O=*9404RZ&-=TZQPJW<\(/!-KB4P/CK.?L,B
M@36%+5LW8VEI"=NW;T=[>R?.G3Z/UI:6"K@6D&&')$HX;22PRMAH8XH9![WB
MUV=S+28H8OB:]*6/$S=O8O#R)71V=Z!_QW9T;]E,D VS@R HY2G*&UY;+&NR
M78& Z[.QVAH&HG'2MCB$%@"1H9Y 5_8SATF;>JXL?571EXVJ#>.E\G&65HT2
MOGC/?!873[^'H>M7T=/;B=V'CUD]\?H);TJ4'CB[N+(QJV]%5>9ZSTZ8NW'Z
M+$:O#V+/H7W8LFL[2G+KI EYR@?6-\7/"8];%;R)_1HX'SUE\\FJ8R6"^RSK
MXPK+8_?APXC(#9H_R(Y%#2(U=0C&XH3($CMA[!@P3Z*-S1@9F\#HU#@V[]V'
M6'L7?QH29DT7@//V\ 14[W4O_?[PLR?([WP>"*GFR)_W%/"#Y9H8'L',Y2OL
MF"YBV\XN;'[\,:"F$[:2F\&V*ZZX\G'%!56*"ZJ?%!&X.$V3D%13&;QZ?<[&
M2R!4+! ^BUD$/'H-7T QY<>UL:LHC@RA-E="DH"5FEU!9F(,F<F;2,[>(!A>
MHUY%<O0:TL.#U.O(C P@P^^9L2M4[A\E"#*<Y.@5)"<N(SE&';F*Q-@ LDOC
MF)HBA :S:(S[,#YX$1=/OHD+9][!Z??>Q/4+9[ X,(C%LV=0&KB,V.PX?.,C
MF#CU-BZ]]A(;YS<Q<N$]W#AWDF![&K>NGD#ZQCFT)B:Q</5-O/O*Z[AU]BR&
MSEW Q.4+F+IT$HLWSJ,P=@'QR0N(C%W"_)6+F+AV$S=N7<#D\%6,C=Y"FHUL
MN$CH296P,#Z'Q5F"-QOF)/?G4QED5M;LU7\C&^WZ2 S)Y54L3,Z@L)9"EON7
M%A:QLK)*F/&C;]]^''KP4<)4!P+^,!M;C9MD1X!EX65I: Z)>'5A=@ZC$^,$
MOMV(ULC]CYXME@W_U+@;=%+]!#%/-(HUGC]X_A+V[-Z-EM8VL\3Y"$X@!,E"
MI]?2@C\'G_B_K%N5;UKQR3[I'AKSRT[)&J%Z86("/9M[L6W_/D1DH22493,9
MA!C9*&$NGY9UBX"B:PA'P\-#-HE'/CQK:PFRC)\<NX=X[BP[%IU=76CO['3B
MI9K'< SI5 \)1+;"E45#GWU(KR7A1P"]77UH:*Y%0T,M;MX:)/CV,O\Z<?[,
M51PX= "[]FQG' 0^L!69FML[S"HL *ZDUK;.%\$1[U#(H;BZAJNG3]GRO4\^
M^PQV'SF&6'TCKR5,V5" RH0P7<-R$OS[!/P,099&E9>^>%E@\AA1$H )CEF&
M?EGZF4RS>%.5WY;0.Q0$_1Q!FN"H\9JR8B83N'CF78P,W4#OYD[L?_0S"-8U
M*D<LK^UI516P:J \=+:FK),%WMQ+J"Y,3K'>+N'@0P^@96L?#[&.A30>5.5.
M*8>=0 Q4%:Y^":I;*87Y9Q/K NR\S,YBC7&35XN0EI2M3FBR>J1QOSG'K9O]
MAI1QX^8@5E@7MNW<A7@\#BUW:T,7?++YJU.F>S,^-DZ5:2.T>OSL,'NR_.;D
MN<_+3,PL(W?SNG4FNV-E[-K;A]I]A^"IW\(D"VX545=<<>7CB@NJ%!=4/RFB
MQJW:/*GI9G/![RH]:_NXQZ!!SK7]1922&0Q=?!.=DP-H2,W!FUN"/SD/_^HT
MO"N3\"U/ '.$S,5Q^!<(D L3"*Y,(<CC@95Y!):7J OP2Y=XG53[EQ:Y?Q&>
MN5E$4PDT$XX["#*=LE0MS!)N1Q!>649--H-:PD*HG$4NLX1R,(UH<Q")4!FC
MB1G<7)K ;#&)N4(2BYDUK)56V1RF48<"MM77([.X@!L3\UA97,8BP5&SE(ML
M!+UY0F@I@=I@V:Q;ET>F\>ZU*9PGD,ZN+&&-()K/YK6R.#($IWRQC-X=6['O
M^%&T]W:C>_-F]&SIQ>[]>_'@XX_AP+$C:.UL1U-[*SK[>K%UYW9STM^S=3/V
M'3J(1Q]_'/V[G,D]&@,HH+(G9KW%9;E0%^;F,#X^CFW;=]AD)CM'!7*WR"I'
MP%DB2,CJW$D0K*VK90A$&UFOF(^V( 5!T'C&0J)6PM)K7[WFE:64)&0@HZ&P
M!>;3S,@(X<%KUL7IF6DL+:^8<_UBE@!1*!-*<S9K7NZE%J:G<&-P$*M+*[;L
MK":.+2\M&7!K.S0TA):V5EM"UE9/DF5OPV^% ZI.7NCUNJ ZDTB;^Z7FQF;F
M00BQ1H(J[]':TH;VGBTX^<YI]&W>Q/!\F)H<,ZMM6VO%R3T3L;[ @*"H*KR!
M<ECWUX?)6T/(LL-Q\, !U-7$,3]-0)^>(9@M8&5J%LLS[)@0VE?G%I!88-T9
M'L?<R#AR2VM8F9S%XM@DSYO!^,UA3(Z.6YJTQ*[2H\_5%'[0[Z(F=BGOBR7F
M,S]K#?R3;[V.U.HL=N_9B>U[#C#^ >3RZM#((X-HN'(QY8YP628E I^799)B
MW%.)->PZ>@B1]C:6,>_#?+=A.,H 36)2!JC,#50E=L 1Q9_YEF9Y)Z;G,#(R
MC-6U-6S=MHV@J@4$=._JJ4Y:E=>6Y_RL3D(-Z^VFWE[' X2=XUSD7,N\L?LZ
MOSX"4UE:!;&*C'4"1/SL1&1O#@'C,V@*>-'2W8S@SKTH-_7R.J;'!5577+DO
M\;"AV_"D_^<I'_2#[,I/D:AQ4@/!LI*C;6*'J1H8V3?\;"3D !_4?":%4H2?
MY])X]??^.?9<>1VMZ2DVB $&X\P.UZM1?U"3E0A-U>+G/6Q,'^%2UB99#26J
M'W9[7G=[K7N] @6!(X(L(4A^$^L:6WC<C_FE589)J"F%4"CZD&:8Z3P!-.9'
M/!9"U%>/M4P:<ZM+R+.Q2^0R_)Y!.1Y"O#Z&=G\(6^)UR/*:LR-SR"&*7"G,
M^\EM3PIA?P&-D3):ZVOL%>NUZ21NSN>PX@\C$@YJW4Z H!4GK*[-KB+<U(FG
M?NE/H/_QAY'5Q!R]OB<,^@(^1.KKK'&7?\Z,_$DJH?8\L"$6+/%C.%8#'W=K
M<I:6GI4C?9WA3/*R Z;7KU[!.^^<P'-?> &-! W+*N;OW2)03"82YM;KO;??
M04=[.T&USN"@MK;6(%<+!&A\IBRE$GM&+5Z\E953T5YWE[(YY D*\B5[Y977
M\.)O_3:\$1]"S#]O- )_O ;Y0@EAGAL+Q1EO 2?K"].N5_.3DQ-87%Q$2W.+
M,\N>84OC!,";0[?PV><_CT>?>A*A6,2!T0T *< 1L"E6>J6N5^SS$S.X-7 3
M94):J,9+Z-^";WWSF]BU<P\.''X<__S__%=H:(PR#@5N8[9TZN;-_=AWX!""
M,5D,';!;_TU2W>-':3:=03@8QKO??@G?_MKO$/ [D&:]F2:H:C*17X\'ZYK.
M5>9KZ<_:.M:UV7D;@UL?KS7 %^C':EAO69Z!^C@^\S,OX.@S3[(CY8=?;M:J
MLB&M55'>Y CYJ@,Y$/Y8GS(+"_B__\7_B?IP 5]XX?-HWKJ;ST&$X448A#H<
M#LA5R^^.W]ML$7G"G9_Q&OCNRSCU]EMX_$O/8],#1_GLY&R5L#+SU1[],NNM
M/NC!8W[;5":!H_5F](PZ'1BY2EN>6\$L.Y(JLT?8&8NSGMN0A<J]]3C+DJSQ
MY )ON0!3RFWE-KWNCT9M8J0Z5#:$A>$H#;(.VU ,A<'L4:=*><\4$J.55H:R
MNHR55]_&S:]_!Z7E6?0]M@O-_^5?0G''DSQ>SSS9D/Z?@"B?7''EDR0NJ%)<
M4/T$B/VXJK4BI+(E5L-0Y&>5W&U0S;$AD!_&''*^%/SI("Z\_0VTG'N9T#;#
M5J4 FR/-!MBQTN@:0@\#4>AJX&71TZMGS:(NEPE]%#O7KN$^:V1T@1IQC2,,
MV$I0>3;PP4@-_.$H04RP0_@+A<SA>+E <"+ AMF@>HK$JG(('C9P4F]$J_B4
MG/&#,=X[RN:NR :5$$>R0H8;;ZB)K6#<X892BN&EX"UFR)J,!^.:9CQS 3:L
ML19X"ADLW[J&L7??1'E\% .GKF#)$\:7_]O_"OU//(J"/TCPK#=0SV73UDB;
MA8Q0&-'*/*(XBF8[VZ0R?M9QI5V^,:L_%LIYO4JUG!,X$$8&":HG3KR+SW_Q
M!3035.VYNE>CS/U:MC88C6%E9M96$-+83DU T]C,8)C '8LB6!-CN(0/O0(V
MX*E<+^%YLH"59+4+^S$[-8%7O_:[>.WKW\"VO3O0L7D+NONWHKZCC< C:Z</
MWK(LL'K52ZCS\SZA(,LM*]RQL/3*?VUUS290A8(A?.?;W\9#CSZ"SWSQ>1YG
MYX5E)Q^JU11]$*B^^^8)UD<?DMDEM'<UX\TWW\#SSW\)>_<^B'_QS_X=[ULF
M0(9P\- >G#U[AL"Y"<<>?!BAVICEZQVBGV>6NYSQ:Z)0@/7MI=_[ YQXY0?8
MT;_-_-G.3+(31F ,LXY)E$T!0G?_MGZS#DZ-3>#B^?.(!%C7V-%875PFB$>Q
MN+P(+_/Z*W_AE_'(SW^9SPP[7JR[5:E:=6U/-5HL.X7A92>OQ#JI)7O3BPOX
MZK_\IVB,E0Q4:WIW\!K6R:+7O!N(\VREJDIX=Z0P5W) E1V2[_W;7\>+?_1'
M>.'/_BD\\:4OHLQ.ERVE:L\JG[U"Y7EDB1G\,DP^O8J2P:*&>,CWK-55;\C
ML\ R:^GHM'/M3<"&YD[ F6?\9:GV\;FW81>*HWX79*U7)Y9UP>%@WL2NU6]0
M!55YJLY3VC3.UJ?ZY6,)LA,Z^[W7\,Z__4U,#-[$L2\>QK&_][^@L/4Q/K?L
M7,K\_Q,4%U1=^:2)"ZH4^Q%RY:=;/@:HEC5&53#(1BQ37$.HW(2EW"SJ$V-
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MYQYJ_!SA,06L#?^\I%I+IS6,=PEW$W/M@V*@"38"I70QC$#1B\*YMS'S6_\
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M8/H%&;+HRNI9G5!ED[?XW4"E C$6,8:19UPU&6Q9D+NP0.#((YU((+VZAIQ
M5/D5C56L:46#0%TL:]_N/7OP^).?P:X]N[%[QTX</G (QPBI?9LWXZ$G'L<S
MSSZ+O?OVVK %0;5$X+263&!IA4"=3H)T8^$YRI0)R)@W\@,K6!.,*5U^EI'&
M60;U^M_'\BD0J#)YY C16;EQ8MQT[MSLK,7?P)SJ=%PL2+N%PFJHJT=-30WW
M.9.$S'M!Y23G;">/[RF5\'3<^:AR<EQRC8V.8^#*5:076>_XIQGUVKY/E/]5
MK8KJ*<NKME8S[641U60E6>B=#H^EP]0Y78M2Z#R_K/Q,D]16>U,]XGD&F^I<
M2;11?6(Z[Q =YS_K@%!T#TT*L]7&>*Y=SW"4EU;/*L<CK&OQ6(1Y&+5%%53W
M0GRF(I$8.VDUR/+4;,&+1,Z#)?9Q$CF"M3-(V/+*%5=<N3^YZ\EUQ157/@VB
MQE<3<O)L-37I:7QT%#>N7,'-2Y=MQ:7KYR_AU@5';UZXC-%K@QBZ? VWK@V\
M3V]>O;:NMZ2$TE,G3^&E[WX7W_CZ-_#R]U_&#U[Y ;[_TO?PWHD36"$@2PPN
MU-#;MQ^OF(LD!J^P!=*".,UD%]R&^3D:B1B(F&513NC%)#QF[&(7$<X(.K*<
M9582F!X;-_=$-R]?Q<#9"Q@X?P%#@]>Q2GB5JRU=)%#-%0B/_-7T10A5[:VH
M;VU&IIC'_,PLEGBNCP"HR5_34Y-XX\TW\-IKKYE' ED)-298KJF^PWQ3!R!6
M7V_D(I^R$BU'*E^>&B^KI7.UVI=?PP4(8'G"Y^K\O,%KB>>EYI:P,CV'\1M#
M&!FXCKG):7NE+ZNMX%N@9D*@$W39ZW%-#B)P%10&TR*XU%AD;346LUI>)A]"
M5-:)8/[+(T'52JD5MI*,NPI%G@D\ZJRP#MH8SX^H +* RO(MV%0<-#;;'/JK
M=!A7[:M:3,NZYWHGYTY1&&9EE?(\FXQ'<+5T2>Y*DSHZ#)#U1^-G-3DNC\7%
M)5QC'3]U\B2N7.3SP3IP<V 05R]?P2#UYB"?AQO7;>C$.'7PW%E<NW@!UWCL
M&CMIUU@6Y\Y?P3C+)I$I0(,J5(:>@)I:![Y=<<65^Q-W,A7E@RPWKKCRTRA.
ML^N\SBYY?"!VP(\,?$4/<NQ[%I82R%QZ%4W%%42CK4B':S&=3V)D:@J#;$@O
MV7*8@QB\2B@C= X/#6%B?)R-[PANW+J)H:%;%1URE/L$6_HL-T!7+ETRA_P3
M#&]N;A8)0M3L[*PU\I%8%)NW;$%=79V!1=4RNO$)$SC(^K6RO&)^+C?U]:&Y
MM<6!&EFR>,Z'/9(&'CI!X*(=A)+T*L.Z?!%#-P9M/.GRJI8O;<#<] R2:RE,
MCHQA[-:PC1^5-3%0HQGUA!\/P2B7-ROQ-4*YTJ77X:N$[<L$^U@\CLY-W09F
MMH(4XVU@0^+-4Y<)CUJ^LZ&^ >U=G4CPNNGI:30W-2%,6!X@U S<O(%C#SZ(
M6&T<YT^?85P3J*V)HZVU%2'&0RZ?E"0-T3#+8#7/J (S'90E-,2.AX_773US
M#K_Y;W\-[YTZ:>5RZ^8MS,[,$'C]:-%DM*8&)_\T,YYY<>O\5:9I@B"]C(7%
M!5RY=AE7KUQ"8FX.#83Z+=O[L?70 >:%W\G7RKW7Q:EPCMAQ_F,Y%7-.616S
M&;SUXG<Q,S&.O?NW8]_QA^$)A7E_S0YT(/F."K A; VC*'D(<(3+&^P@O/?N
M.>P_NA_].W;8C'][C6\3$1FWLJ!;%U6"J&PUK,6I4P1CEH\LSO(R,4]X3[)N
M;M^WQX9.J,S,FB[A-8:[BI_?\;<K +W,NGWKU@U<9[U4/9B:G,3(\#!NL-YK
M_//XV*A!ZL3$!"8FI_C\L#/'YV)X9 )#[ S>'!]A9V0)?G88DE/3[ 1DL7M?
M/_H>.X92G/5(D_IX3U=<<>7CBPNJE#M^E%UQY:=<'&ZX!ZB6"_P<0W%E"4NG
MOH/@X@P"P0A:=NS!UH>/H'__?FSMWX7^K3O1OWT[M9^Z#7U;MZ!GTR;T]/:@
MM[>/VFO:1X#4=O-FZI;-V-RWV=;1[^[J(NS%"8*U-H%&P"7?H&WM;0R_'YO[
MMR)26TL(T3"$NZ"'4@55P:#6C^_>U(-67NL-$$8$JTJ;<ZJ!A$,CM]7"(UB8
M[U*&(_^KFM R2B \=_(<:J(13"W,$1AG,')S!*/#H[A "))5+)_/HJ6E&?'Z
M6G(/ 3 <9!Z%L4J '2*0)!(I J,? 7\ <[-S:.OH,*\&?IXG*YV-%Q4XD7)F
M"3(+,[-H:VE!VY9>! F=V:26^<P@ZM<XQ0!6,X1DPOR./3O1RO/65E;1U]+!
M?-IJ$Z$"X= ZN-B*5'>G5?LK*@NA)O-<.GL>I]XY89X /$H[X]79WHY]APZB
M>VN?P:^6V)5KI2'FR<O?^ [>?/TMZZ!<NGH%-]D)F9X>QPI!*L3*U,.X[^"U
MO,BLSE9FBM '"<O(CF<)J_R@B417WWX;LY/#Z-C<B;W''X2_OI%Q"S'/F,=%
MQILT6?92N75@4_#*SUF6MF;7,ZY73YW"U:N7<.#((6QE_0P2[%6^5M\%> 35
M:MU75EDPRB?%AG5*]:H*K,@4S*J]S$[$SMV[K2SDL<%\#4MT?2#@=$#845&<
MTKD,TJFD68-K V%X6!\5S60RA9[N'NPD/&_NW\*.52_K["9T<E_/IEYL8L>L
M>_,6]&WNPZ:M/=C<VX(0877Z\@6LSB6P;7,[^IX\C%+M#N:!%CJ^<[*;*ZZX
M\N'B@BKE[H;4%5=^FJ7:6+\/5 E/>8106%["\JD7$9B?P-@D/T<;T/O0473O
M/X"FCBXT=W2BM:/=P+*5@-/:V8F6MC8T4^4WM(7[I,WMK=0V- E$-<N<VT9]
M;FA B(U\+^'UR+%CV,*&>A.!5ELUX$V\1G$S'Y05\-DH=X.JKFWEO64UY,D&
M'>M7?,"SJ;T&)'JU[9>' P_6YN8P.3:,QQY^&/6-C0A'H@3Q'=AWX!#:N[J9
MOE:+LRR?P4C87O5J?*%@K[:^#ET$YIU[]V#[SIUH9YXL,+PZ[N_@^7(,K]?I
MBK>-Z22 Z;C ,Y?-8N+6"(:N7C,KWI4+%\V22^(U^%XA!._:LP=-C4V8Y_YZ
MQJN>>>B :IAI<%Z[?]3OD"T,P/L.W;QI3OJ_^/,_BT>??@H[V-G83HA2V6E%
MKIPM"UH@P <0U!"#(/-AYQ[LWGN 0+Z&>%T<#?5Q!)C^*"O3YNU;L67_7L;#
M&8-\KS);%^UF'FA3*A#R>)Y\MUXDJ$Y/#:-]4SL.''T ?G9D9%%5?+W*MTIP
M=CG_U]9V:6X7J5^VV:61<217%G'\L4?1Q3KA9?SE[DD7VY\M#J#:K[RRW95
M*,R_JEB]R!4Q/3EI5OL=NW<YH*IX5T!5^6U;UE$-[9"/VGAM#3M=+3AZY"CV
M$&[W'E#';BO:F:^;>C=9/>UB_6EIY;/2PF>DC<^07)CQ>6IO[T!;9P?K5AO:
MFNK@G5] ^M8@ZK-+V+&K%:V/'$"A=I>-%9<S.5=<<>7C"Y]H5UQQY=,F I0
M&^?1T26</'L14[,+-CFHF,\A5\ZC2)"1A=#&\G&?W/F8/U5^E@H^Y')*6N+^
MZLSJ4C9C@"=_IEMV;$?+MGZTL('N98/>I^^$5 9JCM0U/E!R&R$<L>_\K_H:
MUBRC%$%-=<RCA-_XW]U7.]?;&$R]@B=W*+ZRN\G"JR$'6O-?%D:Y2O(S#[;L
MV87C3WT&SW[A.1PZ_@!!K<Y<%NFN^;4D4JD$,\R/MKY>M!-$&MH$Y2W.$(&
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M!*K"8ERLL[<.]XZZXHHK/[JXH.J**Y]",3!BH]G8$+89R\W-33^>AK,"']9
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M"A;T!1/C$Q@?'T>L)FKCC.UDN\0)J[H4J7/I[3!U+\L;@IY9$2O'(Y$(0J&
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M+#)O%#>-TS4O 01" ^]T&D6>-S\UBXOG+F-R; K7KUVW!1$:(CY$O'GLV7\
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MZZ8NM&[K0W-?#QJ[VE'?T69NE>3?LTN.W]M;X&^N1YD@K(EHOGP) 4985KL
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MNC KH4#2:&.#\'RSJ%+-]ZE C)\%"P*_C:KXWE/M?(7-P'4>PY2%C(?0V-"
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MQ 555SYILN$)=,455SX1HG:.JHT>8#\;33\;9E_)"S^!1J]:O<4LTHE9U$2
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M85/P[M5J581M/]4K'['ZS.MTKB\49KP*MJ1JB7E0EK63=2?'_)$5V6!6=84
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M]:*&H!J0NQV-D>._=5^@5+V-E']'FY'/K>,2B-])#09H]D>XXO^:!9U:6<7
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M3I91GF>=.+_75L52RZEC,7;\:D)AQ*(UJ(G&4!N-P%?,H9A8000$7/)K?30
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M[6FT$7:3J12GGB59&;<FDVJP^F1K&]IHK1)/8S,:EBTGP^54A:_&Q&(Z5#O
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M:4O9 9F4K S"*V.\G<V'5 FG8-<T&91AU8(?QY=8 NWBK?:LH&P+I8JH>+.
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M54NKV]*@JJ6UE4BJ0 %2[S.?)J(R<+_ES<N8JO)U*6D2\'GDC9WJ*.L0*_<
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MN(9E2"M'F@EH:6EU1QI4M;2V-"GH]"I,P<"LZ\*Q+$3<,$(Y"Y8=@HTHEMC
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MYGE7'0R#-M?RSX=R&?M4'I+$NYKCN4RVMB'3W*S6A>(Q+K<B%(NBJE<O1.0
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M)HA7(<FTY*2AM!%!944=JJOJ66817D<NFAV2>23!3:4DPU*X(3[,E->ALFX
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MI"R+A)W\.9@%IRV *D/:D"I (TKF0TQ/A#LP483C/"$T+R,1,)%FR&(8.8;
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M8<Z<N3CEI*_CKW_[,PX\<)3R!C_YU&/XOQ_]#*>=?AKA=A%^\/T?X,,//\2
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MX>:&_?"SY_Z&"W>*%-Q3]3CAKJ?QQV-ZH_WM&W'H:;=C$2'S@H<>P\]'5?5
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MN.BBBW#QQ9>@MJX7#AE].$X\Z21\XQO?P%Y[[XN]]MI7@>>))YV,FMIZ0NU
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M187K@O7K6R<2L!2O:"'<RC:9B@K#!Q8H&/!?3*"T<)O6EU';89_]O%:C:)Z
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M\Q(F.$[Q>(NK$'@+ 3.(8WU 7)B6SL<MW-8=23HD+FE"T)V\:&W):L#[X][
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M7XE'?GPIOG/!Z3CHX+OQ/L/-FS(3J*A"E;48$Y^;A"6:5+6TM#I)@^IFKF+
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_81.jpg
<TEXT>
begin 644 image_81.jpg
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M5D.NVK[F 7L NJS/?&FRP03E2\$Q8S2+#.!#CW/6B9SD4RC]15/0B1S(\OG
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M0\$0-\3#V#.3LK[T8]GI;I0XCA&@"UY<Z$#6":,3C%09]8M^$B'J.PP!2 \
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M=L)3?"GG@#N<R0 O!W*FF8:!,*?1WH/K/>13(3:#Z]%*J6&Q:TC:9P9]Z><
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M?)O_!<,38/"91Z'\V_LCRLVJ0V^[\)GL=?>TE0;"WN(CIHS3)!MAI4T:+12
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M>EJ:H5(1VVK/+S$G39:BQ_I,!TV6#-0S'*+V+K$OPN?9UPHDAS'H<W:GYR3
M8I_PR=@P8,$_\45^^KX@4*'?")52/-29O-%N2NM0,H:VF48?]A3(HL@;<S[#
MNA6(H+@GY>11*/#E(Q=DVC227>?=^ 1T,O7I> .1(6653J6C2$<;#0]1\$8(
M0G-@=X;,:D^5=Y6]WTHY G%:?@HT#@AQ)3>@ZL+^;#%?SHZO@[@BCM&_K<:X
M@'YCF[I%&A(Q1_2I+.RF=TWR]X!@R:(0&0K> XNO?,'/%P"D6Q[K!Y>S9\EW
MCB$@.HLB'91@GQ&R3&Y>QRXE5 J0,"71>30>*1EY+K+,RS^UZ9?'4TYRZU!/
MUS-^XF_;@P8!10N8!J/-&8BIGP!\(Y\ Z#L3Y 5,TO2GSO!A88*=DI.[,UYB
M# A)RE%T'"KI"0S#])%FI!H'9&15KLAQ_G=SU_@"]QJ5*<)V>/U;".@5^@L"
M-%8_\#$-GI!M)%+B:)QXK4>T65Y@__B#3!U=S],@_2=^AE-0H27T=."DL"*P
M[OPXE3]#P#L1.PJHNCN-':H?'=+V1"@_! 1]QR^POBQW>RO97X$+W 2#X'!T
MV X.#S(7_)V/D)$G75X6V L*69!5^QJLD#)D*(@F+@08[;SY5.9VS%Y2Y4PD
MW/GWTPC9%M[\JU.%OJA_R)5_8((?4ASNK/(V8S#)>F5 >=@:=D>_(TU(44X%
M?8*%$R>M;+$-+@JYQNL0?<PH(VQ#9NN82GI OB>$S,.%W:H?$!Z*.OO%BOA&
MQ-@ #S909D"4--HZ4+8]RX!."99)MB88QI?UB6L20@;L[JWB+3T^#B9.MZ<"
ML754.B@GH,,3$0;@(@&B0[T^)8\^,,$7"328;EC/A*A7\B08EZ'R%3ME=0,&
M0>6*SWD1P^H<[>>VMZ<0T(6251<@7>Y\VJZL8P=XJL7CXV_***A'P (H0U9>
M / GT.9R_2(XZ1X9Z%KD8H/[M?"=O4(F1B'[L9(6D<""J1;Z0/D''INH=$C1
M![D6';B"H!>(H?#,'\,J%TW6K /HN? 2FP[H%&K *2 B54;PG$(ZSE66&V^Y
M=)J 3(]CI2W*^.!WFYE<=$I[CE=1'8,08,$@T?Y951!1%,76('ZU%7CE7&9[
MS#RH>\UQ!680EO9.WBYF'*LL%S'&8F-^C$E9UL\'M,>5Q3K0)^*<'^DA0%ZF
M#4M*?@'U A5](/G(*R R^@)Z^0S ^$PG!,WIGTYP1LXZ%WS4PK9,P(3&J&NA
M) 3?.*_V\7BF+T:1?P/O\]) AOM0@NLUA*BL$B'3%Q4*[T#&TIT%X7J93RDC
M(P^52>Q4XCAD+F#HA H#FNC+UJ"@H\I[G/+1X<U6^!,0S!,PB<J4;($_UFF3
M,KVF<*"_XG_Z*CZB//(EM'YW3-IXUX<8< 7Z=(+;*N?;D-D'TQ/N 311K!N0
M."D36\%,XI5&#QD=HKP.J,IQJ!#KG0' BZXC;1*.Q_2VD&<Y\:DU$A!6G80H
M%VV>RT.LJ .=W-B8"&2*J*09D^>=R,=G IS%GTJ846G:\#23/#'","PD'P&>
MX>8?L+U\I@4J'UQ!!S@E,I-B0X=,F95%YD#>4 ;0[6V$CG.9+0C3?QZ(*,CJ
MG(^ZD&'C$JP_[:B^73:ALU[,-^0A&;@R)&);5V7Z#NL:J)!=[3*4BY\C51@L
M9WY3@@IG</]#3DP&G0[(?*J$7*'LCG.OL#J/^(7>2XLH$PYY(C0'>?X-'U\%
MVD4#J/X0<V26*O+8L8RPAC?\VZJ.;AA"&TGT,:?4/!"R50<_62S;H0F6#N")
M!")"CUT(2@G[)GDHK7_XJ/.I"TU#,%EWP<&VS,>_H]5:D-#MGRP+OY="GI(3
M'8OAHBFA!M*A%SFL'_[Y;_WC*!+,?>&+7^\N !2DZ YB$Q3EG4%>R$:CVE&>
MP(%!1_4 #RS<J!CJL2S)J4T6T!531D;L99_S'8% 29?I4QN+/LCQ*JO%"39%
M8Y/.!C1GT4<=BU_)#J(^)4/IR!H*I^H;W86BR0Y[$L*^*NGT1LYET?$D2'%?
MGGF*E*8N0_L"*(U.V>.B8])YIL'=LZ,KZ.U!QL'HP!< 2/=VBDI)!AG]C[+1
MB"M9?3D GCX"D>U!%96#1P<F!Y<K1UP!8" P(<#&.PCJI2,$9-'N7J2+UFUM
MV4P\M< -@)8PYH4;F1Z&HBFY +6PQX;E\G?UJ6@3)R=\$J6R1[)Z=-A)??R"
M/3;HR%*)AW3*=&X@:Q("W[?Y@)8)5GT>G;P@\4"!13[=FO&E4MO.I%^;?\O@
MJ[BT Z"1*VH21OA"@])6FV ^AVBK::LG?"*^&,<GZ?XV4#*1Q7^L(U@UL] H
MD]W4D^24K>'MH"LY]L$0R+I.$8S*N.-Q.$DS# 'EK^"K//TGID5Z5]CL>4)U
MFN3)=-6G@^A+==(RQFGBJAN,D[("7[@ XT H<.'HL!OC4=YOFNDW26MY1,Q1
MT4_ NF>IG_BI'-%5Z/J':)$3?5\<$I.GAY"/4H?!O,X\F#S,+?4W=D"WJ!BT
M!2%*0U\%SQ'0XLC4.0W%/TQW.+X4<9"((8W!ID>;5-YS"8'VLXSP8<T+]IWJ
M$',5]8\V#/:P&WP]/>&+6Z4/@QR8Z_JGKB(P1\$3\R9@/+%#C 6DEQ[\8VUF
M2".2HOC*[Z6G(.SL(;A. G05 A$1ND\':#,Y 0,94X!=IY7ADTZ_\@37J>A/
M%W>BGB4;K_1%F7 4?N[[=;0]_3CR'5,/J'<_'Y:'GJI/C*&>UWDIB?*@\WET
MBK^/ Z#K91IC/-#KF82J,Z2DXS,)R!Q"QY/@\A*C-'.$?6*=X3..GC]RC/LE
M8J8-?$'@F&<(PW30V,;4CTR?NW)\A!&4NWA"UL<%\RCXH[BO*_GH9Y[/C>]M
M4?$)OPT1GO%$&Y\!D)$>SN+T.^CXJ\XJ"H@4-O$=%'1P4C*$ =Y8J4@SL]#0
M#.AL$W&)[N7(+(Y]'17)U9T_[^57_%:^BK->!!LA,)^%8Y=PIH^V&J[A/@J*
MAC]/L S$#.LL'/*FY71UF0+3A4GD.)CVWO29",6BH]^HK[F@MY_8=F0?]=S-
M^Y?$AI_K?%JTT WI 4P0QKY1@?!!R\G0/,E' 70%75D&"Q) 0][M )^ M^T7
M!"WGZ:#OYKL,0."0$['K(_GS=0% <)KKJF]QK.+.SQE*A\$HSF&1C5%BM#(3
MO4L0G*ZO4,31 P.J+<?Y]+&HW!Y V>!U-70EVSS!5_*'69<F3<DW5?K0MEBF
M;%$E9F;CAEMW <#C$1EP]?+=!@*OE427)8)>SQ 0 WYX 6#F?_]_^+]H?A2K
M!X(J)Z&C\6$N2GHE$>$.2.-_A*%Q_\BKKVEG5(A!2N]+L^!GP1YE@0LC92S'
MZDCD^*HL%G]TF/@_90I@K<4.LOTW"*:-QR#H!<1,EDM+2[* E\AE?<R#HV+"
MHN'G-)%VO*6%B$/VZFH :;9_8E$7-O!W3 9[5QGQV3)TD;5<(/(,IJBW0!%C
MBESA(@X>^X1 9$R J\$@]^#N;>D"1,B13:8MD'TISGJ020NY^2U3@4A,T#@M
M*GRWO;W5MG>VC>,*58'E*%!U%J+=7XA80"J+E._"96L'#KY!@*\F9-="7_[&
MT4EPKJLL%KM2QH4\DW3Y>?['V@;$B;WXH(DC4#8X@MD!_M(-3=\OD$';94NH
MPK[K3+(3$C8 <6%+LK(/609)VD2?Z45-@ E,:HF.\:_ZN.2Y+N I*I6%D%YT
MLX%CDX0.[,+^A87%L!';W/^B/]F2:"B+<;'+&7?43PAL*%V&I(<XXPK5CB%M
M$OP/1H Z8(WUDE7T)>,T %MMPQB$CDM#^,1><84F>;VHX9-U[""SR.)3=@_U
M3_*5\>2A)9V^,4YQ\E&32 DJ863P=7W&1P%X/D)DSQ)$*6RN6_9=,"$?^@BU
MX<0/'MLIG[H$B,?IT$$R<NI3%,,35)+1_\UG]'N $UZE0K8M51(TLDM3 +9V
M2@Q>>! 791H![WR>Y.KEG#8R(>J9>DT_.5XZW681%>W-N!3>?G!?RWK*!M.3
M&>@PH-=QI:.<I&T2% <:;9/MQD<J)YH5WE33_4A!>4L5#K]R_N"I&H]IE<5Y
M-.KF!0!TEAVRH)^;GV]S$A9T81.QSVL#"*U!P=\!85-:Z9;A8@)@N3I'0V\J
M):"M^A+S=X#.9ET*S)L?O@Z"(B.:Y,#](A)!^642LIY6!D1,WD_^*?9YUUA@
M4@9VQS0K.A?UE$/ ]Z?IM]ZI.2ELF933\Z*1TEY68)R(R'U>(7G\5 !U< =4
M+#P4Y.(\$3Z(>@K;Z>HOU$0E@P\\$':6;%+%%Q Y"I+.1^$M7SE]AS[I3E<%
M*@J+\J,^Y1&5=-8/>]J/=99&OA<[@& TFVBZS9RQ"9DI.8#UP*-V8AUAF\ )
MRK;3]07D*S$$C(:4-P!L"54<\&7Z5_6%TO5*._T7F6S*:LS"HB"L<1:CS8']
M:GQ =UZU;L443YIQ J)FE99L>,T#-L^!3H:=/ANB0X+K_-6O02;!=3ZUJ'R)
M;K4W8]#9V+##0['[@0#]KJOPM<%%K&G3WV82GC*&ANEE*WT?"F( [_E_Y2$2
M;<C ^^3Y4J_0;QLISU!0;=O[^B04?4=K@0J*?4<5F3&9&"B/6A5]I$/WL%T#
M(I\9@#0RC!P6!*[Z3?A4Y44BQ;R[I&1A-A1.NX^)AW6U$ORCS$B^\Z9<-@W5
M!$\<NQL'^E(GVP2Y8I)A8\;ZSDD/78"U^+S6_CYW46^(T@_L[2S3.0N)H@3E
M1"L>"5I8F&]KJRM)[Y&5_2;F@MA84T1)^!B_=/)%@[_*SAY/_S0F]$4G-H25
ME$1I\!*SOHEZ!X6.RM2-$,;3\ ( ,-K?<]E8_</3?(+ITRYT^)1"$ V\U9U4
MS)+.=/0CYI+QP;Y*A%1;SLTMR,\+8HJQYSYAF<@I6Z+/U8WN&:\GH@V\QG!9
M[[,A_-'O_S\S)3G_Q__JOS[VF]U'*+!KU(E&OMM2$QS"'/LH,\$+1^R-C!8A
M<9<BE'4;+OBR@T1!&#8$&ZG9N;]S0F6C@G/:^"L5-)1E@W8G4>F("P X*CN@
MO.X-J<K7UM;<L0_D7/YC7@S!KQ RH84W+@)TNA ONTVGT'>DJ%.%FLP,1:.(
MI-$ZV*;(*9*'.ED!'EBI,W3+<M% !J[BZ0%0$Z3M<#OT;14J."A,Z(M.B1AD
MX7&XS!\U[3HFN;"E^;?_V]O;;7]?G13>G   Q]"+CL6H]2O8&F@M(^K/R8JV
M*J",.^(%58^2 90>($[*@6>."+J*(T"_,+O0Y4->\F%+)Z[L@"=DL&@C[@&?
M8S-,KI$@!)@J;:@39/%"[T&I&,^62&),J;8*^650$G4[98!VB \@21U]Q:63
MEV4A=Z1QV__309;)Q]'/F4RB!O*$XR!12E]WJ>S0GAC3EGBW1N@+[M!;\BON
M83+O&J3C'2GT\@(B/\F'W(Y.1;4 *S\P)K 7G,\9DR)-XTTA(0N'MM8%#@#:
MH;Z>Q]*-"U9AA4ZRCOY>8!L40DK8&A-TM%'(BS#K$RUVA'SJR4@ZZ=\>0G_8
M'G,$6/&E#.>444F7#BNL67-OX'UW8C#^^!D2_,BI1@M=0,1<9HK%GHC2Q!CY
MF4GH['><,N!3D!;+C;I&>:\G@'KU(J.-7 \"I#94D3+A/VB"A7)(:J+NZ*?
M.D43)2:RG((^';+#1CJ=+%?D+'CS01?@A>T 4;;#X+1PG6S+0$)\ /M7?65!
M"P*HHWWJ8G; T!_!%W(-S$.*2@?U1R9='[EB#6I].]L2>"JQ/#(-ODM56D07
M_L W90'R(P\5O>)H;J:-9,^A C&/:7KS(#]:K^K&XY+SBA?'HS8_COX!S8':
M=5_G^A'R4F9H(>AH!/U!/+)M4;S(@1(]X]0)_:+P2PISR0-N5+9!*R?-I0V4
M[VO16_;:'Z$RZUP0;38OW4M<E)%^M(_ICXX9+P)WP-!*8/A1QSGUO7GQH9?-
M:DB+MK</18>-^]B88Q;[Y\6WH 4D_&Y3<8U4C(]=9_'ZY8>P8*_2;!RL77GF
M5/3-*5Z0[F4U.M,^=L./KD.=HL?0TDZ(T<$\THF]V#"/'*51X_:2S_;FL2%4
M#<$R%"B"9T[VHQLYL5&G=!*B#\RJ#\RWXX5^S1 @VP8LB,"V!=5E03[%WK'.
M?]3';9A];&DDW:*VW[*^^&LD!'T,+0OT(]'CI[%TT#^PXU T(_'&Y@R-83OU
M65 >W?/*TW;HQ(\'LIUZ8)/;6FT[Q\"X!UAJ\H_$3Q^D78J%<[1UJGR>/BN]
M^-)]2*%T'\C1;D=LP.;DY^(:LX/['OY(FP%\<: U\4AC#OG+PKN=5,;?!6(<
M/6*DM<6. GY YZS;,(2X_U"FF'60YRX*.$@F<F<9J\H3:/\9T;!^P<Z1]+L?
MBJZ;:P35U*@AS>W!9=',83_U1H]"@<=/VG0OR&%IH#_ P_F8N("YI>R("P#H
MH._1DYF^>IWH*Y5#W:0'(OLRZJYH4!0@P[PYSFS0! _CT3%K5/D)VYAC1AIW
MN_/SG@?H'XRM!<8#;2,:^$;JB_OBV5,GIU\<*;9M4@3=TFBL^8]^RMP0?87W
MZ/B&G.G5MAKC.QJ+]+%E\3&GHJOZ7[>G ZBT K;R!"SO9^-B GDL8I[S137J
M)K^'GY2F#O"15$P[T>\/17>H]('Z5\S/*L^ZKFA<+QW2EX5(F/1?^9USJ62J
ML&L' 1>@N&GLC;EHJEUKW38^B#(ND'O&ZUE-2P@W42_Z@8+K'S3H=#6-!Z&5
ME/31?FSZV<C'118"K16,'&?=[P*B;Z9MT*M-O<:WG?@/?P=O ?D__+W_)G/*
M_Y_^S_^W8S9NXT,$BUC?L2\ <-<\!NS0.<JX@BRV?*5.>>XX0BOI28)C"<EG
MHW$TY>&0LLM&JI=BM)6G&>2YTJN4@I 6)5H*'<(9KB!.<X@.0@S7^OJZ'*-.
MOK_7#MB\INP.T,U'CB[]<74LBLONG@D[;(CK,+P @)Q,1J,F0(X\UUEY_&9\
MTJ"U-EC0N0ZIPXOS-"8&4S))DS<^[FQTQ(A=GO1!JY"*Z(SPQ6,DD&$Q\T[<
M13+6-+W^J.YQV]W;:SL[.WZLW+Y59P/HF.ZT_D:[.L@V622*J)=+18/&^ 10
M%A=Y&#C01)\)_82@207&5%GYCZP'7?)"/Y]/FL3B&?JJOT Q-"DE<!DS^4'O
M'/1*P!4V )146@")=4:ZP/0*H2=L2#,BW74:/)B,'3\G[DQ646=7+S< .2&K
M)IOP YC0"0Y@+-73,C(@ A#% 7(JY/@-Y6@TJ.OU.GLP6<H'(M7G.Y#<N/1
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M,2!71#C %P!PC""<%?RN.!Z3O;'QDL,4^]'"5 2^%J0%&!:;O)1EVNP8=0'
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MN7-M41O&QD\DW _"?OHS>K%C59OB->DBO:@T?8$V= =E'K#_,TRUA4=GRNQ
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MV+ H[3W70[4'FP(V;-0;O],&Z[2_PY/1%O+IRH7STE]<7 #B+R"UD;A[UWV
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MP#KY"0(X\?ON>)(B@_<\'+W^9KOV1W_<KOR;?]OVO_]B6^5.O_R^NKC<O8/
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M).AK%/4/?.$$QFD9(U\-T29V3-*'Q"5>:ORR!]3VV"Y!NZ0I0F%%'WKH.3T
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M[Y>\*I!7O5Z$1K=IKR[EP%4,C1;Y<Y>XDC6N#;&O-5X/.MP]&#RW^,0Y+[L
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M%@@B/+G@H!X,_M=!"I3,L\)/&M'E@704*/D!9EZ77FEJ.)6*D#$P9P= X(*
MH9B<5SJVO-=2F5P=J ?X*X@V\/ ^*@<M^#U]>1MS14\*'-FE,B-P"!_X^!9K
M\L/((H6@7JD!XH,JM-'8%&@<KSR09^#/:O^!% 5;_9L!UR9B6I[&)58Y?Q%
MN./H64@E@&P/#Q^(PPHQNP#(RSS@Q]7UD#C!FU^@?VWW%;K"4?8^D'_NDJK6
MHWF$(P^ ._+TPZ5 N*'FQ?]^=+Q-;2N/?E)#?DX$XCC2:]#.7R"<<ML/UR,H
M&'M^/,CQ= ZO/!)'KN7-K159>PS?B65 R^-J#->;''CZ-)"25$-#I_6]_U%U
M_#OJX/?5#J =F4B[P=%N;MRX5A;G-3!0.@P'9CZ/>5=-SQQF0I6/C6>;DW<(
M*!>7IY4!!QUD7\&\4)RXZ@GHO@O3SVEJ.,]?"%T9C2#I\,N?P5>"C:;APK=%
M2EI"B./\:QNV<PRXH.A.7M->!,4U];4,_)I^:L__KM#G5VBH +T.",^@X")T
M/KKIY*M")R,5C],3SU?:G.C7;0-NDU]-.T!E:+3DWO_KC_C2.0GJ(/$O( &Z
M>"EW8B2_8!/@;YYSC5=6(KK$'3B-(K5X RS!R3_38@+QX!E_Q=1-O95O^]7G
M%E!A$))TY_HT_6L&2XLU2"X?12 XN25&HV&00N R-T?\W ]2UA_EU:^?EA@M
MMOM")6!+(F<(>+)X9\?]![3#*V]O'ZYG&^@9/W8U$-YD&\_TN\$?*H!<_5_Q
ME85U60/3-G@4*,Z%9V?: ]>1H)LD;<%XGTO[.K2T'>CQ''8'A_I$'92$>.T>
M<)R^#_JBW@+]N ;1^YI?'\XA[V,Z1V'R;'&Y0JB)JW3;OY5!5[G6QB^6'W]O
MU36"R I+),'G*!V0M.'Y(K =PJ_FX_P;HH9/5]_6?\&KV^JZ:!>RLK_]$M"5
M19>6!J#?_B(8V+#@K_75$B.7^H,6RHE\$1ZN)%7G3+"N)-'M11T0 )DN+1]#
MVA0>%46%//3I WS7/8:7+:MS6,4+:+I8OPU:3.+X5=RZX..^OMJ%Z?\5ID%
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M+%:PW24O9*DE<HX0<0$)=?3+(%Q)VF15G^M=]71XNT)3JCERTQ\@IE3)M_'
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M:^7MM]]6_[10?O[SGWMG#D:X6H'+Z\&E %UM?:.?]8SY1R\F&5)$I!?YTT5
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MH<%/,9D]G)N;+[=NWA+],^61!B_(%+0[O=!F5<69&&^]27Y^J,0DZP3)P=<
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M 0;W;*?V.2#P0<C B?S1UM$7R.&X] *#*WA^10,Q\J;^O&(BOI(O;95\.2>
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M;_WYDW*JC@9.P!=H9#<.,L$A4!@4S)ZS>DB],P!8N;+HMD%9F=##$$1)\7J
M9V4E)[1WWJ?"L./@*CH##!K:"88DA4*>4*:L+G!B..5R1Z[R,_& 48%!!1^@
MB_?XX#F39[R7SRPO;<T#%+7[,76:?A?;2EQU*5XC[]1/UV;:17X&&.\J37T!
MR+$2N [X!-7*"BOBA^Y\>!>X*4T,TC9H1>[;C#-;S?B\4PYEP4"B[<2AP-&!
M&"<8KRAIYUEI4*YZ&I(!LZ+RK]COA0R M@.@E0,:D2O:'H8) WTVX,U(GA86
MEI7WE-"P,V).!F.V<!(?_MO00;Z,J_)!@%Y@Q8D3YLF7@5WR#< A^,V5]W 7
M-5"=F9WW03T[3+I8KV?G$_*$7 VI;EZI\U]]^'DYDEQA'$DLG;?;<G5L36?"
MC]U'&(ELZ;4LZLK$RXNUM;*A*VY5 X"UY]D.R*X,7I'8WMUSY\>$*[J6"01H
M%4%V_IEPR=WX5)D7;R=E[.Q)OMDN3GW#(^J/&C NI=G2@./YDX<:5/!Z2GJ]
M6@4&ZIQ7.N IJUNLZJ#/:4TJJ61^MERY=D/Z[88/.EQ27)Z99&8"8$D\O';S
MAMO6O7MOEFD9#Y1E8VO+?0ZS__"$#EDY6_ZG)V<\6<LJ,+OIV ;=5@)22SCH
MI$>43I9>8O"/?L+(YU46MH>S+9SZ12;@EP]!J_J>CIWW:=D5Q/9D!C@,\.%!
MVZU'GPN/9]E5)R,78XQ/EK'RCSY87ES2(&G9NI^!9-/[M-$9T4Z;94**<FY(
MUMC2':,*?<)$UJAT"I.%[)PY$R\GU*]<*S=O7BM7KRRIC^"<&K9.\CJ [ 0]
MYV#!#)"09<I,_X$.H#W39JG 2'Y^V!WH(/HZ>,&!4>[OE6>,J^@0!A,8/Y29
M/A]_>&R\*EOBZ4I54 $"5XD@\LX#=8@T,GDXYH'4I/0BDY_82>Y'%4Y"<!F?
MB.6J),9+ZE&5BPD9MF$?F-XZ,2?^IET3T1ZY%_ 8.M&Q3-;QVDG;"8#]HDC$
M%P[B0@9E(HR#NIC<D)?U&[)''\% E[Y,II_3F$9G29^*_*D=D*]\&-0QR<]@
MDXD#$F T>Q59;5&-4SS /A1OG6*@'VBWU,?JLV>2);:WJ\Z5=DIRAJ[E]2!L
MOTR\YNL<R  ';)DGQJ>RXU0F^IMKLC/0LVL:F++*1YT3#?+1A2@J=!D#:?0*
M;<.Z4^5&EJT+K8-UE9ZC/;2%%5X[8'>6..DVC%F&<8U]B_XC$]>#^P[.$IDS
MO?0/Y$4^# C8V4![(@YM;F-SP]N/>5T67<J9-[15V\KB 48\DQ17KUS30&PD
M:75ETA#;D#Z4B0#DSW2+?NH9FP=]B]V(?-K^@$B5DWYJ1S8-DZ7Y&@,[@.J
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M?5T$G![TBS[:\XCD QQ,9-">;0,K%?7B)N+ZDFX3;SP!"&\DZTR.L&"''F7
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M9U4.[YN\^?:;4J3WRI__^9^5U=4UA4;Q8NRAJ/A&Y&_\QJ^5;W_KZQH4WM;
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M:09=O+O!N\SYO CO^C+PEBK70(=!VMX!6[[VRJ,GS\OC)QH(;++EG&_Y,D'
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M-CDV^BGU(#SBR]$Q.W;1Y>*#R@ -](6\4NNO1ZFL+!#X#(2QX?+W__X_,J^
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MR3?BHZ\H;VV#XBU\P*"QD[^UA<K6G*32=(DD&[_@-LW)TOQ$YAL- #+L+QU
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M#FG]_S'VGTV6)4F:)F;!G',/DI&<5Q;OJNJJGB8S.[W [.P"B\57R$)6!"L
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M$8[@B& JXC@JG4_/T-@?XO-9E3"O;8%.[]3/1[B2H%84'.'=<^(^JEH^[1)
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MO?#UTM0!:R?^I)#RUK#$(S,G-+0!Y$L',V+@\ZZ,'(=]!$]$$5-G#CH"(#2
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M?9P0<.#0E1#6EX?RSKJ+^V3@<BZ7+;F,*15'8U2A"2(($&?^#NE0W9.L$J!
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MRZA$YG[J*KS*/\*]]H:*CV D*#YMLI>VHDW<A ;01#P&SC:X5 +I;,X5DWL
MJIBF?A4F>FA%!A-O_J$UKNYE >NUUR]%4ZUTN8[[DHB5D6+S3#SS[JZ4#;U/
M Z8"2N4?@0-?J#15!\=]OTI/4B7^2&<^NO'DU=E6\RV!1YB^ORL^ZOF9#[BZ
M N#H8#]&HLY.3_K0K\>8=H;LRMPB=>O(M#-0#E@Y^*, =@]P/V'8MFTXO# 9
MY$%ZZ=VWN+BDH%MIEZXL@H,# >1!W-0Y]&L(N^HXBK:Z6F85)I[2RS:&\L]+
M[JMSJ+VF"M@N[*7O^!$^JQ0]X\PR-)GU=D .(I:BF+KJT7TOB CQ'B[^ N(5
MV*E:>>TN-P5SZF?+(TRI7;@)*^T07TI 1?*_>8^.3/IF$-'ZB:MKL@.&"I?;
MGU0PG(TY/O;SF<@_% %71MG)/*&3B:?#][NN(_V D5;2"R)OZL3!K.IS6G:6
M_;E'3!JN@P856F6;IJC0))PX[_'&RRVQ@"EE\UD<?!D2HXWPADS\6L>U:]?:
M&V^^T;[ZM:_EWD[J%[_\9?O)/_VD??KI9Z0!"#376 I&/=N@7/^ZGW7B:T)<
M$)JZCFEW1:.B%<J*_$X^AJ7=<R\?F6 H]37SI<)AL+*9]N*, 8K YM5K[=IS
MS[7-[>V4+>CA7%)O;&?3_)2K^068,(@DG(C#'G^TGW(SV"99U9+WLL^LMY[$
M1_ZSKU'AT9#7E:&AXBK]R<JRT0YM?_*U:<U77-TG[NQR\ ".9Q?D# KBNCS?
MU1'.ZJ\ZZPY]-&:<B7BPLYL9:O,4KO0TO0:(\2Q@;?^ILIPA=YQ9=O VATX9
M0YKP+LND8RPY8WZ8>XI&.=R6Y:!+EV'(?8TJ94T.+E683]S@5X%R,5^7 'M%
M0)JV!G3<:E#+J*6- XW308!0._4MC^@%I7)O_RJ]503K<VLU*UEMH+S8V&YR
MN)YI@6W:O?WZ3OXBBI?> 9+(==I'C'X\)(2.P .(>(B3=>@^<0FETN;6R\S*
M 5<O\7(U1:[=T1QJZX8RY"'UAW&A\N3@MWW);#\%'IF='8Z\E%OJ=0<H\)E%
MO;H%K\Q)6;(".'EYG[*"CS0H!;WP  2PIS2<I/,RB^>,,TX\_V),P$\U* Y\
MGJ6]L]K5-@N&>5]QD O0R87@81S4 8?=>Q\XY2NG<K;%*HUY%[[\BY?6PZ!1
M-D4^Q15?I(Z0\]FF9][6'^F"*^W$66/;HGU!VJ,&CFTRS"V=Q*O*:#W$\(='
MY;7C4W0YXUM>2N%5?;S.UG$@P#,$CFA3^QA:ZLL:RY8?[&S*8BF=^+,^S3=]
M$MZ]XTXFJ,OJ71&9?D:=*+[N):QZN.^<;#$/#:-0S'P$;AYF)M_""/JL"HUN
MI*\!8/67?*Z1>\LJ#'_E@BWXIA9CF#E Z/700SS5\<R3_XB.M'OU? ?"(3[A
MELM^T?[6>J!.,+1L[R>N%!UZ+G20%M)]ML\>]3[K"T?O@0ILSTQPUE8ZC#[.
M]B-2#NJ=JV<#SV7_QUQW>/_ @> KE]N\2_YW'[15Z)S9>B"?(#_VT;MVD*N'
MI*=2VN;!7GN%=OG*UGJ[<>-:V[SY7+M\]6I[N+W5CK>VVCDR?OG!3KN^O]LV
M*)M'K#Z&?USV?XB=<$2?=+*XU"[1=LUOX_BPS<MKG<RV@PQN=1DC_GD>SE?0
M-3/DPTD Z=$?=0;9Z*?;8Q,0GM9)/YVZEVU8F?D(&I[*/X2%%_$.1ME.M$V<
MY5;N#_M%>N;K<M2=7V3QW !EO_&M1YG==PXR^(GA8]J N8XO<-02_#*,%^:=
M)'9RRWIW0*)F[*O[<$8?/L&N,$]A"R<KA:&CN#FH[M;RE97E#%HO+;LJ!5CA
MN9JL$99\EYG^2PY /(W1[RKUE157Z]!GH0I?OG2.?Y()[8L7Y2,_[XE!WQZ2
M3VO+Q/4@?E>\:]M4FRL=UF?[2.7@:,OI_TDMR3.03MVY?5YZ.F!P?.3*'NU!
M!Y0MI\^GL=WOWKW?_,3NK+MXK("A(982H5$F\Y]E2X"G_QYVX[Z^^:WBJI%9
MWY%]L/.@W?K\\W;G]ITZ$ @DC#>^!VPE/J01Q("A MT/+"/5B*=Q_=ZI2Z9J
M=M<"^SD%B7P)PDK ,>._LC37-M86V];&4KNZM=R>N[[=7GOUY;9(HRJCM1A1
M)5YOQS$T+P5N.A@:CAU"E$%\.@A_G=LUSF0@780'C2E*5V 3R#]A&<=&(XS1
MT=2UXA4>$#=7!9=8=$\#K$$'GRK,#!10.4CHP8/D[>H*\XZ 3Y0: ,C ##2U
M<3CC4@,V,HY&LO0#5H=G>L,R,"#S$%[>^46%(S?@+1.9B<P? ZKG)XPQ2U "
M5"&I*X*->,-9UA'73!0C5<H>CX=<?6<]0$<[49G>$SG+&!\I$HUWI[T#Z/42
M'&BT@DO6PC)ORZ5B8_YV0"4T@@/OS,>XNB,$I0=UZ:S'B#M'P+F.SLK,O2]?
M=(L;&<_ZX!Q."@TJKRJ'R4(78?!</%8S<+-PL_S(NC =>6HHGCBJA\#38)0M
M5=+#4\2W7FQ'49YIC^$!9Q%0/#3^STX=8'.9U,-\FG)_SU'_X@_Y0B]?%!_9
M1:F (:4NN/]/@^8L!X2YZL=VJ9+A ,3@^9J-U!C ]S:5E2M]MLT$?IY38T(V
M"U^ <]5-[YSS[+5H(,WJ5VY"\SC#>YLE@F0W;>H7>H\VY[_@@A)L/135<5[P
M$YKS5SE5^ZWT7LVC,$A<^,G,(D]P%:]\'''RW-^9YQC B0*>C,LE!3BK%&4;
M%(:_@SS'A_L([GWJ86R+4N8ZFBOM:]5(SXWD7\3#U1E/H'7)MEF237#$C>!*
MXU74Y?5^GU_A.[FF_+H9H-V--E;M@_H,S!K@<OGSJZ^^VK[^]:^W-]YX(WW!
M;W_[V_:/__B/[;WWW@M?.7.L(:TEE*6K&F\X\PP_I U-73!X-N@_RXF3DL-V
M)5]HC"D3S4=<4W/<2P-GOJP[VV+2T5^\_=6OM6_^R7?:7_Z+_Z+]]?_Z7[4_
M_\N_:F^\_96VN+P2^#F%EXZXY(_EJ/859"%*4:[JRNN0^\\X(H4GX[[D/1%\
M;UNVH\^W?+-V&:6!MFH[M]]V)L!XSB#7\E?W-MI/742^:OPO9I!;([5P\<L?
M=2"@<8=<$!-7"MD6S,O^GZK.P/0P_DM?J %_O^%OOZ%<&(<V'<0?I2X=9'2F
MK+Y][L2"N'HPJ?J$N@!YG*KL.(A)62+'2OEQ2;U.A6R<CS-X6%?W/O1V'/HY
M&.&LN'VHG]<;>_F+5ZWCS)R"VY3NW5&/O"FCIK<K!Q^B;(4G*^,R3+E/_N0K
MS^!M48,&3B:XS2&KS<@GLHYVDX%%DA)=,2DTWA</2!-G<M*.UM:R8B-IY:W@
M7W@]@[=X\'SBC!$&E%RWL;X"SLKA*O/HQZ1!Y!G/YFMQ3.Y>TQUT#Q7CK-0
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M0K68NHQ^RU!+\KD'7ATN4S.[PP!T\,#!'#%PE,[&XRGD61X*NM9%A(4_\E<
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M:G5J9GF1^<[J9O 0G4]:A->3KN1^\IWQY2A!>+^<=$J[3/L:Y<09!S]X($'
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MWUE?%!+Z4$_XX;SWO77J>],)HP:AW29N&RV^5:YZ5HMRPU5V&LGV)ZE7>&F
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M\AKUH4YBQ"?HINICU<>)M]Y27\QDC')Q'>/# 3;+1L*4:Q;W+[JB9?E13NE
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MA=+W]AWJ):+ATO3$"U6K3!,G3_"L\GV(@B[/U@#"0H]@E+1.FU_Y7M:J!XQ
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M0Z;XTLD)VZQA6?4D/_5Z&W62U2_R!6$9$,#K MY_O<Y2-YW_8^?@;2^VT1H
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MN'_L@LN,YU]_DV3QY7AO?<!WTG<,  2V;RF[7\:QCT][.E-!=KF_*\C RT$
MBNB2Q8<8[&</Z7_.'J-@N*I,&-)9Y;'T W'/0!/A-5-LWTW_ 2S3N.QQ#^_W
MN0.3J\[ZZ-4QB!*:.!N_\V G09Y<K-(FWK.RA1+V.UW18Z2U'&68^;UR!V0J
M3N)QKY^ZZ8/T<B#'?;_S??!!&:<KNLW<S-#>0/L)5RXX>+&QN9'E_%E),N,&
MI,&5'5AXX#[E]5-EYND*$O$VBU*(IWE-RLW%< =[S--5?\[B^]GF4H(=Q#>G
M$@_A-7SQ3<>%>Q5@\W?EBPIN]4'4'W%MS]$/B!>) 2&]^GDLSP+P2P3ZYZY?
M:S>O7V\;:ZM9"2,G"-^LQN#!I P]_PD.NCS[U*EBE!X_+-(C1@;#:Y;/:_@'
M9USO:R"@<K>).C#SQ>7LPY4LJ+2V/R,8TB'F.:MV2J(E=(0+?!BSRH&<^C_G
M<EKZLDG4JN/DHVSJ91C;5T=_0(SD,(R?\B4[I@X8U*>RT/K)X% O^Y APAUT
M^&,'/7J[C$[^U %6]/+",/^G^ K#9X.@ 8FL?9N>Y;#>#9=/#1/?_+AV<($Q
MW*!OZ?+V_=*L>]/Q;+M3USQ[>#;IMS*1B/QW_,8EX_EZ"&':C:G3+J.4:VZ;
MJ]5FE6_I$DXZ=F,0F!/>'X[;U)?EM6S!.^CC\S)M2Z-_#&@%+GQGN\Z \9S[
MUZN]Z$R?54?<.(ONIIIE[I?1YQ>0#Q? XXS,=N<7V^[*:GNXM-P6P>'*SDY;
MI@TOT>_,B2<P#Y!Y]];6V['&H@/3&/T+M+459/D<M+)_.H8?;H/' V ]T3B%
MQ@L:_N[Y1X9=]/PT?[T^+)L:3O3)A."D"65UXM,M/)9FSC(KUXF5R4=\^'CB
MK7?I6;PA,0V3R<W)^E%'TQ"U;HT76PEXHXTJH]V&)M?)VVD3::OR/G"MRZ!F
M/7<YY%4>"D\%7/X-^1*<# &>> Z>Y&V>TU=1%OG"[6MN)90B?A+0;4WI]X7?
M:>%!EPX('QZ=P/?J<-3#Y47@.KM>JU75Y>79V%L=E^"?\HJ/,N@A,!T@N-+6
MW=N_O4F_MI!!XSMW[V2"U>U:H$<ZVL(CSS(XIN\\S/V3QV?4P].VO.19"G[%
MRJVX'J)XT(X.'[2#@QW\ ^"XC;'R/[4]N;+OR67P7B#,/E2.K/. E ?EQO59
MAR[JJ$DMN7%/8S4F"5O$M;)SQ5ET__H_RPU8.VOW$M*I.K).(37JJA%:*R/C
M2@.T_NOP$R9DE:-I7D87A,:^[*-79'CPDH>C/:9P$1+\&[,5) 9?\ E*/G>&
M%5A_-I]^RWT]IUPZ(ENA,K/*G>&0(6'BYNAFEFOQ/L)8!A"'/@+M]H4LL027
M/Q)$.AX5I#'2:,0RU.@(C"O<G(H-4ZZLHAS0 <:!1%6DS#UE>L''J!9/89-_
M&'0V6^+ZG5-+:3[5T4MQTAG1=.1G-^'HL%</C0M=$K]P+-I2/_@A*$RK<!V-
M0WKH3)<.P#KA3V?TT+_C79TV"AP*F , Z11X3L-*G$I85Q/7O;!C7/8X-N*L
M+NGQ==[-/H=>X.-W-5W.Y=<MY/M2:NTHB_;6[:1>._SA)O>%"BX%XD6_ZJ6]
M9<897SAZ\Y=FQA&^2D0IG+T,@U9);WU46EX:@XMTK3HW+.&![;OB<3LNW<C3
M? 8/)DG'S5S+P'>DUW9HF#"(-/%^!]4#\QP5=M: 3A$>M P: ):YX!*7M.2:
MJ[SATC"%W*/S,X3:*45RNT,?6#$_8,60D/; \K.;//$;5QN<,_EUNKBS9J<(
M;.LG?!5?>:=<7H&N$ZX*M8JCWG>A(ZYPI6B4(VU(2A V6?8[KN+)JS$(H(_R
MT-];#CU8I%XM<[[+;INP#GB6)7P?JA#'YY%2&H07K#1QZ"ZPOA 6G/'!A=1B
M[;.0_&\>YB(_%>]*HTA)DR</803N%.Q_Q!5$RUB^DB0'VQQ>?K*=>_B,1H-+
MF*_=N-&^^O5OM.]^_P<8_^]@W)RU7_[FM^VG/_MY^Q##?\RT"DFZAX>D5:#3
M3:$ 23M>DJ$\7+GJ1IT5,G5O4;PK/\4V7CEI_4HIB#[UA*<Y(7LCVY09E">R
MO+=Y0BL[,QC8F8:$R/W[=S]K'WWPN_;)A^^V^W<^;2='>Y&3*@_RF+!M7[9=
MDQ32)"5<)4E>-I[\IY.N52PRK8SC)F7N;HJ':7!)Y,W4F2:&06_?<93!_.;]
MYKZ&)G26OID9MN/TCZN']AV?/$3Y<9^F2_//X\].J6N_ '(.G'Q10.X3=V$X
MZZ#R89__".7$F?\#[I'ATCG9=_X?Y9GAP>)SXSUI>WN[P'K4%MR6 9[*!?L&
MXX2F 6;A<U/IN)>>;O51F5Q<*&.Z5BH(6^K6+WU7$O4\>4Y?@$PY1MF6'SR,
ML(QIXO2L@K?T+,9)6IW\H )Y]^[=E,D3\CT;2=Z>Q3?LFF3AS/% VK-V'T-
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MB'QM'+=J.)NN;' "QWK+0#FPM"E,GSPZ7YBISX5GR22?DYM\@K?.M9NT+\?
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MGRE^PJH^M,I6,K> 3]UL^J3DW^#[A).7, .W@^Z7Q"-20$HAZW"T,<MEWL[
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MV7-U4?5785K/'4C@#WFI2YGB?4A(X.::'WGDR730"/CVDU4'ROH4K-<+)76
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M$AFQ]#KPI.&!HWGTT8>V+W_E2]N7O_BE=')_T+?4,X(^=I%H < 1CED!UR#
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M1W%,RESGK#+(C\O0R7P^.#_WN<]U8FHKL-TS^*MM)K(QN/QFD24Z#0WY)^6
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M(_G]>H5:N:8S@Q=;Q(?.\ A08B=UZC4,K72F?0O\=.TT,N5_P++ [2Z%!95
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MZ3C!J.*C0S(B>WJ4+"YYH_\HX"V.,;1TFW!2^@D.=.[\5;9*)A/-9-*:P7.
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M#!/OZ4!.!&8*L?NVF?#/WNBQ;[C=X;%WW]?^Y)/1CT4:='JOR!F?1@JO)K5
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MU_H. W4*JX7I=.I9=/8"K+.Q?SL$] -@S>+VWKYB_^?/^7YR;#_T3MNFH_#
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M[PX=] ?.F?1][WUP:?LG__1?;-_[P8\S3OXDM#^\/?'8+  HUYT@Z4O7.];
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MK_7'D'28<2K%GHE RMX,[>FG&GWR[$X;^">]6RW?FRG!G[=ZXCUR"<SB3+Z
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M.GXAL@=TX2C\Q)%Y2BW'F#!R$>;8\OFU?9L8*I&TI2\U5M\VD^J!+Y M@73
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M,C*KGTG9Z7-39D]GPT/_WA9-+NBB@I ^&B\=; 81O9ZTZ0O'AS01-3L=Q\/
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MZ/[$*;2FW;"AY-<7AC88R<0['ARK+T(G;/2F;*D*3:A FI3>9> ?[?Y(#OZ
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M,(-[<I+J3O^$/GZ1SHXNG=/K<#8RY8>2/'(AY\##3TE-X0XP""=Q>$2S>N-
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M>*X]H#-7[0LLBJ1-=-PG1P6@4I]>9@$ ;HLA(P=%$-D%&F<E;")^Z.7_]P)
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MR<A^=,$Y.'L@+KVKK.!,!/E\NC#IZ4MI9-<5Z/F W?A,7;3-6+!IC!RGNZ3
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MF:)39=&YPAY8VQ&3YZWC^0T_&%E.AN,X^T&[1F.,B$FM-]_CA/=0S'/SY5I
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MI^&7"5<FKG&&+/:JJ>_V$Y,:2AVM+ Y,6J/@*JWJ._#).3CA6JZU\?G<Y<G
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MG6$\P4VY$*#WU)A.G1UVYW=DS&>;LXISG#BPIG..0N_.0H!?+I?4'/=S(ET
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M*XOJ+OW!0_TRUZO?%1?V(V?P'W[WLN>[;_1TQ]3MP)GHN*-'233>EP;!KS*
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MIZ6Q,_[+1=\\%M,[MOEK^6;O]IX?O4U*92DK5W8V.6I3XL"<R'$>AY'^*)^
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M)R;']316&(&>>H[*C@WI=[U;L)7+VYD$IVK P(>8BGO*[(E0&;Z;2BQ6R>I
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M!U[!D1XY#K[*PG&UB6>17]/2I[5=/4^>L8ANT8E>H['ZD7;:N)@?CS&LOM8
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MPP'LPI(W)9NWSK39UBN;5BW,?5S%-J)G<8/8">M0^JET>3"RKG^1]%GP\@C
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M%Y_FY?CP870H?=N+HYY\^KC]1G^Y^_''?;<$W:4+%C+8$PL9'AVY<\O"XUH
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M&IOWA;EP$9!84'X2^H*Y3,@Y1]JD$TK26 !VS=:!^ZJG&4Y(,U.N#E0\"_W
M!!X>(ZN1B3?>#I#9)=*)0\JTSZ3<=AK*G=U&@*.O$TMX+]YI='"*_@8'8X+^
MZAK/ZDM5TZ;,*80O)N5D,7P?E/0YBW%=B(@=K?S*0SB7O 1P COGR2XNY-D
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MP=W[Q\T[=[KCR @3]@7N\!?D"@)^N6K_:&"C5I'_V# %=KDEL9W\]PU:&;U
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M\JCX/>=Y^=0GS'"L[8/?A?(  ;OX:2,)Y=$*Y6&J*N?F -KT^_*T^"4L&/!
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M\"EPS75YF+E&BWU.V5$V?RWLT*&V0(O=Y2OX"MMBDGANSYC,?'J!%K1\OOV
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M.!(R3QW"Y@LO;K_ZZ[^IQKK"1WJALV_OP?;RRSND:#M\JR27S"U7HYB_@/)
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M.F :6Q[TM:,)P$D<P-'2FJ07C3SI0X\[3D^<_$IOQC(9A"(R!O,QL9WYR$!
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M!9P,N.2R2WP'P,;-FWRLG7DV&P#8; !\[WL_<+Z[7GNU_?C'/VQ//_4$S,7
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MQ&'QPD5_[!"QZZ2.89B]L^,2M]3-E5T;*H27LM4/@#/S1L4IG[K-W@O@;C/
M&1]$\/@A*Z#++>4+0)DP^+8L$ P-?RIG0<4;!QK=&&QUNG;3Z7<9RP0W?NPR
M)+ ]<$,=I+1. _]!&.1AD(4[^M#++[X@4S*CK(:>/HE&)_]FRN# ;J#C8/WK
MT4P04L(.<J8!D47D%UH]$^&[31 D4W4""NG2%F@8"4<VT>*>7L!WDIVK$I51
M+CTORJNP).KQ*7/$5/PFG0';[M@.QRO\0;8=AC0=H$4(^GSD\%'I?FY,)L_$
M0:LS8QCUA'9%*/^M4_PJ?\)Q(\LN3X11\801&-P1?[3CIKYZS3MH:E.T\!K<
MN3"W[*E[TCIU_^'BWX@+FCAS^M"OT!&*-G7&,7KZ)@9UY)>^K^I,>-7'2G?2
MSTWK6G\#_YV;[A_+WGESGFA2-Z!5/MT X;W;_.1QG!*8A&PF%T=Y!TV#-WT.
M>?($ _ZJW,"T+L8<"N0OH0K ==MQV10NWCH5&\8*CPWJ1]$C<X5,0'4^U1>D
MG_3 *QM@DD*XT09^"GI^D.-GF70<A2MGVQ6&5!P*KPKOTA&8@ T\=6$1(3S9
MR,_^I*M%/=1P. D^\G2A2)EX%@20PQT[N,E#J#TPOH"+C R=MA,SD!\FR:=I
M #!-MD?"=6'EOT#I^1%K&U1PL7MX[$"-:>!1/D^6*2=!1!'>T\6=,)YFE)0&
M<'D4:OX26T02A-L4NETFLJV)ZQ ,5'G<IG"E/^I9#,9R,Q  ?M$2;H_* A^^
M"!@->."8#/^P_9^XWN\;EWAB>EK^2.MP_@4GJ;EI.I]>S1P"KA5OAH/CM#U#
M6 UTAVDIKKR5K/M=M@[$V1\F'(8?8YGJ1ZC#B 0?/VZ@TCDPH5/ZALX X:GY
MU.\4C[8]-]F9P'P8$0.53E[_1KH.#8H ?-6$;?#X2H[#'8?=RS8 5$+;.*9=
M(8#PO5&$7L4_UC($1]\,**C:#VT*UTCSS) ZIKZ+@ZF!1G[.,047) ZP#O*0
MK>OBP%67EYW=#''X]#>0,^#IN1'1XW&7#7T^$0<W65#-;@"D]1$++R'N?$T@
M[M%T[HS60RR+RK/S,?$S?F8,90S6O(NP7FZ_@L<&4,]HZ"_@!WS+AK!DB<U3
M95XY1H;,X0J,IQ_<4$3XBOXJ5'B$\]HQ8]7KFD-Q^1SQ+.Y8%_ D.8O W"7&
M"1V.R?/9OXWG;_(=6,=YTBX:/#S@HG7HL,@\=.A@V[=WCS\#N&_?'O7!Y-_Y
ML7C$N.W!BMT]<.U%;Z^;+' 5R;IOT#4D(!!?E,''W^%396/S MYYM1%\X\H@
M7Z^%-._AC@(6TVQ<@,-\ D->/%2@3$L6+^D;^J'A7^4KP!U^Q!&V\\&B?A4G
M6B=5<=NV[VQ[]AZPFX5T7@_0@EI\NVRF, O0BT$.LO6KI^N!Y&W#SYL)HDN=
MRLZZ37VS?K#%'*8^DX[\>)J_?OUZKU58A_+E&*=G[B+>D">+?2_\1<M%PZ@,
M=-UPH6*:EGG4[TS0I0::?:X]\YV@E!UJT#-5N\$IF&X S/O,K_S'P5#23$HG
M'9DX1 &P*7BHI\%1.!-%D87N)SHJO(4#'0G(:87B(Q8J/)^&2&7267")6W95
MAIL[U2!\_$;&%:X?A>"H"=_L9X!$T5 X%D\K5RQKO_C1#[7;;[VYG?/&R;9O
MSRY_I@,FI@6FPC%Y?Y1)^#E>_)]\_41[_,G'VWT/W:O&=Z0M7[&HK5HYOQT_
M=K@=D6(O6KRZ77_C'>TSO_([;<DR/I6U4!/7D^W@_H/MM9V[VJNOOB;>V!D[
MMRWE5D>51^0%R"T[?5%P>(E=E04_0/'9JS7XR*_+P#)%C@(PY_=/2)$.? )M
M"U"ZY-?IXI:!5FW.>"=</W)3B'$+IFE-?^(GSW-XEP<W"FSRJ?M,&N0/=O\O
M'^&FP>2UAT-;-O4*7Y47LK5.T3@Q^N5T YU,+E,3HB=(X%5:&# -I4G^(V3R
M32@Y)O\12->='3(@@*F(LZ1+&CH/F4F<>1%07@S##GG0D(FQ;Y:4=9B88([Y
M!Z!#3DHT)"QYH60#52*&_.>"P[O>3\'RM"/I0XFV=J+MWWM0G=E:ER/OKR-[
MHPV\G"T_H/3F/P2*7NPR0/ATEZARGRE?ZV)WGPVFZ?B467=U R2?N;0&.0FJ
M[XI[[&.P3VK Y\@> S;'_WGG#]T%:"?@8#)52#K3@KYLARB>>F+ V?7::^WQ
M)QYO+[[X@F\1_NA'/N8T[">]\LJV]MS6K<+9:5*GRSMYL)"_\**+VY577ND+
MB=BE?_[Y%]ICCS^B>/&O_[R+Z(T+]6OTT9LV;FKO>>][E7;<I0;8T7[^^>?:
MO??>J_Q:>_>[W]TNN.!"QUF#-8J5/)"9Y28Y(P.^SG+WW7<[?P9)OI]+F7A"
M GF.^!TZ=*0]\>23*N^+WB'GV[B777:9=\PY_D??34[T-7Q*YZZ?_,2;"&KX
M[>)++FE77WV-^N'%@YPM$YD]NW>WK5N?::]L>]GID;?CD)LE8#1/<+:<OZ5=
M?/'%OL QX4QR7F\__>E/?<\-?;J!9"XK_I2;S^=>>MFE[:*++S$",?1?C&GT
MW[2C ]*/1Q][M+V\;9ODPE<.A"2@;UVV?*727M2NN/(J3:(6*;3SIA]CWH]^
M^ ._<I;V6@:(#0^\:TI](SO>(QW4/ P/AO^,@I3IP8?N][T^S@U\H\"_//KC
M%8.5JU:URZ^XO%TB.3-^&&2YOT)XJFKR/RP^[[WW'HV+KQIE]>HU[2VWW>;C
MC?5),H"G)M3)2R^_:!EPN_0UUUSC3V>F?Y'18@N:VU1O?,N9^X;0!;Y2=//-
MMYA.C3O\HW]@XOZC.W_@3Y@B^XH,RRJW_-#@^.:%%UW4OW04G ,']K<''WS0
M7S5:N6)5N_322U6?5PSQM-'7=KW:MC[[K.]$2FGFM1MNO,'?_-ZY8X?G.7P7
M^BVWO<6Q'L^"V+[YS6]FLBBV+E+>EU]YA6_[!OB$+M\/_^E/?V)Y\@41^A,N
M5(;F^O7GM9MON75&+P V[VB33S_#IYB/^C/,EUQ\:;O\\LN$9L:5W6R_CTQ[
MDY9'#A@$5?G29EV? E 8/QW5LZRX H(]>57X-,Y]AN@.JB)'M,[4$J9XS$0M
M3H.19L8A_/[J!SP+3$-QQ8-:DG$#]!4\1,DQ[@7SZG9ZTH[I"Z;\XX)WQHDN
M1JCYAT0RHD]X5UK"IGQ-[0+PS;,S".%IOL!TG*8+/1W@H'/"^"$PS<F<(.-4
MIZ]?C9NV>Z449]/<X6\N/Z&'B6_D'0K)CZ]GL0CCL\'HZQ0B,2!\D;;R1LNH
MP2F4S,BB\@0R#M?\I_?O'<)?>+$ED[#9^7 9$!+,O_3?.7V5H^U^0(E/(DT;
MCCX#<%QU!&W&(,]/-<XQ)Z3\C*<L#CW?=KU 1XMJ]3V+M$Z ,,?]>7*\=,7R
M=N/--YK^P?Z:P+HU*]OJE<LUGSC0'GGD<7^N=\?V5]K/[OY)>W;KT\HXXTG-
M388R8E(DN>5##CT&GFLARV?Y(HO,X]V/]_;%IVV]V%>?31K66LQI&!,WGK>Q
MK5ZUVD_SZ1N(.Z+%+N,Z?2_'XYG[<&(<F4"/>PZ6"'_]VC7J5Y>+!V1(?4;.
MM;8Y,X1[\R^Y+EZVO!T[\7J[_Z%'V_,O;M.:[74OO!D_>166![%\MAMQ5+EQ
MQ)UZ "PGF?D25MI0Y1/@8;@RM'M60T.#V1KJP&L9U#^IR9N3DSQ *UV%+JGY
M3=LU[1?95+T97!_!\P,%,A@ /8(O>CM0$^<Z%$]IWX2$)H:XT@]ARC_F_\4O
M_*_=)1E<<^U;? E@6.D9F7 :&0+BB3X3.93<3Z*]4Q5F4?)ZT@X>[XMXT=H9
MP8B42,NVDS!-C!7&(IA@TGJ2!(H,D%T:F*8@3*194(<G=M?@DZ\ 7';)Q6WS
MQO,:G^,[K(&?;S]2*>$!08<WNV% @)^G<YA]^_>V77M>TX+_B 1\2I.HQ6H
M\S78JD*7+VL;-UVH2=D-JF :1%YK0.%Y%^6P#)-"/HW(SA?R@"\ /FNP.MVH
MTBB?W 7RQ9Z$%;\*[.F0>=_E<EX]?*"5B@]>*MQU8-EV6D!W9BP8\[-3QNF[
MPDSI>1- X7X:IS#E)OJ2I_Y-5"T.\JW&U=T#"Y(9?*5>$FC:E*FG-]_=N"X)
M5%1D+)UP?08O('N2QN$HE !\)S8X59P"80X_:%9H2D*:Z"!U!AG(AAZ0='95
MGAT*AQ(5$#3Z<"<?P&E';]R=7,FDRC&6IY )Z\XY,"U[H9A-9Z=_U(7K0SHB
M.=-Q'SU\U!W^4'^=$?B8^8GVL" 0E"S^JC!R%BB9S?(<G4;O2B?/!"2I5$DY
M"T5[A#/S.BG.:>!=]U[/8WTCA_#%3CFO)[%PYAZ "A_S3GLA#^>N?]:!(4^'
M>I"\_[Y[VI_]V3?:#W_X0_<S'_C !Q5+BYO7GGKJR?:7W_U.^\OO?;<]]N@C
M[=%''SV#>40+IZ?]KAF+&2XDVK%]A^A]OWWE*U]JCSWRL,RC2O]H>^K))]K3
M3SW=7G[Q)>?_CG>]RQ.9:FOPQ7>(__S/_JQ]]2M?UH+CF7;CC3=JH;FERR!E
M '>0C?5*XX'T:?LKK[1_]:_^]W;__?=YT&038/VZ=6[7E(>=>RY&^L$/OM^^
M^Y??;=NW;]=D8:47G#Q!,1\2&ED=57HF1'_RQW_<'M*"[?'''G-_OV'C)G]V
MR/+M/,#Y*\J;Q?-?_,6_;X]I\?V8\!]__'&9)]ICMA]O3SRA\HLF^<(3GV?B
MTB-*=E+CRA_]T1^UG_SD)^WAAQ^*;$7GT<<B=^3_B,QSSSWK#2!.C7DAJ]P9
M&SQ1.G;$&SEW_?C.]JUO?ZO]Y*X?:V+WB&5/>GA@0;SSU1U>N*Y9L]K')>&?
M"=W!0P?;O_R7_Z+=\[.?M4<>?MAUBZ$LYJ';6[=N]<6]3)9X3]$3(N3@.HRI
M_]BOO?9J^[+J\P??_UZG S\I6_'VJ&@_JT7O?M4/$SPN/V+\F0&J7P3!^]*7
MO]1^]*,?FM9K6AA?>.&%ONG:/-A('D<.MV>?V]K^_;__9GM .O'<\\^;WXT;
M-JJ^6>1",GWQ][__EZZ[>^^]SQL6%UQP0;M -$.+4@BZ$SDCIY_=?7?D*]X?
M>US&]?ZH=$6ZKK;STLLO^:L73-C8N$%&;.9_[6M?E:[\L.V5#->M6]\NUMS"
MA5,\FQ8_^]G=[=__Q3?;3W]R5WORR2>=Y\477]+NN_>>]IWO?%>TG_(FS=OO
M>+OBPAL;JNC\__P__T^JNX>LKTS\V6A:K3*3-[>"(_-_]V__K73L05\<QH;"
MG9+C0TJS[>67VU577-F6:8'/.!G@\V,'U):_W/Y2;08=YDD3\CGOO V*Y6?N
M^W_TH(O- B,\/!; 2Z7 "HV1$M&4BU1.B1][ H[W6*D8X^97T*D/M@'<&<!/
MJK1AVH#IJ@]0;^&8DF\Z[#.9SKD2.P2>ACA@I $OD!EC@'!8844OY</?$\!;
M_3IRT;6-4\;T$SS$0^],0+RKXLU@6E>"$3\.^DSG+0AOW3@P_^>"12DHK#/!
MZ>%Y;YXQSZ\*SQFC:T8UA="G/L -/PZU7*9N@)Y DE(!*V2,"[BL'9C#\; P
MN@R(E@J&?PB39><0AA%-AQ.6>2FA#E=^QK,!O>("B0M?7HRJ#S_)>D3M_'#_
MKCPTQ*B/A"_2HA5Y<=/^DJ5+VEKUC\RAV8R'QM*EO&^^T'W)=HW9>W;O41]R
M7&/9R]Z@#(_% ;(4=&]GI8>F!4$SZX4L+H<GY5I+>+%+O'[PS@8I7P*J]0QS
M=,8D-@58_*]8OMR\$P:_7'Q,6>&GYO",>_5JM.>0LOGB ?U:ZJ[+%[G,2/)L
M(%Y%F[&5B]E?WK9=\X4#?AC(ZY;P7/F;?OXHELM;?CJ2G*(CG##RGJU+XWH]
MA7[BY=<CNBN:&"FS'N.(/_6:.DF9!FQEYC:1I!V@7\XX0DW&]43\-('HF>&$
MU7]^+M]I4/3AKVB->-,3 'V[A.R+Z?R&</Y444R,4.S73TI@/-7HT5[\*1ZW
MN+1_ #)&P00()]]D3.4C?"N!%*2^\8\B02O,5N<0H!#CB8&$@[M,#8C=)YZ2
M)#T[,/#::9$7/-$QR!]>8R@G3RDVG[_9NW-\AY,='!1JQ8HE;=5*CN*P<]S+
M9+$HK6E$!@YV!2-H6P+%Z5='-JM":1R8V<H=(9(/K@VXI*%AJ>R^$&O!U&@R
MT"NXZ)<=@E%Q)(I[H"L3/_@Q V_0ZS3Q(V]W[N[@\ZY*A2>?3HL\\%G>#@T-
M:#M>(3W.>)V^\R1>9@!P9-*@A$NY,1U7_ZQ7ZM>M)I8V]:&.1PK8Z\:A3C\+
M8YC?FX<M_;RAX/R2SEB=KY(1R,6GT_2?"SL'(*U4W1<49V?"'2A -R6# 0?;
M./R3>PX?(YBR>"\CSB:F,.2Q?"PCN9VJYY/T>=_KY'&U&[6C:3U2#DS2P"/N
MT5;-V'9EV/Q\,*UN"HK?$>"3$R?HRHA9=5!@.O Z,7-A1B[\A#1KA#-+UC#4
MB_,LD_  <>@F[8(!2.T">2";7E\>=,&O)!W<CGK;\M%?\77D\('VPO//M;M_
M^A,M%AYIAP\?5#K)P>G#!_T/GV?E6""?8]TW,7RI9>>.[5ITO^RGWXNT:*.O
M(._MV[=Y$;2=+[AHP;-WSYZV7PN; _OV^PGH02TH6&![T+"\^5S-42]&'M'"
MY,X?_:#MW?V:^E ^, ]/;,K*B8$_P8R<Z6_5#T.#)QC;M/""9_IZX@V41TXV
M8_?NVR,>7_%-Q^# <]%B7 'OX,'#/H7 5VB8$&$>DYR0E2=_O8\O8"S@B?"V
M;=O\-)G%ES>T.UYMZ!+W@Q_^H'WI*U]L]VA!=^1HOHJ X4LW.W9LTP+]%<EH
MG\<K/CN+8?/AH!:F3V@1__6O?;U]Z8M_ZM,;&6>47C*$]K>^_1?MW_SQ'[4'
M'KA/B\)C/C'&*0@,XQKR^>ZWO]W^U?_. O8GJI>]:4W4A<JU^[5=WDC9N7.'
M%XS0]U=R*(O&+$Y%L(G!D^:O??4K?FIN@4T _7*[1O]E(V-DO6W;2^VUUW;X
MN\4>-SU.9RSE^.F33U*VK[1_^R?_INW6XMCO5>L7FNADZNFAAQYLSS[SM.L9
MPP84IR?J,JV:?*U9NZ9==]UU;=V:M=:MAQY\H-US]T_;2R^]**3@8"CKW4K_
MZ",/FP\V5FZYY5;G7/,,],YM0OCPQ3NRV[>_[+1LG+@\-IHCL!'ST@OMKKON
M]$;6][1PINX!YA"<A*"N=JD-14=5AZH_YA:///IP^^YWO^/%/QLG"\]=T.YX
MQ]O;I9=>K#G"$B_&2;M#;<]/A3I_Z ZG6IY[=JOCMTE?'W_\46\H@$,YF$1O
M?>Y9U\.KK^[TYL^FC6R&+%1?\&R[YYZ[O?G I5*2M,TQRO+"<^W[W_M+TT;&
MEU]V:;M,!@A67#7?P>B?1"QAV8R(X7<TC&O\4L^A46V<(%43S=,PA!O06OSH
M;4S!D&TW1?UT( UI]3_9FTYM BMFH,W/N'1"$^CB[_&"(:-.4(8RNPYP]]!
MV@CZ"I2..7_Z=E\(&I?;*#PY?^R>WP0RSZ@\R4U&_N0Z"^:G]QWEGPN]Q+9'
MZ+0[ON=6\*7?0,O_8872C7Y@ZL83^>(I^3(&IWQC&4&,VP^F+(?$%XY<MD-#
M/!FOCY.X/68F/ _,(DOSSQC4QZ)SYB?_XJ'<S$-C@N_^LL=SHHTC]WX'>R'V
M0M\C@SE78^ZYBO<M\ MDE'\=]Z;=V1!O'.CD5GA_BI9\39_Y</+W_!2^50;/
MD96.Q?^K6KSOVK.O[3]XR!?M,?WBPK^5JU>U->O6M&5:4%/?KO/)W(R^C+MY
M&#NK/..)6^0I?5-^R)7&1'UA,_+90 HTP'4171 AT^&TS+#X%QWF]LB)13J+
M?\M"ALV Y4N7MU4K5OE3@."QAH-?YC0#[^1']^*A5_25]MCQ$QYO>:CD\58<
MH8NYN)H$\($Y':*S/=[EEUPE?TXFT+_R8 $MYN'KXD6LU_CJ J]>+FR+M1C'
M\!!WL<JR9/&Y*AMES%/_^?/@G5/L>?#HN8[^+$+R-@,Q<' Z&,-IT0G3 -?X
MZ3L*Q^EIZVZ;4Y/67_:0C\L]"[R.5*'5MK*F&L'BM"%4^+*%TO%/;Y<%:) A
MS,= *170B=HEI5+%G52 W[,YI0F$%@OL<'N76X:G_U"89F9&,1(R=)A49$&9
M;TD"Y,71>A3>3WM[W@$ZXNQ$D<])+_+?\.>V#FFR?%@382;##/#1YVHL5089
MPA6626UP:/!T",N6+)-RKVZK91;.6Z@%$"<<&.QHX&GH"$5)1"I/=;P1(E-L
M$A?*"0@/X<-E=_KXTV&,'5G2S4*5GSCPAG266SJ=D?9(8:Y_H*.P,>^D+1XP
MM;&"*?JDP9YV?L;I:=*1IYP.(V_RLR*I%^AE+KO,E)_H0<Q4$(57_/D64.5/
M9XR?V.)Q3#C2'^M>_AYV&CB8AA)<#.F=3.'D0R?6$4=ZW3\#3G,Z)$U@R&>.
M^VP +QC+H+NGH)#9L*(I_:2MT([2,?=PF;E086G[T$I:; /U>#8NA>[-*>K#
M/':W>9KE]<UXF +1A9+R0[.7<Y)T2L=TN_NL,,&?*\>?!] /+^$G<@H0-I:Y
M_!D4S6.EU:_J<(9WDLF0G$&!A2K'D/_Y/_]G[7N:V/,T-R-JZ!A1P"#(46^.
M!=]\RRTVMV#??+.?FJ]8L<P[]A==<G&[]=9;?1H!V+MGKY_*TIYY4GCC33>U
MFV1NN.$&+\BNN/+*MEZ+K S8650^\_13[<M?^F+[%__B?]."XWEQHL4<Y;+4
M4Y:I3 C*1M-4]Q)5<G)83UMQLT!Y*RU][>CF*? ##SS@24 V(^=Y8?SD$T_X
M4D&/#W-T?PIOO^..]O&/?[)]^E.?;9_^]&?;)S_YJ?;!#WZP77SQI9X\/*O%
M% M9-@R&M&X'S9]V0EZ?^<QGVV<^_<LVG_K4I]K;WO9V'R<_>/" G_#^^*Z[
M^B*0,>NX%G#WM&_]Q;>\Z*/N.!;_:Y_[]?9W_^X?M+_SG_U^^^PO_[*/P/,$
M[64M@O_P7_^K=K<6Q-2!J]VY Z_[E,/;;G];^^5?^5S[Y5_^5=F8S[7WO>]]
M/CK.T5.>!O_E=[X[Z3>*0OE[7=A-&=_P4_IWW/$.T_H5FU]KO_++GW/8^O7K
MO #GB/JVEU]4F;)H#JC/4#E/G#PFW;V_[67CHO<+G!JX]]Z?60:6Y9!G\_'W
M#WS@ VVY)F[4X?T/W-<>>OA!R4VX*B?S@6]\XQM^TLXB_1+I\MO?_O:V8N5*
MTZ8L<\$+K;A<5V^Y]2VIJ\]\1G7]*>>W:=-&C3?G:*'^BML:"_;3@3(Q#\G[
MP.C$=[_S;6_R,%9><,&6]MN__=OM#NG2<DX);MR@^E\O_%.6 T?WT3]DS F4
MAQYZR,4VVX(#!_G*$/<'Y<D9FV[/;MUJO44NG(2XZ::;Q?^M?C"!'G!RA V$
M/-@X9??7O_[U_OK&/)<5'4*_$,VTK140-ABJ@SC:Z@0']]!_=1A=9X;"#6T[
MWQ2*-X"TT[R \O-_-N[LQ.?2 (HV4>6F;'/+-PO@3>-'&B-0SO3[598SE5VI
MDK:/R5-SMORGL@'F^@O.$MQA'&=(/[07#3CFIZ=-N4XW%KQE'<24;=9=;9Q0
MSPN9C^'O\87CQ7O'M>ERH\T[OO FZ6P4G_PJS]-Q!YHRY)^Y)'/6/J_L89X[
M>AZ;N2PGHVK>68;T4WI3NOXDM/)GS0!-:$&CRNVT9E2"DX7?3_J7+-:B=4$[
MJOZ/L90QX:CZ,MH]?' \'F%3ELB=<=6EMA]\<"G3L$AUK S\D6<'PB'ARNT5
M[/K$T?'\@"COH;AL#M70ALME/">?P6-]0][H*7@<ZV?<X<0U836WY))CW !%
M9U%>%R%S5QLTZ+O.53G]:4/)<- QY9GY5#8D$A; /;83=U&B0_\YOQTZ>$BT
MCXE77K>07%1"L:AUW&*_8K!\^5+;:\3O.O6E:]>L:JLU9O"@>(G&]T7GJF[0
M$8T!B\Y=H'*M<!PZ,.8M([HUA_D/@BE^Q&X:969@$O9F^5BU]*]^59^$#9G\
M'*@VDS0C]"%)8.65E/L@&H;2<>#TA702S"E-QO3G;S!B)",AB^BD$@G"L%O$
MSAN[; O99>,XIX3OQL-B3O&Y; &3QC;+( *B$I2/%.VD&H-WDI0-3XS\OHGH
MP3>?NCJG?\8D3Z:B;/6D1Y0<_H9P,.1#@SYO[?IV[377M:NONE;T5FJR\H8O
MF-BSYT [>H1W3"-T:,7PM("CT@S$E!+%',5X9H OX6J",,]&#4LA?I]>:1?(
M3!LS '_N+/%08)E>-8:@1])YLC)&5CT 5>EN\+BQ);-\YB*;''7"()U:;LF$
M0;_S3USG#YZQE>- FWY)DAZ,+[8KX[".)QI%"W]!N2,A:BER-J\]G6L !..F
MPZ"J8\2;/W@#7?0'?\>731KOH,EI^K)MB 9#^%P0Q+M/E#T\<LR2O$X'6)CR
M?S9X73I9YI1O!*@<4S\8^"&&6LS.'251_KXPR]*F));Y O&IZK#Q$W%B19*2
M)TYED%V\#7+M>6'TS^F*>\N87[=1,XY:<2MMOD+0$:?@/D+E,M_%O^A+$8J7
MGO4,C$_:,<B'^H@I",\R\"%FH/>&ZH;6\KKBG&:.(=\W V(M3='$Y/W_A,8.
MC/H$KG1(MA>ZPA_CDL*[[1UFXA 8^-)9QZD@XESELH1<!Z=Z^8%IW7#\_)__
M\W_>_O'_\#]XH<5"M_CT "E).XV"KK[VNO;7?_MWVC_\O_PCF<_;_)_E_B_^
MB[_7WO(6WC\^Q\<*WZ^%+<>E:=?(E"/J+$XXXOXV+:;^P3_XK]M__=_^P_9?
M_H/_JOW!?_Y?M+_UG_QN^\6/?4Q%$++J_\^_^6?MG_R3_[']R1__H1:F+XCN
M6%M&T3\_=8>X( .V_'V"0/BT?HU/N&Q2^**M+@M:;5JN2NUP#/V _!&G^7_J
MJ2=\U)R)Q^8M%WA!R.1JV\O;',XDA/RGKX+5TV)RN>G&F]N'/_+1]O%/?K)]
M[)<^WG[IXY_4HO?7VL<_\<FV>O4ZX<Q3_[^W;=^YP[(>ZD@QO&]XS=77ME_Z
MV,>=_I<^\8GVT5_\N.OB7;_P;O/"A.>(^.&K"N3-._$<$=^_?Z]?JV&A_GN_
M]Y^VC_SBQ]KU-]S@A=XG/_F9]I_]W3]HEU]QE2>7;#YPRL%/\0%E+E$8%B]>
MJC2WM$]^ZM/M$]U\\E.?:K_[G_Q>N^/M[_1[X&P"[-BYTWRK-W$[PECC)5#W
MY[T?COCG*=W*=MT--YK6)S_]Z?8I&6S,;6]]FW!2"6S2YU.*+)#3^D^<..;7
M&%BL\[XHFR%L1K#P9W.&.)^H4'H;Y<LWCV^][3;)[3V^NV#'CAU^Q8'-'62W
M73)XZ,'[O8EPWH8-TNO;VBU:Y/KR++H@*44FCNA=ZHF)VQ2X^^*3JM=/?!(9
M?:;]SF__C?:YS_UZN_32RYR.#9E''GYDD"WZC;X5,)%]_OGGVQ_]FW_=[KGW
M9^W0X8.JHRO;;_[67V]ON_T.U56^B<V]!&P \+1NF\K+JP>UZ?'""\_[% 1S
MH+P*\8;;(*<"]NW;ZXH%=Z?JB[9!]KR:P(;'6V]_F\O-1)1-"%[?>>FEY\T'
M[_[SF@/MCXV^=[SKG>VBBRY!N!8R>0/NPS!R5UC9AAX/5+LKL$QMU)(A*[?#
M]&-,JQ]C7.'K[^?"3/X"^ZG3WJD[#U<JO*2?SO@X\@8D/_H<^L;8&$XH$:Y_
M3HTIFG/S!LX1+H:93>@%]]3K:L.B=^H-GMQ"N_<%0QY%J\(PD@YI12<7THUE
MPS"V2&3--[%K(DTQ,45KI!G CWY&1_E7\:(U;_9]^T#)J4H>V9D->%+ZDRH/
M=EJOPH5N\0JF\S-ZAXR%HP'1\\.B+W?XKWQG@?E,?NF'3%K3*^;@%LQ$YD#I
MH/5.N%7:P"1?FS$_Y@$8?\V,S\ QGV,NHCX!VJE/S=WE9_T";>5JGCS/D(D<
MDK]EP#Q01E25 W(I;.:' >:++!Z95Y,/?2%Y$;9ZY2HM1%>+E[SS?^+$*7\F
M>%@TRS!655^!_B &\H8NFW_PBY1@![$/&R?B6&*S2;<GGEUW\"9$U16+?7ZS
MD@JX>,+WPS_9 #K-0XC=G"P\L,^O1=.^F;.=U-H+/B/'4^VHXHX<.21^>]L3
M/0QC[J$#!ST&4<Y*4QS0UYB?7DX*!?O6G\ZSR+M<7FNZ<*2=I[']E!^"DI9[
M#)9KT;^4#1W184&/G!F;.&D>02)?M=.3)Q0'#@]]M2;5PI]3 7P^?L/Z-6V3
MQI?EZG.92IHE6*$^Q"F<6U<PN(O7 CE9=W*R &QTCODZ-(1IV;E\>,\ ]#GN
M=SRG3JOLN9PQ7>I3.ECU_*9 _)EJ?X2! I/:3'I[@  A<(NF!U95#@HF;1&S
M-'H)B):D/R^Z5&*KI=)@:I(10@A);*/43$8)$HX57>&U U?'RZT80+=1($\T
M43ZU8A0+<^38D7;BU/&V:!$75[!X59ZTV9XW=*:&QCV *HT%MH^^G*,.0T+E
M@KT3QU]O!_8?UL0#)>:K G0-E"QE@6\$&EZIB- DE"AXY&AFR<%Q99>9\M&A
M>)P+"ITI"_2GM,\&A0><2190'D#.A(U\5)JHX>GP\W@PG>X^$U0^Y2YZD*PX
M#.4H''<:]HT ?V/:D9]*/TV!GYH\&TS3%Q R8_2O^!SRI>&6>V* LJ<R/A,,
M> +C=?[YD?&4+E0<UTVEP9Q)]\\&E2<#(2[:%!TX[7'DYG0@S@N]/N$Q7^H/
MBK_BE[A!#U.-?V48TL]I2W\5H+/^#P'/1<X$/7S,F[I 5PF+S"O./-(GBN<:
MX(40VP#>9/"3F:_HPF 1RY-;[&NOO;Y=>]WU?B_Z3)#)P2(O!EF4\B0!PWOJ
MO"O-L<?;;W][>_=[WF-<F/4D7W5&O1'&MVBY6(V%QP$-^G#"J8'JGX'GGGO.
M"S,6+K?=]E:_[YS)#URKO"!!5K0I]Q0L%XP0H@,)!\:=]=0KQSNAUBD:2I<'
M_97%PHE%#V58(]E\[&,?:[?<?(L73#M?W>F+!GE*@?Y2CN'^@,F@QF8G&R+$
M4UY?4J0T+%J'L6E2AZ2? NEYJE-C&7G[4T1,3.!98PI/47 C\R>?>-R+-<(N
MO_SR]AN_\1^UU:LX]B_>F%#*G*N%Y,:-F]OO_,[_P8MAY/7""R]X\8B,+.Y>
M!I'7)"AC9LK8CZ:*/D^C*<^T/J9R!X@K8]H%RH.R0@O:97Q$5F-=(7$1'7R3
MM.@PV?OQCW\LW3UD_M_SGO>V][_O@RXG3X3^\B^_(QT[,)NWY .OG_WL9W/Q
MH>J".PS8,*$NO_BE+UC_%B]9VM[[WO>W.^YXA_A#]TC:=4( J8)I. PR68Z,
M,/D,TQ577.'W^RD+>N3)XD0.YDW  X:=.U]I__)?_F^^;X&R<?H#?GD- =FD
MO;>V:=/Y;ALK->%GPLM]#YP<@"[I.,G#Y@_W9J!GS%/ X54" %T[N#_RN6#+
MA<)=J;*<TRX1S4]\XI.^6!!:/[OG;M\5\?CCC_EU!-H#]'[E5WZU77+)I=9-
MT^O]<MI=Y%WNN1"9S?9C!=9A19=<BQ:\&";B'F5_>AX%R6E*9P2%)&Q.>& <
MQRIMTL?@KO).RSS@,W\5C#P6T$8ZOFSD=I*'3*K[UUGT0\_CW,\WU"%VY6W.
M9%<\[AF0-[C$G05'4#Q[07P&G#ST0#[T<S% Y<L\/?F,AG# M"<B"9U1UF>#
M8L&X^HU]Y%S>SD[GY^8QAQ9\3M,X[V[."'."1[S8EJ/"L-FHJ?Q *[J2IL>"
MDOM4?M,P(*<-^F7F;!JQBA74^H:^AY-,;"KR^MT+SSUOPPDA7L5CT[-7B_)F
M#I=-!61+NX8?G[3MLK;D.Y\8N.BL##P17E!XI*>L7M>!UPVAS(,H+SB,;[QZ
MRUH7_:0O)3UI_"EVF<[N# PRD>&4- 1H4^ /\Z(.\.'-1;.;NACDZGC*Q?(X
M^H],Z4?7K%GEQ?Y)T50F='CMF,:@XT>/M#>4!V5@'LMF"WX$.U_I%RJ-3Q/S
ML%/EH\P>&[P)PMBM,L)*SR]?_2B0JX_!5$'DB4UY*:XX)0!P7-R#/,X(":\R
M1Z]&&10OR,;_37,,?3,8>.D0?D>^"E3G"%ZN"9-BP?^Q!^:5+@O7%&B8\+MV
M8MY01=1NLX6)I/3'+@B59WR1BRW:#DM>8<Z,V 0G!H'XV'T7#HL"@([ZQ$G>
M%26]TLGP+BTG#7(,B*>YO1%AI@(0709Y:'%+)3=<KEJVTL?_CQX]T8X</=Z.
M\92?#0"G57<@9>9I<1J':'GBF@$</HLT%OFX\<03MYS>?10N)Q/FFJKXX.87
M8C%YC4(_<&0\.%F."%^X& %Q/Q]"XTR K&H@<3[%F_RN:M=#F9'O0)C%Y[*?
M"7IY(AOLD0_HE"EYTQ6'/,A&&O,TGF((%S_$YPEM<!UG7SITXF)ZG SH3F+B
M(Q0?E'QJ^$UQJ4])P3\_,0!+!,==<>3A?3[7%VEKX,?XZ8+38)(G=6J_J19M
MTA.2>IAR&\RD/0TLG. GG0N;?'J(?T+ IOX=/S6B,=W-#)_AT3O7G0/*$@Q*
MC6#M-+A>.H'.TAQ0"MJ*XDH.4Z@^QWU,IX$!BW95)NFC#HQ!:7.14>HY@//T
MQ3\!E+-+!I;%4V1+>1,77FDG(4C;I#^@GHZ=.);^06&T?<?+X&4G6E'#XA_#
M?S84UZQ=WS[WN=]H?^VO_6:[ZJJK-3"-B_$1HDGN"2BD7-!X]MGGO ' C>37
M7G==^^"'/NQ7F_C\&NQR_)_%_B$M]GE"S>5K__R?_=/V3_]?_\_V+__%_]:^
M\8VO^0DNP DG2'-[.Q<"_M9O_XZ?FK/94."L96S9$[!\!C^%3 D#;_@I/N^J
M<\KA9S_[:;M;YB<_^;&/?_/N]4BI^J$Q_3ZE95%(&$^86<QQF=K*E2O:X4,'
MV_///2O[D.5!,B23*J"N)GRH'N&%X^8\8>8+ =RY</#@?H>S\;)Y\V:GGY:-
MH^\LYKG,[ZX[[VP_EL']S6]^P^^QLY@\?_/Y?A4C3U6R.&;BQP20]_TYWLUX
M,LB)/QD6UM=??_VP$<'F3-VF'P@?8RDZ7^HGV*1YZ*$'?!L\=SFPF.8]>T>C
MN3TO?I2\MU3;IB*B1[10Y2GSCW[X_?:C'_W 3YM9N']/A@4G--')C1O.%W]<
MND3" .7C@D0NJEJW;FV[_/(K?,L]"]>3D@DG&?;NU217BV+GV!LN]7O^^9N]
MN;1!]<E]%O?\[.[VA7_W;]N=/_Z1GT9==-'%[;KK;VB;-F]1FL@M95<[$ W7
M,T+I@AGE(^CYN/>5S8^%-_D ;"A0+W.!\9R+][[\I2_YXCY>[4#?WOK6VU6W
MMS8NGO($4;CT*YR>8/'/1)^CK^@H$U N[^+RS%U:Z'.T_]9;WR+=6N>VS@8/
MESXB]YW;7_'='93-&PG"A6LV/[C \QWO>*?D?Z[O\/C.=[_5OO[UK[1''GG8
M_<OUUUWOUW?8-("A4:=27M=UYY6PZ7C=8VU(Y+F$!#CM(R-1=)DV5',"6R09
M(./#3)"A^(D'@U^XW>#NU33 7']PX1D^ ^%^U&+;2E1A^:5D7N!U$UTA@]"K
M</W%5KS;B/P^;=+#$,.(&^;*/<AS8FB7,2/^ ,J_YJM"D!GI%2B5?U6*E$3_
MA5,A\,6<1K-3__=X%)=)GY9OAVE?B,NU*]28,6X6* ?EC,$_%ZKL4Q.\,@#T
MZ5>33_7-=)=A:XH+Q$^YIC#2'T$AIX455#[.2Z9.47KNV4^P5+R(P*$-;B@#
MY4+V!>![D<^:0/W),%= )_3S174:1SF:SA-V-NU>?OD5C57/MY=?>ME?%"MR
MQ;OY$SW>Q6=SF@U#XGBP:%U#IX0W\-N!>F$NQO@VI64\/"HKFN-UD_HG^FU>
M2> [_B?4-Y\X=6+(P^@R/-'F56F/Q>IOV @ ( _=RL<<48>LB90_8\&1PRS*
MCWD"1JJP6I(5)RX+B4.SM"I<*@RE\*:O-=21!PX<-&W<T7-1H[RLP3398S[G
MAQV4@;DH#5E^^ 2?TP(^<6V%$UE!W1/A3X4*'2BYFA?HFSL99-C+3/K4@?#T
MCV),FX^=X/;&E?ESE;+2BBOER_HR>HDNY20V/!*6.#:!P$T& P\#],QER,ZR
MZ;AEGPDD+PK$ C1/U5$.&RDKQD>;%.^.APISQLD<]V#D5Y9FUCM5SC1QT.83
M?DRXK*!@.UT4%N,)M/DD+#PP84!13WI7EETU%(:)@QC7/Q;O**<G6TIK&N2M
M!I.G)"S6Y5=8A "'^2E[I5>YM>!'N$L7J8'*??CP434"&@D38>228T)N2*)0
MNW"4MP8': 6$<R9A]R#0,-#D<X?LPMDHLY+M8&.$;5LFLDKYL2,W_"BZXF77
M)D*9H6ZZF0MOIAC$.8D,M.9N4LQ=_(_TH3G2G3:($>@ 8)NRG4[#MA%B$BI"
MD_"4.VZ@<D7Y<=5B$UIN$#+8U*)JL&.?#L5'>))!'TO_)Z;PC"OC]D.=3'0Z
M1O$RA>>?<(KYJE?C2@]*)^H=U.2-[*'5ZV$27KP,?)DFM /%8\+Q=]UWGJ%A
M?GJ::'GBDTI1$:5,ZLU V$R'-C4C3!?]YD.R(*^!KXD!J>Q!-[M-N'E%EIT&
M,8[%&RLFT3'Z639V,:$C0:4,;6#*1^I=B$91F65C2B)CJK1W&_4]Q#&0LMOM
MF]+AO?,/X$*^V(RC4RU<LV9=^Z6/?Z)]]&,?\[OY+"C&$IH;V^12:0+Q_^0G
M=[5GMC[CVW:OOOIJ+8ZO5&C2\Y]%(AL /*&D3^6HLC\A]M13/GK]O>]^U[?E
M\Q0V_?\IOW/]B4]\JOW"N]_3+M)".SP$BH<4L7SHC7CM<K0.=7\![US_]*=W
MM3__LV_XJP)\Z8#;U[_SG6_G$KA)+E.ZNU[;E9OR50;Z]9MNO-%?$^ N RZ'
MXTDS[T5SP1KCS!1&*F^T^^Z]M_W9-_ZL?>7+7VY?_>I7?(OZ%_[=OVMWW?5C
M+_2@==GEEWO!A]31N>K$N'SOX4<>:E_]2M)]Y<M?\A<5OO47?^%+"?FTW+O>
M]0M>U,([1\RY9)&- \8/[KTIV0#0CQL=.D<3Q67>)& #@*]),$'K6/HE!5]+
MX);[+W[QB^V+7_I3V5]H?_QO_K#].Y6!A3HRO^#""_PJ"&EF4\NH*!4^@'A@
M@<[B^XM?$MTO0O=/??<#=U%09RQ$/_VI3P\+V&CO.9+9(6\<<5KAI,;I*ZZX
MRC?_(S]NT6?<YO46[FA@\Z>JM.J$B2Y'W6^XX2:?8$ '?O"#[_GI^.HUJ]L[
MW_G.=N655VF25C=( RD!0)"#':1_'8>+^SB*_\UO_GG,G_^YZNLK[=O?_HY?
ML6#AS\D6>)T+O'Y#VA_]B$T(/O^8NQPH'_FX3U=>Z7M5!BW\ERY;[E,U.3FP
MTW.7YY[;ZB=\; *Q&7+U-=?Z23WURVW>Y(-^//_LLZKKHWZED<\MKEJ=SP-2
MWE4KU[0/?O!#[;++KI#_''\%XH'[[S=-/J?YD8]^M*U?MU[SD@76)9L,@F(U
MM6P#HX+T]VF;8[^HG_O6Q $#K7@5D-X*'K#G0J<25T\+!%/^Z@>"DE#[Y_9G
M25-AH0-?-<X Y 3GG7N/0Z?_AK)VNU+ZO\((=QP_\Y<<,/+*D+92C##ME^8"
M^=A K\K<H>(,(F$RKJN$#6G+]'+#(S@)F_"D?QE/4B?#T61%G)W#0.4!W0&?
ML G/A6/=&$SF)4.<\+R8ZE#AH[O253CVE';" N6.?XH#C1&OH,<-OA%&*H'D
M,X'N'5*7P)Q0_VQGH]U_G0^59$ !*#EK OJQ.H'C*-$CK=]5YX&D^@CF=XS#
MO/[SXHLOJ6_8WO;OW==.'C_AN+I<#]JLH[B<$(A\YWFMPKUK;KL#;A@I_BSK
M^N%W+#SA(DW2TR_3G]GPSGZ?M^ O6:.?;&QP*2D;$<4'-IN=OKBXVH+T..LO
ME5I!](.<:B!;-@V0$;A>*%,6\5;]IRETW0V7H<.&2F-13AI%P#>?6$1'&4N9
MZ[ Q#5V:$118^/;68'_9(B>;./YW6^F@R0DWQK0J"SR,@"]FD+&U8-HF!4H:
M.S0*XAUI@#<"GO"1J,@V]S%$7OBS 1#CLO;PXG<$*"C.],S-SP6M9%$$+O+C
M>X[<V,@QE2S6"4=1K&@R<XDZ?W>^***J#<9D8!X_MR2S\.?69"[M"\U^V[\4
MN,@A1.C0T3'YY+9>+OCC'1,N^,OE@)J4*AT3TR&=%(%OC_H^@7Z/ $8R&(0U
M",I9H$A2B/Y2!^G=$$Z<LN 6+UHBO_AX_1SET\2S&IP:7<1*AL[6-) )!MHV
M"B>;@;FS O$IJR?+-J%U)N-%=^\<N.VY%I3P25K(60DQ= J]8YBA07KG%Q/\
MGL[\F'N8.PV(M2W<D6:YNVY ;":]B2><\G7W7),.8*0[=CR1:<5Y8M+I#!S1
M8<BIVAUR%H9C4YH>WI,D+#!U3\$IACQ%RT;ZU@UMQ0,@Y99MF7:YICS=;U,X
M(U[X#TSQW6DCTRD-_*);,B)IY9,V.<G?^(F;:X:RR%WYDI]I=Y.)7]IWZ?!0
M?N,K+<F[>R9,X/8E<#@VGB[@A(RVX30Z<PV6_G5<FPF=^HEK_2IFA.)G"I!0
M<62C5V62-GQT.9:9R&<:GIQ/!W2'ML<30/OA072]&ST'PEUI:'P\(?R%7WAW
MV[CI?/6?FBR0;%*.JB-X33EB>%K/4P5N2]^]>X\6-!?Y":R_&=[;"#8+RA7+
M5_@)(^;VM[V]?>C#'V[O?__[_;2;8X@//?! N_=G/W-^Z!A'GGFZF,V(61@Y
M5REZ6=VG=YF1/B8\AQ$MH@\=:J]H0?C\"R_8\"3TN>>>U\+O)3_Q#83Z5 >8
M-#WZR*->V+%08H'+<4 6F9P"H)_GB?F==_[(3S7@*>(+EUT0[=[[[FM_KL7@
M%[[P!2^:O_;5+_N&?A;;G"AXWWO?YZ/:3'A2]]0WY9/^J"Q[-6%[[OGG9)X5
MW\_ZTV]<Q'928Q-/>IB4<),[O+,!@(&V2V*=0]<PG27#X-"$9K$F(_"<,/!&
MC7O#7P>X6PMU>/^C?_VOVQ_]X1^VKW[UJ[XEGD4M3ZG?__X/^)@Z8#ET&?!?
M'.B?2X0E"&T^8<GD]-FMS]KPO7L,82Q^F6B=N^A<;[0P!J>-S=-"=K=/GK"8
M)?_KKKN^;3K_?)]DP$TZOI)P[SWW^$EX >4J_;_HHHO;'>]X9[M&"V1D@SZS
MT*0,;[W]]G;>AHW&2YZDC0Q/A[&D\,EG)__D3_YX,'R%X7[5/XMGCNVCVQ>I
M+4#)]#I)ZHS[)+C!GPT/3N+L4CEY_833*P"Z ;Z3R:Q2&V'SB'=..?)_@/LJ
MGG[*7UD -J@,?)Z/.Q^6+%GJC9-]TB6^>L&F&V7C*?Z6"[:T9<N798HIPL@<
MN;SO?>]OYV_:+-Z/>E."SQ?>_K:W^?0$)W/,N@I?BV&#K*K]R"5VR6_ $^ ?
MQYI90U$9:9.:>BCW7!CI#4"=B88Z!EGI"T*E4R"JYS,"[@JK-MCYF_SFP@P-
M.5WRD)J!V?SB#F\9 Y-VRF/"YD+1*+T\,X37HF_C<75,GX88$QQ'RL0]F"I.
MCY_&X2?6U@ )FPL#/G_BQ>.:*MFT;,> H%BY\W###R$<EC0U'F9#L(^G/3O3
MPIYK.M)T;H&9CK/.I^8XA&/WN12RJA_Z0'SQ/@LC7O+6SSC)W]"MH5^9_!]L
M<)'%8**_<O@_^DU[J./Z4X NBSDVK.&3#=#77GW-8QDG %YZX45O1C+V,F:Q
M",]XR9J#HG)\GOFF\H1'ZJJ/J;/S?'AQ"K(U#$7L<B9Y+Z:Q(G>EE6V93^@9
MAV649,T:W*\8JA\'JN]GPV-8U)-9$1?@9-'/:4=O'B@]&P:.X$^F^IK49Y>F
M_T$'F?8GWOJ5Q)E/D.=2T6.LA2?&G,J:9N0VKX!*2Q2U@L\/<9UE<L2-/$D/
M%UYKP==$-P>@\<4Q,2.4#@V UWR<OEBOE*%//I$YB4:>X9=%?V@4X)Z:HFUW
MMTU@3#)3CIDR"<XY=>J8%MC<I'^H\<DI;"99; ;PCD4V 7(2P IC98/M-'X%
M*HR&JD4]EXMXYX<C)L>SF2!C.ERH<HK/0ASQ,4W?BND+,=*(J5SR/73T4#MP
MD(G3[K;_P!Z9O9HT[G<Z!O5CFJCPQ0'24/GP8V61IF)WYF*)MT$6%!P_BW_W
MI(FIB2J+_\LNN:*M6+9*2G:N%ML<;3RIB;/*3G+*K338Y%V55@+GZ 9OE;@2
M*OPT,"7]1?EBAT?<\(N)/&7<T$_YA$ U4#(3RFB<M-+*W3<&S".FE\]T1-,=
M.7[%Y4ER3P>A<#(''&$(;VHH# ATR.8'"$]XT8/H"7G'MMOYE.GYZ@>](:SC
M%0SXHJ-(N<>.PPU<ID"IA\$I0#VH4=AUEI(I$)-.(2F<G&*1V6!8_"N0-D"]
M4';YX3DF/)GFG%\&21-,?"SC)ZX'#%SBC_'/M E7K'3*9:]XI3<OE!S>;$+/
M] >Y&[V[(_-!UCW,;H$OSC$^'6+I3@:(#$X]+?4F,Z6;=^D$(2#9QE"L:@]5
MRO@"@Q]ZIMOY-G%D+ITBK@,T7=_P8JPQ#ICF-07S3A:HDZK4EYK*5!UYHB-S
M4OFQ@UU] _T6_6!-1,"=MF_HP@(GB+#IEWI$XN9 \:&FFOSAQWQT_!G&2:^R
MDC=MF'I0 M*#2Y_XH!;N7%9&O\O34HPO ((4]/2W;OUY[1WO>%?[%#???_HS
M[3_^W=]M?^VO_5;[K;_^VWYJS1-*GD8^_>03V6CM?43X/UW& Q /[_#%QJ[2
MD):)2TQH!?+9U:NNNL8+E]MNNZW=K@4>M^AS/)I%DH=K^EG8UC\,_1]/V"DC
MN_5LEC"IXG-[Z J+(9X>,W[<=]^]7L"1ISF6+%V"SO[Z=>N\X<&MQFQ0<V2>
M!?<EEUS4/B.Y?.8SGVY7(3\E&,H/#1F>\%Y^V>7B]VWF^6UON\-\WW3C3>:!
M)^&<++CKSA^[W.@!3WN9+!4-C,%,Z:^7D3KFQ!UZ%W\@,0+KVSS39'&]>=,F
M?Z+IZ-'#QN)2O9MNOKG]ZN<^YPL-.49."O>0<I#<M2A=US_'A7J 6_/1&Q;B
M9;C\[ZJKK_$]!]Q/\4__Z3]M#SSX0#NDL9ND?!*8#0".HP/DR6<GD3^;.:M7
MK[)<F$@^]N@C;<?V[;Z<T> ZABGT=%Z[63)$EMPA0+^^Z-PE6O1^H*V7WA:?
M$4OD-6L('WOZ-,V\?[][]R[QL]?S!YX"<:J RP'?^<YW>1/,&ST0H$%U8,.&
MXZN<$&!3;M-&7GM8Z%<9[OG9/?YL9OIB##K"G11KM'C?K#H\I0G];F\2O2!]
MS66>K6W<N$DZ>VZ[_KH;)&LN:CS<MKWT4GOJR:>\(( >WP=?MHQO_2^@Q><G
MVBPN^(+!9=(]%ON\NK!1]?_N=[]'E,])7Z ?O1@_P#J$4W:D(E-AN)6?QSN!
M<>/H?4;"C(ZZ6#:,.I@W@] K" T1$$&X,\$.E0\0O.".-F;L@RB;6@@2L;M@
M3#L:],DGSYPUQVHS+R1._^PV"7!<A^G7(Z.N2;)G#&DZS,W/=.? ;'S&C#+N
MZSWO#9ZA,JHTX$H&'"B?"^9%-*A/Q@7PAOF(TX6&B*EXL4^#GC[C.%YLTH;>
M:#3^J5_B>#@F)Q SUM=37!]/[OTV$/X1O[F9,82GJ')/#/6,J7Q.]C&W'D*>
M5'_J</$RG7]BB/<80UDF]'R*67@Y58F?--0%.,5-(')0F--3AI3#<>"2KN=A
MD1:@/]3CM"Z%0SC]&*\BLU E9J_Z1;[MSX*?OG#;*]M\0FC7[MWN;R@C-&IN
M01E(Z O'I2^^?T9] _)&I]$CP(MQA<?TI_)^@IX6CJS1:3^)UUB'\;A@" W2
MY(X5]$T\R%!NY+6 5Q#T\U/]&L\I*[)0NO#9Z<AX\;\@I["7+EW<EJ_@6_U\
M]<THA=I!GB[0&@^TBG)P\%P"N<,/$6R*\HD_;[@HW&L!W ;JAW+G9R+@R#H'
MFWCC]/K6O(4T^:2OUJGRVZB<)?_H=1G]5T$H2Y7G;)!3#%F@VS])4.6I,L$F
M]+.N"1YRD*_G:D;LF@OF![N[\SK"F!>0_$Y/?PY/9!@H^1;MT6.'_2U@/OG#
M+C/A1S50<3J Q7R>YJ.,= K<\$CX48=S^R63$;Z'>^# OG9(Z=E,()TOVE$:
M&."69@;%/!W9[XE"\< QQ#V[=OF) 1L0\,%N.D]4>">2]S7A#QH .^Z4FN_W
M6XP47'G0&5)Y<:<SH.Q,BBUO 0V%72E,7AN8[V.XRY:M:@O/Y?,<\U4N*3U/
MW5E40T 5@*CI[E RPB+X'(GA6$H:457'"*ZDSA^_"M,_7/8##NNV8V2SJ7!F
M "=T!YC3X0]Q \J(ZXZ8?'J0>9MKZ!BQ.\U26I_(0 \FAD93!IF?W4 WC6^:
MESNTSI-S=%@J##>ACNOA-MT=/L-; ;CN)%2^P@.\!V37+)B.\$; 3>=)#=-I
MF-0989"S8"X->,I 78;2C7P"),\[K;T^U7GTP(X1FI7/3 XS^9T.I'&>@YG-
M&X $>'7AC"3A,/ '67<S2VO,N_(IYN"T^)W"W/1.0_@D+GEQ05?"!J(=BF[A
M!R<P=:?S+N!DDG"E*T-YV+2L.G'<K [@'G"-3_R8Q]2&)Q^-DPQI#U,Z9P+'
MRV 7IH^]>=#H 0+BR=L+?_-.FM0A1^+N^O&/O<!9S3OF6ACP)#%I1MY9Q'"1
M&I^<^_@G/^$GLTR*A-(V;-S@X_0\Z>4S@3M?V=Y.:M+!R2BW;>$A%X/?ERRZ
M8[NO/L W'<O0;^(';RJ'BRZZR)?W_>[O_NWV>[_W=]K?_<_^H/W^[_]^^XW?
M^ U?DF=0V>G7*EV^I?Y">_6UG?*]X?<*_]D__6?MG_R3?R+S/[4?_. 'QJ5/
M8JS@*#Q/6\RC^VZ3$9S3/O6I3[>_\W?^3OM;?^MOM7>\XQVJJQS+9TSRD4:.
M4@N3NIRKNSP)8?'_^W_W]]L?_/[_L?W!'_Q!^V__FW_8_O[?_S^UCW[T%[UX
MW?KLUO;M[WRK'=?XQ4)]XZ:-?F<<HNF?P@QV]4F1VTDO/-F$P8T"H+I*(6S:
M([QPX_SF]JN_^KGV?_U'_ZC]WG_Z>_E\H'2.2:6?)$D?W!<*.W6$4?W(>/-R
M"(LQHNB>=][&]N$/?:3]O;_W]]I__O?_7OM[?__OMW_X#_]A^V_^F__6GQID
MTX63&U_]VE>'NPF8(SS_PO/M^>?Y0D3*]Z=_^J?M'__C?]S^Q__Q'[<__N-_
M,Y27.GSFF:>M7QX[^2FNXMG 6+5JM1;DRWRDGJ?^G,A@TP7^C!=4P^G]2B*+
M+O',#SC%P@;79S_[*^TSG_UL^[5?^S7IVQ^TW_RMWVI77'ZE<$6;>8%3!TB[
M=MW:]L$/?%AZ\KOM@Y(+3^^Y.^"!!^YO/_K1#R,[P/W+O/XZP45*FXO GGKR
M2;\ZP?P'>KQJ0+_ )M<&R9J3'BS\^4("<R#Z7<K+Y[+0"XO%I,,;7YA@@X5W
M5=FTV'S^YG;))7S-@(58]0VTTU&N& B5>UKOY0=_"D.Z#G/]0(55.';HEMT7
M6N(K=L?KN%,SA82-.EKQHBHWQMX!"F_:SV"FZ3%378&$^>QXE0<X<\B?%:9I
M@,IG;KYG,^'B;*"XWL=.(6G+7?[DF?)'!@.2P,Y9,@;X+MZG=KD+E(-HI#Q5
M+LO-/!8/'1GHR0G*5X3"XYM!T2Y3^$-^LAE?RN1T<EX-]GOK,IPN9NRJUW2\
M1CE#7U?&\7TN%O\X_GN\F-N&W@RJS*3M].D3/%?L27D-F4U47E=;NVZ-^H(M
M[?SS-[EOH^\^(7Z2)P\6F/I1%TF+,"D3I!:K;URQ<K7'=T[!Y0)@[A=8X0U<
MPI8N7=ZX\-0; =,*T;]SF%]RZQO$<2N4I\R^"/W<<\UG=(#^1+)A[2/#6,9#
M7![FYA6"C/D Z2@#,L0 S+DQUDO-\5G4^DDUD983&RF]_^Q0\BL=M-QM%(8M
M8 P[>&"_UY:<M(0F]Q2M6+G"? "D=DMV_?<YB,HPS.OT5SCXV=3A0;1UAS(X
M7=5C^@JG(XWK)?P16>$ [C%NE$'*G?!I_!2F]#OJ# SR.TOZ B1*^RSX>?C
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MW/T37U'8]LK+_O+ _???W^[ZR8_;,UN?=ODO4MFH"Q9Y',]DH<>F!"< .)G
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M>AZG WK'PJ^/:SWT;#"5E5WX)^F8S8U0[AZ+UV:6EYEQ?@Z/SL]D*CPT(]7
MZ J^^X/X8"TV*;J[RN"C_^KW>1I/GY;PQ+,FX**Z7:_FXG(V",%_X87G_ "5
MI_^'#FJ1?ORD^_V+U)?3/[! YA.@JU8NUYC$)U>/*\U+C?79N8L6M&U:=[VJ
M/F.^YAX8YFIL"C!G]2)4)@M^N1G'^@(T'%M"J2?5%XM\GG0S_OEU7HU_BQ=K
M<:SQ#GJ8X''O0QYX4#_(FWM*>-5 +<IS5M9#OA?"D@H@!_I*9+)\&5\W66;:
MR1^]3=NL^6QGTN'$$YYU6.=>88S)S!GV2::LU=SA*IR-!OBC?;.IP<:!UVGB
MS:2%@W:Q@0 UY$Q:XEC\[](XMT_U17[N?R5;3A4<Y?)#U5TV3$F?$Q[,=XIO
MRXJUB,,QK",4ANS#N0Q,4!*%]73![3L#\E..*D/)R++L[M-@)BSNY ?@'\/L
M,[Z,\OKU7QM/ ,R__J:W?YY)ZY$C6M1*X>HR)]YI?&7;]O::E)AOX!XZJ$F%
ME KEYA(^)@I^FK]GCR<<AR5(!GC>/3QZY)AWP%Y[;7?;O6>OA=GF43%99'/L
M99\,<9PV.*"T3#9>>.[%MDL3HWU[#[0]>_;Y.[F[=^]KVU[9X6-]['0Q<>*B
M)-\*_>I.OZ^Z93/?SIYGOO*YKE'0@ M? K!AIPU9C#@L?HYP8D'Y'E,Y:4B+
MU3@W;-HLHXFN%!S>F1#9\ 4$V>#QOFR=!A":*A%7<K+M_.W"8U-Q!OPR:EX*
M)Z8ZN=G*']W3U+@97 32OB13N09U4 "!?1&#UPT"FWR</H";QA&1]+R)-HIC
M91,YRHT@YZ4_\(O'RG_D>810ZN$2&*2@Y^PF- J(IS/*+J#PD&]OA&F8-*2Y
M()G0:\N$;@\F9SHK'STFL PD*5=/Y@(Y>"B++8\$1K 7&N$O-A)%OBD?$;(,
M<9"&_]8]UOK*4^IH8S=X6*<9TJBLDH$*G/3]5^ \R<96\1!_K#C,I^4"SY$[
M7P%AXKWHW,7N\'EJ3E&](&4W53+''@9[&<=-.ZR>#X <G%TWA7,F\"62Q'=_
M\%-PRY)T98CN-HAQEP&@PZ4_#$CX1(,"(R?]^30 MG]&"(T)_0%Z7.4WI!%
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MC2-LCK!8IUS<Z(]\UJY=W[9M>\5'[SF:SX)OL\8;WNN/P;^YW7#C3>W]'_A
M>_=[WNO7W^J=??HH!G8O*B5GCL#SCBGT.0;/[?(L]F]4>IZ48U:O74OA7$Z
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MG_W;Q6M06NCP:3DV)G,"0.DZ'=)AJJSA)=D!=8$KS9P)ZR@/X?DZ6-P5'EI
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MNS9$W);DSX,OGBQ3%V#01XD#]XT*$)_N"PRA8<MYRB&KRN(R]GR*W[(L4U>
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M/![A51Q\*+EPT</N=EL5#FG!CR\\*XZ24"^@N?0F5WCRA'R -.:$_Z;B^(3
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MXR?EFX]YP5=YD0@6":6^S6].;T!N-EHL6"><5D"!#[#Q[8+C0P[LGY^R791
M3%I C8-K4"+MUVV9)'@&'Q<=8DOI6^E+\><Z@.SBCL>>&B]]H<<UTT&**IO^
MV&%XL($0AM)]54?IR!WQ(F.KPO2%UQ<74IZTXD'%E0\L>33-7+&'6!LK_806
M XJ7DJ'D>.F1.&B4]8:;,<:TEE!]0WV/0NDKJP[%4\9-&79.AP?1R.SBY"B
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M?W_Q%8 /?^VWO\]+[,Z>.VN#^_G/?N[-/ W&9,_+#KA:_^N__AN^JN^W_I]
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M8[>U9<IXYK;Q.$@\\K,F/[FFO<_)$]ZDLOD_>9S;WS/?(B^TN$(O#=:G]G(
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MG4YC4'XF(Q[9R*EC8('C<'>N-J;$)R,20 =<-NA)XE_P@V%1)OP><+KCHLD
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M'^RGVZ+;RM\DAKXTX381?1^<2"YHN)^A,XGKTWST77T2NR!/183/%31D93%
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M%Z59-S-) ^,[M.8%<]$+984UCJC]T@:K$+SHH<'U5I3QL0\ VG98:'!EEOY
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MFT0!]5%9M^^L<]K;_0"_G?J4^X?"WO@HS**+ON9T-B,JDP4>&\368SRJSAT
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M'!2 QP$"[TW(80(O/.6MZ<Q]VFQ:;@X#.#2H3Z:*?@X8:F[$J=Z\#^C%$;X
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M_D [LU;GL,1W,KF ZBZ<W'V2-5/*XD,JNH(487S/DPZ3Z,)@)HW2>"$JYZR
MR\4/G22_!"C>3N&2D>CL5[X0/':G(@L7MF[C8N)4@J@G*I)3JM=5DDM]W_8F
MWVNCDI_BU/>ENY'Y1QK(W)K(571.<WACY5,-RGU' *>MV:C(\%PF0M%H?O9*
M/<<G24HCWJ>^!PQ4\LG'MU.8BK@!)0&/&M"R3=,&7E=V.JQ_4I :7H;%,R'D
M0>3) 1OUYZ(5H^0E%[GRAD)1= ;L;!;HP#(M=QYJ+@5(Z=S.PHL'F71?:,./
M.*?6N0'EL>3=%YLTF)W*I"/*R$0S0&H\R'H@JB1#\0J0@9L3P9]=;M\PC6\
M:6F2OW7VS4#>8:?_56[)1]P7<AQRSF^796N$F%UHQC*CH[;0;X;.;2I \X'^
M7#_Y3HH/(%=W?$JLT"#O%=#TEG0#JJ-MA,44=$4O0I0+4 3[=9^0;;L_F$[R
MO-@HVK-+OX!,/J<##70#1&Y/W/3!6O#TM_%]2% N'5IM)@]'07P/HY)WN@-
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M%!Z!X;%>-OY7KUWWW2N\=X [51[N<U%TWQO0:(/'S6(C/1_5P*0?=8"?&>8
MF[M@'C_2QON1#P!H _3)F'CJU*;V$&N^PYK#O>W3VWX$@+NO_^JO/O)!6AX!
M>.C/L]^Y?7.BSWX@()X.)MXR (@!G]QM?4JHZ0]YUQ6Z)%9]1(WIQVI8$TH^
M+A:QH?=M_+(WOD; Q5)L##O)HT1/+-\&=Z!J[<.PP1WA?&(07O#D!?/<A0I-
M*=W2T2-MZP)DP'4D;6<VOJC%'HL]'FM7OM9V[_X#SZ^\/V=J=Y %)BF7=-B)
M']G051R5F3SQ=DK'Y7_Q7P T<<$LJ+[8-*@+PZ'%*+10@V?E0]=TR @2;=/.
MX[/2':[\IH]3T915A5S;A4S36LPV@44*WS0:(Z'?^_WY$8!C[[[WG>_G[:L9
M-%FD8)S>&+#)(<V.34]NX_<&76D,+J3EK@%N">.;S#SCE1/(IH-/)\"0.3UC
ML^4-NGS>N,_53DZ"FU<;!<#FA(HW+0XC>.OI<]&B[%MOOC[.GSMGXVX(G9RJ
M66.&**4!FMS6XF^*R\"0:6_OWOC\\Y^/BY=VQIG3,G@9W-;.A7'ATK?'L1-;
M6LQK<'NF 4/U93"@SNB7TRXQ++F+AS+@@2Q8*GD6QXY!F].WZ)4\!J*Y_K,.
M''=YA4UVT905QFM\^Q5G,(?^E-X^?^+!) KDQ''!7RZGP<%5P&$<;3[AZ6>_
M\CI,6W78$G:^^2:<Y(27+F#$*<T\Y2]YQ<TTR,.]#.EXC0,'POJ7; '%L'_:
MLR?*!B\JJCR5Z;?_\Z++IZ7;[EY=#'^2U?8[IV?3%7 ^>N978>0PKVIS)7F<
M25ET,??)[K.T%YN*[H_8%N'N,\C++90\H\Z!'FD^R5:^OU=< T]/I V126TH
MWCELB%R,+RH1^Y/#MU.JR%@?#'B$5.*5X-QBY04AOL/\,W73%$7[&>WDE_ZZ
MS&'P.O001#8&0]6!\,(UN(Z*NWBE=_U=;>F8NI/3FQFWA\8985GG' !P98$[
MFK8VMI2?NP&:C>E39NI#LTVWWSC\6KK(VO4EE=JTSI"YY.P" L?QY4R;D/(=
M3TQUK@)&G0MG(EK5CV626\K;X92':B@W+K"D,?%!V8J0EPT% )[<(1ZFY8)Q
MH8V]H_MGL4NSB+S(WF$[LA9 6M/&N0^89N1M,#>G1<ZF0ZNT1)$O-"T[>6ZG
M.4X']B*= PWW716 'Y24[7HHW1U=X*M]5>\E.*[VLJP+/0/A'S#::E%!9 E:
M_"-:V(;.*IB^W$R3NE,&>W^9;^.1%MTG'3!>X>"Z'+"D$=_> N:$93G3F:0N
MVA4#(N><K]()%BQI-9!$NO/*9\[-_"A=5#]YN63D.0S-8Y8S94FW1/+;MHFW
M33#NX9':)>DJ7%UG (0>0<M7KG,:,J:0%_N.#F;/96C',)+O1/Y-<?(0*?->
MTP%"I*Q 4>R]92V;:7:+=IGFB@8%<^@%3DHW3*HH_,CC8'CJKZV6_Y$E@)3N
MTUH?TH_\4CLN4A28HNL$'?EBED-RY)MY@FD4ZW'I*-;< / 33]G4$V>T2@OC
MX!BOV@<DQB_F[B4?EUJ))Q_=]/SO9\6W-L:SFL>94QJ??-O! 6.+U@4*SX\6
M9OUMFS,4'Y61I_1>CZ;=[: MGS4AE0&'EO/GO)D'BP8$TAX5-W9!T7R9]IP>
MES E\>G/O3Z9=(OL^K,NY3*&9IW5=,*2,'[J#1]\-O[[VMQCF=L[NX/'3)BW
MKVG3_]EGGX^OOM(F^\Y]?Y:/-]MS5S&'^M2%BYS4G2OI@9E7\T!7#8V%?(^U
MP?>Z7_*0CF/3_,Z[[YK/M6O7QH.'#_Q%M0L7+EC?/__H$U]P9*/.W51W[]P9
M5Z]^[;IZ3:# ?" 2O^, 'ON3]?63VIR?'/X\KHKY,0/?441MNA;2+>L*ZXS$
MT#JA#?^I#;[RMB%=:!.N.9OZYCTD67.R)D)/O/2808O]%SJE_/FS9\>.OSS
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M;:<V[')I>[GVG9;'%6Q3_$@OOV6$SF&(^4JGUB0\A>4T_5$)H)N8*-F2K=L
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MG9V0HQUY1UOBZ"%MT.V0M7?LDGG/<RL&AGV5O:I$^GX-.>B%C3>/)7"W! <
MUK/K#CV^()?WQ$&'BY"\F\<72!]K/Z8U]<[VCC\?B*R,UR#VF.:H '58CSCB
M$"X@A7T%]DZ;?_[Y%^/NW7L@J<YK92^T0^Y \'Q6M"@=$"__AVW"T(5_QQK7
MS50X'G_UHW>:'-"^8)(WT91S64HW1._+<LT5?&QDJGNY)72\_<A3.'B-WDG@
M.;R4(4#>R@' .^^\]WV_8$$-O+-S6HV\X<7KYM;&.'UF1R@OQLFUDV-='8#O
M4VYM8PB;8_OTUKAT^:(ZT-FQN[L[3JN!M[>WQH4+Y\?%BQ?'V;-GQ[GSY\;E
MRY?4@:Z,\Q?/C4N7+HS+ER[+SU7[M]YZ<[SU]IOC[.Z9<?8,IT3((!H7SPM/
M-$0;.KMGSO@V'/A _XW77S?-[>V-\=J5*^.-UUYSY^-S@VV,!W(,NAYT5&GK
MJ12H@ V&32II&9R.C(=[]\9GGW\RUDZ=&"?6U''4R4^?D9QO?T<ZV'*YW'K$
M)W)X*<B>C.V9#SR GI!"L_@2KO9(N".)KT(9CQPOWTNVS= _%Q4Q? _0-?#)
M,SUH9V!,NN.3(XT%1_Q5%UG<Z4R_\3M<<0^L&J3E_"9Y=SKRJKS<,2WF>T-8
ME4;R\A/WS_AF%SG5@JZ/4?A/K1TSGM-$ !6#3:+U5'GXT57[<[E5GT$B.#.=
M'&!Q,FQH?--0Q&DJQYT?_<;B1:>-8#5B*FSR7FZ0AR-<,?W#9?"EK8-3(B4<
M 4._\NR.U,!&S+P"A>T0R<85#<C8)N&3W,(+S"'RH KMR!W>R7%)RRJY^5<%
MY\<&!.1)/PDRJ+'Y9R@5597Q!*08=.D;5@*YY"4'$DZ/3I/'+Y,!TO$?IW"*
M3"XFI]SBV?@3-"Z0;/WE!_#N .R/ZAGPN561!81I)JWEQT>^OF6211DV1+NR
MH>44WCH4S_"08S)QN\</$[R6H_&HT"Q]: 342TPWB][HJ@\ 9JP93"6&8)=6
MCO-?T59-[ ,3+?N)6UXO@$JOI.$G4@< !)U0-!S0O^H+RB,*!@N:C",\DTB*
MQE9E,KZV\\M>Q=-MJCS3M*\\M0OA'N,4$5HYXR4-'/*SH$6.W('!K:#X2SNE
MW#3N62(YA3,N*2::L!*F<K0<-_DJFV6#RX!D&G*V'PX %@=)[:"5?VQ$'*'T
M N #)%U%[,R1@,"/LV#\X!I-_Y26_A\^Y-GFEF%TC Z+![+.H+#KK%S3H"WJ
M &,!Z,0XE6<;L$N^^2&+8^VG/1RR/$99 9)['#*LR!:@K ]:;2<51LYN#PO6
M' /]LKB7G<KZ/S'8-3_''()4=!$\\.G[E>O_@'-!AH;IQ%ESH$DP;+87Y,XO
M'<'=+WF;(+086Z1DQ40%VB4M$.D;%*M(RPKY)3BM2H4KT54D4&P["D_5</K+
M])=N);U^&7H@LK1QVA:(#HQ)>?_Q Z<8"0@YNY)F'I7F/-*PZ1RN=O\#H2VI
M#P"=7*FVDP+2I[8OXM#"M_T7,ZP>[D1=WF5HXZ(7!LZ<9"6N?)S+D08*R:97
M92L_4/BB9]M51F]HV=3QF!D;/H\(1;](V%7,.FY],.XR#!Z7S[J5*\9L'#44
M^^LYO'2;PP';:#GK)*3D,8XR[Z-+$2)/X/6T-^JSCMO&/?:R5BS]>P.,$)"5
M\X92CC2^X$49YM#>U/GB$@<#FBO8@&;#QT8W+_#VL^?'><$=M[ESA9HUJNA8
M,G@DQ,7%QURDU%C,)I^-/WL*+D*B]+W]/>/X4$0T),8X?_ZL]SCKTA/C''7A
MI7:\&(]]$[)1$3C $7VYO6A?M[-9HS7]!R]S%KJ)!? 8P-K8/7O.]L5M]NQW
MMK4/>OSHR?C+O_SYN'']A@]KX'WSQK7QQ1>?J1QE\X@AFW_?[G\2?<$3^X]O
MO&E,$4>E^YT0JDM(("NX[>HB)S3T8Z-/?=G$<U<$!PL^I*&M:%_1\R/@6A>;
MG(AP )#WI#WT70SL*[=5GN_XHR?^Y5&WTH#B=E.84"*Q)6R(NQMX5./%^/2S
MS_RX!K;!)]]M-PHS/7G= %TJ U G_^8QDRQG.V_V)\<_Z8Q^Y@O82IUD<TQQ
M[*OE+'#,.B\@W\7)D0L"_U)W.:\/: O3,H+I+FEWV!@*NVXA4XGE!$ZN\.0?
M@N4C $?^L__C_^D%;W5<6]]TIXH@JJ!\#@-NW[[K,!T/ \#H[]V[IX[RV"^J
MH,,97YQI"#;JO&$3''H0QKRIC?W]!_?=T4[+&#BUN7?WGF\3@>:#>_<]L-V^
M=4NTGOL6&$X$O_CR2S?\0V_,9 0RQM.G3_L08#Q_.O[\A_]:'7V,UR]>4O2I
M9+WE0P . '@? 8J"%P<:\ZD51L.@H8&$4S*,6>Z9Z+'Y_\$/_IMQYAPG34^-
M]^%W?F?\3__G_W1L[5R2#,<&WZWE>:.[TLN-&S=]XL7)%'JSP0@+'M#$!W(%
M*(.TVXZ&QR#E9Z&V"&MPRF(: TMS$$.7.;3(W08,Q/QW&]M8F=*,Z0'(OJ(5
ME"PIAQ[CBJZ@EB<"R3 -%I&=82K8<[E^T1IV71S+D<? 3JGN< JW$ 7-(K0K
M0KE#P!49&SN4I",OHK7)I(.;NO,:@M-IJ6O15!*R6,<2FO==]. (-J>A#_?W
M_=(7)TM RF=@88 7I@887E;Y<)^3S:>213C,$ 85\H":.B,"U[PC2^MQ46\E
M49>D6CS7I\&V4N -"5I2-F_@=]L35AXE: /KT8.,4^2 :-<%72F2:M"R;D@'
MEW!*T4Y,5+%;N*+/;+2"&T!^#[[T)]Y_ 2^QX'-.U!G;]J3 PK7D8>%AN4T[
MKNV"&DZVY$DEZ0W(8]V)-AZWD'7?@A\UU3_^I#ST;TH%I(8>]F3]V;#XTP^=
M@E%%D,,+/?JB7Z*DL40;T6Y+)II<9<AILU](JO;B<26^9L(5FN/J:QR@GCB1
MTW<KS,3G!1R+">2:;0C9JGTDA"<8.=<=F5D8*9^?E4!9-*>\9T=",S62WW41
M/_KJ;$]DQ(8 DLE9;CJ@[WQXPL\^,F%CH0-=ZT/I,;MEGJR&?'AUV6A8F<)7
M'C2]R/)B3@LKZ0!;H$NP,>=J"7><,8X_EWX9UU#3$0[ 7(?A.[#0S;$3.7",
M?3C+GCF*)HL4QDV>/V3LQ%"Y791WRK!0\298::T3QLDL/$MF^8Z[HHF3A9[=
M%H+4E:QJ(^3RY]E8'#WV<ZA<!<K[(C)&03]M#%UJB \MGA%6/54A82B%.F0A
M#-#FR_&4>K.@IB3)X%'<8QR_XF7<A4\YYU%T(D?=TO[F 0ZV*H)"M2Z[WTU@
M.ADGVHS"1\X>=0LD/7("MB$!<?*\>%:2KXB4;I-) -S")Z0@BUAPFT[G@Q%[
M\;]*HDY<+17=B5Z@%Z.^X\ZMBAZJ7 %V @ZE[!<-;@5N3)<QV90_LGA65AH*
M7>=C;PHH2RG*29]Y7FVL69XL\1 ?Z9^#,+  6$ [<J0]H.T,EX(O>;B4^29@
MZ#8E^P&D9%'*62ZEPP\G3/JV[2%TK8=RP*K.2.N\V-3DDA+\LC_Z!9IGHQC=
MID^&/I02)@M_7N2+3@I8-LNGLD84^/!9$3:\W:\M;>7S%9^CT*VXZ1&!A^?H
M0 Z7:._HO ND+U*)U)%#>N9%*M%R*8(@WC1-<3ORY53.;4@LW@KX*S3ZHY^Q
M[N8.65ZV=N'<F;%[>EMU9@P3HIRT8GK65:VIFB2B>K@1-WQ>"K?!^ZZTN76>
MF' HZS& 'XD%3)EI>\GJ9/*=)1 ]U7G9%P)P1@_P7LUY%2"[?Y+=WS.7WQLZ
MZ- 7UKD*;'V[0(&E553M)?D\'DDGN)YO =9X>YJC#S2OL!?QA<37WO MZOM/
MGHS//_M"&^R;HO'">Y@[MV^/\]IKO/O.F[*=(]ITWM$\_]1[EG[LA\<-_.BR
M;*4/P5F?^!"[QHPDYOUD7!7/>/G"=[L=T7QS_L*E\=[[W_9>B_I=>>WR.'/F
MM&]S_V__/__=^-,_^3>^.'IV]_3XR4]^./[Y__L/3(/APH<0:$0-ZK65Y((V
M8TC&0#G)[L<6O(90^R$O-L/8*=6X+Q$N.XZ^L'7N$#E9>ZX+KK?W@)J[X8?^
MN2N<.Q7X9#S,F'?V]Q^.!P_OCX?2(9OV]][[EB_24@=OU*7_%S7WLH[FAW5,
M:PUS5YKJ8Z<?\^GIG1V/2W_T__WOQI=?7;7NUD]MI%\+CT^4VG94GOZ$/]F*
M8_1SXND?^K,\41*\R4&/D8-]&WBV7].8@7VC"P 0L@=/>#0W_D,Q>C>K2@?7
MY5AGNGSJ2EW8J_98A;,,9@6M\/$:EC!]CK8@W/_+-AE_'$K40-G_VW_Y?ZF8
MYH#_]#_]S[[_WGOOC9VM'0]<9\^>&>]]ZUT_^W+Z]*X/ 3@ENZA-]EMOOCE>
M?^WUL79BW5?>.17B%IJ-4YON""Q^,0P. :B 'RN@,ZBA>7/C_?OWW>"\Q.&K
MK[[RHNBT:*C0N'CIXCBU)@/S*='S\>#^O?'DT2,9SWN^58>796"$.)1R[\X=
MU>;YV)(!K"N/6_[WM?E_JD[&HH#GNKV0L )3\2B/P8H##9[]3\>AWN!^]ME'
M2M]7^,'8V\\M)A<NOCG>__!OC!-K,5X&53J\/P.XM^^-#0WFVY&TP' C5D?K
MQ5*N2L$[<G2#X@,TJYNV&BH=0>EI5X%-QCK-8B_XZ1I!],+/87C'&6\1CR,M
MA#U@3SP"1+T00A8&&1MO:#7X-'JEH$O9,5=UK>)4OB0-/?V$,-<BOU>!4Z6[
M"$EY$@3H3P1(+A464!\-%A[\:B&G?%"8N*!!F"N-/40XI &/02SY^G6[B!8\
MD(\47_U_JLVM)R<PPH\%A-N5"0AP(08C;"\X<+=N<(6#?-:$$N:#E\.@=-"4
M#T9*R,Y<NNIH^M@?=-(&&<*KEM*AXY5'S,X3%$B17XH0&_FD41]\ 3Q+"*=!
MPS8!PTIG$&/20TKK0FV- \!(72F"+@F+D+QL/I,'7<"+K&032?T8Y C+T:](
M"T -N<6O)BZ<-Y7.5QD1]F)9/^Y0H:QIJ/^;+K2JLNY[^/J?JR70F2@IGO)
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MX-[=^^.?_==_.'[P@Q^,K9V=\=KER^/++S\??_HG_TK[G:-^#!EYJ5<VGLC
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MGL(?M_O;=WN!#VZ@^Y@/\)2>A9(<JFA:<L%36,Z;"-I8CHGC0),%]:;/\@Z
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M$A&2<23-A0)*1(<I632IH^V> ^07OE"VL[V9\B5(R!"NNF+:Q!0,/>0AGCL
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MZ^;-\?F7GWMSR5OV<?W(,S13<Z^"(@MLDJE?VIC'4SO.?TGJ>-8ELFJO;7+
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MT@;I[Y2A]!'AJ"1RTB[%Q[Q(-$H)#@[EP*.PT^6*EM,H0E:E-_28FOD5W;C
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MOY!\\6/SO?]HWW1QV$"_$-%.F_(#K5F%BHHF//\L1L:CS%/1 _&\!%NV14'
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M)7U5J2<+NUH<M8S-'V?[9E!2^5XH@;7$T9]]VU(M*N:K2$77A9!9VF&\8&P
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M.CCXY@2>77 8__RN'(TS'DN9A]P&*E.RI.^F7:Q[A0&3@#X_\;+\'B?(=T:
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MJ#L,D-Z\NI:N)_+*V2;:5_LL]>HZX?P3B"?C!X\JPOOX,0XE>/]1]G!<X><
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MJ3RTJ1LO<.G)&!J^\DJ<9Y_MIPZNOQVW1CWSW1!/Y$^'3:X';90Z-'_JO+J
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M",J#]AXZ!N],7O14W#2FJ+1Q&J>-*P=TJ_^IN'7B>^6![+C+['(CA\3@Z2)
MTF>"M'2*+O:X\%<WP02O4!=L,42'?L=37/D$N-KXSC);]FC($5WBPG-GI&^1
MB;85 4C8<,"8(+U8>W5NFWIV5GZ7.=$Q*9-_2B>?@3Z,R"L]BXZIUPKY0^M)
MSMM/Z*0_?.W)_W$<W/43S_D]PEWI=\(=/=#_.^; '3[[RQ$/,_Z?:%I:)2._
M@>^\XU_8.LEI\=ACP>0R]M 8DQ\[.O[FO4E3<>SG]NO$[8>Z.<=7O2^3(I/<
M^Q)=;]]Q;'<F@/=EHI7)YFG2J=S9I_ARWIMN*7]W8C\EWN.4ZUO>6Y\/O>@(
M_)8[H\<X,!&_.X:K)/2X8OENGYP^6%GM\LH6WAIO*Y53O4\'J=^5HVQ]ZODD
MX7E=\FY_#'(+(4%2'K9__%VPOD>8MMWCVOC9 KO;Q^XR];DG$_^[[XX^Q-_:
MMA7P\IA_Y@=]3"]RUR9>@.>FJ#R/0=^\>>-PX\:-VC5C=TUZPKYA(GKAH3XR
M"V;TG<XNW5]]O&.R-_0;EX.O$__@'ID BLZ[DGZAX[QW#VAGM+9/^#DF[O[2
ML X3!L[TH15;?OI#P^)[^"?SZ(\V.I/]#N/ST"=SH<@I\D&7;?YN(GOQX.81
M[1Z#L+#A:P7TID@:]*F-=Z>-?3D/=^;__N%[E3AJ3 Z?UI[P-LX@_2B2))X7
MD;8[3?,<$\_#%GKSEJ+58%& Q)XOCK"[&V!"TC>X,Z:+-[#VY'\K<!LQ/R3L
M,KN#'CNW>N%ITWKD48==^1JA,'.]Z==1=&Z??KCTP-S]1])P3EA14O4T_DJO
M@A1FZJYR-1")22Q.;X,\3MYSK)%B0)J>,CO?#H%UWOQE9(JSY9=QZ_6ISO$Z
MB@CVKB/.H@"'.,>MT.@E5^>5U<3S>L?T1>>&N]-/LIWK'7;'.'8095=,0N,8
M6^(9&+N-!L <"'Z*+Z60WG*!>82KKO.!5\W0ELI+6V7:]F0;7EIO0!5'BF]$
M-5@Z+8,VCML8J('<XD==V3HLCN-$QSE5'!BZOXW+#E-O&,%[Z*B,3IV]L,&L
M81Q8#',-R2=GCE]^XRS!.XZE;ZG7H43+E !Q )=98:XW'Z5].7J.FWZX;*?F
M6'2"45[0/_UZ&^YC9-R3-OQ-&!Q3_A2W\1\Z\5(')D[ST+#*H6W]<.(.?O-R
M+$SY3E(?IB-WTO;1W[K>,C]>:VX'QYX/#$<5CW#R&YH6OV1;NC?<@=DV:5NA
M%\S1QR0NN!-=S\& .#"GS,!H^R:&PUXW' '0Y]B;V@YV0#\]]?7:G^B3<N4B
M7D2/B7>&4M)CRQ_#J33ZT,9V"T?ZOROL.E/N>X4-:\>V-YW+>65?0:4<?'1(
M.0XRG8Y.3%_,,?V1CK5L9'.R&^G7X=T"YGZ.L8XGNY4\M@YY>R?/MDFU9V19
M&YB8^A901J9D//+43@",CB1J%[2GC2KAM'L1-.9_\K<^MQ^';CM ^EA,CCE)
MF?#9NHGX3EK[1LJ+P[N^,O&H?\>8:_U%F915WB-U)IE=; A<<>AQWM.2N$^W
M_%SO_M3^E>OSM,)I7!D.*WW'9IR=.Z(37^?EVG_0W_.DQ;9'(U)GRIV'0FK:
MAK?J%-4N*_U[\;OK;'GM_/"[ZI_'.JJKS+'.HOW3,'>9\G9LA]4&:P% FXC&
M$-%BJ^.&O=MX[*OZT@;GV$?G",V?ZP5/O>I4[33\0X<T>;U6=Y=SWC+X6WDK
M%M;*&T1E=,J">5;N%(U!B<I,+542R?7.>@-[XK3;X)AR$S?\TV+#P)_^$KU0
M#JPCK> .[_+VY+8Q^3F9O"-UPNAX\3?(/Y49F*YWGU C,=F%GS+%O<IL*#O,
M]93;9S-F+-B-0_/FU_F^/H];)L?8<77BV.*)Z@Z.U3[1.76G/\^1C6LH6:=Z
MP>"L=#FR:OW5+K)YY5ZEAC1MXA+*+K?&G./8P][6GN::K^CF5&,FCIF@6VR=
MY\U-]B>:X-4?S5%=$[_]S703J OQP2_&!W=76-Z>A'KFNU^1R;5XK[P5X>/O
MGL>Q]7,^?NP<Q7DQ+5F%,S[B\G4G9@(:G[$WM)8\Y?,CQ=/XD?S&P74*6XZ)
MK3NR/:IA@C;3CH(VZ#%E3N<BF*X1.?3N/*WG_\05U*G/.W17MIE06WQ)<M*4
MI3_+!NE[\??&#K%1T]> ;/W0K:ZX)]ZVL;_UUMN'-]]X\_#>N^]VL;[]"VF+
M+C#*:^&,7,YMFYLE/G^^/ULX?7QP[_%_QE%V35\?7OH<_6Z_,+3M=,=*?:$P
M3K!.?2I4A9;1^9,-(<CJ=".8::?\.F\-'5Z0_\'MT))C;7UIG4\?FE/933AZ
M'=W2#R*OOH0V\(@#_^0N?_<#?69$M=KI&%?[5F[HG5@ZE2^MJ\SO%[Y7WB";
M\*GL^D< (O+X\H=>?RJF\-0]&<NM9)L@.17Z.HY#DJNIT@;3L(38 >G(9!IK
M37#.&TTCV )28YS?3!)!E^!%%A%X'3XK*N04I^SNX6'>9CDK1^BLH<HQF8W%
M 5(N*:0&9E 8Z]FRKUSRR\_0DTM(>DXY2A=R FB_R1[L*GR.8S &;V6T<8.;
MBF+[-5KO7>6+>Q_!"OS\V\K12 Y-1UE@Y<+X /T,QD/+;A='"DXI0\F*TLF>
MG&<P:5L4[M2I4H*Q<#;-=4++0O1=80%('#DDHC=Q^$Y<5(L;YC'F-YT1C'/X
MN\X*"Q@:1E>TR1B-<;@8.$8AZ;NSK\"H!YFS)%N02O;F/ZGN_G/8."7CH"0F
MIW'AJ['9,<*O<6,P$K=Q46_#W/*HL=ER;=H>=%TA*[#VW7A1W[@+_D4?N&+*
M5@3%E7R&*;Q7-TMIL 867&0YAE_]1=\* VO*^XW#DAC:MP'>1E9]-))5$G(,
MK<6;F')39@>X)HZ,##)@)58N"X^\X-EO""?[:;.UDIQS=TP\>M"[)H'<NRE@
M!>:\_/(<KS!X)XR<V]%6V'2AO_(8::[,T\'"@_<D'!W[T+##AK%#KBKC:<J!
M72AG97;8[3UAE=%NU3<+,4//M-F$]D4#1V/.<RT8L+HC($?(U6@,"JW5EEVT
MBM5=L>?:'_I3ON#(^;TC#53TX+&0I9_BL1^=U9NZCO2)LZ']DY:_K?_J.?JO
M_-$.)?:;NOKPFMS*Z_;'<*4Z&# 4X/Z_9+OA3\Q$/O6]Z-.U/EB=#O,<MP@P
M\ICVCJJM<_#<!4E^ MO90;QWLF; %VO:F+C5S[KC+,?;M]YO;'N&;WU4:Q@L
M.G'4MSDB8J[MPO'&9W>3.P$BLQW#]\C%47]AYT8N^HRMAH[[W0ECE\A.')GN
M"?2V'8Z5LU]XV)%T'?==RT;]A.C[2[G51@TY2IN8<H4[^<6)WF5'QPY,W#QM
M>Y!_A560(*E?6"LY<4S8QC'P]WGK'=,7[,9-1WAR3-&YU@[*S\)O]3=D[#OU
M)WU;CZ2E'C3GN(XXPM=,7H>7PET1S^!U3$F\%3MWZ]:\';MMIAU3UQNS/Q#M
M*ECRJAS90NVM3'1C["U\&U?:!^[6.=$P_*WZY-ZXR@5&8\[Y7AC3W]N]PZ_^
MLMA,<*(]AYX&C1U]]]C1O!QPY#%\#.TCFW,:%TTIM_5C]%D=BWOBT">F4HZ;
M[A7QGKS-)_GF)#&P=5PPSW"5]M Z-@:^)=,5]:U.2%I62'EY@=>K"B%RB6#Z
M*\W2)GA!9$JW/VW[)Q8?E$U/G>* >\,8_&H?RR2>Z$@(;],F9W$!A5'L_]0Y
M4G0B;>S?HN$\!%/KG29C4C.>&!]#]_@C4[\^W[)KI5']+0O5$I2K/\-7%5/'
MM<D]5:I];(0A^>LW/@E?Z,S_*2S7QK0UN3[+&_]IZ5M3S])+JW,VF[\/-GA4
M5;JRJ95K=%79 Z5MBT!H'')N<GF^2X$/[]-QLT@,[II/&(<[%DL?/L0B&6#M
M(X[*#3^3Y:1JTICSM(5D989>M'L!WJ60.O!JN]O>^=&')'<.<1X&8.NK@[]Y
MU]F,5_?EW!BE;_%MO)1V8FQ/[)+S#]O/,EX%M'8TP;5P8A&&%OK*R[5KUP]O
MO?UV/TG(QK3=R81LR##\FK!C"JS:F=UJ2:-[>Y<M.WC[=L:PQ-NW["SP?C6T
ML'GZ_?1;XYMO^Y,;2,/CP"2;N;%PBK/P-K+:_>O8QRH>[1&:5PP'DU'!IGSX
MZF,HB6P->?1K$VR1S[7?#IT^W?[^C<.M&S<.[U^_=KAQ];W#[=#_47CQDE$0
M??[]^K5KX3,\I1YY".@?OV['D5_[RK$-5P@]KIJ>8^N>Q?. U_-0?:'GG]:5
MA+O'. Z 04 H W24<80R0+>!FJ,R.L),P#UG',&$Z>VL2F-D20X4*R2(Z<"^
MZH._&^;3#;4;2YDC38[20J?M*'VQ!#QK4!#*41!8:42;?&'#+PV)MF-5F6]<
M/[SYYAN'=ZUF60B(LD^]P(&['?!,L)6909+11R>XPT^QYWB2W1G>%7>:\J/,
M"^[J^#OLLN?T]QR^)9]=9@?7QWHCB5P/C'/8PJ?K"BVW:)^%B%'*3]?]7O!V
M.-)Y1]BZ\[W#.2GJ5J=VJ.+>2:LRGZ8+WG$Z/HZ3=;/?3+V5CGC+D4,>H\+1
MDJ^>FLX[& 9\S$5^%JF6$QC]8)S&49OK:>_OCG.'<=,P.MSMQV0QY#44[Z+]
MG/XZ3W&"VB9)JX,2&.,H#._R=ISK%,V1> 9ORG.>&)A51ACGX13&R9M CQI3
M9L?-4VG0K\!,^T4]N[5:+Y[*.2Y=='Y79&\A[!1.M H;O@#^V(N33&<!9>1W
MDO6454W<92<N>*'+8A]!N*[QO\/A&ISZ;!?J2O/$:2LB"RWG[9MS UL'JK0_
M>%L/3O#,'?4/@P<)@_E1!H3WQ\BO8N=MO>V1P=&Q]*$UD8S'(1X<JF^'RD1L
MZ\KF:5]/ (L=-+ANOD;&)WGAQT Y>1O..!8$$WB)5$[<[WXHC!Q[=UE<]?*O
MF'=[H7O'D_R5/]41T<V.GX)S]O3$VZ:OQRW(A/,\\12F7\G;LABX(^/1%7DK
MK*J[#1IBY]4K_PO^V/@<$PWH=\6IR(@U,04O9*RPJK_;]][TK3[FEKK2NF7Q
M?ML:;0WT?>)[EXSF/0$CA:&K<N8H18]/U"=HF^H&/9FRH2@Z<>HG,Z'35J.O
MHHFFHY?5LGU[TBE.^='Q@3EPZ8+@ *YVAW??)<)7]2Y']0;W:FMTYMAZB;4?
M/4[:P$7S6MB!OU]=6746_>#N=MEP<.Q\ZQE>-N_%O6+AG*65]I03=MX.YV4=
MIUT24[X+'Z%%.(<K8'^'8]["M^.D31WXIQUV>U@$B,.[V@#.\K+J.3<>;(=Q
M'M$:/G;[[;C;M9]=7,=]+DZYX6O@GN XPG=.MS3'MO%9."]3WEI/>MJ/-D9O
M3[3CZ31F=J*9N*\W##R*VG9^0XOKQLB/7=QMN.'0#[#.Y= =<$>X(]/-]\ \
M!==3-OPN/2QMB[Z-(X6.\&:L"/[J[N)KQUR?IYWC._;A8SCIQ/37J:-^X2>6
M/K\S.,*=U\Y37MEC\IR/[3L;XW,]:2[FR/+,HOKH'1]"FS?&;AFG]MUYYW"W
M7U0LD07=#KY.NN,GGJ$;VNNS_?X!'O91 &]\L%/;F<RY2ZR/C%Q&_L7=LFCX
M;AE]NF_N<.0M^1.GH,G_/M]!/=%$O L)QGCCMO--<_E+&?:^Z8N?=3R/X&\Y
M]CK^PO;U]T39CDN[Q% R]&BSC F9?":A\?KUZX=KF60V)&G#;_Y*$S;]^@T[
M2UYP7[ITH>\Y@Z_C;_4_,LXX81S0C\B^\F[]D3<^+2"8#PP"52W01Q_29CY9
M3CYV"'@O0#^99Q?'_?<='GSP\L%C(&VSM&WI I.<UJ**,./SJ3WW>7TC=B#)
M=GM(NWG# H&7Z2H;.48&Q_+?(WZO<!193_"U$L["L7[CI%7>"?4-V2\[&,PO
M;MXXO!^Z;MU\_W CD_W;[X>^\.NFG 4-.R5NI/W(H L3Z3T=YQ.GKVW=2"3G
M'*6A;[?ST'IJ]QT_'7:Y_S'AGI=>_*%?F-6ZA?Q,@>^]*TYJ"@VXT]F$.PF+
MNK:Q:A1TBC1NC4/HFYJ4R)9ZAN2D6,+N0.CH':V[;*=(AT%78"N[!],:YD0.
M_\7[[C_\@1_[T>X$\#S*AQGP.NDJ#1I- ZJC$Q \Q<[@=]OVDP\/[YL<IDZ=
M_-#TZAMO'EY[XXUT[J'%UP&>?.*IPP]^[G.'1QY]K#2BQ5L=;UQ/8V>@5;<\
M4=3\*I/P4YG\<QIB9)-\!CEQ9)13_/4Z5[+PL'@N/_C+WR[?D#SR;4;C*;1,
MD_-/;$F <Y;K8MIT]I!V3436#B5QG;>,-EFGGPZ^OUN57 ;R%/._^.7#L11W
M 9G/"@*M[1S)>NKT.GF518ZC=R90:IQ@'V,JS*KP"=;$G*=MIH;)DCN\F;!Q
M%-8Y9YFA9608.-0&Y.'C#R+C,Z%L7*53.852&@ZA^A<<0^-)QBV?TX):1J]&
MH3HZ.C[7!KG62!U&4CURSS6\^2T)%B9Y-BWX:MS1M^#3>^3MA8#)CCXE;#Z*
MFV&27E9663'_8*:'8ML(P)9IX?YF4@<>E5R#3WAI0LNF=$_1,WCG.GFINQ<F
M7.L:03)Y<[IPJCMT.-<G)X3^X.*D'//U%6PJFK3\2X1'^4)ME%S;DI-!<3KV
M)72Q%<U+6=L,;57T3**Z,Q!R0F-[4F+><9(!=QCH7QU--.6G;0VTY3$V1@'U
MNK"I+'F!D?SMB-%W:5TAME+=LN!/H*-=2$G=3B"#KRO5B1S64;8EV_4K7CPZ
M7=?B.(H6<Y><I\#@J\Q3^RQ6;^JHS2+)3@=RMT.O$_0WL-G[?5=A<*;.@C.R
MG(G-ATON4-^3./HUMI7L[O<\G3&"? HC^-?84KK(H+@3PVS?"=-!]5 \WLA_
M.[A2#%4IMP,\<X"KGY)MOYH^5G"5)WA>=+06+^A@,[7/Y'FFM=M)@WMH$F="
MNIT_=U:,E]U*F"A]%J%S1#-^5]FC/J $GM"MG>M48DQ 2_ $T?"_=&'21TZC
M*V-K3HMPY.;.3^089S05 S^5CB'XBEN@6^EOG7SMB9/V6OULA9'_Z;C#Z1K-
M%?21?GEB^T)"DY5'>VCK8ND1IXCN4UL/Z+D^X3G!16/Y#ISRJRY^EOT;QW\]
M'A)YJW-JNY$I6Y!J">B>]CC&(R_;MD<F,.1('P1RG''LK"V#:_KIZ$CK+CIG
M\J5=%OXSFNJ(-IYH%,EH_*:1HSKL4/$5]_0C--!7\&?Q _S@.<K%HN+@/<E\
M^%*NQW4]>*@>&',^"Y*C%T?1A(;B6/25+XA29L:KX$J:>CM6O$F7UQT1Z<-X
MK"X$QN1-V6G?74]%,DX_S6F@%_9>Y.E$LC0!$;I*+WFO?->+SJ%U:+ HMN44
MD$UKOV.#$TZ\)IR5"9 <A][&7JNW^ENNBW/3E&-2$T<NC4V)ML0N=&'19 JR
MJ9YHG-Y]-:&TS#5=Z[9X=B?U>43%6WU@ZQR7W4G$^_OQD>I_I%AIR;^QC;&G
MTI(0"1=^<:U?+]5+H1R.>=7R,UXV;Z"W[$(R^K[R" *,5 9KP"TLJ3!E5)RP
M%R&4*)YU?0KENO3M>FW[-88([9<KCEY,'CD-7XN0A.J0\:AC-")7FF/JS@0[
M[=XT_V9.]-033P1F9)Q)([F;I/,Q/%__>[_W>X=77WNMMM^D]^VWWCR\=^5*
MVP6%:#GYS$"G34+;RFP:FV-"[KUFGD4?WV46G/<B)#B;-Z'M'QMX_QJ39M%@
MVRMVP +;[<Z?QJ[-.#9CU(R3MLC;P?WX8X\<'GWDX<(RQBN/1/15UQ*KA^#G
M-[9C[%H*5\>\G^TQ<@K,W_["[QZNO'LUO*5TQ\,9 _V$W5X][[CN/-'?)"?0
M050*6W[JL852V WIN4!L*Y)Y8M%L'*[WL2S=&9)07BSFIOWLYJ*&0))EY5H>
M H%HEXSQW+R<5^;!!?3F:X?SZZ%_73M^*F[2[O@*@&^,<\PT? 68@H!L(N[)
M1,OYIQ$?"4N8#GJ*'4@C0 SU+K+.DO-1KA'[)G8KW+XNGN+[;ISGEY351.W#
M"/1\TJ,S3'O%<*5,W]1K6TL[WUK=2GT-2=$8^&,'T/&3]_[-]S/)3V,E7VA>
MST=.8&]';*0VY4YAY/?[!3 :P3RKFJ1UO!/>X#<H3-SY V.NS^,.3O?J[YR?
ME?/+\1QF.]'Y]8H=O.2=I7V7+5WA5 :,'??U#* S..=\R1Z^9"X T8'$+9>M
M QTL>B:,GI#Q^2IUVR.%2MLB\%3NY$!+$Y78SD9_2:@^V/(#SM+!+:.]+53Y
M'>C4YF%X<Z17HT\Z_)Z8;!F">0JEHL<C72DS@V/JG\EL\$[<[30.XL8;&I6-
M(\X9[QTDNG\[-'8R#@_I!>/F SUE9VAK7'D3G6_\8OIUTCN!B(%V5#Y(2Z<Z
MP]Z)QY,.+-C5LXE)7.5WN>&77-MOEWS'P9WTC;/\HF/)9YRTX;VR4P9=\EIG
MZ[LC>N \:]_"0M_I>F^),W@/?Z.KI76W1>EVM<]3/[&KXX%1QSWY&\\.&Q>Z
MX+CU_MRQ:QIXZI)#CG0QX)9>B#F/+_%1[/?0O?+PE0MI8)YX7KR5OJD#KC*<
MDN-V^Z2)0V_*+5BV'0_>$Q\MF_J%53@CIYZGO4Z3>1-M=^AL@T][+]W8\ 0Z
M,+I/+I-^RDN-&/5.S.Z=/GZN7VV&7J=^#W?"1RN:AN8Y?AK^#KM\\P),7BZ/
MY25O^H32MN*F8<+H54HV23[[XRX)>]0Z?CER /ILZK)ATJH#VD$C'TS*1V\X
M.QPM</9+F1YX8)RZ/G>(;'47#^UC(Z!%_^+-=74C.-)')J:];L]NJ?:WMI]W
M@622GW(BGJ8RGBS,X"(!'+_"/N$4!N^G]*;Q=#TZ>*9':P%HY]FI1X<LV,R8
MO>MN_9^XSP?^T'LG[M%+O'4K?>\21V>7?2F?.:_-CJQ:9]$Q>0-SQRU+8?.Y
MXZ?U6-ON]N6O.)Z"Z^U/#2PRW/6W7=S]?W@YIV?R7>]\QUT&?^ZHGM>I7@;E
M)J/U=IW(9I=MNR]9;%R3%WC:PSBS^_V2U7DP!DH+Z+,P%Z43S-(\<,_A;#Y&
M%I]NRRGK2!_VEN)3VLA"O?:IL[H3DS>0%[R5CM=5%FIQ\C??B\:UP^ \??1+
M6NS,IV0FEM<>@Q5\,>5RDK^466TTY6?\..$>6",/_*Q=MRV#7FWGB-[EWS8.
M;\KI2\,W'W86N0HK.E!\BY\3GL#+T8V1RC+EZD\F1U"DZ<4_=8:W7>(LWW&5
M5_8HDR6GIB_(*7F"IU)3YKS7B7=TGX3"W#(GSY39QW]>P.^&NW'FWS%-F/,S
M.G>Y'=!2@LARQ4GL_QU:1[55WC69]UT)B9(W7/;@\N4':^_'=HS=$)01QX;<
M@6$=U3=F6J#>/L[0/3)?/"0ND"TO&J?@=-=_%J$5F'IVT!H?[*YE4QB0O9A9
M?"NJ,U]IXQK&CV(?[&2*'1M8)SJ$K3-;1\GD*..@IW?]<E7RZ-^FU0]?YV%D
MXV3DNW&$LI;O>0[J]WQ0',=.\#;\5;QA8)W;-O#7V2Y_#'/=F*M-A]@YZCV1
M3^1+UIV7)))A%_S)<\U3A.DW"U'""8[V-;>YTW?8]3X=OE?>W9Q4SY[-=C&#
MK@%V#!B%=_<CM;HJO%=D-9+/)AR?N=!H8AITZG%8A\FN[/0.REV'B_=[J_X0
MV8 1,&.<I.BL\SF&!3^PZD O9B>6G-:%FU*8/T4,A7T4B&,*5B$)M)&09D5K
M[K1, [B3Y&X_/>_=K,C!W?VK5]_K8P%$SQG;?6O3/XVB,3A%TY$FRD>K ?V\
M[ 3G>,9[_F&\RH\/DU_U6W['A5C:I^'\?G&'*O?Q<BGLBJ?RSB=_ET'6Q.2C
M;17J7>2<MB1:Q5[)'GC3N:>#GQ^/<,@LS(J]3MY\BB-E<SV#%C@#KP-8X8Q!
M$,$0Y]E<;Y&]O]MM^^G'&LKH1.3H#N%TLC%F^T4=TUFTSVJC!;=&R:]MD&2+
M8XG0-3]ZT,G\*B\HC[9Q1AW1.K :U0$W,?_*;Q(GK4(>.*2X^;-:'0C-GPDM
M6/MX)E-E*Z_(#PU-'[CZ8!V1EB?O^9T[)NKN07)@G>6MM-T.N_V&MU.Y\[+R
MS\_E,>C; =EEY55KG&YX9_GTH'T_\<,,!A-/MFEX'#SENT?7YWAR;%PPX3BK
MIP]R[C?>3K:7(]OG;A/AVLZM<K,+(>6[92\#FD%-.9.(E+/M5 S*AFV\-U_B
MMA_'M-!M8-M;ML4]\:\N+:?.@$;V[1]H1W-BZ4_L)U;5X>2YIA/+GIF$&[S+
M+WK9^A7+7\_7<<NY90,S<62*CJ&%KG?'#'Z56W2H8_)V.W;Y=OE)S+6)@C(X
M3]<[RF"'<YNJ#;>LSB/#8S@ZY><\$'.H7NM!G .A=H0ND$'E,&VL4DNDW)0%
M<.KL,%<#5SCB2@S[K-;2M^V@3\D3#[O.M/OD&X?8(B]C.CDBJ;0BH8PM*IFI
ML^-VXMD=MC<CV>'>C&-]"5'LVH6,9>ZN]&[-_1RWB>,8[+$O&!N#>YUW<7[1
M@IK1Q]$9.E ]7'(;?O R\IRQJ^0FEJCR?VK7*2^F<(]]:W[@]BY084G;\=1&
M/>?HX3]ZYCG0V[=\3SGC_2W]) [E;;NU]%=1>?HZ='4B51HG.B_==+IX]"WQ
MS)XLNO:BYH?@R5M]L?K;?A7Z<I0_;7OB03N?M]OP3T@CIO%/QA]I.QQE17;[
M."=S"(RMA='1&6^;? RE 1[G6\X9)[;=$TYZ.&T&] (OL_D3P5M]_%AGCLU7
M1UCUDI$8&;?=MNR'AG/9.RJ+'A3UN>B""(S2[#@XY]TN0^N&E<PCO2-3?)S3
M/;3C*N3VO# C1&/\Q#T)6K!WF89M5W?>"=YY0,78E=":*T64JZS0U;J[?M*6
M/H\LP%[RD!]\XI&>%:M#J[Z^"-[4F7/I1;S"AE%\BY:62>AU_IT6!>3-L9D-
ML7-A,SDY'USZB+YOP:UC4OJ>?E:QC^A+0V&G+^P^=>0%#<X7_\.?M)6>_#VV
MRSL>R6?UO_&W-[(=T+^)&'F-3%:YXE5FR56?7+;E2(,R*[9,Z,])Y2'_7+:[
MGXP63)V>;1AS<;R>LCGF_ AGG<HO#<>LE,X?*-+WSJ_:T,*:EY)[Z5UW:N3<
MG*3SG03P!MA V]C5ES3VHPC"_^PN>#?SF;>O7#E<O7:MWZ37QIMN!6.:CG?\
M?7__PH59!"BLXLI?9.0&&9B,OAO$OL309]@#8*@9_")[Q]\6JG?^ FMD$>ZU
M@?/DY= R[2=T0/D=4M9-6?X&4HRCW0$8W[ZR6&4*LSC25\.9V%T:*\3ZAL_P
M9,!:(5)+A5T&K#.\#9-VQTZ+%C]=G^KMLI/&U.T)NGE)YR:Q_>8EI[G)Q'X:
M/FT].W,VC:$_<AB^(IL5=]#>,[XOW3F+_V/"/2^\^(._X,4S%@$^W(->A.]<
MU! <O'D9UC1,'1^-E.-T+FD3AWD3?Y,L1(18!(<)=RS4XSC6*$:)VHD3C[ V
MH[TVD%&T$?(8)P/RK1XY@Y___.<.CS_Z2+=A<W);-L+H]I-T&DY7A1^%H30F
MBU:F=#;"]6;1^0[G_8<WWWSS\)WO?*=X\<"QD/>'_] ?/CR0(^=*^JWW;1._
M$86\69KPB%YA=CR<&D38"GIL1#RW X4"BB=_E:&,6P8U;N"OO/-PA/,]\H2F
MYX_#L%KA>X2=NN^J33A7GH&S8LHW)Z=U1!IT^OGM<J6MAGG3B->S^NM<W/3/
MX*N>2%T,7*-;F\\-[U0/O!@8NU2J;]O!FHF_=I^.M3M9RFS>(G<#N:W_7I3E
ML13&Y?W> 9OG2]OQDG_L@&C>@PU.MIA*RBKC'%7P]$^A)#KOJ3)XG4%NGW>P
M3%[[W))9\16GOUPOWE.@^0(\RFUY3.(87O(H']*2G\L:(.6:GK21>?K:DK-R
M ,B;_GL>3L9(6?1B"@WB;@,0P!\;,I.(D8V<4M/#::"$S^GHQ]:_XA'+[QS)
MOV42I[U] U^?(18RVKBFS@X;]\A[Y%>9=U%%O;$_^*MC$S@&R$Y@<Q3@,K&Z
M/[K$?)!\[>,'GKF=Y_[QX,];B95':#$O^%L6 C;;?KF<A4=W_PMAY;,A9&H+
M>08$LE6V](UL:CNCN^K/XPJS("$])18?I^>E*P.TI(RX;;RH;!=-UG5U%(Y%
MKX"Z#JY)V_S4!N9ZR[5M?C96*"/0CTY,(S_. N%LY]PEN]MM^78,6#1(O>(W
MC">?(V%AUUW@.A[]!"([/O(543CZ;&$[8Q:Y+/SLP?T99-WYZEWEC:/:- &^
MH2Q1']I.&0*22A+5R=*UCDL\ZN[Q2ALI#Q=^X6YZVHH3IYT[$3_"G@!6Y9AS
MJ7#LQ0:V**5;K@7R#_=H-)[-8P.#2]_8H? ;USDH.4Z9R3NU<P%/?MIFY P>
MAR1E%UZR[IT:\DW[BP-7?@)XJSW W?I&)P:(J/SH=%'OLMK$^-CSR#3G,XD9
M.=!]$Y+1WYF@3[\9V4_?=[[QYY@!ZYCN&'JKWXO&ILEKNXW]) /L:(_I$\HL
M>LHO7.+0W9BTF:3OZP4O?)*WEXMMV1=^X_(7R'@)$"U[C&B_I"_*J=LR='%@
MX[N8BM-YLQN'AX'9\_#5.TR)VG5@+IL=/NN;!4[^M99TL705[^H?*W_"X-[G
MIV.I6O!RF?KM"XGA=DI5[E-&W#9J9<YQ(2KV76X=%=E\Y5_+]31I]?W:]^;N
MVLAT9"64G2&L<.J/+IC-.1[5F+Z_KX7*Y,A'H?2\N =XP]0'=P.<.+A6>FSJ
MJCYEY[1A9#+E>]SGB<;S!^)7>\\(G"VRR^4X=D@XT;K;?CX[33M.;8GL 1T:
M@M>BL)UIX/33; HE;Q]WOZG=4Z=)ZSQ'[31%IVV;+Z^IZWS%E9F_V'OG=TAA
M0LM]ZGBJWZ1IUYP/OI684!$K=HQ3[]B.2:LN)9)1(YW*GW*%UWZ8LN268^&3
M<9(D#R3:[3=@(6.C.MZ P=]NLD_RW7-XZLFG#@\\<*E;_K6+Y^8O7KJ02?K[
MA]_XC7]V>#WS$I/R*V^_?7C]M5</-V]>+\P&!XA[V%BUS]!6/,%IOL2_L.@I
MKV/BAI&@%EV8A>/9!>#-_WV4N[GL1OI28OM9A.E7G\B\*F6K'TM6C4M6#SWX
M4#^!9TZVZ=HZ+8R\^>;Z;WR+^F1#&_O4-^N''N=L_Y>_\M7#S>BD77#Z-ID*
MI[$X](*56-A^9+/B/M]!B21,M95\GB^T;MM<L3F2\Z?#L?ZQK+1MZ\E#'MTZ
M3?[I6>WPTK?2*(V>A-\]EQ).<AE$YW0>\_K_>U$WX=_^MTZ/ -SSW(O?_PO;
MT>4,=F6\ ZO5]ENSZA+%[?8J@VX4IY-X=3A8&3#Z_>ODS_:.DP*D^X\1Z( >
MM4]#O@_6VI+?MYT;6 ,/CJXRJI.ZLT*XG// I;@<;5L4O7F1PTU=?NJG?OSP
M])-/=*#D/-9X)(=S6 5FY'(^@\ (?7=NPK.*U.=B4O;M*V\=OO[U;Q8OY=&O
M'W[XT<-/_/1/'1YY[+%^PY%X.7 W+ #DB._A=Y10X^Z!=1J=P@]/E0D#T#C7
MTT/]S;4?159N.^!G;=ST[72-T5T99V'C@D-^\9RG-PY-^;?*K'+RSLH&R'?3
MBK9<M\/Y'8]3SXD?^LJOZ\09#.2OSKKR!!/PX7F5S?G<5<&G*I/>#M%R)[J
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M2RT:9L&!G0ZLM$_Y3+8=:$;F(7'LN+%BQD ZAL>YBT:V)QX<)U3?4V[&8AF
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M:]>O96 QP4UB@GJ]<YDZFS^&:O=/=!$$69*+8U\TZ)C*%L/PH"SZ+(B- \/
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M9E*3<NAAC^@G^5BT,GDP\ G5EZ6'[N1I<S+2#WKW..D&P,HM<G149R9O="A
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M&'<%W4FW2.%.D"UT=Q]>?.ZIPU_\U_Z5P^-Q&F]>OW:X8>(>Y5.[@U*4!TY
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MX*DGGRY\$V^[*=YXZ\W*CNX^]LAC<12OA(8KE=<\MQ>[2V=,1,A7J$V*G<Q
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M&&&<48=.\"'8"V,.6-J4S9;VUIOI[Y%:%XSX-8%'5RTP=^&*SJ3]3%S)0N_
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M6K>#M2<,;<^TZ]#ECDT<H41&D$3HM1TKZH[3-XX[G&0V/'' I2WG#:S@->'
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MZ[JH-VZ&P4HZ?+E:A@*=SI7=@U;36V[3-GP+1UQS10N.YX7;.HX;?_Y2WNG
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M&5D8F",;Z[P#3K$3RO7K4:P=B?Y$3[59;% GX]B+V,"1"WTT'7[YR=KXO7Q
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M^UYX8;G^]91%+N;S@_.98#*L'NP$6I!9Y9-IG3AR/9O^C;_"'JN[NAH$-'%
M7^#0RB5VAG5OR\D^'>WRTG)K@I3KJ,RN(DG:L=]C#]]\\]KV=NJ*%G1*VZ$]
MHC,/7'JPN'S:@:=9T4!NE*#]H5N.J_,_^0TVL.U'>+!)-M3JZV"U#3-89(!#
M?96U!@ &'ET7][8W/S"67"[(I42>XP>SX(G\;.6*?$1V43G*Z_XGH6<'I--A
M8(OY9<4WL:O4T#-!.:4QNH4_(S.C ^Q,Z2%M$M*YT?&4%1E1-CFM#4U=.XB;
M.M)';?34YUCTV\]7QTJ:W"@>QX,T8S/3QM*)^'W*1=?ZR_3C[MB[9-011BA^
M[0PZ&*#2!GX6>W)]>^6EEV-'WAZ^)K^ _I:/LXD".ZT]LGJ"#"I?FVA5G+TG
M7+\9G6$_E[U%0VGRJ/41E Q'G5:Z-?P<&D_G0LR-_*L_FAP">S'/T&*GSSZ+
M*HW_>\;>4V'_Y]Z4+XUGJ_V I^?'^2"L(QH5IUY-(&OTK&'/XYYZU.?<.Y"M
M6Y,<P06QH9=S/BA,FI6ON+J'%_LSOX;BNLI(=)XHW-971I(NZ4V8L'F6Q5^^
M_'IG_77^7WWEE:X048Z^PG>_^]WMP8<>[@ 5_5#6M=A *P"LZJ+'5I48 +@>
MNSD%]:^T&1]NT6#N^^^G#+).%MA-^ K348Y.3>WW?'O.'*2K_Y X(>G+,SP=
M6ANH/G_^XO;0HX_VM3<#B0;XR#&[RUX; .A@-'\_9<*QY?8\X%(8W@^>Y#UU
M@6,BDKK/-]>V:7_??.NMMG_L$GN'/VS6\F<$\/E9XT?.I/;T;>?H.;LA7WWP
MV!'^A#;"];(IJT/?&/CU:=(_GO)$_D)BTDV>Z#B*!H_A!;HNFN[R="Q.V.G@
M;-$WC]:]^D^]=Y0/3:HOY=>"@RN_&N9I(.1$^N,# +?]^_^[_^,7*F\5@(;1
M#J(<50)SZO3Y"-XL114Z:IEK%2L"\6*-U#"N#)-@!0!A))1A71T4CAQ'XLZ[
M[RC\;OR2/!BFH5$A#6 @E@ Z/0%18N:L#A3B2M=W:6-@/PFC+K_VTO;M;WUC
M.Q.#:!34\C(J2( LZ]S[MWL([  E8+?'<&J MBBJD7X.A&4WCSWV>)WO=MC2
MR.MD0 1F=Q/D!Q_>[KKG9(SQ!]L+S[^TO?+RJX6W-CTKTR,H%$<CX)-S.J.$
M1\#$G@>O-2+EO#,?*;]&).4%\]1U<JQ@1JKO;54J/'0]"F_@9HY-NJ>9L,Y6
M![:[YOO+\?/ <VQ9*X_CW$B<<H2!OZ<9Y&#0XWZW20_WFK8U*5_A*M^RV4V,
M64FFPWW :Z7S*(F7LD[Y4<(=CX)/6.!<#EJ<CCNVQY]X8CM[[L)V(S+QAW_X
MT^WW?O]'7;KZO>]_)SS[8CL9!_WSR*89/#O]XSFX-Z/89A^]SM%W,9-&/GQ6
MFQK;\$DC7F5-'N4:L"+/[2"K#X>2PQ$Y-\++R*].#OT0R+Z&75F<&73J  "
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MY*#PF79+N4%DP55W.-QUSY$/?@CQZ0N[$:[XK#[AM7ZR.J$?26B:'??$TG2
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M6.,[&I);]+.:SB#>X#*?1[LK]^$!)OIK6S]F>\KOE)$33KE.OJ#<D'CX$+3
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MZZ#!UXQK=4DG0V(9][(%#LAJD)1EUJOW<\MMN&GTJ[>Y*3W=/]0KM!A#/(Y
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M"/XAWGU?VY9^76C'34"'3HSB 7N\WX=WPR+3?AEJ-._!UTL\3LMU;\7:X$2
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M2W'[?2>,&%*B)/R"\Q7B?!9G-N95Y]_&4T9V='@H4IW]*A5A^SR&ZHX. LP
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M8U'X,LZ]7U">>W8+Q(95UY7W*,@?6J%GCV $)P1M6,<=\@%&\NW/FB.W>N>
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M<\_^<GO^N5]N+SQGH.#9[:477^R*(C)V7SH0='H%CJMZX>NA YXX#O_05.S
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M+9SJK^9<'-JB21^5!I7.W%B=H+4)'UIWJ7Z>:=N\2NK5*KXS>;.25R>Y,'>
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M%<ZNIPN.B3%XLJGS&E;N)Y_/S:UTP^C0'6J]I7Z[#=WK7_SV>GV9)L*BR_&
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M.OC<Y>5FS#L8D)B.L\ZS51K*5P?VA]Q,92>J*3X+&FJZ5;SV.GJD >SR\71
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M.,W_/];^[-FS),D3O$[LOH2[1X2[Q[YF9N12N=36W3/=- @#PC P#+-TTX#
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MW;?A/;5W&KN!UGS!NP,J86!I0('K0#_E]( _@Z&6K9ZCI!<NK@8UI8U&!V8
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MCS#O9S,"*!Z#J _2(5Y(IVKUWWM+PADDY U&TE)@E,AJS+QR6I9B]GHC4R<
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MW#*@<2VM=V?0-^U.6K) +D9F #E*1QX.N21"-#B'L+C%*^Z ;[DNO]SB"W<
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MWW)[O=LF5AYMJVUIU[?T4-JYP;_/%'FUA'$DK ,5[2]^?9Z,?.OXK?:8X'9
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M&,?:!C_WTO*C#!+F/G'=_M1MNH_5@+]UXV8Z[@==N:9H#!C&37UX]#8 U'G
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M:4)Z33D!F)1-/RLB"=OS*<O*J4=Y1BF%%,%-F3HS6Q0I2.V6+ BO'DF>D9_
M#H[N!Z]#V2I/4[\'@7,G;;RZR  P1M#MM-.;-ZY7KCU_D[0.6?%:D85\*\"\
M#FNVV0>_L%;G:@<(VM=X#,Y5SG )WC[M>6-_1_IN#_9C8 UNZ&4BQHZC?@8J
MG0Z&E'=XJ^/)(%MZ?$4E]1W93,>0:Q+F?NAC\L3G9$:&#;+E'QCBN\,@-#/A
ML0X2I>=FI7UH.5[;FWM7<J"=6)6O;LJU$[EMOW8DS02&@28<_5]R3#89E;:O
M7KYTI9-F';AG(-G=*(%=V0[=#K;,Q6 UF?7BBR]M+[_\2K]A[ZL,WW_[[>V'
M/_S!]NIK+X>FU[?K-ZZFSO<SZ#2!]DCH]_CVW'-GMF>?.97KL^&'5PSL$K-5
MG7Z_$3T?7MR*3_Z;R7_C>GRNXCX+C[1%Z=<!C.B,#K92]C64U!U]EZ^,E1_:
M1.+4V]7K'<G/-VZE:7O=93)MAT^&RB]I7VVA >[CJSFTDY:Y7_.L_*;)%8[B
M)KW="=,_@EH>[').IKZ*KM..9\4F+3NZ8R881_8J3_B9ZQA0BDAX> U5*P=]
M#MSBFWPUDJ?[:CW0Y4!75Q=J#^0>S98'%[:I8:[KWE^@MHSQ^SVXRLTSWPFG
M^/)@3W<TW[_;39J1T[W-H2TZ"Y,"'O7PRK5IF[FTFFMCDE=_;I+%%WF^@$3I
M--18>=$O^BIR,&<4(4#\SMOV5TG7"3SWE:/ S]]!&S_B1XZ6'WTRV$Q9O6NY
MXT<O# _<K_#ECJ85/'[P'\#HM.NW(VE;]N[+Y_VZZ"MS]3IYX1/'SRM$VL.T
MC=4NT"(9\Y?R2J)5%E!@N:3<P#I:;FF4=N<Z\.9>&0 5E^8?&&JVU^[ @662
MRQ;I7__ZU_7OO??>]NG%B['E?*(Y^@#.@=?==2FGAZOB2>(ZF2S-XI.XG3_%
M!=ZM3U%IW+R>9R+7X.2P37:;< ;?)T[,1+T!TXECQSO)?,)6X?0;?<TL=*H8
M$J4%EST4O:M/,ABG:[VNHQ]"&V<4J;NZFAA@HRK?)(.R1Q_&)DE:_2_]IRT#
MKBB9K2R:3&B=]O 5YSIR-G43V_JQ779;8MI=$N,W<3WP29TR*R>1?S(P<C \
M')GZ0_?MN&^G^_OR?=LM."M]+_/O0%X\'=1Y3\<UGZN')*[-E4KYL97$KWJ@
MQ](C7//N_L EOC;DGHY]<30?N\_GY<A!!Z:A7?O4V*#*T7\+GT$F,#- 7.T.
MI@L65O0*MX0;NU:_%=>%PL2M'6XM(WV<2),!,_$9O9=G@^SN"HM,U>?>@-M)
M^\?9.R:A=UD@PVLL<4B3N9+]X[&-+ HXYPP^!W)1(B>_=K#*W;W[6J^)_X/=
MD7SJIF\=/13^I+VRAVJ/A([2+SM;.^A8('V@]@OF#+#1/&')2V:=@Y $A5\:
M)]QD>2<TZ7+1:%?T=)@6BS*&^>)^QA0F&\*[Y%E])_\ C.HZ,&=<Q0[I^"IE
MVE&Z#A"=77Y\^OF#^[$5V26M=TO5%M4O,E1;P3,"[;3QW^-RJ5?8T/1'W2&O
M#EV2[0.5"%H)E HC(./#"AZCVTJ,BILQ-TD@K<'\XT\\E?1/A"#?1%E]&45D
M!3 =UP/O'YKM(4ASZ,&QXV:"O(MIZW7R!X9R6[T2UVJ^;1:)BU_;4,QH]A3P
MI&7LVHX[ YY[FY.1*?*(R\SF1^ ,S*?#&B:41(0PWC.F+@:5=*6)]Z]T)E&<
M84P0BJ?TY!VC#//6C+,\KKSL[=1WA8&>4Y8RIK.;^Z/ANR'D_DC:AV?#XP(<
MEE5>32>\"!^ZA#=$'@(]-=[A+#_Y\V]%Q^/U!(UR/"RCQF*N[M6['6/"AF[+
MPTM>]9=N!KAK4D!#J&_>Z2 6'76DJ_Y0*0V"YQI@PGD954L13P<#K\2!45PF
M[4I_B%M\XBD_#<JV[!O7KFZ?]_WLSQ,6/(+CW33D6WF^[%NK%R_G>JV[.YJ_
M,&$WRH7<6ZV7SP#%84.ETXZ_I/*I,Z5 )K23RDEDJ?EBE%R[=KWT.7W&>X%G
M,A!R!L#P8=K!E"E@&6&-;!GJQD !/W[)BU_NV[[#U_5;.#6>\LS]HOORZ%0C
MK'"GS@_S8'F\&!CCE+"4DMT4C)N$QE.@!A*^:VL"P)6B5DX0J?)"DT*8JKD<
M\:.'6K>4VPF .Y]%)]D2GL'=G<\;9SN3LA[$8+(KX(O/;V^WKE_>KE^YN%V]
M<F&[>?U*>']CNYOP+S.@"K#H'MNT4I_D6YX,ZPS5">]JF*9<..B,S6!;=?$N
MIW?9GSMW;CMW[OGMF6>='/M,.KM3G5GO&2 F':PRAQ"KXSXZ:$<''<64HVU)
MDZN.IYW/E%T^XW]P0.<$['(_?"K/%N_D5Y>#L.'3P7V?IUW/KHU4.$"["J5#
M,;._ZW_ZV*M=-V_>[O9Q]^5U^"5?#9;XT7E3#E[V/;_XTZ=.AS;/;2^__.+V
MZBLO]=U4LFKP;TOE5U][#>'!YDLN/F4GCS0.R%J'9:J'B0AG+YB\\Y6%=<5[
MGV74!JV&F6BJ,4_/['1C2)G8<R7/705+/='R0.XK6X-_!_SA!QB, ^6CM;B1
MPS'^R\]>TP:J>W;O/K[I=]_\9"OI1W?EOGQ(^2GC$'Y\*(S+C' X:SLF5#MH
MWOE6/4*?&/RW/H0B^9*9[*RZCK#DD@2,'OUA^ZG=&E#6,@2FW-%?:.*@WID<
M"LR46^,E>#C?X\X=NR_(+OJH-Q@T++]@Q+O&5X] )F6UG/Q;]%+OI5_KDT]X
M$QYQ4T)\PN?>Q,,D6G#0[]M.BOJD63[_&DIF#!)_^5>_W/[ZEW^]O?/..Y6?
M:6M'\^P\C!_>A;YT;OE&#D:.M-\UZ=LVN+?#U4[:UI=\RAO8TT[!&7E8_C!<
M^8.R^_P=E'>8?M5_:"@M5]Q['3W</IA,[W)[6+^5;[\VU[AR3)CT>SEM[ZV#
MNFC_)C1GA\SJXY8=EZSC]JOGEE,X@\/4!T[C1V?M_9FR#X#$[0)P)*0R#)9!
ML2W2W@LV$7#UZM7NYM(_F[ADG"NK$ZJAK3H%>'W[@=1I^#/Z?N%)AB5;EK7;
M8-:XE6:UL65+D77.ZTAW/KL3/76G"Q9E('C[M<!<4F=MEXRHC_X#;#O);/V^
MFGJ9X 359'1WF=%[J1<P:X>#_O5>9+!M+S2D.^OP9/\M_5$9(MOJX3Y^)OCP
M=VBPZLBO_ OGTF/AGWQ']5YAI4Y+CD>6)_R/^576NC_Z?!3&'X/S</A<!T;B
M6K_#/%/G@<^MLEJ>:ZOS1WZ)PY<#?9GG;U_GEWMI*O_2CWQV#!.:+X<'GFL7
M)JUVB:?Z,N,A6.S4'ICY+?S&'=X?ABEQ_*AX^O PMD%Y1BOE5=:U,W&)7*O0
M!P-_N!DL[_W&FF0R(9 :M2F.'!=PW:*'],9A[.2^ OB$ ZZGG=JNS^[5MW@=
M3/BB[:+O.+9A8_=G#OQ2(V7/[C3(D^,4GC*-*]>Y:@U*F:-C]&=+GQXZ#T,G
MKP,&4G7;@;Z.7_9:)PLK:Y&CX-_^.391=]8E;O4'ZL@M.B\_[<%$@#C]A?#I
M&V9AA@_\M%^VQ_0SHZ<>PCD/ZJ;J>_7K_?O&M6ZG4?Q#)(U;//JVBRT^#%B*
ME\-@E50!,QUW/C<!,(>/'#_A!,,(1 ;K3E-_Y-$GHI ,BB+,GW^S?7['>_R/
M;_<?>$O%.Q7'=N/901!F1JV &AR-\!D,^#&:CQ]W8,23VU/''^_G_AS6QD"T
M6O2DKPKTDPJ^..! /2MX0P03!K,-L>COC0;34Y^]3L(PH.]*8K3.D?+"_L29
M*<;49*M!#'A)'J##9*>M>E_8 &)@$GB&55>',"TT+#T3?H!,W%'B3Z<Q'2;C
M;"6;%'G8N3E\$7\(IPVP88QU92A_RI+LH,XPS_,?>/2.KS'8^RE_!F2'_*AO
M_)'[\&>VMDY98+0N:WN?9S]IZW<%$F^;]=0U&:7)E1]8DW:<9[A*AVX3IDZ]
MG\B4,7@\[ ;6NF\#Q6^=\;[2HU'#52,UT/=). ?77<K _Z-/+VX??W)QNW']
M5O.,07C8>5"$3C:W>MP3?FW/C2Q5!Z7$X=]<EQ* ]_#+!-.#M)'/NJ6+TO>>
M];///--.O'2JXCVD1>M</AZE#\4V'1S)5=I.HIDU=2]LT2NN-*D!-;'R+U_%
M%KF%+W\T[L"GK Z6=KC<U"L@@Z]VUX-EXEM$/(4+]AKD+EB'==IG,BM/9"AU
MC%\U2)*X 88'!GU]_]Z[9??NMKUUBW>2H,/UJU>V]W[_V_C?;._][C?;;W[U
MR^WO_OH7V]_\U7^]_>TO_NOM-[G_W=_]S?;A.[_?[F7P^+7!86$YK'"?18[K
MBG;X.QWTT-V]U7Z?B7&^P-GSSQ_X%UYX<3N?J]EN'9 \L>I25[RGR%='L!3^
M*/W5P?3=M#P;. QM]JJ[+ZU#J_R'QX%LBT/+TG.G:?Q#_,MS6)#[_1H_@S+9
M)[TX,'6:5O'5X91)J3.125M9TWE[Y^[8<:_,S.?[R'+YN)<#OQYV8](V.K,3
MN+YYF_MCQY(W.EKGRKAA:#LDT Z+NU_<'5H?<Q)O]/TQW\$W>3+UG+H.ON33
MI,4R-DW>:7?.![ E]G#6G0S/%3VU?RN =$!=8,YJ;> ,55-$Y"O1JK(,!O'*
M7F[1:QFZ!QU^:3AT6/>KTUYI%TXZ]:Z2]7XZ]\;73[GF9/1%\+4S2OC" GRR
M->\F,LA&Y]<GD3SM>Y*VK2CAXQNPZ^WT:>'?\MZ93& -5^6DA-S;+_5(R[^;
MP;Y!_^T,9&9GS.UN+?:5#[OP9J> G."E3TP^=:_,530&!RD\3_@1FL4?R%&)
M-EAP\BU=N"879]4L?8WXA+=R\:N>N@.3;A,\' 9OE15DY>S@\/>_^_WVBW_[
MR^UO_N97VP<??!!9N5<^+?X%8NE%YX,/K=5FEO>,[N5QV_BT=_+*#5[CYWED
M>PS]19.]VBD/CI6_X@#7(G*0?[G!0QI([?DE3;K*Z9Z&6W4_2+^[A5=U+B]P
MC]95'-PGSD/A)@R<ML?4=:U0@:%.],@:/+@NWW)V_;7\P.[_/6SZ\XF;YQ67
M?[N7?B$7W^>FZFJ[B<=GZ*[HZO6^,:0EJRZ/7Y-A?''>?>%(0\;BI_R$5:C<
M>!JB#"KY5Q3 /4POC*XWH+MZ_5HG(TQ$E&[5&X=\:_+<SP# A.B<846VV >V
M_]_.==GAW046V.+'>?7@1)[MX'6&D?>SO6=,+N=5PD6FP5D^9>_\3,;#2;B1
M^\%M3[-P;?[AQ5&_PEN"9+*Y@$D_JG.O:1_?]L&O?G^>%=OQ1Y\[:?.07X.T
M#,!"CP._QZ'QFL"?0=LJZY#VRWO^@[#=<RO-JNM*?]1//K$D8:=%'W.-;QL@
M^XTYTMYVF&CLO#1?&")!7HO6KJI+X)PP]Q9;O8(,IC*YO:0#=P"S?NHC/4]D
MT*-]9:[+)L,K[<ZXS@Z\6;S0!D:>"ZMU3%I/ ;>>Q:YV+4Q1GL&R8-(=KMK%
M-_JT606WLQJOEIZK+"N$.P)W@OQ7IR/>11E=?-[[PN \_=M1VZ'@6HY=/RTS
MUX7G[)10__3%H;+^N3LLR15_CS^T#4WBK?LUH=L=GV0MW@"^]([SS*ZSPZQY
M$Z>::W)\U;NR5A[(I^XK;OS#X6@R\$E3??@VO-IE2N2>I_HHM_MC82R_Z+/<
M8S_]V8]_[D;$4MXR&319D;+2'O0S.']B>_J4SQ_81A3!2>?H8++/&0E)>__+
M-);'GNIGNS!)V5W!IY"?>C*#A!3\]?T9Q*>(\*X&WV,Q&/4Z96 J8Z I7V>>
M;$/)U> FT5&2LP.!D4[)SP& I[977WZU)[X38)5LPP\16R]*/ XQK&C8[NW@
MB*\J4.)B\*31V39U^<J5S98X[WH@Z2C&9$PZ.Q%^_-.?QB ^T57-OI\9!L.=
M4(1+K<.LTL1PP)A Q\QU.,AL!Z<4IN-9'=(2W#88):_G"/9AW K'?F8U-DU8
M"SJ(7QV>:\'M8=B2^#UBW8L;^/LU-SJ2Y<>P'__8/O$#YM23 $X#-('CNI2(
M^JV!H?OAK_J.X'9[=M*W/I"8*M1SR*Z@"O/NY5]^\DKORLLHT^3QW<[GGGUV
MNWSYZO:[W[T; _;6]K3#@7P>T-<!TLC-I)L(,"'TM5T!]].!W'\0$!K=K.SH
MD#36XFR0I_S =_5>'QH,3LH=Y"LSD1U*T)9 2I$A_>%'G_0 $^_'O_WV][9G
MGWVF<$=F1];0QY6O7,4=3T=O$":.;%<=['3B4O+0X^"K$NARF*#OLN6Y)/6\
MP^>ZG<M]DJ]P,LO)MWY]=MGSK?*7S'9+;09EVD57)$)7'3AE2R:TN3JZ(Y=4
MI3AV6Z3"ZXI$RX='Z[+3&3_EH9QK9$1I?W[G\W9<9,]9)+=N7*_B]GW^:Y<O
M;9<__7B[^,E'XS_^<'OW=[]-FANS,AMZC[(]7-7FP#*(S[_@/>_!&2"?>>;9
M[9GGGMM.G7ZFN'B=H+/.P<^*M!T*=^)-5%C%3\O?ZQ%/@?/JE)C6-O<K+)5L
M/75JE:5=OJK[XMW#I\94.IB%>_/6>1XY!;UY=X,<#>G"F6A@8,%G\I,9,FHP
M[ONW9WN XMG6T=;54VDGY\_[PLJ)M@/;UW1\@]MCD<NGHG=/Q3MQVZ=S1@]8
MR7?XE?=2?<;NU[_Y[7;C^HUVAG9M,6Z>/W^^!S4ZA5<=KUR]LK_2]5EPFTY,
M.=4Q=&;UB$E?])FZJ6ME:-<Y2XXFWWSZ;QW::75-?>T2J[%3FH:JJ1=>U$56
M*Y?@-.B 6T/KAH5GVA+9K.PK+V4W8\HM?@E/?.LQ6?9_X2'>!5:#XL80\(1V
M\RE:DQ>5%5LRT\?2.W1(MVR&KWTU)W+%D#,9@J[PA$=AAK<M;]"K3$T]U R>
MHX/;)M5%8X9[\L/X?MJ6\TJ<Y]%M\FG+]%.-\I2W5E7'!O!^Z.C%ND7+P"'?
MTC%^1EXGYF@[:+^V[O,?_68+*!SU*<-_\"L3XK317.G#R3E517;/B=I#XW+3
M8E.F?M<AE%>O7J^N0M<77C@?N7^N,C%]]I3I%3)T@_.@/3@!CEVK+OV8D9^\
MN]?VR"3YF_OY'"R:"UNPU$<8OKN?MK_' =[B)DUE>M$X;N4_A#6X]?XHG/B#
MO$GBNN#5_A ?7SBMR[A5/ZXTR#^\Q'^R!V[U4VBZ=,VJBZNP91_ 1WGE'QKM
M>+5NXO9TRR_\R.=!VN3C<EN_RNE6^^,G.W$Y@^#'MU=??65[\<47>CI^)W3+
MD^%IZ[N7J>]I6?$'9>+#7M[02+F(,<21WUE!E<EX@<JUZND@8>>4.(O 3C\Z
MZ-S9L^WGZ3Q] SB+M/IR.UH%= (@.!@L7;UVM;K0KE1?N'KIY9=*ETX(1#>H
MZ\LOO=KR330\_N3CVTLO/%^=BN[7HFL__?1"X*I#ZAF]H4[=W12;AM3 HC9I
M<)Q)MNAT=.KSSI?2Z@@/=E_ZQ1^&+;H-;RI$@=7VX%X%<QV;8:=E?#1"94F<
M^S70//H[2!OY6Q.K]-":6)!?6/5H_6[W\RTO;HJ?6\*\7^'.N7J6_^CS4>>Y
M::K'<@W0J=]X>FMLH>0/;128F*&A-,+SZP1'^-"!8?$>3U[UK>KL-6FODUAH
MNG#A4G66^K[W_KO;Q0N?EG]3TK?=E**^I9UZP"G7*7W:/QZ[3KBP0YXN6UWM
M%P6D4G[MKGCUKZWOP+P]??.FC2U]I\YL:D[[JBY,^P",?B\]V^_I"XIPPWJ3
M-$/;R%3RDD]]C44(B[87+EVJ/7\_[>>QM+W' UL?BJ:5C>Y0&[PY=$8OU0V:
M>WE\\%.G]&TS2<064+^=QW!LTDF_)GP]LQ<[>8>'\<NM5Z6_^<IB,GKIX[5U
M]^"-W*&1/ET[4\]4.%A-?#%'OQTL"HT.'3EKNORJ2YLZ_V43FOS&F6 Z<Z"Q
MN<<?O#*&^\_^Q_^1Q'6= *@ EX$4NEE([QM]L=V+PO+M8!, 3Y^*$7SF1!05
M9C1KTCD1^LMTIO>V+S)PZGLD*2!D2MV],K!% 3^^'7^*(>U[I@POLR%FZ!C)
M!E8ZV70H(%(^5H%4-D@31I7Y^NO[[: 9F2=/>+_D1!3KN2C!5[:S,5C7*IP.
M"0%6(T7$ Z)%^UCU][FPEUY]M4:]^MZ+L6Y;(&/*H1($BNM[ZQEL,)S1YOC)
MD]M/?OJSU.%XM\6:()E/C7FOUD"-\:@\]!FEF:('C[@^)UP\M\*7$\]S92(8
M*5>J)LV_HVD.%%[J4\&-@R?7LJ3-\TKO?VD3/^"6$"6->'G0:O>CT%W%[?BI
M4-PT^GW0F?H<II-W%[3D[[LJX"\\$L:!,N5X'I@#8^X/W2B*/PSG#NEW-+[%
MI!P'P?GDGU7W2Y<N;_>^^'([X;"R=,;XOE9C*;1@H@>*O ]?GZJ\VJ(U6YTY
MAG<[Q]1M&N\8;979A+4QERYD;7CB:O58.I-D%RY>VC[]Y)/-^16OO?9:!U>,
MDE$L%(E!)[BCM!C>>LT3&7 R(*=NAWQ 'W]H:;"J[-([:92]7" WC!O<#A66
M>D\<.N]R(4VCYIYK.$VV/]=@8%BDSG=B]%R\=#&TFX/+R)7!OPD4-+';P:2>
M\!;(:@[.;>>!4Y#JD7LGH:H#>LN#C]IJ=THDCE+%![AJ=Z^__MKV#_[!7VQO
MO?E&PU^((73^_-GHA6>WM[_[UO9JC*?SD0-76\U-^CBHK]M#DW_>Q8I>Z"3
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MR6,UELVZ&<S BX%Y)H;NG^P[ &P=_RP#.@Q'=@.)$CYEZZ@PO7P*;'0= 2*
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MO%^X\,GV\DO/9S!ZLH-,;8*K<H\\P9E<<5TUCM(^<=+[S%YUB9P'9S*'[P:
M+[_R6@^)LV7IG7??ZSNG\OW#?_B7VVNOO%P#VF!J#NX9*>=T$)0_&MC=8BNC
M1CR#/$@M.LW@10>%7)&"4FC1\4'D,D."@^?*C+8N,3>@\H?>XZ6)_@AM)@T:
MS,&)PSL#])=>>64&R,')MD6=54SVPM7>I#7XK%$98D\[L&H_@T^PY[TTSU^U
MK9%IV#/(*?=?IDV:D3[__+ETD"<C6W,2\O5K5Z-S;O2;MEX)\!G0M]YZ<WOI
MI9>V!T'6(-4DI,,!M6?TPS,KW1]\^%$&FY^WXS !::8=W]#_0O(Y>(Z2M*OH
M> :>WA-V*!/\$8*.L2+C=8#WP\N+GU[<ZVA":6;05YWQ0>=D<+I6/$R"H ]C
M<=$:F7%>>QJC,G_Q)I'(I57\<^?/EK8Z#AEFU=^IP8]VL+MSLTXY9+6=$MY%
MR(TG>[K_Y4LQDJ^6W\\^=W9[-@-JGY+[Z../MD\^^F2D9P&#1  8))T_EX'W
MJ>,SP1L>T*6C>[Z9077J:;#J>_^W;M\J#),]!N,FATP"J&>M15OXH\./I2U&
MNZ</F*]%S$K'[ "0-MUW)P.@H6^QQ;:#T6/':XBM7]4-/9<T](O)CTY&Q3"V
M XV0T\_RG@H^/3_FT1#&Y$GT-U\#Y.MY=0/N0(YSM[>-\HHOMQ(5:NF$T^%N
M=*_?GO%A_97K?F^U@@%@>[^0U1;)ATES/$<'6^_U=R:LR:WS& P" K7MQ)D"
M>''E\M7JB2>?L(J=@5;@FGSHZ>Z[+*%/T4HYREKMNH93^JJ^%YIRDR7QR9MG
M$ULF%M"L$RD9Q*B;W1B@V7GBU;XS9TYMQQMF%X+),K!FA4LZ8?!&0\9Q!^&,
MD<BG/H#K@D(<W,B4JW[$8*=]:7[53Z58TD4YE<X,R-Q,W>:?28_>Y3KM2\ZA
M,UF4;B;6DSUYX7?4+;CYEWQCD_ ##U\#+SBV_X1G\KN?R)V^"%E8"G&=@45Q
M;0&';H45_A[7 4[OQHG3%K@%^ZAK_+?@+K?BUFH7Y[EX%_<FHB1V'2>-0'1!
M=\_*S%W*UC[+HX3@(1FBDV0;/_6OS[U!O]=8!N8X>8M-^*,US'RZ9_6,CMOE
MY)O(!9P8QK(WGDPGU_1S H=>^&+5^_T/WDV?^_+V_(O/=W*W@\NI9/%?QGO^
M50X,PCT?>KAPN?<_Y8&-!A,25)I=GY:0T- 7@IXY\VS[$[;@1Y]\W#;LD\.O
MO/ABX@SN[G4A0OP:D*]=L-W=$SHI7UV]EGCUZK7MVM7T<>F[V#$&\OH;M'_]
M]3=CW[S>Q82_^=6O^DG [WWG]=@M+U3&+U^YMOV?_D__Y_0/7W?GFO;GJR(F
M=O7)=F8:_^G+G@HN^B*+(*C4<USV-J$_8E>,[;JWE2J3>+(>7"IW@?7'Y+(R
M-LR-.R#LW^_0=6]#![EVAOB_]-9J'\&H_Q^6?6EP:M+"U5UQ;QL8U_SB%OQ<
M/?>7^G*1W(-P&68RD"SBT^"Y\IC0JDV;O,*UD[[.O.K_S5R];MS#:S.@-_%.
MOE]Z^=7MY.G3U<'H96?HV=@7)G+^[M>_C>WZZ[YF^%_]E_^7[6]^\6^K";H8
MLG#[>QP\DB)WDP;=R ):=&*9+LY]O?CB.WIJU:]UA'O+.BS/53[P9G?J/+OR
MH02J5$<\=^YL=[?UW*;0SPC/5YH>25\1L.VSO1H!3S"J\PLK>"7_X#D[ )S5
M]O_Z-__O[5>_^6WH]V5?7;2(!(\[=[RB&'LR8\K1\3"8^LU$C+8?'QCZT"10
ME5WODI.1%:Z3_,D71-+W#IW4:V@RU^JF)?=[>FD&7Q#'2;MD5Z#Z]=.*P1F]
M6TY<:5T\]SRK?6FON;8VGN,:G'Q3)K!T[DPJ;AD;$]/VA8E4!MIWC'+\J>U_
M_[_[WQ0&MT\ 3 -N^A1";'3^-Z* ,.FK!_=B!)R(XCF_G7\A1G\4\_VN_#^V
M7;UT>[MTX7H&SU\D_+$JM6^^OI?!SZ/;"\\?WUY,^F=.G^BN7UNLS=+:-:#!
M,#[8"0X;THEX1XJQBTAM;"$PH\C,GL\)?O4UJGK?X['MSEWEI"E\\_CV#__!
M/]G>?..[)6@_LV# #TB<>\0LL6-T,G9//?OL]J.?_C1X?+7]\J_^>ON7__+_
MMOWR%[^HT6.+J&^'(XH5.PK8YUS>_L$/MG_^/_M?;&>>/=M#D:R.F,W5D!WZ
MXH"GOA=<8VTW6D+3*H(J4?@DM-3.G1'6W,6'XNO1?7"4'!^J</ ESX79=+M
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MU)1I$)MR^,A9#8\^YSYEJ9#=+ QWG?7SS[^0COK)'J;XYIO?23MYIMO$9\
MAPSR;]PLK]3;8(&Q>N>S.YU O7GC5D_]MP/ >Z\GTCF3HP[.NMO+2IC3K\G
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M[@+4.,\)ISP6_,%M9&&%/>S%3[X .0A?Y<!A!#OY$3-.^!H,"??[=[F_M^S
M+OZYA[LR\[ _CV_^-#*KAXP  ]=K&?PS+(\?G\^6685__+$G:TRN@UBLJ'WW
M.V]LQZIX[^_&M4%2^!JX[2!;K6ET^+S:RY-I^ X9H[#A0&9XJT/*M*K*@2M-
M!X)H%1XQ),G3Y!V9U<ZTF^LWYMOISYT]N[WVVNM=34TM0X.1GW%HM<)VONS.
M715RVLL<CB9DT5YEJ$#YD[:TW&/V).O:737!CQ*U^FH'@&WY%"\CV=D&O_S%
M+[??_.;W;6=V6WSP_@<QR&X-?9*'T6)U'EV[%3+U1H?#,A_9?O^[=[;_U__S
M7V^_^M6OT^$]V)Y[]EQQ_OB3C],>']M>?.%\!I:GINV'?@RDJY>O=#+.9(\R
MAB\@!O!8S:7)T%LYPS>^\<N'#IV0, DC/B$&3? U$<BM \YX[4X9.FUM;>B^
MRM,T\*0%-@WX_5LZ(EZ>X=G.MSY/^UE>\/QSW2_"75?X@4MXRJP\[SK'O>(#
MN;^5+DBUN_.9/9\:\LJ)>W*KTW8*/SR;-OGL/+A]\^9VY<KE[>F3/NOX1'AH
M8O>+I'BD)_&;Y%*$57L'-.*[W.UL$T[\T)A\HQ_]YFHB-93J@&X9OI]]YE6N
M&>1^=EN?<S-T_KH&-B/Z5@Q< UCM1UW1^\L,9,!Q2"N9?>.U5[977GZQ.$A'
M!UV]=JWYAA;Z*!/4G_43A,YT,>#[XN[4ZV;";]W^+-V<[_-OB9M!#@7#<-#G
M&?#HCWQ[^W)DT?5F\#4A[A4U7Q^Q0PY<;3E53[WNA]YWNZ)Z._64QA4<;>SF
MK5O]4L4''WRXO?O>>[F_7'A:*]I812RN=SZ/Z#J(R;D*3_2U"+CUT,7 JW[D
M<AUZTY$C4PX.]*ZR S.]^M$);;HI?#9!0G;0&7VZHRY.F+;K $[O,W_XT4?;
M>VGGUZ[?;+@^U+DEU^/MO&J]0C^TO-OZ?M[7FC[\Z.,:</0&.(RG.TGK$+??
M__Z=[=UWWPN?KG? 0Q[DNQ%;Y)-//ME^\8N_2OY/MBM]G_I6:4K'V\7W5W_U
MB^WCCS\J+V\EK[+)CG3"G4&D/Z;#&&%3QR^3]O/MMRGWU[_^3=L"W40F[7#Q
M'JZ)B0O!U8GK!IA6[N"&%\I@I-^(KNZ7@S+(4R=IO!)E$E1:7GDF6^"@77IV
MK2C&'6W/;2_X%MW2!/X>BI_[;^L SS/(C7X,_,8WS,2%224\-D%U/\$40V2J
M=#"!05YB0Q4D.=G;;0*ZHN^,B.*4%A^>L9/H>S2<"6(9 W-O'Z-K][XROZZ(
M>^W*@#0ZKWUJ\O3<IU6-Z<@&W_99HQM=.66L.O&#X^AW.HR^>#3]C$$'_!J?
M?'2$-.BR\N2O7CB_PH;<;D9?]3D1U?/J.%%M'_HP$_/SJ=LU&70O=+&]?W:$
M<B;Y;T4O:4]VHIFLTV;!J@V7NG9R//&S*\C$)SUQ)X/\.6"5LTO%1+>=6?AE
M$M,[^\_&IC'I@/[7HZ>UP\JZ"8#P"%Z>U[O:>*).[NG\X??0>.W2P#.+2ZJK
MQ_&L,^EU=R,/1U:[=W_433_"B9ORT;'A ;[@+;ZL^[J'0?VA:SP@NZ_<P38T
MU*_NN#7I?CV O3O/2[X.<7W8C7TYLE@?'BT'*MC\RO]06?Y2W]7NV0-HC=?T
MUPLOO-C7%PV(Y7/(K1V-9$N_=SEC%&< ?-!7 "X"UG3%(S_-"!:#44+R/*4/
M'LJ; ?+4CR_/]C8ZB:?^DV_5;>HC+WDHG+U^VNX:'REC>?:3]F 'X)G39QZ2
MC;;W'4_>H+N31(E;?*-/)GWLY[21)TP>1/:[>S/EW4Y?X"P,NV'8 Q;7+*R1
M<_ 6+]&Y=FMH/BS8]<WNIHR1Q:6GBEV>U;'A&:0K=](<UKV?JN_SV/D=+SI7
MX8EYG4V[IPO6[H@BL+NE%V;WCQ+WL45+SWWR3]O+$UV#4GOY?^@3'9?D*=>=
M<20]ILRT[ZE1T@W/X6G!YU_\\_]$XKK'_NQ/_[1G #R(@N27,8M--].I&0BK
M'(5DA8"")2H&%+8-SBREQE%4@W0*385F0#'(ZPRZ&A !OWK-%O[;Z= 9/59A
M9KNE"8!;M[R[;[4% QD[CZ0#_2(== REQ.EHZ*@R*V5H,!3C6V^\U6^AJBZC
M,MJT=4!7AS@,(\8GM$+DDW $Z&H,6I_WNAF!\@DL#9-@4\X(AI&$\LQS9[>?
M_=F?9U!YLHJ9$:G31. *N;O4%5,1&[U*FS#$BMZBZ_+<P7UI-,\&T.WXDB_J
MIC1]..WA\W[3B[)%]NHOE9_&.<)ZD'Z2C7=)7'_-/\[MHQKD*OP/W*07O7PS
MQ:<[$)WR]T:4>_31&"D0G1$^++S$CW-/V81^\B<$W#:@(#*=4ZY[^J.SQHM*
MZ[^ZZR0-],G=>^]_M+W_P2?AY1-13L<VG^#SKFH'\L7GT0P>[F_/VT*7SOM^
M9-PS65++F5.U6D0!0&#JS^-O%;(4H?$HUNV@GCXA8];; (#QZ%UKJP&V[?FF
MZQ5;EZ/D&;F,9#)ED'$W[>+))WW.['P&OB_U/6JSK55N\:Z=\(B<:?168:KT
M>#B$!E6*P<-A759RG7LQNUJF\S=9MNI2!6_PBV]E0,(3RXG3'H0S_!@[ME>;
M4&/XO?O.^]O__?_^+[=+Z:B\-F-P(G/?D]_?B_>.? \#I"@2-XIP)MJ>>,RA
M;MOVJU__>OOE7_]M#.UK'4SZO)_!]LWK>3[VQ/;B2[[Q?R[*+D95X*#5A4\O
MQJB^E?BG^C4 ^!^VDVDS;8/JFF"\'IF:.NX)VU['$$.3!L1H7+LR]J2)\FU;
M*QJ H=N!H1N]PK7HA'7 M=(E3$3Q2CD=_%<?P.EP\ ].\>FC3%3IX-E5T^#$
MS4%LHY?4I>U .8T=7%<]P>QJ2R,'9ENNVY1AT&F[J<[&RLR]Z%\K]5UI#Z^E
MAO^#E.\=6P.;XR>>#B^/E68&HPRC4TE_]NS9?@$ SCX#N0Y@1!OU&0S!B^Z.
M;C2)2H_.&2_ZH)%M WF#+JM>^@/O2IH,8+PSAI'F_A<SH.\ -3*B/2@A*+5^
M=H3\\ =O;V^^\5IY*/[N%S,H(S^G3S]=;T72Y!$_GQP\60/,040,<4/?IXX_
MG;81&4W8B9.GHC_.]>1AD\A>3^A.F/";W!MX&T#C%ZW0,P)"8X:>SO?)U)7Q
MK]^J@</O_8QX;5!:NUYZJ-E['V3P>J'MSL&5>&/28=[/3I]LTD"ER4+:DUL[
M%@P<T%8Y\R[_R,MXKSC=ZT#]HK[/P63)9^)G]( TC)#HD.2?USB"=PRM?A(K
M<5[]\ UR*U(^&=GVG' \FET!#MVD;]'V9//*YTH.'!9I8*Z]DAW\-8C_[6]_
MN_WV=[_+(/IZ</HZ>N/YOH+"&6S;WFR"Q 2009YZ.53+JU)_]5=_U=>&R"@:
M.NOGF>=\#I1^?U">*H\>0G/ME^S8P?3;W[];PY*,,\B\5UH>):TOB=@90W]?
M3'W12T=D!8_\*<\DQQB;[ <VDU<(8V]$[N#B4\.WD@^-I",?1P>"ZL%5CK65
M>&W!0#GD*JZN9/S@A]E''29.0R\>;6W[<P<PX.D?4C;?!*FKL.GO8B3C8W#!
M^^J[>"K1;@;YV5PR^M70#3W9A$O'0F'PEZP8-%S>;C&.UZ]VTB"Z Q[=R9&Z
M'"S>2*</2AWASX\N2S]%UR9Z!F3CDZSEL2%MJ79H\YGPOA.22=^\\36.P4P=
MV_?OL.5?Y?19W>.[H *O %<GY'8-P,%/VL!9LF1G#EDR^40FZ ,ZE1VHOS?Y
M@R^=@ K/BU?I8Y>1'4?1PY$KX=K(3*S8Y>J,@9.=S/>Z@04!NPU,7&H+^E"O
M%YH<Y=I.TA>3,3(,WIILQ:^IXS@T, Z9D)2:ZG6E&%'BUX2R< Y_9B L?.3(
M;C)T+<O<E2>A5]/.<\/B%HU;QSU\9&?DBW<OO+*0'YC%,+3AA<+!9&E_06[]
MI/4:G38V=M%N2X.K?R%CE=-=UO9R.ND2KTVMB;%$M5R7R3_VP:39?<*YRA/=
M&#V]XI;K_4ZO-0Y %_J#C-A5_-)++Q<N^'A&+] M)G+8B";@WW_OW>W2A0L
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M957_I2V4O\4&SG!,FH3IT[1MD^06K_07X'WXX8?;U>O72E^[$?4%^MQC3\W
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MS1B.C&953*GAR^][&NU76W%%"W#;:0>09W*D<9+&UBUICW:\2U$4%SR&;_N
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M_*W"U.>97*U+(1WV; *&#.@R^LIVLL0 I?XU/)?T>,M6*G)8VS.P3MX:@.M
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M/1&7ET'_Y[Z==AK8X+-U>>B)$Z>Z D"C?^_]]SH(0 @PU&>YK!'AP=^50DK
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M8==/Q4U@WU:0+;H,A$-7,/'JK3B(L_(I@,E+T/[4=\L@$Q>>!W'73U@\Y_]
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M%-GB%#S:CKF= =;LD_]J>SI@?,CW5=P@AQ^Z]#7A2YGI?=XU:D$/C@U;^.R
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M]Y!I< ([^N;BMKK6KPJ;*_I5+B6\==1\AC=6WZ0^U.]W!@ >^]Z/?]8E$56
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MZ6++:G"!$2H=U,!CQ* O0U+GJOQ]GW]@]V'OT-5W!Q$3)GC*Y-_X@[::W\#
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MOHYAB>"A\GE79__-4!C(,KM^\=+E=CB4E<,!@*%EJZ%TC<O]A$_91VG^MNU
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M'#8#OK^!"6+^!SWM0EZ42>7QC&?,0E9)R/73S\(3N9*3Z@+.1K@-GOE,E;;
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M9QR$-O+KZHI<?:K,M7F D;0=<(%7[JM7)+\:-?2.P!D<T&WT#@@S<CVWOTS
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MP<\H6^VF[2K.@(+\P4$;!UFV[>>GGN0-CY9!/@MK&<4IC9FU>^^]-\KPJ1K
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M;'_ZDQ^F[9XKK7[]F]]N+[[X<M)_V_:-MC__^:]:#O"M1':.6/E*^\CU:'_
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MZY]<#SUW&9GV"^B"K5S:@G3T;H14$FVO1E_+<L3H*EZ+ED.WY=SW,7V'.&C
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MJ9[A4<9X9WD82@Q77SVQ*N):C7XRR@I K4<=2KL,W .?/APO* ,#C?)[.-!
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M]+6-Y8'8 D]^[_'TXR>BC[VZ_?TO?Q49;77EE]7U;T\[)I</!@"B;_ETN17
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MN4DL $+#E2A7:6K<Q,EU8B6/_8[BT8[,\U1Z?F!,FN\XY6J\ "YRRJK13N/
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M+*541V9_*'4K'@]L9WH2@\<Y:_ &3'):.R*SR&:#)NXI8N5A/_7%[TLWK:S
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M[[R"M]YX8\XL"%T8V^@%]D<??ACC_YV>#D[.,.2^_?:KMDM&BOKP90URCE*
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MTC2>ZW[O;;.):]9"#A+,9? 8YW[11_JC P!'WQW)-+?RB2O\_!)F3Z\#XW2
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M&(,^/3E&T<BGROE4/EXJ0>,B2HH#^<;9+V\@;ZU<P=?BIJI*'SBK]2IWJC<
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MU@EU0,:^R2A?;?=1KJ9,T\%3-'1X7Z4SUA&#9Q7)^2B1EU-GRF84^^3)>SJ
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M\;'!8^U%.=BG,_ TN)&O:*).0Z*4#P^&!D&.#<R7'^*G'QK]>-RWVW_WZ!:
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MU:6^&!)!THFN4XX!) JVYEW+"."]!,L)"RWDD1'PVO4/.X@QZCP8940]G6'
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M^>SLJQ\9=>1%^>:2Y"DO]=[HJS05;X)*6 N8K+]P'3?OX=>=Z.WCZ:^??,)
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MB!]\^,'R00C&<C<=WFN=TJR1M%T!P @0OS]"ZM%TQD?//]$3CBO@K8W:&:;
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MK#2)4@>GOV8 ^,;W9/!%UQ:(_V)X&S:^\7/=*^!MON%^&GI]+^R+#A'XI03
M!V@5[+(30CL"Y!2_@B">BHTP0?#YO/N@GW_^V9;!(F/)6*#;$DP5W.:*"!'_
MM0PRUZ]1E#ZL$"6M3H"Y@LC2;(2Z?:/U2!CZPX\^MCSQQ)-5FG8, ) =>!@
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M/QW F++M$L5B8<!D=7!Q9M:EC"?^SFVG/=L_2:"+DAXA#F,X?D*^!UM'_<@
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M35X<!3X/0X?-C&<8"'P1T+N2C)"0_.=PU15?N:(_O)Z *KZ92W!0T&W',6N
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MHBCMWQ^%, HC)ZYR=Q"4JV*$U2"RITT(6V9^?;[0:AOA/6GX^C4U"&\X%47
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MS;"H9^LH7>+-WL7Y-);]D(QEI\_:&^G4\Q,#1^B(4(6.IP\;X] PSY6:YYJ
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M+84YW$-N7G[YU1#7_BZG0A2<SKT-W,J>SC*S%V, >+1G -C7"0\&NJT#4&K
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M_>7!\+]S9T\O/B?XR4>1[[O<?=IOVF5?#93D9$IUL)*Z^(K)_<&YS]W>[98
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MY2_7$&4&\*D(@%_^RE>6YY__TO)1A/U^>_3C3\*@9[^1+P=8%9-BELL1/C"
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MY>*%=Y=77GYY>>75E[KWW, @+0<N%D4#@]G*TD[@04?%0^,,TREMYI>>7YA
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MIP&N :N;%*[C=1LS]WW.=02\W?A<PP.\\ML(89P$+)T)@JT >"9"'128Z42
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MQ];ZZQ<S'@QFA.[B;+M?\=B ^.)^WFWM.L0^Z3;/=4Q)'+K!)I-3;M2I2G\
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M9[>6DT?O6^X_<6 Y>NBSP&T5 )@+?>"@UQQ<[MUW../3@>7BM5LU 'SX$0,
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M1H%/6:W[K@&@9:\.Q%NY$PQW4V<!$W>+L%V&B?8O84!O9^Z[^2?=YK=G-U]
M]=[[N.U1_F)/OA/JNMUO;C?_>2/-K[NM;>78.__B==R][HM/<7G?_.2?^XD^
M)<S \NO0Q%5*24E>].4P+C T+*ZO\F_RFW?'3IZH-=RLTEMOO;.\=^%2#0*8
M@L.H'.HBNE)#M6U3G5J'HV1CQL <H6D&<_GNEH/$](69Q1*FLV,09O^=Y"K=
MRZ^\O%R(@'8G='(LS+/+]M(1D>B<''P<Q!6XI$>/F-_A"# \#%_/0'#M^O7"
MK6W AO$Y[.O\^<>6)QY_O/E?OG*Y X1OC3MQODI5ZF2FR%(MAY'U<UY1[GW2
MZ];-$4C ;GFM^A-(M1*+K<^ V09#P+"O$+W#00T ::]- 00_IF-EC??XAW>;
M<-S!(&FG?N-G!E!^:8'4:;?/!^GQVZR?=)UUC7<_^8Q@37'8EK<1U$>1L+]Z
MA'Y]>HQ[HYR"J8)TRU&,<J9.PJK8KO I&SQ<E=7<:]L.I/GM.KU@^%?+#=X+
M0_(2#ZZD^4T.WF75W/P#5&X&K@T^^5/2!J?J7<4#S\$;P96,*KB!+?>\G- F
MHRG#".6U]>Z;T#4ER$W3HE]&4P.)6>KT@= # 835>G"RB]L-G_4[=#N^X\'.
M_;1G\\V]\GNH6X71A.H$@6+2B)MV2(A^Y16\XL>$(P:+XGK%B<%O9H0&3W \
M,YWH=^H%"]@'^F#(8IS[/_X?_L\9W"^6%^A_! 4"#=QQZ A]@0G=;4HL X!W
M>^ETX!_ZWFA$7[-?_\,(#[8#=98N-&I<G$%ZE%\5%'_Z_6:DFG%DIPSOUW%&
MV-:V[K5IC0EI"SS.%@#*(7Y"6-Z4?N_;%Y-'T%&\P'FH9JX)YJ=NZC3X%]<]
M)ZW^!S8KE8:>!PYU:;IB>]IB\IC\I"V\X$ W\5L:SBG&PM&%>E1YWDD3.M$/
MBV?"FFT$<W@@>H4S2SCQ+GGBB;;GH5%"V$?>X>>)KW[ZR%'?1G:RN/Z27X&.
M@]?MJC^IT=XSA=P0JBB6\,Q@"VZRQC9VH7GU4+Y\E-E<Y9GRFD_2S1:6N\G'
MJC.?<9U]JGOC#0[U<=L=1\A6!D%.G2]<N%!CLKK[OK2)#S1VX>*%Y<5?O52E
MX<0IAS9:^675VAPVMSN.X3/#.RH<Y@KG$**LC?_!P[A5SI V,$[%IG\UBO#X
MC1>)TFCU*ZX;IZDD[K.DZKLC.ZQA=>AR[1/@KA&@>3>WYMNTJP>757*4*+-H
M%&5]#SQX0.NVTE++Z67@KLME8(4C0O,(T%N<';C"I\25%]@V6#B&4SR3PL]0
MI8_BF^B",B]W;8Z69(+&/PZ_)9=2!"A:\&Z)\1NOOY;V.[A\\UO?Z3BR;9_!
M]Q@SC=>^]'']QH=Y/EP#@'S1_FNOO5[%1+J>_Q+?"L?AO<5!'%Q2YC8%85O%
MJS[3CN/'J?1Z7=WT=VDF;*X;SJ9=M[ OIINTC9>V4[XVW-R6'[?!41CSS$N[
MY=<VS>V$3=KZ_LAW0_-HN5'6.K0,=?;8D'%;/CM.WKD(]\H571H31C="!^.Y
MB;?KRP?Q2.^%Y:>O#=QS &&-/C=O=>;8V55@N?'1'$IW)?(<7@.0B^G?K[_V
M2KFW2+O0]['/J@5@Y7#%GS;61_)27Z@2F7@#GWZ^ILGSW*9M$A\\VXH:JTV=
ME85>ME*UR>0AS1ACRT>2#?X,;F77"!D^1-:HTX<^CXSD2P!'[UO.G Q-'PJ_
MO.<0P )2& )]_@ZEH"/+[<\/+A]\]/GRSL7WE_<_O%&#M3H=.A!Y/W+J[5LW
MET\S/AA3'8#[Z*/GE_M/GZOL[VL*GT3G^\1*OL@:^G=Q$=B,[[8&&'\??/"A
M'M9MK+'R@NRK#X\L-?V=@HZ7^OJ/U5?P37G_[G>_$QB,41]UE1^GOOI_^7?I
MW(S]YU'P/ZK!VZ?!?_NW?[LKN>"('.U@00;<UUY]H[+(W<#,>+=]=:VTG7ZJ
M7=UW8H)LH8P\DW/&L*R=\M/^*1OL_!__3_[3PL;M/__XL]]#B%/!^/6^ GBN
M(W@:M)-8NT("8F[\&2@ZH"."1,AC![X\MC W@".0RT"^$)92:OED%5>^07\(
M4OYY*T\#9>++Q\R_S_S-04$?13#X;'G2MQ0?>[25K("2= 8D\>V_*)&N,!QB
M $C'8GUA)2>@5] @W*R$BF$=C'"P8[T]D YP_-CR6!2L9YR<GO>UT"<^HNF
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M,P$6O-E3[P!WA]-^F#[U00\.C(S7L6J5RU*:E> ?7KN^^!:_\U.LAG4N +G
M-_H9\ZOCI7Y@-].O;WV</+5-M]\%AF>>>69YZIFGBNL//[A6/@_GVAA_TE I
MMKBS8JL\/#S@T4<>+=]X\LFG4\^#RX]^_-/E7_S+?[.\_\&'D?>/ET_4 ) Q
M8L8N;37&#Q30,3H\@=R@?<?8,BO+MOX[[1RD)\Z?_/'_H&'<_K,//OH] Z?9
M=0!N0A/+9&<_VA 8'"%@!N,)FV5-4[$I@'!7X<F F_0&[\]R=2HC1FBODAYG
M*2EF^<&U]\N\Y-]T\0Z]((".T$D0@W2=13XL//9*W2R1^:3"ES/P4<JZ7 ^\
M3FT$4^#3X538U0J $Z?N[TGP;[[U5NH8^.ZF+@AWA1OR(%BCN4(@IGSNX8>7
M9Y]YKD2#L.8S&,%'"(M0+'V%EKAV+'@D\"5L\^W\A67M='ENS'2F[;D=)7%T
MZ(FWID^GQ%2^F-\69S>>LOM<0";S,:1,!_QU)PH"\::=LK!O==AU>\._$*<)
M^[?KUSCSFRBS/$BG^R(,6_S>Y_W&,-IN\S9_GAM%I.27.JWU^?4Z[=9]A BK
M-UC=?_6KEY;77WLSC.QX:, RN2/%)P'S7NBLS#1I":/R0'.N\M@4_MY'Z=@K
M@.RZJ3-ZZ:>S4@^TX5 1LTT4_J>??&IY^JFGE_.//AJZ/1_E_>$R OW'8$K)
M<4X%7*$_AJ=#EEQ%J7%VP9FS9SJ+22%ZX/X3RV.//K(\\?CY*O/=2A!E@U)C
M'].3*>OYYYY;GGV6?W9Y^)&'^KFQ1W)E,+@_#,X,L'Y,X0<#.N8(H_ +!TX;
M1C]7KE[M"@ X =L(Q>L*@+PWV'>V)+^F+=] D]-6G+3*\;C1N.:=,('%XD[<
M\IS@</:@RV\25-A..[%RVJ+C8!F*!#=Y18%+7;:9Z0H_X,E/'<51F+IO9;MB
MLN+OA7=[YXHF]PJ'X$V-&DX8P#,)>1TH5EBGG#%\R!M/JQ$B]_!(..6&7^(A
MH=_0.QK;RH'C.11M^-_ DGBYEK^J9Y7JNQ4L.SN9=.+($_X8MB@%9J:*DZ2I
M53IEFX$- ?8^29HGR[3\S695D<K]!B-\;+QH[E?\>BY/9*A9%9\X>%8G[S=>
M-$Z?V;_X[&5/Z@T,W8:0OI 25_0Y8&N,6!L^!F.H3UOD:<6A]_J'0=(Y,9L2
M*0U<&_.-8:?/G%M^YW=_MY_EM,3O9S_[6??@,0HR( !;ORR\E*&DKT*8DHNC
M_+:[PI,RU$O[H*'-$PIJO A,TQZ!)[@8Q,3[*S_D_9\?VJF ME-*G.=X]6A>
M\HF3-QPH^Z.,:^"V?_1$^)ZVV6VSX6>#\ZD+G;;]$UQ%X926[-,.N<=WA>4]
MA5T>C!AXI]48%<C1:6DGB>Y)V(R:S]9_IB\T:!SX\_-.FZF#+0R61X^!B8$+
MGJ9/?I;QO/0>O_7/)]-VS[WP0I5=GTN%+[,NWC/JHEN'+'WC6]]:OO6=[RQ/
M/O5D:?_2Q8NA49^O"I\._R@^I_)URAB!"7R;0)7'5FT.EL4?T19A?:-E^:B+
M],-O+$UEO#I1NB*0'3EZ*()C^'3XNKC*0-N$S".$UZ3EP".]MA,$'.T]<!+N
M[_50V9=??KF'_Q%4E0&/#,+& E^$^9OO_V!'>$<3WIO0<.B@ME,?#BP.NE48
M_ EFW%"6EMTHOP8O,(6_6HPS-#HP;W "<<NW;KU%(S.VSS,G'J6G0=+T;Q<N
MCJ$63' C'*Q;'^ \PQ6^>^W:M2K,9NVL[C%KR0"^FUOHO3+9U@=SR<M?AVG+
M^PMP--(:,<'E5>*F_+UI]''T59Z;/HG'DI'!]U'D$#*JF7O9X>7.+#!NH">3
M3I0*RK_5'4X OW#AO9Y9].6O?*V\27[O1R'13^P]MEU5OW1H&6.HE7U6 9CA
M_<E/?Y*V9GP< X!^M5.'.'6:6@W-HU=T,7T"W4^]>#37<TARG;;\VSCZVV[#
MRVZ9FVO9D+ Z[;B5M;EY/[Q)N'*G;\9](=YXO(_;R4/RYI'GY&],V7[-TYL]
M^7#I]>6'&WS\WCCM*^D;2K*"T>KE?D5AI<G-*((^*C?4B$MO&IF$,13/T&;X
ML@D7](H^\"1R@CZ+)U#N' 9'(15GDRE\X_[*I8NEFPVV*5.E=I^G[GUJ6X(=
M#J=]=YTZ@FFGOM"3].1#\@0^B7=L7M:M@WZ4>W2K)!,"SK$ 5_EW')D0'N!<
M7U&VL($A5/;9[>7@OCO+_2<.=@7 T8/A<_><\3+&A])%%&*? ;RW[^AR^[.#
MR_LW/EL^NAF9](,;_?0U&8+AU+Y\\54;WBY<N-+3_@\>/K9\^:O?B%)_=KEZ
M[<9RX=+5P'FK$Q_::XQDA\I'*INM?/_XJ9/+5[[VU<C.CW1LTN_P9.WB3 []
M>%N]9K6ML<HDT/G''T\?/-,ZTF7US1VY,^,JGE29)GP8'3C+RX'$\OG6M[^S
M//'DTS5<F*3P]1SG)LRD7O04_3/EERFO=*R^'<?OCLRB[8S+RM"GUYAM@[9Q
MXOZ3/_G/&L[M/WONH>])9) IH89Q4;8QLRY/#.#ZULS>C6 MH\Y F*$O0P7(
M")P81:])Q^)N0":4 [Y"62)C?HP"XE%N(4[CB;L)*UO',:NE(HAVVY?J?KZ#
M;B_SEQH?;!7\I"],B#H^]Q#DF\0',AA>S.!IMA.<E*T1DD:(QG!TYLUZPK.N
M.P3PV>>>3WVC1 0_&*JZJ'OW3GH.#/ X%M;I5$5,E(2\K$]HX[4S)UJ>>E_&
MX/V.SSOQ#"BMQ^3$JSNG(V+4_.;2OQ.N',5->D\-6:.5.:RN\-8CE-WPS6WO
MYWZ8]#!B[;'+E">&3K[%W?(%1[QK 1@<;6Z+-_<;L>976-=X:WWZF+C-)?7J
M8\,5,,Q?B/S0$N:%B7W\\<WEI1=?67[YBY>7@P=\E_I$Z<I^>48OP@P&PI(Y
M!_&ANV%@4[<9&/-0V#8\<'/=?2;0ZW@$+@,#(<2WLPW*EMZSYOL$B%4 ]O#9
M+R_.Z2[)/[.<3%R,U*%VZ-6JE:/'S?Z?6$Z=C# 9)G?<;'[N'X[B[]OB#T0
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MF2"RNLY8[M/ 8S0&3[=WA![U3?U#O])V \,2Q>5DQSHT916MMB:?FX54-^,
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M,F5.?/EI1&@B "N[,QJYGLC ^NSS7UK.U0 0 B/45R@EX([UQCWXZA07XIH
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M?Y(O?=V7*AB(9U)+?YOV[5:T /U?_.?_I[89M^_O__W_^CV'4%FV0&$@=&@
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M_$9LF'X9_UJ1TDP$#DID]V>G''SBRI5+RS4&D^OOISW?7]Y__^IR([B6]ZW
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M,>PL%R3OY]]X;7O=MSW/G^^SD79*(5@V/_Q; P!<%5SN53C\;$<XSZ53\-)
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M#]/V.?+?;7UT0&3XQM.GJZ_9! XZIL=U%)]XXJFNZ+%:VF=K'_SY3[>?[P,
MG^SXCSY3=#E._FH*%XDO'LFT<;R[)FT6?ARE+YGLRJSVOZ:H]!E'SK1-9Z)G
MS.3/2D&3CJ.3Q&5GD!F=T:X4BYRR#]^*/:G?>")V@_I(;N@ADPGRMY)ZZKEV
M91^$2/JHR^W$\6NW&_8S;S[Y)#;'>Q^E+?]H^^%/']Q>3+O>%:[!X[W04.?;
M.5K77'M]]8))B.F@IZU*G5 /U1VV7R=RU,FT<[8F?)8R.W!TG#*9%$@<*^5B
MHZC/Z*U#W15YZDAH*+^//_HTL/6;U:74"^U7=*%S4]Y^Z\+V7FS.RU-F]=+D
MDQ4Y9(&\=> _<?4G3.P8'"!GZ(.NMFI<C ZXY-(9' F6"8>/R87IY%]W+/HD
MZ967+&FSZ=(9G%(OM16+Q],W^1?_SW]_BAIWR6__C;\7^S*$)$P4LU_E9>YQ
MMPU%"M&];RF\CKC,/DUFBPD5H!CB%<+ $9_ (33C V*S7//*$<D@EG]%;!0$
M0V30$$:H"*!GQBO<C'SKY#O1FB'X=_XS?VO[K=_X]>V:"(A]OP[P,8*=?RG[
MKFB"'PR/GSJSG;GEMNV%EU[I $!'8^+-_NO4&[2 [S5IW!AU5Z1C91#@[$TW
M;[_Z&[^Y_<[?_-UTBK?MG<3U?<</8^1V=/<C,W0Z02%T\JMQN?#./=R51>._
M*BJW&*+Q5/Y1J//6?_2?JAM _$Z3G3 [K%T)YEE^?!VZNB;."E+75[R5#R/9
M $^?YL5XCR&:,@%07@:6//NN_T5-6C"K2 3D/;RB# [RR'M\D'YF4P9OKO_S
M+ Z@^Z7/I27^22]=HX(]\==RM$DPM^/(WF7]5O2-I\]NCZ3C^G_YO_Z'V_=_
M\./M_B]_I6=:6!:J8MJ/JU-W+!4)S],<I_-VOJM)G+:J0IHU83#KW',S #!&
M)->]NJ&3SM_:!T\1K@84C2@:2_KLYW*:OGU25@!\^WO?3KQ+.@OV^JNO;[8!
MV%YB5-5,IGI'D8(%/PU]!^'"#\:H08)N$T@^/N]']EJ7D3HTH @,1G/"P?%%
M#>=SG#YY,K@.+=7/93SK *G#E),\S[]Q87LZ1N6++[Y<A:I>4+!H;$!#)S_1
M*\N,;C!TWHRX6AV@,]A!LM816V;2"0@<=0.MI(,B/"H99"WAE1<.\#AY]H <
MJQZ"E^74-YZZ8;OSSMNV4S?>4)K,E@.'I:0!T/$(_:R4H P94CKF;U/(4>1F
M^(2#+B?E]MS9]>2)INK&E&]DV P^V-,P\J%?+I8Z3\.B4_))Z:DALY399TD9
M[5V^'4._([)R3:;MF.26$6<@A2M.:2"$ZY"M$?/2(VEU_#46REK9@T!D4OPK
M(E?H"0\.WEH!NEG#T=GJE%TG7N><[C)C9H6*V4,-"AZ8?7KB<=_4/E]>PO/Z
M&)QF%!G6Y&YH-C/][1#E6KT37-"2;G08S^MOG.\LAHX]&1#WIIO.;>=N/EN#
M^,K@V\YI:&V_^..//=6O=K@G-P%8WJ+=J73NKTNG:HE&6-+RZOPS$JZ^]JK.
M=E)V+7MP>3&=>;,#?_?O_?U^#LY^0;*1&,5=_30S3]\HE'JDOC[^Z./;O_R7
M_W+[R4]^VFT\UW>IG<,1YPLVY$?;8>\MI_.K?G2 +[CZ4D=E.6B IWXQHNE+
MG1+X=?EN"M/&.IF3@XMO76S;ZAU97@):&<C]\'3"^BXW](\S0<@E6 RT=JX3
M0;LK?VTG1P?,8,/:(S@ZAL$!7HU !M).$^$Z^?;XR^>2\$F]\.DE=/>^QE1@
M6&%"SMM^EB<S8 =E]5"X_)59>0S>J%<U^H(+?,BN:\L.O?)Q=.ATI&8090TH
MJEL&%8IGZ$9?,T+;,46DE$6>'4S79#3O7$%!UV1"!Y<^R0L>(T\S"RK/U;ZI
M_^20#%_9<I"B88-RP&?Q0&?<8"EX8MB[N<H.5ZMZ##: 95!!6V0V&UT63),I
MU<O!"ZZM5REK;8W\NATC^-WWP/W;V;,ZO-=MSS[][/;[__KWM^>?>S'MWXW;
MZ5-FWJZ+7&L/U,]IS]E;):WV+/6;OD<66R@_2F?_X_<N;I^\_];VX=L7MG>[
MU>K]M#DSL,+XO!2-@R]YMQH@ $O>SPS^7Q'9NCSMZ657I?U)OLTO= @-X*VN
M6VU7YUV0FM48X_#WLSRPS]8*@-6N7B&>0H1O9 4-/:*I@SPML;WI[,T]=ZIT
MO=( 1%D;&1J[[* .Q:W[J0OR'E<\>T?/>Q[O?^VRI#, ,$$RB/>7S-0'V_0,
MF)-):?#9(+ 9SB9)^L+(/7[B(UW>U4$?S " +0UH<-]]]]=V-B@,GGO;C="#
M3GWUU5=[*/?7O_:U#MH_^^QSVY_]^?>WJX[YPLJQP$_]B.YG<W?R)7([4G8X
M*&:2X># RO#TZ H ]%>&(%QYEN]1?BUZ+,^MM/_?!@"$D\$5?R6KLMMQ/'!Y
M*1YY<3T:(Y"#C]_D[2KLW^GRNGJA;H>;NVE_EXT=-Z)1N"-W5I:]6[W5<OD%
MEOA<8DSY*N_<O%_.NTZ,IEW29K!'3Y\]VXZL Z$- /@:#QFRM>LG/_[Q/HED
M!<!/MY_]Y$?!:^RT5=;"W:]3EJ%I;95X[XI]\,7K#L@U5#FU"S/! -J4<]Z5
M#DGC0-5;;KJE6VL-%K)SZ-W%1ZNLP>CR^>@&NK!G^41^X6![4CO!R8R\=4 T
MZ92?3 .C[1G]S\=V2UUAY^IW.JSOG=B2+[WRQO;G/_CA]O++KZ7.3[F"<-N\
ML^=NBGW_0.K&#=L;YV-W//'D?D @_1_9;;G7RH4/*V(FTN2G33-@#Z#RSRJ]
M#X)CPM,VM..=\MKN>HQ-&;Q05#S) B1/H^NT)]HE?54#'."A&1712>[$9+>P
M9^'C/1N(_9_DM?'AB(:VIAEL,+D1LH5.,P%T^17SJ5GMJCP_U@ZGK=#>&\RH
M7%IE$=B\9_*JG?D/_^__.U2KN^S.NQ_XO48PHKH3OQ6\!<E]$):P!CX 8>XH
M50V:.,+GW>H8B-OECWGN;&G>(3XF:9B7,K><;!GB0XSI#'@GC)</&9[\+ DT
M0I-.=0AUWSWW;/??=V\;UX\_L&>7P>AO!'@4#1]&IY)==\/)-"B?](14PHM@
M!%"'"[%58'DHBRNC7H5T&.*=]]Q=!CKUG.'-P(U45FFW4>XS@VT4D3\5M$+E
MD0^>+;MKZ$O(5T4M#T247N26@'A7Q.L89"I<1] 3[,TR/!I;F']-Z7G25@GD
MK^D.TFI\]CB! 4X;H)2A94DPN,*YP6CRFP8!W/B^4+@F:9B@KAS)P_!@SV>/
MT-\>-OR92M2R'/A]0"6^\9KXT+5,G$O>KWU-HN$C \SLK\\ /ID.B(,?+2_N
MH7NANWV]XAF57/MCP3RL2.-UJBO[J0=X)9Y\>.GQ$$W=XUL[>)%#RL7^SQO2
M4.LP./ R*+9#;624W-]\TTV%[=3>5UY^->GW9:8GCL> >[9+C\^G(_16.@56
MJ%@&5@,[^%+B%&GE*.DZXQ9:[22(&RR/4LU[AB>E0C$;5;9/R]))^_O![Q*E
M-#;P=#KURR^_W /&S#:WP4D^R3"@*2GT&AE1-HJHO.3W=SJ9BZ:,=_1DS*_&
M"_V.(BE,3:@#4S'J4C=#*\8]XX12ONW6<U'X]VRWW.+K#@Q=I^D>KW'D(*\;
M^DU=^[(MNPR?TZ!HB$XDG'%\\L:371:,WCJ.WIE9<7JT96)D: Z7&M@G$\](
M]C1F]G%>TW=K5M#@A'3%03Z!I<,@C>5S,[-H=5&4.2-KUS'D3SBOD^3 ,.FM
M\)AP@Y)71H]:W4"/SHG>9E'E2Z]ZOC;>/CWZN"LR DNGWA81@YF6GJ(%0\]R
MLPAN9_7.I6/?K[JD8ZZ<^.4L!;+0/>)Y)FMH?/K,J1[T>DLZ\&?/IH-QYF0_
M]7KF],GNT3]]\E27H\+?S.PSSSZS/?_\"S6^1[=J^*[8;CQU<GO@2_?UH$G>
MP;!CY+ZUO?;JZV,@1<\2#2)@V;7R51R"M[I"UD:&9B"I*T1"KX8G#-Y6:QF5
MO^N>>S>?4GHC<OW**Z]&MM_H@)"E? ZA<_5LY<^[;[_3@< GGGBB^\+Q:F;_
MIX&G%ZTF(>/:"CC(4SC9%F:0I/QMF[ITO3KX23N/!DRTGS.H'GE79[0C^PHV
M,K%FVN;@N1@I@:]2>"\_:< 7KZ?V&\Q,7 -/E@A7WBH#\]6!GOB_?P^>;J+O
M:I#%8*%/S!)?%=D(6LE#G0Z=XYW(GRCM7,.U^=%3J1\&1\D8O)5;7? L;ZL$
M+-$L/2K[L_097<96&'WJN6QMF:8],\E@0($,,1#)H5FB,=)BG)56P2_IP:]=
M$@]';>R""U\T'+FANK2WT^9JH^@E2SJM)-#>U*8)36DA<<B0MJ>\#@_0K@,,
M 5A=Z&\'/GK0BH.QAUK6I&DY=SE=[00GGGH-WPYL[# _F]>%9S5,&Y/\>>;[
MD#\T4%]\KO-,SYIP<-6;VW///M\!M/(CNNSJU#=\;L<OL.%166YG9LJ++AI3
M,OB)0__BNP7 @)2)E<BM^&;W%)K^QBYTHE]JF^1G\'_VY\?.NR1Q]W(W8RZ7
M\CFT[V/>H<?X!HF0O[0?#._( MB<SFIY*>[^6W&U!V\&5^=XD'7M[9RALX .
MOYOW+W #\] =1E.J_!9RLA1Z$$'XM+-XHYU\\R(\SG< 0!B=K@[3U0=EC!L(
M@U-Y&QE(49JW.J #!88#R-0I,D)>)6RG)A'9*.J'CH"VB@[0D7CBR2?3%J3#
MA<]P#F#E=S\8#R+(,YVRR$(J.;E0!T0D$I7Q./2QJK8RS%=>BGW??9&NPM9U
M^5_D#M\/7P\<F:];5-IAQA^M0\LEI%=8K7>VTC;)_N/\[]T.?D*Y!"A#PQ.:
M^\8-@"GCGC8W[M^+7E)O^[YE'X"-NT,=4$WE[O,N_.[ ;.J5\X0,&G?Y=G0&
MG6E%CT%@@S[:()U1=?O%%V,3OC[;IKY(@Z-NL'>SEX-/_-&]>"A$>6&<=_E7
M^?-\I#R<- [$O?%4=$SD4/ET-,G>PJ%ZU36ZQ"2). :1.WD;6,N&.92=Q(ZN
M&&5']L;&-ABI7ZC\E^UGC6S]$L 5B7K9]E9L9Q-2SLM2'XI]D*=K3>9]\QM?
MW^Z\\\ZVE2^_]&(GAC\.[937X%;[7L5S/PR;O,>OBD>_T,NNZMAJIY$+IN[7
M!& 'C?<Z)>V05!W6;_@P\:W.3/NL7YM(^@GXG4CSG+BV3TX;YWR;#S<K6BWS
M=^^=P3MZCRZ?=DQYU=.Q2>@X[*(_Z QY#*9%:>@=G/%P;(W+MW_\#_]+?<]=
M=L^7OO%[EIDZI1\1EP$K(D'H85A!6@,_GY&:AAYC-<I&.(QV,-@H:N&CO&;$
M6,-T^LSI+FVQI%Y%+S(A2D_XCT 9(-!X,_#['M%R/\(RU<G]C)#"@U&R;6?/
MG-F^]:UOA*'!\SU[9I= CA O8B=I3V^\_H93"?ML>_2QQ[K$<0T"S&R+0X4P
M?!IO.&!>!P!NOW6[X^Z[.\JETNK4P&.-TG364%X19OD/#O'[/=P-;G0PA$\^
M'2!I^2CH(\I/,K\\8^4$S:_P59@][JJL4V$]]Q+G)K[Q--9N"=R\:6K@_%8B
M<0=LPXX:2N4#(B9"\RN4Y>"YAPGNJP%T 'NYYG&8S^?=GF;WGAHUC*X_@L=J
M .#H-W%1:/!521UB=^RZX]O%&/-6?;SSW@?;C9'#:](0,\XI, J P=R#FABV
MX2]8G5V*/-<I;WR50M[7D,K/=2K4*)"^VQ5KT"HLG^3R=0R?'G1O-/S\&W/P
ME7W..DX?)Q\GC6KH[1.ZY]Z[^Z6"/_F3/]X>??2Q=DK,T%IU8H_JJ33R1F,9
M>^1T*2/Y+GHK SK5N-I_J*K>F+77T7>HF67?X#MEUO[F&1"XV(;& (!15 V0
MA@DL"K%T;SG3(0G443Q[OGA0/@PN&I36EWIUA*&SRXI8.S^'?V.(+)P;V%CK
MGWH\C0LE1^?<>MNY=%K/A)]7E4_TP] @"K;T2/YTE_Q31W4@FO.>CWCJ;9=G
M,\ 27WG AN_8(#&RDG:60"H'G1&EG<XDNJ!%8PT)#FD 9PI^CU_EG$C@,&J7
M'NLU8370E$%E[75HUO3Q9L(^_&A6:LPJA>D(P'<&]::LTAC=AI]X"CSPAR;A
M6/%IAR?YF]7NX$@:$OG: D+NGGSJJ<XJDQ/;+30TL[_^RG;T=3@[BA^0EJ2E
M(.4E.22/9.R11Q[9_O"/_DT_=:;^, (,*C!0C>S??L=M;;0[B!$CV0%FSSW[
MW/9RZH,&3CUI!O':I^E4)T\T_ZQ"T3P+.^_,N*J/RDB76_Y^\:UW.O!WEP,W
MDZ0=OL"=3N6,F(,T<CH#50;PX/CLL\]T,$)GEY[0D3: @=9HS!A2!]O [CJ
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M<%\!&)MZYQD>Y9Z$M6T++OC9,S&Z__^PHP'1\A/_//HE;'1\RB'Q(MM>IL.
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M8;K]VM#QGW?[NT8]C O>XFU")]87$C?NGNVDS;6VP@XG?Z53ZD/#1)Z_E>S
M35[H/1Y_EZW8\%S ,NEEP)LMX"#E;IN*7-'EOLKTTDLO],MFK[WRRO;ZJZ]&
M)_KTWN0&5O':W<+9Z]K+Z]V.M_?J1/$7;:>'=\L+:YV+G%FY??;TN>I',@HG
M^EC'GSP";("*K:HNT*$FW#C]1/K8!)E!<N&=_(E,6NDP$T"K\[OLS^EPD_&%
M;SW<@C/=Z>M57=K?MG:WCSX)OH%_[SWWQB8\6QRM 'C]C==*9V6>574S808V
MMV@W;73JH,CYZV343@OUG<J: 9/1OVB[X'BO3O6,L[BDJ!W0<^[B2(E\ K'W
M31\X:&:@PWUI'D^>RI?*RR<'^*&19_3GT%F?75KE7_I#+G(<.UB;DES5IY1)
M>F'_])_\P\+@+OL[?_?O_YZ.^\DP^C8S(E%89\Z<VNZ__^[M[_[M_^SV[_U[
M_VC[>W_O/[?]QF_\QO;UKW]]^]I7OK+]RB__\O:-W/_ZK_]ZOXWH.X=?^]I7
MNO30LDN=KI_]["^W'__D)]OC3\1 >.[Y*J077WRI#9[5 %^Z[]X:E@Y#8_@Z
M>;TCXO4[4V$=_^G0( +EH*$QEL.?[<93Q[<'OG1O.T/=(YCPEC0$8&"7*<//
M?C_\Y(UGVNG]P0]_=*",Q>MA93&,9$.14H:N1M.OBU%X6SK_OMFNL3P8D4/P
MI"V^P:N\W_&L?N0#?S462P@TEOP>]<#U.?&)R"3>%6NQCP,CZ1V(Y[>'-FR4
MK#3S/-#VQE%@(H\BV!L=ONE&L$<P=Q?DNLW [<*_C:#[\9Q3UZ<L^5>?_.,O
MNT3'>O#AVR%U+Z,!VS"_%F(/\P#,!,;G;TXD36 NS?OP[72.=OP(M@Y2)&6>
M$SZS;2>V\V^^N3WQ%$5P(<;;L8)3>1BK]NHQCN')Z%X-FWMR1EES*IF*9V;&
M2@BR8::G1>#S;]%JZ!4Y2H=$)\D>="L_[$5^ZO&GMD<>?B2R>UGKBL[/R1NN
MWTZE R*NI5T_W;_Y^NN_]NOQOQ;YOC]*[>[4Q_L2[V3W8MGC6!S0-&YXCBJA
M:GB.D/@R'<VI,V:WZ_"/A_XD+^X-X!(XO)H._:J'>U4:=^3]QZ$) QPA1A8T
MW@/3NSGT+]?<4])K!@T._85><N[(^*>)L_-//#*R%%OIFVNW&H77]L+_TB]_
M)X:00]_HAG1JTMA4#G8^B%]XJ:>=#6\>\]RZ"S_A'3R@7#\,KM-9@EL'45(F
M>1]TQL&#1^]'Y@;'&01L86+8>#<']NEH)7R7?[K-.22K7-YK).<Y<7>CJ'PX
MXI-M\$I^E"%X/+>R=.\5C"P)"SQX)V6O\J(?9Q7"#-H$R4FKGD8F.8/ __H_
M^4^VJR*S!G._$GU/5I][]MGM__7_^N?;:S% OO/M;_<T8"LO#.".+K2%*G T
MD''/II'^R4]_MKT:O7[3S>?:=CC\;SZG<VH[?=I^U6L[$)#BU3G$Z]EGGNO6
M$T;1,1V:&,#X@7P=+(INKKPC0; W2- 1^C2&#'XZ#XWA^XKO:+]CB?1UVW<Z
M # #?F1RZ0\\ZG+&#]XM[Z<S=&D/UOK)CW[:[3G773/?4#?H7%ZDO/+1$=0(
MCW'T\3Z#?:$X:X_,UKRC4Y).J/9M9O4O]DL45G7H_#=.=-&[Z33@;^M)<%/$
M=6J[&=8.[N!A\)\9<3.Q'_:K(/3%FV^>3R?\A1J+/H_I4Z:OO_9J\@CLZ!7M
MFWOG?] 'Y%U] [/RU_JYSZ8;#$@99_\YHV<^M_=R#%!+RU](A]\9"HPQ[2=9
M0Y=/XM^+/NV6H?RZ##PRW7ISX$?>IZZ9K2'3\H]L.C4]'7^??Z0+^W6,-R\6
M;S"3/$Q7%X)GRH &!NX9QV1DZ6OR;D" CI\5#58?.!%Z.E?3+D8:@J^! >U!
M9W<8B#' #7)8+=?.MK8Q;9ITC1,98QAC$/W006KW>[YSNO?[<YY"ZA ];=FH
MP243+?)49ELGR<V)XZ//00"#7W7;?>4>#P*'; JTXD!'4V??2J"S9\]L=]Q^
M^W9].@ZOAC\_^?%/NY7FK-/$C\W,\\Q2&=AE;">OX*'.*U<[R<G#LM/-*I/@
M=_Z5E[:+;[RZ77W59=VJ<^L=MV\W)I^KDD>(TT[^98SI&-T&N"^)\6]F[U+[
M=@\&!N"+?KDJ#SIY#@^5C8ZO75(=MO^\\"Z_6=I*QTX;S$\<W!MX>,F1CPNI
M"SK(MKZ@M:T::[;0RM'R9Z=M,XTO/XZ\&Y^V@\U#%Q^DR75_ABU9+M8I3_?B
M1A>HFR^_^EH',,&E-PV6ZOP<V*=-E7P+)^ "IRL6U#]A@:>N.Q>([6Q X\L/
M?"5\N"IE4R_>*0V<M4%'^GRU?.D_*PW(F3KN4X!71V]9+568@4U/-^]Z,Y*1
MBWCR0"[6 <>+QJ5STO'"+HT]YKJ<]W/M17-RZ!+F?0>U5H0CKC0-/9<LBE];
M<8\_*P*6FSB\=(WGV:L=O^577,YEI:O+ZV5_1 0]'KB#.'%SFS+ON!W <.W[
ML:V2X^!PX%9<]X,//=I!_LAQS]W9W[E9[_NUD]#=Y"9>T4=77^LS;I?UO)H7
M7GA^\_6D.2SZE>BV]Z*5)O?B]06G3E@Q#-O^$D?;3'^H[P87V*#>$7.BC'3\
M] 74V?P/3F3[ZJNOK<X9^VD&L=G(^FN=J=>1C2[PI0!7Z<B;%:V6V=-WRF3%
M2NE#[U2'PE;&N=V+X=HVF(XFFX'5@4^>O$>?VYIG99\Z#V=;:Q.Q.OO.]-5\
MN0U=>WY5V@_MFH%[_40Z=^D,HJ >C]PHOSJ"&)]VMMYY.-T6%5]<@H.84-7Y
M-YL/%'VAC,H<--JVJ<]<5RBG_=!'\$X<Y=?&5&]B ;K&MS MCY1P&1CBR$.[
MZ:H/.RN K@P?M;'LR.")<^0G^K?YQD]_8&SRZI?<_3?_Z3\"MN[2?___\'_8
M_D__Q__C]@=_\ <UVC0F?SL=_W_P#_[!]CM_\W>Z+YGA=NKD#35PG(S\/_V?
M_$^V_]G_['^V_;-_]L^V?_W[_WI[Y>47>_*CF1"'5/S1'_WA]I</_GQ[.XK(
MDGZ-%V$U6OW44T]U] A3;3FX(XW+U[_Q]<XP(.PP1($9RY]M'VI0TX%0D!DM
MMT1DEC+JE%$@76++$$VB,K$%!6-4W<?@?,@0L1)@/XDXX=-Q:\P*)N/KH(,2
MYZ["05MPB3/& [CCO%ZC+>Y#Z_A6NSTL^)0YA^Z+E7;%6?&73T&:P7H_G85#
M@VK%6\]'W<KC:)S>^S4LS^E,? Y6KW//_54\$S=&0KW\@I\8K=2[_Z(#J?#$
MC>_!++S?+XC/B;\Z6KPR+_]Q>,0?W$<&7%=<7OKN(4HG',[D1./;/>X7WDH.
MPS]Q*3%&ZYLQIIYY]OGMI2A9\K8:(A6=87C]\1.5P5ER/6=-K!% ,C@-V1II
M@\=T@.%"(5C*ZSNN#'6=CMMO\ZFBL^T(.7S-(6P.?=/!.GOZ]';OW7=O]\3?
M?__]_6Z[#M0##SQ01<B8Y2D$#AZ6*#E,AB?C1A?).?R\YY<1]<5G?O$/2X[R
MY> ^Y5A&BQ#+F!B4TR'#YWFW9$>(452*"#T8Y):.SBP=^>'Q;?CH.];MQ(=7
ME">^K>^T5^Z\+Q]GI4]][@_S&^=YA16G_,G?(%W#]O?@J4]]%LF,4]]-/5H4
M6.4?N?(.[*->G(D'#ISQNX,(@5>:A@[S;A3UR,<A+@<N%4,>J[Q#IY%_UT99
MB+4&:22/R%SB-6ZW8TW=7$XXAV<&-I.LC3F:XD/WR270/M)O??.;/5A1QXS.
MEU8=()_WW7=/.NTQ/B&2?)6/_"QY:^56VI3A[;<O;D\_]<1L-T@G3N?4)RX9
M,'2_!EF:ZM34G5G&[OO6<RHNN:#KUUX],#L0E_I7F0F=!__ABRM88-J+JTTH
MG> :#\=V((/B$:JW?(R;U7[XF<$^ELX.G57>)AQ\@T7S*=B925^Z93KS[R-J
M#_E#>^^]6WBUG/$0.,IW96\]*NX,B\4CG0&# :.GY04F_3%?XC%+'GI\;+!A
M3ARF%V:+GFU[Z<B'5CK_/GNJ8P#_?ADG\/AV_G?9&#=E)5M6?#C,C"%E\%['
MQNGDAV5RB)WS YRK<BSWU]98U&'60=49FT^!'JFS\=*W?GR<=CDXP@N\SHB0
MHY3;E8XQ8R,/ANA:#NUP,ZN[KKWV^G1('6IY>)*S 8G\5?];/67 M(.FQ^;\
M"F4C6PQ(^T/9)#I9V@8&)2.U<*\$-SYEDJ?!_X"O_%2>ZM!JZN&:R5(.*[KH
M>MMV6DYEBS%IY8B!:30P.+%D%_W!7#)2.=F?J]L9>D?JB32V*+&C#%0Y9)-A
MC*Y6&B@3 5]RZ5-62W>AD=O4VCS3'2/7Y7G@?Q;O<U5F_DZ>.;.=/'MNN^[4
MZ>WJZZ_?KK[N^NW8\1NVXZ=NW*Z]X<1V97CNJP"VY5AZ;A# IP!)SX$_HH16
M7JMM7V'_-B?MU EMU"%-./>'?!#OD@[0H&^WVATQ].7Q[_1^^WWQ^X*?=[G?
MZPU^N>)M!_JZ]>S=\H0L.[27/,WY*4/[!6<0FLMR*V\.?_#UR:>>3"?^X<H)
M&5!6,.B=%<;FI@_$=WBIO-FOJ^UH>>*MP 5]Z9ZVW?%K\*7Y5[B/..&5E=S4
MIPRU^P[;HN46[D=87?=%'G'%"8S &ID<]X5HT#QP)A8\2KM@#LZA:7CB"J<9
MR#G$ASN:KD[:W#;^+_"%>R0]YZFU9P\?VO:VUX;'NQZ%I4WQ-22G^ZOK='6A
M%97I_*N?2Q>P#=@T!G06K.K:E!'Z!Y-."5^XK"NGC.H*V6![':7]T?B]"Q'*
M7^'[._5EI:=_Z5L'>9(Y*[+8%Q#0*;>25G]//.6 Y])GXLBE^*>=JDY/N[:R
MFG)-.S #WB-3Q6U_S^UHU9%C\:TH=QX&>.PINA=\*\H=/(R&ZH1RT)OL3RMQ
M;4FGJ>6Q!KR4T_.J*U/^>.]S78=M6V'8,P"*R+3'!JC&[J>O/7N'#F/C*C\<
MM4-62\&G*W+33EQR>?J@:5NVRZ]._W;;WDD;K9_[4?CQ4:X?I!UZ-^WG!WE9
M';KC2&^2W3R6UK4Y]L'ZQ?M.AJ3<)B;<PP]J_!%R'KA+51J-X4-FZ%]ZL1WS
M&YWF'$/0:*+O\!L51"Q. _/4DT_5(/CQCW]<__P++P32)6UH*:/7HXQT_J^-
MH7C[G7=L]S]P__:E+S]0>)8.OA*#0B,,Z0IKD.P!@;ER"DCG*/@0>]OLJV!8
M71V&7%WAW!O&$-4H?AN(I&W\I/740A/TSQAD&M Q*.0)?D?Q#O(80A\HI=PO
MP?S\>^'Q89RH%) ;O[4$A", W 'QDZ[/N:R.5)W;X-A1\7*7GWSF_>#4X#Y.
MQ6K8%Y1H(T!CA[64.MR7 Y9O&<"1O'GL+Q*0E +SV)>2>>KO,'S@+CK_V]S1
M=W,_\/Z=#I'@E,+4PRON" 8'83!I(Y>R:.AX91LW%90"?>^=]SIS]G&-\EE&
M4\44>1\%]M'V5A3=A3??Z@FOE0T\Q_O <+IZSZ&(<S*GLHS"&..D%4U<:>!@
M-B\P.UL7I<#0UM%B*+S^^JMC$ 8>!6.)II/?=8K(M/R>>>ZY&J9&_F]PTG8Z
M8)006>\Y Y%_ASMUY#Z=)#+-]YR$>)]7ZZ <11!%Y%EYUX#<Q&=PS])7"J,&
M-J6?\"#1LBVXO&?*+H6L\3!>V:?#T[X?NJ2AZG*IQ,6_SH2'[O7M<)B-WSLS
M\0SB688<6O%HQC=\C*ON<X\A.X,(T]AP4Q\.Y>&ON"(U=:7U;I=IF/55PH2W
M456I=P?>,BRXH[);N8]?DK_XSJUZI5RK85ENY'9@#TX>YEV3HVWI*SAY!]>I
MZWE2UROM$DQYI_X.?N, :0:]Z].!T:9L2]>I,Z/;Z*RPL+ -'.CD_]9?^\UN
M^3*P^Z,?_6#[\0]_T [E=[_][>WK7YO9*/DWC[WL.FVNI5E@FXVR<N54VA+R
M;T;^9S_YZ?;X8X\'UEN1)TN*#SLV,$"O#J;V:1RCWBQJ<<Y[]<FL^=2IE,'
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M%/)+G;T";\&(CT!;(=)1_W:0I]'53G60JDN I[-VL&(E[9)!+!U[7T)XW4&
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MQ 4;':WB>^EEVR%BF,9(]2FJ4_:JYSWYL**0C#/2K@LL ^^,69G TZ<A36+
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MX.);<Z5C',CX_>__V?;@@S]+^/G8"&:AWH\1Y@#D)[?S%V)<AH;59:$I?A@
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MV5<V0#M[=.5.?_ OO'&^*P,,$)BAO?#&A0XD,.ZL3%,VZ92Y)V%'7_C6L_W
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MIZ^\ZIKHKBO;P6?(NI<'_?7:Z^>W%].IUXF^^.9T_M=78I9WL)\S;"[DO=4
MK[]QH8,#SK/0\3:(,(<=SC8S R0&;-]*1]QAG%8-F$$C_[@R7\-@GZ24OMC@
M6D:-ZVW+/MI.1[T#W?Q. W6=<?Y.ZM;;[\2^8^-9F6"+5_+EY6T0@JVG76#?
MJ7/J:)?ERSAZE;R7[[L<H;O[RO*_Q8FYVOH.,*4RV!HC3#TZD$GZK?<C8\L=
MOI^"#Z]W[YF\Y%J-GK#Q:#97E:]V6N >^ODE:M^1$Y[]+#]TPP,K1&R#,T#
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MR]B#TX?HZM3DZ9P9 WA=/;1[<MC#_R+8RJ6=,'EMH'?5.65BO\!,_7:8H:W
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M(!W9OW3BXD?S57AX#;:MC,G3,X6IHAE(\<F6U@&**S$U4LX*D)?R2(O?-6R
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MO+@UI%T;-#\\TD&X/KSV3?%GGWTARO.M=EX,"CA97H=.Y2;'&F,==3QC>#'
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M^C'NZ!SQ\6+-V.A(L1<,WC.\OO:UKVZWQDAC>)7&D5$#/ PV1J(\9==\E2E
MU#]&]$,//AA;YL7N4[W_WONV![[\0&FJ_3#(Y%!!^W)U5&'LGR7U5@"890;'
MS+L.-T.=?C-K=RR&8)?TWGCJ8*59Z9\_^]H9A6!:PNO34 8&:ASN[0RX,C-
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M4!1_![>>.WNF R"+OK1'E7\&2C]_8"\?SZ#$ '!/E!M+ZK[Q#9]9NZ\SHVM
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M+\6=8B*D@7TM4\:0]'-7=6/<,WN/N=KC;1 CH-@RQ"#RLY__8KMT\5)/577
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MS]0KG2'7=H8#!X=?O6"RD\=TZ,%-[_>\RQ2.N(D_J5?YXK=#'W%RF';KPS"
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M#P_XX"<^Y17ZZ%; M%.5F,!?E\Q\@O&V*$04;EL G2MQ_X,/5B'21^KV//W
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M?B\N'$PZ98Z;M&5"(!"W88&\\3Q-&?S"4?[MRFT&R3!2 Z<#D1[_]9/;%2L
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MJ?9CK;9TTF%8]HJ]=F6^/,#"BND2CGPGF=)^*8K]JQ'L[<6EG&L;BGA7/$6
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M&0!S6KKXC#W'HAS='KQK&T8)^Y(O!(X'[V>P>&S[^M>_WF7.!")MJQ4<[&I
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M.3'Y^1=>2I[VYB8LC)@01_BYT3+WT'N9<6BCUM^TX12QEY$?1MV]TV7R##G
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MY #P=.7*>Q_TLWE6&SDYWE80LSB,Q0191( VWZ1HOS%G/,PVKALKM-LO:IP
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MD?1&E%GU6VVQ_A?"A ^L$[H4^D[*A9[@4#7$*1V ,_@^R&4N26-BA (\=,@
M<.+8\:Z>(C]HCY5.7C,VVZ(X$S*N,O,.KVU?!=5.1W"@J)66TW^6T9<#]]#*
M;)%,Y.V]R JV89'5N?*$P-E\(KN0*6MXEWOJ:3+,H<D.8-9GQ5=R];UD[-G8
M3O8QINN/#+/2%O[ T'#].[R,8<YD%+K07G @CRKAQH*DH2_T\^#!TZP89KB;
MU:GT1KP!CH0S'%AE[JLS5GN0/_ &<ML7#B$-3FUK!B^\##Y@;MJ[:K*GO2W:
MSLF7# 5V-(+F))$N:-K^]M_^FXD[[KK?^L'O_KB#2S+ 2*?#:\1][T($(0?'
M]/ 8EL4(;69K6"4)F&:3G&)MZ5+W!4<(>MW!76^_U?@Z 635BAZF1!@D='UB
MUBIELMH37NU= V49%$*-;R4#,< [$U@FGD8ND_TD _B-VX]^],.N*&!EKP&@
MG0^M(*QA+,HQD!+ 6;W52QU>#6&8?3)H?QX8)(0X1"]=,HBR>'*[]_[[^OWS
MFWIB]K9]FL;K05@A ,CWKT*+\A)!4GDA9LN7P3MU&49V\&N\'>"XEMF;&9@.
MGI,VF2FF,.5?WHUO)H)R\5Z:7H]X^1\^KY][5+&'$_Z^](OKNR__A %!L>,3
MNC]@*%/2<NL^B>(&MK3+P:\Y'L3ZJD/2&"/>F?\3&+?STH:T#G7@P+ Q=0=]
MF0TYL3WU]-/;DT_\)FW^490ER^E\NLUGV$8 H4!)JW-UEB5T2:%$:_EK83,S
M/ JWSL6[Y[53Z3MTXZ 0RA,G*6MN3^]/OZ#LO_N>_>T8&(.:Y_?[W76']%US
M#7I'Z\.\*MB%#AG'#/S]:H4PL.PTNF#BBT?MT"O&"%;TB$Y6J^R(R_7 :(&&
M]C!_J749:)=KJD"3#&[-4A,D]<'NIPUS<Y BI:B6TEQ/1>DWVP0^?=C^U#_X
M@S_<7HQ0(B]XPDRK9 :/^,XPK<&Q&7';)3!!AT[ILP$TZ2P73;[P<=,MVVT1
MBECWX5F]Y8O^G,+\2;].,E\UP']$*B-/6Q]M.X.JS_ )[VQ8E#9E,QRM@;@S
M.0F#T])(^KP\[+O'N+4'*C8[?_HVW\H_LYT^=5L%-$M13YVR'/5D!TY"G/HP
M"!#B;CM]>Y<;R\<]VO3=;SR0 0 O-9,#-[[[;=DRJ^Z)X\?ZB2F'E9GU?^OM
M69X.OPT[<T=78SW[W O%RX<?V>KT05=Z&53M=P?WKQY_O+Q0>S"*V7M(>427
M'[[_22WFZ)608E8;7N!(#ZY@D_)6WT=G;8OROZ&MH<I&*^[PX1EKIC>[KCW!
MME=H;RM-T/D!;21U:25>GF;V]<N TYR'YM-OT+$PY2=>74$$7Y[CX;'"1OHT
MVC:P<LNP@7X<>IL1(^,416?&&3A1GF^M.Q_!(/Y2!+-_]D__:;_3; GNZZ]=
MZ=8315OY1BF=_C4XJ,LMWK5"#E[!97DTO*7&A1N&C,43I:D"KSC#YZ;_"&Z>
M,DL>E%7MI8T4P""EF ,X*MR'9S6A@E*N=_.W72LLY<"@L6H)WGQG+%.VV2IM
M*5WA2%AS]YPXJRQP*JFMG3 T8\9G!)C01&!M7=-F@RO&+32!]T0V, ZWCH##
M&Y.^X[]9D2B?^G;<9+?7(_G(R_,(E&/@&?EF'T.; "S."_FP0O4[[[P5?O%A
MX!F<*7NU'R,8 X ]^P1/ASS9[N0](=U$QWOODX?F:QW.++&"1=EH"A\^&P'O
M5'@;/%(0Q^#E8+C/NB*+$CDRSX#7-H;+I(=WP\((@.&A$7B-"01?"JAOAS>]
M>"FSDSA=(31G%4&+S[<^]."#%6;AY:VWWN[GXLSFZQ=X(+X./^J%#BOTID#U
MEP8QHC7M,$: F:&4?_M.V[E5*-[ JAT_LQHM5VGER<\7F,([FR3_$AD_F#Z@
M_::<.GDFOVD/\!E[E)<'L*ASZ.:CCS^M3'KB5@< 'QIP)KG_'#J9YX%QZ!%?
M$A/OG0+']5W!0$?D4V]GW%>N,4M_8_1YZ\TW:C@DB[X3N=)JB;>#9_S!^52V
M=9%+M-,R-H !#AU**9]1\*/LY\JA0]M/&;HX.#(VX=<,S\[;^B1CQ1UWG*X!
M@"&9;'[UW7=K !AZ2UNE_=3;<^N=^^(WWG-G#!,&7R,[3#QI-%*C*K__=]Z0
MO(K?7,LP_%MIXO3.O.ZSNBZW<,Y-&>.;]Q[-9>(<+4_[3TX3+?]3D9'51L^8
M-A3'.W]#4\T%GU+_;K-2OZ'S@T*_XO2]ECNY'<#)E:]-IGUV0<M3YO"\5<>)
M,VF5R>E7E#I;/IWYT\_P)9S,846@@^H8Q)]]ZNGV448^_<;J[,L7+Z8=DU=\
M^VSR:JXI9FH[.&CMDZDR*S-&/A5'_R$7-/WZ[; 6)\&-OCDRYHR-E:=WPT0B
M%7XTY7#XCK=)5]X36M,OFA<:5_:1\77&6(""3U9SE6;!0 9>]^HA/3CP0RM2
MZ):S_3KU1H,)KTQ*V4Z=R,YH@0P[D[LS\2",(:+C2HH%*X.=/CS]^YK(V]Y3
M]F>E57&;<+R.\L_AH=I(?F#HX?CX8T"6MO'08](9S]9!VWA@RT\9W485_=AJ
M+)-G/A=ME0*:8+QT@'EZ:_''>+16]"WZT<;E]RG'%D;EJ\=,5+B.;*Q-I!L#
ME#YTS?:W_]81 \!=%Q[X<0_B2D;<1!NG468PGJ7(*K%F:B@P]JR]]::E_V\5
M^,L1@AQ.<\7J *<X$Y8#3!L/L07((C(*CV]P8[88FE-N T 1JG$.F8\T0YPJ
MK)%*LGF&X'OON7O[QM>_WDI:I6#E0M\=<9[7J=YK23BB *_EI@3<*@II'&X(
M'I&.H(G0-<AWOOOM"@;J 1<'2[52%\RGGQ#;8=;PX*P &29=ZW8\16RM;%AP
MYO9+KAUB;^0#=U GD;T[DJBW"&,P].>YYKE?P>5IQ6U8BYL\9@ <UW=[6N[P
M.1ZW0U1YGKX\[R;W/^NT[4JO#'[R&G?T?KE5:_GW7I05;;\_6F++J/<=9/LX
M;]E>>NGE?MO\PP\_V6[/('JZA^<<"QW:IC*?: I4![2N/3]V,-[>X;3EP#YE
M+#B]6[YU:AQ03F?K@7VAB75OD$JLU&4Z<\M(F0:B*B;PWKQ9$"G/JQ\D?"&B
M^25_-18WWC.WKH4EZ3"!4812AP.:V6'W+_'$W9/537W0,F$94U-6^D3Z#&LF
M@\E#$205+6'07!AMU^D^V#+C*4O>^H[5#B\\_UP4II<:IG\;3!9.*<8&0&&L
ML)1ARO,=]CE&H#F[?S+.C#\E^704;+/IRM5>&)^KJNF[7X2_6)XZRO_@7-P:
M4%)V!Z>T";RNTX!G0& U=358#HPWA%^8)72/6;__7A3RY N#>(1W6(N!9-S4
M6WL2YN6O+3!]O*/AQ=>4:U#N(5*AP9XF'<'.F1&,!.5I'SB;Y>/"5:-(KIX9
M-UB1"9;XK=4D^++#);__6[^5-GJXPC#^9D!Y)T*IJQ4)/H'8P3]P/O?L"]N5
MU^:;U2/(SNHM!C &,VVT5C*<]MG$L^D_IT^75P[M!+]I;KA=@B7^.&VK5PV]
MS?]B9X^#-H>VY;7P(8P%OO?H-N\KA 5GB=P<EF_Y_>596RK/->5[Q[DH<QX\
M$P[V3UCFUVOJ0%+U#EZ&CN67LO->^?J$Y7GV!VIW2\%[^GSPV_VW22NLG[%\
MX<4*)[8+H!OY5_G92]RAF:L Y<]?\ID^ >8.W*$KM6SLQ),7W"ZOW.*R]1\^
MT=5\X6&?IA^@XZ4(38%H/Y'V,B1P==?7^W7ACRO.4F=TL)YAQA5D_ND#>%F%
MC(2;)-!7NIHB2M K4309I+1-E5D_/#'Q"<#X(=I;LQS#BV>)[K2/0A8L^A-A
M> 3B\<,KQ7TKBM@__:?_='O\\<>;CY4M$J^^+]_R@&8>N%OVI\GSIO)^GUEE
ML!5N'#'[1E9XX<47#_;+GSM_OML([[WWGI[7X7[.[CB5]WCOC#\$NP<?>K"'
M<MY__P.%Q;:!-4.&OQ)N\1%X^^S3D56TU]#@X!A\A-@EH[1]^+@;HBCB'5U5
M%1Y6>2G1Y*_.TA*('61\WWWW-!D\^02IO>;DF"KI\? RW_P/720>OH#?K:^4
MD ,[-N2]N!6L4\[0XM#C./2!'BFW!%3Y?]KW-6SC@?'(<OKK7!=-\V!<OND2
MOQ-#H<724>^'YY")X!(\9+(QD(SRHG\<QDM,<.YE<2M\<BEE]WFY5*%M  YX
M6:ZQDO8 #\&/B2UR15>'[G0U>!N:-M$D'[0&+O2.C^,EC$':NR>4A]> WWC!
M(, P3$ZIO)D\T""%88T#ZG+'[;=M9^\X4\!>N31C@O:_-F-S9RH#!YA7_5HO
MN,V/ 0_?F[:86=%ICU9Q=_M-+G!&25R\9R(M#U]IOSV>$.44[WDN'N/@H^^_
MY(<.?(F@LDOB%L8\&P/T"6Y*.72)U38J_1QYN_(]'!O ,'"/C&0<G#S_/#=Q
MY#E.7@<.>/LMB+PY?)]K7J;DW0\<R\--65J\-F+8M](/3FH .'$\\:XM[WS^
MN>?:1TU4Z(]77KV\7;KX2LNNW@$_>2H$\DXX'S0V#TZ?:;^)5YY^(9WR%FTN
M)Y_*<0O7R5/\60H_VUJY26M<F[3JHF#Y]C[.F.@9#:/?69&2O$L+HSPOG"RW
MGI7/3S\'R\2Q=_[2Y<NE>Y4LC>=JC+[11$'I5GSG@GS<55C@;#ND[>4''F.&
M_B?O]K5D;WOO+;?L!X%;,A_%WKVQR82X9^.Z,\/(P_B,F*7EW'V\5IW24YM'
M<DF_LV6]VPX^8!A IZ.H&Y]MC2 G6!VF?^,7Y"D&7GBLWA"X\5SU(J.L-NR8
ME[+A47\$#YG2.4+DN;;%WCYM64 EY$LK .Y_Z&L_1D@$?HSQ^AN"J. /( 8<
MF501D%FN9KV[EROW9>XA2EY\PD<5J P8D#L #((06O?!1?%? QF@.ECI#2FT
MP*=2 -5)BD4N<)4H )8$!E'[+"PY=@"0_%E9E%E70MQO=_AU9IW++)8#="Z_
M>B7"V]M[NJGK:A@(AO2!WV<=;ME^]+L_:KB&,&N& ,W<JM,4-.#6 A7/9/]%
M",*J!QU77M[#<8D<08;XW!TXM^N=Z^Z]:+S<J]>D%PHZ ;GT^:B;&,O)IC/!
M!\$K;^&+.4ZG_ZH[A&-WN<=R7.4SWD6\K^9Q&"==OG<[U U;-9FZC(/C_ESK
MQ=]3[-%6[&(0L:1<N6 &N;1#&2@O7WFMGP$T(-YZV^UE1"SLGZ5M=':? 5M*
MNK;T90=T; !'5VV[P])#?@QB/&$R@W_N>Y*^CIZVMIJEX>@<W/6A0?4 ;_!<
M827IFE_^UUB0?K6V'1!T8$N_%(X^^>[UT_\*VXX7^;J)<ZU '5C$:7#\U&7B
M[5$3/'@O$V^X?J(N!%3[K].7X2%A8 83PXG#MM9*(5DL80I]3%\>0;+]-Q$(
M-T\^\60_-R?.+(^ZN5=U90&]XXZST[?R7%J,IW#KIV:J&.DH% YYJN(5H=R)
M[">/GVR;F7WQB2R'"KX9;^;:)P\[@(<1$B8P3#2"1BVM4A^K"@P$%,_RG<1;
M.!I\Y'[W/M5E9@=>*BBU'3\/;/;&OM?V$7_1!<MO\9/RRK?R4!K@_921'[C&
M.##UMK5 &@<L,K#"0Z)5J3.87;[D$* WBH=^/2+^X\1A4<:G[KOOP:XZL#*+
MTF4@80A#2SZ[ZO,VRF+,_>,_^LEV\=*KI8_Y#"9Z, Y<OYVZ];:V$\57?Z'\
MF\74?QA_S3[IC 1Z?N$#[/.;NI<,5+8NSZDC :-")KPD'<&D I_.G;C2X,52
M@4URZ=I/@]<>"KN/&Z[PKFP1Q>U]''SGE<0)']A*!RD!O^_X)@]EYET5G((P
M_4)_('AI[QK!:D">65I]T>HX=3 ;1P$CN%G1T1GBTL08"HP5P#"K5_Z8,H>/
M%3M]IUQNU6.-&?7J%SR837SG[;3Y.U>;O]EK]"'<.*;M:@ P8YN\*!.4PU0M
M^:RQ7)V+M-+$T*.KL"1*7(8KB09_ :SWTQ;&=_S%"?Q6!8+G^1><$?32]O33
MS_1+/L\\\VQ/N[>Z3FOJ"S.C>4T-6!3@R2MC8V+HPW@GP]/PST^[Q= 6/7W@
MM==>[PR\?H\'6"TE'^>I\$ <I>K:;LMXYJFGPF^>*A^S&L98@,Z46;X&/ZDK
M04E;6VY)\9_Q/)DEC$/7C(MH%5YN/14EZTZSK#>W#KY =,Q2S^#9V3$^]7>Z
M!\N>VLXGWKGTF3.G3T=@/%'#&[E@)@/@?-I\9M^M=KH^2D#>!==*UR[PH)SN
M_\Q5'V\[#GA-[QX?TW:5QSI6?%)Z<96'>CC ]<+==[>?.7_&UP5>>O&EH<T"
MDRQ25[1A" 4$6I''C(?R'%FG G?JH+_H0R!F.-"'2FQ3@\;QGK&[?"5XQ'L:
M+W&L9M)_5GG+'=!I 1M>0* =/\K,=953AR>(1P8U3JB/F<H>.D903IR.7\E#
M&<.3\"$/R7N'Q6\:Q?-1US<)USE$.'R/M@MB7TU?U6_16?MW_-05KL9(7(5E
MQY4PM*B_&C?Q%GQ&/?7-KB()_DZ'?O%(!P:+.W+J36UCXQ+8R#(,4&3*EQP<
MEWY#T>&L6!5778MO[:>Z"[\)Z_B3<!Z]FTT=V+G#.A<?;3-*(F]L.^KVN(FS
MTI>F/1=?"T_#C[DE/_#*;[@XXL)R'A?<??4E>%0?HO,GCSU,K#ZD(7KQ+NF3
MT=S+:)>SR0DS_B3,7Z_B['#)+F[2[>\]%W\';^L'HX=E'/5<\=Z[O1XIPYD]
M^AG9D^'0A(A7)C49F'UEZ+KH)6C$-J2+K[R2.N.<*Z<I.X7DNF!>Y<(OO!IO
M=SDGL8"^VD$VH_3G_9$VE1Y=D W6,O@D*+_F.V8DCREKT8%V,J.^RYWQQDW;
MYM!C5P#D7?&1M@';<L*4/>6KQ^2YMV#;STHK8X%S+KRW,E ]9.<L+['+Y\/C
MX)2"+6SXA-O!A;X&;E_UN37CMLG \HO4D9[D;"!@5"9*GV;84U\\G!&C)87N
M/DTY\"<=91]]N5\TK4R?]H17<?7YRO7!(WY-5\:S*/_22S>*_(W!G3,,$I;\
MY(EWE'\4/W.^@3Q3I?)X^L[!:@MX 6/_]Z;P<%\R #SPT-=_[*:$L$=VK](=
MJ/;TW"0_S&BYU:GKDPTFR!5)2:_2(UQYO_(<YEU&W\ACS<'\=,8AD.;0?#06
M8F&%L0?#[,BI4R>W^^^_K\RA!X-%B- QY+G\$GPTN!-3"6J$%RL4[(,E"!,Z
M- :"@F@>$DO:Z0"WGCZU_=[O_6Z0.@<VZ*@$+D*YO,<%YL"'<:+#'AKT<6!*
M Z?&K</Z-S.!%(^]TR0+<;R?NNZ!^W/OZX^ZHV%PNM_G.NTS*;_L)KR_(VWH
M_L]KTZ^&28[8,"WWBT'FWZ'WXHA;<#6_(W58T(.E;K^(YU?AL^TWS_O+R>](
M$8&@&1WDLSLSIIC-,\_Z"L S493>C^"F_>UW/)XV_Z1,B;# *4MG,B"7<80>
MIK-2GL&1,N+1-J;F/>'3/NWWHQ"M \VNOOMNA4F?X6$HHD3+<\WZ<#HU!54Y
M:$CG1X>VL.@GG+C@09NC_!,4(O0FOZX>V 5E FJ%-,:!7.T)5&Z%[+RO 2'Q
MQXB0>,K,NPKB34=(W,L*DY/.$B;ER6<4VP 4]+)^/O:U1_,,QF'61VE$M"H,
M<6A<FUC:Z.L>SS[S7./J5[9=2*8,?>WXB9-MVY:7^LE7>K@ E[AMBP#2]&;*
M,U ^^,#]5;@8[0C'[[[[3F'#(PBYI9TV'*:,M\RLBGYG$ !/VQVNTYZ4$#@:
M(TCPL+<-W%I5H*VJJ/3=;@3<VXY"Z#U/8):/Y>/:6OP^&TCPU<"D7(HK%M !
MQ[O H:[J/U]4>+VSCPP;E+Q^BJY*D/-9TL[:*4I.#R<+7B[<?<]V[MSY[B=]
M]MGG:^0T>P"F=]Y^*WW =[)#FU%<?2KJ#_[P7U2),[-]>Q05BI+]IG>>/]^S
M4B@Z<'WZ]MMJ '"OS9RG 2_.B: 8^*PJ7 W\J5#JY]Z IIY<^]#.^V?P&US
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M3K ^(O0'#W #QV:"O_'UKR5LE!Z"0E&.5[1F>XND[^HK^C'&]IO?_&9[V@J
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MA_]-F.9\K6 =UJ1.&MD@,P-=&&?B7A\X'GCHX>WO__V_GT'LAC32AUU6R !
M$(=@G>&FG6EV=J^=G$ Q2ZXKY,1I6,-G!Q-PIN%#0NUPM> +#\&;/0O699'.
M,!TN-_'B#8XTYJJ;]AE&,V%IM$GCN>6%";3]XI)?O91)-P=G3+K"(UV<@_6:
MOVQ<=\]AR7^>.TB[7YLF<&F/IJU WP=_A9V;<C%'2MQ8MY8;)K/#KH[PG<2+
M84B[&!L'7N[\^?,]%?</_O"?;__9?_Y?;L\\_W($U O;'0D_'EH\$:7\? 3T
MVV\_W7:1#GU>B9)H9FYF(2U]#)..6_7O@8,I6OF?I#..<@VNF:7I@-GXB_YT
MT-VBWH$S[7V]$UW#V#[1;O)-"OGW'L-.^^4ZQH3DG2)1BB70\J,4=L!,GBR*
MA#^"CG:5E_1PHES/Z+MX3#%S=3/MO?"UW+P?(T$'Z90K;[/-]]U_]_;[_[U_
MJV53,+MO/OW&#$_;]8@SLV]V[OTH%/_@O_JOMO_K__G_DGYUK+/+\K6D'2+!
M:=_;8U_[1K]??]<]=W?+#0."^A-\]7G,$OX(E5=>?7U[^957JK2>.GU;RX*+
M*L=IKY=?>#Y"X+'MKK2UK072J8-V-XA^FC9:JR_T"PHGOB8>/B</ IBZV5Y@
MT,=4&9O0BN>V?^IM:2[2FSZ? 61GY)9?WA :XRC+#$MF>X\GG!)^YLQMVV=E
MY&G3M,''&2Q?>/Z5M*6O(41!8I1"2Q4@I\TTV^R=OJ$*FAE1O%"X \3>#JZ[
MA+P#;ZK4TK&.S[<3QV_<3M\VGRU\\HFGMO_X/_Z_;9<NO[']Z$>4_WL[HX1W
M\Z73E%_:3B8U3J9>[[_ORR<?!LZ7BB-LY+H;#( 9L%-@EQ 'CPA?^>7#_J&S
MP%EZ*YVX'QZU^A7G>9SG"5OO5QP.+D:9)X"*XSG]ID:!!& %N23W>LZ,2'E$
M>9^V!L/D->4*W^D_>:4+2-1\O8<+0AN:G#*'3NHD3R"%[]P=9R/L[%]+2-F=
M4<U[2OIKK_F6_&NY?[]GA"SCBKY=V@KN]8W6-6D6CJ8O1X%D@-SA'G@L(Y\E
MQ-?O<;45QP#]:13V3T/CQC5"Q\IO\E8W8TP>4M[E*Y>W)W_SF]*][0N//?I8
M!2A]!+P.7<(/+U]Z-?WBXRK_5NW<$%Y&X&%<>^"A^[>_^)?_XO;(UQ_;;LG8
M_<Y;5[?'?_GK[;_\+_X_Z9,O;'=?N*O>@7GZK/I_&AX(]7A*E;5^F>66SAJ1
M&7Q"$R[Q#>-RH$U=@BLWP2\CG=E]!P_^T1_]Z?:G?_K3*/XGMY.G3G<,UY8U
M[(@?&M!-K?(AS*G_&INUK;'JZMMO9DRX=?NK?_5?V7[O+_[.=FWH&USZ=3M#
M" ,^X(&"C@:TP1I_**'_^!__X^WG/_]Y8/=]9ZN1CF<<^;#&DML"UZNOOIJ^
M^DX5\[OOF>TV_1YY'+HCY-F7SR"C/<JG4K;M!R.;A$[RO$Z0)E]QP$,<FI@L
M9VG_I5=>37W.;-_^_@^VAQYYK'3$R/+44[_9_MD__<=1*%\M'CKFQ)LHP5M.
M!(?J39[Z8N=SR@$#>C'3SEBJW:0!5V48A:=!C65P\^X''X8FC1_'DO[&XEFX
M\O"Y]N7TE))ETW[YVGZ=*^'6F$!>4><Y#%#_AW<\\//M32NH+KZRW1'ZI4CI
MC_J&_<OMU_&R7O>Z6>];6ES#OLQKT$Q=F=F\XQ>,7W6,W]<[WRD$5P. \29>
MEKX*1*D#.V.6^LNG_&;/NP:4.&U_^<J5AIW/&$3)L&K%=C+;Y*QRZV=B@T];
MUDR&??M;WRC]_),HC2^^],IVZVT.#PSO2MLQ?.%#ATKOU MO8-P<^82LP@ P
M*UFAMKPUOS5AQ4O3U3RY%BUZY8ZFA1]NQ>?%:;@_W0BN,R[A5\;.:<L5=QD
MZ!BD3?P1;Z.T)5[*!9,QH/DUVYE(7.WTW^56#/"C)V4NF)N7.KL)G_%N# !Y
MGLHVC!$;C:OZJMO*8]%,6S5Y#9_?>009(]'(=58 , !?N/O>MB.9Z/;0KL_-
M:H<W(S/\P3_Y;[=?/_E$>1E^_OBO?K;]R1__\Y2(:A?2#_&V'*..L#4!4 /
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M1M7%VU:<X-)XVI)SK^[SI8_!M01B$YK-)+A:/>1@.MO,+-$5'^UK0WO3Y<'
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M+A%/>^N(BVFU>DE_R!R:RY31LD(K:3,#<8.28.UW%V:&6%[*D"^FX'VO>4\
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MSF[NS]YK5^-5ZYZ\I2R.FME^C>L8%(^?V#9U__T/=&EZE;,XBN<==\P*/ 8
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M<-<'A;2!W Z,2]D8>$5KHF;;Z*@[M.[N@#:E38CZMW[Y0P]HRC8.,[YP8B;
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MRR> D_H,JN;?>TV]ABFK\FH]UY$]CFI@3ENFD.8[!OV^=CIP-B>7Y*\LA1(
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M;_3VK=@CGW^\[+LK\.Y+_I]]O-SX,'+5#+_(5?8 >10QD6?1*2E'I^38G[Z
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M)TZE#8^T;AQDSM:,3-T=&6!D;#H^-J6G?4QOD\<8#D,G'77(Y69@U8C:8F
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MO%D:Q%^6<#@: 3>BJGVT.]CPRU;?+\&@T=:R-QC4@Y$&7FU^_OP#G96"9L%
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M^#@CZO/L<\^57FSP>N[<^7:ZV"SR^=R_=.GMMMWP:YS?X%W4P=W654!H@<R
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M++!0=@-?VGG-CP'?D"/4YLY:GOIM\ 7V%;ZA_W&:X4L>%*+CX)E"UGDWM%0
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ME=#!C":)VB4W(#WPW]VE!8]_Y<G"HSW8.T:?7PS</_G)3Y877GPQM/]1>>]
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MJC='8>I?IS/Y>M<MZ3<\PDB/ZI9Z"/)JIXV1L'4T3*<#%AF9#P^#C,H1E4Y
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M(F6&(6V .48%(V.$0F.5PC"M-KTGBG@^ 1CC+ H/#C!L#;88,!3FIZ$#=:C
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M;O9D&?[4D:\3ZD"<*1U,=*FVHG-\(>',Z9/)<5E>?2WX#PQV&#<(,+/R+.5
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MAF9X3&$=H4E9#&6\1Y%M2E(9G OMJNZS,=*=541XM#*A]#BTV_8)$//% XI
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MDR=.=#H<YU;CHK!99U,1,\10@K@C2O7,<OZAAY;GGG]A^?$/?Q1$7:UA0BA
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MGCAQ\D3E-SQS%!]^^,'E='0ZXZ9? =)^=%J0!U_%6?Y79H<N.,4'@AM._G0
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M5HD]'5OE;C,C[C(#,\^;-YH []!9[>B 4EY(6QHPZD O>8\G<A^>I*-S=3
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M5HP+N-$)A;YU0%2V!@8RQBR'S@:*;)!.&ZN_$65+=SBSG$0=)NULCX'$\68
M,Q89?/"H(TX$-WF 'CNC*7BV"1WZ1BN<7# *(\_6.A:O::><'\P[_9Q3#:;/
M*W,-*NBL^-K7OM;I\4;0[2W@F_O#_\FA[:+MQY"ZNP;<&+[5-ZFC?7S8-M+
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M2'GDCF7'.G$_O&D&JUE0?.C9W%CQZMD!Y;7-;>S/KJNMF026F_*#?OO?^H]
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M**%#>2%]B#3D%-[%H/9XSVJ>$]M;UWUG.?UJ>*$'_:;]P<\V*JO\; &D*!H
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M0;L''GAHNYRK%3UH>W?*>T^N]]UW?]X]T"U7Z.MT=WG9]XR&Z.I[_(Q'<2A
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M"0QE4O<S0#6?QE2.#@)$'J7X51K5@4$0*R1LO5!><<P*+OD OL$_ Q?B+D5
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M0^^V'[6Z0?ZV$= =VB<%T7.1U;YH04DE$\LO*2_ZZ5.=6>"@+ ,Y#MTE4SH
MGSA<:1N\$[#Y#CZCE<*MCITC\;UO?V][]MEGTJZ2MWI+>&4T'[G+O1<:D>N'
M/-?VA9?V*X4+SN+8IM&R^&S620?1#2[BINL/#'5J,&L&1+[WG>^5QO_]_^'_
M8#L?0\Y9*#T(\%_\\]#RI1HF:,?8]OF_?^_?^[O;;_S&K]?0_=:WOKG][_^W
M_[OMU9=?VBZ<N2OZT/1M5F5\$%K=<MN)U&_D1-)^[@M?W+[ZM:]UQ:#!HWZ[
M._P/+^7%F^Z?B>'_?_^__E^V;W_C&]LU>EYPKB([14^=WKG=D_I^^)./;E8!
M_.;O_';YFY'ZYW_VY]N?_LF?;#_^\0\K5PVDG3YSKC/9__F_]Y_??N57?CEY
MW+8]^?.GMO_9__1_NCW_W O;IS[UV/:9SWRF.I^!(7K4TN?0>]%9G_9V=!^&
MTJWA<_U-E]VFT>!C@X"V(3QT^8'-%W'N.CUG '"^@6V 3_TP9()891M^6CK-
MW^0:)^7?BQ^<1C92!LB0\^<O;??=:SMJ^H)$(AL-6GM@G!L(L=S;2A=TYL D
M:_&:\G5;77C,UCUE<#BE,OODX^7+#V[////,]J?_ZL^Z]/]O_[O_[O:5KWRU
MLO^EEU_;_N1/_Y/ME[[VI>UKO_35[<K5:]M??N.OPS?.K-E7Q*1-HZ>5B\Y,
MJ3ZT%[FKS';Z:N/N3X9WR&>R!)Z*[UH^R?OV%:'ZFK7DU!->:C\M +\DOD]A
MMPWN/O_*$_UD9@1,X2=Z(4U&[BK/*YO!"%^V/19'[3YY2+?'Y=9]\_B;G%=%
M8>F+*8,*B],WP<2[;IW,SWOT<%T#'M[#8:6G W69?\NE74\?R,$(O87I#VQ!
MO!;91V;1,?2K5F_=>_GR]O6O?[VK L3MA%+Z>:M6__6_^M?;E<C3&\\_M=UR
M_=IV&]D1E-\/[]SWZ*>WSZ==78T^\4\B*YYZ^N?;8X]^LA-0/IO^=MJX[6N,
MTJ!:A(ICZ-=/+*<=7PC/&L##)_; BT<VX%G]FG)=NG!W$M/IWFTY],U6<:$)
M_2N5G3SF4XOZ0#3I =7QY/3:FCR_X3/Q CRRX:[R9[=+))TV@0;VN'?U3614
M#S[?98'V]-0S3VTOO?)B[-+8AK=JA^F?;J.;Z\M3;T=UM_-+RNRJ_.K?O\;Q
MTZZ3+SZ3=VZJAY(GU2G% :O]";S?[N")P9RVD:9A4TIC4/[M[>(Y$W/G2V-U
M<.W:ZVE_/C./YG.XJ;(K)WVMAZN7+M$5<WW[G= WL#KX<!+OBY]:*RWPUX?;
M'>GGU ,8=' #&,J(3N3(Z$KR0(O1=;17JX+^U__@GR!"W6U?_LJO_M&UZSY9
M<J$S49:2V(=KEI^"0M !VF_8]SJG7E.454;WFJ9 3O_^R4]^,!UQ:*TS?3Q"
M_?''/U,F-S*KL[+7Q%X[C8%2U9'5%N!4E/ W6@A*'^+K%.7K("9G$CBHRMY,
M H31\- #]T8Y.!]Z$!8,;8J?T:#;CV;.2N1X3(#H5103OWNNH]Q@= ;>HVDX
M#_FJ012.'JY%$4BC( A<?8?[_@<>K+%MQJE[,4,?A.4Q F%!Z9P178P%+X(/
MNU'0QVLPF&HI6FLD:#$L/_?'3 PVO(\:$H$4;PEB[]O(>(R.TUU<^8&QTASZ
M_)MKXW'"\U_\YK/"N7F>QM/'HS#Q-5!N73EWT^;$"2,G[M'Y!&"EC$V_<!J@
M Z-P4JLIMPZER>(GQJ2?:WS>=T!CAR>]QL50IB03)(L/&%'JB!'@%'IUQIFY
M,G-G3ZZ9"7NC&6I/ISV\$$7,TDZGN/>SF"^^U(/>[,&EL%EJ;_L, ]Y>62?5
MZ_0-8FDW,%6?'/Y5)OM?[5&E %N:1QFV-X@!1E!08#JRF'9&2-KS^-)++Z8M
MO=#3T^T)M/Q5QV&FQ7):>X@[>AA!8;39$GV*@*6B9@O@;T9)/#-X]O [T$O[
M!/-%>WR??S$*QW-5SBQ+>R;E?_:9>>=P,@,/7#N "*CU6;WN%0U/ZZ@)3(;X
M%#G\DOHP,EZ#IQU2%+N\\[DLRX4I=0;[S Y:+FE/NL%(':7.>0S.\,& JZML
MBGR CW:L+)UU>L6!HM<[<$F&$(BN1DD9[3IL0IPP=R"@_='.,''8FWW;9HW+
M.\$9OS  C=(>YVDT_4:%O?IU\)HZ1V.X&YG6P>E$#/# JW46_N M\7PM.#K0
MKGO0@TM9/?1$-VWYCA@[.AF*3_D\[RE,!DSE]5S@64&@C,HC3U\5H'3W4+IX
M\ME,7 ]ZC$?;H>^U'D34[1M[A[UDC-:%-PVDFI''2PP^6['0MH._*>>UUH^#
MZ%:> WO\[%_O-?'0: 96;J3NS9X:V(JQ05Y5KH7+U4GPD9]X!@'@YAY,=6PT
M6P>H#LPTKL/W*"/BD>?NKQ;&C*"OE4OJ43HPT04L,)W1\=*+K[0]]VR*E),2
M#C:\#.J\DO:)[QVT]]333V]//?5TZO/%TH3AK6S*KPSZ,LJ4#GDI^_A)?FBB
MW6E;VNR5\ J^5*9W][,MVE^%'XYGG*?#)_M%@%.-G=!5_6N3#B-%H\Y(!0=R
M3#OK'L/P[BC.9&/:[-[G)*C].]D$!VEX=>90WK;'J]=[5H2M(F9W#8X; #/[
MXOOC9(.5@ ]_XI'.Q*[O#%M=@\8,()]5(@(HA'B'#-77?;+][<.1 10TR^PC
M%\2+0<>HZPQ)WAG Z?: LV>.!C96FZ"T.?S/P9O:&UGCW<S.RW5W;A,?;#/7
M]O]33,D%2]SQ"F6ULSFIO\[*QD^?F<00"VW7UA7PJQ^$A]M>UR_EQ6?DKH$(
M]%I\T/+HXP^N]!1G+WSG.]^I\<HX5TFVJ5F5^>BCCVZ///)HRVX2Y>M?__7M
MMW[SM[<O?.$+78F);@8&?ORC'_24\!,IT\7SYYMG<<^SMJ =WW[BU'8QQN-]
M,3:4#U]+KX[09PU42T=&VIK0<U^B?),M^!.?&KPRD&55I[W'#S[T\/;H8X\U
MK8$!@VQ6/#@PVLH0,_O.E_KMW_JM?N+9  Q=P #X?_P?_\<U5(0Y&\  0&<#
M]_I=_;7[I5_TTU?A6?N+UYE-!B+5OSZ/3.^@GQ6@J4]EF^JCBXT.6!\'YC@,
M\O&N?+9\?\+23@,+%.0S4&N%C('AZB%[&Z.\X[.>BQ'C#6Z+I_CR1?1&>$'-
MA!C92@Z1-69UM1&#GM*MU0T^/VL0' ]:U?AT#"(#Z9<OW]_VK*^Q<@W])@_M
M4M\Q>HAG]:W_EO_M^S:6([STW>'/ED-A6^;$3;P.CB7-Z)H3?[GC>_HAHTGZ
MH?%ZIP['SWWU-7G#I]?$2Q+I2]^D$PX/5VFP;?7%_([=X?V_S4T;_FA\$PZC
M@TZ9FF>\]DUO[=5OSU>_J_U8"C[+KW,-O0LK^%6.1X;KW\E2L,S8*Y/^L-N2
M$L>73*P$L*I2/VU5SLB*M-&TVR=__O/M1OC@K1>?VVZ)/G0K_26\;I#B]L@7
MAWM>S[T#->DOS@N:?&WSBQ&;OLB$1+=WX(/2;O1P.$5(%">^QF(K9A_8B-[L
MWD !&E0?2O^B7R4C7+6Y0$K:">>5G=W466]EB9=6'<)CG9NDGS1;SM:KW YM
MNU(W[69FLV\)OXE+-EN):M7Y'>TW\8$!P,%M\E<(Z,/'(=IT###GGDV8]G*'
M_B6RXX05=@9\3^?9(,2=P<OV 64?&IT[<R%RQE;R,[V>/.D3VB<#SR"^ST9;
MF<96/1,ZGVZ<TW>>3SI;S,X%]]C&FXDB='FG\D'=!J7BS^XDS]"6D6X2MY,2
M2:4^M#D#+/1!]6& X7KT3CH2'6 & ,C'Z??T6<I/7K-O1W;N;2IXW'''J?0C
M#VU_^^_^_3R/N^VK7_NU/X*@T:@:9@& V 1,9^("D2>\*#F4!,KO= [OU3@.
MOC5 ?O3#[W:44<,GA!TXX3. E@_[%(_OPQH N#N=EZL9'H)$_BJ<\JQ1&/TB
MI"BT9L@H#A0RBDDD60T'W_O^S&.?['+&&GD,B^")R=K!YCJX4Z*0<]RZ(T0(
M1-^I-7IM . +G_]<!.SI<A&%X*P#B"+<#69\X4M?WNY))ZSV&'<.\S!+B, 5
M#O*,+R-'Z*-)OYN)FQ*'X6_V?UY@,(*/L(%SGG>!LX3/O%M>.*Q'L*(9F+>$
ML8WT$Q;N11*WD9M@I=UA]O[0@W:,4P+J)T^WWA^[P_#!?Q2&0]S[KO<KOGL,
MGFOH<C0:N)>O</)NA&^\WTJ;.& AT,!=\=7Q=%KC)^YT).(,#1HO8>J'$-"H
M":,SY^93>>43'HQ<3<]0<L;PB2%#>8JP-?-=XR**':.)XFC6=HR5,2;&X&-<
MIA/8RT& @D\9G/U2H\ B:I6P="+2V\MNGZY.NK/7MU (PL_AZ?<LJ8WWCF"W
M]+;&C;P"OX(Z>1JU=678RG^6N%*6WJ\P8%PS=GKZ_VX,VF^Z[L?(8C!:P>"[
MT_-<HSR&@'9"^&M*LV1IE&4'PE@JK'P$=K"/PZ<M9O>?:;.$E;H+J4,#2Z\(
M?/2>0<8]X=1S_-3Q#(SI+.8:X;W/J.5UVZE.%ST8\CK0X[(Q$&?9-Z6*L=>.
M*;B,D/^@=6SF7WI&.+E%]HV?&=R.TD>64>;Q"5DR\H9"]7YA.,L!;S"DNJ4
M/Z1^&+'>=5D_@SEQ&:KXA*&DT#JF=GHU]ITID0XE2C;ECG*K32!A.XEX][8L
M*)L]=W,.Q=DJFF/8X7?7\7!6*V31(K*<*Q,3-@;K7E9M(&X-?+C6>"UOSQD/
M[50*:YRZTJDUWZ3GW4^[/_11)**LZK#M;;=B:JVPT@^L=)4#+</QC"0<M?<%
M7WONJ'WRQP?'<F'RD5X[,X "1@>$:Q0ELF(G70<&4N=MT^%Y_=LH-S&(X]=
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MD IH&<&8=A)8A3?AW-3>W^P6+XU#^05KX-)U^3!*<-:F]4-7&D]:R\+QZ.$
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M/W''# "L08#;;T];27J?GIV#/2]N9V+@WW67P3WRQD"!K>6V2,;X/^U+(S-
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MVH-QE$$GI*%(+0^*N-4)!BAN3X#M$H38.JV_F<5/B:9\:"UMRPO']Y1!P,Z
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M*>CN5S/V?^%>ICEP8.J47<%8=<SHA1\\1YD%?BJ-(N+[EX2*;^C.[,3@89O
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MTASS+^X0Z\.TP_>]:3HQCGW)(?6>.9ZL1YM<T6OE,1$&;F_[KAGM;LJ 97?
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MHL-.DZY,ZB"T&=&9&9E!:<]D& 1W/-THB\+@NPK'O*CB<^PKXXH?XXUB.0,
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MDS]_8OOYDS_K_C=Q'0SH6[IO)9Z\''IUC3+PZBNMI"$*1L+4#CU2Z$7(\8C
M5P!7N R#J\F.A,55(313ER2,?4NKSL1;RC6K&,+0&E32*3_E2#XCU%.>$CKL
M!&[<5$C@IW%T+T\:^(WK]AI>:=HJ*+E2=I9_CW*8LO2 P7>\'Z5Q/+KO'-HR
M#-YAH;XKO*0_\GO82L>OV;2CY\/WH1_&.?0S>B_N7"><P. ]+X_.XX[C'?N/
M"\M?KY/_,?Q#-_&$?TP<A^^%!*W;(UJ,:[K6_;%KNM+-0ZY._,VUP8V*1Z8#
MX59>KN@_]^OYF+:K;K2'(]K'BU_<=GAFZ_H)S -4B^>>Q\JOOORL<8O,#T_]
MVUUXL&7F28W0*X+"?7(HW&,'M_TV#HW15Y2)M_/9W^0^AFYM3W''@FJOKP/>
M7>5#$_$73F-XK+*"+7S>]WZ/EYN\5LZY/WK/'=":6^_&ZSOA-=>Y7W@>EG6'
MQWNWU^4A_BO-<?VCVX[#1]S$GS3@+%AX@6*L0UKM9\'EU7O) :R]?*O^$\88
MNN,.ALP<,K;H7MSS*RUW.)TA3CTL/$=.[C@1=3JUO;C-*C?B]6!6_$S&[WP]
MZ:?<XAW[8_J!,Y"X(*N-M3[7N^/KA.\PX*7<^_/"?_R.;W%?:<C]A.5^P1IX
M>_B>KN$'/-&!M0/X ^N8_J[+N6L\<0I_G#B'-.!6.U]>'\'I)];R3@#!DY;,
M.,POF/>:&(GGG7IC0"\C,8I\H@3ZKD0%GZ1=\!8<BIZX5>+$$19<&K8K 9PW
MJT2K'$>XQ,!__ST#H?;C7]]\,D[]K[+IGRAZSO+1+UI6/GWA?-*-\SUX6QJ$
M]23J@!87OEW2?N7-?N;W2OKT5V-POO+:JSW,S"" N&3&]?3Q#%:K_L1]\\W7
MVT<Z!?UJXIDXN+HO-Y?/[)6>]J#&UD *8]L5;E.&,2+(@,)/^<QJ*X.TC.]%
M&\_2+(='/TC?C%8WA4,Z3H@TB5;XP[/S;KFFVNEQP8%Z,>(-WYET:7YBY#WX
M<#9H01:N&E,7;P=7VQ+OBG).X4_DELO*H/ONO[Q=O'AQNR\&?(*F#R #DLX@
M#"-?/=C& 0<#$!39;N6(HF_VWSY[$T&SK!<^'W9V_7R,4H,#9KCQ6HV>M+E9
M63*.W)^5*+.RU'W;:>)J%\JT>&&U$S.9!IFN=C+(IQ-]#G*^**']+(>6RM]5
M,/'D$YH95%IUO-K$H1,V!N[0\-_F#MO"L<NS\/"E? ]]=;=<T>/"A4N;[_R_
MX#.*S[_0U19P$0=,>/ M0[Q[#E[B&<30/M!.F)44KN+Y:L4+\6#-LFPZZ=3-
M]-^V<FP'@TE3AL-\E]M?';F5_Z$,7N[C:#9ZDOHWP#!NI9-RY136J,/3X-1@
M^AAXA^X(S@$.7--K'RWRO%OM\S"N]_(+5_?YHW XM%#>EODPKX/[A>?"UK/V
M=(A_PS[RG'\WA7&>ETP&OP9S<#]WYFR_LC$4,T!@-309-)XM86!@#BV=05*3
MJB80G1$!4W#I!&P6AP4JFR*4+^,YO&(P"6_89M+!NX3C0?J!=E2:A(]Z@'E>
MC@[".WB/?)\5K(SLM],NI=>??AB<'>YJT*\^O+FN\JR,BER^V1WSXD==ZR.O
M]VJ((S?6?OOIV^"J;'3N&2P]L=VI_(UC@)?<TN\-W0U@SHKP5D_]T"WQ^<#P
M;(#-%5^5?U+XX26)I-ME=*Y*,.>FY:Z^%-GA6(%S[*61/SN;C%4?RY^ZDPR>
M?)<7G\QO?GG&>.CO7=.<]*6425=<"W_2AJ./;(SAY=1DS_@);@IQX"J_)3IY
MXO8>U'?^HD_5G-W.G#_3" 08H73C^MOM 'C,0,AS,M"(9C]8#-@8ZV^]=;7A
M1M,=M&,4^?1=I[9+%\^G4M*II6/Q?"'O+IP_FXHU,A5!&F7#_C.#"E3>VX)P
METWGO6T()T[<LIT, 6U! 'LJ0L&G\O@A]D$#=-%HT3-AX9M<*#!YD;#5X(;@
MRJ-1$.KIO!RXH:P[)TX<>^5NI -Z.S0+\0.SC3HMIB-0\69HR@MQ8U01-J.$
M+'QQ8III.^75D6B,KF7L(&JYZ=L)T]C F4$- F1@MXSR=@UJ8\^Z5[ P#?KL
M%7\+1;*M2J[I#!B'NV_G$=P(I3:^P%[O9%:EQWNS%MT> E9B@54_0G,)D)8K
MU^7+(WMY^MP<AC;'?L'14<WS"NO]$:YSK6*=\"!16&AQ5.=QDTX>#.^YBM]]
MAOQ1G'@&X7O!+Q%GG\\>7@\/UZ0_,AI+EI1SC UU/O2#U]!SX3T=3!+(+Y=9
M'KK3>*?3>^*"59][U9KW<RZ7^IY\Y.N-<N*[\173A;;XH:G+# >^$(6/QTKA
M#FPS=1D8_7TX_#OEAO_P=)=NMGR#/S=* .\>+D1F8'O7&''AO93RYK#EDD8'
MIP0#!Z!!<;GY;,S"WV7*K[P(BF*]1X=&&VJ(3W@J)72'?N,7K+T8;=<-$:"2
M\%EHX+Z'8\43%X66**MM<Z7CP3,W^!T[Y0G$8#G\?^B/VD_PZBAOV^!*..V&
M(8BO6L>!TSUW^^P6_JI8RKM5+USYKWG.X('9P7;6\=";^IJZ:ESX['7.3;D^
MC$^>AW"3 +WF#(ZILZFW23<RV3M=S>#(_0)- I-?M%3__26#Y1-:CS]4VU$=
M>A805UI(JSS-.WDB2#P0:-"8>SN8^LN_21XW-U.&PV!Q0KD@R-\1>-WCOGSZ
M(7V'69%;;U\^854T=K_7$[ST337.+>>,L7+B)!C'RR<7?5S%77OJ6[8%9^^S
M^A4;N/9Q^*%+0,T4WVFIJ$_Y1N';/^F[#KFM02<N>$G+WY[\],>^V8R&R[E?
MLRX.)],GP=,LKYF=()H^<&2P6>?NW0S-/+\76;$42O>6G7<P*7$8Q6WO@6M@
MZ:677MB>??:9;NFCT*J_&HB[$IDL*W_,;%Z[&L,H^L<K+[^<N-=2]@]:GLJ
MU%45OY0%#==OT18NG:V]@^%JFR(6F9/9'WGDD?*B_EY[J@LI]+?R7W2C?)Z(
MHEWC-_S=0VGQ6YWRI\R1';Y]_7X4=#J1@^G>>U?+%T-?9'L%A7MT# 8N!\=;
MPY]' QC:(YF+OGGN3'ID )HY)-'@AQ63+[SP7&@YY20_7GGYE>U[W_WN]LS3
M3W>0Q"QB^Z3\Q$%;3KTX2)'!,+6N;M[O0 A=Q<'0)Z(3SJ<G0\EX?&^ X=(]
M]VP7[[Z[VS)Z^%_+8\![=!0T*SW21[>-)VUUL\"[+3J36;OA [P][4F<<D;2
M-W7;7V[PE7Y9'L&9H2T_1A&>-,CTWKZ:DF*,OCWX<)>CA0->X >XO]U-."?+
MR7;"&M55VL"KOK#PV9UZ<5"EO RD,'2JQP6?&]>NA_8W@DMX+/31QW40<>&R
MWR\_8;[W?GU[[5438:]NUW.OKBSU[E<WXIU1816(--[QY8W00I@RM*\.W?%V
M0<?#E4=?_,G@RUWN=WF?.&8G3Y!1@2>M^EBN8 *L<')=.'/'^!_S"0].[PL[
M\H\<RR\AI>VTFG6WTB7&ZCOV](VUPY3'RF^]X]9[GDQ;;QHWQ>MAM>W\)JRX
MYGW] 9QYYP:>TW_Q"R+Z];60/;^/NN99(#>[Z>?C=QJJLVM7KVTOOO1R!WPX
M[8#1NG(#WV"G[=#GSY[=+EVXT,^P6B'@_)0[8P-99?-NZG-TYK2+\" <R E;
MA:Y=OU%Y0?>V9#[$3=WH#X9WRL=)8ZO5M>MS?L@5@PQ)2VN[)?%N29_U0=*]
M$[E@X/%&;("W(KNN)O[UV$(4+]NY3Z3O,1!@NX#^IMNZ@GO[.\:N50'AL=)H
MYX 4<J>E^X1/0RQ>8T=9Z1C^3U\YJZK8A5*G8O?WK26R<^\WV;(.HV?7V<)^
M>VQ'Z6V+.9G^4)^X_(G"#<_%=V#$-?D=\6\1&Z=/S*NTQ:$=S\%8/'U!ZS (
MLEMO 2O/=SA#+L9Z*BM8MZ#M<T\&5W1!HSM/Q:@W,)#X/GF(3MJ#TCGX]=;0
M[F3DM2^]W!%Y,Y- L[JCNL6.R\++8?WDK3/[>NY-ZJ\Z">(=N%L!:N(4H(P9
M05H!$<&+27G"2,? &Q!0.5.YJ>P 5WB5N@QG0L9G!'4DXEV\>*%*"6*?/GTR
M3'PZAO_I,/6=V]DS$9XGPY"W)%_G!B0_AO7%"Z>WRY?OWB[??W&[[]X+VSUW
MG]O.)?Z=IPC%.](P[MK.I2&H\)(T_UKAR4-Y5L7!RRV!TG#$"<%45 5=&P1"
M3Z-9#4+G:9;BJM%H#2AA#'\=#>&)*>^*<+94![P2>6<>L-!Q&+U(%$?YB:?2
M#RO->YYP0&]Y=.9]3U_!"/>6*3C[Y?[(*T,K-_%2P6"/G[*647*5G)!81MT8
M%7O>KON]:Q60Q.F(</P*YX:RAV["6]YDLF).Z+$[R.7 38BT?#L99:\G+-&1
M#PY-O\<G 'K/K?!?=$>A37;<B53 [/?YBYL.T_.AZV/2^?4]N4/!RT/3(NJJ
MAQ)F^*UWC>,Z]/-,,6D]YJ^=Z8KG*M%18M?)5_VONCX.XQOSP G#*^'%"!V"
MQW7X+)&+RQXSB87S>$-[&#\"8QD[!JO6N\[X[/&%ZT@&C\#)=49<%^\-_RV\
M^>4^>E]!!R_W@>&Y]WQ@N%_NYB(GD8 &AH8'=?H+,1,V>>T!NSO$A2NX)$>Q
M,2KC79MVXJXDJ\REXQZX\A\<;G9"U/3Z3<ARN=^#FCX\-C#F.OP_SF I6>O=
MU.TX,,7%5Z'$,:)'KJ5+\*H7-!%O7HE^S!/Q1\;LH4P=ONF[RKOA@4,WL%<>
MB1=^[![$\LLO\D1"]G[_..S0"9LE;$;"M</$R9_G\ESJB#P^YL?!\1CGA=-^
MW^>/A.6ZXD-E/:O7F0653[SPH[0B'L,IK]SD!Z?2KS[I=WKR^JOR3]-.N/8W
MU[2YM#'QP5K7N9_W$S:*3P_?:QC8%)&)TWXI?N*B63P%19[-%_[QN9:.\,T#
MN/HALTKGSUUH^3@&E@3Z*<:/)8^,7&%X=@UFMY_<^9:L+='CG'AM6;^EI?HE
M2YVY=_KI,RO@HJBF#);WRY,1_%YT"GVPR0&SPE;1W7__?=O]]_ET\?GJ&'5M
M+^-2(TT_?J_7XB/:5!SCS&<*+:DF[^ ]L];.6C@V7GGT,) R"N2)TA3M5KG$
MW>_V?.A#H4W@@(=6](I^WF_/0_]J (!.M1R\FR8*^/2%'W36[_777^L*"7J)
M]/*Q6M-LN8$&?!$TMS>CH]DB^>133VW//_?<;*M\\<7MQ1=>Z&=#?2=?O3N9
M?HS\$\%U.X+I"P!+7],2U+-ERE8-7+EZM?N+JR>F?U8>_*!,033)HQ>%1M4)
M0QM]MX&.0WZ 9*BS?XH,'/(JP2$F&K<0Z"">=XQ_RVIWO:B\M#O/PM<[Z=VO
M.ALW@S^MDSQ!03D/W8>)RD]P_N7/XR&,^4TXM_+5IM%>4G2!*YV:QF=UBD\Z
M2JDMMDR) Y^%^RK3R@NO^M:_^,)=.?7$8-#'E3>23EK(=L5 VL<,?LQY">!5
MQYL"UZTR-2NX[(&5*6GW(S-2GK2_8WR6G#B6I=S<'S> PW<HW;J.&WDT_<>2
M.6**O]IEWQWYD?--E[*OM!/_((_ 7[1<]^/S3M^9\/7N,.T*^__'3;1)Y_:C
MJ6[.=_QA>8[SG<&UUGGU;[VS<]7N[.P_WL/_73Z^3[#)K)0*3'>!GKJD#[OS
M.GU_\V*WL1=&7B6P972XJ"]1.$3TQ1=?ZM9IYWUH_R^\$'F0L%=??:WQWGC]
MC>VU>)]!??G55_;/H;[:;22>GWWN^>W)IY_N%H-GGW]N>^;99[<GGWEZ^WG\
MSYY\<GLV<L7G4U])7M):F?WBRR]OSR</^=G^@PK'?=G.7U.0(3$?-W2<_J+M
M?Z_'2>\_&XGL-"D2_@ZM>J:(ZQZ71[=;;[65RL!9C&SV9P<&PN-X2QT5AZFW
MTC7YYJYXK+I++1[Q[3H/X)A7\S;E*:XN;*_J3/KZJ9MI6Q,F8K+)?_ FO?"6
MN1J;>A_<@U#C<XM,?%,'CWDGXPE=;F =NX&[EREWR?(F=]O7OO*9/^KLY[N6
M-H4!';* $ $$25="A8#I030J(]J:3A=Q,:XXB\$9;I8X<. 08(07I'VR(F(I
M:6_?3L7(C[Q)'BHWZ79C4P6=.7UBNW3Q3#KF,?K/G[\KG6Z$09$7WZR'50$G
MMKLO7MSNN72Q'=?@-,I.BQN\T*K>;U4>!DR<0X*JP!(O@1JH??Y7KEU/!_9!
M#^/YS../5^%57IVP!D.XEPF2'E,1_,I:89^*GXJ:7*:R*0T,J9UY\K[A%7K"
M-(Y1Z%R5L:-?BZD2+X#;R*=,;N=FF#1Q\G[EO1AO&!$#3IW 23).O()P+2WF
M?M#><>^[_<KON!>7/2PWC=OWO/LDGW?K[3P?-2*X'OD50QP)W7@:' 9N[_;K
MS0Z,>7?P,K=]C)^E.NZ'+\9-F#A'S<:[WL[SY"N2^YVV\=RJLZDO0F7JJ(T[
MGC)]-#"SUUWK&Q^!&_'B>96?1QN"+P\[G:<.BT+^B=]RQ($P\2;?69X$E]5Q
M#K\6_R::/.#O_;25P7W*,F4X2K_#."K7@8?7*B?PBW>'UP9/>0_/3#FFC"O-
MW"=2[[E27)&.TGO@O=GA)*S1]S2+1A-/9^ARG$>>IN2YAU>C%5:N99GI2 >?
MQ&DZ\7<8._SCO/-ROQ[GO?NXD2'#.\<.!O-_^15C[D?NN)N\A>::P/VN_UOW
M":,X6LIK-=8,Q*[OB$N;*+Q4"T[?#:[';6_><8WG+[XTDH^_ QXXK,LE8X<7
MIJ[0ZI". W._ZD;=N]OSG]<CH\ 885%T<E$/.P^X2MMX$]>S<E19;5V M>?Q
M-_D]7J&KKCVOH91G^>6=^];#S?FO?.>ZQP=H3SL>/FBR7RN/^8$#^((W/#ZP
MCN#NY3N&-]A,W,EKX@0>O^+=E%;]Y^K7]PN_E<]<N4+O[="@>*VK%PGNP4[[
MC,ZY\^=B=)[-N]NV)Y]\=GOZF>>Z54WXB2A9C&A\S$ W^]1![/3I/<0J!C_]
M *\S^OLM^C.GRTN,3WUISPSHJH/PEWXRY1'7K+/R,81YALUG/_N9[<$'+W<F
MI9_#C'$*98I740\B?ETIHASIFWU)P+)49?/.Q(;][ ;KUT!^:;N_7_1$DU[S
MKQY ,126S[WW'$7R>&!=7[,;(HF@_,K((*;L@UQH>5\Y'!KKIQ@)GFUI0(=^
M&SSQI6<4R=*,.T/[_+ESV_V7[^L7FIQ!1'=!GZ#>R1'?$)> $4]>P-^,(B/_
MH8<>[A><EKQ":^4WPVC;HUE&Q9+6P7:V2\B7PW.]AK>;3W!IO@D_D7N\@"C*
MJGQ+;H#?53REB^_<1[:D#N'EG?*YMA[0)JBA[:)]P]TGGU4_8,TJA \Z4$$7
M= 8"&L[9#%-7[49:=W^#FR+5+9HDE_[W6^W&F\EO#L.T5Q\_*]<;;URM@>3<
M*_Q]*?JI@99N0XDO7_*)>Y3'7E[YT,')"U^OX-'-H *^=PZ NKE\^?Z6SP&+
M#NA4YD\\_.!V^?[[>A;&L\\^M[W^YI7@&9J'[_%%7?(;(U\?GSPKPT>_$&;U
M$H*B:WW>+SD_-,]S<47W=3WP2K#?YU_*,<969?Y.P_Z\"QQ7<KSY[W)SI1]Z
M !BTA<'G*!Q?H-_8*=Q<\F_^]G]BSH];QB%^Y!:>RZV\/^H+;$4]CK[CL#_L
MKFGVZW(=&*I,B$MYO:)CV1_O<+]3=]W5<T[PC,&?\P8UPU?7KUW97H[Q_?J+
MSV]OO?+B]OZ-MR(?#1HEW[23TY?NV<[=?<_V=OCC1S_[60ST9PO?DG;&_Y(S
M!NKPQ15R,FW8("%>L@+A+;/XD0O.G:@,CJR1[MT8V.7Q/+-W7G_CM>VUUU[M
MRB-;ME[/]6KDIW=6 =!4Y&/+V!N1Q<Z->2,>SYMIKZU86@T1\0_:"5HDG+I,
MV4 K^408[UD_PI@'J/9H\EL5X%)1?Q ?K^#K#DAV\*! \VZNW,1WL_LX;W$L
M(!-WYX5U[7U?QP7;_=IX?2-_\<29^(+)*?F-74?.L0EFP,;@G7>+/X<*4X:F
M+W0M>F!RJZPK[^70=MR$:W_R.V$U1Z+]\F_][KR.N_6M&+F\3T>\?2.5'@'T
MP7NJ<SK?&K-BZLQ"X8YF^^Q>#/$N<917/R5H^=R[);@1<DL:C-C8EV1YJ$\)
M^HK 77<9]==)).R.][:[3GV8SL@^$0+ X(-]3'EWPO*7.[;S9T]N9W,]G71G
MS_@*@;T>#J>X)<)7)VFIB4-GT@F=..X\%+YTSS\$&,/F6/"5;*VY(9PT[3 2
MEZ S.MU!@*MO)<K K,!+2A5DE-[(MPJ3;D9-,8WTN4_\YMU\ET(C/# *"W,:
MD=)YCI+54=YT^F893N;Y9!A79ZKR:F3J'$-?Z?-/X0;W8'7D]_(N.L!!-$F4
M79[+CP ?,.-#%2 ;?Q?<TG_T)^S(H[5$QZ[EWM,NH5W:)VP9(.U(]LYE:#0=
M0'&*7[@M>.M^F'K"ENO[_7KT7.\!'TRY2GOAR><PCPD7!=^'3GG&+Y;=H5EY
MQB",T</P&$&DSESGWG*<6>+$5VGV'IW;T T(#1^LO=OE27Q1/^6O%Z\T@>.B
MT="P82W7>$BC?^E9.*X#I_Q8.,>^,[8IQR@!'\DWZ6?VT1D7PZ]'8? 5GF=P
MFF?RG@$F\'(]I"4\=WR/?)2!!7?:1X1?PJ<,4[ZC<J465COL>S I]H6=]PU?
M?MH#'"D[E5R%-7[:_M!EZ,3#79Y B2^;'8<^#\ZE'_A@%6<)\G['L[CFW<B2
MR(4*XV.WPD90>Q8XOH,\!^]K*.@@_-I1S/VXX<NC#J!AW+R?=%&RE:-EX8]C
M#:Y[/> GY=FA>'<H,TJ[Q)EOQ:>^U']X>69CA@>&+_CAHUX3?P;"0MN]KN0U
M=2$G!I4\ O>F$J0,:9_J86:@=5;IM -W>74GG\K)>,N6R<L[Y%>8\ICZ.&PK
MQWZ%PVWA?.R/T@<?L@*^RQ_),%[ZQ&W[1,.&'>8MK]7>IMT?/2_ZUX-#S@S_
M)>@HOX^Z!?LPKZ.(^WW#/N)&*1GG]2I_\:A?O+_CG4C"Q,6G>3.&0^[5@<_M
M463)$%M7&!]F@QV$VU4!<4<S=CR>J&R,TA8#R(G5C"6R$2\REO ]H[;Y(T8<
MCL9?C%^R4EP5(PX\#(C+NTOGD[[*=91<[04=:ECQPUGU'02(FWAS7T4KU^83
MWS:>](N6_G_4!W G*N#<1Q# &Y")A)Y6(4ZY]>/M)X(W!X\J[ZD<R\8-IC <
M;74H;<U0A:]M;[3/_LS9<UU:;J9P7?4S#OUC!'[F,X]MG_W<XX$Q RGR<N+\
M9S[]V/;8IQYMG>$]>*&I)?_WWW__]N6O?'G[G=_YG>TK7_E2=3RTE-Y25%]"
M^/*7O]05%NK24GN&-;K03ZS,N"/Z7;>[Y+UR]IRGE'O-4B]C#LS*"FW6_MPN
M725#1@Y;&JP_I;>!:\ !/N(T?>7,P))_^63W([]3*_E;Y%\#$*V9ULMX@P S
M$,"MZ[&3OGY/PBT^$'_R'_Y$RT9I/N)[&ER$,)QDY2#&<V?/M(S>'/%5KFC5
ME3;Q#=\SQ8OXX>PY/'&J>=V(<47GMDJ$;KA6O<XA8.]%S[YSL\46C;5--.\
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MX4A0C!H%V<X]:3@=I>].K0:ORCL&OKJS\$!=X:8ENG1WMA5F.F^!UXH/?>/
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M8WW#<;BU/#H>HFKIS ^N?$8O*9B$3,HUWG@YEOY%;GZ*AX!=8=IK>!CS[Q"
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MCNU,XBPG,F&(3=J=%PST4F8$CFC; "]P'4PB@BY+['8[3']-#KXQA%IG"P]
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MSB ^HB\#7SXQKC1V8H:7NC/([01]$Z<"F!CO]ST#+ 9P&:KOGE$=VE1?1;O
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MI_!1>/ NTWC(/V0J >."7+1MDG[SM@WJF9P85_&W@9[I-%S.PH@=O%$V_Q*
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MY5<F8?Y1"12__11JND"J6R*%>F",+S-5(O"VA_&;\*>PL2.HL  (Y33L#)\
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M/WP_/%4\CL,>.WK(BP0L " G[\(]RZWR3[<V30.>;]Z\[<T6#XQ5SIQ0H+Y
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M6>%ZYN_-_OT__&,UV/N\T\^@@ OYN.2&2UT8</SC/_ZC.[=[=^^Y@[UV_=K
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MCDSY=3S >9+-0@VWMMI/P;!#F#4(G'C$QH]_G8[\1A'+IBSL)T]67"D7ZAB
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MGO>HN8@.$3^XOS9<N7S%]+E3X,+Y<[XT"UUD%Z6!LJ9M('_PRDZ+LC*<X3.
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M\-Z]>[YPBSPS_H'6U-:9H.L] T &681YL/GDZ< =1(Q!V'5F@,FBA!?^% =
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MFD$RI!*@P+F]-).Z%%8J/ *%40HM&4)1\BX5';<ZUE=[AD>;'!&AN!%@A!C
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M0Z1MUZAC>L#3B DEMV Z"7G1]WC1C<<=-D#:&&*]%:J"T&<R868QG'?H60!
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M.IQ-"?1PX> !Z\;JTJ+JO/#)BW1!\W_5%18/LP#$J1_N'.'+$]VFNNQE<RJ
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M "X/3N1H'@*)/V'FV72E#^U/OQDW0_]^B(^Y*<0FBY0:&G7D&H\1+WYYGO2
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M\SHQ!_SP=7WEC^<W\*C5M"_X)\R3VFI0YP,58Y2[\^#\(%L]NB.+=_R+QPR
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M/M&3C3/2Z4\TQ4 3^%)>3E YP/B#!SOE3?E!>ILI=#_M5-%*[1]0>6DC;U:
MWS0KWG'LZB=CTB;.9O+[6S#*S&A<-?"IK*2Q99SO2C_H?/S=70:8^CE%PS'V
M8K-!-@M='VM4'2UZX($G*M.37XV/;* ;P&4"HTN@MW!QG-'O-%[BE8(53U29
M#+'HY9X?;P (-WQD<HH]M)7<G@BI+[#HSKBN>,4-/)4!JFX&!4'K4$\%>>%>
M[>4RXF?ARV3XF19AO./^DLFRTJK9J,X@MWE2@W.4*7##%S^YUX(8V6,R.J<)
MXZ+J=UP3TJ<<[]_9:X^>;/H4)1=Q75R_[$4[?.'.A$N7+K?UBY?:^;6+;75U
M31/Q19^(X16,2Y>O>-[A!8%H97)Z\^;-]NFG'[?//O^L?2[SP0<?M*M7K[4+
M%RZV9=XO5WI>\X2/+-0Y&INO-3SST7$>@J#GJ(<7GC+HFU11W!H:4;SK\L/3
MP2PR&#>1&9YHYJF6VU#AA8\'.,SA?%&>YW)Y,AJ=%K?G:J4_U&#5CH9RJR/1
M"]''?G C>613U'U,Y)$L_3U K@D6 W0!@[[M<[5(A4 9THY9&.!V7: MD0B_
MZLY&&!L=2M=E-FY-_N6&#EZ/X-4+%H9LX+#Y8C[9G/") 0!9A@_@IUXLT"B/
M\DG+PH+%!J<R?$GFL[S3#/\YL4*YT$7[PL?(J%$[G1DC<+VH#W5UT,@K0T_K
MJ0CU=!!44?=JGVQV!0'MY%1F"PL/9KK1E*5 2.-$II%4Q5/GD7$9/8W#9.--
MOS(&0AQ_% I7W+8"W3.4_;>@YQGP\.>\H<G]7'24]O=/8='C\(7^GT4U^I$V
M\ND9VG,H>]0+;!*A;U@C("< ?OI QCSU)\D&.HU7@?;4;SFE@UC;J$SX F1C
M)C($T+8>H]4/,?1#Y,'K$LD/Y'"9:G0'[_+G%))/J;SD]!8;N:JSY8D-8%XW
MR5/JZ&!X1)_(& U.;T)1%^@6/2Q^25\0O@E,/*P$#_7 ]#A!G!61DS!9](JW
M&@>X:-.?.93.ZHF5+#^7K7*K;^$?QEG2=?ZZ/-'!@UWZ)+2XH@(V"[@?@=?=
M6>PS3G$1ZXKT\9GY!>//^B ;X)[#^Q<,E$D;RV$W!G=165#IL*D?,H.!OFPH
MUP8 [8K>$<^@67%^(*(\E1:MY4L\>WDNTP!/J.M8+G!\[^!8V]E_VQYMO&B/
M-E_8_>+5R?;Z[9P&O)/M\=:+]O#QT_9 YO'F\[:]^[IM;#^7?U]Y#MK.WBL)
MSQLU!IV<AJ;AJ0RDZ*?R2GG80 @%RW!1!I_*&239,= H]LCD<D -!JY@!O>\
MKY^G3514+4;=7'%R&Q7NJKSB/+"K<6EDW.#PI7XH8?WH7-S$\.SE@?.?.[_2
MWO_@5OOPDX\T$%]4F)A.)3IX8.H=#L$^+07/,1 N _,1#@D_=5'MS ]U 5R4
M1 Z881IIQ%*)GJ32V44'QZVG PVF!B>[98^=K$RE-V?M1B"S6TM^H584KW'4
MXM_*98"QK'CE=GD=/_3W>%A!*0H9VU?M-6.H84_OCM'Y%_QQ3X&0B(!R.DT@
M^1WL?X-L]3151CR4.<7M3-T$X'%DY BX\$#A-)]EL,?P\+?\Y(,WYHC<JGKO
M8\&1WPBSU&G 5B3Q**<Q-GBY#">X!')TKLJ9^.0D*OTEGAY'?MNA?8CO4 HH
MDZ/0& .N*&6 W#X)01K;X3UM&B6C/.8Y&-4O-!E0;N/!!,H6#/3%:Q[:IH3B
MXSN,8@/0%T6>BYQZW8?Z53I1(2?Q!>FQT_8(CV)Z.EG$(\-Y,D!9,?KG!*F7
MPKI>\B5(Z">4M@;/0^DF@(E/)C\=IT-!PP0!6[1@%,9_<P#>PM?^FX;5!5.4
MC=M/@>BCU4%<0&C$CZM@ZCX*M8$*/5)M:D/JFTE,U=T+2RVV,1Z$.T9T"Y-6
M;K[E]O;HON#P45REY7U^^.B+PX3'N #HIASI=8[V9P&7>-QUO-4#O_F<27'=
M@P!>#WS@%/[H-39P@SIZ!P-_BD>RQ2@WI1DFMRP;?F:$&\<RH$ITHZ1*U*-B
M5SZ5Z6A0&H+',C,)Q<TD#AZ88L4/<N=TF-0C,@"M"@67PH#T/?H@<=27.CA"
MOHZ_\R3X &S2)6UX$G=*[/0K;\6!GQ^=B*/>GH0H,6/G6XVC>SO[;7=[UQ,Q
MTG-' '+(6,K8!-!.50[@MG2?$7VJ._WW4.U(N;G8:*4M+HT3+BZF\A,QX5 2
MY1$NVD >>,LK(+[T3712;Q)9MF0(=3VZ#5!'DL-7GN)ZPMWCZ&?D\_Q"=LD=
MB]6GFAQS%)XGK<\T6>;2-C8 N(7;[\2+?]6.P18:H:>:@ V44S+*(IZ]\=/]
M)4TF>9WEQSOWV^W[#]OO__AU^_:'.R+F5+MV[7J[=4N+]FO7?#G7H@RHO)BC
M9;C,4 N'Q<7EMG)V17.0/*6B0/C.*QL\=6>#C$4X_.3DXM;F=GO\>*/]^<]?
MMX>/'GM!P=/BTW.GU9F;YD <]7_AI_;DJ<TWVC0R)8"O&)6'Y%3=O=AD(JU%
M0[ZY+_YANQ\KI0SMS8*?Q3^\I4^S #FZ$9"GWGG(DZ?YD5'J9WU4/[<5,B1;
MN!RG_-&;V2PMB!S%7^T.$&:__AR/7W(6^8_L@Z_&P0+W-=EOD7M.T<J(41)1
MR2,R0!^5G*%SWDCPV+#9WM[QHH6VJW>O,\]2/U-=S)L7+S2?SH5D\((BZ?.8
M>H+IMM8?>7B'>7>72\RXA#K]O^8LUL/H<:4;*2<K]72O3P"6TO2W?*U_P( [
M^8IW3BAWC"1298COV-6W*<]I Y05/,G/#^1CBH#]4C(E4VD+\A45H028N?CO
M"! .7YQ]DL2Y.YH!/U[5=6KT#P;8;5T[*=?C.30IK\<'2Z4#]+__/$:R;LD8
MQ??QO=8@>=7/^29E(V^2%5B*#JI72UA8PELV"N#M-J_G[&QI<2Z<(UFN"U[F
M W['O]/('&%>?9OC^AQ;]V8]&U)NW2SBT6>\=F19(U1Y3IX^TTY)1QT_-2>D
M/ Q^V;A%/R>D7UF&N<#2]XT(6 3[_@#Z09<]:$+'>RR#IQWL5KC'>=454Z]6
M,P<I71'9A5>$8Q#1O(Z OF#3@A-*_AJ,^*MDQL4F,7H$8/Q(O:DS969L]$);
M>("!-LI7'/$ ?<%R('Z=/C,O/$L^<87NSA@<^>A=T?S&Y5F?G*-\V9H X9&!
M2L.<(!LO+\1G=# ;L(DO62%?Y@\C+T!%&M)ZG:MZ <A/RAG!94DVIW#BQO4/
M?_?LQ>OVXCG?%7VC 4X+^F<<M<O1_F=R$__L16Z0?2XW7P)XS<1 C87,4"8*
M[FA-:^)*>"FY3-!8E*+0,@ [SMP.I-(!V,D@D5O<U;$T(+Q6ASIU\EA[_^9[
M[6>??^;!KB;>5CX])]3,L$!X:20:C<8G[ICR[NSOMJ__\E4[>''0=@_V)?A1
MY'ROF"-[[++_XS_^HX3\E% <\\5$?&:%B?,B7R+P($E<+YDZ4[J\%A#JQT\#
M@3L>0J[($KP($UE"F_Y,.__#,X0L_#/-LL.[CCN)708T) ^FA\H>PT9C?L@N
MN@V.2]O$V],>@80[N0T +0/,Y(F[<.&K_-29^)(/P+;3E1\E&' </:ZWXPBD
MI2X]C:'L$3SY[AW<&R["[-UQ_,KGN%Y8R A_JOQ RG([%JXJ4V&DC3+M>0E0
M>/(-Z"V+%3\.J+BAJ7?^1-I.QY>_VW;W]."&! \#SC)-4[RNM'(6O8X+[V/&
M=HALQ5VI70_PVMW+<$32%#]&2.Q(2R!^7.1*V6J0P:_2N]WSX'PGC#@K";@]
M :, FX2SL::"Y*7L4?D63.M+NLC'!(@;\J2=759OJ]0]?3.0M$>P6 ;1Z;1Q
M +Q!'9-\0+G3-CCZH*W)8;T"=6[E?/I"SXL,V+;!#:(>9SMF@""VL]+$#7WQ
M$%X3NYI*BJ*!+B8P; 9X4>"TZF<3>;:?^H)<)N7(* R[R@$KWH&G'4?"R0,-
M4, @*W_/9[TJ0GA:;7J@2S]B0F,,_EFH<F<A9<68EAY6<:%OK!]]610:/>'P
M2B[_I<C4QVE-1_+]+4@9XR27]F4R2-[@$3[30%TSX0 2%Q-_<#A]IRMVZB"/
M3,\GOR<5"B#.BPG9+$IX9WEE==47_W'+_-=?\XG<VY[87KZT[B/I/.'B>&KP
MNGA/6 #:PO,!^D:O/V7E2>>KMK>[H^"W;55EG#NW[+KF.^I[?M(3NI1/>>$!
M3T 7%A<]H:4.T Y6XK(YWG4:_4)V_.@4AH]LG!%6!H ''#%E,ZIX>&CZ^B15
M.MV+_EX_XJD?$S>>0M$?J2-'_=_T^S 4[;3PAJ=J/#7B21*T,5'ETU[<0LW-
M_@<<957:,YIL<FR<_$STF;!C^.3B[AXWZ^>[\2RRN7P0FSIP%)4-&/S/GAV8
MGH-^(S\7SCUZ_*A]__T/[=Z]^S[NZ[L*J">M(YY1!D?-[]ZY[;R<ON#I9'@0
MO@"6#<D0D\UZ%9,T@"]#E*P03CIX5A-YYER8\"6\@P]4NN01V:2=RT^\%Q#\
M(C8&4RUY(8P\V2!,>O*S4*ZCNZ0>\\HQ1=3!LB*Y2&Y,9(:\;*3PFDMPC0"E
M?FJOLI Y3,HG/WDC>_"*3[+2UK0+<LO)#C:XD//,%1 4R8G:F]<MN'^!OG'A
MXKIE'/DB+S2P,0.M?F*I;&R^7KETJ5V\L*9V>-5^^/$'/R7V0DYQT,+B 'X"
MYJGPA*^!A*%C>)<XNL9]I->G('PJ-_]H,Q95Z?>6=[AG?!V7[-[U!$K GQ)2
M[^"+SJ=-G9U4"L 003&F%<.\EW:P'Z29@XTYB2J<)5\="#.VCNMO&, XBU_.
M@\W2+F[J;(I5[*#C>MY*3SAXO&&NNH8>1PEW=*LJYLM1J<N)4VQZGO.F$/4A
M#Z<[MK7@9\'+IT2___[[MO'DL7%IR+4-TBIST&O"!\_FU =X-WUY><FO!OG"
M/.D?/Q57.O=CF1.2$^2*13SOT?-UEC-S\][P?/+DB=-O[VSZ1-=SK1&?25^Q
MX=2KKKQL&.;U%?C J158Q!-T=#KW6ZC2YFG&HMZ^4-[7,N87/_=C5\LRE+J)
M][).GN1$H-I=6;-1)IV+W"K_*=$/O_E"QJM7+RS#;E/E#D_@5W_G7WJ(4S/H
M*WC->&*Y4@+NZSBE]/0;PC*>T%_"6S9CJI61"1.JQD"G$E;M0EEN1U,O>2 2
M<%ROOPS] +K'34^M=Y$-8?/&J](0QOC!Z_> ZP--T"<=1 '6M9(U2[GGH.H;
MRHNQ;H,7HN&7__B_,@[@Q,>??/D[Q%HK8;S*R@"M"04[EV]A .^DP!PZG@:B
MWEA9L)$^G0I34!W!5*FQ[7-=Z:C8L$6V(J9/-H!*4P!F*@6#4#+^U)Z4' +U
MQ1>?M4\_^=@[7MY!EC"@-/UDC5*IL'^A+B6P.!,>X7JT^;C]_NL_MC]^\Z>V
M)Z%Y]DH"(?R+O-\QGTY(?2^O7VZ__?M_\!,NZ-S9V?4F , G-7CJGYVK4;!=
M7A>8D1^I.PV2A:])5)B,?MV1G:<C0!V&O(*:J#DGX90M7\KJVM;%RBTA,7X3
M11A%B4:%AP"'=)H1=/PD39Z1_#A4FO\[O,<Y#P.RRAOJWPT)"7-G[IG\OR<(
MGR1_KLX0:-Y91A12G0BP#<YR=QCBD\!_!98"A3,9&7 JP%SK&9,MM#JX&V=P
M>X&0S)$JZI(%EA/)D)[V8$>S=A>K_3&)AW(,8!R$5Q)P59CQRG9[4@X^)0)?
M-T,0/\($U,GMG8B>+L8 S8._YQ%R1(HR<0]I!2F%>I%5OA BP!V>(G]X.@D"
M',AE\@5$X]1M7.#$FU(B0T79D+C'V3E O$G)#QQ\/M3UFZ8%M_W0$SI!.&#O
M#N1M@"ZK8_L*@2SSR0LCT!".C*8P9)_V+IBV/;]:C+-83GQLO*ZU=9]^E$LX
M_P0]F=.#D[1\GI5=>!8+O#]-&36P EA4E7!#E>7_\M*W[$A9(Y".=L3N>0>@
M#-I3\<ID6M6^I,I$T2&QT4>TO<P@']+C[, 39WW5)Z7&J1_ZJ$JL<A@<:_%%
M6N-1*B9524-I M5G&)O,)QGARP2"%(4Y= +DMQ,+7)-PQPE4BB=(WB2$UDZ#
MZR>Z_.2AAV$RF&=R. UCS'$^XQWY"(37U"MQ>),64_%)3UC2Y3\R51N#RF*[
M((M_3,>5!% F2^F,#[]^M)/B#S5^UL3<O!)^>$_^<ROG?"R?,N_<O:\)Z4-0
MM+6U"WYBQ *1R1NRX'%/O/<D5T"_0>:8K/@)5;![X@9P/)5/'/%^J2>2FI R
M.=O7@M>+74W8>%+-A/*%%D/4DB>H+,[,'?-%Y<J3,9<R&(L4IQC"^ T/'MQ7
MR1E>\R"+)J:N;D-E1&[SSG5P -A(5#U=IG[^OK2?OG8:]/-I%L7Y9)#:@*?N
MVU[HYS*]C<U\2FIG9\>;'/X<U>:V-SUVMG<\Z=[<V&R[?MBPU1[<?RR>WVNW
M;]]I=[40>/#@87OX\($6][OMA]NWVYU[=]J#1P_:O?OW%7^W/=YXK#(?M_M*
M^Z<__[G]Y2]_:;>UL'^@,%C%9P-YLH7L^#URT<5G![<W-NSV47;QB2=2>_M[
MWD3 WM_C?H L9/VZ@ RT9X'*ZP-\HH[;MU^)EWG?'7[AY^M2Z"WP[VM!['1L
M"(A/S"\YNFPY%I,MT_#2[851GU%[66XXQ0B7>U^O]+0;[4T83R3]^H$6"S1S
M;^HX9*;]!+#,^%<@-[I# 5[@2VYQ.Y?^D9[).8LU%DT<\R?/""F'^NUH ??X
M\4-O O"ZQ8KT-1MFT(AN\F(2Q#)LP'#G D\VD7=>_6!AAISPW7(6*F<7S_HB
M2!&H^F5.NLH)FI45ZR,VYO:5'[[,:7S@U0SJ2WNXCDH_+*B[FW[!@LF;!AB5
M8W_G >HIM8-0Y!RZ9<NX_PBWO9VO0F?<?&:7,->S](X -_E($\P)]U/4;H8V
MHFW@E7"Y[VK=X?5'4:2"8U2.\8V0/)J?0S)S"\7/U%UXTO:APD#QT*85&^@<
MIS#;Y(,L>2C/I)*'(,41!C9L]W]LZ861MMBTN>55(=SQ05IN_.>(.8MHXM#%
M.]O;T@-;[C]__>M?VH\_?&\9 0]<=5U,60"7%\.2QY.*XR0/&X[("P\IX5]M
M5D'; ?=\J-]24<(XV<0BE!,!;!KR24]PG%M=L1Y")[]^I;YVJ&;A1[]46R*7
M_FR@>$E=<L?%,==G57FID_EE7M 8@8S7N.!EY*KZM7JV#/Q260KS:<-3;'3R
M;KW*4A@;</0I3DDAK\:D\1?]RR(?'0Y-]2H ]+*QPL9&;53"28_9HD].;U[
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M9K+*91. @9H=&YY$<'R/'2X8@'![]U[I_$X4P@CSM*(_>4J,K"=%,!5&RJ2
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M #=/!/-$!#T]U!UZ67A",W[A=1AUAVS\O8]B'"9_=&@.NA:?A[XH,WQ>SIG
M21K7U'Y#+[O""@\ BXJ%\,OC2G^Z"9"6:.O@3IS[2L]3//2B_M1I31JT^)>;
M?I;/DV'$*_&6.W[$#9G4!7V9IZ9,5MF $!Z/GXF''OHH8PSNO5W>3=]Q'A9T
MC)WH/8AA(<(&_FO99YCH*-P/"#3. ;Y\26Y_+HMPSS/ZF*AX\#,!XKCCA0OG
MM1"]TC[XX&;[^*,/VN("3S5$A\8!GGQ3/I=_>O-4F3'Z[_&9"5]=2L=1229]
MR -D$.]W*U46[I?,6T07\QYD)9LM_<F]CYV>$B^B0PIJ YVQWOF-/W4$;V\6
M><@3'@)N)YQ*ZP<%+%A5KA)::EU"#[.A'/#9B$?PB7(PG9RTO6C1_,A/D57O
MG&@ :VB-?X+'1N7W"3UR<OR$)HZ+/+E?5OOGRT=0Q;O 3$(Y?<"&#$\*><*,
M_"N1#77GRTE\0>G52\T7>9C$JP:RF^3XM=J NYKV]P_:HT=//)\C#[33WZU?
MP240A2'<WH0%Z%NI-/2SX-WGDL+=;=]_P"6#ARQ(Z0>>#T5>_2J?[,+_4Z@X
MZ5C5F9,BY@DA*@[] *_>ON&55>:_E,,1^-!/7M[7YA45WA.^=/ER>^_F37\Y
M@Z.X -+M>@DD2>X7F;-$KG#S:NOFQA,_S>?"2_H?9, GYCN\_G%9N-<OK1LO
M,HYL,QU%CGEXYWFF\M18VQ6<2DU?G@)TPT?&%4U.E4(9L16FRBGN=72FRG\M
MN=K=V&A;CQ^U9ZKG:]I/<W!UFO96:X*W+Y\W"5X[IO"W;*:)1V^T.!.SVC&-
M5\?84-#2Z9C*8HX!1U)>\1Z:HSO+'_K&^ *J0=(CU>F@P'XA,. Y.>VI.@RX
M^+/RI#S2)CUZY+C#.H!C,)-P0_CIG_.*3^!GKB]#.9'MTJ=9\-'.Y/&%PFHS
MR/%\5;K:3_.1$O&>M=;\/*_14!;:6I0*'^/,*?53838-1D"%C@ DHSO0<VQX
M;FW11[1H5EN1O,9;YM)\WN[\ZIKU'2=S'CUY['?_ >NJCKYTE1_*HIN@-5&N
M[W23#;X3:YI=/]%]6N,1O*+A;)30\VB\>,0SQGIT 3QRW4B/"M%Z4/V=TX_H
M#H Q@(TEOTXNPUK3&W."DG7ZPV'?_.#5".:<S!E8^/-JU-+"0EONKTR=[GI>
M?Z8#FGT2BW%';:B,[97:EK7P*\DTKYI9-&HM@.E=CKI,Y3;TA";<]BF:%.
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MV11YPT*[/_'W17#2+]'W;@#57WYTCN+<'N('&P$>9TEBWD1VDZW:(R:Z&'?
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M.DGE-,%1>M>>=T#QTGCD=_N3W.D[;?*8I?B+MXX'P!\[!BCWZ"=YE>'R'![
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M/KQEN>(D+PN7$Z('/K.(HL[(+(9%GF7&-4:,J)/ZI8(RWU1]]<]S6\W?V93
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M/_(SAL4629IL5MM8#Z@,+J@A+)/@8QZ<.(G$:T=<"G6&R9324*[+45[2P:W
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M-H9ZDYLB4U[Z!89PF;#38<@BBR.W*V$R<)FXLTO+;=67B9W4!/VI%B6/O2'
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M[3T-X4KG =[C!+1KS&BR>\[D[I#B;8:^5E#T&:]^I(,( -OQW:\T?(K*82+
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M&<0R@$%KB"W!PKA[=?< Y23]-'P"Z8@C3/.G'!S=K<:FADG1X\3 UU)Z "<
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M_."WGD'/N6W41X4OIVC23N879=K H\P':',6X-P%P^EL+KKD'I+S%]?;JN9
M;BL(M!W]RGP75K_[-5R%";?E"MGI\N/3EA1N7,3%/3PL []^?.WB4(MJ@KB_
MX<F3QQ[#^!0HIY_"W\Q/:$-T'/29MS( M)DOW#W#&*P YC+<'[.UL^]/@O*
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M*K%#:Q:X7OCT]%D(4786NP,.T<<D@LUJW!S)W]7"B8T+=+CK8CIY!>Z%PUE
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MF'X6:UFH@P19\'BE,O:VMKWX$)/-2_B3Q;_<,IY+N6S9"C0.;.;GM)G*\[B
M\-1* X(,R@<]I'<Z:" =^%(/($]J.V[%(:?0&Z =H!<RDMX/,NQ438:R>CS^
M"DL3SD*7(X#_]BG?8*H**:#;D5(_7-$?.F%^D4U5[G4X:&?/G?,F '5 1I!]
MOGJVM;G1OOWVK_X:1(W501O<,Z#V $2!>4ZYY@E\5CN[; ']DW ,8R[K*'#"
M+Z^9X*L:TGW,>H6Y%WJ!^QQR26OJPUC)'2CCAB]]\N1QUE#S/@'$T7C+DP#5
M87VK/]HKKY2@3Z,K*6_*,T6YFO0/^23[\QZ+T>F\=W_ATJ5V;O5\$E%KZ.KY
M\5,6,NRYJPT6='?$W7;[6W KO!O]Y<$9;HSXHMS> %"=X3>G:QX^?.!Z\ 60
MS,=2#G5B/$0?4Q]X:IS";OF4[,LRC?4:&J<3EI97VMK%=9>YK[G..;DOOW^K
MO1'O=Y\=MHT=C=OJ;Z]>P\AC'O\8V^ESZQ<NYDX"E4-)7,C)O2"TX\P&P,?>
M !#3Y2E%53 (3K ,-G#4;3]_-H@>7L+'-+;%6S/?1FXU#L(#S)0/GB0P#8Z3
M88!$::*T4'B_^/+G$L:3^5ZF#*<#*(H- ._"6,A3#P00!8B2I,+L9'&#\?S<
M0GMS^*9M;TJ!<0G@ 9\4/#2Q"XLK[=+5]]OUZ[?:R=/S$O 7?K^+"1(W5_N5
M @8-T>E!6 9WJLN_JFNO;S<CR)-D0SK\.0J83D?[>%SB'\)73!58^2I=;1Y0
M-^=3N,2K*S7BPF,7Y7+2T1PFG.4VX3+3-K42\0\OHM]Q51F55Q G:2@5HUPB
MHL*GD%S!B@\\+I<. KC\N!7[-W#P"ZZB8_1C)U^7\"'< 'I^E.DZ4ES<@^*4
MD</YG)Y$E5_@/"[(-4T"QR?1@-MYG8(2.PWQFRKCL%=.0I#14%W@^ODO]4A^
M$.,F! ?*JW(E/OCE(FFGP2EH=[M%$?1;*:<>%FG2=+";\@6N#[^@,ICF'A^A
M<V%XDKX'&?#(1+?0/QG,2=,33--V<)TML_2M1%9R *HI'1K&^-Z.N&6LUN4X
M2GNY4<;6Q$> ZACG-%,OD1"JG:@:. +D"4]HR\X;A26\VU#=HP+EF09VG,YK
M!>K), J?F.6ELWW 2?GU<Y&]/ 8(\QJ_Z"0LP?@#T27HCTPJS6N3$3[66%!/
M!NPFK-J/E+)QX+/;-:3M%-;I0>Z89'!CN+^^HLEF';7%U/O?F60KO?+QI0,6
M;CN[NW[J?._N/4V*-CW9\")1 _&A)DR,#WP9P8M(31)J 5WI,"R(\?/DC44W
MBWKRUE-4GRJ0#F4@YKU9+XQ5%L?KN"N&-B4]@S5V<.0]=2Z42UEYDLWQYIS$
MRC?E2<=BAH6U%\!*RU- +TJU$"8O"^'@"]W91! ^31"Y#.C^@P<^ G^@Q1'T
M4G<VQ7UAF'#R)&G_*9<4Y7@U"ZWM[2U/)EF0[XA_3WF"OK?O"X;PLZ$";CZG
MMZ5TN\K'!@%UX(DS3_\Y1LWK=HL:,Y\\V?0& &US[MR*3Z+DUG(VX5G JKWD
M/A >Z/:B7&XN%.38/7[3RD)>A@4[_$.>D.6\TY@VY&D_^7"S>(8G '(*L%A!
M'AGW:.^TN6SEIQV9 &KI(SZI/>%1;W_X[#81_RR?7;X14^<1;[VI@TPIC5]/
MD($NTM'VV5B8;+B3AW+MKSF!^A%8E<>+4LFX<?=T7L#+SP01F?(]1HZK$Q"\
M:ZHXA1'ONLE$WM@T4?F*@Q_@*Y/%/SH3+OF?:? "5I-NYC_(,I^> Y]/?J@<
MPAB"V8!C_D'Y+**_^/QS+ZBAB_)XZEWZH_HJ>4Z?5C^6^\UK/DGUIBW,:R$J
MU<3QY4>27>2".H.7/L!<"UT3\M@\@+:3JA\/6R2??@K*J9!#+Q@ 6I2*>?XH
M&FFC /5#)TE'J5#P4,]A#ME!Q;@LTA=09^H#8)&'.PQDH;(<5]_)3[*,-=[8
M$5W1A7W,03\F13BO?RRR.#H-'=Z8DJ'-X*F/Z8I6Y(M+_>[=>Z#P4_[F./CA
M77WJ\BP7<&IA!9[(_(MV:?VB7P% WN_??Z"^O.,3 !#OMA6OH83% 1 :(X^9
M'Q/6ZTA]T+^J$XLF^@#U(!Q][04U>5TO8B3GKUZT/?0CFVEJ"S92*,L; $H.
M?^"GY42VG_C#([41QZPI"UN"X_BA7;JEP)X>/@NA](,\":NZR*0,E:5PYE#P
MJ!:>-$*M-4!,^@Q*U*$*DI]@XJ;0O>!SG.MM+(D .@V#Z6')7+(7FUC2P.<E
MM2='O]F</.<- $X 9+&V*]E'KVYNL 'PK9\RTXZF 3PNR\X4HSA^&6M))PM^
MNXW#_VQJBB_B/;J6=]:Y=X,--\(8CY&#M!6O'$:WI>[$Y^)8EZ8PUD$9[_(Z
M%;*&?O,XKO9:6IQOB_-SKBM$0AK]'TB?ZGU:N## 4#^5GS)X**MQ 1F<FS=-
MJD5;YL;^RY?]?CY ;N-!GW9\Z%9O7O0R$PYC* /;P:._ RU,,FS"39-09'WR
M1K*NL5UC- ^F&"?OW[MG?G+G ?JRZ/"KB2K?:T-!];VB#7TGIS< V*PF/2<:
MOOS%K]H''WWD2_TV-0=9O72E7?O@HW9,?-"JV./GKL9POS:@O*1[)GIH2^ZL
M0Y:0'2ZQYPX.OL)!&_SV7_^O30=PXJ-/OOR==T;&>ALB6+W2'>S&*R.1&L*&
M</5;55ERIS!^/<[QI/6_-$H,#3/Z"XS.^3I:"6ZESZ3@A97PVOGS[9>__(6G
MW?7^(4^\&80X\N5++:P,NE(&F_ @S.!GDN%=<#'PA29V3QX]48?C_7Z>E&AR
MHL5^.W:F77_OP_;1QY]+Z,]HTO!*DU">F(CQ;S014%.@Y,!7-$)SZIPZ%-!Y
M>"<'FA B=TKH0J#$%X0A) 8/]M!15 8=!7IKHFP>)8/3 ,Z+E-(.X(<V+N<S
MET(,-.%WG#SPTDK3MM(1ULM@Q[#"'0>(IF :RPU0WQA28$P?1DD'GO2P(0YC
MC26+-$>-H,?.%&G^]'P%^(X:H+AB *51BP)LR2OR3+!EA;;I<?QS6]%V5?\.
M1(^V:NL\1](8'S;_B%,:_:K)7%]LL#ALI-@X]9\J5ADH)*<FG_/&D+IP!7?%
M"7IAZ0/!3!NB<'##1R[:9!,@?,@ON6:A8^QPQ"?\,V6+<,**5FSS4*;"39/X
M,J1S]J0W;7)BB"MZ2%5M!,"E/,G"E3"@<%;?AX]N0O*!S)9^U-_9%-AY-8#"
M"X]1&Y=+M#>!Y.\^DMDD3P\6$-A=#A\GI)T4IQWTP1"6>I,T?91C=TV3NBQ(
MH(9W0GFO-+)'R 04!L^C!W'7I DWO"$/Z814.J>>&%I'4K*BH0$<F4@$1_#$
MQKA<I^MZJ>--'=,NZ#?P, CE!-9I3V2S( %/GJ1ELIAZ,,'/0ER#G1:!; #P
M7N0WWWSC'7?T)/FL"_3CB9@7W.(/$Y%Q$:T%7QDM G.Q7!;M3) 95Q@'4;=>
MD(D/'%%F\<D3N>^_^U[E/7*=_$UCTDI=LR S?BU6#KWPRH(I&S2:##%>>9'(
M8DV+8$T43 -T==JR&(C[N?+@9T(!?5[DJBS:A2=$7/#%13\;FA"RP&&BP:3?
M)P14/D?;641D4T TL'!]&;_?E^Z3,^CG"?NAG[+#,S9'U.X*%T.-$R?-R'O'
MJZNK:J^3;6WUO!;[2YKL/&QW[MQ3&8>>:/!4TD?YQ5> 5G=;P%<6D2RV52?J
MX./^0LZ%9R]%6\*?(D*>_%(6KQ2P0.>F9>J\K<4%!''? /2P"&*,Q^\CT9JT
MP@N !9]/]ZE/G#[#5WXT&1-R6.FV8&$MNF@S>)T3%UD8(*,<7T7^#S6Q,_^4
MCJ>OV]N\C[EE66+2QC%4MS_R(YRU *?=P&,^:VYAMV@')W7 3_G9Z,GF$^WB
M]E)>%LB\KPD^9(0TR"5E<>H%FMDP0H8Y7<&F$XNTE)G-J6PNL$B/;DJ?3W_G
MJ3 3570&=.^Q :-V25N!(PM[OJO/1J#E2G7^U:]_8[KIA_"!31L6G\3[":!H
MICV9=/+4\OES9/BY\"A<8??OWFV/U(>0-<\M1 OUILP!5$_R/-:"EW+@._5E
M\FS](+Y3#RL'DL-7T>NQ3&X@Z5C\UZE/YC)]_$8M.6_T2^DIH**,7H9O>3-Q
MQDW6O,<>W30%Z[Q![\DOG EC$<I0F[D'"R?*RPF4IZX[IT>Y1)I- #H;\\\?
M?OC1BWU>N[A^_;KU(SJ(?H";)XR+2_EVO!>.SYZV"Q?.^T)L=-GMV[>5?UOK
M8RVX1)!E3/V<-HW.%YW4 7<WU(@'6>A?-F9KTX1V11> ASB>PA(N:<I/>=CD
MH:9[FYOMV=,]M=4K^WVJ0?SRYP#5%KE<L+>%VT/C!OP4G</[VPJGK% 4/?)6
M3O,6GBH]BW]O CA-TA5D7$M;,![ >W@&9*R/K*4_X+ OA41\>KH8H.2-<.@B
M?)0:(R!1[ F0W?0;34<N,#IX*!K@R9+T)R<LZ.N,Y1CDEH5ZQJUG;4,+?UX!
MP(Z<A:9N">CG('>)<?<RT\9R]+#T-]5!O$1'HD_GM*A$'[R5SE$*:FDYH:[T
M5^3 90K8R.+SE\19YVD,0)>A_ZD#_9&\O#YS7&E6SBU+KR]9'OPZJNK*)COY
MA[H LMUW92J,&GA<%LWUP!9]SRD]]7CWD?5+EWP),HG1L;7I6HO^/"#-NDRH
M"!*DW$$."A1'.Y,&0WHG%XROYTJFE.E NNFE-R9YJ'#0'F@^PBF*E945R[D*
M-3WH3-+ %PI#'B-'*D.%0 ?MSV8M.AU*+ZI.O_G[O_>G_1X]V6A;^T_;V8N7
MO0GP2NG88$/W\C":DUO0^%IX^/+!:_'O_/IZ.[NTW)ZRZ;^SK7[(9B:?[YUK
M_^J_'2\!5#O!!.B"I!Y((PA1-0(P=1<D[VPX?A@X,$TF"C%FF@<!H$-ZT($;
M/<S@C,F3=.!47L(D@%8>@MH](1ZAH^/,S2U(Z62W"4BYZ;(1OI1'^.F3$OS3
M\^K0QS5(O6Q^H4+M]/S9J_;@P6;[RU]_:'?O/)#P<HLERHFC**?5<7*I3"E'
MRF-"PG<GH:DN4,'.MW^YDR"[;0R^/$GQ1%<-$YZ\F^<UL:%S8G!7.AO5@31E
M_(Z9E#0[RI3#)3C8=6E'!K#PE5,2O']#QZHRL#'@L*U\OE!#^9R7LI471J1^
MHTD8[6_B'8\-SZI>9<\ -V!A.0_Q*&^Q6P;1MKOC>F?^_QIPYWU7^<+978"+
ML8D2K;H5;>'?R$,,8;5C;AQ*ESB+\$R9E%:R6%"XAW*&LA76XQ(^EHD_D/ZB
ME/X_@\=FXDZ*AOHYH6S'U1?>:D+L3\C)1N/Y)(#BIGTR990;2'^T@NT#PTA7
M3_(.(%TE&&CJ9H#N?B/[M>I_*&(8DI #'\&:J3MVY UZ4L/ +(]&_]0 6-UI
MJ/X(8)?NLE\%Y<L>LU#I 9QCV<6SV;*+KTDSYB6<\@C/H*VR]:O/=5H6]$M?
MI$_FB5+I.B[]@\8JMLHK7)'=PJ_)G/54_&G/M#DG>TZHUYT0:2D[]>H].WCU
M2][.&\+,*W335+['^I$>/8A^YM(:]-+2TEE/^E2T!DF&=)7)Y%.T'CO&T\8W
M?@+/@H"[5TR%$C&!]C>G->%@0LG BTY%'AGL71>08JB3<A;?H2.\"&W0#GBP
MUJ2<A0]\9,)"'!O+?'6!&YC9$  W4+R#X863!8/OA!$+R!_=RX0U_*I\A/GV
M8.M6\/!$II]<8WS :*S@J<PP9LR=]L8S[\ SX2"O]34ZWXL=)MO(1,:"TZ=3
M!AL63"I97#,1XSU^%M#<U,UBFX4#GW&[=/F2W[WFTK$KERZWBQ<N^#OFI&'2
M53,B%K4L4EGL<0J7$P)J,'%!,J!*T'=ITS-JXX6%I;9VX6);4EF\K\EQU^5S
M*Z+AG)_>+"YR>F5>_!'MJB.3IPLJEXLM*9>%Y\.'#]LCM3]MSH03N:7>T,3$
M#S?\87SE- P;$AREY;(HQVL,9(R#1LI!"K(YPFG!]"?F!;5A9",W96<AG2<\
M3S8VVF/N'_!I!4X-I+]D$IRGY]6':&-D^*1DX8PF7<@:BW3R^<2#%^Z9W#_U
M:8T=AU$."UY.@_!J!!-'C[_@4QUJ@80H0QN3O]QIH3: [\BC(J&'C2X6?^[3
M"J=OUJN/;.(L2A:@D0D\=+$@I;^ @LO;^)8\[Y B3]2+/O#[W_^^_2__RS^W
M_]=_^(_M__[O_N?V[_X?_[/<_Z']Q__/?VK_\?_]G]K_]'_[=^W_^'_Z/[?_
MR__U?VK_\H<_M:^^^D9Y_MC^],<_M]L_W/:F0?4#R@U=Z4<VXA-]#QDC+;R
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MX9_2VO%V"*Z =9'C^-<3>: =?,95^,I=<8'11YS(%01'W".X/M@RY((6^AC
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M%C31W96737IO5,E?FPD\$38/U1ZT.W'(,.62!SJPRXV)CJ.OT"?TO^N&H6O
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MD9NJ1S<"VL&##4>YZ&?"8:5(7,>7E )YJRXH2S>A(+RDOJ)#@2Y#<> U;G4
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MX!#&<Z\@2D_)],N]=]+I9/?FPVV$]:W"+@OA^TXG-1W##&XI[!G 1[CLW_?
M\JN_^'/+;__FWZF O1#A>/7*Y2293R0<;.<2,(7,N8,# \ '870& ,+,DL8/
MEW???7?Y?_R__\'R[OE+I88E<;_P2[^X_,(O_U)/+OZ=W_W]Y+LLMV[?JP'@
MK__FV\OE*U>C?%QKHU(> V![O>S]$'9P_Z$*?%FWH=6'$4,@#'DO J%+!%,I
M72&05\([2"F-^%%2".XQ&C@=>#HU'9\9Z)D]Q_RC@+H:*)@!MR*APC(TT3#
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MX/?<C<0E2[4C6SC.//I86(+>:I5E^M/TJPP0/K>&5]]ZZ^V>9\3(AK;Z"/S
M*4+Y+IELQ2G-5%AH:*FV,C/\DU7*7%Q7.6*U:V>:$SX4CVN=:#/J(]<\MQR-
MDUB Z$-#V^IWX>6>^A\Z>V;H#_  DI]TXJ]7BMP:3O=2/YM\D__&%YMKO. Y
M??N'.V5LO/6ZURD;5WK(3UYZ&SAZ2IB[>;,^)PTX[K?\!_Y<Q2X>>WXR'R-@
MTL0/Q^8NL/ *1]^Q8D0?C#>TJ:U?_=8WOY4QRGRF7/ID,WG!>?6]+RZC4\JA
M\CWA[6]"._6J7?2]\-2E9.-&UBI?DC6\V.;:B44P\JY]5OST=<,7B;CCY%R9
M%/G  ,/@QY!7@V;\4%8L;D_".K &=B?(FJ?Q ?YAR)@\+?E'+X>;.AG?UWRX
MK=RKD%S;^-!@?& WCT3ILU2?QB$A2:N_A<LG7S->I/[2GMZ/KN(+= XIO'/W
MUO+RRR]'U[Y9/8RA>\80(TO05'E\=K;Z8'[:5'$,U&[/SKT>RE?;M-MC)T^-
M@31E??.--T++![L5\DAXY,CA \N3:?,GCAQ:3D3_.WE@WW+@_L"(WG4RM#AQ
M])'TEQ>7]\(S]Y+^:'C*"DKE_[7?^1=:$NZ!9Y]]\0\),X2K<%5QA"KAV@HC
M8 FC^ @E'0/+E,&V>PV^<7F-+NFWYZF,J13Q=! 4QZF@"9_E4./E+1_"2H=>
MRSL< @O5=$B(H9-"U,<>/;4\\\Q3K2R?RJ!L%F8J">[%.7#E!P9E1*=NL&1P
MK=,Q0#'(.7?^_/+C5U[N?@H-S.G#I\*XEN3X[N1G/O/9P%@B<.\NK[_^UO+Z
M&V]7V274R^RA$]RV_>"E1^*/$C0"F+4-#;NG<X>N<]T9[ =_%G&#EW8".MDP
MAYG6.:@P ^ P'&MU6F\9%+[ETI7!T< ,T#V#H S2,5\9/S0C<*:!)VW<CE#*
M!1[*4<,$02V/P!1%6>1%B$R>J#H-I'D6QF R\-8Z;IVR!A,EH1/<UKK9XBAG
M[W02A3?7%+#P*S2*=\)7V,HU<0?W.Q&4UZY?C;_6#E&'"ZCR=-"< :*!:??3
MI## CU(P @S\XI1?%>+D ]?B"+GPW]!N<"L_!>_R7$=O29^R=K]IWDV])D[X
M8]N#ZAD\[6PZ9;Q.T1K^*,\$DCBC, X,9=CBED_P+A_>:%[RQ6/Q55JE2=AX
M1A];)F:0+:TBU;A0_'U'E%%A!.J=W'>IMOBAJ:6#-134CS'A5@;:# @U"O0Z
MAW==NWJC7\>XED&!98<&^0;]MEQ<70]_H[ 8^+L6IH%^ZV8&[\T[>#!,,""H
M.[. '\ S^37?*CTW:G@0WTGDUY/WMJW$Y^-*N]""TN?P-O6KW"JS@IV;:JY7
MI]-.AA<(YVU@-G[:R_:,1WI-_)D1V8W;3I2RDG#*GAFDSIRD[8BW[<?B\502
M]>H3H4V_OMM\8<5OG3FOCLDQ]-G*XYX,LF2: OCN>^^5==%"/=M_;V]8Y?<'
MZAG]Q[=><ZWA+VW'(6\.D_')4S-14U=XA:%(_<V)WC46)[Z\N^)F=1N>RJ-#
M]%D_]>:<#3-9>-, P+(V)_V3O]=N7.L6IZ>?>G+Y_.<_MQR*#%9_VOP*]1/7
M5N?JA'30[$$;FT9;'#:G716O-7S'KW3M((!,^50ZXF &WVL\SRF7N*[EA2WM
M&B?_\C>R2[Z-MX:MK]?GW.S@FO^-YQU<$YY[^8FWY3]IQDV9>'$F+*2-3)A\
MITY62KG=22K!I.<WYVYHM^LHB0;<C#$',H C<PS^7_KQ*S7:Z!.>?OJIXDG.
MX<O.+-$GXLDF_3L#@*72^C"RMPI)?N+@27WZ[%?WG?,,C)2MOZ7+HE]^^97E
MQS]^>;D17M27:V=D8@>-:>M)$/DYY>'UM95[J\Z Y[B-?INN4[^EJ9P>O\GD
MGE&3Y\H4>;1<0RE^@R&.\.I->6X>GI-/FNM.V*1)6C!ZV8596+EG\*WNLD;3
M!^R\SWUU+/'6/#=:[^27<'1QL+'!OS;(R&(P;SN=51%FW>U?=37 M-+2^^ZQ
M37TXR?[JU<L=U)IH>/J9%[IJAS%^])>U?E*/!O)DE/R#;>I6_YI!S<VKRX]_
M\-WEW+MO];-9<$!7?!YL:Q#"&[9Q7+=-*#+H@^0/SBZO3WV5&/ZWO'OK:^II
MB\]WL!J^9.#7]BC/G?7OX!76O?39^Y&U=![IDW<;W0R&I<5K@\LX^<F?7/?)
MT!.AL?9IB?8[[[S;/JU?+3EULG%N96  S^*VPM&G\/BEJR\P2=ZI6P9\.@R#
MB;S5&3GLG :K +IR('QY\?*5R-4;73GSV)E'PZOO1S=]<[ETY5KKQ0I.N*I?
M=1VFF?ZP%!AZ*C^G/E*D&EP-W'9E5N(F/**K<FXG+"XIYG_@SEE%8P2:."O-
MZ)K:.OJNOJO)PD<A>MZMNBP\FD8><)JZFOJ)SMN\(>'=Y+_AL>'4LJ3>U(W"
M;.%[7=^M;KMOVM5O>-?W[:[;&W^O*QT2] F:[;AY1B/)28&-?Y3I</K &DI3
MY_K).5G^@<H [4$_ZU.X[[SS3MLF&)_$8T]>:_AZR:O@T[:PZB#D;NB^;5O>
MZKZX>%Z-/FT#\R;DG-4U&XRVDSTTZF2 _L8O<#899<SBU/I3&<CN#\]5+L9K
M6KLX[\%]<X%M_-$VYY<H'41KN\7CP?8Q=&\&LM.//;X<2K\!5Z[Y!Q_7"?)O
M</7;7&G'[PG;<2G'SON=UP,?C'N1C[[J\5'&I'C&RH9WHL?H9]3?&+GU=<9+
MP2GEIG,YM'/ZQH'4<4+PW,8-'\1;F>"@U<?2SAG)7WOUM>7<V7/+H0.'EC,.
M:NT*<'IE9%-P>C#T?R#CZ/?IQ9<N+4=]F2A]]<7(HLN1W?>'%@?WI\_5?@+[
M5W_K]UH.[H''GGCZ#V=&+!6(0>N'.74D6V7.0&0Z19W#"-TALHZGU@O7(%1#
M *8P^ ECFSUPJ,N=$(EUEY  JS!['UAY)IPH[?6))PQL=5 EP0 E'8AP>T*>
M>NJQY9FGGFIEL8X2?N[K"GOK<&?0Z,G;*D7^PDB$$P7E_,5+42Y>ZGO[%%EM
M?6+J]*./]M3<%S_SN::[>>MNE)YSR[OOGJU [N!UI=D,LFZWD9JIE+]]K7-H
MQ2C)A#::H*$PG;1TPJO )[Y/@[#Z]<3'X*:3@_!##^^OT.RG4U*9ELK =Y02
MS4^QAYFV _$8$]2?^MAIP!&VFO?0)[3)?_>,#5,G!#FZ&^AZRVD%,R@6!YD-
M%N1E)L"L@7+U  MYAP[*</L.J_[,[E@*0\AIN+ME=JX#Y0P.PV_RT7GI4-!3
M^76&&RWE8]\,'H0=GJ1 6 :JDW/2>'')P-&LMS,$##H,:/"ALJ&!628-B=#+
M*#[P9@O#QN?\1OM2-]'*UX';6?K4,1H;@(NG')W1SJ!4^7C\T7*IG_KA>5M%
M.A##!^6+W(>&L@'+H H=QV]T,BA>8>?*""#OTJ9\-#PU;0:R4Z\LL918 W6&
M);Q3/DD]BC\K5[35^-"TQJ-<2_?F)\Z\5QY7^!BPS\!]78V09P-) _BN.LA
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MX98\#=P8!K:P;2"K<5R_?C7O,H@W6Y&!_+4H+)>B5( +?W6)]QACS/RBJ?+
MD_)G5D'="K<_M4IBRKQ9]?'7^Q_<*;Z,%C6^I!PM8W!#B[T*%QI31M&W,Z;!
MLW%SU4D;B.XLLX^'1VF=/.5=V@8/>[DH9)13-&NYDQ_%"KRAQ7CYH2%XO2^M
MI-%^U'>$8<HWGT>) ,$O42#AV@XC/(H/+U^ROS*\D#2>P;B;P?=F/"C=\V[:
M\AA":FP )XI-#07X)5?&#THBG#?>EB\#7?DON,PL_]0K8=U/,J[YR=N GV&
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M^NNO)UZ$87!0468W"71+IO]=_YY_3X6I&=US9R\L;T2)?=LIR-?'X&'9H+8
M-KBS;.Y8SQ(PTW4\>!\_;G;K2&AR9#E2P\+1=H0^H^0="P]%V3=[3Y]^+ .7
M1Y<SCSY>+PZ_[^"!Y;X(:TU7>5E=#818A@Z%D9RNK(R8W@#(OEH#>#"?>"(=
M5?R)XR=35X=3/P?;V#1F]%*WM92F_ Y!-'/'>KH_]?KPPY:%$?@S(\"EN22-
MI77[4J='4H:3I;/3PRT)]NUP#*Z3I"AHA$?"'P>#CV_LVWYQWWT/I4[/!)=#
M>=9AKYT/''+OG 'W#!B6B;'D^7S0X2-'ISZ3CP.J#AUZ)/@>3C:4MX?Z_6/E
M?.+Q)Y='SSP>I>/$<NQ$:'S<*I83%4@,3)19=6*ERR.!"=;^E)W!RJ<@3Y\Y
M'=[S7=;P<08M>%E]HKG92M^C-IAAU#KZR"@VELK6-WR>G5)Z,#A.G1\MW2W/
M0QN*BJ70!#3?6=?0QLRJ972=;4U]XID:<1)'N[*T?93'#)2CZ%+4\02+[2/!
M!:UU)):KFGUG+!(7;SILAJ*D0P<3S<'U3E[$< >98>H.)"*<"!Q.6\5?VO..
M#YX,?J.4CM&@LU2=V4@GE#B<</R&AP@\[U*(Q!WCAV=U6AJ$/F"@%[JH>_R!
M=PS$R8?BVT'N*-#XSPSRL:/:&3QGIII,\0[7;HJR?-4#G#;7EC71O&A84=QN
M]CBTW,(Z /3; VOO@' GK4OB-'ZC3K@X.O10>HT_<,#;.MG);YPXGD<ILV1R
M^,!23N=:X U[J:VLTH&22?6)W]F WF=PD*LV+[PS(Q6@R7O%N3_W\(-@PUTF
M?'#-\PH3UOSE2Y>6'__H1\N/XLT(&WB\\LKKRX^BG%Z^>C6R_(GEMW_[M[JG
MC3*@<YZ]<ZG;X*N.& #!;]VN,@\]>+PS?!;^1&?$'(+V_5SG?J,A_G7=Z[?W
M\O',;67:7.$E2#X&''C7F2=,#NYG^?G:3C;8TC3Q>FD^[M!LGI&9$W_:B7!>
M>?HXZ?QR'?AI5XDK36&T_0<F96;%>Q>'HEVO[M5/RQ:?I^:AW8VA%M]-MN+4
MK_<;,MK:P;1Q?<>ERU?3_[T;'>!69W1'R=K7B0!& (9;$#:\R+JN0FE<ANAI
MD](Q:A\\N*^#-<8[]:ULY<G@K 0F%,Y'Z?N;O_GK*J&,C6<BF\4U^%>W^@GT
M89"WHLK@?XP/0S=QNN=_I>U&BU$4&:#LV3Z3_O:)R/Y'>Q!3!ZF)0TGW62>&
MT4W.X(76P0IKVM2\$[[7"<N?NSY[F&=N!CU-E_LM[=3\*@_"+$*]:]U77LXR
M_ZW\HP^,@FU0UL%8ZA5>9"#Y3GZ2F_0IAW.1$8PRXN"#,3Y\T'*#916%V3KT
ML6KS<Y__PG)?Y/,'E1/*JH[BH\!VL)'R/ZP>/K@39?2=Y<W77^K@<S->XU5G
MA.A#E7FVD.H/9J6=^A0.7^&;VRGW2AOUN95WY,">]WE7_B_MZ+4,X@^W#Z=7
MRD-Y9^!#7_.<.LBU*T<3IBQ-1W8J4V2J@;,JDY:NHL]$)RL T!2G,;2_]/(K
MR^MOO![=-3P:'8+3)L:X/OC/"@SU,P<)DH_Z4$:RMN-$TV;IT/K#K2[TL3X3
MI_Y,WERZ=+FP3Y\ZL3P9_5@Y#8X< MM^,C)>G78+0'E!O0WO\>K%X%__P2GK
M;&L;/H9+ZS:X\+:;;>_Q;?%<^YZI7_4W6R[TU^*043,XG_ZCAF5\GBMJZ'^D
M4]X.T.+;%XF[71.O@UJ_IB^H-<YX^:D/AJUN==C@)MS[W=G?*8\KG+:R-2RP
MZ]=XD\_<*^<6)BZ7-_WYZ_/ZGNN;X"__K3R;467R&:,VF9<7U9V,D^AFB1G=
MUZK'63'[YW_ZI\O%U.NP3_Z5E.#+97.[>+B:S-*VT9/ORH_D,V4%!?^#HSS3
M)@2(N^E-\-NIB_ !/M16I]^+K $@XS!M97#WI2Y;CNXN-Z]?#SB?%)^5A^JV
M&<9MO _1K1SES<UE4 VOZDG%=-XQP$AKY0O#V:'($8?ET=G%J1RLGSX9G96A
MJU'P5<H(DG<HP)$E@POX&RY3OQ,:ET3PZ;L$WC-Y>OW:<N_N[<@+AVS>[%<
MT.'QQQ_+V"LZ?679C&?)$?E8^6KK.#SU*;;T6#D/M](F?\:-S[_PF8PO3M>
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MM>\&M7%Y;Q#IP-?V&<G;;"1>U2;UH6I,&OB3TUV1EOL.H!-_J_<Q7(R#VV8
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MZOZ^W#\2>I[,^X.!<SB-TQ(:C>:1PV:M@C/#47C%X$[9O;>GQK)(/#J"1KO
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M+*-1%RU;\B!8E5VG6>4C1**@5I%*O0@SZ"3$!J\H)BDCP6=O/CS4!PLM?C3
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M'R6/ >!B](OKURXG#:,._E!_J;?@BK*'#QWNP7KZ];/GWDO\BS64ENZ)3]]
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M@YEWG$DB*XS)#X8C?&^P9[L3>>I3S XBM:7$F1#_\__I_RPZ\@\+8:/#7@,
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MC#_/+G_T1_]Z5^T^]]PSR\GHG.1(H$C>/H:!E&/8JX$$O0,/#>!L;(6/QP"
M#LX&>[_\W8/1TR\&F1G_A>SH,OB NM(S?&,5TNW -TY;2UUCISK!PO^I/_QO
M-92[[]_['_B/AZ52\$!1F6, V*N\;DY%QP?11"@C<=.)CO6><YU.>HP #@C<
MEB+LM*ZXSB+FMH2?$G@H4\FG)\J&0 C!8E)"A'"LND[DI;[^"[_[6\MO_/JO
MI67?:P5<OW8EZ2D-$>!AT"ZK5'\5=(3-6H&#0HOB@#L&@+??>V_YUK>_D4;R
MX?+(L8/+ P\['/#Z<N[<I<!-I_F@Y6ASV)J.$)HZZ4T 3,EF<+8)5(?LV0K
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M7F?5P ?+=7IT^,O*"/'T$605@^M_\K_RWVP>W/T(OG>0,F3Z:4X6J;#%K&P
MWL?B\G#20>K!,(QEQ"P>^Q+79VQTA ^FT]/9):C++\=7FJ8D"&#IN@+R#DEA
M&=$1W;UK2;B":CBSO%M!X"H=YNF>0F')8!AG"*%V#4X,6&=V66.E1$X%3B6*
MAS%R&_@4 @./=&EAGC#@PSKS"$/&!-\=/T!XC[<_BJ)JB9].8]O7J,/D538A
MN\U8;70=C]:NR3\5UT\>9= H_D/)]_WW'=8R#=\,/@-%/X$8VE2A2F++V'V[
MW??PG9@]UCRSY@$9AK7$KR?J)A?%<ZU0W)3/%1E4X.!8X2!.0K45C")M&&2]
M2CDU.+/2H1&?=T&[>\,8 1X.G(>3S\,9'#\4>.+*OU1( \;HTZ!SC_'+_/PF
M4"$W=:- +%HUW!!<R4^XNIQ&,X/RW71<*1P6\W_7E;_CI66!NQW%[VZN9ICS
ME[BHL?I=4% N?JQP//[;Z*7."38=M*5;EGX2/(4"?XEW\.*$?9(?--[6"T8L
M?TZ-\8-3V^[ROK82G.=S5RF[LL2CI3 * WHT/SCF0B";^3X:O'R_FP72H2-M
M!VV#B?JAN.HHOZ1QWWH._N)5 0L.[AE4X(6&;<.3U?B&#<;21#T8OME@]3D*
MRS4'(IVOTG+AW-GE; ;IMHR\ZX3O=]_M]TQ+F )/O:9^'8)S_NR[R]MOOK&\
M]*,?+#_Z_O>7ZU>OUJHY]3YUWC3)M >:I6T*V9%MQ2TT=0]\G#OO>4Z5)<K4
M7=P*<8VS\FI\S\"HUS%NZ3>?__*(5T?BU9"Y\BI>ZGOT6N-S0 A?*V$GK C!
M6]Q!JV[B;_?RRS4PZ_N\OESS6(M6T-YI,T%\LEKK4I"!R=8^>VU[36?5,E &
M\!C&,<A(^@&81^527][),541WB;7YH#3F1T51A;A^]DBH&VO<CWP)2;GAV\H
MIN/;+H+F3CEXO+GZAB1?$LS]QG&]%\<M?%W^_[H5^;C=NT^YX+J# Y]_HPSS
MGW:?@K+6[;A),_5% 6*$G-^N2YR=1_%2=^&AZ?-"ZQTGTE[O7?!,N<U@M@T&
M1W*[^)9FJTOTUE_Y9\4#/KT':^I2Q,K:\++!C$$/&8-/S+2:9?0I*R>QSZP_
M$6Z0,;);GL-[B8^GXNU)O)>XG &4_EQ: \B1ZTL'21<N7E@N7;ZX7+O&N'"C
M!Z"9J:8_C/%$&8/GZG=X8G4MVQXEDQLZC('B[AVGW=^NTO;T4Y9T/U8EMKP?
M?/09]<(2?^L+>#^#);-.-6P&L'QJ9 A=;%OJ-@>#[/>C[\1/^=.FXDL'_1&C
M]CJALK4U?NH9SNI?O21\Q4T_/WMXZ4GSKK/TR</LLL\F;]Z!>&#SWMEWCLZ3
MWZP(T%8/&,BG'CCR;?KG388EC_6GW'7H&6] N\&G^QP]]DCZ'WO81?JH!H$+
MY\XMY]Y[KV=_T/,X V"#>4O<;5OHY_)2#C1&LVUFK+F%MKYD\WKZ@O?.^L[U
MC:;GT>Z=]"-FVQGAR5YU/#/[T54#8Z>?7'$G*39.F3YOVHETW+3-N=_B, #T
M\]*)QX/G*T8WKM]H.9R#<3GEL]7I\N6YZJ,K(]+^79MFK>_B(U^R,GTL7;=Z
M3WA)F["4&0KP0!,Z(\,'XZFZMF**/EK8(]#[4P8>STR_H 3\ZA)5>)AUO9]V
MM!MGKOX+K5MO1./+__'XHGI29('R@+4KZG9N?L*U+:XP"I"?-ZO_*6XM(R=Z
M*)<Z27WXI6ZTZ2W&3LP0HOU WNT=!XR<6,L8N'Z5$7XI0_D]?F3&O/?C]O*&
MZSR/W](-7<++=#039ZLW$+X=GMFVPI %<%'G<-06U;M!K(FY&DK#%_#4G-J'
MKO@/9N-W[N;A4VX")]VDGP$_FHQ.6R-4)[;&=Y"9?+?Q5_-+^5JF^)%_@1P>
M<M\)V_  F5<CUBW;EV>EE3)6=\1F5A$F'M\]_GEG*XQXX,LG_])6IN_@Y$F^
M<=H'/4^<KDA:^T[QX0GW?EWMISCQ5DI,^7O_SW,_E9 -GKH&9>0 G!DCG76D
MC3K;Q?NAG=5@8D)9_<ZX<588CNY3VO2]R<NT_8<GCFUHX#<_LC_\0L:V;RA^
M1:+T(<_UO[Y$TY7(*STU_?9;H?->9PW9S&ZN_I-*A4)N!2WJ^<,PK'^(;[8@
MB%FREJMP HOZOX)NY?23-WGP3$A O KTVJE "J(.M.FL1.[;Z6@\29\L(^1F
M7W8+GS1#P(>7HX>/U!# $N)[W[/4Q5*]Z;QR"2IAHA 4T[CW#C%8Y/GW[UDN
M<3-Q\B+*4C M;@3!0QGL'S[B=.*D#9/-+)4*3,5:59"*44&L.V8IS,9W=G9M
M+!QQLJ,L) NDE*]]E^@#)]]0MJ1>[-)E%1RE']JDPT8C3KSC)PP\3W3&8@X8
MC.\2R^!R:/]R).%P&0;#5&DT%+'B-)T#&M9JIS[]4O4.7U-1'?!#-%>^UG)*
M1J[$:VF^IM_H/P:$P UP^93=I047'(U>N>(M6U>/:,+Y/W=P37JPVY!'H5K?
M]#\.%;>"JQWQE%'-U1J&1PT:UGCE7U?HQ,N3(E<K7*[M(%<\?L(- '\[3KG@
MYI-E]N _>N;1Y9B#7)(WWMV$U$Z^GX*]/<&[ F@5'B%:PT6?64:XSK7/B0-_
MO+,I1Q0(7[_0;O#+M%5TSGW:$ =7_'DP'0I%Z*$*>@.KY!^>0&,>W="ZN."#
M(HJV:(K'1J *GI*-&_RF;E%'!ULC43P^>##EDE?Y+3QOQ8C5"8P12MQT*9.X
MPS=HD_N-+GE?P9>ZRK_EX\@+ATM)-WA3N"-$ Z/\E.>VG_59T.:DV>K#91N0
M<W)N?GD4LI6)(M#.)_Y>\FX=IUUNJT(FS@9SY?&\&^5^!LZ5)VO>S0_/D4_K
M\RX/CM^]CPM*\"IN>]QNVI_T.ZY*S1X7&)^,N^4BG+5=YP)O95W+J]QK.1DU
MA%<Q7^-1V%O>M.\M;[B2-_876[G1?B7OAL7%,_A?.[K(++-N9A9\?:1?( G/
MSO8I,Q3#?W#DW&]\TI )5K35?:+$=94_:X1=6NXD6)]W7<NQEN6GN8U^=3\!
M=TV_XN$>[;;Z_[3;8'WBO8:^!S_/2#ATGL'AQG/C5ASJ\[_9YU^OWHS3'CJH
MVY/7%C8XC@S97#"K7)JV#WI"$I>AV]<U[!OOX*K*__ [6.A0N9QKY5+"-K@;
M>&$4XTUVX0=]O%PH,._7"# \2,ZY;C*!49@!ELR: >^VMY0W^,@U!&N90J\.
MEK7#%4=>_OA(.O$,XJML)0P\:0R<N\WQ(WW%9K"@J&Z#:><7Y#[QMT'UZ#+B
M,AKD/GY3OKJ%#NR\'R.B^M2_1W&[P_CO<VWVR<]>>;0IO!4^;Q6D/>^=(>P
M>-)U,!]=J[*$UI&KS^M]@';!E6<P&/YAS(#CE /]T56[L_J&O![9-NV>%\=U
MKSS<'!K"T4#<H)RAQH2*_)*HN!B<XB-U;&4DX[G!*X/.V;/O]9 [Y[L$C>:#
MSNCPZ;X-#0SPY4%'LUK$EHMM7SQ# N.0.JF!)&GI:=Q6ACI!%0S8E.Z0:W@
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M9!1&]:7<]M$;U*$S"Y7]FHPQ>*5UBD\P2F)O0I;K\M)<2X^4<_RN$L&U[MJ
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M6<4QS$GGTU,&S/('=^*S!M_K=B1?^C"P-BAGY.S /\_POWY-OK<:%_S.6F9
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M $]/>_9>G4C3]**(L2=O9<0'?N2!_IU1YL'(IE=??7UYZ:676\\GT^<[!-6
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M P$- -F$Y%6:A,";$8  K[+>_8"W(S<^2'FM-+ /+4R0!C7[F3 _FCL%>9;
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M+UUXG\%_\E%6<.''6,;(B\8&^HR>ZL&*!*C00^G#$EAYJ"ZEWWC EAG+Q/'
MQ?0U[YT[%UH<*ZOKB\A\V-(W475WF3@=<.JR$S#Z:G6PTGLKDK1J6*EWZZ/:
M0</+:VU*(\<X[SM@%S_WI4_^JOL9W*^Z50/[?Z/A\%KKNN]'YH%C ,VU3<Y-
M[YJVO]WGS4T9=O/AMGC %[; %>_)=Y,=+9T6M.*RA0R.@V>>!E#?Y]5.3F!O
M\2< [ZRP\H?_&  VF5!#>'A:&W+V [XQ+KI\^=+R2@T %Y*\F.=OVC57<&11
M \28_#::"]VI RX)X(Y_IBW.(%1_WZUB@;65;Y;@K^^3#O36?>-,/_S"9UY<
MOOJUKRXOOOABVN+#R]OOO-W5A/3K1T^=Z204WFB_D^M&CXUV?.MA\WE7FL1[
M!T=ZP,/I,TZ>/)745L6, >#,8X\M!R.WM_+P[C?X^=?[:>]#@_9U"=.VFO?Z
M/D_UDC2>.'T[SY[*'RG'[>O7>BBT=,:-K[_V6NIO?U>X;P=SFI0UQMKE)V/G
M:?.;H1SM-_ARWXP#I4O?D*G2JYNUSM)^H#4X#;P:_DL18XND;?S$#:S2)31T
M_YN__V]N&NZ!KWSUE_YP3I(=!6\CG KN)V4 +.-,9OPH&'/@ >$)404^?>;1
M#O+)%LCL+,=0C(1!@G43\<V:;QV$0E+*>W)N",DB<C.*)"67HCR%GX962U3@
M^A3?9S[S?$^110("D^ L0Q9GA8A/7DX%?7A_!-Q#'R]7KYY=_N(O_S@-Z;W@
MX13_69J"6<]?N!!AR4*<?,)LMVY'V;][,PWR_N7DJ6/+HX^>2N4>2@=C)</1
MA#_8/8CHM^%8I:,,@FE]WQ_-WE_V'[@O'8S.< D3HU>4HKRSA]#>O8<>NB_"
M'O,<6 X>>&AY)/?[]L\7!@X<"*TB%%J9:8SH,WMC0D^,DE_W?41!P^!IEGTW
M PJ'\<Q,W'T?A2 ;7?C@Z.*?=!W(KPKHU@#:.+S/OUKP4\^LTM-)Z#"FLQ )
M++B4V5>:<,+P#"8E0!PDUSVI:Z-@M>R 8^6SPBIB17&-F_ODT-4#*UQNX\F)
M#X?<)"Z<VN +<P6VNEJW"0#I\A-O)\9Z+XFRJTOP]D+P#JT.1;$Y??+$\L3C
MCW4&"2_!3<>_+;.2!Z,,Q:(T\XQF:SY[ 1=?=1#<K"H8X3,SI ;_]I6#U<%[
MRS?TLA($OP%%V)AMF0,;XR-X]^79"@#6V*FW*#VY*D/;<LI8H:RLTB<O^(+/
M:1^<YVFOZEB(?_(=?NGRSF(Q;97OBWAUBR9;&N4D X01>!PV*FYHL])E!TY<
M%8"\P'<&_5_\TE>7IY]]KM;?/5F%[S_(X,2WH)T$/<O>NV\]]=*9]PS<.U.=
M 7-7'66PN@VL+T7F7,K VJHC ]GK";<_WHSUA0N7.D-ND&L@;?;<S+G]\8T;
M!<TRSWZ>*W',L%L6=N%\T@6>O9L5TL%Q8+S?03DX'9BGG9HE,O"'"]S,WC!&
M=$:5-].>,.EO1=[9.J!\.$4[(0^ZS#^#<8,7W^-M)Y-R3ST._50#&:?.M<,:
M+0-/9Z2.G5B-WNBI?=[+3>FK(@I&':T<ZEVN:E_3G+WF>(G,M91M/M5%2:6L
M,Y2</7N^\I9,L-U*N#HO#^1&OZ%/VN3J#@_TOWJ>YQT'G_".X)$E:WC<7A[R
MHFV';Z3!G]ORP<-^>''']5:\"9LT<^\4:K<3!:\WU+\=V,+&"]_>#=]S6SQY
MJI]=F;5=M_C3EK8RD&73KKA=I6T'O\)!C\VKMX3EO7B5.2N,R1/\79KTFF '
M59G5L.()?K;87+QXJ6W8F3=F=JW"$Q]<?#3+[^]&]LP6I,)/^3H@B.\VF@3I
MU^#3M@^/Y.N*#T4@'[3CK2W0%=YZZ^WE]=??6"ZG7>%K./'2;&7L+V5F\)SM
M/5/&ECGEG'XDM,K/Q 4Y: O DT\]V;VY9H+'B#7UE&2-V_O^CU/>[3U^6?.8
M%C%Q.73A9UPY-. !$JOO>Y> E&?B ;?5+:<\PO,OKO!R/S.>:_W%N^SF%T"N
M4L.M\.3##1R/E>W>)6[Y1^ :3:PM!9A"BG_Q6&%L,5RB ,I+/T(_L'*$'*"3
MO/[ZZ\NWOOFMY<*Y"U52;>]D1)*GF<_#1XY$%OCJQ^@,X$VQ\&E@AS9XBU&4
M7,8/W&QQNMM\NRIO,P#D&4KGSIU?WGWO;&7CQN\U<*?.*.G.G3 1U%5\<5O;
ME'Z]29F+B-+G,E39_GO>Z%'^?__#ENMBRG?EZI7FB<?@94\N/A4F_QD,C%)/
M/])FS/S"@4'COKS7SS DT(/T=U;82B\O*!X[QO!QK/WZY<N7E[?>?F=YY,C1
MT'Y?VL[=Y?;=.X/C5IS*A/".=H,6[H,3_6 F&90%'8:/-EU V8=N:WL./O L
MS_!]1O%QZ%>9)FX\OA)7/_AI/:YM.#BH&S#DA>;2-B]QW"?_R7L7QSZ#'5SD
MT;1KV/C-2;?GN7$:NL:2>LJL7EPK)?2=N>\@V_53OFZ#M?,XSQX3J_?-*$Z:
MT9=2G^$[M(?[K(2; R[U?[,Z[UH_;6D%P 4K  I#OFD?*[P&QD.E[W/35_DG
M9[B4=OEY[D \_*8M\:V3Y&<;8O7T/"OS=FT=KG0OSZ1>O1OJ+,L++[RP//?<
ML\OQ\""CUTLOO=05A<ZY>"JRE#[:<Z[6?EW5E09@K/0KCLF#FS EF/8T^H]Q
M4L:9I\_T2N=R_M&CCSW6%>;2;%Z:W+2\[1- 4OZU#.7+-1\_X<.C:[8)3\S<
M3+K-#7RPTR>EC=Y+N])VT.[55U_M^-"9=K8T=B5;]?61-?0H>)FX'7[R%QX(
M+B9MX6EE@[9!']/OB2=WN$D[*TNCM^5>G0QJZGW*+4!_0(XTK\":^MR>/UI^
MZP_^+1+5/?#Y+_[L'Y9@>8&YU><,!D* %+(=1C(BR U"$0-3[M]G;Z=EWWW=
MF?T3&0RQ]F*+:9R[2& X@@;2*NN1H\>JQ/?D^%3FH<,'EL.'#J;#O1.EFU+M
MH!.6Z&E\Q3&P**T(X-3[QY]X=/G<YS_702DA>]DGV,+4B.,0E]"A@__(M,"[
MN'SCFW^\_!__3_^K#-K/1YF9/197+E^+D+Y<13D(IN+V=S!W[T-[&.]$B&90
M'K]OW_UAYH<CV"-(4T('0#AWP"S5QPZY4<;0"XY*7LM/\C]YTB<$/PZ<!],Q
M/9@&;E^LI7"4$B0R6/QX.7$BBL>3IY:C1]()^H3?099MR^B&[GC.+)ZEMQ^\
MK\-@I)A.P\$.1],!S, 0O:9#N7O78.?CT.9F\)V.C2,",([K*"\\WM$(9G
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M4LP/GCXC@SSR:6<[?D:;78,#7DZ^TP&>0UR6HBQ=Y:H\JTQY=_G*1Y$A3)^
MZ/J6-YYBK/++#YSI/ =>8%DYY'P/\G?+*&P,)08H762?73O4>\?:UTCX6^GT
M>_:)L:OIS/O,V(VKUSJSZ4R *U8%1!]<NW*MR_RO776*_B=1]I\TG*[KH&;\
MG L0>/MVI<YDZN1? R^PHQL,%%RY='G[*)UDGS*S],_Y 6: NEV@!L'@+CTX
M&@P'33DI6CDLC;W\T>7@>[7/WG<  3U" WMPX=)/H=U>YPL8O# @-%LD;*.P
M:H*?;]3JR"7LMJ78WAD80=_P2?A%_76E3_*P2HOQWIFL7#])7CIP,ZL?'L:C
M\708W>2K)3J0<PX 0P5?I&Y39_,)'C(Y<G'H#N\77_3@M'BN/)_TRR\W^AI?
M1>;[*4NZ9MAH.;RS[KBO9^NY^G&_KGB]2]B@T'^[VWEW#SK@Y1405WD_$N>K
MZ2?-42-L_#*&OQJ7R]M_S<^[E1=_"*_I]K ]5J]]WN/I,*ACG7K\@X_48?7D
MF?F<63\[:]8H;;\.(*)WNXH.7>2^.CG$ G9U\#ATQQ,&E/"K?'7T?0[7'G'+
MG VLTQ&U66I8,;3D?2:=K(>W<_<[",XA?D]OCSU^H5\+>22&Z7F#M8\^MCU^
MX<GMJ:>?V9YZQF?DGMC.GCM?3\W0$<J+QM6WRE_46K-SF[#2I?4^;KTY>D;
MUYVS8/#Q:*:XDMO=Q"[=D^?HN\35#L2O^ICZD6]C^U>W]&,B3' >\</,5N&/
MJ<N^SQ7NDJQDX^ T4E"UO*>1HFGC*W\'8=(G3>I),K1J1T\>H:$MFO22>@JP
MZGCZ0,?6)QGM9_XL/*13[. P':#YUK=#[@*73-+C2=?< [>_/"Q;LI\M_?!2
M>/!6Z0:&PP3-IFH7#%)I8T8\!^;10H.+1[6EW=)(MH[02'LG]Z:0?^LB/)&\
MVIZU'9LVTD#P^>BW^PTPI6-?O1X=?_Z!\]L++[R0SM'3'4##IZNC,399^"SY
M=K5=RJ7L5L"^]\X[V]MOO!%=>ZOEP=OV_1OD\)E#*V[XL_>?BVR<+PUNIVUH
MFPIG90W.G6!)T,);^8:?AL=SEQ_Q]%\]39W2B54IRP=7KCJJ=W'KW>ZF/"E+
M9-^DF16X_-CUR4=^KGX+GZ8,MZ%'XAIHE%>B]?W09^@E;.$>1,,#8Q_H2,Z6
MTK3WJTZT07SBD.FC[<!X:=FJR^MLCU]V4>U#=*C'/YY)R?PZ&;5?DTMM2/ZS
MP+MC<#WV\0P>\@Z%/FS#\*2RL]NF4SQE0]#1Y8?WR:%Y"ZGKS=#!Y%@(%]KB
MW8&S7.4\N31E80I+RCV?50?#?_%@J!-U'5 QVP;)/![0O1"&)OT<='WLRLCY
M3W_VT^T?_J-_N/V#?_ /MA__^"?MI.(E-FE12Z$7SR>KP)MRR: XBA2/7X<&
MP7T/$V<Y>- !<#71T/YC:3P3<,KBC)A9 6;+K/SEX3<V[,AMRI!Z+FWW\HTG
M#2O/P>/P?KQX_8PNG@LM/DG?A\R#!:^ACW.GV('SV4[M%GJA(3M(N\B?2)_S
M3'3#V7@#A.U[)$L3(:57G_<\\_/Y9K;:Q[&]OK"B [XAZ*I'KK98RB:O1<(D
M[_/0_-#EU9 &LY< >V8(9R1=@TPY(S0CMH6*H>E;N[SEK120_:X7WWLW'6M+
MK=[9WGSSC>W==]YNV!NOO[;][*<_[1Z)5U]Y=7LM5_M9WHR2DZX"&X*]\<:;
MVVNOO=95!@QQG5>XK)D%>):M$P8WLZ\4?XV&P$CI5$_3*%<E+6'78\B_]MKK
MVTLOOKR]_=;[P>_2]L'[5U.F&17%C">.W[,]_)!9>/O '+SF!$L=L(AY!/KV
M;0=FI>.>?."#N6>6TVBR7$/#5+".ORT!8>6\2V5]?"TTN]6TMS\>@UWCU$8J
MC.-$[5LWTV#Z7%\JU5[@'N 0(3 ;9VFN3H09 PVF[1.6RVIT5X6Z-XC1\!A%
M%!7A ,=,-*&=%07I3![?8IA]N9T\>\]V_J&3VYG[?:XQD*H8"05%B-::/Z-[
M89*0\ZBA.TI4@ZH#EFMH<="14U?)G]];WZ:R1 E+5B'G7>LR801F-:[Y-UY\
MR0_N=WA[_H*/,K)[C1?CLHU^(O@EIEP*JW'BX=UOTJ<>>>7EISS#7S MGP4"
M=8"&8.J@F$52#V:4S$"1&[RGDT41PH$@:NP9KU:[6(JJ 82X=POWEH]WWZ#!
M?<J#6C&N\%AP,"+9$N5*V;<Q"<SE&3#KY/^U?:!;&/+34*$[I017>!I8ZGU\
M#[JK-WC%ZPQ2,I'WQ)U&E'&.ACOM\Y<F(W(RG3E?A:"X#AJ2X&B44P.0Q"W;
M0;E==E\ZYZKC1Z898XRH5??<U.>AD^93#4S@EB;YAT?11*.KXWFG,X51NFT8
MT'7X0]DU3I:CWG1@7W293X'>NJTS,P.;.N&7X^D-L_XSPZYCFWJ.\FV'/G*L
M\ZZ#38=9SJI37F/,%@ G^4>6+;]<,^UF_6TU$D8/:#2:OH<+7HV!/ <(VD/'
MMX.5./)K@Q7Z&3SI*@$#GKE^'G@&3O!?!RX"2YG 5Y]F3.D/>>FL-3RZR+/.
MOU'I@R^LI![46QO Z!_Z@_?.5H=9J<"XPO,3UI45T=.^D$*?3>.WZ[?$E2?\
M'=A%QIM/ZH'#C^*K/SJ,,50#(<_JF-[BU'\-)Q&_YK[")_NO]WO\I@WLPV?Q
MN,'!0^5M#VF<%6./,@:)&Y'G=L$=:/O[N(&STA_R_(IWB,=.Y_Q?40["<SW(
MZ(A;Y?BJ&THMMW#G)L>1"[I@=(;[T1]'.SWU"4\&O3^DB?! )=/R3Y@.BTYZ
MS[\(OSN;A&XTB.,@-;.J(LK+,FRS[G2LU2ITBO*"P7!I6Q"_RK7TU*()?J 7
M3J>=ISNOVN87>3)PZ_[B^Q>W=V-CO/?>>]N[%]_;WGK[[>TMGP9\\\WM]=@3
M9GV=%?#Z:V_V "W;_3ZZ?&7[Z-*5=$2OMGTUX&F 0MXS.+4OJ8>2]BU4.. 0
MM)@7?7^T/GK?L/UY+G&3K@&Y+CHN)]WR0_?):]'@Z'M %CMRY:\)WO_%)VB2
M2I.\0F<S@/FW1QF>:5X'7AL1F0WMT6&EQQ/ETUR'K_DX>?#:A'AULN[)_G3"
MHE>J-PT8CKZC?[6-VD^SAK_ZJ]_?'GK8P=$Z,D-S>IM^';R2EZ8Y.)DY'$,W
MNB)UI"W6$?;YNPM//+%]\ULO;-]XX?FN!!&/'BFB<6Y'AP@*7&%Y4!=\\Q)Q
M+V/O&_G0>\S__MKAF@1ML\[??S[^@<C!\*D!S^>>?VY[_OGGNRI%G!D D'H'
MW>O !4Q'U.K2:]?PYJ7J:;"L^CP;>/;XLWDO7+C0+2KL"KAK;]K.H'-DS+D#
M')L&BK.R<<GV[KS VR4P-WC-G9I.N(:ZC?415WPG9D'TO^ )7UXY6];>J]<]
MG6M^U4DI6W60.H#CCF?3U,_S"N,6K_+MK/-X ]]YEZLRB5==LK^?3M_NV7N%
M,;A_%=91&9A\^,/2YAI4YDZ> ^?@N;@,K(;(([[E#X3E:7[\2;J*<UT!B]Y[
M::1?95MN[G8HY+)I#M]SE54T.ZHLZL@0FJ*O*%,/VM_*S%YOJ^Z6+\0]ONO@
M-64E^Q]^^$'T[>O;*^G;T<7LI+8QD>O))_B5EUR+R+C"0PUEQ;.HYA&.HQ,4
MH?E%/O"XZ"8KW0M7IRUNDK$_V9P&Y6R=[L#2('!0OXL/EI-./;B#0[%4R#UL
M_!$7!.#<<[3DE?;-0?.S5)\-RBX:G6<%AW:ON":ILJ"_00"3=5TA?S*=_\#H
M%]\" _XFU(59)6Z@,F1HGN@_TAE T>D^D5LZ[>\X=;+J;=(M/IKZ.NKN1@C&
M(V09:F-<SNRN N'--7NT!",0IS#QWEM"^FXJ_6<___GVTY_]+->?;2_]\J4N
M66FG_]57T@B_MKW]]EMECK?32+_^VBOID+^XO9BX/_O)3[8?_^F?;7\:_])+
M+_?S/E8',.*-)G\:0Q:>W6>_CZAA)CA^92D5SCAPL!N&,E+\^NMO]H OQJY9
M*\;Y=-K,UG^<SMQ=Z=B=WLZ><5JZ\AM1_21DGEFM&N+!QZ"$SC\*&)EQD)]/
M$AZ[3Z7._FWWQ^XS&VS)G,^:F=F<SQ*IB%49#.IK5V]O[[SUT?;ZJQ>WM][\
M<'O_/0,K!AL^30?DUG;IHZMI#.PA_BQE-$.FO):U8%D5/IUTG?]3IW103Y>Y
M=+X,CK3SFEA68MP7W!)<?_S$/=O9^T]N#SURKJ-077$16E&.:%>E%QI7$9>)
M=I^WRY.6[K>-=U]%FO0587%+GS&H"*)R,[;*6X6[*_C<BUNE$R_Q(<."E^N^
M\F 4\M3MBK,$NKYI!O>*B;C%:^)UE8:98#-):]6#=Q0#'R6S%/Z4=P1Z8$:A
MA;:6V>$W"L6!9CIJ5]N)N]9.&*,8;W'*7A^BXT^8EY>#UUZ,AO,CL$9!4\;4
MQ=U3C+T,*V[B0&RYWL\*GGYQX^2I[>SI,_W4D"TU!@.(11M"](J7O^7P[2R'
M)\G]+(N?CJ1G>Y5Z@%S>+WSA,'BC#5PIH)&[-AI!I5L-6N?>00\WI+Z#I4&)
ML^D@V$(!MPY2)#Y_)L^//?)P3^!^^JDG<O](9U4<*O-H[IUPK!-07MIY)M"+
MQR('%*NOU#/9CB&)9Q*M>. #,LBX_/CCR/-MWPIWM4W X)RZO)8.]/7M=NK4
MH-TL^:=08W0RX$+G0$H>Y'<&?I;N=&_@I*L]4G>&D'#AW9'!8S'6CJ=N?/D$
MCDU;CQ_'ZZPO[STZRX_A.-NE- BCZW2@W(_NPUOS#6!ZF@PP^#OH]*6EM$[Y
M=Q"409X9?)A]H>K<()Z!3B=IZ\@YA)0.&9V OD/;J??EVE"WD*Z[L97\15%F
M[\'N9P)3-N50$;,T?/AIJG!D>#V/#T]@VMW5 "PSY2'^$(O!2TCS[?URPQN8
M<@88)?[S;@?Y%7>TS',C#GSH)5[@NG[=23NZ;J5/[CO,@3$_Y1'>*+OSL/R?
M=V 4SIYHX!^)^Q5@M-_0KOHUOKHCX:YK$&"5=9S[2<?C4U>.C.,W>93?PAOJ
ME9ZH#)=/AQ_!4,?X0=P3^#[\A*?Q'-YH?>ZNM.IU^ H/XUEQ>3#HKXNQ"VP?
M,;-Z_H$'MVO1M;/US_[HM)TQ0M_U><F+[VYOQL9X)[;&Q<2_>/']IKWX_CX
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MQKU=':]_927HB1/.9IL51F=.S=E0[(TTNBU#\<@/G5."\6A?&I,M[\?1+P8
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M<,.TF,[^GIGQ459T%L:0GL;ROGO6Z;0)[S:%-$KGSFS7P]@^4:;QO*_+V'2
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MV9W'EC,\?IAG@A/>UW@A#WZ=!5DP#CQ8HY.&_W:>GX@UBA<L<3@=9G6AKG3
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M,<LA+?5$4R-N>=%1YZ2G$,VX&TDUFX(FU0GR*ETI2)V<V0?]Y 5?>7BJH\@
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M-&]=0OJ.#YV2CN3#EP<_-[T.>7-MS/%R44\Z_KY^0?9F'_D8[Y6A_*I$#]S
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MM05@E6&@CV-<D)D@TM4EY(]\<K_\Y:MIYW_9K2[V?#**KH?WNJPQ?%SY5:8
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M "!&RU)$\P?WW0!(NGXO>K]O8"Y!_\\YL!?\/D\F=0'?,N-[^"5B_6B"E6Z
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M<_"M7%;VA^;0[L!99$A8]4O#)TUUSN[70'$X8-*B,@ ']Y.7N*[CT)"<3%Z
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MV@N7T@',*#%XKD:L,,L?P4&ZE$FY#3)Z1[G*RX%Q5A+!U:HB=%C>.0,=D.M
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MVEL*_LZ[[VUO7[S8@0#;=S1J#-H?_."'/9#*EA<'@7X4 _7BQ0]BX'Z2, ,
M@8T? TR<V??G,;61L(53_E6?=6M RK!P7@X=X 3WQH\[D'/7LOPA++ZO#HAP
M"&]H=23OK[B)-^"&!A,OSP&XY"$A\YL7@[?[\(OP 2,FOISKJJ-0.KZ8'?C!
M=>Z']L&_$=%D?P&9N,IE(T\YFF]]8.P,OOC:4WF*SD^<ZC=RM9<%WZV.AP$
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MG'R]JZ&$-E/$A*+XU"6X_[K\.>_1<95QW==]/5G@?!V6)V%T4XTIN@;^>QE
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M(-T.G\*7(I9'D_L'E*+E"L:B?15]^6-XHQ[==AX0?TG=:MRGSA(.D48 .&7
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M/*)!V-D@[ZBOI7RF-'<Y/(EPQZN');SJ%XX, IUF*? !.JEC(%8YY.<0$"3
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M:#UXKWM>63XSJ-&JYRB'B3L3(]"VFJO//[]=NWIU>^G%:]OSSU_97L@SNNL
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MY?K0(24Q<JV,+T:/\AG"0'16P$<0NAT6,RGI)+%5MJNK*4-S<]\MO_$&' :
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MP/;=T/(D=1DZI\X&K$GS0!M/.O)T]>K5*J)S9\^U7'FE;?E$(GC!R+-Z%8?
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M!IY6O'6<PX1)%_)UP-79(HITA\5/&**970W\A+7L?;:UC*R;*R)R-8[X!->
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M=8LC^4BZTW8RG0;=Y:LFX \>$)ET(Z-3U^BD1"6T-"4_Z% YDLYO3U_9U-8
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MW'I61F[VT.7RO ?A*9VKK*]C6Q>GM&5MLF,[MEZ>UX1JZQ0O76WJV':^:N,
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M#W9.[S@/_1-<VNFX;>DW()X!"24XA^VH YG[+(,7V[ 0Z86K+W2@^3"X>?V
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M#[H%PTX0U,; OZ39X;,SY&OYY"Q7]'6_W**628#IS[_;[J==?_GP0>_A:P>
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MN7WK=L)O-7Q65NZW7*>P$^2_?O?M[2]_^5?;IRG'H!O?ADYX% 'K+/H^6YU
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M/E)?E!MNYG7M @!'V;:-V7'$ +-[P 01D5,NVIH@<%"EB9I^YS5\HUB53>>
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M?J[MI]S";-)S29O_#(J[T>'=P9.8@YREG&#2\*;>8=,2\W]H6 ]BDC4^,FR
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MXQZ\@R\,6YL8WHS)Z91'2&WE&B;QTB-PF5'!U3F,<EIQF, W#2,E]VU</]#
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MD$R>I[M=_EE4#SYD=P;0_3Q0VF]7O:- T#Y@4\Z>/P64E_VIMA5?@W1&^]#
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M*\T:57(7]\2U>BTG!FEHVXF,(-/@O6-L75I/7-D[('(6;Y"$)^K9P5SH:0?
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MD^XT.JU#@Q*Y^@GUM/#7W5:Q(Y55JK<AC#Y;]O+"7?S(G%=B+6)HQ[7H%';
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MI[Q)AU,G0;M&M\VJICV?*(*6IRPZ-K 7![C6C\PUTSJT-<"@;9F90^VK-LK
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MF#EU>>(U[OX.OJU,:%B!SOL^#ZT[JA>2@ENR-DZEM8J>-"D%KETF'^&Q3-X
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MK;/R),==\@7GI,U?ROAV79Z\$Y[T'82)T44>ZI.7 :4V'L&+GL(C1@Q82]_
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M[_3LK*1=="-3"-*24B2YZVK^^*/NV.NOO_832Z8?!= *7")*H2..%Y:#6>)
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M\Z?;B=2U,R=?V:Y=2N?^U5OIX-_JDC=[XXT UN +PR@61IG!)!W_&]>O=XL
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M Q;+8 ,[MW"3Y:1=ST.K1:VF;1F[GL@_5_&=9U(Y2JSJ!._CZ\3OPZY+_4O
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MX?^*I^TP*#:=Z]&I5DJK$_IA#GNVCUS]<T#F+W_^BT+_\4<?[EL 9@" K+7
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M1=OEP# _'8PY<T$<$BFOUNE<_1I/Q)4^.DH=;=J]?@Y/]SS7O?"4W20@W_,
MHXZY@V@\3Z.4\I+GW'\=734' ,H#_]1?I_Y:[B5-._O1*5WB7[TPKL9X\NH
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M!VRA>MP2$LMF:X1C1KSW,U*]A<$CI/)#</$LL[#7G%'491@57N^35QK4@^_
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M*U%M62G3S!<9]ZWX/_S#/]R^_\[;:5<^3YJOFTWK*[G;Y7GTVY@"+9/?77G
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M30?>$P+E,B[4T]!/!WTZXR6N^&' $HYVC' A[S6&.E>?W?FL##.**PY'YIQ
MZP3OG@:;C@\C1-D86P.^RG>,Z#8$3:<!T\A$R'*_A+4588<#T.V$I[SBM<>1
M9_>#I9% 7_1G!$JS\A]T$Y:\5R/'@YU2 J=&DO<L_V1>&AP_/DN1YM1:C1^>
MX4-HE?:@!FM^B=UK.ZPI6R>GL^W@CW"B+6A>3/G/(R=?Q[!)Z[B]$HY</G]V
M^\,?OK/=O'IY.U&>#[P *<S%&VT@[MTX>3,,->(,IP]2^7[U2P>J?%;9<W[
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M)X&;- 8.#7@:/%2_?#:XE$T9O:!I\> BX>ITVZ]5GVF!,8#!0CX9X<HT&,[
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M5Z/XSA4GM!A.#%"]0]CPS;D *E#W(X9^\G,ZZM_]_=]W#SH93.9),W"A(QK
M4SY5')1<</PRL/+!(N7B<W!+G*!1.NO4^2RDN#KY>+_>25.BI5+B1T^\+TGP
MA<P/#^H#]TH+]O&C*'L:^A[6I8B![:C">K[G@\>*:X<M5Q4?#58CIR0*45W\
M_/Z][DO](G7$[&N7#7&)-S%M\TBGZV'J2WC$D-00H:<9A"6'A4#>C+'"/O6"
M(U-DCF,$V7ME>5@' L-77_-@3']^]VY'0CLB&CD_T O[/_DN7/V?<G5N\I+"
MBR_431 'AQT&#MW0PG71<>*X3F>;,C7*?B&- Z-4H57R*=!V _AR\I4.# 9]
MU''WWE>'N*> )"3RJ1N8\>)+>.0[M(_2X7U<'@X,X ;3G)_QX@N6:R5NDL\7
M*6*0A.:CIP)6Y*T#3(&O'>RD)WOH(J_.-B4^)P_>R\K23@,PKOK/36.&%I%O
MM"DAR2@=-L:;S^^0*Y_&*,S)HPU^WO<Y!E!*D%WY/CP:F(H_/:6Q+NWM+W[6
M9?]W._,4W4:FI0U.X/_!.^]L?_Z/_KRS$%[8<WP_C1YZ,"I'-S)2DR<88\AK
M%SA&0#M,D;&6MPM&&_)Z:;SC]X[N[I<LD:WY;%F+A\CDD:L\#WSBH$MG<77T
M]@Z6NNB\"NEK<,DU]T/GE=W0B&2U#*7NY7"%)/"@9=,=<>(M6) =7LUT]^M=
M>1':3O"$\X=N2N9:3G[2K?0KOEB%55U)GHQ4!M[0;=*.&[J([6=VRDRW]L$G
M5G_^\U]L=^[<B]%Z*30[L7T3VFD3G8'CL%!;0.S3Q",=JTXNZ/BE/6QG/,:O
MNG ^=?4,P]>LLRT"*>><^IO.D8Z[U0*6H],GG][^M%L)WGSCU>T__Y__Y]N?
M_=D?;Z^^=B/QKF\__-$[VQ__R1]MW__^][977WUUNW$]X>E8W7PMG;>\OW[5
M*H-+V]5KE[;77K^YO9YP':YK"7OMU1O;FV^^NKTA;M[;EM9/_GW]3> ]L5UA
MM*>#IF.HT]851H'7[.^%X*)#=^W:E78H=9Y]D]V!QA<N,OI]/>ETZGH,-%1%
MTA"Z1IPV.[*/*]JL#NR'+WC73\_N!C6YTY$V$SVS<0E/1O,)UNGHH^V)R.O)
M&/CGVID_T6O3)'WW@T:G. FZAY&%I@:/#0X;Y/C>6V]NKX66T9+1G^=2GKWM
MLYQWX-AG^0QVQ%NRWN7^O/>)!Z=5+\'\<LK3UL 3VO0O_6W;V(WK5T++<\G#
MR=F!UQ=K @<\;15ASY"3\BBT?>W56_6OOY&.?#K2.N16B-RZ&;ZD\WOURL7M
MK3??V/[R+__1]LX[WV_]M07SX>.'Y?\_^ =_O+W]_3>3WO:4=/ACBUP+/PTT
MO?'66QUXDJ<._XUX'?A7;Z2\UUY+&==KLY!'@U4&JEY__=7MG1^\L_T@_F;>
MXZD#:7UUP$#3#W_X3LMSOA7^7PI\5ZY<B@Q>JXTKCL&9B^G47ZN<IW,86;]P
M_F+X=JZ'=TU['\+%78L\,^P_Z8&X!@#2QCY^M!U+??VC/_A1)U8,"-R/+F9W
MJ\_J;_5U[E>MKLZP+20ALE;=U?GJMKRCISA63U6!L*37=BP=D<#^\=*R=T8#
M+K]<A7UN#]SHH6FKQG_7'83[BV^;+[Q>FZR4>5\G?O6F^UDM0>;8'VQA>GSR
MFTD\ME?#$AT<$A6/Y%J\Y>G_GM\!/(DC:%[,]0#K(9; H25ZA?XF ]2!*U>N
MUBY1OO.09$>^I:'_\,KD#-O!1)J#D)VQ8JNCF>8/WG^OAQQSRL(+3HDS0#]0
MEPX['/HAG""^;6GR8A>Y7_T)[8 #XAJ[<2:>J\].]AP/G<KF-N4/#.R&Z;S3
M,:]$%QD09)/8PDOV3@6?#@;B8?*V%:_(IS2P-OT.5\/Z7Q2R%AP3S@XS@<(6
MNW8M=2WY?A7=?")UQ(! 5VTEH7CML.^\F/9K\-;_.(1AR7/BY*=,7L'A]/Y$
M)@0>O,W_Y!V=V2]NQ=Y)#L5-_]3AMR=?.3YMX-[A5A;]6'JE+%?]U6"=^Y%9
M!UHKYVKP\JEO W8^QXHW^N2ULY,G>*N_Z?OPI%LTTO_]\DN#Q_J*^BKZH^KR
ML>W)E\[-<N96[/'86B:3;:7[;_P'_[*X<"_\9_ZSKZ</K[,11(YK9$ZD ;RR
MO?V][Z63>W][]]T/MX</'A>(%U_X>CM[UN%:,19>_'IS:-^9-([3X518D XQ
MGWZ9SG:,O6=!\M'CI_$.Z%&!ID/>_7P1<,2V#.O"^5/;K5>OII+H$,8H"9^?
M?OG-]B1I@W?RWC\#EL[_5\]L'[ _3QXZ)+8AG I<%[9;4=8WK]],J4*W&I]&
MKQ!282ID5RJ$P-(2_+XC>/$&+<:(U!!CXIQ$C$D:0>ZSN[?[:8[WH^@MF\>X
M.=W1" \!3$F8K;SB]W)@NM$9C0LQ;,3W>2%*(*1H7 U_&\MXHCB#!Q&6@)7H
M<2I)*E=\%8OGI)7W+"5+HQR&GXYP>.<3.^_^YMWM-[^. ?;P<4+,TKZTG3)S
M4.$;I84?=HY9.O(X F+V3F?9*-*)& TG3IR:&=S0@H\UU/0$4273$7X4X^%>
M&MC[J1 ,?QUGRV4-)/C6ODZ0*L:P9KB]G@;:S(\1<<:^3^<YX&2-=G&@LS?=
MGAV\5)Y90LN<*<"__IN_V][]X(,./K3J(FK^*! -!<-!,*6F<V)08GWMX*N4
MA[8.Q:BR#4W0PPS,.NR16]=V!N'4BCQ+X+P3IJ*M+0!B4\(SD)!KWAD]AW>5
M6WA,EV'Z5XE/KKX*[31$ZI_G*K#X44I6/:012YEK%/7<:9_5G.^D2J,./$HG
M],&CA\%S'[0 =/"IPB,SX1='UG7V?=+O^]___O8G?_A',1@N%1][V W>4%#R
M3C:5S]5!'1C5@]2UR(59/(-S!@;OQ=AXG :6$6G__R]^\8OM9S_[:0?YT'5]
MLYB#GU';&3P96@]]UTBV1B <+0UV/O1_TJ5\KGDE'3@+:^ZG[H4'\LK]L730
M?_C]M]-)>*/&)+?*&KP81Y->N+P-_"@?C0QJR'<ZE>%%\NM*ER?SR:Q[3NM.
MQY_1]]4SIZZBNLJ,=JV=T1?V<+X4>)0[6R34RY.,]/#02+&& ;Z2XP\\7*73
MH.H8.^R4#N/*@\!<.@6NH9W//<[ A5CRM/1+ [F<O'H"-#UC"?"Q&6GN2==Q
M&FKZA!&?[(4DO\F_M X3Y,_9!]TOI:3,&AKQM@!]^/&GVW_T'__K[39Y^.)I
M#TSS,VOW%W_Q%]O_]'_V/T^=OYS\7^S!53[5>3N&K$$TND C&L*UCH#-[/^S
MZ".X*H?L+5?^+<'8'?#D#4Z^_!7F'5^9\C0X+[=D0)XK;5/L\?GU;LFGP=#&
M364%Z^2;G.5S(+'?*<<O0*P\N2GKT'E^OO/D]SGOR:_KT&C*YH_FY9ZLK+"6
M6TJ,$]JM6HE#=YD])I/DP]L.8 9G\FB W;)B@Z,&_ISY<>W:M>W_]6__W]O_
M^G_SO]O^U7_TK]-N7Z\AEJ:Y#GIDV(RZ3O"94\?3F7EY^Z?_^"_:>6*<<,Q-
M?+'WL23)OU4'4GK;:VTF77W_\P?;SW_VRZXZ,&#QC_[\S[8?_>CMR/N+VX-[
M]SM @PYKPD%[28:_RK/M.F%6C40&:I?#PS\ZLX?#:?=2IO,(+%75?CG(\J=_
M][/MW_Z__BKR>7'[DS_YX[;AY-V[3D3$)EI&7G$.O#K(0[L9I"_GD]_+,:"[
MS>X+ R1I:V,@>J=],!#V28Q]^N&SS^X6'O7!5HK5MM<V2"4=?4</S$!]!ZN7
M7@!$RM9.GTBG^O@K,_B/I]K8AX^>1,_GZ<7@F';OSN>?;Q]_\G'?F9&_=O7R
M]H__XA\FG^>A X-_OD&N/#R!CTY5O_N?\D/@>K;1Q+$2S611ZG^>K2R$ATY/
M -_N?G9G^_S.G::YFLZWP9:+L?VTZ??!%G*9ICD9O&NGA:YC#)M=C(_N0E<S
M9:5!,*,'X?M5^&C0V;81G7,R\IO?OK_]/_[U_VO[V<]_MOTPG?1_]L_^R78A
M-N;7WX1W,8R?I,PU.VY0BKY?[8B:#&:K2[\I'Z-3HI/XB$[+%P>,/5,GWN%N
M_^?_R_]M>_>]][N]\<<__F$''JQ&=*BV;:*OQ%[;OIER\*I?6(I]TD%/G9B4
M1"YLH;I[Y_/YXL[GGT46SG25Y2]^^9OM@X\^2?SCU06//K^S7;YP9OL?_P__
M^]N/?_1.SUZQ.D?MXL '/_5QM;&5E;SN8'-XP5809\XNR@LT2#@JF,131]NJ
MI6WI(*TXE6L<B-OC?]>/&SC0CU[IG0SCIA]X))_?X]97K5KN'C8N^6%]I6#<
M*G&YU6[1UV-7A'<K>L+[O.#,"[>)';P'3N79DTW>U@#"45C5#7[ABRZN*QZ]
M]B#I\[#=N!7=$??!!Q]N?_LW?QW>WNGJDA_]Z$?;#W[T!XUO6[3!)P,YOOSQ
M-W_[T^C7_Z3VV?'(QW_TK_[OT7]_U3+1'TZ<*C!0H<; 44.2RVUMU]0'JS[I
M>7V&Z<^,7J [.VGTC160N#XXL#O,^I]*/T#]:!L=M_ >/31MH$.\V=TOOT*&
M#"I\U?IEJ\/EBU=:/VKO!-ANQ4VZ1:L.-!2:,$"]V-VT^W3-V*-??/&X?9X?
M_/!'V\,GT9EW[F]GSE_8_NA/_J2KTO1==)2?:3]RO^=2V6%/@A,M&II,AWS)
M7)&+_SLOA9>?^;5=+\U%B!W]^/YV-WKSLP_?[T"Q05:'X/_B%S_KX.O86R8M
MV7FV[$2?!??A<?HCZ; [K$_'G'P[/!E^5LR]I-_<P;LI'W]L83+(:Z78#!BG
M30A=P-E#E]/WOI=^WH/0Q#8J$[\P8&/"UQET/NM/CBFO_^W_X?^8M^..O?'&
MN9\8<>*Z)#W*#J-.I4%_^&CV$^D 6!+7_?II5")+!7 ZKKO22)%&=HSR.YCO
ME,,#(V@:6AT%(QD:-M_J[_*XE &8^1S+H7%E=M\!@O?2X.M<Z%C,*< $KU'C
M":#EZL^W2Y<M/YQ/E,'#R''W3*6A>$$"AGT2JR2=3<[5.0*$*G_U'AB8"X8\
MM2+PX/=LU(8@J"R6_MY_>/_@/9@T'G4[XPCUY/_"=OZ<K0]A1LH5LH0)#$V<
M,&FJZ!@H>1[/N0-['^+VRJ>B^,O+XA+^V'\LKD:-42=/!HZ&6:X,"94:CL53
MF;FV4]".9GSPQ'_X$N0O(SCRT$&6M[)4I%;.'<:US:,=X8*EPJC+ [3_XAK=
M[G?DKUTM3[M"I :?ADCNG-1H@U<, -^PM#SJY>W^W7O;;W_SVWY>CE!+@5N4
M&^.KC5CB=]EB%*92P= .9^$+[4 3) K:@)=8*KDW?3O!1=;-&,NE&;S+-!*5
M>/FW\JU,MJPHH2@@>W+@U.CYAU[XD8S*LQY\ESA=Z9%.HE_+(Z"Y1Z_%)[)E
M$* #6L$/#"H_ \MW@Y\XV"CW*:1EJ)=H(8T.6)>')OQ9X+*BYY$O,:2N7S3S
M=N9,Z!4CI_BDW,KQY'_0$4 W#"UD.B%/4P[C<$:/>?'Q@'*:D_P?5ZD5K>+?
MQ"WG6=*51HSDP&W@(LF'3M#OK7L=@B,=F3VLL.W/=1[$\9>K1N;R)<LLSQ>>
MB3^*'"Z<E ?IXY:L@H>4:$@8^G<>W$NG]LYVY][=[?,']V.H/NSH/4-4AV'!
MMW)"?Z.W.B"5Z^"*3A3_ZA"@J[VF9LO A7[=,B5NGCL+G;KJ_ (C[V0?7P;G
MO>[NM)CZF[J*[XRDX%X:%9J!YS"<>'F.#"5</.\9O-Y-0SGI$KL=Q\+;_)HX
M[Q,G:98L\^3WWOV'VWOJ9?2U\R<6E>'VX.'#[=_[]__]&K'"GD2?^&R.T6ER
M-<L?4W_II\AW\XZS"J,X[K!R![+@!Q:_!/5Z\!O0)@4W_*^ Q#7/_(+%81PR
M&/JG@#WN.$'-O6GR>L79P\%Z -M>AJ=ZD1IW_,&+44UM_+DFW^^;0^*N/+_K
MT,L;_"Z=_E/BM<R\:M;[;SGW^-/.3JX]8"FT;]SD!U3I=?[5X5[3226WEJV:
M4?Z;O_W;[3_Y3_X?W8HEOGI@\.WP(%5U29W3ECKA_JOMVO6;Z82?C#P\&1\#
M\?[#+]HQ?1S[P%D_9C@[$!G]XC.TY!^>/B7L='/XW[A^K;/\EF#3<SK&VOX.
MZ,:;3>Y]X+2WEGRQ1PQ(=! @^DYGBT'%&&:@6<9OUMZ H=EM96I/+26V;/O-
MM][8KJ3=LIV%76/E@AE<,^6\SQ#S]IZ?.W=RKN=G3[>![]-6#$0?T4D&PBY&
M/SFSB._)WX$QY.TJAXL7+VUOO/E&RGRSG=FK5Z\D3P/F,XANNZ,SCV[<N-7E
MKU>N6%%G>?JU_9W9< <O7JR.OW3I<F<?KUZYOEU(WL]?>*F#_C[%:1:980B.
M*_M,/9BO7G,>PVP#0#^&[.4K5F6<W\X&!B>66Z9^9K_.#/[L;VY>\>!XU4&0
MK[[>U2,=[(@>I(O,OEL]P2ZRFNQ<X+IR[<9V[<:-IC% T#A79AF^+1APMTI
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M)#A.11ZCNQ4IL)?7J5R<=#II9N.=-V"FF^"MD==7DIYLRP>^C?\LM V]S,Q
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ML7[) PRVM3%1X-G;HT>>)7^DP3T=03[U1V-U;IT&\)0:A7T;2AJ!)^JD,:%
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M[_[]]HN?_]P[P=CQP#C88U$Q0%O$ A'T(7^>G9\<N^&1[S/I[H'&OWQ2F8D
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MI-P=QY$*1Y['M":>9(Q>X*]HSM5Q< FG@\@!?70>:(<,(M1H2=/Q0$[E4>V
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MRAF\5$!O3Y'?&2GKI5>NM=??>;M=>?75-K>XI$%O5E6)YUT$3S \O1,X:BP
M!F$,:C!.*#@&Z]RY#1LR!AD>W#E?-= J?R!;*=5AL[&9%96G&J=@\@[ZW?L:
M:,EX,-CF/9E]Z06##$YCW]5U[^C(J]A'RA/'I,-CY<O@E[PHY] 6^N#7G0,J
MMRL^E;SX4Q['JB0T[!J4>R5>,1[K_I'DQLP=,Y8>^(N_R$R\"M\CI7G(^U&D
MT\^#1?%GIWL;1-T_?'CH]X)P')#$UQ*8O*A5@?PHJS*"DUT N>8>GMP9[7SA
M:SY[.1B/\9&NX]( M%:;>4Z=&S=P:?0<)CYY9_O&K9OMD^N?BFY..![0"^I&
M5Y1!CEEP!N,,Z+ CX"'O :\&PX-,Y- / )UFE?O<VKH:P(MVERYRD.>&7REB
M, S #^6&_I:K5TZJPY=R3SQC%VYF6KVBS[WE9G2^)V^NT D]QB.\&'<F?"A+
M])U=$)SLOZ\RX\ Q3D.W?.6@@R]><% 4=I#/_#UB5XDJ'8>4,@E GEXEU!7'
M0)R&E_S1OY37I*S0+YH[PJG#&?2+9L(YY$GR4T8>J'GEW_@3/SR%+X/B9?40
M$83_A""GR T?_$R'PWX3@",.6^W&K>?%A<X#5]N>[B\6+2MDC-V6NGC%EH:H
M] !P6>@*25 R\#""4%KP8FK)BTP35_0@2_\25L[)=2568;6_03X5(#KR$S@X
ML2F/<F. [$HZAD$>Y3H=L>X=M2"RC2QP0[H>WY@18M$A6;L89L2+G,0JG>@Z
MH_#B"3SH!AQ;ZQ3H\P+TG#A=%L3CKN<;!HF%ES)2&J3*Q%--.GL QD^$))\N
M+W#ZIK@,/9VD@+/6/_L7C\I+CG:,3DVUC::LTX6$N,697^2@.!4W=<$I'+]P
M]^0"9VS^/.B6?SF RQ!5 *["2WWSBC_XY3)QHC E<%W#$;\<Z3N...[S#-A/
ML5)W._W<^T>$T%GI0ON+@,"D A<[6VA__8XZ'4/1[3Y!!_*UG@PNZ0NLA5U,
M@RM0M,C-L>3T'UE:NVA;H1<ZNH,_\XC-4IM/NV]]P0^7?#T1))>=#G+=O\!Y
M*3[^I$.^Q+":0D)/XC9>#FL,5=S3'M.^FU:@IZG' E30WLI?7,03($ &RH-Y
MVFU=T[Z/VW 23U+ACYTCJ2@;_"80^;F&@ ,'?MH&XLG!H5?#X:G'&QB6"Y6J
M^YUW7(61GOAXV<5+3D^X$= >5/D53,J/7R_#'M9SB!-BQY/NGBS3WP3FY;=
M\',=Q>WRF'(O@<HB?.AJ%WZHK;XF ],SIFG,0X7A+"OZ&[IFU9I^2?I8))>W
M^I4L+K'S]:$/>&,!85_7&Q[4?Y)#_>[<UICK7KM__Y[S,&WHM6U %AFP+1RD
M1QTN>J(?N&*.*T[<*+[[#K*%H9<(*1,OXHE7VR67%66F>\5E/.&)^+.S0Q^?
M.)[TZ([^A&T_8;:#P4$^[&Q@@$X_"9>^+@>"[KF>P-S4&*H#Y5J\> >$9#A
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M_/19%6CS( )FUM>6VZNO7FZ7KVRVC4T^A<=,TUFYS$RC6+5=V((0,VP7X5.
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MB3[1 ;>QA,N_^")VCVIZJ]VK<.!D.0=&?HI*]/$$BL,K7;^ZHTO[8%?\U2_
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M4B6=E^SFVC/IY+-3E!NR1!\PBEFQIHRCQ:FL+B_XI=)JH.])!.7-@2*>U-
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M]"/0X\!S(CK-2;Z,L_M15B=A'%</*5/)62FZU\BOQYWP,PWE3[PIO 6CLIP
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M]515-YZZOQ5^FE^-@';DS^NE3&R@*XR=6(0'6*3B-4\6IAC+D)]?+19=E '
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MQ;")##);C2)!(_(BK@$92+X<6LBJ+#( 6 'EU$N7@926*UOF&7 MZ,HW,#W
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MI&/A203J$.6K-."S/G#M];7L1]V7K$X"_J$5/C)3OKJVYK+SQ)5L)833*'O
MU'E@LH!.*W2*=#?JNE74\%QE5$ ^4ZZ7<)5;70L&_P%/E?&DK*=3!, M#3(9
MY.!G$<;U)!0M0'!VVD9QN2?LI#]P\GD,ORD,<!W@ZO\OB=_YG )%0R;0U$FN
M?[JX .2ZC$;I)_B9[$$F_5'/MKDJ6QSWY?^;(/GW?#H\SP-ATVVZZP&^_7GL
M'[N7=I'!D>TA^'L>)_-[$9R,$PH"@XV5JWQYKOAI?^24 AMHG1_"G^<7F/83
MK_K_F\J>>NJ))N WQ#N)8_S,O=O. 4UN3$N_CND=Y-N?"^J>]/[UJP+L;V0G
M8*!C"!/.[J7 ?D/@"Q*_ .C5D*?MJV@T*&G17C"Z-9@O.?2$B4ITIOIG5<XN
M:SU[(H$?UXYW[+#SL7_2 08VO6\VU@W^V^E?I2NH9USRZ_<]WX)Q/.NWXIIG
M/=ML"B+!_"?>& ;95RS*:^3PA@_H[E&>AYY_O[4;D3B$O0S(YT7V=/Q\,FP
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M#XPEX=-](^D3_4N/Y_3S8<_JC_H :)6A>=%/J*U[*EJYO$; 52B<EU]34WE
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M??KNTI4K[=SY397K67]>[X$J/CA229YZ=1NC0%G!!_H";3;BIIG*\L1&@\]
M/GBH@='>7KMW]YXJQX'+ H/$)]A6EY;;\B*?R."4_<SX,<B)0\(892H:ABZE
M#M_P5[R5D>*9@;F?=7^DP>T1A^_)F/".>HPKA:&R<J=3CL%&SX.MU!Q$R2"8
M[3I,<E /A-)\@Y\M4*]^[E6YU]K-.UOM3__LS]K['W[8[LL0HL,,2&UP9YD
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MDRI.Q1N#[;%@R*GCKKA<W-;:,%"J/:_ZG:"1YQ?Y/0_X45ZT,<]<QEZ-1?:
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MZ/=#.GX=#SXOPX.C+7;GOG#TL!>!L5%A!95^*J[13*=U_G;YV<(119Y%W_-
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MSV0 F7%B/P-[5GL\@)(T(GC>15=F(HK9+K8[1S!D=4HX52F$&SKI"*^NKFJ
MM:Z"X]U@.I@E;AB&>1&OJP>)(A[F<.[\21@81\],R971# ***<X_#)@-6F9$
M^+9V!N9=(<!;0'KA8?#O[Y;K6H8^ T8IM?)GX,(J)TD] <!V?D5+5.@$&71*
MZ17?NBP?*I0[5592-8*D5QP7MA" /Q,&1F#@/IU:7853Z")G/5<\\!T<'&J
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ME&@#5!Y#NAZY\!6,\P#J^:3[;2!MZG?/PX37X*&^479C?WZ R1S3_0)X$;]
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M\!RV<8#<%)L\0)+B)"]=^S(W9:6:;7TFH6TIM-IQB1S=W[1BJ=R[H\_.CDK
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M5-0^LBK.KDS.=G*_5G4,G63AS*^FJAUEIW2J@GASWSWR\P!><D-]^"H5#+&
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M>,6<>&?57Z4?RL)*Y)]RIIYY_!-A#0X[A^QB=]&%Z"/E1[^6?AG^__H_'DT
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M 7'M3@+BD7>T^75GN<I%]O2]S8_^#*1R/<*2[SAT&@YY&Z^O<6/YE)#RJI_
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M"]@F509VUW=B24<'Q@&-3' $"?&!G:2>)3<*E\^/XTN<D.!X%72Q[PUU>/#
M0H_VF+NVDU^ZPJ"&S;/AQ&*0DS%4C3@4-=IO;-B++'2G1']MI'CQA@34G4DY
M%-ER$15:N<:KI,H++CA&,B0.O;&)><:.CANY>",]Q^THSXM]R8.^J'?+</A\
M>OI<[4-VRWL GI&F^L*F%% ^==#H3&[A37[)@!MY;Y_'*MB![C?$4M?H\#R[
MQ=)Q%I*3/\/*SC.\NVH0F':-+.<B!T?=& RI[WZ_A3*@0>&I,/6%#!!TL_B0
M0:=GSS-P,*""5^UHX'MQ^E_Y<JE_T)7O.\,:7-#$D]T]#VK(2]NFC!YL:.,_
M^]G/IN]]^#WQ?,&GD!X^?N(3/M@D&ZF\E @_ S?4F5BE?/I=-EFPD[1Y6 @>
M\B7<^4@# XYCP[8[_3IN0#*_SI=+MTD@@WXF,P%\N-*/F0AYB.G,=N2G!-(5
M$+A$U2>NHJ)FX_@R/,@I8'LH4G*%($\I).=""+.\QB]'JGSH]>2A<LQI0-MD
M9*^\;H_RF31VAORSO?->%S9?T4GR@,]XR.:4D&"?-@%-YPI$[P'*BQ[*)E4F
M]>DY@'EK/_F@2W6W'71?0!]!V>#0'D&$IWFB!!TRKP$Q;B?@4(Y<^Y8#GWPX
MHM ?]L5%N:X'QSH_E($%YR2POHQ<KOCK_-U_@U=)*T#)%B#_#-!#!\FG>(W=
M_GRD]$5?+2U+)L9HY%!!53X:BA$B67[^4WIX!,J'MDC;/@N,M_(#P$,K"[@7
M4P0YW>^['10=$!6<NYS%6P'&%^+3A\&YN9<C<V3'8>\ O+4=N"T*C?Z#&RS,
M+UD(D>X-5.N:,29\N:QF;T47 3;3N1F 73 '#L>1?\$7#9]:4I KV$P0I/*'
ML!!FW3J[Y+#-Y=HT70&DX=6/?$ISTZFL=OQ3*.62J'"7!719Q@:,B(4H!KJ)
M7Y>]]4R!<Y_##[S* ^V,75U&(+0*3\YT*GZ]G(:VE<:AKLRA2>G?6K[9]A1O
MZL8;'?]($0U^YED.#ZAK,%J&E)FLUG-0Y"2G?K[9!I_4%XFD.;D" NPR>"6S
M\C&WN'OW[O3WO_C%],M_^(=I:V=[^O33'VDL//)CP,RQN=/_BU_\<CK0G J[
M9\WQ[>W;?D:]-YA=I/XQON'/:Q27$GVP:*<M,"_GW0-7>)>3QG[R>MW''%'\
M]-R'O&X?ZC_8!(<(O+/ ]DU*Q5DOI63/&^6XP8!>739QH@M-'BGG1#GSKJ7^
M@^/R-3\\\ARU;O(0C^/,KO3&7"P;7"I0#MW<N)F;9Z<T9]JY='6Z]M9;TUG-
M@SR'TGP$'MW.U=X9S]@@(#]S*]HM_2/ET9ZAAXZZW)Z75G&6GW5NGWQ(NYNT
M?CM0Y1[Y\7-N^#[0VF5_?T_S_ZM^5, O'!?0MZ +;."%YCK_YO_[[Z9?_^:S
M:6__J3?<>>,_:X#NEU"MUV9RRPT/ZK9L7V ^S5S"#G$M!-L!:X1&%L0V<LW-
MQ/_]__'_[#"@?I4"J&B^ ' TW?[VWO3%%[>FK8TKTW_P%__A](,//YU>OC@U
M[>WRC?GLIO ,"<]+\"W)["QP+.KIQ*<0GFIRQV*)12L9X,.3.AA59:(L%D1\
MGHM'!'P4Q97$T1&.L1*7TP >R*249AX#86<$9V9D^!B' 1PY.B?O0JE,&Z?R
MV(@<A@8--X;O!:!=#-!'UMEQ$N_.)QQ\+YP8'*0G']]G(7M:DU\YCGOP90*.
MFF2RGCN6!X?/_+P.1X,Y"JP"_+D_WOK_4HN\YS*6%X?['K1S-"/\\LOF XLW
MC@>++]'+PB2G \PG_*&!URP,DY?T:*7NVM"HE1=CXN43?DNFXO@>^1YOT7SX
M:/KJZV^F+W[WI1;?#SVX,:&*46%,&"5U<<X-BZ,\[&IM7I"<JA<,&-XX,A1=
MA7_JW"'9I'E#)_ GYT6I\^0D F\"9[%(7FC!)PLM[H)S@@#C=<,;?G2(F0Q0
MD.@KK^O/=VR?Y]3"$4?0\PP-:6P\\5P3=[(Y!<#.I-]?(7VRV\@;0'_YRU],
M=[_]=GHJOKS00\=R'G_%QQVE_0]_^S\8C\4Z&S9OW[PY_>5?_+/I)__>'TT?
M??][TP\_^6CZ@Q]_ZE, -V]>E\Z8*&!#='"Q5>R=N[;4"\>8.,Z$@]=9WNK,
MT]E&5FQK@>H Y"P__#HJFS[8R]BQHUMLV_8L1.JKG>W-\4D#7'<*PX_;H.R
MQU>VV=F4ZXX31/*QP<>+4W): 7M(!YZ.E8Z=LMB PB951QK0\",O U;*M-]A
MU6UWRL0UOY1'//S95R(RL\.*'-YP<WIPT1I]"'U*/R/&21XZ5Y\>P Z><X0T
M)WS2\=(?;:B/N^0%K'>9I0>?[A%!-5>W7;AEH*$?]&ZL:&*;,$R?(3;,(\Z1
M?+=8R0P,R.7!Q0-,[^KG,Y@,V+QTT2\!- [I]#FJ!UUS?(S%-.E>U#AO^CU
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M ( ?%N]>^'MAB7QI"#FMD(:&O,LD/;)QC2Q>&(LZ?1T\]=U @+IYH@70/2V
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M'\MY$[3^ .O,(=%25%,-CLK];E(K@+U1=M>TLW9^;+#*_$X 1PX[9FZYQPD
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MZZ(9A3_R6"YQ)]G2GI"UVI9\RUW.V?2;Z=B5?<28C1, D__0"&^Y^I\"32E
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M/;2UG/,)6+]HGH5KK?D86Z!OI[*@V?Q15KAB+993"-Q$Z1.I\,:ZP'Q8?NC
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M8Y$%&7  _("7&QL)(TNGL4[H1?]1S:5*!/O&<<02WX^K+->:;R@][34",J;
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M/-9IN?2;"3<X'KT1-92WCA-8E>/WP4@#6"Q-H*3U]).@RSD)M^/P"/]^:FL
M:;EU69C?V!P4WV,WB)1!G.V1L5]]X9$6W.1F(\HWS)3&&,$I9,!YRF\;Y;EN
M_([+O#5S7.)H*?&ITTBU\ @-YJFLF;AK_6IZ^C0+?Q[9SM%W\%//Y,/6?+R?
M5:WB*"?EX]=IOAE7,C-9$Q#G&V2BA<W2]WK1+W=DFMTN%"<<RG2;K33?;()F
MU<R1YF/$>5&O-1<Z90N"#>;(!PW&&/**MF/@ \LAI$3X@P_)"7_MD*'=#(JG
M?)%W/#<'-R]L3!M:Y_&E,-8"O$^ 3[MO[5R<SF]N3:^D6];&CW?Y=/:>;_YY
M+2%:\##?T**NRP;X$A3S>NC?N'9C^O@'/YBN7[GJ%P5RPIRUH1\-$, [+O0"
MUKGBZ&S/G3_C^>BUJU?\J#F;$[Q<\I+65BOM1Z!:6Z(P?Q,-GUH(9%%-13QX
M\&#Z_///IF^_O>TWU__)G_[9=.7J6].W=YY,?__++Z=?__;V=.?.X^G^P]UI
M_X!/0SWW\6$^&4:%P:!)NP-)F50759N* PAC>3S+KPY),3U)X:ZSGYFVX85!
M_'F!7\J8:<ESI<KA1R[Y["[HST=+6*1#BZS*YUU7@1=!<BRD/5E3'N^BH _C
M8Q O5;'/U-D?J=+XW-?&M+W-)[]8N$*G9>+X1;Y/Z:,F6JRSFQQ]+#S#MB?#
M-"@O^HMG@1N 71H(N!X5J2_]:&"$O? 7?WZ>S:-NZ.)Z( R==1>Y";MA4%]J
M.FX^8<%UR',E]Q_>G^[>O>LP.X>GV=4ZQ4(Y=RWA-=\RSR+H%<\V>^%2 R]E
M5./.,3R,63RH#-)H9.AJ<V,+B52&$B0KN@"K=7LDO3]7&<]?L-&@QB3Z?DLO
M]@.&,X9]=,D="A;E^#0F4D"QTZ]4;8B-JDR5*PO(3V$Z6'8&<7D$A<\[9M%G
M_4OW\,]"TYL(Q%7GAW-OI(;>URSRJ3L/JI+5\EKE"=L.H()^J6-.BUC/<LJ_
MXOQ3_<X_(#9"V N<\I,6\!V3*-GMX8PZCU=:J.X_W9^>:;'[7'6)3D,Q-FN[
MU%]B0JUMM6'!DRS2BP>FVERSL\S!Z?+%C)V2K$MGUS7'FFQ7LI.G=)SR7PB5
M7H([X,Z]6GQH6>'PG$X=GS[2FTH>(* M'_LS 9P*Y\Z&P^161ZM%_G3J>=QI
MW O1>NF[^QOGM?AG,U(#$CQCRQ[4.;EPQ&YM># O]&O"H0C:!!L?>9&,!C#T
M4;K@VHXVHFMD)^S3,Z+'9IH?BQ!DL"(?-(6K8GC\RN,)\26O=_75%X,;'&06
M2_J'TZ4<@U/%"]5XNO#FBTN+C@@;AROQ3-WBG$PL%4=(A?L.G*[[)3K(@94"
MT*9LTKO_#KB$! 6DCT#93&#R7@.L*$7;HBC>6/@)D3_Z15?1L^/Y$3?3#S\+
MH,&%'M": !JW=>BV2QSU0'T[<Y4ESS6E=/<%YE9.X? QEE)9VR'3R-8 ]//6
M'_8MVP*-NLR=I*0UZ?4R2'!<%U00DU6$^5S ]"@ 67'Z(2?] _TQ[@5]OWQ2
M1IIP9MVT'$7#P7:59I[Q<[D"+4/CC  _%1 LJ::M2^P.T2C(_'38<JZZ)4[_
MJ\PQO7E?H'%&_$#TICJJNZ5O@N]*&R%U$'D 9Y,;2X56Z F+=JAPY$^>$5HJ
M<.#=8X0BBFS^DU:_!D)I?]%'YA=):QCQ 5\=9V$&\U#I<-MS!_I#]YGTBRX+
M^<!2"8RQ.+4G]^-NTTN[AB_F!GRVE 56+[*B'] 6'J.#SKXPZODB#7A@GO+F
M-B)OUIGU)Z=(7UOK2[[6E?M6PJJ?^6<T"NJ\B\-VW6=R[;*B=\!Z=J2<XQ/;
MM-)>]%-Z7'J@I@OJ(O-"*WI%O] B'2H ?$BN04<!4LE'/YNR<<6F89X?$X<'
M#3LG%R3?6J1AC&WY#0[7M1 LBQP^O/;)'L*.1UY=^1U/R=6Y#;.N<YEZHBWQ
M0P8J2S@4TTBN6UTL+HM8YANP9S4J+VL''IGV8],/'DZOO'$O?,HLQUC)',5'
MS_FA>SG2.&J.K0O%[0)^/&?R^D8UU@M.X<X@?"Z?:W'Z[*GFS\_4GGAD3_,#
M[EKKK^@A&K9)WQZ^X;]ON&430#-3+7X]_U4YGO=J#H#?_./ZVO-\S2FX$T[;
MX ZY]8*,Y6@+/==8G/ E.[JDDM % <^%U(YAKM=*$3=Z\TTC.>8T^7PQ_%#;
MS)\S#PP.N-3/X*1;W_!2F"K&$>^;C,R%&>\H7PG<\)3ZID/I9G=_;[JONMP[
M>.KG]A\^?#(]\,L$LR9&SWY4GD>>>;G?/E\8X)UIT>DKYJ6J#V;^EW8N33_X
M_@^F[WWP_G1="W@6[SO;?"%B<SK/I\A5Q^@$#NS@2SXZ8/VZO;,]7;W*HP0;
M/NWPFINQG,R4W8V@M0>M@(8*2(GZH5 6)1QY/\6C *I8GOG]\JNOIM]^]ID5
M_\DGGTP??OA]X6Q,#QX<3@\?\_FY<]/^OB8 3!Y%)\H+BPVP["J&4_U9".'@
MVI!IL&;+C3?&A7'GV=$8F?,+N%96YP=L](9NF/J'4>$HHUPO_$&WO&V\SJ+_
MCE,GIH6_.T&ED6<9D.+\3*-R\2U(E V/&!"-S9-BI=HX]4,&[A+RG7Q."E!>
MTLR*=4X>[^1I@@L/WN166HP08Z43RK5%<X.E\8<_=,M/-A091=EXR"V\#-+1
MQ>@R("7-/"FO.Q2%FP83>':ZN).WM\?C'WDNA478*3H"-4[*3N<A/:$K.7>\
M#DMG]I5'CDZ,3H"RD1*?\C8VMZ:+ER[7R08Z$&04Y:I#8;H<:+DARKGA0EOZ
M 6<!Y*DZ1K_24Q;<D:M0_*_U@Z.L><*JQ@D3\'+N;!;_/HU"7=6F5.O)NE.0
M_(#;D>RG[T!WV5[\LU$@?N*GWEG8F"]TBD]%RE?I<M@G^B@7M<7IW_);!>K#
M=6R'[M%3.<L:G7%JA>_#/G_YS!-Y:UF-R!1+50TNPW%+0G2P"D01;ULJFV+3
MP_J3[*G/AI35$P1PTR;#,YL\SU37O/223I<^QOHXJ=SZ1YD.JQ#JQ,_>R[T0
M 1;$?AE?V8S^D@G0!4?WSYWGA,^9Z?S&:=DE+QX].UW84!O>/">7-_W3IMGP
MH6;1)7:=G=T< XX.T"'2T<Z8B+"A0?F\&T.XMFV*95#JNJ&]M*.ME*TK#*78
M6G0(J&BEYQ,Z=AI8<+R0E4=L& 3]V(#D#0Y]M?A%'Z+M0;5TX[:)GA6F/9 '
MGE)^!D[2/2B6G(#]LIFTI? &KSU9@-W42L+-O^6I>,4N<8-+G/_7-3GR2QL/
M3D/CM)OSR&^G?_8IT:4FRCG609@5.@D0!GG*GBI65;2 T^-#JW\-X2\PAXK'
M=8B68P<SLL+I*T;HQ"K84/X)I(WE9!*HH_C DGOYS7U*V6B/X[10]Z4B9AS9
M#^VCB,]<C3(#UEWAK,-H*R.$D\[K@)UC[8-#7P@_<LV'_^"O+G%.4J!E=KC+
M;!<@;I47R@\^,.?EM\;S_U@PK7*0ZE*@ZG:I-NG(H?Q ])#8A0>/4::G6)SB
M+(_Z3&R(0F:6Y7?[LO-\@[&-I,@\R@J EQ#Q@R,2F[)= >U7J"[AN.T&^>B3
MW._0%TG4V91,DDQRA!ECX<\],C*$(+3B5OEMX+KKDRP>.Z289)\+,B0_/E=+
M>VN_P>@FAM>TXP#3,8[^4"8PT%QQA<M_^U1:@X/)+^J5H?P1'!_,=@;QD[Z;
M/^G-G5;R-Z_F.X$BTYQT6LG5SM>AY<O"R[R2U,7QCSCLJAV1ZW4$V.YPRM \
MN=P"Q^%4#F6E@-B2V[]YKOD%R94U=;J4%ZQ5\'P(/;DNAE0%.S\E",-^%KBT
MS<QS62]X[4![Q9XUAO+\.&F 'X&6;*93XVSWYRO\$99'OK0-YA##"3\+A?Z,
MZC  35[FG+E!WL5UY$=/R,-FC_2NL.?PIIVVQIC/XK47[1[7AW*:/C[ESWP*
M+&?-&WI=F$]JHAOYTN?BD&O)"T#+9<KO>J;_)@Y'48Z7#U_T#]QXQC%7S,T/
M^@WDB&,NE/<=\+S\XKPI\^RIPGE)^0O%Y8MLTO$+Z>T97Q@X],NO]X7[F!=B
M[W.S[*7U^N!A/F_\9/? FP![6N3C>#$^&P)/'N]-NT_X(L'>]$3^GO!P!X?Y
M#"'O7\#G=,+%[1V_-^[MFS>GF]=O^ 7R5Z]<\<+^XL6+/G&^N;'I^6>O15@S
M;6_M3->N7+/_\L7+:?_)WG2H]=K^[JYX/[#^&L[\^,<_^>NHFXKS?[3)_S(<
M50<5Q41//B]&>/_##\3$]>GQX\?3G3MW_3UT<"D\QH$Q*U]UGG0 &3!<@ V<
M!"JZ\9DT $OCI_Q4>!9-Q"/D62^>>?D?W_WG[OKEBY>FG8L[CB,/_.:9U$@V
M0C<TTC 6'&7@2,' 23,?9[(XR[%O%GG3=+"O"G_\4 OA)VYT+D\_>.2.,$:#
M =!P$)9'!WC>GR,8\)>%8!;ZEDV_T%B _H7!#H.G,9H__>B\#+H6UPX:A2CI
MEF];'CX]E+&_<%H&Z."M%"#H,O$#D0,P7ZX#\@Y.O&37$?UD44L\N+S5'AKH
MMW42FI2AO/P)#SZ17P'%DT:7 *:BX%5IO(P/FBS.>,-\: 8W3N7@;#>XE,4?
MM+SHIBQ? :1#W_^CSTZJM/9-&QN1[_R0I7#K)+8 #=>-:<163%-B4:^43Z=G
M.L+QXR?(A=]AT8*^!REH8VN5%_L--T,'CN[+7F>@?/.@?^TGH/_031W&CKHN
M%KT19M*.79T^JX7NQKGIU-G3TX$Z-HI!_]&%.8V,^I$/_;5]N=X&AR<T2G-:
M!EKJA#!YHB^W4SFC*FT&R.AG7#D@(D@&\QS]V)Y*Q@:'S$.UZ_K-<N,7'4\&
M)*B"K@>($@[?K]2>3TW;%WDYC#I6'_/?\+&S?N3';W/%)MAU%T"?>F< PDZS
M&$H9,&:9%610=]]C'IQ5$%GF2;EX\(\P>/!9M*QO9 )+:7:DZ]HTU??!0R8;
M#+(,E*0F#WT<?40F);&!(R81QM>U:#"9@'_D\ 2< ="#.'*!_\J+?^X*',I>
MGFAP>:3Q@!,-9D\E>="4X_K'/_[Q]).?_E3]]$7OAC,8[N[NP[%U25_.0$8[
M0%?(C(O]R [8C'4"H)#K'8C\P4N?&CPY_2%O +R0MOYP#MLSM&U0DMLG]E7V
MMP!T:!/0JE\3*<_UX8FB'-- X4(S?7'R!.!;GESW[=TV@E-.U_,FESWB?#7[
ME)2 (MQ]I5^BKVE=A1_P8![^Z)^@%1VW'-)VM;LNI//PIW^T%?V9&C3+V=;U
M \>RRL5>A:LTIPLO338X/2;,.AS N$)V_>.#7VE <64(;M-1+ E%$Y4T7H"R
M0\^"D%Y9[%=;(G_JPBC^G[ Q$U,XC>%XB "*2@XF]G5'[CN@2C5TO@;2.ATR
M72Y85 ?S,X=EM^1N2F T'KX71 +JGCE7XE/7QIKKHN0H0L2T;;K BC.F<<2=
M?%-1>OI\I\J:L(D&>)-S'L56/[T :8NTA$<PCRZGP5BV+<MI%YM?PHD/_]@3
M8W"<8D4L-%< ULC7S< %IE2C)J@P_ <7B%>) FS/6+(IE1Q;KK:6?*0'OWE$
M=W.ZXILUZT7.\<81;@@(\"NL#.3)*1;Y30B8Y:Q Z=?T' C= &F5[D3)H#2"
MN3&P"HL.J/^R*=/K_ %H&!RO?[.\D2=TL /&Z\P/?(.NB/3-NF[88L4%\".?
M:2DY-),G?=,"T J/"[1^1[S./_HN3O^LNM*?8O)7>&9%9;)X9)QDLQS:K!EX
M8SSK! AM:%W S:ZM[6V-UR^F2QH?+^[L3'S*CINM7WWYE3\WSF/$=^[>G>Y\
M^ZW&W&>H3#:5\1L]P4:S@ER1!18B$PS!&N^U@C7"Q&?]E7$/WMT>]+_S.K]^
MS 59X'(-3N3$ ;')]._I5Z -'YN;6J1JH4J=]8V#?%4JGXLV4*Z<KT0G]L=U
MYJZ^>7@D?,T[N -^_?K5B3?<\[D^YCHW;KZM.<2&YAKPF<5_;N[4G$5E-GW+
MK&M>N,RIQ+X!A%R9%RD/]54^)S,HWU\TXF;-TP,MTI_Z%#0O.L^CZ.=<)[=O
M?RLYLSZEGG-S1+3%5S87>!DZ"WP^)\XF#'J0?7!:5'@NG_>G*5_GY<0#:URO
M>;6^9,&_)9UNG-_PN\9PK"OYE#R/PI-^^>*5:6=S9^+ESD_Y).(!+^)7^;([
MZ/Z'?_6OT+3!&P!=F38 N33"(* P5P ,8L2*N_G6VSZ>@/!??_WU=.O6-W[3
MNU^ )B9\ATKY4'DZ-+GAN#V3.8PJ$U,:>0PPQ_SS/(DNRXC@!QH<R^<[Z3EN
MZ[?ORV?1Q&[(CM_4F$5H)K8R2"_"TP#H@ &'3;L--F'BR0<_0'BF0V(2%9ZX
M6WMXN*>)ZR,MMG>]2X2AQ)#=XTQ[6H0_UF080V0BQB!S60V<E__YF1NT4KQ(
M33',*M\3?/.12;=9,6KJAR#X=(EI&,[(%%,)KS6QWA]XDO%0CV17>GS**GWX
M1PK_(W,A&6('R$1CE*.S-4)1<CR!R1-WZH7RW&'0(2D)ATZ\LX@^E:47@="D
M;"_FZ.3AE8% :>C,&PK*>G!X(+NC =)(Y90'V?EQ[5U%ZXH-I,CIS0G*TQ7%
M Y&SV''<S&%\XOI2 #]$TMDYT39HBDXG#LV['.)-./*A&Q:"Z!F9V-!@=\Z+
M?.'9GH4+W_ U#_@*^W_9@1>HXFEQPL;! L5%$$/SVT 9YEW(Y$U:PMA?=]:T
M5<5,YS?5IK3(9<'F75..)4D&);E>_4X".:#E33\A5_SS8AC+(K3(DA<S@4<\
M.J -0 <96T?., /,=A[*Z5CPXN"9.^><FG#YY0SMR4]<R:Q09":T %<XZBQV
M1<1KV?0T;6^?FRY>WE(CAG?U/[))-CEY6RS.LG@2J3*LT[1=?[92/VR;=NSG
MNZ@'D<:.Z>CG=F+YPZ<TZWRQ!_@0OG#@R_TDM,"O>/?)6JC'_E.G\F#?8>>1
MKN0YWB_?9,!1_^#!6#2H;]X:FT&/A;YTJXE(!L_$L\AWOZ+RB'_.CGK%,Y'A
M<T7[&F2>[.UJ<#LT;[:MX@O9?OR'/YY^^M-_?]JY>%E]Y-/I_OW'[BN1,QLJ
M%ZQC/^>F/^>3(&E?Z*14A(:4B?IR6T!81Y-/\>C.B*&3&FU=TR>*GC&"#W0]
M+*1B[[--%1BGZ.'\4KUUO"JS>7//*I_RYO8RXXO.&CY]7]KN\E.TS$>(LZ,^
MR1M;:5+Q0=:?])<-D8$_M1V?1!G*,V?0&?!<JJ]SU>!K7)<IF.G(=;^<_B!M
M.E9?MBG[ <RSB%D75&R16_02@%[SEHV,RE?IH1P>@-!;: ,E;<JH."A87AN5
M0,DY'IIVDCQ%#Z<+9R_G1&K6_'%2K_NOZ"%7UFSRZ\J/@E7Y;X(LJHH!09</
MS&FZ) J7#7BBR-!M!7V"@"<Y9VNOG^)D[<Y!WV <\)7F..L2WO&$YVO)BNT0
M!R3107 "277119,PHSSO1]70)USF+9DC=-W&)I,7@#-L)6%L9=4NW2Y)T5_'
MTW[CAY:LQ;A)C_.[?SA9R>+1"\@SU<97]>-"Y:>]Z:_GK8Y3LN*['MS/)<,*
MA"W_LWJL(CF?^C,]U8I\R^:VHF3WD\F;_HYX<^02VL8CH_ J760*#TP<8 3Y
MRE.X@/,VCL*1H^CI9QOM= &]%X[TECEMIG 65/-@#D/,'C+D'5M)-P@)FZ3]
M@3?K@!_7^H?#/G*"+OQU'P!0=V3V&.JQ%?I8V@+6B?(1A^MY/0 G+J?H-5"6
M75V/$/F&% 47?%V(:,HD$#S&Y9<:)_WYN:I?QLW^9!RVR,OGKEV_[F>V633R
M93!>],=[UW[SFU]K;75+:ZJ-Z<+&!2\Z[]R]H\4C8RQS@98)B0*4#]T6USHJ
MMM/WPS=K.?$E&HHLOITDUB6GT,B7>0KC..\F8#Y F2"!7_8%E![<QS/?$'TL
M1XA^HSZ.-H>>F&\P9\B\$U"_)7I89MJ6:+NA6:NN-W\U0',-[('WR+S]]MN>
M>]R[>]^+_>LWWM(<^[S"^20Z:Z]>4&=.(SN"-^JCYC"^PZ\%.5S,)XJ0@;#6
M&]2%;\)"0XO[H^>J,SET_UR+=[Z0!H^\L?_*U2NB]WSZ[+/?JAZW)CZS2+VS
M>0"P <"\:UGP9U/"Y8HWSQFM.VP>'C-O$GD![2'].E]J8LW+H\P7)"\; ELJ
M#_WN;%^<MK7H/W>&N&VM3Y].SP\S?V.>[4T7R4W=_?._^I?F"Y#N8P#I<-*X
M$Z?.@,;+L606Y9H1OQ(3]QX\F/Z[_^[_[9<"?O2#CZ8_^J-_X@IA8LP@>OKU
MF>G:U1O>^3ESAF/N+)Y%#T&4'T/QG2$QDX814^%ME&<D'!U,\[,\\W_&BTS>
MMDB#Z>/S,4Y>*(5PJC 9%?2AS1NG,:'>@<-Y T.5@7);P=V(70%2E#MIT<8H
MJ[T8P(FQBC_]:'LN6X8(;>Z:4:[+%FV$HN(Y:H->SI_;\ #$3A&G"/8U^67B
MS37&YDE\57X;0#=K&JS?+*QXWJB/0:<L3<SE>%O[H0Q:BBO\R-1R)0Z6EKA>
M! 96.Q"N\W(^A>5WW?6DCGQT8GP9X/%C/OMX8!V0E_IR8R87D]G://%FBOS.
M3T?1$V]O!%EN?*7!(PP+N.OJES;*OK 1[!*^S+EMUF@S)%?)56FQIY1/>0WI
M$+&3X!L/6:ECA:T+_45V!>"+$KB6;8YTT0U'G*4!-[C6[;&)G\*P0#IU&%SJ
MA0$M\;D#N]A";PA\%ZS*U77]W?G"HVSZW&D?_3]S%GG!EYPJMR&#+VVQ91WD
M$5 &N:R+:A]@L)CC_1AY RM'Y<]Y(D9^\C#P=[_C05V^K7Y@&=PXKL(;DTF>
MV^,3)[R0;QD( RO\K=%J:+H-Z,*ZLKY4AG3"77\6V*#!J^4TW^+7S[_Q)E86
MK=%+^JK3L6&W7\KHR8KJ577M8_?T237 N)X9S+%!Z?[XH*P4ZDGE0AN(7;"(
M3__IP:3ZGEZL^[B>KDFGK7DS0*)A6WXF3M?T)4^%=ZC!BT\]'FAPXU&O@\/X
M^P>'TZ[Z*3X!R:D0^ACB2.,K+X0Y,I<7?J8L^&RMHJO>P*!=H(?6A1<?O(K>
M%83NZ0]8D&1" +A^D@6R1G4=%>24!P'"B4MZ:,9/W$FNT[\+@O=F@,=U'.+F
M=D+:&HD9?6':GNO< B] RNL5V0*F+1CC"'>_3M@^/^+M%OSVB9S#:]#1*:IH
M-,]O ,M@.=9@+GLI:[75!LC;=FXH)CH>GZC>$/%8 1J.N,(E#;VU \P_OISS
MV0YQM OB0"SD$2I?0U^E' =7X#O[HP'6]6[^J+\A?^,T#?C-QIYPE98V5'TO
M>A/:*K?)._- 'OHF77=_I8M*:GUD'@6E;F/.[[$A4-1F(+UY,#G*D3NM/'RB
MV5]>4KPGXG+KLH]@G@1C&<T_^9(_?#8MZT(XX3/X_CDN?.'R#J",94T3&/E)
MGKH0."PY6J_K^=8=,.( T4O*)*E3N6YY <>OY5V!(!2=D_%,GW3]T'GRK(+[
M7_F>YQHW>48PA2'.>%P;.7%O@L:=\YP *^G\275@6H]=K_Q0:>D5( T MRFW
MWAMHW^MQ(WQ7&C#:%:ZO\1L(>]Y.6J4#R$.8L=WS -5OWZSTC03F0:QW%.9F
M)I]\0P7D\8)5#AJD>W%<='T#B0TDXSK* &[L*]H OQU0T<[3\^R6!R OO/DM
M];)1TL AF44JBU8V 1H/G[S!B_RA-[I%9RYGCF/]1USD(LFG#E5.^T<U/\J-
M"2W\.2V@<EKV;KOTDSEV_]C/W7-W_>51RF"#I.=)K$TX&<TZA747/B>+F>&&
M]YQVY65];!H\)P_KNII+O7CQ3&O#%R#[ZSE^!.#)$]/FO7#H@PT UGKX/";-
M@A_K5,U8QMS Y"1 -AXXYL^-E&?/COP> )\.D)P\B@D/UJOTP68(_#$ME+CE
M2V\*^XL^_.IQ8&6Q7@\/V7Q /]*Q.,AZ@E!N<HW@+PSAQD6/4>1S?)UGGL^>
MNR!!-TR09QF^_N:V7PK(Y.\'W_O^],G'G_@-]TB*$E1_TX7SO!%_4V0T\1.#
M)BHE,/CTPC^@R;86'F<UX;8!LR"00FD@OMO&,]?L>LCQ_?F\P UCZ@DCX2R&
MJ1" "N%(LT2:!_\L-*HQB0\)$X425+CY\: E%'_Z":7A%&1O%!G,BW@SF+CX
MEF.1ZB,8<MS1@L_0?&V#X\A*CI1DXP/>,ZB(_YBBPW-M>UK#O7X&4?BG2L0+
M.A+X95+V?>E&DP97'3LZ9Q$O4J]H%"K#NX;Z0:,;<Y^X<'GHA@4_=[9X608&
M%6IRT5\#Y6&D+#@.#O?L7AP]D[%)-OUHR!QGP?#8_:,N.0F #7E73YUC%B7I
M/ @W3:[/:G%U]<JUZ?+EJQ.?Z4 !5 E&#DV.^Z@Y>E/ GUWC#J+JQCN-U#7U
M3X>!\R@8_5E4<J)+QT4NRT;'0@<G/S84=^J<[-/Y M#C<V_^2H;"F,'\Q0CI
MD,:.W;/YX4&_Z@(5(YOK2:7W5S;H^/Q\MN)PD3.-MA=0MMLU6(_+=>(DD8.-
M8_DP%MH+C)"H,.V$E]EA-VQ$@4.[(0WG":;SA8>3^+#^Y+]F0?N2%[/PUE/I
M*,JV+OE$#T?<^'S*B^?#HEUY8W\*VL$GH0"TG5_.[TO@6HYV"&\'3P\T"!R:
M?Q1,'>/[/_Q"9 #K06 YY* U;_@Y7?S2(2JG/V6I3AI62:7>Z/-V=W<U #R:
M]O:>N+^C??B.DOG$/ZNVKGKC%)!L@;)\/(WVP.ZTHN&+NWJ$O.UA_:H^5':>
MJ0_GI^5C>TRB+9NN/?%50\BGSD(?#K$;@KZL@-^.2UN3[KUAH!\;I1S!8S/"
M=(2'KKR)*1[Z95F\V.8 QP:!!BB>:=O70'O( ":Y^QF[0P8S-E>5G[I"Q[!
M#?=&8LHPFZH[38C.*XZ!5H,K?!T^W9^>[#Y4/[)/DU(?*SUR# -:B")BKD_L
MB/IU?8>><>82Y;!=7S>D_ "V03^(W(1-S:XQ7/O"'R<W;K.4/[B4@\TYFX
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M 5@AUO7J,F)SP5QHF"BZ5Q"=]9US1P@(YA(:E)GZ@Y\N-TC02? 8.#TH45K
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M2M/ST=.SLC_>%,MDVWU1._#E<LJ)4UWTK^ECTT]DXF <:$DN>()7RJ0_[PT
M'F,A_JVWWO)&K7&5ESNX:1,\%B3[4SDYJ55W2_37_?PZ=*QMQ;_$M5[@PIM_
M;-YH,,R[5JI_.CST'00&5FM'O.&6S4TT=G*Y1$>G*:/#XE2_55[ZNCBS,[]V
MZ'>\C@/&<$/*$#BZTFC\(0OEA4Z%';]&9X2VJSD/&6:W#C,'@3>3%8PT$HX-
MAJ\5EL0#EAZ[# = E]9]U1P6K,MDFSLAC:A$*R[)=1V\C!4+?H*%4$#4H&;Q
MB4]Y:=N^4KK+GUTEK4.EV\Z4WXX^RGULI1?M6%9@##<8W_\3 EJWX*_F7W5
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M<WDF$G!XOB: Y)6G:5<,K<,AQ3D;OIURP9L+'O)U5D$7,>K'=(;KE$ZKC[S
M4CZRT^8KOIR!N':^E"^[))WQ5-.YZ84$Q>7Q@> !*W0 IZD<? G4<RWS5?1'
M</XJ&ZVX'YAY5EKIHIT;^-"/*%)A.?GHDKX]D^6,XXP#H#!'90%&F'Y%_RTG
M+F,U^A$?W"" K'[T?\G/%3_B^8<>")P,Y@N_7(/Y+X #UWDC5%+*XC+EHW_$
M97'"?)-%#UFP3WCW!K;D48K*%;W11>MV)B):6##YHO.%/W0WPQ@D'CSR$!Z=
MZZ I%(UV!4MJ >62Q_PEO1TZ62!UM.H"V$F[=>@Z77?NS^AKK7@0R^&!8[TF
M >Z),\*L2W3-'?<L[AA/T =AQB=.-Y.'A;<"=M#!48_/6!_)'IF'9>&N-,5#
M!WW%9E*FUW"*ZW&*-N&Q6,Y8)H]<\.OLHI.[V/T6>[XHEL?D5*[FR7X/#_,=
M(1/VYOA,#UJ$L2GI ;KM2R>M:_C']6?OL*7,_R*KN+6_ '1;)N1(^X,?>,O7
M K*.9,S.<_;<A*/MBI;[ E,99.=Q@=R$83WK<13^*QWHLMQ^Q9'(FT[+P:Q3
M:WO'/WV1>3&YNR[/:@$N%L6;Z&J]RHULTE8V >3S/CUN:OKSX)H7<1+WP@:?
M]>,T Z<(&K*6A.<+OFF<-/AL)Y;<EDECC8%<.+]@N>:JF<L@5^0907T)%19E
M\X-1)J>Y*T[%8GB3&#PW;6UQ!SZ?X.-Y:EYX\-577TU??O6EWXS]_,4S*P)C
M99=C>WMGNKASV8Y/ VYO75*EYYD'[OS&X,2HE(GQ\AD&];_BD@G<A>G*Y>O3
MY8N7_6QH[IC'N*#M!1*.Q;:4@T(M!SK!*=R5SW^[4AJ53'IV@VPFOG;'*CR[
MSFM\F"*<1074:(S\>F+$0I9%:W;/DI?%DLQ(::H +8BY"PHM[PR)]PP> =-0
MW@Q\7-L+,P6II_AM6''<:3QCPX<?"_O[0#CHR3+1J#'\<O#2,,?QJ_AZA\C"
M.Z[2P'TNN\#QZ0P6BPRH;J0R1'CO3_M%'C4L=(93IV-#%3YZQ'";'_J4S<WS
MTZ7+%Z>+%W=6= &D?(5]IQY>J7\Y= +-*B,+N'R&X^DA[JF_1\Z["_@4&AT@
MG1\O[#OB39S*"SW?^103%-.3#>B+O70^Q2=N#"^\!:CQN>ZP7V*4C!SM '!P
M7#>MD0X :N,W@-&XMDF[R.Z.&[K>E&-7]O1T<6M'"Z(M\V+N1GISF;0/WD9/
MFS,)R:BZJ?H]IW;$ I?&2^ZVRU&6?.M=[93R%:_FHWA\NM8LDH@[A>YLC[0#
MA=5^)(E8$ Y\P%/7B>A0QLRR:;()J#)T29W[+?,<R:<<&RYER7,>KLF'C-CH
M,Y>5N_3HOVDC/_6&/<F6&*P%R,BNZWEUZ-[HE&,7][PW!#C.7B< 6-R+'M^'
MQ?8WU4>BBPO"-:_HP65%UTV+_HTZ8H$:1J.1!!>[ +)1XF !NLW (\I*$XU%
M< -YVU8#E:?RM?WAD#6TQ!.;KY[P4B/0$5^BLPZ=E[=S"U4.V31023;L@$D1
M93.P\P@5Q_*9.*_#W)X47GA5F+HH1SQE!6BGZ">\665+-C^JQH!*FZ#MD@]>
MB.>.#(\:<4U:^HJG[B<\ 5*?A.-1IX47RH?OU 'OU2!-4X1Y,N$?8?'JS52%
M9Y9FO@.+'-\%RJV_? (HML"DTQM@Z+?J"P=T78RTS8_Y@)-VB0= C<OU20 ]
MM_<J=[2;AM +;PL?"3=_#4K)N%C.<83=1E;[0_WS-?@-A' M SBC?31-TRAY
M3P3R8T.EVTRJY:!%_<DU)!U:[2_0:=Z(DPQJ7)"-'""8G_"$G9C'08?&4_ZQ
MO([' 8QIV+(Y6"F?,F*7OBI\?.BU7CJNTXDC# ^QH^[+PXL%<!\0?(!DN_F"
M_D;S1.9ZZJ^S9;L*IND,"Q URM#E-F_K$#[+CG!SW'%;<=TU[9GWA:Z3*EDE
MVJ?.,T<./>BZK &6,KB3F[KJ.0) /AP0.W)0%_!7\;(SOS>)_&+"K,R(@873
M 2A;>8[45[$X<MZ26]P64D'Q /38V1 9!GZJ;/->/K8PYJ%;B%MP8QL+3NA6
MNO\OT/$C-/YZ2M?'.I@_N6X?;0M=_]\)5;[YJ'#G&6D<YV8!^/J]Y0C@SW6D
ML</S6K4)=-<Z\,T>M;.>9T:'6LSQ$D#-%S+'#PXY3B[S.)_81@-%.9]H8VNL
MMUA Y\74>>DN?0GK,EXZQZ?I^F0 P-B,'-!HW:R$C17[Y=KVHO&>+Q]! T<_
MM6!F'376E7W)3WM _E1-V9#XAB8B^9U>H@OMKA]X\SQ7?O(HDGY*@$[)FQMQ
MJ=O6_0C0AJ+;<FTTN%VH+6DEK'Y,Y2O_EN8)G!*&5SAECF!<:&OA/]_D1(:(
M)AJ257%>^XD7 %[AA;%SOLLO'1 _.L Z+CT!<,\U=L$->K\S@KFHKA&^U]B\
M7\ O"=3\*GI=X,P?_L%/_YI ,XEGIW\JVDKJ!3!,PSQW.WVGC$6M?#Z#@*S[
MAWO3AQ^^/[WS]CO3>^^\,[W[]GO3I9TKOGO/L_P\ [ISD<\#GE>>34V6M\3X
M!3'.'<@P3T-@<<)Q?Q8GO.0/\&1-E>Z=*<I737'TE&/,ER]=FBYN[X@&QU#%
ML]*H6T^^Y A'*NI5/L)9F43HS_BJ'O#D4Z4Q3- P0J7[KG_N_/,=R&?/#B>.
MDJ)4+U;AC[)="C05QMB5'WFVMK;]Q8+SYS<D,\:1W< ^;HH^^RZ3[$B. 3T_
M6%\:W,R^(N6+3X+08A%+P_4D6O&N4R:C2T\-:Y%582ZAFY?/P;M^R(J3KEE
M];$YV&A#S<OX3"I@OA;C)#_IO*'3>M2%C5AQY#<-EXO,/(N;/'WLWY]*8Q'N
MLK5X%0[ZA!9EPP>=%S)'%@J+O.;#@I>L<K&!V )L=#AI*L.R9R>-_$IRO#=T
MJG[5K%UGED:^Y9=/T^P3"US#&PV=3B-\X(#N[.B$:G(.-?B%[^2BVNSF;.:,
M__",#DD -PCX1C>=Q+7=6T9%I0.A_-SY9W%Z7@M7,K*!Q@M&LC.;O$?542,/
M;9YGWEDP<9>;_"R.?*J!W=1S62RK@JQ'>(</.J5^= A\RO0G,D4G=4W=JA/G
M&ZNR>WBDKJ&#;;(Q1U_CB9?XBGP$H@MX10O(Y(Z=<A@@A>1--.Q>M8,<;'"A
M6^^@DM%TE-OMFTMTQ9M:7VM1SN8(E'/M9_+-"W7*@$"'+"+H5C[]'^50KO$@
M*K \PF'3(=S*OMC)U:(?W90HRH?-R![D\ZP]CS=EYQV[@UT&"OBF?/"CAS@H
MX(N>]% 4[8C#WKB$EYSL2?PL.)Q)3\DFXO+A%'Z+M,N=WXEAFI1%& 1)+MVR
M>&<SF#?S=A\8B:?IVO5KTW_Y?_HOIT\__=0;(]C7DR?[T]V[#Z?=O7T5^4IV
ML3%=V&0'G+X%'E.X2K9/NQSO>I/NS[%1!RK/I95LG.#Q)BOYA(->N3!-H<TO
M8<IE_0,;ITO3I*VDOO*B5S9X&%@S"6,205QO.F,_V#+]-X^!'&IL8-.-S41T
M:9U1YUV, M%/R@+<5N6+8U]CGW;$.F/ <OA2_XS2:?@=!I(7?-N,?M*B?4I*
M=>H*G9%N'.40'Z]4;OBB@*)D_M('%X<&\V-[2WTXSO9!B.O$V[S U9_[(UW'
MWK'MTC=U!;Y^WB21\X9AM0]:)625*KDA&+V%'CR+!I$DR>'/Z5P0)UB1FY]E
M()$V&]Z<)G:0.;+7S^7@R!-N9QK\D<]R+&%?.PYLPL6*TOLN-I QF.38;6)5
MEOA/'1801F'0-+^I9].1,Y]"\Q@#+M'\" RP7"_Q?8<XF:!E#JQO]R.*GNMY
MSF\M12]53M-H>:*#X./!EVW)<8N#AC=Y76=$@5?]CL).=YX%(JU0T<D X)$/
M:&W.;,C9*YH _VTI"H##N&*Y+#?].U3TH^Z=!=HA1KKYLN&13GP*X]=ED#$Q
ME*,X1Y-7N&$UV4FP+R!(NL-*(9N<^T/5/V,00Q+"-=Z23V536+O\"P'[\0+H
M-GDL"S'"\Z8&BQMIPV0J#9AU[XN*-Y)<T38](FHQ9AUA9_.X4M'Z9<--]2"=
MTQ[(F_J')V@%%YCYD$\[-ZY_B5]$6T)S&'KH;XUHTUSQEV0'?=DD.T*BK>?M
M!'3H]Q)I+M)S5@@PAO!R:TZI9:[YTG,DQL/]_;WIBR]^Y_>*L:[A%.+>[N[T
M[;??3@\>/%1NZ0GZKG,7)H@.7+[T2H])491'%&,7&PG==]#'LAG!HI_RN;8&
MA9PI3MF]QL',DR,TM%(?Q8-=@\**)\WO-U!9VSO;GO.[3I%?6%[?B!YAZ,U\
M*S\\$-EZXL=-5=9*UV^^Y;74GN8.N[O[8N2LUI3<)-[R> S,^: O!Z_<%4]_
M@W7@-,.CZZPV37_N,=C,*(YX.<JNZ1XDY2(S<YZG6N]R,ID;/7R]B)/PFJ:(
M%V[P9"%N)QSK''MW?2$G0,G0@S 0;3;?./H@(D?>0<\F'[CD$Q5=LZGN&WO"
MZ_9 7M95K*6@I:3I/_D7_RF9#+J$F,-F Q8@3F5A %Z4<9>8R;DZ $_FM]B1
MTF);>-_>O:.)W)/IG7??F?[\S_]\^MG/_A?3G_S)GTWOO?O!]/+%ZVGW,6_%
MAU:4C )8!'-2@..AV?%BX9Y=*8YUT D@*$;'SDK?M3W2PJ2%1CGP1N?@2:,T
M'^5:)!LS,G2CLQR2;E0N= #$]W$H.:L8'X628L./_*D$L%6V%$H92Z52,9*Q
MK 4L*@#^EI=;09WDT(0'9,R;JK/X]^*B8 DMD(J.T?A''CD^0;%T+I01/B(G
MY>%27LJ1+XU0''&4V[IR0T4V03K?.!N4@'(;S$^%NVPA^QO>7',$A;I#_]3C
M@1H-CPBPV*-Y"<E9T*6/VWG7ZH5W'Y/WN7<HZ:B\$-=D<&?GTG3CQ@W?L:-C
M 2(G\H4>]N-)&D[0]A"\X$?.Y /< 1 _IQ6^=1-<@'KT\X TJ-*) L$5"AH!
MTQIV,G:0W5W:C?4I_%&G0/(O_(QZI_,F'$@>Z[X<<;#G8TGRW:%14ZI;72FO
M.D'I"CO$^82/\JA)*9D./C9E&U<Y7NAK0;:SO3%=NK@EGP4\CK9/6=@L&P?L
M9K^@0,G$-][/^H3&Y<N74S_<!5?[9!#C% #Y.4G$CF7L$)ME@HO,B]RY4XQ/
M^V808@!#AL1Y PNG/'F+>_(VS2-OUBWM:M%=\(#H64YTP.,8?FI-=J9^UT?W
M+]#!PSMUG3S.5UG['2;8!G5*_?:715PM75<J'OVT70$L4+VXE8\,.24D?8@6
M]IL=9%J)^D:5J1253;$B1)X40*Q_(W#MB6';<<=77(Z$Q;[3!Z6/"ZZ<>&C]
M^+HHS/+[6H[\Y)$S$)60@04>F[3IE]6GBZ[;'#_EI5X8!["-Z"QV.>L-&1,,
MZ!KZ1).W!^H1K]%IAX1M6OC"<8S[A,9"A/"R*AOX*0.7A6CJQ->T8^.(HJZ9
M3 :/QSTNV'Z]T<:I%]D#[8I- (R >?"\\..:GUDB+OJ?ZTW\D/0F<+XUL QN
M'Y$?I H9'$]9ZX"BZO1"_[HO9+Q"+]1S="34^B_IL59?.Z_J5R+,S!&'5/FE
M?&1%7\ */]"&#9=!7.R!JX#D6BYF7N8\E!EE5FYH&V. BJB\7;9I-3F%VP%@
M^-H%D0<?U\0KHP"\EFE%M@+/ XBK:'*JM@<*H;$.(RV2PQ]QL3\H)6[(.P8K
M#=>TFA[,F%;I;F8.FO"F2\H82:]#6RHXZE)<CJ^AW33Y4YG=IL(#M$D&*S08
MGVA7;2,CWP%HPUOB1V@:!O)4<(9C$:O094 7V\\[3FBTCG2:04$N%YX2SG7%
M&6?((QB+)\63>7[@*K&QX]=_TBK!9<CG1IS''O7E7&=N&G"9T%HK>X;&E=<\
M+[P?S^?XV3;J6K",$[ZJ_XGK^. &?QW<COX1,-([!HIO?D8@[H3H&=Y4,OG>
M6!9@/0R@RS?A'VD.PLN!\:'+O(I3@(QYK&UXSK^S4JL.(X_UE7F)OP//31K&
M9Z51VQX_C"J]T-^N2!/^,__--3TAUYP2(6J>Z\J^,_83IESPTN<"\,Q8MP[*
M:F<N^P+" W@NHY_;,,FRT_!5OC.,F5)F\VN_4,#GQBB/M/AF:],62L;FU'7J
MO.6/ Z"(;%UW2#KKD)_G10O^DK=PX(&P\U!&3JE?V.#F-3>U@ID\U)OH*4Q=
MX0/PU=!\ ITG;L%#;\S9(YOX59SKR[SBFW-R*#U]9>B2MV@H/C<N6&,O\C6<
MCJEEXL(BA=S8DR><$H*AR?RHH?I'@V4@J&L^O?79YY]/O_OB=]/;;[VMA?_[
M9)E^^YO/I]_^]HOIP8/',O3G$]_4YM,(W"UE%XK)T?;6AAPO^COO@0<#596J
M/ R.799\;YOCEAQA\$0$KDF58"S8O3LK?CQ@P&@)B6ME^?-KY,7-1AA*Y"&O
ME2S[P'E@+PBN9S,V-EVH,6N1RO,H6JRB.^YD^+-:XAN>T"@_@.L^"DP[,(MN
MR*+I<D*_^8%/-QQ?)TX8J-2VZUCY:((.@3M-?I9=#3L&K/1DZURZAAZ.U1YW
M1X4@&C0AW\%4!G[.HS!ZL]%:-Y*)!0V&J+ G&M85#F4%0*<T;(=X^.&NX-[!
M_K0KQZ?26,33Z1T>'OBXM13AO"X/I[KI$QX<O\]1I!Q)8J!C@P@V,>CM[3S/
MRYULVZT$ZKK*SZAQI;ATE%R#%T="&HUP /RR[4@D(.^,'US_T ^-KO6A:U!H
M.ZU#\K@]B91]QT$O]N[*A'?*:1X,<-!2N-24.SO94SG"M.-NL]A[+^XH"[)T
M -S-9%>6!8K?I0$/WJ'(0A->J#LZ'8X3[6Q=F"[M;$X7=RYHT7YVVMQ@AQ&^
M0[_E@Q\?<Y>=\]P[[Q3 02//+:$/%N.\*55X//>D!;47][1;RQ@Y ?@%CYUG
MW_EEX<\N.'?GO2$@N17'>P*X2Y]FU/G1=_@BRGJ2O2"7JQ]Q2^>D66Z#^B7K
MB;+C*&M3,O!\%L#=;@9DZM9UY[HG/_0 \2KFJ1/$P><] NB"KYCD)7C2F]IL
M+Y@MJQQ^VFCJO#MSTZ:>C!V(396<NK:]X4C#=LM^'0>OSA4@G'S\H,M../T
M_0G]939+V6T_4AMF4R(; _19Q9\<?NR <I,7VBYK*)!/YO")6&Q*-2:Y.$4B
MG4JOV"3OV/"&% OK<HQ%[D<EOUW10DG4F5]"6.F>7*!O8?DGV8ESO!D1OT4
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M=7E<0L5R(1A_8<#IZ4>""RTV<_@-$OAN+&"<IF&7!.=W0;J6!TTF48Q3F4!
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MN+JW$Z)XE?#1XXD,_[4/KX31(:W[)X]&X'*5&67;RXHN?4+?I;7*8O= ZOI
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MD@G>5< R./ LGR5\ V,"@/?=9.%2H T]Z(AW<%FNX(1/^KT 2;/K[;@1U-5
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MFN-M)T%RG?(^YAIP3 1RH'/?=(SZ75?D.K2/&]J/]Y+UTG1]W../^ _\VMW
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MQYM$D8>R:2-'Q<;/;"X9JUKJ/5#4YM?\)[QZ9?]IUW;)F."3)WJ7H4&F6_;
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MO)X'A_JUO>ZT\Z[^*-(IAW90"M"6X!K1.ZTU/O.;UU7FO;29O-BJ4W[^YTT
M?+]?O.B$;F0HY'7U_]UW/ZS\^]SB@_M.UW5(IX-][A3OBR^]'/Z.X;5H7.5
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M]=[*,66%.^G[Z>VD$Z8_:5]^ EN>)%Z?9:OTF=>)$R<^F.(#GS3ZIBZV!<>
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M)C0>/C"C'<$(LF05_<9!VIN6I65-6W-%9/FST[X,IJ.,+QCE'M[YAS<RH'?
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M'+Y/_E9Y1Y<41W'JMP8.BJF3^-#6MM@XG)YX^!>ON-I];$QZL>79<05';<3
MG]$/.\F+OI8]\JH_*#UYGO(:A,8VC8U"9]*K=";]1[^Q)>6Y]%WS"'X.S6R*
M16-Y=7!3GO[0L/OR-WD/G\=W8'B2]EAN:< ?TQUQ@0R/XGL&3^*?,NC9ZQ=
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M]YS!7^P,';=")<YY59UH"%V#5_V,#6'26K_(/M//Z;<<_&VB^D[[L;OM[\D
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M=W"K#01MZ=)V4.G+&NJL [CD!8<) -O].T"(5RZUCG65J;W40O%<75.>)O#
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M-';&]MX/?.ITM5^K_N<SIK$0I=X[3FD]D#64C5TQ?4_DBJX,WUN>N+,3"K.
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MOLUJ]E2"P2EC5!F55=DZ>U6%%AHS,'\015P>I@X82U9G-%J#U_/>T[EPL;L
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M>JKKN;1C[X=;'?9)&60_425[_?,[J?]+V^V;#@:DKZ*_Z(T@2DG*'WQ/43J
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M4T8YP"5$?#<4:5.#ZAM=FUS:275&:!_Y&1G-8P &%[=HD='"._F/DVY@QW=
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M\1=_;OM;?_/?O_W+?_VO;6^]'3U=@_')S7?\?_C#GVR_]WO_=/M'_^B?]).
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M-"E0SPQ]DU#:00:/WK=/WEY)L%.F,\:191-[MZ+\;S.D M.RQVM;%RY?ZCD
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MDL=B*+2]$KAM$.V-;!*$>)I_ H=D_HX-M&-W7W[QA>6%"^?+>W=NWRU< OX
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MA]@&_?2N70D?TYL/19^8[=.L?N 1:)\H;R0@3GVG+2>)[A%@6EX S#29=K6
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MH?#K.CON@'+I;W5@Y/Q9<$BW1UHC/]:.Q]%4)G \8C-S#^V>!P>/[FU57M&
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MZ"R%UIN 3>V43(UB_@ RQ93+E_S^^&BOVKEQ8 =1CBJ-$,DT>Y\K87OFMS<
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MG\N[ 8HSU;I2]]!ZGO Y@;C6IAZU]\AU^'5A^JSO?OB=_S8\\[$<3+U@=3W
MIA]C*T#*+GK.HYX"T@0)P3>_-N4\"U<K'!ZU]TCWBLAU-H L";0DAXX=-L44
MKJ(O! *IJ Y-'\Y_;4OKFR]J]G5MH!_SQ?_5G=$#JPR O8G>/I#' L=@R8^<
MTYD<<*B.R&C:+4^B6>[@@^F;XF@[-"Q?IQ\K3M3D)$L?'W.U>(67?):'<WE>
M>^CK/$\FM;ORHGO:&-H,=;4U,@7A_JT\F^_Y@J?92S:;/B&/_(K!7^# )]K=
M@/@Q[.JAH=0U[?1Z/UW%+FJ9P"._6B,[;YHYOIPRP5EPO,+;)]US.S\^XJ_
M]CSV]$#LLE'_/_H3/[+\[(]]97GMW*GEL1D L4E\A$>Q'W2N(!Y [,[H3B-W
M1LSY1<5@97%?^@T'ECN!$^VQD5'MH\=.M _\ \"8^6()A20HNY_NQV;%+N>+
MO3 DK\U8-)-2!WSWO,2Z/05\/Y*@H?2(+3B8AKQ51!!E^C*]S-U\D+Y<OG5W
M^=7?^L[R#[_Y.\NU[=C.X,2HNP2 /9&@!^[H-OP';^.[:7IT=HG<8_U<CPUU
M\UQ]NOQ;]0V\P8UG1U^%;I(VJ3-7&@"IGP_JGGXZJA_A-75M+N7(%_]RW0&F
M@IS_1@_T<@Y\UB9;7CDT8%_8<#K4 ((":%5^5'A3P3H@TDOZ%OXK#^9"Z1Z_
M8W.SLLBF>M)@EB9SL_< #S/PJIQ2U?4?P1H,Z+-D29"FRGD^G^0DR-^P_M3G
M/V4TG[_6B58%=BWCF0T><QTO57_D>_]:%%1NYWKZ#QX(JMR1)\\5WJ5^*)U5
M_9YZ*SO^TI[?:*FMJ6^>(_N"O=IE# 1OH:=2^)LL@$."C9\JT#:RSD?G=_9U
MS9$1N.[LB=8;/SSUVH_#I^#3C+_J\<0Z:&S 5G.FU$LRC!^QSE@RR)@^IJ!!
M(KY 9W.B#=@ E#Z:IB\AM#Y3_SG7NJ]):+4ONNWQKB6A#^L?&MA@4R0>)!#H
M#+,1#(B-KY#ZTV[YICISD@ ":'V&+W$9_T'@S5="!V_5FB73@R]4:W_BT[+/
MDB=\DBY1S%]'T>.3U$^(O*,;7A/\HX?XQ;X%^J;-L7E#\WS$U[=T:&8[V6A;
M4D'?M&\IQTX"='QAD+&Q%+V&C],_]4LRT74=C E=FKCO_9$Q^.YKY-.603$\
M 7_N@5W217WVN\O') !27Y-SP?OPH7W$0I,\YUCI-/T9OE7_U/-\N14__Z97
MTP?OG_G,:SW9)DD9?/&?_HU/S #XQ5_\"\$$9LX9!G%6F<%.4%5A]#6'AHIV
MD&X.1%!@!6(]*$&!ET[66:.96J=C%,_'#I43;N9SCCR?YV1PC"!YY</7_N#7
MNA3@M==>79XF$+GTSIO+W734R!C$"CH8E8[DY+MU^H)9ZU;<-])F)-1KUQP,
M=)$<6 G4DYR.KC>5#<:X>4Y?JL##B'9;!RZ'I[V/$IR@=>!OV9PKT1!4!E8]
M-2S%YRC,JLG@J+^"FO8^Y3 '9Z33,_N,) +C[K-J*&7&X#JB:DLZ#A[A8(0Y
MZ90^@9G-01[525=FIH3N;_\I@6Y(%9@P.,5@<Y4#=?SW5@@IO'6=3G=6#@P$
M$B-V!'7_,#"FM^^!7?8%OZ%(:#PP=SE(VK.AG>!6$H+3 .>4C.GZ*5A%J$>4
MX[DS9Y8SIT['R#]-('9_N1%C?C<!IL[NVW\P//!TN;_U8+E[>ZM+/W!7,[_I
MDRD_ I%N:!;\"-#AB!K7URH,05C:E!&51>48UFG+_0.'K,,R7>= I[U3&RA&
M"4DP20 8;3Z2^R<#*R7@GN#<;K>G3&DZ>30XL:':R(#9#9149WCX_B1X-*K_
M,+0-J\'_J9,GNL8*;2?Y%8=GHP2LX4>K)PE.F[5-'>JE#*O4TD%BUD1'Z!,T
M1Z&=7'[\:S\8F?#*O-MQ  0#DP2:63;6H7DU6NC?UZH<*$_L2DH\2WWQI"JG
MX?_R7]JKX8SAD4SAG!GU>>(=^A$#AB[LDCJB1U*.DZ&_>:BTMH\"5,(F>MGX
MB>/!=#M71[+.7=I"SWG <QR&7'=RV()_<NJ-!Z?.'%M>?OE"E+?1G>BIB&E(
MDC)MND%X@]6T)P&B38&//1*\OJ[+#HC[,^^PG^!_^YYL]LPZZ=X)P<&Z!I'B
M)4OT7B40CM+7TB%7Z($0QK\:7GI2&71ST;,,U>C&F:9G!D[UY49_I'CJ&H?G
MX,$8R-2E]B:Y8ECP$#E7N\1,Y:R=&/@*1ZXY^J:4#3P.=:&1N^.TZG^>W3@'
MFP*%<9PIS]*7X0%/S;\<KH^A'^ABZ#;&BQTAZU$1X]0JH6RN T3_H'.F.KL)
M%K#/<H(\U?[H5V_T PTD1.G#S7,YUC(2!]VEN\[I\!]^(=/ZEZ>'-ILCV*VN
M[6A!9!KNX;-]UO_"7<BG?0\5SE!:^[V<O_E:G>Y8]8R+KJ>RRH-#=^FT3\+A
MJ)SU+WA,^WV^1WN0S\WO?!0V6BET*B_E&MR4EH#),S9&@Z?:[? 76L(!VAPY
M.&M,'4T:Y2Q<_MO W2;7HS3ZN/WY!M+Y]M%(IF(YR2T'Z6-^T8<<BJ?^?FR0
M-C5P2/NE=J_\IQQ>28GR7^"%=_9K75-?5FH)_^LO'>%";!R<YVMU3NXU:/"[
M]:XGT )A/N%#>X6S($=WA9?K/ ?'/B?QH"SG.3H-3\%='F$C.>?T4F=AA4_A
MI6RZ:5O7'/HR]-7>V*.6RR]ZF[P4'SF+TY3'DY71!B:Y3S=[(G4.EO-+^5RK
M_LP7WWNDDLJUYV-7]L5&6 +PQW[JQY>?^_K7EM?.G^X> .P3.\3O:@(@? ,O
M[ Z;"ZAQ0/D. QP:FT6E7!W6--P]0M(G]L';%YZK(XXZ^O$CV&@S/%>'EV.:
M'G44S9X]=D$_W@2 F0*;!$#*UOZEO6/V5\HU"8 #@<FT>O7A.760G_N!Y?*-
MV\L_^S>_O?SJ[[RQ7(_O8 F  &W_OCCA#23,8(#3W$A_P(=3:0&'+N*BTL)U
M=,KIIS7ZZ58+K?RTUH5^Y!(NNK0L]1(A;6N#SD%/?=%WWU-#?:YN;)T&V86V
ME7N6Q*C?;_(+W').KA4V9?)9'LHU &ZZ5)RH#VTZ(S9E&J3E*'^TCOQ6@6M@
M[5?]'5W;0++*>OK.9T*WRN44G;H  Y9<';F8.@<__=JC0?5&I_@ DU_EX1QK
MW_J\YW)9N2;!5=1S;JW_*Z1,GX)/9?*[LH0W@[OB/G2'?]\K;.EWZ;,I-[8J
M?8\/%4CS;7@"BE8=,7Y SB!<ZZ[32Q)0Y$3=K;]W)U#EVPYN-^WP2=B>R Y9
MX8,H8TD=4G@:C]IHN/Y_Y!%L]-K,F&%SP3.?#I#2<P9VBG_]U)OP@KNC0\1E
M8I:I2[]J-P+C1[B$/SRWZ2-?B2^?QGJO_-)^#6];RCDC_-Z )=D<GZ6\/CQ<
M6YVV) '86OUUSW/D!!QT8&?[Y#K].C.?)QY2%AVZ?T9]#?#I^\CL)#/&)W/R
M'_BX!L)F$_3HE_2G"8 @%]QX29L&3/6T,W?SG-C. ">])A$SKP?/&5CU&BSU
MKS^2U0WNP:&/\3'A#:J&7V96]=C>T&1SK7Y>GI/869.]C8OHSM0U_>*'[ T,
MTQ\XUW[A:5]'[PX^R1M=G5@H]1O,6S=M5W[[_KW.:/A;_]U_W[8<>W[AS_YR
M=$LJ1M -$C6R(A;Q6C"_4V<8$/'=GVL?W<OUS<\<.I-G RC&Q]CJ[)W4Z:CR
MUDGU;ZY]?)1EBRS33DP!MHF"=VO_Q$_\Y/+5KWXE2-NW7+GT]G+SVK5FJV44
M(5D6V"@_HG;M:0)#\%J'9@J[[/6,]$L8"#X%;<,,8 .E==TTR=,P#2)1G)S#
M3KW& OD<A]_/0)JV,3"E E^$&.P8_52"X1-'CU0Q"1 I;\KT"6*E[-[G8''=
MR&;,>*YU"OVA&+O 9HH/9BVL<?(Y(AB$X, I(<<0%%6=DORM^":0=LO<NF<J
M]Q@.>.+$=(IX'*,)(CTORR4S'J<-G+E7A94[ZB<\JW!UFEZ,-'P)W#W#4*"9
MJ?C[#QUH(J:OLPA\E,><CSHU7C9JT!@<AC;J-P6=D:IBS3^.U/DP[CFO4@QX
M#^X_6*[?OKO<OGNO>!*P4P1/+ ,PC7Y7)MWH/L=O%+QL)?X;I8EA9Q2"X4(\
M_>;@P)/UA0\>/NZ^#SN>"]R,G/4^)T\=PXW!N:2,=VW.]'IU'CX\65EX<=U(
M">?#6QQ.GTX@O]?RCS2=YO$,OEB#&OIT=N6/,HY2LF[+%"WR)#@W,X,C%&"F
M[93%'S5R*0]?^('L1E4LCX-')\<3OO7[Q/%#RX]^[4NIYT[W;3"+8$T$4:@[
M"7 ?EJ\HC+F>6@,C97JHR34)AW2\[=(.@GPS&&;J8OKTV/I.H\L#6]='459I
M?_H:)R3*B-*4G**L)WL:(Q&GCM0QSFAF(SMUK(X>OG?:O=\4.+Q"KY %\F/=
MIK=.4&$G3Q];CJ:_>X-S&V6:U4!/4)1@,F(]HW(,"+DU:OFH.*[2S'6^[>/'
MH7'XRD:37@=H=D SSN$K?2;' 3%\<ZQ!.YKJ&[I1M&2M^B+7*>T: 7*TP5UG
MXU#@X?$4+=_2'W04_%<?I1TT[/KB?)=AQC/*FO+/D!H]@D_ZZ,C164M._M6A
MOLJ\!O0XO\'&,4<3O$@DZ!F_.=DVFQ*8VG=%GPMWSA(P]>12:=$^YAJXM.=W
MRX</*^_X+WU41O+3!F_6HI=V>1XR&*J^T2%\8PVL@)U#./9!NY(AZ6_NT4MU
M LIODI&;P#+?*U,]PZ/NQ0%#<_C5]S6A-[ML&\5DJPI X:5'S5!1_YW8BP8]
M:?M@?K-IHU^# G1J>_F=9_69+72OCD1U4N2^ 6#P!+[<!%>?2Z_(@][9/3U%
M>K_RC&_27NUE?@,.9NLTH5T3K$,S5]"DCDSP!*XZ"-&YG"XT1R.O<C-*(1BM
MCL]W[7 Z\8+IXV"O+2'SN5<'Y3G>2UO*^PN@Z*AP@SQT" P"+LXKB*H#0AO+
MB[2E;QP6=%.VSRL#6!7FGW[OU09DP4_QW-KRA(-=X"/D:TX\K9\"RB-T=?0T
MF"66]5F_:E=274>"(CM-^I%9-C1PU=:DNGUX9./LM7]Y7C#7>M*G<:CP!_W%
M*9V=I<')":9/T,GL-".JDA&2&9:)!9VU9>IUCZW2?XXXG@8@O0TEY5L\GL_'
MJ:]]#80"6OLA&&UB:]$"'&Z3'PY\OE5/@KE>2WBJP66^K@&G:_W,@9:>"2*6
M/8'I0/#V8O3ES_WDCRQ_Z$>_LKQR;A( E@!X#98^:8>>QF\=73?3+!V;S3'I
MC]29^O%+=4O*P743 /D.-C)W]-C)SIZ4 - 7T_2-H'H]LD$9S[*=H#0#CB[E
MM,\F7WNB V-3\^?]W^R\V9O'3IYJW_@J!R+3^/'!CA'%F:;;A$-TT <W[RS?
M^.WO+O_JC?>6&]'SC\*GH_OV12^E/Y$AL'7F0F"#K7!*Y0_.(U*T46VI003]
M:M(U-)(<<I0&J1,Z\".\>,TS/Q+]MW=V4F/J"^X/V5\G,-3WJ-X9GF8G[,T
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$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>exel-20210101_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:exel="http://www.exelixis.com/20210101"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20210101.xsd" xlink:type="simple"/>
    <context id="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib4fd9aaa36234bf69289fc29d0946344_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="ic1de7713dd784687b13406c4c8917075_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i3034fe7f1e7741e5b7767f7a26a08254_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ibc3c42d191c44c598831337fe0fcd696_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i017544c12e89414a8fbb94db33dba5ca_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i49ae4188c769426b89292d8f4cb182cd_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ia0f75b6132534e759b7a2f8f4f543224_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ifd63dabbf6d046f6a7c8d265a33ee88c_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i9aafd53bd39d4ffc9927ea4ffcd6a8ed_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i08966774bb054fc088e3056e8afeee22_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i5b8b4097af0141c0b296cf3b6ba2950f_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i0062b098130b4f129d9e3ab3551e84ba_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-09-28</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i5cf18789764c45368c669217aaffdb67_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0fd92776c3fd4e93a43d434422c20d5d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ibf8a6adb4b164967870e4ec8b407494a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic5eee05a10d6452b9488c1814f28b285_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iadc77df98a1c43b7b450a7d15340ba09_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8951b2a4fc794481a8bec7526b2fe718_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i51f4593048134c2aae052c2684c52ab7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3e8fcb09c95f4a81a55d006ee3b40c7c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i05f1fb499cf24490b6739fd15fde0a70_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5ee659f1b4184a299e8ef1cd870aaacb_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i52da6ed6384349dab85a714e3d9f3121_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i08e75e71919b493ba1d1e2d3f874d754_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i6ccaed2e3f744d798f678ef8e8f549bf_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i30eaa7c0999b426ebb923dec46907033_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="ibd2971170a1e4aa7b66cf3c6bff48467_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i452886d25bad4d378ac6e98c1cbf46b2_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="icdfd210ed07043f6a95731b55f3bff0f_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i6f9755c807a24f8cb306629ef867b038_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i884c78d408784785ad24fc34a5d0c20e_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="iaf0a67523fe04dd69a9519798a6eee12_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i2c9376ae494c4c59acb1a1ea66a6591b_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ie30c343186df43e1b9b015ce00d68641_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i46a1936b47924d069d3624adfa0f5429_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i7de1f6ea286142e1a15d7747bbae50f2_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="if4fbc439858a4ae4bbb8754989dd1aad_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i64bf936cf9074f0d908fdc47b6f7a66d_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i42dc949dd41c462aa7f7f0448c9e0258_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i8532508de83a49b88e77f0e2c020cf28_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i558c4cfa6cb240c793e2ddc4e22b9288_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i84c6817fdc914e70b2207f8d04c39cfb_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i5aaae69174fa4f95900ea3fcd832f187_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic8bcdd3025c0460d83a19962b5f3e147_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6aa081489d4f49229307745612d68ff4_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i70d57544c852419d89d807ca969cf9dc_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i05ae6057ccd8434a925a70647c5631e9_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib8f792de05b44b5c9f144e5e61238bfe_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i8a33372a3f1347209075c0020d6bc068_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">exel:FinalCalculationOfBrandedPrescriptionDrugFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i68ed0b3579a44a409ff3f00c4b884aa2_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iec86aacc21384a4996d1876a8cb648cf_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ie579a8fa324847dabc4b5225b2c0c290_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i1461cd4bfd3c47c3967b22b8dfbe9be7_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ib990f420d40b4a3789297972cf1c7e68_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i73502ab4116542529d603ec4cd2116b8_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="if458bc56436a40b686b3ffa6d5c137e1_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i2ca0bb3135aa44d8bd3287f9952cab2f_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i1493217f6b6d4b069dce0c3795c0b005_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i67f9d798ccb34676b3e9f4fa0c493d84_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i3c6f0b98ffb341dcbd502a864903e546_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i10483cca017b4a299e08efb033233f44_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="iaa643e65f4a54355aecef91480e17f63_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i670b9bb21b274bf1a4d1c34421fc3303_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i88900c20d16b466197d1afc11b84f873_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ibaa2590ddc5b443eae95962cb972cbdb_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ib16eb294fd16430ab148fb14f058af49_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i8836d60836b24ea9a6548c71ad67321d_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i0be59e66b12446da9b1ef0b4f3d06cac_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i2bc1d30b7d3a4f06af43da57ce01f0d0_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i31bb491021104aef928b3404ad05a9ff_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i5b5a944195d8434c8b42f2f1eb355ef6_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i9df29850b2244253875bb007d882a698_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ieb1450fd8a55400fa9281132060b8fcc_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="if81951ec5a864326b312312ad51008a9_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i18d9b118c50947b99a376ebee947e030_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if5a25303cb764f61869e826e0f35954d_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="if4ca2a47a8b64d7ca69c61e19f993397_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="id1016e220053480cb358c5dc63979dcb_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ibcf42c7314ce4ba9a503ca92535ee0e1_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ia7d5dbf6fabd4ed8b76f6fac38c3a1ac_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i1a7007d99a1d42f18d5f5f017813107a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib39c621c29354744ba506f00b8b68407_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i14840edd307b453b8993c676800c743f_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ibcd263e91c514880aab3ad046d770b1a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="idfce732a0e594583ae51712fb488f5f1_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ibc8d4270737e40e39a71be8687219600_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="if76434a400d24ae7b1196c9db3361389_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i18ed95db610746868908b7b47b43533a_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i70f8ef5fe5f34df2867857968fdd5135_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="idddf53d05cdc4b41a5f8f99bc44c6c7b_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib1ba8f2854a74c39969dbab674b0387f_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i927f62b2ab254dd19dcd6f11991f1c06_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ia435deed54c84325b684daa442718f36_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ia1b0da10f24b48bb8d2940b955a6c0e4_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ib930a4d0eb864dda920bd8ef624bdca7_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ice8e7eb846bd436b99ddee2ea5d4de93_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if799ebcc579c4d499fe23a1a040367cf_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i28dd4195ecbd4524a57b68e9b5121e06_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i703818facc0749cea8bf6a915c610cf2_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i972f61963894489d8bd8d96975249ff6_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="if514cdad25cc48d282b48650879ae9b7_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i18681346850c4142b0cd3f7611f296f7_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i569e8490f11c4c2397bf2fb735ab9284_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i068e290e4adf43a6ae27c34e6c1a6b8d_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i0014908918c44efd817e3fd6b0997259_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ie7037c5690ef4f0eb73f27b75981598e_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i588f2ef914e74116ac5406f6a9c01b36_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i8c5ede1c91f84818b0783db0bb304518_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i40b5a386ffe8410abe781ee1be62b794_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i41ebfdbd93854a33891fe6df6de3c3b6_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i2a7cfa1b7a7f4ba38dc76cc810d3400d_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ia9c97e81888f485bb64fd4ed361390ac_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i485f8f534a3b4af3bbd86f765dd82388_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ic4e2d4955acf43d8b9d5c3180cca3657_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ib9d678bb169b48699b45ef9f3a5ee83a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iac85cedb1c81483cabfe7f110f14f7bf_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i3448dcea3614442a9a77d8d52fcb6e28_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="id261962031d24c9c96d500feae66c4cb_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i3edf5cd51c4c429ca9fd36162d5bfb83_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i175c1256c42e4ceb969e04284a7f0b85_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i6e51030563a74e4ab6a25f0c1af5638f_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ifbfee036b7344af7acf82053445607ff_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="idbb74c8b1eec4b309ba8b185f47e746e_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i798095a51aa64ee99fae753389f50df8_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i9b3a269af46e46d4ba478888e3772c6b_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if7aa81d937ec42618a7404c5d7df25a4_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ic048c678e69e4a2696e357c75149ef17_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i647bc5092dce48c290e3e40bd7a16822_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i98980155e99342fdb4084a583ee15d45_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i6a84efaf8d1449868eee0a1f360e49d0_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ife1791e1be864b11836b55144b0c084d_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i73471fb9991d403ba0e68dd720fe1b50_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i4c7b509b13bc4e9d939f403b1f05c90e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ie037b8583ad749bc9122949aec189228_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i5718b7dcecd84defac7a854084c0bf25_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:InitialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ice580bea9a0e497face411c0858d3839_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i26c711accea64d95bdd1a6048b3bc497_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:RoyaltyTierAxis">exel:FinalTierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ide639614f81d4101bd26fa5346aa6494_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i10e2147b6a2c4b3e97bebda7cfdbb8a8_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i69c49af6cac24b6aaf78ac9bf15ebf13_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i59310ff945004ea6a249b2f169b44e59_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="id2ffb053e94f427c97510610790a7fa1_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i9f066209f19547159b014cc341b71222_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ib6abb9ba6ee941bf966fb2b8bdb7c6eb_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="id33fe3c37c9e4d0e83192b2e14809965_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ia166fd55b459460880c354bf9715e1c8_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ib55343bda1c447eaaec24e61aced15a2_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ic4da49014e834ce4a25784b67ff9a020_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ie33ee4113b464bb8805d9fd13ec03adc_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i6ccf4e0d483843eb99b3aae67e446fb1_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ic692135e06904b4e9f53251b1bda6e6a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i12696a9f70bb4520879173dd02953d2e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i6443bf806be740278539f1341106b36e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i04d73fb71dcc4abba01472ab63322c3d_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i0b172a5ff906435aadf5f99c85c38a22_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i5706545d66894d3d921d401e933a36d5_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9ebd3eeeea5e4c2f8ffd32d9ad345d16_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:MINNEBROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i2544c6fb6a9b4a6fa37e6ca31e607dbb_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:MINNEBROMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i914e005fdf1940ce8583162f9bd6ea5c_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithCatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="idc77b7509ab54848ab388e7bd8d55ff7_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithCatalentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ie2ccf58a565b40458488b69646144466_D20200104-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithNBETherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="ib21b7306bafe44138821e7d078f9b318_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithNBETherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i6901a20ec19b4d62afcecb76296051f6_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ie1dacedabe3d4737800441a7d9194116_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i955e5bb70aeb486b8c2d62388f3e44a0_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i983d2a459669479ea167c4f7883b0a2a_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="ic9d59bfad27b4babaf33ea9828f5e7db_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2b3fd10a6b8e4b88964207e8afc24c36_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i31f84a4833d5496fafe3fb2b06ee4da2_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:AdditionalDevelopmentAndRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i18fefd085e3c45968805d31566f5a911_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:ProductCommercializationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4bf737b2abae44928037ed75a133e223_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithInvenraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:DiscoveryProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i81c0e0276859476d8764f5e4a7c6a702_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ia5be837eaece4b1e827b2ac075babd6c_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementWithStemSynergyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:FirstProductToReachMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i17d081623400481896632ff697c68f09_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7af67120954b4cc4a261206766a42684_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i719d03a237a8464abb14ec240d32bb64_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0dc5c758e799403d8bf389459a614860_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if30b2890deda415d995921e5add2f92e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i3abfb693aa34441595492bf56588fe6f_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i97a4320d1955404c9d175bf4c6946164_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i5d0a04be132f455c9b521c192c5d4816_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i4a6aa1d2955343a4891ce98d02c37c65_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ia13a4caccaf947b896a2346494374f6d_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="iaf372caf57ca4f559b15221706d0804e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ia0157be3fc964514bc2958bfb787c58a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i8fc6a38873324d77a83f8d597f112838_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic0eaa96e028b4053b1efe87fba0c9717_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6fc2641cbeaa48948ef1c5857c38598b_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i069a49e8f5be408d82aaa57b1a6719ac_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ida017550b79b42f19804feb9178fe6eb_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ia4d1bc6310d94e49a10dfa40633813f8_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0d9fe388a10f409382aa696ce09464b2_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i20ed515384c7421c990b3a08dbbd6099_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0c49a80af73c4beba087da528040761f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6c0f3562ea854a648ae333d957392a30_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7639ff188d85446bb4eb34d103edacad_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i4d5ef12d4ebf4f4cb3fc541d5b53ab44_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i2ad45f83363a4cb8a086062be42c031e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7a1df0270288443da1ddfde204282b4e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i92e63c05de294a7cbe329b32c4008c0f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ife44d28f1dee43d38997d75f2a09fa60_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i986255f527ad4a68a1be4173bed991ad_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i85c8c3490b0545f487d8a0d33ebd6813_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i35781ca0758f401a8c144a5efb7fe50c_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if18b5f0c5ebb43f6b8c762bf61f6bda2_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ibb849f127a4644bf8dcdc6b5433726b0_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i40d84ea6c5fb486b9667f60233ed45e3_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="id7119ffed0114f1ba08264ccb9cca54b_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="if934e0098e2b485187fb3417498f8c7f_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="icc5bb0744d9e4ad8afb77bb50648a4eb_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i39b2e5c3b01d455c8647c0de87550b58_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i8094749dc1cf43faa8d4a49cc37284a4_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="id214d22093b342b5bb46f742fa9a8d1d_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="iaa35986fd3ca43b8a2ae20dce6d9597d_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i402214e5b6cd492ea640e28a56b8c84e_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i7cf947a15c2442f7b9c355990703eea0_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="id59418bb9d714b4aa3e6fca17c908d91_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ia39618bc0e2441e6a4d20c14598583b9_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="if21e1073886448ea9bd7d5e0a33dfbf3_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i6557679589e544abacc2ec388a331430_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i1c5519e86b5a4926b1ec10602426647e_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i62e1b62fcdc14ca6a9f31d5d9be0052f_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="icac617d311944d31900ede53774bb2e2_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6a8ac00f5aec4ccabaefa0b0d9356610_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i838461c261004859a7bee283a1308e10_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i84bd021da59c4253a45563017be7db6d_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i860abaa1da4847479d900fa60c22e404_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ibf6cf0349c204074bedad9d2664384d1_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i3b8747a320f44fe4a77fe534734d347a_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i4d449cb77a0446d693fd6c3747eba20d_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i7f0498a995a2400bbec4140ae912e037_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0e0bd3de5abe4d67bbbb22990c63c5a0_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="id5915973202f4822a05789837fd15e95_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i9908b52633254703886d1ac7263e2148_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i29200dad69e047a8b7cbecb940c93115_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ie1bacc0a00bf43eba9ebd3d73dc83589_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i6f71d3e4f66641b59129ea1f7de0d2cf_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i42ce43d4b56040f2843d79745b7c30b1_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i311c3d1a54394d4a813f2d882cd22021_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iee23e46acdf243f48669d23de632fc77_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="ib25087bb5db74d7892082c9d2e8abbb9_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i820a33ad0ad94d8bafca231d31e69e59_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ibd1cc29eb8f243d28b13b3d0dca0006a_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i986427a5d3f3498d96c6bb4bbd51dfe2_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i44d1190b6c354c31b284d1b82fbdecea_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i7bceefc7e604400898f9025b1854d66c_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i1948960d554e495d831941884b909a9f_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="if16546baee294f93bd2321559abcd2b2_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i848fd90527f24228a2613e80e7e75990_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="iea1e1804983544d4b95b89863885736c_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i4e926b7757e84307b3dcf2ffb4e5018e_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i387d9657f5c347799d82def766e2b85c_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i30cc87f6da8e43de85cc36cc45397719_D20200520-20200520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="iff59e3f4289c4d0ab16af9324d631d8e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i46ce9985487045a6bbff1b6565bb56c1_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i8b8d59c75c8249ba84de243ad87e2493_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i49dea6f971c2436c9436d84debc9c88a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="iaccd048b7b154d2f9b562e5fe5bbec80_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i474cd4190d014fb9afd7d07dbde355fc_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i44f2592c3afb4c108a552d2de2e9f677_I20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="i9e626170338d40c684a71ad8956f3dc8_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0ed65fc14d1f42458a26dcd149381df1_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i630c039e42614958998ad44ba50df6a3_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="iecd5c77b48af4ab390becbba00955ec9_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i48fddf5f44ab4d8295e428acbb15cc42_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="iae79675a497d45819d1a3047a416388b_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6987ce3f2e0b4c65ba714f40a364ffbd_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesClinicalTrialResultsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i4cbb645856904aa9809681fb8a88fa50_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i4d6b47f808c84efd8f867da26a8406f6_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="i74084a38afc04950ad513c20f60c8d62_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6aeea19c58964ece8f259c21248b26ca_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ice8b3be356ff4b8c971e27c9baa061e5_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i22de33cb9fa4466693147fb2b3a08fde_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i0f1e640f034c4c9a8c524f75ba45a4ab_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ibdd294e2e4ab4132b8b50c9a18c91bd6_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i728bdf824bce4e3a8e6c9be0a205fc81_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ib61e2f06dd994f53bfa706d07d66963c_D20181229-20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2020-01-03</endDate>
        </period>
    </context>
    <context id="ic36021c41bb5446e8080959a3441b6a9_D20180101-20181228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="i2793983ce6e243b5ad8af2ec5ec6c289_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6703fce613684225b4063ab7dc405264_I20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="i655272f3bcac4b5e8db4788f93444fb2_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i4a3a848bbc8a48e9aa6faab6645fee01_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:HeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i5942d56a0a5c4771a6eaf148a1122cca_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="ie2db56eb211748d2a452eafb230ca08e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i60096daf93c14de585b95a04778a59d9_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i19a576c9dd734120a4d6a896a2880fb4_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-07-04</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i9976757837ac4b5ab75920208383f366_D20201003-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-10-03</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="program">
        <measure>exel:program</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewal_option">
        <measure>exel:renewal_option</measure>
    </unit>
    <unit id="usdPerSqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF80L2ZyYWc6MjdkYzE1NjQxOGE3NDE2Mzk4Njk5YjEyYTNlMGNmMjMvdGFibGU6OTgyZDAxNDMxMGY3NDMzN2IzMzQ5Njg1YTdkNTFlZjIvdGFibGVyYW5nZTo5ODJkMDE0MzEwZjc0MzM3YjMzNDk2ODVhN2Q1MWVmMl8yLTEtMS0xLTM5Mzg_8804e1ab-67a3-49b3-9e18-0c0be76811b6">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF80L2ZyYWc6MjdkYzE1NjQxOGE3NDE2Mzk4Njk5YjEyYTNlMGNmMjMvdGFibGU6OTgyZDAxNDMxMGY3NDMzN2IzMzQ5Njg1YTdkNTFlZjIvdGFibGVyYW5nZTo5ODJkMDE0MzEwZjc0MzM3YjMzNDk2ODVhN2Q1MWVmMl80LTEtMS0xLTA_d894cb1a-7bce-4a47-b4ae-f8b8dd671e25">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF80L2ZyYWc6MjdkYzE1NjQxOGE3NDE2Mzk4Njk5YjEyYTNlMGNmMjMvdGFibGU6OTgyZDAxNDMxMGY3NDMzN2IzMzQ5Njg1YTdkNTFlZjIvdGFibGVyYW5nZTo5ODJkMDE0MzEwZjc0MzM3YjMzNDk2ODVhN2Q1MWVmMl81LTEtMS0xLTA_823f0c2b-1aed-4947-afc8-48511c2f3006">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF80L2ZyYWc6MjdkYzE1NjQxOGE3NDE2Mzk4Njk5YjEyYTNlMGNmMjMvdGFibGU6OTgyZDAxNDMxMGY3NDMzN2IzMzQ5Njg1YTdkNTFlZjIvdGFibGVyYW5nZTo5ODJkMDE0MzEwZjc0MzM3YjMzNDk2ODVhN2Q1MWVmMl82LTEtMS0xLTM5Mzk_23bc055b-40ab-4422-a7c8-629bd23f66e6">0000939767</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_4bd66db9-0068-4d77-8491-049fcf2c6704">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_a8b46ed7-baae-4463-b21f-4d4716438745">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDkyL2ZyYWc6N2U5ZDViZTU3YzkyNDQwYWI5NjJiNDY2N2EzMTU1Y2EvdGFibGU6ZDliMzdiYjQ1OGRiNDFlNjlkNzY5OGVmNmI1MTgxZDkvdGFibGVyYW5nZTpkOWIzN2JiNDU4ZGI0MWU2OWQ3Njk4ZWY2YjUxODFkOV8xLTEtMS0xLTE3ODI4_33e972be-7643-4af4-9b17-0e9a5a58c256">us-gaap:otherassetsnoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDkyL2ZyYWc6N2U5ZDViZTU3YzkyNDQwYWI5NjJiNDY2N2EzMTU1Y2EvdGFibGU6ZDliMzdiYjQ1OGRiNDFlNjlkNzY5OGVmNmI1MTgxZDkvdGFibGVyYW5nZTpkOWIzN2JiNDU4ZGI0MWU2OWQ3Njk4ZWY2YjUxODFkOV8xLTEtMS0xLTE3ODI4_e1be24de-1d1f-4569-a6d0-20d08ca7d5db">us-gaap:otherassetsnoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MjViOTBiYzRkMDM0NDU2MDg5OTcyNjBlZGU1YmYzMmIvdGFibGVyYW5nZToyNWI5MGJjNGQwMzQ0NTYwODk5NzI2MGVkZTViZjMyYl8wLTEtMS0xLTA_407d3e23-7029-4182-9deb-37f14964955e">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTcx_5aa169d3-0638-486b-9896-f33afd6fd8c1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8xOTY_8100a2d3-9ba1-4fd9-9098-70fe8c8351e8">2021-01-01</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8xOTY_9c6dac3f-b525-4e0f-9efe-d3bea642f12e">--01-01</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTcy_335f9ddb-9cde-428e-88e2-eec39f909924">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMTc_1a2d546d-3753-48fe-961c-158fc7912210">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6YzhhM2YxYmRjNzIwNDI5M2JlZGUzYjZmNzZjZGU0YWUvdGFibGVyYW5nZTpjOGEzZjFiZGM3MjA0MjkzYmVkZTNiNmY3NmNkZTRhZV8xLTAtMS0xLTA_77d5e7c6-3066-4d92-acf1-94b4ced29d83">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTE3OTMzZjM5OGMxNDhjMjgxNjdkZWM3NjcxYjRkMjMvdGFibGVyYW5nZToxMTc5MzNmMzk4YzE0OGMyODE2N2RlYzc2NzFiNGQyM18wLTAtMS0xLTA_c5ce9fca-b881-4ab4-8bb4-e8a809329c4e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTE3OTMzZjM5OGMxNDhjMjgxNjdkZWM3NjcxYjRkMjMvdGFibGVyYW5nZToxMTc5MzNmMzk4YzE0OGMyODE2N2RlYzc2NzFiNGQyM18wLTEtMS0xLTA_9efb2cb6-39dc-4527-8b08-4befb52d5a16">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMzA_17a5e658-9e17-437f-b89a-87dd55737cfd">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMzQ_cdebb02a-9d05-42db-9016-aed081d8ee69">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMzc_88360484-4923-49aa-a7de-e105fdbd9f56">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNDA_c5c79ba9-0c1e-460d-88ad-2382bbe54af0">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNDU_99885d73-6346-400e-ba99-a3cadf86b219">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNDk_d6e82757-08ee-4603-bf82-4a14bb9e6bab">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6ZTI4NGFiYWIwZjQxNDkxYWJiODc5YzBlNjZlYjk3NjMvdGFibGVyYW5nZTplMjg0YWJhYjBmNDE0OTFhYmI4NzljMGU2NmViOTc2M18xLTAtMS0xLTA_d90ffebc-39fc-4c63-8aec-a784758019fd">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6ZTI4NGFiYWIwZjQxNDkxYWJiODc5YzBlNjZlYjk3NjMvdGFibGVyYW5nZTplMjg0YWJhYjBmNDE0OTFhYmI4NzljMGU2NmViOTc2M18xLTEtMS0xLTA_8ef824db-5e98-4e9c-9bb2-34b806d1d9f0">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6ZTI4NGFiYWIwZjQxNDkxYWJiODc5YzBlNjZlYjk3NjMvdGFibGVyYW5nZTplMjg0YWJhYjBmNDE0OTFhYmI4NzljMGU2NmViOTc2M18xLTItMS0xLTA_b9bc0129-342d-4be7-9372-68cdc15670a6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTcz_71364c1b-fe65-413d-a735-353a01310cb4">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTc0_93e54b47-11a5-450e-b552-c87a3d872442">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTY5_a71c78a7-a219-4b45-a6c7-6af1ecb0faeb">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTY2_3325aacf-b662-4734-9618-f38ed6b04008">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTNhNjg2YmNiMjRhNGI3Y2FlZmU4Y2NhZWE1OTQ5NDMvdGFibGVyYW5nZToxM2E2ODZiY2IyNGE0YjdjYWVmZThjY2FlYTU5NDk0M18wLTAtMS0xLTA_8e3225ad-6b4d-4b5d-832b-4ddba4ced85e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTNhNjg2YmNiMjRhNGI3Y2FlZmU4Y2NhZWE1OTQ5NDMvdGFibGVyYW5nZToxM2E2ODZiY2IyNGE0YjdjYWVmZThjY2FlYTU5NDk0M18xLTQtMS0xLTA_ac268a1c-cf2a-49f6-9a28-be2a8bcf8001">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGFibGU6MTNhNjg2YmNiMjRhNGI3Y2FlZmU4Y2NhZWE1OTQ5NDMvdGFibGVyYW5nZToxM2E2ODZiY2IyNGE0YjdjYWVmZThjY2FlYTU5NDk0M18yLTQtMS0xLTA_a922d05d-9c8b-4c0b-bb83-5863410e1f7e">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8xODE0MTk0MTg2Mjc5OA_b89cf926-5220-4705-97f3-97b24bcc3fa1">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTY3_9941c610-3c47-4de3-b210-bddadcb7ef2c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ib4fd9aaa36234bf69289fc29d0946344_I20200703"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8yNTk5_f942afee-00a1-44d2-93fb-42dc0b46d0f3"
      unitRef="usd">6399562142</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic1de7713dd784687b13406c4c8917075_I20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zMTkz_0512a829-8d69-47d5-90e5-fc968c0f6bf6"
      unitRef="shares">311989661</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xL2ZyYWc6OTM3M2I1M2FhMzY5NDMxZjk2ZmU1M2I5YmE4NTY3MTAvdGV4dHJlZ2lvbjo5MzczYjUzYWEzNjk0MzFmOTZmZTUzYjliYTg1NjcxMF8zNTY4_e31e128a-46ff-48e8-8622-c292f59e64f3">Certain portions of the registrant&#x2019;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than May 3, 2021, in connection with the registrant&#x2019;s 2021 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNi0xLTEtMS0w_f55d3bca-eb7c-40db-9c5c-ed7a2f302c81"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNi0zLTEtMS0w_6cbaa6f1-b4f6-45ea-ab22-e2cdaeba975e"
      unitRef="usd">266501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNy0xLTEtMS0w_a132d08c-c6c6-4b83-80e1-8c36083c87e5"
      unitRef="usd">887319000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNy0zLTEtMS0w_b37729ca-5bc5-4876-ae08-bf8d43390f3b"
      unitRef="usd">585742000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfOC0xLTEtMS0w_1d7f1604-3f10-417d-a485-cf27b75355d7"
      unitRef="usd">160875000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfOC0zLTEtMS0w_8207284d-3a5f-4310-a2c5-13531a3d0b46"
      unitRef="usd">119073000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfOS0xLTEtMS0w_6037a375-c925-4ca7-842f-e0ba0b8f159b"
      unitRef="usd">20973000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfOS0zLTEtMS0w_26526bd8-2f34-4aea-b4ab-d96b92e2bb83"
      unitRef="usd">12886000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTEtMS0xLTEtMA_da427be6-6e4e-4ca1-b516-a548fb05de6e"
      unitRef="usd">57011000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTEtMy0xLTEtMA_fc1a9b3e-3420-47f5-98bb-0cdb65e8d254"
      unitRef="usd">26988000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTItMS0xLTEtMA_d2624911-cb30-4fa9-a5ce-24bba730a5b4"
      unitRef="usd">1445395000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTItMy0xLTEtMA_69ba8570-78e0-4093-a57c-010cc99dc3ce"
      unitRef="usd">1011190000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTMtMS0xLTEtMA_b691be1a-b0f3-430f-92f0-4aeccf1b0684"
      unitRef="usd">332306000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTMtMy0xLTEtMA_cdc3aa4f-489c-4c15-ac36-b9c67994375c"
      unitRef="usd">536385000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTQtMS0xLTEtMA_8a8cc335-6a3e-473e-a997-94e84d6a9e66"
      unitRef="usd">67384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTQtMy0xLTEtMA_87405877-8155-49bc-8ba7-bf417a86ae33"
      unitRef="usd">48892000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTUtMS0xLTEtMA_7ed10690-82f0-4303-b020-7787fb67bef6"
      unitRef="usd">156711000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTUtMy0xLTEtMA_92b2e77f-4e4a-47f9-afc5-d6e9841f70ed"
      unitRef="usd">172374000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTYtMS0xLTEtMA_d5bfe52f-23ee-48af-bdf2-fecb10a70f08"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTYtMy0xLTEtMA_9cac92e5-1d3e-48f2-9c8f-e52e4273c7df"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTctMS0xLTEtMA_07f2f529-ce10-4068-b9f8-c5a4c30ff7eb"
      unitRef="usd">71853000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTctMy0xLTEtMA_1bf86256-82a4-4e69-ad77-c9d8a345272b"
      unitRef="usd">53145000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTgtMS0xLTEtMA_374d9112-76cf-445f-a42d-f0cd6dd36614"
      unitRef="usd">2137333000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMTgtMy0xLTEtMA_91bfc0c8-d9ac-4d23-9531-eb245eb6bc08"
      unitRef="usd">1885670000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjEtMS0xLTEtMA_003d53f8-2724-4d17-92a4-7c2d34772e22"
      unitRef="usd">23632000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjEtMy0xLTEtMA_461ce639-60df-4f4e-b3df-6f9b1ca80f07"
      unitRef="usd">11581000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjItMS0xLTEtMA_de873365-67e2-4884-99b9-fe804ae346a3"
      unitRef="usd">51189000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjItMy0xLTEtMA_1f6d1082-0fb4-4e00-84bb-4fc4ab560a68"
      unitRef="usd">37364000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjMtMS0xLTEtMA_1e2a2ae4-e1a1-48b6-8cb5-130424e4adaf"
      unitRef="usd">52251000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjMtMy0xLTEtMA_692a55e3-f7ec-44fc-b5f7-478b0c03b6e8"
      unitRef="usd">38777000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjQtMS0xLTEtMA_4cdc4e75-b69d-4132-91c2-946ca2dceeea"
      unitRef="usd">20683000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjQtMy0xLTEtMA_fcfec1d9-03c6-48c3-923a-1b42f998384f"
      unitRef="usd">18719000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjUtMS0xLTEtMA_1c4792ef-c31f-4992-8b74-4b34ed06c020"
      unitRef="usd">12456000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjUtMy0xLTEtMA_56b25c1b-c6d6-4909-8e03-254bb3fb9528"
      unitRef="usd">11856000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjctMS0xLTEtMA_e180e064-3606-4826-a9ea-cda2d8c51f60"
      unitRef="usd">44447000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjctMy0xLTEtMA_cb7229b7-b1fd-4907-b46e-f674b38b1b99"
      unitRef="usd">24449000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjgtMS0xLTEtMA_d017bd15-719e-4e3d-85b2-c14b79f057b0"
      unitRef="usd">204658000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjgtMy0xLTEtMA_3d25c362-748b-4af3-8876-ba79f0911a0a"
      unitRef="usd">142746000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjktMS0xLTEtMA_7986779c-7cdc-439f-8ed4-061806212126"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMjktMy0xLTEtMA_2ac63b9d-5136-4769-b837-8d0802ed6db6"
      unitRef="usd">6596000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzAtMS0xLTEtMA_26aaf161-b159-461e-a9b1-c7392ff11c13"
      unitRef="usd">49086000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzAtMy0xLTEtMA_11bba8c1-edc1-4b29-9b21-74215aa31f0f"
      unitRef="usd">48011000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzEtMS0xLTEtMA_d57307ca-d078-4bd8-99b7-6374c9b14618"
      unitRef="usd">721000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzEtMy0xLTEtMA_32cf5c6c-4d31-4fcb-b4e3-5f2efe1eff9a"
      unitRef="usd">2347000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzItMS0xLTEtMA_2829dd98-f18d-4f1c-ac25-5e8fb65316b1"
      unitRef="usd">258220000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzItMy0xLTEtMA_ee49e719-c4c7-484a-b6f8-a99f83d097b7"
      unitRef="usd">199700000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzMtMS0xLTEtMA_848deaff-4493-4961-bb21-cb759c310124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzMtMy0xLTEtMA_e72b3eb1-45a6-4896-bb0d-a5e9fa18f752"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2MzQ_479c21e0-fef2-4a9e-95f6-3b16ebe95d2a"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2MzQ_5d196ed2-1c60-4666-906f-d8c6a23f1087"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2NDQ_2496802b-c1a8-4866-828a-4598b55c3279"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2NDQ_68153813-367e-4f20-958b-7ec703ea3c01"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2NTA_659b42fe-d03e-4557-8e34-027a4cf927f8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjVjMjFkNmFiMDFmMjRjYTY4ZTI3MWMyZTY4MmQ5ODNlXzcxNDY4MjU1ODA2NTA_8bbeb7fc-286b-457a-8d53-f883c35dff6d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMS0xLTEtMA_5c76a376-393c-4821-8c19-d58ee303ecf9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzUtMy0xLTEtMA_9ec9d919-f192-45d4-876c-f890f2c1abe3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzcxNDY4MjU1ODA2NzU_13136dec-6937-4bc7-82f1-47ad157a3466"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzcxNDY4MjU1ODA2NzU_efd6e78a-37d3-452a-b1c5-2a5f1e144a13"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzcxNDY4MjU1ODA2ODY_9a72b846-53b7-421c-b0fd-77736adba440"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzcxNDY4MjU1ODA2ODY_f92644ec-d595-4c9b-9529-1078e223d598"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzg4_31d80fc4-c74c-4929-89f0-d23f3f8e1e4f"
      unitRef="shares">311627000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzg4_82a70e77-e3ef-4d70-b3f6-6846117e8b45"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzk2_2f386eaa-c1e9-4a3f-91d3-8c0ec5d18981"
      unitRef="shares">304831000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjMyZThkZDYzOGQ4NjQxMmZhMmM1ZmM5NDYxNDNiM2ExXzk2_926f9f70-5762-4e92-95b3-d088ed3eb384"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMS0xLTEtMA_d57ad19c-e90c-47d4-ac63-a9309ec6a301"
      unitRef="usd">312000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzYtMy0xLTEtMA_0da66c61-ccc0-4ab9-8097-a1d06071d613"
      unitRef="usd">305000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzctMS0xLTEtMA_b6923014-60ae-4f93-8b79-6f7448dd8330"
      unitRef="usd">2321895000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzctMy0xLTEtMA_06999d8d-7547-4a2a-8bd1-4555288343df"
      unitRef="usd">2241947000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzgtMS0xLTEtMA_cf88d808-e8bc-4d43-85b4-725804542f42"
      unitRef="usd">4476000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzgtMy0xLTEtMA_af31c21b-9f3c-4efa-a431-ad910b1281f5"
      unitRef="usd">3069000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzktMS0xLTEtMA_67aa5280-a6d2-4aab-892b-2cbf4fb3693b"
      unitRef="usd">-447570000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfMzktMy0xLTEtMA_44803d55-dc21-47f9-bccb-09868c5f25c8"
      unitRef="usd">-559351000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNDAtMS0xLTEtMA_8c4b24b5-c12c-4e0c-9d7f-1a445f15c1c5"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNDAtMy0xLTEtMA_1fbfacaa-119e-4336-8f8d-0eacd13850fb"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNDEtMS0xLTEtMA_26806cdd-bae0-42c3-998d-f5607283c140"
      unitRef="usd">2137333000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF82NC9mcmFnOmM0YzJiYTMwNjExODRmYTk5ZGY0MzE2Zjk4YzNjNDEyL3RhYmxlOmI0NGRkNGRlNDA2MDQ1N2NhMzg1MmFlOTI2ODBiN2M4L3RhYmxlcmFuZ2U6YjQ0ZGQ0ZGU0MDYwNDU3Y2EzODUyYWU5MjY4MGI3YzhfNDEtMy0xLTEtMA_c95a007b-cfc3-499c-bc36-473446a9831a"
      unitRef="usd">1885670000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc3c42d191c44c598831337fe0fcd696_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMy01LTEtMS0w_0b9dea40-7200-4b35-9fc6-d650d6464035"
      unitRef="usd">741550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i017544c12e89414a8fbb94db33dba5ca_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMy03LTEtMS0w_581a2c31-2fe7-4480-948c-ccd1a271fe48"
      unitRef="usd">759950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49ae4188c769426b89292d8f4cb182cd_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMy05LTEtMS0w_fee54294-4ac0-4f82-87a8-88e544e39e0c"
      unitRef="usd">619279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0f75b6132534e759b7a2f8f4f543224_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC01LTEtMS0yMzcx_dab3a4ce-f44c-46ff-91ad-a35e486add4c"
      unitRef="usd">167295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd63dabbf6d046f6a7c8d265a33ee88c_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC03LTEtMS0yMzUy_351635b6-70a3-44e6-a9a3-5781fabcfbea"
      unitRef="usd">165914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9aafd53bd39d4ffc9927ea4ffcd6a8ed_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC05LTEtMS0yMzY0_c57fd49f-ce7a-442c-9004-d70a2015d100"
      unitRef="usd">200272000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08966774bb054fc088e3056e8afeee22_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC01LTEtMS0w_7778ef7a-460b-4fc3-94d4-e95458f9b478"
      unitRef="usd">78693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b8b4097af0141c0b296cf3b6ba2950f_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC03LTEtMS0w_6711a4ac-cf56-4da3-82a5-090f7f338b1c"
      unitRef="usd">41911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0062b098130b4f129d9e3ab3551e84ba_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNC05LTEtMS0w_a0f5a8e4-e451-470f-8256-7e11d2f45f76"
      unitRef="usd">34275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNS01LTEtMS0w_6b482854-1188-4765-97e5-c57cbba1d6f2"
      unitRef="usd">987538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNS03LTEtMS0w_8a1b5165-2f14-40d0-b234-e1e3adec99ed"
      unitRef="usd">967775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNS05LTEtMS0w_179e68cd-617b-4a44-b7a1-8e6d46261d18"
      unitRef="usd">853826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNy01LTEtMS0w_19bce8a6-00ce-4cf2-953c-0c0506d9085a"
      unitRef="usd">36272000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNy03LTEtMS0w_3a3bac7f-e8a1-474c-89ef-5e6450430313"
      unitRef="usd">33097000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfNy05LTEtMS0w_a8aa5847-27fe-4bd3-a434-bc82b7ae336e"
      unitRef="usd">26348000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOC01LTEtMS0w_e47bcb97-8311-4ca8-8a56-7b89e1077f93"
      unitRef="usd">547851000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOC03LTEtMS0w_089d8030-ab17-4b08-882e-934ac8702b10"
      unitRef="usd">336964000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOC05LTEtMS0w_52b6c1ed-596f-4ff8-bf3b-839ed1475e96"
      unitRef="usd">182257000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOS01LTEtMS0w_2955ad71-1b6e-4b7d-b233-7d8affad4463"
      unitRef="usd">293355000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOS03LTEtMS0w_a0e1857e-1bb9-4ff4-bd5e-1303028573bd"
      unitRef="usd">228244000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfOS05LTEtMS0w_f1ff149d-de8c-428c-a327-a2c2f5129139"
      unitRef="usd">206366000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTAtNS0xLTEtMA_e19223c5-d79b-4a99-85e0-51f26d5012cf"
      unitRef="usd">877478000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTAtNy0xLTEtMA_04e0869c-7d56-48b8-af73-0521f21b8e94"
      unitRef="usd">598305000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTAtOS0xLTEtMA_46c7c0cf-0519-4a35-b9f3-f57887bf32e0"
      unitRef="usd">414971000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTEtNS0xLTEtMA_48ad007c-48f4-49d2-a6c6-ddc70c14d593"
      unitRef="usd">110060000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTEtNy0xLTEtMA_20b15321-54bf-4ba7-9103-dfa54828d7f5"
      unitRef="usd">369470000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTEtOS0xLTEtMA_821411b4-9891-4a33-b7cc-9920f9805dd1"
      unitRef="usd">438855000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTItNS0xLTEtMA_6f9a1ed4-5a51-43f9-8585-032f3f1ca721"
      unitRef="usd">19865000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTItNy0xLTEtMA_afd6b480-8387-4f48-ad4d-376ff31daeda"
      unitRef="usd">27959000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTItOS0xLTEtMA_b64d99d8-5b68-4b3a-8385-2231156d0139"
      unitRef="usd">12840000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTQtNS0xLTEtMA_23c85a26-1873-4d53-85f4-4ee8b31f0f51"
      unitRef="usd">912000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTQtNy0xLTEtMA_7bc82468-89dc-4869-b4e5-33707bd83b95"
      unitRef="usd">680000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTQtOS0xLTEtMA_e75ad382-659c-498d-9b2c-173ac739c401"
      unitRef="usd">397000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTUtNS0xLTEtMA_f3c76a7e-ec7a-4d7d-8a63-e56dda90884d"
      unitRef="usd">130837000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTUtNy0xLTEtMA_7ae91f80-a6a1-42f1-ab44-2517d407f093"
      unitRef="usd">398109000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTUtOS0xLTEtMA_5372a779-e6e7-4a42-829f-a505a9f572f9"
      unitRef="usd">452092000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTYtNS0xLTEtMA_188fc480-08de-4098-a6ec-3b9855779ed8"
      unitRef="usd">19056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTYtNy0xLTEtMA_60be30a0-7973-42ab-b6a2-16da10e250fa"
      unitRef="usd">77097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTYtOS0xLTEtMA_61a427a0-3115-4eaa-9db4-eeb6458f6fa9"
      unitRef="usd">-237978000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTctNS0xLTEtMA_0233ee16-3849-4354-a1c6-7deed24f3116"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTctNy0xLTEtMA_54698d9d-355a-4983-8a78-1e4325685b13"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTctOS0xLTEtMA_71954d78-296a-47aa-b453-1c0d6fb08477"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTktNS0xLTEtMA_d28a696a-982e-404b-9143-60d754541daa"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTktNy0xLTEtMA_eaedea13-12fd-476b-a541-71b73da97e35"
      unitRef="usdPerShare">1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMTktOS0xLTEtMA_8d90e575-b48d-41dd-9977-4c71beed5244"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjAtNS0xLTEtMA_83ab8308-0dcd-440e-b337-df33ef846d21"
      unitRef="usdPerShare">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjAtNy0xLTEtMA_94f11cd9-6ec9-47f7-97b6-752ace117dda"
      unitRef="usdPerShare">1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjAtOS0xLTEtMA_c2f746a9-b2ab-46d8-b64a-24ca0e571fa3"
      unitRef="usdPerShare">2.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjItNS0xLTEtMA_e8097716-0ce6-4f71-a3e0-6d4aaac91bb6"
      unitRef="shares">308271000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjItNy0xLTEtMA_e67c9716-2eb0-4f34-a651-338315e0e5d7"
      unitRef="shares">302584000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjItOS0xLTEtMA_b988c492-8c2f-4050-a523-6faf7bafba14"
      unitRef="shares">297892000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjMtNS0xLTEtMA_6a952b94-c5f7-4c51-8bd9-5a4e71b64f0a"
      unitRef="shares">318001000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjMtNy0xLTEtMA_12226a9b-f29c-4b0f-9b91-949c8a83b5eb"
      unitRef="shares">315009000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83MC9mcmFnOjNkNWIyMDhlYWJiZjQ5YjhhZWQ2MGY3ZDU1M2JlYzZlL3RhYmxlOjU5NmQyOTIwYWIwYjQ1ODRhMGNkNzE2ZDgzYTEzMTA0L3RhYmxlcmFuZ2U6NTk2ZDI5MjBhYjBiNDU4NGEwY2Q3MTZkODNhMTMxMDRfMjMtOS0xLTEtMA_5a0ced7c-48b5-475a-bf6e-dcfde6f25b4f"
      unitRef="shares">312803000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfMi01LTEtMS0w_0233ee16-3849-4354-a1c6-7deed24f3116"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfMi03LTEtMS0w_54698d9d-355a-4983-8a78-1e4325685b13"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfMi05LTEtMS0w_71954d78-296a-47aa-b453-1c0d6fb08477"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC0wLTEtMS0wL3RleHRyZWdpb246OWE1YjZjMGI4YTQ2NDY1YjhjYTZjNGQ2MDY2MzJlMzBfMjE5OTAyMzI1NTY4Nw_87f6cc37-ab4a-4831-a9ac-46dd039d0b75"
      unitRef="usd">394000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC0wLTEtMS0wL3RleHRyZWdpb246OWE1YjZjMGI4YTQ2NDY1YjhjYTZjNGQ2MDY2MzJlMzBfOTg_5f5e6802-141e-4da3-bf7e-615b13c58aa5"
      unitRef="usd">1049000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC0wLTEtMS0wL3RleHRyZWdpb246OWE1YjZjMGI4YTQ2NDY1YjhjYTZjNGQ2MDY2MzJlMzBfMTA2_85396faf-230a-4d14-a4dc-4cc3f1e974f3"
      unitRef="usd">-156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC01LTEtMS0w_54c8e7fd-ebbd-4058-a78e-06d21372bbb3"
      unitRef="usd">1407000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC03LTEtMS0w_27fbe2d8-e631-4180-aae8-c2ff43dc0893"
      unitRef="usd">3770000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNC05LTEtMS0w_9fb53a53-3169-474a-9362-d023e3a33b3d"
      unitRef="usd">-354000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNi01LTEtMS0w_a211010a-c902-40a3-8ebe-d965e725d03e"
      unitRef="usd">113188000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNi03LTEtMS0w_9453ee2d-edbd-4694-bc16-c60a6af2996d"
      unitRef="usd">324782000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83My9mcmFnOmY3YjMxNGVjMjJmMjQ2YmQ5MjVlNDRiYzQwMDc5ZTE1L3RhYmxlOjg1NWY0MDIxMzdlNTRjZDVhNmYzZGFhZGE0OTEzMDQwL3RhYmxlcmFuZ2U6ODU1ZjQwMjEzN2U1NGNkNWE2ZjNkYWFkYTQ5MTMwNDBfNi05LTEtMS0w_12f7c916-2ea0-4f9b-96b2-e0a2c943644a"
      unitRef="usd">689716000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5cf18789764c45368c669217aaffdb67_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItMS0xLTEtMA_87a73b8c-3630-4f1d-a8f4-6d52a7d19d76"
      unitRef="shares">296209000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5cf18789764c45368c669217aaffdb67_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItMy0xLTEtMA_21e690ba-0b30-4e66-bb82-568dbd9bfe7d"
      unitRef="usd">296000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0fd92776c3fd4e93a43d434422c20d5d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItNS0xLTEtMA_f2cbc797-b5ad-4b38-8518-cf251713156d"
      unitRef="usd">2114184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf8a6adb4b164967870e4ec8b407494a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItNy0xLTEtMA_f25448d0-8d39-4528-88b1-80e3bd07254c"
      unitRef="usd">-347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5eee05a10d6452b9488c1814f28b285_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItOS0xLTEtMA_828ae86e-83b3-4622-b145-117a815ec5c0"
      unitRef="usd">-1829172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iadc77df98a1c43b7b450a7d15340ba09_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjItMTEtMS0xLTA_7c7e05f6-1fa3-4565-83c3-98ddc174a258"
      unitRef="usd">284961000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8951b2a4fc794481a8bec7526b2fe718_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjMtOS0xLTEtMA_5ad0b712-b2f7-4069-8edd-b4662fdfacfe"
      unitRef="usd">258505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i51f4593048134c2aae052c2684c52ab7_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjMtMTEtMS0xLTA_f499c60b-503a-4fbb-baa4-f4706c2b52f5"
      unitRef="usd">258505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e8fcb09c95f4a81a55d006ee3b40c7c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjQtOS0xLTEtMA_2dbc1daa-28b4-4b14-acb5-5e120c300d3c"
      unitRef="usd">234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05f1fb499cf24490b6739fd15fde0a70_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjQtMTEtMS0xLTA_c095b1aa-4f8f-45b5-9463-dfe4d4a658f1"
      unitRef="usd">234000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5ee659f1b4184a299e8ef1cd870aaacb_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjUtOS0xLTEtMA_bc97336a-67ca-4680-9b1a-7bbb9c017206"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjUtMTEtMS0xLTA_b166d20f-c2fc-4d6a-aca4-c43af3be6a7b"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i52da6ed6384349dab85a714e3d9f3121_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjYtNy0xLTEtMA_2eca4990-7251-4618-9473-3d2ee81b849b"
      unitRef="usd">-354000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjYtMTEtMS0xLTA_2adc6a7b-d951-4853-a42a-8590d6fc5fcc"
      unitRef="usd">-354000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i08e75e71919b493ba1d1e2d3f874d754_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjctMS0xLTEtMA_1cb2e95c-9276-42e2-bc43-8f2642a50682"
      unitRef="shares">3667000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i08e75e71919b493ba1d1e2d3f874d754_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjctMy0xLTEtMA_8f619186-98da-44ed-b0b2-c7dc9eb3fabe"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6ccaed2e3f744d798f678ef8e8f549bf_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjctNS0xLTEtMA_e01b8c99-a902-4aba-95ad-69e41ae888dc"
      unitRef="usd">20981000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjctMTEtMS0xLTA_1831e169-3e3c-43da-94ed-1d489b9af4a2"
      unitRef="usd">20985000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6ccaed2e3f744d798f678ef8e8f549bf_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjgtNS0xLTEtMTk4NA_d09d7bd9-edba-4010-ac97-ed66c61ea9be"
      unitRef="usd">7574000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjgtMTEtMS0xLTE5ODQ_06b05473-b85d-4314-91a8-a294f07553f0"
      unitRef="usd">7574000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6ccaed2e3f744d798f678ef8e8f549bf_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjgtNS0xLTEtMA_140daa6e-539e-471c-aa90-61f430b73211"
      unitRef="usd">40626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjgtMTEtMS0xLTA_eceb3b19-b6c5-41d9-bec2-99a0900d0226"
      unitRef="usd">40626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i30eaa7c0999b426ebb923dec46907033_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktMS0xLTEtMA_0a0ae176-e5b5-4030-8cf9-adb6d5b85a9c"
      unitRef="shares">299876000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i30eaa7c0999b426ebb923dec46907033_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktMy0xLTEtMA_e960bd59-1684-42e4-a4ae-fb9cf921c412"
      unitRef="usd">300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd2971170a1e4aa7b66cf3c6bff48467_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktNS0xLTEtMA_21594bb1-77fa-404d-b7f5-668b544a6cc8"
      unitRef="usd">2168217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i452886d25bad4d378ac6e98c1cbf46b2_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktNy0xLTEtMA_1acf5612-0a07-4b21-a1bb-d191d448830f"
      unitRef="usd">-701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icdfd210ed07043f6a95731b55f3bff0f_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktOS0xLTEtMA_c258d44f-bb3b-4467-a780-7ddec1c6bfef"
      unitRef="usd">-880363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMjktMTEtMS0xLTA_612ecad0-c501-4baa-a0af-22fedc1396e0"
      unitRef="usd">1287453000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i884c78d408784785ad24fc34a5d0c20e_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzAtOS0xLTEtMA_a63d5173-34ca-4c69-8f89-c9796168b8ad"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzAtMTEtMS0xLTA_9775e9e8-579f-4dd4-9dbe-129890778940"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iaf0a67523fe04dd69a9519798a6eee12_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzEtNy0xLTEtMA_643ccec4-fe95-41ea-8d35-7965e4cffedd"
      unitRef="usd">3770000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzEtMTEtMS0xLTA_40e2700f-f13d-4a86-a669-aced2433a954"
      unitRef="usd">3770000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2c9376ae494c4c59acb1a1ea66a6591b_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzItMS0xLTEtMA_57eecb52-d081-409b-8571-52d64e3f1f21"
      unitRef="shares">4955000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2c9376ae494c4c59acb1a1ea66a6591b_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzItMy0xLTEtMA_404e63c9-b50f-49d5-8d29-4051f4ca7a3f"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie30c343186df43e1b9b015ce00d68641_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzItNS0xLTEtMA_8d2e274f-0ca3-4933-838b-598db3fe9c41"
      unitRef="usd">27032000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzItMTEtMS0xLTA_dbc18fbd-460d-4802-bea1-5dea3e43cd0a"
      unitRef="usd">27037000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie30c343186df43e1b9b015ce00d68641_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtNS0xLTEtMTc0Mw_128bf1d6-a15e-4291-8455-433fee2ebd84"
      unitRef="usd">9904000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtMTEtMS0xLTE3NDM_71504c76-80b0-46b9-9a3a-b4cf0f391be5"
      unitRef="usd">9904000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie30c343186df43e1b9b015ce00d68641_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzMtNS0xLTEtMA_10015229-ffd9-4416-985f-cc58402c2dca"
      unitRef="usd">56602000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzMtMTEtMS0xLTA_ad7e8a9f-0311-4a8b-b1da-561de0201f5b"
      unitRef="usd">56602000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i46a1936b47924d069d3624adfa0f5429_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtMS0xLTEtMA_a141849f-08ec-491f-a7af-41ee2730309b"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i46a1936b47924d069d3624adfa0f5429_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtMy0xLTEtMA_96ee162d-17f4-4593-84dc-45eab30cb299"
      unitRef="usd">305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7de1f6ea286142e1a15d7747bbae50f2_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtNS0xLTEtMA_79f8022c-b510-443b-9501-bc128e297181"
      unitRef="usd">2241947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4fbc439858a4ae4bbb8754989dd1aad_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtNy0xLTEtMA_64359f1f-b14e-4c0c-a93f-e2b8eab532ae"
      unitRef="usd">3069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i64bf936cf9074f0d908fdc47b6f7a66d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtOS0xLTEtMA_e4568924-04b1-4230-af54-e572e60fd2ca"
      unitRef="usd">-559351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzQtMTEtMS0xLTA_ce4b2c10-840d-4933-8cbe-04e8e2326cf5"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzctOS0xLTEtMTc1Mw_0233ee16-3849-4354-a1c6-7deed24f3116"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzctMTEtMS0xLTE3NTM_3ffb3892-2695-4208-a9ac-ca410681108d"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i42dc949dd41c462aa7f7f0448c9e0258_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzgtNy0xLTEtMTc1Mw_c7b5d63f-f11b-43e2-b01e-9720cfd961bc"
      unitRef="usd">1407000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzgtMTEtMS0xLTE3NTM_01592b3b-59fb-4049-af46-dd0380119a3a"
      unitRef="usd">1407000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8532508de83a49b88e77f0e2c020cf28_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzktMS0xLTEtMTc1Mw_2c1a7341-82d1-4309-acde-64ab9873efc7"
      unitRef="shares">6796000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8532508de83a49b88e77f0e2c020cf28_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzktMy0xLTEtMTc1Mw_1dd21ab4-e49f-4649-a7ca-dc7ebf7e555a"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i558c4cfa6cb240c793e2ddc4e22b9288_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzktNS0xLTEtMTc1Mw_92710647-9e1f-410b-968c-8ff6108e7d1a"
      unitRef="usd">24896000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfMzktMTEtMS0xLTE3NTM_958ea81f-5b34-4cb5-b684-64f8a41f3f0c"
      unitRef="usd">24903000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i558c4cfa6cb240c793e2ddc4e22b9288_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDAtNS0xLTEtMTc0OA_fc762a9f-cb41-4e02-a2a2-58ea81647b9e"
      unitRef="usd">50018000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDAtMTEtMS0xLTE3NDg_6e942c00-7109-47a7-bf62-c85c8b1fa524"
      unitRef="usd">50018000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i558c4cfa6cb240c793e2ddc4e22b9288_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDEtNS0xLTEtMTc1Mw_3e46a568-edcf-4ed7-adfd-49492d5fc720"
      unitRef="usd">105070000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDEtMTEtMS0xLTE3NTM_a48b49d8-f831-4820-94db-c5a6dd48abd5"
      unitRef="usd">105070000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i84c6817fdc914e70b2207f8d04c39cfb_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItMS0xLTEtNDA1MA_5a26bc70-28c4-46b6-9105-85a68c7b7bcf"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i84c6817fdc914e70b2207f8d04c39cfb_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItMy0xLTEtNDA1MA_b37d8ebd-65ed-490e-a62f-b37f1cf75994"
      unitRef="usd">312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5aaae69174fa4f95900ea3fcd832f187_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItNS0xLTEtNDA1MA_4e6b094b-10d7-4496-99e4-23ac0e3cbf54"
      unitRef="usd">2321895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8bcdd3025c0460d83a19962b5f3e147_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItNy0xLTEtNDA1MA_466077fd-b03f-413e-a7f7-9681f8b946ab"
      unitRef="usd">4476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6aa081489d4f49229307745612d68ff4_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItOS0xLTEtNDA1MA_d5164e90-7314-4ee2-98ac-700e33e175a6"
      unitRef="usd">-447570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83Ni9mcmFnOmU2MWJmNzYyMDgyNjQ0YTE5MGE3OGFlYWZlMTZmNjA3L3RhYmxlOmUyNzIyZjk4NjA3YjQ5ZDQ4OTUzY2FjZGNhMzBlMzNmL3RhYmxlcmFuZ2U6ZTI3MjJmOTg2MDdiNDlkNDg5NTNjYWNkY2EzMGUzM2ZfNDItMTEtMS0xLTQwNTA_87394a3e-ed16-4508-b224-85b1a63f5236"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMi0xLTEtMS0w_0233ee16-3849-4354-a1c6-7deed24f3116"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMi0zLTEtMS0w_54698d9d-355a-4983-8a78-1e4325685b13"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMi01LTEtMS0w_71954d78-296a-47aa-b453-1c0d6fb08477"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNC0xLTEtMS0w_eea54fbb-a63b-4a3f-8ae6-9bcb31ef156b"
      unitRef="usd">9141000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNC0zLTEtMS0w_c55ad9cd-f62e-4b4e-a99f-33ff5c49b4f9"
      unitRef="usd">8348000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNC01LTEtMS0w_294ee03a-23d6-46c7-a69f-9f2e6b9a08ef"
      unitRef="usd">4915000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNS0xLTEtMS0w_d355489e-84bb-4ae2-9a07-65e925f46c2d"
      unitRef="usd">105070000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNS0zLTEtMS0w_bd0f5792-9c6b-4ff4-8ba8-759006125fb5"
      unitRef="usd">56602000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNS01LTEtMS0w_11525910-a837-4682-9f5e-e41c7627839e"
      unitRef="usd">40626000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNi0xLTEtMS0w_30363865-4598-4a93-bb80-2b50b09ad32a"
      unitRef="usd">4830000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNi0zLTEtMS0w_0f59ccf3-43af-4740-a1ba-2c9f4f2d2820"
      unitRef="usd">2819000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNi01LTEtMS0w_8e947324-6192-4186-95d4-07be9cc4693e"
      unitRef="usd">2854000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNy0xLTEtMS0w_018b1471-fd3b-48d7-bca8-19cb0aeb3e39"
      unitRef="usd">-15265000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNy0zLTEtMS0w_c2633e57-0884-4a21-981d-cf70222d0dde"
      unitRef="usd">-71002000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNy01LTEtMS0w_89cd9200-2265-403b-960c-672739dfab79"
      unitRef="usd">244111000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfOC0xLTEtMS0w_1bf4db2f-7e75-4bf1-985b-a516d2e0b955"
      unitRef="usd">-3035000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfOC0zLTEtMS0w_f506a24c-f043-4f44-9fa4-839c82fc49d5"
      unitRef="usd">-88000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfOC01LTEtMS0w_e88d3657-6182-4695-9763-b1448ff12271"
      unitRef="usd">-1129000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTAtMS0xLTEtMA_32fae0fe-6872-4d0f-b45a-86564689d875"
      unitRef="usd">42470000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTAtMy0xLTEtMA_0206dbf8-d1eb-4e2f-95d9-067a61c109fd"
      unitRef="usd">-43716000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTAtNS0xLTEtMA_27e283b4-1432-4819-b405-d2099be7b049"
      unitRef="usd">85471000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTEtMS0xLTEtMA_494502f4-672e-407a-93ae-c790e7c4625f"
      unitRef="usd">21897000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTEtMy0xLTEtMA_09017018-8b51-43da-9be9-971d2b9925b5"
      unitRef="usd">5731000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTEtNS0xLTEtMA_4ad5c34d-3a37-4299-b556-2233df7648b8"
      unitRef="usd">3181000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTMtMS0xLTEtMA_a3c15b19-2c53-4386-adfb-1d4966885275"
      unitRef="usd">25831000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTMtMy0xLTEtMA_dc210b30-0bcf-48d5-8dfe-fb494ac79e1f"
      unitRef="usd">5723000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTMtNS0xLTEtMA_4a466726-c94d-480f-a91c-26ffe10cc41d"
      unitRef="usd">8525000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTUtMS0xLTEtMA_9b516c27-b2c9-402e-abd8-081a68890ed2"
      unitRef="usd">-1051000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTUtMy0xLTEtMA_92364a36-db33-47b6-9da8-78fa262cf7c7"
      unitRef="usd">-9301000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTUtNS0xLTEtMA_0f993d46-be2e-4b95-b9a6-09c442f9db85"
      unitRef="usd">271000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTYtMS0xLTEtMA_24ec122f-9aeb-4466-9b0f-d8224c03dc16"
      unitRef="usd">51109000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTYtMy0xLTEtMA_6657313d-650d-48c8-ba93-5fd471d5278d"
      unitRef="usd">44124000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTYtNS0xLTEtMA_98ca99fb-f593-48ba-8c58-2a98ab498ea4"
      unitRef="usd">17143000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTctMS0xLTEtMA_49ec7271-f792-4432-ba11-2ef48a7e5a89"
      unitRef="usd">208982000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTctMy0xLTEtMA_082a276e-4e21-4317-9b77-06982ec413aa"
      unitRef="usd">526956000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTctNS0xLTEtMA_e287e520-1952-4b65-8df5-18ac53b38d92"
      unitRef="usd">415720000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTktMS0xLTEtMA_ed59d706-4159-440f-865c-828de329d6b4"
      unitRef="usd">30345000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTktMy0xLTEtMA_2700b250-6f2a-482d-8b0a-2dd3b9649ab3"
      unitRef="usd">12834000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMTktNS0xLTEtMA_9b3d60b4-ddcd-4ba8-b098-8fb130585f19"
      unitRef="usd">33297000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjAtMS0xLTEtMA_3a5da3ce-ca45-48e7-ae31-5b5839b8b9bd"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjAtMy0xLTEtMA_5b8c12a1-d568-442b-ac0c-f598fe8a6733"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjAtNS0xLTEtMA_7048dbb5-8679-4902-af66-cfd91aff9ae1"
      unitRef="usd">308000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjEtMS0xLTEtMA_ddb7a9ac-41e3-4554-bd5b-dee27afd770f"
      unitRef="usd">1070269000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjEtMy0xLTEtMA_1d410743-e1e9-4037-b55f-d15e86151576"
      unitRef="usd">1182682000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjEtNS0xLTEtMA_4e77572f-3955-42d1-aa4e-2cac153aa231"
      unitRef="usd">557832000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjItMS0xLTEtMA_c7b24234-b97e-424b-a5dc-d99748dfa682"
      unitRef="usd">969399000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjItMy0xLTEtMA_d2d6dcaa-97cc-49fb-86a6-b146b6ed84fe"
      unitRef="usd">608269000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjItNS0xLTEtMA_b642b874-20c1-434a-b827-7887aa950d1e"
      unitRef="usd">292971000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjMtMS0xLTEtMA_565883bc-89ec-41b1-b1ec-df7db8378df6"
      unitRef="usd">-131215000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjMtMy0xLTEtMA_948dee7a-5644-45e7-85c4-02d01eba25b5"
      unitRef="usd">-587247000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjMtNS0xLTEtMA_0591bfe5-fe19-4d8b-9e0f-11a48983b567"
      unitRef="usd">-297850000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjUtMS0xLTEtMA_c411a89a-93d8-4e73-a253-8e25a4d926e2"
      unitRef="usd">24886000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjUtMy0xLTEtMA_eea32dd5-c689-488b-9126-b6956f6d77e8"
      unitRef="usd">22499000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjUtNS0xLTEtMA_9c109c92-db5d-4130-bcf2-f9857433e39f"
      unitRef="usd">17278000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjYtMS0xLTEtMA_58b956e4-4027-4695-b47d-0bf619ba03e2"
      unitRef="usd">50018000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjYtMy0xLTEtMA_452845e1-6546-465e-a5ae-3679cc078ea1"
      unitRef="usd">9904000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjYtNS0xLTEtMA_6ddecab1-2e4b-4c95-972d-df1dbebfa980"
      unitRef="usd">7574000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjgtMS0xLTEtMA_c0cc482a-6f3d-40e5-88de-4db95a602c35"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjgtMy0xLTEtMA_57b9de4b-27e3-40ff-ba94-d83e4f613fd5"
      unitRef="usd">-42000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjgtNS0xLTEtMA_16c9d480-e0da-4d43-902a-5914abb760a9"
      unitRef="usd">-13000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjktMS0xLTEtMA_e5c6098d-92e6-499d-b535-b52a5073e036"
      unitRef="usd">-25132000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjktMy0xLTEtMA_890898fd-eef5-43aa-8155-1cc77d5910a8"
      unitRef="usd">12553000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMjktNS0xLTEtMA_e91acee8-1128-4b75-8b3b-2fd509f14772"
      unitRef="usd">9691000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzAtMS0xLTEtMA_b8fbff06-8624-40d0-8fee-2e9e7463d110"
      unitRef="usd">52635000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzAtMy0xLTEtMA_b64d9ec0-d797-4280-861d-01c7c53d9256"
      unitRef="usd">-47738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzAtNS0xLTEtMA_01235148-78e0-4ad4-ad7e-89d80e3190e4"
      unitRef="usd">127561000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzEtMS0xLTEtMA_332818f3-936d-4bc0-a2f8-429847f7bd28"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzEtMy0xLTEtMA_1e7e0c13-a285-46f2-b986-61baba51b26b"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iadc77df98a1c43b7b450a7d15340ba09_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzEtNS0xLTEtMA_c34475ab-80bd-4b78-bd3f-acf9d9776ec3"
      unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzItMS0xLTEtMA_3209da6d-730e-48e5-82c9-98062ea39815"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzItMy0xLTEtMA_6d54716d-d560-4f79-9b01-c031bc985f21"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzItNS0xLTEtMA_53eaf67b-6a2f-4c20-8aec-822e1fc600b6"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzUtMS0xLTEtMA_a2b90264-5a2a-4767-b183-54d846a1a1ec"
      unitRef="usd">4115000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzUtMy0xLTEtMA_b51bd83b-e69c-4151-911c-6e6ca6079bb9"
      unitRef="usd">7873000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzUtNS0xLTEtMA_c0e96dd8-8c3e-45f9-b4c2-cc7af3d7e0f8"
      unitRef="usd">10677000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzctMS0xLTEtMA_afa69fc5-c045-41c8-a4e2-6536b1e2251a"
      unitRef="usd">4017000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzctMy0xLTEtMA_b51dce65-d337-4fce-924f-b601e0dde1fc"
      unitRef="usd">29562000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzctNS0xLTEtMA_cc5a7a49-db42-46ef-b3f4-35101fa6307e"
      unitRef="usd">17180000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzgtMS0xLTEtMTM4NzU_ddd73502-9361-445d-bd02-d545111d2c8b"
      unitRef="usd">842000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzgtMy0xLTEtMTM4NzU_10915bb4-0db9-4262-a782-76477dd594b1"
      unitRef="usd">26000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzgtNS0xLTEtMTM4NzU_4d0bc1ae-a1ce-4667-86bd-bc662269c475"
      unitRef="usd">802000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <exel:InvestmentsPurchasesIncurredButNotYetPaid
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNDAtMS0xLTEtMA_0b47154c-7711-4caf-bdec-34f5f18ecdbd"
      unitRef="usd">1615000</exel:InvestmentsPurchasesIncurredButNotYetPaid>
    <exel:InvestmentsPurchasesIncurredButNotYetPaid
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNDAtMy0xLTEtMA_916f734a-0c33-4c7f-aae8-1502901a37f4"
      unitRef="usd">0</exel:InvestmentsPurchasesIncurredButNotYetPaid>
    <exel:InvestmentsPurchasesIncurredButNotYetPaid
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNDAtNS0xLTEtMA_45b24d1e-8ffd-4b3a-9a2e-3d8c6cb7a644"
      unitRef="usd">0</exel:InvestmentsPurchasesIncurredButNotYetPaid>
    <exel:AccountsReceivableForUnsettledInvestmentSales
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzktMS0xLTEtMTA4NDQ_640f865b-8bf4-438a-9fb9-f35a5bddece2"
      unitRef="usd">6180000</exel:AccountsReceivableForUnsettledInvestmentSales>
    <exel:AccountsReceivableForUnsettledInvestmentSales
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfNDAtMy0xLTEtMTM5Mzc_d11ffeb7-673a-4877-982e-d13ab8cd2dd0"
      unitRef="usd">0</exel:AccountsReceivableForUnsettledInvestmentSales>
    <exel:AccountsReceivableForUnsettledInvestmentSales
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF83OS9mcmFnOmIwM2NhMDZiYzg1YTQyYmE4MTQ4MDNlM2UyNmU4YzA2L3RhYmxlOjVkZTIxMDRjMDllNDRkM2Q4OGVmNjk3YmMxMTZkYzBlL3RhYmxlcmFuZ2U6NWRlMjEwNGMwOWU0NGQzZDg4ZWY2OTdiYzExNmRjMGVfMzktNS0xLTEtMTA4NTY_8da05522-2d50-4cbc-b4ce-67adca202842"
      unitRef="usd">0</exel:AccountsReceivableForUnsettledInvestmentSales>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwNTg_2bc249c6-872a-400e-aafb-ba6b069b19f6">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#x2019;s OPDIVO&#xae; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#xae;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program, and is being investigated both alone and in combination with other therapies in a wide variety of cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of multiple regimens to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We remain committed to expanding our oncology product pipeline through our drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made&#160;reclassifications&#160;to our prior years&#x2019; Consolidated Financial Statements to conform to the current year&#x2019;s presentation. These&#160;reclassifications&#160;did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2021, January 3, 2020 and December 28, 2018 are indicated as being as of and for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In  March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. Accordingly, we recorded an adjustment to increase selling, general and administrative expenses for these fees by $5.1&#160;million during the fiscal year ended December 31, 2020. This adjustment resulted in a $0.02 decrease in basic and diluted &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;earnings per share for the fiscal year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, we adopted Accounting Standards Update (ASU) No.&#160;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8-18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 606) when the counterparty is a customer for a distinct good or service (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter 2020, we adopted ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, we adopted ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, contract assets, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investment Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#x2019;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. As of December&#160;31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts for Prompt Payment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to our Customers, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to Customer, plus an accrual balance for known prior quarters&#x2019; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Customer Credits: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our clinical trial projects have been executed with support from third-party contract research organizations (CROs), who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of Topic 842 for short-term leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising expenses were $25.1 million, $17.9 million and $14.8 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock&#160;Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Provision for (Benefit from) Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our provision for (benefit from) income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for (benefit from) income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for (benefit from) income taxes in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December&#160;31, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#x201c;Note 9. Provision For (Benefit From) Income Taxes&#x201d;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accompanying Consolidated Statements of Income. Net foreign currency gains were $0.9 million for the year ended December&#160;31, 2020, and not material for the years December&#160;31, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will b&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e effective for us in the first quarter of 2021 with early adoption permitted. The adoption of ASU 2019-12 on January 1, 2021 will not have a significant impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i70d57544c852419d89d807ca969cf9dc_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNTcx_75196d4a-4e06-40d6-8c96-0840f63b8261"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i05ae6057ccd8434a925a70647c5631e9_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNzc0_7c0c1930-e0fb-4b70-be55-e2055272217a"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="ib8f792de05b44b5c9f144e5e61238bfe_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTUwMg_aa18b255-fc41-4e3e-9102-f3d48b17b7e1"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwNDY_2c94e652-cb8e-47d6-a2f1-f0859558a97a">Basis of PresentationThe accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMDU_d99ea7b7-273d-48f8-8709-2b1c93ad3648">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2021, January 3, 2020 and December 28, 2018 are indicated as being as of and for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMjU_c11fdd7e-17a7-4b13-a3a3-0d5dbaf056ab">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzIxNA_386a34a3-36bc-479f-bff2-fe87bf539aaf"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMTI_9723afb5-544f-47df-90f7-f64d924f4900">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In  March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. Accordingly, we recorded an adjustment to increase selling, general and administrative expenses for these fees by $5.1&#160;million during the fiscal year ended December 31, 2020. This adjustment resulted in a $0.02 decrease in basic and diluted &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;earnings per share for the fiscal year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8a33372a3f1347209075c0020d6bc068_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTM3NDM4OTU0NjczODI_750aae0f-002c-437c-ae70-f7254f8f4d47"
      unitRef="usd">5100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8a33372a3f1347209075c0020d6bc068_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjE5OTAyMzM3MzMwOQ_a1b26790-f994-4592-b6ba-1e8570c593f1"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMjA_271c4c16-47f7-4eb8-8ce8-b39f05cd04c1">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, we adopted Accounting Standards Update (ASU) No.&#160;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8-18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 606) when the counterparty is a customer for a distinct good or service (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter 2020, we adopted ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, we adopted ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, contract assets, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will b&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e effective for us in the first quarter of 2021 with early adoption permitted. The adoption of ASU 2019-12 on January 1, 2021 will not have a significant impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzk5ODQ_1133cdac-94f7-491f-93db-bb798c268810">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwNDI_95c48a03-2bd8-4288-976d-20bcf0f03808">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTI2NDQzODM4Mjc2NzU_05e07204-8f46-4fb8-9eb1-cc465d779dd4">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMzc_5832e7a6-4088-4a53-a2a3-fc0065f3f778">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. As of December&#160;31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTg2OTE2OTc3OTEyNzY_b7ad002a-9c30-407b-8b4d-1f55689f92ca">As of December&#160;31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i68ed0b3579a44a409ff3f00c4b884aa2_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfMy0xLTEtMS04Mzg4_fe91b791-e0a7-42c0-a19e-25c18b0a50df"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iec86aacc21384a4996d1876a8cb648cf_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfMy0zLTEtMS04Mzg4_a6bd69ea-cf12-4618-b460-c226aaf5f98f"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie579a8fa324847dabc4b5225b2c0c290_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNC0xLTEtMS04Mzky_af09e418-658b-4fb5-8809-0ef098f510b1"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1461cd4bfd3c47c3967b22b8dfbe9be7_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNC0zLTEtMS04Mzky_eea6b6bb-0414-458a-a8db-ee0ef06ed2a4"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib990f420d40b4a3789297972cf1c7e68_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNi0xLTEtMS04Mzk2_f9e440bc-951c-43d7-a369-585485eda434"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i73502ab4116542529d603ec4cd2116b8_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNi0zLTEtMS04Mzk2_867c3724-2e81-4204-b72d-fa4b5e63efbf"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if458bc56436a40b686b3ffa6d5c137e1_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNy0xLTEtMS04NDAw_1c9e59e3-ac33-43f4-aae3-0b318d717c0d"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2ca0bb3135aa44d8bd3287f9952cab2f_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfNy0zLTEtMS04NDAw_a1ced206-c728-48ca-b6e6-f80f940e0f16"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1493217f6b6d4b069dce0c3795c0b005_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfOC0xLTEtMS04NDA0_ced913ce-e648-4d9f-af46-bc7d6e94c1cd"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i67f9d798ccb34676b3e9f4fa0c493d84_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfOC0zLTEtMS04NDA0_04683c04-19a6-4d64-a51e-df3aae0b77e4"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3c6f0b98ffb341dcbd502a864903e546_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfOS0xLTEtMS05ODEy_bb6e1fb2-b3b7-451d-a629-3608c8876c0f"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i10483cca017b4a299e08efb033233f44_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RhYmxlOmY5NWUxZWJlMDhhNjRlYmFhMmNjNjYyYjQ4MGY4MTA4L3RhYmxlcmFuZ2U6Zjk1ZTFlYmUwOGE2NGViYWEyY2M2NjJiNDgwZjgxMDhfOS0zLTEtMS05ODEy_72210d0d-fba4-400e-84b6-5defc904cf37"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwODk_7b924c7d-0917-4fa1-822f-37c9241158a7">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzk5ODU_7d13d567-028c-465f-a54a-122a0d6117b5">Property and EquipmentWe record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iaa643e65f4a54355aecef91480e17f63_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTIxOTE_6f6200a6-226f-4d56-95ea-150fae6aaa98">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwNjM_c5d4cafe-0af9-4344-ac11-fb1c269b1b7d">GoodwillWe recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTM1MDc_386a34a3-36bc-479f-bff2-fe87bf539aaf"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTM2NjQ_e0c334ca-788e-4492-9696-5215108339cd"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMTY_9a2aba97-03bb-48fe-99d0-75fc57d7b3b2">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzk5ODY_aef35a3f-5627-4431-ae04-e1b20cde2add">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts for Prompt Payment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to our Customers, plus an accrual balance for known prior quarters&#x2019; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#x2019;s shipments to Customer, plus an accrual balance for known prior quarters&#x2019; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-payment Assistance: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Customer Credits: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. &lt;/span&gt;&lt;/div&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <exel:SalesRevenuePercentDiscountForPromptPayment
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTkyMjY_39774fee-fe76-40f6-af07-31da1d43cf84"
      unitRef="number">0.02</exel:SalesRevenuePercentDiscountForPromptPayment>
    <exel:SalesRevenueDiscountExpectedtobeEarnedPercent
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTkyODM_52a6e27f-94d2-4b38-9945-30e40a557d5d"
      unitRef="number">1</exel:SalesRevenueDiscountExpectedtobeEarnedPercent>
    <exel:MedicarePartDFundingMandate
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTgxNDE5NDE5NzYwMTc_f915b58d-3aa9-45f1-9d68-82d0e1835afb"
      unitRef="number">0.70</exel:MedicarePartDFundingMandate>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjc0OTM_bff152e5-346f-4079-ae09-ac754b332089"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzk5ODg_1cadfc3d-bdbb-43ba-9915-1b0e930e8431">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our clinical trial projects have been executed with support from third-party contract research organizations (CROs), who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMjM_ced960bf-4278-413d-8273-9e22148dae6a">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such &lt;/span&gt;&lt;/div&gt;options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of Topic 842 for short-term leases.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAxMTk_3eca80de-7821-4bc2-8916-366bd467860e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising expenses were $25.1 million, $17.9 million and $14.8 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjE5OTAyMzM3NjE3NQ_1672c1d9-cf15-4178-b9fd-819bba0214b1"
      unitRef="usd">25100000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMzE2MTM_03c9e7f2-9dcf-4c51-a73e-f432e7ae1e84"
      unitRef="usd">17900000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjE5OTAyMzM2Mjc4NQ_be6ba6a7-ba38-4709-9af5-6a612053b926"
      unitRef="usd">14800000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMDc_2c64f41f-dc9f-4411-849c-45abeaab38e9">Stock-Based Compensation&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock&#160;Compensation&lt;/span&gt;,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMTI2NDQzODM4Mjc2Nzc_39f5d3e2-84e1-4ba9-a314-66f0a8be4a90">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Provision for (Benefit from) Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our provision for (benefit from) income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for (benefit from) income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for (benefit from) income taxes in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December&#160;31, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#x201c;Note 9. Provision For (Benefit From) Income Taxes&#x201d;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfNDAwMzA_bb236e9b-5e3d-41a6-bc76-4677dc174a4d">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the &lt;/span&gt;&lt;/div&gt;accompanying Consolidated Statements of Income.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF84NS9mcmFnOjQyNjI0ODU2NGIwOTRhMjI5MDU0ODJiYzMxNDQyOGRhL3RleHRyZWdpb246NDI2MjQ4NTY0YjA5NGEyMjkwNTQ4MmJjMzE0NDI4ZGFfMjc0ODc3OTE4NzIyMw_4586dc22-3aaf-4c4e-89a3-56e584416727"
      unitRef="usd">900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNTMxOA_bbe14a28-6656-4925-beaa-b86aaa6cc31b">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GSK on sales of products containing cabozantinib by our collaboration partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues are comprised of net product revenues which are attributed to geographic regions based on the ship-to location and license and collaboration services revenues which are attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending allowance balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowances for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Presented in prepaid expenses and other current assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020, 2019 and 2018, we recognized $9.2 million, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.5 million and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $8.7 million, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, in revenues that were included in the beginning deferred revenue balance for those years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; December&#160;31, 2020, 2019 and 2018, we recognized $169.7 million, $161.2 million and $198.1 million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to milestone and royalty payments allocated to our license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, $86.1 million of the combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements - Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d; for additional information about the expected timing to satisfy these performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNTMyMA_47c5912a-ed3d-4f40-bc36-39f00de3eded">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(197,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i670b9bb21b274bf1a4d1c34421fc3303_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMy01LTEtMS0w_b56f5d03-9c22-43c6-84a9-69a4d1dcd4de"
      unitRef="usd">962591000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88900c20d16b466197d1afc11b84f873_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMy03LTEtMS0w_7843ec5e-9f49-4cb2-8fda-922002532721"
      unitRef="usd">957621000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaa2590ddc5b443eae95962cb972cbdb_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMy05LTEtMS0w_2d0c48f6-361e-4918-8424-84ca4a371884"
      unitRef="usd">738529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib16eb294fd16430ab148fb14f058af49_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNC01LTEtMS0w_5fd4d6ba-268f-49c6-8087-c2046c3da5be"
      unitRef="usd">-221041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8836d60836b24ea9a6548c71ad67321d_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNC03LTEtMS0w_5f2bc4f2-ef82-4d12-ba8b-cd78ac5edb55"
      unitRef="usd">-197671000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0be59e66b12446da9b1ef0b4f3d06cac_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNC05LTEtMS0w_4d4d8e93-81c1-4790-a73b-b26df050956e"
      unitRef="usd">-119250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc3c42d191c44c598831337fe0fcd696_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNS01LTEtMS0w_0b9dea40-7200-4b35-9fc6-d650d6464035"
      unitRef="usd">741550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i017544c12e89414a8fbb94db33dba5ca_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNS03LTEtMS0w_581a2c31-2fe7-4480-948c-ccd1a271fe48"
      unitRef="usd">759950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49ae4188c769426b89292d8f4cb182cd_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNS05LTEtMS0w_fee54294-4ac0-4f82-87a8-88e544e39e0c"
      unitRef="usd">619279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0f75b6132534e759b7a2f8f4f543224_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNy01LTEtMS0w_dab3a4ce-f44c-46ff-91ad-a35e486add4c"
      unitRef="usd">167295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd63dabbf6d046f6a7c8d265a33ee88c_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNy03LTEtMS0w_351635b6-70a3-44e6-a9a3-5781fabcfbea"
      unitRef="usd">165914000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9aafd53bd39d4ffc9927ea4ffcd6a8ed_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfNy05LTEtMS0w_c57fd49f-ce7a-442c-9004-d70a2015d100"
      unitRef="usd">200272000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08966774bb054fc088e3056e8afeee22_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfOC01LTEtMS0w_7778ef7a-460b-4fc3-94d4-e95458f9b478"
      unitRef="usd">78693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b8b4097af0141c0b296cf3b6ba2950f_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfOC03LTEtMS0w_6711a4ac-cf56-4da3-82a5-090f7f338b1c"
      unitRef="usd">41911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0062b098130b4f129d9e3ab3551e84ba_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfOC05LTEtMS0w_a0f5a8e4-e451-470f-8256-7e11d2f45f76"
      unitRef="usd">34275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bc1d30b7d3a4f06af43da57ce01f0d0_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTAtNS0xLTEtMA_c5dd6636-a47e-4cd5-9a4b-af2c96769330"
      unitRef="usd">245988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31bb491021104aef928b3404ad05a9ff_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTAtNy0xLTEtMA_43fb19d2-64e2-47ab-a4cc-d3ca3f20034e"
      unitRef="usd">207825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b5a944195d8434c8b42f2f1eb355ef6_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTAtOS0xLTEtMA_f85ee708-481d-439c-94fd-298bb143bb97"
      unitRef="usd">234547000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTEtNS0xLTEtMA_6b482854-1188-4765-97e5-c57cbba1d6f2"
      unitRef="usd">987538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTEtNy0xLTEtMA_8a1b5165-2f14-40d0-b234-e1e3adec99ed"
      unitRef="usd">967775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmYwNzQ0MGRkY2RkYzQ5MDVhOTg1ZTgzOThlMzc0MGFkL3RhYmxlcmFuZ2U6ZjA3NDQwZGRjZGRjNDkwNWE5ODVlODM5OGUzNzQwYWRfMTEtOS0xLTEtMA_3d7a54e7-59c5-460e-af79-6c9bc7c4f135"
      unitRef="usd">853826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9df29850b2244253875bb007d882a698_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMi01LTEtMS0w_fafe1f0c-519a-4e75-b218-0491baa5dbe8"
      unitRef="usd">718687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb1450fd8a55400fa9281132060b8fcc_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMi03LTEtMS0w_b178dd96-00b1-4b49-be47-af202b98f99d"
      unitRef="usd">733421000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if81951ec5a864326b312312ad51008a9_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMi05LTEtMS0w_dba34b6c-5d94-4124-b68a-62897cad12e5"
      unitRef="usd">599946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18d9b118c50947b99a376ebee947e030_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMy01LTEtMS0w_b832cf61-e376-423c-90f8-bdc89f6d563c"
      unitRef="usd">22863000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5a25303cb764f61869e826e0f35954d_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMy03LTEtMS0w_64ade714-025d-4e77-878d-536c1ced73a5"
      unitRef="usd">26529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4ca2a47a8b64d7ca69c61e19f993397_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfMy05LTEtMS0w_a2e5fb5a-dae9-40c1-9dd4-1be038b3b696"
      unitRef="usd">19333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc3c42d191c44c598831337fe0fcd696_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfNC01LTEtMS0w_b428e935-7ab4-4975-b791-2eef700a04e3"
      unitRef="usd">741550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i017544c12e89414a8fbb94db33dba5ca_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfNC03LTEtMS0w_b1682041-3ee9-45bf-8c4c-161e4e89de2e"
      unitRef="usd">759950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49ae4188c769426b89292d8f4cb182cd_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjA4NWUyOGU4ODU0ZDRjMzRiOWY1N2MzNjZkNDExNDZmL3RhYmxlcmFuZ2U6MDg1ZTI4ZTg4NTRkNGMzNGI5ZjU3YzM2NmQ0MTE0NmZfNC05LTEtMS0w_3ada0684-ee35-4344-9c58-f77bcc5c8218"
      unitRef="usd">619279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id1016e220053480cb358c5dc63979dcb_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMi0xLTEtMS0w_7fe36842-d3d2-4894-b588-0859f78e04e6"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibcf42c7314ce4ba9a503ca92535ee0e1_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMi0zLTEtMS0w_eca7f4b4-4498-4ce0-b21b-d23343567316"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia7d5dbf6fabd4ed8b76f6fac38c3a1ac_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMi01LTEtMS0w_d022cac6-3557-4e0e-93a0-ff1860558452"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1a7007d99a1d42f18d5f5f017813107a_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMy0xLTEtMS0w_f527bde1-0d51-49a9-bdb9-e3770caf9771"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib39c621c29354744ba506f00b8b68407_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMy0zLTEtMS0w_89abbb8a-7afa-49a6-9274-d893e4953cc0"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14840edd307b453b8993c676800c743f_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfMy01LTEtMS0w_298aaa1e-6867-4a4c-9e95-aca0ed440d72"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibcd263e91c514880aab3ad046d770b1a_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC0xLTEtMS04Mjkz_6eafbd1e-98aa-47fb-bd17-9a3d1191efa4"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idfce732a0e594583ae51712fb488f5f1_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC0zLTEtMS04Mjkz_4eafa4a3-8f6b-4b4d-a296-1ceceb825f6b"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibc8d4270737e40e39a71be8687219600_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC01LTEtMS04Mjkz_de304009-db1b-42b3-a646-6084238da1c4"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if76434a400d24ae7b1196c9db3361389_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC0xLTEtMS02NDQ4_d115cb1c-1e2d-4d93-9bf1-ca4cec30c3b1"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i18ed95db610746868908b7b47b43533a_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC0zLTEtMS02NDQw_888d7f16-955a-460f-9bbf-7a6872a7455a"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i70f8ef5fe5f34df2867857968fdd5135_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNC01LTEtMS02NDQ0_fdbad962-1c4b-4b71-ae2e-6a815954c168"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idddf53d05cdc4b41a5f8f99bc44c6c7b_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNS0xLTEtMS0w_37c706df-80f1-4a1b-b056-602bb909417e"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib1ba8f2854a74c39969dbab674b0387f_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNS0zLTEtMS0w_3591ebe4-5e62-4b7c-ba71-c06c4a101df6"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i927f62b2ab254dd19dcd6f11991f1c06_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjQ0ZWQ2NTM1MGJjYzQyYTg4NzA1NWVmNTc3YzJmZDRmL3RhYmxlcmFuZ2U6NDRlZDY1MzUwYmNjNDJhODg3MDU1ZWY1NzdjMmZkNGZfNS01LTEtMS0w_fdf0fc8c-8dbc-4867-a980-05cf5eb02f6b"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNTMyNA_39415e08-7b2d-4d94-8eaa-1df1ab073b54">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;967,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia435deed54c84325b684daa442718f36_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMi01LTEtMS0w_6d1ebb22-4e76-4daa-b3c2-a09b546a309c"
      unitRef="usd">752890000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1b0da10f24b48bb8d2940b955a6c0e4_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMi03LTEtMS0w_46fef87b-75a4-4c6a-97fa-79e750bd3504"
      unitRef="usd">770244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib930a4d0eb864dda920bd8ef624bdca7_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMi05LTEtMS0w_4fe0313b-f78e-48ae-9366-78aa528b5ae4"
      unitRef="usd">632927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice8e7eb846bd436b99ddee2ea5d4de93_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMy01LTEtMS0w_6137e91d-e7c1-4855-9bd4-344b0ef482d8"
      unitRef="usd">151631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if799ebcc579c4d499fe23a1a040367cf_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMy03LTEtMS0w_f4f57ed4-786d-4482-8cba-a4618d013014"
      unitRef="usd">152771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28dd4195ecbd4524a57b68e9b5121e06_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfMy05LTEtMS0w_90537502-e01b-4d28-af43-d17f8af686a3"
      unitRef="usd">182879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i703818facc0749cea8bf6a915c610cf2_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNC01LTEtMS0w_9f6f72c1-8c20-4e1c-9ef2-474113242fdc"
      unitRef="usd">83017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i972f61963894489d8bd8d96975249ff6_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNC03LTEtMS0w_2facc6d2-e1a8-4bb9-a656-87d3237bbff5"
      unitRef="usd">44760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if514cdad25cc48d282b48650879ae9b7_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNC05LTEtMS0w_f2a09c8d-27fa-49bd-8483-b95065a8df1a"
      unitRef="usd">38020000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNS01LTEtMS0w_4fac9952-0cb9-4992-a5bb-bbde9f2ebd04"
      unitRef="usd">987538000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNS03LTEtMS0w_601daefe-be16-41aa-bf0f-726f8029a8e8"
      unitRef="usd">967775000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjUyNDFmMTFjMzAwZjRmZWE4ODU3ZDg5N2VlNmExY2QyL3RhYmxlcmFuZ2U6NTI0MWYxMWMzMDBmNGZlYTg4NTdkODk3ZWU2YTFjZDJfNS05LTEtMS0w_40103182-c140-48b6-a26e-54347a572ccc"
      unitRef="usd">853826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNTMyNQ_be1087b5-8b6d-4624-9c47-1d75fe6260da">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending allowance balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128,733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216,738)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i18681346850c4142b0cd3f7611f296f7_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMS0xLTEtMS0w_588e621f-6e90-4017-95b3-c666592914db"
      unitRef="usd">2322000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i569e8490f11c4c2397bf2fb735ab9284_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMS0zLTEtMS0w_3a9649e3-3d3b-457c-9c82-be0d5cb16b19"
      unitRef="usd">3038000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i068e290e4adf43a6ae27c34e6c1a6b8d_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMS01LTEtMS0w_e2455940-dde5-4348-b302-44f44a99ce42"
      unitRef="usd">11916000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMS03LTEtMS0w_db738b69-dec4-4bd6-b7ef-0b001efd91ce"
      unitRef="usd">17276000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i0014908918c44efd817e3fd6b0997259_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMy0xLTEtMS0w_723536e4-8701-47e4-b444-b95cb29b6ab2"
      unitRef="usd">129936000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ie7037c5690ef4f0eb73f27b75981598e_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMy0zLTEtMS0w_2a097672-6d68-4ab4-b364-28befe3977e8"
      unitRef="usd">15605000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i588f2ef914e74116ac5406f6a9c01b36_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMy01LTEtMS0w_d32e8c76-e451-48c4-8c1a-e4481216ad95"
      unitRef="usd">48250000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMy03LTEtMS0w_d4bcbbc7-c782-40bc-a7c0-8ee1e6f1cda5"
      unitRef="usd">193791000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i0014908918c44efd817e3fd6b0997259_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNC0xLTEtMS0w_f0323f03-2150-4f49-a986-1da3266db94b"
      unitRef="usd">3989000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ie7037c5690ef4f0eb73f27b75981598e_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNC0zLTEtMS0w_3dff4b7f-d236-4f1c-a198-e4f27d7d7dca"
      unitRef="usd">-111000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i588f2ef914e74116ac5406f6a9c01b36_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNC01LTEtMS0w_d94e6767-4346-4588-bc5d-8161c351a839"
      unitRef="usd">2000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNC03LTEtMS0w_084f61ce-8bb2-4149-8a68-5719a2681ea4"
      unitRef="usd">3880000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0014908918c44efd817e3fd6b0997259_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNS0xLTEtMS0w_ecfa8d64-64c1-440a-9f33-2113541683ef"
      unitRef="usd">128733000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie7037c5690ef4f0eb73f27b75981598e_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNS0zLTEtMS0w_b81d15ae-4af2-4973-915b-6aa15397b313"
      unitRef="usd">15035000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i588f2ef914e74116ac5406f6a9c01b36_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNS01LTEtMS0w_bc415b62-0206-4b20-b2a9-a3a0a8844964"
      unitRef="usd">44946000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNS03LTEtMS0w_957f9aed-0993-4146-8d18-3a8afce14db3"
      unitRef="usd">188714000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8c5ede1c91f84818b0783db0bb304518_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNi0xLTEtMS0w_6528857b-a8ee-445e-b4f1-dd931bdb8848"
      unitRef="usd">7514000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i40b5a386ffe8410abe781ee1be62b794_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNi0zLTEtMS0w_8f428b52-5b8b-490f-8af8-0cd9755bf202"
      unitRef="usd">3497000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i41ebfdbd93854a33891fe6df6de3c3b6_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNi01LTEtMS0w_010492b3-0f06-4327-be85-a6b4920ff619"
      unitRef="usd">15222000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfNi03LTEtMS0w_5922aa2a-4837-4044-8ed1-946e7137b9ae"
      unitRef="usd">26233000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i2a7cfa1b7a7f4ba38dc76cc810d3400d_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOC0xLTEtMS0w_75f2307e-eccc-4d6f-bd86-a9435e523a28"
      unitRef="usd">146537000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="ia9c97e81888f485bb64fd4ed361390ac_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOC0zLTEtMS0w_583e442f-f6b6-4209-83c9-c7529a78008f"
      unitRef="usd">16162000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i485f8f534a3b4af3bbd86f765dd82388_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOC01LTEtMS0w_51d499bc-930b-4611-84b4-948090ea9f5f"
      unitRef="usd">58049000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOC03LTEtMS0w_055c573c-fa64-4872-a6b2-a2b581507d4b"
      unitRef="usd">220748000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i2a7cfa1b7a7f4ba38dc76cc810d3400d_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOS0xLTEtMS0w_e36b3132-a55f-4f32-bcc1-2e1ab775c5d7"
      unitRef="usd">33000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="ia9c97e81888f485bb64fd4ed361390ac_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOS0zLTEtMS0w_fbf6c561-3586-493f-aa08-c2689cbf41c2"
      unitRef="usd">-352000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i485f8f534a3b4af3bbd86f765dd82388_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOS01LTEtMS0w_7ddffcfd-f277-49ea-bc8f-06b20387aa0b"
      unitRef="usd">612000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfOS03LTEtMS0w_04f780ad-4ee5-4146-8914-8cbdf3b30122"
      unitRef="usd">293000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i2a7cfa1b7a7f4ba38dc76cc810d3400d_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTAtMS0xLTEtMA_cfc08754-a4b4-4abb-befe-0d9f8f636632"
      unitRef="usd">144231000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ia9c97e81888f485bb64fd4ed361390ac_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTAtMy0xLTEtMA_71d1fc7f-ead3-4879-b164-52b31d7f3751"
      unitRef="usd">16028000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i485f8f534a3b4af3bbd86f765dd82388_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTAtNS0xLTEtMA_b1bc3f1b-d18e-4bfc-a0f9-8f18f948751e"
      unitRef="usd">56479000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTAtNy0xLTEtMA_45d8b29f-9b3f-4019-bd75-b984b173480a"
      unitRef="usd">216738000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic4e2d4955acf43d8b9d5c3180cca3657_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTEtMS0xLTEtMA_c878dceb-7fbc-4064-8dbe-da220a9d0ace"
      unitRef="usd">9853000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib9d678bb169b48699b45ef9f3a5ee83a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTEtMy0xLTEtMA_51bfcc33-5761-4214-92c8-2adb549c2209"
      unitRef="usd">3279000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iac85cedb1c81483cabfe7f110f14f7bf_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTEtNS0xLTEtMA_685bd337-90a7-41ff-bb3e-58201434b63c"
      unitRef="usd">17404000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOmUzZmZlNGZkZmJhOTRkYWFiYjE1NWY5ODk4NDA0YjIzL3RhYmxlcmFuZ2U6ZTNmZmU0ZmRmYmE5NGRhYWJiMTU1Zjk4OTg0MDRiMjNfMTEtNy0xLTEtMA_5eb2d03e-0432-471f-8d9a-e0750f7fab1b"
      unitRef="usd">30536000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfMTI2NDQzODM3MzUxODA_f39f79c9-4775-4d49-8f43-1b22732cff51">Contract assets and liabilities were as follows (in thousands):&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Presented in prepaid expenses and other current assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfMi0xLTEtMS0xODA5_f7d10668-0b4a-4128-92dd-99d80b60fb46"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfMi0zLTEtMS0xODA5_6e3905fe-20cd-4dea-ab43-5ee8041bd86b"
      unitRef="usd">1062000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNS0xLTEtMS0xODE0_1f975427-ef9f-42fb-a185-07fa24f708e4"
      unitRef="usd">1790000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNS0zLTEtMS0xODE0_8619c76b-ebd8-45e0-aa3e-edd6e70d7898"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNi0xLTEtMS0xODE5_f902bb12-7ee6-4842-b5f0-19c4d6fc240c"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNi0zLTEtMS0xODE5_1632d884-75a4-4655-ae6f-552fa9ac8450"
      unitRef="usd">6596000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNy0xLTEtMS0xODE0_253d2be1-8cbf-4f5d-9b31-e27c27144e7d"
      unitRef="usd">5545000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RhYmxlOjM5ZjczNTAzNjYxODRkNjM4YTcwNGQwYzQ4NjNlMDFjL3RhYmxlcmFuZ2U6MzlmNzM1MDM2NjE4NGQ2MzhhNzA0ZDBjNDg2M2UwMWNfNy0zLTEtMS0xODE0_477ec9a6-1d51-4b15-bfcb-63f27f5bc9af"
      unitRef="usd">6596000</us-gaap:ContractWithCustomerLiability>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDUwNw_3ba6dde1-4846-407f-9bc4-cef86cc1783f"
      unitRef="usd">9200000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDUxNA_69cb6c4c-84f9-4457-9425-16e9533abbf5"
      unitRef="usd">6500000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfMjc0ODc3OTA4NTI3Mw_4a447cfa-a381-44d8-97c5-24339bc932b3"
      unitRef="usd">8700000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDY2Mg_97f8e980-6fac-416b-b1e1-fe6ca94f463f"
      unitRef="usd">169700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDY2OQ_23f064fc-bea6-4fd1-be19-0774c9c58269"
      unitRef="usd">161200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfMjc0ODc3OTA4NTI4NA_2701fa98-ef4d-4857-87fb-0540b2c71f5a"
      unitRef="usd">198100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85MS9mcmFnOjhmZjZhN2FkYTE0ZDRmYzlhNzUzODI3MmMzNTVjNGYwL3RleHRyZWdpb246OGZmNmE3YWRhMTRkNGZjOWE3NTM4MjcyYzM1NWM0ZjBfNDk0NA_ad24ce00-39f4-4e97-89dc-d64aa8cdeaf5"
      unitRef="usd">86100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMzc0MDc_de2d2fb0-b9eb-4215-ac5b-6f9c30676df8">COLLABORATION AGREEMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib franchise. Additionally, we have entered into several research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Consistent with our business strategy prior to the commercialization of cabozantinib, we also entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, to receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#x201c;Note 2. Revenues&#x201d; for additional information on revenues recognized under our collaboration agreements during the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Description of the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the U.S. Food and Drug Administration (FDA) or European Medicines Agency orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#x2019;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consideration under the Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of $210.0 million from Ipsen in 2016. As of December&#160;31, 2020, we have achieved aggregate milestones of $350.0 million related to regulatory, development and sales-based threshold by Ipsen since the inception of the collaboration agreement, including $20.0 million, $55.0 million and $140.0&#160;million in milestones achieved during the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $59.0 million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $450.0&#160;million and CAD$26.5&#160;million. We excluded these milestones from the transaction price as of December&#160;31, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2020, $41.3 million of the transaction price allocated to our research and development services performance obligation had not been satisfied. See &#x201c;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;, below, for additional information related to the revenue recognition for this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;receive royalties on the net sales of cabozantinib by Ipsen outside of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he U.S. and Japan. During the year ended December&#160;31, 2020 and going forward, we are entitled to receive a tiered royalty of 22% to 26% on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to pay a 3% royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding the following clinical trials which are described in greater detail below: COSMIC-021, COSMIC-312, CONTACT-01 and CONTACT-02.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product is supplied at our cost, as defined in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from the Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Description of the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive and modified certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02 clinical trials. We determined the amendment in September 2020 represented a contract modification that was treated as a termination of an existing contract and the creation of a new contract under Topic 606. As a result, we allocated the remaining transaction price to the performance obligations identified in the contract. The two remaining performance obligations are the research and development services associated with committed studies and the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. In allocating the transaction price for the modified contract we estimated the standalone selling price for the performance obligations. We utilized development costs incurred for these obligations in process and the projections of costs through the term of the arrangement. Revenue is recognized when, or as, we satisfy our performance obligations by transferring the promised services to Takeda. Revenue is being recognized using the cost proportional performance method, based on costs incurred to perform the research and development services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Takeda is responsible for a portion of the costs associated with the cabozantinib development plan&#x2019;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding the following clinical trials which are described in greater detail below: CheckMate -9ER, CONTACT-01 and CONTACT-02, and certain cohorts of COSMIC-021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to this collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) two years after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#x2019;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#x2019; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consideration under the Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $50.0 million from Takeda in 2017. As of December&#160;31, 2020, we have also achieved regulatory and development milestones in the aggregate of $92.0 million since the inception of the collaboration agreement, including $66.0 million, $16.0 million and $10.0&#160;million in milestones achieved during the years ended December&#160;31, 2020, 2019 and 2018, respectively. As of December 31, 2020, we have also determined that it was probable that we will earn milestone payments totaling $15.0&#160;million for the initiation of two phase 3 pivotal clinical trials for additional indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, as amended, as of December 31, 2020, we are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of up to $139.0 million. We excluded these milestones from the transaction price as of December 31, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also receive royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of 15% to 24% on the initial $300.0&#160;million of net sales, and following this initial $300.0&#160;million of net sales, we are then entitled to receive a tiered royalty of 20% to 30% on annual net sales thereafter; these 20% to 30% royalty tiers reset each calendar year. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to pay a 3% royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#x2019;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from the Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, $44.8&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We identified two performance obligations for the Ipsen collaboration agreement: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We identified two remaining performance obligations for the Takeda collaboration agreement due to the amendment in September 2020: (1) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements) and (2) the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. As part of the original contract, we had a performance obligation associated with the exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have allocated the transaction price for each of these collaborations to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We re-evaluate the transaction price for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended December&#160;31, 2020, 2019 and 2018, the transaction price of the Ipsen and Takeda collaboration agreements increased as a result of the achievement of various milestones, and the reimbursements of research and development services related to committed and opt-in studies. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December&#160;31, 2020, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Development Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb Company (BMS)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#x2019;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC in the CheckMate -9ER and COSMIC-313 trials and for HCC in the CheckMate 040 trial. Under the terms of the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#x2019;s compounds in the conduct of each clinical trial. The parties&#x2019; efforts are governed through a joint development committee established to guide and oversee the collaboration&#x2019;s operation. Each trial will be conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;F. Hoffmann-La Roche Ltd. (Roche) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#x2019;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#x2019;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in three planned phase 3 pivotal clinical trials in advanced non-small cell lung cancer (CONTACT-01), metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03). If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, a supplement to the joint clinical research agreement was signed amongst us, Roche and Takeda due to Takeda opting into fund the combined therapy trial of CONTACT-01 sponsored by Roche. Chugai was added as an affiliate of Roche. All parties including Chugai conduct combined therapy trials in Japan upon the terms of the joint clinical research agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#x2019;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#x2019; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply of their drug for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated during 2014, we continue to be required to pay a 3% royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;collaboration revenues for sales by our collaboration partners. Such royalties were $32.7 million, $31.3 million and $24.0 million during the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Profits and losses on the U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See &#x201c;&#x2014;Performance Obligations and Transaction Prices for our Other Collaborations&#x201d;, below, for additional information related to revenue recognition for this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cobimetinib Profit Sharing and Royalty Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. On July 30, 2020, the FDA approved COTELLIC, in combination with Genentech&#x2019;s ZELBORAF and TECENTRIQ&#xae; (atezolizumab) for the treatment of BRAF V600 mutation-positive advanced melanoma in previously untreated patients. Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#x2019;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive 50% of profits and losses from the first $200.0 million of U.S. actual sales, decreasing to 30% of profits and losses from U.S. actual sales in excess of $400.0 million. These tiers reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. We are not eligible for any additional milestone payments under the collaboration agreement with Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daiichi Sankyo&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo was responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In&#160;January 2019, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May 2019, Daiichi Sankyo had its first commercial sale of MINNEBRO. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have achieved milestones of $20.0&#160;million each during the years ended December&#160;31, 2019 and 2018 for the approval and first commercial sale of MINNEBRO. We are eligible to receive additional sales-based milestone payments of up to $90.0 million under this collaboration agreement. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Such revenues were $1.3&#160;million and $0.1&#160;million during the year ended December 31, 2020 and 2019, respectively. Those revenues are presented in license revenue in our Consolidated Statements of Income. Daiichi Sankyo may terminate the agreement upon 90 days&#x2019; written notice, in which case Daiichi Sankyo&#x2019;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenue under the collaboration agreement with Daiichi Sankyo w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as $1.3&#160;million, $20.1&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $20.0&#160;million for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; Research Collaborations and In-Licensing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a collaboration and license agreement with Catalent, Inc.&#x2019;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., (individually and collectively referred to as Catalent). Under the terms of the agreement, we made an upfront payment of $10.0&#160;million in exchange to nominate and have the exclusive option to license four targets using Catalent&#x2019;s ADC platform over a three-year period. In addition, we have a right to extend the target selection term to five years and nominate up to two additional targets for an additional payment of $4.0&#160;million. For each option we decide to exercise, we will pay an exercise fee of $2.0&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. Catalent would then become eligible to receive up to $44.0&#160;million per compound in potential development milestone payments, $60.0&#160;million per product in potential commercial milestone payments, as well as royalties on potential sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NBE Therapeutics AG (NBE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a collaboration and license agreement with NBE. Under the terms of the agreement, we made an upfront payment of $25.0&#160;million in exchange for exclusive options to nominate four targets using NBE&#x2019;s ADC platform over a two-year period. In addition, within the first eighteen months of the agreement, we also have a right to extend the target selection term to three years for an additional payment of $2.0&#160;million. For each option we decide to exercise, we will be required to pay an exercise fee of $10.0&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. NBE would then become eligible to receive up to $90.0&#160;million per program in potential development milestone payments, $135.0&#160;million per program in potential commercial milestone payments, as well as royalties on potential sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Aurigene Discovery Technologies Limited (Aurigene)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as six programs to discover and develop small molecules as therapies for cancer. Under the terms of the agreement, we made aggregate upfront payments of $17.5 million for exclusive options to license up to six programs, including three pre-existing programs. We are also responsible for research funding for the discovery and preclinical development work on these programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, we exercised the exclusive option to in-license Aurigene&#x2019;s novel XL102 inhibitor and incurred an option exercise fee of $12.0&#160;million. For each remaining option we decide to exercise, we will be required to pay an exercise fee of $10.0 million and would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for up to $148.8 million per program in potential development and regulatory milestone payments, $280.0 million per program in potential commercial milestone payments, as well as royalties on potential sales. Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Iconic Therapeutics, Inc. (Iconic)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, we entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer, leveraging Iconic&#x2019;s expertise in targeting Tissue Ffactor in solid tumors. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#x2019;s lead oncology ADC program, in exchange for an upfront payment to Iconic of $7.5 million and a commitment for preclinical development funding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, we exercised our exclusive option to in-license XB002, Iconic&#x2019;s lead oncology ADC program and made an option exercise fee payment of $20.0 million to Iconic; we concurrently assumed responsibilities for all subsequent clinical development, manufacturing and commercialization activities, and Iconic  became eligible for up to $190.6 million in potential development, regulatory and first-sale milestone payments, $262.5 million in potential commercial milestone payments, as well as royalties on potential sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Invenra, Inc. (Invenra)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we entered into a collaboration and license agreement with&#160;Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities.&#160;The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#x2019;s B-Body&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technology platform, or with other platforms and formats at our option. In March 2020, we amended the agreement to enable the use of target binders in non-Invenra platform-based modalities, such as ADC platforms. As of December 31, 2020, we have initiated three additional discovery projects and six binder projects. Invenra is eligible to receive up to&#160;$131.5 million&#160;in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a B-Body product in the first indication, or in lieu of such payments, up to $43.4 million in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a non- B-Body product. Upon successful commercialization of a product, Invenra is eligible to receive sales-based milestone payments up to&#160;$325.0 million&#160;as well as single-digit tiered royalties on net sales of the approved product. We have the right to initiate three additional discovery projects for development subject to an upfront payment of&#160;$2.0 million&#160;for each B-Body project, as well as additional milestone payments and royalties for any products that arise from these efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;StemSynergy Therapeutics, Inc. (StemSynergy)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1&#x3b1;), a component of the Wnt signaling pathway implicated in key oncogenic processes. Under the terms of the agreement,&#160;we&#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&#x3b1;. We paid StemSynergy an upfront payment of $3.0&#160;million in 2018. StemSynergy will also be eligible for up to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$56.5 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, sales-based milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
      contextRef="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ0Ng_36e34e99-423f-49d1-b3f9-aa2f0ea03a28">P10Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
    <exel:UpfrontPayments
      contextRef="i3448dcea3614442a9a77d8d52fcb6e28_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNDI0MA_a0dd7407-d61c-4417-bb17-ab10baf4c523"
      unitRef="usd">210000000.0</exel:UpfrontPayments>
    <exel:MilestonePaymentsEarnedToDate
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMxMTI2OQ_16fee832-3eb7-4da1-8402-d7f17a8f5941"
      unitRef="usd">350000000.0</exel:MilestonePaymentsEarnedToDate>
    <exel:MilestonePaymentsEarned
      contextRef="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwNTA1Mw_f0333f27-e3ad-453b-9500-a6f06062749a"
      unitRef="usd">20000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="id261962031d24c9c96d500feae66c4cb_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwNTA0OQ_ea6ebe45-3e5a-4c57-9b0d-3c3d6538ae55"
      unitRef="usd">55000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i3edf5cd51c4c429ca9fd36162d5bfb83_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NTQ4NDQ_8f7672c5-2aa0-4fb8-b78e-849b21bd4d36"
      unitRef="usd">140000000.0</exel:MilestonePaymentsEarned>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMxNTU0Mw_2edba791-6e86-476a-98c3-0c58acf65887"
      unitRef="usd">59000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NjMyNDM_fbbb72d7-c635-4ba5-9546-3bc1222948b1"
      unitRef="usd">450000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NjMyNTk_9eb44cc7-7166-4316-a23a-a8b9e8a0ce5d"
      unitRef="cad">26500000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i2ffdf33d4d344ed4928ad1de3983ab85_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMxNjE1Mg_65147a6e-cbf2-4c90-9899-4b9858402ebd"
      unitRef="usd">41300000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i175c1256c42e4ceb969e04284a7f0b85_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1ODYwNA_2565ccbd-bb63-4d82-b0a7-06a47d3f8dcd"
      unitRef="number">0.22</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i6e51030563a74e4ab6a25f0c1af5638f_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1ODcxNg_53ad76ec-d17a-4f24-bb28-420ffdc9322d"
      unitRef="number">0.26</exel:PercentOfRoyaltyOnNetSale>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNTMzNQ_bff152e5-346f-4079-ae09-ac754b332089"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
      contextRef="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNTcyMA_a876380c-dbef-4e99-b2c7-e14ad6696826"
      unitRef="number">0.35</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY2NjY_a3e6389c-8e17-47f5-b1d6-43392e1fe3a2">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Profits and losses on the U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbfee036b7344af7acf82053445607ff_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMi01LTEtMS0xMTEx_7008c5d1-6e76-4589-b6ff-86eee39a6190"
      unitRef="usd">93495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbb74c8b1eec4b309ba8b185f47e746e_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMi03LTEtMS0xMTEx_20a2345b-f28c-4f2b-ada2-6e76c63e35ae"
      unitRef="usd">117360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i798095a51aa64ee99fae753389f50df8_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMi05LTEtMS0xMTEx_dc300f4e-113a-471f-b639-6420ec47d440"
      unitRef="usd">157569000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b3a269af46e46d4ba478888e3772c6b_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMy01LTEtMS0xMTEx_e0b936da-5e96-42e7-9e3f-5cbf603a77c0"
      unitRef="usd">58136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7aa81d937ec42618a7404c5d7df25a4_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMy03LTEtMS0xMTEx_b7dd05ab-08a1-40f1-a5f8-91985096bada"
      unitRef="usd">35411000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic048c678e69e4a2696e357c75149ef17_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfMy05LTEtMS0xMTEx_a9fc541c-314a-408f-ad0a-c0cd30ed3f5e"
      unitRef="usd">25310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfNC01LTEtMS0xMTEx_b51e6711-bc1f-4670-a003-95dafd993d08"
      unitRef="usd">151631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id261962031d24c9c96d500feae66c4cb_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfNC03LTEtMS0xMTEx_a731ec9f-9590-43de-949e-4dbd3f0a43cc"
      unitRef="usd">152771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3edf5cd51c4c429ca9fd36162d5bfb83_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg2YTkxY2E2YjE3MDQ2ZjBiYmYyZGYxYzQ0ZmI2Mzc4L3RhYmxlcmFuZ2U6ODZhOTFjYTZiMTcwNDZmMGJiZjJkZjFjNDRmYjYzNzhfNC05LTEtMS0xMTEx_cc286448-b9fc-49cc-94e1-ea32c1e237bd"
      unitRef="usd">182879000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
      contextRef="i647bc5092dce48c290e3e40bd7a16822_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyMTI1Mw_bd8efa03-d987-4d7f-8554-5927d34e7520"
      unitRef="number">1</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
    <exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
      contextRef="i647bc5092dce48c290e3e40bd7a16822_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNzk2NA_12f76ad4-8e47-46cb-8c33-310f1e4d1cdb">P2Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
    <exel:PeriodOfSpecificSalesVolumeThreshold
      contextRef="ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfODUyMg_ea20202a-fe80-4852-833c-e24d4951eea7">P6Y</exel:PeriodOfSpecificSalesVolumeThreshold>
    <exel:UpfrontPayments
      contextRef="i98980155e99342fdb4084a583ee15d45_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfOTYyMw_9a99a0c8-517b-40a7-88d2-9966940ddc36"
      unitRef="usd">50000000.0</exel:UpfrontPayments>
    <exel:MilestonePaymentsEarnedToDate
      contextRef="i6a84efaf8d1449868eee0a1f360e49d0_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwNTYxNw_22b9cd21-bd34-4032-b49c-035b5fe64eb2"
      unitRef="usd">92000000.0</exel:MilestonePaymentsEarnedToDate>
    <exel:MilestonePaymentsEarned
      contextRef="ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwNTU5Ng_a02af88f-babf-4050-97a6-af29f320562e"
      unitRef="usd">66000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="ife1791e1be864b11836b55144b0c084d_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfOTgwMg_4e0145a3-9772-4082-a1ca-8d652a6c1380"
      unitRef="usd">16000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i73471fb9991d403ba0e68dd720fe1b50_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NTQ4NjA_e45f20cd-7b99-41f8-bbf7-a7ebbc1f18c3"
      unitRef="usd">10000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsYetToBeEarned
      contextRef="i6a84efaf8d1449868eee0a1f360e49d0_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMzI5ODUzNDk4OTU1NQ_6061768b-cb42-461b-b1da-9bc1a042f1a1"
      unitRef="usd">15000000.0</exel:MilestonePaymentsYetToBeEarned>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="i6a84efaf8d1449868eee0a1f360e49d0_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1NzczMw_09d1b8fe-8479-4738-894c-014f644ad47d"
      unitRef="usd">139000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i4c7b509b13bc4e9d939f403b1f05c90e_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNTY_73e816f5-b7d8-4f24-8f46-c73e226f1656"
      unitRef="number">0.15</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="ie037b8583ad749bc9122949aec189228_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNTE_e40b848e-c8e4-4997-83e6-5655edbf84e4"
      unitRef="number">0.24</exel:PercentOfRoyaltyOnNetSale>
    <exel:RoyaltyTier
      contextRef="i5718b7dcecd84defac7a854084c0bf25_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwMzU_3f51c5c5-765e-4a22-ae10-1835a09d6940"
      unitRef="usd">300000000.0</exel:RoyaltyTier>
    <exel:RoyaltyTier
      contextRef="i5718b7dcecd84defac7a854084c0bf25_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwMTk_21f09cea-45c0-449b-b539-cef5e4356a7a"
      unitRef="usd">300000000.0</exel:RoyaltyTier>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="ice580bea9a0e497face411c0858d3839_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNjE_26f2270e-9066-41ba-b357-59e4ea0ed48c"
      unitRef="number">0.20</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i26c711accea64d95bdd1a6048b3bc497_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNjY_f9e7a575-ac8d-4d28-b0dd-d427fe374398"
      unitRef="number">0.30</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="ice580bea9a0e497face411c0858d3839_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNzE_8e6fec68-36e4-43b6-9c10-87110121f895"
      unitRef="number">0.20</exel:PercentOfRoyaltyOnNetSale>
    <exel:PercentOfRoyaltyOnNetSale
      contextRef="i26c711accea64d95bdd1a6048b3bc497_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwNzY_ae3eca1f-37ef-4c1f-8c2b-a9eab660adba"
      unitRef="number">0.30</exel:PercentOfRoyaltyOnNetSale>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTEyNjg_bff152e5-346f-4079-ae09-ac754b332089"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide639614f81d4101bd26fa5346aa6494_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMi01LTEtMS0xMTI2_1f9f268b-7688-416a-9110-f4d34a95c192"
      unitRef="usd">61115000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10e2147b6a2c4b3e97bebda7cfdbb8a8_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMi03LTEtMS0xMTI2_5be04714-cf4d-4386-8589-43260e5e032a"
      unitRef="usd">18112000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69c49af6cac24b6aaf78ac9bf15ebf13_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMi05LTEtMS0xMTI2_2cd10e4c-22d5-4fb0-9f20-25d7119be7ac"
      unitRef="usd">9055000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59310ff945004ea6a249b2f169b44e59_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMy01LTEtMS0xMTI2_0dab27df-3704-4dbd-bee0-5d05cfe9d196"
      unitRef="usd">20557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2ffb053e94f427c97510610790a7fa1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMy03LTEtMS0xMTI2_dbe07789-8880-460d-ad39-eb9d5145a10e"
      unitRef="usd">6510000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f066209f19547159b014cc341b71222_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfMy05LTEtMS0xMTI2_13a34e43-bc91-47aa-9276-0ee040e36b8d"
      unitRef="usd">8965000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfNC01LTEtMS0xMTI2_d7bd1f24-ce9a-4524-b9ce-83303560cc99"
      unitRef="usd">81672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife1791e1be864b11836b55144b0c084d_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfNC03LTEtMS0xMTI2_88440c0f-4d89-471f-8aa5-f15d076849c0"
      unitRef="usd">24622000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73471fb9991d403ba0e68dd720fe1b50_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjg3MDAzNmFkZWM4YjRkMThiYTE5Yjc4YTJhNTNhNTE3L3RhYmxlcmFuZ2U6ODcwMDM2YWRlYzhiNGQxOGJhMTliNzhhMmE1M2E1MTdfNC05LTEtMS0xMTI2_ffe36027-4e00-4b5d-ab4c-735e77532dbd"
      unitRef="usd">18020000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6a84efaf8d1449868eee0a1f360e49d0_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMwMDgxNw_04e384a7-251e-4647-b89c-a2515562b055"
      unitRef="usd">44800000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i902c90cc9b5e4fe38ef4f61cbbaa7b69_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQyOTg_bff152e5-346f-4079-ae09-ac754b332089"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="ib6abb9ba6ee941bf966fb2b8bdb7c6eb_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ2NDU_7107b926-39a6-48f4-9eef-88d90d8beda8"
      unitRef="usd">32700000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="id33fe3c37c9e4d0e83192b2e14809965_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ2NDk_8805b529-d26a-4def-a377-0323426ae5ad"
      unitRef="usd">31300000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ia166fd55b459460880c354bf9715e1c8_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ2NTY_69dc9705-2793-4b7a-8ec6-aea621ba5e9d"
      unitRef="usd">24000000.0</us-gaap:RoyaltyExpense>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="ib55343bda1c447eaaec24e61aced15a2_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMi01LTEtMS00Mjg0_23276a9a-1eb4-49a4-a91d-9e2d9cdf9bdb"
      unitRef="usd">6261000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="ic4da49014e834ce4a25784b67ff9a020_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMi03LTEtMS00Mjg0_36e2e7b1-ff04-452d-8bc4-0dedffd0c749"
      unitRef="usd">4615000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="ie33ee4113b464bb8805d9fd13ec03adc_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMi05LTEtMS00Mjg0_f73231d7-d495-4303-93d7-e4132fb8551b"
      unitRef="usd">8084000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib55343bda1c447eaaec24e61aced15a2_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMy01LTEtMS00Mjg0_01420b9f-9b07-4913-a370-0240f70694ae"
      unitRef="usd">5079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4da49014e834ce4a25784b67ff9a020_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMy03LTEtMS00Mjg0_6778eeae-e5c0-4320-866c-99a2d16b7a6a"
      unitRef="usd">5679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie33ee4113b464bb8805d9fd13ec03adc_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RhYmxlOjhmNzM5NjJkZjQ1ZjQ1ZmU5OTVjZjI4YmRmNGI2NTA4L3RhYmxlcmFuZ2U6OGY3Mzk2MmRmNDVmNDVmZTk5NWNmMjhiZGY0YjY1MDhfMy05LTEtMS00Mjg0_79e8af8d-3794-42e0-9d6d-6104d9ac8a85"
      unitRef="usd">5564000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ProfitSharingAgreementPercentOfProfits
      contextRef="i6ccf4e0d483843eb99b3aae67e446fb1_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyNjc1Mg_42b0df1f-ee75-4035-a159-f0275b98ae83"
      unitRef="number">0.50</exel:ProfitSharingAgreementPercentOfProfits>
    <exel:ProfitSharingAgreementProfitThreshold
      contextRef="ic692135e06904b4e9f53251b1bda6e6a_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyNjc5Mw_d2c93f22-f22d-40dd-a467-3a91a19a7c4f"
      unitRef="usd">200000000.0</exel:ProfitSharingAgreementProfitThreshold>
    <exel:ProfitSharingAgreementPercentOfProfits
      contextRef="i12696a9f70bb4520879173dd02953d2e_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyNjgzMw_9cc9d800-ffcf-4a30-9676-02f032047dc7"
      unitRef="number">0.30</exel:ProfitSharingAgreementPercentOfProfits>
    <exel:ProfitSharingAgreementProfitThreshold
      contextRef="i6443bf806be740278539f1341106b36e_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyNjg5NQ_0cd77450-c45e-488e-9125-d44f9219f727"
      unitRef="usd">400000000.0</exel:ProfitSharingAgreementProfitThreshold>
    <exel:CollaborativeArrangementAchievedMilestoneAmount
      contextRef="i04d73fb71dcc4abba01472ab63322c3d_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwOTU_29f155b1-8395-4f70-a615-7ac2dbe60f9c"
      unitRef="usd">20000000.0</exel:CollaborativeArrangementAchievedMilestoneAmount>
    <exel:CollaborativeArrangementAchievedMilestoneAmount
      contextRef="i0b172a5ff906435aadf5f99c85c38a22_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcwOTU_f2f77cc2-fad0-4dc2-80f0-ca921175b177"
      unitRef="usd">20000000.0</exel:CollaborativeArrangementAchievedMilestoneAmount>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="i5706545d66894d3d921d401e933a36d5_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzMyOTU0NQ_d2896e32-4a12-4120-8c2f-30d2a0867791"
      unitRef="usd">90000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ebd3eeeea5e4c2f8ffd32d9ad345d16_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1MzM1MA_14e37047-170c-49a5-a261-9534c7307a14"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2544c6fb6a9b4a6fa37e6ca31e607dbb_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcxMjM_7cdf18c0-872c-442f-9ef0-80f7e0716e3d"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborationAgreementTerminationPeriod
      contextRef="i914e005fdf1940ce8583162f9bd6ea5c_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcxODg_2bcbbf94-19fa-453e-b0a0-52eb1aa37e7c">P90D</exel:CollaborationAgreementTerminationPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i914e005fdf1940ce8583162f9bd6ea5c_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTM3NDM4OTU0NDU0NzE_5c4ce70d-7898-4813-ab44-71431bceb928"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b172a5ff906435aadf5f99c85c38a22_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjE5OTAyMzM1MzQwOA_188759c0-c3c2-44aa-bb9a-a393a541870d"
      unitRef="usd">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04d73fb71dcc4abba01472ab63322c3d_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NTQ5MDU_198b56d0-0493-4015-83b3-3b8207c4a2dc"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeAgreementsUpfrontPayments
      contextRef="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY4MTc_679c2de2-b650-4476-9cd5-e2906f05813a"
      unitRef="usd">10000000.0</exel:CollaborativeAgreementsUpfrontPayments>
    <exel:CollaborationAndLicenseAgreementTargetSelectionTerm
      contextRef="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNzE0NjgyNTY4NTYxNQ_9330db65-d654-481a-88cf-0836afd3e0cc">P3Y</exel:CollaborationAndLicenseAgreementTargetSelectionTerm>
    <exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm
      contextRef="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDcyMjI_2e200088-a4b8-4ed4-bf84-8273384e8c32">P5Y</exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm>
    <exel:CollaborationAgreementsAdditionalUpfrontPayments
      contextRef="i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY4MDM_0c7d2096-48f0-42c2-89d0-f5c54279f915"
      unitRef="usd">4000000.0</exel:CollaborationAgreementsAdditionalUpfrontPayments>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="idc77b7509ab54848ab388e7bd8d55ff7_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3ODk_88197786-a877-476a-91cc-08c0907e1597"
      unitRef="usd">2000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="idc77b7509ab54848ab388e7bd8d55ff7_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY4MzI_ec104510-f985-4a2f-8eb0-e6e4c241ec71"
      unitRef="usd">44000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="idc77b7509ab54848ab388e7bd8d55ff7_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3NzQ_06627157-c3fe-4cbc-a6a2-b935b2fbb23a"
      unitRef="usd">60000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborativeAgreementsUpfrontPayments
      contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3NTk_8bfd96e1-64f3-4aa8-913a-135d0b1b4a1e"
      unitRef="usd">25000000.0</exel:CollaborativeAgreementsUpfrontPayments>
    <exel:CollaborationAndLicenseAgreementTargetSelectionTerm
      contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfNzE0NjgyNTY4NTYxNg_1edb350e-9156-4ab7-ad13-fc28782aeddd">P2Y</exel:CollaborationAndLicenseAgreementTargetSelectionTerm>
    <exel:CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm
      contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTE1NDQ4NzIxODM4MTI_5badd50b-e27b-4679-8e8f-d86637d4f334">P18M</exel:CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm>
    <exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm
      contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTE1NDQ4NzIxODM4MzM_0fba7ddb-b9f5-4e84-b0ab-6b34201a5905">P3Y</exel:CollaborationAndLicenseAgreementExtendedTargetSelectionTerm>
    <exel:CollaborationAgreementsAdditionalUpfrontPayments
      contextRef="ie2ccf58a565b40458488b69646144466_D20200104-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY2OTk_e786152a-bb94-4d11-aaff-3e0f3cc896a3"
      unitRef="usd">2000000.0</exel:CollaborationAgreementsAdditionalUpfrontPayments>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="ib21b7306bafe44138821e7d078f9b318_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY2ODQ_2a407ee1-848b-4dc5-9d40-c83c36809f8f"
      unitRef="usd">10000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="ib21b7306bafe44138821e7d078f9b318_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3MTM_eec16115-fcb4-42f2-a57e-2b4696b568be"
      unitRef="usd">90000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="ib21b7306bafe44138821e7d078f9b318_I20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTI2NDQzODM4MDY3NDM_95a72f4e-3f9c-4499-b607-84eab14bd6df"
      unitRef="usd">135000000.0</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborationAgreementNumberOfPrograms
      contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjQ5MzE_8c4e5947-6219-4b9f-8c81-981452a08fb3"
      unitRef="program">6</exel:CollaborationAgreementNumberOfPrograms>
    <exel:UpfrontPayments
      contextRef="i6901a20ec19b4d62afcecb76296051f6_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjUwODA_704d81b7-7230-49b2-b551-921b4f18ba5f"
      unitRef="usd">17500000</exel:UpfrontPayments>
    <exel:CollaborationAgreementNumberOfPrograms
      contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjUxMjI_8c4e5947-6219-4b9f-8c81-981452a08fb3"
      unitRef="program">6</exel:CollaborationAgreementNumberOfPrograms>
    <exel:CollaborationAgreementNumberOfPreexistingPrograms
      contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjUxNDU_e814a89a-8e54-4f1e-a8c9-730ae33ac4cb"
      unitRef="program">3</exel:CollaborationAgreementNumberOfPreexistingPrograms>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="ie1dacedabe3d4737800441a7d9194116_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NTQ5NDk_954917f5-15a0-4939-84be-0aca72e0c6b7"
      unitRef="usd">12000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="i955e5bb70aeb486b8c2d62388f3e44a0_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjU1MDk_c40a1fc2-f375-4a9e-bcf4-724ae2f4842e"
      unitRef="usd">10000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjU3MjU_d14c7b0f-6e52-4584-8d2a-cc0ec92f0845"
      unitRef="usd">148800000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="ia2a4a216bd474a0c8d4f8343fcc785e8_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjU4MDA_178aca65-5a90-4ef1-9147-8d22915d61ed"
      unitRef="usd">280000000.0</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborationAgreementsUpfrontPayments
      contextRef="i983d2a459669479ea167c4f7883b0a2a_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjY0Nzk_5d80a3af-9124-4ac9-944f-6f962f940838"
      unitRef="usd">7500000</exel:CollaborationAgreementsUpfrontPayments>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="ic9d59bfad27b4babaf33ea9828f5e7db_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjY5Mjc_40da5c16-38b8-4130-bf11-593fbfb4dc8d"
      unitRef="usd">20000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="ic9d59bfad27b4babaf33ea9828f5e7db_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjcxMTE_c45f7f2b-0b79-44ae-b11b-aff784084fce"
      unitRef="usd">190600000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="ic9d59bfad27b4babaf33ea9828f5e7db_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjcxODY_82c3930f-3367-4ccf-a63f-06e0fd2bf55c"
      unitRef="usd">262500000</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="i2b3fd10a6b8e4b88964207e8afc24c36_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjg2MzQ_65c26bac-ab16-4dd1-b43a-74adbbd5a629"
      unitRef="usd">131500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:ProjectInitiationFeePayment
      contextRef="i31f84a4833d5496fafe3fb2b06ee4da2_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjg4NDM_d42f1bcf-d67d-46a6-89f4-720518ccba2b"
      unitRef="usd">43400000</exel:ProjectInitiationFeePayment>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="i18fefd085e3c45968805d31566f5a911_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjkxMTQ_1700341b-3e72-4fa8-950a-64ab5b6807cd"
      unitRef="usd">325000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:UpfrontAndMilestonePayments
      contextRef="i4bf737b2abae44928037ed75a133e223_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMjkzMTE_b2ee02b6-ba2e-4014-b218-4af234d0ac6d"
      unitRef="usd">2000000.0</exel:UpfrontAndMilestonePayments>
    <exel:UpfrontAndMilestonePayments
      contextRef="i81c0e0276859476d8764f5e4a7c6a702_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMTgxNDE5NDE5NjMzNjI_bd8d6f4d-0e17-4e4b-9f1c-6d76b8441c3b"
      unitRef="usd">3000000.0</exel:UpfrontAndMilestonePayments>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="ia5be837eaece4b1e827b2ac075babd6c_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF85NC9mcmFnOjkyMzU2NGEwYWUzZDQ5N2E4MjQ4ZWFlMWY5NzcyZGMzL3RleHRyZWdpb246OTIzNTY0YTBhZTNkNDk3YTgyNDhlYWUxZjk3NzJkYzNfMzA0MDM_15ed8724-5746-40cd-be87-ef169f392c35"
      unitRef="usd">56500000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxNjc_029d65e4-784e-4cba-8e4e-a62509eaeb9c">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.470%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit and, during prior periods, a purchasing card program. The long-term classification of restricted cash equivalents is based upon the remaining term of the underlying restriction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $4.5 million and $6.2 million as of December 31, 2020 and 2019, respectively, and is included in prepaid and other current assets in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.809%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.877%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All securities presented have been in an unrealized loss position for less than 12 months. There were 14 and 9 debt securities in an unrealized loss position as of December&#160;31, 2020 and 2019, respectively. During the years ended December&#160;31, 2020 and 2019, we did not record an allowance for credit losses or other impairment charges on our debt securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxNzI_c7dc9da7-23ab-4701-adc3-e13ee4cbe7ac">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.470%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxODI_2c577f19-92ce-412c-b2b8-5e1f28c963e2">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.470%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzItMS0xLTEtMA_f55d3bca-eb7c-40db-9c5c-ed7a2f302c81"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzItMy0xLTEtMA_6cbaa6f1-b4f6-45ea-ab22-e2cdaeba975e"
      unitRef="usd">266501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzQtMS0xLTEtMA_9611a1ae-94b0-4e19-926b-14dfbbdfeb13"
      unitRef="usd">1555000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzQtMy0xLTEtMA_0d5dfe0c-43d5-47d9-8b40-54106fb70580"
      unitRef="usd">1636000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzUtMS0xLTEtMA_8856bb40-8f73-49a0-8b81-a1a18a52dcc3"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo0NGQ5ZTk5MGE1MjQ0ZjRiYjE5MzFlYjlmMTRjODEzOS90YWJsZXJhbmdlOjQ0ZDllOTkwYTUyNDRmNGJiMTkzMWViOWYxNGM4MTM5XzUtMy0xLTEtMA_cf8d5cb9-ba28-4f51-b2ed-3a4ff2b0ec1a"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxNzU_623cd6fd-1708-4fca-9cb4-1089fe3f19b4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i17d081623400481896632ff697c68f09_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzMtMS0xLTEtMA_2c73cd3a-d7ac-4b63-9d49-4800174c080a"
      unitRef="usd">569456000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i17d081623400481896632ff697c68f09_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzMtMy0xLTEtMA_7eeeb037-6a15-49c6-ba80-d59e0c3acd0b"
      unitRef="usd">372000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i17d081623400481896632ff697c68f09_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzMtNS0xLTEtMA_8ba5cd6e-fae2-41ab-8cae-91596f4d66d3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i17d081623400481896632ff697c68f09_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzMtNy0xLTEtMA_0580f808-c954-4e88-b2c9-d630244ba7fc"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7af67120954b4cc4a261206766a42684_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzQtMS0xLTEtMA_d838e16a-4547-48e9-928d-c2325c79126f"
      unitRef="usd">543520000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7af67120954b4cc4a261206766a42684_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzQtMy0xLTEtMA_59370034-e393-4888-942c-28c575957b2b"
      unitRef="usd">5244000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7af67120954b4cc4a261206766a42684_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzQtNS0xLTEtMA_6118e8a4-6bbf-4068-9594-70e1e44a1de9"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7af67120954b4cc4a261206766a42684_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzQtNy0xLTEtMA_7971d703-4d4b-4848-b153-630be8901472"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzUtMS0xLTEtMA_8588427e-d984-4d2a-8124-ab08a0ca4498"
      unitRef="usd">208326000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzUtMy0xLTEtMA_fb128b03-9d24-4e1e-be6c-2fb5861f793e"
      unitRef="usd">232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzUtNS0xLTEtMA_275fa0f1-f47c-4f89-81c8-805f862eff75"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzUtNy0xLTEtMA_c2ea075a-d1ff-4993-ba7a-14ef2bd8f637"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtMS0xLTEtMTA3Nzc_7ff82bda-5d8a-4fab-90bc-0d1ed100fd97"
      unitRef="usd">28680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtMy0xLTEtMTA3Nzc_396e85e3-ae3d-47fb-91d5-6d298a754c87"
      unitRef="usd">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtNS0xLTEtMTA3Nzc_bff29e0a-188a-458b-a599-0accb02a21e9"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtNy0xLTEtMTA3Nzc_b6aa855c-40a5-4d1c-aba4-52ffc45085ad"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtMS0xLTEtMA_485c3ed0-54b0-43f0-9aa1-e76efd6d46f8"
      unitRef="usd">1349982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtMy0xLTEtMA_16d75d3b-3636-4f1b-b40c-274d4dbee880"
      unitRef="usd">5931000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtNS0xLTEtMA_8efadbf0-9b70-4a7f-9d9a-d4a9a685328a"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzYtNy0xLTEtMA_abef4e5a-a0f7-422f-b090-4b4866ac0926"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i0dc5c758e799403d8bf389459a614860_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzctMS0xLTEtMA_702c88ac-3a04-4e4e-91bf-f3ce8a083e5e"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i0dc5c758e799403d8bf389459a614860_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzctMy0xLTEtMA_ae70809b-7cd8-48f2-98e0-90106db9621d"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i0dc5c758e799403d8bf389459a614860_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzctNS0xLTEtMA_b1d54423-f985-49b0-a060-ff083264b9a3"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i0dc5c758e799403d8bf389459a614860_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzctNy0xLTEtMA_2d65a7f8-5563-4005-8a45-16b898278201"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzgtMS0xLTEtMA_9981361f-ac6a-441c-8b2f-3de018921d3b"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzgtMy0xLTEtMA_d6d812f0-6b5f-4a7e-941c-327c5eb8801a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzgtNS0xLTEtMA_20dcf11d-667c-4af2-b3cc-f438519fd03a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i6bd10b48f7dc449791391c5ae72c2c0b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzgtNy0xLTEtMA_054e50c6-8af7-4078-97a2-c39d1a90333b"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="if30b2890deda415d995921e5add2f92e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzktMS0xLTEtMA_bdee9a67-2328-47eb-8f74-7f0b1db5754b"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="if30b2890deda415d995921e5add2f92e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzktMy0xLTEtMA_5ca65e06-995a-40a4-8e31-1e2b36e10893"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="if30b2890deda415d995921e5add2f92e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzktNS0xLTEtMA_11853d6f-c550-424d-bb4a-304c121a7bce"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="if30b2890deda415d995921e5add2f92e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzktNy0xLTEtMA_ce43e3dc-32d0-4e1c-b36e-1924af93c8d6"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzEwLTEtMS0xLTA_49e8a09b-79ce-4376-853d-c3edf3bedfe9"
      unitRef="usd">1532923000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzEwLTMtMS0xLTA_f48e1c80-ff10-4a55-8372-bd68d80c700f"
      unitRef="usd">5931000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzEwLTUtMS0xLTA_f6709cc6-da40-4506-8c58-8be4d5b9eb9f"
      unitRef="usd">12000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphZDI5MmVkNWNkNjM0MjIxYjIzMjc1Yzk1YTU1Mzc2Ny90YWJsZXJhbmdlOmFkMjkyZWQ1Y2Q2MzQyMjFiMjMyNzVjOTVhNTUzNzY3XzEwLTctMS0xLTA_1afb58b4-e0bb-4ace-b4d5-ec8596779930"
      unitRef="usd">1538842000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3abfb693aa34441595492bf56588fe6f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzMtMS0xLTEtMA_687f29c5-880b-4939-858b-8e6f3ef2d4b4"
      unitRef="usd">389573000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3abfb693aa34441595492bf56588fe6f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzMtMy0xLTEtMA_6826a0ad-e1b4-4f00-ad5f-59f728ae2897"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3abfb693aa34441595492bf56588fe6f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzMtNS0xLTEtMA_093db4f1-cba3-4b0c-bf09-ff481e5dbe19"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3abfb693aa34441595492bf56588fe6f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzMtNy0xLTEtMA_e90b507c-cdc2-4350-b602-16294e8dfab7"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzQtMS0xLTEtMA_668fee18-be0b-47e9-a9ad-b913b6544120"
      unitRef="usd">752295000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzQtMy0xLTEtMA_81e3cf9a-8001-4e79-85b9-e5c1199612ba"
      unitRef="usd">3934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzQtNS0xLTEtMA_8de13ac6-ffbb-437e-9a2f-7e5e9f9b3934"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzQtNy0xLTEtMA_63471485-a587-4cde-a2d5-4380180f1755"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzUtMS0xLTEtMA_a11342e1-d846-4ab4-8536-84d76bb98c26"
      unitRef="usd">166483000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzUtMy0xLTEtMA_4c46f064-965f-4093-b85d-cc670f06a378"
      unitRef="usd">187000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzUtNS0xLTEtMA_f0784180-8978-48a0-bc33-829bb1243f2c"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzUtNy0xLTEtMA_55b86582-1a8e-4402-99f2-5d1f4f9484d2"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzYtMS0xLTEtMA_9a68d92f-dd0e-4a41-8d8a-5b4ad3af523d"
      unitRef="usd">1308351000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzYtMy0xLTEtMA_436da75e-dd6d-4aa6-8416-c8bca5480e15"
      unitRef="usd">4121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzYtNS0xLTEtMA_ae544b6a-d64c-4e73-aaa6-bd0c0061dd59"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzYtNy0xLTEtMA_ae9174d8-4b03-4656-9889-f67ebab86108"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzctMS0xLTEtMA_4780961c-7954-4295-ae3a-ef205da9e35b"
      unitRef="usd">40964000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzctMy0xLTEtMA_1337f740-51c3-4b9e-a1bd-b502395a3ca4"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzctNS0xLTEtMA_fe3fecf2-0521-43b0-bfff-9577dcee60bf"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i116781c6bf0d4a50b73d1f6fc589f03b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzctNy0xLTEtMA_35de8e9e-1fa6-4a20-8a9b-81cbf43446c7"
      unitRef="usd">40964000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i4a6aa1d2955343a4891ce98d02c37c65_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzgtMS0xLTEtMA_c2d28581-5f57-4c9f-8b72-e5600229e1bb"
      unitRef="usd">2467000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i4a6aa1d2955343a4891ce98d02c37c65_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzgtMy0xLTEtMA_a724893f-738f-4a2a-b8ec-8ce93de2072f"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i4a6aa1d2955343a4891ce98d02c37c65_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzgtNS0xLTEtMA_71a83717-2a85-4b87-a2b5-e8ba4502877e"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i4a6aa1d2955343a4891ce98d02c37c65_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzgtNy0xLTEtMA_b8f57a07-44d4-4bd6-a46e-7431e9af0057"
      unitRef="usd">2467000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ia13a4caccaf947b896a2346494374f6d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzktMS0xLTEtMA_da42bbe0-aa91-44a3-9bf9-841e07f3eaaf"
      unitRef="usd">32728000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ia13a4caccaf947b896a2346494374f6d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzktMy0xLTEtMA_92fb7684-4d97-4f1e-a54b-46bb21d90e62"
      unitRef="usd">5000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ia13a4caccaf947b896a2346494374f6d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzktNS0xLTEtMA_5f20b998-2ec9-4f3c-bd0a-81b6e29c11a5"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ia13a4caccaf947b896a2346494374f6d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzktNy0xLTEtMA_46bc328c-f66b-4afc-b72f-67d5137ed73f"
      unitRef="usd">32733000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzEwLTEtMS0xLTA_df90dd7b-5930-4e57-8d54-8c8c220a70f9"
      unitRef="usd">1384510000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzEwLTMtMS0xLTA_c63ec277-263b-4ada-b20b-0b635c46cd50"
      unitRef="usd">4126000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzEwLTUtMS0xLTA_720492cd-9119-4cf9-ad57-821f54f1879d"
      unitRef="usd">8000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToxODA5NTY0NDdiZjQ0YjcyYjQyYzBjMjkwOGVjNzIwZi90YWJsZXJhbmdlOjE4MDk1NjQ0N2JmNDRiNzJiNDJjMGMyOTA4ZWM3MjBmXzEwLTctMS0xLTA_e83be208-24c6-42cc-a9ac-b8108ee9d4ee"
      unitRef="usd">1388628000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxOTkwMjMyNTkxMTg_c474a7bb-1f26-4254-89c2-3d677f44c03f"
      unitRef="usd">4500000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxOTkwMjMyNTkxMjQ_0043f151-40f2-45bf-97bd-7d031f41ed05"
      unitRef="usd">6200000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxNjA_203daaf7-a795-403d-9faa-1ba9a94064d9">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.809%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.877%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7af67120954b4cc4a261206766a42684_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzMtMS0xLTEtMA_d035a4fe-bb4f-4482-a499-6e919948ceae"
      unitRef="usd">28445000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i7af67120954b4cc4a261206766a42684_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzMtMy0xLTEtMA_5fb52b6e-126b-431d-92c6-9cfaad314364"
      unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzQtMS0xLTEtMA_cffa1728-404d-4f53-84c2-4692d661065f"
      unitRef="usd">21989000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i719d03a237a8464abb14ec240d32bb64_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzQtMy0xLTEtMA_4755e176-e23a-4475-ae6b-1a686c722073"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzUtMS0xLTEtMTM2ODc_a1eeacc4-03e5-4d8d-a99b-df06ff9a9672"
      unitRef="usd">5865000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i53dd92b8be66418ca6e6e1a20e1d4626_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzUtMy0xLTEtMTM2ODc_5f4f9451-4bab-4acc-802e-4789d34556ef"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzUtMS0xLTEtMA_1da44907-5203-4e98-9741-6a1a612c14bb"
      unitRef="usd">56299000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTo5ODE4NjU0YTI2MzQ0NjY0OGQ0NWRlZTRiMWJjYTc4Ni90YWJsZXJhbmdlOjk4MTg2NTRhMjYzNDQ2NjQ4ZDQ1ZGVlNGIxYmNhNzg2XzUtMy0xLTEtMA_32d6425e-7650-407c-9196-5d2f7b117613"
      unitRef="usd">12000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzMtMS0xLTEtMA_eff5ece7-5895-40fe-b307-91e4101844b4"
      unitRef="usd">14529000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i97a4320d1955404c9d175bf4c6946164_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzMtMy0xLTEtMA_651b23ab-36df-4af8-bb8a-3a0e5f7c6421"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzQtMS0xLTEtMA_f5a77891-cd52-4e26-9fc3-db569467f067"
      unitRef="usd">2848000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5d0a04be132f455c9b521c192c5d4816_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzQtMy0xLTEtMA_0c31287b-3edf-401a-9e84-98bd66d1a1f2"
      unitRef="usd">5000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzYtMS0xLTEtMA_b1dc3c8d-f2f3-4df9-9b30-8afae8ec541b"
      unitRef="usd">17377000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZTphNjE2MzY3NWE4YWM0Yjg0OWU3MzBmNGRiN2YxMzU2Yy90YWJsZXJhbmdlOmE2MTYzNjc1YThhYzRiODQ5ZTczMGY0ZGI3ZjEzNTZjXzYtMy0xLTEtMA_5b59dc75-65d2-4895-92bc-b6943d897003"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzEzNTQ_10f8d054-72f4-4833-a43c-6dc80f6ce384"
      unitRef="investment">14</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzEzNjE_8aff97de-f7ad-41be-a8cc-fe8aa73eab04"
      unitRef="investment">9</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzE0ODM_1e110bf2-6057-41e8-a4f5-986a078bc4ed"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzE0ODM_a16aa40d-c9ff-4c19-9f64-748123dcd490"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90ZXh0cmVnaW9uOmFmYzE5YjVmYTFkODRkYThhZWZjODdhMDMzOGFmMzM2XzIxODQ_1c91a5d5-b91f-4be1-a599-705ce434e233">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzItMS0xLTEtMA_c16a9bf5-cc19-436b-a2c4-39dcf4ebc8c7"
      unitRef="usd">1034150000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzItMy0xLTEtMA_76bd69b4-dae7-4321-ac41-d526d2433760"
      unitRef="usd">789913000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzMtMS0xLTEtMA_e67cb74b-d9e8-497c-ab68-b19585ca6e7f"
      unitRef="usd">321751000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzMtMy0xLTEtMA_fa2101c4-141e-4ebd-abf2-f1acfa037132"
      unitRef="usd">522551000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzQtMS0xLTEtMA_54ecbe43-6056-42b4-8912-cb37d004ffff"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDAvZnJhZzphZmMxOWI1ZmExZDg0ZGE4YWVmYzg3YTAzMzhhZjMzNi90YWJsZToyYWNkNjMwYjNkNWM0OTJlYWM0YmIxNzFlMzI5MTc3Mi90YWJsZXJhbmdlOjJhY2Q2MzBiM2Q1YzQ5MmVhYzRiYjE3MWUzMjkxNzcyXzQtMy0xLTEtMA_17fc3a3f-ec4f-49d2-85c5-8931ddcf2838"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90ZXh0cmVnaW9uOjgzZmIxNGM1YmJkNzRlMGZhMWZmNGY2NGMxNzI1ODI5XzE1Mzc_38386169-4037-483c-af1a-1a7482e02aec">FAIR VALUE MEASUREMENTS &lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90ZXh0cmVnaW9uOjgzZmIxNGM1YmJkNzRlMGZhMWZmNGY2NGMxNzI1ODI5XzE1MzY_5241c8f5-ac22-485a-8ad0-97e9cddff248">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;756,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf372caf57ca4f559b15221706d0804e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzItMS0xLTEtMA_d5271092-c2f2-4a90-9f2f-24c746c803e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia0157be3fc964514bc2958bfb787c58a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzItMy0xLTEtMA_f827eabc-98a1-48f7-9d43-0fab437e0880"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8fc6a38873324d77a83f8d597f112838_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzItNS0xLTEtMA_08fbec96-e252-463a-b671-71299ea6dcde"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0eaa96e028b4053b1efe87fba0c9717_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzMtMS0xLTEtMA_6c6b6441-ef7b-4ca1-ac8b-13ce06c93977"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fc2641cbeaa48948ef1c5857c38598b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzMtMy0xLTEtMA_82f2bf59-25b9-4e69-9503-17fb3b5c50e0"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i069a49e8f5be408d82aaa57b1a6719ac_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzMtNS0xLTEtMA_2f168818-20b5-4915-82e5-98997cdecbb9"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ida017550b79b42f19804feb9178fe6eb_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzQtMS0xLTEtMA_23e67f23-e474-48ca-a2d6-31d76d5b885f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4d1bc6310d94e49a10dfa40633813f8_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzQtMy0xLTEtMA_4aaa6fdc-a6b3-40ae-a264-026c29450966"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d9fe388a10f409382aa696ce09464b2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzQtNS0xLTEtMA_ba98feed-0f66-49b7-8066-9f5c4a71c0aa"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20ed515384c7421c990b3a08dbbd6099_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtMS0xLTEtMzY4Nw_786d7a1d-e5a6-4e48-9473-10d83d1d8855"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c49a80af73c4beba087da528040761f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtMy0xLTEtMzY4Nw_73e10dcb-b55d-45dc-9694-d093886274a1"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c0f3562ea854a648ae333d957392a30_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtNS0xLTEtNjExMQ_68ed19ae-98c7-4953-97bc-48c2801c0588"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7639ff188d85446bb4eb34d103edacad_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtMS0xLTEtMA_72d568f7-de66-475e-80e4-703d06e09e22"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d5ef12d4ebf4f4cb3fc541d5b53ab44_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtMy0xLTEtMA_18ed2603-febc-4b0b-9e75-388eaf4cbe21"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ad45f83363a4cb8a086062be42c031e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzUtNS0xLTEtMA_e705e025-ab55-4553-b128-a84ca7073a6c"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7a1df0270288443da1ddfde204282b4e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzYtMS0xLTEtMA_c2b2ec5e-1b29-4be6-8f67-ad7f2dccc25c"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i92e63c05de294a7cbe329b32c4008c0f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzYtMy0xLTEtMA_9af610cc-75ec-4e67-b74e-5c95d7c42734"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife44d28f1dee43d38997d75f2a09fa60_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzYtNS0xLTEtMA_2824fd9a-6531-4e0b-a8ec-9e8c74740032"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i986255f527ad4a68a1be4173bed991ad_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzctMS0xLTEtMA_732aa79c-b210-406d-8586-dd2e3b32c774"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i85c8c3490b0545f487d8a0d33ebd6813_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzctMy0xLTEtMA_a26bc113-5af7-416b-95e1-a8b4c95de1ce"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i35781ca0758f401a8c144a5efb7fe50c_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzctNS0xLTEtMA_6b8abec7-9ce9-4f2c-a75a-c1f95afda02f"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7639ff188d85446bb4eb34d103edacad_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzgtMS0xLTEtMA_b8e0e101-b097-4ff5-ab05-1021c2e3906d"
      unitRef="usd">40761000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4d5ef12d4ebf4f4cb3fc541d5b53ab44_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzgtMy0xLTEtMA_2e8aef7e-347a-4326-b7ae-834ad4f97399"
      unitRef="usd">1415905000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ad45f83363a4cb8a086062be42c031e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxYTg2NTM2MWQwODI0ZGFiODQ3ZDRhNzM5ZGZiOGI2MS90YWJsZXJhbmdlOjFhODY1MzYxZDA4MjRkYWI4NDdkNGE3MzlkZmI4YjYxXzgtNS0xLTEtMA_54d5ed74-0c9b-41ef-810a-84bf36228876"
      unitRef="usd">1456666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if18b5f0c5ebb43f6b8c762bf61f6bda2_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzItMS0xLTEtMA_0094125d-5002-49f7-b46e-c536eaef2bbe"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb849f127a4644bf8dcdc6b5433726b0_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzItMy0xLTEtMA_b6d37bf0-c327-463d-a00b-0fcb8037f61b"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40d84ea6c5fb486b9667f60233ed45e3_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzItNS0xLTEtMA_8ff183fb-c46d-4662-b4da-e9022b7c13c1"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7119ffed0114f1ba08264ccb9cca54b_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzMtMS0xLTEtMA_b4bbe3f6-d415-46c5-9e39-3cdeab82dd16"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if934e0098e2b485187fb3417498f8c7f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzMtMy0xLTEtMA_2d6ed05e-8ef3-4a6b-bc91-12d506b87e98"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc5bb0744d9e4ad8afb77bb50648a4eb_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzMtNS0xLTEtMA_1d5f1b61-abd4-458d-a48f-a6e0e275c9bd"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i39b2e5c3b01d455c8647c0de87550b58_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzQtMS0xLTEtMA_86f69c00-357e-465c-974b-6db958704c10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8094749dc1cf43faa8d4a49cc37284a4_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzQtMy0xLTEtMA_23efbcea-e9c6-4618-a548-584796db30b5"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id214d22093b342b5bb46f742fa9a8d1d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzQtNS0xLTEtMA_3555224c-9eb2-46c7-86e0-dce4fd5ebb8e"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa35986fd3ca43b8a2ae20dce6d9597d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzUtMS0xLTEtMA_05f82300-2ac0-478c-b8b8-410dbd918768"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i402214e5b6cd492ea640e28a56b8c84e_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzUtMy0xLTEtMA_45c26c56-98a8-47ad-99d3-e504e203c3ed"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7cf947a15c2442f7b9c355990703eea0_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzUtNS0xLTEtMA_3bf18142-88fb-4939-a738-7939e70c525c"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id59418bb9d714b4aa3e6fca17c908d91_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzYtMS0xLTEtMA_5cccc7de-2af4-4eb5-bb71-943e6ae122b6"
      unitRef="usd">2467000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia39618bc0e2441e6a4d20c14598583b9_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzYtMy0xLTEtMA_e0e95be7-5822-4e93-ba73-e9091f02c32f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if21e1073886448ea9bd7d5e0a33dfbf3_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzYtNS0xLTEtMA_f6c5899c-9542-4ef6-b56d-9cf83e2b0dcb"
      unitRef="usd">2467000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6557679589e544abacc2ec388a331430_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzctMS0xLTEtMA_fe265eb6-e419-41dd-924b-fea8df0c378e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1c5519e86b5a4926b1ec10602426647e_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzctMy0xLTEtMA_31818b85-0df3-43c1-a1ec-126c09c541f1"
      unitRef="usd">32733000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i62e1b62fcdc14ca6a9f31d5d9be0052f_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzctNS0xLTEtMA_135d679b-f1bd-4531-99b8-e9d6b0191874"
      unitRef="usd">32733000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaa35986fd3ca43b8a2ae20dce6d9597d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzgtMS0xLTEtMA_10952b1a-16b3-44a2-a364-c936ca30ef21"
      unitRef="usd">2467000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i402214e5b6cd492ea640e28a56b8c84e_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzgtMy0xLTEtMA_18168b46-1cbe-4ff8-97b2-6dafe5398936"
      unitRef="usd">1345197000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7cf947a15c2442f7b9c355990703eea0_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDYvZnJhZzo4M2ZiMTRjNWJiZDc0ZTBmYTFmZjRmNjRjMTcyNTgyOS90YWJsZToxZjMyNzQ4NDRlMGQ0YWM4YWRlZTkwZTNkN2QzYzMzNC90YWJsZXJhbmdlOjFmMzI3NDg0NGUwZDRhYzhhZGVlOTBlM2Q3ZDNjMzM0XzgtNS0xLTEtMA_4cf45dc4-cfb8-4921-98d9-600f98c359ca"
      unitRef="usd">1347664000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzIxMg_dc3b1ef7-e3e5-4dc1-b274-206dd715e72d">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Write-downs related to excess and expiring inventory were $2.7 million, $1.3 million and $1.1 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzIxNA_2fb0708f-abe3-4a46-acaa-dcb90a2d08f9">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzItMS0xLTEtMA_b1dc9d6b-57b0-4c79-9ff5-7ff1031c55da"
      unitRef="usd">7773000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzItMy0xLTEtMA_52780be4-a473-48f5-ae50-acf2ccdd9808"
      unitRef="usd">2709000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzMtMS0xLTEtMA_fb3a052a-8d47-42f1-bbce-56cb69f900d3"
      unitRef="usd">20610000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzMtMy0xLTEtMA_b278e9f6-2c30-4f6e-91ef-c8e8730901b6"
      unitRef="usd">9447000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzQtMS0xLTEtMA_9674c78d-92ef-45c2-95ef-d64e3a0c64b2"
      unitRef="usd">7291000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzQtMy0xLTEtMA_2e755234-7bb1-4306-b055-2a34ccbf1187"
      unitRef="usd">4367000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzUtMS0xLTEtMA_8d148202-d523-47e9-abad-06216f387f3a"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzUtMy0xLTEtMA_f58a0fb2-d3dc-47e9-b0d6-78e667da8deb"
      unitRef="usd">16523000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="icac617d311944d31900ede53774bb2e2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzctMS0xLTEtMA_778c08c5-4ef2-4f6d-b225-ae4c98942a89"
      unitRef="usd">20973000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i6a8ac00f5aec4ccabaefa0b0d9356610_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzctMy0xLTEtMA_47d73503-5587-4883-b2da-7d02a78ee1d9"
      unitRef="usd">12886000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i838461c261004859a7bee283a1308e10_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzgtMS0xLTEtMA_59102005-788b-4df1-8328-2dd1badd909c"
      unitRef="usd">14701000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i84bd021da59c4253a45563017be7db6d_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzgtMy0xLTEtMA_af520108-3587-4d3b-9236-1a10db4b14e4"
      unitRef="usd">3637000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzktMS0xLTEtMA_8f6be0ca-ee3a-4165-acb8-5e84624bf02c"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90YWJsZTpjMWM2NGJmNTZkM2E0ZTg3YjBkODA0NWQ4OGE4ZDYxMy90YWJsZXJhbmdlOmMxYzY0YmY1NmQzYTRlODdiMGQ4MDQ1ZDg4YThkNjEzXzktMy0xLTEtMA_2bd6ce18-53ba-412e-9bdc-f36aa8bda32d"
      unitRef="usd">16523000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzEzOA_11394b0b-934e-4a44-b902-fb19fa85510a"
      unitRef="usd">2700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzE0Mg_503e6e84-c228-4db5-85ba-6ee6b66ed8c4"
      unitRef="usd">1300000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMDkvZnJhZzoyMzk0YWY1MTk3MjY0NWE1YWE3YjYzYmVjZmVjZWZmZi90ZXh0cmVnaW9uOjIzOTRhZjUxOTcyNjQ1YTVhYTdiNjNiZWNmZWNlZmZmXzE0OQ_4611bf94-4d9f-461e-af3c-6e10a9667baa"
      unitRef="usd">1100000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzE5OA_fef16978-c35d-400c-91a5-ff53b8f3c615">PROPERTY AND EQUIPMENT&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $9.1 million, $8.3 million and $4.9 million during the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzE5Ng_a7672512-44a8-450c-bb37-0c32dd2f362e">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;up to 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i860abaa1da4847479d900fa60c22e404_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzItMS0xLTEtMC90ZXh0cmVnaW9uOjc5MzFkYzNiNzVhMDQ3NGRiYzAzMzQ1OWJjZDg5NjhjXzcxNDY4MjU1ODA1NzA_a415934e-8e58-4325-b4d3-285338539515">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibf6cf0349c204074bedad9d2664384d1_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzItMy0xLTEtMA_e587dd60-2283-4ed4-b7d0-9561c5b8ed21"
      unitRef="usd">40694000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3b8747a320f44fe4a77fe534734d347a_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzItNS0xLTEtMA_e00d3799-dd04-4ccd-ad79-3a1200edffc2"
      unitRef="usd">33904000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4d449cb77a0446d693fd6c3747eba20d_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzMtMS0xLTEtNjk2Mg_6adc13ab-6ae6-4d99-91d5-6111d2fdf195">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7f0498a995a2400bbec4140ae912e037_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzMtMy0xLTEtMA_4e25a3aa-15fc-49ec-a06a-b230a18d5273"
      unitRef="usd">18376000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0e0bd3de5abe4d67bbbb22990c63c5a0_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzMtNS0xLTEtMA_bf11c1dc-3851-4704-9cfc-4c0da3efaf21"
      unitRef="usd">17338000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id5915973202f4822a05789837fd15e95_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzUtMS0xLTEtNjk2Mg_88b4d216-d8ae-4040-bb29-f055e2ec4974">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9908b52633254703886d1ac7263e2148_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzUtMy0xLTEtMA_399d71a9-2baf-4bd4-8704-fb15443e7b29"
      unitRef="usd">14931000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i29200dad69e047a8b7cbecb940c93115_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzUtNS0xLTEtMA_8c507094-4a51-4886-ad00-5a57bfbcd4d2"
      unitRef="usd">13053000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie1bacc0a00bf43eba9ebd3d73dc83589_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzYtMS0xLTEtNjk2Mg_58b83ad9-1ce4-460e-bf55-73429a59a789">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6f71d3e4f66641b59129ea1f7de0d2cf_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzYtMy0xLTEtMA_eccc2d3f-5b1d-491e-87c1-29cd675c668b"
      unitRef="usd">11707000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i42ce43d4b56040f2843d79745b7c30b1_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzYtNS0xLTEtMA_93f620ca-d03b-4fec-aaaf-0c6dd6784c0f"
      unitRef="usd">8904000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i311c3d1a54394d4a813f2d882cd22021_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzctMy0xLTEtMA_bbae70c0-fdc2-4f8d-bbd9-2f502db55fc0"
      unitRef="usd">16360000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iee23e46acdf243f48669d23de632fc77_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzctNS0xLTEtMA_63afd910-3261-47bc-95be-ba4b2e3b5e10"
      unitRef="usd">1253000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzgtMy0xLTEtMA_534e546c-d9d3-415c-a868-86bb2c32d001"
      unitRef="usd">102068000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzgtNS0xLTEtMA_cd5aee0d-cfbe-4082-a6a4-0934e569d8fa"
      unitRef="usd">74452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzktMy0xLTEtMA_7f5f6e52-f026-41e2-bc94-29b0da3cc364"
      unitRef="usd">34684000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzktNS0xLTEtMA_279166f8-b2f2-48d7-86ed-5cee9ad0f4e9"
      unitRef="usd">25560000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzEwLTMtMS0xLTA_bb15b3e4-3755-4844-b015-2745a3912d71"
      unitRef="usd">67384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90YWJsZTo4Zjk3MjU1Mjc0NDg0ZDkxOTI4MTlhYzM0NmI5NDBmNC90YWJsZXJhbmdlOjhmOTcyNTUyNzQ0ODRkOTE5MjgxOWFjMzQ2Yjk0MGY0XzEwLTUtMS0xLTA_73979b35-4b15-46ab-8289-4240668755c4"
      unitRef="usd">48892000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzEzMQ_60d37fe8-5942-482a-888f-781430158e5b"
      unitRef="usd">9100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzEzNQ_0945ef71-3056-4df8-9763-63e50ab8b6b7"
      unitRef="usd">8300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTIvZnJhZzpkYzg3ZjY3ZWJjNGU0ZDA3OWVkMTczODhlMTZjODU3Yi90ZXh0cmVnaW9uOmRjODdmNjdlYmM0ZTRkMDc5ZWQxNzM4OGUxNmM4NTdiXzE0Mg_3ea96c8b-bbbc-420f-a125-f20740c6e8dc"
      unitRef="usd">4900000</us-gaap:Depreciation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxMDI_1ccae2b4-39c5-48f8-94a2-bfbb1f9233f8">EMPLOYEE BENEFIT PLANS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans and ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several equity incentive plans under which we granted stock options and RSUs, including PSOs and PSUs, to employees and directors. At December&#160;31, 2020, 17,100,727 shares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option award and 1.5 shares for full value awards granted in the form of RSUs or PSUs. On May 20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by 21,000,000 shares, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors (the Board) delegated responsibility for administration of our equity incentive plans to the Compensation Committee of the Board, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a seven-year life from the date of grant. RSUs granted to our employees and directors generally have a four-year vesting term and a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;one-year vesting term, respectively. PSUs and PSOs granted pursuant to our equity incentive plans vest upon specified service conditions and the achievement of a performance target or market condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#x2019;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of 85% of the closing price at the beginning of the offering period or 85% of the closing price at the end of each six month purchase period. As of December&#160;31, 2020, we had &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,704,580&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares available for issuance under our ESPP. Pursuant to the ESPP, we issued 534,419, 483,009 and 330,492 shares of common stock at an average price per share of $14.55, $12.60 and $15.74 during the years ended December&#160;31, 2020, 2019 and 2018, respectively. Cash received &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from purchases under the ESPP for the years ended December 31, 2020, 2019 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was $7.8 million, $6.1 million and $5.2 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used a Monte Carlo simulation pricing model to value PSOs that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options, including PSOs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options, including PSOs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We considered both implied and historical volatilities in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#x2019; current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs, including the PSUs, was based on the closing price of the underlying common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for stock options, including PSOs, during the year ended December&#160;31, 2020 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $27.1 million of unrecognized compensation expense related to our unvested stock options, including PSOs. The compensation expense for the unvested stock options will be recognized over a weighted-average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted 308,365 PSOs to our President and Chief Executive Officer. In addition to the standard service-based vesting conditions included in our other stock options, these PSOs contain a market vesting condition such that they may not be exercised until, at any time after the grant date, the closing market price of a share of our Common Stock is equal to or greater than 125% of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. This market vesting condition was achieved during the second quarter of the fiscal 2020. The stock-based compensation expense for the PSOs is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant. The achievement of the market vesting condition did not impact the compensation expense recognized during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal 2020 and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on December&#160;31, 2020. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $106.5 million, $54.1 million and $39.1 million, respectively. Cash received from stock option exercises during the years ended December&#160;31, 2020, 2019 and 2018 was $26.9 million, $16.4 million and $12.1 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Activity for RSUs during the year ended December&#160;31, 2020 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $103.6 million of unrecognized compensation expense related to our unvested RSUs which will be recognized over a weighted-average period of 3.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Activity for PSUs, during the year ended December&#160;31, 2020 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, in connection with our long-term incentive compensation program, we awarded 2,327,840 PSUs (the target amount) that will vest upon the achievement of certain performance targets related to clinical trial positive top-line results and product approvals by the FDA (the 2020 PSUs). Pursuant to the terms of the 2020 PSUs, employees may earn up to 200% of the target amount, or 4,655,680 shares, depending on the volume and timing of achievement of the performance targets. The 2020 PSUs were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the year ended December&#160;31, 2019, we awarded 1,926,605 PSUs (the target amount) that vest upon the achievement of performance targets related to product approvals by the FDA (the 2019 PSUs). Pursuant to the terms of the 2019 PSUs, employees may earn up to 200% of the target amount, or up to an additional 1,926,605 shares relative to the target amount, depending on the volume and timing of achievement of the performance targets. The performance condition for early achievement of the 2019 PSUs occurred during 2020 representing 150% of the target amount. Employees have the ability to earn the remaining 50% of the target amount if the additional performance condition is met before December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2018, we awarded 693,131 PSUs that vest upon the achievement of certain product revenue, late-stage clinical development programs and discovery pipeline expansion performance targets (the 2018 PSUs). The 2018 PSUs and 2019 PSUs will be forfeited if the performance targets are not met by December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. Of the aggregate outstanding PSUs, 3,206,897 relate to awards for which we achieved the performance target or had determined that it was probable that we would achieve the performance target. As of December 31, 2020, the remaining unrecognized compensation expense for the PSUs achieved or deemed probable of achievement related to the PSUs was $11.8 million, which will be recognized over a weighted-average period of 3.5 years. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance target is probable was $128.5 million as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exelixis, Inc. 401(k) Plan (the 401(k) Plan)&lt;/span&gt;&lt;/div&gt;We sponsor the 401(k) Plan under which we have historically made matching contributions to our employees&#x2019; 401(k) accounts in the form of our common stock. Beginning in 2020, our matching contributions are in the form of cash. We recorded compensation expense of $6.7 million, $4.6 million and $3.6 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, for matching contributions to our employees 401(k) accounts.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxMDA_3ccc8a6d-628e-4566-9c1d-76a62097ab81">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib25087bb5db74d7892082c9d2e8abbb9_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzItMS0xLTEtMA_41cf378d-e524-47cc-b859-503965b81037"
      unitRef="usd">37198000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i820a33ad0ad94d8bafca231d31e69e59_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzItMy0xLTEtMA_77cbf62f-e1b3-4c07-907f-b966f711e89e"
      unitRef="usd">19374000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd1cc29eb8f243d28b13b3d0dca0006a_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzItNS0xLTEtMA_19f03531-70d7-49e2-86fa-64fbba53c731"
      unitRef="usd">13115000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i986427a5d3f3498d96c6bb4bbd51dfe2_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzMtMS0xLTEtMA_394da7ed-f3e0-43d7-b033-f2a5d869e42e"
      unitRef="usd">67872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i44d1190b6c354c31b284d1b82fbdecea_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzMtMy0xLTEtMA_fc56fb54-a784-448c-a438-bd41e58fd5e3"
      unitRef="usd">37228000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7bceefc7e604400898f9025b1854d66c_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzMtNS0xLTEtMA_c2ea0e21-5ba4-4e56-8674-7a9e17b16273"
      unitRef="usd">27511000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzQtMS0xLTEtMA_36adbba5-73c2-4422-8f49-799305f706fe"
      unitRef="usd">105070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzQtMy0xLTEtMA_ecc12be5-b11f-443c-b7a6-4cb6f71ea81d"
      unitRef="usd">56602000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpiODU5MzA4YTBkMTg0MzYwYWUzYmIwZTYwY2U0MTA0My90YWJsZXJhbmdlOmI4NTkzMDhhMGQxODQzNjBhZTNiYjBlNjBjZTQxMDQzXzQtNS0xLTEtMA_8204baaa-b06f-479c-881b-bb35ea47c349"
      unitRef="usd">40626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzItMS0xLTEtODc2_41bab354-e837-468d-963b-b4f86949b534"
      unitRef="usd">19863000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzItMy0xLTEtODc2_bee0ccfd-ac1e-4314-a9a8-9165a4fe7457"
      unitRef="usd">23422000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzItNS0xLTEtODc2_8147c25f-f685-445f-8e4f-85b4b34ef8ac"
      unitRef="usd">18896000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzMtMS0xLTEtODc2_12f8086d-5f2c-4be9-8bae-6115d0142ff7"
      unitRef="usd">35675000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if16546baee294f93bd2321559abcd2b2_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzMtMy0xLTEtODc2_c8710cce-ac47-4b95-a8e9-a29dd5d5da93"
      unitRef="usd">26056000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i848fd90527f24228a2613e80e7e75990_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzMtNS0xLTEtODc2_70b9d704-db1e-4742-b8c6-c94e6b729c0e"
      unitRef="usd">19569000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzQtMS0xLTEtODc2_983ddbd6-5d7c-4d67-a6c7-1dbae5c35444"
      unitRef="usd">47106000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzQtMy0xLTEtODc2_9b6a7f34-f524-4f7a-b4e7-e887c8eae7f9"
      unitRef="usd">4878000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e926b7757e84307b3dcf2ffb4e5018e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzQtNS0xLTEtODc2_48dd27d6-f045-4458-88a1-cba34de51473"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzUtMS0xLTEtODc2_7c998b32-4495-4e96-adec-f133a797b14c"
      unitRef="usd">2426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzUtMy0xLTEtODc2_1bbb0500-d722-446b-8e64-6881366922f0"
      unitRef="usd">2246000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzUtNS0xLTEtODc2_6cec6873-5119-42c3-83c1-b3d862f2969c"
      unitRef="usd">2161000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzYtMS0xLTEtODc2_32aa273e-5084-4da7-a5be-793cba7a2f99"
      unitRef="usd">105070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzYtMy0xLTEtODc2_99b19d3d-42bc-4c6d-a44b-d08b692d29ca"
      unitRef="usd">56602000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo1MDg5NmEwNDZhM2U0ZjY5YWFhZTQ4YmZjM2FiMDc1OS90YWJsZXJhbmdlOjUwODk2YTA0NmEzZTRmNjlhYWFlNDhiZmMzYWIwNzU5XzYtNS0xLTEtODc2_1e8f74bf-bc92-4a90-8e58-a34b70d0bd54"
      unitRef="usd">40626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzMzOQ_0041d6d9-23a4-4416-b2cf-66ac20651b91"
      unitRef="shares">17100727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzExNTQ0ODcyMTA2OTYx_12c4ffcb-2162-4ba8-8632-e715c03d12b7"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzExNTQ0ODcyMTA2ODk5_d039248e-fad3-4ffc-bca8-7edec85bce08"
      unitRef="shares">1.5</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i30cc87f6da8e43de85cc36cc45397719_D20200520-20200520"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzExNTQ0ODcyMTA2OTA0_ecd7045e-c24c-463d-b8fe-bbe05ec1cf7a"
      unitRef="shares">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iff59e3f4289c4d0ab16af9324d631d8e_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTYyMDk_2007db4f-c11c-43a0-8e34-19710915307a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i46ce9985487045a6bbff1b6565bb56c1_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTY1MTQ_ed8f8938-a819-4bc4-8f9a-a3275387603f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTYyMDg_81849f00-a069-4952-97d5-4fb6d3017e55">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8b8d59c75c8249ba84de243ad87e2493_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTYyMDc_58d00fbb-5974-4f63-a723-636cd0f0aedb">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i49dea6f971c2436c9436d84debc9c88a_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzEzNzQzODk1MzYzMzU4_bbf12abe-dc1c-439d-8689-787cd9771e4e">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIwNjQ_ca1a5a04-48b4-4891-9115-698eb227cb92"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxMzE_f0128213-ed51-4580-8b56-e267663714a5"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzcxNDY4MjU1OTg5Nzc_9df895ad-96ca-4bcb-b956-083e7616deb0">P6M</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iaccd048b7b154d2f9b562e5fe5bbec80_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIzMjY_8eb8a9ec-f27b-4e76-8fbc-b5bae856d61f"
      unitRef="shares">3704580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI0MDc_3375fb16-5ffc-4358-82d0-20bd60f8f5fc"
      unitRef="shares">534419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjM4MjY_9fe7d879-f935-47f5-876c-36c5771c6381"
      unitRef="shares">483009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjQwMjE_83eda3ab-7b2d-42b3-9238-3ae4e27809da"
      unitRef="shares">330492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="iaccd048b7b154d2f9b562e5fe5bbec80_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI0Nzc_12200719-eeac-4a46-b456-016524fc58bb"
      unitRef="usdPerShare">14.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i474cd4190d014fb9afd7d07dbde355fc_I20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI0ODE_bf9d2e6e-f1dd-4da7-8f45-0cd42bb78725"
      unitRef="usdPerShare">12.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i44f2592c3afb4c108a552d2de2e9f677_I20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjQwNTE_4e85f10f-46c2-4b17-b2b6-fafb392a567c"
      unitRef="usdPerShare">15.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI2Mzg_e0f4479e-38dc-4984-b295-83a7803451af"
      unitRef="usd">7800000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzI2NDI_71fc7838-e7fd-4ff1-9e23-7ecd51104ebb"
      unitRef="usd">6100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjM4NTg_0055e40c-bcfd-4e9c-b506-2061ecddcc85"
      unitRef="usd">5200000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxMTk_8a98a731-110a-47cc-be56-29db22a00b8a">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options, including PSOs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzItMS0xLTEtMA_67ff2638-d579-4188-bf0b-86fdd271a189"
      unitRef="usdPerShare">9.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzItMy0xLTEtMA_e88d1ca9-1e45-4865-ac01-cc6a45c23243"
      unitRef="usdPerShare">8.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzItNS0xLTEtMA_1427c393-cb0b-4956-9819-1dad3e318eaf"
      unitRef="usdPerShare">9.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzMtMS0xLTEtMA_5228693c-c259-404c-b2ed-bd0ce14bdc95"
      unitRef="usdPerShare">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzMtMy0xLTEtMA_87623b17-d65d-4820-b0a4-cd81921e8d1b"
      unitRef="usdPerShare">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTowNzE5MGU1NzY5OWU0OTYyOWQyOGVkMzU1MGQ0MTQyZi90YWJsZXJhbmdlOjA3MTkwZTU3Njk5ZTQ5NjI5ZDI4ZWQzNTUwZDQxNDJmXzMtNS0xLTEtMA_628fee52-210a-4800-b3fb-cb9b4d3fea1f"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgwOTQ_66ad8a2a-4d0b-4f3c-b36c-905c27cf856b">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options, including PSOs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxNDI_ad77efaf-6c8e-4738-b713-aa394311bc69">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options, including PSOs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzMtMS0xLTEtMA_fa778310-bb4d-492d-ba4f-2bbd015f5dc8"
      unitRef="number">0.0030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzMtMy0xLTEtMA_f6c3e6df-6f4e-4d24-935c-b4408fb51dc7"
      unitRef="number">0.0177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzMtNS0xLTEtMA_c5194ddb-d7a9-40ff-ad08-c7619a8e1c0a"
      unitRef="number">0.0281</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzQtMS0xLTEtMA_82653c7b-2e01-4929-9673-fbda2b7639ce"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzQtMy0xLTEtMA_b2a87a54-7597-4b7b-b317-02431c7d7261"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzQtNS0xLTEtMA_8128ffc3-c5c2-40a9-80d7-4d3d71c74ae5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzUtMS0xLTEtMA_6497a8d5-f865-4fd2-bff7-272d8b508008"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzUtMy0xLTEtMA_607a2b4e-03e1-45ba-ba24-d937a32bb19f"
      unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzUtNS0xLTEtMA_9d252a9d-e2a0-4f84-a558-daba60a89468"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzYtMS0xLTEtMA_04310358-7094-4c59-bc44-007ecacdd2d1">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzYtMy0xLTEtMA_a8591083-b0af-4ce9-9eba-2847c80ec9a3">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzYtNS0xLTEtMA_e0cd8f74-422f-49da-bfc4-8e135b165fa7">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzgtMS0xLTEtMA_2e6e48d1-2800-45e9-b023-724c2c3613ab"
      unitRef="number">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzgtMy0xLTEtMA_34b7f87c-08ac-4e4f-af5e-b6174cebbb39"
      unitRef="number">0.0216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzgtNS0xLTEtMA_9c1482fe-5c55-4069-9759-f7e3218c551c"
      unitRef="number">0.0193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzktMS0xLTEtMA_f2662874-7a09-425b-b310-c5609e11fe42"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzktMy0xLTEtMA_b28d8390-2a8d-4356-9c63-775b16f2715e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzktNS0xLTEtMA_1f9b6202-e158-4f36-a939-9ad26f5e06a8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzEwLTEtMS0xLTA_9e454835-7129-4c64-8671-aefe4105da24"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzEwLTMtMS0xLTA_463f4207-6d5b-4de9-aca7-9051046591ad"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzEwLTUtMS0xLTA_7f104b98-e144-4dc4-b732-07457d043054"
      unitRef="number">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibf9cf2a3ad2a41298f16d30283d92ee9_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzExLTEtMS0xLTA_cd9e7aed-b1a0-403c-9a95-2c695822fc28">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibde6846e4f514d90955bc42a2eff0107_D20181229-20200103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzExLTMtMS0xLTA_cdcc6fbb-c2e1-447e-9350-62e44db75c87">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i387d9657f5c347799d82def766e2b85c_D20180101-20181228"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTo3MzI3Y2RmNGY3ZjU0YWQxOGU1NjUwODIzOGNlNDI0NC90YWJsZXJhbmdlOjczMjdjZGY0ZjdmNTRhZDE4ZTU2NTA4MjM4Y2U0MjQ0XzExLTUtMS0xLTA_fb0db89c-cf1e-4934-acf1-e49ecbd8d231">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxNDA_fc6ae57e-c843-44d5-97cb-42fae0993ee5">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for stock options, including PSOs, during the year ended December&#160;31, 2020 was as follows (in thousands&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzEtMS0xLTEtMA_3394916a-8718-4539-96db-d698a35849fe"
      unitRef="shares">20443000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzEtMy0xLTEtMA_053504b4-69d0-478c-a72d-e4ef28765b21"
      unitRef="usdPerShare">9.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzItMS0xLTEtMA_ccda8792-8afe-4511-9505-5cdb9381709a"
      unitRef="shares">1637000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzItMy0xLTEtMA_fdc12190-7fe2-464f-b487-46dd13d9e5ee"
      unitRef="usdPerShare">21.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzMtMS0xLTEtMA_db0f47f4-38d2-45f8-adac-ee0ff8736767"
      unitRef="shares">5633000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzMtMy0xLTEtMA_d227c9a9-4184-45c9-958a-4e16b75050db"
      unitRef="usdPerShare">4.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzUtMS0xLTEtMA_8ab1fb2f-0694-4937-adee-0cc070434bc3"
      unitRef="shares">318000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzUtMy0xLTEtMA_54921791-d373-41d9-91e6-1f07c930e15f"
      unitRef="usdPerShare">20.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzYtMS0xLTEtMA_6b812290-aabe-42ab-a68e-035a7d0e10e7"
      unitRef="shares">16129000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzYtMy0xLTEtMA_8fd9b56b-b4a3-4ef8-bd61-274a1de4afb2"
      unitRef="usdPerShare">12.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzYtNS0xLTEtMA_2f863d74-7fb8-431a-91a2-45a3dafdffd0">P3Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzYtNy0xLTEtMA_29d97107-a0fa-4df0-84c3-ddaec389cc42"
      unitRef="usd">131729000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzctMS0xLTEtMA_c7af5460-7398-4979-8809-46d3b01bcea7"
      unitRef="shares">12656000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzctMy0xLTEtMA_a62a67f2-a566-42ce-91e8-511673e93abe"
      unitRef="usdPerShare">10.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzctNS0xLTEtMA_6a36796a-9c84-420d-abe1-d4006cdf8ffe">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZToyNjc5MDE1YTI3N2U0ZjJiYTBjNTI3OWQ5MzRmMDE5MC90YWJsZXJhbmdlOjI2NzkwMTVhMjc3ZTRmMmJhMGM1Mjc5ZDkzNGYwMTkwXzctNy0xLTEtMA_0a32605b-829d-4a55-8064-43eb980301b1"
      unitRef="usd">128740000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9e626170338d40c684a71ad8956f3dc8_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzM4MzA_1dee2c74-b7a5-4bfd-b1cc-9a97bcc0e76f"
      unitRef="usd">27100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzQwMzQ_a3f873f5-332f-49ae-916b-aba1c0535bdd">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0ed65fc14d1f42458a26dcd149381df1_D20180101-20181228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzQxNTY_a406387e-461b-4f6d-a54d-87679993405d"
      unitRef="shares">308365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises
      contextRef="i0ed65fc14d1f42458a26dcd149381df1_D20180101-20181228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzQ0NTE_ef53100e-56e7-4a95-8e9f-4c4376b64239"
      unitRef="number">1.25</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUxOTI_f2e1b326-3616-47da-9e51-479a522c1424"
      unitRef="usd">106500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUxOTY_f2b4eab2-b8d8-4091-a816-3040b6c4f5d7"
      unitRef="usd">54100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUyMDM_5cc2f717-51c9-4f06-bcc2-c1fa6cb19397"
      unitRef="usd">39100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUzMDQ_17bf22e1-7558-41a0-95fe-3c903de1d242"
      unitRef="usd">26900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i85af7f1979ca4b5bbb89e5a9a9260a3e_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUzMDg_f06e47aa-b0ac-4c48-9a39-6f6876f18d96"
      unitRef="usd">16400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1948960d554e495d831941884b909a9f_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzUzMTU_271ff0fd-325d-4b75-a80b-275bca3190dd"
      unitRef="usd">12100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzgxMTI_5f886c10-a9ba-4606-ad47-374b0140fdc3">Activity for RSUs during the year ended December&#160;31, 2020 was as follows (in thousands&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;Activity for PSUs, during the year ended December&#160;31, 2020 was as follows (in thousands&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i630c039e42614958998ad44ba50df6a3_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzEtMS0xLTEtMA_743514d9-8667-4483-a9d9-5cede79d2204"
      unitRef="shares">4422000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i630c039e42614958998ad44ba50df6a3_I20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzEtMy0xLTEtMA_4416c3ef-5fa0-45fe-8dd1-1ec90150cff8"
      unitRef="usdPerShare">19.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzItMS0xLTEtMA_c2b8e15c-060f-4219-b9f1-b6647b62c596"
      unitRef="shares">3053000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzItMy0xLTEtMA_3a250e87-21c0-4bd8-b087-420b0a7cf09b"
      unitRef="usdPerShare">23.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased
      contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzMtMS0xLTEtMA_fd10aea1-698f-45b6-b3e0-b7486aed5da1"
      unitRef="shares">1699000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzMtMy0xLTEtMA_ab5d947e-3311-41a2-bb1a-3c47787d11a8"
      unitRef="usdPerShare">18.20</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzQtMS0xLTEtMA_85c50bcd-11d2-45bc-9917-33f95db01f98"
      unitRef="shares">398000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzQtMy0xLTEtMA_78f70936-e60d-4ed6-9d33-68e4e7352c58"
      unitRef="usdPerShare">20.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iecd5c77b48af4ab390becbba00955ec9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzUtMS0xLTEtMA_488fdb10-0ff2-4a19-8f94-ea1dcb7f66a4"
      unitRef="shares">5378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iecd5c77b48af4ab390becbba00955ec9_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzUtMy0xLTEtMA_b72a5b58-a2c2-450b-bdba-3247f556a58e"
      unitRef="usdPerShare">21.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzUtNS0xLTEtMA_110b5c43-163c-4acc-9f77-36244cbde948">P1Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="iecd5c77b48af4ab390becbba00955ec9_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTphYTIxMjk1NjcyM2U0MTlhOWE1MWZlN2UwMzBiZDdlMi90YWJsZXJhbmdlOmFhMjEyOTU2NzIzZTQxOWE5YTUxZmU3ZTAzMGJkN2UyXzUtNy0xLTEtMA_8a65cde3-da92-4840-8f90-a2b4d7c5c304"
      unitRef="usd">107933000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iecd5c77b48af4ab390becbba00955ec9_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzU2MTU_d554bf12-5335-42ad-9537-625fbad7e651"
      unitRef="usd">103600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzU4MDE_bc1b183c-8123-47b0-8e07-0084da7a91ee">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i48fddf5f44ab4d8295e428acbb15cc42_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzEtMS0xLTEtOTY5_a7a22a96-e33e-4def-b50e-77346acb1b46"
      unitRef="shares">4379000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i48fddf5f44ab4d8295e428acbb15cc42_I20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzEtMy0xLTEtOTY5_5cc16734-4057-4646-bd66-e3d3fe31a863"
      unitRef="usdPerShare">19.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzItMS0xLTEtOTY5_cf71819c-ed5a-44d2-97ba-48763039a3ab"
      unitRef="shares">4656000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzItMy0xLTEtOTY5_31ee5fd5-75f2-48aa-8ac9-fb2333b5d925"
      unitRef="usdPerShare">23.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzMtMS0xLTEtOTY5_03b78a35-052b-4bc0-8103-e35609e960ea"
      unitRef="shares">1529000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzMtMy0xLTEtOTY5_883fae4c-41b5-4105-8496-937d1732626d"
      unitRef="usdPerShare">19.39</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzQtMS0xLTEtOTY5_0276a1f9-b613-4de4-958c-8ad301cc8d9d"
      unitRef="shares">128000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzQtMy0xLTEtOTY5_165daa5c-c4e0-4919-b491-7bd9778d7d6f"
      unitRef="usdPerShare">21.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iae79675a497d45819d1a3047a416388b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzUtMS0xLTEtOTY5_27272400-c14c-4608-9427-d7c0d9a99b24"
      unitRef="shares">7378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iae79675a497d45819d1a3047a416388b_I20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzUtMy0xLTEtOTY5_78e3e9f7-4377-4dfa-aad0-4e87fa50672b"
      unitRef="usdPerShare">21.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzUtNS0xLTEtOTY5_61c328d0-ad02-44ff-b512-4fd4dbf2476d">P3Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="iae79675a497d45819d1a3047a416388b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90YWJsZTpjNmI0Zjk0ODkxZTU0Y2E3ODEyNDdhZDlmMWVkYWI1OS90YWJsZXJhbmdlOmM2YjRmOTQ4OTFlNTRjYTc4MTI0N2FkOWYxZWRhYjU5XzUtNy0xLTEtOTY5_2b0094ec-ef16-40fa-b303-56c1e161dcde"
      unitRef="usd">148076000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6987ce3f2e0b4c65ba714f40a364ffbd_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjcxNzM_4b329931-96d3-4378-bd8b-c0bcdc7c5ad8"
      unitRef="shares">2327840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzExNTQ0ODcyMTA2OTE3_73fbd61e-47ce-42a3-8992-3dc374523fdf"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNjcxODc_edfae773-acd2-4aee-bff5-262ca801e988"
      unitRef="shares">4655680</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzU4OTQ_33516b2d-594b-4d32-886a-6071d8f1bdca"
      unitRef="shares">1926605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzYyMTg_6465f56c-2e23-476b-931a-95e4b23a84df"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="i4d41a1fe907c4fa7af524f0afa7971e7_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzYyNjY_64a6ddef-34cf-4d6a-9e0c-5926267d8390"
      unitRef="shares">1926605</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i4cbb645856904aa9809681fb8a88fa50_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzE4MTQxOTQxODc2NzI3_9b014f3e-d4c7-411f-97bf-ba9e93638433"
      unitRef="number">1.50</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="i4d6b47f808c84efd8f867da26a8406f6_D20181229-20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzE4MTQxOTQxODc2NzMz_2330a7f7-bff7-4014-ac66-2adfe93f9a52"
      unitRef="number">0.50</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4e926b7757e84307b3dcf2ffb4e5018e_D20180101-20181228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzYzOTI_cf95a0f8-fc4d-4d9b-a177-c68c372e11e9"
      unitRef="shares">693131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i74084a38afc04950ad513c20f60c8d62_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzE4MTQxOTQxODc0NTAx_477534b7-2537-487c-9d74-0f0ee502b6db"
      unitRef="shares">3206897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i6aeea19c58964ece8f259c21248b26ca_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNzEyOTU_2dbbe08f-4e4c-45ec-9f62-78d853cb8930"
      unitRef="usd">11800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iea1e1804983544d4b95b89863885736c_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNzI5NTc_6980f019-86e3-4104-8a10-52bdd077f8cd">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ice8b3be356ff4b8c971e27c9baa061e5_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzIxOTkwMjMyNzEzMDY_51b4b4fc-4d42-4c75-8667-6660086fa05d"
      unitRef="usd">128500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzc5MjQ_1fb23e1f-b831-44f3-9ff5-f052ceabd67d"
      unitRef="usd">6700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzc5Mjg_5a29dd30-83f6-44d5-9388-9d84e44f65f8"
      unitRef="usd">4600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMTgvZnJhZzo5OTYxNTg5MTg2NmQ0MDJhODdjNjFiMTFlMmJlM2I3My90ZXh0cmVnaW9uOjk5NjE1ODkxODY2ZDQwMmE4N2M2MWIxMWUyYmUzYjczXzc5MzY_fe5e6301-5c56-4fd4-bad4-d5d764ca1942"
      unitRef="usd">3600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzcxNDY4MjU1ODg1ODY_20823593-baac-4cd6-9e14-a55b4bbc37a2">PROVISION FOR (BENEFIT FROM) INCOME TAXES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income before income taxes is derived solely from within the U.S. Our provision for (benefit from) income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years ended&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; December&#160;31, 2020 and 2019 primarily relates to the utilization of federal net operating loss and state taxes in jurisdictions outside of California, for which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e do not have net operating loss carryforwards due to a limited operating history. The benefit from income taxes for the year ended December&#160;31, 2018 primarily relates to the release of our valuation allowance against significantly all of our deferred tax assets offset by state taxes in jurisdictions outside of California. Our historical net operating losses were sufficient to fully offset any federal taxable income for the years ended December 31, 2020, 2019 and 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2020, 2019 and 2018, respectively, to our provision for (benefit from) income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December&#160;31, 2020, based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December&#160;31, 2020 and forecasts of future operating results, as well as considering the utilization of net operating losses and tax credits prior to their expiration, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December&#160;31, 2020 and 2019, we continue to carry a valuation allowance of $67.2 million and $61.7 million, respectively, against our California state deferred tax assets. The valuation allowance increased by $5.5 million and $3.5 million during the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, we had federal net operating loss carryforwards of approximately $92.6 million, which will begin to expire in 2036, and federal business tax credits of approximately $127.4 million which expire in the years 2021 through 2040. We also had state net operating loss carryforwards of approximately $427.9 million, which expire in the years 2021 through 2036, and California research and development tax credits of approximately $42.9 million, which do not expire, and California Competes Tax Credits of approximately $1.6 million, which expire in 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through December&#160;31, 2020, and concluded that an ownership change, as defined under Section 382, had not occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to prior year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to current year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2020 will significantly change over the next 12 months. As of December&#160;31, 2020, we had $80.9 million in unrecognized tax benefits, of which 50.1 million would reduce our provision for income taxes and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes. &lt;/span&gt;&lt;/div&gt;We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 2001 through 2020 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzUxNjg_837f2246-8a17-4985-a2a8-ebf444bf0c48">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income before income taxes is derived solely from within the U.S. Our provision for (benefit from) income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzMtMS0xLTEtMA_7741d7b4-7328-4aa8-aa50-707022c894af"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzMtMy0xLTEtMA_207f3ea2-bb61-49c6-a317-442d82f105e2"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzMtNS0xLTEtMA_6c594cb4-2668-4b32-85d7-c9f55f6c22ea"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzQtMS0xLTEtMA_33892abf-f936-4694-9d28-734c4e2cd00c"
      unitRef="usd">3791000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzQtMy0xLTEtMA_30547ebe-bf8f-4700-9a14-fd6c9b4485cc"
      unitRef="usd">6095000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzQtNS0xLTEtMA_0ccad3f9-355f-48c2-a69e-3b52313ee105"
      unitRef="usd">6133000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzUtMS0xLTEtMA_168ba646-287b-479e-a145-bec9adacde08"
      unitRef="usd">3791000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzUtMy0xLTEtMA_67e3742e-83cb-4da4-985f-02da92f754d2"
      unitRef="usd">6095000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzUtNS0xLTEtMA_16881f08-dc85-44c5-b590-a73b45d62dd8"
      unitRef="usd">6133000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzctMS0xLTEtMA_618a3e0f-799e-40ae-9c2c-24dfa6ca4465"
      unitRef="usd">14886000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzctMy0xLTEtMA_a321db14-e724-4e8a-bb56-c3551aba5cff"
      unitRef="usd">71580000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzctNS0xLTEtMA_5393d7bf-e8b7-47bb-b3ae-42989d5a1942"
      unitRef="usd">-238675000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzgtMS0xLTEtMA_c29c3e1e-7458-45bc-8608-8edd2dd4dbe8"
      unitRef="usd">379000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzgtMy0xLTEtMA_0e489cd0-8780-483a-a102-00516cc8433b"
      unitRef="usd">-578000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzgtNS0xLTEtMA_5c27b2ac-81b7-43ca-a314-e164d8974c75"
      unitRef="usd">-5436000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzktMS0xLTEtMA_5b6e0426-04c5-4a51-8eb7-2d9feb8eb934"
      unitRef="usd">15265000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzktMy0xLTEtMA_ddc99fd8-b393-4d46-b074-0dceae322105"
      unitRef="usd">71002000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzktNS0xLTEtMA_7f8ce76b-0cd7-45df-9694-78131a491f6b"
      unitRef="usd">-244111000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzEwLTEtMS0xLTA_031e53f5-45cc-4268-825d-ed3d1f4e56f6"
      unitRef="usd">19056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzEwLTMtMS0xLTA_60fde132-8201-4554-9e53-8307c774fcf8"
      unitRef="usd">77097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiZThlOTQ3NmY1YWU0ZjZiYThhODFkYWE0YjVmYWJiZi90YWJsZXJhbmdlOmJlOGU5NDc2ZjVhZTRmNmJhOGE4MWRhYTRiNWZhYmJmXzEwLTUtMS0xLTA_45a89169-1678-49c4-82ce-0ee2872bc566"
      unitRef="usd">-237978000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzUxNTc_531527ff-f6f7-4c49-9fd1-0070182b9567">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2020, 2019 and 2018, respectively, to our provision for (benefit from) income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. federal income tax provision at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded prescription drug fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzItMS0xLTEtMA_ea141903-f5d7-4588-a029-5c5830eb1faf"
      unitRef="usd">27476000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzItMy0xLTEtMA_6b21d3cb-052a-4c01-b1c2-bf622ff2bf35"
      unitRef="usd">83603000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzItNS0xLTEtMA_1717298f-8541-401f-8644-698ca11dfbba"
      unitRef="usd">94939000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzMtMS0xLTEtMA_fdab122d-73e5-4aca-9a72-3d5ab44782b5"
      unitRef="usd">-2232000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzMtMy0xLTEtMA_b8887604-ebe4-46fa-b377-0522d376ae91"
      unitRef="usd">1148000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzMtNS0xLTEtMA_b4746693-e4a0-4030-bd9a-96610b703bd0"
      unitRef="usd">4690000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzQtMS0xLTEtMA_fed735fe-617d-4afc-ab87-562aa67897fc"
      unitRef="usd">5525000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzQtMy0xLTEtMA_3574c832-2265-4578-829c-b4cd43655e46"
      unitRef="usd">3208000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzQtNS0xLTEtMA_4f3a8981-f88f-48d7-b9de-0a8e18ad16ae"
      unitRef="usd">-315394000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzUtMS0xLTEtMA_4a466174-d0f0-4ecd-9389-86e579c1fb85"
      unitRef="usd">11356000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzUtMy0xLTEtMA_3ace14a6-2a38-499b-b1d4-55abb42822b8"
      unitRef="usd">8299000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzUtNS0xLTEtMA_2b8836f2-b45a-4aac-a83c-c88c2fa2d3ff"
      unitRef="usd">18308000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzYtMS0xLTEtMA_658f3e4d-4c64-469c-b951-66aa8355314f"
      unitRef="usd">-20399000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzYtMy0xLTEtMA_d2c31d46-7146-49b9-8dda-56f6a41561b7"
      unitRef="usd">-9177000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzYtNS0xLTEtMA_5fb18d11-cbd5-4a38-8303-bf48278408af"
      unitRef="usd">-5998000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzctMS0xLTEtMA_c81ae627-2503-412a-9236-66a48b57453f"
      unitRef="usd">18067000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzctMy0xLTEtMA_4a259748-24ae-4147-b5e5-d544b8e3a1f5"
      unitRef="usd">4228000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzctNS0xLTEtMA_fd888ca3-9951-49f6-91e2-c3618a42c8b5"
      unitRef="usd">1111000</exel:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation>
    <exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzgtMS0xLTEtMTM3NDQ_c688a94b-9daa-41e1-8bda-d5c85b5d7ef4"
      unitRef="usd">2537000</exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee>
    <exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzgtMy0xLTEtMTM3NDQ_d1182cd3-f0a3-447d-bcf1-cdca7ae3f262"
      unitRef="usd">1099000</exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee>
    <exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzgtNS0xLTEtMTM3NDQ_ea876ba8-d5be-4e99-8523-d6da584c3b93"
      unitRef="usd">371000</exel:EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzktMS0xLTEtMA_243db141-f2aa-4ba4-8c2a-084b3538b99e"
      unitRef="usd">-562000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzktMy0xLTEtMA_7e5f67ba-d1ed-4038-a5e1-55b5d786f7b7"
      unitRef="usd">1287000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzktNS0xLTEtMA_818ddeb0-f266-46a5-8856-539b5ccb87a1"
      unitRef="usd">611000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzEwLTEtMS0xLTA_8c9f8afa-f7fe-45a1-b94b-62b41e1d4a80"
      unitRef="usd">19056000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzEwLTMtMS0xLTA_dfee0845-c0b6-42d3-920a-27a7807fe287"
      unitRef="usd">77097000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo1MjUyM2JmYmQxY2Y0MTE1OTgzZDA5YjBkODgxODg4My90YWJsZXJhbmdlOjUyNTIzYmZiZDFjZjQxMTU5ODNkMDliMGQ4ODE4ODgzXzEwLTUtMS0xLTA_fe9ae364-80f2-4267-b363-84ba79aef3b4"
      unitRef="usd">-237978000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzUxNTk_74c049cc-f8f6-408d-9a62-78ac7b3a09a4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzMtMS0xLTEtMA_4696229f-5d12-4d0a-a5a3-2b1cd3c916f6"
      unitRef="usd">37454000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzMtMy0xLTEtMA_61181a52-0cf7-491a-b9ea-ce8b766d8907"
      unitRef="usd">65131000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzQtMS0xLTEtMA_1a66215e-3763-4fb8-8f4e-363076697820"
      unitRef="usd">126625000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzQtMy0xLTEtMA_2f54fff3-34dc-41eb-91b9-0045190ac0a0"
      unitRef="usd">110037000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzUtMS0xLTEtMA_502dba9c-b0c8-4ac0-a2a9-5f56f44f9250"
      unitRef="usd">18414000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzUtMy0xLTEtMA_f4d99b02-573c-40bb-8154-e34fe45f8325"
      unitRef="usd">26792000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzYtMS0xLTEtMA_2a3688f3-01ed-4791-895c-7d4e99c0bce3"
      unitRef="usd">19818000</exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified>
    <exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzYtMy0xLTEtMA_69404a38-31b7-4f9e-95e7-3b5fe695f10d"
      unitRef="usd">14966000</exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified>
    <exel:DeferredTaxAssetsLeaseLiabilities
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzctMS0xLTEtMA_bbb474cc-3122-4c60-9b2b-e97c1bff7d63"
      unitRef="usd">11908000</exel:DeferredTaxAssetsLeaseLiabilities>
    <exel:DeferredTaxAssetsLeaseLiabilities
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzctMy0xLTEtMA_f2354af6-fcf5-45a8-919f-63662d6d66a1"
      unitRef="usd">11211000</exel:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzgtMS0xLTEtMA_3991fc30-8095-4f25-b8d3-b66d0e300959"
      unitRef="usd">12207000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzgtMy0xLTEtMA_7c22ee7d-3995-4b8b-8ccb-fe537a29c5fd"
      unitRef="usd">8248000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzktMS0xLTEtMA_500404ee-1e2f-4a63-b772-69c8d6e24780"
      unitRef="usd">7637000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzktMy0xLTEtMA_90d0c4f5-7594-4677-b864-0036746c1519"
      unitRef="usd">6547000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEwLTEtMS0xLTA_7c9aaf78-283c-42a8-9df0-73cba4472e8b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEwLTMtMS0xLTA_2aaf8a56-98ed-46b7-b2c0-cfee027b254f"
      unitRef="usd">345000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzExLTEtMS0xLTA_5dbb399a-9bb9-47bc-bd22-dda297b3b491"
      unitRef="usd">234063000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzExLTMtMS0xLTA_7cc14728-0109-45c7-92e2-aa4c0920110a"
      unitRef="usd">243277000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEyLTEtMS0xLTA_455b7bd2-a887-4d31-b12b-4d63efc81ae4"
      unitRef="usd">67185000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEyLTMtMS0xLTA_9b9248bb-0569-442c-a908-f04a96b74168"
      unitRef="usd">61659000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEzLTEtMS0xLTA_eb248992-9d31-42e8-9059-b9c920bdfac6"
      unitRef="usd">166878000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzEzLTMtMS0xLTA_21726f76-cb41-405c-9d27-bbb6a94a0584"
      unitRef="usd">181618000</us-gaap:DeferredTaxAssetsNet>
    <exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE1LTEtMS0xLTA_29292b31-53d4-45dd-b9f7-73ac2625c691"
      unitRef="usd">9510000</exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets>
    <exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE1LTMtMS0xLTA_9f291214-eff8-4628-814d-e23bf50264b1"
      unitRef="usd">9244000</exel:DeferredTaxLiabilitiesLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE2LTEtMS0xLTg4NTY_fb885cae-4a19-4edb-895d-89c04e98753d"
      unitRef="usd">657000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE2LTMtMS0xLTg4NTY_3ea61146-effa-4a65-a970-5ccbab883849"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE2LTEtMS0xLTA_032f4174-bec5-4bb1-8bf3-7353a2ac49c6"
      unitRef="usd">10167000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE2LTMtMS0xLTA_4a285182-5a0f-4454-a277-8163c0fd7f32"
      unitRef="usd">9244000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE3LTEtMS0xLTA_6c733d3d-871a-4644-8ca8-c1694a5ccbc2"
      unitRef="usd">156711000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTo4Mjk1YmE5YjQxOTE0M2RjOWMyZDU1Y2Q2MzAzOTNmNi90YWJsZXJhbmdlOjgyOTViYTliNDE5MTQzZGM5YzJkNTVjZDYzMDM5M2Y2XzE3LTMtMS0xLTA_9cceda92-5984-419d-b428-ddc2d09b642b"
      unitRef="usd">172374000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM2NDk_94840e89-1d72-49f0-9e19-451c53423e6c"
      unitRef="usd">67200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzI3MTM_029d3228-6027-4192-92fa-df12920c9a2d"
      unitRef="usd">61700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM2NjM_8823a3ae-6817-406e-ba2d-98c55f058708"
      unitRef="usd">5500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM2OTM_11fa450a-3e81-4893-a7e8-cf6381b2dfb9"
      unitRef="usd">3500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i22de33cb9fa4466693147fb2b3a08fde_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjE3MzU_b8662e54-5d29-48f0-830c-99a7f27d0c7d"
      unitRef="usd">92600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i22de33cb9fa4466693147fb2b3a08fde_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjE3Mzk_ec08edfc-979a-4aed-8d5c-881daac54d6b"
      unitRef="usd">127400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0f1e640f034c4c9a8c524f75ba45a4ab_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjE3NDM_af8d410d-ece3-4e11-b30e-56a969e4518d"
      unitRef="usd">427900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ibdd294e2e4ab4132b8b50c9a18c91bd6_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjE3NDc_1e649b3e-2dd6-42c8-bcb6-21a0719da038"
      unitRef="usd">42900000</us-gaap:TaxCreditCarryforwardAmount>
    <exel:TaxCreditCarryforwardAmountWithExpirationPeriod
      contextRef="ibdd294e2e4ab4132b8b50c9a18c91bd6_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM4MjY_a1979184-9fd1-48cc-a51c-ebe91baa0022"
      unitRef="usd">1600000</exel:TaxCreditCarryforwardAmountWithExpirationPeriod>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzUxODk_293649ed-352e-4a69-839f-783525812e6a">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to prior year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change relating to current year provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzItMS0xLTEtMA_7095b94e-eab2-41b6-9b1f-8314f72e3598"
      unitRef="usd">79078000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzItMy0xLTEtMA_b2303f88-3af1-4382-a544-9857d09f03ef"
      unitRef="usd">76060000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iadc77df98a1c43b7b450a7d15340ba09_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzItNS0xLTEtMA_06832bbf-6584-45b7-9ee3-24a1564eb230"
      unitRef="usd">79342000</us-gaap:UnrecognizedTaxBenefits>
    <exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzMtMS0xLTEtMA_f815579d-ac59-4dec-b0ca-6e9dafc6ebb7"
      unitRef="usd">591000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
    <exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzMtMy0xLTEtMA_a918366e-7543-4867-b913-6706654d9a16"
      unitRef="usd">589000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
    <exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzMtNS0xLTEtMA_cd172e82-caa0-4ce1-8e00-34069557ea1f"
      unitRef="usd">-4254000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzQtMS0xLTEtMA_52855a76-bebe-4860-a7ee-e77358cdbc57"
      unitRef="usd">3305000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzQtMy0xLTEtMA_7a5f4629-b6aa-4aa0-81f3-9905a9dd0da0"
      unitRef="usd">2429000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzQtNS0xLTEtMA_a0913307-a7d7-4898-8fe5-03107c7b1b53"
      unitRef="usd">1083000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzUtMS0xLTEtMA_ee8f0ffb-1dd0-49ac-b8f1-d56880533fdd"
      unitRef="usd">2033000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzUtMy0xLTEtMA_9790eaaa-fb09-44e6-82f9-fb2555acf39f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzUtNS0xLTEtMA_725b27f3-0096-4c4a-9c10-093c9214bde1"
      unitRef="usd">111000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzYtMS0xLTEtMA_71ffa4f2-975e-4956-923d-5e192b72272e"
      unitRef="usd">80941000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzYtMy0xLTEtMA_36da8a26-9100-4712-a0b7-b16331221b18"
      unitRef="usd">79078000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6f9755c807a24f8cb306629ef867b038_I20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90YWJsZTpiYzcwYWNjNjAwZWU0Y2NkOGYxMjJiNDc0OTJmM2IyZS90YWJsZXJhbmdlOmJjNzBhY2M2MDBlZTRjY2Q4ZjEyMmI0NzQ5MmYzYjJlXzYtNS0xLTEtMA_89584081-76e4-4113-abed-d567b0e6c0f7"
      unitRef="usd">76060000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzQ0MDM_bce773a3-85c6-4b75-8cd5-8c9b54cde0a9"
      unitRef="usd">80900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMjQvZnJhZzo3NWQzMDM2YzQwOGQ0MTJiYWI3ZmVmOWIwOTkyYjE0OC90ZXh0cmVnaW9uOjc1ZDMwMzZjNDA4ZDQxMmJhYjdmZWY5YjA5OTJiMTQ4XzIxOTkwMjMyNjM4NjY_e918bed3-69d8-441c-b007-1ee83a75582e"
      unitRef="usd">50100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90ZXh0cmVnaW9uOmUwNGIxMjU0OGQ4YTQ4MWJiM2I0OGRlNzZiYzUzMWMxXzkxNQ_1cb90c37-7914-4954-8815-76481a38581e">NET INCOME PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options and PSOs, unvested RSUs and PSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they are related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. See to &#x201c;Note 8. Employee Benefit Plans&#x201d; for a further description of our equity awards. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90ZXh0cmVnaW9uOmUwNGIxMjU0OGQ4YTQ4MWJiM2I0OGRlNzZiYzUzMWMxXzg5Ng_9b567503-6744-47c2-a108-5a69970b65e3">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzMtNS0xLTEtMA_0233ee16-3849-4354-a1c6-7deed24f3116"
      unitRef="usd">111781000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzMtNy0xLTEtMA_54698d9d-355a-4983-8a78-1e4325685b13"
      unitRef="usd">321012000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzMtOS0xLTEtMA_71954d78-296a-47aa-b453-1c0d6fb08477"
      unitRef="usd">690070000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzktNS0xLTEtMA_e8097716-0ce6-4f71-a3e0-6d4aaac91bb6"
      unitRef="shares">308271000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzktNy0xLTEtMA_e67c9716-2eb0-4f34-a651-338315e0e5d7"
      unitRef="shares">302584000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzktOS0xLTEtMA_b988c492-8c2f-4050-a523-6faf7bafba14"
      unitRef="shares">297892000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEwLTUtMS0xLTA_80e3fbe9-cd64-4592-9f5f-bd349208b237"
      unitRef="shares">9730000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEwLTctMS0xLTA_78cd963c-c24c-4054-a95b-e8755c0feee2"
      unitRef="shares">12425000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEwLTktMS0xLTA_f3c4afbe-d3c9-47e2-b39b-1b5bd93c3b23"
      unitRef="shares">14911000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzExLTUtMS0xLTA_a50ad356-55f1-4835-afbf-70bde3f16d1f"
      unitRef="shares">318001000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzExLTctMS0xLTA_58a517fa-db9c-4d16-8fb7-f8e442e6bddf"
      unitRef="shares">315009000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzExLTktMS0xLTA_9ba39d1e-b2ba-4025-8e08-a1d10e40d6b9"
      unitRef="shares">312803000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEyLTUtMS0xLTA_d28a696a-982e-404b-9143-60d754541daa"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEyLTctMS0xLTA_eaedea13-12fd-476b-a541-71b73da97e35"
      unitRef="usdPerShare">1.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEyLTktMS0xLTA_8d90e575-b48d-41dd-9977-4c71beed5244"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEzLTUtMS0xLTA_83ab8308-0dcd-440e-b337-df33ef846d21"
      unitRef="usdPerShare">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEzLTctMS0xLTA_94f11cd9-6ec9-47f7-97b6-752ace117dda"
      unitRef="usdPerShare">1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTozZjRkMWQyY2Q0MjA0ODY1YmIxYmQxZmM0M2E5MWJmYi90YWJsZXJhbmdlOjNmNGQxZDJjZDQyMDQ4NjViYjFiZDFmYzQzYTkxYmZiXzEzLTktMS0xLTA_c2f746a9-b2ab-46d8-b64a-24ca0e571fa3"
      unitRef="usdPerShare">2.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90ZXh0cmVnaW9uOmUwNGIxMjU0OGQ4YTQ4MWJiM2I0OGRlNzZiYzUzMWMxXzkyMQ_b687d729-4e00-4e9c-8f79-0d4710441332">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i728bdf824bce4e3a8e6c9be0a205fc81_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTpmNjhmYjJmMzM1ZmU0YWM3YTE3ZTllYTJhNzgzZmFkNy90YWJsZXJhbmdlOmY2OGZiMmYzMzVmZTRhYzdhMTdlOWVhMmE3ODNmYWQ3XzItNS0xLTEtMA_cc2ac7dd-1749-48f0-9446-4f076fc3ceb9"
      unitRef="shares">10959000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib61e2f06dd994f53bfa706d07d66963c_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTpmNjhmYjJmMzM1ZmU0YWM3YTE3ZTllYTJhNzgzZmFkNy90YWJsZXJhbmdlOmY2OGZiMmYzMzVmZTRhYzdhMTdlOWVhMmE3ODNmYWQ3XzItNy0xLTEtMA_20271ba4-1c60-49d0-a244-8122be671975"
      unitRef="shares">9111000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic36021c41bb5446e8080959a3441b6a9_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzAvZnJhZzplMDRiMTI1NDhkOGE0ODFiYjNiNDhkZTc2YmM1MzFjMS90YWJsZTpmNjhmYjJmMzM1ZmU0YWM3YTE3ZTllYTJhNzgzZmFkNy90YWJsZXJhbmdlOmY2OGZiMmYzMzVmZTRhYzdhMTdlOWVhMmE3ODNmYWQ3XzItOS0xLTEtMA_aa21c183-f9d1-4317-b3ba-8050b7dee59a"
      unitRef="shares">3968000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzExNTQ0ODcyMTA3NTQ2_443aa7b8-f1b1-4329-9fca-6a2ac4191e97">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Headquarters Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located in Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018, April 2019, August 2019, January 2020 and December 2020, resulting in, among other things, an increase to the amount of space leased and changes to the lease term. Our right-of-use asset, lease liability and the related lease costs reflect the 228,941 square feet of space we have taken possession of as of December 31, 2020 (the Current Premises) under the amended Lease. We expect to take possession of the additional space provided for under the December 2020 amendment on or prior to June 1, 2021, which will increase the space leased to 254,690 square feet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The term of the Lease continues through October 31, 2031 (the Lease Term). We have two five-year options to extend the Lease; these optional periods have not been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made certain tenant improvements on the Initial Premises, for which we received $8.2 million in reimbursements in January 2019. At December 31, 2020, a reimbursement of $1.7 million was due to us for tenant improvements to the space we obtained under the April 2019 amendment. We were also provided an allowance of up to $1.4&#160;million for tenant improvements to the space expected to be obtained under the December 2020 amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_4bd66db9-0068-4d77-8491-049fcf2c6704"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_a8b46ed7-baae-4463-b21f-4d4716438745"&gt;Current portion included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities for the year ended December&#160;31, 2020 was $4.6 million and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future tenant improvement reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the weighted average discount rate used to determine the operating lease liability was 3.1% and the weighted average remaining lease term is 10.8 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Build-to-Suit Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) for approximately 220,000 square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The term of the Build-to-Suit Lease is for a period of 242 months (the Term), which will begin upon the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the Term will begin in April 2022 (the Lease Commencement Date). The monthly base rent under the Build-to-Suit Lease will equal a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by the lessor and any development costs we pay) and is currently estimated to be about $0.7 million, subject to an annual increase of 3% during the Term. We will also be responsible for paying operating expenses related to the New Premises. The rent payments will begin sixty days following commencement of the Term. We have been provided a tenant improvement allowance for the New Premises of approximately $16.5 million. To the extent that the total development costs of the New Premises exceeds $525 per square foot, we will also pay 50% of such excess costs prior to the commencement of the Term, and we are required to secure such amount by providing a letter of credit or depositing such amounts in an account with the lessor&#x2019;s lender.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Build-to-Suit Lease includes two five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the 180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that, under the guidance provided in Topic 842, we do not have control of the New Premises during the construction period. Therefore, we will not record a right-of-use asset or lease liability for the Build-to-Suit Lease until the Lease Commencement Date. We will evaluate the classification of the Build-to-Suit Lease as an operating lease or financing lease at the Lease Commencement Date. We determined the cost of tenant improvements during the construction period are lessor assets and considered a prepayment of lease under Topic 842. The costs incurred as of December 31, 2020 of $2.8&#160;million are recorded as other long-term assets in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of and $1.6 million as of December&#160;31, 2020 and 2019, respectively. None of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we entered into standby letter of credit of $45.9&#160;million in the aggregate as guarantee of our obligation to fund our portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which will be recorded as restricted cash. The letter of credit will be reduced as we fund our portion of the tenant improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. The sale of a generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i2793983ce6e243b5ad8af2ec5ec6c289_I20210101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzIxOTkwMjMyNjE3MDE_81eb296a-40bf-45d9-aae5-3bd0040f2011"
      unitRef="sqft">228941</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i6703fce613684225b4063ab7dc405264_I20210601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzc3NA_3a5c6e57-8d62-4354-a9b9-cc29378bd1ae"
      unitRef="sqft">254690</us-gaap:AreaOfRealEstateProperty>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i655272f3bcac4b5e8db4788f93444fb2_D20200104-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzg3NA_fcec5a08-4128-4158-aa71-13e71d732a5b"
      unitRef="renewal_option">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2793983ce6e243b5ad8af2ec5ec6c289_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzcxNDY4MjU1OTY5NDI_c644d400-ab4b-45f2-97b1-8bc2c345c6ed">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="i4a3a848bbc8a48e9aa6faab6645fee01_I20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzEyMjE_485806b0-f2d9-4f18-86bd-a4c4974ac0a5"
      unitRef="usd">8200000</exel:TenantLeaseImprovementsAllowance>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="i2793983ce6e243b5ad8af2ec5ec6c289_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzEzMDM_a0dfd327-31a9-4f8e-b0c6-6eb805d23d58"
      unitRef="usd">1700000</exel:TenantLeaseImprovementsAllowance>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="i6703fce613684225b4063ab7dc405264_I20210601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzExNTQ0ODcyMTA3NTQ4_e361790c-d2ee-4012-a807-cc5a0b6abef9"
      unitRef="usd">1400000</exel:TenantLeaseImprovementsAllowance>
    <exel:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUzNDk_ed8f61cf-6fc3-4156-aa8e-165e3cf80a00">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_4bd66db9-0068-4d77-8491-049fcf2c6704"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_a8b46ed7-baae-4463-b21f-4d4716438745"&gt;Current portion included in other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzMtMS0xLTEtMA_c9941575-545c-450f-a1f7-1ab5ea2f2e1f"
      unitRef="usd">43010000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzMtMy0xLTEtMA_c2327f2e-2d35-419a-90eb-a0436a2c1e08"
      unitRef="usd">41835000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMS0xLTEtMA_82ab717c-5b8a-479e-8620-16c9a8f3acae"
      unitRef="usd">3025000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMy0xLTEtMA_d79c3006-ca9d-465e-aa72-262d881648d8"
      unitRef="usd">2728000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzYtMS0xLTEtMA_4d21baa8-e74e-4996-bdf5-5327951ca0c7"
      unitRef="usd">49086000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzYtMy0xLTEtMA_5d90d67f-c684-4e60-ac3c-bacb98ae2ec3"
      unitRef="usd">48011000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzctMS0xLTEtMA_957755a4-67d2-45b7-af90-1b918e17ebc2"
      unitRef="usd">52111000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8d6ae031ff9642c6823d52f9a9f51d23_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzctMy0xLTEtMA_eaa289a6-9c22-451b-a310-36691e2278ec"
      unitRef="usd">50739000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUzNTg_7cea1c9c-9ef6-42d3-b064-c57c13ab2529">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzItNS0xLTEtMA_3b7abded-1ef5-4fa4-893b-5ea213ac7bff"
      unitRef="usd">4825000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzItNy0xLTEtMA_a5e8df5e-680f-47ff-b593-c0abe4dbeba4"
      unitRef="usd">2844000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzItOS0xLTEtMA_6c6c8542-d583-4ace-9c31-d97537ca4519"
      unitRef="usd">4189000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzMtNS0xLTEtMA_b24961db-b373-4a41-aded-2b322fd47083"
      unitRef="usd">2830000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzMtNy0xLTEtMA_b84be88b-b8fd-4f12-b01f-3c9cb73192e3"
      unitRef="usd">1024000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzMtOS0xLTEtMA_e4e1b126-90e7-499b-a9cb-3b65bf9cd1da"
      unitRef="usd">1661000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzUtNS0xLTEtMA_03205c15-1b45-4cae-9042-2bc0900ed9c6"
      unitRef="usd">7655000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i46aac8dbd6ac43b5a547d1b1c68389b1_D20181229-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzUtNy0xLTEtMA_bff78d2b-2cf3-4a97-a2df-b980d5c11f5e"
      unitRef="usd">3868000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i9ef3e429e23c49149ee112f586953a4e_D20180101-20181228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZToxNWNkYWI1MzVlMTU0MWQyYjUyOGRmMTdiZTQwMjQ3Mi90YWJsZXJhbmdlOjE1Y2RhYjUzNWUxNTQxZDJiNTI4ZGYxN2JlNDAyNDcyXzUtOS0xLTEtMA_94274440-ea17-4fb9-9e58-cb1ef85d4e42"
      unitRef="usd">5850000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzIwMTM_cabb709c-0dce-46fe-8f82-691ff570915f"
      unitRef="usd">4600000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUzNTU_fd5742c4-960e-412d-bb64-ad12f46b1010">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future tenant improvement reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzEtMi0xLTEtMA_b3d244c8-f532-4c33-853d-7189a0ec60ae"
      unitRef="usd">4834000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzItMi0xLTEtMA_556dfaad-4cf3-4073-abf5-b22a09f49d56"
      unitRef="usd">4994000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzMtMi0xLTEtMA_d8381117-20a0-4670-94d1-3c811f77ed29"
      unitRef="usd">5332000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzQtMi0xLTEtMA_5ea9d0b2-f2ba-49cc-b010-047fccea0949"
      unitRef="usd">5600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzUtMi0xLTEtMA_41923e1c-96ca-4d07-9602-371da5975265"
      unitRef="usd">5773000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzYtMi0xLTEtMA_43946714-6da9-47bd-aec5-f717f69ac475"
      unitRef="usd">37290000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzctMi0xLTEtMA_144e13f9-7fc6-4b9a-aaf7-c739f288761f"
      unitRef="usd">63823000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzktMi0xLTEtMA_e4825b8e-e541-42de-8864-53e2a1e26701"
      unitRef="usd">9970000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzEwLTItMS0xLTA_d90aeeb9-ed0f-4ce9-afab-489c3a1ab766"
      unitRef="usd">1742000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo5OWI1M2Q4YzUyYWI0MDM0ODJhNTM4YjdiMDgxNjhhYS90YWJsZXJhbmdlOjk5YjUzZDhjNTJhYjQwMzQ4MmE1MzhiN2IwODE2OGFhXzExLTItMS0xLTA_c9b2128f-c55c-4046-9079-937f1314e78d"
      unitRef="usd">52111000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzIzMTc_125f24ee-1c50-4967-bb9a-a48a1aa7b0f6"
      unitRef="number">0.031</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzIzNjk_698077a2-8f6c-4c21-bd52-9867de57867b">P10Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzI1MDM_0fdaf1a4-18b0-4d7c-a9ee-80ae722c1254"
      unitRef="sqft">220000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzI2NzQ_f5a8c7dd-01d4-400c-accd-f296de705053">P242M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment
      contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzMyMzc_52a5aae0-829c-4548-8c4c-4934d6dbebeb"
      unitRef="usd">700000</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage
      contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzMyNzQ_9eda8931-48fd-4165-bbf1-bde47475f1ff"
      unitRef="number">0.03</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage>
    <exel:LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod
      contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM0MTA_a57bf032-f0fe-46bf-afde-e5d0976161bc">P60D</exel:LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM1NDA_fb21a725-4a75-4693-9fa7-946237ff6a7f"
      unitRef="usd">16500000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <exel:AreaOfRealEstatePropertyAvailableToLease
      contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM2MTk_39c18453-f4a7-4374-ad18-d8a9d5a78f1f"
      unitRef="usdPerSqft">525</exel:AreaOfRealEstatePropertyAvailableToLease>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts
      contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM2NTY_d0c1da77-bed7-4b42-98d8-d38709b2d3d5"
      unitRef="number">0.50</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzM5OTU_02f7867e-194d-49f6-9b6e-ba581d9a1c34"
      unitRef="renewal_option">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i5942d56a0a5c4771a6eaf148a1122cca_I20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzcxNDY4MjU1OTY5NDM_7a83689c-d6ec-4066-be1c-888dd2b63abc">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod
      contextRef="i7772c1a79c7f4acb86f8fbaed80b61e1_D20191001-20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzQyNjE_a65428b0-23c3-4746-b8d9-4bbde27c8222">P180M</exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod>
    <us-gaap:TenantImprovements
      contextRef="i3034fe7f1e7741e5b7767f7a26a08254_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzE4MTQxOTQxODc0Njg5_9367fc04-982d-44ea-b8b5-742127fb06f4"
      unitRef="usd">2800000</us-gaap:TenantImprovements>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie2db56eb211748d2a452eafb230ca08e_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUxODI_7d5e416f-df32-484e-8dcb-8f3284a515d0"
      unitRef="usd">1600000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i60096daf93c14de585b95a04778a59d9_I20200103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUxODI_e08f78e1-89e7-45d7-924f-1528a8bb634a"
      unitRef="usd">1600000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ie2db56eb211748d2a452eafb230ca08e_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzUyMTY_e67c3355-b485-46b0-9f08-c68ba68d5671"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:GuarantyLiabilities
      contextRef="i19a576c9dd734120a4d6a896a2880fb4_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90ZXh0cmVnaW9uOmE4MzdjN2E1Njk3MTQxMDE4MjcxMjQ0MjZlNTliOGRmXzE4MTQxOTQxODgxODM1_65d3dd95-fd72-4057-bbfa-cbe3be718699"
      unitRef="usd">45900000</us-gaap:GuarantyLiabilities>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzIxOA_37b57195-c959-4802-9c8c-596ecc5a58c1">QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected unaudited quarterly financial data was as follows (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal 2020 Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal 2019 Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)   Total revenues for the quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, included      milestone revenue of $0.1&#160;million, $43.5&#160;million, $13.5&#160;million and $29.4&#160;million, respectively, compared to $10.0&#160;million, $20.4&#160;million, $50.6&#160;million and $15.1&#160;million during the comparable periods in 2019. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)    Gross profit is computed as net product revenues less cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)    The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzIxOQ_eea2750d-ec54-4101-83de-fe7de8876610">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selected unaudited quarterly financial data was as follows (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal 2020 Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fiscal 2019 Quarter Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)   Total revenues for the quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, included      milestone revenue of $0.1&#160;million, $43.5&#160;million, $13.5&#160;million and $29.4&#160;million, respectively, compared to $10.0&#160;million, $20.4&#160;million, $50.6&#160;million and $15.1&#160;million during the comparable periods in 2019. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)    Gross profit is computed as net product revenues less cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)    The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8yLTEtMS0xLTE3NTA3_e678c4b4-edea-4230-a186-5fc1d0e0ab2e"
      unitRef="usd">226915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8yLTMtMS0xLTE3NTA3_745aff82-9ee0-4631-a9e6-76d7e27076d0"
      unitRef="usd">259479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8yLTUtMS0xLTE3NTA3_a1702b30-7d6d-41cf-b583-99a105f9f785"
      unitRef="usd">231092000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8yLTctMS0xLTE3NTA3_cc03c269-6129-499c-acb7-13baf15809ed"
      unitRef="usd">270052000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8zLTEtMS0xLTE3NTA3_fb3f0a0b-77ff-4381-8a51-b41b8385e07e"
      unitRef="usd">184591000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8zLTMtMS0xLTE3NTA3_eda0410c-b74a-42c5-af06-2d29050f8c9d"
      unitRef="usd">169509000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8zLTUtMS0xLTE3NTA3_7e0fb72a-9733-41f8-b5f5-b7002012a274"
      unitRef="usd">159862000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV8zLTctMS0xLTE3NTA3_300da5bf-12d8-4385-b0f2-523f54b9c106"
      unitRef="usd">191316000</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV80LTEtMS0xLTE3NTA3_7154063a-5274-419d-959a-a5a527a0fff4"
      unitRef="usd">52809000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV80LTMtMS0xLTE3NTA3_21322e43-6fec-4175-80e7-b92590768936"
      unitRef="usd">75534000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV80LTUtMS0xLTE3NTA3_125cb53d-2d70-43ec-b0b5-c78dbcd85f55"
      unitRef="usd">-42580000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV80LTctMS0xLTE3NTA3_fa319eb1-b60d-419d-b83e-d4b43b523e9c"
      unitRef="usd">24297000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV81LTEtMS0xLTE3NTA3_c89585a8-560a-42f9-a475-ea5f5c82a813"
      unitRef="usd">48612000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV81LTMtMS0xLTE3NTA3_b01dd264-50c6-4163-b12e-8bb9f84f17e6"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV81LTUtMS0xLTE3NTA3_1090c1e4-ea86-4125-b47e-4ec096a2a61a"
      unitRef="usd">-32040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV81LTctMS0xLTE3NTA3_9eac3bfa-4a98-4524-99bd-89ce642ffb07"
      unitRef="usd">28388000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTEtMS0xLTE3NTA3_de0b1174-ae48-4bbc-af16-003c357e8c71"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTMtMS0xLTE3NTA3_6fae2ce8-4b4c-4639-9620-56d4d222f877"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTUtMS0xLTE3NTA3_c2a99e7d-df29-4356-a07e-09c2631457dc"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTctMS0xLTE3NTA3_1c8b9e56-0f0b-4cb1-870a-5cc583a56432"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV83LTctMS0xLTE3NTA3_bec29640-38d2-49cd-9270-ee7d1348c952"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTEtMS0xLTE3NTA3_8bf30de0-1da7-4a63-b684-da014917df32"
      unitRef="usdPerShare">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTMtMS0xLTE3NTA3_1a788ef1-4cf2-4b8d-9c63-8c6f67bc89c2"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTUtMS0xLTE3NTA3_c4ddd035-ba9f-4fb8-9a72-03bfab08e46a"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTctMS0xLTE3NTA3_0f0b210e-dd55-4092-8872-278b9771acf1"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6ZDE3N2ZmY2VkYWFkNDdhZGI2ZmRlZWQzMWU5MjAxNDEvdGFibGVyYW5nZTpkMTc3ZmZjZWRhYWQ0N2FkYjZmZGVlZDMxZTkyMDE0MV84LTctMS0xLTE3NTA3_3fcbe78d-bbb3-45ea-ab66-da5acf6f6a1a"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8yLTEtMS0xLTE3NTEx_c771b4ef-bb4f-4f60-8524-7cd293ebf844"
      unitRef="usd">215487000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8yLTMtMS0xLTE3NTEx_e22c9b35-45c1-49e8-a356-7f99d52010aa"
      unitRef="usd">240275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8yLTUtMS0xLTE3NTEx_48589aca-5224-4e19-ab6c-0361a712e6c4"
      unitRef="usd">271703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8yLTctMS0xLTE3NTEx_feec5cf6-1d2d-45b1-b91f-45472e67189c"
      unitRef="usd">240310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8zLTEtMS0xLTE3NTEx_49a4e900-8b82-44a9-bbe7-3700c0a849c1"
      unitRef="usd">172080000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8zLTMtMS0xLTE3NTEx_37f89102-edfc-44a0-adec-68c1a10b85f9"
      unitRef="usd">186136000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8zLTUtMS0xLTE3NTEx_0b0b570b-096f-47c4-951e-0b9ec233af40"
      unitRef="usd">184231000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF8zLTctMS0xLTE3NTEx_89fa72fe-7702-4d15-9fc4-32e9dd18fba4"
      unitRef="usd">184406000</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF80LTEtMS0xLTE3NTEx_d189c86d-54cb-46fb-8a8d-34aa36202fd9"
      unitRef="usd">84559000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF80LTMtMS0xLTE3NTEx_d0cb6ec5-e02f-416e-b65b-f7206c871b2e"
      unitRef="usd">91989000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF80LTUtMS0xLTE3NTEx_974613ff-8cc0-4578-bad6-00f5f82a7302"
      unitRef="usd">115606000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF80LTctMS0xLTE3NTEx_f81db746-3e47-49dd-92b8-1061980a9614"
      unitRef="usd">77316000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF81LTEtMS0xLTE3NTEx_549798c7-9d28-4b71-a246-2f639954c7fd"
      unitRef="usd">75775000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF81LTMtMS0xLTE3NTEx_7b995dda-6ab9-492b-bf61-4bcae4aebc85"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF81LTUtMS0xLTE3NTEx_4a3ab4b0-4bf6-42e7-b84a-56cfff6b8ee5"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF81LTctMS0xLTE3NTEx_f0bb9467-2c9d-4911-8399-f7602993da4d"
      unitRef="usd">68743000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF83LTEtMS0xLTE3NTEx_84be3e03-c29e-4f19-8518-16db6d0dcbae"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF83LTMtMS0xLTE3NTEx_21242ae2-b56a-4461-94ac-b3e89c06113a"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF83LTUtMS0xLTE3NTEx_d66b21e7-e121-4fda-9caa-466673ad9a23"
      unitRef="usdPerShare">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF83LTctMS0xLTE3NTEx_d85bac77-3fab-4f20-901a-7b64efa725c9"
      unitRef="usdPerShare">0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF84LTEtMS0xLTE3NTEx_bf83e51d-ed03-4529-9ab3-595f0556e67b"
      unitRef="usdPerShare">0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF84LTMtMS0xLTE3NTEx_4c1ec441-c682-40b4-9711-ffd1834a895e"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF84LTUtMS0xLTE3NTEx_925dbccf-715c-433c-ab08-03a7d4533aa6"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGFibGU6NWU1M2FlNzM3ZWYyNGMxOWEzNmUwN2QyZGRlMzEzMzQvdGFibGVyYW5nZTo1ZTUzYWU3MzdlZjI0YzE5YTM2ZTA3ZDJkZGUzMTMzNF84LTctMS0xLTE3NTEx_f49cea00-f446-4edf-9a37-36697ffa4644"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareDiluted>
    <exel:MilestonePaymentsEarned
      contextRef="i7f3f5d6cada24efc825927858de205ca_D20200104-20200403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzIyMQ_53d8c290-8059-48ff-b0d6-d1ba910e7784"
      unitRef="usd">100000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="iea562264c8dc4d729233be2a45ffaff7_D20200404-20200703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzIzNQ_eb89b919-6b44-416e-bfa6-7b956060ec7b"
      unitRef="usd">43500000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i212ab6b55f2c4d7da03bda9abaaa167a_D20200704-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzI1MA_6c004084-7796-400a-b3bc-9c7ca4721d33"
      unitRef="usd">13500000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i9976757837ac4b5ab75920208383f366_D20201003-20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzI2NQ_d6b829ee-6137-42e3-9044-139b5125bdde"
      unitRef="usd">29400000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="ic3e083fd450c43d4a6a716ea5d355ba0_D20181229-20190329"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzI4MA_0e79bf0e-2ac0-45b2-9936-8c74b275d0d1"
      unitRef="usd">10000000.0</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i6bda8cccf7404ad2a2d6f08b1fc9ba8a_D20190330-20190628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzI5NQ_3f1c9dd4-d8cf-4393-8647-9172a13a276e"
      unitRef="usd">20400000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="ifa1f1437c7174e6b8d79671c37d90d01_D20190629-20190927"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzMxMA_7dc5489a-fbd1-41ef-b3d8-c4ef1df61639"
      unitRef="usd">50600000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xNDg2L2ZyYWc6YTk0NzgxOWZiNDZiNGU3NTg0MzUyNzliNDAwMmM0YTYvdGV4dHJlZ2lvbjphOTQ3ODE5ZmI0NmI0ZTc1ODQzNTI3OWI0MDAyYzRhNl8xODE0MTk0MTg2MzMyNQ_0de8fd4a-64be-48bb-82ac-45bf61d01910"
      unitRef="usd">15100000</exel:MilestonePaymentsEarned>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257308576408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,399,562,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,989,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than May 3, 2021, in connection with the registrant&#8217;s 2021 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257308871208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 319,217<span></span>
</td>
<td class="nump">$ 266,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">887,319<span></span>
</td>
<td class="nump">585,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">160,875<span></span>
</td>
<td class="nump">119,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">20,973<span></span>
</td>
<td class="nump">12,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">57,011<span></span>
</td>
<td class="nump">26,988<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,445,395<span></span>
</td>
<td class="nump">1,011,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">332,306<span></span>
</td>
<td class="nump">536,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">67,384<span></span>
</td>
<td class="nump">48,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">156,711<span></span>
</td>
<td class="nump">172,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">71,853<span></span>
</td>
<td class="nump">53,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,137,333<span></span>
</td>
<td class="nump">1,885,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">23,632<span></span>
</td>
<td class="nump">11,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">51,189<span></span>
</td>
<td class="nump">37,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">52,251<span></span>
</td>
<td class="nump">38,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">20,683<span></span>
</td>
<td class="nump">18,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">12,456<span></span>
</td>
<td class="nump">11,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">44,447<span></span>
</td>
<td class="nump">24,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">204,658<span></span>
</td>
<td class="nump">142,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">3,755<span></span>
</td>
<td class="nump">6,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">49,086<span></span>
</td>
<td class="nump">48,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">2,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">258,220<span></span>
</td>
<td class="nump">199,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 311,627 and 304,831 at December&#160;31, 2020 and 2019, respectively</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,321,895<span></span>
</td>
<td class="nump">2,241,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">4,476<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(447,570)<span></span>
</td>
<td class="num">(559,351)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,879,113<span></span>
</td>
<td class="nump">1,685,970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,137,333<span></span>
</td>
<td class="nump">$ 1,885,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257386346648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">311,627,000<span></span>
</td>
<td class="nump">304,831,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">311,627,000<span></span>
</td>
<td class="nump">304,831,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309195384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">36,272<span></span>
</td>
<td class="nump">33,097<span></span>
</td>
<td class="nump">26,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">547,851<span></span>
</td>
<td class="nump">336,964<span></span>
</td>
<td class="nump">182,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">293,355<span></span>
</td>
<td class="nump">228,244<span></span>
</td>
<td class="nump">206,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">877,478<span></span>
</td>
<td class="nump">598,305<span></span>
</td>
<td class="nump">414,971<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">110,060<span></span>
</td>
<td class="nump">369,470<span></span>
</td>
<td class="nump">438,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">19,865<span></span>
</td>
<td class="nump">27,959<span></span>
</td>
<td class="nump">12,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">912<span></span>
</td>
<td class="nump">680<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">130,837<span></span>
</td>
<td class="nump">398,109<span></span>
</td>
<td class="nump">452,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">19,056<span></span>
</td>
<td class="nump">77,097<span></span>
</td>
<td class="num">(237,978)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 111,781<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">308,271<span></span>
</td>
<td class="nump">302,584<span></span>
</td>
<td class="nump">297,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">318,001<span></span>
</td>
<td class="nump">315,009<span></span>
</td>
<td class="nump">312,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 741,550<span></span>
</td>
<td class="nump">$ 759,950<span></span>
</td>
<td class="nump">$ 619,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">167,295<span></span>
</td>
<td class="nump">165,914<span></span>
</td>
<td class="nump">200,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 78,693<span></span>
</td>
<td class="nump">$ 41,911<span></span>
</td>
<td class="nump">$ 34,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Basic Diluted Other Disclosures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309509720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 111,781<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $(394), $(1,049), and $156, respectively</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="nump">3,770<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 113,188<span></span>
</td>
<td class="nump">$ 324,782<span></span>
</td>
<td class="nump">$ 689,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257308006312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized gains or losses on available-for-sale securities, tax impact</a></td>
<td class="num">$ (1,049)<span></span>
</td>
<td class="num">$ (394)<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307488776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjustment </div>
<div>Accumulated Deficit</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2017</a></td>
<td class="nump">$ 284,961<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 2,114,184<span></span>
</td>
<td class="num">$ (347)<span></span>
</td>
<td class="num">$ (1,829,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period (ASU 2014-09) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,505<span></span>
</td>
<td class="nump">$ 258,505<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period (ASU 2016-02) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">690,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">20,985<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">20,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(7,574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">40,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 28, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 28, 2018</a></td>
<td class="nump">1,287,453<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">2,168,217<span></span>
</td>
<td class="num">(701)<span></span>
</td>
<td class="num">(880,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">321,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">3,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">27,037<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">27,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(9,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 56,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Jan. 03, 2020</a></td>
<td class="nump">304,831<span></span>
</td>
<td class="nump">304,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jan. 03, 2020</a></td>
<td class="nump">$ 1,685,970<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">2,241,947<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
<td class="num">(559,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">111,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">24,903<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">24,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(50,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 105,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Jan. 01, 2021</a></td>
<td class="nump">311,627<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jan. 01, 2021</a></td>
<td class="nump">$ 1,879,113<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">$ 2,321,895<span></span>
</td>
<td class="nump">$ 4,476<span></span>
</td>
<td class="num">$ (447,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309755384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 111,781<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">9,141<span></span>
</td>
<td class="nump">8,348<span></span>
</td>
<td class="nump">4,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">105,070<span></span>
</td>
<td class="nump">56,602<span></span>
</td>
<td class="nump">40,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">4,830<span></span>
</td>
<td class="nump">2,819<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">15,265<span></span>
</td>
<td class="nump">71,002<span></span>
</td>
<td class="num">(244,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(42,470)<span></span>
</td>
<td class="nump">43,716<span></span>
</td>
<td class="num">(85,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(21,897)<span></span>
</td>
<td class="num">(5,731)<span></span>
</td>
<td class="num">(3,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(25,831)<span></span>
</td>
<td class="num">(5,723)<span></span>
</td>
<td class="num">(8,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,051)<span></span>
</td>
<td class="num">(9,301)<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">51,109<span></span>
</td>
<td class="nump">44,124<span></span>
</td>
<td class="nump">17,143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">208,982<span></span>
</td>
<td class="nump">526,956<span></span>
</td>
<td class="nump">415,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(30,345)<span></span>
</td>
<td class="num">(12,834)<span></span>
</td>
<td class="num">(33,297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(1,070,269)<span></span>
</td>
<td class="num">(1,182,682)<span></span>
</td>
<td class="num">(557,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">969,399<span></span>
</td>
<td class="nump">608,269<span></span>
</td>
<td class="nump">292,971<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(131,215)<span></span>
</td>
<td class="num">(587,247)<span></span>
</td>
<td class="num">(297,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">24,886<span></span>
</td>
<td class="nump">22,499<span></span>
</td>
<td class="nump">17,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(50,018)<span></span>
</td>
<td class="num">(9,904)<span></span>
</td>
<td class="num">(7,574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(25,132)<span></span>
</td>
<td class="nump">12,553<span></span>
</td>
<td class="nump">9,691<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash equivalents</a></td>
<td class="nump">52,635<span></span>
</td>
<td class="num">(47,738)<span></span>
</td>
<td class="nump">127,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">268,137<span></span>
</td>
<td class="nump">315,875<span></span>
</td>
<td class="nump">188,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">320,772<span></span>
</td>
<td class="nump">268,137<span></span>
</td>
<td class="nump">315,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">4,115<span></span>
</td>
<td class="nump">7,873<span></span>
</td>
<td class="nump">10,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract', window );"><strong>Non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">4,017<span></span>
</td>
<td class="nump">29,562<span></span>
</td>
<td class="nump">17,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred for purchases of property and equipment</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InvestmentsPurchasesIncurredButNotYetPaid', window );">Unpaid liabilities incurred for unsettled investment purchases</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccountsReceivableForUnsettledInvestmentSales', window );">Accounts receivable for unsettled investment sales</a></td>
<td class="nump">$ 6,180<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccountsReceivableForUnsettledInvestmentSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable For Unsettled Investment Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccountsReceivableForUnsettledInvestmentSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InvestmentsPurchasesIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments Purchases Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InvestmentsPurchasesIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307146840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program, and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple regimens to treat advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain committed to expanding our oncology product pipeline through our drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made&#160;reclassifications&#160;to our prior years&#8217; Consolidated Financial Statements to conform to the current year&#8217;s presentation. These&#160;reclassifications&#160;did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities, total operating, investing or financing cash flows or total stockholders&#8217; equity.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2021, January 3, 2020 and December 28, 2018 are indicated as being as of and for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In  March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. Accordingly, we recorded an adjustment to increase selling, general and administrative expenses for these fees by $5.1&#160;million during the fiscal year ended December 31, 2020. This adjustment resulted in a $0.02 decrease in basic and diluted </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings per share for the fiscal year ended December 31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we adopted Accounting Standards Update (ASU) No.&#160;201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-18,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606) when the counterparty is a customer for a distinct good or service (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter 2020, we adopted ASU No.&#160;2017-04,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2017-04)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we adopted ASU No.&#160;2016-13,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-13)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, contract assets, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Impairment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly, we assess each of our investments in available-for-sale debt securities whose fair value is below its cost basis to determine if the investment&#8217;s impairment is due to credit-related factors or noncredit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the accompanying Consolidated Statements of Income. The portion of the impairment that is not credit-related is recorded as a reduction of other comprehensive income (loss), net of applicable taxes. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of the available-for-sale debt securities for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. As of December&#160;31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration partners</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did not recognize any impairment charges in any of the periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts for Prompt Payment:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Customer Credits: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial projects have been executed with support from third-party contract research organizations (CROs), who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of Topic 842 for short-term leases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses were $25.1 million, $17.9 million and $14.8 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock&#160;Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for (Benefit from) Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for (benefit from) income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for (benefit from) income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for (benefit from) income taxes in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December&#160;31, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 9. Provision For (Benefit From) Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accompanying Consolidated Statements of Income. Net foreign currency gains were $0.9 million for the year ended December&#160;31, 2020, and not material for the years December&#160;31, 2019 and 2018.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will b</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e effective for us in the first quarter of 2021 with early adoption permitted. The adoption of ASU 2019-12 on January 1, 2021 will not have a significant impact on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307135752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GSK on sales of products containing cabozantinib by our collaboration partners. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues are comprised of net product revenues which are attributed to geographic regions based on the ship-to location and license and collaboration services revenues which are attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending allowance balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2018</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216,738)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. Contract assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Presented in prepaid expenses and other current assets in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018, we recognized $9.2 million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.5 million and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $8.7 million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, in revenues that were included in the beginning deferred revenue balance for those years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2020, 2019 and 2018, we recognized $169.7 million, $161.2 million and $198.1 million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to milestone and royalty payments allocated to our license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, $86.1 million of the combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; for additional information about the expected timing to satisfy these performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307088248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">COLLABORATION AGREEMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib franchise. Additionally, we have entered into several research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Consistent with our business strategy prior to the commercialization of cabozantinib, we also entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, to receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (1) the expiration of patent claims related to cabozantinib, (2) the expiration of regulatory exclusivity covering cabozantinib or (3) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. A related supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the U.S. Food and Drug Administration (FDA) or European Medicines Agency orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen were to terminate only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, we received aggregate upfront payments of $210.0 million from Ipsen in 2016. As of December&#160;31, 2020, we have achieved aggregate milestones of $350.0 million related to regulatory, development and sales-based threshold by Ipsen since the inception of the collaboration agreement, including $20.0 million, $55.0 million and $140.0&#160;million in milestones achieved during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we are eligible to receive additional regulatory and development milestone payments from Ipsen totaling an aggregate of $59.0 million, as well as sales-based milestones, including milestone payments earned for the first commercial sale of a product, of up to $450.0&#160;million and CAD$26.5&#160;million. We excluded these milestones from the transaction price as of December&#160;31, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2020, $41.3 million of the transaction price allocated to our research and development services performance obligation had not been satisfied. See &#8220;&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, below, for additional information related to the revenue recognition for this collaboration.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive royalties on the net sales of cabozantinib by Ipsen outside of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he U.S. and Japan. During the year ended December&#160;31, 2020 and going forward, we are entitled to receive a tiered royalty of 22% to 26% on annual net sales, with separate tiers for Canada; these royalty tiers reset each calendar year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a 3% royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Ipsen.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. Ipsen has opted into and is co-funding the following clinical trials which are described in greater detail below: COSMIC-021, COSMIC-312, CONTACT-01 and CONTACT-02.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain responsible for manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement with Ipsen to supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement. The product is supplied at our cost, as defined in the agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda, which was subsequently amended effective March 2018, May 2019 and September 2020, to, among other things, modify the amount of reimbursements we receive for costs associated with our required pharmacovigilance activities and milestones we are eligible to receive and modified certain cost sharing obligations related to the Japan-specific development costs associated with CONTACT-01 and CONTACT-02 clinical trials. We determined the amendment in September 2020 represented a contract modification that was treated as a termination of an existing contract and the creation of a new contract under Topic 606. As a result, we allocated the remaining transaction price to the performance obligations identified in the contract. The two remaining performance obligations are the research and development services associated with committed studies and the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. In allocating the transaction price for the modified contract we estimated the standalone selling price for the performance obligations. We utilized development costs incurred for these obligations in process and the projections of costs through the term of the arrangement. Revenue is recognized when, or as, we satisfy our performance obligations by transferring the promised services to Takeda. Revenue is being recognized using the cost proportional performance method, based on costs incurred to perform the research and development services, since the level of costs incurred over time is thought to best reflect the transfer of services to Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is responsible for a portion of the costs associated with the cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Takeda has opted into and is co-funding the following clinical trials which are described in greater detail below: CheckMate -9ER, CONTACT-01 and CONTACT-02, and certain cohorts of COSMIC-021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (1) two years after first generic entry with respect to such product in Japan or (2) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration under the Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received an upfront payment of $50.0 million from Takeda in 2017. As of December&#160;31, 2020, we have also achieved regulatory and development milestones in the aggregate of $92.0 million since the inception of the collaboration agreement, including $66.0 million, $16.0 million and $10.0&#160;million in milestones achieved during the years ended December&#160;31, 2020, 2019 and 2018, respectively. As of December 31, 2020, we have also determined that it was probable that we will earn milestone payments totaling $15.0&#160;million for the initiation of two phase 3 pivotal clinical trials for additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, as amended, as of December 31, 2020, we are eligible to receive additional regulatory and development milestone payments, without contractual limit, for additional potential future indications. We are further eligible to receive commercial milestones, including milestone payments earned for the first commercial sale of a product, of up to $139.0 million. We excluded these milestones from the transaction price as of December 31, 2020 because we determined such payments to be fully constrained under Topic 606 due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur, given the inherent uncertainty of success with these milestones. We will re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also receive royalties on the net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of 15% to 24% on the initial $300.0&#160;million of net sales, and following this initial $300.0&#160;million of net sales, we are then entitled to receive a tiered royalty of 20% to 30% on annual net sales thereafter; these 20% to 30% royalty tiers reset each calendar year. Any variable consideration related to royalties and sales-based milestones will be recognized when the related sales occur as these amounts have been determined to relate to the relevant transferred license and therefore are recognized as the related sales occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay a 3% royalty to GSK on all net sales of any product incorporating cabozantinib, including net sales by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the collaboration agreement, we are responsible for the manufacturing and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a clinical supply agreement covering the supply of cabozantinib to Takeda for the term of the collaboration agreement, as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply. Furthermore, at the time we entered into the collaboration agreement, the parties also entered into a safety data exchange agreement, which defines each partner&#8217;s responsibility for safety reporting. This agreement also requires us to maintain the global safety database for cabozantinib. To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from the Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):  </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, $44.8&#160;million of the transaction price was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified two performance obligations for the Ipsen collaboration agreement: (1) the transfer of an exclusive license for the commercialization and further development of cabozantinib; and (2) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified two remaining performance obligations for the Takeda collaboration agreement due to the amendment in September 2020: (1) research and development services, which includes certain committed studies for the development of cabozantinib, pharmacovigilance services and participation on various joint committees (as defined in the specific collaboration agreements) and (2) the research and development services associated with CONTACT-01, CONTACT-02, and certain cohorts of COSMIC-021 studies. As part of the original contract, we had a performance obligation associated with the exclusive license for the commercialization and further development of cabozantinib, which was transferred in 2017.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have allocated the transaction price for each of these collaborations to the identified performance obligations based on our best estimate of their relative standalone selling price. For the licenses, the estimate of the relative standalone selling price was determined using a discounted cash flow valuation utilizing forecasted revenues and costs. For research and development services the estimate of the relative standalone selling price was determined using an adjusted market assessment approach that relies on internal and external costs and market factors. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the transaction price allocated to our license performance obligation is recorded immediately as our license represents functional intellectual property that was transferred at a point in time. The portion of the transaction price allocated to our research and development services performance obligation is being recognized as revenue using the inputs method based on our internal development projected cost estimates through the current estimated patent expiration of cabozantinib in the European Union for the Ipsen Collaboration and Japan for the Takeda Collaboration, both of which are early 2030. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We re-evaluate the transaction price for the collaboration agreements in each reporting period as uncertain events are resolved or other changes in circumstances occur and we allocate those changes in the transaction price between our performance obligations. During the years ended December&#160;31, 2020, 2019 and 2018, the transaction price of the Ipsen and Takeda collaboration agreements increased as a result of the achievement of various milestones, and the reimbursements of research and development services related to committed and opt-in studies. We further updated the transaction price based upon the actual research and development services performed during the period and changes in our estimated reimbursements for our future research and development services. The portion of the increase in transaction price that was allocated to the previously satisfied performance obligations for the transfer of an intellectual property license was recognized during the period and the portion allocated to research and development services will be recognized in future periods as those services are delivered through early 2030. As of December&#160;31, 2020, variable consideration related to the remaining unearned regulatory and development milestones for both agreements remained constrained due to the fact that it was not probable that a significant reversal of cumulative revenue would not occur. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Development Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (BMS)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors (ICIs), nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating these combinations as treatment options for RCC in the CheckMate -9ER and COSMIC-313 trials and for HCC in the CheckMate 040 trial. Under the terms of the collaboration agreement with BMS, we may also evaluate these combinations in other phase 3 pivotal trials in various other tumor types. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the collaboration agreement with BMS, as subsequently amended effective March 2019, May 2019 and November 2019, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement and its supplemental agreements), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination Investigational New Drug application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying finished drug product for the applicable clinical trial, and responsibility for the payment of costs for each such trial will be determined on a trial-by-trial basis. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">F. Hoffmann-La Roche Ltd. (Roche) Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and Roche&#8217;s ICI, atezolizumab, in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated COSMIC-021, a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, and in December 2018, we initiated COSMIC-312, a multicenter, randomized, controlled phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC. We are the sponsor of both trials, and Roche is providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a joint clinical research agreement with Roche for the purpose of further evaluating the combination of cabozantinib with atezolizumab in patients with locally advanced or metastatic solid tumors, including in three planned phase 3 pivotal clinical trials in advanced non-small cell lung cancer (CONTACT-01), metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03). If a party to the joint clinical research agreement proposes any additional combined therapy trials beyond these phase 3 pivotal trials, the joint clinical research agreement provides that such proposing party must notify the other party and that if agreed to, any such additional combined therapy trial will become part of the collaboration, or if not agreed to, the proposing party may conduct such additional combined therapy trial independently, subject to specified restrictions set forth in the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, a supplement to the joint clinical research agreement was signed amongst us, Roche and Takeda due to Takeda opting into fund the combined therapy trial of CONTACT-01 sponsored by Roche. Chugai was added as an affiliate of Roche. All parties including Chugai conduct combined therapy trials in Japan upon the terms of the joint clinical research agreement.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the joint clinical research agreement, each party granted to the other a non-exclusive, worldwide (excluding, in our case, territory already the subject of a license by us to Takeda), non-transferable, royalty-free license, with a right to sublicense (subject to limitations), to use the other party&#8217;s intellectual property and compounds solely as necessary for the party to perform its obligations under the joint clinical research agreement. The parties&#8217; efforts will be governed through a joint steering committee established to guide and oversee the collaboration and the conduct of the combined therapy trials. Each party will be responsible for providing clinical supply of their drug for all combined therapy trials, and the cost of the supply will be borne by such party. The clinical trial expenses for each combined therapy trial agreed to be conducted jointly under the joint clinical research agreement will be shared equally between the parties, and the clinical trial expenses for each additional combined therapy trial not agreed to be conducted jointly under the joint clinical research agreement will be borne by the proposing party, except that the cost of clinical supply for all combined therapy trials will be borne by the party that owns the applicable product. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the contract is within the scope of Topic 808 as it involves joint operating activities where both parties have active participation in the arrangement and are exposed to significant risks and rewards. Payments between us and Roche under this arrangement are not subject to other accounting literature. Payments due to Roche for our share of clinical trial costs incurred by Roche will be recorded as research and development expense and payments due from Roche for their share of clinical trial costs incurred by us will be recorded as a reduction of research and development expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the joint clinical research agreement provides that it will remain in effect until the completion of all combined therapy trials under the collaboration, the delivery of all related trial data to both parties, and the completion of any then agreed-upon additional analyses. The joint clinical research agreement may be terminated for cause by&#160;either party based on any uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party will terminate upon completion of any ongoing activities under the joint clinical research agreement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated during 2014, we continue to be required to pay a 3% royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of other </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration revenues for sales by our collaboration partners. Such royalties were $32.7 million, $31.3 million and $24.0 million during the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits and losses on the U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See &#8220;&#8212;Performance Obligations and Transaction Prices for our Other Collaborations&#8221;, below, for additional information related to revenue recognition for this collaboration.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cobimetinib Profit Sharing and Royalty Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. On July 30, 2020, the FDA approved COTELLIC, in combination with Genentech&#8217;s ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of BRAF V600 mutation-positive advanced melanoma in previously untreated patients. Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive 50% of profits and losses from the first $200.0 million of U.S. actual sales, decreasing to 30% of profits and losses from U.S. actual sales in excess of $400.0 million. These tiers reset each calendar year. The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (Genentech Collaboration P&amp;L) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. We are not eligible for any additional milestone payments under the collaboration agreement with Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo was responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In&#160;January 2019, the Japanese Ministry of Health, Labour and Welfare approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May 2019, Daiichi Sankyo had its first commercial sale of MINNEBRO. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have achieved milestones of $20.0&#160;million each during the years ended December&#160;31, 2019 and 2018 for the approval and first commercial sale of MINNEBRO. We are eligible to receive additional sales-based milestone payments of up to $90.0 million under this collaboration agreement. In addition, we are entitled to receive low double-digit royalties on sales of MINNEBRO. Such revenues were $1.3&#160;million and $0.1&#160;million during the year ended December 31, 2020 and 2019, respectively. Those revenues are presented in license revenue in our Consolidated Statements of Income. Daiichi Sankyo may terminate the agreement upon 90 days&#8217; written notice, in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue under the collaboration agreement with Daiichi Sankyo w</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as $1.3&#160;million, $20.1&#160;million </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $20.0&#160;million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Research Collaborations and In-Licensing Arrangements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions LLC</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., (individually and collectively referred to as Catalent). Under the terms of the agreement, we made an upfront payment of $10.0&#160;million in exchange to nominate and have the exclusive option to license four targets using Catalent&#8217;s ADC platform over a three-year period. In addition, we have a right to extend the target selection term to five years and nominate up to two additional targets for an additional payment of $4.0&#160;million. For each option we decide to exercise, we will pay an exercise fee of $2.0&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. Catalent would then become eligible to receive up to $44.0&#160;million per compound in potential development milestone payments, $60.0&#160;million per product in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NBE Therapeutics AG (NBE)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a collaboration and license agreement with NBE. Under the terms of the agreement, we made an upfront payment of $25.0&#160;million in exchange for exclusive options to nominate four targets using NBE&#8217;s ADC platform over a two-year period. In addition, within the first eighteen months of the agreement, we also have a right to extend the target selection term to three years for an additional payment of $2.0&#160;million. For each option we decide to exercise, we will be required to pay an exercise fee of $10.0&#160;million, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. NBE would then become eligible to receive up to $90.0&#160;million per program in potential development milestone payments, $135.0&#160;million per program in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aurigene Discovery Technologies Limited (Aurigene)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into an exclusive collaboration, option and license agreement with Aurigene to in-license as many as six programs to discover and develop small molecules as therapies for cancer. Under the terms of the agreement, we made aggregate upfront payments of $17.5 million for exclusive options to license up to six programs, including three pre-existing programs. We are also responsible for research funding for the discovery and preclinical development work on these programs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, we exercised the exclusive option to in-license Aurigene&#8217;s novel XL102 inhibitor and incurred an option exercise fee of $12.0&#160;million. For each remaining option we decide to exercise, we will be required to pay an exercise fee of $10.0 million and would then assume responsibilities for all subsequent clinical development, manufacturing and commercialization for that program. Aurigene would then become eligible for up to $148.8 million per program in potential development and regulatory milestone payments, $280.0 million per program in potential commercial milestone payments, as well as royalties on potential sales. Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Iconic Therapeutics, Inc. (Iconic)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer, leveraging Iconic&#8217;s expertise in targeting Tissue Ffactor in solid tumors. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#8217;s lead oncology ADC program, in exchange for an upfront payment to Iconic of $7.5 million and a commitment for preclinical development funding.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, we exercised our exclusive option to in-license XB002, Iconic&#8217;s lead oncology ADC program and made an option exercise fee payment of $20.0 million to Iconic; we concurrently assumed responsibilities for all subsequent clinical development, manufacturing and commercialization activities, and Iconic  became eligible for up to $190.6 million in potential development, regulatory and first-sale milestone payments, $262.5 million in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Invenra, Inc. (Invenra)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a collaboration and license agreement with&#160;Invenra to discover and develop multispecific antibodies for the treatment of cancer. Invenra is responsible for antibody lead discovery and generation while we will lead IND-enabling studies, manufacturing, clinical development in single-agent and combination therapy regimens, and future regulatory and commercialization activities.&#160;The collaboration agreement provides that we will receive an exclusive, worldwide license to one preclinical, multispecific antibody asset, and that we will pursue up to six additional discovery projects during the term of the collaboration, which in total are directed to three discovery programs. In October 2019, we expanded our collaboration to include the development of novel binders against six additional targets, which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology platform, or with other platforms and formats at our option. In March 2020, we amended the agreement to enable the use of target binders in non-Invenra platform-based modalities, such as ADC platforms. As of December 31, 2020, we have initiated three additional discovery projects and six binder projects. Invenra is eligible to receive up to&#160;$131.5 million&#160;in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a B-Body product in the first indication, or in lieu of such payments, up to $43.4 million in project initiation fees and milestone payments based on the achievement of specific development and regulatory milestones for a non- B-Body product. Upon successful commercialization of a product, Invenra is eligible to receive sales-based milestone payments up to&#160;$325.0 million&#160;as well as single-digit tiered royalties on net sales of the approved product. We have the right to initiate three additional discovery projects for development subject to an upfront payment of&#160;$2.0 million&#160;for each B-Body project, as well as additional milestone payments and royalties for any products that arise from these efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">StemSynergy Therapeutics, Inc. (StemSynergy)</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1&#945;), a component of the Wnt signaling pathway implicated in key oncogenic processes. Under the terms of the agreement,&#160;we&#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&#945;. We paid StemSynergy an upfront payment of $3.0&#160;million in 2018. StemSynergy will also be eligible for up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$56.5 million </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in milestones for the first product to emerge from the collaboration, including preclinical and clinical development and regulatory milestone payments, sales-based milestones, as well as single-digit royalties on worldwide sales. We will be solely responsible for the commercialization of products that arise from the collaboration.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257305707256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">Cash and Investments</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.470%"><tr><td style="width:1.0%"/><td style="width:73.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit and, during prior periods, a purchasing card program. The long-term classification of restricted cash equivalents is based upon the remaining term of the underlying restriction. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $4.5 million and $6.2 million as of December 31, 2020 and 2019, respectively, and is included in prepaid and other current assets in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.809%"><tr><td style="width:1.0%"/><td style="width:73.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.950%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:73.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.877%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were 14 and 9 debt securities in an unrealized loss position as of December&#160;31, 2020 and 2019, respectively. During the years ended December&#160;31, 2020 and 2019, we did not record an allowance for credit losses or other impairment charges on our debt securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307090664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS <div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div>The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257305468984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-downs related to excess and expiring inventory were $2.7 million, $1.3 million and $1.1 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307253624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to 15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,452&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $9.1 million, $8.3 million and $4.9 million during the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257305477176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans and ESPP</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several equity incentive plans under which we granted stock options and RSUs, including PSOs and PSUs, to employees and directors. At December&#160;31, 2020, 17,100,727 shares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option award and 1.5 shares for full value awards granted in the form of RSUs or PSUs. On May 20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by 21,000,000 shares, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors (the Board) delegated responsibility for administration of our equity incentive plans to the Compensation Committee of the Board, including the authority to determine the term, exercise price and vesting requirements of each grant. Stock options granted to our employees and directors generally have a four-year vesting term and a one-year vesting term, respectively, an exercise price equal to the fair market value on the date of grant, and a seven-year life from the date of grant. RSUs granted to our employees and directors generally have a four-year vesting term and a </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one-year vesting term, respectively. PSUs and PSOs granted pursuant to our equity incentive plans vest upon specified service conditions and the achievement of a performance target or market condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Change in Control and Severance Benefit Plan for certain executive officers. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing one month before and ending thirteen months following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all their outstanding equity awards accelerated and the exercise period for their stock options extended to no more than one year.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of 85% of the closing price at the beginning of the offering period or 85% of the closing price at the end of each six month purchase period. As of December&#160;31, 2020, we had </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,704,580</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares available for issuance under our ESPP. Pursuant to the ESPP, we issued 534,419, 483,009 and 330,492 shares of common stock at an average price per share of $14.55, $12.60 and $15.74 during the years ended December&#160;31, 2020, 2019 and 2018, respectively. Cash received </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from purchases under the ESPP for the years ended December 31, 2020, 2019 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $7.8 million, $6.1 million and $5.2 million, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used a Monte Carlo simulation pricing model to value PSOs that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, including PSOs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, including PSOs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered both implied and historical volatilities in developing our estimate of expected volatility. The assumption for the expected life of stock options is based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs, including the PSUs, was based on the closing price of the underlying common stock on the date of grant. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options, including PSOs, during the year ended December&#160;31, 2020 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $27.1 million of unrecognized compensation expense related to our unvested stock options, including PSOs. The compensation expense for the unvested stock options will be recognized over a weighted-average period of 2.3 years.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted 308,365 PSOs to our President and Chief Executive Officer. In addition to the standard service-based vesting conditions included in our other stock options, these PSOs contain a market vesting condition such that they may not be exercised until, at any time after the grant date, the closing market price of a share of our Common Stock is equal to or greater than 125% of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. This market vesting condition was achieved during the second quarter of the fiscal 2020. The stock-based compensation expense for the PSOs is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant. The achievement of the market vesting condition did not impact the compensation expense recognized during the period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal 2020 and the exercise prices, multiplied by the number of in-the-money stock options) that would have been received by the stock option holders had all stock option holders exercised their stock options on December&#160;31, 2020. The total intrinsic value of stock options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $106.5 million, $54.1 million and $39.1 million, respectively. Cash received from stock option exercises during the years ended December&#160;31, 2020, 2019 and 2018 was $26.9 million, $16.4 million and $12.1 million, respectively. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Activity for RSUs during the year ended December&#160;31, 2020 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $103.6 million of unrecognized compensation expense related to our unvested RSUs which will be recognized over a weighted-average period of 3.0 years.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Activity for PSUs, during the year ended December&#160;31, 2020 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, in connection with our long-term incentive compensation program, we awarded 2,327,840 PSUs (the target amount) that will vest upon the achievement of certain performance targets related to clinical trial positive top-line results and product approvals by the FDA (the 2020 PSUs). Pursuant to the terms of the 2020 PSUs, employees may earn up to 200% of the target amount, or 4,655,680 shares, depending on the volume and timing of achievement of the performance targets. The 2020 PSUs were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2024.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December&#160;31, 2019, we awarded 1,926,605 PSUs (the target amount) that vest upon the achievement of performance targets related to product approvals by the FDA (the 2019 PSUs). Pursuant to the terms of the 2019 PSUs, employees may earn up to 200% of the target amount, or up to an additional 1,926,605 shares relative to the target amount, depending on the volume and timing of achievement of the performance targets. The performance condition for early achievement of the 2019 PSUs occurred during 2020 representing 150% of the target amount. Employees have the ability to earn the remaining 50% of the target amount if the additional performance condition is met before December 31, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2018, we awarded 693,131 PSUs that vest upon the achievement of certain product revenue, late-stage clinical development programs and discovery pipeline expansion performance targets (the 2018 PSUs). The 2018 PSUs and 2019 PSUs will be forfeited if the performance targets are not met by December 31, 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recognition for PSUs commences when it is determined that attainment of the performance target is probable. Of the aggregate outstanding PSUs, 3,206,897 relate to awards for which we achieved the performance target or had determined that it was probable that we would achieve the performance target. As of December 31, 2020, the remaining unrecognized compensation expense for the PSUs achieved or deemed probable of achievement related to the PSUs was $11.8 million, which will be recognized over a weighted-average period of 3.5 years. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance target is probable was $128.5 million as of December&#160;31, 2020.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exelixis, Inc. 401(k) Plan (the 401(k) Plan)</span></div>We sponsor the 401(k) Plan under which we have historically made matching contributions to our employees&#8217; 401(k) accounts in the form of our common stock. Beginning in 2020, our matching contributions are in the form of cash. We recorded compensation expense of $6.7 million, $4.6 million and $3.6 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, for matching contributions to our employees 401(k) accounts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307450280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Provision For (Benefit From) Income Taxes</a></td>
<td class="text">PROVISION FOR (BENEFIT FROM) INCOME TAXES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income before income taxes is derived solely from within the U.S. Our provision for (benefit from) income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,002&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244,111)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,978)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2020 and 2019 primarily relates to the utilization of federal net operating loss and state taxes in jurisdictions outside of California, for which w</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e do not have net operating loss carryforwards due to a limited operating history. The benefit from income taxes for the year ended December&#160;31, 2018 primarily relates to the release of our valuation allowance against significantly all of our deferred tax assets offset by state taxes in jurisdictions outside of California. Our historical net operating losses were sufficient to fully offset any federal taxable income for the years ended December 31, 2020, 2019 and 2018. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2020, 2019 and 2018, respectively, to our provision for (benefit from) income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax provision at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (benefit) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,978)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves not currently deductible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,167)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,244)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,374&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 740: Income Taxes (Topic 740) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December&#160;31, 2020, based on the evaluation and weighting of both positive and negative evidence, including our achievement of a cumulative three-year income position as of December&#160;31, 2020 and forecasts of future operating results, as well as considering the utilization of net operating losses and tax credits prior to their expiration, management determined that there is sufficient positive evidence to conclude that it is more likely than not the deferred tax assets are realizable. As of December&#160;31, 2020 and 2019, we continue to carry a valuation allowance of $67.2 million and $61.7 million, respectively, against our California state deferred tax assets. The valuation allowance increased by $5.5 million and $3.5 million during the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had federal net operating loss carryforwards of approximately $92.6 million, which will begin to expire in 2036, and federal business tax credits of approximately $127.4 million which expire in the years 2021 through 2040. We also had state net operating loss carryforwards of approximately $427.9 million, which expire in the years 2021 through 2036, and California research and development tax credits of approximately $42.9 million, which do not expire, and California Competes Tax Credits of approximately $1.6 million, which expire in 2026.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. We completed a Section 382 analysis through December&#160;31, 2020, and concluded that an ownership change, as defined under Section 382, had not occurred. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to prior year provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to current year provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on the lapse of the applicable statutes of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2020 will significantly change over the next 12 months. As of December&#160;31, 2020, we had $80.9 million in unrecognized tax benefits, of which 50.1 million would reduce our provision for income taxes and the effective tax rate, if recognized. Interest and penalties were nominal or zero for all periods presented. We have elected to record interest and penalties in the accompanying Consolidated Statements of Income as a component of income taxes. </span></div>We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 2001 through 2020 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257386937880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options and PSOs, unvested RSUs and PSUs and ESPP contributions. Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they are related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. See to &#8220;Note 8. Employee Benefit Plans&#8221; for a further description of our equity awards. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307043480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Headquarters Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located in Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018, April 2019, August 2019, January 2020 and December 2020, resulting in, among other things, an increase to the amount of space leased and changes to the lease term. Our right-of-use asset, lease liability and the related lease costs reflect the 228,941 square feet of space we have taken possession of as of December 31, 2020 (the Current Premises) under the amended Lease. We expect to take possession of the additional space provided for under the December 2020 amendment on or prior to June 1, 2021, which will increase the space leased to 254,690 square feet. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Lease continues through October 31, 2031 (the Lease Term). We have two five-year options to extend the Lease; these optional periods have not been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made certain tenant improvements on the Initial Premises, for which we received $8.2 million in reimbursements in January 2019. At December 31, 2020, a reimbursement of $1.7 million was due to us for tenant improvements to the space we obtained under the April 2019 amendment. We were also provided an allowance of up to $1.4&#160;million for tenant improvements to the space expected to be obtained under the December 2020 amendment. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in other long-term assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_4bd66db9-0068-4d77-8491-049fcf2c6704"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_a8b46ed7-baae-4463-b21f-4d4716438745">Current portion included in other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,739&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the year ended December&#160;31, 2020 was $4.6 million and was included in net cash provided by operating activities in our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.186%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future tenant improvement reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the weighted average discount rate used to determine the operating lease liability was 3.1% and the weighted average remaining lease term is 10.8 years. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Build-to-Suit Lease</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) for approximately 220,000 square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Build-to-Suit Lease is for a period of 242 months (the Term), which will begin upon the substantial completion of the building and tenant improvements by the lessor. We currently anticipate that the Term will begin in April 2022 (the Lease Commencement Date). The monthly base rent under the Build-to-Suit Lease will equal a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by the lessor and any development costs we pay) and is currently estimated to be about $0.7 million, subject to an annual increase of 3% during the Term. We will also be responsible for paying operating expenses related to the New Premises. The rent payments will begin sixty days following commencement of the Term. We have been provided a tenant improvement allowance for the New Premises of approximately $16.5 million. To the extent that the total development costs of the New Premises exceeds $525 per square foot, we will also pay 50% of such excess costs prior to the commencement of the Term, and we are required to secure such amount by providing a letter of credit or depositing such amounts in an account with the lessor&#8217;s lender.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Build-to-Suit Lease includes two five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the 180</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that, under the guidance provided in Topic 842, we do not have control of the New Premises during the construction period. Therefore, we will not record a right-of-use asset or lease liability for the Build-to-Suit Lease until the Lease Commencement Date. We will evaluate the classification of the Build-to-Suit Lease as an operating lease or financing lease at the Lease Commencement Date. We determined the cost of tenant improvements during the construction period are lessor assets and considered a prepayment of lease under Topic 842. The costs incurred as of December 31, 2020 of $2.8&#160;million are recorded as other long-term assets in the Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of and $1.6 million as of December&#160;31, 2020 and 2019, respectively. None of our letters of credit have been drawn upon. All of the letters of credit are fully collateralized by certificates of deposit.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into standby letter of credit of $45.9&#160;million in the aggregate as guarantee of our obligation to fund our portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which will be recorded as restricted cash. The letter of credit will be reduced as we fund our portion of the tenant improvements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. The sale of a generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257386937880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text">QUARTERLY FINANCIAL DATA (UNAUDITED)<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected unaudited quarterly financial data was as follows (in thousands, except per share data):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal 2020 Quarter Ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:41.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.312%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.312%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal 2019 Quarter Ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Total revenues for the quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, included      milestone revenue of $0.1&#160;million, $43.5&#160;million, $13.5&#160;million and $29.4&#160;million, respectively, compared to $10.0&#160;million, $20.4&#160;million, $50.6&#160;million and $15.1&#160;million during the comparable periods in 2019. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    Gross profit is computed as net product revenues less cost of goods sold.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)    The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309222200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December&#160;31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2021, January 3, 2020 and December 28, 2018 are indicated as being as of and for the years ended December&#160;31, 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In  March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. Accordingly, we recorded an adjustment to increase selling, general and administrative expenses for these fees by $5.1&#160;million during the fiscal year ended December 31, 2020. This adjustment resulted in a $0.02 decrease in basic and diluted </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings per share for the fiscal year ended December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we adopted Accounting Standards Update (ASU) No.&#160;201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-18,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606) when the counterparty is a customer for a distinct good or service (</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer together with revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter 2020, we adopted ASU No.&#160;2017-04,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2017-04)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. The adoption of ASU 2017-04 did not impact the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we adopted ASU No.&#160;2016-13,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2016-13)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses as an allowance on financial assets measured at amortized cost, including accounts receivable, contract assets, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board (FASB) issued&#160;ASU 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. ASU 2019-12 will b</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e effective for us in the first quarter of 2021 with early adoption permitted. The adoption of ASU 2019-12 on January 1, 2021 will not have a significant impact on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds, certificates of deposit and marketable debt securities which are subject to minimal credit and market risk.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text">We designate all investments in marketable debt securities as available-for-sale and therefore, report such investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. We include <div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">realized gains and losses on the sale of investments in other income, net in the accompanying Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as long-term investments in the accompanying Consolidated Balance Sheets. The classification of restricted cash equivalents as short-term or long-term is dependent upon the longer of the remaining term to maturity of the investment or the remaining term of the related restriction.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define fair value as the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). When determining the&#160;fair value&#160;measurements for assets and liabilities which are required to be recorded at&#160;fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables, net, contain amounts billed to our customers for product sales, and amounts billed to our collaboration partners for development, regulatory and sales-based milestone payments, royalties on the sale of licensed products, profit-sharing arrangements, development cost reimbursements, and payments for product supply services. Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method to estimate credit losses and consider our historical loss information, adjusted to account for current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers. As of December&#160;31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration partners</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These write downs are charged to either cost of goods sold or the cost of supplied product included in collaboration services revenues in the accompanying Consolidated Statements of Income. On a quarterly basis, we analyze our estimated production levels for the following twelve-month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into other long-term assets in the accompanying Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentWe record property and equipment at cost, net of depreciation. We compute depreciation using the straight-line method based on estimated useful lives of the assets, which ranges up to 15 years and depreciate leasehold improvements over the lesser of their estimated useful lives or the remainder of the lease term. We charge repairs and maintenance costs to expense as incurred. We periodically review property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. We did not recognize impairment charges in any of the periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">GoodwillWe recorded goodwill amounts as the excess of purchase price over identifiable net assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance. We operate in one business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of our long-lived assets, which includes property and equipment, right-of-use assets and leasehold improvements, is reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2018, we adopted Topic 606 using the modified retrospective method applied to those contracts that were not completed as of the adoption date. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration to which the entity is entitled to in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of Topic 606, we perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients. In addition to distribution agreements with Customers, we enter into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. Revenues from product sales are recognized when the Customer obtains control of our product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established primarily from discounts, chargebacks, rebates, co-pay assistance, returns and other allowances that are offered within contracts between us and our Customers, health care providers, payors and other indirect customers relating to the sales of our products.&#160;These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the Customer) or a current liability (if the amount is payable to a party other than a Customer).&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted Customer buying and payment patterns.&#160;Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of our contracts.&#160;The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&#160;Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenues and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Chargebacks are discounts that occur when contracted Customers purchase directly from a specialty distributor. Contracted Customers, which currently consist primarily of Public Health Service institutions, Federal government entities purchasing via the Federal Supply Schedule, Group Purchasing Organizations, and health maintenance organizations, generally purchase the product at a discounted price. The specialty distributor, in turn, charges back to us the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the Customer. The allowance for chargebacks is based on actual chargebacks received and an estimate of sales to contracted Customers.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts for Prompt Payment:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Customers in the U.S. receive a discount of 2% for prompt payment. We expect our Customers will earn 100% of their prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program, other government programs and commercial contracts. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contractual discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on Customer and payer data received from the specialty pharmacies and distributors and historical utilization rates. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our Customers, plus an accrual balance for known prior quarters&#8217; unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for rebates also include amounts related to the Medicare Part&#160;D Coverage Gap Discount Program. In the U.S. during 2020, the</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part&#160;D prescription drug benefit mandated participating manufacturers to fund 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap amounts are based on Customer and payer data received from specialty pharmacies and distributors and historical utilization rates. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to Customer, plus an accrual balance for known prior quarters&#8217; unpaid claims. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net product revenues in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment Assistance: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using Customer data provided by the specialty distributor that administers the copay program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Customer Credits: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We&#160;pay fees to our Customers for account management, data management and other administrative services. To the extent the services received are distinct from the sale of products to the Customer, we classify these payments in selling, general and administrative expenses in our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply by analogy the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: nonrefundable up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Up-front License Fees: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which generally occurs at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from nonrefundable up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory and Development Milestone Payments: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related variable consideration constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Cost Reimbursements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time based on measure of progress. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Arrangements: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Sales-based Milestone Payments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty we are required to pay GlaxoSmithKline (GSK) on all net sales of any product incorporating cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. </span></div>We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval were not capitalized as inventory but are expensed as research and development costs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of (1) direct and indirect internal costs for drug discovery; (2) upfront license and project initiation fees, license option fees and option exercise fees, funded research and milestone payments incurred or probable to be incurred for our in-licensing arrangements with our collaboration partners for research programs in development and prior to regulatory approval; and (3) development costs associated with our clinical trial projects, which include fees paid to Contract Research Organizations (CRO) performing work on our behalf.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial projects have been executed with support from third-party contract research organizations (CROs), who specialize in conducting and managing global clinical trials. We accrue expenses for clinical trial activities performed by the CROs based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include direct CRO costs, the number of patients enrolled, the number of active clinical sites involved, the duration for which the patients will be enrolled in the trial and patient out of pocket costs. We monitor patient enrollment levels and related activities to the extent possible through CRO meetings and correspondence, internal reviews and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. As described further above, certain payments made to us from our collaboration partners may be presented as a reduction of research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement includes a lease at the inception of the agreement. For each of our lease arrangements, we record a right-of-use asset representing our right to use an underlying asset for the lease term and a lease liability representing our obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of lease payments over the lease term. In determining the discount rate used to calculate the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. Our leases may include options to extend or terminate the lease which are included in the lease term when it is reasonably certain that we will exercise any such </span></div>options. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. We have elected not to apply the recognition requirements of Topic 842 for short-term leases.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses were $25.1 million, $17.9 million and $14.8 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. We expense the costs of&#160;advertising, including promotional expenses, as incurred. Advertising expenses are recorded in selling, general and administrative expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based payments to employees, including grants of service-based restricted&#160;stock&#160;units (RSUs), performance-based restricted&#160;stock&#160;units (PSUs), service-based&#160;stock&#160;options, performance-based&#160;stock&#160;options (PSOs), and purchases under our 2000 Employee Stock Purchase Plan (ESPP) in accordance with&#160;ASC 718,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock&#160;Compensation</span>,&#160;which requires that stock-based payments (to the extent they are compensatory) be recognized in our Consolidated Statements of Income based on their fair values. We account for forfeitures of&#160;stock-based awards as they occur. The expense for stock-based compensation is based on the grant date fair value of the award. The grant date fair value of RSUs and PSUs are estimated as the value of the underlying shares of our common stock. The grant date fair values are estimated using a Monte Carlo simulation pricing model for certain PSUs and PSOs with market vesting conditions and a Black-Scholes Merton option pricing model for other stock options. Both option pricing models require the input of subjective assumptions. These variables include, but are not limited to, the expected volatility of our stock price and the expected term of the awards. We consider both implied and historical volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense over the requisite service period on an accelerated basis for awards with a market or performance condition and on a straight-line basis for service-based stock options and awards. Compensation expense related to PSUs is recognized when we determine that it is probable that the performance goals will be achieved, which we assess on a quarterly basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Provision for (Benefit from) Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for (Benefit from) Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for (benefit from) income taxes is computed under the asset and liability method. Significant estimates are required in determining our provision for (benefit from) income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the differences are expected to reverse. A valuation allowance is established for deferred tax assets for which it is more likely than not that some portion or all of the deferred tax assets, including net operating losses and tax credits, will not be realized. We periodically re-assess the need for a valuation allowance against our deferred tax assets based on various factors including our historical earnings experience by taxing jurisdiction, and forecasts of future operating results and utilization of net operating losses and tax credits prior to their expiration. Significant judgment is required in making this assessment and, to the extent that a reversal of any portion of our valuation allowance against our deferred tax assets is deemed appropriate, a tax benefit will be recognized against our provision for (benefit from) income taxes in the period of such reversal. Prior to 2018, we recorded a valuation allowance that fully offset our deferred tax assets. In the fourth quarter of 2018, based on our evaluation of various factors, including our achievement of a cumulative three-year income position as of December&#160;31, 2018 and forecasts of future operating results, we released substantially all of our valuation allowance against our deferred tax assets and recorded a corresponding income tax benefit as described in &#8220;Note 9. Provision For (Benefit From) Income Taxes&#8221;, below. We continue to maintain a valuation allowance against our California state deferred tax assets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities based on the technical merits of the position. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in other income, net in the </span></div>accompanying Consolidated Statements of Income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257305792488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text">As of December&#160;31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration partners</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257387000520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text">As of December&#160;31, 2020 and 2019, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:73.862%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration partners</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue customers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967,775&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,826&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending allowance balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2018</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128,733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,222&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,233&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,028)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216,738)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text">Contract assets and liabilities were as follows (in thousands):<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Presented in prepaid expenses and other current assets in the accompanying Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Presented in other current liabilities in the accompanying Consolidated Balance Sheets. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>(3)&#160;&#160;&#160;&#160;Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307134424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,631&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,879&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues under the collaboration agreement with Takeda were as follows (in thousands):  </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits and losses on the U.S. commercialization and royalty revenues on ex-U.S. sales under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257308008472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.470%"><tr><td style="width:1.0%"/><td style="width:73.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported within our Consolidated Balance Sheets to the amount reported within the accompanying Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.470%"><tr><td style="width:1.0%"/><td style="width:73.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in long-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384,510&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.809%"><tr><td style="width:1.0%"/><td style="width:73.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.950%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:73.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.997%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.877%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257305797384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312,464&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345,197&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309225592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307462488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up to 15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,068&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,452&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257386298392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our ESPP as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,070&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, including PSOs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, including PSOs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of stock option grants, including PSOs, and ESPP purchases was estimated using the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, including PSOs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 months</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of All Stock Option Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options, including PSOs, during the year ended December&#160;31, 2020 was as follows (in thousands</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of All RSU Activity</a></td>
<td class="text">Activity for RSUs during the year ended December&#160;31, 2020 was as follows (in thousands<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>Activity for PSUs, during the year ended December&#160;31, 2020 was as follows (in thousands<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair&#160;Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,378&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257305722632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income before income taxes is derived solely from within the U.S. Our provision for (benefit from) income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,002&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244,111)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,978)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the U.S. federal income tax provision at the statutory federal income tax rate of 21% for each of the years ended December 31, 2020, 2019 and 2018, respectively, to our provision for (benefit from) income taxes was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal income tax provision at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,603&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax (benefit) expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded prescription drug fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,056&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,978)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred tax assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves not currently deductible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,063&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,167)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,244)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,374&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our unrecognized tax benefits (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to prior year provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change relating to current year provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on the lapse of the applicable statutes of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307148504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share - diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307181944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Balance Sheet Classification of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our operating lease assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in other long-term assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_4bd66db9-0068-4d77-8491-049fcf2c6704"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjY4YmY4YmZiNWI1OTQyMTc5MmI1NzExYTQwOWU5ZmZkL3NlYzo2OGJmOGJmYjViNTk0MjE3OTJiNTcxMWE0MDllOWZmZF8xMzMvZnJhZzphODM3YzdhNTY5NzE0MTAxODI3MTI0NDI2ZTU5YjhkZi90YWJsZTo3OGI3ZDdmOTA2MDE0ZmFiYmNlMGQ3ZDlkNDBlZDZlZS90YWJsZXJhbmdlOjc4YjdkN2Y5MDYwMTRmYWJiY2UwZDdkOWQ0MGVkNmVlXzUtMC0xLTEtMA_a8b46ed7-baae-4463-b21f-4d4716438745">Current portion included in other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,739&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs, which are included in selling, general and administrative expenses in our Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.186%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future tenant improvement reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257315600616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Data</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected unaudited quarterly financial data was as follows (in thousands, except per share data):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.292%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal 2020 Quarter Ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:41.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.312%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.312%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal 2019 Quarter Ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March&#160;31, </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September&#160;30,</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)   Total revenues for the quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, included      milestone revenue of $0.1&#160;million, $43.5&#160;million, $13.5&#160;million and $29.4&#160;million, respectively, compared to $10.0&#160;million, $20.4&#160;million, $50.6&#160;million and $15.1&#160;million during the comparable periods in 2019. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)    Gross profit is computed as net product revenues less cost of goods sold.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)    The fiscal quarter ended December 31, 2019 is a 14-week fiscal period. All other quarters presented are 13-week fiscal periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257315524584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>product </div>
<div>segment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 293,355,000<span></span>
</td>
<td class="nump">$ 228,244,000<span></span>
</td>
<td class="nump">$ 206,366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charge on goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenuePercentDiscountForPromptPayment', window );">Percent discount for prompt payment</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent', window );">Discount expected to be earned</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MedicarePartDFundingMandate', window );">Medicare Part D funding mandate</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 25,100,000<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign currency gains and losses</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">Collaborative Arrangement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Cost of goods sold is related to product</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember', window );">Final Calculation Of Branded Prescription Drug Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Decrease in earnings per share due to change in accounting estimate (in dollars per share) | $ / shares</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting From Discovery Efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember', window );">Products Derived from Cabozantinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products Derived From Other Compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MedicarePartDFundingMandate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare Part D Funding Mandate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MedicarePartDFundingMandate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Discount Expected to be Earned, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenueDiscountExpectedtobeEarnedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenuePercentDiscountForPromptPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Percent Discount for Prompt Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenuePercentDiscountForPromptPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257387144712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Greater Than 10% of Our Trade Receivables) (Details) - Accounts Receivable - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Trade receivables percent</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Trade receivables percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Affiliates of McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Trade receivables percent</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Affiliates of CVS Health Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Trade receivables percent</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Affiliates of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Trade receivables percent</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Affiliates of Optum Specialty Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Trade receivables percent</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257386537528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Revenues by Disaggregated Category) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,052<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">962,591<span></span>
</td>
<td class="nump">957,621<span></span>
</td>
<td class="nump">738,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(221,041)<span></span>
</td>
<td class="num">(197,671)<span></span>
</td>
<td class="num">(119,250)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741,550<span></span>
</td>
<td class="nump">759,950<span></span>
</td>
<td class="nump">619,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
<td class="nump">165,914<span></span>
</td>
<td class="nump">200,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,693<span></span>
</td>
<td class="nump">41,911<span></span>
</td>
<td class="nump">34,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,988<span></span>
</td>
<td class="nump">$ 207,825<span></span>
</td>
<td class="nump">$ 234,547<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257310147640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Net Product Revenues Disaggregated by Product) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 270,052<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718,687<span></span>
</td>
<td class="nump">733,421<span></span>
</td>
<td class="nump">599,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,863<span></span>
</td>
<td class="nump">26,529<span></span>
</td>
<td class="nump">19,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 741,550<span></span>
</td>
<td class="nump">$ 759,950<span></span>
</td>
<td class="nump">$ 619,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257313844808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Revenues Disaggregated by Significant Customer) (Details) - Sales revenue, net - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Affiliates of Optum Specialty Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309777720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Revenues Disaggregated by Geographic Region) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,052<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,890<span></span>
</td>
<td class="nump">770,244<span></span>
</td>
<td class="nump">632,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,631<span></span>
</td>
<td class="nump">152,771<span></span>
</td>
<td class="nump">182,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,017<span></span>
</td>
<td class="nump">$ 44,760<span></span>
</td>
<td class="nump">$ 38,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257313456168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 26,233<span></span>
</td>
<td class="nump">$ 17,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">220,748<span></span>
</td>
<td class="nump">193,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(216,738)<span></span>
</td>
<td class="num">(188,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">30,536<span></span>
</td>
<td class="nump">26,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">7,514<span></span>
</td>
<td class="nump">2,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">146,537<span></span>
</td>
<td class="nump">129,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">3,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(144,231)<span></span>
</td>
<td class="num">(128,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">9,853<span></span>
</td>
<td class="nump">7,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">3,497<span></span>
</td>
<td class="nump">3,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">16,162<span></span>
</td>
<td class="nump">15,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(352)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(16,028)<span></span>
</td>
<td class="num">(15,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">3,279<span></span>
</td>
<td class="nump">3,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">15,222<span></span>
</td>
<td class="nump">11,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">58,049<span></span>
</td>
<td class="nump">48,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(56,479)<span></span>
</td>
<td class="num">(44,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 17,404<span></span>
</td>
<td class="nump">$ 15,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257386457288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Contract Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">3,755<span></span>
</td>
<td class="nump">6,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">5,545<span></span>
</td>
<td class="nump">6,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">169,700<span></span>
</td>
<td class="nump">$ 161,200<span></span>
</td>
<td class="nump">$ 198,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to our performance obligations</a></td>
<td class="nump">$ 86,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309437576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="nump">$ 43.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
<td class="nump">$ 20.4<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">86.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">Collaborative Arrangement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="nump">$ 140.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Minimum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen | Maximum | Final tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarnedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarnedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257313752264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Ipsen) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,052<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,631<span></span>
</td>
<td class="nump">152,771<span></span>
</td>
<td class="nump">182,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
<td class="nump">165,914<span></span>
</td>
<td class="nump">200,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,495<span></span>
</td>
<td class="nump">117,360<span></span>
</td>
<td class="nump">157,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,693<span></span>
</td>
<td class="nump">41,911<span></span>
</td>
<td class="nump">34,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,136<span></span>
</td>
<td class="nump">$ 35,411<span></span>
</td>
<td class="nump">$ 25,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309886856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Takeda Collaboration, Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="nump">$ 43.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
<td class="nump">$ 20.4<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">86.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">Collaborative Arrangement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PeriodOfSpecificSalesVolumeThreshold', window );">Sales volume period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarnedToDate', window );">Milestone payments earned to date</a></td>
<td class="nump">92.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.0<span></span>
</td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsYetToBeEarned', window );">Milestone payments, yet to be earned</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">139.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 44.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Initial | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Final tier | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Final tier | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarnedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarnedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsYetToBeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments, Yet to be Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsYetToBeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PeriodOfSpecificSalesVolumeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Specific Sales Volume, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PeriodOfSpecificSalesVolumeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257313562248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Takeda) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,052<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,672<span></span>
</td>
<td class="nump">24,622<span></span>
</td>
<td class="nump">18,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,295<span></span>
</td>
<td class="nump">165,914<span></span>
</td>
<td class="nump">200,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,115<span></span>
</td>
<td class="nump">18,112<span></span>
</td>
<td class="nump">9,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,693<span></span>
</td>
<td class="nump">41,911<span></span>
</td>
<td class="nump">34,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,557<span></span>
</td>
<td class="nump">$ 6,510<span></span>
</td>
<td class="nump">$ 8,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309510120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaborative Arrangements with Glaxo Smith Kline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="nump">$ 31.3<span></span>
</td>
<td class="nump">$ 24.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">Collaborative Arrangement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Collaboration agreement percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257393820616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with Genentech) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 270,052<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits on U.S. commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
<td class="nump">4,615<span></span>
</td>
<td class="nump">8,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,079<span></span>
</td>
<td class="nump">$ 5,679<span></span>
</td>
<td class="nump">$ 5,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307586552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Other Collaborations, Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,052,000<span></span>
</td>
<td class="nump">$ 231,092,000<span></span>
</td>
<td class="nump">$ 259,479,000<span></span>
</td>
<td class="nump">$ 226,915,000<span></span>
</td>
<td class="nump">$ 240,310,000<span></span>
</td>
<td class="nump">$ 271,703,000<span></span>
</td>
<td class="nump">$ 240,275,000<span></span>
</td>
<td class="nump">$ 215,487,000<span></span>
</td>
<td class="nump">$ 987,538,000<span></span>
</td>
<td class="nump">$ 967,775,000<span></span>
</td>
<td class="nump">$ 853,826,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,079,000<span></span>
</td>
<td class="nump">5,679,000<span></span>
</td>
<td class="nump">5,564,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievedMilestoneAmount', window );">Achieved milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementTerminationPeriod', window );">Termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo | MINNEBRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember', window );">Profit Sharing Tier One | Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember', window );">Profit Sharing Tier Two | Collaborative Arrangement with Genentech | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember', window );">Profit Sharing Tier Three | Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember', window );">Profit Sharing Tier Three | Collaborative Arrangement with Genentech | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievedMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achieved Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievedMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementPercentOfProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Percent of Profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementPercentOfProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementProfitThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Profit Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementProfitThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_MINNEBROMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_MINNEBROMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309668072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Research Collaborations and In-Licensing Arrangements) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithCatalentMember', window );">Collaborative Arrangement With Catalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementsUpfrontPayments', window );">Collaborative agreements upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementTargetSelectionTerm', window );">Collaboration and license agreement target selection term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm', window );">Collaboration and license agreement extended target selection term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsAdditionalUpfrontPayments', window );">Collaboration agreements additional upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Collaboration agreement option exercise fee payment, upon exercising option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithNBETherapeuticsMember', window );">Collaborative Arrangement With N B E Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementsUpfrontPayments', window );">Collaborative agreements upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementTargetSelectionTerm', window );">Collaboration and license agreement target selection term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm', window );">Collaboration and license agreement extended target selection term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsAdditionalUpfrontPayments', window );">Collaboration agreements additional upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Collaboration agreement option exercise fee payment, upon exercising option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm', window );">Extension option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember', window );">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">$ 148.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementNumberOfPrograms', window );">Collaboration agreement, number of programs | program</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementNumberOfPreexistingPrograms', window );">Collaboration agreement pre-existing programs | program</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">$ 280.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember', window );">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Collaboration agreement option exercise fee payment, upon exercising option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember', window );">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Collaboration agreement option exercise fee payment, upon exercising option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member', window );">Collaboration Agreement With Iconic Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Collaboration agreement option exercise fee payment, upon exercising option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementNumberOfPreexistingPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Preexisting Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementNumberOfPreexistingPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementNumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementNumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementsAdditionalUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements Additional Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementsAdditionalUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement Extended Target Selection Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Target Selection, Extension Option Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAndLicenseAgreementTargetSelectionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement Target Selection Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAndLicenseAgreementTargetSelectionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment(s)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithCatalentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithCatalentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithNBETherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithNBETherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257406903368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Invenra Collaboration, Narrative) (Details) - Collaborative Arrangement With Invenra<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember', window );">Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">$ 131.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember', window );">Additional Development and Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProjectInitiationFeePayment', window );">Project initiation fee</a></td>
<td class="nump">43.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember', window );">Product Commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">325.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember', window );">Discovery Project</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProjectInitiationFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Project Initiation Fee Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProjectInitiationFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithInvenraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_DevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_AdditionalDevelopmentAndRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_AdditionalDevelopmentAndRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_ProductCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_DiscoveryProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307689752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details) - Collaborative Arrangement With StemSynergy - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember', window );">First Product To Reach Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementWithStemSynergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_FirstProductToReachMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257308007752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 319,217<span></span>
</td>
<td class="nump">$ 266,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in long-term investments</a></td>
<td class="nump">1,555<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 320,772<span></span>
</td>
<td class="nump">$ 268,137<span></span>
</td>
<td class="nump">$ 315,875<span></span>
</td>
<td class="nump">$ 188,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257313561368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Summary by Security Type) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,349,982<span></span>
</td>
<td class="nump">$ 1,308,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,355,901<span></span>
</td>
<td class="nump">1,312,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,532,923<span></span>
</td>
<td class="nump">1,384,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">4,126<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,538,842<span></span>
</td>
<td class="nump">1,388,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">569,456<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">569,828<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">543,520<span></span>
</td>
<td class="nump">752,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">5,244<span></span>
</td>
<td class="nump">3,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">548,757<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">208,326<span></span>
</td>
<td class="nump">166,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">208,554<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">28,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">28,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">82,176<span></span>
</td>
<td class="nump">40,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">82,176<span></span>
</td>
<td class="nump">40,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">40,761<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">40,761<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">60,004<span></span>
</td>
<td class="nump">32,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 60,004<span></span>
</td>
<td class="nump">$ 32,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257393601256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257398313800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Gross Unrealized Losses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 56,299<span></span>
</td>
<td class="nump">$ 17,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">28,445<span></span>
</td>
<td class="nump">14,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">21,989<span></span>
</td>
<td class="nump">2,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">5,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257305569928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments (Summary by Contractual Maturity) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,034,150<span></span>
</td>
<td class="nump">$ 789,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">321,751<span></span>
</td>
<td class="nump">522,551<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,355,901<span></span>
</td>
<td class="nump">$ 1,312,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309904824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,355,901<span></span>
</td>
<td class="nump">$ 1,312,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,355,901<span></span>
</td>
<td class="nump">1,312,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,456,666<span></span>
</td>
<td class="nump">1,347,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">40,761<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,355,901<span></span>
</td>
<td class="nump">1,312,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,415,905<span></span>
</td>
<td class="nump">1,345,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">569,828<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">569,828<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">569,828<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">548,757<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">548,757<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">548,757<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">208,554<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">208,554<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">208,554<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">28,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">28,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">28,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">40,761<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">40,761<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">60,004<span></span>
</td>
<td class="nump">32,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 60,004<span></span>
</td>
<td class="nump">$ 32,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309009880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 7,773<span></span>
</td>
<td class="nump">$ 2,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">20,610<span></span>
</td>
<td class="nump">9,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">7,291<span></span>
</td>
<td class="nump">4,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">35,674<span></span>
</td>
<td class="nump">16,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">20,973<span></span>
</td>
<td class="nump">12,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 14,701<span></span>
</td>
<td class="nump">$ 3,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257308365352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 102,068<span></span>
</td>
<td class="nump">$ 74,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(34,684)<span></span>
</td>
<td class="num">(25,560)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 67,384<span></span>
</td>
<td class="nump">48,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 40,694<span></span>
</td>
<td class="nump">33,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 18,376<span></span>
</td>
<td class="nump">17,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 14,931<span></span>
</td>
<td class="nump">13,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 11,707<span></span>
</td>
<td class="nump">8,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 16,360<span></span>
</td>
<td class="nump">$ 1,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307149944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257308573704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 105,070<span></span>
</td>
<td class="nump">$ 56,602<span></span>
</td>
<td class="nump">$ 40,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">37,198<span></span>
</td>
<td class="nump">19,374<span></span>
</td>
<td class="nump">13,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 67,872<span></span>
</td>
<td class="nump">$ 37,228<span></span>
</td>
<td class="nump">$ 27,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309281880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Schedule of Employee Service Share - Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 105,070<span></span>
</td>
<td class="nump">$ 56,602<span></span>
</td>
<td class="nump">$ 40,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">19,863<span></span>
</td>
<td class="nump">23,422<span></span>
</td>
<td class="nump">18,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">35,675<span></span>
</td>
<td class="nump">26,056<span></span>
</td>
<td class="nump">19,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">47,106<span></span>
</td>
<td class="nump">4,878<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="nump">$ 2,246<span></span>
</td>
<td class="nump">$ 2,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257314149752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve under 2017 plan (in shares)</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,070<span></span>
</td>
<td class="nump">$ 56,602<span></span>
</td>
<td class="nump">$ 40,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,637,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses relating to stock match</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,863<span></span>
</td>
<td class="nump">23,422<span></span>
</td>
<td class="nump">18,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,500<span></span>
</td>
<td class="nump">54,100<span></span>
</td>
<td class="nump">39,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises and purchases under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,900<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">12,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Share-based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,675<span></span>
</td>
<td class="nump">$ 26,056<span></span>
</td>
<td class="nump">19,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Instruments awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,378,000<span></span>
</td>
<td class="nump">4,422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Share-based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,704,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount rate from market value on purchase date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount rate from market value on offering date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="nump">$ 2,246<span></span>
</td>
<td class="nump">$ 2,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,419<span></span>
</td>
<td class="nump">483,009<span></span>
</td>
<td class="nump">330,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Average price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.55<span></span>
</td>
<td class="nump">$ 12.60<span></span>
</td>
<td class="nump">$ 15.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember', window );">Performance Share Options (PSO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises', window );">Exercise threshold, percentage of per share exercise price of the PSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,106<span></span>
</td>
<td class="nump">$ 4,878<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Instruments awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,656,000<span></span>
</td>
<td class="nump">1,926,605<span></span>
</td>
<td class="nump">693,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Employees percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest', window );">Additional shares to be earned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,655,680<span></span>
</td>
<td class="nump">1,926,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,378,000<span></span>
</td>
<td class="nump">4,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,206,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Not Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesClinicalTrialResultsMember', window );">Performance Shares, Clinical Trial Results</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Instruments awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,327,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member', window );">Performance Shares, Achieved Before December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Employees percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312021Member', window );">Performance Shares, Achieved Before December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Employees percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_NotProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_NotProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesClinicalTrialResultsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesClinicalTrialResultsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309644296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options, including PSOs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 9.44<span></span>
</td>
<td class="nump">$ 8.19<span></span>
</td>
<td class="nump">$ 9.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="nump">$ 6.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257310076728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.77%<span></span>
</td>
<td class="nump">2.81%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.79%<span></span>
</td>
<td class="nump">2.16%<span></span>
</td>
<td class="nump">1.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309409592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Summary of All Stock Option Activity) (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of the year (in shares) | shares</a></td>
<td class="nump">20,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(5,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at ending of the year (in shares) | shares</a></td>
<td class="nump">16,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of the year (in shares) | shares</a></td>
<td class="nump">12,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted&#160; Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">21.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">4.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">20.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at ending of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">12.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, options outstanding at end of the year</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable at end of the year</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding at end of the year | $</a></td>
<td class="nump">$ 131,729,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable at end of the year | $</a></td>
<td class="nump">$ 128,740,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309945480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Summary of All RSU &amp; PSU Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares)</a></td>
<td class="nump">4,422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="nump">3,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased', window );">Vested and released (in shares)</a></td>
<td class="num">(1,699,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(398,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares)</a></td>
<td class="nump">5,378,000<span></span>
</td>
<td class="nump">4,422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160; Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 19.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share)</a></td>
<td class="nump">23.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share)</a></td>
<td class="nump">18.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">20.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share)</a></td>
<td class="nump">$ 21.96<span></span>
</td>
<td class="nump">$ 19.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted&#160; Average Remaining Contractual&#160; Term</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 107,933,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares)</a></td>
<td class="nump">4,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="nump">4,656,000<span></span>
</td>
<td class="nump">1,926,605<span></span>
</td>
<td class="nump">693,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased', window );">Vested and released (in shares)</a></td>
<td class="num">(1,529,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(128,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares)</a></td>
<td class="nump">7,378,000<span></span>
</td>
<td class="nump">4,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160; Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 19.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share)</a></td>
<td class="nump">23.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share)</a></td>
<td class="nump">19.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">21.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share)</a></td>
<td class="nump">$ 21.70<span></span>
</td>
<td class="nump">$ 19.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted&#160; Average Remaining Contractual&#160; Term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 148,076,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257386981384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes (Components of Income Tax Expense (Benefit)) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">3,791<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">6,133<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">3,791<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">6,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">14,886<span></span>
</td>
<td class="nump">71,580<span></span>
</td>
<td class="num">(238,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">379<span></span>
</td>
<td class="num">(578)<span></span>
</td>
<td class="num">(5,436)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense (benefit)</a></td>
<td class="nump">15,265<span></span>
</td>
<td class="nump">71,002<span></span>
</td>
<td class="num">(244,111)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">$ 19,056<span></span>
</td>
<td class="nump">$ 77,097<span></span>
</td>
<td class="num">$ (237,978)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257393599576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax provision at statutory rate</a></td>
<td class="nump">$ 27,476<span></span>
</td>
<td class="nump">$ 83,603<span></span>
</td>
<td class="nump">$ 94,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax (benefit) expense</a></td>
<td class="num">(2,232)<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">4,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">5,525<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
<td class="num">(315,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(11,356)<span></span>
</td>
<td class="num">(8,299)<span></span>
</td>
<td class="num">(18,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(20,399)<span></span>
</td>
<td class="num">(9,177)<span></span>
</td>
<td class="num">(5,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation', window );">Non-deductible executive compensation</a></td>
<td class="nump">18,067<span></span>
</td>
<td class="nump">4,228<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee', window );">Branded prescription drug fee</a></td>
<td class="nump">2,537<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(562)<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">$ 19,056<span></span>
</td>
<td class="nump">$ 77,097<span></span>
</td>
<td class="num">$ (237,978)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309180152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes (Schedule of Deferred Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 37,454<span></span>
</td>
<td class="nump">$ 65,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">126,625<span></span>
</td>
<td class="nump">110,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">18,414<span></span>
</td>
<td class="nump">26,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified', window );">Stock-based compensation</a></td>
<td class="nump">19,818<span></span>
</td>
<td class="nump">14,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">11,908<span></span>
</td>
<td class="nump">11,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals and reserves not currently deductible</a></td>
<td class="nump">12,207<span></span>
</td>
<td class="nump">8,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">7,637<span></span>
</td>
<td class="nump">6,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">234,063<span></span>
</td>
<td class="nump">243,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(67,185)<span></span>
</td>
<td class="num">(61,659)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">166,878<span></span>
</td>
<td class="nump">181,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets', window );">Lease right-of-use assets</a></td>
<td class="num">(9,510)<span></span>
</td>
<td class="num">(9,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other liabilities</a></td>
<td class="num">(657)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(10,167)<span></span>
</td>
<td class="num">(9,244)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 156,711<span></span>
</td>
<td class="nump">$ 172,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets amortization of deferred stock compensation - non-qualified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309191480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 67,185<span></span>
</td>
<td class="nump">$ 61,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="num">(5,500)<span></span>
</td>
<td class="num">(3,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">80,941<span></span>
</td>
<td class="nump">$ 79,078<span></span>
</td>
<td class="nump">$ 76,060<span></span>
</td>
<td class="nump">$ 79,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would reduce income tax provision and effective tax rate</a></td>
<td class="nump">50,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">92,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">127,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">427,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">42,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TaxCreditCarryforwardAmountWithExpirationPeriod', window );">Tax credit carryforward amount with expiration dates</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TaxCreditCarryforwardAmountWithExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Amount With Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TaxCreditCarryforwardAmountWithExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257308746200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For (Benefit From) Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 79,078<span></span>
</td>
<td class="nump">$ 76,060<span></span>
</td>
<td class="nump">$ 79,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions', window );">Change relating to prior year provision</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="num">(4,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Change relating to current year provision</a></td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions based on the lapse of the applicable statutes of limitations</a></td>
<td class="num">(2,033)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 80,941<span></span>
</td>
<td class="nump">$ 79,078<span></span>
</td>
<td class="nump">$ 76,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309192136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 28,388<span></span>
</td>
<td class="num">$ (32,040)<span></span>
</td>
<td class="nump">$ 66,821<span></span>
</td>
<td class="nump">$ 48,612<span></span>
</td>
<td class="nump">$ 68,743<span></span>
</td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 75,775<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,271<span></span>
</td>
<td class="nump">302,584<span></span>
</td>
<td class="nump">297,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,730<span></span>
</td>
<td class="nump">12,425<span></span>
</td>
<td class="nump">14,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,001<span></span>
</td>
<td class="nump">315,009<span></span>
</td>
<td class="nump">312,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257307163016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Outstanding stock options, unvested RSUs and ESPP contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">10,959<span></span>
</td>
<td class="nump">9,111<span></span>
</td>
<td class="nump">3,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257309912392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average operating discount rate used to determine the operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuarantyLiabilities', window );">Guaranty liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember', window );">Headquarters Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the lease | renewal_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant lease improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember', window );">Headquarters Lease | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant lease improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember', window );">Built-To-Suit Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the lease | renewal_option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Build-to-suit lease period</a></td>
<td class="text">242 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment', window );">Currently estimated amount</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage', window );">Annual increase percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod', window );">Payment commencement period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AreaOfRealEstatePropertyAvailableToLease', window );">Area of property available for lease (in squire feet) | $ / ft&#178;</a></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts', window );">Percentage of excess costs</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod', window );">Option to terminate lease (after period)</a></td>
<td class="text">180 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AreaOfRealEstatePropertyAvailableToLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area Of Real Estate Property, Available To Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AreaOfRealEstatePropertyAvailableToLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate After Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuarantyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555860&amp;loc=d3e11019-110243<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121555860&amp;loc=d3e11049-110243<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuarantyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_HeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257386703528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Balance Sheet Classification of Lease Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseAssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets included in other long-term assets</a></td>
<td class="nump">$ 43,010<span></span>
</td>
<td class="nump">$ 41,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:otherassetsnoncurrent<span></span>
</td>
<td class="text">us-gaap:otherassetsnoncurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in other current liabilities</a></td>
<td class="nump">$ 3,025<span></span>
</td>
<td class="nump">$ 2,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">49,086<span></span>
</td>
<td class="nump">48,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 52,111<span></span>
</td>
<td class="nump">$ 50,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257305617752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies (Components of Lease Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 4,825<span></span>
</td>
<td class="nump">$ 2,844<span></span>
</td>
<td class="nump">$ 4,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2,830<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease costs</a></td>
<td class="nump">$ 7,655<span></span>
</td>
<td class="nump">$ 3,868<span></span>
</td>
<td class="nump">$ 5,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257386597048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Maturities of Operating Lease Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 4,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">4,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">5,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">5,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">37,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">63,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(9,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Future tenant improvement reimbursements</a></td>
<td class="num">(1,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 52,111<span></span>
</td>
<td class="nump">$ 50,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140257308852072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 270,052<span></span>
</td>
<td class="nump">$ 231,092<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 226,915<span></span>
</td>
<td class="nump">$ 240,310<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 215,487<span></span>
</td>
<td class="nump">$ 987,538<span></span>
</td>
<td class="nump">$ 967,775<span></span>
</td>
<td class="nump">$ 853,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">191,316<span></span>
</td>
<td class="nump">159,862<span></span>
</td>
<td class="nump">169,509<span></span>
</td>
<td class="nump">184,591<span></span>
</td>
<td class="nump">184,406<span></span>
</td>
<td class="nump">184,231<span></span>
</td>
<td class="nump">186,136<span></span>
</td>
<td class="nump">172,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">24,297<span></span>
</td>
<td class="num">(42,580)<span></span>
</td>
<td class="nump">75,534<span></span>
</td>
<td class="nump">52,809<span></span>
</td>
<td class="nump">77,316<span></span>
</td>
<td class="nump">115,606<span></span>
</td>
<td class="nump">91,989<span></span>
</td>
<td class="nump">84,559<span></span>
</td>
<td class="nump">110,060<span></span>
</td>
<td class="nump">369,470<span></span>
</td>
<td class="nump">438,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 28,388<span></span>
</td>
<td class="num">$ (32,040)<span></span>
</td>
<td class="nump">$ 66,821<span></span>
</td>
<td class="nump">$ 48,612<span></span>
</td>
<td class="nump">$ 68,743<span></span>
</td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 75,775<span></span>
</td>
<td class="nump">$ 111,781<span></span>
</td>
<td class="nump">$ 321,012<span></span>
</td>
<td class="nump">$ 690,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">$ 29,400<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="nump">$ 43,500<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="nump">$ 50,600<span></span>
</td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6M)88=TX/' :HCC77$=Z!ZF*&;E/DP6395QP#,=Q6K[C^5V$C^L4*NG48?3
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M,\@\ />70NC]B7G!X7/0Y;]02P,$%     @ _:5*4H]W.1VM!@  :QH  !@
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M%>J!*Z.038X!X3.D$<FGHA;K.<S"'(8\9UMOJ_9\='>  NFP$FM[E/T@4-G
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M0 ]>IF,X/[N ,^ 2/E=J99@L31Y:BL[Y"(LVDH<FDN1()"D\*2(V\%Z66![
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MNAX$1UF2N X<@4$^G<M^DQ%A82,RWLEI>U_QH9+#JX\F#YH8?!HB8;;E ^A
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M   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL[5U9<QO'M?XK4TJ<(JL
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M9"!>L"?P&3#/Y2BU:C^RHS<?CB>I[.,;D6U?91L0Z*836 V;^B=P6HPL #7
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MO)M7)2$Q-!! NEA:&LB[L3K:#67'/B%+T,&RZC('RT29#IZML36(+FE"!P3
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M+O$(U,R1\-&K##RCC;@HLS<0YF\4 =B0]4&Z 0TS'@37-C=%CFD@T17<NN>
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MM4=_1B>:5[/^_NX)^CV:)*%%M1<0*9(3&CC*G>GU2W$<*.WKI#3( 1PE.-G
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M.]Q^J'L'RBH1BD(L(3J?Q>&1)4?#0ZMJ\\%IH5K017-++:AH: !^7RJL3O]
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MAI9,GIP10<*.$<)"Y( ;@8_+P!P:OIHMC8:U4M,CWM6FQ,&T"D([J@!Y98Q
M]BS5= GK:=RJ;,UNM7:%J"\3DS6IGQ'I'LTH;O@\SZHT9GR #M-"S@TL0)#G
M65%.X"AF/?$3B [B+M-F3@:O &JJ%-DA62*<NDP 4 "S4&,%XAU$9 *<GMG-
M++*E3& '<[DD;HB819'.JBA!9:TL$DSE!M'S '-<C4M07GD.2QM5W ._F:C!
MY^/,E#!<ST=5852]XE.>8*++0P/$(J+9R7OB5BGQU[^<#X?]YQ^R4HEA3]S
MG&FE#'T]>$X 2']0@&RLC&D3437RTPAX-@4!!Q2IB(Y(W :"0GH1(^** $'>
M6,)I,$!.$-OB-6 _'\'@(Q:\??S_X(((!Q_.@?G"HWS59(RW.4C0YI<PHQD7
M.G<\APLV'WB;BC=J5%1@%. 2I[35#2:4Z]!@3N15OUHN!>PG8'%@4 ONFL5A
M;X&AYT2WR )AF0?ER#B!$WG?!4^!IH(][U51("AT+C(\T:AO)E59 :LWA*9.
M8SA?3&:PKHR.E8/OI]YMCV;X4>:H,YW,I]-,X-(9J=%0(=T ()QDH\#>!FD
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MG@*TZ"-H23)"IV2]S= A(Y8!*5ID"4X@K;" HPU>6$P,1)Z"*LE"9B_!&5;
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M-O=WV-H-CJCS;AYR@_##/=' E? N\_IC979R#6M3H&WL^DPKN8JNK'#-6E$
MF_& V9G<VH!'2BQF2[,+=%_)TVF&]M27G)T$[TBN$1QU]V/# 2>2D[FT\^YZ
M&.V]-PKK_ZA?IN/^&X_J-K"W:X&&;OEV6'A*=R@K?P4IJ=!PR]H<L&7/UZPF
M?5(U6Z2F'5>P(8>N2R%\)[]F*\Y5>XSAW"-X7*1_WC_'PZXQSGJ/^3=7,V+#
M,VC4UH6M"RPA;OKC]D;)DF_2#\M07)-/W8#/Y?'4"XVV$FU2(V2NS6=C8R-X
M>1BZ8Z[CP+%.90+CVVTF>F;A,@67DP6"THK[,948(%;@02&"X,4'BUBE6YO7
M5.*(/-S84!<R;S3*._7:2)<4L4LSKTFR6"ZW53P!&%3IV+#S]4- J4PG'!CU
M0H;1KIEU,UA;0T</-4[UHZ)*:P[,VNA2.?.9IZ6;I"/:U HM1;O%E@XYME3+
M(@XSN:SA=HH\*N"$0/PY@D[-@!*;?JL$=;?A=U;-[V ]8,,!F.,?QV7&_C06
ME"V:9H!OGMJA>G]CD@(6>_@[(Q!"K$BC3*4SX_BNMM46@Z[*LDY 86<KZ\EI
MJD#",Q10X=R?,UQ[(:GY$^VTVI)4_LH.9_;9J#92V&\'FOY\W<?F&+%LO+W
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M]@!D_X[7#IQ>^+>SB79.5_YS+CBN>K0!ZU.MW7I !VP>4R__"U!+ P04
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M'\M[[V]][I3+BAD\4>*:5W8[#R8!5+AFK; 7JGN'NWP.G;]2">.?T/6V61I
MV1JKZAV8&-1<]F]VMZO#(\ D?@*0[@"IY]T'\BQ/F66+F58=:&=-WIS@4_5H
M(L>ENY1+J^DK)YQ=O)>W**W2][/(DCNGC,H==-E#TR>@20J?E+1; V>RPNI/
M!Q'Q&,BD>S++]%F/'Y@<09R$D,9I\HR_;$@N\_ZREY*#4VY*H4RK$7X<KXS5
MU T_GXF0#Q%R'R'_G_*] /U\=?;YZY>+[_! LU34[<9B!6H-=HNP5H+&ALL-
MO.*2-*HU3%;F]1&<8HGU"C5D?;UB>B13N& =M8=%S9DP< !%6!09O=.PB*=P
M31,"Y*C1JD1C"!*.DQBF89X7\)9+3HU4P4:IRA RG2:0A]FX@*_*,D%>LL-P
M7.0D)./P,,U@R023)<*EWQ^E8,;P-2^9&[@C.&FUIL2@4=I/()>E:*E3' ,^
MY'S@6$P]R20-)Y,Q?%1R\X92J/^)5%07#6*PH9AH#20Y99A %HZSI_E>:V[Q
M3:4Z:6BC".8J;17@G:\&59;$AFM7[P>"'5+7'*2C@N9/"*(3PD$RRO8G#R-%
M,BAH5?K+NT>F#: ;CK^O*^SORX%)F(3$QS3H=Y2X'_VK-:-'4UZCWOA=9JAG
M6FG[@1^TP[H\[K?$@WF_:S\QO>%4 X%K@L:CXC  W>^O_F!5XW?&2EG:0%[<
MTLI'[0SH^UHINS^X ,-/9/$;4$L#!!0    ( /VE2E*=-@*R0@,  ,$&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*55VV[;.!#]E8&0AP0@K*MM
M.; -Y.*B+9*N-VUVL5CL VV-;*(4J9)4'/]]AY*M.FB3/NR+-$/.G+F1A].=
M-E_M%M'!<R65G05;Y^K+,+3K+5;<#G2-BG9*;2KN2#6;T-8&>=$Z53),HF@4
M5ERH8#YMUY9F/M6-DT+ATH!MJHJ;_35*O9L%<7!<>!";K?,+X7Q:\PU^1O=8
M+PUI88]2B J5%5J!P7(67,67UYFW;PW^$KBS)S+X2E9:?_7*AV(61#XAE+AV
M'H'3[PEO4$H/1&E\.V &?4CO>"H?T=^UM5,M*V[Q1LN_1>&VLR /H,"2-](]
MZ-U[/-0S]'AK+6W[A5UGFU'$=6.=K@[.I%="=7_^?.C#B4,>O>*0'!R2-N\N
M4)OE+7=\/C5Z!\9;$YH7VE);;TI.*#^4S\[0KB _-U\:FJ]Q>^"J@,6W1M34
M<3<-'6%[BW!]P+GN<))7<.($[K5R6PL+56#Q$B"DI/K,DF-FU\F;B!^Y&D 4
M,TBB)'X#+^TK35N\]#>5,EA*KMS+@N'?JY5UAL[(?V^$ROI061LJ^]]-_0W.
MPQ_+Q<.7?^#JTRTL_GS\L+Q??/H"+^"Q+V&MZ:I8AP7H$MP6H=22[IQ0&S@7
MBE9T8\G#7ES"PCI!)YI,'RV6C80[NAH6;G&-U0H-I%W;(_K$$[A#.O9;+0L0
M56WT$_IP%IH:G(9X"'ODQL(99!$;33(2TI1-H@QN=%4WCN!^Y.@SMKIT.VX0
MTH-GG+-T/()XS-(TAW>-4<(UM.^-2_'L90OCHW'&)FD,<<JB80IW?*4-=]KL
M3X(<,XIC-H[&D!^2433@IN,":@<5LB%<LAJQ=!1!S!+"BZ.$1:,<QAG+A@E5
M;NTE,<>ZJ1K9]JM XKZUX"W,>9JQ49Y=P'DR9,-1=/'*:!@HHM<S&%&%N6]0
MEK-\DE"_3\#PF8C6(NPX]7(RB.FV2TD;#,[R07K46N"S;##I%XK&^!'[@7=E
MH[^ /\^2=</T_B3DC"C5UMB2HMP/?G7JPQ-:J=!L6O*T=,X:Y3J&Z5=[?K[J
M:.F'>4?N]]QLA+(@L237:# >!F ZPNP4I^N6I%;:$>6UXI;>&#3>@/9+K=U1
M\0'Z5VO^'5!+ P04    " #]I4I2C!41..\/  "M,   &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6S=6VEOW$B2_2L)K7LA 13%LPZ/;4"6Y5DOQF/!
M<G=CL-@/+#*K*L<LLB9)JESSZ^=%9/*H2Y+;!@:8#R[QR(R,.UYDTJ\VI?Y:
M+:6LQ;=57E2OSY9UO7YY=56E2[E**K=<RP)OYJ5>)35N]>*J6FN99#QIE5\%
MGC>Z6B6J.'OSBI_=Z3>ORJ;.52'OM*B:U2K1V[<R+S>OS_RS]L%GM5C6].#J
MS:MULI#WLOYU?:=Q=]51R=1*%I4J"Z'E_/79M?_R;43C><!O2FZJP;4@269E
M^95N/F2OSSQB2.8RK8E"@C\/\D;F.1$"&_^P-,^Z)6GB\+JE_IYEARRSI)(W
M9?Z[RNKEZ[/)F<CD/&GR^G.Y^1]IY8F)7EKF%?^*C1D;A6<B;:JZ7-G)X&"E
M"O,W^6;U,)@P\4Y,".R$@/DV"S&7[Y(Z>?-*EQNA:32HT06+RK/!G"K(*/>U
MQEN%>?6;V]4Z+[=2BK>RD'-5B[L\*:I75S5HTXBKU-)Y:^@$)^CX@?A8%O6R
M$K=%)K-= E=@JN,L:#E[&SQ*\7^3PA6>[XC "_Q'Z(6=I"'3"T_0NU\F6EZ2
M!3-QEVSA6+6XUCHI%I*O_^]Z5M4:7O+_CRP6=8M%O%CTPVI]@L['N[]\^MOM
MK7A[^]?;]Q^^B+N_7/_U7MS^HU'U5GPH4G .KS;D15)DXO;^[D[\+D62YV6:
MU!"V7DH!/TJ_6N'3<H60KA*."OF-KJ5 >(NRT4(:RJJCO.XHTVNFGE08#O*;
M2IRK O3+IL* ZN*E^)M,M/$ \4ZF<C636H3&AAY^_"G]3,1G66%@NF2ZF7Q
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M_7*1EAH\N#CV??/5X!/RE00K]*$\Q0:RF_F:O'O:?8M_;3Y![X>;#_D_0A(
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MM#:L579_U\I:_LHM!*LE6_:&:U!O4%DT7C0KALPSEI:Q%NLCL&'_Z+0TE;0
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M:@KXON5F8>J9;#J20A.&OF ?_UTU0=N _$EBZA<2- R![2PGS1J$J9<B!X+
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MH@5XOU2J'6Z(P>ZK[N6_ %!+ P04    " #]I4I2J$\2[#,$  "-"0  &0
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M]NJGVD[5OEX"Z.ZSON5L<\8KX"&=/9!@V*TC%I,+TZ"L#3NHF9 [_!&Z)T*
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MY<4-SK?"D +NUUJ[_8(<C!/SY1=02P,$%     @ _:5*4E^TX5G>*P  ^9,
M !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL[7U;<]M6MN9?0?FD3TE5
MI"S)<>+82:ID)4[[=-)Q64F[IJ;F 00W*;1!@(V+9/:O/^M;EWT!04I.]]2<
MAWF((Y+ OJR][K?][7W3?NQNG>NS3YNJ[KY[<MOWVY=/GW;%K=ODW5FS=37]
MLFK:3=[3QW;]M-NV+E_R2YOJZ>7Y^5=/-WE9/_G^6_[N7?O]M\W05V7MWK59
M-VPV>;M[[:KF_KLG%T_LB_?E^K;'%T^__W:;K]V-ZW_?OFOITU,_RK+<N+HK
MFSIKW>J[)U<7+U]?/L,+_,3?2G??17]GV,JB:3[BP]OE=T_.L2)7N:+'$#G]
M[\Y=NZK"2+2.?^B@3_R<>#'^VT9_PYNGS2SRSETWU8=RV=]^]^3%DVSI5OE0
M]>^;^S\[W=!SC%<T5<?_9O?Z[/F3K!BZOMGHR[2"35G+__-/"HC'O'"I+USR
MNF4B7N4/>9]__VW;W&<MGJ;1\ =OE=^FQ94U3N6F;^G7DM[KO_^U7>=U^<]<
M0%0OLQLYGJQ993?ENBY799'7?795%,U0]V6]SMXU55F4KLM.[*_3;Y_VM!:,
M^+30>5_+O)<'YKVXS'YIZOZVRWZLEVZ9#O"4-N%W<FD[>7UY=,3_RNNS[/QB
MEEV>7UX<&>^9A\PS'N_9(R SRZZ;NJ/=+@.@WK6N<W4O7Q"TWI1U7A=E7F4W
M]*4CS.V[[']?+;J^)=3[/T=6]*5?T9>\HB\/K.AUWI4=IHJGG@+]'QCFMUM'
M%%(TFVU>[W#*8<-N.;VWLBZJ8>FR7E\=\"4-^^,G5Y6?: I J;]M.H=OFZ'-
M[F^;JMK-F_N:QNR&15<NR[PE!#K+:'YZCL8M>_K\G__QXO+BZU?9:JB9>&GB
M8FA;5Q>[C ;&C+^?W9QE2QHO;\^RJZJBY?2NU0T0H5:T8*=K:/.ZRWF@+KO-
M[URV<*[.:)5$4-C?V9'#>>X/Y_E1J+XINX*6^<ZU9;.<.I3CKW]PLK)\V6P!
M\3Q[?CG/FC9[_FQ^[]S';"7C[US>9EO0W8[ D/<$LB5!O6:8O&GIO'9941',
MNS[KF^P'5[C-PK7_^1\77YV_>G;1]6?9FV@DHI7S&9U+6=QF]WDGTX[GFV$2
M6A/-0D0V@#LHF<V295V>7WPS&FQ_\1.#/>/!SOFL1N.]^)S%V6:SRQ<S?IGV
M2A LFOK.U24ACYM!D#C@D0/^$M (FUJW;=H^RQEY>0WT$L 9S=+I+'O[G]K#
MWCJRO'4TW9)8*9]M1P@(&MN?,IYK?'8S/2V F5\2^! 1;QW+MFIW#)&_\HC\
MU5%,O'%KT'?VMA:9?X#'?/8@&:$X*1,M@0"@;VHBPZ&C][HNZ_1QQNA50W+/
M>:1>TBDT=Z[=S4C:TB:;+3\* !"U;XCFB2^9!"-PUJ0);!S!&D,S8)?EBJ08
MB>EYW\Q[TEWZK !W:(GO_$ILZ?JV=,RVB@%@S'[%XXXP*Q=64_#OLG8<V](5
M);22^2;_B,<V>4T*C/":O*H:G#+0JB.>!T0C.@3WTP' A"!"Z.L>?"WFLPNP
MYC/FO6778YOW97\K:!K/BE5LVX8&[V8\]H$M9 S(>(I91B!?5VYN(%]YUEY&
M9P6P;8=VV_!!K#)WEU>#[)YVP<\Q.=%?KL@[_F$U] /A^98Y8#0N 8)@3PM5
MV.#9 !P K7,]?TL2!1* UM_G[=J1NGD$G[_V^/SU453\7>3/C[3(#0YF"ID_
M;P0(*P*_V^:MQ[K^\^4G'0L R?B1!_5JVQ(8RFU%\ZQ=32A#(A._.Y8+9>VE
MG['&UOUC* F@BH="2$T&Y,S^/BSYF GZSB^?\;0C/7PKV,A4EZ]6Q$5X<&&(
M8%0;+]3I>8=1JC)?E!4+:1J2)NYW8$'$8 <=V7TBBZ'#S_C4NHHA "HFL40(
M J*#!D5$L&ZP849ZVHPS+'.,TEVD??JUGX&+0 OG1\*6Z!"(1OJF+<&QL826
M&3ZO@7Z\(S6C&>@YVE]+H&D_NGX.OHD9Y"'^A99+BP![&</G'EI#53H@9T-_
MTJ-Y1YK)HG+90/Q:^'=1ML6PZ7I6/F8*349_ %'."X?.O_#&F=24I/UI9?F"
M+"@9,6];1BC QD5GP:N.CD./D2BP;GJL;ED"<;:$I4SG;;/132KID=I4]$,@
M4$+(H5HRMV08D3I5,O+QJZ+(10?QMLY^R5O:C^H0V&GAB'B7O&Y2+D6_(N%X
MG5?$?CVMX.A>DTX&(0<=M&A+AG3V0SNLLS?.,4QD6&R2</YJ6),MI-^QJE-"
M*?S# ]N>'&V#]HFQW@L29S>NO2/>Z44R"_ N!SV*OF%4!Z )11(R$\T"(42T
M1:B)974#3MVI-/)CJ@C_)AJ<SZ1HVB5X],Z 2I]!C#3/\N\$!2-P/R79N,2R
MUC/C%T+@2P)^">.#&:I1I2V!7N,5+7;9%\_/+LBTI#$(4LNA!;*-U)^11I*9
M,@*]'8I^6%<"ENR+\[/S2T@N#QO@O! <H>> !VGXFJ;L(#BR[A8(/*& '5S!
M$0GQPDN(%T?Y^WL'L4.(?J7*=VSLMDU-?Q?*L[%P>?S(0W\E^OM?KK?AI@3.
MOVU!;VN%5$OD\0]210F;@7.>*//](4@&U<N\);OA]RWD4W9R=?/[*2W[#/B8
MO9A#K;R&:;5H%'VN6B*KM<YY\ENSI4-\<?[B]&5V3098N=H9TC YB:U%3+*_
MAZ'E'V?PR:>OSK_B:9D4:,)3POSPB4P8C.JY&JDR?0[1%UMR-GR1K#0/*\V(
M]?6D!Y)(IE5WM\S>%MY8=:)VDY*'YP T+\>$H4^"[+I9LE3B'=(.KD_#CF:>
MB3![(16 ;?].M+AK]N:0UFD I#=.B9LX.4)94XNUL)&;J_N'%L++A BEM9",
M7C>D7]%7G7*JDZP\<Z0.Y+3NDC>B.SP5 PC?=M'705*H-D$*]I8Y5;03XORF
MUZP'4F,@3,LZ.KT(GMLM"492+<4C8*C@7V/_7=&0.!=?RH:8 2D".*(9]*C@
M1A&^8)I"BA+T(/L;.N\E$"CK &Q/J;YB2@<QR01C^!CR$:1K_N80"C&HZ#0@
M4Z,3Z1M23R%+><@V/O4B/75[!1*33B"#:J7B*CK2!6%<Q4> P^VBTY5A1,C$
M"],UV99T%A:.<J@C7(A?.';L]5*U%G]@_%UT9H(6!);Q#,2\"6D6HJ"QVD4*
M:=6L=ZSA#J1!M&6O( ZD1=H+["*8#@VMOV2< VYBO<"MMB&5&&Q*1P.B!^6+
MM,]<7$0SM0G-=A+M!YB9J-?B.S&W\!GQ0"P47%*/)4(ZYJ#LEU$L<\O ) 3[
M@C64-8NJ7*N%1SI:4Y2,A7Q$T DB+&N2PXQTMZ/'DYW0VB'&_2)."4W8#'&F
MISUN>8FNV V+O[/NW\13I:OUV.AG9I_=(<")OT:AW[J^;8*30LZ)SA0V)AN+
ML5>.X-P;\:J%Q'1\ZU)6L17];@&K>1=/?7Q=RW+)>R[)4.,M]ZP &\Q4\8@7
M%QV]'LQA.R^R[FC>MS4]Y\ZF9?2^@*95J@C^>G[^Y0RBE!"D)!P7?^CEJY^(
M-]R3HL8 _)7YCXJ29\_/21;?T*ZJ2!C_!B\@]N1??$OK+ENF8I.^F.PT\[P6
M'\GVXH' 8]?V:AE>[9U8_(N==Z+:E!WQ#5CTO=N:^!B]J.>S$87."PEOQ4*9
M#F\4M_ $>).+F=(_77"8"<O'2D0M3TPF_9%9K1BU^);9EOM4.$>(!\FXHLG$
MO%+!G\,[-><]3"]^'[D8;&/D^FR?P %<F=3G KI\-;]X-HO&>UN3VC_P@(HX
MUZU;TJ9_;CJ8 (8SEZ1^&!9@C @+\!';J+S>&T-BTRP=L=N/=7-?>R<9^^=[
M-C0*++"0.4F4=_:""5,O'_S#E:R,F,TM6])B46%(^XT8M;>RX>(SQ&&@,()Z
M[-@SP(ZM#1C'^X-WZM[TE>"]4F-;Y1^)DAYH19@$+"R:KH_5'A\&$5-8Y),I
M!-Z'(C;MG1.3J8.RVW6@-G8-YW=Y6;%; 3@.V_",5,>C&[AG>;DQDUW]RNP\
M50@8Q@8!/X'#?.B&PQ*-2+PPBM;-0UQP&K,_UVP"*01/.H<6S/"7P2?5\]<-
M_2\[>7-U\_J44*T;E%0PP/SB<J9,.?LM_Q0HX>LOST_G8^89#8^#2-^+A@R6
M"S[%K#,*C-DHI8S2\RC$M$BC:N[PHUDXX$OF=A*I9T9]Y!?T>C@M7)2>8(2Q
M[0_FB@_N4RF<VJ@E72N3S2)SF6/G'Q0S+'+H3-)-L:$+46C()H>"95A$LG)3
M]HBE'>*0/.-^"$D6\2#&L9/[020[X@SXQCL#OCEJ>U_GW>V4Q?[P6PSZMQ%=
M?W"BC;)(H4W>ENM;@EE5DJ1+.<!V:$G0=:8LPCG:EFMV<6V@&I?]3BBZ=8Z8
M*<?-Z: JQ$Y$-!98 $0HR3&AM^O1-SY>BV7,UVV^)-Y$1ES;S^EP-\EZZ/AI
M%K=33RGBL$MB7$!2,7[%$;DDF=J5$HN1)YEO+=VBAR* =8,.1#)#VXPT37BG
M-HA_""<+0V1MV7T\=I(7YR&WX?SHJ42',9FA</SM#]@)L)%M#XXPIQ ZO..8
MC<^)I.9@X\9Z6X>HR<SBCNP=C(=&",QK)#/!B*$FBZ=BF;,F-J'.7Q6:YB&$
MD5@4PV80ZU><O6#2K;M%'LV=,_YS@E?5.Q MFZC+%',.( CFS=0]T;$F-7X\
M%N>L )I3G="^[H.K9$/V<K-D_[TAXN$MV5BYV,0CP,O&9"LS4@;Z/ZJ8@T!%
M]N[4OQW/9&[_9:,>=590E4.R,\3TBBBR)V=,+V[$I&5*:IVH-,0 E7@)0:JF
M7D]2WO&=O);,ANP&*3^2..$5B,)[PF%%M:6H"F,^D'<QV8.-A)4@S+B%9DZ[
M&K9Z#/A=V+]X!I#LQ5+2B6V6LJ@8B)EJZ:-W_$B"J+98F./'Z#[*:;HXGHL!
M\OD;*_2_!+_%- _X0R-ES!M(272Q\:":L'FA!'_,2>:#(PQ6PVSHG= * 2A2
MKX/+:L5FB(5W=AIE )U#[$9>+>\&5>Z9^#QS,4)BYXTX?$DQZ$'IA2,N\ $N
MHZ7#T>@AW2;[VL0[%Y?I9  J\'FEE65DMTD,8\3:(@&I9C=4')(*B(F!X>1+
M1./RM4/P3G=(H-"<$*?@-7!XY58#?,*8($_2/<@6TOC>%/AD="5V0,N X\_,
M']!,^#BA *8#'8/1U[Q:C9V#FEQQ6Y/XY]B@'7.$_@)3%8D\T%&"N P$<7D4
MC:_,+GGO[9))8OCL4;+?H$=$YD['#%F,'NBS1@P$I4KP@3UAWA7.B09MLQSH
M]#@.-E,-=O*UQ"6%HZIMC"@U!))U#1G8D);)Z0485Y%A4]+?/9)/MOE.(^-M
ML\LKQN"1W%%OV])6V,%=W:S*?HXX%6O;D1,OS4]A>=FZ<K,8VLX>8,>7SIMN
M?=ANB:[-RR9Y*0%*H"G"/\)1Q'2W-/DF+]S0<[0;@R[*AG&K87>KR(XD)BQ9
M*:/\ ?&73L)TZL4?AQ8>2;SU7_D6Z98?C+:!S2D>L%P&AS.S6C8\LKRQ /;P
M+/+BHP*(!19G_0P1F(A8#70\;\X  _]<XR!$O0"B>,-_8BIC-D"F*%^ ?111
M^LM,(YJ">>;>YN6KQ(>3BYWC/LW!)P,PQM%QDH0U*YY39%CST!P9.,F:#2E)
M81Q-P,!>$@HABXW?W(M\^OBQZ&>D@L"^)E;)XG7O.,C8]-&+^]N&T]'NRN5@
MZ2511.SB_$_"@%N?N;D_'OL<<AP/#KA[.;% #FY?3^/7VVU'0N?R6?:G[-D+
M^N>W_*-;YC0U_7U)_[U3PK#02J"%J]6*.*Z9(+\4?R$CB$:^;MJMS7*!$2Z^
MI'_2AZ__=I/]F91.!./BQR_P^/G>XU<T7RG)$J\=X6@]\=;%WEN_;OMAD]U
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M;^$FX[AZ>F?97XG#F;OUO;F!/DA9$4M2BWZ$^%S%*=V=]W$BC[TM%P,KT^P
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M-0($Z!ZN^ @+1+SP2N?WW)Y(#11?Y6S^#\M=&,5%0QWU+(Y\,BX-&GE&M<;
MSO4T+N+SP"1+7-,KU R2KBR.DPH)F0@F]#ZQP=R:87#$E%;K><YB\-FM&@4&
M7T?I+H+E=UPF;_#SZ*6Z&F]K 3LGH>/HX#C.-:G*C45N@JW06SR2>R*S @<;
M^0"_L&3X.#@SK=S U%O(ZW"6UV+)+*=>'C,W5DP4F]VG/E2T3>@?:>HM.&G;
M<5N($:1$>^ L0VB,(^6418:E]+(,$(]2TAW"EYY''092Z)#5R"?% E\SIP '
MK4Z7:O:X!8"4UZ4%[9;%+%/?(>MX_\500"!!_S$1^@XT;%=KFP3 >9N&J+7[
M@54SZ]Q:0\0$QHC C'KA. V32>,LNP[,_V7\@3$O2'@^)($HRV1#N(A,0B9Q
M)AS:1$T^K:R=^1K5>!#;L9)\M;.BNDB H7W40'*ML("ZE<V38D"D,FANQ!NW
MY.3UH/"$ZDU=*AO?9<[0LL=O)!WFIB"I.2"B]Q-;X._"&W%W+LW!4.D5!UB:
M]*G03\.#2=+.Y""9!B+7!I.04/,D]-@\A#B>^> &SDUBBSRR8"O[CTWR:IX;
M0XK@(*M!YM]";(?)F7QBVWAU(6GPX*LZ;E"JF#OY8I>5N*0\SL7YO!:'CW[V
MQ,A"MT[['##CB8R=&*G.(O4-<[Z3E)YWPLQ?2B,>C\91FI)-&9T-^R7^="@S
M2".\B6XC! [BS"[.D=YB\;WT_8C::'^SV'N*1&#6*)2E^&"0CM7%I"K^+JXM
M3'50)MS ,!)-&UHY*WXO8]U6Y#5_[Q.GO<T09@PM2'Y![R-@!3>]D"$![76;
M;V:JC$3DN)5?+$'*&BK%XDS'\+P:?LY\U3MKTH R!5H)0IB<OK1*J(HUH051
MW@HIIU5>QSF6D0;(ID"B702+C&L=ULS9@XXA)L]6N%#G"D9VFR=HKZ;;&%RF
M", #.$+^H-@T;;(NCX6M[Z;C79[$]ZP7E>3P!8W#K/.I9R5R)6M(=&*O_ZCB
M0W^QFN3)T'M6]RSNTGD3,;7-(P4O7D(K4O1]M(S +\OZKB%VX[F4+$4654KE
M <F*W,/;N[!)[VX!-(UWF"31QF<)^XBTC-B%O'"A%-!@:,JH^BFU72#RVL6'
M[WMN13)M6PU2YS=:$<84'54J'W1,WX-PJ'F+>CRQFJ%ZA1U<T"]2W8(]]4YS
M"47%X/"HK.,S](M4I>"J/NN[<G:(97#$R/C&5'\$SS%H)^_0!^,'T@F@3Y-Y
M\5.^]5S;6(@O494&C-(N)O3E&8^UC=OP+,&1C$0]$_/L@.U'^GJ 64*0E< L
M:H^RKSW/WIN!%(ZA5=S2=:]IW2(<1I-KOA0R+JJ22ZLC[] ^N7HT',^9S.1S
M CZ?</]=1/MFD'H_T\[CY;&5H-0[0; $D?\1U&H ^Y<)E5T%4W2Z4B#=<<O1
M_W>4>LU>'1:^5]ZS\Y)02Q"1LW.Y%C*2Q@')I1F'"SUQ!)/%'Y&(1^S&=*<B
MS!F\29(UB<VYI-:$5<*I%_8T0U4>8A+6?B&)I6V/$5(X*;K0V)&G$J8-%=H/
MJ,)BJVIW*TE5Q_[@*-L:BY+>"'YT*7\GO>H#2R[I?#66$!)1T5SOT$IO)FN+
M>NM%KK>TQU82O4DL;A<G6IH"+<:=]'\)8EQ+#V+7=JR^2]%,*%J#WNDK"LKZ
M\WJ!E1-UM=/IG6D6=QPED"0.G[8QT><DJ'&C$M"KF^O0&^JQ':<"#D:9(J*@
M($WS[^QI#AFAW/5;BS(E#8K?6310'8&U3IN/2'OP$2:;[R/JNV/.1@)BTPFK
M2-PF7/TC":CWJ$C?1P;CM=&@*U*RNB.!.X;/O14]+':AL<[M?J,?WU)C2&.E
M'"ZR*)W'O ,A,]\HH)[(C(H:(8G?EUX@7B[94BHZ\^+VH4F81]_'&>2'@FPQ
M:$9-D/8:('DP<2ALJG75_^_$]#^S$].'),YVN%O23#';>VBM*Y*)1$[@\1P>
M[B .-JK$DIP?YJMENS0N(&:A]^@*9TT#[#YJ9?JT9[SB\0'>(X$KJIU)(NPO
M"8QUZZ"'2-O0[9SX/@<49/V02Z_^A5*V5X?JR5X]5)KVZEAAFX3+DRJYX&>>
M*I/CFB5KJJ=Z9=P%8Q^XZE_A->[79EKIM?5'3?,U>U]:4@$8*@'5/^9YT0'&
M8CFZP85NIKX%JSZZ7;(BJ%6& %&DPG2_&4EG$K90U&.8(_!9<4=J(8V."P_C
M,U!WPDH:3Q%-U:ZR!R=<#B&X4VHX@VM+K2 PPALRR)'QA$YGBF\_*[Z]<7 V
M:3J5(>%1JIE*K]I78D0[.IB,L0?R"!-\S],D*T.U]0/DP^J<)8AXJ];VX^/7
M]@72'S49HMU[W'=I"%\@[U)#>IP0B')+M6']CO5ALQ""XR1$P;F&*A>+"(VN
M?7^4%.G><%5Q(0J:#^6)5+)><@)>25L2TA&;,*40U<PX+*1<W2;;+/C\#M#$
MP6SHAUXD2$FZ#,Y62BH([3EXNI<%( Y6DC'^.7$@Q&)&\\=HV2+TM.TY*91=
MM]>BW)!&VHL_$FU$Z%C;:<ROXM6;+9C*Y\7R6IB=A%1;-?)L.[4#L>5H5Q_B
M2<FH$>SB#MD325[PQB7L_X>(H_SBV;_ZT.$W[O?1BY>[W]+24AMB)C55'!VW
MY8YQP3^K=6HA*=E'%6ERN>>@Q1K4_>!]")$#P?L-'@B$Q@F''<0F\M-M$*L$
M?+MZ9'13@*U13K'I?<Q2<3$T<0R@\>F>#Z[W+#JCH"K$G1=5!>3; =J$ZW@G
MB2;91/T%(I0 K=RQ9\)&/'H..6XRX!X4Q("K#*VW6&'J=WO]*CTI8G@N;K3N
MC#"SU(F^?T)R.4N=<N,C\G<FE9UB1=P=D>-:4!B2;*;$!*<PM('C'Y) 4;]V
MWYNM=8%WG1DAQ10?DM#VB%^%UCQA)%'VA:CF@#W>X8,<7V41G6I,61QDVWD>
M<2"5P&<&])H8,,6&QDWQ6%!+XL04ZE[5.T4Y[[H* :MV:36Y42( G7=Q.Q^V
M=HN%3][28*[JHB]3TS[F1EEN4BV4@XKO3O59U!?"AVQJ+FMW6A8[I76Q(\L[
MT700JW >4QJ4K-:IM1$'/R*: H*)'G@6.3]*LQ?T-Y_KE_LV^F*33"H;]';7
MS,2-@8GWVE-;B]=#^'R6R(5KL,;WB78OT=4C[6=CG=;TBJA=P21LV4V-P^CR
ME>MW4=)TCH13*>1*W2E 5371Q$^#PT'7.!;$H%K&.&]O1WEHXI.-K&M5TW8'
M_&A>A8K?/]Q#Q%*'_.8G#R)_Z"@";_*4)C*KM%L&QG98*/@TK?[OKC#3IVV&
M]:W/-/+&5'1R9Y.YC][$"I#LCC+$A/M%FIMW'TQH16?9GYM[B$]6>Z25CUT(
MEO>'83W133MDPJ>-N)'(Q5=,2!%OA'O>JR?Y[%(\*MCC)2T?F,\"U*Y8T^.9
M1Y295FP&QZSJ9=2!=)3Y->GO%$'Z$[&1&K:9NM47!%?"U7(QFTKGSO4&!!J9
MXVMBE8_;O8D#61([:[W>T$OMR4N1HGG-Z^][FO#M0HE#BV,OA%*,)SQPY#NS
MF\IB.U#3UYEH  &,$H1L@$A2D;:?!\%B1>O(4^(XAN>'I.*42C,!SU@9.'".
MAS+V'YLQMY\MEQ0+I>ERI/2SIT4T_IO(X3.E\;^9+ /Q'?:\S^8Q?9!"']O]
M7RTC-US-(46U0;A:1[.0!SXRNI< ISD-Y##<LD$]*7"N=YN0=9D2LF@_XK^?
M= Z81,^U9LDK@&F>L.3./:P@IH4\K9Z&UX&#;NN_BC3':VW"\1-[CV\0;K[>
M[]A1)D'X*$<ZS2;T\=<D\2[/GOW)+TO)+NZXAA#73U7^J;DAX7K[%VZL</+3
MS5].664#KL7>.^B74:,0ZW"#;AI$#/]$O2YS*Z$0V4D(TG.LR>>#,_F8TXI;
MF<REE4FT6>ZM8KF\6HSG.W3,."B\M9\M=;ILEW-)IJZ:-61],0J3BQ9LP8<(
MGF?9L:*[<$/,Q4,WLD22(]:V?E3),5F.]R^.F;U_2%[YQ$PZ$Y1LZ3%(@VG]
MX%6/ !]6V_R]>E*_-6Q37W2DC6BFHE0Y.,>W@,E#6IHG#CB<EWQVG\ 4U*$]
MX\ [.SBBW4QP&*\(25K?PIQNXY0"\4[.90UC7_6AVQ:29G%^)3[YK:SW=%O?
M!W7"X-8",BY>&^MSDS<_F +=LRV@<!U7) L<+:/3,G,#%B0YK]G)]?M?3XV#
M 0RX_MA:)2_<;5ZMM(W<].3Q3:A\;Z M6)N7F2X=:,\;RQY^S=Z*.BZ>\;5A
MW .$]116PY2L.9C.;:DK.N9JM,(NSDM([JT:[22*[?HV S[=E982)Q:R->_K
M=H-H9J"%NE,@+XQ]GD"O#TTG#=?;<=PADO]63#%THISI=-H7GC-(_$DK;=(J
MC5NRFW;@!FI0LBT9Q-4M*N66XP<T7.T7UY62(,I1<'UZ.>R5)DGNGB6:E!(D
MM#F"(ZO4*((^BMH2J34I4,3!*^9#VC3$&;AUJ3PG(TG!L[1UBCV<T7FE)0F^
MAL5,'L %22Z<22^"L$5M6X/.M 5W=U"F)H7W-@^W29%: I^NR:KZD7L#L0XN
M#HGOOPQ-^%6W@#D463Q61CBZ-E,J-3BW/XP@P4&!/Q[@U%/.$-=+&J7=!O=N
M9MO2VXYT'DG9A-T/@:+B.PN6:'5(K "HHAQ[;J06_P%ILC=?T)04F'RJ'O^X
M3X"3JB/>@EKW'/];^OM95FC:@K2!!<F;F7<!>,:_06]!#:%:><8![JV;#5>R
M?+Z1=[0*/W2)OSC>\/UG](*8EOI'7YPNPI?1TFYZY6HOT<!\]KGVF<HGW/V)
MP24<C#F:=<60%\>A5\.8B=X7\':&*[8PAG=E23A,+*A*ZK/X#3,20C<L\63J
M%R'3;&_H5 EGZI!W#%E(I/G<'OGE8+>.J#/QJ*35[ 5^GVT8O81"NB,G-5Z2
MWR?^!=\C(EU3W#TLM/]ZN]]3.0GCBIQ HH->8ND>.Y]$_#KK=%A(,@@R)8E+
M2BU_N[>/H]SM "1$?Z@$.6,?81.NJ& 6+I6:VAS(14.&EM#C:$F$&Y%][;-)
M=N'.O[@VWFN6N;FGCU#S9;@HX/)XJ_^KY1VN-H V.472CW\[B__V?)4;7'QQ
M&=VS.<N^N/CZ[!M_[280]HN++\]>^&^,AJ9N!,\>=QFX%</47>C-*29?6&1L
M]</YV:A4BV[QC;TPD]M+W#>?F8-XC!M?AH;OE\?;M-_TI)G,7S.^7Y,R1T,S
MID\>YA\;:NPUZ_@Y(;$X#\B1*MGLG$O\*61D:$*E>F2M-7EHT\_CZ56-)^]O
M?H<B';DG'GCAG;R0CBY/**U.C98\@$%8?6?%3^OCS#T&3G-Y?GZ>_:C;RQA.
M5I'GLG<H[#GY\>;=N],I_R%2/;^6:T4#2.<RQN$#2[$A=#N_/-ZG_!U<_IT1
MT<GK*%GC-+G'9Q(]_DUC,^O<ID\ODJ>3NX#*SAIE+F//*8O36)KM?)S[9NI^
M[-075*8BJ/F<%=$$^-NGPJ53>-%22J\PU^>^U-Y?.D3C9%5^SS%9-:)]Y"QX
M\9;.$G'H\0/R>Z]V2M54O (7",=E"]=%7?JT*:^9N&/Q$R[XZJ*$YY9'U!X+
MX<8Q]._3;L6/62U'I()WW&P,[@JL&MJ!PE ,ZI\[-+KXT,LV8O;1=D)LVNI2
M3FA[\.FUNVC:[A2RW]52I<F[UA)#O0QJ)(!\.[UT]9WE0D<=O^ %1P YNO<@
M5-N57=(10UKW[X,T6*RA?:+E>W G!=\^L0.6^E3>-KZW=F+@F"ESH"$HDZ%-
M/&.5E S,@G-^$2ZLF>K-.H_3K9S%#"=AD/-]-Q(BF]J\)RZ[M=X\"V'MXT8-
M5G4>.C:P(R3_)-?*MV6WE!LF9DF'A3C(&T!AY?-X<E2D^!B8!<^9H"D[?#7A
M.V9:/E>-];[ LDCK%X6Y[.(6D5*0NY]+GX? BWFS0V(WX/1'CB"$*Y+^'+E0
MJ#)-\Y_$ED4T[F<P_W&Y$&NVMBT$)16@OAE;N%%E<GL,&-0H(UZPXEYVTQL-
M%TXFG55#XS>/B^PW"7-I7XL(.V<C]-1D(\M33U)%^"*S.=_KKH#@B\0D:H>G
M1YKNQ8O'HZW"A^V+)6?M](AA2"?<JOI7L$+[BAOD@U-*0OQVHAY!\M@+0H>,
M5)/+\U=_;<A&^H9CS8H@;V)=XLV>+L'O7;RBTW"T5.VJ#:-Y<&(FEWK9RH.[
MNB8&1E"LRUSDWC1.)/(YVI#Z9WS>&/]F)]=)LY%R]2#+-DGGS]P(J1NZGON;
MB,_6?<I]MUEUZ_(JM7ZA=-VX'8ME0./BAMX+6YL'24UB^TB3F*8:/)_82]OO
MW,%]:@=K)=>",P?U\D*?[I/>E6D<%3.%N\)65LVF35&.*;_A8HC+XY<[$"HY
M8K)Z96BQR]Z[J&)D4N,].N"TP^KX+-DO!,\>"L<!'6;IZD9\!9+&(*-P(GOO
MFR5)^E==J$5:V%2BXOH+60<U1K4)WEB-27-W(S8;>Z;E CID7JM$&UFT!V^<
MFSJRIQW:^_^0]_GWWVYP;\BU0W47FX[?/8%-Z[]%AR+X&E]>73YY2F^&Q[__
M=INOW2]YN\;**K>B5\_/OG[^1/Q=]J%OMA@2]6Q]L^$_;UU.6BL>H-]7#?$:
M_8 )$.[@Y7W_WU!+ P04    " #]I4I2+)]]^D<#   5"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6RE5FUKVS 0_BN'H;!!J5^2;EU) DFVL1?*
M0M-MC+$/BGR.167)D^2FV:_?27:\EJ2AL ^1]7+W/'?WZ"6CC3:WMD1T<%])
M9<=1Z5Q]&<>6EU@Q>Z9K5+12:%,Q1T.SCFUMD.7!J9)QEB2OXHH)%4U&86YA
M)B/=."D4+@S8IJJ8V<Y0ZLTX2J/=Q+58E\Y/Q)-1S=:X1/>U7A@:Q3U*+BI4
M5F@%!HMQ-$TO9T-O'PR^"=S8!WWPF:RTOO6#C_DX2GQ *)$[C\#H<X=SE-(#
M41B_.\RHI_2.#_L[]/<A=\IEQ2S.M?PN<E>.HXL(<BQ8(]VUWGS +I]SC\>U
MM*&%36>;1, ;ZW35.5,$E5#ME]UW=7B.0]8Y9"'NEBA$^98Y-AD9O0'CK0G-
M=T*JP9N"$\J+LG2&5@7YN<D7LV9*_&%MB50.RU8=T 4LQ5J)0G"F'$PYUXUR
M0JUAH:7@ BV\N&$KB?;E*'84B<>+><<Z:UFS)UC3#*ZT<J6%=RK'_#% 3"GT
M>62[/&;94<1/3)U!DIY"EF3I$;Q!7Y=!P!L\HRZG,-?*4M;YOS(M#%I4KIV@
M6KT7BBDNF(0E32)M6V?AYW1EG:&-]^M(1,,^HF&(:/A$1$LZCWDCT;-1/)P8
M3$M_+>RM/23"<<"I]5!OD6.U0@.#MGA)2"]+TC>GX$J$&HVGH@/JK8DR1SJ,
M',5=$!]6VVZ;$L2FU"!4+NY$WC IMW3FPJ[!'.CZ@#0Y ?I4V@0LW9@#>!ND
M56;)0=*%82\/!.B#HQ)(R5:Z*T'-C%-H+'RL21;(!G "@PMJ;M@MYHRHJ9_1
M;V%TWG!'E'>H&NQCMS M"B$%:1?*<L4_H[6$/->FWK&D'B$=4O/8>/YM"1^0
M25<^-D^]>;)G/B4^82E]CC,T:U0'O-(]KR^U:RI8UNAWF=O"HF1T*_$M7.Q8
M;O;ETHYV9)?K?VOU&&Q/J!_(3'N>G]*,FHM.H?3<1_W*J[*?ZE/U])5O'0=[
M/D<$ZYMG%K158'!8Z^>*]P9.#AWZ^,%577E__R!9"*5O;^U^MG_SINU5_\^\
M?3"OF%D+94%B0:[)V>OS"$S["+4#I^MP\:^T(\U#MZ1W&XTWH/5":[<;>(+^
MG\#D+U!+ P04    " #]I4I2EJXW3CT'  "M$P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6RM6 U3ZS86_2N:+.S C$ML^9L%9B#OM7W=]_HHT.YV
M.IV.L)5$@VVYD@*/?[]'LN,D)*2T76:(95FZ7^?>JV.?/4GUH.><&_*EKAI]
M/IH;TYZ.Q[J8\YKI$]GR!D^F4M7,X%;-QKI5G)5N4UV-J>\GXYJ)9G1QYN:N
MU<697)A*-/Q:$;VH:Z:>KW@EG\Y'P6@Y<2-F<V,GQA=G+9OQ6VY^;*\5[L:#
ME%+4O-%"-D3QZ?GH,CB]RNQZM^ GP9_TVIA83^ZE?+ W'\KSD6\-XA4OC)7
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MV+T$5>4YE:MKEHGE9<?KK#L>^&RN34=_>%'2&1LQ_:F\E]CJMUHF/&>%XJ(
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M9C<&U".XL5#CD?0;M^DW/II^MYAB,#Q'*+1F.U%?/7'VR#@;<R8M=B7AWC@
MJX5#F?PXL$>3D@VX10MN9L%5FR6R!ESQ&C;4 '>DH6P PI))]GWUP);KGG/;
M[O[HFB08!*&)):;@MZ1>#S/BP&;=W6P;.@GN#I-I:V*9PP!WXV"=</:3S)LL
M\)"5Q"KUWV8!9KS$;N@U3"]V_#BN^7V$TDE+Z>2UE%Y7,.^W*Z*=+W$L.K
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M"]F"PG+E743GEXGU=PZ?!.[UD0ZVDHV4C];XM5AYH26$->;&(G 2.[S"NK9
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M;JC3HG8!=+Y2RNX7+D'7NV=_ %!+ P04    " #]I4I2J8,SD X#  !)!@
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M??B,1STSCU=J:8<G'$;;C"*6O76Z/3K3OA5J?/.G8Q[.'(KH#8?DZ) ,O,=
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M\,]-H1^@J#,,#?('%@8?K,[-ZXO)> Q,X7(4OT3<%#7*%XW"!>K@"/[D3+9
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M)2W ]U,A]'I""KK_J*?_ %!+ P04    " #]I4I2IVX2Z'4&  !I$   &0
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MJY*['GJ 5KAR8^@](&,3TABIGH<$[F'ZG4V6D?03)LS^XF/0/NV8-:7^X="
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M2RVV'K8"3_"&8_7D<WZ!&;H:$9#]>)_WH"V\X;;>0(K2O.ZU@#2.X!XA1/>
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M;J\[86<W\$DD:V,'NI/QAB>X0/-Y,U?TUJU18I%AKH7,0>'JNG,3OIWU KO
MS?A#X%;O/8,U92GE%_OR/K[N!)81IA@9"\'IWP/>8II:).+Q3P7:J?>T"_>?
M=^AWSG@R9LDUWLKT3Q&;]75GU($85[Q(S2>Y_04K@P86+Y*I=G]A6\T-.A 5
MVLBL6DP,,I&7__EC=1!["_J#$PM8M8 ]6\#"$PMZU8+>2Q?TJP5]=S*E*>X<
M9MSPR5C)+2@[F]#L@SM,MYK,%[GU^\(H^E70.C/YJ!*>BZ^\=$(>PZ(, ) K
M6(@D%RL1\=S 313)(C<B3V N4Q$)U'#V@2O%K=_.X6R&AHM4GX^[AFA9\&Y4
M49B6%-@)"B&#>YF;M89W>8SQ(4"7[*F-8CNCILR+^"O/+R (WP +6/AY,8.S
M'\XW2L9%9#0F%+7F!^B"7G.%NH7O[4O0>PX]J-!;4&9^E!E&%\!&%B4<M:(<
MF-ZK_=ESL+V7^/-FSY\?#_U9._&OWPD!WAO,]-^>_?OU_GVW?__$_A^*;(G*
M1@])DPT."ICJS#7\NWML"Y(2=^APK5H]3,)Q]Z&%RJ"F,O!269"8T/9O(,&<
MJ*0NO'E,222T*>.VC4<).MCCP:YZO<$@"(*:3QDF+3/9B/7[1S-G+3.#86\X
MW)]Y8..PMG'HM?%]MN%"V2.%B,(Y02"W)U+&6Y&F;=8-CYB<8'!9,[CT,IBC
MBNSVL=!.(8!J$5"R91L#&_YTRMM^4'81!#]ZHG%4DQMY<68[4OBXH4*#,1@)
M2P3D*G^N-"4O/UX8!-]@=E4SN_(BW6-,B:@0YEP9F,&JR&.;*QD%*3>M@>D'
MO/P6LS!H2D+@A;J)'U 9H2T?>W"Y;N53H1Q$]8!.Z#A16F:&EU<M,V=M,_NC
MPYF'5NT5NM"O3.ABDQJ!G JK4IA'3Y!09Z2=,*12Z]9J,*UP]SE=^1BQAA'S
M,J)>)>5+64H1W% MS1-TN;P59@T_I_Q1+C)Z_,VN]+FVJ0[AZY2'L*D/H;]
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M(X]1V0GT^TI*LWNQ&]1WD)/_ %!+ P04    " #]I4I2!$F]P)(#  #P#@
M&0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6S-5]%NVS84_15"0($.Z")1
M<IRDL W8;K=F6Q C[KJ'80^,=&41H4B-I.)F7U^2DB6[L^D4\(-?;)+B.;J'
MA[SB':V%?%(%@$9?2\;5."BTKMZ'H4H+*(FZ$!5P\R07LB3:=.4J5)4$DCE0
MR<(XBH9A22@/)B,WMI"3D:@UHQP6$JFZ+(E\F0$3ZW& @\W  UT5V@Z$DU%%
M5K $_6>UD*87=BP9+8$K*CB2D(^#*7X_CR,+<#.^4%BKK3:R4AZ%>+*=VVP<
M1#8B8)!J2T',WS/,@3'+9.+XMR4-NG=:X'9[P_Z+$V_$/!(%<\'^HIDNQL%U
M@#+(2<WT@UA_@E;0I>5+!5/N%ZW;N5& TEII4;9@$T%)>?-/OK8+L07 PP.
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M'+LA,J-<(0:IH0P&$Y-ALG[AU!4M2G?GOQ/:W,%=,3>O0I"V@_F>"J$?*W:
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MQPVR1OQ"L@O@PG. 7 0'!"U^Q1WG[JY%#JYF!^?Q\$B\^T\+<*\[-SFD]!Q
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M VZ/-^P//G:*9<X,WBGQRA.;C8*K !)<L%+89[7ZA'4\?<<7*V'\%U:U;SN
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M7-5#,/UGPZ<\R^J1M(Y?[:"#W9RUX_[GI]$_-C>O;V;&*CX5V3_I0JVN!_$
M+/B2K3/U33S\R=L;HO5X<Y%5S;_@H;4-!F"^KI3(6V>M($^+[5_VNPW$G@,D
M/0ZH=4#'.N#6H8G<:*NLN:T;IMAD+,4#D+6U'JW^T,2F\=9WDQ;U,MXJJ7]-
MM9^:3%FU JQ8@,_%AE=*+Y"JP.O;[:*"V2.XY?.U3-4C^/Y8\C?@]0U7+,VJ
M-V ([FYOP.M7;\ KD!;@^TJL*SU0-1XIK:L>?31O-7S8:D ]&OYBQ14(X%N
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M].]+(=331?T.>?=_!B;_ 5!+ P04    " #]I4I2Y"$<V6\"  #_!0  &0
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MI9W0J%V ?;]4BIXW;@AT,S_]!U!+ P04    " #]I4I2UXA&42(#   2"P
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;(U5VT[C,!#]E5'$ TA
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M,PB5)%XV2N5$LI5I'5Z85(V(&::JN<1<&ZC]!6-R.]$'U.WJ]"]02P,$%
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;,U674_;,!3]*U;$ TA
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M/)?V%QVK6,]!R4$J7E1@G4&1L?))'ZN): "TT'X J0"D#0C. /P*X+\6$%2
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M&'H-_"IKGK<Q[69_LKU*Q ]]+5RCU>JEVZ,5T" T]K1H88M1Q@*T*W5O2Y&
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M3'XUL F3SR)#1VBH/*H41B8Z<6RSM96NT7VJ#:T@>B+C;P@!^0GA^.0"V92
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MS>5<\%246D!]/Y.R7M_H-P\V[[)<_P]02P,$%     @ _:5*4E?B1I'M @
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M/$IK8/9G0NCMQ!Y0_V7H_0%02P,$%     @ _:5*4KS%EHZ? P  I0X  !D
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M_OUL0RD#AU5]2;"YYW".[X5[YR?&?XD]@$3/54G%PME+>;AR7;'=0T7$)3L
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M3*V],_C&8*\/QL0JV4CY:">?\YD76(> 0V8L \6_)[@#SBT1NO%OR^EUG[3
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M&%;23Z *AVUQ#6EKB,<'_HRNPYZR 9OTNJ?KV.9#$HV285WC3M?X_^K*:J5
MF#<H&Q]Y%,?!J"?MV"A*HKZV8Z,P2.-A:9-.VN2LM#4V,7?G:'=AY 0+QA1
M.*VTZVUV0JN*LXQNL-MI0TUML 'B%F<E,Z[&!IO8Y#@541#'/>7'5OVC.L 3
MAN&P[+23G9Z5C8WS#\66'A5(&EPG_2-Y;#50DLL!JU<EV4CP#^ZM$M3.W?^:
M9+8K-:V\6^V>&+?N9NVM+_#IT;P4?M,T[Y8O5&&?T83#%BF#JPGZI)JW0#,Q
MLG*WXT8:O&O=L,#G$RAK@/M;*<W+Q'Z@>Y#-?P%02P,$%     @ _:5*4HI9
M%5B*!   ,1(  !D   !X;"]W;W)K<VAE971S+W-H965T-S,N>&ULK5A;;Z,X
M&/TK5C0/K=0&V]RK-%+3])*TLUM-MSO/;G 2-("SV#0S_WZ-(908AT0[^Y*
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MJRY1B.L ]3YC3.XG^IRVU[+%7U!+ P04    " #]I4I2<4,%\[X"  !N!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6R-5<ENVS 0_15"R"$!6FM7
MU, V8%LIVJ!!@VP]%#W0TM@B0I$J2<?IWY>D9-6+[.8B;O/>S)L1A\,U%R^R
M!%#HK:),CIQ2J?K*=65>0H7E@-? ],F"BPHKO11+5]8"<&%!%74#STO<"A/F
MC(=V[TZ,AWRE*&%P)Y!<5146?Z9 ^7KD^,YFXYXL2V4VW/&PQDMX /54WPF]
M<CN6@E3 ).$,"5B,G(E_E27&WAH\$UC+K3DR2N:<OYC%UV+D>"8@H) KPX#U
M\ HSH-00Z3!^MYQ.Y]( M^<;]L]6N]8RQQ)FG/X@A2I'3NJ@ A9X1=4]7W^!
M5D]L^').I?VB=6OK.2A?2<6K%JPCJ AK1OS6YF$+X"=' $$+"/8!T1% V +"
M]P*B%A#9S#12;!XRK/!X*/@:"6.MV<S$)M.BM7S"3-D?E-"G1./4>,:KBBA=
M1R71A!5HQIDB; DL)R#1N3ZN.;.G?(&^@<XPNG[3_YR$"W2>@<*$R@OT$3T]
M9.C\[ *=(<+08\E7$K-"#EVE8S2>W+R-9]K$$QR)QP_0K0ZAE.B:%5#L$KA:
M7*<PV"B<!B<9;S ;(,__@ (O\'L"FKT''EJXUP//3L,SR <H2 W<3T^H";MZ
MA98O?$>]\$&],B)SRN5* /HYF4LE]+7Z=<)KU'F-K-?HB-?O-0AL_"!J?X&<
M2]57VX8EMBRFX;R.HS2(A^[K=KX/C8(TBG:-LAXF/_W4&>VHB#L5\4D5SU@0
M/*?P'Q$-2;(37^CMB3@T\KU@7T2/49+X_2*23D1R4L0C5Y@BWE.0WMN6'.3Q
M,HGW*W)H%*9)NB?FT"A.8V]/C+O5B2H02]O1I0YOQ51S9;O=[M&8V%ZYMS_5
MCTG3^__1-"_1+19+PJ06OM"4WN!2AR2:[MXL%*]MOYMSI;NGG9;Z001A#/3Y
M@G.U61@'W1,[_@M02P,$%     @ _:5*4C">'@T. P  + D  !D   !X;"]W
M;W)K<VAE971S+W-H965T-S@N>&ULC99=;]HP%(;_BA7UHI58$^>#D J06JIJ
MG5H-]6.[F'9AX$"L)G9F.]#^^]E.&FA)H#?$CO.>YYPW^#C##1<O,@50Z#7/
MF!PYJ5+%A>O*>0HYD>>\ *97EESD1.FI6+FR$$ 65I1GKN]Y?3<GE#GCH;TW
M%>,A+U5&&4P%DF6>$_%V!1G?C!SLO-]XH*M4F1ON>%B0%3R">BZF0L_<)LJ"
MYL DY0P)6(Z<2WPQP8$1V"=^4=C(G3$RI<PX?S&3V\7(\4Q&D,%<F1!$7]8P
M@2PSD70>_^J@3L,TPMWQ>_0;6[PN9D8D3'CVFRY4.G(&#EK DI29>N";[U 7
M%)EX<YY)^XLV];.>@^:E5#ROQ3J#G++J2EYK(W8$..P0^+7 _ZH@J 76.;?*
MS)9U3109#P7?(&&>UM',P'ICU;H:RLQK?%1"KU*M4^,)SW.J]'M1$A&V0!/.
M%&4K8',*$IW>$U4*JLR8+]'/ @0QR^@.M'7HCI(9S>SR&3J]!D5HID??T//C
M-3H].4,GB#+TE/)2ZMARZ"J=L>&Z\SJ[JRH[OR.['X2=(P_WD._YN$4^^8H\
ML'+OH]S5/C5F^8U9OHT7=,2[ RD!>I]]Z#5&O/70E+P9-WOHN@3TYW(FE=!_
MU;\'Z$%##RP][*!W>'!5J2*K,KMV/0X'03ATURVLL&&%QUA^&ZM2]7=92=+!
MBAI6=(P5M+&B/584!'X[J]^P^L=881NKO\_J>UX[*VY8\3%6U,:*]UEQ'+2S
M!@UK<)#UE()NXDL%HHTXV",&L9]TE)<TR.0PDBN2H<PV@J+ZT[?N\&0/W@\&
M?D>]V-OV+>_H7KPXL*OP3@?$!PNYS8M2P4*W*FT?2-7:IO!>%=^2).ZP$&\;
M"O8/LF]*W5\!*6"$*43S0O U&"OU$4GS62DD=!I;A_Z0$X[#CAV"MVT&'^XS
MV^Y6O=QLV^5;T]CO/Y&/,6[2J#MURV->'"2?LG5WCC+S'7%/Q(HRJ5-9:IUW
M'NL HCJ:JXGBA3W=9ESIL](.4_TY \(\H->7G*OWB3DPFP^D\7]02P,$%
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M[D^D4 JMI5AF&O)^JXYVLI*4^"2RO >P,$TBVWL B](0V]X#6!*$*;&\![$
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M\'5\@E-44;7JG2$<Y'N<D(I=]U$/YB#:J$'^8;;G+9N"P_^)Z"]02P,$%
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MV4(8,Z>8R$(YLX7&U]6ZO;NM'UHH1Q;*F2TTCKDP/KQ,#_I&.;)0SMZ% PN
M@[R9(POE[%TXA$GS9HXLE+-WX1XQKYY@TKR9PSW1[%TX%,U!WD06RIDMA%=]
M!X..+)3W%IKU3W:O7Y4AJS6J_!C>PH7CA:R*A17=GWX+792DW3:Z=5M5;\.Q
M3\T'(\OCCV2./_!Y_1]02P,$%     @ _:5*4KM)TM]B @  M"X  !H   !X
M;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:2VZC0!2%X:U8+""X[JN<5IQ1
M3S)M90/(*3\4VR"@U<GNVW(&]D$]Z$G$&:$"<?E'GU#!TZ]R;,9#>Q[VAVY8
M?)R.YV%=[<>Q^U'7PV9?3LWPT';E?+FR;?M3,UZ6_:[NFLU[LRNU+)=1]_<S
MJN>G^YF+U\^N_,_$=KL];,K/=O/[5,[C/P;7?]K^?=B7,E:+UZ;?E7%=U1_'
MV^FAOA[2PV5RM7AY6U?]RUNJZKF#!()D_B"%()T_R"#(Y@]R"/+Y@P*"8OZ@
M#$%Y_J 5!*WF#WJ$H,?Y@](295P2)$VP)M Z(=>)P.N$8"<"L1.2G0C,3HAV
M(E [(=N)P.V$<"<"N1/2G0CL3HAW(M!;4&\AT%M0;R'06R8OVP1Z"^HM!'H+
MZBT$>@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z"^HM!'HKZJT$>BOJK01Z*^JM!'KK
M9+.$0&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]#O8U ;T.]C4!O
M0[V-0&]#O8U ;YML=A/H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z.VHMQ/H
M[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMDX^5!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$
M>@?J'01Z!^H=!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>L?D9Q,"O0/U#@*] _4.
M KT#]0X"O3/JG0GTSJAW)M [H]Z90.^,>F<"O3/JG0GTSJAW)M [H]Z90.\\
M^5F00.^,>F<"O3/JG;]3[V'\/);AUO.UAN>OOI/J\7)ON3W^NOPZB3BOKCC7
M]Q7#\U]02P,$%     @ _:5*4MTG:PL8 @  A2T  !,   !;0V]N=&5N=%]4
M>7!E<UTN>&ULS=K?3MLP% ;P5ZERBQK7_S=$N0%N-R[V EYRVD9-8LLVK+S]
MG!20-K$*5*1]-XU:V^<[\9%^5[WZ\10H+0Y#/Z9UM<LY7#*6FAT-+M4^T%A6
M-CX.+I>O<<N":_9N2TRL5H8U?LPTYF6>:E375[>T<0]]7MP=RL^I\^.ZBM2G
M:G%SW#AEK2L70M\U+I=U]CBV?Z4LGQ/J<G+>DW9=2!=E0\7>3)A6_AWP?.[[
M(\78M;2X=S%_<T/9Q0X]2_FIIU2?+O%&CWZSZ1IJ??,PE"-U"I%<FW9$>>CK
M8]&+T\FYW# =/_G9^7.94X%EYWWT(96)1?IXW,M(IM/+4 I1S-WI5WQ-+*7/
M?C^:IMU2^\[L<KV_?-S/\TAL?IQ_QW_.^+7^!_L0('U(D#X42!\:I \#TH<%
MZ>,+2!]?0?K@*Y1&4$3E**1R%%,Y"JH<156.PBI'<96CP,I19!4HL@H4606*
MK )%5H$BJT"15:#(*E!D%2BR"A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DE
MBJP215:%(JM"D56AR*I09%4HLBH4616*K I%5H4BJT*15:/(JE%DU2BR:A19
M-8JL&D56C2*K1I%5H\BJ460U*+(:%%D-BJP&15:#(JM!D=6@R&I09#4HLAH4
M62V*K!9%5HLBJT61U:+(:E%DM2BR6A19+8JL]G_*^M/[_2?'S\]Z<-WXDL_F
M?U]?_P902P$"% ,4    " #]I4I2!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /VE2E+SE-R[[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( /VE2E*97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ _:5*4L*M: "2!@  &AH  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( /VE2E*/=SD=K08  &L:   8              " @=4.  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #]I4I2K,]0]*("  #4
M"   &               @(&X%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ _:5*4N;QN(R?!0  BA8  !@              ("!D!@
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( /VE2E(T]3_K
M% ,  " (   8              " @64>  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #]I4I2)E.AEI0"  !"!@  &
M@(&O(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ _:5*
M4B$6/MI+!@  =AX  !@              ("!>20  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( /VE2E(E;5+PWP<  $XA   8
M      " @?HJ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #]I4I2[EH>)1$J  !%A0  &               @($/,P  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ _:5*4KAW5*.W"@  C1P  !D
M             ("!5ET  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #]I4I2!2Z/C\8B  !'A0  &0              @(%$:   >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( /VE2E*G[=:=^P<
M %@5   9              " @4&+  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ _:5*4BXMRF=S!0  + T  !D              ("!
M<Y,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #]I4I2
M0C,7M ,#  !0!@  &0              @($=F0  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( /VE2E*=-@*R0@,  ,$&   9
M      " @5><  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ _:5*4HP5$3CO#P  K3   !D              ("!T)\  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #]I4I2UPMP%44+  #A'0
M&0              @('VKP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( /VE2E*H3Q+L,P0  (T)   9              " @7*[  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ _:5*4J$*;Z2R
M#P  :BL  !D              ("!W+\  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #]I4I2!'>][_<$   ]"P  &0
M@('%SP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( /VE
M2E)?M.%9WBL  /F3   9              " @?/4  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ _:5*4BR???I' P  %0@  !D
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M=#(V+GAM;%!+ 0(4 Q0    ( /VE2E):N5T)Q (  ,<%   9
M  " @:\9 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M_:5*4JF#,Y . P  208  !D              ("!JAP! 'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #]I4I2-#]]^UD&  !3%0  &0
M            @('O'P$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( /VE2E*G;A+H=08  &D0   9              " @7\F 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ _:5*4HO7(L&+ P
M9@@  !D              ("!*RT! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " #]I4I2EW F="H$  !A"@  &0              @('M
M, $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( /VE2E+C
M846JY00  "$+   9              " @4XU 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ _:5*4L>]UK=>!0  CQ0  !D
M     ("!:CH! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /VE2E)5O47(V@,  %$/   9              "
M@4I0 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ _:5*
M4OH@'S4T!0  P18  !D              ("!6U0! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " #]I4I2YI $4G(#   J"@  &0
M        @('&60$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( /VE2E+8;,.)B04   L9   9              " @6]= 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ _:5*4JL47S)@!   (A0
M !D              ("!+V,! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " #]I4I2G<Q#)A<&  #@'@  &0              @('&9P$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( /VE2E)<<:V?
M7P0  !X4   9              " @11N 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ _:5*4EEG.!/4 @  - @  !D
M ("!JG(! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #]
MI4I2 T^YPL@#  #E#0  &0              @(&U=0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( /VE2E+["K:,&P4  "H9   9
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M970U,BYX;6Q02P$"% ,4    " #]I4I2>^XN0_X%   _(   &0
M    @(%4C@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M /VE2E+D(1S9;P(  /\%   9              " @8F4 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ _:5*4M>(1E$B P  $@L  !D
M             ("!+Y<! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " #]I4I2?,(_P8T"   ?!@  &0              @(&(F@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( /VE2E+'@H6ZG08
M #8S   9              " @4R= 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ _:5*4L]/^C9$ P  N@H  !D              ("!
M(*0! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " #]I4I2
M!U2RS_ #  !#$   &0              @(&;IP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( /VE2E(WUB?Z; (  -<%   9
M      " @<*K 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ _:5*4AU'/!T[ P  ]@D  !D              ("!9:X! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #]I4I2%A33PWT#   T#0
M&0              @('7L0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( /VE2E(D4JN=_@@  -<R   9              " @8NU 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ _:5*4E?B1I'M
M @  /@@  !D              ("!P+X! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " #]I4I2O,66CI\#  "E#@  &0
M@('DP0$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( /VE
M2E(B+*R-_@,  !</   9              " @;K% 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ _:5*4L)OE'T&!0  $Q8  !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( /VE2E(][L+E:P,  )P)   9
M  " @8?? 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
M_:5*4HI9%5B*!   ,1(  !D              ("!*>,! 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    " #]I4I2L39N*-D"  #%!@  &0
M            @('JYP$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( /VE2E*_7<1-'@8  !4:   9              " @?KJ 0!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ _:5*4C%AC.8M P
MH@D  !D              ("!3_$! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX
M;6Q02P$"% ,4    " #]I4I2<4,%\[X"  !N!P  &0              @(&S
M] $ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( /VE2E(P
MGAX-#@,  "P)   9              " @:CW 0!X;"]W;W)K<VAE971S+W-H
M965T-S@N>&UL4$L! A0#%     @ _:5*4@>BCX%A!0  :18  !D
M     ("![?H! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
M" #]I4I2:%*?YU,"  !<#   #0              @ &%  ( >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( /VE2E*7BKL<P    !,"   +              "
M 0,# @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /VE2E)9$PVPK04  &0T   /
M              "  >P# @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #]
MI4I2NTG2WV("  "T+@  &@              @ '&"0( >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #]I4I2W2=K"Q@"  "%+0  $P
M            @ %@# ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     5P!7
+ -@7  "I#@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>314</ContextCount>
  <ElementCount>454</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>100</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114103 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2126104 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2133105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2136106 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2139107 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2143108 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2152109 - Disclosure - Provision For (Benefit From) Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes</Role>
      <ShortName>Provision For (Benefit From) Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2159110 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2163111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2169112 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2334305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2340307 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyandEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2344308 - Disclosure - Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansTables</Role>
      <ShortName>Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - Provision For (Benefit From) Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables</Role>
      <ShortName>Provision For (Benefit From) Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2360310 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2364311 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsandContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2370312 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies (Greater Than 10% of Our Trade Receivables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Greater Than 10% of Our Trade Receivables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenues (Revenues by Disaggregated Category) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues (Revenues by Disaggregated Category) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Revenues (Net Product Revenues Disaggregated by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues (Net Product Revenues Disaggregated by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Revenues (Revenues Disaggregated by Significant Customer) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails</Role>
      <ShortName>Revenues (Revenues Disaggregated by Significant Customer) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Revenues (Revenues Disaggregated by Geographic Region) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues (Revenues Disaggregated by Geographic Region) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Revenues (Contract Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues (Contract Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/RevenuesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Ipsen) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Ipsen) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418411 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Takeda) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Takeda) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2420413 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails</Role>
      <ShortName>Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2421414 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with Genentech) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails</Role>
      <ShortName>Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with Genentech) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2422415 - Disclosure - Collaboration Agreements (Other Collaborations, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Other Collaborations, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2423416 - Disclosure - Collaboration Agreements (Research Collaborations and In-Licensing Arrangements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails</Role>
      <ShortName>Collaboration Agreements (Research Collaborations and In-Licensing Arrangements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2424417 - Disclosure - Collaboration Agreements (Invenra Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Invenra Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2425418 - Disclosure - Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2428419 - Disclosure - Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestmentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2429420 - Disclosure - Cash and Investments (Summary by Security Type) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails</Role>
      <ShortName>Cash and Investments (Summary by Security Type) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestmentsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2430421 - Disclosure - Cash and Investments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestmentsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2431422 - Disclosure - Cash and Investments (Gross Unrealized Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails</Role>
      <ShortName>Cash and Investments (Gross Unrealized Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestmentsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2432423 - Disclosure - Cash and Investments (Summary by Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments (Summary by Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestmentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2435424 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2438425 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2441426 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2442427 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - Employee Benefit Plans (Schedule of Employee Service Share - Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails</Role>
      <ShortName>Employee Benefit Plans (Schedule of Employee Service Share - Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2447430 - Disclosure - Employee Benefit Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails</Role>
      <ShortName>Employee Benefit Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2448431 - Disclosure - Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails</Role>
      <ShortName>Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2449432 - Disclosure - Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails</Role>
      <ShortName>Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2450433 - Disclosure - Employee Benefit Plans (Summary of All Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails</Role>
      <ShortName>Employee Benefit Plans (Summary of All Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2451434 - Disclosure - Employee Benefit Plans (Summary of All RSU &amp; PSU Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails</Role>
      <ShortName>Employee Benefit Plans (Summary of All RSU &amp; PSU Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/EmployeeBenefitPlansTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2454435 - Disclosure - Provision For (Benefit From) Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Provision For (Benefit From) Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2455436 - Disclosure - Provision For (Benefit From) Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails</Role>
      <ShortName>Provision For (Benefit From) Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2456437 - Disclosure - Provision For (Benefit From) Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails</Role>
      <ShortName>Provision For (Benefit From) Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2457438 - Disclosure - Provision For (Benefit From) Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails</Role>
      <ShortName>Provision For (Benefit From) Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2458439 - Disclosure - Provision For (Benefit From) Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Provision For (Benefit From) Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2461440 - Disclosure - Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShareTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2462441 - Disclosure - Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails</Role>
      <ShortName>Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShareTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2465442 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2466443 - Disclosure - Commitments and Contingencies (Balance Sheet Classification of Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies (Balance Sheet Classification of Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2467444 - Disclosure - Commitments And Contingencies (Components of Lease Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Commitments And Contingencies (Components of Lease Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2468445 - Disclosure - Commitments and Contingencies (Maturities of Operating Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies (Maturities of Operating Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="exel-20210101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2471446 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="exel-20210101.htm">exel-20210101.htm</File>
    <File>exel-20210101.xsd</File>
    <File>exel-20210101_cal.xml</File>
    <File>exel-20210101_def.xml</File>
    <File>exel-20210101_lab.xml</File>
    <File>exel-20210101_pre.xml</File>
    <File>exel20201231exhibit1011.htm</File>
    <File>exel20201231exhibit1032.htm</File>
    <File>exel20201231exhibit211.htm</File>
    <File>exel20201231exhibit231.htm</File>
    <File>exel20201231exhibit311.htm</File>
    <File>exel20201231exhibit312.htm</File>
    <File>exel20201231exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20210101_g1.jpg</File>
    <File>exel-20210101_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20210101.htm": {
   "axisCustom": 5,
   "axisStandard": 25,
   "contextCount": 314,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20210101_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20210101_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20210101.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20210101_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20210101_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20210101.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 638,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 4,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 8
   },
   "keyCustom": 76,
   "keyStandard": 378,
   "memberCustom": 54,
   "memberStandard": 46,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20210101",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106102 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114103 - Disclosure - Collaboration Agreements",
     "role": "http://www.exelixis.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126104 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133105 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136106 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139107 - Disclosure - Property and Equipment",
     "role": "http://www.exelixis.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143108 - Disclosure - Employee Benefit Plans",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152109 - Disclosure - Provision For (Benefit From) Income Taxes",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes",
     "shortName": "Provision For (Benefit From) Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159110 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169112 - Disclosure - Quarterly Financial Data (Unaudited)",
     "role": "http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited",
     "shortName": "Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340307 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.exelixis.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344308 - Disclosure - Employee Benefit Plans (Tables)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansTables",
     "shortName": "Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - Provision For (Benefit From) Income Taxes (Tables)",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables",
     "shortName": "Provision For (Benefit From) Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360310 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364311 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2370312 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables",
     "shortName": "Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Summary of Significant Accounting Policies (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i68ed0b3579a44a409ff3f00c4b884aa2_D20200104-20210101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Organization and Summary of Significant Accounting Policies (Greater Than 10% of Our Trade Receivables) (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Greater Than 10% of Our Trade Receivables) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i68ed0b3579a44a409ff3f00c4b884aa2_D20200104-20210101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenues (Revenues by Disaggregated Category) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues (Revenues by Disaggregated Category) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i670b9bb21b274bf1a4d1c34421fc3303_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Revenues (Net Product Revenues Disaggregated by Product) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues (Net Product Revenues Disaggregated by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9df29850b2244253875bb007d882a698_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "id1016e220053480cb358c5dc63979dcb_D20200104-20210101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Revenues (Revenues Disaggregated by Significant Customer) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails",
     "shortName": "Revenues (Revenues Disaggregated by Significant Customer) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "id1016e220053480cb358c5dc63979dcb_D20200104-20210101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Revenues (Revenues Disaggregated by Geographic Region) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues (Revenues Disaggregated by Geographic Region) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ia435deed54c84325b684daa442718f36_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i8d6ae031ff9642c6823d52f9a9f51d23_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues (Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i6f9755c807a24f8cb306629ef867b038_I20181228",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Revenues (Contract Assets and Liabilities) (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues (Contract Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:MilestonePaymentsEarnedToDate",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101",
      "decimals": null,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Ipsen) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Ipsen) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ia0512c253afc47e1a94ead42bed0b2ee_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:MilestonePaymentsEarnedToDate",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418411 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements (Takeda Collaboration, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101",
      "decimals": null,
      "lang": "en-US",
      "name": "exel:PeriodOfSpecificSalesVolumeThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419412 - Disclosure - Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Takeda) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements (Collaboration Revenues under the Collaboration Agreement with Takeda) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ied2deb2880064d80aeaec0690b100c0e_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ib6abb9ba6ee941bf966fb2b8bdb7c6eb_D20200104-20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420413 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails",
     "shortName": "Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with GSK) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ib6abb9ba6ee941bf966fb2b8bdb7c6eb_D20200104-20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421414 - Disclosure - Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with Genentech) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
     "shortName": "Collaboration Agreements (Royalty Revenues under the Collaboration Agreement with Genentech) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ib55343bda1c447eaaec24e61aced15a2_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422415 - Disclosure - Collaboration Agreements (Other Collaborations, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
     "shortName": "Collaboration Agreements (Other Collaborations, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "exel:CollaborativeArrangementAchievedMilestoneAmount",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i0b172a5ff906435aadf5f99c85c38a22_D20181229-20200103",
      "decimals": "-5",
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementAchievedMilestoneAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423416 - Disclosure - Collaboration Agreements (Research Collaborations and In-Licensing Arrangements) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
     "shortName": "Collaboration Agreements (Research Collaborations and In-Licensing Arrangements) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i093a5d070dca4ee2ab4ba58e79e08c75_D20200104-20201002",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i2b3fd10a6b8e4b88964207e8afc24c36_I20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424417 - Disclosure - Collaboration Agreements (Invenra Collaboration, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements (Invenra Collaboration, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i2b3fd10a6b8e4b88964207e8afc24c36_I20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i81c0e0276859476d8764f5e4a7c6a702_D20180101-20181228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:UpfrontAndMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425418 - Disclosure - Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements (StemSynergy Collaboration, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i81c0e0276859476d8764f5e4a7c6a702_D20180101-20181228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:UpfrontAndMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428419 - Disclosure - Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments (Reconciliation of Cash, Cash Equivalents, and Restricted Cash) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429420 - Disclosure - Cash and Investments (Summary by Security Type) (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
     "shortName": "Cash and Investments (Summary by Security Type) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430421 - Disclosure - Cash and Investments (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431422 - Disclosure - Cash and Investments (Gross Unrealized Losses) (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails",
     "shortName": "Cash and Investments (Gross Unrealized Losses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432423 - Disclosure - Cash and Investments (Summary by Contractual Maturity) (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails",
     "shortName": "Cash and Investments (Summary by Contractual Maturity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435424 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i2ad45f83363a4cb8a086062be42c031e_I20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438425 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441426 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "role": "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i7b6993227e1c42338fcf094ee0faf565_D20190928-20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442427 - Disclosure - Property and Equipment (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Employee Benefit Plans (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ib25087bb5db74d7892082c9d2e8abbb9_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - Employee Benefit Plans (Schedule of Employee Service Share - Based Compensation Expense) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
     "shortName": "Employee Benefit Plans (Schedule of Employee Service Share - Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447430 - Disclosure - Employee Benefit Plans (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
     "shortName": "Employee Benefit Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448431 - Disclosure - Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails",
     "shortName": "Employee Benefit Plans (Weighted Average Grant Date Fair Value) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449432 - Disclosure - Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
     "shortName": "Employee Benefit Plans (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i301b0876450a4cfeadf94fa8b96cc495_D20200104-20210101",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i8d6ae031ff9642c6823d52f9a9f51d23_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450433 - Disclosure - Employee Benefit Plans (Summary of All Stock Option Activity) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails",
     "shortName": "Employee Benefit Plans (Summary of All Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i8d6ae031ff9642c6823d52f9a9f51d23_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i630c039e42614958998ad44ba50df6a3_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451434 - Disclosure - Employee Benefit Plans (Summary of All RSU & PSU Activity) (Details)",
     "role": "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
     "shortName": "Employee Benefit Plans (Summary of All RSU & PSU Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "ie965684178ab4cdcbcdb0308ac1d6f06_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454435 - Disclosure - Provision For (Benefit From) Income Taxes (Components of Income Tax Expense (Benefit)) (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "Provision For (Benefit From) Income Taxes (Components of Income Tax Expense (Benefit)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455436 - Disclosure - Provision For (Benefit From) Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails",
     "shortName": "Provision For (Benefit From) Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i5cf18789764c45368c669217aaffdb67_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i5cf18789764c45368c669217aaffdb67_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456437 - Disclosure - Provision For (Benefit From) Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails",
     "shortName": "Provision For (Benefit From) Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457438 - Disclosure - Provision For (Benefit From) Income Taxes (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails",
     "shortName": "Provision For (Benefit From) Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i8d6ae031ff9642c6823d52f9a9f51d23_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458439 - Disclosure - Provision For (Benefit From) Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Provision For (Benefit From) Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461440 - Disclosure - Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share (Computation of Basic and Diluted Net Income Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i728bdf824bce4e3a8e6c9be0a205fc81_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462441 - Disclosure - Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails",
     "shortName": "Net Income Per Share (Potentially Dilutive Shares of Common Stock) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i728bdf824bce4e3a8e6c9be0a205fc81_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465442 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466443 - Disclosure - Commitments and Contingencies (Balance Sheet Classification of Lease Liabilities) (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies (Balance Sheet Classification of Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467444 - Disclosure - Commitments And Contingencies (Components of Lease Expense) (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails",
     "shortName": "Commitments And Contingencies (Components of Lease Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468445 - Disclosure - Commitments and Contingencies (Maturities of Operating Lease Liabilities) (Details)",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies (Maturities of Operating Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i3034fe7f1e7741e5b7767f7a26a08254_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471446 - Disclosure - Quarterly Financial Data (Unaudited) (Details)",
     "role": "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails",
     "shortName": "Quarterly Financial Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "i9976757837ac4b5ab75920208383f366_D20201003-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210101.htm",
      "contextRef": "iae8a514896904fc2b2af28d12d8c7366_D20200104-20210101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 100,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccountsReceivableForUnsettledInvestmentSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable For Unsettled Investment Sales",
        "label": "Accounts Receivable For Unsettled Investment Sales",
        "terseLabel": "Accounts receivable for unsettled investment sales"
       }
      }
     },
     "localname": "AccountsReceivableForUnsettledInvestmentSales",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccredoHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accredo Health, Incorporated [Member]",
        "label": "Accredo Health, Incorporated [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AccredoHealthIncorporatedMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AchievedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achieved [Member]",
        "label": "Achieved [Member]",
        "terseLabel": "Achieved"
       }
      }
     },
     "localname": "AchievedMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AdditionalDevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Development And Regulatory Milestone [Member]",
        "label": "Additional Development And Regulatory Milestone [Member]",
        "terseLabel": "Additional Development and Regulatory Milestone"
       }
      }
     },
     "localname": "AdditionalDevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation",
        "verboseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation",
        "verboseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation",
        "verboseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliatesof Optum Specialty Pharmacy",
        "label": "Affiliatesof Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AreaOfRealEstatePropertyAvailableToLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area Of Real Estate Property, Available To Lease",
        "label": "Area Of Real Estate Property, Available To Lease",
        "terseLabel": "Area of property available for lease (in squire feet)"
       }
      }
     },
     "localname": "AreaOfRealEstatePropertyAvailableToLease",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "exel_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Balance Sheet Classification of Lease Liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_BuiltToSuitLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Built-To-Suit Lease [Member]",
        "label": "Built-To-Suit Lease [Member]",
        "terseLabel": "Built-To-Suit Lease"
       }
      }
     },
     "localname": "BuiltToSuitLeaseMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementNumberOfPreexistingPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Preexisting Programs",
        "label": "Collaboration Agreement, Number Of Preexisting Programs",
        "terseLabel": "Collaboration agreement pre-existing programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfPreexistingPrograms",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_CollaborationAgreementNumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Programs",
        "label": "Collaboration Agreement, Number Of Programs",
        "terseLabel": "Collaboration agreement, number of programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfPrograms",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "label": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "terseLabel": "Collaboration agreement option exercise fee payment, upon exercising option"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Collaboration agreement percent of royalty on net sale",
        "verboseLabel": "Cost of goods sold is related to product"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationAgreementTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Termination Period",
        "label": "Collaboration Agreement, Termination Period",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationPeriod",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]",
        "label": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementWithIconicTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement With Iconic Therapeutics, Inc. [Member]",
        "label": "Collaboration Agreement With Iconic Therapeutics, Inc. [Member]",
        "terseLabel": "Collaboration Agreement With Iconic Therapeutics, Inc."
       }
      }
     },
     "localname": "CollaborationAgreementWithIconicTherapeuticsInc.Member",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementsAdditionalUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements Additional Upfront Payments",
        "label": "Collaboration Agreements Additional Upfront Payments",
        "terseLabel": "Collaboration agreements additional upfront payments"
       }
      }
     },
     "localname": "CollaborationAgreementsAdditionalUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementsUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements, Upfront Payments",
        "label": "Collaboration Agreements, Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementsUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementwithDaiichiSankyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "label": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "terseLabel": "Collaboration Agreement with Daiichi Sankyo"
       }
      }
     },
     "localname": "CollaborationAgreementwithDaiichiSankyoMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAndLicenseAgreementExtendedTargetSelectionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And License Agreement Extended Target Selection Term",
        "label": "Collaboration And License Agreement Extended Target Selection Term",
        "terseLabel": "Collaboration and license agreement extended target selection term"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementExtendedTargetSelectionTerm",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And License Agreement, Target Selection, Extension Option Term",
        "label": "Collaboration And License Agreement, Target Selection, Extension Option Term",
        "terseLabel": "Extension option term"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementTargetSelectionExtensionOptionTerm",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborationAndLicenseAgreementTargetSelectionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And License Agreement Target Selection Term",
        "label": "Collaboration And License Agreement Target Selection Term",
        "terseLabel": "Collaboration and license agreement target selection term"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementTargetSelectionTerm",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "label": "Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "terseLabel": "Potential development and regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeAgreementsUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements Upfront Payments",
        "label": "Collaborative Agreements Upfront Payments",
        "terseLabel": "Collaborative agreements upfront payments"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementAchievedMilestoneAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Achieved Milestone Amount",
        "label": "Collaborative Arrangement, Achieved Milestone Amount",
        "terseLabel": "Achieved milestone amount"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievedMilestoneAmount",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Achievement Levels of Commercial Performance, Period",
        "label": "Collaborative Arrangement, Achievement Levels of Commercial Performance, Period",
        "terseLabel": "Collaboration period to achieve specified levels of commercial performance"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount eligible for development and regulatory milestones under collaborations agreement.",
        "label": "Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones",
        "terseLabel": "Maximum amount eligible for development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementWithCatalentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement With Catalent",
        "label": "Collaborative Arrangement With Catalent [Member]",
        "terseLabel": "Collaborative Arrangement With Catalent"
       }
      }
     },
     "localname": "CollaborativeArrangementWithCatalentMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementWithInvenraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement With Invenra [Member]",
        "label": "Collaborative Arrangement With Invenra [Member]",
        "terseLabel": "Collaborative Arrangement With Invenra"
       }
      }
     },
     "localname": "CollaborativeArrangementWithInvenraMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementWithNBETherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement With N B E Therapeutics",
        "label": "Collaborative Arrangement With N B E Therapeutics [Member]",
        "terseLabel": "Collaborative Arrangement With N B E Therapeutics"
       }
      }
     },
     "localname": "CollaborativeArrangementWithNBETherapeuticsMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementWithStemSynergyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement With StemSynergy [Member]",
        "label": "Collaborative Arrangement With StemSynergy [Member]",
        "terseLabel": "Collaborative Arrangement With StemSynergy"
       }
      }
     },
     "localname": "CollaborativeArrangementWithStemSynergyMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaborative Arrangements with Glaxo Smith Kline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen",
        "verboseLabel": "Collaborative arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software [Member].",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets amortization of deferred stock compensation - non-qualified.",
        "label": "Deferred Tax Assets Amortization Of Deferred Stock Compensation - Non-Qualified",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_DeferredTaxLiabilitiesLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Lease Right-Of-Use Assets",
        "label": "Deferred Tax Liabilities, Lease Right-Of-Use Assets",
        "negatedTerseLabel": "Lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeaseRightOfUseAssets",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_DevelopmentAndRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Regulatory Milestone [Member]",
        "label": "Development And Regulatory Milestone [Member]",
        "terseLabel": "Development and Regulatory Milestone"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestoneMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_DiscoveryProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discovery Project [Member]",
        "label": "Discovery Project [Member]",
        "terseLabel": "Discovery Project"
       }
      }
     },
     "localname": "DiscoveryProjectMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_EarningsPerShareBasicDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Basic Diluted Other Disclosures [Abstract]",
        "label": "Earnings Per Share Basic Diluted Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicDilutedOtherDisclosuresAbstract",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee",
        "label": "Effective Income Tax Rate Reconciliation, Branded Prescription Drug Fee",
        "terseLabel": "Branded prescription drug fee"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Deferred Compensation",
        "terseLabel": "Non-deductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement",
        "label": "Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement",
        "terseLabel": "Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement"
       }
      }
     },
     "localname": "EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_FinalCalculationOfBrandedPrescriptionDrugFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Calculation Of Branded Prescription Drug Fee",
        "label": "Final Calculation Of Branded Prescription Drug Fee [Member]",
        "terseLabel": "Final Calculation Of Branded Prescription Drug Fee"
       }
      }
     },
     "localname": "FinalCalculationOfBrandedPrescriptionDrugFeeMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_FinalTierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Tier[Member]",
        "label": "Final Tier [Member]",
        "terseLabel": "Final tier"
       }
      }
     },
     "localname": "FinalTierMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_FirstProductToReachMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Product To Reach Market [Member]",
        "label": "First Product To Reach Market [Member]",
        "terseLabel": "First Product To Reach Market"
       }
      }
     },
     "localname": "FirstProductToReachMarketMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Smith Kline [Member].",
        "label": "Glaxo Smith Kline [Member]",
        "terseLabel": "Collaborative Arrangement with GlaxoSmithKline"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_HeadquartersLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters Lease [Member]",
        "label": "Headquarters Lease [Member]",
        "terseLabel": "Headquarters Lease"
       }
      }
     },
     "localname": "HeadquartersLeaseMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_InitialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial [Member]",
        "label": "Initial [Member]",
        "terseLabel": "Initial"
       }
      }
     },
     "localname": "InitialMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_InvestmentsPurchasesIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments Purchases Incurred But Not Yet Paid",
        "label": "Investments Purchases Incurred But Not Yet Paid",
        "terseLabel": "Unpaid liabilities incurred for unsettled investment purchases"
       }
      }
     },
     "localname": "InvestmentsPurchasesIncurredButNotYetPaid",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen",
        "verboseLabel": "Ipsen"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "negatedTerseLabel": "Future tenant improvement reimbursements",
        "terseLabel": "Future tenant improvement reimbursements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursements",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements, Percentage Of Excess Costs",
        "terseLabel": "Percentage of excess costs"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursementsPercentageOfExcessCosts",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "terseLabel": "Currently estimated amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "terseLabel": "Annual increase percentage"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Payment Commencement Period",
        "terseLabel": "Payment commencement period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedPaymentCommencementPeriod",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of options to extend the lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Terminate After Period",
        "label": "Lessee, Operating Lease, Option To Terminate After Period",
        "terseLabel": "Option to terminate lease (after period)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminateAfterPeriod",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "label": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseReductionOfPaymentsDueAbstract",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_MINNEBROMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MINNEBRO [Member]",
        "label": "MINNEBRO [Member]",
        "terseLabel": "MINNEBRO"
       }
      }
     },
     "localname": "MINNEBROMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount eligible for commercial milestones under collaborations agreement.",
        "label": "Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "terseLabel": "Maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MedicarePartDFundingMandate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Part D Funding Mandate",
        "label": "Medicare Part D Funding Mandate",
        "terseLabel": "Medicare Part D funding mandate"
       }
      }
     },
     "localname": "MedicarePartDFundingMandate",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_MilestoneObjectiveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Objective [Axis]",
        "label": "Milestone Objective [Axis]",
        "terseLabel": "Milestone Objective [Axis]"
       }
      }
     },
     "localname": "MilestoneObjectiveAxis",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_MilestoneObjectiveDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for MilestoneObjective [Axis]",
        "label": "Milestone Objective [Domain]",
        "terseLabel": "Milestone Objective [Domain]"
       }
      }
     },
     "localname": "MilestoneObjectiveDomain",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_MilestonePaymentsEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Earned",
        "label": "Milestone Payments Earned",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "localname": "MilestonePaymentsEarned",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MilestonePaymentsEarnedToDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Earned To Date",
        "label": "Milestone Payments Earned To Date",
        "terseLabel": "Milestone payments earned to date"
       }
      }
     },
     "localname": "MilestonePaymentsEarnedToDate",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_MilestonePaymentsYetToBeEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments, Yet to be Earned",
        "label": "Milestone Payments, Yet to be Earned",
        "terseLabel": "Milestone payments, yet to be earned"
       }
      }
     },
     "localname": "MilestonePaymentsYetToBeEarned",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NotProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not Probable [Member]",
        "label": "Not Probable [Member]",
        "terseLabel": "Not Probable"
       }
      }
     },
     "localname": "NotProbableMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OperatingLeaseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Assets [Abstract]",
        "label": "Operating Lease Assets [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "OperatingLeaseAssetsAbstract",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liabilities [Abstract]",
        "label": "Operating Lease Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of royalty on net sale.",
        "label": "Percent of royalty on net sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "PercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_PerformanceShareOptionsPSOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Share Options (PSO) [Member]",
        "label": "Performance Share Options (PSO) [Member]",
        "terseLabel": "Performance Share Options (PSO)"
       }
      }
     },
     "localname": "PerformanceShareOptionsPSOMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceSharesAchievedBeforeDecember312020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares, Achieved Before December 31, 2020 [Member]",
        "label": "Performance Shares, Achieved Before December 31, 2020 [Member]",
        "terseLabel": "Performance Shares, Achieved Before December 31, 2020"
       }
      }
     },
     "localname": "PerformanceSharesAchievedBeforeDecember312020Member",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceSharesAchievedBeforeDecember312021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares, Achieved Before December 31, 2021",
        "label": "Performance Shares, Achieved Before December 31, 2021 [Member]",
        "terseLabel": "Performance Shares, Achieved Before December 31, 2021"
       }
      }
     },
     "localname": "PerformanceSharesAchievedBeforeDecember312021Member",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceSharesClinicalTrialResultsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares, Clinical Trial Results [Member]",
        "label": "Performance Shares, Clinical Trial Results [Member]",
        "terseLabel": "Performance Shares, Clinical Trial Results"
       }
      }
     },
     "localname": "PerformanceSharesClinicalTrialResultsMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PeriodOfSpecificSalesVolumeThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Of Specific Sales Volume, Threshold",
        "label": "Period Of Specific Sales Volume, Threshold",
        "terseLabel": "Sales volume period"
       }
      }
     },
     "localname": "PeriodOfSpecificSalesVolumeThreshold",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductCommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Commercialization [Member]",
        "label": "Product Commercialization [Member]",
        "terseLabel": "Product Commercialization"
       }
      }
     },
     "localname": "ProductCommercializationMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromCabozantinibMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived from Cabozantinib [Member]",
        "label": "Products Derived From Cabozantinib [Member]",
        "terseLabel": "Products Derived from Cabozantinib"
       }
      }
     },
     "localname": "ProductsDerivedFromCabozantinibMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products Derived From Other Compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProfitSharingAgreementPercentOfProfits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Sharing Agreement, Percent of Profits",
        "label": "Profit Sharing Agreement, Percent of Profits",
        "terseLabel": "Percent of profits"
       }
      }
     },
     "localname": "ProfitSharingAgreementPercentOfProfits",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ProfitSharingAgreementProfitThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Sharing Agreement, Profit Threshold",
        "label": "Profit Sharing Agreement, Profit Threshold",
        "terseLabel": "Profit threshold"
       }
      }
     },
     "localname": "ProfitSharingAgreementProfitThreshold",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ProfitSharingTierOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Sharing Tier One [Member]",
        "label": "Profit Sharing Tier One [Member]",
        "terseLabel": "Profit Sharing Tier One"
       }
      }
     },
     "localname": "ProfitSharingTierOneMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProfitSharingTierThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Sharing Tier Three [Member]",
        "label": "Profit Sharing Tier Three [Member]",
        "terseLabel": "Profit Sharing Tier Three"
       }
      }
     },
     "localname": "ProfitSharingTierThreeMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProfitSharingTierTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Sharing Tier Two [Member]",
        "label": "Profit Sharing Tier Two [Member]",
        "terseLabel": "Profit Sharing Tier Two"
       }
      }
     },
     "localname": "ProfitSharingTierTwoMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProfitSharingTiersAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Sharing Tiers [Axis]",
        "label": "Profit Sharing Tiers [Axis]",
        "terseLabel": "Profit Sharing Tiers [Axis]"
       }
      }
     },
     "localname": "ProfitSharingTiersAxis",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ProfitSharingTiersDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Profit Sharing Tiers [Axis]",
        "label": "Profit Sharing Tiers [Domain]",
        "terseLabel": "Profit Sharing Tiers [Domain]"
       }
      }
     },
     "localname": "ProfitSharingTiersDomain",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProjectInitiationFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Project Initiation Fee Payment",
        "label": "Project Initiation Fee Payment",
        "terseLabel": "Project initiation fee"
       }
      }
     },
     "localname": "ProjectInitiationFeePayment",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent",
        "label": "Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent",
        "terseLabel": "Research and development arrangement performed for others, reimbursement for costs incurred, percent"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting From Discovery Efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RoyaltyTier": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Tier",
        "label": "Royalty Tier",
        "terseLabel": "Royalty tier"
       }
      }
     },
     "localname": "RoyaltyTier",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RoyaltyTierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "royalty tier [Axis]",
        "label": "Royalty Tier [Axis]",
        "terseLabel": "Royalty Tier [Axis]"
       }
      }
     },
     "localname": "RoyaltyTierAxis",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_RoyaltytierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for royalty tier [Axis]",
        "label": "royalty tier [Domain]",
        "terseLabel": "royalty tier [Domain]"
       }
      }
     },
     "localname": "RoyaltytierDomain",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_SalesRevenueDiscountExpectedtobeEarnedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Revenue, Discount Expected to be Earned, Percent",
        "label": "Sales Revenue, Discount Expected to be Earned, Percent",
        "terseLabel": "Discount expected to be earned"
       }
      }
     },
     "localname": "SalesRevenueDiscountExpectedtobeEarnedPercent",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_SalesRevenuePercentDiscountForPromptPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Revenue, Percent Discount for Prompt Payment",
        "label": "Sales Revenue, Percent Discount for Prompt Payment",
        "terseLabel": "Percent discount for prompt payment"
       }
      }
     },
     "localname": "SalesRevenuePercentDiscountForPromptPayment",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "terseLabel": "Additional shares to be earned (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Employees percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises",
        "terseLabel": "Exercise threshold, percentage of per share exercise price of the PSO"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda [Member]",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TaxCreditCarryforwardAmountWithExpirationPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Amount With Expiration Period",
        "label": "Tax Credit Carryforward, Amount With Expiration Period",
        "terseLabel": "Tax credit carryforward amount with expiration dates"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmountWithExpirationPeriod",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_TenantLeaseImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Lease Improvements, Allowance",
        "label": "Tenant Lease Improvements, Allowance",
        "terseLabel": "Tenant lease improvements allowance"
       }
      }
     },
     "localname": "TenantLeaseImprovementsAllowance",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions",
        "terseLabel": "Change relating to prior year provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_UpfrontAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and milestone payments.",
        "label": "Upfront And Milestone Payments",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "UpfrontAndMilestonePayments",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_UpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment(s)",
        "label": "Upfront Payment(s)",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "UpfrontPayments",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20210101",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r112",
      "r119",
      "r210",
      "r349",
      "r350",
      "r351",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r112",
      "r119",
      "r210",
      "r349",
      "r350",
      "r351",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r112",
      "r119",
      "r210",
      "r349",
      "r350",
      "r351",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r182",
      "r281",
      "r286",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r304",
      "r306",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r496",
      "r534",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r304",
      "r306",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r496",
      "r534",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r182",
      "r281",
      "r286",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r178",
      "r281",
      "r284",
      "r497",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r178",
      "r281",
      "r284",
      "r497",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r294",
      "r304",
      "r306",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r496",
      "r534",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r294",
      "r304",
      "r306",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r496",
      "r534",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r281",
      "r285",
      "r536",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r281",
      "r285",
      "r536",
      "r555",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r250",
      "r305",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASU 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r40"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r35",
      "r241"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r55",
      "r57",
      "r58",
      "r521",
      "r546",
      "r550"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r58",
      "r59",
      "r109",
      "r110",
      "r111",
      "r416",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Operating Activities [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r352"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r391",
      "r392",
      "r393",
      "r394",
      "r498",
      "r499",
      "r500",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r308",
      "r311",
      "r355",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r311",
      "r341",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased property (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r98",
      "r161",
      "r170",
      "r176",
      "r206",
      "r413",
      "r417",
      "r435",
      "r503",
      "r519"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r51",
      "r98",
      "r206",
      "r413",
      "r417",
      "r435"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r191",
      "r218"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r196",
      "r198",
      "r515"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r196",
      "r197",
      "r514"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r190",
      "r192",
      "r218",
      "r507"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r313",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r31",
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r90",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r84",
      "r89",
      "r95"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported within the accompanying Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r84",
      "r440"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r120",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r120",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r405",
      "r406",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r249",
      "r509",
      "r526"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 311,627 and 304,831 at December\u00a031, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r62",
      "r64",
      "r65",
      "r68",
      "r511",
      "r530"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r432",
      "r433",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r432",
      "r433",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total",
        "verboseLabel": "Trade receivables percent"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r182",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r259",
      "r261",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r259",
      "r260",
      "r282"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r259",
      "r260",
      "r282"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r259",
      "r260",
      "r282"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenue",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "verboseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r72",
      "r497"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r387",
      "r397"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r387",
      "r397",
      "r399"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r387",
      "r397"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r148",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r193",
      "r218",
      "r224",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r202",
      "r219",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r203",
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r201",
      "r222",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r204",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r388",
      "r397"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r99",
      "r388",
      "r397",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r388",
      "r397"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r383",
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "terseLabel": "Accruals and reserves not currently deductible"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails",
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r365",
      "r380"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r385",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofDeferredAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expenses relating to stock match"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r87",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r87",
      "r159"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r281",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:",
        "verboseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r69",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r125",
      "r127",
      "r129",
      "r130",
      "r131",
      "r135",
      "r136",
      "r512",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "netLabel": "Basic (in dollars per share)",
        "terseLabel": "Net income per share, basic (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Decrease in earnings per share due to change in accounting estimate (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r69",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r127",
      "r129",
      "r130",
      "r131",
      "r135",
      "r136",
      "r512",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "netLabel": "Diluted (in dollars per share)",
        "terseLabel": "Net income per share, diluted (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Unrecognized compensation expense weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options, including PSOs"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r114",
      "r122",
      "r124",
      "r142",
      "r210",
      "r257",
      "r258",
      "r349",
      "r350",
      "r351",
      "r393",
      "r394",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r422",
      "r423",
      "r424",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r423",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r422",
      "r423",
      "r425",
      "r426",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r295",
      "r296",
      "r301",
      "r302",
      "r423",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r295",
      "r296",
      "r301",
      "r302",
      "r423",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r427",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r96",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r222",
      "r223",
      "r226",
      "r227",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Net foreign currency gains and losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Remeasurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r232",
      "r234",
      "r502"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r96",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r87",
      "r233",
      "r235",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment charge on goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r307",
      "r309",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r71",
      "r98",
      "r161",
      "r169",
      "r172",
      "r175",
      "r177",
      "r206",
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuarantyLiabilities": {
     "auth_ref": [
      "r252",
      "r253",
      "r508",
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur.",
        "label": "Guaranty Liabilities",
        "terseLabel": "Guaranty liabilities"
       }
      }
     },
     "localname": "GuarantyLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r238",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r100",
      "r161",
      "r169",
      "r172",
      "r175",
      "r177"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r368",
      "r376",
      "r382",
      "r395",
      "r400",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Provision For (Benefit From) Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r123",
      "r124",
      "r160",
      "r366",
      "r396",
      "r401",
      "r532"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes",
        "totalLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r96",
      "r362",
      "r363",
      "r376",
      "r377",
      "r381",
      "r389",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Provision for (Benefit from) Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. federal income tax provision at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedTerseLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofReconciliationofIncomeTaxesattheStatutoryFederalIncomeTaxRatetoNetIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r48"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r49",
      "r96",
      "r139",
      "r228",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "Cash and Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r462",
      "r464"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Build-to-suit lease period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r98",
      "r171",
      "r206",
      "r414",
      "r417",
      "r418",
      "r435"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r98",
      "r206",
      "r435",
      "r504",
      "r523"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r98",
      "r206",
      "r414",
      "r417",
      "r418",
      "r435"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Line of credit borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r60",
      "r63",
      "r67",
      "r88",
      "r98",
      "r113",
      "r117",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r128",
      "r161",
      "r169",
      "r172",
      "r175",
      "r177",
      "r206",
      "r435",
      "r510",
      "r529"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r161",
      "r169",
      "r172",
      "r175",
      "r177"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations",
        "verboseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r456",
      "r464"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion included in other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r452",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets included in other long-term assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesBalanceSheetClassificationofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r461",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average operating discount rate used to determine the operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r460",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r108",
      "r155",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r40"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r61",
      "r64",
      "r411",
      "r412",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r55"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $(394), $(1,049), and $156, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r53",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "negatedTerseLabel": "Unrealized gains or losses on available-for-sale securities, tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r80",
      "r344"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r81",
      "r83",
      "r101"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r80",
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Cash received from option exercises and purchases under the ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r245",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r34",
      "r240"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r242",
      "r525"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r96",
      "r242",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "verboseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r18",
      "r25",
      "r524",
      "r554"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r360",
      "r570"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r96",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r95",
      "r556"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash equivalents included in long-term investments"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r258",
      "r352",
      "r522",
      "r545",
      "r550"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r114",
      "r122",
      "r124",
      "r210",
      "r349",
      "r350",
      "r351",
      "r393",
      "r394",
      "r541",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r157",
      "r158",
      "r168",
      "r173",
      "r174",
      "r178",
      "r179",
      "r182",
      "r280",
      "r281",
      "r497"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Royalty revenues on ex-U.S. sales",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r149",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Sales revenue, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r283",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesGreaterThan10ofOurTradeReceivablesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation",
        "verboseLabel": "Transaction price allocated to our performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r459",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r311",
      "r340",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r311",
      "r340",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "Summary of All RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r35",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "verboseLabel": "Schedule of Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r11",
      "r95",
      "r501",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r313",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r318",
      "r329",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of All Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r375",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r147",
      "r149",
      "r150",
      "r151",
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Discount rate from market value on offering date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Discount rate from market value on purchase date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Instruments awarded (in shares)",
        "verboseLabel": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Awards outstanding at end of period (in shares)",
        "periodStartLabel": "Awards outstanding at beginning of period (in shares)",
        "terseLabel": "Number of awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Awards outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Awards outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0 Average Grant\u00a0Date Fair\u00a0Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted\u00a0 Average Remaining Contractual\u00a0 Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve under 2017 plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at end of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding at end of the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r320",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at ending of the year (in shares)",
        "periodStartLabel": "Options outstanding at beginning of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at ending of the year (in dollars per share)",
        "periodStartLabel": "Options outstanding at beginning of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted\u00a0 Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r310",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Average price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r310",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails",
      "http://www.exelixis.com/role/EmployeeBenefitPlansWeightedAverageGrantDateFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r96",
      "r313",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r309",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r307",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Nonemployee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllRSUPSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r335",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansScheduleofFairValueofEmployeeShareBasedPaymentsAwardsESPPAssumptionsandWeightedAverageFairValuesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value, exercisable at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual term, exercisable at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options outstanding at end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r15",
      "r505",
      "r506",
      "r518"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r409",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r109",
      "r110",
      "r111",
      "r114",
      "r122",
      "r124",
      "r142",
      "r210",
      "r257",
      "r258",
      "r349",
      "r350",
      "r351",
      "r393",
      "r394",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r142",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Outstanding stock options, unvested RSUs and ESPP contributions"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentiallyDilutiveSharesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r257",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r257",
      "r258",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/EmployeeBenefitPlansSummaryofAllStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r258",
      "r312",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r98",
      "r188",
      "r206",
      "r435"
     ],
     "calculation": {
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r199",
      "r200",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r391",
      "r392",
      "r393",
      "r394",
      "r498",
      "r499",
      "r500",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInvenraCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsResearchCollaborationsandInLicensingArrangementsDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsStemSynergyCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r295",
      "r513",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsGrossUnrealizedLossesDetails",
      "http://www.exelixis.com/role/CashandInvestmentsSummarybySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r361",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails",
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Change relating to current year provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Reductions based on the lapse of the applicable statutes of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would reduce income tax provision and effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForBenefitFromIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r102",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r457",
      "r464"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingenciesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r126",
      "r131"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r125",
      "r131"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555860&loc=d3e11019-110243"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555860&loc=d3e11049-110243"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e12803-110250"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r571": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r572": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r573": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r574": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r575": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r576": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r577": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r578": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r579": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001628280-21-001852-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-001852-xbrl.zip
M4$L#!!0    ( /VE2E*)^5G^WJ($ )==+  1    97AE;"TR,#(Q,#$P,2YH
M=&WLO6UWDSG2+OI]_PH?GG/V[EYK#'HIO=$][!5(8-)#DFX2F@E?6"6IE#@X
M=L9V(.'7GY+M! (! B2Q;V-FH!/?K]9UJ>JJ4DGZ_?^>''9;;V@P[/1[_[PC
M[XH[K?_[X/?_I]W^S\-G3UNK_71\2+U1Z]& <$2Y];8SVF^]R#1\W2J#_F'K
M17_PNO,&V^WQ-8_Z1Z>#SM[^J*6$DA\='-S73IALC&AKZ4L;BI'MD,FVA:6(
M.A1+Z/ZQ=U_E8K24T%8NQC8H[=H!0VI[$5WRVNBBQ3_R?>MCX?]'$TT )5U0
MT3@I$42@4$JNC]T?\;?C;]@;WJ<3ZO[SSOYH='3_WKVW;]_>K1]T3CK#NZE_
M>*^^K^#_W9F>W>WT7E\X^R0.NG?[@ST^4^A[]7#$(9V=WAGVZRM\X8KI&6<7
MU(.Y<W[^A^?:>Y.#9Z=F^NB\(:6[>_TW]_A ?6_1%I);='KZA5=XJ\<WE2&$
M>R>U+<[NF?K'O='@]/+[3@]^>N_[)\/.9??GEY;W_K/Q=#OMTR&V.[WA"'OI
MO'&&@]'Y506'<7P-?WC) XY'@\^V8;C'1\\;_.1SYTENZQ[C0Y7 [T\?77[^
M^U/OC0;8&Y;^X!!'W!?JG4Q;J+:RYR\W;.\A'GWZ7:8'+OD^_-PV-^N%9Y\U
M\]<>[3]L^$_X> ':>O1#9G6^1,0/T;G?Q=[>/^]0K_U\^PYW%\+\X/=#&F&K
M7M^F_QYWWOSSSJ-^;\1&H+US>L27I<EO_[PSHI/1O3&K[CWX7__K?_T^ZHRZ
M]*!VJ_99=_K]WN3#W^]-;AW[^?3![[GSIC4<G7;IGW=R9WC4Q=/[O7Z/^ 4Z
M)_?KB328_-C)F7KC'_GX)ENB02=-GG\R>D;EGW<Z2!Z-!!]L$%"2B@J+\EFJ
M[)/3UKY:K:#PJT#[?1?OX6%]-'7NK[!QR]7 />[BWIU6)_,ML_[[-*[VWSQ5
MS][LZHWC?+#VYN63<+!UL N[A_7OR\[FBW6YM?/7Z<9.,AN'ZW+SW=K)[LY?
M;[=>/#<O#U^^?JHWN[OO^FKKR1^']>_NP=^=S9W78N-@36_M_,$_IY.-%VMB
M8[7;W7K!5SSVXJEZ>;K[(MF-@_QZ]]V:W#SXZV3KR9K>7%U3&^]>P^;!:[-[
ML':ZN[/9W7BR>;AQL/$F/WG<B4^>VZV=O=.7JRLGFZL;)QM/=OF:C7>;:OW=
MQKN_S.;!GMS=R:\W=QYW7QZL3Z_YFY]E>B]W^F9K]8_7&ZO\+N_6WKX\2/S?
M#;U[P->OOE9;JW_O;ZJ_Y,:+OP\WNO[TZ<[::&-;G#S=V3 ;[_9>>2^ ),:V
M=:C;$*)N!Y*^+9*(Y*R7,MH[#PIVA_3[O0LPWB2J9U[K<6>8L+M+.'C,GPR7
M^'X-7_$>WY57V0=(46+;Q41M0'#M"$AM=KH^9^LD*7/G005B9M#^R??OYR6X
M5P)7?@BN5[H(;OVV1,K<<1E<+,FWP1LIDV*%);CC/MZ]16C7>NPK3A\QN /L
MKO<RG?R;3I>P?@U6==$FOWZE=$S"&%;.@@TS@%)M9-W<MBK$S+!;2PRMX#]!
M!V?=MT#LLT426I82+*ADF4;9J,+RG,4\W_S5^A1B?8;L5!O=WSJB :N;WMY3
M8MW\M(.QTZUP'P\&C/CVB*.+VJ^WRN-.C^5)ASMW?]BI<FCMA.7&L!.[?-5P
M-%M"G# 0;U[V_MA_^>YH?VN507F7]S=W=@W?6VSLK)QLK:[KC9UUL;FZKE[N
M/&=R[+]^V0EB]\4?0P96;SU9UR]7\^'6SHJJ +\\?-S9/:SD^8L_[[[>7'W8
M?;GZLOMR>WK-?_[8CX>YNW608)=)N*EVS<;J[MN-G6>'?+RSJYZ_Y?N]WGKQ
ME]AX\O?KS<._N_]Y]WRT\:@2@HFQ\@IBMC;'T.8NS1T\.]?V$&1;0"BI,(A.
MP)T'YSB-]FEP!D^'AE. OH4D6F@HY(HDYT"2B8Y95APJB\(K V.27.C^2Y+,
MFB3H(UC*[.*173R U>VH) ?I&9RTH+T#<ZTDN2Y+\JRF&[;*\R&M#(?4'(ZP
M)3\]\RZ;BN^S^G>'N<!<>7VZN?K7V]T7Z^PE^-K57;6IUMYM[#R7NVKMW+LP
M#SH;[W)G]^ ON?7D&9_WN+MYP-QXMVNVGOQ]N,GON;&S=_)R]?5'WN6(>;#.
MGJC>^SF\?+(N-EX\5\P-S=X,7K[85;L'SYFCCU]O_>U/WGL7_BZKZ_!*:PI.
M16H[I@7+P@+M$*5K"PIHT/BDC'W/E'YE"E9DALR$-#MCLN3)+?.$9"0%F=HR
M5SMB;&BCS8*E7Q8^H<LFQV_ER;V+28$!%>+S$@TOR674G,C]X3@CQ4QJC7,D
M]T>G1\R08>?PJ%L3(.//]@>5:!?2%G=/AIEO<>_B/2;/?__0Z3L,^\>#\6_C
MS,O]*7LGK/D>27QV(QKKX;/?.KG^7CHT:(U?B"[-*3U:__=%:??QQ0_./KIX
M]Z-Q('7VVW"$@]$J=Y '9QDM 6?7O3]V_IKY[%0Y/E6^?\3DR-GO9P^Y=Z&A
MSNYSW.M,&NUXW/:3#P^YZQX/Z,$T>WK_^?;JV>5GA\Y^K]=?BD&$D@,B:JLT
MQ&*#\BQ\5,@BL)L#F'H:QYYF]DT_R<Z-I@W/5E6?WVAZY!M;<[B/3-%/&G0*
MYOC@-[=HDIFML=0Y.P_6NR@U")L@^2"=<&9JD]5<D/F#%I4UG_N>G]_6HA=:
MX!N\TKRU@+R>%O@&_397+3 Q9S_:J]A&_4F#[=I]SK]>[KSAU_KPU+'?PE%_
M\)WF[)/KZX>KU.L?LF2YY+97[=07;G'OXMM_U9HFG4!E&60"2"9XKZ76KI H
M*=LP"X\V_=JT5_7<Y-?,#SLYZG929[1!AY$?D3N'5=350<[A8'3_ST$_'Z?1
MUF";!F\ZB59..L/W:F1Z='+I[_<NO>-Y4YT_>%X]ZP7\A'2&@9.*?  )Z$N,
M 7+4.D<T"2M^TDNE0ONV.G!#\9.^+55;A:O@]Y'5^0'\(""!]"P?;0!EHP\J
ML)HL-57O5<H3_&JW:T^!]$O\/H??A4[U!?RF4/MKP ]%<29:J9710,Z$R*JA
M,'[%@%8*%L)^/N5/>D-:1/M9LM49(\<168 MMJ;6L[(&M2;B;KD0]O-6\)N-
M_>1(L&2C8]8A0RDI!.4(ZT\L:#TMAOV\+?QF8#^%#]9RT!6C,%"2\)ZT,)8\
M%B)2:B'LY_3#1;2?)OH((C@L0H),(JI@4]'11E3!B+(0]O-6\)N-_13"JBB"
MEUI$*%*%'$ACU,9(\A!Q(>SG;>$W _L)%I$52V1OET!'@P9<EE$FZ[4/4<Z@
M_S6"]X&*)E"!E$X0) 0B*54QW@:C$6@&O&\$WURT(7!@XT@F4%K[DHH(0"0*
M%F/-N-V"",K/+=]"6X0/&N-V^&92D=YY_@Z0P&CKD[5!2<?RM>1H7<VO2B>5
MGCMY<VY$SX98U_Y[7(LX^H='_1[_.KQH:_GSPWYO>]1/KZ_?WKY/_$I7*:VO
M(_4M2N:@P=FD2P8*W/MU!ET+K9(2V>2%@68EY_& .';_Q$Y>[SW"H\X(NPV!
M*1:/%G.$*"T$Z[P3!)2J_'00 !<'II2.#X^[=7[.N#"GGC>@_7JW-[3>2_W#
M&U R-P)9,AS#"8-29 M&Q0#>)W:F4)2/RIN%@>P9C;#3H[R&@UZGMS=L"#Z8
MDW.Y!(^RBD<7P0AD^6@TB(@BW!X^LVH!'XR,"J$D%P"\1!\I.:-L5(6<]//+
MT!KU/)K8"38+:Z50&DWJY[?*2NX?54,_(>F5SLP'Q\-1??17J'OEGO/^CL/'
M_<$FO66S5B>B<??@8*W'/Z9QQ_K4^$W/XJ[7RSC(P^='F3LAXP B7-?;+7:_
M-K* "5HPH34DA<A&F,6,]9",PCC'8G/)ZCFFE2:.]J((*9@"R,;2F"R$)=*L
MP9)+2UK-ESF:):NM4 UAM3!%E@@AI*( @N!@7(?"(JAD8C4DEJQ>TNI[?#"1
M-:'("-(#JA#(4Y$I<]B*B"DV(+$^=V)I]NE/HS):RE9[T! R1F_022"=0]%2
MR<5#=2;9B-D#+3PYPQ%@D(%]@XXHLR25=?$.LC.P>$#?:.)V]H#:E)"R(ET<
M,(+!%^O8(GO6M 9"+(L'Z*VE>V</KA:$Z)((@7NKLA1C4#I3 AOJ1)!Q]?I"
M8'I;HRL?0?,C:?NL@I.258\D8)"BK?4AR<92P,-TX&L1H)G%Z,KUP01&>6^S
M,A$S9.T\)DO!)YEB 1O5XL TX]&5ZX,LY9*5%)39Q($N%H-Q6D9CBN;.)<K"
M0':K6=CKP\>6X(Q)7CA44'R*6EBK FL.ZZ+0_O;PF54+> _)^0S".P^.0Z7,
M#9$TH,DB*4$-* Z<.ZK.OG0*BT#KC-*%!.1L QL>&5A1<V1,)-7BH3H/,? ,
M@%8I:&>1($"J<P.Q+A\F":U%:X*,BP?T;<; ,P"4M&#KJR4+O0*:9 Q12)-(
MB&R]A5D4BRZ**)\]N&!1!FTCN* @"QNRM@HP%Q3%@ JW-X.[R9WTNJ:67RR:
MS23K:LC*6PF*V(B:[!RX&)&,*&IAH)E!#'R-,!4H,8$.WG@$=GLQ1N\,!!]R
MEHAY<6":;0Q\C9!9B(6-7BI!."@B!^%+3MRS;'&L4Q8'LMN,@:\1'U Y!>#^
M S*!58BNN"( ? HDE/$-F-[7A+XU^WF WFAEA,_D-4*(WI-CH$DE?I]4U ("
M?6NQPHPF=AK/05]!FZ*JU5U!D\IL6DFI&)1?0$!G$BO,J+="LEXZ=I5! CD1
ME1*N^"P@Z9!*O+WUKIK<26]D(2Z#B&2#9#F#4(()0A#JDK+7JDXA6QAH9A$K
M7!],R<>4LV8-DP18P>AP]!VLBJ9HDK! ,,TX5K@^R"RB\'7QS@P%@E)!"P["
MC94J6U_*+2[RMTBQP@_A<[X W]%D_OXGZUK695SO3P^>W>/*ZUHZD<UX=31O
M%,B0&7DO7,)@V<>%G!H@83Z_ML&X99[1\+A;*V4?#_J'JYUAZK^AP>E:*?W!
MZ(;'GF:TW)UAYRB,2^P/00,&9= )"RX9JR6%YD,Z/31<Y49Y0[D"^PAC_QW6
MBNA.7$10HR\NJ$S"1(!H4B@2@ RQ9=8^%EI(4,^=:?^XEQ>EK[Y?IGCRII?;
M\^G!;[;G'K763K$:EAJ<$D$X5E_\[;*-2=@FA:2/]K&WQ_+I_5R'M>&H<\@M
M_?"T;LOV 7?J>O;=1]A-X]D;_=Y6>3C 7J;\YX"&:= 93]Y8'1SO/:9%R2R=
MTZAW7%_\,ZM='_&/W\PAZRF+J(T+"%#WEBQ%%R$21.\!L0GKC;V/;7N)ZNY*
ME0#/.L/7#T\?4B_M'^+@]:4S:H;/*%'G#<;NUXAR)7NW@0?]P:/CX8A#@,'P
M \:N'PVI=UV3B"[YEN\[R/E)T[?XY.0%Z1 71_&3KXL^)24U4Q8XZLS2.XL^
M10L^-6')M26%YX7",RI$J?;7%]0*/+B,D>VO4<I$E41202RM\(]3> =?4\:?
M@<.S,<,2K$P98LDZ<?RI@W51J>ASB10BN:497G)XWNUP#$$4X  *1 34KJX^
M[X)3J<CDJ!$1U1?YLU)*I]OAQAGVRT;Z-PV'_=ZC_N"H/X'U!HEU:_VG">2>
MC8%VV@B%$:2T!I11(5NA*4'*BC^*O@$&>DGN^2?W;"QW >-C,A:T13;>UMNH
M2T&;39+:D6R Y9X'@EVY@SWZ>_M?A-W1_NWTL+EA]VQ,MTHH8M12&T2 [&/6
MRKL2@N$C42U3'$MV-]AV2PA:25=LM!P_UID:B432+I@DHA!F:;NOD]U;9:5N
M-SO9UO4A#?;HEE32W+!\-C;<LKVNZZRD%#58Q_J$0H&"(C']LX>E#5^RO/FV
M7"=;1 R^%&:YS"GF&G1Z"X%C30--V#^S02SOEZVCT?'A]A'5#=Y'IW_NX^ 0
MT^G/P.\99;D%>)U8CDL7)\L8"D\E"JV5U@665GS)[T;;;T0+FFQ=T-B -@89
M\A(D>$%5H>L&V._*K6>UG.C]6J\;>-(Y/#Y<1(,4A$I!I!2B(2BDV1I!L3+%
M.%Y<K"D5H)\U!D^Z>-+?/NR,]O_=[?06I:+KH\B %5.,2D;E(!:)D&6J&^[(
MDK063>ES7Z_W?#+H#Q>EM/.CA9V"J"LX96DC6"N#RQ)+DC)Z*-[I!JB"N4%P
M1B._B,H$D7.J1=>:D(()5J581W]C;L+RU/.$X S6/(W24E0!"G="T (CBY;"
M_Q1A/!9HBB/\.H+;V*7A>')+U>0KO;S2[?;?(HO3!;6MVF8K^-^H@#"@->"3
MDYBMTTKFA;&M,\-U1COM1C*!K(U2 =B,(4HJ==-=G85-F!;&XLX2UQG88163
MS%I$ES6R\;5L>W5&XQ()641N0BWK5W!]U.]V,5XME=Q(DZMEC! DWY)10H[_
ME8\:^,<L#(;2A.'F^8%P-M;51$8*0 8SGAA:MP55115)=2MS*K;YUO5V(9R!
M(0VYJ.!-78P$0!GMG8E1")>]5VA#4XI1OP0AXW=(H].3132BQ+&'$25[- :$
M*,A65$JMA!71EY06P(C>#GPS*BCT;#LE)5,'+[6R4=<MSQ1F(X7P&!; @-X:
M?#,PGM)G#BBD3T8$<#$$U,Y2).+?2.B%4*$,WJ#SWT6TG<4@.SRA4W2VCF9X
M&\@K2Z)H$PPL0,Q_.^C-JA8[H4)PZ*.%[!*+E60ER5!"T-S "V Z;PN]&5C.
MS+A84MRKC 8O$@<,;$5SLMRX(4\V:FR Y5R J<P_\A:?J>1X1F^H=TSC573Z
M]8HT>M$9[9^]X2+ZDI@*J.2TA$00,:!AOU(72M*&2% 3%OE?\GDN^3RC"AV7
M38[%%HP9*'N62/67I'W2*!N3-U_R>1[Y/(M(#5U-:G&$)C/4)5VS*:8(Z;S4
M4CALNMY8B'E%BT;U&4D1S8&0DDD%;< !JQ$C;!$B<J#D031AB8PEU9M&]5G-
MZ6-"4UT1VD4P.GH._9-UU@N1'.@F;"^]I'H#J3Z+PK.4E=449#+,>B\0H\8L
MP&;G1)0+)6!N=UV-)=/G2[_DDLAIA8), .,UDI%.JA*9]JS9&Y]*63)]_I@^
MHW+PY#D8=<)I1ZQC=$ G(WGKG9+!"K%(\F7)]+EA^@S42W&V;AP 0F0%2"Y*
M)G@*.6IMI?9-*9O_/--3&E#N3P1ZW9]E0G+*2X[_-+I%>LK!Y&BE<&#9B@?A
M(\>E_']MM,;&ZY8EQ^>(X[-1+$X43RS"R10-N2AOG3<N6%]R-E*;QBN6)<?G
MB^.S*$W)N1B=A4DY002)IO@20DP R2;7^-*4A5J^:-$H/Z,A(QG1LS4W@*YN
M1AHL2W.,UD$4VKNF3,594KZ)E)^-D@G*%:NBPJ@,Y"Q#3MD6#DN#+#*)IDQ=
M6E*^H92?@;!!CD,S43:0/&AE:CE KDO]*B=]T4U8-:]2_GP_UB?4WQO@T7XG
M87<"[GCR\^#T_O/MQ?+/**/(*$51+$A]C#ZK "(&8] F04U8#V[FR,UJKP\M
M$+*@Z"V[&0Q*Q,PAM&4D<\*FS%*8-7(SL):)/#F&#6S,H&T,(;/Q5(0F0Z;0
ME/6ROH!</;QV/.@?+>1Z9\6%0#$EXT*"#"$44K5T68#0UC5BP[XYP6\VEE/Y
MG.O* I2X_QD%:!P+%@K12"6I,0)]/O";@?UT0GN6E9B2<! 2H8_%8I F62E2
M:<*>KU?T?'_\N5B6,SA5K Q6^P#@0]T(Q.=@@^->&,K9JAY-MIPWC]R,YL0:
M"2EC5B8EX"#!*PX7K!'>!63+N4!J\T:1F\E* M9+#=8;D4""BB)E79R5LJA@
MBWNU/J^ G254_L;N\3CM\G[AL95>?D9#&KRAX4?;JS_:Q\$>14ROZTGGRY8]
M[@_^'/0/CT9_XFE]_/7[Q4Z/\>1S/P7O[,AW@&?JP@$01)$R05+<M+&H$ITV
M&(/RL&#@G9_S^'WJ\=& <H<!)!IB+S_J,X KPV&G-FFZ 7ES(S *EI<J" +,
M!31:).62!K))HHT^+S",TU4(GG&7'-W$@H$W@Y>0W.E\D#X!4,E>.M(EVR@"
M2Q@3&J!3FF4\9R]PB*,*E]C>BKH O2"VL46YZ$SPDO_2HD(^!R9W]N ;[XL:
M[Q-!KNXOB\F L#6H3$)&W82X9.X-]>Q1]LE0)IF"+!Z\]%$XKW.L.U,*,-)7
M+[Q X,Z!$OX8O!]PR2"B0>UM*2R(I<!(SDLB&<FJZ (L&'AS8)9O!D9)L>28
M@ZXE05JSQBID<[&9=-+1+C",MZ>$KQ$OA2X5E-&A*Q"Y ^;D;$I>BJSKG(L&
MY%J;93QGGZ1ET1,<L7]D403>Q&BAU)5ZZGR:("8+]"PBY'-@<F<//@->?#&:
M;7,$+#K&S#[769.S5]HW8='FN3?4LT<Y :D,M<@GU=T-? S9)"V]2 FU->.<
M\ *!.P]*^"/P?L E,UC6^1BE#74,)O"_AF/7HM$0>8T+!MX<F.4;@1&3-XER
ME"RFZIZL& NY(J4H$HJ+98%AO$4E?(UX"2-54D9C2>!(8@#"#"I2%E$1-<@S
M5FBVRLI@4'<9K==>OBW%&_K@E+>=T?Y5EC9LI#_4 !S8$/L^"0 * SJ7?3:J
MI&A)C56/M&>CV[:NI+_$]MNS?O;JX]^V)@CUM2SZHFK%B1):9@6)8QN;C1"%
MD*Q-D&*#<KOSC.U,,KJ:<C$IFSHX#BHD#*6&J59E$TOTN@%5*<W =A;[L)62
MB]89,EMGXFA%><PRDPZL<:,W\Z^/Y@S2ZU)%Q[W.!**$^;SI#PF'QP-ZT!GV
M04EW_]'*ZMGE9X?.?J_77XJX="9)9=@J*X)$,=A  I0'=$54Q.=?88VQ?=8_
MQ>[H=(?O\ 'BCSL][-;/?G1&VF7[PW=Z5]@?OJG$G;T^M&18%@AC-3H@P&A1
MF2*2Q,*?^;)DYF>9B2=+9MX@,TLL1$+;Z-A+8G&8BE=UYQ,P5KC2!&9^?J^:
M,]2?\B>]X=<2.TL2?7>(%*.K6VQ*H@11BQ"1?_&F@",'M@FU3TL2S3H6<\&+
M8-!(1 M$(10D9^H(?S$B%]^ 6&Q)HED'?2%J5#9@8:L#-D-$<)[_D'9.)=N4
M%9*^3*+IAS\!B68U/Q?1RQRT8W>FK/0LV@4DDUTNRF!3UC18DFB6[BP)\,DZ
M3S9PP,<VR9(V+CDC(5"139GPMB31+-V9!1?K#KXJ)V(ZU2E FD#$[%!:KWZ.
MF<HW3I\=?$T9%]&345:9HO)>" O9"R2D)&P040J1Q,\PYKRXX ;/$9,TAD,E
M#:KD",(#&J^)I,DP6?'6G7D8MXB#SK<!KG17M_SNVD:=+7J@@L5G"1"\]40D
M4!9M!4'(8G%'KVX*TQLIZBDD79 TWAL#HI1>VVA8XD%D\^H;L5'[O.(U>PGO
M-#A98@A!9A ZHB#K<W9*,.S1-&$3E(: .P-I#<DQA"%*'1-0X&@_E JR+,*D
MT AI-+\#N5>BS5??X@M#CNN]SJB#W464=22TB[[N+I8=A)A"]1X06+A+'Y1J
MP@R*^1W'71+S!R:Y.^FCRXE29F7#XC0Y]*8&'4G$HII07K.DSPSG#)'Q(A(&
MK!&,8_H02,DJV?BLO6["1EL_=W76XF92E$U.2DR)T$(.)N8LT0KPL8K#X);4
M7 2WWDAJ9K(Z6 G%<PS*O(M9V8)&@ZUE$@$:0,W&5$4L+HND("7!U;+36J!%
MP46*N2[-D&/TZ!N0IEJR:.;Y,!O8&6*Q"9,"YA(6YS&%6*0A_J<)LV66+)IY
MXLT$+44I 8P0P((+%82HRG@V.I!I0AS0F,*(Q?5H6942A6%7!@642\$9*>K^
MMD$@QY9R(3S:3\2B&6VU5H2U2H0B@P$G38A"0DH:9'3,';40'NWG8M$,/!I+
MH1A#1$MLC60LP=H25?0Q1Y<L-:'H^$? '59TGW3QI+]]R#_]N]OI+>325EGK
M4A<99&=#==\LKV5049$$+T*PI@$NIUDPS\8GH.3NFXV)8 )8X;U(V@#W:O8/
M)%,3YJ$T#N99&&UC-.B8428 1XC$02U9B8FR--B$TMH?]<A/J,<_4=I?1&N=
M(",$EG-LIR'5$GSC/$3K./1$?J<%M]:WB.^,UMO7FNH HHY@(48VTR:'DJ6F
M)#3FM.!F^G;QG<74AY0*D,C@M0=-,=2I?4C6$0#+:]D ^SP&D&.STAEM[^.@
MT]NKHW ?;H7]R<&MKSK;16'5C+R"#4IJ0W4.!$2@4(Q61D;)0L"2Q<5DU<[;
M?E-8]=47^>[ZB$;R5=:)@QB*$Y'C$56WRY-.YRQ4,#JK)E2I?@]?]P>TM(,W
MR2L+'/L4+VPD!T(Y;W0H4K.>XH^T7?)J]KSZ+DMXI7*<1C)60':Z1"=S2H Q
M(H=V3F&T6BN5=%X\O=_OK>PQ7\]XLXJ=3MKO;&/O]>G7W'DC%;^(D@$U')\+
M"]H@YF)*"'69:^WQ;#!FD2+VF2(\BVW2G+ &3+;6!\@ZLQ;/("0%K5';O#A+
M<MXNL#<RLS%0S)KX#QJ"I(HO)6N5 V;-"$K; (7P^:'1,5X;ZYN;:P^?;=VR
M()A=IY]1<;4!2+9$#F,BH"VH'=F$6I(5+L<FK)^])-(\>(^ZNZ80IN0B XA$
M=8Z<M*J$F"U;J2;M*S7W",](XP>-)@LG<D(@8G4/$8TG%TCXY#Z:8<;_%:KA
M"%^(#E\PQH]PA%V:IXWA1%ORV>H:X,W)U0V11<!HP(/'J#V#&^M.&2S[)[M&
M+5']_DT;+P#U ]J/5$K%>#361!!@&"L?;; PWM[$VI^@'VX^7-O9IP$>T?&H
MD^9H$[?KZXY1R>BTL!$+ 4CNBTJ28_/KV:7JL^V,E^#.L%>>;Y5P-*@+IQU^
MLEW"^*M.#Y[=X\K[):!"0"5MS.  1?(9BM>@2TK.&QH30 ;A&K]NU <ZJL*_
M<CSH[%&/QAOYO:'!Z0ZE_5Z_V]_KT/!IY[ SHGSYU3?)%!G:PGVP>-0/V&\;
MA$0E*$D.N;)56!*EZ*P*5AA9)MO1,["37.D2X1M%^$+@-,;X:HG5C^CP(Z4R
M,M>J-HRDN:=KYX5@>X\N!PZDI+2+F':[419\];UO<VCF9K)_QI")T0FDND=H
M]$FQ'6&)4#1K!5R<Y>?FFC(W5==P,Y3Q.K.@,,': !RQH[0N07'>ZRA8:DR=
MCCES.F;1G,XZ-T<G?2@LUWOI[LT[%'-UAV*NQZ&DD$V(!;-R-4/# 836A,$K
M7PQ'$'%1K<-M(7PC_5-%7;(4R,:<('K/X;P2CCR+0P5)S[$*F"39.UT:COH]
MVHH'E,9!W7O(5ND-=?M'8R#K#L)[QUT<]0>GYQ?-LNACS)S>&^H-FK*JJ9;%
M X+7.AL(MF A76>T"4L$N1%S([[.F96<.[6'8_?G9<_L4_[2%RI9>$,Z5>TP
MKN/7TEA;# 8IFVR5ID.&C_J'AS1('>QVWHU]RL+2Z4:,$<3",6M4+#,X] C*
M"^TH.X.218=2>B&,T7F\P9RI1Q>6(K.W.%XF04(YZPW'*39[9X%E*Z!+%IUH
MPIS_'T5W>T2'VZ<]&NR=+F(A(9I(GHT$4F*E*\FK:CZ2<(9CE6Q3DWW*X\Y@
M.)HZEIW^,\*TOX&#US1SBW&CG+H1QR(=ZPYIE08AP$L.B*Q6I=C AL 7$>:7
M)F=8U94=>U58K',K#([?HW5VPGOI\2='K%]; ')>@'%8K)-*! ,1:K6WLOR;
M==8B*.MA(8 9'-5^1 _[O;Q-Z7C L0C=[$CD-0(D0Q8:E7;HP=9J? EU^KS(
M6L5H%P&@Y]L[@_$XZBF'A$^J-.O=] #@-0)D=,ZAKD!#UH+TJ<YMI/&0H,Q@
MU1SG>JX,T,9QC^]PA-W:@YK2<41.)KEQ15L H;./1?O <2]:"=XV8%CEZY8-
MAS<P8^Y&T+ Q2Q'!%Y<31Y8N2!UD,DA.)95$ ]+87^\E+"-/)P+Q\7%S^DG1
M(BH?1*:,($T.P00ER6#.J@1%"X#,(QK49R36 ,.MLDI'_6&G*>Y%8RS1!HVH
M 1@?%FKL;8JQQOM"MDPJQ^:QDG\NE?-')?(_,@;K$+02609CZI;%(4L.>@LD
M&\#*J3!K.C"WKYRO#R"3!0J()#G2!&-2B$;))(-*)G,,:A< H%DHY^L#2$KK
MO$PV%I$!C8A.9UEL2<:'(G1< (!N7*%='QJ %E%F%<:+M2%XUF<4?!:J+L-H
MS0*@<:L*[?J00<EP)$P)2P 7?;"H--0=*;2#8O,"('/["NV'X#FO%>_TWM!P
M5)]_>;GX^^-G=[IZQ7C1'!MA,2XA%&-"E$8IZ83-P@M8"%W^3<+OZL_%SN!O
M[![3P]/S'__%WP0':?_T:2U N/@:YR>M]XZ.1\/Q&?(&7F9C GUMA\<#^N\Q
M]=+I9][D@U.'SZKPJLNJ-"1B02&-BZ1+"A:,A)C8IWB.8IQW[-IQ2=R;)*Y:
M$O=[B>M+LJB]=UHKR,ZAU\5G$UR14GGME\1=<N6\+%<08K DE(\@C(Z2"GE7
M(HH4G'0-X,I<><F;244L"?SYA'Q)RH),D7G,L1YX*I*],ZM-[4WPBY"0OSW.
M++WU#,;W;$ (Y(N)!,)GKQ"1A:=$ZV3 .:X\FD,"_R2<R1R;.%,SC2&"*C)P
M(%TH!NGJ6 HUP>@URFM_7WYZ2>#/Q]:094Q62Y$#$ 3D'PJ"L%I[R=%* P@\
M/YQ9>NU95.6$0AQC,W$+,+VJU[;!)A*A[BVAE@1><N9CSBA!V4BC/20'2J80
M1-3(DB_&;$58A.+A;ZJP:ZA8^.EX*^H6SEY@<3I!I,B4=1F-8M$IG)5ER=NE
MCYY'WMHDBC96$7H#:,$C::US,$X'A7H1*F=OG+<_"56<U:$4Z7UFJH"-$2AJ
MCE&$IHP)<P.HLO21,YUQG T5J3+SID"!%'5)!F0VT6B,T(3I+4MG-=/@ #.8
MXK6VM4@J>A995E@5"5026C:A3.:GP\RAS$4H)Y3W #KSK[ED4@*45W$A2IN^
ML=1PZ:Z:P=R@R.HD#),UU%4,(FD5HE8)A/ LFY?,7?K)^61N77<Z*U]D)F*3
MJWT(+CM3%(I0<"&F0]X"<W\2L@1OE3'%*,?J"JU'R7I*.ATIAR"78=W<$NCZ
M.E.3YTQZDWS2$$04AH,#\"YS7)"UIIBME_KGH&\#G>62ON,IOZ9.BT/AC"\@
M)/HD =!0B:Z0$4VH;%HRYG;%G?31%)$,Q0BZU#7$G56Q6,D_UT5$%V"&V/Q.
MN6B@3O@QXE[?U,88/80B66>"!8C%YY23C0:T=LI&L23N4B',)7%!9 ^$-IDR
MWK0A6.N*%8HU9@9#>DG<)5?.JXZ=E*$4RD)**++6@2@+*<60$AIHPCH'<^4E
MEV7SMTS@$G3=#C9X4FSLC*SSW#1(!\$75IJ+L0;1<J[0XA(X)1.C<  Y$&#V
MR*&TB]&(6MP$U 0+/#\$_DDXHT-49)*.0N:Z?)2WX)+(Y,<3B(QO &<:Y;67
M9?/73& O K"+SDFF KH@^@P(K#DYM*Y;SC2 P//#F:77GD'<I"1DI9A8K#95
M9!<.MCA0!0-S62["NE=+HW?=:Z6A-L';DG5"T-&C0E(B)[(YF.":P)FY\MH_
M'8% *#8[9*)-&8(BM"!(>31U4,5/:Q,7GD!+K_7]Q:VIKM*(TB0%[*M<#$D;
M$^H6X)H(FS"D\=-AEDT Z6,,V4F(P$Z$;$DH70K"YR ;@-D<%,<MW=4,](X.
MEIF;V$<!2++(BEDD"2R"C-<Q+)F[])/SR=RB)$GAM/<6P!.&F%TV)%#K7&)9
MA!'4G[T@^?K(8HUA\(+Q@0P 1DQ)4:KKB&@M03=+5/U,?O+Z.E/#E@B_N--!
M,D8&\C8:Y*#21DE)"BL4*&O!+8/*)7WGF;Y6D8Q6E91962:T&(J6V>0020BC
MFC#^OV3,[0ZX8[+292UE .#_!"$HD]'.08R*&K#,UT/L,CRTO4\T>MI/X\WD
M+^(SWK=[U!\T9R]1BQZ3$,4@)4BI[O)>4$21@S;6R@:HJ/E!Y1K':;4'*Y-B
M  1X$]!%(N4U2BT\R0;,S/P\*N--4+9&^S1XVN_MC6APN#(<TJ@I'<9#S'R_
MC"8D4$8C&&.UD(R0R[$).^_,&337V&NL8/N%C UX<.!"9A]3)S(GI0@$O%J=
M0@/M>>\^?P[Z_,5'IW\R5*.57E[[[W'GJ-[CX6G=(?ZB?7O*FH3V^]V\?G@T
MZ+^9B)/KQXQQ&8Q667J\1PW.[W-^[+P]\]FI'_6]LR/? 7 L-A6A(215U\N#
M2!ESR#5@8H.9Y?R;Q7G$]68F+$;//1"U$@6@$*"K$Q4U.,W:CP_,OYF<<ZBN
M<7@[ _>HZ!P* )MMT"7;I!D^BJA$7C2S.?9RC_J'1\?LX<[/X+.W^V7T%@>T
MB*;3%0'!8P@&%0@1(\M]"0(I2$5"-V!SFGG%]F;6B241L^;P&"-!MB[R'Z5"
M$,GJ9)I0,=  N*ZU6$":X-C;J0)>*13&^>"U*UD:"F;13.AYPNIXT.N,C@?$
M)S[NG-2?%E)X<L?ST2BKM3+@1!V@S!*3XT](26C '@MS".O-K/T8N)]Q5& #
M"9:9/M8%V5(,(%+04C9@R^+Y1NKZ;";).F0KD,5( <U2,U!U>4[GY+7Q8=%L
MYMC7/<589V3U!Z?GYRRBO;3%R:P)BN707$;VCBH0RN(RB:Q2 ]9$G#-(;V:A
M997JNG\0C14@BO+\BPL.#!M-+6(#2ASG%Z5KG'0H9=*L-@SHP*$ZUDV=5/9>
MI3H11BU:TNM1?SSVF6I6>KW'E^ZQ2VN*^B!2;/4LIEP4: X%K U9<1QGM2K)
MN07I43/$ZAK7&5)&^#KC.T<'F<,U);A/,5SDD:/M)NF/]5[J']+VB+UUO?+R
M4=!G-*1:FL.@KM;2F_X8UK63([[;0J:\O*J%HY@%9C:</F))J#3K$DD<'9@Q
MP-)+I4)[WGOEO ,L?5NJM@I7 ?BC'OPCPT%9IL3",OIJ;;/R4>JHL\B)@PIA
M<0)P[;CM*=)^"?!W WRA6WX!X"D7_'6D7;P%Y=!D730$GX--=3^9&+.1N9!:
M-!.]3=UNI[?WA'HTP"[#O)(/.[T.^U@^^0U-D5[(#!M EC*(:),VD+2,J@[H
M1J]*S)0(%\U8SP74LS';+B8B5L/$46?=(R'X$H0R47H#V=JT:&9[7J">@0'7
M0D86V1:,0$B%,)< !7UD2YZ@4>,B*V]QD#\-@=8.C[K]4V(.]-/KK:.*_B*:
M9V^PN"*#"PFA+KL1Z[0;#!B4995-#3+/\P+D;(RO#."#%=F8NE>XR5[+.L_9
M0PR"T2P-,KYS!.0,3"L%:ZP'Z3Q&2#G%E*/0PF.2V19AFV]:.=P9#3II1'D,
MY?->9S1\MOU\$<UKD=: C4AU#ZD2=,Q**VE,0(951=5\\SH3,&=C8CWXDH,P
MRA4%;#]16:G)"W+DZJ(?S3>QLP)S%F86)3%8$#S'I9#931J6/MYJ[XW3DV"E
MV6;V3QJ4_N!P,B4 %[2 AY&3* L%X1('( Z+45 $\H_!27+--["W#.-L3"M0
MG2GMG''D00L7=4Y%E1*!#+\2-=^TWCZ,,S"JL02&#35FA2!5\*Q_LA;*ZQP4
M49.&WJX2A"RB08V9./JP!,5(8+43C(D)%"HJA?%: (-ZBQ#.QIAJ[S('D:Z8
MI,&Y$+)7F8JSEE3TIDEYV+F <";YU92\*S:CKY5<Q*@E75.KAIO8R3-#:I@U
M9S_<-(3?8;T,O]P5J?_AJ3\2;Q<32!=0/B3( J.TR&&W@FRUS!,=L4 .Z$I9
ML"L_\<D N2G'HQ['PX^&.JID>8A#RG_BZ7@JQX!/WAL/CIR]T2)Z0[")0O &
MO!-@T,98BHS66!.CL4DVB$_?B>YFOT=7 _CVF=U(2OGHLPG)F>05A(@>,BE@
MR>P=_S?HQ:?4%0W&C_+I)THS0\B$M@0G$U/)IL#_Y$JLF$+R'A>?4[=GIGXB
M6F%*68"/+DH#697 /D^1*63J-&/?@-5J9A,_W,RD#@<I@PPB"PDE!BS99>$R
M!^S:F)+FOP1]YF!<X](*4)0)*FDL$9(4'HU1F:-L1:'8R7R 963])3 ^#I9_
M (Q 5EGIA-8^@TC6 SK)>BH86^JDP\4P4S>EB&]HF8-LV29)R)*#<3!UK#2G
M+%G?>IF+;&X*:CSI[.-D_@2;X9_;6XN8C+):)*$# ?<RJ.LR!X\9(*(1N5AL
MP.K=LY9R-S//.F63G(O@L0!&'42=$!]1U)P]I=!8LS<+6*Y1I_F2<S&E+ET.
MV:M@N.-X9&2D20E48WO++8Q@WLRV&>2"=74Q;I?9$\F0)>JZA@3(6NT1&]M/
M;A>0:UR:-GB72!=%@L6S-9'E&A00J"V4$INT+ME5Q,'P4;?3ZR3L[@PZV&7C
M=MQ=S%4<@6V<Y1YF;!" &+P(ULL2/7I?6"PT=^CX<EQ7TGZ'WE!^2/PYK5(:
MWT[+^N46<5P9LHW@BA?CS?%*]L5;EUG9HP=AB_V)\/W:[AR-Q->!X-!9LYQ,
M@G6^P&RD3DH4*Y+/=HX7<A_C]V'*>/S!&7XWG!!NK!M&(I0A<4!G@<GM:THK
M*:G 1V43-@WN/P?]B+%[T_G_IL+- $<=21M;"D2?:GFL<BE$1&$EF:;!O=D?
M+1'_\I)Y*I/6*8:" -;:H"6[[ZBB1L%!*LTOXA>GX>[@R<KQ:+\_X%?[> .(
M$0UZ552_H=XQ;=/@#?-\_=EV0Q 219(%49<^3Y "^E2KUQU'1,#Q*C8@-/T:
M0N,IU"N]7&=0=_\X'G2&N9,:E,B..:L I*AF<Z16T4<C&"G)!E3&;.<?(<;F
MT8!R9_0(!X-3-F35R%V^_LAUV=%%)X53/N;B%<1$0!H]V53WQT(E3$F^255A
M*WR'W.D>UP4+MNNV5YU1AX9K)ZE[G"D_'O0/)ZLXCY<_V"IK..AU>GM#=HF3
M:HS3RV_P,=[]]+K>AY\^OE%=A&P1,R"1A90JPN8< A2C8T''OPF7V?M:G9H4
M(2\H,6836B=MF6<)9(R&M1AYX44P 37P1Q9#D\9#%Y<8MS.V>MSK3%@Q_&\9
MG:-\.-E_\,'Q:'"_'CB[^.SSL]_KU9>K?<=8>YW(UG+2:#![+(J2H623\G,\
M'#A9Q[5NM/)!0=^'H=Z_"/-_CQD.&@S'YS5$)U@G=&% I+8>E#(1A-4874X@
MC+(PA<3^!)!\]8G#P>C^^7I+VXEZR,T\>>#XT/23Q_T!)1S>^$K,]KL9<-Z]
M!]2CM]A]U1\7AWS2T<?->/&<;^[SUACE5-$Q88)HR.<(SOL2V*] B4U81V\>
M.O_LA2,@1Q'@8TP>P5- M 4Q6@NF$(GQ6M R"*F7^'VQZ\I0(='78;Q- )6-
M18$F@7,2+6&1X%&R.DN3]+@,K.";!\G#XTYWM-/?/NZ,;@,1*:X'$>><2A)=
M2*X INAM\24B92]JX#4I*F1$)B)Z"<T5-.\8G*MIWH]P_$[->SS,-1+X4/GF
MSAMNT@_/W#P^I/&:_A_[S,ZP#TJZ^\^W5[_D*S^YOGZX2KW^8:=WV6VOHKDO
M7'[OXIM_S4V3RM%8BDI*![ZNC6 4&Y.HM$@H? ,2\9,,XF-,G>YEV;Q>CJ=/
M:51-_%:9G-L4B<ZM97.=(UR+E<EX$X-!P0;?HPDYS'^UWIQ!<WUU>S*@<3:%
MG)T&J01"MNB#1>6]*/$L>II#371CT#0MBKHF*>:*+B;;A!D54$F^SKUQWOA,
M2ICTT?1&(>#F>^L-1A5\*EQ/UI'06*4L))\39*>"TCI2=3^E8"ENVFYPUFYN
M+ML-KMYN[GK:34G%L5<TIJC:;AF%CAE#W8,<I75G?'/3=F/%J>:PW=R5VZUJ
M0'4-[1;JVQOGM1NG(S Z[J?\ *^]+MI.ER[EYM*WEH[X]G:KC:&OTF[7%_TG
M3=Q&)8,1J>[;A1:=Y'#39&U,Q(N%LS((K<*<M=LWC*K4$%U_<.J/3$SB7NE3
M2L6Q":MKCJFZ0JZ/LM2RILFT]]I<6DS:S=[\J,JW!V#<&/HJJ^344^WU3.@J
M*(L$[9+C>(1L]+G.D)!)NSR>7CQM-WO&-W:V<]AN]NI\X^_AOK7=[G5.[@]H
MV#\>)!I.?MTGS..7Y<#OP>_\SY2&/A;^?S2QYHRD"RH:)R6""!1*R:^JE7M_
MS7!TVN5VXF"RO4^=O?W1?6V/1K^][>31_GTVCO_?G8OGX6"/3QWUC^X'/JV^
M7!N[G;W>?19SK!WY[%$M@CL[/_8'_)+MU.]V\6A(]\]^^"UWAD==/&4AUNWT
MJ#V^Z+?IW6-_-.H?WC?\@#<T&-79"M.'C)\W.?S^%>^*R6N.N#%&^>S)T\-W
MQX?NC?*GQ[2ZRQ+DLX?%7?G98[.Z+5SIMO?&+3%I#6[PX1&R&-=WSBXXPIP[
MO;W[ZNBD)2^"V*7R29M/FGM"@P>_UYN=W8COW1_<_Y_:ETKYK3!7VP4/.]W3
M^__G$5\;!YW_\X\A]H;M(;-Z>L*P\X[N>W[J^+>W$\J!$+^-:3"E8.7=Y+4R
MI;JA(H<3]X][S*1Z%K\*SOH56OL#*O^\\S]?[VYLK';&/:)?6H]J=^Z-AK_?
M0T:I-N595SS#] MPB0K6G6\_=<R&>^,.=OZTC[O_9?WX,TAS.WU#,TOXJ)W=
MQ^VL*N6?;Z[OK*VVMG=6=M:V+[;,'+WE]MJCY\_6=];7MELKFZNMM?\\^M?*
MYI.UUJ.MC8WU[>WUK<T9O+JXTJN_P.$^,V/4[_VCM7KWT=T6AZH0/ONZ5S#S
MDROCX-Z#'[G+#SB+CUU#_^C,)81PUXAQ!_B,2[C0CRX<#.ZN,Y\__,5KK^W&
M4_M]=L89D'[RE2[M^=.FFWI.[OVM8;_;R:TS1DV/5R@^/?B-#N&PDW.7/JL+
MU,4[#.K+WUY''4N!QUO/-EI7-K#SU7:WW%2_LY+L]7OC08I.:DT%Y[/JW#I(
M'HVL.[D$ 26IJ+ HGZ7*/KGS"/KB@'ZKAU5W9^K<7^VGXYJJJW,8[DS$:=9_
MG\;5_INGZMF;7;UQG _6WKQ\$@ZV#G9A][#^?=G9?+$NMW;^.MW826;C<%UN
MOEL[V=WYZ^W6B^?FY>'+UT_U9G?W75]M/?GCL/[=/?B[L[GS6FP<K.FMG3_X
MYW2R\6)-;*QVNULO^(K'_N2I>GFZ^R+9K9T-O:'6Y89ZO+_Q;M=LKFZ<O#QX
MK5X>/N?/ULWNX1IL[O";[:R\R4\>=^*3YW:#[[^U\["S^^[9ZXW5#;&Y^EQM
MK.Z9K9UTNGGPL/ORR7/)[_Z.WW5ZS=_\+--[N=,_Y>]B-I[\<;#YY*^W&^_^
M$GSOMUNKK\WFNW6U\>3OUR]W_NZ\/-@XW>WZMT]WUD8;V^+DZ<[**Q N:U*Z
M[02'/2"]:H=,L:T=ATK!0EU3X<X#*=K_'H<"[P&\3%9<(@ ^:Z2_Q[!?%V/]
M7?,U4:9NA++C^30COIJ[+D>)K'C[W8C=;G\4^R>7,7JEUSNN\SR.^H-1(YG]
M-^1__=%]J;IOXD'?;+Q+[W8/GK_;?;'V;O. G_?N\>'6#M]_AS\[Z'9V=_;D
MY@$_^[%_5]_AE:F9QY UA[W:M\';V [<Y.VB-99L"S<V1YG_^W^" _O;QPP]
M-\PW1)K+!=#*YN;SE:>M9VM_;CW;:?WY_-GV\Y7-G=;.5HM5W0Y+MY;4K:UG
M+6E^R;^VMAZW=OZUUOI \)V+O95'._6P#!J^K/8ZO9I1.'/;M]I#'O<'K=$^
MM4IGR*ZG=4HX:!&_3F[=9-^YG^M0#]]Q/^-I?2;U+NL\?XY3'&N3Q,?/U7M.
MMG9V7WEVO*BX\X2(L@TEAW80P;.I+^23UT:2OUDC=P&HBR ].AXP;*/'8^+L
M,H8_+TXAV8Q)EW8TRK2!1&D'*M3..A):4$4J]L%_(+N"P>G__A]IQ6_R8UOW
MCU8%X,L^^@.[,163[:H<QX;C3%ZV!^<AP*=AU&\?FIMV3=_=MKWI#ZXB%?2W
MO-@+_M;UFP\;+Q9V!OS^G9H_^ED%P^DKK4T).;-,2)G:H#RUO2?5)DHZ%#9_
M0<%4,,"<"(:=9RN;V^MC9?!SB8;1.5];D]&(5AGT#UL7_XSZK<O^W)9ENUI\
M,HWH[1<R6+=&IT?]P\/.L-;%M!YWNM1B<D<:W+]^0?;> *V-AZ_JTR8/^\D,
M#[_[*\E"RX#-'#@;S8$*N^]@96I+XTMR02INM?%@8%L+I<UG+<^\I#:5@+OB
M.U.;3)&S:[\W!0GNZRG(+Z?)SD8FOI(:[QSNM8:#-"E1/B?WJSUY]^!H[TX+
MNZ//'?KHA</1R7>-*H(_.KES[],TRK=E9;^0')P:N,^E!V]S6./&3= SVAOO
M0]\;;?*11IJA22IP]]W^_H;:/=D]?':P^6[][>;JNME0?]04()N?EX>;[UX>
M\,]B]\7SCU*!1P=;3];XZ./.RR?\W(,5?L?7[W8/:PIPL[-YN*LW#S?YYV?[
M+__V-05XG@IT+AMRR;*%LK8-.:@VIB+; 2(DRBIDK^\\6/O/VM/U_ZQO_Z.U
MOOGH[F<#CB_P6/[ Z,*,>>ZN,)9[Y\$O:R>81F-RUK'8P3DI6SAL#8\HU>*/
MW.KT6IW1L)7VQY.$?OVTZ6XPDWI[0V3?7S4!_FX0GS_\O>4-WW#;[R]ON)R,
MYP4.MR4(;V;@Y>/ =%@KKX\&_3>5\1>S/!.S7!=&&1Q-:QO&==J/^L>]T>#T
M43\WV4IO[-3[;K"UW3!;3S9.-E?W#S8.]DXV#_+KER\V=!6(NP?/7F\<;'P\
M8',R_@[O-@\WWKV&W7=K@J\_W5I=4YOJ&7^'I#;?/>YL/N'O*NN S7LKG4RB
M4!*VH_>R79?G:?O(_S"07@2M0@(V=ZO4Q;<XH"_:YR6KOZ0E=O!D?5JIE\;$
M;7!L<]MT?3^^&*A$E2*+BI!3&XQR3%?AVQ#Y@.&8":7EN C:6AFGPR>!T66"
MHC',_8P\&%O 5G_0ZH_V:= Z^& EJ*H7.A]:R_%I@SWL==Z-?_^UB3WX,^VP
M?O?9W>V[K>EV'X/6Q>XV35Q\OR[ZWF*BF6=P;MRTK>0\H.%P^I^G_ *RD6;M
M!U(V[U9>28>&K/'M0-*U0;O"/C5@V[N<#1LCETJ^\T!Z(UO_P@'KX=9#/&W]
MB8/7;_'TZ@F<GX9.C_C'K<%._VWOIR/37Z]2IAB%PG;(PK1!U1$((6T;*0M?
MM^ E&^X\6.ERTV7\QZ?LN26,QJYG:_ GBW5V,\W4WC\"5'KEO;8"/+0A*,W_
M(+;196J3%*;DF$,Q+$@>K<P,HC_['$]U7W:.&AL<_< 0WNHXP'$A8FB+)*D-
M5N2V]YC;2GL5(QG (NX\"&#JW+W&&.%?;I ^U?"N# A_2L(\?Q6"]R8[W;8:
M;)NU)K69/J&-.F$NWD8EV?1:(SZFRZ\WV:?'B[S^N=_O_9QC8INKKU]E2UXY
MX]J"W5_MR;H=BU=M0 DQ!K(1XYT'7KLV]YE/T+G6L?API4YZI5$X?9.#O%]-
M,$^,R=15_*/&BMWC&NRUWG6.F+^9_M'"7FZ-J$M'E7RMWIA]'YZ);"JFIU[(
M3O_O__%*NM^&K:,!G]PYPFZ+3BB-%ZSD,SDNH^&O,V^AJQ89O%]B<_H5:4"Y
M=70\&![73/RHW^(S:IPY+:A2O\1?:WO4PH25-+H_;XGT$.YR)/)=LP_]W>##
MM>?1I;_KU.<O_>[9A_RV83'3\]\Z^7"G,YK,YB-,^ZW4Q>%P4;(_7_S: QS;
MJ>W3P]CO_C)<F)37E[[TYG2P< PUG:3]NDI:J]]KO=WO\"?O3=@U)40OFS+$
MQN;K!1.+DN2?^H=3J>*XGS52GTWR^B]WUF&3?]Y]L?[VY<%?)ZR]3G9?_-'9
M6DUF]]W#[N;!R^[NP6N]^4E>_ZB[<; G^-S]W8.'AYNK:V)KY_'^[B'?[UWW
M8./)<[5Y6.<D);4A+Q8+Y"!*H9C:.I34AF1UVR,ECJ4]...%##5Y5FO1F,/C
M9:U;_^]=1J/FSUI_8_>8:LU?:[PV]A5F%BWY_:W\GEK1B1%=DOL*Y'X_:.6I
M[G*18]M0\&V@D-HA1M76$+VP6>904Q"U$F9)W1NK*JA.\-."@C.SO39UD0VO
M\[H]=J^?LSN&F(14@>FL<AV(=>V@G6I;GW*2QCJ!EE48QT&;.,SXWZGYWL#!
M:QJUGCY]=,TS0:]MG.Y"$?<L9J=\>\RY]TTQYSR5F6_V>_1-R8 93CA8[^4Z
MJ$RM>-I*^\1DYA=\W>I,6OZ#^KS.L(6MM]3MME_W^F_Y!0F'_#TS'Q@>URP*
M#EN92J<W*=][=MRE"90@S!F0'Y" ,;T[.3[Y]\:'$%[PJ_^[OOGV],77Q^_=
M2 /Y0Q.!WKUR4EM(,K8+6=,&J3-K4VW:VFBLBZ>*%.'.@UT:?FS-+@#V;3G(
ME;K3=>MYKU.S:ZV-[1^D[?FTYF]ZB>N:SW;3DZ$N?^IF?VY:'GY;1/O6ZX_X
MD_\>=ZIK8H]4ZARAP7B^X/ +KDK70J3)[+/W#NN"<>.N-&==!WZNKG/CWN7O
M?O>X-\+!>*;78/CS>17Q*F@R$,&UI43V*J:.-1JCVLD[U-D[!:"J$;O<J<Q!
MG[!--VIO]VE<-?F19?M%_CIIXWV6:-6FY19VN^>&[4.+%VEZ M_X:T;N S%W
M%G%6PU</URFVK<Q'>WOC4X\&E&B<N)9J<K_QP@?#UB]\4PYN6\/CM-\:[O?K
M;(^S":^C?1Q]_%7>XO!3"SV^>/IM?IV,\?VB/OC*D>-D/BD>\!>J%XW/YROK
M^TQO-MYS8_PFX]?%X:@5Q.0.&4^'MZM4I\L_3":JUSS5>)_KG\ZD[)I7Z&1R
M'ET;E0P<CH-IHTVN;;%(2E$4I+@4JG/G;9="]<9M>K5K;-(..Z,16T+JLFD;
M]'LU*]H];=$;&IRVQCNA8QJ7**SB""=3WC^R]N_O\:&^K<%[:QJW/Z.]X^ZD
MZGR[O=/ZI4+K?FLIK>Z>1_:=\52]HSI5[W-FOW5-%G_RPN<VG(:_WFW=?/WA
M!VU9FW)JH7\^DZQ>::T,8BKM:*UJ@]-0)_/[=M&>LHV"R>V7)GEIDG\^DSQ.
MD';Y&U +4V*3/,!J5ZN1JMG1WJ6?MKB'M"\],#QD6\Y/&9S)0#9KA_SM3_]1
ME3@KUMI4>ZV]0?_M:/_LV%U6Y31^L7$J=KR S+#:Z%K IO@[?N;UQH?E;V>G
M??6$S[_<V8E5A4]/_LR[GIUY(5DL56RKLPCCP[#B[KP5G?W [&UE[BI]_55G
MZFZ0[B9JV6RX_EHV;@.C[0VT@5;J9MK S.NR_S<S!?'F![''RFIL7JJ1W>L/
M3B^;(#].J#V:GM!(Q74VPWAS?_-@3^T>;G8V#I[M;SY9U[OJ<9>O@5VUN?_R
MQ5I]WWJO3V<8JS6UM?JRLZO63S>?K(G=@WRP^^)O5FG[!_4>NSO/^3I^]X\F
MQ'OBWF PMVV$.IQM<MMKMK"0<\2Z<(FO*Q@_O=PIW%;]QK>6&UZ?)A&7I?ZN
M=0^(&VJ"Z^GA*^\1GSC?*>P_4E$ZKP##=P-\0P;]5I'>O$QD+H%>F)Z\/9'C
MDUY\KLDGOT[5]L*A/;LU92>Z9-SF#X^'_&+#9B;G;U67L![YZUR78%+6HTSM
M5!2V(13;#JA\N^Y$ZF,J7@CYV95H;]B0?^\.3S^'I5F[/)9?6I=KMBYG[?QD
MW,R/)JV\M#)?LS*G%ZQ,4"H+CGE"\ASS)!';,7K=-MYJD()D<70S5N8JU;US
MD> L-2_YF?Q<G1=[Q=JI.AHU'H-B;5F+J$;]UO%PDH?D;SC9].*2%:W[@_&S
MNJ?UX6\[_&A^;*M';VN&<T!O.L.Q5NUA+]7.S0JV+HU73Z[[AF<<Y#HAM_^F
MDR\O)6ZY7_#77]2OOSR\K&BA)A5;WYJ-7R;$OVV,<EIN,DT4UTE[-3&,HQ'5
ME1$K1@Q77>KS$'NX-Z[#.)]KC<,A2ZOZT1EZ5 J-!^&JYAJO!\97=FJ2M\>H
M5",]Z'=;?78E']#F?8YZ/*?PG!P@X(-YS=LXB,BW;6^==.ET7,CRBS2MYW>W
MZT9]3MDZ"?K7^L7??\MI"7OLLH?X@)RE,SB<C&4>\;.QGL1\'I=)Y_$;XW'N
MC*;O]?^S]R;.;2-)WNB_4M&S/2'MDFR2NNW=CJ IV>:T=:PD=\^^%R\F0*!(
MH@T"'!R2V7_]RZ.J4 !!B9)EB;2P\7W3ED0"=>2=O\QL?==I,'>KFH$[BGNX
MEBCNY3?R/G#&&ZEIOF'2R#&\']=T/>Z>_NGNG??^-3P\<D='W?WF7K?;;NX>
MM/>:1P>C'?B?87=WZ+H[(V?Y=*6U'2_PB(Q6,I%!H'6"V%J&\B\D;H![MM<7
M /O2MMT5GN@FFW3?!"'8^=?1T6['W>^TFSON[D%SUY,[S2$<97/H>8[G#@_D
MJ.O>:Y?56?L:'+NDTHQ:B*(8<L9CD&;XTY0+]&ZHN%H)J9N(M#7:(YB$5S^Z
M7):-B*-T+H!3"0M+6?H18D;A:0E)PRQEF&PL1V 'A*Y$2X913S[\ -J?VQ/@
MKXH/14A3@!#3) H\RN;38L%J 0M(#'V/;:3D"UH7]#!8,0&>"L^ABBNU%WK<
M4 6CA.?,]1\J6MA,HP2-#TR.!W,VP"7N!217%'IZ7-V_,VJ]_D;\AQ*7[PG_
M!&_/0I^%999X/Q6EYQ 'J3F.L[/?W=D=CO:/NH='($2/O/;1+OA<N_\:D/0\
M:(,3Y4G7GSI!\C\_M8MST<)LZD6I^O.B]+P@>^M]$#DI>&*P5$E/>$UB= [K
MV?O7Z&@7E).4S78;1]CM>MWFT<YHB T6P=7=W??:HYV??MUO[!P=-?;VNXW.
MKFD*I^_RUQ9B+(+, YI.L-U <@?=*.)+J.)5,P:X<@E"3&XGD;@%/EBU3=1S
M"P7/!XH'.S=!WOH% 32E]DUQQ=:!B5G^_B,+U'"Y'1HFIZ#AZ+W %X9. I82
M&?S$I?I,IL"&0T3B@%M#V,4)\#BCT2U94O56?@X."%07E*C^QPHU23>53*(L
M8'][B"(FA*]G_"+CN-.BT&ZS%B9F$3E6,F%Q%=TBX(@/B!R5D/_=P"?EOW8=
M[=+S[]2*\!>Y[X8?G$7 GW[ESDC4%8\)C4SEN*FZ _@0.VJ*X+1;1P&"X@-7
M @6M@T[B/G</Y+$H2RG.05J*OO5>#F-KT"$/-C3CJQ8E-+^O)*3=CB</#CH[
MGG=PN+M_>##L[.RV]]U=]_"H<] ^V",AW0$B[]A">G#V_D%BFMN;4'D\-3))
MSO/=O%:Y_1?XF'_]J[W7Z3J'W:/FH;=_!)ZE!YYE6^XU1^[1_J';'NV#XOSI
MUYU.IW%T>-38W^\L2.UOFHCUK)7PQ^?]SZ<G9]=7.!'G_/+B_+)W?7(LWOV?
MN#QY?W)Y<M8_V106?H89[4D^#$1Z[^:7VK*\AA>]"X"37AF[P#-V_R5W.K+3
M/72:N_NC47/W4!XV#_>[W2:8E=W1WI'<WP4S1TB0*#,,L( *_.G7OHQ3QT=-
M%QL$[!*)JW&R-VBX1U_G@B:VD"ZSZ^&,\K$"R&BE&XBJ-5JP4$F15T]T=GL-
MTM;P,\5:@'A/P41@DZ*#X7:DJE#IU@IU9Q:-GQ<\_UR<2DF."VR1I.T$G JT
M9D#F6N,28 L3("9X1<%E\4-8XP58^F(P&)A:#O7D2Q.S?0]R7^"@^^5#K<K<
M:TUF>PL&!P7^W\02S^)&YA#:GXNM>U07CW;^%6<(7A+X6DN_4B7R%ON<5/5+
ML?\7'TB\M7\X','_&^X-]\"^[AP<=8=[!YV.L]L^DD>CD?>O@Y_T=R9QG@D:
MR^8PELX7\!+1:W*"6V>>X.PZ>Z6P3'4L>S@4;K4=+9=SH]&#Y-P*4NZN+GS_
M[;ST$L0D1FG[MY7NZ)H@WT#1?134(%O_^Q>G\OZ?HW%4I[V2MBS/CUNUN<\S
M+[-W=O:Y]TD/Y#T_$^_/+T])/*SMD@=GQR?__($J" Y;AWNKX=$?\M2#[],-
M%Q>[&M)_K;&6*V(0[7CMVJ)]GG8O3SZ9\OONMKIIWP7H\/L;R!Z]1)?"AVG9
M^T7B/?UVGT#3?^L:5E?U.#KZHG=YS<0ZJ-#RWZL9\/?17]6L. "71 5]6D\O
M7 QM?B\*?&C'Y^]!@0]<PP,H<.>G7S4.> GYO7B?T_K^[KZ_G1]?;O1JP;%N
MA+?_TZ^7?O)%O'<H-54+C\V\P]W.CR\]WM728]TH[^BG7S^'L017ZT9ZXBIU
M1B.*0B\)=M6B9 ,N=._PAQ<EW5J2K!GA=;O@0L?1#,]4UJ)C0V]P[^B'%QT[
MM>A8-\+;^^G73W+L! ($B"NIV5\M03;T(E^!!-FM)<BZ$=[A3[^>PE?$E3.2
MZ5P<^XD;1$D6UY;(IE[GP^1(G5%;LXS:3J>04?OQ4VI[M5)8,RFRLPM*@4NV
ML$G Y2("4DW//%&54)<(+*0HF$% BE.L,N>"#\&SGL1%%KL3)V$(/G_7 G36
M^F8S*66__<.+J/U:1*T;X1W@3$/5\^2]:3:!W>%K.;*9U[G_X^?Q#FHYLF:$
MM]M&4V>A]PVZP1F7DZ#]T@N=8(Y5IE@$:(1-/PH][JB$G[F421:D])'SF>0E
MU3;-AI+$_H^/2#JH$4GK1GE[>S_]^K]8NN:G5*=%<@5^$>B?K>B<Z VC+-6C
MKQ''5,N:S;SQPQ_??SJL1<VZ$=[A3[_FELR5+KKE<,U5-IL%]+,3SVN?:H.O
M^/#']ZF.:MFR9H37V3GZZ=<^U>5C>U 2*6"Y..-8*B'S!Q;7][AEIX._ !^J
MEW?PQ"]8,1UC]-12:$.)H=-]!7*H]J?6CO9PXCDV((CA(DBJ$$S*J]$-&WR?
MKT*6U/4>ZT=[X*J?4YOF0<B-V.!1M139T)OL=!\4X:U14FN&DNKL'A9A4C\^
M3JK3KI7"NHF2O<Y/OQ[KWK8-<6*ZVI[KKK9H=?9U%SCQ 8=CH&-;^[*;>MT/
MU!R;*6KJ-B?K1WN[/_V:RQ><7R'#I#9"-_DZ7X4HJ0N.UX_V"#Q)N.NY.+\-
MP4Z9^#/JUJDZ][Z3H00#!L/O_'>R8W*@E$(\+45]UR)I0\FBT]W]\4527<B\
M=K2WW\[;AI-<0?0D"*6D(&FN<8@E=^$';XOSBNQ\B0&\=8:C+FO?:G,IX%5(
MG[H(>OUH;P=;L/BAZ\_ XK&0".^E&C1P)>,;WZW3AAM[O0\4+77 ?]T"_OO[
M'/ 7@]]_?!U1UT2OGQ YPOC;Q!_Z*=B>%=A9<>5.I)<%M9+8V/OM=/=^?-E2
M%S.O'>T=='_ZU0QY$E?9=.K$\UJ*;.A-=KK?V,FKC5?XTP]RWS^V57JP]].O
M5X,/9[WKSY<G5S7+;B++(AQLY\XBO%]HE)3^_>*8/9HG]^QC]E:[^Z<V)VB@
M5^<I1OGA[)AZEM^/.<OOQ>BU>@ =!PY>?&[OBJN]NCCI#WJ?Q-GY]8FX//G0
MNSP>G'W .7]_P#_%I_/SW_#GJ^O>]0F-]WW0QA:G<S[AONA);_P4/NZN($>N
MHJG4TV&3O B5!Y#C+UUGQB-DL35'M_W6'MC1H-]UWNJ_?<<^'OI-^ 'U-CUS
MR/Z3#!)YBX->L>QM^2Q7C><$6Q_'Q(ZB^-:)O68015\PZ)P?1$M<3V12.!K\
MPM!)I(</B[)8N%D<8_1!?IU)-W5T;BQ)LNE,_2"3U)_2M'M<Y"R._N0AM_ S
M-1' QPS5=N@C^ L@DRQ)XSG]P@]O<,Z!^!)&MWQ,6<C_CN%"X!59Z'+VSHSF
MC0@K/^*KXKGS4V>NYMC3PJ,IT-[<W%44%]YK?A_SA31$(&_@@/%B, 5X0YWG
MX(8(C(_3=.$!CCOQX5-\5#Q &#<>PS4'<^'Y(YJ\FXI1'$UAE7,QRM(LEH]_
M!YPZ?)>N Y8^G06^Q--JX(\THQI^1:G+(3P("?JNRS[/\.DI$HQ:$)TD?@TN
M4$T9AE?CB_$L>3\B 4'EC\!4#%/8)&V-!Q?S(SSF 5K7O4MX7[@OY%1U8TGF
M3H1CCI"&%[M!YL'2)A'\/7]+SKP3Z:"%JSFF, V)6E;P3^J=AI$2<2N# /];
M?O2*_,6SDA\VIGV=I"(S/5[]%&FTR$ENE 6><. :7.9<1<(C(\^(^UATP>$K
M,FB)/R1?3>I\D2*,1#0$#<>SL8%3LIF' &7BB67T@9\#NP&[KFDR)!N-+IN^
MKD=8QW0?RV?HKIG"O1Q<_2;>]_K7YY?BZO/I:>_R_S:6> ;A#<I[N#>?%422
MCTQ78ARN34S@*\*36).-MX9BO"7>R2"Z%3[^/>$@%/Y-2]"R,/^"Y(+/A/<1
M>2R^, &=E+$WA!(1WS)OB<$4J8/$58/I1;_-B^!+.*0=?..8M!$( CT]'C4-
MO_M6XEID2_0\UMRP."]7]84O\*/A2#TC-/ /:C/ZS0U;[###+;ZO ;(PI*'T
M41;>(^B$EG&B)-Z&>,8K<<8..I4<)&AB1.#-[EZ)X)IW.C7/1'"TL7TSJ/8E
M%U,ZKE:[B^=#:G7H!XAV! DVCH'&+0,$Z=U%>G792% PHA1$8L0*T\6Q3C')
M5E"#+M(E>D.]=^>G)]?_]T^D*Q]EX0Q,JQNB,P\>IBPLI<!'64Q4Y<*:\4WP
M'K THADR3@/DY1C9)$)SBYZBQ'CUF]DP'D9_8:NHT!^"S@?1#Y1->M')><):
M2$UQSTAQ@Q&*##35LY"<YQ35+8';0.1,T4S&?[M8#00N"UUU+/WI,(L3UK0C
M90T#+7B9"\2ES#H?]/+,B8&29\Y<8LU1P7B_]0.D%+31Z@M_Q@N_B'T7%0!>
MVVSB@+/@RHPD2GZ#ROK^W+IJB8F#AMQ4661H2L?22:CW28HA%NV,)FX,CP$9
M-02S3,)'E5P@DTR,J9J,+'?T7,9^HE3M,/*T&R:Q6-E5H.TQ&.[P!^U6*A<'
M/XKN!%N*)$*4>TC*;^+<2%JY5#8G6 L2MD3^"!!?C*9@1OH==ZY_;6@2];Z<
M9>R:UE3YC%3Y28;C=#*WM<M,$>JBQ)F9UAA*\R0I>;!QA'H$J(1(*T$G-TK(
MH;7I#ZX\37Q/YB3.?HHG Z L_.64.A4J)Q;>\ O1A:8X+[H-T>D0Y$ZC/Z-T
M+RZ8+%2D*:-A-5,UU".4N0O^J21.(D6H"+,FN6<E.26%E "S#1L2*G!#&*^
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M4&-'-%L3MG;8;E,PB+[!PRZ.U*]P\(9+LPZE [X=#APASSGG*A[:[<(;T"&
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MBT&OH82-D-9%WS$*8,<4K$0WV$-'T%I9TE"W:-\<X\TXV"?S8UXP^)=N$OZ
MX\R!BS'$#13)AV^>!!=+[D!3ANCHXXOH.%O+[=X[F/&@NP82J&\=Q)4*%-.!
MO#N]VA )TRLJ.9LO*6 EQW/CLA;H8 24Z4[\1))-\UX.XPQINMON'!!YD;]
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MX"3!R(^3M(DK+*6W"P:$[<.:R#G^![U_QENX^6J >%QDH\ !XVE2)78R\-U
M0*+8,&'RO(@\F#<6F84W?W+: R<U\#V%3)/K)7#05Q:# ?G1RNW+P1R)RFND
MG$8>S!*,_ZE#Q(@+7^K*=TKWEU_:B)S54JRA>#=P>BI.@KWYP1*$/?]%B0G*
MF,'K79!6+?$.(Q'%]3%,#V,+^28*>[MC ZA;9!P3<D<F('CF4:@6]-G&/O2R
MA);D-%"*.!X7][Z+G;]\Y?4CAL9*$%F^>6$M)L1AO98"R>=N&N4$=>U\D>HE
MYV$D+B8.>/<N!:U)>+<:XE/JM<06_'6[84>9[)B;.68B>@V,QB!(R('Y?SA
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ME+XC1"#!DA%++*8(A06'86Z-)[7FSZ_5?5#'"GM<@S+A.]CH34\BI@T:&EZ
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MV"'5RRK[P*PF[W"43O("I47"45&O2NHCPK6$F<D@49\#J0JZ5)4ND\,HMVE
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M%EGQ$\XR%O-O<77!BAWL_'3V=E?R]0%<_5,#V@UE+-UZ^OU++XW<SU_BSQT
M23I.U/B:E J=>\<--Q!V<Q("@E@7A+'ZHDRQ2MV;%O"<229D'V%%AN9K>AQM
M 0/$B'[.+;"E=22E*7H>V;+R5?!0>\6;CR,=,VS7(]!.-0O*KJA3@P&5&U-C
M]PA^:G3DW0!_%'"-7N*99JT\.*8+? Y7D)B0CF!T.R_/C\^/=N^+G0T:>UGD
M5'F+*VE-;Z16CMA.I>O.EAO"M#B*T0MI>UK'C!ZF:UFE\7$4UJ1D-LO*I5Q;
MV4"]^F.U#U"TIDB:6@B3@MO**#V'[#Q5:$I$(D>';KT>HXFA#*VPRX^=I:%
M&E381%8!HAG$5?:';)ZM5FJ>7,$- 1N>8/8&039KHJ-'8+%I6D%/X4.4("6J
ML8!II;"NQ7HPAUV%WU8?P#9&_X4*'?-TP4/GWO'(<F()S%AB$ID$N"23E+FW
M%]A+ W-]\#6L""#/("0KA?YVRPLJ\LAK/:%+$%\$G\6$5VMD^(#/V'@#F4K$
M&>F2SI4T3L7^XD2V='\NF;@E97(%RU.GC,T4]B+B ::3[U:.EJ2E4LD%#>A/
MM_9F9N'A.*JDD<E)@TEV.B1574P^P->P(14ZGKC:&+C+C->Q2MW(N$,+GV1:
M?2E7\.]L#6[#]E=4A[$F5FL_O60*-Q\E3>LQ;EPK8:*(52U>&SK-<3;>"?*F
M!(=7&*8H[X5$%IT7)74T&^=Z^,F3,PS6 @76EN@C5QO70@V=3<;QU;S@\;B_
M@U.23#[@!:,B!_#^F4TD))7CC9K!G,E\0ZM):V!$+I"04)$QU(8/X/<OUMW0
MK7HI6]YB)&?G(QP.B;)/IQ\GV2HSAC#F:! FS908[HW>O!UCN^' <R\)F;%?
MX_MR\UNE *!\1-8&1OG8ZPJ$\K=S@%QLL67C>PL(4144-(KY:+"3G4@(Q*?G
MPD>C"NH&P[XR! 7?,Y8E[MAZR+HI2RZ*<]_2K@#\$#PH%L4BCU?-=]+G&L!*
MX_!5-4ES]+IY[' 4/H"%,$V7!(=UGCWU;ZBS)04%0M<0WHG8'R-O;IXN9IQY
MV79-^G&GWRP?Q:Q.+$P)XI1J@=SQFW^=OAP=/!O0D432,JS-S!0&1,4<LU(B
M=FE^D5PX(!P^$,[+M& )8<>+(_E4% (6!:>^TMF,I5$NI91_SGYX  :T@0%/
M'X !#\" ;RIE@DVORD@YV-BSF'H9/(4KN:9X5T4TO8Z7+5NN$O  A2VFHR03
M)H\BYF#)A'>DV+?!_5-K5I:94Z2"1$<,TYS84#"4E>+T)IN';@X110LE?DA\
M?TI$Z'JYGI%WADME<:.7X87XI*,\6:S1"8?W_9CEH*Y0UQUK@I<Y$B3'!5]Y
M8Z%D:0%KX_MUA1!,[?L*^_ 6MGMP>CH<G-;@(?R=QRU\D4=YCBC?=X3_0QT.
M2[,<'.R/?B&S/,KL^)!Z;.+D:4W](.=2!."M<0D$KGWHU_DWSB&(+6@7_"V,
M@9,4%@]AL0XX.0/XOSOF6H&?CX\]%4\4= N&1-2=-_#V9#,MRG/IPC <TIM,
M'A9^P^5[#&)U/3MP+!>;LG]M"J"F;.=?- +*(1%N2%,)ARD\?H;I-7?M/%J!
M/([^N(3<U1B5HC*!?BA1YFL:<IKS=E?S=&A2:ECG'+.6]\034:Y6860=.$96
MM_QUVBGG%1*-I<Y<_TD]N2LQ_MTC7"YJUN03,?;Q$'*2EUXAK$O5EB$N>:.C
M?(TJ:=3/0;N+THW42)*E)?D/3+(*<X+A&N-JWI05.0 ,#<%/G;$Y3Y-%/9\P
M\WPQ2TF@PG7IL#AP5 \D+MB/1-';3VZ[DFA]U6(/2*;%BF@#$;.$A?UVPHR3
M6,*=;'P+?2N]CM)J;\BHE\@JZM7.@P*G_S::4UUU<]-9+%3S;%9S! H.-4<7
M6?1J^4:=+M+5G%I*XC)>9B45>I [E4@:@ :_>6D?].<6^I,)(^Z)V'G3]&77
M80_Z+_Z0<TG%8BK]8U!4:4;H:EZ  $G:\7?RT#%<1C@MN7[,N9>G$LO$L-L0
M%;!/72&^8$%A*%"[*[PT7@"T\LO2])N"@IOU'_C"HZ9*2\=.][[0V*)*)I^I
M"!'UJ([W2J2#Q/8C*(%F*D/[-S!3B B:])(EZD1HAG[<F:+[U&7G^9"<9P>;
M^@FI3:0P5$M86*L#G^_LBINPA%B(U25<W&  MI10!WQA E32C6;IU9T%#F-1
M)4"6$G94P[EBW($[[F%^(=7X#85U8%A$^AT3C#.^P$&V$HH>+0S42YDM$(\)
MB,D[U71@V^AD%!,^754IWZOWR8=TFG#42S)Z%).58JZ>>K;VMD46-V-,C?!:
M"8%$DO/1=Q8UE<60E=%];D_A7+LQE;)9(X6LE> 2*ZHV_"3O,X,53<KP-\OT
M<L0*1Y<AN@@>24<J*3'38L^3 <(!<;%W+2EC?B"_JC+82CA9W32N6EV:8Y;3
M:Q=8)5#/@I).#>PR;I>-MX'6?*/E/K1*2/71^ 10S+Y_?$X6./156->/+9XE
M:F=#AN@HT+*ZE:'4)IY;-&'&L,7WY8*![*?&/6E>-:4(.UQ) ^;WU86+<>@3
M3]TCUM*:O<%_$DQE.D=0)H$_L^48;5[SN_0(J\0W/I^$4L@G'V&<']$8X?>?
MJR+8.3DZ/]G%"#XK9OQ/&H,J2-S(A'K^9A(@A[%3?A=36KZ/#'DBN#BN1KZ6
M55N"";!$]#@RF!>ST:J8H$)C]C>?I)M1.U\,OZ,]GNL#B78 !,"H\P;,Q!%Z
M0)'O42YQ9E;>!$05)KM:Z3.<;^B<?-TJZ\JJ#@TZ>T4$S$D#+G^I=T>^/0QT
M_(XNB.\6&3&JA>&,I)R(H]_=49_Y) =7H*"26<1=_DS6O_C/F'FZ)W>9_:P-
M/:&L&QON&+9!T10(HE(7Y$1Q*QHY;_/DCZ2<HDD7Y]P)Y#HA7^BWM(VKFL&N
M4X$[,4$**QX>VC1>X7E888R>K18)AL8XR[=(KC0S2X$C,FXOL PC5_1:@W4H
M48H:4W)@5\*3X9<+-0) "ZV*BG'B/?/15B*AYS 3BPY%1:RCS"1].J18,3I6
M"'R,,DK]Z*&^V?2U_Z"]J&IM!K18XQQN>(X$W70^#R30G833WQ\23G_1A-/=
MZY;VBNU6C(.S5E'2R'NB75XVEI&G-ECJ@!KL :M<I6#.!# K(*/)",&5)48<
MY0D<0L"NXY1*D1X$2)$"MLU@$=8M(*#V!D<+!$Y>^8]!Z<QFS+-;@D1F9(;J
MJ\%\?0&F53I4#4+D&,[UKX6"!8.*@A<G?2?Z4!H2I8OT$OUH_UK>3=@FPK6K
M^81S,2$^7A3%= 0_R;D[)[9(U<"T^"QA]&6JXV=A7R[6 1T*AR#- X,BDY!4
M+L2 [H@\2\,<;$ZJI8>+JPM-O@V(=0H"F2I+:$Y>:9N'14\6)TW&IBA<S U)
M10:OB$=7RU;;LC%0.X!_A(Z* I :UYBD4]*R$==Q,49+513@,@';>FJ,,56$
MZ(8S8EDNJ>>P5J *TL2.JQ47R,GY4+"Q5+6*7P3CED6-ME4/QX<<JXF"B6%&
M4E#SD]3V$YU$T/L%/QD]RP!0"JO*S2'D!&8S./T->.-S!-4-L8Y"%GF2C.&H
M1(D!S,Z!X4\<1EDJ1-AVK*G3)<7/P[TCA[ONG@ Z)NX8W"&O]I;2]S<S,T7X
MGJ5)1:<+9OO.(8XT&'YW9GJ]_XYM\((U+8=";AN?6.X-7%&*FFF+R/6&";"+
M1XCFP+K4 U1P7&18(YS,$9PFD1%$GM5TZ :\OLAKC2C?JFI"V<9Y+<0(.&D0
M%KG@?X\6&/E*0,\W><UW%/G"R#6E4>()'&%.9S3'#FXKI 9;FS3J*!#EHD4H
M+_KF:/N+'J'%D%L=C':8/6F'+)^5"4B"1I">EB.)&*E -M1S";5SXY]TVAET
M#O>T1"G@DNQ8UY<T :^7YG-.V\N&T=X5Y-%/.2#!-/9%7< )"@&':;8DL&E4
MJP5:(*^6692!@BO;4#Q<1518HW%ZD>32"[0IZ5\JU"32+;LR]+N%>RYD^UP2
MW("LQ/- QX/;B*+D$MV 8 <FZ0GD]+&>YP;%O#=QEHX@!D[!TN+@UUSB-A0/
MQ)4PXJ]1$R-M7MUNEXEO'VIT9,H*VXTMY:@AAN7)#&T-5FNRXLM%J;2#Y]8>
MDBYYEDA'ZFOMC-X#L53QI \F#Y7,Z0NJV_8-624/J=:  E+M)F][R!3LGZ/2
MJ*BBLJ ?1TH>:UY^+\8@,S0KY,TU9Z/=$Q&JEA6U:-5Y# =(>3@=O#U^%]81
M53+A"W E8?9$'('9X#&&$<#8Q>JN9+4293[FS/(,I:*B<BESI(<&K;*@\$G9
MR@WTMTW3W0J"@5\@:I43WXI\!XMCVG!;U"QL!@Z8*F$L4.J"DE*UPE7]"=Z\
M:KU<U=B]I$PF'WBB(=6!=PN3VOBAVO=XS1,YAG$M-)KW;JX<S\0N\=1^%8;E
M" SNT4&ALOX(KRZE:6Q(D\UVT613"@,%%:@:FF.I5L(A42<X5'7#>4QL;K)@
M+>?J/-009AP9"I"(@+-:E:*0[:0F,*X+L_2IA%+EUJ:'!W"9XOL-5#W%Q.U,
M^NQPA&J)P5[$;.#T6@7>P?O@X/!2\P=E.DISV-"4/40<&NR?A?Z"[X132Z25
MRR+]F%TLDJIB)2,1M) 83E#U1L73<[:$,#O_!V:'Y)]LM:]DYG@KETGU(30B
ME(F(AT-5H]/?&T$9,8P<KKS$P==P@I?27$5RN%Q++0D!U,TTF"0KV>WS6AK=
M5S@*Z"M)P<52@G^Q.>-/&HD'L-]@_Q=K,>8B_ O*GRHEI_B*<*O!66%'RU)G
M>+/Q!TDM[G _Q)Z(+N?)E$3<%(^VXEIRGWK&'-A:SC.W%P13!SVV"# ;E2R(
MSN#FPXL00O!FUP/29@NDS=W,I_Q$T7JR;=Y9N/KN"/E;NHY]#5_NSF1N] ZI
MDZ9@0)*R31*@8!QJ:]5*VOP.CD\US2;!;<ERJ[P/C5S1SJ[B!N)1S311D]4;
M>\)$)9=1:AX#=#%4,=0NL2ZST8?@QS4I*$%8:Q!FJ%I2?$:,HPTW)]!\:3$'
MX((]Z. $ULTSRD]IY;#DVX:F\:*:HR&75](C+:/EH118"U;5H_ ZL>R9Q)9^
MAX$E3-"R]S.43E.##VFZ8HO.(['8 @A=9CV@Z+Y89>^Y"Q?E_TTC.K:(<8I'
M-I2^)D8$+8UI>35#8UI".(AJ(FN(TJ651+ZEV^\_MEF=1YAO0T\MOQ@MTAG,
MX$EKO49?4CCWKQ<IG:?/OW[Q26LI]O:ILU>.?-XB%UH^?\(!'')BX$)@_ =M
M&G*&B -E;!%=(9>?X%D/*5AB)'%YE[<&T-OYZ=7;W:T0J@][>/,>$K&TF64P
MEM/7+QU?.\:?*F.IH[8"8<^K&A&.L"-?:#*W[!R1[EWL?8NZK*$__%I\(XD3
MTIV!6PS#,&)3D98CPI&U4)-\S*CB2'[5$7K(X5-<I*3QF# D*KO)<J)3X4<G
M:.RRWGU %K21!3\\( O^BLB"7FWPE<\><DD-*<"67();3!,*IC4238'GO$!8
M8&)&=4+=3 KTRNVK&O@5N!,KU EJ63-*U7B:-R G.IT"V7Z"I7E0I)])D09Z
M5)3GF,A-$6V64@"%PX0:;+W,TJO!N$A*0I&"1$<V* S,(><S<<=PF^=HSSB-
M(IM*G_.?Q1+F@A8PIAXV]'-MJ'((<49@L1@YQ&7_K;K6HA6E+O<6S"QZ,-FY
M%J9PK'O';W<)Q*"8:PX7AVQ0BB4J6(JDT30/YD5I$O>VP4@I8GY-EF!4CVAB
MFBI].#.?Z<S@*K?04BT#>_ :[CZQ_!VY)BH[KU\>[2I$"SW?6<P;Z^ICB](Y
MN&RR5_!K*:1P[,H)A9-]>Y?8L,2,DF0\K;:%TS\!BL*_?#@>G_%X*(UJ5*_8
M/B0OE&MU\$J(Z*/3\N+5)YV6A%,M*4.Y;WI)16]Y.%5W_E1AFS!'SZ @.NJ6
MO8$9F_$$RMYK:BSHD )SUST&"/WR>]C/D)5N-0V7[R(HB\E>C6HSQMC_=/:6
M%>#QVYA-[N%<?*YSH>U 9@0V&,Q22?"CR! KE!7(:V;FA0L_:/(%543BMP=7
M"=:K<EES6CULS.>R+..&G\:-+,PJ6<[Q5,HF6/VI"-B'3?A,FR!Z"Q<>S'9*
MX@RHV<-E5A7$BRC^&"9\ZJQ",2I_!Q7J"TR[/Y';]1P%W,-^?9[]HEQHJP>S
MR"VV?T6 X7_#_]Z7%!A")926"*?UVDUSN,'-I#*)]8J;'<1.9SW':E7I@4*<
M&-A11OLZ)6MJ];5(5KA,8VUBG4X?4F*?Z92^I08^!X/1X)R3(YI+\96;0CYB
MA?^UV?UH6\=LO^; $Q4IG8>*>4P"A4D<=K""]X#>E3)/@AH1SJTWP4"J1I/;
M=;$ KX'S$_"^,0BX%><6M,USM1QVJ5+2CY,RU6:B#)U;RZ@'A2<N.<T')<X"
M^YGAA :Z<IA46O-YS:C'<':1,T(XP1+8JD7UB6>:^F%T6[FCQ.AF]WFA:9'%
M/DV$&9F(<QGBA;>2@&S4G@.&XILN()*))SGDX*PTH%A;&[QNJR2;WU@F".HG
MGDC4"8IB/?0]:H+WL49 QH*53[I@E$%;&-*4N T;G,R2K3B/XVIRV#HKR\<R
M[]".E7Z<(< \K!6!P+DJ"+^"=?J+E$F]CO3=6!!UE:R%-NBH4IB7-H4>]O\L
M^*22]L>Q$C["9B7G@(#AQ-AO4E#JU[>2\ \R:UN9=1AD%AVZ(%3(2$7*SQ5I
M*.,Y2&:S1>;;'+A>U=P GL"")77?"[T+TIR.%&4[,, 9-85 KC'L-(B95 EP
M#JFS&:()ID5%L!KEA$,PY[PHZQ&V%AP0-XFPJE"U-<$X06@@;-Y&J8=];W"F
MK-$KF7]_CL0MA"!3U+>MK4N:R[T*]0*5=\,A)$P_=9KA%AB$B:0Z=.)ST'YO
MK5?O#71/*K<C0>43KCM$H]%3!_L!VRDPI%EO=DLQ:'(7X>+4X"=H"-W4(;B*
MC</.$$]FP<.FTAS%.<^;?%I2!0:KEH?;^%EOXR.XC;\AF[\1 M&?/;I [U-T
M9_ O.7&57EPPPDU*0^3R@-+-+](VQB!S6M70P FE,-(55])(Y@$I]3*D-].3
MZTQ2*3-A97V1"#0OC0E+PT4!(Z*I6TK0U<&I!<!T)!U)4= Q-&4P(I P'W!8
MG'FVBM0B RSBIGZ2W0GVPFJ^KC*0%;DYW_?%B5"L*-L@I%"'TGD.1I$)7HXZ
MG*+X="W,VIX%0AV<49-59@M8[50Q$@8?/@*/34:)O)QB;(,)@O) 9(D,L^1&
MHWK0U]#>B-%4F4$#YA=W)^,2)OR1]'=J(2C9WV:D*G8 $>Y);&,/BR'MIPP
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M[L<">M402 4[6E"[V.1"0WR^?S.3#Q):$AY&I$T4-S;R.T&G3,JBJD:(-,S
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MV5[Z3;)U?'#0'55 =/9Q1+='*YXWW"$\CG*/U!&F$@?8BG^"798' ^6D@2,
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MUL8XWSPK7=AI5[V!K?/@:/!3J<%JA_)04)_<Q!/5)DP)%UG3\J!T6$5TN,M
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MX0Q1V^"$$YI":*#X535OL>RQ-+W[#%<@"(O$XQ5$6M[.$Z<0/;@VMSDT?$I
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MGVU=-'/1.SZ>O.7;RAO:))/FC^+K^_]XW=)K9OQX]+2M=^?KW232)>+M."G
MAVRNAM$?OZX.UAL%'A'6\IXTRE<(6K0B;<[V!XE)WL;D&5^2:I9D[/EB()=\
M])+2Y?CGR4M)V8G5Y2"263K++:/I4J*H':[(MW#HIR-Z(6#0'G;.I74R?+$S
M(N:G.-4(L+\<\))*-S1C1+T^DQ/1_-F@HG';K2BSALGJC41P@O @;AY:"M,T
ML+J?=%ZK,AI=RQ^A;1"7YPO3C0,I4@A(!F>>LB?%PATU^25Z5^OV@EUG:9'P
M/^(87@L?*^XC0#T.72_6 =$A%>9P[=F3GO65NRB:55+'C<K5AL;I>/*W,)Z"
M6Z?"R."=5,,:#6R\1+S7Q6NS]\*\3#FP5F>B8O?4MHISX+E::2^I]T"[0<W^
MEEA,<NVF.Q;7[K3&L7R[W\5^<U>:2I1,BA;2**CM;N6,M]:L7:$G0#\?&I9,
MK=XBOY2= KR!C^PN73?[MHDYLWV9MYA0CY[X1S(PVT@!C>(VR51JY,;XC%]-
M>YS)YMH</1D+&/!03#>8S2Z4-@'-*!J58HXREKE"9:V3"1]C"A8L<$PU^RBG
M59*/<#'UX]4]'2@W^"=2Z*=F+VYR?VH+H0W!NXWQ$V$$4#R,.K[PB$/1/C-*
M](P&IK HUUY.ORR3)VX(1%K.G(F81Q[IRM07!95!O8G:T</7IK&A_ C3"MHW
M[23N>Z&!W8%[8I*8F?-_C5B T:>60"*FE2Y04$D0P>FCW9T(_):%R;\G"I5)
M'^0J+]B,#&]FNS\[-I2Q#V .3-*B2.K#Z:E*MY.<[_[*Y#AQW1WL$KZV3&F9
MVZ1BR0NVV5NM]!:XF.N =Y,& \GLJDO5"UHQ;J<, "I[HLE>["L$2;;O(J_'
MRYMPHI+XOG/[X\D[' KZ-(P1([\M4Y8'4Y,"?7;Q4>B$Z6O9<))(ZW,)>5KR
M(,E[R4K2M(%VZ,F?T?_6*_TE5PNM^]-=#U5'B4).(-$H(7<0&DGY: DUYS#J
M(G"0E,-B?DI!&=QGNP*G7UP^2"L0[R=7:DE^Q<A,:F2QZ^S(#4$^S'ZLJUTN
M"@WL[N2365TUS9%AJ;<G:DB.5:%W5F9F6:W C4$9-<GM8$J]26W57:.FW9ZC
M0]R^.DW=E*VU1J$<$$>(.R)#JKDB PVR$-;[34W2H!D"D+1Q?;"P=O@)E@M(
M7%C#<. E>#?+2&Q;&H5]/.!O5[M.M:()JFA\,J:G2L*&.GQ0+<3!1,-E>*J:
M%X->OB$/>JMU))FQF(WR;[JJV*Y$_MK.]7H@KU[S3 JH$)&8E<")!NT&AI2_
M*0E3;LRQW].UT A2N^A7>3&2_*"-?L4,E\&"A3J9H!3$^_L \[9R31/'T[]\
MH9U",O5#1YP H<W:XE+DS5#'^!JAF/&,S,@"A%_I5AP7F6JF-#AK%)FCRSP^
M7:_&22&'S:DB.+T4?YU^;>)>D3AH#+^SS$[T[9/CGARDHHF@!EV+J?-K&^DI
MQ(2MNE:&0T>@1Z $@MO:ZKSX';\LW&4* AB EU]4 /]13V_8VY:(A>PB-U-*
MYQHOYHIU!]!(WK7:/<J% "*E"1 'J&=J=]KZ;SO $7^,$RGSO<+];W$,'$]>
M"6!"IIQR-&W!/+*11TCNDV@VA-O=##_V^;RTN]#W_,[T&KREW4I32A_\+3;L
MO!;[[[^ >N_=<4)_#U7-$+%ZT80.(#^)=$+P:8*$#EE]VA8- 9FD%W^@5T,6
M1$WUXHI-6:QL:BV3EQC5M"B1\<W(;UPG2,F-%\-S0WE*P@[XL:GF!!H>KB,G
M73,28'#R1[^9XOFS(0(:$[-$,LH.1(+YHW=,74=)!JEG<E['@>.X!M-;#@=S
M2'O +RQ.0($:E4%?/O)@VCO#?*&CD77I+N8@RN%\=>./(%=J<MR5?@&O+(OS
M+C.<%D2XW! &&Q]:[5MEJ2J$F]50E% /"Q/Q%$%:KVA2[+@/<RDW$=^TV;9S
M9#B02)/@AY.6Y(D$8*!4#/H3KY!%.5_J"V!VE:.(YC>4& (O47>_#%.+6XI9
MVGL@ES5['*=4E _F%\[[)B(+1Z;:AHM5-:6SGCM-6"2).KR:0N]E.&#ZY/4,
M$0S4+6.*%UWU$9D7OCG'DKP,,AURE\)^XXQN^'V@PR >$'>U*VVW?]$*:[6K
MGO$J[:]3%IT!<)NUD2./KK%U07N,'BSX63)XQI,TJ6^QFA( 'BK-W4KSTT.E
M^1NM-']I G$#+T<1QYGP+I9*8J]J<G;L4>D9(N$<:LY;Y:7H&G#,JN4>.6\I
M&4A!PWKC9Z:FONB@]F(K2__3YC7P?6J2ZIR:I)*CD1,="-'FP?38]Y?P32RI
M/Q\N0R")&AZ:UHQ^7N25"@)CYNQA6%:Q!OXJM#3B0@N0.!7BI5MNW3YDM3->
M[I.;M9%]@S!]:V[/$4^UDR?J]M+-:&;AI<1>L4BYN>9$N[!Z)XYL8R"$0?5T
M0.EHR&5+V[.YKV+#H=N5D_P$*H!830Q"I7B\>Q5.9N!]4/ZA'C&_X7;'DW/O
M0P. L**6\D$^F,ZU'()])I[M*+YY9W*J:'&%O-;Y)B1K5:=)3TMDHB^+/.GC
M V+4K[BR M'BHFTP']IF?_;N_.V;LZ,G)X^S^.\GX=^/'I_0OW_^Y?3LEZ-'
M]M^/S;^?9$I]:S4"^R_XWW]_].*QV<T#Y,;=?A=IC/##7=6T];8)U=IG'! %
M ^S==?[S@7U'3LF0XIBFTIGKC!SM"GT:E.>8:3]'=_,'>6A)W?BA+8_@<.NS
MJL\:7YZ# 1EH-Q]<.REFFV0GO>?T&[<&D7 T7S=X;\+:92]#_KBV&TEC'G"^
M5RH;7 6(="Z: %6IG$3<Z1HOQ@^_DT??LN0DUPVK>AX9K&$ (HMUUVJ+XPDL
M=;JW:=_J$[/Q'M;IDF%6:EU>DH &D0L)G2DRB!UA EBX/[:=9#@#\4=UU>P]
MG%\YQ0NCX(;NHK:.=7P$+X+@&33'P@$=3A]#G)BR)3+M4L1*4+39M9B=!H3$
M]A2N%NMC^M(OW8"EX6:8H: QGI%\#D?)HC15$WT)<AY"_.P7E \M99432SN<
M 55R['DGAECWNL3A-6)QEJE<9/$X9I:3"CTV@7 FG'R=DYA3F@./>E^R01T6
M\\$YSE'MT<0SU]X[V1RELJ0Y2$4AC0\82,>J*1T&CF/0,<(>*7H*+= Y6!G(
M1?=O[>>O+)BTYG25^\,D]YY[6VYWG$E(]\R<#Q+)9LD&&J+N-(9]Z.T,E9RB
M"8=IG36SQ+CNH?R2@G! HG/3D622E/ ,W71:%'/!.=H49"Z0E9-<?M.NC51M
MHD&XSC_Y\_PW)\.@W (A98^L4KX.4A8<<LS)Z"\6NI,EGZ =>0!W!/;B?.&L
M J6T3W$CT?YT%(,Y68U(+6>O_JVIHL9O0#^LD.:KPUHU8Y/@ 3J9QH[T1K,I
M/G(-%LFPACDN%@HRXQ>]%'E/?X!ND!>73HV:@7;RF+-E!>Z$NEL=TB<<F_00
MHQ#6J4+O(/!"1I-QF+[=K["A%3Y"^(W;Y_U=;:4];[+Z1RT(GQ+VT0?*7,&E
MN"R8HX-%.TC/_))IQE0MHS.+B0V3197R#7>/S9))J62=DOD.H[ZSRGU&XW-$
M/\8<.$8/:WP<#=\R+0+H<!GZR'T[PO"F)563T=UAPLQDNTMI<_!)RW%:^(IK
MD)0')/.IK.'4L>N# P!_ ]9 3_+?4W2YS\65 *Z<^O=WEP;&:&H=H8:RI [_
M0(0%!@-[;G5+,(8,8F1%%J!+HS)^IU$2:8U\@D6#0GA1^;-@MLP!@)!@6Q6F
M& (L\1:U1S(4"NU>*:"?S^]BL>6]Z^>!TU ,*_6+#^>^7X%NLX2H!UWSLJA1
MH4><F$N:!P>RB18[Y#JSD=9@F $"3--Q0YX&"-DMCH419@I=0.!I%V9.0R)9
M%2JIS\3*:& ;RS+7/5R O?/HC?67WI>5'.C@\A"1SL4% [7::5G2)'YP-.@]
MU9HH46> "N(%--X'^"@@(79MM/@!8R2_4"%;^E,"PPO*87=:-8P=G(-.V'Z=
ML%_@!<09L_?AIQXA"RW&H 53[WQSA4S>EX@R>?DE4EJ!+-L.48KF#J&@>" [
M'&L*/&B$0&"<D;_K'RC&/>G0H'2\<EX+=&VD7A=TXG4@A56MN3<,DV_*":,U
MFGU>U572,1%%.2601(./7Z2A$NK#QTV: B>=:<&,$7EZ8]. _O!I[1'VU]@$
M0Q_[VQ')I:SJB,0,V@V2791#7:-/?S;,J9@!>@;N5 N<VF+U8 ^JF2Y$@I4P
MP)@CHI<:"R"<0F=#>137;G 9I$2B%C,\X4NA#J&!D'>9%?6L74OZ-.F?8VB+
M(XL4WI <1I'%0*"C)SD15E9BJ(P?N_>\/IZ\&_0W.NTJW2+3J**1QI^9%KOX
M04V[B969=\W,;W/TJ:O$G.$;&1.TYQ*-4R>4GOR(4&]QZ _U[FZ]^]FAWGVH
M=W^)E89Z<P"*9USPHI($6Q8A&0TLW2FPE[L%9DABCL&EN;N@G;F$DN-2L_0N
M5X ^<Q3%0W\:=7V4E&%;73CZ_/C__*^3YX]>WI_#.291.MXE\X"0G'=%/A8B
M/O)7:\W]X?N45@$Y,VM4F *UOS! :6W)YTU J+-7JV%=O /S[8T@U4)^P[C3
MZB-B$A,_M40G9S'KTJ;T<(8@VE/RRS1NB1$NZ'.W3J%F1:GMBLB?H(Y;V7[K
M_A<81&WTKZJK\HJ";CJXF"=9$RNHEIJ+;5I_.'J'M!8R2L*6=X\XC2*2L$<<
M68R)N=[<3;=<QZ^U#(KB1JB"UI3$6$3:6%-]&;T^T][&Y](X&O*%&M;]!00Q
MSH7PCHYW0ZXGV 4N4T?X.A$.^*!..))6J\ _E3*(#3KB/:_YGNS+D%&*!.8#
M8<\V%5Z% ]V%S1)2?R\W5*=DER5Q89)SS3KH:*GQJC+H5NJ1#)M([VEI5*FS
MFCOSC+<GTPY1!3\./>)1Z1B>(O4X+V(M3EN29XXYEXM&@#R*WJ"'TYQH+,D&
M;@*U+@,HI 2JE WX\;FA&M? /14][O(,4K9_R[1XH2U>RRB!;K24SB'-DG%,
M9(&G-.M1+,H)V;1_,MJ0W50= T*VLEDN\]E,  8,4X!D9.P*U*?QBX+<2^B!
MR5A5&VV]PUPI;E^O2'EMB>W5DO=8(D8[=/<RE2GA>(>FC -D;J$(Z>-,&O$T
M:\ E73XFT)L!*):N+<[W2^Q@:"!YXOQ:0B?3\Y?R/]3=,?F1RQ[2XR3_0TU*
MP%S?'0/S&1BEV5?"!/$XZXD9TC1_% 5=-M&J2BP,Z#']NS40O[I5UXYHF^XW
M*A6I.3>.CBQR=6Y&TA6F];F9^:'4;XPW;:B03G)3M0 )U&Y!_LR2Y7/\UZAX
MYL<Q]$[K3N094RUH DL-YO_\QM)]2\7_U+%@7R)HC73:&P.Z-:X0N#+R,6 F
M;MX%Q@9(1RAH) URAJC>"IQ+%6KR2]7A@N[M"O)-"5C7@:@2W4]@Y@MY" ;?
MTQAFINR8)=EA>%-APX2\I;0A^843<L3(1%<=F Q/(TZU0KF:DX<&O$5;SJ8X
M-63>Z\ N6U9=9HXK(;K>.QJA+38L8*-M "81)VR#2E4DKT#]J>'O '4$[X?O
MC2ES7 L+>=K.&HD33TEL6 HW*K.@33F0A- 3O7:J,.$7Q<JO2KC)WJ@4\Y:P
M5<3QJ>0RJG)[C=FT V:/YYOD\Y-TL_:<\OU,=RT0*.$UXH,/C<P7,^)WR"[?
M\C DW)OJF%!#=5Q50EWDAR%F$7G%L/?,[D- WF>4?$"AR$1_\6JQ2%/4/2C;
MAC/_<D*HM;N3PWO=L6?\^LAL$("2/N@M"8F_FJS=&CG<4$?5U9M8-ZV66+94
M3K5'66B@E(3&2B;RB@&O002;'M%X$Z:X/- &'G$0I$O?5"$?06<(@Z\"B6IJ
MA$*.V09=DMOZ$&S-\.(9W--#KY\EDMAT2J3R#\9KC@^GZ@Q61%3//Y/U-P@$
M4)R&NLE MAXI@#W>0UC%(^#VS% & !B!%@I%U:9%1X5=T5C>]+X)N<U8Y2'
MJ<X,[S*4[;;H?F<6P>C#?:X)">H%/:R>6!@D++$B.+RU4RE <!:Y+QAX9ES(
MI!>(Z>84VVG&>[SO/DVBG3,K[VJW'_PU#-V0--J0:27ZMAY[F[YRW 'Q-P#U
MZO(-$B@F:8R$4<]3KI7APU],>!YSSE(HU2.[3[0?%V H$:TT 5#9C"9S9U#2
MX;YP$KPN+XNZ0CI0#.=[V8A_5WFQ_Y^]+^UNV\@2_2LXZ?0\YQR(X2J2]G3.
MD64Y47>\C.1.>C[- 8FBB!@$&"R2F5__[E(;0) B95(B9?1[X]@D6*BZ]];=
ME\,1+5M*[M^I"PYPY+^\Q,<0\GB*!.G)3.]10)U@D%J4SJ,+.<RT 9P.*/N@
M<$2/2S=(HY]31D;DAZ32IUE,#F!.8P "M#-HS1NTJD6M@J@=WDSIFYA5$"Z.
M19A_N"=DRS-*'34H2&9>HGH?RB$^ !Z#'0VB0L?8>U%FC#^[SMQ3PT!M_-]Y
M:6:U#4&S0CH3!0;.HW+^ 'JS?+X9Y&;3PTAD7Z4ISIUTE1.:]5[VA_^18QZI
M:>=2VJWDZQ/,=B^/\;/*=ZCO[40N+Q>5-I+9BVR'Q#HWO1)AD3/7)X\G3TMB
M@5DU ]+XW>L(=SG"?5I'N.L(]V-06FF8V9+<D!43J.H9CL%!4!P>)$?X+$4C
M%6_,8I+OP)"7:HVK^U:A6)E%V"-C#>/0'<,PI&,WN2)NHO;)59 !-W3.M1EE
M2PN[T,"*94H67AF;7-I6JC7?F5UC+MOUDB].#D,/3,&D*.@_E2-4)7"X @S8
M'6-">1HQD,DAK.)2Y14LPU[)3+<(@JB0Q:H,C\/1!;;7ODB^V9E9K%D:^M6C
M@2<>U7\A+:?:Y%<UQLMD?4!0N<_=(:EG*J@7#;>IXXYI"AQW0I5DKKAERA*+
MDY(A1H5YJ:498%\MGGJB\U/0-1C0Z":5KZ'>BU7$I+B:O&7Y3Y7RCRG47BC*
M;0RI@2'9E)C!C4G@<LR86X'B4H=#-1+'%ZHTK)PO8*=Z5SD%Y&FS\K1G[A_@
M)]Z=5^JLHW2BI6)2DQ(PILZF=LX'MA$FUX"'R1D5 P1TR5M4''9JX<?"<EKP
M7"N,ENJ8B%QDWKPNL%^": 675\ KU_X6;7>;RY*Q7*AQUPVBBI*D<C00F^+!
M;(2](]%YH-P@W$:0!S]SFP@:!4S]UVRFC".REH]1:/]F\=N[RAZ&&E158B\C
M;[IN7XB&%;<FL$_AS3#T7NC!GANA)L\@\VDT_(_%LD?K[!QP#YSD&@LN#H=E
M;BE(/E!E$I:,<!H7-JA;/W=4NI?![ 0>$!Z-M,!(0R:'F!<RUL:,1@:"/G[I
ME#*FF,G>S'@[RH^0LA+FV!\U$Z5B!U-\0F7,=LK,)$8?H1(5=K:5MI^E7?]R
M$TAWT(9$]3.Z.0G%!*#1*\'^Y/'5;_+UG;YZ_'81)5 TFFT\.T4> +*YU=RA
M.$@QH0(!]6^7!Y_91:[XN!RF*GTQ]\Q77*V!J,26B@8TW)#$]#^_KY>*:W0=
M/5YA]?(;Y<[6]+09/5F*P%PD5" I,W6I#8$9](E\Y!S_?G7Y/UK-46F3-+]&
M52))#U?,DZ8QQ<'4.=I>/-T,'D@J\*6C:YG>N()%CIG5\T1J(M@1$>BAP DU
MB$+LT, =';!/"CRG$.TC_^HZ*T5=XJ7V,T6^5-$?K,;O#B]Y%LSDW*R*P+4)
M3IJF.'H\#\GW4A"=_3BP;3 58]679TUHU:1C%P*[W#NDL@2T1OZ.D%_*&*'H
MJ=2(N;=3(0N9DDA4660A44\/12OTA;"9N5Q51WZ*3CA\\L0,</.2Q(M4I9XA
M*9W\4.T$K*EB/U1AVOY; 4EN2:9Z8EH9:5%A?AC/AN.B;Q63TD+?KM)WC<?%
M+I,']<&/.=CDX^@7LM''8S%GYQ17N]2(W[TLH$1[\G1059;RTNBZGT(SM+)'
MNN ;+/>2J[&U*\VL4-Y!@QE-TSHYR--E-;U<1N)1;=YR\]2"A%[A'BP[ 5]M
MU$B@1NC]",TCTU+8+V"SC&EEJI?R?ZDS#UXY_$[UY5%.<96WCCJ\2")=W</6
M?F6J?8&Q2Z<!=6*5;2 =:@/)W2(K>S\E3&$8 Q")9?##ZIZ#445=ON#+*;&X
MF9JA[],C%+%O1W=8*;4.(=3HS _M;JE1LD>4%+N-ZHF"I@;QW?5[/1+K[/V;
M,U</0#:^O0E[6(+QTF#?I6Y2-3)WA$S9O06]Y9X<.Z:S 5>[+"MK'6J<[ @G
MJCV=1 /GFP& J0%6=1*(]D>52U^QE8N5OC>+?2HRRRP;V+@<36,GCG&KTJ0)
M7&B[+-VJ6EWO%;-4<=G_.Y)=Y:0DI3=B8H"TJ%QG=<[UBM X1N'5=$W5(W!6
MT^(>F;T7&6>'J$ ))5#@5!YQ@YG_XS_S@/,@:ZSL""NA'C%MW_<-ADK;5\BD
M5L@AAL0\,&F9YRVNQM8WFQ;;K]-BO\6TV)HE;:6T@&V-QGGJ8*;=C&4TE6W1
MV 9?*IE@H:5BG"<R43;RPH7J+6E*;&_R@,=\:-^J5<Z+[:DX_0.=LM;X5=7H
MN3C+0"FMP/_^$*HU?<46J%_YHNIEM?S:H58!D*#1V[*7@L1Y*7920WQ'$"\T
M&I+.U%$0FU'>+OZS7*&9E&LV 9XYJ':+&B\[PHMNFAUB494S"N/QY[0R 4YF
M)5=_*?F5+!;&$DW,]B1[T ^ \_) 3XQX66U&Z*?3.,2Q(S5"=Y9MP@4F:OH/
MFL34J:2JV'<48P<\6?)?HV"'TH5+4?5(%BL]0[,\W7IE-L?B 6XE7.-@-SC@
M7+E0>FY=T^*2+- XE/7JNH6*G24Q45-5K.0+F9^;1^7D+-/7R$[N2TJZ7RGS
MK^36++;*4XU?5G:CB2P%E<]W2/5*]^5:JU80-JCM.25K&N%P @4>>'6B=JG*
MCEIQD8B2D*)>G$P<IO&?^@XCLP6MI*IO!"V7%OMXN;SW:8#5Z'(87V$4EB7V
M9%HXY8:@1W-*DQXRC$MB?KDA,5G1GL1R0I;LC[66LJS68DA@7D2-G'X-/@MN
M7E0>MF3MR[*@*,R-0V#DG&]]7RC8J*Z2N3QEKZ_J/KAZ0@(N2<VGN"\JW;$X
M 5*)*!>?:<2>8JE[M/-,NX#3HTP9H*EWH\U/A$_WWVJ[FD[S#+N^RG:92W=(
MC6:,*QO K<.@-8W/_G5U[XT'T)H:V,#]@.4-4!4%9H;G<EL^,[RS6*RQU  R
MVZ0&HN%<4*$@ZG<6" JS03E%J=PHF@@!^R[HFH;EP28)330Y%D9V*?LF>2DF
M7NE367VQ+0@%U:S+DU=TH2.3QAO@VIZ!<>BEJ<QA<(SOM<PYU%17&F^U\O?H
M:=7%5OERB:!=C<=3D.G*X863K9FJ>WD_9.34-]?5[ P =X))*#08BB:3I';(
M$WM;X%!&/Q[G)GF3$_??@%BX0UX(_]%]73\+2A@T,0Z$5*[GJ\@RV!$(/*R^
MXP93L:KLDK:7RY5_IN./8AIRZBPGD^.V$/6S>98J>\]>A8L3U2A):@LO6_6H
MFNU5M&(&7=\GW#ERA_D61U-=]G$9QWI&M,(V]5A94!4\E:EB^F_.3<O+@Y97
M8-N3TEM6[&-1&#=(V1IAI?YO"G>OR5*$#]\H<[[AO!:,.7QN^7N'>#J-G:%Y
M:"09YO,86_Y*_K^RUYQTK69J"J:"H&S6!^PT3R(ENR@CEL]YWS$U):Y]L1*W
MA>N)ZHVH"^UVY:5 X$Z#D23B2"?H52$0/KL#289RCF8=1%GMJMAE>%U&8>5E
MJ+C)V)<$IP(C$YH(REYF=JSZS%KH<DQMI,WC1]002;8XD6H*<"W9^0VX LT\
MLKJ_65,_:+0(<OX @[6620?*/-#'-)BS-F5,@"GH+5AX2YPRH<DE5K]<R4K)
MFC"L-%76F!QSQ[7.*M->TN4R<&JOS6Y+Y<B0!?BC!E!HY#\A<YBA[J !JEOH
M1WZ! ,E@3H]H%KCISS"2$E7V%\9R0:DKD-13&J"K'F#KUDSKMB06T.@U]^WA
M<3CM9D>9XUJ1_%DZR<[E6Y 7_^K=J9NK6#2Z#.14LKMIC+<N+7:-:?7^KHO/
M\HS2IO%RW<9TQ_BN4@!U)I(;V>&$RY4#-014-K/P;(-QBI-*%L+#T $F,I1L
M1L&#YJ19$T1RUW)T0AI'ZOK[6^_6!96;VJZPEI+@,#6]9T\U(]7, 3L/FP%H
M5+T!@/U:\OOIOT?)CS\M+Q+X__CN_JR#UO"[]6]N]1Z]6<8E*&E.ZW7#^7>$
M3>1#A-TU=@FFCAF<%W$4-_9]O,X ^6;3DP:KTY,V)]QV^[LZI^GYYS0]%?MI
M-[#5+G5H%L?";CX4O :%H:<@AL)XK!0$.1?5=?"U($^CP),MS5D) +4AI)$-
MGNQ,".AKMP?NL-MR4EP3S'0A.#(P!X.Y, (BINHI&G N]&Q7+[+;ZK=[;K\[
MK%S*X03P.4AW;(OH_#./A--RG7:SW2*#6^X,WA8D'(7X *H>CED!U:5%.^'Y
MM'>Q,P%&>H*:@1//]4!:]CESOWE<BB)!9HW6D-0F8HP$+4S4<D9Y$/J YQ-R
MBTK@J(1TYP4N]EH]<HV/_(J/_*"\&4G\A3+,P*H .\8%])</;T&'<R*L@2/P
MY1_>6)BQV,H_48UL!A,-1Y4*4,76N!E=49-J=]O86"V;:K^@[#M_$T0JKE9T
M^^*(%'M*%X%)A5\ S'*J-ZH_K)U+!125ICCA%K]\%AHYI6KRV,12=0'V+I!X
M@39"I(<V_7Z$0_ XB2Z5&/4+L$O*K=&\,?D*64,L3:6)@%AXKBR.+ZDR#3:4
M3KT#5:LZ#<#_#2#O(W8=$HBL8V%O<$VOQ3PCGYRYJ&#IB0 U1$^9@T"2&<V:
MQ*Z(LE0>:[F0=F?H'U+E%U2]"13Y[OJ]2T8DMUPTI5[4J8%<S5ZYYHLDFN[)
M0T7RV+K5KA\#LX6N27%;TD6(^_WH)<!#O/G4N?S-P3EGIN:E7"^,=$H!RX\>
M3>]['\/+!NZ@WW?[_5/7&;K]=M?M=-NNTP+^TNG"5QVB:/HG?-WKJTM-L8$@
ME;( X7"F+)0WV"C@HRIDH4T +X$M4J#1N0 [">!"@<X+^$NNA_-@3%,[??".
ML4VT)X?!RFC*"KE(B9K.ZSC^W-C7EM9;[O=2A1_XY$U20^C7$H>*RA4)HN'T
MW5Y_Z';['5=V<Y_9N44SC]XTI^?)ZU_^_<#M#OMN>]#%0,%,9%,6"^AIX%\U
MG ^6J!RZYA9.@I!(FD0"=G[4E? 1U1N#^8;YU6\"'MH(RF">9+I?C?X8/6;*
MZX!?\FM+M2'R] !4ZIB<T)U=/HN\&[JW,7D6RO6=N''M7) L@4[Y'D46,QIU
M3'PAGS/(=,Q"IUKHD],D"W'#P0MO&4MF9S2H!*Y1P,/E$/_JI#YMXIVW<'JD
M^S2+O$X2CSH2ORA KR0VD^"0.FZ2CDC7$>%D*QFKR4OJ#_33*+Y3C#%].%LT
MVAQI;86YGJBFH:,UB/,T7)SD$6\5]F^682I(7ZXF>(+?2G+6L&RU+& >',EN
M>)K5!*TPOY:P$0[MMH+# VE:>&,:"_/0(ZRG_/<BH*PO*P..=I'R+DCKMZ"[
MM ^@X$WD(2G^Q1=HCZFL^G:Q-0LZ(GDL*<U;QF09X)X^.1JEFJK#!MKOB-'&
M8DM(IG?"S9V9YT;/1[%N] !+ZAY0UE61PW'6</PU]%*)"JTZD#Z.I)Z9UJ'*
MNHH-NQ\@R72:<FKKGZIKM9I!'?T1LYN6* HI4^)(!G&U#-%92GCS545?X8:0
M^49A%0SCQ2$5:\H<)0]S%-![2]DBNMEJ.IX*/P]ENQPB<;0/CD2QE7W(28GB
MGHV8 X5W$/_+;9?14*-&39A?G].(,WP"J^%Q=HILZ4^:_=QH]MQBFGI\NXZ\
M59K!PDJ&W1KED$>'<OH@ZL_891OS#'@@C!F]<XV[TI,0[)<2 N5<F4)N&4^:
M*8VJEBW(]51IZW2VL5F<!,SI+EXJ/^,&ZCSBX.$VV^! ;3808.^P^=NU-Q%
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M0B_-1SA+*0,\A@L'_F!\".?6"W.F=?@POJ,;YMUX091F!')?3$22X)KP'DX
M/B:@=PGHG^"@OA@G"(T4B3.LS JX$\0O Q!CL /'9T[$D)Q["[PK"FS78IPC
M5.!.D+S$SK+OXPQ6QU\1YJ8B])W1 C"; 47#-P"]&"X2(HAXV!LADDF 3YF[
M" O. #P+U_FU\;&!6T4>Z59OXOM!L]'4]$#'"6. +:U^'80!,%3G-\"K6#BO
MO>BS60XO,*XPINVG='K\#(XD9O.,R8NYLGQ7M]'N_5T^S\<%J1( !0-E 6<&
M)H'GBFP0#%<3BD12KPM87,Z+4%U!J6.H]2M615XVS4^\41ICN_^5/ZG22%BO
MV6T#MPU5DM-V*9G#^A-W'?C_^"XX'8PF\/]'O5%OV&VW^L/VJ-=OM;QN<RB&
MDXG_?]WF=^I'T\3<O1MQ,@(2_WSB3>!D+[WPSENDW_U8A < PP;^9G!;#:7)
M9!LH#38 $N,(;FO,,N4EB71.AOEO[ZFWX$P3,?G'=W^['TG][W[Z1 VGX0*A
M]L0=JKR?J@B@&O"MWAY5YJ6><T2?+*L;%D-"B=[JO]J=BK"2)SRZ\4 KO<0:
M_&"\P=V]1FDKN2'(THS DTJ-$[@E:3=+RM7.X:=4+-3M08.X Z7U)(QC:BE@
MMM5 F9<6-HH_P+PR'Y4N%.T@P1*4)N++7(PS7MU%*96S"(!_B#0#:8@\'?<S
M3^(_X$F6%J,X9PUAE*< JY0?P0\ :6 >) O5GRT.;X7S.8KO^%1YQ']/@O0S
MO"('C2/)0.%@&8EK (039P+61@QF0S;U,F?F+9RQEZ,N@QMG&:E!"U+(?J_^
M7"J)KA."[AX2'&'1X#;(0+X"0 %\,U)X4.\<3P-XBD'%]@<>/&&%"4P"4(,0
M6&0-P<N=29Z!!O#P=P#4X;>$#MCZ;!X&9.FX^$\TA$ .LS(W6K#X7X?L#SFN
MGJ%B+3>D13P@$)^&?:$! U\@+/D\3@J"D(R=*(-#TM%8T> EI +.%MA]6WA;
MP!?>&XFQ-!]/07M5( 102)T6'HWA^\);Y/U!/L1.CM99P[D"2N%_R9?H.X Z
M6XB%:4MK 2[$W105.G4U5QL>ZK(@R&:(VR(%@I$(.IH'VQ\SQ4O43_2U):I=
MLDV<WP5SA\S[+$ ULG1-I+"<;6ZBI55PQ>= X(3X9HD^$NZ$#?JY,JO86%ZM
M<1TZ=P5833W@$YX?SVDDK--KG^!=Z'7@A^(S0#L= ZC)6)K'L.B"20T,IQ2Q
MB1!YFX!I#YPB!%I("7C*H&+RZ;32#"C56HF])G?3 &CT#LB(7EM^GRNM,WC+
M/ST@(F0Q1)OD=8$_)X456\/2BLLG6+5B1_EQD*)*JPZVV6?QW.T!6Y,-I'E6
MXJ- D \D$?)6IOJB,"GAI4)FAAN1AJKU*N7.J89'U9EHI>IMD6@"8D2O"Z(^
M!>Z+UV!Y!U6>)(7:2A<8'C!%\09V1;@XWNOQ"1'C%U4(3ZD0-V#^)VS8^SX)
ME=2 G, 1 #MAD8 0/(G!B#LANB)1"I(81?I(9$!14?&G#4MQ(72P5V*[]6R?
M)%U:1#C8BL:[<3^3!FD2H52>H&>[)"KVK+):7BUD__=XL$HW90VU(J.8!*'R
M!Y!?X>*<5A2CQ-R@=H]I>U/R?62CX0-@_S80=X=SN>Z3-$A^\,(XPG?=+$XF
M,= )JEI!G(GQ-*)/E9K)% N*); 04@V]\5B$2!N"Q3#@&B\ J&D^ZH#QG"0W
M4A/.,Q<)DEGP%\M]H*M(W#DS <P.M6:B&%2-@C'0'8#H) ,3'E4G5(M!A[@.
MR.<MV#E%Q,_7I34<=EW\ -W=L9^C;YXU#V2=I,N1_T[MSA$3>!<\1&(6?G(C
MU<]LFL3YS12D9A!AW,<^!;+/L8"#HVOH)@>%-$:]?@X_OY5Z#PA:,'.#=$I"
MVYQ8!AY(W7-N@2>@/_Y&P&N]^914?8I1$0COXB3T00N[BPDUH#+1*^D08[ T
M_D+/912,7%:_0N\FG09S9Q:#8I2' L4EO&4:C((,;8&),T,PS,'XSA9)C.:)
M WJ5=/XAQT$0O;OXY#IG__G5=7Z[^/DM'71.^A[Q@8M/K%7;KS> AEV^=,[/
M7G^ 1?[W/P[%P_!C HSPI2?[%I$(:YV?N\X(=$K'"^-(2+,(035"MQF2!=W_
M#Q_?7/[VP=4"3T4Q@*\34<!2OYR?OZ+OS_'-5Y?_@UWD .>B]&Z%7@"C"\26
M>:A1!F/GW:=SU@$R4GBSQ5P0KV-R<XNGG9(@)B<SFBCR'R2844.E> G_.!&D
M0DN].0,T;D>2#,X/GRY^_?7R?!F;[R[^Y9KSP:[F&%NPT6S#$@@U -JEJ\J7
M"14 -',0-#/6*11N9B+THGCF2=T_^2Q,I RI.0P!(HF%I)]!UD;()!@/[R[?
MO[]X?458 RAYH0MR+0+I+I(8=%'X9RI"5C^<41B//XM$^1#>7;E%I)&UAAM6
M/MXIH"?)X"C2'_M/#]DDOA:4!OB8/?UOO "TPL"Y]J+/B_B 5)Q[%!I0U]^<
M@?Q+0%/7<#!W:L4-F ,NR XB;-AW#"%T-D^"D/S6KKIF.J1"P<9,OA:L;X\X
MJ7ZAUAHT=P/8*DO5VD@>W;^5AG.FPU@AR(5 J_E2ZJMMK#CW$B447P5< $R!
MF#GY"%6L"D#1DRF0Y 1T_1'H1W&:$9,C6S^V=M16:ON:7:WF5PY9(X3&$T3S
MNHT78'0LA!HK@;@DTH4%H )3CO,L#7Q6#_[=N&ZX*, )6Q1T( $.U"5OL>,!
MKY9>(0+3Y1P$)ZWXR?LL?(\\"2 W(QG;X^_)4X,;)4ZW>H\%GJYV)GD0;HY^
M0JQ%QH5B^=J'O4'QJ8;S.JXX"\C -"8'5Q*,\LSRHH0+VX_"5T?%WR9Y0J+E
M)HQ'10UEM9Y%\2U[9Q. (##*E#02%E7S&/WRJ*U(\U/Z0&'-.U'(1P 5Y3,[
M%F!72EV?2<<#XI"=?J#8-)Q_9P%L!&5>0!)0*T[H:4VR0+J:;,TI0+J(Y+FU
M8BHE$JX4@3$%6W E0%$VJ^T1RL074(70'Q312Y<A,@=!Q^JF)EH7:9(]5JN5
M/-:'0B\'V+'F:90KD20HHU&;JR LUU*VI /QXM]\4<!6\SV768?A%V6M26M"
MOS!W]WRRS33KL[@><<%5K.\RTFD%Q(NO0=%3,@$]!H9&7[^[QH#F+,CHJH'\
M=2XO27N5,?+Y/%1DHFCSXMT9607,-&58U;!*#/\4N(3--E>?W34V(;X $(&3
M@!"4)!S*.V,LC4#UB2)%>,CJ$[JAB%BTT% M&X-:R!0^*MY//#L2"1Z&8;!T
MW%5GU/?)IHB16,12O[_X-[ P/(YTQBC0$:/ V\-T[FH>P8YR'_WBH"#"!<8H
M-]R7.&(_%>/-D!<1\)PDSCL0:^BYS1/25%%'TY?H3-.T]G7K+;S[Y=??\?=U
MS+H<L^ZLCEG7X>?G&W[>IR.IFM(L/EEDCDN*Y#A//';I@CZ.?H8Q#W<&)FI9
MNTJ$W+=:80FE7%L>$@ZYL(WL@!2<$;/SY@L2+1_&66QDB>)@R.BCV!(F0#LY
ML%/2\]!U8ECK$C<D5H0"81->5A0P:_3T#0P+&Q"N$4=+4#T6W=T2_ AD=#[8
M&DZEYJA\$E)CT1HRA?T!@^CS1<@'/BM>')"V_03HG8@P-Q8A#@#-3N+)";FX
M[G^[42/)9B!')2K,\SQ)<XKCDIRUM%5Z2T'/)7\E*4BX9Z/BLCU+27#T3923
M#J3=/Q8Q3&,9]529A5)>!JEV79)1@OL3,H601AK8OCIV>>'=2^'+$.T<I;!7
MD:G4(.AFT?E1XW-&2>SY!86?+J8W(_=L$J0$E%OX)4@1T'YO8OH@(54F A1I
MMV:&L7S8S3B)T]0HL18H\4@N.>EN3)9Q-6Y=)YWC?$:0?U9:"+]"N1Y\,1=$
M^G)('<9^.9X<H6],AMIG7D :F]R>\L;BJ\^OSL :IYV\/[\\.?]T\5'E.EQ>
M?U* 0":$CBU*%:!%O5LO"(F9@<KH:5T'T%X"AENV<N259[]V!<P5#UEA5]%6
M-<$!<X9=B/!$1&CGZ#,V@#,"70:W5#%,GRF:5?Y"Y?PEBN,;B0[(\P_7[R[/
M3SJM%GN"%;KG4Z3I3FG-%83I8,9CGB*!C,4([T2)"UZ=79Z F$TH_+]PWGPZ
MMTV.DE3(Y\2^[^*B%_DD T9(OD1-T"0L+&\4!9[1$HSBG-@LP< <$5Z(_LE,
MVG,GG)B*^:3^'$Y-[-L'612EF4P\L-(Y4'-&57W&Y.=\?'M-%Q;M3+;Q93!1
MIC/E_L*DLL O05O%NS/UHANA+1U^3)*O:V=?&.-R$H0LJYSTO2)>Y5=BQ;UU
M+-)#\C>\\AB=\1(@:++3X2X+R</HZA!IQXK>BK=#NQ5M5\,R\[L\OY1.%DSC
M13=:,%%WUCR;:D>(1"^:W>B@9]@K,FXXK_,@),,H)M^@OO8D=-0_XA$ YE99
M=U.*.EG7!/.$X"6@[  <G%F,,?K9+ <HS7&+%%QPLAR^ )*\#9(X8E9A77_C
M_*<S2]?.K?:6+%CX%+U'2[!A,*B(@I:+JZYWU1(>6<J"7XBP;CCG4S'^_ [1
M=3*\0%?\_5RDPK0OO!FA&\&/PWSFC60HG)6$-,>*$;F[2F?R:F7+)=S*U ^A
ML^PJY1(9\8:CL,V):(KG[)Q5J5V6KYPLZ52E&>'3*J>(&(NX67!PA\&A&%(5
M-P(FXP 5H4<OU-D);C%+"_/&D8/8O^5P._W60^B<R("-\HL%,Y/K0(KUU17+
MV'0:WRG&>1]RB X,=HJI;X"FG%FPH+Q$XJT@T;S4L'Q:% LB/#1 %'+9UZ30
MVZ#1S+)DJD!@JKA %6/!CC_"/P)?,H7KQ0RQE<^<2T>>YN+ZW0?GMR"AM#ZP
MX6@7G)VQY,1B<,!UY@ 9_GSD(;R4Q ;^NQSAV-1T>*"+OQCW ,;OZ"PO=@(K
M"E9P1.J%5QO(-;N8"\7*VLDXGI+R3=>T]6/['C%?=1Z#_U5:*"FMI<?F(--F
M],\E7:$B\%*,6U7<\%^*=SI VH%S*+X,/YH)#W7"26[2.9?)![%Z=GW^P?D9
MF$6"]PAU3+QZYYP\8-%4$1$ROTRK&IV-N1]\"#ISMNZBN:NA)Q6OBIOZ((!7
M@);8!5HH\#%E#\YCT,7H1E-8#NB/LYV1*>,=AL-@4"8!4M1N6 ,7?+T@N8_D
M*RMDR )<8JC2 J DS1,?\Q<BR;2$Y6UDH+(>U&ZL]C4>EB*$9K0RC%EUI**A
MR8($$0 T5&((:<%65[1N8R)@=/69YA%U)IC ]L\VM_DJ'D^%YFKP&J#C3/P5
M@S6-Q-,PF&RCA-N QN]7)*SU%3WK2,/]POV7"G&NA#6*Y/PF3S-FZ#*Y55/F
M'45\F&)]T/!4)K_.XD?*<Y"92A4)3C$.YIQB3.]@-759$>"$-0S#3[UPPCE^
M& ZFJSA1J<8>*5W2 T)Y)<67;*+X*X3@92*$L'4O.?I(&A@EGI,"<+.%#$UB
MWM4(WK2AZEA UQ(O">.QS)JLU+U2^*7/&FYJ ]PH_2(:PPWP;NCOF,/EC7FC
M<L\$-EG>X+#X2JVH/;[.6U!2HU3K55J"'=M@=LF_71*W[Z_/?]TT&0!0 W>$
M,UW.KSYN^C,1_07XR("A^*1]_HB1JE& E)90.M-89$QE/@<X*;,8.*7G!S+;
M:URI3 %,TG@"' 5LB5SZDPP]25IG,.M;  !@B[OE]CMM PQ)QIJ_KJ3I,)N2
M?X7DO%4?P0G7*#V-6TROSI0_^L,*74D.)IF>5;6L426QJ>J7.0\(*Q.^!"DS
M&WZRH"!S90D3@R]";[&4084O/__PV^6;D];0(6J9!6.5)[B\,PT5UW(&6=?0
MX!]+?I-<NJ<#KI,G$Q*-C8K<0&T>+'L@5UFX-EDK3B(IO+AKP[A5K6HB1#7[
M3OEM2XE:)!Q<6.G]I[/S3R?-EO7WMM1_Y#]!_]G"RMN L5A,A"ZH*R\<OK44
MY2VDISL7%D-1')HP5K2#;)6"5G;5>\8A96$C-:GH!^:CE3ZVV(E%"LLJIDK;
M))\OT7:DJP6DHQ*KP"@WV3!(R\D]$<+'?B1FNR .M&21)& <EX;,@%1)P!A_
M%29*%Z4*A<QU+JYOS)J ]!4&N7'O&BE4AWC+(=YN'>+]1D.\3VU;_*YB(!0,
MDWDWL52$E/C1^5#2"0@28"[8$R'#)7Z2WRPG%JN**=339G,O35GLIS-L@*&R
MQSD7)L 7!.-4A3H4)U?FR2SVX;BZ1G4FT#<>I#-=\1E'G#!>6MSL22]LZ=',
M^CPGB4>H^$L52IX\B"8)FO8Y!H"%+3L]!R&/UCR\O-LXU3T@\)B859\:5PN@
M%S.(;X6EG"D-B;U/NML-I]^A0F2RZ BP8]R1SW7 LC>(L=LHT &LVZ.Z(V3*
M"EVXY4GHS69F>92,(ZS>4QHA[Y2,0B^_81UO'11-@%3C'B66EXRG12T@E2Z>
M$\ZR)+ E"<8SK$Q+CCERH0<N*:(;8')DBZW:@8V'ZTS,KA>12&Y8[3_+DP"+
ML3C'WE(* XK02:"JE,&'[=OJ\5(!*$5DF'>N6_V\EA7:9"JW7YT77B<_O%*;
M.5_>S*6]F3-K,TOM?F2WG]8&W7[8J<PZNB);.P2IRP4X9UEE2(8KKCK:D__Y
MM3E$A=&)D*=Q51R#/('???K7)1O5\*0TFBF@H_T"K5)X=%FOTZH;FX8S$MF8
MO2H)G[F-'Z?B1& !&+]=:5O+.B8=>NM N:U[NL1-S''85()5Z%H998YT?RYD
MDCD,N 45/ZU4[P&%!%#E:^SHWB6/-36G_>"I.9&_T[UN*,N<BP]7G\Y/,%9_
M=G9^Y;RX>'_V0]$+6TP6DGG&RB6)Z(F1]K%=V6S&A8-(321D6'01@9PP@4CT
MP"+\MWL](!0V,UG'KF4SWX$$X?Q1$K]$1I8!JVC8#C/*5"QC6E1;&ZX#/YW%
M "P5'#=Q*=0F4U7M9CP31B98^5.1<_G^#9[Q/<:U=> #=_2?7UO--I\&7FWX
ML,Y;8"&%I'[^YE]]E:"A?)#K&$ A?G$D_MK?K<0A*FU4>E2)=5JR%%"L/E?>
M$&9V^"]E!FHER95-'? C75R%]O$H]BEUY^S-N=W+(XBB^)8COT;16I.F)*O.
M<,4321M6&L7OZ+ (,4&8U\"J3?I6Y!DN'.O(N=1)5KVDD#!1?@^Y902F>2''
M9Z^M^.*A4\I5]JI6@BKSYG6RC*F)3#U6UPD^4@F;XPW 2F&0B#$VG4#WIBHN
MO4GB.]13N/_=LI9J5998U036OAZB8A!498Z;DRO9-\;,<9+0&M&4C408'B&U
M)UKA1O*3?7+8Q<,Q8H1(KO*$+/7(*KK%IB=<ID>[0.X(((^I$D1*=+$DWPF<
M<5)-C;*.4[K)'P:125P%?%T>=HD-%1(/M)]Q#/S#==Z_OG"=<Y"YH1+D9[['
MFJ$)@0+O\['$PR\2HG*1RBK$K]$5N2: KPJ6$"./M].]?&"PL?&+O+5)_#^O
MFP6>^HF\M++-"T)<,U=V[\F3+Q6FZ.,H==W.1RF4&DMI6*Y!8+X?Z[0TY&'*
M#E0=#N&>HZO4DUU9J.;A$97PJGMY\/KW\0BS);IE,PV/K9M/V9JK\B5CO;X7
MS-B7Z8W_S ,MW JHQ2PGF4BJ'0V:#7$">2I,2Z5(>^C'4P^S!.%@?[$;0=7(
M46U8KLO *$QJ\>>5*5G%4]CF/V4/9NCV-HG!6D O&>F<XTJBZ LU\*(0MM;W
M*YP268P=B)2S_?Z+:H5#"L\IQVVUS)5W6LLGN-FIYC^'V=U"QUJX1_*1W)HS
MG9%0Z!)58 =N=2Q)WS02]BRKT/V%'96"V=P;9ZJ!G+Y\NF:3L[9-QJ1N-5?0
MJ]TE1;20"U^HI=3BDAXQ+, TUH)/,8TJ(5>H\@; $T!HF''-5*A46*!W>&R6
M6J8QZ7+H$\!D\D*(RD.VDL+G(T%R-+Y[N2GZ"YUPNWMIY+AE!Z%SA8)/G(3]
M) 8R*+B B07Q((%5SY*_9E:'O<1F8<O$HYI#R31D=M9ASP>4EDR?C%1%V):*
M;$6G?>)97$T(*!8B4J+!BC:;3GXR%@L/8_L6L%YE#JM=,8QYP4D@^R/*CF1&
M:S8Y<_CK5+NB(H%/H(F)- M*%*I7^LB<$:%U*+;+9O E)WVCT_F7^ Z8<^):
MU9\Z3,:YELZ?8,)F'-/6R8)6_(X+$=),?>\JIX0"%C7DD)4CF\&+;+];ZDKE
MWINU6KAT<Y#1F (0EJHF< 7841I'D0B18DJV.D'5M>+98*(B9#&)3N;E".[U
MKOHZ*J1*)4X)1WI1=?&(84=^3,&'P"K84#]'DS.UVS0O<5B=LB39J8=.0&I6
M>$LUZ6D:4 $6L#>IGGB<F)MF8B[CW=@PTK3#5SWM'5+2=3R5@JU8/FQ,<=M2
M!8.$7)<DF(U74":O2)O3)$&P]A,D541=S/(%0L:&GIZT<*?  I &5=I.Q:4F
MR,HN_7\)=!E)HE96(";*L$Z!BW\V*3-6OP"X&G_D::9[>&Z(57DRM'GYK!9)
M,R7CG:\@-RMI(2UG\J0AI29;/<27R #;JZ*Y2CE(P<0)B!^H!0#K6(C$64GH
M!F!6A5 !,-9![.4@=J\.8G^K0>S#4[?>H(;[IJ#A?K3LI#?&GGH*1<P(,M+5
M=;'.S+0B60JTR>Z'4GQSCX=)C$,C."2-'8MC"DJG.? UG?A6[H\BI\0 3^<"
M)%EV 89QF'$G;:K, [:''L621+O.I#F#8 !5/PJXUOHL]&98=WV. UV ._Y.
M[V !7;4OL)2I 24G67'&T*+H#R[6OF7!3(2Z8Q\#(A- %>B(,$#B'BUW@EY@
M!=RE_6342%(..9RH= 65*"HE)"6>RQ<H,]T$1FSUC$I0BV^XJ^BV0>EV5E2_
MN&OJX +O'0LY/R1(_!.DC@5WZY'-D"UEFV.W52JWI91R7V;$<S 6RJF<2)^\
M(KG23DC+3>!(0JAH:9#H7>14NF:F=E1,!U*"7B.MNOW("@?'%N!PR8O*1J8G
M?UCT@.)^4,>V!K PCJBG'EXUU15[LSS/W]7E*1C#Y&D2,ES.VZ:Z6959R+;%
MK2!-1CE/+8>1]/Z8'#Q7Z5RX)>E &F$[:^+5U 236K14AI4B?R5H8_(:D6<.
M(:-"(";U&)<)J?C4W+B]*5%';,T;;\F9YJQ/(TG.5$HU]>:D>38<LA$J]!8&
MLT"60@=(]"=LQ\GJ4JFZ&_E ZGB"@6?\3D41U%0>($4QGV*P@1Z\E?5Q=)4X
M#RLEQ]9"Y96IG![B#%.!&>!C'HP63S@37=D Y%35M?-,<3/.RK:#!]QDGRY9
MPWF/M 3/A=16Z9YW8(<N;+0OV\U*'\&R!XYND+1%C+&U<ET%7WE/5DC29:M>
MST22!C*ZNN:FJ42A-+#0*-T$8.\\='YD&")*,^7[PT^XO9L%R$IF)H695@0F
M(7J[#6,W6Z SP!W48:)""%CU"4#FSHTK-'OD+@RR%MIB184@SHK]?5 >#!"M
M\T"Z$D$Q"$-!N@%7R4O5Q' D.:-"75#M)D7)$$?AHH2%@F^U%-X.*+&)6RX
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M/O:[W@Y_[+Q3VP&X74EFBH=6+_\64L*P<&0<).-\QEI#"@(HH6DBBBM5F-1
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ML8-A4=>Y\[!%2 !P@&,X?B[P*Z^PB]0+X;6W<9C/!)>?1O"Q^7YU=T9X5Q;
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M ,"S,;T(<?$1;*]Q(%):L_4*215HF9>SWD,T#!>53#4O@WV\!3**QB#(G&O
ME4#$J$7XUXAA#R!!6_X(0L^YO'2=2WC4&3"J@]0YBZ(<EK@2\Q@>@%V_C9.9
MTVJ>_(OUM$WTP1UK"KB2N8HEHOX(=BS0Y2_""^$J7/,X.F<:IW/LH^X '8<V
M_'$M+M9QO!GN7=$X"6;8PW@*="K0.I+J(>DHH(\"H3E LP!5M[R'K5_R3OB
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M[?0/5+Q^HL'&EGBM!>O#5.7-FA$>.%/O]#ON<+#K;CK':N\^"Y2VVWVW?_I
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M)I'8UA1_PHY[FF.T]U/WP6IV,8U'A49_4!V=<SG("N2V>\A_;B/"VRQ *?)
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MR]17%8?75F"N+, I0UD=IS) 9XPWY):\4KL;?K$Z-4(5\^J-KY*_I_)-JWR
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M3]D/):Y<JLIH9T!AII:\J= PCT;E]'^"RDG]E9.M6G6XNVW].4$Q5!9+P;G
M+_KEW_=K%$=K5R%Y'>EPRH>L^+HFE/U)SM8SJL!4BH$L5:U0&@)I?X)>01/(
MJ-WN*B!L:IK*BFZL@E2QAD)._0X5>?A[UB]K!-3[E)*O'N@UXY/3,=]*BP-F
MJ/$I3#CXQ&0[&R<BTF8*-#]"0Z!$RE,QB[R$XA)7Z!(RX:ILVF* A['\J7;%
MWE)0[ZPLJ#.,MJUC56=5^C@:VP!'-42]4$5 BG$^J0N#+V5?VWF(.Z%$QR3'
M@]$N#A-H4SX(%6D6,Z9Z<SB#:SUO6];!/7='8;*FE?7B+QVX:M(YWMDCS ,
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M8O0_BG]8!W!^8].(50RN?K7.85T7UKMW[]N9S%WF!BN"2\K<U5G"5-(9&+O
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M#EHKQJ[#0,).?3!DX8KV?$1'M%-@;&#Q4%*:.*GGIV&PM>-Z8 *UJ3O+,J-
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MM)1*HM'"\V1\*?-.>BXD/0^;EE*0<D%EXA%0=$%ZNBD&FIA/;-=)W93&(G1
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MM[H,_^QKGN5K::K]FRBR>%WYZ<G%^:T1<PLK6FNN2[V7^2F*\N7ZOIQ9O>E
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M+*XD_.6;[-]L2![ *ZG[?]D8T;(%"*BK)VDG11:6(K3AG(V9#-.$R"A*$!V
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M?[(C@%?^9$< K_S)C@!>^9,= ;SR)SL">.5/=@3PRI_L"."5/]D1P"M_LB.
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MC4-:*(($#9)'EDBBN:M#WXA-ZG]<'?%K4EC6P-FU?_E-<^_2&N281\F\04Z
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ME3R5/)4\]Y$\E\G1H\$;;D+@Q'-)K55))<RY]B9B*O0ZU:HZ1^(F%;&WR_2
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M?/5)?NX7.W\VEVYPY,S3@TX "!3///X<9X"\?=!!9G::[1J?U9&3(=PNZSI
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MSL)I\X#KK07[3F?AG'L:?^%^6O2];G=]^G#=A)]W/NUMOV%:6L:!5YAT'DQ
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MGL:G?$G.A11967$& -?QZ3"]Y5G;V#0'3#8?Q/C-.2C=L!0I]N#LP& PA[E
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M]$W*3YV&0<34F*_\W__03]?MY=JD8*LX8855WO*2"58:!X3/)2T*9K#2%;N
M>[S;B1C/'>6:.:F+PC),I72NI %;+S@Q5I,'Y[V'6&D(9YK##R<H3$J50C.0
MUJ4/HMSDY.,W,8?=SR)9PO%/A0Z6:E?&1&1;,;'!U\/I (8Z^C)R)WH\/DV9
M^">3F-,.C#+C*B[^*_\RG0V.IKDV0$SN7GGL2E+S_<UBOL,)MULUV&O-#OX;
M/I&;2K-+9WI%!%KOV+C'6<=W8O_N5EYHGWG<9Q[?Q<SC6ZE/_CL(1)-SC\<E
MFA'>^48+DY/(/U8,2@X76'@"<CVG3!;64"XM=U9052IGS05N4+)J- *M)A)
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M?/!4E:5/I3^'HOCAY)F>P#>/P+F4@?B@,/.QU)'0EK-"Q*)6ML"&7DOAFY[
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MW5UW0*$13'59]D)'%F<5&JFE?-*.BSX6!_7OHF[Y@8$,>2?8'X#!,T-%U?3
M3KVGL5"$4 6NF\7:/T.XEA2(SV$!K8UZN/M\M2((UK4<FSI,L.3 D.S \#A
MI>*L$'1[Y?8%VPR\;VX'"Y(([.DHUCRT7%LE8F$I#U,NDXSB#K8^_'YT_+IE
MV(*6P +KD^RM;]#)X-A.W\&453L4"9_N%A6<')Q=(VA&%$=:*T.4BAGA)@V)
MHC(A-)8\,2Q+C49+=1%@Y;]P\K>;X-A& 64TBIE,N.52Q3*,,JH#F<%G:;:;
MX/N=8/WE^.(\8M(DL=7$!(DD/ LY3'68$AY2L!@1]RUTKLB2"78.ZV &&U&E
M[;K>LI[8D73'27#-^QW6%Q?\6AC=I1+PWZ-E4MC3.#$# ZH']<]CV9KV!S>=
MSW*<.S^F7<[1S'%6>\1\5K/ALCGW0[4 SJXO"Z>FJ@#U^PIZ"!U?5(?5(<Y!
MG_BDN[/4&JZ;T\-]-R&E>= '!P=L/V<W%E!WS4(3]$XLS)LM')>J-645WV);
M'LML_5WVR14Y>I0.B;5>VVDK04,PV+46*K(\LRRU&<_B0"LE9:)BL4%;A:L*
MM(>#*F:RTV"+12VGO=OC-^<JRX(HM!%A/,X0V%<0:2G\HY.(*\9"FHIG+Q?=
MIO^J-<^P\_N[_W$ZK-]OFVNN;K<X:I /]' \<A,S5]/?C!C7MY?6W:-;#),1
MZBU48*BM,S"EYSM,RC4_?Q2[1%1 4,RB$ACC'E_< 7\?*W$N:GYE%TYPKBO]
MK<\B_MJYZ ^5.UZS[-4-EZAX/_8)CX!C*:R=7MM"@Q:G#[O-8X[E.7+L;E&?
MN9TB^,:RD+8B>%LXZ:"#F\FD^LA&X=Q: _^>H):>O&T>A,\P,@OC<N2Y_DRA
M0IZRPM W6 67)F!"4C!SE,V(.\^!F&_$!ER:.!9Q&L98L+3,S,E\Z-/)6[<Z
M"5:5_@]=L3\&65PU-P)^N )K)XEE"3Q6O\/WU<%EA/Q 1YR4*\T%2*L"Z/G*
M^NO+' ,W8PS(XMENY8L^+Q""PQU>GLJ\[Z,$OW1>G;SK';TB(&O=\G<6A/C[
M\>G^JU-" Y]H*/\,'Y&R&KO@XH*^NI*#&8:7O?_J["M_1&39B654^/-%9DL.
MAV,"WQ-HU'7-JP]NN#K>@3\N6".GK*Q 6SS)7C1X=T1Y\Q%EL3NB_ 2/*&\\
M<CQW1)E3KH54)@-ER6F@H!U26<&-I!QZ)1_0$>6EN!5N(W$Z(<.37)=X^!B4
MB<7 FL$C7J6-6ATZ0N5F\,Q7KF;3HKJI.&LSSJ?#L8M/KH.(:)W.N=,!P<I.
MGOC&(L0IV'L>$6?BH3",S9JG%.HG/)QM9\L,P]L*\[7,L+:Q&1<@W+XCN-\[
M#9(QZ]N3;-4IW\G^P"#Y\XJO&RF1B5NA3Q8,\/0H/#YX<WMRT..]@[/P^./9
MN606[$:A26J#A/ DBX@*#.;LF0AM 'Z_#!>P$;(DC)5-PR0PW)@@97% TT2)
M**7,TG@>&/#A&ER5G&^T@)J*RZ.@3@IS=M)Y[A;^< 8M,9,7O]P=T\JQ\=5V
MBZ/_<^^'U_Q2_O(K:+Q17][\D@]<!]Q-\UQ_\,QZ:]^C?GLOV+"+YQ=?[[FO
MYA@+_7<QW4LI7_DUW0N:WRUA7BU;"MK /I@K[]S]8*ON;_&=$*M?NN[.?U9C
MTSL]=@.-^QP3YJ*IOJ!1OB^G[#Q]WG+LM>5LH=]U62!&ZIW';%&9_#C /:>J
MSC 9>]A*QG98T&V-V$XR'IQJ74:^?5<2VX<HAFB+WF$N-O=QGF'\^P[4=Z;)
M7C56@=B-U9W'*MU&ERV6^VAM;8/!_HY<\E>Y,7W[@_G3_RRRK"6<[&-5;IOF
MXHXD]YT[SM5/X;K_/W=F,-^NTW?G)O^1O=VBFCA3F;64Q2IAG,LLD3I+0QK!
M'U%,DVQ3J0YAVY<5^_-6BX1(AU^*+.S^9&+A_^94?JG27>QQAC NSZZ^]$\^
M7H1GIY^^G(6'X1F\HW?P)OSP\;<<V@O7G7TYNWU#/UP=A;U;S<M[X%VS#^'[
M^.3@P^7)Z>N/9Z<?<NC/]?'!AZO>[W_D'S[^\>G#Q]<?CY&6Y>/9[?'M9=;+
M:?#GZ>&T]XY^Z9T>?CD')9WJR.")JR0F/$H%47&6D32VUC(AXT#09R\%ZW*Q
MZGS"]UDW^-66ZV?=KKEI%YG?>7<:[PEK/*-4PG6J FLU5XP*)>&/-,IX8A,>
MVTWG_W<:[T%I/-;2>"&5(>.1(EF8:BR"5$0:&3H%J&-F623!] F"I,OB56?X
M=BIOI_+^62HO$2D5D8P"*6-NK1"9M$G$6"JRB)HLW01YL5-Y#TKE12V59S2C
M-..6! &3A"=!!D8>$R3F(84=+C&<@Y$71$DWBL6C4'E;!PV*,T*/(6C03B]7
M!_8>>PRANC+<;IJ6;BB/4L<*Q608"YF!"<ECPY7D20K_LRQ)0AVKG2/]B'3L
MS9PC;:D2+#:21%: (QW:A C+,A)IE<64R231H&.CM!NPQ?,U6ZK8Y<KLN]J.
M<Z]<&:A^LHL[2Z1, R-8 CMJ& >I3+ H+3*)R<)(\IW/^*@6=]MG5(DQ-)**
MT%0&A-,L(#+*4B("D494Q H\2*PH[_)@D7QXM[@?_>+6E*<Z3E(;"\MQ#X\M
MBQ*=1 $7-@N2G7?TJ!9WVSN2(M,1#S1A 0?OB*89D89*HJDVC%K#L@CLV##J
MLN";XT'WN+CO*6_JUZAXH+[0*8(%/E:/YXXN<G%(@\%<F.$,JR#+\5SI0S^-
MH-M]#,RCWWJ^%8AZM_4\G*WG^-6<TZBBP,9)$!"E@XSP.*%$4LJ(B(S,C!#,
MT!0#<T$W9M]L6-[[XGH<^8J=>MVIU^\'];Y3KP]*O;;==IFPP&J1@3X5E'!F
M+!'@L!%N%%CU5'*F-:K7L)LD._6Z4Z\[]7K?ZO5;F11VZO5!J==VX$3K,(TY
M3XD2F29<: WJU0;$2A;JP(8L04C3( V[:7+/:>6?J%Y=W.5?[N1A$[FA00.[
M_1G/E_]7C?_U\A$<D5Y^<F<9ANHCZ,SR<[ '#G2EQ2WU0#NVB6SP#SF8R?$-
M$I4DRU!(YH[W#AJH<.VCOGY^NP4R#:)Y(UFL_<\,KD"NV"N/'>JYB!$ M.>P
MASU!2D_>U)PI[^QHZH^T>53KZ;"+:':#BXH)&9;GI-NY&IH\\_RY'NS.LW W
MP(\F#>I"3TCL(*+D9#+4N8.N<DWW8,@%^MOH4L)>HH>?\XN\[R"#&\ OV+PF
M.-\:%A2\$AN(  @E]#>^WL%0(2C-L(%$/ ?6Z[ 7"'+&(/+Y$I"K^1ZL1/*9
M!PYRD.9-($ W># UGCUX,#?X"&>.8(R.0U9Z)E0$;?<]TUXH/.\]X@ Z]"$'
M"2CGF:5E 0#F.2>+QQ3 @AV--Y87=@;VNKYD#C[>(: C_^]DUO>H.0U8Z\L2
M#LCA)RT 8!>#NQS4>@)[.\+4NOFJZ#-](SRRQ?1ZV'C\JJ>@//B&; +7GI]#
M1!S*IPY#<0HV2"%M7_>L6AX:*$]AUR,;5<)X.1Q[VLX:(*I\MP,P*H:V1*-:
M'-$2':06]'+:4)' 9%]5$X,X]D;VD41E8OM]SY;;?,:* 74".YOF?0<VN;@2
M\@+7K'S.9&Y2L:E#!_%?CB;\_='#,GDL9O>8Z248$A>7"U@GLH;%V.L4QB-B
MF\S!<3JR83EQ ND!T6^<5EDE)4C[70)MEL,+[;K*$?VSFE406*]56Z]6%N]H
M-& V*1_A] L\QU$0./B[9@.N[/1R:+HU]?K<""+NI;_\;E+7;5 M]O'[>CBK
M9R+-N0?ZRR<.\Z'@^E8@'?"&K&_UM!8N& Z'KK8X (]D0RV,'"<@;4 RV2DF
MI4;16:;(W3=-?++FP(]@/ZKHKMT %V!EV6PZ&Y=8BPU$NJ(YPY&;DC80G5<&
M6P(R\T3IB(K0:,M3'0IJF>54F40&<1J&6P(R[[ -OQ^<,_3C"'DQE4EM)BDC
M1J1(S)ID)(TB3B(1)H9QFT0AEO72Q:SU?]7+>2LI;9A+GL)EW""O+NC@\0'*
M#FR6.Z.M0)LOQ/6'0B->6OVIAT#(1!R^70.)>(>]\[$HJ;]@_<P<UO-P"?U#
M$Y00#3EOMW>;DU-3D:]D#W?&=D-#C8:([X;,:(6N:HD/C$5A3+H=VXE#M]ZP
M/4AK01^-K7-[5=UJ6Y(L5*+0E,=YQ,?R!=ZJ&XYLP[=!UJ*IO4";&YP!W=37
M12L*_3LW9C"(%[C5>9/:FQ*R\W$( @RC9?5L6HX66GC>.Y CW*G'N*S05:J^
MG#P6.7H_Z*-=!2J\G^,N7QC\*"SK@*$N*_? ZX<2*PMV)+RN1) CZH:48')@
ML>3P-;AXL'+QV>4[86Z>!R\ZZQ#5OFK/:L03873T+V8VOAZ.#3A"JU"Z6PAJ
M#5;'/U$2)\.LID=KL-'\Y2BBGM@F=7S[*3S>/P_"+(FEX22U'#:F6"N2:L8(
M"V@66&X";=2SE^AT.<+5^?A9QV%X%L2+%["5X,3#>(]O_!954*YV2J.GQN\N
MD U!03T/7WCCU6T,*$O[_@/[992/*X]T)*?.W^C+_*KEJK?4"B[IY[\MN[_!
M@EIJSGR*)&F@,.8QM>>TTZHU="5OD!2@7G)>X3J2-G7CHZ8V=]$2U%LWM<T_
M0UL)*0:PSZB/$1$5QD?Y0,JPO@<=A<&G\6PTU3>E$FQ\C0.(+YW(S,)?\)2)
M<]=>8T/Z<ISC$_RF4=FL&>R\SE =ELRZG2+(@6P#;J5XHZ/BT6SX+Z7C,AOA
MB1<'KOYYV =QP*'_%[P5':AAX??8#&Z#':S!V^M%99VJL"8T5H5I2FG,34JE
ME5;36% %]I&FR\MH[J@J_%(_R=X501U$[9_\V[7_M.2P?V**X.3@_4WOXMQ*
M'-50DLRFE/ T"DG*F"8VY(:+*+!6)L]>3O(O*Q3!4E121YOA: CSZ6R*;$/S
M K\)S/1OZU99M<3:4*6=/"LM(O!?^GWK6/N0.&PT<O#?CC.@4!RXT!%X_F;]
M&_>=1O.75 N@+V'%7JXT8BJ[;+&MJW2'6S_3:]O_C(&;P?2RLFG &($>7(_1
M#!D@PYN/SY2&MG/3+_,Q<AH.<L?$.*XTPTH&W!7:[;UK12-&"*/3U%A=A\I=
MQ)K!NH*]=>K'<-:("_AYEK/I$%G/P/+K-T:AMB"7/:9X #P*'CC!.82-8OP9
M[33O)3?:YDQ#=TG[5<I"AY%W<MPWU^!QSUEN.[#N)5:C<S5W:-U/#JU[(_KV
M'&@N[,()-Q&- QIRP;.4<QZPE#(5&Y'QZ"?#Y&Z9,'S5(H&JT7-?K8&)?K".
MG^<V:/2G#.G4@8$F=90W&HO  $ZR;*)_KPP^U*D[W'!@V\K&0PR">L)AE,-M
MZ&Y%*E(:1)$5@O$P,XK3E,LH9=8&D>&.+#!(RB*3) C95_)CO_?M_*O@17ZR
M]+8GIV<WO>MS(8605*<D"A)%.%(%IJD)B1!Q+#@U1K/XV<NE5.@5I:T#52]#
MZP.7JM[$A S"X\-%R!!:^!JFZ8G-)S4:6=T*EAYD\<)%E[83M5BFW&8R2TW
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MILEYXJP=3X&40T41XTP9&6C.$RNEU2&W<2"U-4$DP_L@E)M/_WZV^W49V=$
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M]X$.M_:$Q7[1AU[9A?TK)&%XNK&FTZ/P^.#-[<E!C_<.]/7)Z?OS4&1!%*F
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M2BKGPI<%>\1)S1PE^K#C=(87&)QFE&!_]K>4E'S@J)!+I56^OZ1S&QK9+_R
M"5)BR38T 7*KNY#7$G#I$MH1UBKLFVXUN*6P?LUAMU%J??NJSUMJ=>7Q*J^"
MMF)A4BPS 96Q2BU7:2IB'M+$IC+3(=?LFTM\2MNO\)@],GIC5=_%^RAX%YW'
MO;,5E]F*%V'O]LUY'.DP5E(3J<#]YL8$1'$F2<*E4<I$,@X%GH8)UMB*7H+0
M8/2"5TJOJY>PULOG$I+#2C6Z%5A/&*Z-2I7>)>==./*%2FVB&=6P#X@<K<O#
M&&-/_&1G[E6X1FMC=GO7G 59RB5/&3,1%W$F,\LR%2JPMRTW,KP/FA.W,/[R
MXWM4#6\=5GK*@LSQ6)?A818H<'5,G!C"8QF35+B"(AH%J=9*ANK92\[V^'J?
MYR>+,.XK<W*\U\&8(8JIMI-)-NLO,2GA=;*\OKM)[6_@'OW*72%(,YL9FD:6
M:4R I"F-# NB.,XB*8)@MRL\AL7TZ4OO],UY &XPXX$BS"8AX1GB.T54DIA+
M%:DXI8DVSUZRI0!/[5VA$1HH/"K/)0KF$;J@K7#! .%52EK1FGK7FGHEE(3@
M^&T%TE(:2W>RE7"9-1=D@_%L*6;9]@N!JRQAB0JEDI9S$::4)=8DD0P8LV'(
M[FT[*))](.J5@.\2?Q\_W6+L5876TE#%H.9"BZPPG*@P2 F76<BXH5+'9CE:
M1UM^L[*JN=;)*"ZMF%=#X):H4Z?Q*S'W$8U*MQ=NO1R['!=2Z?GC##:#"Z>/
M.&+V;FJOWMV <PQ^V[*BC,;WCRB,]H<<S.1X92AMY?G?C5&UYG M/P:S-'11
MI5$;5(I5$<8KV.#!HOF??(#<DT%']D>7LO/\U?\$_^__(WCTZXNNSVN#<5$\
M%-_Z-^I$\/REBYJ-Y/3R6MYT\JM1'\UG3YGZR=ZX5U]83'"!**-A<J<"/]_;
M:UO\U\.!CZ?0<>_0-\?!$5P.G"7?3+>[F%KY1Q'5\S<O'82RMV[O&,G<M-[Q
M[3"5:: I:)HD3O$T76S2).999+E,="P3&MX'5=A.V]_E1,O'WNWQQZ-SA"V.
M,VX(M4%"N.6*B"S0)#9)K%+. \W $6!W@:;$"=MKR8N36'>:32W-Z#XHMLZM
MZK\C95.P4R3X"%P%-@W1@M$TB914)M8[Z_T1K(;;?8K$#D%D00V%G$0)C\'V
MT8; Y";$9D$L,B9"S:)G+Z-X7?KO9\1Z8<7-^<-U^*:,Z6!X%GS?B]I:FD\M
MU&>25^X:6YZC6.HOM].>+=^FY=34.9FB"/[O^MC;9-CWM&7MC)?OU!(7?YW1
MN)8D>6WA^]):[)?_5XW_]7*E9?9TB^7CU<7RV&RG<#86;T,_G^U*[/]))?8/
MA>OS^.3TL,/WUH+22IO**."IB 7EF0YAH\_"U 2A277"YO%&BTV_35J+$<:)
MR^)/C@8'5N&.??B?63Z].1I,IN.9^P8<D$OX'/^#WWUVG"F3]P.0<.1_-VZ7
M][_^CJG7/X?H19Q".W_K#_6GG[M[?^D=['_^,/CC\L/MZ/+#5>_+";SCP]7A
MEP\'%_3#[X?\[.]_7YW=7L!NO'_;N[V\_(#V9R[HA_^]I/KJWP/YMYB=7+V&
M:PXC>-_5V>GK3R<';S^=G<*U?W_X>')@+F&WOCWY_?55[[87_N_MT9?CC_J<
MAL+$X$"0).6.V $!&> W&8<12*:T2FAOO($VAT&<.L(M'AL1Q8FE 9=2*QIR
MQFQ 0\:3*.7/.A9LHA%,(,P-K,)7^^_^N[-_?- Y.O[WX;O3WN'QZ;MY?-NV
ME"\]0K+YM>UF1L:H)#5)8&,-9@D7BELM$\.9,59%\=<IL.^RCE!HD1!V<MEI
MR*X_6@:2#P.$OO#\]PMC]AV7(%*IFEG?GF3+UYE374]Z,=T>G>O$:&%D0D(F
M%>&(-"6-9L0&S%I86S:1>GYQ_+!YJP5IQ0P^X<D[.3@Z#W64)%D@"'@LH F#
M4!,5JI1$-H!!UR)F-ER8O <;/MS'_-MPH/-^7AGTVFD9_+=CZWGO%DY)I6;F
M+X#O1L,Q?E.P&V"A"U@H[I"5"]+])OONO->[2XM<&:ZD"BM>L+1VX6Z?N\3H
MF1S<N*!9\U'OIO"?"O[-:;S7_>$U^#[2P<UEX'?@G\_=DX8S&",S>?'+5D'=
M.8M^ZJRNRFD8@^E&G'LSFMA?RE]^-?EDU)<WO^0#-]CNIOGR)7A+82"+9 ^6
M/]K(TS'\F/+QA?F\Y[[ZU]0L?I>PO3 *5GY-]U9_M^ZQ0; 7!.RK'KOAE>%W
M:FQTI\?^RXVO'V.8*Y2"_^\9>U8[.0:=\U]H)W!+L'Q>=:E8N#0<?<&+%T5E
MH5C-^9?WM:[%G0R%9A%7)?/W,0[UI<4*P!4#UQ9'*<L./8I!PDVQ-3C?T-$G
M,F"!V$::%F/,6EL+?O6:WO9MMECN>:]]W;PSTM+6]@&ZN7UN7F0V=?;.\TX[
M#WD\_L_WZW>SOZY^XD%T>)M:.\IX9L$JM$G" QNI)(F3+)%A+&D:1GQ%GH+=
M(4]1&NC+C?']Z2LY'J-Y]&_9!TNS3#*P1VJ<G_W]Q^3#Z9 >__XF^G#Z*>K]
M?ACT/KZA'SZ^S<\^'D:]V]?]LX_]J][I6S#0#V]/WA7W_.\?E^K*]$_P6FS'
MZ:?KL]/W-\<';Z^.?_\C[YU^NNW]_>_\Y.^S+\>_(VM3+P*#?MI[1[_\>7HX
M[>V?9U%DF-*26)5HPJE11.A($VM@'C-&0YT&SUZR0'3#(%F1I?MN2P2_W7*I
MK-N)-NGE^=ULI^*>O(I+32PM94&686&]CM.0F2C,A!19%)B0>58)4'%LI^(>
MEHJ[J51<K)64<8;%]%E,>&0ED2H,B0VUD59)D41(D!G'W8@&CT7%;;!!2W\<
M>F+7:\4?=>761G-1F/$8C.:W:\)#Q9$W5ZO5'PXNB#N)E]<YFY6^6+C=X"S=
M9!ZETOT!=F4[W'M< 53L].Q6>O9-TY04<1#(0%HBN$+<0Q<LCA4)N,F4,IE5
M 7OV,NA&T6*MRY9:=KEN^*ZVXMPK5T8^GNRJ_0&FTF[5WM>JK:TC:B)8FA1\
M/Y@NPA,C2*HX)1$/:)RIA$8IQ54;LT5@E)^W:N\I!.<77[@71@_4LGCUE4DI
MN9B7^KK,TE<:OD5U&8,A-L,99I#*,7KB3O-]#,RCWRI^4.!PSJ5>2/&W/VA<
MN=M/MMI/WC>MP#2-8H4;2)HEC' AX3>5!@0LPR"546BT9GA<D7:3)+Q?;_L>
MUM;CB#CNM.M.N_[TF.5.N_XP[5I;ZSI+3:25P*.T*>$PH42%UOS_['UI4UM)
MTNY?4?#>>^.="!532];6,T&$NW$[/#$2;3=N#WQQU&H$ C$2M V__F8=@1&+
MVRP"CD1UN&V!MG.JZGDJ,RLS'R(<Y,Q]D7=T)99INDS,^;CF&=FUL?;_WB05
MS5917$J0O?)S:U//_BI6&$KER:0\5?+1RHCDIM"SL<EC:BHUSIHMX:@-FB)G
M5YJG30M<<L?23G0GD])499@FD](R*4YK-X=#_)QQD^"-3QT=E=9)Y4O&*0Z:
MPION>;>PP_&@-%7&NQO%XFF4IF-AQY6J&KSB<;Q0VRFMTBY"FF'H)I/I!9]E
MU/V5@S(X[]=Q?'C6L>-"JFJV5]FT5J#Q5\X_KFDA=<N4MF?(5)[VF[TAOOL$
M><@7^?PEB;_D\&\<S%Q*34,^_?!)<1&BRI$P30N%!D=L$;AGU-C2+*CHXRY.
M)NNW%3=SHG"91YJZO28OM("HY9FA:.RL4GJOU%#0JYK:^6=;TE5#8>ZIH735
MVN]_:;W85E[L[5;70Y--.5O<K-O.M>S2YT^]_4NO=H;R'JV>]8?#V!#>J_T1
M7B)NW=_EY&>^P%]&DZ,KY9;M31]>D$E_,T8;K:T3?F%-MO4*FU+5NB;KFFS1
M%4XKI^NBG.^H_NH&XTZ3"GG#R"YS048IZ.],4CB/\K@_W6!8G"B21^-&8N2G
MVU3S/"A1\3;+[ZY''?4B%^,BYY2WV?Y,BPM9E4-WF,8/R6I9EL.UFVYMX8_'
MF([4,,4%?A(89JQ2@N>LK [*9&KGD'SPZIRC?QV-?T>&+AS^^S<*_^;H%8?J
M9S<9+,N)&+YG_2U>RQ][_8_]O?YN#[_K[=>MW;>GO=W MD[WV-;F!]8[#;Q_
M<N5$;/_7O=[NWLGVQW=LB[\KW?!/>KN_#GJ[O9/^Z1^[&YM_[/0W/YSV3[?$
M?TY[L_D&/&@1HG D:A<(>"6(C6 )&$J9AD -=:7!FNV";%,&VYSR3BLMO7A:
MNA/WA'"\7_KKI=BX>9</C'Y.2'%ITWVMA'170KHXHM<I)4^%)LHQ2<"&TO?:
M4!*E330(%R(M/4\?GOQ4R:B24>O(:-9&.DWC4723G7E15(FL5(JZ+T7U9W(T
MO9,AJH3K*W$"S'EB0BG<8=*6=LU*1;&RUJBC\7]4FJHTM=0T=2=7[H*G+K-6
MI:.[TM%,"9(T-!MJ2+ 2""1CB.?!DJ@$Y0#>Z1RF+ISAID5T]&**D$;CPU&C
MK.E'!_%^!<LWW/KRE#YJEY5FG.+R]1 ".*[P)Z65<L"5F4<]2PTI/2H?72ID
MCD:8Q)0C($$3,*D4,AM<REQP&;1E7&7D(Q!=R;^G7''7).L6%:%4/#\_GFN8
MYG% ?F%T2"L:83V2A!4(<C0Z+/! N E22RNU+QJ5LHL&2(7X@D#\?Y\$XS68
M\?Q G@EF*,9,,@Z(\CX3H*KH8UH@FB:6 !R+R:ZL72^&^EO%;]OPV^XMNKK^
M\P+OS&&)U2QJBAMP!(^[,*#KSZ0@Z/G[9"QEH'DQM4U7RWG5,SZ+Z[^@63$?
M5G]?[6SBGC4Y/M.^_%QD, ]*G1%IE+)&17*S20@\+!I8M9W9=:IB-E+AN-#.
M0%%M]@Q2X$"CX-ZK&AUH/65=;G AC0&N$XG6 /(6=\0P#L1Y:AP-#L":TC3<
M= 5?PH23BN?[X[F& %J Y OC(WO&C:<E88R7<P>6B$\J$)Z]-(IE;45I#"N6
M,%-C25%\IP# ,\.X!@ > N.9  #7,CN:&<E06MAG8W%##H88*K-1'$U^+5?6
MKD?Q;A\ J/A=IEVX!@">';PS#8UX<E1+1R++F8"U@GBG'<')S-Q'DY704VM:
MR@<'XMMZ]D];ZOWW$']A<.B&]>#_9A*2(D;+O4&S40$SP:FD$G.<)A9!<55=
M^[:3T=:%:[_Y2O1/PR>=LT'F<41&X]"<<)Y8Z@.AD:6(*R1'6QC)=)6IA_\5
MT]6];Q>:3RZC65B5C$R"N"0B 9T1S2Q*HB*WQFD)P2":C:A(7A DW\7%?VXH
M5Q?_(5#N7]F8?<[<)HJ^@2D;LS2>.&DMH2X4M7O'63GHOZ[@5 _Z6P?B=IO8
MU<^?%X*O;,9>.6>D+#J33A*(+!#G'1#)<PX@J9$N-J:U5O-J#=^VPWXN5W5;
M#_LW1T?HZL<?-IQYR!'_=QN0+"E]/8'418T0/%6$X-4G,#*(%(L\4M$X$YD2
MZQPC2:N4H\(=*9NBEB3 =JV9U\'A[4"S0$<2E06>F@5JN.%QPPVO/C$5=='2
M)D()12 S3SS00+B&"-&G9(J0FNQ:\6"1V4H++::%NP0H[L\+-4#Q_."?[:B0
MLHN^6 ->HUW@="8V6D<B..N4D8(;AW;!=8/@SDD(%?1M!'V[;8$:T)AW0./5
M)^=3AB0=<31K IQGXJE%['LP2KE +5>-)R!QRW^XKOR3H'^9^^@6H92:P'"5
MC&@,,FAIDK86J(C&9V$L2-RT&*YC^@ R2E_3\&%"<9="%Y6K[L15839JH2D/
MQKA A*,ET1E*JR>?218A&=QU1))I9<WP+M,/KEBH9RC+BO*K[=P>#O ;0A$5
MYG>%^8Q)DC0UU'JB0S0$3.;$FH0^"<ZLBMXJSN+<VKI5G%><WQ/G)>I0<7Y'
MG,\$&SR+$H +DJTI'68]12=$49(S;N5<@;=N?NT;*\Z7%>>/9+47I99&J&5]
M, G#T>1XG"K8[PKVBTV=1R6=SH9(J03!I2.)<2 )4]Y8P[7A.,OML]WGE#/1
MRE!";W203CK[;KR7CCKY^+Z5$4M=GJ5\9-2C#:IC +#:,F%9D&BB\L #]36P
ML*#D]'DVL&"M84*Q3%PH[1*!!6(\ST3$1)FQZ&\(O[(&M*O5O"*@"WK*45%>
M PL+!O,+&R2J:!C/E"@O<SG=3,06K NN@TS>&,K<$O>+KSA?$)S7P,(]<#[;
M20$=R\Q8)$J53@HN<^)%""2#,)+97 KN*\XKSFM@86'!/JNZ $G2H(AQ)8&!
M:D.L=IP$82-SE@K12MM]J7,4RC5DO(JC-.F,,D+L<#09'-6TA:L\E07UW%@:
M4W3 9+16HK.9)-XLSY:G&EU84(;:FXTN^)B2=4H3+K@AH),GN#,!T9EZ%KW4
M$I"A%.U26GNT5Y37Z,(BP7Q&B2$X)1-5!.?7E=)0("8)1ECB7JC$J+'U.+/B
M_-EQ7J,+]\#Y3'2!,2-%5)D$*2D!#I%X#XX("H%QYK0/J>*\XKQ&%Q86[#-]
M'1.()&(Y(XBT]%8.I&SFA%D.+EL13%0MM-WGV>I!Z):&&:9]'@*N_T;187#P
M)X*B*#I<RV.X93G*]"Y^$GCC<73LAZES?O'?K5>Y57U7:T;LSCJ[<QR8A:?]
M1RQXFT.PYB#6_AF/NBV\_M)L"8T=^.H3V%)Q4G+4;4@$A%:D6(6D=-7(PN-?
M31.OKA2\:_F#V_+-'8XMERZOA%P)>=D)N;8R>226[GUCZ0P&+7932@I8:6<@
M)3%"<^*C,M'0H"G-C]++I#)T9>AE9>BG; SSK#Q<N\H\C(<_7/"PTM2&H$AT
M@#PL*5K+01IB?((HO4W>YKFVE:G\6_EW6?GWQ5C(E7+O3+GA&^4R5]3_/)!$
MO4?3-R3BD6M)"D9:I;6U@DX#%*9K8,X=/I^1?IO(]]^/RJ+"?^/@S[5_XE_G
M%[[OQI\'!\W7V\N$%QKM7_R4YJW?;G1ZN7B30W<X23^=/_A''$P.A^[DI\%!
M ]#F35<O#+_E'U\&\6BG '>53L%[%I0_^_RSIU>;IZX,\O0YT*NX=W[W:;K*
MOOO<7WTLHZN&PKT^]J^?L_;[7UHOMI47>[O5]8,CI1\?%[-KK[W![IC"\''W
M67MEF]57MUE>!FP]A;3OT[@C6+?#*;.7N/"AHS%C&=Z!$6]MH<U0WDT<]S3#
MV!#>MW.';\-WE9.?^0++><CE:WOH9-5);QSIMD[XA8/?UBLL >!)79-U3;;H
M"DLP+-5%.>=1+=E:G29=ZX:17>82H?4?JK/\]-URH5L,P=R6W[VS(^M%MOHB
MYYD@Q_@J;ZL6TB^C_?TT#@,W[!RZPS1^2*GCD@6*ERS4ZWSVR@KG!  P:258
M[K-4TIB<5&Y"O90R*JI T]WBMZ.O&^NO9']SB_;7XV![]QW=V@TG6[OO3K9.
M?][M[>Y]V7CSQV[_].V7[<&5^.WN:^BM[[$^OJ?/_[7?7W\_Z)_B-:[_:[?W
MIG>RL?D*MC_V1&_WY_W_G/9F:P:5T9G;((DQU!.PPA)3E"(-3J5(F4?PL+(F
MC.U*/:_LL@4Z_:JT]*)HZ6I-5!6+>E::.IFAJ7*4Z"))S .!3"EQ468B;=;<
MN,1-$9E?VDXKE:8J33TB32UC M+3T=1,R2:U(GK(C 3O! %/ _&96I(S&)9D
M](G92E.5IEX&357-K6>AHPNK*5GJ)=6!A!@X 2$I\8IRPA2WD$S,SNLV.G=S
M"D@O0-!L?#@:XX;<\:/[=L5>Z@IXJQT(3B.S4@*%8"/3TF<(RH)B"FJPJ>U\
M].Y2L$GA[I&8(3Z58)-.ECB+3IVW3'@E<:?A=&5-2][E5K:HRKUVM%@:/-=0
MS>. _,+H0$='A&P=,3B1!)(N$65O29*!,6L5X]ZAT=&UHDV-+"K$YU6*=7^,
MUV#&\P-Y5J,[)B9<4"3GDMDO2A=[QS/122:;K1>(8 3R VJI*G[K%EU=_SF"
M=^; 1(!F8"1QTF@"(2;B>)0(8T.9H1DG51936W4Y7T(=K-:[_A]6?U_M;.*>
M-3D>GS1MI3Z/\+H.2ELI,CD<'4QP XN=)E7P<#R838FLW??/J$I&ZBAXW*5X
M!BF#]9*SP"P/,H)AJD8'VDY9'V:C XXQ 3PQ$@TH LY#:76DB(&HE??6!*Y6
MUIA273!MBE96-8UGQW,- ;0 R1?&!P10F2H@5A7]*VH%\4;B(@Y*4WS""6T0
MR497%"\(BN\2 'AN&-< P$-@/!, R%0;0&>!&*L- >,H\4$(8KCUGG$0F8>5
MM>N!^CLW4ZGX78I=N 8 GAV\,RH1TALE#2?,F40 *"?69DYD9!FR!;2J^=2:
M5NK!9VTM/?OG<E6W-0 P;2H=?UB>]I"D@(>U9EI(]C)1N40%R]DJX$$9+J+D
MV3J;)8M<U)A VUELZY)@ME,F6IY)C!19S $C)AI'I <7A<L2I[=T%Q+4=(5\
M<'/-N^)F@4XK*A<\ Q?44,/C$,1,J$&HZ+1,2! J(D&X$B]DB@3C@Y-@:&)R
M90VZC%=R6'YRN$N8XO[L4,,4ST\!,V$*ER2 5XY$!:$D' GB"@_X2 .EBL4H
M[<J:>7B>0D5^>Y'?;K.@!CCF!?N3&=A;IB&:4F8E""BIB#7&DJQT\LX;Q:AI
M7 /&NZ#FE6OX-'U%'YX T<J81VG,6],8KO(18TH;%I3/-(*3U&L1658Y2&,S
M%?X!?%3%N9^3KL)L) .TH5:Q0+250(!;25P2CJ3,J8S.)B$].BJT:Q_.5?58
M95E17L6Y6PGS"ZN$":&S!DHD"Z4"W";BF(_$2\J%E4X$!TM< 5YQOB X7R)Q
M[J?#^6QN1!(YA<P)E9P1$)X2CXN:6*EU1%=!49\KSBO.G\=J7UYQ[B<$^\6F
M+F1,)N%6SK(KF<F<$N.L)SC_/H, 4$&WT'9?YKZ^O=%!.NGLN_%>.NKDX]H]
MX0:* J><8Q%=32E .#"6A61-I#P('92L@84%):?/LX&%P",WTC BLRR57C83
MXS4G22I*.;>)>;^R5F*@#TZWKO6:RPKR&E=H)<IG3CLTQZD5F6AA<C%!'/$F
M!6)PLD5,G&H^/W^CXKSBO,85G@[G,W$%S9P1FFG"G9$$O-'$<2]),MZ!I-QH
MG2K.*\YK7&%AP7ZQJ7N#)KNC:+5#! 1[5,2!2D2#8,FZ3*G4[3/=ESI#H5Q#
MQJLX2I/.*"/"#D>3P5%-6KA*4XXA-P47@LL6M#=6.2Y @06A(:M88PL+2E![
ML[&%Z(![GRAQSC)D*2>(]=F6%.M$=1;).?0Z!.]J?CV_LAYRO&"4US!"BP!]
M87%8GKU6!HV-:-'LR"P1)\$34-YS%BU-BM]4TEVQ_(*Q7 ,(;4?X3 !!9DZ]
MM8;P%"PB7(12".&(85XE;@-C3M;$A(KS&D!86+#/5#\J'P0W@62E<!-W&<&N
M>29*1\F$3E&+,_M<M*ECVCQ[/ C=TE#"M,%#P/7?M'<<'/R)H"CM':]E*MRR
MYF1Z%S\)O/$X.O;#]*WNY&%%7*T9L=N+[LQ_8!:>]A^QJFT. 9F#6+MF/.JV
M\/I+LR4T=N"K3S%;&J/V1%I!"22IB8D2B DF<$Z=IMDVM7$&NI+1^=;&S0&.
MSWP*50FY$O)+)^3:NN216+KWC:6#$BEPK0E7HECOT1&/SCNA7@D90(4HZ;1W
MR;PZM%>&K@R]Y S]E"U@GI6':_^8A_'PAV\\K#D%RT,DEC%+(&1;Q,719.8L
M2\C,:!OGV4"FTF^EWV6EWQ=C(%?&O3/CAF^,FXSPB5-#. 1%</)#$0(-Q!M&
M34HV0DK3^(3IJH>GEK2&?IO ]]^/RJ+"?^/@S[7S6^L?[R/@PO3G I/!P;%K
M[O6?^++S6SN#F@3$8I.8AB_X:9S0/!C\F?[Q91"/=LYQ./.NLQNF%V]Q'N_M
M^.C[;]EWX\^#@V8D[&7N#8TDT=.Q"B^7QJC^-MG349OY>V=\?AF'[G,B'@VD
M/>(R7N5/;OC%G4Q6_G[YWO#&9@?R=F/P_3O.^2YW;&YQP]/Q1DXKXM!EOG M
MIW%Y%5Z%>^Y+Z.R,"W__ST 9G_&/EUY:X$Q;[J5FS &UR>8</^F5M<VRUDLF
MY2^%^IO##[=VTUQ>6?933I4Q>FVB9DD%H &LAQ2<CB!B3%ZJ'R_: 5[VP=%/
M0OW5##[*FGU;<(+;2V><0L)MI8S#%S?I_)\[;)&""LA)9Y:T!I:DUUKIK!U7
MCAHNIV)\#+=(=FF+E'=H57=^F>^_7>6WG4TMZ,ZV_9\=&O;_.' ?[?'&_J_X
MFM<2OV]_:_/7O8WU]WM;F_C:C]N[&^MQI[?>.]UX\^M^[[3'_W/Z]NO&YMZ7
MWF[O!*_M:V_S\Z< &ISVGK#,RTY5@N@V<"*BTCH#!%I.6&'U>LI4!]?2L,QO
M.?V[RZ3?TRZJDSZ?2=]]]XE2$)E)1H!F3D#Z3*SVD>A8I@6!&*E<65.K_"\F
MO4D?7\?QW?=IW!&LVRFSUBP&3IGM(BU,#E,H&_?PI#L](IYT!@=A>!Q3.2[N
M'([3H4,#I#PU.MK!3T';<XQLAA\^24?EQ1W\=<>%,-I'8CM!ZZ30;&.VE(!!
MYV<W= <A=7[?2?CZU<NTVUKB?'\6X.A\=H.#27/[PQ'>,8[H](:++$(SO#-G
MZITON*#Q%Q.T49H$?ARFB*8Z#DEYRTERXTDG'92A/9^4J1%Y/C/=9EK.Y\<L
MRF!]3)U]=X!V3R>,4QS@;C.8[)4%,@J#9@U\&1SM=$;'XYG!ZAR.QD<95\D(
MQP8-Y<\WO& X"+@JO^P,PDYG.-@?X @?'H_#CBOS<#3J[. UD/\>XRT<G>#"
MG1RG\=E435_<+,Q]-,*/RD25CY_]4G?4P1GJ^'3VI=,%CY8-SA=ND]//6^W\
M\Y)M?"7-*1DG&1BK+(4<N.<N<Q,9CR9HH=2G]3.6!'*Q1UYFP2N1MBONWN5(
MVV]GIO.W!*;&L-G$R_EY. I[+Y T^[NO/G$JHG-9$Z>M1+84D=CL'&$>W3D+
M5$&TT]T-[;H47Y6]R0MC4S:BG'X ,[8H26FTZ0Q-'-U!L]))N!4=XCP=C8_1
MX-W$E91QU#M_EF&?2J662"ANH><3-,,//Q94:5;:P=5W=\Y]HRF1('WC6AV.
MODPZ_]O0[.@841HG?_OINL,VRQ,W6K$_O..[NEZ- WGAW35.*Q+-T!U.TD_G
M#_X1!Y/#H3OY:7#0T$;SIJON*7[+F?]CS:JAMKA 9XE99Q]_YAVM-M[1%4][
M^IP6J]*:[SY-5]EWG_NKCV5TU<+]/O8'7TGA42Y6?O_I*Q][0PCV?+)P9:7Z
MRKN\\@?)A#],%+;77GI#Q'D*O<>-L-HK&[Z^<<._9E)>BH+]8##:-WMM7!$S
M!R-W" BV<[D4>Z73&"S?K6&]X^T^XK#]Y;G.S!;Y:.'('XYI$R1L#F([%_9A
MY]^-^7$EJO7\.%B^5RYS1[M?1N/#$FQ-'3^ZH9W=+0\W7NJ)ZDLX,-4N*XVT
M;B5X" $<5_B3TDHYX,I\+QI\%^&2^[C$RW(2*C?67T-_]P/=VGS+>Z?O:']W
MBVZ\P7\_OA]N;[X?]#[^:W=K,T#_VDGH'O0V/_/^YON=WN[6:7_]'>_OOH/M
M]7=L^\T?P_Z;MU^W]OL[_=//Z#GW+A784R$=Y$2\ATP #"<.K"4J66;1_0G)
M(?EQTP5X<%'N@JD85<);3L*[2X+>_1GOX;0VDWFW3#7)3\=R,UK4V4ON52*,
MES)%P2*Q/"AB0W8N"@9"P<K:]1Y'BZ+0UCY#>5%>N<R]I#ZL_K[:V41JF1R/
M3Z9QZQ%>UT$Y82&3PW)0-T;GL7%@#\>#60^R%K.?;P#,HHGDN-#.@ +G/8,4
M.- HN/>JFKP+L1F\N]2O.F?'-#<$*$0"60IB(' "RO*H%*-*9C1Y6=<:VZ*:
M]=J?8FY&W;TQ78VZ9\?Q3.\)+65B6I'$A4/751=!.S3OF%-&!<TYU6)E[;H>
MQNV-ND=';_OLH45YY3('8GO(76%PZ(8W!V)OQ>!+W:)8BA@M]\8GI8"9X%12
MB3E.$XN@N*I&V2*0^8<+HVRSQS?6PR?'4G(A *$B20+11.*L]21FJG+)/U6Z
M- ?L&C6O6&2+PHU+"NN[&&;WQW4US)X=RR>7L2PS9 LEA=F[TEL@!&(H3P2T
ML5& E"JAE\4>'G*KUEG[7KG,4;6FK=I=78A:C_SX ]/._>_QBZVJ6=NVK? B
MULBB [!4$\FI()"L(1;GEBC'G&(\,"C:>%)UN9U7K/'YBXSG%*FLG%HY]>$^
MQ?U)M?H4STZD,PK(/"K@,A&M)"5 =2"6645DY%E[QK1B MV)ZP61=X[VMI4_
MVV?E+\HK;VAZ\63E3F>??K::Y.&UJ6^^;_KT>2&4785IA= ]"J'T[8N [E);
M9+2:>R$47;56/\[%WOIC%V+]+LHK7W8A%+.U$*H60M5"J%H(]1)>N<SG[[40
MZD76!=PAJ&"U \%I9%9*M-6#C4Q+GR$H"XJ=99#=KW-DC=1N'N[T=U_SWNF6
MZ'\LK^W1K=W/%*]']$Y_WN^_>3_H\ZVOO=,/?.OD2H!A']^WN77:WPVLM [9
M.GT_V%A_)[<WPVGOS19^]UNQO?OZM+^YO7NE$ I7L$2#3A-IFDXBI21*4$TL
M2\ H,P >5M88="5_<*2V%D)5PFO!#=\EC'I_QJMAU&=GN8LPJI+,<^$\$2KF
MHM=FB/?&$>%HDED'!9RMK%V7:JN%4,O^RF5.V:B%4'/(N8W44?")"9Y!RF"]
MY"PPRX.,8)BJ)N\B; :7"J&R=%H;RTB(DA-(7!&;@R#1R[*KZTR57EGC70,/
M;H!>ZZ!::-/=']+5IGMV&%_8=#0(QHU&FRX5FXXR1VPR0*SQ4:G(',LE:[[6
M02WC*^LQTPM_Y3('XN^6:OU@D947$*MZ\*BTT^IIA^A3]6.>S #:FO5C/(M!
M!!-)YED0B-D2ZP4EQF673 H2F%]98[HK]/46/T^MY+2 @?U*I2^(2I]2OK0Z
MD,_(GS/=T;RT,6A)E(R<0#G_M-P'XI4%$8W5%"?P>>5'J^_9PE=^1TSPN^*!
M[1*N>34<SNIT'([3I!P Q,Z.^S-U?$H'/Q+J0(.P,TR3HC6#+V.\LX]?NC-9
M[6SN% F/1L?CNVQZ(78SEX*5M_U?Y\&J_>.2T;J1SW^^X%6ZH+QZ?X69PI7O
M/C&:3:02B.89D!R%( Y$("H&0[,*29@F+^2Z$E<Y9[K[]-]O3ZW3_QC3O_OZ
M$_H0V>J8""(P$G0D$G$F!)*3<4Z+Y#S%Z;^>$71-!^@'7')9KNVR,MAW--M6
M.^MWT1>;^90OJ1,'?[$XYV7I-:MRQFU&J@[%=?Z"VSR2[=U6[*NBAE34Y/#G
M7QJIL4MVWPM<H'1CO?>))<:HSYPH*C4NT&20GS):< ;W"VU\@!2?H J]3O7C
M3[5CRCF@:%7;G D$9HG-"G<F, SQ&")8NK)V,+I&1M=^T6C"XLP42G+G@]W8
M,V<B?N=Z9N,SX<?!_J$;C!MIOK"#9MQ4ZZRHZEWAN=7.SVZ"''1\>/;\?X_=
M^"B-AR>SGS%.?P[2ERD1)7QV'ZVS.)7E*V1V75BML:4.1D<==W0T'OCC8J<=
MC68E![L=_.WT=8=C7)1CM!2OR1#BM1]\GI+QX)LZ+CX]50[$-^TEO/?!?X\'
M^+$GY_=RKOH8=E(\'J;RPJ-S6C_3%IP1@KSQKO BB_3N_@@O;SC80_:>&HWE
MEIH7X'N^#- BW1D-RUO0%KTD+EFFQG4.T=(=Q?*=1X-]O*#CG =A4 9T^GR9
M5/2 3LZO*HSP_KR;#'!:KLG$'3R>KN';BRO_98AS,,B#%'\^*0K,904>NV%O
M.H(GZSCX+U[($-WT3RQ8YF24Q%N&V/:)$2>M)9K*D$! XD)<%29LKV]U13(1
ME^,M9!']2;,0SU;(.<A.&N#\E1SB[+I^?AE#1NDJG1Y*W*-\U]+'*=^]I^+@
MC\IW'^EB;U=K?,OBPGM4MSUI#=N5 XB;2]86N#3V+E6Q2S5GRU2\>DWGL9UE
MJVT:L+O5@R]TGL;4FCOX7.SJT<$T&-$Y"X[6ZLF744S4KCYW5R,*%[&&$GGH
M??/?/J)7.#C8.$A;N&2_2:LOR6'BZ&3K8W^OO]O[LK6+_W[L4?R>87.HN/_V
M:__TUV'O]*W$ZQ6]:XV:_K6SQ=_QWNG/@QY_Q[9.W^$]_=$<*F[A]?8^?CCM
M[>[A9X03]& NJ6LPY:S/DH02GP"A/'$\ !$VA@S)!_0B5]98%]= ETE:2RDK
M^[TL]GN"!+3*?D_+?A>I%%KYJ*P'$EW2R'Z<$1> $9QA%3D(H15=6=/&=BV[
M7F794NY;YM+ ;Z:KR^@Y7%BO1SMX1Y]W.GGPY]GA6BT);+$=]ZK,'A+9YG3:
M?L59*YPVJ:1V/U*[W!I#Z> U>!)M,@2L#L1Y98AG5AI95!IT7EE#KNMJ>;VA
M?ZT47'B@M\ADJ4"?.] OK)?L"EVCL\:0S@DZ:Q&!GCG)S(7LJ-!,E$I"SKNR
M54"?4VRM^6XN5[5LJ;'2U$/=XBCMZ?)R7X9;NKR=U!?)VKOXJ7+\G3C^4M,'
M"2GX!*+DBRD"''U58QDGP0L=*85"RB4^)Z3L6OI@EI\[D!8C@%>IM%)IB^WI
M2J7WI](+<YGI'(03F:0 &?WBR FZPQ+Y5+ 80^9&F(9*&>^"NEXAL*A4^IVZ
MGXN$PN_5 34+3!F?\8\O56? F;;<2\V8 VJ3S3E^8E2M_#"?Z]' ??-Q?G]C
M\W5'KG8>.7'RFQ>[/IB$X6AR/$Z3]F1&;IT!= 0]OCWH;;[?[7_\UV![/=#M
MS9]+IN/^]N[[_?[N^UW\WI/^YN>3C=^O9$;N?C[=+H!\TV-;^__:ZY^^'_;>
M;._T\#OZ;[8X_AZ!AM>^_E;^Y_0UZYV&3P)1I)BR!- !+04X@3AT2 ES&@Q/
ME+L4IOR*BRW%5X4=102(E-ELF 10P>)*XU1)8;S$-^FKF92_OGK[OO/'JW]_
M>-WIO7[U^X?WKWNO^YN_=ZZOZRM)M+-K?#H]/_[JRY>*IE@&O!=KDX>@E/<V
M>V&]$I)F$5J=YOGK18KG..5A"D>3)E/:[2-O-8]+9O/H>!@[OKPDI,&?Y[GA
M3<KG*#<9Z)-).BKY(H=NT*1U'XWQHG(J*<W#@?.#84D#G1;0--Q6LJ?+2\YV
M6I^.OI1RO;/\[4-7N&N XX"7<)91OM_T_DM-\GET1ZFIT9M-4=T9I+$;AYV3
MSHZ;WL0TWW1:7S-.J3-,?Z;AY%;YIDC*YT1+BL7V$\@KDT4>D\)NGJS_]S^&
M<_5MNWFZK[XR%*N4EWO_=QG.#NN0Z2[XW^-1R=(_1)2E2>=_CP]<W#V>X*_^
MUDQ\4_)T-L'3;/A!&<>R14V7SS2#_WRUH&'SCSI1\YPH?CY1@X/#8QSM:5E(
M4\,P/)O)!NUNC*CV^/5_-KG5:="\+@X0_$<(VS)Q!^<_=3N3X[!3<KLOS_[-
M$SX9X(VZ\OX)DO:T+*+4IY12CHA+97S2V1]%A&CG>%)0BS!WG>G57GS1#54?
M9U_:7'UPA4UF+K>YDU("4HHIQN.1;W0!XO5+K,MMKLM-G"^WXX.9U72V]KXM
MM,GQX>%H7.;#GR#VCX[*EC+N'(S.MX)FCLKF<?$6-&<'&7D#-X*RTUS>!6:V
MB=4KV;U_5=A^=E,2ROR>573^-$Y#5U;(15W _[V\EY]9\/3B+<ZCL7Y\]/VW
MW**FX2F7#J/FRBC-_+TSOLCJ_IR('R>W1YI3]I_<\(L[F:S\_?*]X8W-#N3M
MQN#[=YSS7>[8W&;!-N,=2^5<LP9^0N<,C9%!TQ'!/?<E=-!*03?D?W[L8.F5
MM:;FJIA?I2:K4.D__^[6;IK+&VW<']JL5VQ<QV)6"AP3J@08\6TY0(QX@90%
ME_W*8Q>D??.K7C6V0F\*\[AQ\+X$0DK^Q\^E2NYENUI;GR0'%DR6Q 5>&L%(
M1XR+E%B=;(@Q9PYFL8K0PEGY86A6[Z2I AT<7*7]"^/_K' R#P[<01A<&)=G
M-9KC;UM$;&R':15M^>'H4KW;P;08<[JTIA68TW>_B#HV=?^"L^6J8UNHBS7S
M++K[;@X-DXM;R=:Y5@7U_/J&"R+4=^;MS[=BK@YK,ZQ31XG7L9WOV%YN/GPQ
MJ,M<R/?+:!\-\,;P.40;;UR+]VKYRI6S:Y>%YNBT21U*GR%I/9,<O4RJ(D6+
M)]TN#>@TC4?137:6X-CZ?J[:V;$U?O]GWM_L\=Y'O([UMW3[S:^E;:?87G^_
MTS_MR>TWVX.--V]Y[_>KQ]:_[FRL;Q6W[>OV^BOH[;[?V_KX%OKK<:__YK7H
MG0[WT/V#K=VMKU<J]*+DFE'+2> 9O3QGT<'+/!,.08,*AHI$IV%!QO^Q*#4J
M<TKON56N]X_N:4FSP!UE4OLD<K *) ,?N)4ET*2-#M*XEYD N"#PGTGR-EPG
MYP.QQC$")FMB(PA"L_,@=*+&(/RELEW#'ZS[=">H+$9J7S5NEM>X,3DH)XS1
M0G"(6CLCLHG2ZLQ8R>:J%-=>BNM?6#C49)]PER*)%V$[)1SQ2C.B&;<V.15#
M3$]&<?-BN66NPOUE-#YL3M8[?G00:ZGM-6(*-#EG5:+<>*!2>)9R,CI[1X/5
M3%>OJX6<=*F(5@7E%0 C*6M/(+C2&<!XPD1(5 4KK-9S\[IJ$6W[(*QRX I8
M\(AD,!9,R@S=)JF#,-(:7VV+%N/XPGTR/'.?I25<>DL@*4NLI((P)&/A99"T
M1$\DF*Z6#U:;JCAN'XZIL@YL,EGZ!-1$PYUS4GOFT,2T+E0<MQ?',SX"STP9
MPPSAU$L"EDEB>"I]\ZW5Z!\$[VT;<;S,QT\?5G]?[6R.FPR;DR;!YG/I9WY0
M\C')Y'!T,!F5S)OF,/!P/)BD^WD*-XS(\M!3=)1I*:G7U@,N<FLHY.0MTR8G
ME6YI9E1/X4F9Z5*%-A=)Z<P%2:"+XE!PQ/&HB&!1JRB],3+/^WRF16'8"F$'
MD?F@!*/10@+K\$%V0)40AHE<HY!MQO&%IP!H%ZH< W'*"P+4)<2Q D*Y"MR"
MI%:ITBC:=*6<5W%PQ7&+<(SPS4D8@_C-0*THGH*R*B1J08'G%<?MQ?&,I^"=
M1=,I14*S4N@I>$T,Q4<VRP!.LT"=:R..E_G H(>P*R6^PWI@<#/W<)JB9%*8
MDM3#6;"6>N&HB=Y'1:VM;D +:>?#A1MPN@7]+Y^T45$[%DF2#JDG@2$6M"!H
M$!H164170-9#@R6&,0UH_AOJLA8!?/*(8!V=Y.C44ZU8KB9$B[%\<AG+(B%L
M@R=>RDA HF-@E042BV5H%-?@&)H1IJL5KU!>/BBK0+.0BB=G)#@%QB4A1+12
M"\N=H!7*[87RN3?0WWW]M??NDS(I,HO^O#5!HT<@!;':AQ*K0V9&AT :TT(H
MS[--+N.K?-G:Y,XE^7MY\[^U$C9G9DPTI;.5]Y"\@,BH2-$%%ZM+T4KNFCE9
MT#Q*51*^8RJ1#"T3,30!T51$JA*UB?-:^5'!?P/X(<J4&8^(^0P9@A<Y2&"E
MAX=P'EYH]^<%88"9EJ5HN7!%!<FIV"N>>F*3E@0]D.3*M";.'JW[\\O@@"4E
M .XBR&R$4,+A.C&.&D45]PEXH(+=LNZS$L!SNB]%RT=3F2B7Q'DI"4AT73SC
MAC@#P6FJA5/A"0F@'G3\Z*!C=)!.SMO9Y>-ZUG&38U+ZBU&N*3<&0$3\,>:8
M. 5NN+]M2?I?4M,OZ+&\.HCEG]?_/1[\B?1S<#2YH5USY:8[<=/6)>E8[GD*
MZ)0PSRT:)TD1DY4F+NK,8PB!2^0FH%VMVJ0^5".D<\*QY4F)0"5"UX+3:(P*
M;KW@ 3_9!'K+PX[O!1@JA!\-PA?^A759,1H"T3*%4AVAB=>0B Q61AV :P'U
MP'*),9P30.0FLY@2;L6B9--'+3-WU&:GYG'*48'\6$">+8\P''*TCB@I& *9
M>G01$-(VF:!!XSHI4H"MVXN7N3KBEW(-32O3-"F-2F-J&D?7$HAK=H117,HL
MN781G#*.^01,"Y^BM>RA!Q65?AZ'?L*EDPK!G=,V$(\318"J2(PTBL3(DR@F
MH=;SLR-J[G3[,&QD,$& I9Y*D!F,CL;1*$3R41DFJAW19B!?. 2.*Q\8$T2Z
MK DPY8F5B:$QX:'X!(D5B2-%NY2V*7>ZXGA>JK%2&Q8<U=)DH,R9P "<3-GK
MG"2=1[5TQ?%CX7C&'U#>.)^")C8D2R#S0)R6C@26+4([.LIS"W$\IZ.!!4EY
MNB9;$-QX/+@J3W!7OZQ*VC[^P"P\S\\G.>ROCX>;-5UY_:&\_GG6T?(FT82S
M0CRU:)_E(OZ")C=A.%L!?2V+KM><XSS/+V [IVCOX]UH9<T?C\K"4^93I-15
MRIP795ZXM#P9E[).1(!V! 17Q&N7B!'@(F2KA;4EA0982:&1S\Z:+X,R*VN^
M&%OS*5(1*W'.B3AG8@BR['A1 Z'!>@(L96(8=<2 ST)Q;HQ6#7%*U55*/3MQ
MSC4_\>^-WE[5]ULFR;R%NMBJ[W<+?3]FJ[Y?U?=KU[!6?;]'&=NJ[U?U_:H$
MSO4$3F:\S#3(Y#V(K+P)&GVKK!@^CF[:M*ZHK8M:Y7T+-VM[MW?2/WV'[E&1
M7W^'O^_!UL?WP^W-O2_;F_V]/G]WNG7:.^W_<LW-VN^=OA7]]<^T_^;#E^*6
M;9WN[&R_^6.XL?GSL,>+J];?[9WVZ!5]/THM,"XCD91R C9KXD$E$J10R:7,
MO4\OM<J[$MR+)SCO#6*"<>U  ?AL8HA!>0E":*X\O1W!U4+69V&YBRB\5U%H
MGRD)@NNB\16)H]03FH,W5&C<L/S*FC"V*[6H+%=9[F6Q'-!H(#D59/9@E+=*
M(20H%R)%D$E4EFLOR\V$S$W)J1'9DP J(LLICK9<="19RKG7@8G %H[EEKE>
MORH9_DB?1#-F<TZ1,@:9E8ZF7$$(WH;@)/CJ7[:0DRXI&7KP105<D0A,(B<%
M26P2EH@0D_.&Q\A4K?%=8@AG*R!1:DWB:%M(5G1(!3 -UF03=*ZV18MQ/)/'
M%!6R<.D!F+(@X)0G/EA&&(^2*F]TLF9E34O5Y7Q>A_$5QRW"<0C2>ZH!HDW@
MHG'9:^T]3CX8!^F66W'%\7/@>,9'8%&B':48<3X" 6DB<6 R<2K1Q+4,UL<V
MXGB9#]JJDN$<2@>MYTD&X2F+(&4P"G2@,9E&WE":ZBFTD)DN*1D:E94-E!(A
M=4)/009B-7BBHK?2: J!T5K%O\00-M0"N@4QL)!!9.=,! ?HZ0O-#3ZJ%D:+
M<7PRJTB:?4@E[!@4XI@9XB08(@UHBV 62,<K:TR5M-T'USM4'+</QY$SB)Q3
M*]#1YQ[=!E!9 \_.(J19K#AN+XYG/ 4AI>0<2A<OSTOD3A.#3@*)(4&.)>/'
MI#;B^&55\3^2<,GE<HB7I%W@G) 6;=$H@@/AC>,N<8J+7D4KK;XE>U5'XDF)
MZY)P"979<(&.!'>!$M F$&^\(<!H]-$RHY69]Y%#:Y(]YAC'?('@!\K1>$G2
MJQ#!\N04T,2-DR6SU9PU!Z^F2SL98$9,70:N@E3$&H>XURX2:Z,@25) ,A=!
MI-CH%C#>!?7@%D25 Y:) W3(%I<,PS4$Z+1H;P.:PM92345*KJ9\MI@#9MT7
MGYEAP(DQV1.PPA*GA2$:'R5-@VST 1:. Y;Y'&1.\B7+'5R1%ICQWD;-P -Z
M*TGEX)@.EAHT;N? 3B^O1>+3T-,E^1(9\#\=$SHI&0@D+XGWFA$+.*$N,<Z]
M6EDKU*1;%%NI,=)Y11F$50CC@-X% ,,9A\AI8""MD49X^[ H0T7PHR'XPLE(
M-%GIDR;2<(X(MH)XM#!*MK5EF?(@2I/3>EZYM!C.G"5&T:8T"L D9WW442;J
MA(C9YWE4350@/Q:09SR%K((TU@9B)10@9T6\5)'8D(U(W-,8?/NVXJ6NBYBC
M>,E2)V4J*;72%I=OD@ .[S[P%)"1D(,8B%O&*JH9\;3L<TF\)">N9/**)&"6
M (M(/!P\R<F9F&D0VLRO +\F5K</PRQ(R6PRRDL'EBO/4F!440Y<*=#S.'.H
M0'XT(%_X X(9].B,)#26"@D1&'$XE81Q%:@MS7ISJ;[D72T>7'Q9<=P^'"N>
MF%<\AXA^?'#*V2Q8E-'Z1*GD\RATJCA^+!S/5D@(&=&FPAV8^4B@*!I:ZPWZ
M]5%YRDK^ +00QW,Z&%B0M*<YBY=<+F:O#:4?<6 6GN?GDR#VPAM*/PVO7Q(O
M8=1*[IDC3'FTS\!QXH0"$JQ0P0F:,F?S#?,\?S/IIVT15'FS\N;SYM95WIP7
M;U[XM>C6*N-!$19\*J)/AECM.5'1Y22%-<B?32(-R"ZSE3LK=U;N7,2<Q,J=
M<^+.F5@"A PR!C0R<RE L)P1:Z(EBM)L#<ZA#6[*G;JK'IZ$V!KNO$'$Y.S6
M^L?[B);P0U&3P4%,!T<_"=60Z1/!LA%Y^+B3#B[*J+J=+VD:3.@,#OY,DZ/2
ME&'2\6Z28@=!^]_CT1$^.L1[2I."ML[1SFB29@(4@X/)T?BX>1M^V,X@['0&
MDX[KG*D@X/.'QT>KG8WC<6><]MW@  ?_TG>Y\=D5Q,[QI#QYM#,81W+HQD<G
MS1>7WTU&QV.\@O-O.,9+&'D<@3\;-9BSG,KI57;QTX_2&#^_,VY.6$O'B9-!
M&N*&=SS^LQRY7KS3'2$3[>^/#H8GY_?:O!LO:'J[DP&.O1N?QV'<I7<W]S9]
MW=F%WC $_&P(KK37Q_52.'!P<.P:++1WQ?SSRJ5.:=*QF!'3C@E%T6JR-N4
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MO;'^_KO3K<WWPXWU..B]>0>]]7=L>_TS;&WN[/5W7Y]>D4?S+(:2]T6D]I1
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M3O3N*_A;KP%-'ZTQ.7M"+5ZKHEXZ;QFIU[+L%>L/_$N=5JMSWJO]U,PK2F<
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MD'0J,K<TQ!Q=1A5Q6%'B\$:&TGPPYKK+B%0^HUE!92(#BF548N&0IB8@;H5
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MN!L>F$D,_&%+Z0'<M:=%"\9 V^]D^9FV;'R+%Z 'W;.<&QH>YDXR.X*%IGC
M*$%^&@4^U9IW-K^6T]>V._W:*6@A+!,W-Q-Y8TDX9>WQI)*89W!"P!AB28H&
M*\^3538)RA.V\*M1)*H,.$032@V:EKVBXH0+!C/[8'E^/F),$.EH0,)PAWA@
M%&DM+9)8D: 3<<$79S ,E76);Q^X>X 'WDL!'Z!^CV%SQ#R2S0V_.#<V-P]M
MJ/C<FPC^ ;3_ZY'D4B0A/:*Q*)TA'0)SR**<B\=19C5_ H4K)0FP/[M+\I?!
M9%E E*UHW9N(W<[) 8B=E2$G0V/<)\!;@%H3L0?XS<= 5-#,X'OQMI2:VJCR
MRA7<79?%^1.]R0L@L:5X%W4< $-;%].>=86ZM8[W@VX78'U8[:%@C=UX!CW)
MJ 2?S(B^WCG)A1;28&ZMT=A(39+35NN\!5NA[\*JP2;?SE7P\G\;/E?%8T?&
M8<(3BRAPKQ G).6L)@DY:Z)A8-%REK-@B<="<:.V>;7(']NA#6)=LY4KCX"^
M%(M^_JP[V@^=>?&7CJNDL?::QP0\28/J6BIAU< RR4K\ED;\MB^/*&/8JJ2R
M30WB![((=K:4B-H ZS!+Q@JZMOYHZ1O9G!,48#IV-GNE[1GA6KQE?Y)EL3]G
M,#_U<\S/"$NB4TJH"'B E6/!)YJ2XU' DV.I<]G-A8;*IROS<X$5\>!R=V_K
MR"<C+$X:)<\#T"'CD"5*(2^U9XI&0J)96Y>&U0DC=QB?#QN:5WL-0XNR"]?:
M@UBO95L3]?JY8N+51D. BZW.67'O<">M]"Z%9L_G>HL7M;/F62PV'^(/4+1>
ML><VQ98=V:AZ9*/N3?Y=/'-,D>;INR*-VI* Q^95]<NK6HY7M<'RIB;,@H^Y
M_F4$O.QGR PQ6_;-PL>8)][V\]3>3V'S?3"5+F\]-VJ[0WP>A2E<.U90.@EF
M@R;%L>:6:9L\YD9@&P1AGN(DL==!TNG1&HN"2'>%RK\_2+K&#?#.WL<?1QP6
M',:=0C17?>5:>62"X@@G'&'=H4X&M[;.ZA3+NC;J-D*5_JS"*U"4."VD>UC.
M]0JGPEUR"]\]MN&6S(,FY$IX(Y$>;KG&VGEGT JCA][QS$;M>I'CVK7ZQA.4
M^.&2M;DK^9X2S49=@0]#!)$,X_;=,#4G?'Q7M\]:55G:&"TQ7F@C.71%)RJ,
MIX1R[:CTMJJJO) J-K&W=5G413^BP;F(=4*\R) A(FA8DA0I';1@WFG#LD.$
M-&Z?+1D56*Z_6'WD%XS_K>HCOYJ@;0EHTY$T&E";&*1E9#D+"T?:$HP$=2%@
M!>:\OR]>MS&UX.:=!S1?FCAE*MG/XC K3E];?PKO2":2%[#8/)=9S8SA@-J.
MN9SM*R7NM,\.;JJ\<=9B2:*H,'SA56OS<GOCX$@0QQU/ -^!4\2]$J!D4B$I
M)<9:)HM%F1FC,<6A/03Q7-=W@I9<CX5\K"]D[=6U<WIUWLT?8!_^:((EL=7V
MC1K'Y*=O/]<^M:!IA5$X\<'/-THNW5>#?;%LMSN*1C]8!_OO6.N!H=X;HM+D
MX!25OF_ TW&SU^]TLVG>NJB=VA#A1Q_8)%#4_/9NTPT*.R;3R1Q9<K7!^__^
MD2MV_S)Z@?6^J%5<:Y8^@HPAHVB4;&EV\L!U_+=&[=<(HUQP8/AJ28W+D)6I
MK\VV^(U'>ML[;M3^+IE(X>N:BLOPS5G@TD884\*!\!H,RD8=M8GJ0&C0'MB(
M?"CST"RXN1%37@A^F^AIGJ",A!4& @9"VT\^'Y&<DCB2A)QF)!\!8L!=DT )
M"^JC=4$JP#W9F&(77E'7622 2VN]#O!<ZSESP@JN G'$2\VT<>2!?8=* N8L
M 5^/A*4F!(:19DGFA/P"&; .D D:[!F>I$@Y,J]Q^QS&>-UKAYF$P,3$(J<F
M4N8SP)H8":%):&D$L_PA1W@E!/,5@LN#HQ1%E S&6W@AB_-_"!8]CH((2G)O
MB>$T6Q;W",&(HA>FQ@/'0@J?\=!YK.LY /ZL#()L7=2+!SUR?;RY,#9NDX^[
MW<A#)B X4(4R*+_3_C *2OAE5*"\H D3=PT3.N#Q+=;U.JU!_^Y;IG&>ERB2
M^4C20PB[0=@F?N9F%QH@M4OPSPDG8.Z),M0)18CE.:UQ2N&(Y(P9P[N.N^,R
MK%\C<MUHOR&;H&\?;.O<7O36_G5]1& X)H?_<2-W]SBE-,LXZ4<,4SE+(9.?
M0HX^%+PN?PM:8=^Z";7C;@;2?SP\2PKL[)$#,V-@=I__^U]V?9H$/&'@7\3T
MV-G=VZR9QKU^K2<QR>LK ]@UG=.X9W]L-'N^U>D-NG$/GO]K"QCT6R\#)Y]'
MRP#;^?LS6*C;]. 2GOD'+ -PS\'?6^SP]*_3W;^WSL&2O3@XV<2[O]U<!CPY
MW-@^W[X\/-G9^,AA&?@!2\;QP4DX/?S[0!R<?!3Y_=M[GSDL S]V-@[X]LD^
M+!M?X;^#(XHU9<(P6 @LF,4^2&1B#BP0 DQEYYFRM%S7 6MC^)@78T<Y=5KY
MQ(7D$3/-&/8Y'#$*@9V!U37"0GL&D]#O#D"3/GW9_6OKSZW=G=KONU]J/_VZ
MN;/Y^]9>[?<ON]L_U[9V?MO=WJSM??SOYI\W'5K7Q7>J%?=P6ZZW/6 O28S.
M,1FYY-PE(2AS6KB@&#;L_CP+<Y#'/_UQ#(-6W$W9<]-I%SM=Z4I*A_N,O\8V
M,)I^H=3O5USW?^P ==5,)4JYS%Y0A;C1 EEJ-8HN\3R!V'-]4^06UQFQ"\RF
M6<SV**!F^%??_@"J4VP<Y_,H(:>+ J942]W.:7&F=FB[[S?^;-3R4W*P>;,W
M(F4_N5)DBN__?/VAV=]ILT>UU>J<]VH_%4_J#* ;H??SAYEVX&\PFN*0])@T
M%>FN8 1;]JP7/XQ^^24T>V<M>_&AV2[&H[AI2EGM,4%HX)(D#',$#I\_O-PH
M+MTX$%Y>D[BA,;_S,FZ0.Z_=]UCR],?>?\V8NU_Z?AJK'_78!Y)&/C4W9"'T
MKUB]_D9:@W'Y^LEN$?&8?I5:^+(I0Q[L5 %J!SF>;O.:,9BWZZ\E;WA/\S>1
M&N>Q*0 7<V+O358Z2R\?DYYKV8>*F&JH'CM4>A9L6.J$P+_E R7 -9^31VM%
M:T<O12/?33F5" -C6\^J/; BJ=I6HZS"G'=E;^1LNXS=3K"]XYO^C2'<#:7I
MED=C<1)</]&;,<RHUCS<.VY!F]C.Z0$Y^'L?'YX<-@_VCH]W-W[_=@#O@C:<
MPG>;A\V;&=7^T]K]8U_L;'AZ>/+7\>'>E].=T_\<[_ZQR;=S)K6]+]#?P^.#
MT_^<3A8BW/YXI!0G03F.%*,:<6LULE9@I+#"E'IMN$V9H&I*Z"^K5_Z@0J(5
M0:+G1@=42/0V2'1QA404J\2BI<@Y21 W7B++LG.6PVI"$\$BT@J)*B1:="1Z
M;HA*A41O@D0[8TXDO3#< R>B4@(G<CDMD @*>9.$2-)3FDLS+QX2O9>J\W_V
M;3^^DSKS;V>,W1L;-T2?8B8^ML/_=GR%0<_%H,^3=AD#UDJM2R@9)A&7AB,3
MP$)3C'L>J0\8^WSV4IG;)\-7I\[&N]7E.9LSE2Z_OBZ/+1N&8?:BRWE+\U%/
MA3$REG"4@O3&<:Z%!UV6=6QNGQ"J='GI=7G.!D&ERZ^NRQ.V ?;>!I8,8F *
M(*X]15::B "C*2,,IA:+K,N$L072Y7GN-U'14(MJ&12G5VN^5((<J#8Z;C:K
M.?:,DJ<+,Q@S^V$>V>FE!^0W,)3NB,6MD'@F)-Z?M)"(U,Y*+A'5R@&K A &
M4B60B][88'V(6,_)0II)/Q;<CUPAVPHCVQN8C16RS0G9QO:B5)$I3B/2S.>T
M])8CHX%M8AJLH4D)'NB<[,4*V2ID6PID>P,CND*V^2#;SC7.IDG"&@6O!>+<
M UT3!B.KF.,B2!IRX;6Y6,^O@FRK'&.\$5/,:>M?)LAX\8-WE[6%56QQ%4>S
M"BO^:WII1E@WE*EJY9_'RN\GO362:,LB3D@9$Q''-B+CJ4>4AV2EMYQ+D>LV
MU[5^=MGF*KBO J45<+!4H/0RH#1VM%A&27"$HZ@H1QP6'.2<D,@S(8AU5OB4
MUM85J8LI=44K4*I Z07[]-/K.D=RY5KXK8*GMX:G"6^)8(:%7 LL:J<05\XA
MQVPNN6VT"6*86H\R79?JMB?XYRH$N0I!7CZ;;3K(7 MHJJ!F'E#S==(\\]1X
M%DE$B@N-N' >:8DUTC$$&@(/+N;-=&46**BI"E"<%W^8@U5SQ1\J_7T]_1U;
M,C@"Z/J D58:(ZZ9199@BC 61'J?BXBZM76A;M>1>3Q-J%1W 57W3:E_I=4O
MH-63!H"G"B@4K,4D&P#,VWPDFJ-() _:J%QL!+2ZSMEMG^F;Z/7[BC,.0S68
M##2^RIEY:_P?!5;/#V59'!A;\+V>"J_F@5??)JT(X63$G$J$<V0'ARD% R+7
MCPPF10>_&L9S+?,ZE>\J<JU2_<7:4:E4?TZJ/S9 0O#&I*"18X;E4F@2.9QK
MQ08?;624%N>B%*EC3"O57V'57QKCI0*!^8# A+V2RXA&)1W"/H"](D)")F<N
M4)HP8F&&DW1KZY3S.B&W#^7,O&&Q%+&=Q;N96E!#YM-C\_W/:DT.YV98\XC!
M.(3.(.?U+^;G?87JSW-(%A/T%]34JR!^'A"_>5[ >P'S'X\P(U&P!.:=\!Z!
ML:>1IB*@&%@@B4<ADP0;S]2Q>'8@WQP5YXT]U15<5G"Y\.9Q!9?S@LOM*[B4
M.(5(<@9!F"? 3,&1 ?Q$FF'EE8(5,-=(5:J.S>U"N15<5G!9P>7BNQ0JX)P7
M<.Y? 2<75ALB#2)2Z9P.F@.$^HAPC%0KZKR0,@<_JKJ91U3#6X)FX6GX5U'!
M[JKZTXVBE0M;>G#O.-XH&GBM2F#^8#05D\VZTZ?STNW-U0ZG->BEWSM1VWJA
MQN..0MNC$ML&)A<0KPLOK!4%KF-12CN/XJ#?;#4OR[*IG51+91AXK1W[M<Y9
MS(6'VU]KK4ZO5SRKET-%1O4HV[630;?9"TU?%N?N#/J]9B@K#4.G0&C:35N6
M\SX_;OKCVOE;3%D$"*BU._W:L?T>I_7+VV[W AIY;KNA5PN#F(?&UEK-TV8_
MAHEO'S=[_4[WHE'+VC+I8[NM+*,ZZ/>402?Z[DF!/Z/M%2.9RYU_MZUA85N;
MRW3:MH\U^]4VV[U^L<PU$X!2NP_/@>NCFZZ%-=A>+_9AAE*"_Z^YBR=,9%E9
MM!R#C(%3AC+7$XW=6.L-$K2H621OZ]32H 4M&[[:MB^N9 S>7M0('8[>??7C
M:W>4CF_<J.[^6@5Z-U,JZ]5?<88O,)Y?(KS1@SX5DU55Z-WS1X(1055**,FD
M$ <RATP*!&&L8/JH,T*JY:G0NU?HYN0D9QVY*KT[$NPQ'$PLJK9??#$KWB##
MR+1O=[-2PA,I^6>A#M$":@[?,(M:U*&5O;-20EL7]:R%G:HL<%46>%4:6Y4%
MKLH"K];\K5 !UZHL<%46^ 6&ZOV4!7X4EQSSR.Z4,ZS/3T:UNK[UY?2>+WIL
MQG7;]PY7^L=1H;,_1])[S7Y>$4][AVR?[%]L4WC7Z><?!_0 [MF$-GZ]/-SX
M"%;RK]]V-[[^@/_X]L4-3SO<M[.W=9G[=;CQ^\GA"5C8>_MB=V/G&[2ON?W'
M9[Z[L0G_?;W\[^769-!^M(03@QE*H@C:TQI93 T27FB&HR,I5X"EJL[5G ,Z
M5F(/LD+"543"-PF[J)#P+9!P(N^VHR3DE-M84(NXQP3!C%/DDJ0T)>H2$VOK
MFM4EGE=QEPH)*R1<;"1\S<3;%1*^)1).YNE61%&C$]*"$\0Q@=\DYT@:[2TA
M(3EGU]8-KQLVKXPP"W:88_K!](6$KC]'.[+CL^=7I]&?<PA]10^=S<'(?4:$
MV'5DFYY (_8J[)H)N[8G[=D4K(-5*"#%8CZ$[BTR5E'$@K".<Z6I Q9'ZY3=
M/HCZ)CGSWN"DZ1*I]G(9;95"STNAQV:9TUHK"7 <7>2(RV218TIE*XT&IJ2-
MAJRMDSI@^NHEZ:VT>@$,D$JKYZ35$R:&XXI+:1B*W&(P,1A&+AA8JZ4DV"G,
M7,!KZ[P.+&V!M'J5=P]_.[;MKSFH<EK8:)7K=@$WR\H9VVJ/4EK %SX6\;I_
MC2;PXVC^*JB:":H^7[,H8E!,I(@D40$LBN21=5HA(:FU4FFCDL]I^ 1]=E:K
M*L?FXBGZ I@5E:*_H**/+0TF%/>:442IS D.5,YM8#QRW ?.I!"1RUQ2FN)G
M6QJ5HB^@:_!M#X]6*O]:*C]AAO#$K#::H*1U0EP'A9P)$6&K(]$V$&DCJ#P1
M=6;X2B7974@;Y$OL1=OUQS4/(M_LWTH[M:+ND%?>OW@N-L$'OY7S,YJO"H)F
M@J#]2?."6R[!LN HX(01CSX@ \02:1F%,IXDIW-I1%)G4S(J53L62ZW,"V!;
M5,K\?&6>,"&LCX1;B:AE.6V%<<B1P)$0UCE.-:5.KZWK.C6W R<J75YJ75Z
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M,&J5%<G<(LII LII!6U/1&[N(+&]MBP@ZGV!.'4*66<+1(G!DFAO,%.)W.Y
M;;Z;G7$ET5VAJMP,>Q#ZR3M?>[_D5)03X&XAH2^MP='FA;?S[^S]KLBJM%]X
MX^O>@2$@*HGB2$>?[!?GD!'$H6 #[(TQ&-,4<W '%6Q:Z:+%2[%*=N'-O8RZ
M6T"QO0YHB)_*-E+ "+X\+.BWX(6F-Y+OP 7?6WV8>+]><Z$W,##C_M#"EYU!
M"VYWV5CNIX5(SJ7N:2?T^D>MD]&A2.GB3]^F4Z=.9PBWM.$%@Y%'OQ0!)E/O
M]?[]*^=:%YI%>?8"S[7C8P*P(^%-HW.&4JZ ?MR-,9UV3<Z>ILZ.2D?7U8$=
MF[.IL9>G9&.^NO4<XMJ1VI .0J;/,K(J!0,X:0/X^)JI?0XEL#!%X3FF?=9O
M]2_DX4V69'[AZ#1B=(H!RS&U!WES\OF*#S$?=0PS!4R]K9Z5N82079?;FOK5
MVF5J3JPP.GC(8[]$WR/R$ASH;WPN]*X7RK.CWTY;?G T#E68NFMTHHPGMQC;
M[[:'@YMON8Z1RG-C%Q(M/S$G$2)F5FGJYU%O/(P3<QB0[07S#9D(HWQGVJ?F
MK+_RK\MS@XE-+^3=UN#F&<=XGQFK.TRX7&^?3I$S#;S+=)2N@E&8YQY"[:B7
M1.]_M0IE(_S/"BLTIT1J:H4DQ'"L@X[1'\B5M9W,_L##[Y/4[J0Z'&;MNKV<
M(?M2>H(\+R(+W.. N2P*>+33DA;".\L<-BL79W1^/8GR4! 8 3;2%04O K::
MZA"$9LQKT&'410C/**IA 4[SRQKG9W<4_+ =MN-N)T4!''823H(2\?OH /Y3
MM]W^4")57IH=>/OO[:[[]N;TA=T?VQO?#JAFH'N"+<T$3?FIA4:*Z8BD@@^$
M(C04L,L!M*H36.9!;QA^#E3/)_&3>(O=Y.K.7M=,^_WA,0P2'M(OI6]RK:9H
MBPS;29!TLRP?3M'+Y9"-7[),[ YA8+[_Z[M[*3\SF#T:T5@LY(@B6).V.>F'
M=^-??O.M_DG;G+UK=?(,\TVSX4/PE@EPKN(2/$<1]J/GC[Y>S5_-!$&5WQ5X
M56%^X]=XE=SXW6V/)0]_[.W?:7WS2]_.8-6='ON3E(N'EA7+1+\0EM8S'"VO
M#?F<">4K!=9L@#$1=YE7R86/&\CZTTEEF-I+X46;5TZ"+@4LOJ7]FPH0ORG*
M\II R^7<VZ2BW*7LW5TF>I?B=*]@P8BN%NQ^"Z;N Q4ONK3D[^G<KY.T.6O:
MUW7)F+](X^O- :FR/.;/\KC!CGPEV1TGK;US=[KWI?FU^77]=/_++MZCS6_;
M?^S!<^%]&P[#>X\;=.ML__-,=L?QGU^;Y[\?[=$&;6S\WM[?^?1UCW[D^U\W
MSV!NN'G^$>:X=[[W]<_VO\^WIIN>2ZR%U3R@8"Q%G-@":4LB&)Z$1TD#$UJM
MK$E=Q_,7\;X70[R,9+<*REXCE!512R&<PM)0'I6S#!<%U2&J0EK,5(*R'!6H
M*BA[;BB;M("WE&$6E4+,1((X4Q09P3G22DB/=<0L1("RHHZ+J[5?*RBKH.PU
M0IGQ3DH?M3(D!3A+FX)HI2>"<6P-UAG*)*'LX:4**BA;#)0U)UH9+A2CUD94
MB)1R*ZQ$.@2&*#=$%#PDJ,M:&>-7LW"6$<K>1+W],GR_/,S(9Q[=44)@3F&\
MB&=X(]7WGS!#AUT*4[H!C[9&^4,;H?SW4PZR@,6,O>[QWVF?RK EN.7O46Q
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M2J:T7NY?VHJUR7ZNEF6]0W^0[SD)'=-.O9<!FWH 9]WC5JKX#8]/1X_Y/09
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M2LVT8@X@@.:, J] V 0G@BL<5?I@ZSJO*[Z/A00KM!T_!=/>[(,9%/[N=4]
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M.&63W^6P(XFU[9A*.Z5-?GM<09OG'P^B,,I)[Q$FGH,-A($KG/,H4EWX(+'
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M&[WA86W]Y*0]]GC^LM[<6/\U><K!B)\*4/VPL9[HK/&Y6?O[R "&N3#,)QQ
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MK'8 'Q >@ M@9\)I$D!!?^DD2<S M>Q';M,0"@-:EC#=TG),CU@VP76MD?.
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M?7'@\"0L["!8?<?E"E+_!QRC?EA>!:9OY)5O>UZBVQD<F5%=V  6\]I$]KQ
M?S !75P3 N;*DC\V@FQ#S:TD)R;#M3CP+1Z6%JE97788V?W!@#\6#@?Q..&4
M<"E4"4<L?66!4.$]&'5DSS_$=A7$_]"*&ZOQ860SW!BK_-LF[[/Q'WP?K60^
M.O&<# =6EADUN%''!\$!$B->RU .AD1/RT/<@QZ^)Y0Q[W^S.7,/T++BP0+?
MG?5NOWRH1-9YT$XLDS/9D$[X6X$AF1^_*7I%AO@D.KVA/(L^TY*4N$ID%.(/
MSKPE9>'AMG\TV8H@=Y>-F>T)EA"?>BG1R;=CZQ-!CYHOPL\,ZHW)" X;H;&(
MPH$D'+4_1DMNRC;B1?:(T)LEPHV6\U(DI*/QVXX?QJ?A+@A/3&(V%VSHII[0
M",G"?F <DB<.6H$-VO)$'$+#+82/=YEC'YPWE\MX+)0G:!I*^T,/<_7A.&3/
M6%BO-P*G;;ZODD#  _@<]*/DL*EM8*>(#M$AEZ(0X!/#+Q/#_/^L-<D[JTZE
MW,0<TT)8:2UNX@T9E7N]$F#WEQ#V%;9!W"U<LM4(2CLX"-)55HN472,6>EQ0
MB2A4?H8,7>DPZF'6*,+O"*$E<A%%8FN%0$5+,1DQ$XW$Q$M<[A/ZE"AI2? *
M<;D1'[\(0V#3P)IRV>,5L?4_A;/1(_F<#K[K5R)28C2.URX_)/&ID8>QXZ6_
M#==-6 J>0/Y.J" '"&(,)1>4YF^"I7.&N#V7>QSHT G@$6/&(SY?LWW1UIBH
M)RNUDX*NSVUJ22*3VS#V8-G"!\0)SPTW&XB?2BC,8F].[%^ESTVP(#-@JX(*
M!Z 8"\7(I1L^0/BE4J$%&8&[4CQFE#@Q)/@;1U-)LPP^C+O>1.QOVLF.<29<
MW[!,+DQLAGXRU$Y"P6I8KA%,D4KP!9=+0]!EV7>6F+4%C4/G%WK;4MPXC)$Q
MI1 ?G%^6H_@Y.B2Y$8H3+Q.X,LI_>#OTY%8XQ(CQ:H!:[D+=E\/S96?G.A=G
M;L<F>1.%A( !%8%+\SCT82&FA6\9K*\Q$]DD$?AR&<ML/FJ>-8)S$)?S(TZ*
MOB:#&R<5G$2 9]V)4.U'U')Y\-%HPD$=57I8!H^&D20\^\3R(BMK#$(H-/Q4
M\!$GP">""1=K%U?$@&3>P'4.''B4D!%)$I%Q,N4RXN65?<,:1B<1*JSOULP7
M$P>EC6$$"U^#[%3YL(=,Q.E$(5Q+AD #6%DW;2%(*<Z"N"F[5(:6^"VF<>3<
M+&&8$">1BZE%N,0B8"@D6V!'H^&$ '5!+&J%!![C/H342B\,)^;M<.'#H*!@
M8H8'ZP2_!/S$7JHE:W5P.;Y<U,GXK7W&;VW& QLE^>R9;^I>?84W6'QP=757
MS('?,_/)<4QR!N!:(?A(@$?;HL]&N]]A+;?U2 ?B,P>BNI7<K*8N<[-*X'8\
M6/+.EQJYY>?'2UNDM.>W<QXZ*BB;6?7ZQ*K."XE517 )W_7N'\CEY>6K9ZDK
M!4P?>^A?$Z6QXW"A9>_^E$U@UFMM#6=_?GG?/WNXO1]42/_/_MEO#Y>_]\GM
MQ<7E6?]^0'HWY^3L]O[N]K[WT"<_W_[>O[_IW9SUCV2[B""Z>)-GLK)XW*.%
M D% ,Q[OG3"S(CH!X8G'=C#XD>>+\+.Q."4GSURT02>&)"/RT586/TBIYWBD
M<_UG!VP8H(BS2WO"N,J*1],IIH'%(XO>.HQ""^()5,(P/<>=.<*?/.1':SQ&
M&"Q2RKWP1(:'-7\"%^'92FU\NG,=T$5H&"FK9 -F^Y/D'!>',O ;X4L048RZ
M@E)\:/"H'W/AB>0'S<B.QGUF/=L.@!+7C/FA_3(3.2',_B-KDG81#/IG4=X.
M+#4Q014@7"]8X=D3Q'QB8O;X3'1K1B-8&!X/1LW%.-%9%Y^4A-C'H?1OH7X*
MG$(#.+[D6;;?:IKGFEF2!?72%!=/5@,Q[I#.K??TPQ*OR,N)C&\AT3F#+?]W
M@ P5CH:(@0@3YH:D.?21:$4PJF-R':L/:V(4*+LX7WR-Z0@C%ZB(X0J3:$)G
MPN,4>AM0IQ&2#!TS<8I;+,?B+<7-8,")SGQ!)J_*=PGOK*Q+>EE(BDG9Y,(+
MQ+Y9/0G@8A"5?N+]?&)#.,4!!7SR]/148V'<3 UV42IEQZ SSK7QEO^.]6]@
MEN+(?LU,BW*!JWY*WOTS&GBXB77-5^3<,0)AS@EWP?&P#C<A<[.\!S+*&XF(
MIU2^8RBJ.)((8J)B+R217FOHN#(7Z&'L5']-23!T/Z+8X??Y#C<A/5&+F\M<
M9UH1OH$D@XI+P=5K#I(*USSV2:7Q(LL%%1+:J4 #"YWN)IDXAK@6-0<1(P)B
M7B1H52+)AYX!'OR?ELV,3*SPO8NNV!OJF?1O@9]8T_H;\RMX$Z GIP YPQAO
M'ED9!1/$A$IC:R4B][+9O;Z@@]XLH$:.,*<HM12T8@@!L[UC.ACF4U@V %OO
M&=JFJ1+&K"ZH(I4(<%?<$>N):R],0ANYIQ+VR3>Q8RZ%<Y?<42RO#Y):Z!\A
MQMO+!YH\3;#\EG2"\MKXM*W8^/2VM/%)&]_NY+E:BXXA<W+[9(-P&ELS/H_0
M8?V%V0RD%J^+PK_G$N0ZZPN]#^- 4^=1N 3K:1R+)KZY!<2+R.:DR196C823
M>$PV)R%;-O;RU>>YMZW8*9SV^B+&.8-@=Q@W=WRFZH=,1J@OJI)&H541.UE+
MC1QHX$+%F&NQ_'PHG,11#D0PBPI _6"N80DWL;C:F25A(B)(C+?D\<)S0NIP
MR8/9>'2:H+F1ICG&*GIAY'M4F5*<+Y).+\*DQ$/./#_.I%>!FJ0?'E!#1?PN
M<(TQA6'RI>1)$_W!W=V'2GB'HI!PX2]M1'74J9)+^??X9W)]\X7KFPO7MS"K
M*C#$#NT]H9DP<WU+7!]'NL-'[1=>T1:W?-R(&Q<4%\$4L6[DP@IAPZ4)G7GL
M8_3+)XP!F=#Y1\OF3,9O6FRQ!&])](!:0^@"8=/O\/GAUS7^U4+#)_&=KM3:
M2F?EUXV:\JKOU%KKE4]=-U@XL70:<K [&JRBYGKL"[WE%]J%[;?GWZ*6^ QP
M^";A>_H,0/'1<>>+[=#63&FQ">(69Y^2(3L[[>0CSDV0R'UGM- R;E'>'7BL
MJ50&WQ%#70#,-%@"TD;QXL6>5HCG@+;4=7FE5)Z*P3%]X1@BF;8A#*CX!S.K
M%,8*JG&\[F*A9ZYE'#D+B.'"T(L][H,PJ9AH$9 E*SS3J58NFT:Y*]^I-:%1
MCEX8/HHRB[LPA,J^6CU_SWY$SI_,TWGDN,CR@3D&4U!:Z8</&7![ ;A#791;
M,&8^X3FL)*)4H5!]>=/;Y=U-W\9TKZ5)<3@2N$"29($D0TF219(8FXF*G+V"
M7Q(30+%W^PUM;J0,3LN,'S.TU@@+7CH(::N1:ZV:GF.82SPLR&!5C=^]R#/4
M8\+4C@E*N>%WX[;O\3/4S7AA:0OXXO1+5SN5=J-341KMP[7(WM(*O7E5=@_G
M.1?EO]ZR"AM0?Y]S:M<:S:-CL2(SR7MU-9:?F(QJ5#H-O:(=4D9MK!:,^/^.
M7BVP10;"T:L&VEM4@X6U?)5JL(0?"K[ME':[TFBK&^ZYY7R_4Z']PO*\>4D*
M(_+SZP7+IE94+JMIQ\=C1>:2]\W7*0;')Z'"@.C#<<^6C 7\W5JCINIY-81]
M4OG!\>DDA]EHIT?JT- 41E1J0#/3"="2',T[MR6JX#P-!_).1Z\H[>[KE-WM
M$4H>Y^5Q?LUQ7FD<W7%>"J ]G+8/+X X*M=YX-@2-W'A6F7_M>1_1]3H6_D0
M90HO_@RM"L_]"QASZ(VIRZ*<W[ ,&0_RC+)&>,"AJ"\<AT3&?S:S?XKHQ+@0
M&T9;UDAO;3@G)3[J-7B)5FDWFA6]TQ"#BF,[,W&IPHN-65L9)_:"]SIZNZCH
M%<QXAB.9TA_6-)CB<UL-I:*W6NO>% :_SL(HTKA4K!'F<D5?Q-W1,?0V?!X?
M#@^]#5P<6)RBCH/B%9K0H+-8A-;FOGL>52L>$Y9>%=%$Z4>%T;6I8!+>^B.D
M^U/.6!2>818^:GW0+8TJTXDA>O$4OMG.TYIZC,7;)NK*;?*PCG)$$,VGWWA)
M+&0GD:TJ(NO%<J6J;J57!K[RX6Y1C!LY*[ M/Y-$RQ>"/O&40IX/&!;>Y!R=
M5-\B[^\'OWD?PA!HGNJ+[3DS0Q1L^,(\*B05P\$+>Z:&B^_@">+_I:BUEGY,
MBZNM7-Q[AG67>8' -5M^Z;;-!&N_),Y@/3877DA'7& 0@X\BVBZ18JDW7]KD
M!D0WEQ'X<275V2)*^<[<DIE&JA0#4!<1 "1@HU&!E5@WY!7"-34LY#=>]A"8
MUN,9C* +\ K@**@8[WH;S0O>T!-LON117*@ ]UC?+3.@$]@*XVPN<I)WRT>5
MQ-9GJ!8FXXHT7  ]&#>VA"1Z2]/?&Q_>-S\\*SC_&%AF:H+A$RZO^3U5A51%
M.@0V8(AK2?*\93[CN+J?Y00>KZ<9I\J+8HHAD&8:CF#@59RF0<D05I^,L+QC
M6"\?+K8=NRH>)#K$45XV/#7MN-1BR*4)[?Z'YY&R,!T'ZX['SQ$")AH(\'.<
M!\]7)DKGP9JM]ER@0WHAHQNS7+)ROU2B3(VPQ C."6L>!D"0>39Y)&P_P#44
M9EAAXA1'I\IS&2JD92645AS\YF'J2>J"8Q)>S?TCDR#>WN"D6].UUV>QMQI%
MS6+7:G&V'$]=1&X>6S,OD\SXD"IV*]326,-.>B\92XJ+%3;-;->)[R^2%#/2
MYQG"+DE+C\HI$86\JHA2SC3&O$RL%96)FS68952*)=WOBX5UJ ?8YMA@IY6"
MNXU"743-UNBZI]@!U8CK+PQ8BM\VZK.V89$I63;A6=F$YE;*)K1:LFQ""<HF
M%*?\YN^O!YCN,H"!T1A5F)D+./G1"Z8PZ?E!4$;'@C]C:\@-($GSBZ1$X< 8
M,Q.;_^2%F3TJ\CFE3BKA87^OS=*A71-Z1+8:@!D5)TMU+1 %'N%H.:.N'Y??
M$M7K<V>99][-Q=S!UT#Y0-8=IQ*B+&TB$1D(7MD?-;1D)-9=U%3)Y64E53&M
M\R)U0_S%8(04O?5E]-Y15G^G6U,[^FN2^CM:K=E8_?6KD\2;N1^[HR3Q[<6$
M+IH%EN?%+$NV/-)$VGP3O@.U:LETM[N<+\?W;J;DY/+IYE.T,E#-!%9^.MC
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M:/B P1)2VV#D"[/9R/*YC:%"J$?HE,%X37Z9RSP?P\Y+KD7(7/;RS+R41?9
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MI2;N!9!Q#)_#2U#QIV&E_WCGK";+!Z"+ZS)OQH1N#W?@!!Z9#>K^)$4!)#?
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M^=@M,;LK*R.[LJ'&/@'XT]+%;%I2S:,BDL;UMF*M@FW6/6A+H8-+GSA\3)]
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M4:M0NPJZ\0FGJ?L)Q0:K]MZ>N,9=TY/C3\<@.L^<X3GZ^;O_!U!+ P04
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M7M9>/2J4+A=^/$6ML.\M#EV)VJ>TMXORC_5";VD5M>72<9% 2F-(>,I"1&E
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M@=?K_[,E36CP%D@@UKK"='""%C?MF3,AY:A#H$5NB+6C%\KQE&@DUF=C43;
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M!2T4(S$E7B!*:-Y@[0%<2_1A]JYKB3X2'NU,N@NHIW8MT8NH3H?3NTAY-!5
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MU'(WO62\K=Q-'P&U/G/K6/0AT:Z3:NRB#[6[8KT-\KS0/"$4DU(L.M_IQ3_
M6AH[TSN 6.^G>([3')Q",CN$#DP;)5F('%CAD%1&=,&(WL0??/&<)KRW$6KS
MXCDIS3'/SC3RU32MP6$^+^9 ^Y -W+(<H#HYM;,F2DW+$B2O0XJ^=*R9<OM
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M'O[192_VNB8S["/Z>SVS?+W\@/,KGRU^J_*K<VQ_*MEEM.'.'7O/=>-D4>7
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MO8W(Y(V];_;R= ![*%IY;OC:154]<?7+Y-/E8KZ4@+PYQ&NP60@!5B?V-_E
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M-1G$+LW+3SW;OI/"M\ZV[Z*M(V7;G:\U5DWMRN,"QF,++(0*.1GMLY,43'\
MO4!G( V=,-M^^?$CSKY,ZZN+BV^ _RHOQI_'BR]#)\NW>UNO7/<>O*ZFJJ70
MPE/16DA#*J(WK%V!-;C0TM7K4]4[<SVL7M_]\=?;/_XZ@DK7O^@(VMR"PQ5%
M6AE05JV#4<E(CRDEG5/)596D0J('%;G^E2>O%F#R6["D@M>5CZHH(R23-6"V
MQCGFLG;J#GF\U0+;WU+W;GIQ\7HZ:[\T8J"@:B'-:JP$(Z2#5"Q!5-)EX=@4
MCEV&W!^7S3,\VX== R>XZW!?%)U34<'.-SL&7:K$BE#8E@+CJ@9FC5W#FB.*
M*$WPZ9$NET=W*^@1H'JR&T1WP=DY%2;L>M5\U3)$U^8XI5K!U-*V-PI09+1:
MJN+SF56N[<C@RW(ZR7(Z &5#7^_1C\E_+I7Q:E+>T06UWQ[YP&Y=J^WS-;J6
M>2R0=&+\$SMU[/U8K^56DUJ.2/3+"EFS0LX:.3T*';JQREJH-&9N;S<#48/T
MHK;[6]H<K!!5:Q])().P.692RG2Y(>Z(/+ZLJ9.<.H=A;<#[7HYOKQK>($ST
M&FJF",:H ,F' (%((TF=Y8GN^^SC%YVE*AX<'O/M"L)@I4VQ\ XO+!@2B1T,
MWRHZ%;'GD77 Q^K([B*'1[13/IK 4#<</BI'=WMQC$PE4E4&B(':4,Z$$&5U
MX 2%;(0*7I_7;+ !F7]$"_ <5L 9KN:=X/NHEO"NL]D\EE)D<E!)9C"H/007
M$*S.WKAH29Q9TFIH";PLYO-<S#V!_(CC9=L+) LO=<D1O%"RW0]L(6;>XHJM
MV@IRE,R60]_/D+N75;O/JCU;=>X$UL<8R[N<T<,CED?&RJB%JT"IMCTL%\ J
M6*>BN4>^IN(>66'#+NR_K.GS/(F[0?AQ1@\?EH%H"3K3^N@P53"*UUP*5@$9
M$TH; T7EO/K6N_G&YZ3 -Y>+^0(G93QYO\+%.VJ[!7__Q^ED,<.\N,2+UDL[
M'T6%R<B2(::,8&)!7I"JU2D;JBH&GUR76^K/2@J/:%\^]WAC;PR>TQR#!X7Q
MZOW[&;WGS>,7YG@\F8_S<@?Y1D8CJT)R%0M4YWD[-3'Q3DH*O&TC^'P*SO5+
MT9R(Z>>YW!X#PLYZ6D(PP<>2% @CV/ B(R!D-KRDTXD5X)QP+],2S@'M)]'X
M>4Y+R-%[Y\F#Q^+!>&\@D?0@A0P6T?NJS<NTA&&!</_=!#LHY+$TFF_#T\NT
MA#WN)M@%*T>YFV /13\6$)>"SALMP?-2!^,"'S:M="DH(6O66(Q\N9M@A[L)
MS@V[N^BW V;?$=O0XS9#;-DD^Q<K9/[NC[^NVZF#<L6R?0Q$M8#12D(LPK1;
MZE-@ZT>X/H.X[J7J#-VD[HJ?]M):A_ZVMS2KT]E'G.2KD>#SF][\JI30*4+T
MQ8(1Q,:*YI5(3DNELY.B3S?:!GI>8#2(IHXS1>'M;/IYW+;[U]/9=7/X:Y;O
M+Q/^!/V)?]->K?5;/'6 /OI=:5]IFM>17!'!D\5D?)(A!N^<U<T155FFT6Y<
M#"WWI2/22?K7SSZ*#M;QL3J'HAI=%-L(,1DCO6*GWV8KT&H?74AY"TW<Y6AH
M?;2M93IIF\FTWGZ[S0F=S&_&*APPC&+0]Q]%K_O*8T7W[$ZW:?-2B%!-M3*Z
MK$TN%;/)7H:RA>[WD\S0^/AZA<<[RM-)'E^,E\?0-S01'TR+#[2\@)R/^B^O
MB?=UO+C]>1NRO)C^3HMO?J,KICK3?!0<'E/NJ_L6N52RT<DX;9*O2$&C4SX5
M[XRPV^Q;Q]- /[S_1)5F,RJOYG-:M&MH?AUC:E/#QT>#[S8D'!F-.TME!5Q%
MZYQTE<X)8ZBX&&RH/@M)!<EGN1.X=I3/T%CY'=D67XP_4U<XW'G+431^/V\K
M2HTZRJA5JDIZ4TUIU]PEY5WBK<2[XK90ZIWW'>94?G-@XL?Q!*]%=)V6<4&:
MD(-I8^0$.T%DV&%!"X5=(#+64,8N/2GW4G6H'WVS&/CQ5^NAI3"O7,:+B^E_
MFM<VD@*]:K?+%3+MJ@.2S+@,0(8]A,+.0C%="HZVH.WX_O5P&%EUE(=618>H
MRUV*5HG^\4.+,_PR>?5Q>CE9C*@6BLH(\*%U)6.-@&S.@B*RWOG@?)]:M5T)
M?4HXZJJD#M'A-Y^H;>*3][].Y_,?>4?_4J\*5N<CC3(:)S(D8P.8)#4$+Q7X
MHKS4D12:+A7+FTEZ2D 92/ =JL*8VQ\9K^/%MU1=HQ5SSB%Z TX7!T8+!R$[
M#=+SWF>\=[+6'IBXAZ:G!(JA1#]@-=.RK^0>NOXU7GSX^>]/X]E2#-=S)K0)
MO&U5@F <GY2Q)D!5(I2(2FF!A71]R,S>Y\5/ 0O=!=ZA-/^OR8SR]/UD_#_+
M<^[:7YB/0DG1)5M!*\O\5U<AAA)8"#8*:ZU2J<L1LH&>IP"/(45^%PFV$Q+^
M_("+?TTO+\HO'S]A7OQ<*[41OS=1HQ$JH4FW,B?T&9:''\HV%!XM[VLLF22[
MN'?[D?L,<#2DPN["S!T*LW7RN"J8*Y(Q3DR.DRU;J@@AB*I!D-<QD*,2NFPY
M&RDZ5NUK/X@,(^QS*5.]Y>;5Y>+#=#9>?%F6#6%JAI0NH%1HA13%0U"A@LD8
MM'*Y5MGEFM[UY)RJ<'4@56\"T/XB[^#ZWJ7JNN!B&[IZ5I5N(NPTE:%#*.]!
M/!P@^6,B0R@7,64#&MO]S&QJL6=N"MBB'(80C-!=(FK'1<0#Y9;'!,0N N\"
MA 7-)GCQCC[3Y)+^H-GG<:9?WOUQ74:EO+*A)@U)>P7&"POH* !FE[2P10;1
MI>#M ;I.:)\>I, [J!A.^CVF_"_8$'XU*;_R)R_^S^5L/"_CW,1\39YP0A:7
M!+..;8:M9.^\9@^BS<-05$U=G7X\4%WW_70]$7 ,*?T..\?Z $[;)Y7UF*["
M_(*9UME!DI' 8:XY!_Y240]8;*3H:=F:PPC^6&'U;\I\MR&OI]7Y 'VG,3X'
MTN8V&#E0%<?:0[XALTKC?=8!I&U!7VT#!+0>?%0^.&M-PBX=]"=!R@-&Z6F
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MW;\K<>//]IG$LP\%?8?U'"R3U0E+JAA9R#OEJ\E%H YDBVB#*DK,3MTWS^=
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MJK#S=J>P"?6[M]_=JW)G[5DJ6P+":/;S@LC6U=K4N;7Y9AN*(/;9\$ZH[W'
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M6"RI:D*FF*WD2C0JE#!_0?.GBII-UBJ5>E5G;8URAZ> :LKM9!(DT! F0[J
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M!8K#P.J+K":R2DFUI+0"[\VF0@6^SK8X)5'-6'*.2D522#L<KD>IF,NA&/1
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M OP57_"^_2N.]FSH2]BY71_6>O:CI"&45Z;5V/4;-#TF\*(#Y:]A(FN###"
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MILZQ@9)B I\<4)1=J*9U_3__O<1?QRQ?#H86@I1YC8&B<&-;H;TT#.-%.A/
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MVEOPT=RV*#^_2*_K^LPW\KR."K#S!B#V&F(& N.ARAUM)'UR34A=]P68#O%
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M<GQ"IV"MW!J_M!T;68#R=(T7]$E31WE\W2LPJK*]TQ$/HPB;+L6C[& 16&+
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MDWKACX7? \*<&5(2MO=\]R[ PB%$0_0 #]86&YZGES(83X.,/]DLU3%8-?_
M(..@ZVVO!J'%S<TG<(MAGK"E$*I"/[(7O7,#QC[B>7K^&+(WQ5*E?4"V0R L
MH65 HI_!YTS!^)'87TXD3#E_5*3.N[^!H&]OZ]@OV'70C6H$->+8[2(SS)A
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M&B$E-LT6XG5)? $>8V]'EB3-= *@9=>5VU] AJYI51W.EC9E:O9^U% V)CF
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M^[RGY+L/M&19EG5P7H$$R8*JPAB@$R^-XC$V7!<EF4'N@M&K,.IAR+@[9#_
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M*R]_1>O[2Z-9_MW7E$S2$&.04L\"B@/5J6)@67E!CQDZZI!LEUY[0]P1ZQ,
ME;^RQW-&=']B]EOOC([%&_7RO<W7_^X.##![0!:/(W%)HJ1HX@1YM:E?J9IY
MO"K\:YVTM4=54]TAW+K_.<F'9^O=8H??Y&5*0),!=AB"(EQ=)6 OE9(K)G59
M:X_U'1=MZ#?(Z,BXH3BY>(9=Y^3UBQNFK4M34K-Z+,G<3(\5V2^+QU]W'$U(
MOY42)/8+$?_7'=9BK@!O.ZJ*XL$L 8!0P4+]!,C76B>=M6>.&$S'82@O,[,(
MT0*=/:=/I51T//V3>3S_/<[[)Q[G_>@%=0 880 >.HCH!>],J^A>?)8D2<A\
M-"IEN[D4Q=0!T,LG_KN1(QJ\H!+?XQH^%<U& 9_>>_QP+MU;SVS3TZ%#Q21>
M)4FPL\!'TEI+MD[),%UXP&84(B;^KO)=YTQT5^J#W'2SJWN%7MJ5D)BI7 TD
M-<"RB!%O>4]JE*Q092;%AC(,;YX,W=R=J!)SX4#PDC /B(5,QP2XX6,/O9J<
MOW46PBE(.SH[$&6.FEMF<97G@+1E3@\J+/6:E)FVVVEL-HWZ+!7?!KR1,-^#
M?_VD^8#M =X ?OA7$)IJP0NQEC:!U4(@"L?'H4?MH(OHOI23UQB@0JN%#H3)
M@ E!=X)>0."82 J>Z&"#2>EW+>UJ2QL756]HQ.(KCQC@'1;(0D&G[YJEG74@
M.X_&+W-C.IQJ)(IL9FI%"'*2IS_.WQ*(-J7T?AMVL)Z3\M]46HJ@3&H\0.VB
M2]F!!6N/S-9*?/FV*DNS_WHE6UN":<T[ =P8P@LME^L;(-6PK"T8A-I?)4;J
MR15!#>DVFZE!]7T-QDF"U3=M]DP*;^@IR5*W\\M+S_]%O/;HG&C@4RK,SFP_
M>P[T,)X*:,'3MXBQ4(H&N8DJ,/X(V+!GX(MO-J,TL9)%+M4^SS9>L%UD"XB=
M^3:"AQ",D2/+%,'^U7&HGS.R>\8 '+B<[+R^%_FM@WWC-3)7Z*W2^9/U] <F
MJP'!_+Z+UMM-YRJ+LT[V :; -W9X:6UVF1:!8_<7K/]A(F1,D!H]VY07Q0#%
MAGHAK0HWRNRWA_T] ??_M9S-F@*!'^EE@&R1(>;L?FL1I0MF%8>JR]M&+JG:
M63O?O="Q'.(A1TDD8,=)L82,#^9:S]=N>)1VK^D:%I>I#=B'W-TJXH]\% E]
MN,E.WSNZG8I=7T:V<2/RF98.Y7I70D3UV%0='H$^+)%6;^YA@#P.AE<[+ 8!
MNQGNCRQZ@$4/P&K0-M/)))/.":1D"P'2S1P.*75#XW//H-59AGOL#"E0^BC9
M)#[*'. MXNM%F]1?V,?_*)?@TV+?I]BRZWKBO"?C@JL$<QNGHJYLUF0-'%DQ
MOZG#&=35RL?I<?MIFHO:.^I87__O!RK^YP:,P1"N=B &&C'O!^I'@F5XGT/8
M;YB7Q5Q5_FC2&E4Q W=$P==F55(P4DA< *Q,-6'<5H2L-!$\B.]?F<NGRKDI
M+8:FOPR7[A3U/X-59)^X]]+&]0+R6D[\Y4_#DK-_FXCQK[S^55F>]"=(' JS
M<A?"@L&;%FSGTUC664( )D,#,.@X&2"N=YK"Z2_,22Q3"F';11-_+PW^ZX5N
M7R9+*% YRN>X39"\RMQ6"3<"1B>">3AHNDF[YS/I1Y1U9ALAQRI@O4?1V7:>
M6],)KM8^SJQ]B5-ZNPA7GDS&R^\V,X/N_K&*L4_3^([]S*K&3\D]O4B"(720
M;8$D0RZA):<VR(Z!B+)HD6C(F3,GO\5W=-[,_+:/TCIO1%R9Z5BTV/>UX=;O
MU?-_%YH;HW> BTT"D=;(D'AHJ+*"?/NH'*G#Z1,\@>+9$K?+K_(<V.BXZ>U7
MA]9$J9P+=!8OT<4XP8AQS/X6WS1OD;93:*ECJ/WRR0^O'19NH18]B\Q6E-GC
MAHIR;L'^R.\EC1Z%+?7_K,^(WQ^7G.8'CXO6)WI-QC:&@NL11PNBKO67M#]Q
M=F19:YVJ H]K7#-[3<A.2]I]3(6/Q$$+]4"/F$SZH@/NPQ?TV-H=^RNR=F_>
M=RSZ(ICD@,N6<HO:, JDC9.="0N:9"V<BFB#JN!VCQ_W&QXEQ67A:;:U&5EW
M'N@*;D\HU@.X*-Z$(F0+*T#5B8/WSXD+-">+2,KY:MT3[G4*W/%F8Z_JO!0A
M<TF78R&Z4^SF\%G ]> Z^:L38O\;!O[_9QCXQQ)#;#AR=W'X,-^X2,FX@!WR
M2TG@ 8?3^9;]^JM:TLCB$":V%A[EP^*$F8F-^AHK7'ACC55]Y1K8ID_VQO.R
MU^Q5Q^8+Q9;"TLV@+A\&EIO@N@"\^-->(L?OPE5A+\P%\A>=ZPGXONNRF^@S
M;HDS3#'/(MUH]4.4MR:3= E"."F,F:)[ /-(PV'LVBC:E*K;MN 9/NL,D.%
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M-)!B\B-5D)KK.F9_K96H\2()T>+R(?;H828=PG0KI&#<N72!0T0KRO89-Z\
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M@"8(/TD>&0>'T7DMK.K&3G3#-3+X]\2TN1Y_%O&R4&HLM( JR<1^>=YALXC
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M6 Z8H-TYO$'G5JCWPUDX+2!?*//MS"O2QJJL/_=,WK M#]DN"52.=%A)JF2
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MYUY&,4 <-^0HEDD-;SAD?0P_[VM8O,\636/ZRR2*/"[-%RY7Z/=^"CG09L@
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M8M*WJJ"5;[H@%]33'[^UKMC8V-!AIC'E:ICT8BI&@W\G(?\O._S7_F9UWL_
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M=+Z[MW%'RNAW7>3M6QFR&,*U9!X XGF8 RXS2+_[U4S_#99E,AUM/4O":F_
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M)">53GD.D/U&.S2KOOS0JS0CHJ]&R:?"TH".IB86)!+Y[(#+-2Y 3EAJT!T
MX#B U?(7QT[L#_JM?#X92++!O>F/IASW*KI6>$F,4))J9F#\SB#OD<8#KWZ7
MVB]M1]_SBJS]RK+8:6LX6DD-_@% 8O/MQ;15XX\-5__,7QN0Z%\X&"FW,_^Y
M_Y]U/S)C[R2I&FG(K;:+"!RA79_^2<6;MD,[]DBG?M9%" ,,,]8R41T%X_53
MEC3.W4?P8<WH<Z$"3&<Z0*N=Z1TTX/">"CBFQ.$5B!6*%/63G_ _MV725\*^
MABDIB79#9@NE9"T8ANKN]?KW+P-)IS0IA[]FTD(LQL3[O4/]]XG/"JZ?I*Q=
M>KMT;J*F[;#B?8F#<$#Y_L_Y/E3 TNKN>:_]!'T<UJ:&'K><$5,$N.@895%9
MQ5<5>\6T?.KH,B?FR(9MZ[V:X%>1-'B0=?[WV.PC8;7*T/UV\.+QI?#)U?U$
MASSSOA)4(3D)(7!)62%W0,CA&VOH-I^]LW=SWWO/_=O4'_6NN<N@7TX=[!?*
M71#UV/P?<;M[=R_6 7%.\(;PX4VNGVR*T7N+)6BO[YG-;=[S(11%B"Z%]GM5
M^//Q?0BQ33$?>42H4<]5"W\C:6.. 4]CW59X6OZ9'1U"J*PAKI]TRI=RV H!
M[86>+<2KA8M=W( $$U8$+U^]U%[P8+8UL"QBP\;'_*RKJS[!ZMKWO"KQ%,/Y
M"H<\-CDH_(BQL?&79WP!4G2ZK&ITR@" ')W>@V=B'PRPNE%7>X3/10@_^P+P
MN;?(J5&DWD1SQ??_<HBLBJ?GL: T)/O)Y@,GSL9H//ZIX[DA&; _1@MZ 3H&
M+R:A2B#+C-F+=S3.?I>B HCQ<X4RW XOX6/,Y'F.HF2,!+!.9 5-%&5?UJ<"
MCL1CIJ 'NQROV(U)OXB;2O4C#'G)/P81>F8N+:1H8_2G=6%7B)V-9GW%KK?E
MMQ[:@#L@EB"!W'6['% 1-++J\))$]Z2?B?]"?)#(1AAT [4\4ZYO+-2UMX.$
MR=PTN*OJ[TV+*:K( <:$8+RK5W>CGA7E1.1QEZE:85)%;^O[I6:O.UCON>;#
M:#1RH,550<\I,IB> 7'!_ZN[TV<(CBT?"&I4T'HV02K-L'E[ZWO <!Y<O='=
M87FKDG]P"8[3@ \ *<R+FJ"PY$N?J0!P.5BROD]2G.3;I$;R+P,UU2L9*+*L
M+-R/1EUXU?3I7(IP3E9=%@?@>!T<,O1>LK[,))Z.YSBK0ZZ_Q<5\2M*;>!52
M-];L4K/+%;M[4LV*9J^BU54=6.=[-SV=G%/"1.:88O^NW0(\:EB(<!FWNAR"
MHP)V03K#F8NE=(FW>F,4NP;+%_(NRS2,.-[>C3AQS%> M?FM!='/@]?@M@G+
M1P%+^&;J0D*OXMUY"]E22=&F>\T883GW!ZN<8OUSW8.9J4;2YKA80C#Y+<EB
M5YS86 QCF]<Q6A%:0KZ:T92?!C:RO*WW$-#F=)6AZZK:07T0YR4I?:<($1]A
M5?%L;\SS;3S-MTJ1SB_XS <P&P][F .8SH1MTV/!)&:1+Y2+%0FKM16$[ G.
M-(>ZKB>4[T40BY&V<V1-9!<JD1A;:^_.%54 %M YS2?X.O[-: K9$?Z*_*H6
MKG$;<>J6U-6PXY&J59/O/Y"6$.=1(AK>&Z"+<X@B!36:]%6(J9DFL(9*,YQ9
M^G%GS@+',[$+]^O4,F^"^HI $S3?S0&;G:U%$2_M8=O^+^!ZRKGP:2\-TALJ
M@/7C3B^(K4S.92;J(7AFB3(3JW0SI::<AA5$2 ]I6 %^B(85FGX"%[(0+!.)
MM-<S=^CR'KB(WJ0/A<T=SZ3LHWE'9N/GH#ESFC'8]W?_'M3#2XM4/\C!B0RP
M!KT)IAV.+BK@2W0,W9"KDD[U,>@76*T$R&Z<: ,+8,RP8S?S#">=>V$#-:WQ
M;7$)=?2>BCG4#QK7T981\W.@>0=]8CW-.^PU[-5&T+Q#M1!!BX997$BNY#C*
MU3F*:&$%SN^E,>I5UE"D]AUQ,> ^=2J@U[V)T^V+Q;T.D94J4)M7]+EV/CVO
M6\FMT*5^<>V8S?#^KL7L;5BX8?,AO+::@J)"77S?A;$G\,O$_#RG(3OM_FDG
M\[TD"F)!A6CR?Y>1'J^#X9PR&RH72[AF(TA,&<.%W DMHV;JJ:C6SAN706,D
MNP6G002%(1&7B7FS7),^J>*)9S1XN@)9OMHGIFC@R=:J[DBZM<;D**G1HTZS
MU"C2J7C*8?=)X-!L YL9/_YT=5\(;JSOP=I(2X9LR8?,M_F5RU>'NC;,E$>^
M/-M5F8@^:D-AQ$U'1:<-UF;.^SP^;&?GL&\YBN'E0=V[<X!]^4-#S>8./!+-
M/!)U'_DB6813GCT%\ #H'^KH78ZU_,DM9I__9;V(L'RNP6I^6K U-H'S==JK
MBF!]'8EK] $,2[:WSN_'T@)=7PH#$I>*K319X#T=# E)V&A ):4W\3;=!(V7
M\)_G[>0@KT/@J&(UTDEZ+.B+?O+,\'5>Z<[4K^P5AQ;?[2.,.CV34*K4??V
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M[#_@#B79>1*'03@MGJFR,O1C'=6M"NI+FHRLX586A!=$1+*I.-H2,PG<W:2
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MX9E#NVP$9 ;+##C1C-(MI^OG(A\B9O*%55?R024&C05Y&@OR>-"O0H$4]T0
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M6@E!]X9*9EH AR]I/^GI+1B?CP;BH.K^F@OQ 'N8X?(P9LW&8-@KPG8P8,S
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M#;_#?_  7HWJQA"2I7GVMAM,0R/!4P,9(7H4>[MFXD475\9/FVSVX_?KTGD
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MEOA-O\UFAP?ZWA)#:E&-#E[@>,KFL]E+H<UAWU:-\<ZP89$@%02EF;37OI#
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M\II6G?T^\!_IPT:'S^NDX0]BP8-9()\Z[3JF69BAK1'U KEN"7\L4,CC_,;
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MXIS(I<"O\NF;=&^XCAR I<629Q8W&>[, U1?RL\)P0G,'J;:8!;--YYIEM7
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M1XX5\I'IRY9I:>#:%(>UP(8!AURP(-W#@P$//GI"O-/7ZGG".P>UW]Y=;KU
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MZ6EW=36O#T<Z/TY:B'$4TNU8<V5@<G:VJ33=#/YI569:_Q  @OZ=_TZ_UKV
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M)7&7@Y9.&&$H/W944/VRRMI"=Z@]H8:EZSWKR%.=B'VB7%AS:V)_:J@\]A#
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MB<+AD)AH!,6W#DN_U?5(J<O69:G.L=P7'WS<1N:&[B_),V$]MUB?<8VJ<8A
M8#JU7*Q/C>%(>6/Y9N/[%%K&(/EW^?;&?E'5LM:#7.<+.6OYL#:3+,!%(?Q%
MI!J;A'VB) _QAU.<V$^73)&@#S\NYS>-44DG' (D O.D'S34RYP[T5%F_R=
M QR9:L3=3A:W!#@S8^&FM/%A8^M4L#<8"QM1Q4PEW0W 3G_X4X@QMCWM%G+%
M(/S4J/2-];P"QV#I\YGE7^GX[)16U*(;!M%L/[S+[RD/M/S2ACKV(]S37*B)
ML"C/FM!Y'B:Y_>N/6<K9\GLQ#C=I0'*Y(VWV+>OS01\PKL>[<F,VP-$5>W7K
M1&M^@MZU]P,^@/4'^*N[P=Z/&OIBC<#Q.$YS$=8DB[.-%D#V[F\WYLGTUREH
MOXG_2 .,*K[L:983Z,X=D2O>^J]VZ_[_AR$PBQTT@Y#%OM!CVD.E#ZZ;@Z2@
MQ9K\MMU[<4GJ-<=7!#[9[)'^G"]<.X(VE%:,8W:@_*92(*V\J2QA5RCB<M.\
MZ3G";FH!MB.SU>/JCG=2M"$Q+[BN[NA+JW6FHQ!Q*R>CF<3"0AI[=W>Z*5&#
M7=88YBTIE@P-@39NZ:U_N=V1&Q1UYKF%FM12L]1HOI#]9*++U3;'?S>28$\I
M?_(\F:F'@ #-2U&8J<2E$P8S>>S<E\AXJ!EY>CSLS\6T]5R^BR/AC0!I,/E6
MKZ3]?-]9UJ<NI^3Z6_]^$&*0W%ANWY-ZH4!3Z^BJVSYOP^ ;D?'/.](-)53,
M(2#=C'Z1(<NL#4%%!@01I4W%B7]NWY4W<,0V7E%\;!-ZKR.4'@BO&$$\T$X'
MB3/8?\=]D18)0D/B9) 808@5[4[,(WR]R@3&\7-@X4*8ZT1XN"ZLL;^ (K@[
MHI&>O_(A6KL?O,A/[*N)K(-=97;"-;(5MOI4VN+5D=QN0]D"&Q3+1_*?;EH$
MDPZ:E9I._GK)8SC 6W!7T#X;TEB63RDD?J0M$<!8=:(?N]P)V[^UK@X,HQE@
M^FX;M+]S?J]WJ^*]N 9&K)\[75S#UBF:;L::+!< WP=S@)(/ ?RM2_E)T8O:
M;==M;W4'E:S<HEYCA_Y]1+&+>UR!H1P  #CV\]U_)DX?Y)VHA33;UZSIOW[;
M-;5;V:%$IC=:N^%'0?-(2D-(@5/&&_,GA0=A?9]B/BYV.\5 Q-@:GVQ7G@&1
M-]>$63'?U9N&")60F!(Q:GW<[C\6KDD,RQZ]-B5';ZS>$9W0.1O\_KELOHD-
M;^TFF\..8+2%$0-7]G%87<Q3Y:1J?*\DP>U'L<!"U%6?F;94[?1QI;//[0YB
MN74H>^W++^]]Z-0K-?_%XK\N\1J_=#D^2#OV$^OLAPY91T+E7+R;M9;Y?MP=
M9]%)C.>8^A?4/02V^@JSGL6+A?[9GZV"9MM]B-$>+I//OSI>N=G(:!D<P^G4
M@'762^LX_B1P[(&>P57A\W_+=Q;IEZ#A5#^:5D?9V84>!Z_*"1).]$BQ=N)^
MK8F%G ;TTRRXZ/M1IP;QL8\Z -YIN"P[K.39D:*R -,[!'1-]^G3SFO>0T?Q
M,SLJ=SHZ,WEK%\>Y,J+_J%(JB"B:,CO*85=(H..;CI!6U-"*.EKA[%Q5'\4Z
M;G]7^NSL;M6+[[[+&S.581&1P-QJ_Y,7.+N9+\$^M9 $K'Q!%<6-:%Y+41]^
M&+A@W +M&#KIDSNY1^2.1S2I@KU3,*^Y NW$<E[*.35^YG&*8P )H*0^X5D8
M!UX;N!3@>C[G?D'7@U(_A:_X5#:19OGLV5U1R@UR_(\K3-:XQC]W)4;&I"C%
M 'R?.'P&Q]>GP[A$00VBN(,>_-U%,SW83W[<V=WJ^)>RLUMGPJ(P=OLK(Q.R
M MY<?PX!VZET,\9%F@>E@Q0Z9)^&57[6P=*G_%J!1F'X(IJ7I][4V;13/P$^
M79$XGZBJM)836\F8)@(794GL2W4)M=JTTV\S'^M/I3YV9577PD(^[Q<MUD?V
M2E#7QDUO\&R$O%!*>PA &YS2=SCP2X!K0MV(V0-T< ;N&-+!=>9WB-BFC,G
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M:;;G>/V)KC:=15R  1EK,VPDME.P&F%B;V@F?85+=!P&IG0D1@*3#P'-XH<
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M>1$*'OH!Z5P5GO[),".8:5] ]=*O48TC)'XM^[!^S^C?8OP:Y?JU!9F$F]U
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M,9@[;8+,6G(F%PZY?34U(\F6M*7N[TA0$JS!V-P+%L]LQ58NR-X^-VSIQ7C
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ME5$N@ H!9G<8U_=U5&.57$<P/[[%CIANR>8VO9'#OX2MQ 3M/^ZS_/?H]D/
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M.@3P>2;$$._[DDO7TWH4HZI=@RK#S,<U/G*N>3_ =W[D_'Y"]A @@<"_QK5
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M(V4BIDD$22!CB! F.$X("@FV.Q3@3#:;CVV<HP"-\+JFGY8=Y(NFGA^H&A6
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MIY@F5$I"L8U?;C3JU!SLE9Q@(Z@= 9AA;<8)SA$<F":.@#?L06@K@%R2B=G
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MQ2+ :1S!*,08HB#Q(94!A2P*1.2K_R]@1G6B+A5D<E2^DURGO_]YHPP@*VV
M:-4!5:T/*%<* ;W/:6%R7C*!!M;\2-,R-%?OS(A2 [1Z@+4B8*4):%0!:UW
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M4$:QV9;AJ2&FNA_(MD6UW)@Z"6?W-^X"HH&_\!WI^A0<.(:*17F!"]$9J9B
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M@%,P5KJ;<9K=U+<_3?G0AK%HE'J4:&<F3GSEVZC_I%%,88AQ[/E>$(;,L^M
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M["\3F=E^B42O,,,C&:<7?ZA@N5"L#-AVSDRYR;?[T7VJDN/),$UK<C7LJZ1
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M83!*:4Q0CB,AC+K$C2WXU%:!5O7VJ"W0+R]@>QFN^F@/W^E?<=!ZBP!X:"$
M9(<!>-(@[#^H!,0A,7[,M\I@/S'1=V7@Q6C[FK2'Q;3>!XG02G/04;TIK[!]
M3;;:@X[ZH-)__T&ET_F),5\3BSW41%^7D;9D4WMM[#9ZKS!WO?O&,>49;QOZ
M"BCO[6I?8WQ?08D;QNI6O>2EVBTAPI,H1PG$880@XDD&L42Z[%Z&(I9RA-7F
MU^JT_,4Q;5AGG /NK8#:I*D*T&I[9;7YH0C#.51Y&7K7F,45<+Y.W&(+;R/Q
MD,&+,^ ,&\ X'/25@QAG,+@<R#AWHV/;GI-GJCLU ]Z\["YIN+0Z:*TK)&U>
M/B[+S;HR.<I;_2G>_2#+V\>*'K?GLK_N6HK/HR2,2!YE,&%I"E%&8DC3.(9)
M@ G-428X#ZPZ_8PJ_M1V>95JEI0W\H2;\>=TIW%@,NX6[.BJWJW:416X/U78
MHZ[@44, .AB "@2P42B !H9.Y0_UXY-.E])]B^H7"'S7X( &'9_=B5YE6KTV
M-!I7@W%[(+W*[!RU37H=*:Y8+>EE8:FUL#?W:C>ATWL^+C?K8ED6K/+[WCYM
MRHTR=(OE_9S%.)$R99 &E$.$]"Z I!RF5&T($HZDE%9=JU]3F:FMI%N)P59D
MEV-NK_I^6"RU?X%9___,PGOVU9J!#C2>%]U7GF#O2_!KZ3/^@OS*,W=R>7YM
MF=P6:_VX6MK%8O4G45/P3DBQ7@M^1WY6 =6W/[06:DM=%V"@.8LI5PNLVJ 2
MB$200IIQ"G$8JG]1$XJ3;?ZOV1)K*X)#-O# "^-6 T!:%4"Q]2#QUH-DMTQ:
MSXS9TC8(VN,L1SN8M[+/0"M]U5>VDE\?1CKRWLV\U\9P!=(G[5O+,"I5NR)T
M2*_.SW'(X_@J2J'N4,_CW<C'CLJ_B+5<K1\$5_^MV+K\*HH'^J3,;_UK]:^Z
MEF*I7L$G+:&ZG.FP:49$D"5"PHQ&$B*<9FJ'PA(8(Y(*G.,,\=PX9V,@(:>V
MWVC5K((8>TD8'?/SL56U2M6H0AW*GEQWU:U^P[3"FI4KC6?Z/F8791_JU3!(
MO)C A _,[7MSO1<2[\SUE[VYOFWF^NO17%>Z@H_;N?XRF;FVR)Z8P)R/E"GQ
MJG-OEQ8Q\*3TID ,-?9XZ0X#H[>7VC#T6&[;K1O.J_HT9/&%%/SC\BUY+#9D
MT19:2*,891&'*&"I^H]4>ZLDIE BA-(,)SS!1D:"T6A36^UWP@(M+2R6H)'7
M;M_4#['9)LD;< .OFN<Q&Z  @Q$H/G<W_0..NI4QTOUPWV)VDVL^5'/V^+?U
MJBSGBC=8&L0IE'E U/8B""#)*(81"FE$. ZC++/I-+K_>"NJ&*O9J&T2TQY>
MIAE+KB@,GI[4"#8#E6@^\Y!.J>PWZ6AOA)$SC$YI=YQ.=/(JQQ5_N2EXL7C:
M%,]B5\7NLYK<=ZL'4BSG:<@ICE,!1<(#B+(TA)3',40\8#@D.0VCR&K1OS#@
MY-;]CKQ[-1ZUR.![+;3E&;R+H!N: 1ZA'-H2N Y%>V/ $!JO]L"E,<<U"0P1
M.+(*3.]SS+Y@/P1_6HA;^9]/9*T^X,7+AV))EJP@BX]+O>.I=O/5@;<[\7/S
M1NGTSSE-<2XRG,,@I[FR'V@*,1,1#%$6LE@2PIAEJS$G.::74-VJH1/!MHJ
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M?2NZ<W- TZDPH_0! !Z8I3UA:\VUEDCYI$_3H4=E1$L\#DG.]O8K"\_?RD[
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M9&X+Q6S(3T!L>O$906M&'+X &Y@XCHOJZ),D.OMN -^!"29>\VCZQALWA\9
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MH2U[/U??=A8)@6&&(@:1>CV@[I0$@R0FDJ$D(A:=D2Z--C42J.5M$O"*CL2
MM");[#<N8FVPF_.)X,!$T8!7!Q6ZPLYV?3%\HF>Q._.)XDB[L:O0M-M]F:+3
MN]NZ^)#Q=E>F^NSMIHQO\EPA^>-C*9;-Z:TT(T$<)(%B7)2J/56$(0Z5"1;1
MD)(\(!%A@=F>RF;8Z>VT#EK3'1:5K63W5+BW"W],1(22,(:,!APBDJF)"% (
M0RE2)'A &7?R?/H"?P*%J8>"WLZOZ0O0\=R99['T78BZ"ZJG(M2.X$ZC +4A
MR/Z*3Y] R[GP=/=9TR@Z?4([XX+3I^Z]IL;G'?EY\[3YL:I.,:T>2+&<<XP3
MKE-4I<CTYB7ED$C!8)JB..8T2DF"[(M\'@\T-=9NJH[H!)^MI.![+:M3G<\3
MV)IY,WP@-C MNX'E6.OS/!+^BWV>&.L5JGV>U_ATN<^>ZUU,;5+^T/_?.:G\
M592;=<$V@NM?U&W].O_0N?+F01_'^Y>N\%1NYEE()8J"#,8!"2%*4 QIDB&8
M248$27F,DWB^66W(PL0<]":7%?=LI1O0/]@*![1T-F:,OZDR,1]?90*&MC"5
MF+.CH_DSL%.D_F5=8G+_W_9NF,(DVIBKKS*98UFT(T^JI>WK'?I^\]C?<"-:
MT-XQVC>R_3_>R:GU(-00_]-L-C&5/)51#&4<1Q )766+8@9#G 4B0EF&I5'+
MVA//GIJU_?;V]_=W7S_^I]66?0\L(W>'*P2#>S5JP=P\%WLP6#DH7.$8S0]A
M"HNMK^&4XA=<"GNWC.DY."7K@8/@Y"4NE?T5GRG>>Q;+)_&N*-GJ:;G19V(U
MYVU65+PGZZ7@7X2:W^5F'C&4A3E/(2-) A%3S$0P"?3A!I8DN>"8693<MQEZ
M:NS5"ER=X:\LA\T*4 %$);1-.7&K"3"@O,%@'9@1*[E!(_@,; %^OP]P+?X,
M- H,AK1-1?6A$!^KU+E?Y"TKCKN UU\*W.J)(];H=M%TOWBVTQ/&]O_\MEZ5
MY1_+M2 +;2'K&L[S*!>44(Y@F(9,GX?&,(\$@A31,(AEG@>A:,]##^T'.B&?
MT4>Y?UYZX/6E$A+LI 1:3--LV6'F<&CWD.N\_,6<1"=G]C7G=2R/T97S^U?S
M&]G-\XCNHYYY&,Z)=&K0OX@KJ0<O?PZEOD'<PKLG*L9_%IM;>4=^SM.(DY3(
M0"W'B81(H! 2&1,8H1"'+*."(&P2E#$8:VJ!EOU&$T4EJUULMP]8L_"N)[B&
M=U&=:\DQ TI>?71%23P[TVG"7PS8 "Z?8>"^X4:-!!OH?1@,-KG%C4Z<&_=L
MV^S<E.730WT4N]VTO"N>"RX4+2J+>DY8EE",8B@QUS72\@#F$D<P1'E 0R%C
M+B.[LW"#RVSSM8Z3]-E*!UX*L3#T0XTWQ6;T.*EI&]KKI16!M+_-'&W:S#77
M';29ZU28[^@]V[EOMN^$UMT?+8\V33[)?7BA1UTB1IN#PX5FO('=EJLOZZ8>
MU+?-BOU3622WZZHC,J_&_B+6E73S, ]YD",$9<J5(9QR!@F/**22\SC-42RQ
M44##;MBI!3.4G."Y(I!KVOE:0F^V%O@'=&!"WPH,*HEGVAI6;V[=$ITW/*WD
MKAG='QO; >634@U''I47[= X)#?+N^T8BHMB_J[Q997:1%\_ZDQOW5CBJQY6
M* 5WW5B2 (4H#C%D1#*($IG#7(1<S4% HB"148J,$D*L1IT:/VT%!UW)M5FT
ME=V,HNRP[V>HP1 =F* ,P 3?O1:><$)JQU!E2U&E8'^[7SW_FWI>S4[JAT-2
MLAMK%$YR4K^E)+>;';?X[(?@3PM=&4-*99!M70AWY*<VR;X*K6FQ*"I;[Z!M
M5!P(@:. PC#%"*(XB"#&60*S@&4HS",1!E:6U#7"3(V_6EVTQVQ?;OTONY,4
MH@0W&W#W0U36PI/ZFE[ !Z$FD"PZ5U7;..UGTSZX[LV6N_UK9MMP(S_2' Z]
M1^],WU:1HPDYF-@ANX3YP-7KIOH:><;=+WM [F@K[..9;HS]J6"Z>T63""K2
M.!%(8!C+)(1(=Q;'>1;!),6Q;L68AF%J0\%[3Y\:IS;"@76=#F-)?OO F;&9
M,QP#TU.+A/_.WB<U]DD<^P.,R@0G=3O\M$]?Y/:MZKUC[21KBV&4=4!8K)]%
M^4Y1"*NK*F=)0"/).$RT)PJ)((.4)2E$-..,I,J2(M*A@Y;I^ ZY4*/TS&KJ
M+U:-FMA3N5$$NP9,;=(+]8]%63Z9IMU:3X@9/7C%=R3#YOU;T*Y>,Q!&,,AG
M8*O'KD).#7JKR@QLE?%'-;;H^60AX[%')2A;1 ZYR_I^ASS1N@-UL;S_H,2O
M,E*?Q?I%F4&K];:9>HBS.(VY>KE0J#:&49S!'(6Z%T(L>!@%<8B,ZB":#C@U
M0V4K,M R@ZW0H)':(O7/!.Y^LAH"Q(%)ZA)^+B>H3("T2(OT#.A(F8[7 VN7
MM&B!4F\>HLESQDLMM-!J+UO0YCX[9B[7&[4G%4NR+E9_+,M'P:J^U4T!$AJ1
MA/$ 08II!!'..:1"$S,.*2-9)E%&3>BX=Y2I<7 KJ&4UEWXD^YG6&SZ#.[=,
MH3'^VHU4[S'@U/T=XTW][=!PZQ]@E&_?2,?V@S>[V#'1H=D7W:UNV/\\%6OQ
M9:U[H&]>OJAIWBB+3R<9/^I+YC2/4XQ0" 4-"$0R#"&-\AS2..19D"5)S%TV
MEN823'5KJ1[T@^@^S"L)'AOA9T"T8N_:,ULF0IA/C=D6TS/2(R5$M!OWS0HT
M8H,O6Y KR6<5PEOA/29%6 /F-3'"?/1QDR.L43E*D+!_@GV2Q-MB\W*S%N3M
MBHNY%(G,F,Q@)J)<<9? $'-=WC5%(A:4)&D4F^9!=!\\-4M%RP:T<$!+9Y[5
ML =6/YM< \' 7&&HO57FP2E5KT@NV'O<:/D#IY3HI@B<_+V+0V?U0A:;E[M"
M;8"9$#+B&8<YTSV,@UA]<EE 893$ J4$1S3$YHZ;W8.G]LDUHH%-8;K 'T%E
MXG1Q V!HYTJC^YV[[C9^$C<,QO*'F&!AZ?(X5KC?M=&Y?D07QK&4^ZZ*$[_W
M57+VYF>A(UYYPE!$84(4R2"21&IQ3Q!D888#$F=9F!F5#.\?9FJ\<[J"JI;T
MZF*S%:IF>XKKL1J8HEQ@\E!FMHO"L$5FJY%>N<1L5]O+!6;WKG;/?OXBUL6*
MOU_R=_IL6*J;-L0\AS*B7)D;ZOO/!4UA+@5):2)$2HWB1&='F-KWWPH):BF!
M$A.\ZSNA90CD9>O_:G@&_N2MD7%*13ZIO8>TX_WGCIYB?%*M4^G$IR]T/6YU
M9O^_;>,FPHQEB$0PCD+U>4<1@SG/<YBRC%(1DB2(C'83QB-.[7,_\'GMN[Q,
M^L$Y F_H6O0)Y] >Q6N1=#A<98B.WW-5EP8=^4B5(0;'IZE,;W3CGG>";KX)
M]J0LDT*4-\^D6.@<VP^KM:Z7MLU^47]_6V6+546/,"9(,+7EP!D5:LO!B:(C
M@M5<B!B+($C5_]K0D8L04V.HK91 KMK4.K"PJ#MVU8R8\=30. ]MV2CQP4[^
M&=AJ !7FL"0Z$6]_'FH]/%6/\@&C3XYSDF-4VKL&J4,FO.I90Y#C?L&I+ZNR
MZGE^PY2!^+2HJASJ+Y.D&1*$A1"34$(4Q@S2.!4P2%@8HR@-XX0ZQ(T]B#;1
M@/)5Q1M]SIP/3O4W$1.BV(.Y :U:ZNJ=8J-RKA7,XU&PF5@38F0K'.T(VN[1
M#M&W;1J@,IG_(=BFR40E) \EQ0'D7*:Z!D ""6($"J&=8D&29L0H9:]GC*F9
MHKMDU$9,B^#4&13[N= 3-D-SVR$L+LG/9_"QB.-=C]-((3T'O.P"?/U(],;Z
MSMPZ7MBO7_:]"."%2]U,T]M'H3M<+N^K=M&?"D*+1;%Y>?NTUN4CJX(K^A6Y
ME1^*I3*+"[)H*??]SXVN<*B8^5-1;N8I$6D0\Q!&*.<0288A3216_*@]C'D4
M*8JTV<O[$FQJI+K5J^Z'/@-;U6:@46X&MNKI9,BM@EL#"7S?Z0BTDI;^2F^3
M;F;:OL94#KP&C#R+UF:N;\A]VKK>9!O5X/6-Z*'5Z_WY#J:O6EADL=%UM90<
M.M/D[L]58YA0EG*!$PP369U321G,@PS!A*$@1HKND5EEF0OC3(VM:TE!(VJ5
ME024L!:&7@^F!L:P'Z2&#P6= LG%+.Y!R\(T]H/:2.:Q,WIV1O)E3'H-Y9[;
MQS.6+^NP9S ;7.[HSRU*<G^_UKY,]6K<RJ8;T$%YIHR3.$I) #/, X@"F4*"
M,Z+^FF/$LS 1)+>*;IF,.C4"[99MVE>@KL-5J6#IDS5"W]#KZAO3X7T/IR$<
MM-25%4I>W:)& X_K^+3!XLBU:77S->F]V@NJ#S6_72V54?FD"+ Q,%?+\HV0
MJ_6N/)8H?R^654KAQZ6B!%'J_(#]I^AL@<W+[V+S8Z5^\ZPNJ4X>S;,LR3%5
M9B!/)544)SC$.9.0)U$4R1 '81;9M# 9478KHARA)4J384LK_9J6*&!C7U%P
MS.DWX]B)3NK 3+W7J@5H'@$[U<%.]W;&:XU K1+HZ#3;*R\Y Y\53ZD'*1T6
M^DDM1+[3L$>=+_^YW>.(_PH)XZ/.R^DL]'%%<%P%'QY)L:X\)FNUZCZN2K*X
ME9]6R_M/Q;/@-V4I-N67U:)@+SN;$><RDT$2P92A#"**,<P#]1^6Y6D8Q#G-
MH\3J"(R#$%,SX+6TL!(7U/):+D<N\V"XK@R,[M +Q%9\W9F@54";]$>0ST"M
M!OC>_#F(E7\-GEX)W$6.<9GX"J2.*/6:9SD6K!7JH6+?X7PGU@^W4C-ZE:].
MI< TB%,8"AW-R]*P/ND?\3QGZO]2PJT."EP><FJ\]^:I6'"X6<'R22?@:H%U
M,Y9B95G@T@!L,[KS"^' Y%8+.P-'<3(ML>:X5F:/=7*-\?%://?RJ.-6U#5&
MX:C,KOF=;J$E7>NR2LIL'/H9BQ@.LQ RHML^$<%@CE@ PU"R/&;J-V;^T3//
MGQJAU/FHC[6<EA6SST%H%D&Z ICA(T=:N+9/LUO Z! 4NT#1%>",%R"R LDZ
M+G0&@DOQH,/;1HT#G9'Y,/YS[C+_<9]Y$$B>2!1 $8D<(JR8#.=JP> L#EB:
M<883J]XK?8--C=LNA24L\Y-Z<;X^L#,A G0'SFL09^S8S71"-BZ1FBM9Y#^?
MR%I]E(N7;2;/QZ5<K1^JD722YV)5/JW%]NPPR[(@3P6".44,(IY*F&MCB9)8
M_4*RD"96>S'+\:?&-5OQ.REU'07 3@/G\]RV,V1&20/B/C!+^87<FKD<@?-)
M9K8BC,IOCO@<4I[K8Z[M<Z>=_DO=9JW)=3SL:9>%(A,4PT@0#!'B N(XR2'A
M.!11*$,41FX][?H'GAKO=3-IMI*[=IN[@+D9H0V!Y,!,=A+$;<KV2/WBS- :
MIC?<A;%?J0^<&2+G>[X9WN_(5">[K,\YS\,LD1)*C!.((DPA#E@$8YXEH<0D
MRW.KXA6GAYD<"^EFS,KT5&("UI'3DHA.0VI(.U<#-33): $;C)HBS>!FO5:7
M5"G\=0H'*7^ ]S^U^![[C_=#XY513H\T+G_T:GO$%OU7._BTWZHYU/^O,QB>
MR4)G+7P5RC@JV$8-HGY1MWKJ_$/GRLHKM3O,_)MN9A$2Q@*9(4A2&4(DT@ 2
M2C+(<Q$*&0=!FIL?LO MW=28Z*B^@Q;2QI_N??H,O/&O.2D#LYX65EE2%:_M
M9)Z!G3KU+V_J+G9[_[9WP\F)?<UYM0@HO.;\CA2.>*5YMHMJ##4/O3$1[X..
M%U$9"J^]>,Q@@[A699)"[1:X+JI;9]F<[0S#B$2I2%*82LDABJE:F+.<PTAF
M-$UB(K/$[BB/\=!36W7?B<>U8$U[=5WSD3RLUIOB7PZ;  O\#6,^@Z Z= 2H
M$;JNK=VF^_45U_19#,D6,+\UCXQ''[FTD2TJQQ6,K)_@7/&7"<&K/.JV'="'
MU?I6M\EJO+C+^QNV*9ZK6DIS2B7',E-["YS%$%&60)HA"5$D6!9$2980H_+>
MCN-/C<PJ.6=@*0PK&[G";D9? X(Y,(>UDM?'7'[9-AN3J_6OH)(?;!4 .PV\
ME@9V@<YSH6 K$<8N&^R"SXDBPDZ/N:ZIXE=1U76[6RDZ_7NQ^?%CM>"Z9>MJ
M?<:-2&))41KED(=,<5N&D++6XA F420%92QB67)%BT5;>8P^U/'K8U:G<\ C
M*3A8UQKIYH"*"T&IU0!JW=HLMN5K1'T\C?Q)UMSR"(CS/!K2YI#3,FIWQEEE
M W9DGX$+KF3_31I=41RB9:.U+*_2P-$5L7/M')V?Y]#<49>3VV:QD##((I%+
M*$(U+8A+":E..TH08GE(6)3FS+B[8_?)4S/[*N&LDX.. >OGIZM@&-I7:XJ
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MV2P8I@-/;0W8I4+8D;@YT(R1/$JI6IEU"PP=9R>(I#"F62""+ @9$S9.RD&
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ME[$!WX:%VV+Q'1#VD=9BW_#;+<V.^/6NU+;/'&_A=M1V;QUW?89])L'[)]T
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M:4IT3F^?QN_1&*-:MN<T/#1;SU[G8)/>L!^%>AQO@J(HHDG*LP1RI@\=!()
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M30$'PP,NU\^&@<4Q%L8#FQ#N]0#JB1F^=D-W7H:LW. X/U-,,K>?IX&K-IS
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ME/<MF!?L%[IM_V8D:LO5QY7\IZ2;=[3<F FW7*1YQ%26%S B.C1!C%!HCCY
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MEMNG=^6RW4!=8$J)S%BD>:#0(63"]4":&5UHF2'&BSABRBJ5YM3#Y\8$C7W
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M)PC,1"8@*CB%.%,8"DQ8K"<@."'$[8CIU5!.<Z)T###MM_NN FB"/;\6F=K
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MW-1';-_^X,M'(869A)FC'X_;-F?A+=T8<=CJD]Q\^48W\O;>O!2+G%(5LUA
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M06S7*]FN%?&8R)A+"C.69$T2+(YR#A.%8L[S&!%B=5[1K_FY15M[!T#/@WK
MW_L =DZXZ#L[]\PP+8V/]]BSW--0WYZ!VDM3VQES%UGM,;&?2ED[=!\XBFO[
M0CBLK^W\U DEMGT]/E39]GZ*9_JS4>3Y5;M'JV_-H-6.6 N*<!YA'8]&B.D)
M>QX3B#&*8!X+GC-2$"F91Y[CV09GFJU8V^M1=O<\L'8QZ74X390>7>MVM4;N
M%+M:.P,&HA>Q")HN?;:Q:;.F+_E\E#Q]\0;OQ3Z34->.HH2*A*-8P4)@/6DM
M"@I94:20(D581GC*N9/RS<'3YQ8R&M&YA\9 L-%TO'IT5<<Z!"^.L,*Y0E#F
MYJQLC!AD(E4P2B.6%)0E#$F[0D-7PS=-*:'0 %HO3_J!,O["8XU$^!-E)ST.
MO%#8:V#J)<!CWTXL[IVX*.BAD:XF^6%:<3O?_U27XM17?UI797M.1*1946@H
M<48U4RK!S3D1"G%,<$JB*$)4NC!E&+/F1K&OO^F_24T.RR97=;O>K0D^F<34
MATZU,,AQ#]<^M..;Z7MF9*(:.-31.?7\3$>W,MGX5=^T\VST4QR>2$]P<,/5
MLCF<U?!$T_)XAN_3_;B\$?0W.^)ZPKS:MG5-BU@5.3/RC46.]=0VR4R%;@EI
MPC,1"Q9SY73LXF0K<V/:MBKRSDK/K,33B-H1Y=4XC<Q[[A Y,]@@!"$)Z71#
MD_++H*_/Z6+X8D]U-Y/Q\LJ<,37/U7/AIMC09F-B#K.P]NII?TE[6N+V3[H1
M1D?6Y,D8:OJ%;OZ0VT^;DLN/2FF"6MV]H5NY2..$L31/8)PI(S&"=6B'2 91
MRA.)L?F54Y+SF,;.C8LZD\'&I/S6 <1];3GX7NO]U)D7C?F@S@K^B5: FH+W
M1O3*,5]QU+? COCFTK<C\V?M VP.=?<=!3U/C41=_[K66U"[>P-V;T;]4C0N
M@]KG&]!Y#8S; 87L)NB<H(IW8]H[K33>!,@?:>A-T:;?</4W;<-6-@>3JS:P
M8HE4G"@%TXSG9I2)C.9P FD>)TB2+*:%D[+>B3;F-CBT)C:2 )5GF'H*2SNN
MOA*AD2G6%1QG-AQP/R2)G6IF4NX9\/,Y90Q=ZO>EOY&:-#;UO/BVJN2V,AIY
M#1$ME^L_J?9@(:7*,:4*BISKJ#**":2,ZTEJ'J51%)ER33[[KQ9-SW0G=F<H
MH)VE;IQ@@SJAJ4B9Q%#(1/,M80C2+,,0QZ8S6)H2MZ.+H>">D'\GP=F.BP.C
M-S(W=];6JY^-O3=@C^;M132=R=H!GY#D;=/LI&3N@,-S<G>YU3>L6U?5I\W:
MY",7*(M((C!D,240,1W)X4SF,*=)5"AI"H(ZT4OOV7.CD=HTLW^C;7.-W?:
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MV57[1B.F"I7&"*:"U\>K$TAP*B$7F!$I:4&053JYKP&S(]^]"\UZJ)Y9=UZ
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M0,28<:"UX###,DY1S'#&<Z\*E=/SS,V.[\4$CT9.6/6%JB3UK$8Y ZN;4QL
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MX3E8:1HI@@F%3.O8N*)I#DEJ7-%<*Z:3/,HPP3[&?0BP$U=X-#EZ.T1O@)P
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M1>]-./K A",)FQ/8#A%/0 A'-A"-I* 6U6X@[87MTWGT&GA^_+JA0)R.47<
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M"*%4%(PN.M''*]K==;N!H.$ Z$F,'!D$[Y:A9CZ]_709%[,)\I"-\PE0&^)
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MX#SA._QS_1/]\N\3FPS92;0+XQA=D99G<-Q[L)S'; VZ)/NP/SH3U*V2L>$
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M2J<%N-4;_P;K;NR$=+.,I3JRWA7BDZOS0WD$E4O1P@66'FK6UI/=]2!)S3B
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MZ6X)LVWVUR19971BGER;2+27XB'XJ($KS#QJ+S,;9-3E32+&C3",#[.C!=(
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MJLI$CB)&#SDY,K5-K$U_DP0GHR.;.S@CNKBR?8727AZ4GSY8$D'O\9!!Y-'
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MGJ_3H^34(N1N3#,.U@0I##DYUJN:PY[JIL@59CZC+[5'W2!I--_D2/&#Y'[
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MZU!";:+20D+,M2(\,V-ED2ACGA0^<U?8;RFQ9Y8]C6'?W*/^[^TI*L5)5F2
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M5:M<--FM 9F#X)UPB5D3!R9TM]FF=!@[3+8&SRZ\GALG+V_Q82HJ]"%#<CR
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M1-71H^#J&T$7-I#-65S&8=T8QSE@=)3,MQHP.D8 '>BV2</YR1>#I;:;%JY
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M'Q9DP?RV7/U"!)\N/V_(/\MO\</%:?WXKS<\6)\@]\EH)X![5L>8.06>K&]
MY;VQOJZ!VFW[V_9GFS>2TC>:]R3Q#CRM;=KE/*M%:=( +[DNNS5UEIH/('C6
M(2B#&9M4U[1JBFSF-\T.\GU)><*E6I/63[S'U:?%V>;OR!9?+/-)3(5C+?;W
MG!%5U?ET=>DD0^=MM"DY,=IV>.D+!P'0'"T F\GFP-IPW]*GTV$_WN]-#6?Y
M]=GE>OAZ^>[(I\$\QBU/T'0*XQ1<Z:J%-_M42K(2,%2E&<D$<+*N< \Z!32%
M9QM;/(W'VL(;N!=:TR/DC:]YCQJWCI;3+ZS.'O)88I.6Z!\MO+NB>P\MO&/
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M$X$7J\KU$V-L$9GL>1Z4!F4M!V]-K2/*4O+("L^E!>*>.]#!1 -V =DDTNC
MW'SBA7D4WKC_%W=^\D0XHI9% =Q[)&)C(>:A (R2A5Q,4JQ)"&"G4Q],2&!7
M);@?N6X/XN5Y.-VGQ?GNXM.GL/H:KWG]M;:;3&I2OO@-C6S&X53MWR@,*3+,
MTH/AQM6A?>2T1"D!?38L)T\.39.G:7]&X<N1BLMZQ\"UMMH($,&2J8&:@;,!
MH12'KG8V)8LMN##@; =C$(Y!TKAHTG@9=?!LWS03WQ8);-H+$C,8HA9@ZZ9D
MI3@#GUF ;*76B?MH9!/OXYGSS NOR>6^G%X('6!I4SA(WUSK"]_AZLLBU:7S
MY0GJUO5I63_]3U==#,H['S%%"&(3&@L&G!0*HC,I2-11/5SY.U'7]81$S(O:
M25#UL.-Z+A%W ._;V9YOPF=<737%I.)"5/24%"5#S<PF")YIR(DC8\1.KIKL
M6'GR-#,W7<\&CD>]';M*J@NXK3[7"F?\:5G9>?WZ7!%3K I>I@"ZCI%5)G.(
MEM7<J\"$0DNBKPWL7CC5O &;CN WE>0Z@.%?[]ZO,*PO5E^)K?^H0VW/*I^N
MB#'<.YOI3NDBR.HIBA&'8@(3 UTK;AC/32H!7SS5O'&9;F XG>0Z@.$_+\Z(
MD9_#:;U3-U,6<B2=+>GDL6;D11'@E,B V@47333HFMB(3QUFWG**;D"WLYRZ
M2)'4X-CUY/;"H]56T<4@ETYES."2*E!"#5[*D+1M@K';(\Q;U] -LK:420^Z
M:WF&7R\[Z7^[N+T5T68;K7! MZ-J8,?!:X=0<L%@>$[%-JDA>_HX@U!FCAYE
M$\BJ \3]C*OS15G0CU56_8*?:VG;M?VIO3!)2DBFUKD;4[F#%A@F%8Q *V4;
MS^'Y,PW"GCUZ[$TEM0X >%OC_C!:>NL/_7[36QRC-T))!5BKB55M*'-<%]"9
M^Y*C1L>;>!&C3CFO<]LZ!-U.8!V@\7F2;CLO/4]U$1TPY<FDJ&6^7M O(3H7
MBA7>F":IM6\?K9>)GY/CXN& Q6F%U"'L'MSA3TM2]_^#^>?E^ORGL*XSO<CG
M-C8(X,%BO<!$FB0SUY? C=4LB=1D-O78@\X\BW%BH'P#AY-*;;(:EV:H3.GB
M4QV_@?D?J^5Z?;\CZ"<LRQ6]-G^?I&@RF;T6$(FO*C$&(65"5D1KL_$Z*#D#
M5(>=?MZG?%[\-I!O_ZKV6:)KW\\MT;7SUT2%X(-TH*S:]$<DL-%E:4NP/C7I
M>IGD]/-&O3L%]?;R'0]J?PGJ,_Q0#_)^#];K?2Z<$%\5VF )9KXF]D4B\D(&
MGWS,16.=?KU?&_;^ ><-D>\9H9-(J0/-NE/][VW57:C5)5F!M%&"RLR BTQ"
MBCEPEIBVI;_Z[E$>V!YF2+?VP/8OZKGG%^Y&\5U7X 1-$B4EA*)X!D6^ ,0@
M(B2OHRI:8<K#1F=.=Z:9)VWN'TW+^44[HX.W.]E/> 0GP4?+ZS0R8:0@XKT&
MY\EZTJG.'DG*/,I2M<#U$R>;>;;F :-[5S$?M-9^PD$X01Z1"5O J%#7("<-
M=5$,(".?5]"%Q[ 'W?W$R69>,7D\&!\MYEW=OYE1?C/#I&ZB/UVN+U9XPED(
MW&0/)6A-5UPK"-EHL%9DE90L_.'BJ!8H?^)D\_J%AXSR7<5\T)J<_FU\K#Z5
M0$\9O6L81)WA$^F9XPQR=!Y]8%P+M@<K??S)>]G=T,H'[1\.!VW9?YLY _,"
MS&(2.54]EUGUA3PX# $T\^BB%G5W00\7:,)$4+.7YSAN50/@?*]7[7ZV0A06
MI4$$@3*326$-A"0D29V,6.:ES&D/]MI4Y,Q;Q7SD5VU[X.R<YCJ$&W?"O([.
MD1A+RA:421Q<* B%&V*1Q9BU[^ JS5N#?11W9)2H#V?BS!]UW>QFQ]^44V8>
M?6JCR3(OGW[_TV2X"XDGE("BIF"3DQ"L"6 ('-4CX*HTZ;S8Y\H8\M#IN]YB
M0KH[M3K8.(V2>0-.Z$"O @_@E=#@+0ITVD?3ILCZ\5$.9E;,&)P\'M2ZDP0Z
MR/QO,SOYCXO:K?!GN?[S^J0XF;1$ 3)H7S?&%(@L9Y#"6/HG6;#-'(])3G\P
M$PAW0>K^Y=P]N%^=GB[_.YRE^N>?Z7"+\TT"(3.K&(L,C/$::J<A<;G.CN(N
MF>)225SL'\M/'_9@AA.V@^X$4CR<*=A/>(2U]&Q":_'%;VAD.0ZG:O]6I(O6
MF3I-74L>0?DHP!GO:C6?<RX7P]O,+.UK)J$H(14>)3E^5ETE55$8D%YS+Y1C
MO(U9>4PS"<<@:9N9A&-DU,';_-S@,BMX(4,B@LF.%#<6"SZ8!%$7[:UE++19
M47FP,PE'R7W@3,(Q0N@ 2Y,V=\=$C!.9[BDY<J"BC.2[D;U2FVXEQV*2R"T
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MKG8&!I'(R%;,@?,N@$>?<@P!,V]2R#AIBV77E8U;8FC;+LPQ NTB5GZU&&G
M_M?L-&/.%=!R,]Y>%?!U;@LSHC)/)WJOFB1OAIZP$Z]]=K"V$6D7:+WD[9.D
M*%F$EPQ*C X4MQ)BC'3QC$B8#2O.-%F]].R)#M^CGTAU3B*R7CO6ZQ2 ,\+L
MUVVZKV[_XTE:K9XYRX2#CS:??BO!V^86[M$Q4B&2Y 9U>A:]>G4'JRFR*)<+
M]TT*W5\XT^Z+SAY]]&TKH2[2!"D\(')ZY44I$).4=;R-5D$)P5RCE6?/'VK^
ML413H./QMK.)Q-!K1^<-@=OWGC_\B&F52<,>\Y= (ZQ.N00)3-<H"%G2$+P.
MD)G1$CFK@_T/3*7<3DB\^9*?Z;FEWVUX?(MK@\SJ(!1DCW1A8LK@/0] KR5F
M+9AD;2+"0P_8KZH9@YKGY_A.*)[NU<X.S>.//F-:Q=-ZBN-S&#(E)E,P03(L
M@*K;$0(7$CA/DD61@C)-)L#NPYBY"^B3E'A4Q2;((C!09-'3NUR;B7CT23MF
MK&NR=?#)T_2K4\;@X5GS96O&=Q#-_"F<UF6'[SXBGO]>?[H*I2;?2E*2;#@Z
MN#$"5"H&?"@!I%%U96=*(30!T','Z@1#V\MZV8#QG0+H.INF+187/.@8/5'B
M/03C&,18=#28!---3)WGCS0OB*81^0 <;<'_#I!T?<=N&Q&%YSS7!5]*>]+.
M+I/%1YX@Z*PR,NV*R4U:"AZ=I#_<;"/B9]ZO[?@](V"J77GRY_E'7/V^//M
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MK(TF0RHZD9_"-R.2.*#ASKH83&@SWF%6JH\F3]#%_>T&G]^18XJ>1,8*(Z\
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M#]FVNST=:H)14/[NPKW?9I\-.6<>#90Z#EL%:<$9%T#+9)7Q&EEGM0)3<^!
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M.%UO0]#A@N\2/C_/ZTKR"9<V0$R:*?()B8\8F'<Z,Y.E!>^]YJI)SG,;09U
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M'S<3W^6Y&!$?_9Z*CYM=3L30/;;?PM<EOB^OOGZ]F*;:C;!9F4L_>CN]G&Z
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MMK&LX_F<,KZ@:9-BWXO*8TWH3E]VI]%;H_80-;.^KD(+=$Y#W9%6B@\<HG'
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M)1K;JO$,0])WL*C"^';,V\E]/KZU!_<\/^.$L!CJ<CS-1."!:6<,BRHZ!E*
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M%!F !Z=VVR>\Y0O&[9T^Q44UF'C;MQY<_T'])<(2_\__^F]02P,$%     @
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MMNX8WG_P0QIA3*598# "[1 !A?C+>8>C8EM=U?BD1.I4P0<X25ZA]69RC%W
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M^9T@%DS$A H.*J'R>H(;42+YK3ZXK=<C5-V:3G>ODK,62$90.$[O$*6 Y-,
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M ?VC@N Z<6/QC/>?QNFOKM\]"!A4SLD/!**TGD(11#\\URC7WD!1:STVQ>S
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MUI:I?BDIM=$A-%O@TB>.O593RPE-#/0@*H,4B7[)UZD7)@)3Q,\T?41;@U1
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M37 C,D^G$@Q?M165L0T2 V@3@_Q1L)'3E[Y'.TD3_ +I;Y,)NWI?]&RUE?#
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MIEE2]42RDFPZ4ZANUQUT+N0ENR+%N6**0[>2T\'%NH-S)1U?T%6W0]D58O3
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MA)X7T#,>_8N>T1YSV0)ZY55&88*OAW^57!C )Q2?C=Y@J1V%_L!(I9=\;V^
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MB[IWOHI0?+JW(NS[&6?_ %!+ P04    " #]I4I22C%,*L<%  "('0  &@
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MO<_49I5-"Z:-GP67U^(;I?E:NO<?4$L! A0#%     @ _:5*4HGY6?[>H@0
MEUTL !$              ( !     &5X96PM,C R,3 Q,#$N:'1M4$L! A0#
M%     @ _:5*4O6>J0LU&P  <3@! !$              ( !#:,$ &5X96PM
M,C R,3 Q,#$N>'-D4$L! A0#%     @ _:5*4DHP+MLU*@  J<L! !4
M         ( !<;X$ &5X96PM,C R,3 Q,#%?8V%L+GAM;%!+ 0(4 Q0    (
M /VE2E*DU'3>1H   %?0!0 5              "  =GH! !E>&5L+3(P,C$P
M,3 Q7V1E9BYX;6Q02P$"% ,4    " #]I4I28=$JD5D1 0#"Q@$ %
M        @ %2:04 97AE;"TR,#(Q,#$P,5]G,2YJ<&=02P$"% ,4    " #]
MI4I2Z%K;BNHA 0"6BP$ %               @ '=>@8 97AE;"TR,#(Q,#$P
M,5]G,BYJ<&=02P$"% ,4    " #]I4I2R$FG%&PW 0"6)@T %0
M    @ 'YG < 97AE;"TR,#(Q,#$P,5]L86(N>&UL4$L! A0#%     @ _:5*
M4ET%&/A1OP  *24) !4              ( !F-0( &5X96PM,C R,3 Q,#%?
M<')E+GAM;%!+ 0(4 Q0    ( /VE2E)3%# #/R0  )#B   ;
M  "  1R4"0!E>&5L,C R,#$R,S%E>&AI8FET,3 Q,2YH=&U02P$"% ,4
M" #]I4I2:];Y$*XX   )UP$ &P              @ &4N D 97AE;#(P,C Q
M,C,Q97AH:6)I=#$P,S(N:'1M4$L! A0#%     @ _:5*4I+![BXW P  - \
M !H              ( !>_$) &5X96PR,#(P,3(S,65X:&EB:70R,3$N:'1M
M4$L! A0#%     @ _:5*4D:50A:' P  <@H  !H              ( !ZO0)
M &5X96PR,#(P,3(S,65X:&EB:70R,S$N:'1M4$L! A0#%     @ _:5*4C,5
M 4,I"   R"$  !H              ( !J?@) &5X96PR,#(P,3(S,65X:&EB
M:70S,3$N:'1M4$L! A0#%     @ _:5*4DB&!Q,S"   ^B$  !H
M     ( !"@$* &5X96PR,#(P,3(S,65X:&EB:70S,3(N:'1M4$L! A0#%
M  @ _:5*4DHQ3"K'!0  B!T  !H              ( !=0D* &5X96PR,#(P
H,3(S,65X:&EB:70S,C$N:'1M4$L%!@     /  \ " 0  '0/"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
